activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	119273	CHEMBL760348	Inhibition of PKBa at 10 uM	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	Inhibition	%	1.0
	119273	CHEMBL760348	Inhibition of PKBa at 10 uM	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	Inhibition	%	1.0
	119795	CHEMBL760351	Inhibition of Protein kinase B alpha (Akt) at 1 uM	B	COC[C@H](C)Nc1nccc(-c2c(-c3ccc(F)cc3)c(=O)n3n2CCC3)n1		CHEMBL316065	=	Activity	%	89.0	CHEMBL4282	Homo sapiens	Activity	%	89.0
	133232	CHEMBL760347	Inhibition of PKBa at 10 uM	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	17.0	CHEMBL4282	Homo sapiens	Inhibition	%	17.0
	134976	CHEMBL760351	Inhibition of Protein kinase B alpha (Akt) at 1 uM	B	C[C@H](Nc1nccc(-c2c(-c3ccc(F)cc3)c(=O)n3n2CCC3)n1)C(C)(C)O		CHEMBL93281	=	Activity	%	119.0	CHEMBL4282	Homo sapiens	Activity	%	119.0
	138057	CHEMBL760348	Inhibition of PKBa at 10 uM	B	O=C(Nc1n[nH]c2nc(-c3ccccc3)c(Br)cc12)C1CC1		CHEMBL259270	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	139803	CHEMBL768269	Inhibition of Protein kinase B alpha (Akt) at 1 uM	B	C[C@H](Nc1nccc(-c2c(-c3ccc(F)cc3)c(=O)n3n2CCC3)n1)c1ccccc1		CHEMBL92082	=	Activity	%	98.0	CHEMBL4282	Homo sapiens	Activity	%	98.0
	144075	CHEMBL760347	Inhibition of PKBa at 10 uM	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)ccc12)C1CC1		CHEMBL405145	=	Inhibition	%	17.0	CHEMBL4282	Homo sapiens	Inhibition	%	17.0
	145377	CHEMBL766862	Binding affinity for protein kinase B (Akt) PH domain	B	CCCCCCCCCCCCCCCCCCCC(=O)OC(COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC1C(O)CC(OP(=O)(O)O)C(OP(=O)(O)O)C1O		CHEMBL1161532	=	Ratio		0.57	CHEMBL4282	Homo sapiens	Ratio		0.57
	145378	CHEMBL766858	Binding activity for protein kinase B (Akt) PH domain	B	CCCCCCCCCCCCCCCCCCCC(=O)OC(COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC1C(O)CC(OP(=O)(O)O)C(OP(=O)(O)O)C1O		CHEMBL1161532	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	153744	CHEMBL766858	Binding activity for protein kinase B (Akt) PH domain	B	CCCCCCCCCCCCCCCCCCCC(=O)OC(COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC1C(O)CCC(OP(=O)(O)O)C1O		CHEMBL1161535	=	Activity	%	13.0	CHEMBL4282	Homo sapiens	Activity	%	13.0
	153745	CHEMBL766863	Inhibition of protein kinase B (Akt) PH domain	B	CCCCCCCCCCCCCCCCCCOC[C@H](COC(=O)O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)[C@H]1O)OC		CHEMBL2368953	=	Ratio		32.0	CHEMBL4282	Homo sapiens	Ratio		32.0
	164727	CHEMBL766863	Inhibition of protein kinase B (Akt) PH domain	B	CCCCCCCCCCCCCCCCCCOC[C@H](COC(=O)O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)[C@H]1O)OC		CHEMBL2368953	=	Ratio		5.0	CHEMBL4282	Homo sapiens	Ratio		5.0
	173323	CHEMBL766862	Binding affinity for protein kinase B (Akt) PH domain	B	CCCCCCCCCCCCCCCCCCCC(=O)OC(COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC1C(O)C(OP(=O)(O)O)C(OP(=O)(O)O)C(OP(=O)(O)O)C1O		CHEMBL1161534	=	Ratio		0.4	CHEMBL4282	Homo sapiens	Ratio		0.4
	173324	CHEMBL766859	Inhibition of binding to Protein kinase B (Akt) PH domain	B	CCCCCCCCCCCCCCCCCCCC(=O)OC(COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC1C(O)C(OP(=O)(O)O)C(OP(=O)(O)O)C(OP(=O)(O)O)C1O		CHEMBL1161534	=	Activity	%	-35.0	CHEMBL4282	Homo sapiens	Activity	%	-35.0
	177482	CHEMBL760349	Inhibition of PKBalpha	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ncc(C(F)(F)F)cc1Cl		CHEMBL111620	=	Activity	%	64.0	CHEMBL4282	Homo sapiens	Activity	%	64.0
	178795	CHEMBL760349	Inhibition of PKBalpha	B	COCCCn1cc(C2=C(c3ccccc3O)C(=O)NC2=O)c2cccnc21		CHEMBL109944	=	Activity	%	93.0	CHEMBL4282	Homo sapiens	Activity	%	93.0
	182542	CHEMBL760349	Inhibition of PKBalpha	B	COc1ccccc1C1=C(c2cn(CCCNC(=O)OC(C)(C)C)c3ncccc23)C(=O)NC1=O		CHEMBL109981	=	Activity	%	103.0	CHEMBL4282	Homo sapiens	Activity	%	103.0
	554902	CHEMBL766411	Inhibition of PKBalpha in presence of 10 uM ATP	B	CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12		CHEMBL407002	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	Inhibition	%	2.0
	559746	CHEMBL767050	Inhibition of PKBalpha in presence of 10 uM ATP	B	CCCC(=O)Nc1n[nH]c2nnc(-c3ccccc3)cc12		CHEMBL288143	=	Inhibition	%	14.0	CHEMBL4282	Homo sapiens	Inhibition	%	14.0
	572989	CHEMBL767050	Inhibition of PKBalpha in presence of 10 uM ATP	B	CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3ccccc3)cc12		CHEMBL259744	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	586380	CHEMBL766411	Inhibition of PKBalpha in presence of 10 uM ATP	B	CCCC(=O)Nc1n[nH]c2ncc(-c3ccccc3)cc12		CHEMBL258701	=	Inhibition	%	13.0	CHEMBL4282	Homo sapiens	Inhibition	%	13.0
	590218	CHEMBL768268	Inhibition of PKBalpha in presence of 10 uM ATP	B	CCCC(=O)Nc1n[nH]c2ncc(-c3ccccc3F)cc12		CHEMBL407373	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	Inhibition	%	5.0
	616604	CHEMBL766860	Inhibition of Protein kinase B, Akt-1	B	Cn1ccc2ccc3c4[nH]c5c(CCCN[C@H]6CC[C@H](O)CC6)cccc5c4c4c(c3c21)C(=O)NC4=O		CHEMBL307152	=	IC50	nM	5480.0	CHEMBL4282	Homo sapiens	IC50	uM	5.48
	750633	CHEMBL766866	Inhibition of Protein kinase B (Akt-1)	B	O=C(Cc1ccc2ccccc2c1)Nc1cc(C2CC2)n[nH]1		CHEMBL115220	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	915752	CHEMBL766410	Inhibition of human Protein kinase B alpha at 10 uM	B	O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCn1cc2c2cccnc21		CHEMBL340776	=	Activity	%	97.0	CHEMBL4282	Homo sapiens	Activity	%	97.0
	931213	CHEMBL766410	Inhibition of human Protein kinase B alpha at 10 uM	B	O=C1NC(=O)C2=C1c1cn(c3ncccc13)CCOCCOCCOCCOCCn1cc2c2cccnc21		CHEMBL337642	=	Activity	%	102.0	CHEMBL4282	Homo sapiens	Activity	%	102.0
	953939	CHEMBL766409	Inhibition of Protein kinase B alpha	B	COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl.Cl		CHEMBL3216643	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	962852	CHEMBL766409	Inhibition of Protein kinase B alpha	B	COc1ccc(O)c(C(=O)c2ccc(/C=C/[C@@H]3CCCNC[C@H]3NC(=O)c3ccncc3)cc2)c1F.Cl		CHEMBL1204095	=	IC50	nM	160.0	CHEMBL4282	Homo sapiens	IC50	nM	160.0
	964153	CHEMBL766409	Inhibition of Protein kinase B alpha	B	COc1ccc(O)c(C(=O)c2ccc(CO[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl.Cl		CHEMBL1202525	=	IC50	nM	355.0	CHEMBL4282	Homo sapiens	IC50	nM	355.0
	965573	CHEMBL766409	Inhibition of Protein kinase B alpha	B	COc1ccc(O)c(C(=O)c2ccc(C(=O)N[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl.Cl		CHEMBL1202518	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	969291	CHEMBL766409	Inhibition of Protein kinase B alpha	B	COc1ccc(O)c(C(=O)c2ccc(NC[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl		CHEMBL1204097	=	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	977961	CHEMBL766409	Inhibition of Protein kinase B alpha	B	COc1ccc(O)c(C(=O)c2ccc(CN[C@@H]3CCCNC[C@H]3NC(=O)c3ccncc3)cc2)c1F.Cl		CHEMBL1202519	=	IC50	nM	3000.0	CHEMBL4282	Homo sapiens	IC50	uM	3.0
	1006296	CHEMBL874644	Inhibition of PKBalpha (Akt1) ser/thr kinase.	B	O=C(Nc1ccccn1)Nc1cccc2c1[C@H]1CCCN1C2=O		CHEMBL141247	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	1173967	CHEMBL768270	Inhibition of Protein kinase B alpha	B	CCN(CC)C/C=C/c1nc(O)c2c(ccc3nc(Nc4c(Cl)cccc4Cl)n(C)c32)c1C		CHEMBL281957	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	uM	1.0
	1406062	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1cnc2c(-c3ccc(F)cc3)ncnc21		CHEMBL539424	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1406077	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1c(-c2ccccc2)nc2c(-c3ccc(F)cc3)ncnc21		CHEMBL368896	=	Inhibition	%	31.0	CHEMBL4282	Homo sapiens	Inhibition	%	31.0
	1406198	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1c(-c2ccccc2)nc2c(Sc3ccccc3)ncnc21		CHEMBL367389	=	Inhibition	%	42.0	CHEMBL4282	Homo sapiens	Inhibition	%	42.0
	1406213	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1c(-c2ccccc2)nc2c(Sc3ccc(F)cc3)ncnc21		CHEMBL175541	=	Inhibition	%	29.0	CHEMBL4282	Homo sapiens	Inhibition	%	29.0
	1406338	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	CSc1ccc(-c2nc3c(Sc4ccccc4)ncnc3n2C)cc1		CHEMBL175868	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	Inhibition	%	5.0
	1406353	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	CSc1ccc(-c2nc3c(Sc4ccc(F)cc4)ncnc3n2C)cc1		CHEMBL175619	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1406368	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1c(-c2ccc([S+](C)[O-])cc2)nc2c(Sc3ccccc3)ncnc21		CHEMBL353740	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	Inhibition	%	4.0
	1406456	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	c1ccc(Nc2ncnc3[nH]cnc23)cc1		CHEMBL359730	=	Inhibition	%	14.0	CHEMBL4282	Homo sapiens	Inhibition	%	14.0
	1406471	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Fc1ccc(Nc2[nH]cnc3ncnc2-3)cc1		CHEMBL361227	=	Inhibition	%	18.0	CHEMBL4282	Homo sapiens	Inhibition	%	18.0
	1406486	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	c1ccc(Oc2ncnc3[nH]cnc23)cc1		CHEMBL366984	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1406500	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1c(-c2ccc([S+](C)[O-])cc2)nc2c(Sc3ccc(F)cc3)ncnc21		CHEMBL180373	=	Inhibition	%	10.0	CHEMBL4282	Homo sapiens	Inhibition	%	10.0
	1406515	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1c(-c2ccc(S(C)(=O)=O)cc2)nc2c(Sc3ccccc3)ncnc21		CHEMBL177060	=	Inhibition	%	14.0	CHEMBL4282	Homo sapiens	Inhibition	%	14.0
	1406618	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Fc1ccc(Oc2[nH]cnc3ncnc2-3)cc1		CHEMBL367695	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1406633	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1cnc2c(Nc3ccccc3)ncnc21		CHEMBL321749	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1406647	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1c(-c2ccc(S(C)(=O)=O)cc2)nc2c(Sc3ccc(F)cc3)ncnc21		CHEMBL367018	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	Inhibition	%	4.0
	1406662	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1c(Br)nc2c(Sc3ccccc3)ncnc21		CHEMBL177289	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	Inhibition	%	1.0
	1406768	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1cnc2c(Nc3ccc(F)cc3)ncnc21		CHEMBL362629	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1406783	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	c1ccc(Sc2ncnc3[nH]cnc23)cc1		CHEMBL175600	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1406901	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Fc1ccc(Sc2ncnc3[nH]cnc23)cc1		CHEMBL175603	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1406916	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	c1ccc(Sc2[nH]cnc3nccc2-3)cc1		CHEMBL360302	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1407027	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Fc1ccc(Sc2[nH]cnc3nccc2-3)cc1		CHEMBL367533	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1407042	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1cnc2c(Sc3ccccc3)ncnc21		CHEMBL179751	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1407057	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1cnc2c(Sc3ccc(F)cc3)ncnc21		CHEMBL175622	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1407162	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	c1ccc(CSc2ncnc3[nH]cnc23)cc1		CHEMBL397434	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	Inhibition	%	4.0
	1407177	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Fc1ccc(CSc2[nH]cnc3ncnc2-3)cc1		CHEMBL175451	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	Inhibition	%	6.0
	1407288	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1cnc2c(SCc3ccccc3)ncnc21		CHEMBL176384	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	Inhibition	%	4.0
	1407303	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1cnc2c(SCc3ccc(F)cc3)ncnc21		CHEMBL175730	=	Inhibition	%	11.0	CHEMBL4282	Homo sapiens	Inhibition	%	11.0
	1407419	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	c1ccc(-[n+]2c[nH]c3ncncc32)cc1		CHEMBL175816	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1407434	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Fc1ccc(-[n+]2c[nH]c3ncncc32)cc1		CHEMBL175817	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1407450	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	c1ccc(C[n+]2c[nH]c3ncncc32)cc1		CHEMBL369622	=	Inhibition	%	9.0	CHEMBL4282	Homo sapiens	Inhibition	%	9.0
	1407565	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Fc1ccc(C[n+]2c[nH]c3ncncc32)cc1		CHEMBL179515	=	Inhibition	%	8.0	CHEMBL4282	Homo sapiens	Inhibition	%	8.0
	1407580	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Clc1ncnc2c1ncn2Cc1ccccc1		CHEMBL7944	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1407691	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Clc1ncnc2ncn(Cc3ccccc3)c12		CHEMBL368715	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1407706	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Fc1ccc(Cn2cnc3c(Cl)ncnc32)cc1		CHEMBL369181	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1407814	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Fc1ccc(Cn2cnc3ncnc(Cl)c32)cc1		CHEMBL175528	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1407829	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Nc1ncnc2c1ncn2Cc1ccccc1		CHEMBL266094	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1407844	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Nc1ncnc2c1ncn2Cc1ccc(F)cc1		CHEMBL426037	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1407957	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Nc1ncnc2ncn(Cc3ccc(F)cc3)c12		CHEMBL180422	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1407972	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	COc1ncnc2ncn(Cc3ccc(F)cc3)c12		CHEMBL368714	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1408087	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	c1ccc(Cc2[nH]cnc3ncnc2-3)cc1		CHEMBL367930	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1408102	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Fc1ccc(Cc2[nH]cnc3ncnc2-3)cc1		CHEMBL179158	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	Inhibition	%	3.0
	1408216	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Fc1ccc(/C=C/c2[nH]cnc3ncnc2-3)cc1		CHEMBL367470	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	Inhibition	%	7.0
	1408231	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1cnc2c(/C=C/c3ccccc3)ncnc21		CHEMBL176186	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1408246	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1cnc2c(-c3ccccc3)ncnc21		CHEMBL179217	=	Inhibition	%	15.0	CHEMBL4282	Homo sapiens	Inhibition	%	15.0
	1408882	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Cn1c(C#CCCO)nc2c(Sc3ccccc3)ncnc21		CHEMBL177784	=	Inhibition	%	33.0	CHEMBL4282	Homo sapiens	Inhibition	%	33.0
	1408897	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	c1ccc(Cn2cnc3c(Sc4ccccc4)ncnc32)cc1		CHEMBL180020	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	Inhibition	%	1.0
	1408912	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Fc1ccc(Sc2ncnc3c2ncn3Cc2ccccc2)cc1		CHEMBL179768	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	Inhibition	%	1.0
	1409022	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Fc1ccc(Cn2cnc3c(Sc4ccccc4)ncnc32)cc1		CHEMBL176245	=	Inhibition	%	13.0	CHEMBL4282	Homo sapiens	Inhibition	%	13.0
	1409037	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Fc1ccc(Cn2cnc3c(Sc4ccc(F)cc4)ncnc32)cc1		CHEMBL175665	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1409148	CHEMBL830592	Inhibition of human Protein kinase B alpha at 30 uM	B	Nc1ncnc2[nH]cnc12		CHEMBL226345	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1421462	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4nc3-c3ccccc3)cc2)CC1		CHEMBL260397	=	IC50	nM	295.0	CHEMBL4282	Homo sapiens	IC50	nM	295.0
	1421465	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	58.0	CHEMBL4282	Homo sapiens	IC50	nM	58.0
	1421468	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	Cc1nc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)[nH]c1=O		CHEMBL178397	=	IC50	nM	760.0	CHEMBL4282	Homo sapiens	IC50	nM	760.0
	1421471	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	CC(C)Cc1nc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(O)nc5ccccc54)CC3)cc2)nc1O		CHEMBL178468	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	nM	20000.0
	1421867	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4cc3-c3ccccc3)cc2)CC1		CHEMBL359864	=	IC50	nM	365.0	CHEMBL4282	Homo sapiens	IC50	nM	365.0
	1421870	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3cc4ccccc4nc3-c3ccccc3)cc2)CC1		CHEMBL178349	=	IC50	nM	3136.0	CHEMBL4282	Homo sapiens	IC50	nM	3136.0
	1421873	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	N#Cc1cnc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)c1		CHEMBL255212	=	IC50	nM	762.0	CHEMBL4282	Homo sapiens	IC50	nM	762.0
	1421876	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	N#Cc1cnc(-c2ccc(CNCc3ccc(-c4csnn4)cc3)cc2)c(-c2ccccc2)c1		CHEMBL360333	=	IC50	nM	1288.0	CHEMBL4282	Homo sapiens	IC50	nM	1288.0
	1421879	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	N#Cc1cnc(-c2ccc(CN3CCC(c4nc5cc(F)ccc5[nH]4)CC3)cc2)c(-c2ccccc2)c1		CHEMBL368010	=	IC50	nM	865.0	CHEMBL4282	Homo sapiens	IC50	nM	865.0
	1421885	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	Cc1ccc2[nH]c(C3CCN(Cc4ccc(-c5ncc(C#N)cc5-c5ccccc5)cc4)CC3)nc2c1		CHEMBL181927	=	IC50	nM	2874.0	CHEMBL4282	Homo sapiens	IC50	nM	2874.0
	1421888	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	N#Cc1cnc(-c2ccc(CN3CCC(c4nc5ccccc5[nH]4)CC3)cc2)c(-c2ccccc2)c1		CHEMBL369094	=	IC50	nM	1471.0	CHEMBL4282	Homo sapiens	IC50	nM	1471.0
	1421993	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	N#Cc1cnc(-c2ccc(CN3CCC(n4cnc5ccccc54)CC3)cc2)c(-c2ccccc2)c1		CHEMBL361391	=	IC50	nM	4397.0	CHEMBL4282	Homo sapiens	IC50	nM	4397.0
	1421996	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	Cc1nc2ccccc2n1C1CCN(Cc2ccc(-c3ncc(C#N)cc3-c3ccccc3)cc2)CC1		CHEMBL425338	=	IC50	nM	7407.0	CHEMBL4282	Homo sapiens	IC50	nM	7407.0
	1421999	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3ncc(-c4nnn[nH]4)cc3-c3ccccc3)cc2)CC1		CHEMBL270847	=	IC50	nM	273.0	CHEMBL4282	Homo sapiens	IC50	nM	273.0
	1422002	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	c1ccc(-c2cc(-c3nn[nH]n3)cnc2-c2ccc(CNCc3ccc(-c4csnn4)cc3)cc2)cc1		CHEMBL425155	=	IC50	nM	177.0	CHEMBL4282	Homo sapiens	IC50	nM	177.0
	1422005	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	Fc1ccc2[nH]c(C3CCN(Cc4ccc(-c5ncc(-c6nn[nH]n6)cc5-c5ccccc5)cc4)CC3)nc2c1		CHEMBL181730	=	IC50	nM	239.0	CHEMBL4282	Homo sapiens	IC50	nM	239.0
	1422008	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	Cc1ccc2[nH]c(C3CCN(Cc4ccc(-c5ncc(-c6nn[nH]n6)cc5-c5ccccc5)cc4)CC3)nc2c1		CHEMBL367601	=	IC50	nM	763.0	CHEMBL4282	Homo sapiens	IC50	nM	763.0
	1422400	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	c1ccc(-c2cc(-c3nn[nH]n3)cnc2-c2ccc(CN3CCC(c4nc5ccccc5[nH]4)CC3)cc2)cc1		CHEMBL178872	=	IC50	nM	3323.0	CHEMBL4282	Homo sapiens	IC50	nM	3323.0
	1422403	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	c1ccc(-c2cc(-c3nn[nH]n3)cnc2-c2ccc(CN3CCC(n4cnc5ccccc54)CC3)cc2)cc1		CHEMBL178445	=	IC50	nM	4237.0	CHEMBL4282	Homo sapiens	IC50	nM	4237.0
	1422409	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	Cc1nc2ccccc2n1C1CCN(Cc2ccc(-c3ncc(-c4nn[nH]n4)cc3-c3ccccc3)cc2)CC1		CHEMBL369532	=	IC50	nM	6915.0	CHEMBL4282	Homo sapiens	IC50	nM	6915.0
	1422412	CHEMBL832702	Inhibitory concentration against Akt1 kinase	B	Cn1nnnc1-c1cnc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)c1		CHEMBL182101	=	IC50	nM	1772.0	CHEMBL4282	Homo sapiens	IC50	nM	1772.0
	1429965	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	CC(C)(N)c1ccc(-c2nc3ccccc3nc2-c2ccccc2)cc1		CHEMBL362455	=	IC50	nM	3400.0	CHEMBL4282	Homo sapiens	IC50	nM	3400.0
	1429968	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4nc3-c3ccccc3)cc2)CC1		CHEMBL260397	=	IC50	nM	290.0	CHEMBL4282	Homo sapiens	IC50	nM	290.0
	1429971	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	O=c1cnc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)[nH]1		CHEMBL440560	=	IC50	nM	3029.0	CHEMBL4282	Homo sapiens	IC50	nM	3029.0
	1430075	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	O=c1cnc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)[nH]1		CHEMBL577792	=	IC50	nM	1500.0	CHEMBL4282	Homo sapiens	IC50	nM	1500.0
	1430079	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	Cc1nc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)[nH]c1=O		CHEMBL178397	=	IC50	nM	760.0	CHEMBL4282	Homo sapiens	IC50	nM	760.0
	1430082	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	Cc1nc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)[nH]c1=O		CHEMBL572629	=	IC50	nM	1003.0	CHEMBL4282	Homo sapiens	IC50	nM	1003.0
	1430085	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	Oc1nc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(O)nc5ccccc54)CC3)cc2)nc1Cc1ccccc1		CHEMBL180580	=	IC50	nM	17000.0	CHEMBL4282	Homo sapiens	IC50	nM	17000.0
	1430088	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	O=c1[nH]c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)nc1Cc1ccccc1		CHEMBL3143722	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	nM	50000.0
	1430091	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	O=c1[nH]c(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)nc1Cc1ccc(O)cc1		CHEMBL178133	=	IC50	nM	21670.0	CHEMBL4282	Homo sapiens	IC50	nM	21670.0
	1430094	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	O=c1[nH]c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)nc1Cc1ccc(O)cc1		CHEMBL3143723	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	nM	50000.0
	1430097	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	CCC(C)c1nc(-c2ccc(CN3CCC(n4c(O)nc5ccccc54)CC3)cc2)c(-c2ccccc2)nc1O		CHEMBL428861	=	IC50	nM	17000.0	CHEMBL4282	Homo sapiens	IC50	nM	17000.0
	1430522	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	CCC(C)c1nc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)[nH]c1=O		CHEMBL3143721	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	nM	50000.0
	1430525	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	CC(C)Cc1nc(-c2ccc(CN3CCC(n4c(O)nc5ccccc54)CC3)cc2)c(-c2ccccc2)nc1O		CHEMBL362016	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	nM	50000.0
	1430528	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	CC(C)Cc1nc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(O)nc5ccccc54)CC3)cc2)nc1O		CHEMBL178468	=	IC50	nM	21200.0	CHEMBL4282	Homo sapiens	IC50	nM	21200.0
	1430532	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	O=C(O)c1ccc2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)nc2c1		CHEMBL272292	=	IC50	nM	240.0	CHEMBL4282	Homo sapiens	IC50	nM	240.0
	1430535	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	O=C(O)c1ccc2nc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc2c1		CHEMBL273160	=	IC50	nM	166.0	CHEMBL4282	Homo sapiens	IC50	nM	166.0
	1430639	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(-c5nn[nH]n5)cc4nc3-c3ccccc3)cc2)CC1		CHEMBL271091	=	IC50	nM	63.0	CHEMBL4282	Homo sapiens	IC50	nM	63.0
	1430642	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc(-c5nn[nH]n5)ccc4nc3-c3ccccc3)cc2)CC1		CHEMBL408151	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	nM	20.0
	1430645	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	Cn1nnc(-c2ccc3nc(-c4ccc(CN5CCC(n6c(O)nc7ccccc76)CC5)cc4)c(-c4ccccc4)nc3c2)n1		CHEMBL181419	=	IC50	nM	1089.0	CHEMBL4282	Homo sapiens	IC50	nM	1089.0
	1430648	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	Cn1nnc(-c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(n6c(O)nc7ccccc76)CC5)cc4)nc3c2)n1		CHEMBL180058	=	IC50	nM	55.0	CHEMBL4282	Homo sapiens	IC50	nM	55.0
	1430651	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5cn[nH]c5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL180231	=	IC50	nM	85.0	CHEMBL4282	Homo sapiens	IC50	nM	85.0
	1430654	CHEMBL832603	Inhibitory concentration against human Protein kinase B, alpha 	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	58.0	CHEMBL4282	Homo sapiens	IC50	nM	58.0
	1441908	CHEMBL832001	Inhibition of Protein kinase B alpha at 10 uM with 100 uM ATP	B	O=C(Nc1ncnc2oc(-c3cccnc3)cc12)C1CCCC1		CHEMBL182419	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	Inhibition	%	1.0
	1462034	CHEMBL828500	Inhibition of human Akt1	B	CC(C)OC(=O)N1CCn2cc(C3=C(c4cnc5ccccn45)C(=O)NC3=O)c3cccc(c32)C1		CHEMBL363058	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1462150	CHEMBL828500	Inhibition of human Akt1	B	O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCCCC1)CC2		CHEMBL362588	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1462172	CHEMBL828500	Inhibition of human Akt1	B	Cc1cc2c3c(c1)c(C1=C(c4cnc5ccccn45)C(=O)NC1=O)cn3CCN(C(=O)N1CCCCC1)C2		CHEMBL186290	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1462285	CHEMBL828500	Inhibition of human Akt1	B	O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCOCC1)CC2		CHEMBL178737	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1462301	CHEMBL828500	Inhibition of human Akt1	B	CN(C)C(=O)N1CCn2cc(C3=C(c4cnc5ccccn45)C(=O)NC3=O)c3cccc(c32)C1		CHEMBL362814	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1462427	CHEMBL828500	Inhibition of human Akt1	B	O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2		CHEMBL362558	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1481523	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	O=C(O)c1ccc2cc3nc(-c4cccs4)c(-c4cccs4)nc3cc2c1		CHEMBL426445	=	Inhibition	%	-10.0	CHEMBL4282	Homo sapiens	Inhibition	%	-10.0
	1481652	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	COc1cc2nc(-c3cccs3)c(-c3cccs3)nc2cc1OC		CHEMBL373367	=	Inhibition	%	-6.0	CHEMBL4282	Homo sapiens	Inhibition	%	-6.0
	1481673	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	Oc1cc2nc(-c3cccs3)c(-c3cccs3)nc2cc1O		CHEMBL190039	=	Inhibition	%	-7.0	CHEMBL4282	Homo sapiens	Inhibition	%	-7.0
	1481802	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	c1csc(-c2nc3cc4c(cc3nc2-c2cccs2)OCO4)c1		CHEMBL189940	=	Inhibition	%	-6.0	CHEMBL4282	Homo sapiens	Inhibition	%	-6.0
	1481944	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	O=C(O)C1COc2cc3nc(-c4cccs4)c(-c4cccs4)nc3cc2O1		CHEMBL193232	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	Inhibition	%	4.0
	1482055	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	c1csc(-c2nc3cc4c(cc3nc2-c2cccs2)OCCO4)c1	Outside typical range	CHEMBL192489	=	Inhibition	%	-12.0	CHEMBL4282	Homo sapiens	Inhibition	%	-12.0
	1482076	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	c1csc(-c2nc3cc4c(cc3nc2-c2cccs2)OCCCO4)c1	Outside typical range	CHEMBL191410	=	Inhibition	%	-13.0	CHEMBL4282	Homo sapiens	Inhibition	%	-13.0
	1482722	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	c1csc(-c2nc3cc4ccccc4cc3nc2-c2cccs2)c1		CHEMBL364499	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	Inhibition	%	12.0
	1482851	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	COC(=O)Cc1csc(-c2nc3cc4ccccc4cc3nc2-c2cc(CC(=O)OC)cs2)c1		CHEMBL192974	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	Inhibition	%	1.0
	1482982	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	COC(=O)CCc1ccc(-c2nc3cc4ccccc4cc3nc2-c2ccc(CCC(=O)OC)s2)s1		CHEMBL190143	=	Inhibition	%	14.0	CHEMBL4282	Homo sapiens	Inhibition	%	14.0
	1483003	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	COC(=O)CCCc1ccc(-c2nc3cc4ccccc4cc3nc2-c2ccc(CCCC(=O)OC)s2)s1		CHEMBL189104	=	Inhibition	%	-6.0	CHEMBL4282	Homo sapiens	Inhibition	%	-6.0
	1483133	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	O=C(O)Cc1ccc(-c2nc3cc4ccccc4cc3nc2-c2ccc(CC(=O)O)s2)s1		CHEMBL193162	=	Inhibition	%	15.0	CHEMBL4282	Homo sapiens	Inhibition	%	15.0
	1483264	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	O=C(O)Cc1csc(-c2nc3cc4ccccc4cc3nc2-c2cc(CC(=O)O)cs2)c1		CHEMBL192909	=	Inhibition	%	17.0	CHEMBL4282	Homo sapiens	Inhibition	%	17.0
	1483380	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	O=C(O)CCc1ccc(-c2nc3cc4ccccc4cc3nc2-c2ccc(CCC(=O)O)s2)s1		CHEMBL366201	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1483401	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	O=C(O)CCCc1ccc(-c2nc3cc4ccccc4cc3nc2-c2ccc(CCCC(=O)O)s2)s1	Outside typical range	CHEMBL190057	=	Inhibition	%	-13.0	CHEMBL4282	Homo sapiens	Inhibition	%	-13.0
	1483521	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	O=C(O)c1ccc(-c2nc3cc4ccccc4cc3nc2-c2ccc(C(=O)O)s2)s1		CHEMBL366185	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	Inhibition	%	12.0
	1485099	CHEMBL835568	In vitro percent inhibition of Protein kinase B, alpha at 10 uM concentration of compound dissolved in 100% DMSO using 5''-[gamma-33P]-triphosphate	B	COc1cc2nc3nc(-c4cccs4)c(-c4cccs4)nc3nc2cc1OC		CHEMBL193172	=	Inhibition	%	-4.0	CHEMBL4282	Homo sapiens	Inhibition	%	-4.0
	1489880	CHEMBL828489	Inhibition of AKT kinase	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F		CHEMBL1788116	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	1498192	CHEMBL828149	Inhibition of protein kinase B alpha (Akt1) in fluorescent enzymatic assay	B	CC1=C(C#N)c2nc(N)c(C#N)c(C)c2/C1=C/c1ccc(-c2ccc(C(=O)O)c(Cl)c2)o1		CHEMBL192519	=	IC50	nM	2600.0	CHEMBL4282	Homo sapiens	IC50	uM	2.6
	1498193	CHEMBL829821	Inhibition constant for protein kinase B alpha (Akt1) in fluorescent enzymatic assay	B	CC1=C(C#N)c2nc(N)c(C#N)c(C)c2/C1=C/c1ccc(-c2ccc(C(=O)O)c(Cl)c2)o1		CHEMBL192519	=	Ki	nM	1100.0	CHEMBL4282	Homo sapiens	Ki	uM	1.1
	1498194	CHEMBL828149	Inhibition of protein kinase B alpha (Akt1) in fluorescent enzymatic assay	B	O=C(/C=C/c1nc2ccccc2[nH]1)c1c(O)nc2ccc(Cl)cc2c1-c1ccccc1		CHEMBL190313	=	IC50	nM	4500.0	CHEMBL4282	Homo sapiens	IC50	uM	4.5
	1498195	CHEMBL829821	Inhibition constant for protein kinase B alpha (Akt1) in fluorescent enzymatic assay	B	O=C(/C=C/c1nc2ccccc2[nH]1)c1c(O)nc2ccc(Cl)cc2c1-c1ccccc1		CHEMBL190313	=	Ki	nM	3900.0	CHEMBL4282	Homo sapiens	Ki	uM	3.9
	1498199	CHEMBL828149	Inhibition of protein kinase B alpha (Akt1) in fluorescent enzymatic assay	B	O=C(O)c1cc(-c2ccc(C=C3C(=O)c4ccccc4C3=O)o2)ccc1O		CHEMBL175828	=	IC50	nM	25100.0	CHEMBL4282	Homo sapiens	IC50	uM	25.1
	1498200	CHEMBL829821	Inhibition constant for protein kinase B alpha (Akt1) in fluorescent enzymatic assay	B	O=C(O)c1cc(-c2ccc(C=C3C(=O)c4ccccc4C3=O)o2)ccc1O		CHEMBL175828	=	Ki	nM	20800.0	CHEMBL4282	Homo sapiens	Ki	uM	20.8
	1498201	CHEMBL828149	Inhibition of protein kinase B alpha (Akt1) in fluorescent enzymatic assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	IC50	nM	2300.0	CHEMBL4282	Homo sapiens	IC50	uM	2.3
	1498298	CHEMBL829821	Inhibition constant for protein kinase B alpha (Akt1) in fluorescent enzymatic assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Ki	nM	4500.0	CHEMBL4282	Homo sapiens	Ki	uM	4.5
	1498299	CHEMBL828149	Inhibition of protein kinase B alpha (Akt1) in fluorescent enzymatic assay	B	CC1=C(C#N)c2nc(N)c(C#N)c(C)c2/C1=C/c1ccc(-c2ccc(C(=O)O)cc2)o1	Outside typical range	CHEMBL365978	=	IC50	nM	126000.0	CHEMBL4282	Homo sapiens	IC50	uM	126.0
	1498300	CHEMBL828149	Inhibition of protein kinase B alpha (Akt1) in fluorescent enzymatic assay	B	CC1=C(C#N)c2nc(N)c(C#N)c(C)c2/C1=C/c1ccc(-c2cccc(C(=O)O)c2)o1		CHEMBL193261	=	IC50	nM	60200.0	CHEMBL4282	Homo sapiens	IC50	uM	60.2
	1507333	CHEMBL829440	Inhibition of Protein kinase B, alpha (Akt1)	B	CC(CN(C)C)Oc1ccc(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL425904	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	nM	50000.0
	1507350	CHEMBL829440	Inhibition of Protein kinase B, alpha (Akt1)	B	CC1(COc2ccc(Cl)cc2NC(=O)Nc2cnc(C#N)cn2)COC1		CHEMBL192161	=	IC50	nM	9210.0	CHEMBL4282	Homo sapiens	IC50	nM	9210.0
	1605363	CHEMBL871847	In vitro inhibitory concentration against Akt1 with ATP concentration at 1/2Km	B	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Outside typical range	CHEMBL401930	>	Inhibition	%	5000.0	CHEMBL4282	Homo sapiens	Inhibition	%	5000.0
	1662509	CHEMBL864555	Inhibitory activity against Akt1	B	COC(=O)c1cc2c(C)n[nH]c2s1		CHEMBL200586	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	1662594	CHEMBL864555	Inhibitory activity against Akt1	B	Cc1n[nH]c2sc(C(N)=O)c(NC(=O)Nc3ccccc3)c12		CHEMBL199996	=	IC50	nM	9000.0	CHEMBL4282	Homo sapiens	IC50	uM	9.0
	1662595	CHEMBL864555	Inhibitory activity against Akt1	B	Cc1n[nH]c2sc(C(N)=O)c(NC(=O)c3ccc(Cl)cc3)c12		CHEMBL199658	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	1662596	CHEMBL864555	Inhibitory activity against Akt1	B	Cc1n[nH]c2sc(C(N)=O)c(NC(=O)c3cccc(Cl)c3)c12		CHEMBL199657	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	1662597	CHEMBL864555	Inhibitory activity against Akt1	B	Cc1n[nH]c2sc(C(N)=O)c(NC(=O)c3ccccc3Cl)c12		CHEMBL371695	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	1662598	CHEMBL864555	Inhibitory activity against Akt1	B	Cc1n[nH]c2sc(C(N)=O)c(NC(=O)c3cccs3)c12		CHEMBL382070	=	IC50	nM	17000.0	CHEMBL4282	Homo sapiens	IC50	uM	17.0
	1662599	CHEMBL864555	Inhibitory activity against Akt1	B	Cc1n[nH]c2sc(C(N)=O)c(NC(=O)COc3ccccc3)c12		CHEMBL199759	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	1662600	CHEMBL864555	Inhibitory activity against Akt1	B	COC(=O)C(=O)Nc1c(C(N)=O)sc2[nH]nc(C)c12		CHEMBL370199	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	1662601	CHEMBL864555	Inhibitory activity against Akt1	B	CC(=O)Nc1c(C(N)=O)sc2[nH]nc(C)c12		CHEMBL199737	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1662602	CHEMBL864555	Inhibitory activity against Akt1	B	CN1CCN(C(=O)c2cc3c(-c4ccccc4)[nH]nc3s2)CC1		CHEMBL371239	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1662603	CHEMBL864555	Inhibitory activity against Akt1	B	COc1ccc(CNC(=O)c2cc3c(-c4ccccc4)[nH]nc3s2)cc1		CHEMBL199383	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1662604	CHEMBL864555	Inhibitory activity against Akt1	B	O=C(NCCc1ccccc1)c1cc2c(-c3ccccc3)[nH]nc2s1		CHEMBL197923	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1662605	CHEMBL864555	Inhibitory activity against Akt1	B	O=C(NCc1ccccc1)c1cc2c(-c3ccccc3)[nH]nc2s1		CHEMBL200499	=	IC50	nM	15000.0	CHEMBL4282	Homo sapiens	IC50	uM	15.0
	1662606	CHEMBL864555	Inhibitory activity against Akt1	B	O=C(NC1CCCCC1)c1cc2c(-c3ccccc3)[nH]nc2s1		CHEMBL199755	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1662607	CHEMBL864555	Inhibitory activity against Akt1	B	CCCCN(C)C(=O)c1cc2c(-c3ccccc3)[nH]nc2s1		CHEMBL199528	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1662608	CHEMBL864555	Inhibitory activity against Akt1	B	Cc1n[nH]c2sc(C(=O)NCc3ccccc3)cc12		CHEMBL373001	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1662609	CHEMBL864555	Inhibitory activity against Akt1	B	Cc1n[nH]c2sc(C(=O)NC3CCCCC3)cc12		CHEMBL199951	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1662610	CHEMBL864555	Inhibitory activity against Akt1	B	CCCCN(C)C(=O)c1cc2c(C)n[nH]c2s1		CHEMBL200657	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1662611	CHEMBL864555	Inhibitory activity against Akt1	B	CCCCNC(=O)c1cc2c(C)n[nH]c2s1		CHEMBL371242	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1662612	CHEMBL864555	Inhibitory activity against Akt1	B	Cc1n[nH]c2sc(C(N)=O)cc12		CHEMBL198022	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	1662613	CHEMBL864555	Inhibitory activity against Akt1	B	COC(=O)c1cc2c(CN3CCCCC3)n[nH]c2s1		CHEMBL200348	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	1662614	CHEMBL864555	Inhibitory activity against Akt1	B	COC(=O)c1cc2c(Nc3ccccc3)[nH]nc2s1		CHEMBL200796	=	IC50	nM	16000.0	CHEMBL4282	Homo sapiens	IC50	uM	16.0
	1665743	CHEMBL860241	Inhibition of PKBalpha at 10 uM	B	CN1C(=O)C(C(=O)Nc2nncs2)c2cc3occc3cc21		CHEMBL200906	=	Inhibition	%	14.0	CHEMBL4282	Homo sapiens	Inhibition	%	14.0
	1666380	CHEMBL865768	Inhibition of PKBalpha activity at 10 uM	B	Oc1cc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)ccc1Cl		CHEMBL373011	=	Inhibition	%	44.0	CHEMBL4282	Homo sapiens	Inhibition	%	44.0
	1666381	CHEMBL865768	Inhibition of PKBalpha activity at 10 uM	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1		CHEMBL477989	=	Inhibition	%	8.0	CHEMBL4282	Homo sapiens	Inhibition	%	8.0
	1670011	CHEMBL869961	Inhibition of PKBa at 10 uM	B	Cc1c(Nc2ccc(Br)cc2F)c(C(=O)NOCCO)cn(C)c1=O		CHEMBL199860	=	Inhibition	%	-4.0	CHEMBL4282	Homo sapiens	Inhibition	%	-4.0
	1671526	CHEMBL869961	Inhibition of PKBa at 10 uM	B	CCONC(=O)c1cn(C)c(=O)c(F)c1Nc1ccc(Br)cc1F		CHEMBL201426	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	Inhibition	%	6.0
	1671562	CHEMBL869961	Inhibition of PKBa at 10 uM	B	CONC(=O)c1cn(C)c(=O)c(C)c1Nc1ccc(Br)cc1F		CHEMBL426840	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	Inhibition	%	12.0
	1671642	CHEMBL869961	Inhibition of PKBa at 10 uM	B	CCONC(=O)c1cn(C)c(=O)c(C)c1Nc1ccc(Br)cc1F		CHEMBL203138	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	Inhibition	%	6.0
	1697120	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	C[C@H](N)COc1cnc(Cl)c(/C=C/c2ccncc2)c1		CHEMBL419932	=	IC50	nM	5290.0	CHEMBL4282	Homo sapiens	IC50	nM	5290.0
	1697121	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
	1697122	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccnc(-n3ccc4ccccc43)c2)c1)Cc1c[nH]c2ccccc12		CHEMBL206708	=	IC50	nM	3340.0	CHEMBL4282	Homo sapiens	IC50	nM	3340.0
	1697123	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccnc(NCc3ccccc3)c2)c1)Cc1c[nH]c2ccccc12		CHEMBL381610	=	IC50	nM	147.0	CHEMBL4282	Homo sapiens	IC50	nM	147.0
	1697124	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccnc(NC3CC3)c2)c1)Cc1c[nH]c2ccccc12		CHEMBL203275	=	IC50	nM	69.0	CHEMBL4282	Homo sapiens	IC50	nM	69.0
	1697125	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	CCNc1cc(/C=C/c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)ccn1		CHEMBL382914	=	IC50	nM	163.0	CHEMBL4282	Homo sapiens	IC50	nM	163.0
	1697126	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	CNc1cc(/C=C/c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)ccn1		CHEMBL202787	=	IC50	nM	176.0	CHEMBL4282	Homo sapiens	IC50	nM	176.0
	1697127	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	Nc1cc(/C=C/c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)ccn1		CHEMBL381075	=	IC50	nM	121.0	CHEMBL4282	Homo sapiens	IC50	nM	121.0
	1697128	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccnc(SCc3ccccc3)c2)c1)Cc1c[nH]c2ccccc12		CHEMBL381260	=	IC50	nM	3110.0	CHEMBL4282	Homo sapiens	IC50	nM	3110.0
	1697129	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccnc(Sc3ccccc3)c2)c1)Cc1c[nH]c2ccccc12		CHEMBL203483	=	IC50	nM	6350.0	CHEMBL4282	Homo sapiens	IC50	nM	6350.0
	1697130	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccnc(Oc3ccccc3)c2)c1)Cc1c[nH]c2ccccc12		CHEMBL378823	=	IC50	nM	6450.0	CHEMBL4282	Homo sapiens	IC50	nM	6450.0
	1697131	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	COc1cc(/C=C/c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)ccn1		CHEMBL377294	=	IC50	nM	2670.0	CHEMBL4282	Homo sapiens	IC50	nM	2670.0
	1697132	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1ccc(/C=C/c2ccncc2)cn1)Cc1ccccc1		CHEMBL203004	=	IC50	nM	43010.0	CHEMBL4282	Homo sapiens	IC50	nM	43010.0
	1697133	CHEMBL867722	Inhibition of Akt1 at 50 uM	B	N[C@H](COc1cnccc1/C=C/c1ccncc1)Cc1ccccc1		CHEMBL204447	=	Inhibition	%	29.0	CHEMBL4282	Homo sapiens	Inhibition	%	29.0
	1697134	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1cccc(/C=C/c2ccncc2)n1)Cc1c[nH]c2ccccc12		CHEMBL206654	=	IC50	nM	23270.0	CHEMBL4282	Homo sapiens	IC50	nM	23270.0
	1697137	CHEMBL867720	Inhibition of Akt1 at 5.33 uM	B	N[C@H](COc1cc(/C=C/c2ccncc2)ccn1)Cc1c[nH]c2ccccc12		CHEMBL206444	=	Inhibition	%	16.0	CHEMBL4282	Homo sapiens	Inhibition	%	16.0
	1697138	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	Cn1cc(C(CN)c2cncc(/C=C/c3ccncc3)c2)c2ccccc21		CHEMBL202937	=	IC50	nM	760.0	CHEMBL4282	Homo sapiens	IC50	nM	760.0
	1697139	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	NCC(c1ccccc1)c1cncc(/C=C/c2ccncc2)c1		CHEMBL383254	=	IC50	nM	284.0	CHEMBL4282	Homo sapiens	IC50	nM	284.0
	1697140	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	Brc1ccc(/C=C/CNCCOc2cncc(/C=C/c3ccncc3)c2)cc1		CHEMBL206328	=	IC50	nM	32250.0	CHEMBL4282	Homo sapiens	IC50	nM	32250.0
	1697141	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@@H](Cc1cccc2ccccc12)C(=O)Nc1cncc(/C=C/c2ccncc2)c1		CHEMBL383527	=	IC50	nM	668.0	CHEMBL4282	Homo sapiens	IC50	nM	668.0
	1697142	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@@H](Cc1ccccc1)C(=O)Nc1cncc(/C=C/c2ccncc2)c1		CHEMBL205514	=	IC50	nM	3200.0	CHEMBL4282	Homo sapiens	IC50	nM	3200.0
	1697143	CHEMBL867721	Inhibition of Akt1 at 0.99 uM	B	N[C@@H](Cc1c[nH]cn1)C(=O)Nc1cncc(/C=C/c2ccncc2)c1		CHEMBL379237	=	Inhibition	%	73.0	CHEMBL4282	Homo sapiens	Inhibition	%	73.0
	1697144	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(/C=C/c2ccncc2)c1		CHEMBL205415	=	IC50	nM	278.0	CHEMBL4282	Homo sapiens	IC50	nM	278.0
	1697145	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](CNc1cncc(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL203624	=	IC50	nM	9.7	CHEMBL4282	Homo sapiens	IC50	nM	9.7
	1697146	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](CNc1cnc(Cl)c(/C=C/c2ccncc2)c1)CC1CNc2ccccc21		CHEMBL381703	=	IC50	nM	79.0	CHEMBL4282	Homo sapiens	IC50	nM	79.0
	1697147	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](CNc1cnc(Cl)c(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL203384	=	IC50	nM	19.0	CHEMBL4282	Homo sapiens	IC50	nM	19.0
	1697148	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](CCc1cnc(Cl)c(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL203329	=	IC50	nM	198.0	CHEMBL4282	Homo sapiens	IC50	nM	198.0
	1697149	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	C(=C/c1cncc(OCCCc2c[nH]c3ccccc23)c1)\c1ccncc1		CHEMBL205836	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	nM	50000.0
	1697150	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	OC(COc1cncc(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL380958	=	IC50	nM	24010.0	CHEMBL4282	Homo sapiens	IC50	nM	24010.0
	1697151	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	CN(C)[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL202893	=	IC50	nM	1100.0	CHEMBL4282	Homo sapiens	IC50	nM	1100.0
	1697152	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	Cn1cc(C[C@H](N)COc2cncc(/C=C/c3ccncc3)c2)c2ccccc21		CHEMBL204012	=	IC50	nM	500.0	CHEMBL4282	Homo sapiens	IC50	nM	500.0
	1697153	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1cc(/C=C/c2ccncc2)cnc1Cl)Cc1c[nH]c2ccccc12		CHEMBL206198	=	IC50	nM	273.0	CHEMBL4282	Homo sapiens	IC50	nM	273.0
	1697154	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1cnc(Cl)c(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL379914	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	nM	23.0
	1697155	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL381808	=	IC50	nM	360.0	CHEMBL4282	Homo sapiens	IC50	nM	360.0
	1697156	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL383541	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
	1697157	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1csc2ccccc12		CHEMBL206183	=	IC50	nM	142.0	CHEMBL4282	Homo sapiens	IC50	nM	142.0
	1697158	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1ccc2ccccc2c1		CHEMBL381328	=	IC50	nM	146.0	CHEMBL4282	Homo sapiens	IC50	nM	146.0
	1697159	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1cccc2ccccc12		CHEMBL205871	=	IC50	nM	324.0	CHEMBL4282	Homo sapiens	IC50	nM	324.0
	1697160	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N#Cc1cccc(C[C@H](N)COc2cncc(/C=C/c3ccncc3)c2)c1		CHEMBL205410	=	IC50	nM	320.0	CHEMBL4282	Homo sapiens	IC50	nM	320.0
	1697161	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1cccc(O)c1		CHEMBL203685	=	IC50	nM	875.0	CHEMBL4282	Homo sapiens	IC50	nM	875.0
	1697162	CHEMBL867720	Inhibition of Akt1 at 5.33 uM	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)C(=O)Nc1ccc2ccccc2c1		CHEMBL203583	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	Inhibition	%	4.0
	1697163	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@@H](COCc1ccccc1)COc1cncc(/C=C/c2ccncc2)c1		CHEMBL206236	=	IC50	nM	4040.0	CHEMBL4282	Homo sapiens	IC50	nM	4040.0
	1697164	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@@H](CCc1ccccc1)COc1cncc(/C=C/c2ccncc2)c1		CHEMBL381829	=	IC50	nM	8020.0	CHEMBL4282	Homo sapiens	IC50	nM	8020.0
	1697165	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)C(c1ccccc1)c1ccccc1		CHEMBL203434	=	IC50	nM	6760.0	CHEMBL4282	Homo sapiens	IC50	nM	6760.0
	1697166	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1ccccc1		CHEMBL203673	=	IC50	nM	690.0	CHEMBL4282	Homo sapiens	IC50	nM	690.0
	1697167	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	C(=C/c1cncc(OC[C@@H]2CCCN2)c1)\c1ccncc1		CHEMBL205645	=	IC50	nM	23910.0	CHEMBL4282	Homo sapiens	IC50	nM	23910.0
	1697168	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	C(=C/c1cncc(OC[C@@H]2CCN2)c1)\c1ccncc1		CHEMBL204213	=	IC50	nM	10870.0	CHEMBL4282	Homo sapiens	IC50	nM	10870.0
	1697169	CHEMBL867720	Inhibition of Akt1 at 5.33 uM	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)C(=O)O		CHEMBL378166	=	Inhibition	%	11.0	CHEMBL4282	Homo sapiens	Inhibition	%	11.0
	1697170	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	CC(C)[C@H](N)COc1cncc(/C=C/c2ccncc2)c1		CHEMBL204059	=	IC50	nM	19320.0	CHEMBL4282	Homo sapiens	IC50	nM	19320.0
	1697171	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	NCCCOc1cncc(/C=C/c2ccncc2)c1		CHEMBL205820	=	IC50	nM	14710.0	CHEMBL4282	Homo sapiens	IC50	nM	14710.0
	1697172	CHEMBL867719	Inhibition of Akt1 using 10 uM ATP	B	NCCOc1cncc(/C=C/c2ccncc2)c1		CHEMBL206382	=	IC50	nM	5080.0	CHEMBL4282	Homo sapiens	IC50	nM	5080.0
	1697173	CHEMBL867720	Inhibition of Akt1 at 5.33 uM	B	N[C@H](COc1cncc(/C=C/c2ccccc2)c1)Cc1c[nH]c2ccccc12		CHEMBL383843	=	Inhibition	%	17.0	CHEMBL4282	Homo sapiens	Inhibition	%	17.0
	1697174	CHEMBL867720	Inhibition of Akt1 at 5.33 uM	B	N[C@H](COc1cccc(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL262986	=	Inhibition	%	35.0	CHEMBL4282	Homo sapiens	Inhibition	%	35.0
	1697193	CHEMBL869544	Activity against GSK3 in FL5.12-Akt1 cells	F	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL383541	=	EC50	nM	10000.0	CHEMBL4282	Homo sapiens	EC50	nM	10000.0
	1697194	CHEMBL869544	Activity against GSK3 in FL5.12-Akt1 cells	F	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	EC50	nM	460.0	CHEMBL4282	Homo sapiens	EC50	nM	460.0
	1697196	CHEMBL869547	Antiproliferative activity against FL5.12-Akt1 cells by MTT assay	F	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL383541	=	IC50	nM	3000.0	CHEMBL4282	Homo sapiens	IC50	nM	3000.0
	1697197	CHEMBL869547	Antiproliferative activity against FL5.12-Akt1 cells by MTT assay	F	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	290.0	CHEMBL4282	Homo sapiens	IC50	nM	290.0
	1697684	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Cl)cc2)o1		CHEMBL203056	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697954	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Cc3ccccc3)cc2)o1		CHEMBL383126	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697955	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Oc3ccccc3)cc2)o1		CHEMBL206267	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697956	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(-c3ccccc3)cc2)o1		CHEMBL205464	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697957	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Br)cc2)o1		CHEMBL205463	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697958	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccncc2)c1-c1nnc(NCc2ccc3c(c2)OCO3)o1		CHEMBL202892	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697959	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cc1ccc(Nc2nnc(-c3c(NCc4ccncc4)ncn3C)o2)c(F)c1		CHEMBL379908	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697960	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Cl)c(C(F)(F)F)c2)o1		CHEMBL205127	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697961	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	COc1ccc(Nc2nnc(-c3c(NCc4ccncc4)ncn3C)o2)cc1OC		CHEMBL378592	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697962	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(Cl)c(Cl)c2)o1		CHEMBL204874	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697963	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cc1ccccc1Nc1nnc(-c2c(NCc3ccncc3)ncn2C)o1		CHEMBL379239	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697964	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	COc1ccccc1Nc1nnc(-c2c(NCc3ccncc3)ncn2C)o1		CHEMBL204312	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697965	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	COc1cccc(Nc2nnc(-c3c(NCc4ccncc4)ncn3C)o2)c1		CHEMBL203796	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697966	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cc1cccc(Nc2nnc(-c3c(NCc4ccncc4)ncn3C)o2)c1		CHEMBL203789	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697967	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2cccc(OC(F)(F)F)c2)o1		CHEMBL206538	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697968	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(C(F)(F)F)cc2)o1		CHEMBL380131	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697969	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(OC(F)(F)F)cc2)o1		CHEMBL383255	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697970	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(OC(F)(F)Cl)cc2)o1		CHEMBL205884	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697971	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	CC(C)c1ccc(Nc2nnc(-c3c(NCc4ccncc4)ncn3C)o2)cc1		CHEMBL203119	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697972	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccncc2)c1-c1nnc(Nc2ccc(C(C)(C)C)cc2)o1		CHEMBL203731	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697973	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2cccc3ncccc23)c1-c1nnc(Nc2ccc(Cl)cc2)o1		CHEMBL378165	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697974	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccc3ccccc3n2)c1-c1nnc(Nc2ccc(Cl)cc2)o1		CHEMBL204718	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697975	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccc3[nH]ncc3c2)c1-c1nnc(Nc2ccc(Cl)cc2)o1		CHEMBL206118	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697976	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccc(F)c(F)c2)c1-c1nnc(Nc2ccc(Cl)cc2)o1		CHEMBL203394	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697977	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCCc2ccc3c(c2)OCO3)c1-c1nnc(Nc2ccc(Cl)cc2)o1		CHEMBL382672	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697978	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2ccccn2)c1-c1nnc(Nc2ccc(Cl)cc2)o1		CHEMBL202904	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1697979	CHEMBL866555	Protective index against PKB/Akt at 10 uM by HTRF method	B	Cn1cnc(NCc2cccnc2)c1-c1nnc(Nc2ccc(Cl)cc2)o1		CHEMBL206742	<	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1704018	CHEMBL864436	Inhibitory activity against AKT	B	COc1ccc(N2Cc3cnc(Nc4ccc(F)cc4)nc3N([C@@H]3CC[C@@H](O)C3)C2=O)cc1	Outside typical range	CHEMBL606964	>	IC50	nM	125000.0	CHEMBL4282	Homo sapiens	IC50	nM	125000.0
	1704885	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1ccccc1		CHEMBL203673	=	IC50	nM	690.0	CHEMBL4282	Homo sapiens	IC50	nM	690.0
	1704886	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL381187	=	IC50	nM	26.0	CHEMBL4282	Homo sapiens	IC50	nM	26.0
	1704887	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL383264	=	IC50	nM	1.3	CHEMBL4282	Homo sapiens	IC50	nM	1.3
	1704888	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc2nc(-c3ccncc3)ccc12)Cc1c[nH]c2ccccc12		CHEMBL207496	=	IC50	nM	190.0	CHEMBL4282	Homo sapiens	IC50	nM	190.0
	1704889	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](CNc1cncc(Nc2cccc3cnccc23)c1)Cc1c[nH]c2ccccc12		CHEMBL205994	=	IC50	nM	270.0	CHEMBL4282	Homo sapiens	IC50	nM	270.0
	1704890	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](CNc1cncc(Oc2cccc3cnccc23)c1)Cc1c[nH]c2ccccc12		CHEMBL206732	=	IC50	nM	210.0	CHEMBL4282	Homo sapiens	IC50	nM	210.0
	1704891	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cnc2ccc(-c3cccnc3)cc2c1)Cc1c[nH]c2ccccc12		CHEMBL205324	=	IC50	nM	7090.0	CHEMBL4282	Homo sapiens	IC50	nM	7090.0
	1704892	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cnc2ccc(-c3ccncc3)cc2c1)Cc1c[nH]c2ccccc12		CHEMBL206819	=	IC50	nM	300.0	CHEMBL4282	Homo sapiens	IC50	nM	300.0
	1704893	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	NC(=O)c1cccc2c(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cccc12		CHEMBL205781	=	IC50	nM	2170.0	CHEMBL4282	Homo sapiens	IC50	nM	2170.0
	1704894	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	Nc1ccc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1cccc(Cl)c1		CHEMBL439340	=	IC50	nM	1450.0	CHEMBL4282	Homo sapiens	IC50	nM	1450.0
	1704895	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(-c2cccc(Nc3nccs3)c2)c1)Cc1c[nH]c2ccccc12		CHEMBL380542	=	IC50	nM	6230.0	CHEMBL4282	Homo sapiens	IC50	nM	6230.0
	1704896	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(-c2cccc(Nc3ncccn3)c2)c1)Cc1c[nH]c2ccccc12		CHEMBL202972	=	IC50	nM	3670.0	CHEMBL4282	Homo sapiens	IC50	nM	3670.0
	1704897	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc(Nc3ncccn3)cc2)c1)Cc1c[nH]c2ccccc12		CHEMBL207031	=	IC50	nM	14330.0	CHEMBL4282	Homo sapiens	IC50	nM	14330.0
	1704898	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	Nc1nccc(Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc2)n1		CHEMBL208406	=	IC50	nM	2710.0	CHEMBL4282	Homo sapiens	IC50	nM	2710.0
	1704899	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc(NC(=O)Nc3ccccc3)nc2)c1)Cc1c[nH]c2ccccc12		CHEMBL378589	=	IC50	nM	1120.0	CHEMBL4282	Homo sapiens	IC50	nM	1120.0
	1704900	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc(-c3nn[nH]n3)cc2)c1)Cc1c[nH]c2ccccc12		CHEMBL206581	=	IC50	nM	33160.0	CHEMBL4282	Homo sapiens	IC50	nM	33160.0
	1704901	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	CS(=O)(=O)Nc1ccc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc1		CHEMBL383702	=	IC50	nM	33010.0	CHEMBL4282	Homo sapiens	IC50	nM	33010.0
	1704902	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	CC(=O)Nc1cccc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)c1		CHEMBL205422	=	IC50	nM	12030.0	CHEMBL4282	Homo sapiens	IC50	nM	12030.0
	1704903	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	CC(=O)Nc1ccc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc1		CHEMBL381785	=	IC50	nM	227.0	CHEMBL4282	Homo sapiens	IC50	nM	227.0
	1704904	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	NC(=O)Cc1cccc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)c1		CHEMBL206746	=	IC50	nM	1390.0	CHEMBL4282	Homo sapiens	IC50	nM	1390.0
	1704905	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	NC(=O)c1ccc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc1		CHEMBL426126	=	IC50	nM	9310.0	CHEMBL4282	Homo sapiens	IC50	nM	9310.0
	1704906	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc(C(=O)O)cc2)c1)Cc1c[nH]c2ccccc12		CHEMBL204892	=	IC50	nM	31280.0	CHEMBL4282	Homo sapiens	IC50	nM	31280.0
	1704907	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	Nc1ccc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc1		CHEMBL206179	=	IC50	nM	6940.0	CHEMBL4282	Homo sapiens	IC50	nM	6940.0
	1704908	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc(F)cc2)c1)Cc1c[nH]c2ccccc12		CHEMBL382397	=	IC50	nM	1560.0	CHEMBL4282	Homo sapiens	IC50	nM	1560.0
	1704909	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N#Cc1ccc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc1		CHEMBL427388	=	IC50	nM	1830.0	CHEMBL4282	Homo sapiens	IC50	nM	1830.0
	1704910	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	Cc1c(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc(C#N)c(=O)n1C		CHEMBL268054	=	IC50	nM	1340.0	CHEMBL4282	Homo sapiens	IC50	nM	1340.0
	1704911	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(-c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL208199	=	IC50	nM	260.0	CHEMBL4282	Homo sapiens	IC50	nM	260.0
	1704912	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(Nc2cccnc2)c1)Cc1ccccc1		CHEMBL382379	=	IC50	nM	6970.0	CHEMBL4282	Homo sapiens	IC50	nM	6970.0
	1704913	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(Nc2ccncc2)c1)Cc1ccccc1		CHEMBL207699	=	IC50	nM	18830.0	CHEMBL4282	Homo sapiens	IC50	nM	18830.0
	1704914	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(Nc2cccnc2)c1)Cc1c[nH]c2ccccc12		CHEMBL207671	=	IC50	nM	2160.0	CHEMBL4282	Homo sapiens	IC50	nM	2160.0
	1704915	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(Nc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL383223	=	IC50	nM	2860.0	CHEMBL4282	Homo sapiens	IC50	nM	2860.0
	1704916	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(-c2nc(-c3cccnc3)cs2)c1)Cc1ccccc1		CHEMBL207530	=	IC50	nM	9350.0	CHEMBL4282	Homo sapiens	IC50	nM	9350.0
	1704917	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(-c2nc(-c3ccncc3)cs2)c1)Cc1ccccc1		CHEMBL377771	=	IC50	nM	9870.0	CHEMBL4282	Homo sapiens	IC50	nM	9870.0
	1704918	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(NC(=O)c2ccncc2)c1)Cc1ccccc1		CHEMBL414861	=	IC50	nM	31950.0	CHEMBL4282	Homo sapiens	IC50	nM	31950.0
	1704919	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(C(=O)Nc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL208499	=	IC50	nM	2020.0	CHEMBL4282	Homo sapiens	IC50	nM	2020.0
	1704920	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(C#Cc2cccnc2)c1)Cc1c[nH]c2ccccc12		CHEMBL205349	=	IC50	nM	25200.0	CHEMBL4282	Homo sapiens	IC50	nM	25200.0
	1704921	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(C#Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL206208	=	IC50	nM	210.0	CHEMBL4282	Homo sapiens	IC50	nM	210.0
	1704922	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL383541	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
	1704923	CHEMBL862612	Inhibition of Akt1 at 50 uM	B	N[C@H](COc1cncc(NC(=O)c2cccnc2)c1)Cc1ccccc1		CHEMBL205690	=	Inhibition	%	26.0	CHEMBL4282	Homo sapiens	Inhibition	%	26.0
	1704924	CHEMBL862612	Inhibition of Akt1 at 50 uM	B	CC(=O)NCc1ccc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc1		CHEMBL204355	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	Inhibition	%	3.0
	1704925	CHEMBL862612	Inhibition of Akt1 at 50 uM	B	N[C@H](COc1cncc(-c2cccc(S(N)(=O)=O)c2)c1)Cc1c[nH]c2ccccc12		CHEMBL203127	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	1704926	CHEMBL862612	Inhibition of Akt1 at 50 uM	B	N[C@H](COc1cncc(-c2ccc(S(N)(=O)=O)cc2)c1)Cc1c[nH]c2ccccc12		CHEMBL206602	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	Inhibition	%	12.0
	1704927	CHEMBL862612	Inhibition of Akt1 at 50 uM	B	N=C(NO)c1ccc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc1		CHEMBL206390	=	Inhibition	%	48.0	CHEMBL4282	Homo sapiens	Inhibition	%	48.0
	1704928	CHEMBL862612	Inhibition of Akt1 at 50 uM	B	N=C(N)c1ccc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc1		CHEMBL206610	=	Inhibition	%	41.0	CHEMBL4282	Homo sapiens	Inhibition	%	41.0
	1704929	CHEMBL862612	Inhibition of Akt1 at 50 uM	B	N[C@H](COc1cncc(-c2ccc([N+](=O)[O-])cc2)c1)Cc1c[nH]c2ccccc12		CHEMBL205530	=	Inhibition	%	13.0	CHEMBL4282	Homo sapiens	Inhibition	%	13.0
	1704930	CHEMBL862612	Inhibition of Akt1 at 50 uM	B	N[C@H](COc1cncc(-c2ccccc2-c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL380663	=	Inhibition	%	10.0	CHEMBL4282	Homo sapiens	Inhibition	%	10.0
	1704931	CHEMBL862612	Inhibition of Akt1 at 50 uM	B	N[C@H](COc1cncc(NCc2cccnc2)c1)Cc1ccccc1		CHEMBL383658	=	Inhibition	%	41.0	CHEMBL4282	Homo sapiens	Inhibition	%	41.0
	1704932	CHEMBL862612	Inhibition of Akt1 at 50 uM	B	N[C@H](COc1cncc(NCc2ccncc2)c1)Cc1ccccc1		CHEMBL205419	=	Inhibition	%	26.0	CHEMBL4282	Homo sapiens	Inhibition	%	26.0
	1704933	CHEMBL862611	Inhibition of Akt1 at 10 uM ATP	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
	1704948	CHEMBL868840	Activity against GSK3 phosphorylation in FL5.12-Akt1 cells	F	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL383541	=	EC50	nM	10000.0	CHEMBL4282	Homo sapiens	EC50	nM	10000.0
	1704949	CHEMBL868852	Antiproliferative activity against Akt1 overexpressing murine FL5.12-Akt1 cell	F	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL383541	=	IC50	nM	3000.0	CHEMBL4282	Homo sapiens	IC50	nM	3000.0
	1704979	CHEMBL868840	Activity against GSK3 phosphorylation in FL5.12-Akt1 cells	F	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	EC50	nM	460.0	CHEMBL4282	Homo sapiens	EC50	nM	460.0
	1704980	CHEMBL868840	Activity against GSK3 phosphorylation in FL5.12-Akt1 cells	F	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL383264	=	EC50	nM	1500.0	CHEMBL4282	Homo sapiens	EC50	nM	1500.0
	1704981	CHEMBL868852	Antiproliferative activity against Akt1 overexpressing murine FL5.12-Akt1 cell	F	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	290.0	CHEMBL4282	Homo sapiens	IC50	nM	290.0
	1704982	CHEMBL868852	Antiproliferative activity against Akt1 overexpressing murine FL5.12-Akt1 cell	F	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL383264	=	IC50	nM	420.0	CHEMBL4282	Homo sapiens	IC50	nM	420.0
	1722880	CHEMBL860186	Inhibition of AKT1	B	CCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL208637	>	Ki	nM	8200.0	CHEMBL4282	Homo sapiens	Ki	nM	8200.0
	1722897	CHEMBL860186	Inhibition of AKT1	B	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	>	Ki	nM	8200.0	CHEMBL4282	Homo sapiens	Ki	nM	8200.0
	1722898	CHEMBL860186	Inhibition of AKT1	B	CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1		CHEMBL210032	>	Ki	nM	8200.0	CHEMBL4282	Homo sapiens	Ki	nM	8200.0
	1722899	CHEMBL860186	Inhibition of AKT1	B	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	>	Ki	nM	8200.0	CHEMBL4282	Homo sapiens	Ki	nM	8200.0
	1722900	CHEMBL860186	Inhibition of AKT1	B	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	>	Ki	nM	8200.0	CHEMBL4282	Homo sapiens	Ki	nM	8200.0
	1722901	CHEMBL860186	Inhibition of AKT1	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	>	Ki	nM	8200.0	CHEMBL4282	Homo sapiens	Ki	nM	8200.0
	1726410	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL383264	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	1726411	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	Nc1c(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)ccc2cnccc12		CHEMBL380196	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
	1726412	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	Nc1cc2cc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)ccc2cn1		CHEMBL210390	=	IC50	nM	3.4	CHEMBL4282	Homo sapiens	IC50	nM	3.4
	1726413	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnc(C#Cc4ccccc4)cc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL378211	=	IC50	nM	56.0	CHEMBL4282	Homo sapiens	IC50	nM	56.0
	1726414	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	CC#Cc1cc2cc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)ccc2cn1		CHEMBL378714	=	IC50	nM	180.0	CHEMBL4282	Homo sapiens	IC50	nM	180.0
	1726415	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnc(-c4ccncc4)cc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL209564	=	IC50	nM	122.0	CHEMBL4282	Homo sapiens	IC50	nM	122.0
	1726416	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnc(-c4ccccc4)cc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL210544	=	IC50	nM	305.0	CHEMBL4282	Homo sapiens	IC50	nM	305.0
	1726417	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnc(-c4ccco4)cc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL210333	=	IC50	nM	57.0	CHEMBL4282	Homo sapiens	IC50	nM	57.0
	1726418	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	C=Cc1cc2cc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)ccc2cn1		CHEMBL377764	=	IC50	nM	22.0	CHEMBL4282	Homo sapiens	IC50	nM	22.0
	1726419	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	CCc1cc2cc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)ccc2cn1		CHEMBL206924	=	IC50	nM	144.0	CHEMBL4282	Homo sapiens	IC50	nM	144.0
	1726420	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N#Cc1cc2cc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)ccc2cn1		CHEMBL381273	=	IC50	nM	640.0	CHEMBL4282	Homo sapiens	IC50	nM	640.0
	1726421	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnc(Cl)cc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL210783	=	IC50	nM	407.0	CHEMBL4282	Homo sapiens	IC50	nM	407.0
	1726422	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnc(F)cc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL210246	=	IC50	nM	3.5	CHEMBL4282	Homo sapiens	IC50	nM	3.5
	1726423	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	Nc1nccc2cc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)ccc12		CHEMBL208962	=	IC50	nM	160.0	CHEMBL4282	Homo sapiens	IC50	nM	160.0
	1726424	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	COc1nccc2cc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)ccc12		CHEMBL210337	=	IC50	nM	39500.0	CHEMBL4282	Homo sapiens	IC50	nM	39500.0
	1726425	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N[C@H](COc1cncc(-c2ccc3c(Cl)nccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL208014	=	IC50	nM	778.0	CHEMBL4282	Homo sapiens	IC50	nM	778.0
	1726426	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N[C@H](COc1cncc(-c2ccc3c(O)nccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL207215	=	IC50	nM	1240.0	CHEMBL4282	Homo sapiens	IC50	nM	1240.0
	1726427	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N[C@H](COc1cncc(-c2ccc3c(F)nccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL210093	=	IC50	nM	227.0	CHEMBL4282	Homo sapiens	IC50	nM	227.0
	1726428	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N#C/C=C/c1c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cncc1-c1ccc2cnccc2c1		CHEMBL210628	=	IC50	nM	697.0	CHEMBL4282	Homo sapiens	IC50	nM	697.0
	1726429	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	Cc1c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cncc1-c1ccc2cnccc2c1		CHEMBL378116	=	IC50	nM	84.0	CHEMBL4282	Homo sapiens	IC50	nM	84.0
	1726430	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N[C@H](COc1cc(-c2ccc3cnccc3c2)cnc1Cl)Cc1c[nH]c2ccccc12		CHEMBL210089	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
	1726431	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N[C@H](COc1cnc(C#Cc2ccccc2)c(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL207545	=	IC50	nM	1240.0	CHEMBL4282	Homo sapiens	IC50	nM	1240.0
	1726432	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	C#Cc1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2cnccc2c1		CHEMBL207544	=	IC50	nM	0.8	CHEMBL4282	Homo sapiens	IC50	nM	0.8
	1726433	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N[C@H](COc1cnc(-c2ccco2)c(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL378843	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
	1726434	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	C=Cc1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2cnccc2c1		CHEMBL209513	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	1726435	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N#Cc1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2cnccc2c1		CHEMBL379209	=	IC50	nM	4.6	CHEMBL4282	Homo sapiens	IC50	nM	4.6
	1726436	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	N[C@H](COc1cnc(Cl)c(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL378963	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
	1726437	CHEMBL861320	Inhibition of Akt1 at 5 uM ATP	B	Cc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2ccncc12		CHEMBL208961	=	IC50	nM	995.0	CHEMBL4282	Homo sapiens	IC50	nM	995.0
	1726483	CHEMBL861331	Inhibition of GSK3 phosphorylation	F	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL383264	=	IC50	nM	1500.0	CHEMBL4282	Homo sapiens	IC50	uM	1.5
	1726484	CHEMBL861331	Inhibition of GSK3 phosphorylation	F	Nc1cc2cc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)ccc2cn1		CHEMBL210390	=	IC50	nM	930.0	CHEMBL4282	Homo sapiens	IC50	uM	0.93
Not Determined	1726485	CHEMBL861331	Inhibition of GSK3 phosphorylation	F	N[C@H](COc1cncc(-c2ccc3cnc(F)cc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL210246		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	1726486	CHEMBL861331	Inhibition of GSK3 phosphorylation	F	C#Cc1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2cnccc2c1		CHEMBL207544		IC50			CHEMBL4282	Homo sapiens	IC50		
	1726487	CHEMBL861331	Inhibition of GSK3 phosphorylation	F	N[C@H](COc1cnc(Cl)c(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL378963	=	IC50	nM	3000.0	CHEMBL4282	Homo sapiens	IC50	uM	3.0
	1726488	CHEMBL861319	Antiproliferative activity against mouse FL5.12 cells overexpressing Akt1 by MTT assay	F	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL383264	=	IC50	nM	420.0	CHEMBL4282	Homo sapiens	IC50	uM	0.42
	1726489	CHEMBL861319	Antiproliferative activity against mouse FL5.12 cells overexpressing Akt1 by MTT assay	F	Nc1cc2cc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)ccc2cn1		CHEMBL210390	=	IC50	nM	200.0	CHEMBL4282	Homo sapiens	IC50	uM	0.2
	1726490	CHEMBL861319	Antiproliferative activity against mouse FL5.12 cells overexpressing Akt1 by MTT assay	F	N[C@H](COc1cncc(-c2ccc3cnc(F)cc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL210246	=	IC50	nM	2300.0	CHEMBL4282	Homo sapiens	IC50	uM	2.3
	1726491	CHEMBL861319	Antiproliferative activity against mouse FL5.12 cells overexpressing Akt1 by MTT assay	F	C#Cc1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2cnccc2c1		CHEMBL207544	=	IC50	nM	1700.0	CHEMBL4282	Homo sapiens	IC50	uM	1.7
	1726492	CHEMBL861319	Antiproliferative activity against mouse FL5.12 cells overexpressing Akt1 by MTT assay	F	N[C@H](COc1cnc(Cl)c(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL378963	=	IC50	nM	5700.0	CHEMBL4282	Homo sapiens	IC50	uM	5.7
	1733247	CHEMBL867323	Inhibition of GSK3 phosphorylation	F	CC(C)(Cc1ccco1)C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL210954	=	IC50	nM	2500.0	CHEMBL4282	Homo sapiens	IC50	uM	2.5
	1733249	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CC(C)(Cc1ccco1)C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL210954	=	IC50	nM	0.17	CHEMBL4282	Homo sapiens	IC50	nM	0.17
	1733251	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CC(C)(Cc1cccs1)C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL209826	=	IC50	nM	0.9	CHEMBL4282	Homo sapiens	IC50	nM	0.9
	1733255	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CCc1c(C)[nH]c(CC(C)(C)C2C(=O)Nc3ccc(-c4cncc(OC[C@@H](N)Cc5c[nH]c6ccccc56)c4)cc32)c1C		CHEMBL380004	=	IC50	nM	40.3	CHEMBL4282	Homo sapiens	IC50	nM	40.3
	1733266	CHEMBL867323	Inhibition of GSK3 phosphorylation	F	CC(C)(Cc1ncc[nH]1)C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL210209	=	IC50	nM	5000.0	CHEMBL4282	Homo sapiens	IC50	uM	5.0
	1733269	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CC(C)(Cc1ncc[nH]1)C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL210209	=	IC50	nM	7.2	CHEMBL4282	Homo sapiens	IC50	nM	7.2
	1733271	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CC(C)(Cc1c[nH]c2ccccc12)C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL210237	=	IC50	nM	153.0	CHEMBL4282	Homo sapiens	IC50	nM	153.0
	1733273	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CC(C)(Cc1cc[nH]c1)C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL210940	=	IC50	nM	1.2	CHEMBL4282	Homo sapiens	IC50	nM	1.2
	1733274	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	Cc1ccc(CC(C)(C)C2C(=O)Nc3ccc(-c4cncc(OC[C@@H](N)Cc5c[nH]c6ccccc56)c4)cc32)o1		CHEMBL426140	=	IC50	nM	0.7	CHEMBL4282	Homo sapiens	IC50	nM	0.7
	1733276	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	Cc1cc(CC(C)(C)C2C(=O)Nc3ccc(-c4cncc(OC[C@@H](N)Cc5c[nH]c6ccccc56)c4)cc32)oc1C		CHEMBL211065	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
	1733278	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	Cn1cccc1CC(C)(C)C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL379963	=	IC50	nM	8.2	CHEMBL4282	Homo sapiens	IC50	nM	8.2
	1733280	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CC(C)(CC1CCCN1)C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL207139	=	IC50	nM	660.0	CHEMBL4282	Homo sapiens	IC50	nM	660.0
	1733293	CHEMBL867323	Inhibition of GSK3 phosphorylation	F	CC(C)(Cc1ccc[nH]1)C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL377603	=	IC50	nM	900.0	CHEMBL4282	Homo sapiens	IC50	uM	0.9
	1733295	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CC(C)(Cc1ccc[nH]1)C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL377603	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
	1733297	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CC(C)(Cc1ccccn1)C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL211774	=	IC50	nM	10.3	CHEMBL4282	Homo sapiens	IC50	nM	10.3
	1733299	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CC(C)(Cc1cccnc1)C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL211690	=	IC50	nM	10.4	CHEMBL4282	Homo sapiens	IC50	nM	10.4
	1733303	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CC(C)(Cc1ccc(Cl)cc1Cl)C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL438431	=	IC50	nM	352.0	CHEMBL4282	Homo sapiens	IC50	nM	352.0
	1733305	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CC(C)(Cc1ccccc1)C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL210034	=	IC50	nM	5.9	CHEMBL4282	Homo sapiens	IC50	nM	5.9
	1733307	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CC(C)(CC1CC1)C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL378827	=	IC50	nM	3.3	CHEMBL4282	Homo sapiens	IC50	nM	3.3
	1733310	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	O=C1Nc2ccc(N[C@H](COc3cncc(-c4ccc5c(c4)C(F)(F)C(=O)N5)c3)Cc3c[nH]c4ccccc34)cc2C1(F)F		CHEMBL212067	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
	1733314	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CC(C)=C1C(=O)Nc2ccc(N[C@H](COc3cncc(-c4ccc5c(c4)C(=C(C)C)C(=O)N5)c3)Cc3c[nH]c4ccccc34)cc21		CHEMBL211932	=	IC50	nM	52.7	CHEMBL4282	Homo sapiens	IC50	nM	52.7
	1733331	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL383264	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	1733339	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	c1ccc2c(C[C@@H](COc3cncc(-c4cc5cnccc5s4)c3)Nc3cc4cnccc4s3)c[nH]c2c1		CHEMBL211224	=	IC50	nM	488.0	CHEMBL4282	Homo sapiens	IC50	nM	488.0
	1734134	CHEMBL854407	Residual activity at human PKBalpha at 10 uM in presence of 10 uM ATP relative to control	B	O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)o2)S1		CHEMBL379156	=	Activity	%	97.0	CHEMBL4282	Homo sapiens	Activity	%	97.0
	1734720	CHEMBL865417	Inhibition of Akt1	B	COc1cc(C)c(Sc2cnc(NC(=O)c3ccc(CNC(C)C(C)(C)C)cc3)s2)cc1C(=O)N1CCN(C(C)=O)CC1		CHEMBL209148	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	1735153	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	O=C1Nc2ccc(N[C@H](COc3cncc(-c4ccc5c(c4)C(Cc4ccccc4)C(=O)N5)c3)Cc3c[nH]c4ccccc34)cc2C1Cc1ccccc1		CHEMBL209005	=	IC50	nM	1020.0	CHEMBL4282	Homo sapiens	IC50	nM	1020.0
	1735155	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CCC1C(=O)Nc2ccc(N[C@H](COc3cncc(-c4ccc5c(c4)C(CC)C(=O)N5)c3)Cc3c[nH]c4ccccc34)cc21		CHEMBL379576	=	IC50	nM	80.0	CHEMBL4282	Homo sapiens	IC50	nM	80.0
	1735159	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CC1C(=O)Nc2ccc(N[C@H](COc3cncc(-c4ccc5c(c4)C(C)C(=O)N5)c3)Cc3c[nH]c4ccccc34)cc21		CHEMBL208761	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	1735161	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	CC1(C)C(=O)Nc2ccc(N[C@H](COc3cncc(-c4ccc5c(c4)C(C)(C)C(=O)N5)c3)Cc3c[nH]c4ccccc34)cc21		CHEMBL211011	=	IC50	nM	24.6	CHEMBL4282	Homo sapiens	IC50	nM	24.6
	1735163	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	O=S1(=O)Nc2ccc(N[C@H](COc3cncc(-c4ccc5c(c4)NS(=O)(=O)N5)c3)Cc3c[nH]c4ccccc34)cc2N1		CHEMBL378977	=	IC50	nM	15600.0	CHEMBL4282	Homo sapiens	IC50	nM	15600.0
	1735165	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	Oc1nc2ccc(N[C@H](COc3cncc(-c4ccc5nc(O)sc5c4)c3)Cc3c[nH]c4ccccc34)cc2s1		CHEMBL209503	=	IC50	nM	4.3	CHEMBL4282	Homo sapiens	IC50	nM	4.3
	1735167	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	Oc1nc2ccc(N[C@H](COc3cncc(-c4ccc5nc(O)oc5c4)c3)Cc3c[nH]c4ccccc34)cc2o1		CHEMBL209281	=	IC50	nM	7.4	CHEMBL4282	Homo sapiens	IC50	nM	7.4
	1735169	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	N#CCn1c(O)nc2cc(N[C@H](COc3cncc(-c4ccc5c(c4)nc(O)n5CC#N)c3)Cc3c[nH]c4ccccc34)ccc21		CHEMBL263512	=	IC50	nM	20700.0	CHEMBL4282	Homo sapiens	IC50	nM	20700.0
	1735171	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	N#CCn1c(O)nc2ccc(N[C@H](COc3cncc(-c4ccc5nc(O)n(CC#N)c5c4)c3)Cc3c[nH]c4ccccc34)cc21		CHEMBL379342	=	IC50	nM	405.0	CHEMBL4282	Homo sapiens	IC50	nM	405.0
	1735175	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	Oc1nc2cc(N[C@H](COc3cncc(-c4ccc5[nH]c(O)nc5c4)c3)Cc3c[nH]c4ccccc34)ccc2[nH]1		CHEMBL209231	=	IC50	nM	147.0	CHEMBL4282	Homo sapiens	IC50	nM	147.0
	1735181	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	O=Nc1c(O)[nH]c2ccc(N[C@H](COc3cncc(-c4ccc5[nH]c(O)c(N=O)c5c4)c3)Cc3c[nH]c4ccccc34)cc12		CHEMBL376959	=	IC50	nM	6.5	CHEMBL4282	Homo sapiens	IC50	nM	6.5
	1735183	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	O=C1Nc2ccc(N[C@H](COc3cncc(-c4ccc5c(c4)C(=O)C(=O)N5)c3)Cc3c[nH]c4ccccc34)cc2C1=O		CHEMBL377687	=	IC50	nM	179.0	CHEMBL4282	Homo sapiens	IC50	nM	179.0
	1735185	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	O=C1Cc2ccc(N[C@H](COc3cncc(-c4ccc5c(n4)NC(=O)C5)c3)Cc3c[nH]c4ccccc34)nc2N1		CHEMBL211434	=	IC50	nM	99.0	CHEMBL4282	Homo sapiens	IC50	nM	99.0
	1735193	CHEMBL867323	Inhibition of GSK3 phosphorylation	F	O=C1Cc2cc(N[C@H](COc3cncc(-c4ccc5c(c4)CC(=O)N5)c3)Cc3c[nH]c4ccccc34)ccc2N1		CHEMBL212566	=	IC50	nM	1940.0	CHEMBL4282	Homo sapiens	IC50	uM	1.94
	1735195	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	O=C1Cc2cc(N[C@H](COc3cncc(-c4ccc5c(c4)CC(=O)N5)c3)Cc3c[nH]c4ccccc34)ccc2N1		CHEMBL212566	=	IC50	nM	3.2	CHEMBL4282	Homo sapiens	IC50	nM	3.2
	1735198	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	O=C1Cc2ccc(N[C@H](COc3cncc(-c4ccc5c(c4)NC(=O)C5)c3)Cc3c[nH]c4ccccc34)cc2N1		CHEMBL438439	=	IC50	nM	4400.0	CHEMBL4282	Homo sapiens	IC50	nM	4400.0
	1735204	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	c1ccc2c(C[C@@H](COc3cncc(-c4cc5ccncc5s4)c3)Nc3cc4ccncc4s3)c[nH]c2c1		CHEMBL211281	=	IC50	nM	5.4	CHEMBL4282	Homo sapiens	IC50	nM	5.4
	1735206	CHEMBL867323	Inhibition of GSK3 phosphorylation	F	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL383264	=	IC50	nM	1500.0	CHEMBL4282	Homo sapiens	IC50	uM	1.5
	1735217	CHEMBL866644	Inhibition of AKT1 in presence of 5 uM ATP	B	c1ccc2c(C[C@@H](COc3cncc(-c4ccc5nonc5c4)c3)Nc3ccc4nonc4c3)c[nH]c2c1		CHEMBL207217	=	IC50	nM	41.0	CHEMBL4282	Homo sapiens	IC50	nM	41.0
	1739191	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@H](N)Cc4ccccc4)c3)cc12		CHEMBL212157	=	Ki	nM	626.0	CHEMBL4282	Homo sapiens	Ki	nM	626.0
	1739193	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cc1n[nH]c2ccc(-c3cncc(SC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL378759	=	Ki	nM	244.0	CHEMBL4282	Homo sapiens	Ki	nM	244.0
	1739196	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cc1n[nH]c2ccc(-c3cncc(NC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL207338	=	Ki	nM	8.3	CHEMBL4282	Homo sapiens	Ki	nM	8.3
	1739199	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)CCCc4ccccc4)c3)cc12		CHEMBL211186	=	Ki	nM	70.6	CHEMBL4282	Homo sapiens	Ki	nM	70.6
	1739201	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cc1n[nH]c2ccc(-c3cncc(OCCC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL212098	=	Ki	nM	197.0	CHEMBL4282	Homo sapiens	Ki	nM	197.0
	1739203	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cc1n[nH]c2ccc(-c3cncc(OCC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL211084	=	Ki	nM	289.0	CHEMBL4282	Homo sapiens	Ki	nM	289.0
	1739205	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)c4ccccc4)c3)cc12		CHEMBL378870	=	Ki	nM	233.0	CHEMBL4282	Homo sapiens	Ki	nM	233.0
	1739207	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)CC4CCCCC4)c3)cc12		CHEMBL212259	=	Ki	nM	368.0	CHEMBL4282	Homo sapiens	Ki	nM	368.0
	1739210	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccncc4)c3)cc12		CHEMBL208612	=	Ki	nM	3282.0	CHEMBL4282	Homo sapiens	Ki	nM	3282.0
	1739211	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	=	Ki	nM	11.0	CHEMBL4282	Homo sapiens	Ki	nM	11.0
	1739212	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cnc5ccccc5c4)c3)cc12		CHEMBL379868	=	Ki	nM	185.0	CHEMBL4282	Homo sapiens	Ki	nM	185.0
	1739214	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	COc1ccc2ccccc2c1C[C@H](N)COc1cncc(-c2ccc3[nH]nc(C)c3c2)c1		CHEMBL210403	=	Ki	nM	1.1	CHEMBL4282	Homo sapiens	Ki	nM	1.1
	1739215	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc5ccccc45)c3)cc12		CHEMBL210349	=	Ki	nM	8.3	CHEMBL4282	Homo sapiens	Ki	nM	8.3
	1739216	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc5ccccc5c4)c3)cc12		CHEMBL210740	=	Ki	nM	3.2	CHEMBL4282	Homo sapiens	Ki	nM	3.2
	1739218	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4csc5ccccc45)c3)cc12		CHEMBL263510	=	Ki	nM	6.6	CHEMBL4282	Homo sapiens	Ki	nM	6.6
	1739219	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cc1[nH]c2ccccc2c1C[C@H](N)COc1cncc(-c2ccc3[nH]nc(C)c3c2)c1		CHEMBL208790	=	Ki	nM	2.1	CHEMBL4282	Homo sapiens	Ki	nM	2.1
	1739221	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Ki	nM	0.16	CHEMBL4282	Homo sapiens	Ki	nM	0.16
	1739223	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)CC1CCCCC1		CHEMBL209638	=	Ki	nM	672.0	CHEMBL4282	Homo sapiens	Ki	nM	672.0
	1739225	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)c1ccccc1		CHEMBL207373	=	Ki	nM	465.0	CHEMBL4282	Homo sapiens	Ki	nM	465.0
	1739227	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1ccncc1		CHEMBL209358	=	Ki	nM	1525.0	CHEMBL4282	Homo sapiens	Ki	nM	1525.0
	1739228	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1ccccc1		CHEMBL210020	=	Ki	nM	89.6	CHEMBL4282	Homo sapiens	Ki	nM	89.6
	1739229	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1cnc2ccccc2c1		CHEMBL437122	=	Ki	nM	85.0	CHEMBL4282	Homo sapiens	Ki	nM	85.0
	1739230	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1ccc2ccccc2c1		CHEMBL211018	=	Ki	nM	3.5	CHEMBL4282	Homo sapiens	Ki	nM	3.5
	1739233	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1csc2ccccc12		CHEMBL211865	=	Ki	nM	63.7	CHEMBL4282	Homo sapiens	Ki	nM	63.7
	1739235	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1n[nH]c2ccccc12		CHEMBL211827	=	Ki	nM	6.8	CHEMBL4282	Homo sapiens	Ki	nM	6.8
	1739236	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	Cn1cc(C[C@H](N)COc2cncc(-c3ccc4cnccc4c3)c2)c2ccccc21		CHEMBL208606	=	Ki	nM	54.6	CHEMBL4282	Homo sapiens	Ki	nM	54.6
	1739253	CHEMBL864940	Inhibition of Akt1 in presence of 10 uM ATP	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL383264	=	Ki	nM	2.0	CHEMBL4282	Homo sapiens	Ki	nM	2.0
	1744523	CHEMBL865385	Inhibition of AKT1	B	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	>	Ki	nM	8200.0	CHEMBL4282	Homo sapiens	Ki	uM	8.2
	1746711	CHEMBL853526	Inhibition of Akt by fluorescence polarization assay	B	O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12		CHEMBL44	>	IC50	nM	70000.0	CHEMBL4282	Homo sapiens	IC50	uM	70.0
	1751548	CHEMBL869145	Inhibition of PKBalpha	B	CC(C)c1nnc2ccc(-c3ocnc3-c3ccc(F)cc3Cl)cn12		CHEMBL215652	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	1751549	CHEMBL869145	Inhibition of PKBalpha	B	CC(C)c1nnc2ccc(-c3ocnc3-c3cc(F)c(F)cc3F)cn12		CHEMBL213423	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	1751550	CHEMBL869145	Inhibition of PKBalpha	B	CCNc1nnc2ccc(-c3ocnc3-c3ccc(F)cc3)cn12		CHEMBL213451	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	1751551	CHEMBL869145	Inhibition of PKBalpha	B	CC(C)(C)c1nnc2ccc(-c3ocnc3-c3ccc(F)cc3F)cn12		CHEMBL212382	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	1751552	CHEMBL869145	Inhibition of PKBalpha	B	CC(C)(C)c1nnc2ccc(-c3ocnc3-c3cc(F)c(F)cc3F)cn12		CHEMBL212968	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	1751553	CHEMBL869145	Inhibition of PKBalpha	B	CC(C)c1nnc2ccc(-c3c[nH]nc3-c3cc(F)ccc3F)cn12		CHEMBL214198	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	1751651	CHEMBL869145	Inhibition of PKBalpha	B	CC(C)c1nnc2ccc(-c3ocnc3-c3ccccc3)cn12		CHEMBL379929	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	1755319	CHEMBL868045	Inhibition of AKT1	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
	1755340	CHEMBL868045	Inhibition of AKT1	B	CNc1nccc(-c2ccc(C(=O)N[C@H](CN)Cc3ccc(Cl)cc3Cl)s2)n1		CHEMBL213618	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	1765523	CHEMBL871549	Inhibition of PKBalpha by HTRF kinase assay	B	CNc1ncc2cc(-c3cc(C(=O)Nc4cc(C(F)(F)F)ccc4OC4CCN(C)CC4)ccc3C)ccc2n1		CHEMBL386661	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	1765531	CHEMBL871549	Inhibition of PKBalpha by HTRF kinase assay	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2nc(NCCN3CCOCC3)ncc2c1		CHEMBL215943	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	1769425	CHEMBL910939	Inhibition of PKBalpha	B	C[C@@H]1C[C@H]2CN1CCn1nc3c(cccc3c1O)-c1nc3c(cccc3nc1O)O2		CHEMBL215803	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	uM	1.0
	1780423	CHEMBL911813	Activity of PKBalpha at 10 uM	B	Nc1n[nH]c(N)c1/N=N/c1ccc(O)cc1		CHEMBL215205	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	Inhibition	%	100.0
	1782055	CHEMBL913517	Inhibition of AKT1	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	1790035	CHEMBL854703	Percentage activity of human PKB alpha in the presence of 10 uM of compound and 10 uM of ATP in comparison with control	B	O=C(NCc1ccc(S(=O)(=O)N2CCC(n3nnc4ccccc43)CC2)s1)c1ccc(Cl)cc1		CHEMBL383955	=	Activity	%	51.0	CHEMBL4282	Homo sapiens	Activity	%	51.0
	1790343	CHEMBL873780	Percent residual activity, relative to control, of PKB alpha (no ph) at 1 uM concentration of inhibitor in presence of 5 uM ATP	B	N=C(N)NCCC[C@@H](NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)NC(=O)CCCCCNCCNS(=O)(=O)c1cccc2cnccc12		CHEMBL413460	=	Activity	%	2.0	CHEMBL4282	Homo sapiens	Activity	%	2.0
	1790397	CHEMBL873780	Percent residual activity, relative to control, of PKB alpha (no ph) at 1 uM concentration of inhibitor in presence of 5 uM ATP	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL279185	=	Activity	%	2.0	CHEMBL4282	Homo sapiens	Activity	%	2.0
	1790439	CHEMBL912727	Inhibition of human AKT1	B	COc1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)cc(OC)c1OC		CHEMBL201511	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	M	0.0001
	1800141	CHEMBL911091	Inhibition of AKT	B	COc1cc(Nc2c(C#N)cnc3cc(-c4coc(CN5CCN(C)CC5)c4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL219557	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	uM	1.0
	1811589	CHEMBL908452	Inhibition of Akt1 activity assessed as decrease in GSK3 phosphorylation	F	O=C1C(Nc2ccccc2F)=C(Cl)C(=O)c2[nH]ncc21		CHEMBL220006	=	IC50	nM	15800.0	CHEMBL4282	Homo sapiens	IC50	uM	15.8
	1811590	CHEMBL908452	Inhibition of Akt1 activity assessed as decrease in GSK3 phosphorylation	F	O=C1C(Sc2ccc(Cl)c(Cl)c2)=C(Cl)C(=O)c2[nH]ncc21		CHEMBL221064	=	IC50	nM	12300.0	CHEMBL4282	Homo sapiens	IC50	uM	12.3
	1811591	CHEMBL908452	Inhibition of Akt1 activity assessed as decrease in GSK3 phosphorylation	F	O=C1C(Nc2cccc(Br)c2)=C(Cl)C(=O)c2[nH]ncc21		CHEMBL374701	=	IC50	nM	13900.0	CHEMBL4282	Homo sapiens	IC50	uM	13.9
	1811592	CHEMBL908452	Inhibition of Akt1 activity assessed as decrease in GSK3 phosphorylation	F	O=C1C(Nc2ccc(C(F)(F)F)cc2)=C(Cl)C(=O)c2[nH]ncc21		CHEMBL222254	=	IC50	nM	12400.0	CHEMBL4282	Homo sapiens	IC50	uM	12.4
	1811593	CHEMBL908452	Inhibition of Akt1 activity assessed as decrease in GSK3 phosphorylation	F	CCOc1ccc(NC2=C(Cl)C(=O)c3[nH]ncc3C2=O)cc1		CHEMBL375985	=	IC50	nM	4900.0	CHEMBL4282	Homo sapiens	IC50	uM	4.9
	1811594	CHEMBL908452	Inhibition of Akt1 activity assessed as decrease in GSK3 phosphorylation	F	O=C1C(Nc2ccc(F)cc2F)=C(Cl)C(=O)c2[nH]ncc21		CHEMBL223314	=	IC50	nM	16000.0	CHEMBL4282	Homo sapiens	IC50	uM	16.0
	1811595	CHEMBL908452	Inhibition of Akt1 activity assessed as decrease in GSK3 phosphorylation	F	O=C1C(Nc2cccc(F)c2)=C(Cl)C(=O)c2[nH]ncc21		CHEMBL375142	=	IC50	nM	11800.0	CHEMBL4282	Homo sapiens	IC50	uM	11.8
	1811596	CHEMBL908452	Inhibition of Akt1 activity assessed as decrease in GSK3 phosphorylation	F	O=C1C(Nc2ccc(F)cc2)=C(Cl)C(=O)c2[nH]ncc21		CHEMBL223410	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	1811597	CHEMBL908452	Inhibition of Akt1 activity assessed as decrease in GSK3 phosphorylation	F	Nc1ccc(N)c2[nH]ncc12		CHEMBL376871	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	1811598	CHEMBL908452	Inhibition of Akt1 activity assessed as decrease in GSK3 phosphorylation	F	Cc1cc(C)cc(SC2=C(Cl)C(=O)c3[nH]ncc3C2=O)c1		CHEMBL221222	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	1811599	CHEMBL908452	Inhibition of Akt1 activity assessed as decrease in GSK3 phosphorylation	F	O=C1C(Nc2cc(F)cc(F)c2)=C(Cl)C(=O)c2[nH]ncc21		CHEMBL223464	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	1811640	CHEMBL908452	Inhibition of Akt1 activity assessed as decrease in GSK3 phosphorylation	F	COC(=O)C1=C(C(=O)OC)C(=S)C2SC(=S)SC2C1=S		CHEMBL220290	=	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	1815187	CHEMBL910143	Inhibition of PKBalpha	B	CNc1ncnc(-c2cccnc2Oc2ccc(F)c(C(=O)Nc3cc(C(F)(F)F)ccc3N(C)CCCN(C)C)c2)n1		CHEMBL373882	=	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
	1824479	CHEMBL913835	Inhibition of Akt1	B	CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2		CHEMBL223460	>	Ki	nM	10000.0	CHEMBL4282	Homo sapiens	Ki	uM	10.0
	1824616	CHEMBL913835	Inhibition of Akt1	B	N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2		CHEMBL223367	=	Ki	nM	3150.0	CHEMBL4282	Homo sapiens	Ki	uM	3.15
	1824690	CHEMBL913835	Inhibition of Akt1	B	N#Cc1ncc2nc1OCCCCCOc1cc(OCCCO)c(Cl)cc1NC(=O)N2		CHEMBL373598	=	Ki	nM	1070.0	CHEMBL4282	Homo sapiens	Ki	uM	1.07
	1826443	CHEMBL919919	Inhibition of AKT using 5 to 10 ATP umol/L	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	=	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	nM	50000.0
	1837967	CHEMBL920462	Inhibition of PKBalpha at 10 uM relative to control	B	Brc1c(Br)c(Br)c2[nH]nnc2c1Br		CHEMBL177820	=	Inhibition	%	91.0	CHEMBL4282	Homo sapiens	Inhibition	%	91.0
	1837979	CHEMBL920462	Inhibition of PKBalpha at 10 uM relative to control	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL376505	=	Inhibition	%	96.0	CHEMBL4282	Homo sapiens	Inhibition	%	96.0
	1874451	CHEMBL903964	Inhibition of Akt1	B	N[C@H](COc1cncc(-c2ccc3[nH]ncc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL374805	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
	1874454	CHEMBL903964	Inhibition of Akt1	B	N[C@H](COc1cncc(-c2cc3c(-c4ccccc4)n[nH]c3cn2)c1)Cc1ccccc1		CHEMBL226383	=	IC50	nM	8.3	CHEMBL4282	Homo sapiens	IC50	nM	8.3
	1874455	CHEMBL903964	Inhibition of Akt1	B	Cn1cccc1-c1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL375486	=	IC50	nM	228.0	CHEMBL4282	Homo sapiens	IC50	nM	228.0
	1874456	CHEMBL903964	Inhibition of Akt1	B	N[C@H](COc1cncc(-c2cc3c(-c4ccco4)n[nH]c3cn2)c1)Cc1ccccc1		CHEMBL375485	=	IC50	nM	6.1	CHEMBL4282	Homo sapiens	IC50	nM	6.1
	1874457	CHEMBL903964	Inhibition of Akt1	B	C=Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL226382	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
	1874458	CHEMBL903964	Inhibition of Akt1	B	Cc1n[nH]c2c[n+]([O-])c(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL226381	=	IC50	nM	104.0	CHEMBL4282	Homo sapiens	IC50	nM	104.0
	1874459	CHEMBL903964	Inhibition of Akt1	B	N[C@H](COc1cncc(-c2cc3c(Cl)n[nH]c3cn2)c1)Cc1ccccc1		CHEMBL226332	=	IC50	nM	59.0	CHEMBL4282	Homo sapiens	IC50	nM	59.0
	1874460	CHEMBL903964	Inhibition of Akt1	B	Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL376570	=	IC50	nM	25.0	CHEMBL4282	Homo sapiens	IC50	nM	25.0
	1874461	CHEMBL903964	Inhibition of Akt1	B	N[C@H](COc1cncc(-c2cc3cn[nH]c3cn2)c1)Cc1ccccc1		CHEMBL226331	=	IC50	nM	223.0	CHEMBL4282	Homo sapiens	IC50	nM	223.0
	1874462	CHEMBL903964	Inhibition of Akt1	B	Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL376569	=	IC50	nM	0.34	CHEMBL4282	Homo sapiens	IC50	nM	0.34
	1874463	CHEMBL903964	Inhibition of Akt1	B	N[C@H](COc1cncc(-c2cc3cn[nH]c3cn2)c1)Cc1c[nH]c2ccccc12		CHEMBL226330	=	IC50	nM	0.6	CHEMBL4282	Homo sapiens	IC50	nM	0.6
	1874464	CHEMBL903964	Inhibition of Akt1	B	Nc1cc2[nH]nc(Cl)c2cc1-c1cncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)c1		CHEMBL225789	=	IC50	nM	7.1	CHEMBL4282	Homo sapiens	IC50	nM	7.1
	1874465	CHEMBL903964	Inhibition of Akt1	B	Nc1cc2[nH]ncc2cc1-c1cncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)c1		CHEMBL388729	=	IC50	nM	51.0	CHEMBL4282	Homo sapiens	IC50	nM	51.0
	1874466	CHEMBL903964	Inhibition of Akt1	B	N[C@H](COc1cncc(-c2cc3cn[nH]c3cc2[N+](=O)[O-])c1)Cc1c[nH]c2ccccc12		CHEMBL225788	=	IC50	nM	953.0	CHEMBL4282	Homo sapiens	IC50	nM	953.0
	1874467	CHEMBL903964	Inhibition of Akt1	B	N[C@H](COc1cncc(-c2ccc3[nH]nc(C(F)(F)F)c3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL374808	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
	1874468	CHEMBL903964	Inhibition of Akt1	B	N[C@H](COc1cncc(-c2ccc3[nH]nc(Cl)c3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL226148	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	1891149	CHEMBL905889	Inhibition at AKT1	B	NC(=O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1		CHEMBL242237	=	IC50	nM	15000.0	CHEMBL4282	Homo sapiens	IC50	uM	15.0
	1900590	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
	1900592	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc(OCCN)c4)c3)cc12		CHEMBL226798	=	IC50	nM	47.0	CHEMBL4282	Homo sapiens	IC50	nM	47.0
	1900593	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc(OCC5CCN(C)CC5)c4)c3)cc12		CHEMBL226797	=	IC50	nM	78.0	CHEMBL4282	Homo sapiens	IC50	nM	78.0
	1900594	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc(OCC5CCCCC5)c4)c3)cc12		CHEMBL226796	=	IC50	nM	1360.0	CHEMBL4282	Homo sapiens	IC50	nM	1360.0
	1900595	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc(OCC5CCNCC5)c4)c3)cc12		CHEMBL226745	=	IC50	nM	6.8	CHEMBL4282	Homo sapiens	IC50	nM	6.8
	1900596	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc(OCCC5CCNCC5)c4)c3)cc12		CHEMBL388310	=	IC50	nM	290.0	CHEMBL4282	Homo sapiens	IC50	nM	290.0
	1900597	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc(OCCN5CCOCC5)c4)c3)cc12		CHEMBL415220	=	IC50	nM	751.0	CHEMBL4282	Homo sapiens	IC50	nM	751.0
	1900598	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc5c(c4)OC(F)(F)C(F)(F)O5)c3)cc12		CHEMBL226744	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
	1900599	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc5c4OC(F)(F)O5)c3)cc12		CHEMBL227326	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
	1900600	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc5c(c4)OCO5)c3)cc12		CHEMBL227325	=	IC50	nM	42.0	CHEMBL4282	Homo sapiens	IC50	nM	42.0
	1900601	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc(-c5ccccc5)c4)c3)cc12		CHEMBL389468	=	IC50	nM	126.0	CHEMBL4282	Homo sapiens	IC50	nM	126.0
	1900602	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc(OC(F)(F)F)cc4)c3)cc12		CHEMBL227324	=	IC50	nM	20.3	CHEMBL4282	Homo sapiens	IC50	nM	20.3
	1900603	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc(OC(F)(F)F)c4)c3)cc12		CHEMBL227271	=	IC50	nM	3.3	CHEMBL4282	Homo sapiens	IC50	nM	3.3
	1900604	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4OC(F)(F)F)c3)cc12		CHEMBL226529	=	IC50	nM	15.3	CHEMBL4282	Homo sapiens	IC50	nM	15.3
	1900605	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc(C(F)(F)F)cc4F)c3)cc12		CHEMBL227323	=	IC50	nM	12.1	CHEMBL4282	Homo sapiens	IC50	nM	12.1
	1900606	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc(C(F)(F)F)c(F)c4)c3)cc12		CHEMBL375717	=	IC50	nM	3.1	CHEMBL4282	Homo sapiens	IC50	nM	3.1
	1900607	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cc(C(F)(F)F)ccc4F)c3)cc12		CHEMBL227322	=	IC50	nM	1.2	CHEMBL4282	Homo sapiens	IC50	nM	1.2
	1900608	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cc(F)cc(C(F)(F)F)c4)c3)cc12		CHEMBL375716	=	IC50	nM	13.3	CHEMBL4282	Homo sapiens	IC50	nM	13.3
	1900609	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc(F)c(C(F)(F)F)c4)c3)cc12		CHEMBL226627	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
	1900610	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cc(C(F)(F)F)cc(C(F)(F)F)c4)c3)cc12		CHEMBL226626	=	IC50	nM	57.0	CHEMBL4282	Homo sapiens	IC50	nM	57.0
	1900611	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)c3)cc12		CHEMBL389438	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
	1900612	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc(C(F)(F)F)c4)c3)cc12		CHEMBL226625	=	IC50	nM	1.2	CHEMBL4282	Homo sapiens	IC50	nM	1.2
	1900613	CHEMBL889241	Inhibition of human Akt1	B	COc1ccc(F)cc1C[C@H](N)COc1cncc(-c2ccc3[nH]nc(C)c3c2)c1		CHEMBL226577	=	IC50	nM	7.7	CHEMBL4282	Homo sapiens	IC50	nM	7.7
	1900614	CHEMBL889241	Inhibition of human Akt1	B	Cc1cc(C)c(C[C@H](N)COc2cncc(-c3ccc4[nH]nc(C)c4c3)c2)c(C)c1		CHEMBL227051	=	IC50	nM	39.0	CHEMBL4282	Homo sapiens	IC50	nM	39.0
	1900615	CHEMBL889241	Inhibition of human Akt1	B	Cc1ccc(C[C@H](N)COc2cncc(-c3ccc4[nH]nc(C)c4c3)c2)cc1F		CHEMBL227050	=	IC50	nM	2.4	CHEMBL4282	Homo sapiens	IC50	nM	2.4
	1900616	CHEMBL889241	Inhibition of human Akt1	B	Cc1cc(F)ccc1C[C@H](N)COc1cncc(-c2ccc3[nH]nc(C)c3c2)c1		CHEMBL376394	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	1900617	CHEMBL889241	Inhibition of human Akt1	B	Cc1cc(C[C@H](N)COc2cncc(-c3ccc4[nH]nc(C)c4c3)c2)ccc1F		CHEMBL427426	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
	1900618	CHEMBL889241	Inhibition of human Akt1	B	Cc1cc(C[C@H](N)COc2cncc(-c3ccc4[nH]nc(C)c4c3)c2)ccc1Br		CHEMBL226996	=	IC50	nM	2.5	CHEMBL4282	Homo sapiens	IC50	nM	2.5
	1900619	CHEMBL889241	Inhibition of human Akt1	B	Cc1ccc(F)cc1C[C@H](N)COc1cncc(-c2ccc3[nH]nc(C)c3c2)c1		CHEMBL227368	=	IC50	nM	3.9	CHEMBL4282	Homo sapiens	IC50	nM	3.9
	1900620	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c(F)cc(F)cc4Br)c3)cc12		CHEMBL376792	=	IC50	nM	49.0	CHEMBL4282	Homo sapiens	IC50	nM	49.0
	1900621	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc(Br)c(F)c4)c3)cc12		CHEMBL227367	=	IC50	nM	1.3	CHEMBL4282	Homo sapiens	IC50	nM	1.3
	1900622	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc(Br)cc4F)c3)cc12		CHEMBL227366	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
	1900623	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cc(Cl)cc(Cl)c4)c3)cc12		CHEMBL376118	=	IC50	nM	20.7	CHEMBL4282	Homo sapiens	IC50	nM	20.7
	1900624	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc(Cl)c(Cl)c4)c3)cc12		CHEMBL229968	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
	1900625	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc(Cl)c4Cl)c3)cc12		CHEMBL229918	=	IC50	nM	5.6	CHEMBL4282	Homo sapiens	IC50	nM	5.6
	1900626	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc(Cl)c(F)c4)c3)cc12		CHEMBL229917	=	IC50	nM	3.6	CHEMBL4282	Homo sapiens	IC50	nM	3.6
	1900627	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc(F)c(Cl)c4)c3)cc12		CHEMBL375919	=	IC50	nM	3.1	CHEMBL4282	Homo sapiens	IC50	nM	3.1
	1900628	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc(I)c4)c3)cc12		CHEMBL229320	=	IC50	nM	0.9	CHEMBL4282	Homo sapiens	IC50	nM	0.9
	1900629	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc(Br)cc4)c3)cc12		CHEMBL229855	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	1900630	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc(Br)c4)c3)cc12		CHEMBL390372	=	IC50	nM	2.1	CHEMBL4282	Homo sapiens	IC50	nM	2.1
	1900631	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4Br)c3)cc12		CHEMBL229854	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	nM	23.0
	1900632	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc(Cl)cc4)c3)cc12		CHEMBL229800	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
	1900633	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc(Cl)c4)c3)cc12		CHEMBL229799	=	IC50	nM	5.9	CHEMBL4282	Homo sapiens	IC50	nM	5.9
	1900634	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4Cl)c3)cc12		CHEMBL390371	=	IC50	nM	29.0	CHEMBL4282	Homo sapiens	IC50	nM	29.0
	1900635	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c(F)cc(F)cc4F)c3)cc12		CHEMBL388809	=	IC50	nM	31.0	CHEMBL4282	Homo sapiens	IC50	nM	31.0
	1900636	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc(F)c(F)c4F)c3)cc12		CHEMBL229798	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
	1900637	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c(F)cccc4F)c3)cc12		CHEMBL229748	=	IC50	nM	65.5	CHEMBL4282	Homo sapiens	IC50	nM	65.5
	1900638	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccc(F)cc4F)c3)cc12		CHEMBL229315	=	IC50	nM	21.0	CHEMBL4282	Homo sapiens	IC50	nM	21.0
	1900639	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc(F)c4F)c3)cc12		CHEMBL438483	=	IC50	nM	8.5	CHEMBL4282	Homo sapiens	IC50	nM	8.5
	1900640	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4cccc(F)c4)c3)cc12		CHEMBL229314	=	IC50	nM	8.4	CHEMBL4282	Homo sapiens	IC50	nM	8.4
	1900690	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	IC50	nM	0.16	CHEMBL4282	Homo sapiens	IC50	nM	0.16
	1900693	CHEMBL889241	Inhibition of human Akt1	B	N[C@H](COc1cncc(-c2ccc3c(c2)/C(=C\c2ccco2)C(=O)N3)c1)Cc1ccccc1		CHEMBL226849	=	IC50	nM	1.4	CHEMBL4282	Homo sapiens	IC50	nM	1.4
	1900694	CHEMBL889241	Inhibition of human Akt1	B	N[C@H](COc1cncc(-c2ccc3c(c2)/C(=C/c2ccc[nH]2)C(=O)N3)c1)Cc1ccccc1		CHEMBL388311	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
	1900695	CHEMBL889241	Inhibition of human Akt1	B	N[C@H](COc1cncc(-c2ccc3c(c2)CC(=O)N3)c1)Cc1ccccc1		CHEMBL226848	=	IC50	nM	2650.0	CHEMBL4282	Homo sapiens	IC50	nM	2650.0
	1900698	CHEMBL889241	Inhibition of human Akt1	B	N[C@H](COc1cncc(-c2cc3cn[nH]c3cn2)c1)Cc1cccc(C(F)(F)F)c1		CHEMBL226850	=	IC50	nM	7.2	CHEMBL4282	Homo sapiens	IC50	nM	7.2
	1900711	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4cccc(F)c4F)c3)cc12		CHEMBL427422	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	1900712	CHEMBL889241	Inhibition of human Akt1	B	Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4cccc(C(F)(F)F)c4)c3)cc12		CHEMBL226898	=	IC50	nM	0.6	CHEMBL4282	Homo sapiens	IC50	nM	0.6
	1900713	CHEMBL889241	Inhibition of human Akt1	B	N[C@H](COc1cncc(-c2cc3c(Cl)n[nH]c3cn2)c1)Cc1cccc(C(F)(F)F)c1		CHEMBL388312	=	IC50	nM	2.9	CHEMBL4282	Homo sapiens	IC50	nM	2.9
Not Active	1910493	CHEMBL890526	Inhibition of Akt1	B	CCOC(=O)c1ccc2[nH]c3c(OC)c4[nH]c5ccc(C(=O)OCC)cc5c4cc3c2c1		CHEMBL245030		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	1912273	CHEMBL889652	Inhibition of IL8-induced Akt phosphorylation in human neutrophils at 0.06 uM	B	CCOC(=O)c1cnn(CC(O)c2ccccc2)c1NC(=O)NC(C)C		CHEMBL450013		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	1912276	CHEMBL889653	Inhibition of IL8-induced Akt phosphorylation in human neutrophils at 0.01 uM	B	CCOC(=O)c1cnn(CC(O)c2ccccc2)c1NC(=O)NCc1ccccc1		CHEMBL226836		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	1912277	CHEMBL889654	Inhibition of IL8-induced Akt phosphorylation in human neutrophils at 0.05 uM	B	CCOC(=O)c1cnn(CC(O)c2ccccc2)c1NC(=O)Nc1ccccc1		CHEMBL226939		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	1912295	CHEMBL889672	Binding affinity to Akt1	B	CCOC(=O)c1cnn(CC(O)c2ccccc2)c1NC(=O)NC(C)C		CHEMBL450013		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	1912318	CHEMBL889672	Binding affinity to Akt1	B	CCOC(=O)c1cnn(CC(O)c2ccccc2)c1NC(=O)Nc1ccccc1		CHEMBL226939		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	1912319	CHEMBL889672	Binding affinity to Akt1	B	CCOC(=O)c1cnn(CC(O)c2ccccc2)c1NC(=O)NCc1ccccc1		CHEMBL226836		Activity			CHEMBL4282	Homo sapiens	Activity		
	1916297	CHEMBL894158	Inhibition of recombinant Akt1 by radiometric assay	B	COc1cc(-c2ccc3c(c2)Nc2ccc(CC(=O)Nc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1N		CHEMBL395080	=	IC50	nM	880.0	CHEMBL4282	Homo sapiens	IC50	uM	0.88
	1916355	CHEMBL894158	Inhibition of recombinant Akt1 by radiometric assay	B	COc1cc(-c2ccc3c(c2)Nc2ccc(C(C)(C)C(=O)Nc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1N		CHEMBL389745	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	1917485	CHEMBL895139	Inhibition of PKBalpha at 1 uM	B	O=c1ccc(=O)c2c1c1[nH]c3ccc(O)cc3c1c1c(=O)[nH]c(=O)c21		CHEMBL243931	=	Inhibition	%	87.0	CHEMBL4282	Homo sapiens	Inhibition	%	87.0
	1917506	CHEMBL895139	Inhibition of PKBalpha at 1 uM	B	Cc1ccc2[nH]c3c4c(O)ccc(O)c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL244141	=	Inhibition	%	87.0	CHEMBL4282	Homo sapiens	Inhibition	%	87.0
Dose-dependent effect	1933356	CHEMBL895766	Inhibition of FGF-induced AKT phosphorylation in HUVEC cells by Western blot at 10 uM	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011		Activity			CHEMBL4282	Homo sapiens	Activity		
	1966320	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1ccccn1		CHEMBL232800	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966764	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)c1nnnn1CCc1ccncc1		CHEMBL233829	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966765	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	CC(C)(C)c1ccc(NC(=O)c2nnnn2CCc2ccncc2)cc1		CHEMBL233828	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966766	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1nnnn1CCc1ccncc1		CHEMBL233827	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966767	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(C(F)(F)F)cc1)c1nnnn1CCc1ccncc1		CHEMBL234205	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966768	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(Cl)cc1)c1nnnn1CCc1ccncc1		CHEMBL393001	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966769	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)c1nc2ccccc2n1CCc1ccncc1		CHEMBL234013	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966770	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1nc2ccccc2n1CCc1ccncc1		CHEMBL234012	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966771	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(Cl)cc1)c1nc2ccccc2n1CCc1ccncc1		CHEMBL233826	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966772	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)c1nccn1CCc1ccncc1		CHEMBL233825	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966773	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	CC(C)(C)c1ccc(NC(=O)c2nccn2CCc2ccncc2)cc1		CHEMBL233824	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966774	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1nccn1CCc1ccncc1		CHEMBL391104	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966775	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(C(F)(F)F)cc1)c1nccn1CCc1ccncc1		CHEMBL234203	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966776	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(Cl)cc1)c1nccn1CCc1ccncc1		CHEMBL234202	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966777	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1cc2ccccc2n1CCc1ccncc1		CHEMBL391103	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966778	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(Cl)cc1)c1cc2ccccc2n1CCc1ccncc1		CHEMBL234201	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966779	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	Cc1nn(CCc2ccncc2)c(C(=O)Nc2ccc(OC(F)(F)F)cc2)c1C		CHEMBL234011	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966780	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	Cc1nn(CCc2ccncc2)c(C(=O)Nc2ccc(Cl)cc2)c1C		CHEMBL391102	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966781	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	Cc1cc(C(=O)Nc2ccc(OC(F)(F)F)cc2)n(CCc2ccncc2)n1		CHEMBL392331	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966782	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	Cc1cc(C(=O)Nc2ccc(Cl)cc2)n(CCc2ccncc2)n1		CHEMBL234010	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966783	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	COc1ccc(NC(=O)c2ccnn2CCc2ccncc2)cc1OC		CHEMBL234009	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966784	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(Cl)c(Cl)c1)c1ccnn1CCc1ccncc1		CHEMBL392330	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966785	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)c1ccnn1CCc1ccncc1		CHEMBL233823	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966786	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)c1ccnn1CCc1ccncc1		CHEMBL233822	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966787	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc2cn[nH]c2c1)c1ccnn1CCc1ccncc1		CHEMBL392329	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966788	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc2[nH]ncc2c1)c1ccnn1CCc1ccncc1		CHEMBL233821	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966789	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1cnc2ccccc2c1)c1ccnn1CCc1ccncc1		CHEMBL391069	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966790	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(OCc2ccccc2)cc1)c1ccnn1CCc1ccncc1		CHEMBL233631	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966791	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(Oc2ccccc2)cc1)c1ccnn1CCc1ccncc1		CHEMBL392313	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966792	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(-c2ccccc2)cc1)c1ccnn1CCc1ccncc1		CHEMBL399606	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966793	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	CC(C)c1ccc(NC(=O)c2ccnn2CCc2ccncc2)cc1		CHEMBL236420	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966794	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	CC(C)(C)c1ccc(NC(=O)c2ccnn2CCc2ccncc2)cc1		CHEMBL399605	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966795	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1cccc(OC(F)(F)Cl)c1)c1ccnn1CCc1ccncc1		CHEMBL236419	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966796	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1cccc(OC(F)(F)F)c1)c1ccnn1CCc1ccncc1		CHEMBL236206	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966797	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1ccnn1CCc1ccncc1		CHEMBL236205	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966798	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	CCc1ccc(NC(=O)c2ccnn2CCc2ccncc2)cc1		CHEMBL392935	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966799	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(C(F)(F)F)cc1)c1ccnn1CCc1ccncc1		CHEMBL392934	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966800	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1c[nH]cn1		CHEMBL237680	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966801	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1noc2ccccc12		CHEMBL237679	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966802	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1cnoc1		CHEMBL232802	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966803	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	COc1ccc(CCn2nccc2C(=O)Nc2ccc(Cl)cc2)cc1OC		CHEMBL234864	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966804	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1ccc(F)c(F)c1		CHEMBL393006	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966805	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	CC1C=C2OCOC2=C(CCn2nccc2C(=O)Nc2ccc(Cl)cc2)C1		CHEMBL234863	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966806	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1ccncc1		CHEMBL397323	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1966807	CHEMBL897520	Inhibition of PKB/Akt at 10 uM	B	O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1cccnc1		CHEMBL397322	>	Activity	%	30.0	CHEMBL4282	Homo sapiens	Activity	%	30.0
	1969470	CHEMBL896554	Inhibition of cAKT	B	O=C1Nc2ccccc2/C1=C/c1ccc[nH]1		CHEMBL86755	=	IC50	nM	2300.0	CHEMBL4282	Homo sapiens	IC50	uM	2.3
	1969472	CHEMBL896556	Inhibition of Akt phosphorylation in PC3 cells	B	O=C1Nc2ccccc2/C1=C/c1ccc[nH]1		CHEMBL86755	=	IC50	nM	3000.0	CHEMBL4282	Homo sapiens	IC50	uM	3.0
	1969512	CHEMBL896556	Inhibition of Akt phosphorylation in PC3 cells	B	C/C(=C1/C(=O)Nc2ccc(NC(N)=O)cc21)c1ccc[nH]1		CHEMBL228654	=	IC50	nM	100.0	CHEMBL4282	Homo sapiens	IC50	nM	100.0
	1970871	CHEMBL896715	Inhibition of AKT at 10 uM	B	N=C1NC(=O)/C(=C/c2ccc(-c3ccc(S(N)(=O)=O)cc3)o2)S1		CHEMBL233149	=	Inhibition	%	54.0	CHEMBL4282	Homo sapiens	Inhibition	%	54.0
	1981746	CHEMBL899261	Inhibition of PKBalpha assessed as residual activity at 0.01 uM	B	N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H]1C[C@@H](O)[C@H](n2cnc3c(N)ncnc32)C1)C(N)=O		CHEMBL397521	=	Activity	%	25.0	CHEMBL4282	Homo sapiens	Activity	%	25.0
	1981747	CHEMBL899262	Inhibition of PKBalpha assessed as residual activity at 1 uM	B	N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H]1C[C@@H](O)[C@H](n2cnc3c(N)ncnc32)C1)C(N)=O		CHEMBL397521	=	Activity	%	32.0	CHEMBL4282	Homo sapiens	Activity	%	32.0
	1986223	CHEMBL899824	Inhibition of AKT1	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	nM	30000.0
Active	1988117	CHEMBL898910	Inhibition of AKT in SMS-KCNR cells after 36 hrs by Western blotting	B	Cc1cccc2c(CCN=C=S)c[nH]c12		CHEMBL237941		Activity			CHEMBL4282	Homo sapiens	Activity		
	1989380	CHEMBL898062	Inhibition of AKT1 at 1 uM	B	CC(C)NCc1ccc(Nc2cc(-c3ccc(-c4ccc(O)cc4O)cc3)[nH]n2)cc1		CHEMBL398606	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	Inhibition	%	7.0
	1989398	CHEMBL899084	Inhibition of AKT1	B	CC(C)NCc1ccc(Nc2cc(-c3ccc(-c4ccc(O)cc4O)cc3)[nH]n2)cc1		CHEMBL398606	=	IC50	nM	26890.0	CHEMBL4282	Homo sapiens	IC50	uM	26.89
Active	1996173	CHEMBL899846	Inhibition of Akt at 10 uM	B	CSc1nc(Nc2cccc(Cl)c2)c2cnn(CC(Cl)c3ccccc3)c2n1		CHEMBL400211		Activity			CHEMBL4282	Homo sapiens	Activity		
	1996198	CHEMBL899846	Inhibition of Akt at 10 uM	B	CCSc1nc(Nc2cccc(Cl)c2)c2cnn(CC(Cl)c3ccccc3)c2n1		CHEMBL428029	=	Inhibition	%	68.0	CHEMBL4282	Homo sapiens	Inhibition	%	68.0
	1998221	CHEMBL900103	Inhibition of AKT	B	COc1cc2ncc3c(N)nc4c(C)c(N)ccc4c3c2cc1OC		CHEMBL235157	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	2017698	CHEMBL885862	Inhibition of AKT	B	COc1cc(Nc2c(C#N)cnc3cc(C#CCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL391738	>	IC50	nM	5000.0	CHEMBL4282	Homo sapiens	IC50	uM	5.0
	2021736	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)[C@@H](C)O)[C@@H](C)O	Outside typical range	CHEMBL437750	>	IC50	nM	500000.0	CHEMBL4282	Homo sapiens	IC50	uM	500.0
	2021737	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(C)[C@H](NC(=O)c1ccc(NC(=O)CCCCNC(=N)N)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCc1ccccc1	Outside typical range	CHEMBL396530	=	IC50	nM	193000.0	CHEMBL4282	Homo sapiens	IC50	uM	193.0
	2021738	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CCCCCCNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)c1ccc(NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)cc1)C(C)C	Outside typical range	CHEMBL391793	=	IC50	nM	163000.0	CHEMBL4282	Homo sapiens	IC50	uM	163.0
	2021739	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCc2ccccc2)C(C)C)cc1	Outside typical range	CHEMBL245659	=	IC50	nM	119000.0	CHEMBL4282	Homo sapiens	IC50	uM	119.0
	2021740	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CCCCCc1ccc(CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)c2ccc(NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)cc2)C(C)C)cc1	Outside typical range	CHEMBL394250	=	IC50	nM	104000.0	CHEMBL4282	Homo sapiens	IC50	uM	104.0
	2021741	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCCc2cccc3ccccc23)C(C)C)cc1		CHEMBL246537	=	IC50	nM	89000.0	CHEMBL4282	Homo sapiens	IC50	uM	89.0
	2021742	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCCc2ccc3ccccc3c2)C(C)C)cc1		CHEMBL246327	=	IC50	nM	51000.0	CHEMBL4282	Homo sapiens	IC50	uM	51.0
	2021743	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCc2ccccc2)C(C)C)cc1	Outside typical range	CHEMBL394041	>	IC50	nM	500000.0	CHEMBL4282	Homo sapiens	IC50	uM	500.0
	2021744	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCc2ccccc2)C(C)C)cc1		CHEMBL396644	=	IC50	nM	79000.0	CHEMBL4282	Homo sapiens	IC50	uM	79.0
	2021745	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCc2ccccc2)C(C)C)cc1		CHEMBL396643	=	IC50	nM	41000.0	CHEMBL4282	Homo sapiens	IC50	uM	41.0
	2021746	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCCN2CCCCC2)C(C)C)cc1	Outside typical range	CHEMBL246330	>	IC50	nM	500000.0	CHEMBL4282	Homo sapiens	IC50	uM	500.0
	2021747	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCCCOc2cccc(NC(C)=O)c2)C(C)C)cc1	Outside typical range	CHEMBL395678	=	IC50	nM	322000.0	CHEMBL4282	Homo sapiens	IC50	uM	322.0
	2021748	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CCCCCc1ccc(CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)c2ccc(NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(C)=O)cc2)C(C)C)cc1		CHEMBL397075	=	IC50	nM	96000.0	CHEMBL4282	Homo sapiens	IC50	uM	96.0
	2021749	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCCN2CCC(Cc3ccccc3)CC2)C(C)C)cc1		CHEMBL437188	=	IC50	nM	94000.0	CHEMBL4282	Homo sapiens	IC50	uM	94.0
	2021750	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCCc2cccc3ccccc23)C(C)C)cc1		CHEMBL269433	=	IC50	nM	62000.0	CHEMBL4282	Homo sapiens	IC50	uM	62.0
	2021751	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CCCCCCNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)c1ccc(NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(C)=O)cc1)C(C)C		CHEMBL396589	=	IC50	nM	52000.0	CHEMBL4282	Homo sapiens	IC50	uM	52.0
	2021752	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCCc2ccc3ccccc3c2)C(C)C)cc1		CHEMBL245965	=	IC50	nM	36000.0	CHEMBL4282	Homo sapiens	IC50	uM	36.0
	2021753	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCc2ccccc2)C(C)C)cc1		CHEMBL245565	=	IC50	nM	28000.0	CHEMBL4282	Homo sapiens	IC50	uM	28.0
	2021754	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)NCc1ccccc1)C(C)C	Outside typical range	CHEMBL246137	=	IC50	nM	438000.0	CHEMBL4282	Homo sapiens	IC50	uM	438.0
	2021755	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)NCc1ccccc1)C(C)C)[C@@H](C)O)[C@@H](C)O	Outside typical range	CHEMBL245933	=	IC50	nM	239000.0	CHEMBL4282	Homo sapiens	IC50	uM	239.0
	2021756	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	C[C@@H](O)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)[C@@H](C)O	Outside typical range	CHEMBL231257	=	IC50	nM	229000.0	CHEMBL4282	Homo sapiens	IC50	uM	229.0
	2021757	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)[C@@H](C)O)[C@@H](C)O	Outside typical range	CHEMBL437388	=	IC50	nM	241000.0	CHEMBL4282	Homo sapiens	IC50	uM	241.0
	2021758	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)[C@@H](C)O)[C@@H](C)O	Outside typical range	CHEMBL245918	=	IC50	nM	409000.0	CHEMBL4282	Homo sapiens	IC50	uM	409.0
	2021759	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)[C@@H](C)O)[C@@H](C)O	Outside typical range	CHEMBL269244	=	IC50	nM	445000.0	CHEMBL4282	Homo sapiens	IC50	uM	445.0
	2021760	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)[C@@H](C)O)[C@@H](C)O	Outside typical range	CHEMBL394715	>	IC50	nM	500000.0	CHEMBL4282	Homo sapiens	IC50	uM	500.0
	2021761	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)[C@@H](C)O)[C@@H](C)O	Outside typical range	CHEMBL391820	>	IC50	nM	500000.0	CHEMBL4282	Homo sapiens	IC50	uM	500.0
	2021762	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(C)[C@H](NC(=O)c1ccc(NCCNC(=N)N)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCc1ccccc1	Outside typical range	CHEMBL245587	=	IC50	nM	390000.0	CHEMBL4282	Homo sapiens	IC50	uM	390.0
	2021763	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(C)[C@H](NC(=O)c1ccc(CCNC(=N)N)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCc1ccccc1	Outside typical range	CHEMBL248369	=	IC50	nM	120000.0	CHEMBL4282	Homo sapiens	IC50	uM	120.0
	2021764	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(C)[C@H](NC(=O)c1ccc(CNC(=N)N)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCc1ccccc1	Outside typical range	CHEMBL245987	>	IC50	nM	500000.0	CHEMBL4282	Homo sapiens	IC50	uM	500.0
	2021765	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(C)[C@H](NC(=O)c1ccc(NC(=N)N)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCc1ccccc1		CHEMBL393645	=	IC50	nM	77000.0	CHEMBL4282	Homo sapiens	IC50	uM	77.0
	2021766	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(C)[C@H](NC(=O)c1ccc(N(CC(=O)NCc2ccccc2)C(=O)CCCCNC(=N)N)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCc1ccccc1		CHEMBL395685	=	IC50	nM	14000.0	CHEMBL4282	Homo sapiens	IC50	uM	14.0
	2021767	CHEMBL903578	Inhibition of Akt after 1 hr by fluorescence polarization assay	B	CC(C)[C@H](NC(=O)c1ccc(N(CC(=O)NC(C)(C)C)C(=O)CCCCNC(=N)N)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCc1ccccc1		CHEMBL391132	=	IC50	nM	58000.0	CHEMBL4282	Homo sapiens	IC50	uM	58.0
	2029837	CHEMBL886304	Inhibition of AKT1 at 10 uM	B	O=C1Cc2cnn(-c3ccccc3)c2-c2ccccc2N1		CHEMBL250583	<=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	Inhibition	%	40.0
	2029950	CHEMBL886304	Inhibition of AKT1 at 10 uM	B	O=C1Cc2cnn(-c3ccc([N+](=O)[O-])cc3)c2-c2ccccc2N1		CHEMBL400310	<=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	Inhibition	%	40.0
	2029951	CHEMBL886304	Inhibition of AKT1 at 10 uM	B	O=C1Cc2cnn(-c3ccc(F)cc3F)c2-c2ccccc2N1		CHEMBL248954	<=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	Inhibition	%	40.0
	2029952	CHEMBL886304	Inhibition of AKT1 at 10 uM	B	O=C1Cc2cnn(-c3ccccc3Br)c2-c2ccccc2N1		CHEMBL400113	<=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	Inhibition	%	40.0
	2029953	CHEMBL886304	Inhibition of AKT1 at 10 uM	B	O=C1Cc2cnn(-c3ccccc3F)c2-c2ccccc2N1		CHEMBL399076	<=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	Inhibition	%	40.0
	2029954	CHEMBL886304	Inhibition of AKT1 at 10 uM	B	O=C1Cc2cnn(-c3cccc(Cl)c3)c2-c2ccccc2N1		CHEMBL248760	<=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	Inhibition	%	40.0
	2029955	CHEMBL886304	Inhibition of AKT1 at 10 uM	B	O=C1Cc2cnn(-c3ccccc3Cl)c2-c2ccccc2N1		CHEMBL248759	<=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	Inhibition	%	40.0
	2029956	CHEMBL886304	Inhibition of AKT1 at 10 uM	B	CC(C)(C)c1ccc(-n2ncc3c2-c2ccccc2NC(=O)C3)cc1		CHEMBL398877	<=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	Inhibition	%	40.0
	2029957	CHEMBL886304	Inhibition of AKT1 at 10 uM	B	O=C1Cc2cnn(-c3cc(Cl)cc(Cl)c3)c2-c2ccccc2N1		CHEMBL248758	<=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	Inhibition	%	40.0
	2029958	CHEMBL886304	Inhibition of AKT1 at 10 uM	B	O=C1Cc2cnn(-c3ccc(C(F)(F)F)cc3)c2-c2ccccc2N1		CHEMBL398876	<=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	Inhibition	%	40.0
	2029959	CHEMBL886304	Inhibition of AKT1 at 10 uM	B	Cc1ccc(-n2ncc3c2-c2ccccc2NC(=O)C3)cc1		CHEMBL400898	<=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	Inhibition	%	40.0
	2029960	CHEMBL886304	Inhibition of AKT1 at 10 uM	B	COc1ccc(-n2ncc3c2-c2ccccc2NC(=O)C3)cc1		CHEMBL248558	<=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	Inhibition	%	40.0
	2029961	CHEMBL886304	Inhibition of AKT1 at 10 uM	B	Cc1ccccc1-n1ncc2c1-c1ccccc1NC(=O)C2		CHEMBL400897	<=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	Inhibition	%	40.0
	2029962	CHEMBL886304	Inhibition of AKT1 at 10 uM	B	O=C1Cc2cnn(-c3ccc(Cl)cc3)c2-c2ccccc2N1		CHEMBL248557	<=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	Inhibition	%	40.0
	2029963	CHEMBL886304	Inhibition of AKT1 at 10 uM	B	O=C1Cc2cnn(-c3ccc(Br)cc3)c2-c2ccccc2N1		CHEMBL398288	<=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	Inhibition	%	40.0
	2036737	CHEMBL922918	Inhibition of pAkt	B	CNC(=O)Nc1ccc(CNc2c(C(=O)Nc3ccc4c(c3)OC(F)(F)C(F)(F)O4)cnn2C)cn1		CHEMBL247619	=	IC50	nM	41.0	CHEMBL4282	Homo sapiens	IC50	nM	41.0
	2036742	CHEMBL922918	Inhibition of pAkt	B	CNC(=O)Nc1ccc(CNc2ncsc2C(=O)Nc2ccc3c(c2)OC(F)(F)O3)cn1		CHEMBL247250	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	nM	24.0
	2036743	CHEMBL922918	Inhibition of pAkt	B	CCNC(=O)Nc1ccc(CNc2ncsc2C(=O)Nc2ccc3c(c2)OC(F)(F)O3)cn1		CHEMBL247798	=	IC50	nM	81.0	CHEMBL4282	Homo sapiens	IC50	nM	81.0
	2036744	CHEMBL922918	Inhibition of pAkt	B	CNC(=O)Nc1ccc(CNc2c(C(=O)Nc3ccc(SC(F)(F)F)cc3)cnn2C)cn1		CHEMBL247797	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
	2050260	CHEMBL925558	Inhibition of AKT1 at 1 uM	B	CC1CCN(c2ccc(CO)cc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL400754	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	2051578	CHEMBL942719	Inhibition of AKT1	B	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	=	Ki	nM	3698.0	CHEMBL4282	Homo sapiens	Ki	uM	3.698
Not Active	2071372	CHEMBL928451	Inhibition of Akt activation in human PANC1 cells at 100 uM	B	COc1cc2c(cc1O)[C@@H]1COc3cc(O)ccc3[C@]1(C)O2		CHEMBL253473		Activity			CHEMBL4282	Homo sapiens	Activity		
	2080208	CHEMBL928479	Inhibition of PKB	B	CCN(CC)CCOc1ccc(Nc2cc(NC(=O)Nc3c(Cl)cccc3Cl)ncn2)cc1		CHEMBL253292	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	2080221	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCC(N)=O)cc3)nc2n1		CHEMBL276130	=	IC50	nM	226.0	CHEMBL4282	Homo sapiens	IC50	nM	226.0
	2080222	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCC(=O)c4ccccc4N)cc3)nc2n1		CHEMBL252456	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
	2080223	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCc4nnc(N)s4)cc3)nc2n1		CHEMBL252455	=	IC50	nM	46.0	CHEMBL4282	Homo sapiens	IC50	nM	46.0
	2080224	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCc4n[nH]c(-c5ccccc5)n4)cc3)nc2n1		CHEMBL252261	=	IC50	nM	63.0	CHEMBL4282	Homo sapiens	IC50	nM	63.0
	2080225	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCc4n[nH]c(C)n4)cc3)nc2n1		CHEMBL403355	=	IC50	nM	162.0	CHEMBL4282	Homo sapiens	IC50	nM	162.0
	2080226	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN(C)CCc4cn[nH]c4)cc3)nc2n1		CHEMBL252260	=	IC50	nM	1521.0	CHEMBL4282	Homo sapiens	IC50	nM	1521.0
	2080227	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCCn4ccnc4)cc3)nc2n1		CHEMBL252259	=	IC50	nM	137.0	CHEMBL4282	Homo sapiens	IC50	nM	137.0
	2080228	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCc4cccnc4)cc3)nc2n1		CHEMBL403354	=	IC50	nM	90.0	CHEMBL4282	Homo sapiens	IC50	nM	90.0
	2080229	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCc4nccs4)cc3)nc2n1		CHEMBL252056	=	IC50	nM	198.0	CHEMBL4282	Homo sapiens	IC50	nM	198.0
	2080230	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCc4nc[nH]n4)cc3)nc2n1		CHEMBL252055	=	IC50	nM	139.0	CHEMBL4282	Homo sapiens	IC50	nM	139.0
	2080231	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCc4c[nH]cn4)cc3)nc2n1		CHEMBL252054	=	IC50	nM	99.0	CHEMBL4282	Homo sapiens	IC50	nM	99.0
	2080232	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCCN4CCN(C)CC4)cc3)nc2n1		CHEMBL251860	=	IC50	nM	765.0	CHEMBL4282	Homo sapiens	IC50	nM	765.0
	2080245	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL254099	=	IC50	nM	3.8	CHEMBL4282	Homo sapiens	IC50	nM	3.8
	2080246	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5cc(-c6ccncc6)[nH]n5)CC4)cc3)nc2n1		CHEMBL404554	=	IC50	nM	4.5	CHEMBL4282	Homo sapiens	IC50	nM	4.5
	2080247	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nc(-c6cccnc6)no5)CC4)cc3)nc2n1		CHEMBL404553	=	IC50	nM	64.0	CHEMBL4282	Homo sapiens	IC50	nM	64.0
	2080248	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(C(=O)Nc5ccncc5)CC4)cc3)nc2n1		CHEMBL252856	=	IC50	nM	9.7	CHEMBL4282	Homo sapiens	IC50	nM	9.7
	2080249	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(N)s5)CC4)cc3)nc2n1		CHEMBL403356	=	IC50	nM	8.5	CHEMBL4282	Homo sapiens	IC50	nM	8.5
	2080250	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(NC(=O)CNC(C)=O)CC4)cc3)nc2n1		CHEMBL252654	=	IC50	nM	286.0	CHEMBL4282	Homo sapiens	IC50	nM	286.0
	2080251	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(C(=O)NCCC(N)=O)CC4)cc3)nc2n1		CHEMBL252653	=	IC50	nM	91.0	CHEMBL4282	Homo sapiens	IC50	nM	91.0
	2080252	CHEMBL928491	Inhibition of Akt1	B	CCNC(=O)NC1CCN(Cc2ccc(-c3nc4nc(SC)ncc4cc3-c3ccccc3)cc2)CC1		CHEMBL252652	=	IC50	nM	81.0	CHEMBL4282	Homo sapiens	IC50	nM	81.0
	2080253	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(C(N)=O)CC4)cc3)nc2n1		CHEMBL252457	=	IC50	nM	29.0	CHEMBL4282	Homo sapiens	IC50	nM	29.0
	2080263	CHEMBL928489	Inhibition of human Akt1 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(C(N)=O)CC4)cc3)nc2n1		CHEMBL252457	=	IC50	nM	560.0	CHEMBL4282	Homo sapiens	IC50	nM	560.0
	2080264	CHEMBL928491	Inhibition of Akt1	B	CNc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL252857	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	2080265	CHEMBL928491	Inhibition of Akt1	B	NC(=O)c1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL404556	=	IC50	nM	6.2	CHEMBL4282	Homo sapiens	IC50	nM	6.2
	2080266	CHEMBL928491	Inhibition of Akt1	B	N#Cc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL404555	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	nM	24.0
	2080267	CHEMBL928491	Inhibition of Akt1	B	COc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL404347	=	IC50	nM	23.6	CHEMBL4282	Homo sapiens	IC50	nM	23.6
	2080273	CHEMBL928489	Inhibition of human Akt1 in human C33A cells by immunoprecipitation kinase assay	B	CNc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL252857	=	IC50	nM	20.3	CHEMBL4282	Homo sapiens	IC50	nM	20.3
	2080274	CHEMBL928489	Inhibition of human Akt1 in human C33A cells by immunoprecipitation kinase assay	B	NC(=O)c1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL404556	=	IC50	nM	96.4	CHEMBL4282	Homo sapiens	IC50	nM	96.4
	2080275	CHEMBL928489	Inhibition of human Akt1 in human C33A cells by immunoprecipitation kinase assay	B	N#Cc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL404555	=	IC50	nM	100.0	CHEMBL4282	Homo sapiens	IC50	nM	100.0
	2080276	CHEMBL928489	Inhibition of human Akt1 in human C33A cells by immunoprecipitation kinase assay	B	COc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL404347	=	IC50	nM	42.6	CHEMBL4282	Homo sapiens	IC50	nM	42.6
	2080277	CHEMBL928489	Inhibition of human Akt1 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL254099	=	IC50	nM	9.3	CHEMBL4282	Homo sapiens	IC50	nM	9.3
	2080278	CHEMBL928489	Inhibition of human Akt1 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5cc(-c6ccncc6)[nH]n5)CC4)cc3)nc2n1		CHEMBL404554	=	IC50	nM	85.0	CHEMBL4282	Homo sapiens	IC50	nM	85.0
Not Determined	2080279	CHEMBL928489	Inhibition of human Akt1 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nc(-c6cccnc6)no5)CC4)cc3)nc2n1		CHEMBL404553		IC50			CHEMBL4282	Homo sapiens	IC50		
	2080280	CHEMBL928489	Inhibition of human Akt1 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(C(=O)Nc5ccncc5)CC4)cc3)nc2n1		CHEMBL252856	=	IC50	nM	133.0	CHEMBL4282	Homo sapiens	IC50	nM	133.0
	2080281	CHEMBL928489	Inhibition of human Akt1 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(N)s5)CC4)cc3)nc2n1		CHEMBL403356	=	IC50	nM	79.0	CHEMBL4282	Homo sapiens	IC50	nM	79.0
Not Determined	2080282	CHEMBL928489	Inhibition of human Akt1 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(NC(=O)CNC(C)=O)CC4)cc3)nc2n1		CHEMBL252654		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	2080283	CHEMBL928489	Inhibition of human Akt1 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(C(=O)NCCC(N)=O)CC4)cc3)nc2n1		CHEMBL252653		IC50			CHEMBL4282	Homo sapiens	IC50		
	2080284	CHEMBL928489	Inhibition of human Akt1 in human C33A cells by immunoprecipitation kinase assay	B	CCNC(=O)NC1CCN(Cc2ccc(-c3nc4nc(SC)ncc4cc3-c3ccccc3)cc2)CC1		CHEMBL252652	=	IC50	nM	795.0	CHEMBL4282	Homo sapiens	IC50	nM	795.0
	2080301	CHEMBL928491	Inhibition of Akt1	B	Nc1ncnc2nc(-c3ccc(CN4CCC(c5nc6ccc(F)cc6[nH]5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL253457	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
	2080303	CHEMBL928491	Inhibition of Akt1	B	Nc1ncnc2nc(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL253458	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
	2080304	CHEMBL928489	Inhibition of human Akt1 in human C33A cells by immunoprecipitation kinase assay	B	Nc1ncnc2nc(-c3ccc(CN4CCC(c5nc6ccc(F)cc6[nH]5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL253457	=	IC50	nM	277.0	CHEMBL4282	Homo sapiens	IC50	nM	277.0
	2080306	CHEMBL928489	Inhibition of human Akt1 in human C33A cells by immunoprecipitation kinase assay	B	Nc1ncnc2nc(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL253458	=	IC50	nM	295.0	CHEMBL4282	Homo sapiens	IC50	nM	295.0
	2080309	CHEMBL928491	Inhibition of Akt1	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)nc2n1		CHEMBL253693	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	2080311	CHEMBL928489	Inhibition of human Akt1 in human C33A cells by immunoprecipitation kinase assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)nc2n1		CHEMBL253693	=	IC50	nM	60.0	CHEMBL4282	Homo sapiens	IC50	nM	60.0
	2081773	CHEMBL928794	Inhibition of Atk1 at 10 uM	B	CC[C@@H](C)Nc1nc2ccc(-c3c(-c4ccccc4F)n[nH]c3N)cc2s1		CHEMBL404115	<=	Inhibition	%	20.0	CHEMBL4282	Homo sapiens	Inhibition	%	20.0
	2092201	CHEMBL948032	Inhibition of Akt1	B	O=C(O)c1ccc2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)nc2c1		CHEMBL272292	=	IC50	nM	240.0	CHEMBL4282	Homo sapiens	IC50	nM	240.0
	2092204	CHEMBL948032	Inhibition of Akt1	B	CCN(CC)CCNC(=O)c1ccc2nc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc2c1		CHEMBL258696	=	IC50	nM	138.0	CHEMBL4282	Homo sapiens	IC50	nM	138.0
	2092205	CHEMBL948032	Inhibition of Akt1	B	CCN(CC)CCNC(=O)c1ccc2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)nc2c1		CHEMBL270444	=	IC50	nM	458.0	CHEMBL4282	Homo sapiens	IC50	nM	458.0
	2092206	CHEMBL948032	Inhibition of Akt1	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc(-c5nn[nH]n5)ccc4nc3-c3ccccc3)cc2)CC1		CHEMBL408151	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	nM	20.0
	2092207	CHEMBL948032	Inhibition of Akt1	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(-c5nn[nH]n5)cc4nc3-c3ccccc3)cc2)CC1		CHEMBL271091	=	IC50	nM	63.0	CHEMBL4282	Homo sapiens	IC50	nM	63.0
	2092208	CHEMBL948032	Inhibition of Akt1	B	O=C(O)c1ccc2nc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc2c1		CHEMBL273160	=	IC50	nM	166.0	CHEMBL4282	Homo sapiens	IC50	nM	166.0
	2092219	CHEMBL948035	Inhibition of Akt1 by cell-based IPKA assay	B	CCN(CC)CCNC(=O)c1ccc2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)nc2c1		CHEMBL270444	=	IC50	nM	368.0	CHEMBL4282	Homo sapiens	IC50	nM	368.0
	2092222	CHEMBL948035	Inhibition of Akt1 by cell-based IPKA assay	B	CCN(CC)CCNC(=O)c1ccc2nc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc2c1		CHEMBL258696	=	IC50	nM	253.0	CHEMBL4282	Homo sapiens	IC50	nM	253.0
	2092248	CHEMBL948032	Inhibition of Akt1	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	58.0	CHEMBL4282	Homo sapiens	IC50	nM	58.0
	2092251	CHEMBL948035	Inhibition of Akt1 by cell-based IPKA assay	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	305.0	CHEMBL4282	Homo sapiens	IC50	nM	305.0
	2099522	CHEMBL948236	Inhibition of PKBalpha at 10 uM	B	CN(C)CCCOc1cc2c(cc1O)c1c3c(c(-c4ccccc4Cl)cc1n2C)C(=O)NC3=O		CHEMBL410261	=	Inhibition	%	33.0	CHEMBL4282	Homo sapiens	Inhibition	%	33.0
	2099606	CHEMBL948236	Inhibition of PKBalpha at 10 uM	B	Cn1c2cc(C(=O)NCCN3CCCC3)c(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL272267	=	Inhibition	%	16.0	CHEMBL4282	Homo sapiens	Inhibition	%	16.0
	2099607	CHEMBL948236	Inhibition of PKBalpha at 10 uM	B	Cn1c2cc(SCCCN3CCCC3)c(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL404335	=	Inhibition	%	8.0	CHEMBL4282	Homo sapiens	Inhibition	%	8.0
	2099608	CHEMBL948236	Inhibition of PKBalpha at 10 uM	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)c(OCCCN3CCOCC3)cc2n1CCO		CHEMBL271715	=	Inhibition	%	55.0	CHEMBL4282	Homo sapiens	Inhibition	%	55.0
	2099609	CHEMBL948236	Inhibition of PKBalpha at 10 uM	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)c(OCCCN3CCCC3)cc2n1CCO		CHEMBL270021	=	Inhibition	%	28.0	CHEMBL4282	Homo sapiens	Inhibition	%	28.0
	2099610	CHEMBL948236	Inhibition of PKBalpha at 10 uM	B	Cn1c2cc(OCCCN3CCCC3)c(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL255427	=	Inhibition	%	20.0	CHEMBL4282	Homo sapiens	Inhibition	%	20.0
	2106296	CHEMBL947151	Inhibition of phosphorylation of T308-PKB in human U87MG cells by ELISA	B	N#CCc1ccc(-n2cnc3cnc4ccc(C#Cc5cccnc5)cc4c32)cc1		CHEMBL272265	=	IC50	nM	94.0	CHEMBL4282	Homo sapiens	IC50	nM	94.0
	2106297	CHEMBL947151	Inhibition of phosphorylation of T308-PKB in human U87MG cells by ELISA	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(C#Cc4cccnc4)ccc3ncc21		CHEMBL255592	=	IC50	nM	33.0	CHEMBL4282	Homo sapiens	IC50	nM	33.0
	2106298	CHEMBL947151	Inhibition of phosphorylation of T308-PKB in human U87MG cells by ELISA	B	Cc1nc2cnc3ccc(C#Cc4cccnc4)cc3c2n1-c1ccc(C(C)C#N)cc1		CHEMBL270638	=	IC50	nM	45.0	CHEMBL4282	Homo sapiens	IC50	nM	45.0
	2106299	CHEMBL947151	Inhibition of phosphorylation of T308-PKB in human U87MG cells by ELISA	B	CC(C#N)c1ccc(-n2cnc3cnc4ccc(C#Cc5cccnc5)cc4c32)cc1		CHEMBL404024	=	IC50	nM	139.0	CHEMBL4282	Homo sapiens	IC50	nM	139.0
	2106300	CHEMBL947151	Inhibition of phosphorylation of T308-PKB in human U87MG cells by ELISA	B	CCc1nc2cnc3ccc(C#Cc4cccnc4)cc3c2n1-c1ccc(CC#N)cc1		CHEMBL270640	=	IC50	nM	138.0	CHEMBL4282	Homo sapiens	IC50	nM	138.0
	2106301	CHEMBL947151	Inhibition of phosphorylation of T308-PKB in human U87MG cells by ELISA	B	Cc1nc2cnc3ccc(C#Cc4cccnc4)cc3c2n1-c1ccc(CC#N)cc1		CHEMBL270639	=	IC50	nM	77.0	CHEMBL4282	Homo sapiens	IC50	nM	77.0
	2106309	CHEMBL947154	Inhibition of PKB at 10 uM	B	N#CCc1ccc(-n2cnc3cnc4ccc(C#Cc5cccnc5)cc4c32)cc1		CHEMBL272265	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	2110268	CHEMBL950970	Inhibition of AKT1	B	COC[C@H]1OC(=O)/C(=C/N(CCO)C(C)(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C		CHEMBL271190	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	2110279	CHEMBL950970	Inhibition of AKT1	B	COC[C@H]1OC(=O)/C(=C/N(C)CCCN(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C		CHEMBL410643	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	2112567	CHEMBL951020	Inhibition of PKBa at 10 uM	B	Nc1ncnc2oc(-c3cccnc3)c(-c3ccc(NS(=O)(=O)c4ccccc4)cc3)c12		CHEMBL258081	=	Inhibition	%	29.0	CHEMBL4282	Homo sapiens	Inhibition	%	29.0
	2115422	CHEMBL950112	Inhibition of human recombinant Akt1	B	N#Cc1cnc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)c1		CHEMBL255212	=	Activity	nM	762.0	CHEMBL4282	Homo sapiens	Activity	nM	762.0
	2115425	CHEMBL950115	Inhibition of Akt1 in human C33a cells	B	N#Cc1cnc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)c1		CHEMBL255212	>	Activity	nM	50000.0	CHEMBL4282	Homo sapiens	Activity	nM	50000.0
	2115427	CHEMBL950112	Inhibition of human recombinant Akt1	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4nc[nH]n4)cc3-c3ccccc3)cc2)CC1		CHEMBL401921	=	Activity	nM	182.0	CHEMBL4282	Homo sapiens	Activity	nM	182.0
	2115428	CHEMBL950112	Inhibition of human recombinant Akt1	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4ncon4)cc3-c3ccccc3)cc2)CC1		CHEMBL430217	=	Activity	nM	180.0	CHEMBL4282	Homo sapiens	Activity	nM	180.0
	2115429	CHEMBL950112	Inhibition of human recombinant Akt1	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4ncccn4)cc3-c3ccccc3)cc2)CC1		CHEMBL256212	=	Activity	nM	306.0	CHEMBL4282	Homo sapiens	Activity	nM	306.0
	2115430	CHEMBL950112	Inhibition of human recombinant Akt1	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4nccs4)cc3-c3ccccc3)cc2)CC1		CHEMBL271506	=	Activity	nM	264.0	CHEMBL4282	Homo sapiens	Activity	nM	264.0
	2115431	CHEMBL950112	Inhibition of human recombinant Akt1	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4ccccn4)cc3-c3ccccc3)cc2)CC1		CHEMBL406858	=	Activity	nM	1629.0	CHEMBL4282	Homo sapiens	Activity	nM	1629.0
	2115432	CHEMBL950112	Inhibition of human recombinant Akt1	B	Nc1nnc(-c2cnc(-c3ccc(CNCCC(=O)c4ccccc4N)cc3)c(-c3ccccc3)c2)s1		CHEMBL271637	=	Activity	nM	114.0	CHEMBL4282	Homo sapiens	Activity	nM	114.0
	2115433	CHEMBL950112	Inhibition of human recombinant Akt1	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ncccc65)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL255129	=	Activity	nM	434.0	CHEMBL4282	Homo sapiens	Activity	nM	434.0
	2115434	CHEMBL950112	Inhibition of human recombinant Akt1	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL258276	=	Activity	nM	126.0	CHEMBL4282	Homo sapiens	Activity	nM	126.0
	2115435	CHEMBL950112	Inhibition of human recombinant Akt1	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(n5cc(-c6ccccn6)cn5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL402534	=	Activity	nM	214.0	CHEMBL4282	Homo sapiens	Activity	nM	214.0
	2115436	CHEMBL950112	Inhibition of human recombinant Akt1	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL402096	=	Activity	nM	85.0	CHEMBL4282	Homo sapiens	Activity	nM	85.0
	2115437	CHEMBL950112	Inhibition of human recombinant Akt1	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(c5cc(-c6ccccn6)[nH]n5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL271496	=	Activity	nM	95.0	CHEMBL4282	Homo sapiens	Activity	nM	95.0
	2115438	CHEMBL950112	Inhibition of human recombinant Akt1	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(c5cc(-c6ccncc6)[nH]n5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL271887	=	Activity	nM	123.0	CHEMBL4282	Homo sapiens	Activity	nM	123.0
	2115439	CHEMBL950112	Inhibition of human recombinant Akt1	B	Nc1ncnc2c1ncn2C1CCN(Cc2ccc(-c3ncc(-c4nnn[nH]4)cc3-c3ccccc3)cc2)CC1		CHEMBL404164	=	Activity	nM	210.0	CHEMBL4282	Homo sapiens	Activity	nM	210.0
	2115440	CHEMBL950112	Inhibition of human recombinant Akt1	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3ncc(-c4nnn[nH]4)cc3-c3ccccc3)cc2)CC1		CHEMBL270847	=	Activity	nM	273.0	CHEMBL4282	Homo sapiens	Activity	nM	273.0
	2115457	CHEMBL950115	Inhibition of Akt1 in human C33a cells	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4nc[nH]n4)cc3-c3ccccc3)cc2)CC1		CHEMBL401921	=	Activity	nM	890.0	CHEMBL4282	Homo sapiens	Activity	nM	890.0
	2115458	CHEMBL950115	Inhibition of Akt1 in human C33a cells	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4ncon4)cc3-c3ccccc3)cc2)CC1		CHEMBL430217	=	Activity	nM	288.0	CHEMBL4282	Homo sapiens	Activity	nM	288.0
	2115459	CHEMBL950115	Inhibition of Akt1 in human C33a cells	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4ncccn4)cc3-c3ccccc3)cc2)CC1		CHEMBL256212	=	Activity	nM	1954.0	CHEMBL4282	Homo sapiens	Activity	nM	1954.0
	2115460	CHEMBL950115	Inhibition of Akt1 in human C33a cells	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4nccs4)cc3-c3ccccc3)cc2)CC1		CHEMBL271506	=	Activity	nM	1650.0	CHEMBL4282	Homo sapiens	Activity	nM	1650.0
	2115461	CHEMBL950115	Inhibition of Akt1 in human C33a cells	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3ncc(-c4ccccn4)cc3-c3ccccc3)cc2)CC1		CHEMBL406858	=	Activity	nM	10000.0	CHEMBL4282	Homo sapiens	Activity	nM	10000.0
	2115462	CHEMBL950115	Inhibition of Akt1 in human C33a cells	B	Nc1nnc(-c2cnc(-c3ccc(CNCCC(=O)c4ccccc4N)cc3)c(-c3ccccc3)c2)s1		CHEMBL271637	=	Activity	nM	618.0	CHEMBL4282	Homo sapiens	Activity	nM	618.0
	2115463	CHEMBL950115	Inhibition of Akt1 in human C33a cells	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ncccc65)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL255129	=	Activity	nM	12650.0	CHEMBL4282	Homo sapiens	Activity	nM	12650.0
	2115464	CHEMBL950115	Inhibition of Akt1 in human C33a cells	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL258276	=	Activity	nM	621.0	CHEMBL4282	Homo sapiens	Activity	nM	621.0
	2115465	CHEMBL950115	Inhibition of Akt1 in human C33a cells	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(n5cc(-c6ccccn6)cn5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL402534	=	Activity	nM	1352.0	CHEMBL4282	Homo sapiens	Activity	nM	1352.0
	2115466	CHEMBL950115	Inhibition of Akt1 in human C33a cells	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL402096	=	Activity	nM	516.0	CHEMBL4282	Homo sapiens	Activity	nM	516.0
	2115467	CHEMBL950115	Inhibition of Akt1 in human C33a cells	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(c5cc(-c6ccccn6)[nH]n5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL271496	=	Activity	nM	734.0	CHEMBL4282	Homo sapiens	Activity	nM	734.0
	2115468	CHEMBL950115	Inhibition of Akt1 in human C33a cells	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(c5cc(-c6ccncc6)[nH]n5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL271887	=	Activity	nM	407.0	CHEMBL4282	Homo sapiens	Activity	nM	407.0
	2115469	CHEMBL950115	Inhibition of Akt1 in human C33a cells	B	Nc1ncnc2c1ncn2C1CCN(Cc2ccc(-c3ncc(-c4nnn[nH]4)cc3-c3ccccc3)cc2)CC1		CHEMBL404164	>	Activity	nM	50000.0	CHEMBL4282	Homo sapiens	Activity	nM	50000.0
	2115470	CHEMBL950115	Inhibition of Akt1 in human C33a cells	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3ncc(-c4nnn[nH]4)cc3-c3ccccc3)cc2)CC1		CHEMBL270847	>	Activity	nM	50000.0	CHEMBL4282	Homo sapiens	Activity	nM	50000.0
	2115488	CHEMBL950112	Inhibition of human recombinant Akt1	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(n5cc(-c6cnccn6)cn5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL255382	=	Activity	nM	172.0	CHEMBL4282	Homo sapiens	Activity	nM	172.0
	2115490	CHEMBL950115	Inhibition of Akt1 in human C33a cells	B	Nc1nnc(-c2cnc(-c3ccc(CN4CCC(n5cc(-c6cnccn6)cn5)CC4)cc3)c(-c3ccccc3)c2)s1		CHEMBL255382	=	Activity	nM	1378.0	CHEMBL4282	Homo sapiens	Activity	nM	1378.0
	2115743	CHEMBL951085	Inhibition of human recombinant Akt1	B	CC(C)(N)c1ccc(-c2nc3ccccc3nc2-c2ccccc2)cc1		CHEMBL362455	=	IC50	nM	3400.0	CHEMBL4282	Homo sapiens	IC50	nM	3400.0
	2115744	CHEMBL951085	Inhibition of human recombinant Akt1	B	Nc1ncnc2nc(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL253458	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
	2115745	CHEMBL951085	Inhibition of human recombinant Akt1	B	Nc1ncnc2nc(-c3ccc(CN4CCC(c5cc(-c6ccncc6)[nH]n5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL255835	=	IC50	nM	21.0	CHEMBL4282	Homo sapiens	IC50	nM	21.0
	2115746	CHEMBL951085	Inhibition of human recombinant Akt1	B	Nc1ncnc2nc(-c3ccc(CN4CCC(c5nc6ccc(F)cc6[nH]5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL253457	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
	2115747	CHEMBL951085	Inhibition of human recombinant Akt1	B	Cc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ncnc(N)c4cc3-c3ccccc3)cc2)CC1		CHEMBL402579	=	IC50	nM	69.0	CHEMBL4282	Homo sapiens	IC50	nM	69.0
	2115748	CHEMBL951085	Inhibition of human recombinant Akt1	B	Nc1ncnc2nc(-c3ccc(CN4CCC(n5cnc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL255360	=	IC50	nM	129.0	CHEMBL4282	Homo sapiens	IC50	nM	129.0
	2115749	CHEMBL951085	Inhibition of human recombinant Akt1	B	Nc1ncnc2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL402199	=	IC50	nM	81.0	CHEMBL4282	Homo sapiens	IC50	nM	81.0
	2115750	CHEMBL951085	Inhibition of human recombinant Akt1	B	Nc1nc(N)c2cc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc2n1		CHEMBL401999	=	IC50	nM	107.0	CHEMBL4282	Homo sapiens	IC50	nM	107.0
	2115751	CHEMBL951085	Inhibition of human recombinant Akt1	B	Nc1nc(O)nc2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL270815	=	IC50	nM	244.0	CHEMBL4282	Homo sapiens	IC50	nM	244.0
	2115752	CHEMBL951085	Inhibition of human recombinant Akt1	B	Nc1nn(CCc2c[nH]cn2)c2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL255348	=	IC50	nM	21.0	CHEMBL4282	Homo sapiens	IC50	nM	21.0
	2115753	CHEMBL951085	Inhibition of human recombinant Akt1	B	Nc1nn(CCO)c2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL255559	=	IC50	nM	131.0	CHEMBL4282	Homo sapiens	IC50	nM	131.0
	2115754	CHEMBL951085	Inhibition of human recombinant Akt1	B	Cn1nc(N)c2cc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc21		CHEMBL401622	=	IC50	nM	121.0	CHEMBL4282	Homo sapiens	IC50	nM	121.0
	2115755	CHEMBL951085	Inhibition of human recombinant Akt1	B	Nc1n[nH]c2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL270157	=	IC50	nM	86.0	CHEMBL4282	Homo sapiens	IC50	nM	86.0
	2115756	CHEMBL951085	Inhibition of human recombinant Akt1	B	COc1nc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)cc1C#N		CHEMBL402355	=	IC50	nM	5548.0	CHEMBL4282	Homo sapiens	IC50	nM	5548.0
	2115757	CHEMBL951085	Inhibition of human recombinant Akt1	B	CN(C)c1nc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)cc1C#N		CHEMBL257441	=	IC50	nM	8457.0	CHEMBL4282	Homo sapiens	IC50	nM	8457.0
	2115758	CHEMBL951085	Inhibition of human recombinant Akt1	B	CNc1nc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)cc1C#N		CHEMBL255772	=	IC50	nM	2249.0	CHEMBL4282	Homo sapiens	IC50	nM	2249.0
	2115759	CHEMBL951085	Inhibition of human recombinant Akt1	B	N#Cc1cc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)nc1N		CHEMBL429576	=	IC50	nM	495.0	CHEMBL4282	Homo sapiens	IC50	nM	495.0
	2115760	CHEMBL951085	Inhibition of human recombinant Akt1	B	N#Cc1cc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)nc1Cl		CHEMBL270388	=	IC50	nM	253.0	CHEMBL4282	Homo sapiens	IC50	nM	253.0
	2115761	CHEMBL951085	Inhibition of human recombinant Akt1	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	58.0	CHEMBL4282	Homo sapiens	IC50	nM	58.0
	2115783	CHEMBL951088	Inhibition of Akt1 phosphorylation in human C33a cells	B	Nc1ncnc2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL402199	=	IC50	nM	1834.0	CHEMBL4282	Homo sapiens	IC50	nM	1834.0
	2115784	CHEMBL951088	Inhibition of Akt1 phosphorylation in human C33a cells	B	Nc1ncnc2nc(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL253458	=	IC50	nM	295.0	CHEMBL4282	Homo sapiens	IC50	nM	295.0
	2115785	CHEMBL951088	Inhibition of Akt1 phosphorylation in human C33a cells	B	Nc1ncnc2nc(-c3ccc(CN4CCC(c5cc(-c6ccncc6)[nH]n5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL255835	=	IC50	nM	463.0	CHEMBL4282	Homo sapiens	IC50	nM	463.0
	2115786	CHEMBL951088	Inhibition of Akt1 phosphorylation in human C33a cells	B	Nc1ncnc2nc(-c3ccc(CN4CCC(c5nc6ccc(F)cc6[nH]5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL253457	=	IC50	nM	277.0	CHEMBL4282	Homo sapiens	IC50	nM	277.0
	2115787	CHEMBL951088	Inhibition of Akt1 phosphorylation in human C33a cells	B	Cc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ncnc(N)c4cc3-c3ccccc3)cc2)CC1		CHEMBL402579	=	IC50	nM	221.0	CHEMBL4282	Homo sapiens	IC50	nM	221.0
Not Determined	2115788	CHEMBL951088	Inhibition of Akt1 phosphorylation in human C33a cells	B	Nc1ncnc2nc(-c3ccc(CN4CCC(n5cnc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL255360		IC50			CHEMBL4282	Homo sapiens	IC50		
Active	2131768	CHEMBL937115	Increase in Akt phosphorylation in human HL60 cells at 4 uM after 48 hrs	B	C=C1C(=O)O[C@@H]2/C=C(/C)[C@@H](OC(C)=O)C[C@H]3O[C@]3(C)C[C@@H](OC(=O)/C(=C/C)CO)[C@@H]12		CHEMBL258867		Activity			CHEMBL4282	Homo sapiens	Activity		
	2132669	CHEMBL938203	Inhibition of AKT1	B	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](CN2CCC2)C1		CHEMBL410659	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	2136981	CHEMBL939373	Inhibition of AKT	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	>=	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	2137312	CHEMBL939373	Inhibition of AKT	B	O=C1N=C(NCc2cccs2)S/C1=C/c1ccc2ncccc2c1		CHEMBL261644	>	Ki	nM	2000.0	CHEMBL4282	Homo sapiens	Ki	nM	2000.0
	2147349	CHEMBL922035	Activity of human PKBalpha kinase at 1 uM	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Activity	%	101.0	CHEMBL4282	Homo sapiens	Activity	%	101.0
Not Evaluated	2149605	CHEMBL931302	Inhibition of human AKT1	B	NC(=O)c1c(NC(=O)C2CC2)sc2c1CCCC2		CHEMBL379367		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	2150266	CHEMBL937569	Induction of Akt phosphorylation in human T17 cells	B	CC(C)=CCC[C@]1(C)C=Cc2c(O)c3c(c(CC=C(C)C)c2O1)O[C@]12C(=C[C@@H]4CC1C(C)(C)O[C@@]2(C/C=C(/C)C(N)=O)C4=O)C3=O		CHEMBL444109		Activity			CHEMBL4282	Homo sapiens	Activity		
	2151007	CHEMBL925864	Binding affinity to Rac	B	CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1		CHEMBL257119	=	Activity	uM	50.0	CHEMBL4282	Homo sapiens	Activity	uM	50.0
	2153730	CHEMBL935767	Inhibition of PKBalpha at 20 uM	B	CN(C)CCOc1ccc2c(-c3c(-c4ccccn4)nn4c3CCC4)ccnc2c1		CHEMBL409525	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	Inhibition	%	50.0
	2153765	CHEMBL935767	Inhibition of PKBalpha at 20 uM	B	c1ccc(-c2nn3c(c2-c2ccnc4cc(OCCN5CCOCC5)ccc24)CCC3)nc1		CHEMBL260015	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	Inhibition	%	50.0
	2158762	CHEMBL922525	Inhibition of Akt	B	Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL259922	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	2159780	CHEMBL928166	Inhibition of Akt1	B	Nc1ncnc2c1N=C(c1ccccc1)CCN2		CHEMBL262623	=	IC50	nM	92000.0	CHEMBL4282	Homo sapiens	IC50	uM	92.0
	2159806	CHEMBL928166	Inhibition of Akt1	B	Cc1cccc(C2=Nc3c(N)ncnc3NCC2)c1		CHEMBL263902	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	2159807	CHEMBL928166	Inhibition of Akt1	B	Nc1nc(N)c2c(n1)NCCC(c1ccc(Cl)cc1)=N2		CHEMBL260620	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	2159808	CHEMBL928166	Inhibition of Akt1	B	Nc1nc(N)c2c(n1)NCCC(c1cccc(Cl)c1)=N2		CHEMBL259381	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	2159809	CHEMBL928166	Inhibition of Akt1	B	Nc1nc(N)c2c(n1)NCCC(c1ccccc1)=N2		CHEMBL259380	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	2159810	CHEMBL928166	Inhibition of Akt1	B	Nc1ncnc2c1N=C(c1ccc(Cl)cc1)CCN2		CHEMBL407265	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	2159811	CHEMBL928166	Inhibition of Akt1	B	Nc1ncnc2c1N=C(c1cccc(Cl)c1)CCN2		CHEMBL407532	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	2159812	CHEMBL928166	Inhibition of Akt1	B	Cc1ccc(C2=Nc3c(N)ncnc3NCC2)cc1		CHEMBL405233	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	2168118	CHEMBL927988	Inhibition of AKT	B	Cc1c(Nc2c(C#N)cnc3sc(-c4cccc(CN(C)C)c4)cc23)ccc2[nH]ccc12		CHEMBL402818	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	2169576	CHEMBL936668	Inhibition of AKT1	B	c1ccc(-c2nnc[nH]2)c(Nc2ncnc3[nH]ccc23)c1		CHEMBL261204	=	IC50	nM	210.0	CHEMBL4282	Homo sapiens	IC50	nM	210.0
	2169577	CHEMBL936668	Inhibition of AKT1	B	N#Cc1c[nH]c2ncnc(N3CC4(CCNCC4)c4ccccc43)c12		CHEMBL258837	=	IC50	nM	2.4	CHEMBL4282	Homo sapiens	IC50	nM	2.4
	2169578	CHEMBL936668	Inhibition of AKT1	B	c1ccc(Cc2c[nH]c3ncnc(N4CC5(CCNCC5)c5ccccc54)c23)cc1		CHEMBL411276	=	IC50	nM	1330.0	CHEMBL4282	Homo sapiens	IC50	nM	1330.0
	2169579	CHEMBL936668	Inhibition of AKT1	B	Cc1c[nH]c2ncnc(N3CC4(CCNCC4)c4ccccc43)c12		CHEMBL259163	=	IC50	nM	4.8	CHEMBL4282	Homo sapiens	IC50	nM	4.8
	2169580	CHEMBL936668	Inhibition of AKT1	B	Clc1c[nH]c2ncnc(N3CC4(CCNCC4)c4ccccc43)c12		CHEMBL411515	=	IC50	nM	5.8	CHEMBL4282	Homo sapiens	IC50	nM	5.8
	2169581	CHEMBL936668	Inhibition of AKT1	B	CS(=O)(=O)N1CCC2(CC1)CN(c1ncnc3[nH]ccc13)c1ccc(F)cc12		CHEMBL410235	=	IC50	nM	3190.0	CHEMBL4282	Homo sapiens	IC50	nM	3190.0
	2169582	CHEMBL936668	Inhibition of AKT1	B	CC(=O)N1CCC2(CC1)CN(c1ncnc3[nH]ccc13)c1ccc(F)cc12		CHEMBL411718	=	IC50	nM	2790.0	CHEMBL4282	Homo sapiens	IC50	nM	2790.0
	2169583	CHEMBL936668	Inhibition of AKT1	B	CN1CCC2(CC1)CN(c1ncnc3[nH]ccc13)c1ccccc12		CHEMBL258838	=	IC50	nM	12.7	CHEMBL4282	Homo sapiens	IC50	nM	12.7
	2169584	CHEMBL936668	Inhibition of AKT1	B	Fc1ccc2c(c1)C1(CCNCC1)CN2c1ncnc2[nH]ccc12		CHEMBL407718	=	IC50	nM	3.1	CHEMBL4282	Homo sapiens	IC50	nM	3.1
	2169585	CHEMBL936668	Inhibition of AKT1	B	Clc1ccc2c(c1)C1(CCNCC1)CN2c1ncnc2[nH]ccc12		CHEMBL449964	=	IC50	nM	4.8	CHEMBL4282	Homo sapiens	IC50	nM	4.8
	2169586	CHEMBL936668	Inhibition of AKT1	B	c1ccc2c(c1)N(c1ncnc3[nH]ccc13)CC21CCNCC1		CHEMBL259265	=	IC50	nM	5.3	CHEMBL4282	Homo sapiens	IC50	nM	5.3
	2169587	CHEMBL936668	Inhibition of AKT1	B	Clc1c[nH]c2ncnc(N3CCc4[nH]cnc4C3)c12		CHEMBL259833	=	IC50	nM	42.0	CHEMBL4282	Homo sapiens	IC50	nM	42.0
	2169588	CHEMBL936668	Inhibition of AKT1	B	c1nc(N2CCc3[nH]cnc3C2)c2cc[nH]c2n1		CHEMBL407891	=	IC50	nM	294.0	CHEMBL4282	Homo sapiens	IC50	nM	294.0
	2169589	CHEMBL936668	Inhibition of AKT1	B	Cc1nnc(-c2ccc(Cl)cc2Nc2ncnc3[nH]ccc23)[nH]1		CHEMBL412114	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	2169590	CHEMBL936668	Inhibition of AKT1	B	Cc1nnc(-c2cc(Cl)ccc2Nc2ncnc3[nH]ccc23)[nH]1		CHEMBL259834	=	IC50	nM	171.0	CHEMBL4282	Homo sapiens	IC50	nM	171.0
	2169591	CHEMBL936668	Inhibition of AKT1	B	Cc1nnc(-c2ccccc2Nc2ncnc3[nH]ccc23)[nH]1		CHEMBL428963	=	IC50	nM	151.0	CHEMBL4282	Homo sapiens	IC50	nM	151.0
	2169592	CHEMBL936668	Inhibition of AKT1	B	Clc1c[nH]c2ncnc(Nc3ccccc3-c3nnc[nH]3)c12		CHEMBL260990	=	IC50	nM	318.0	CHEMBL4282	Homo sapiens	IC50	nM	318.0
	2169593	CHEMBL936668	Inhibition of AKT1	B	Cc1c[nH]c2ncnc(Nc3ccccc3-c3nnc[nH]3)c12		CHEMBL409880	=	IC50	nM	425.0	CHEMBL4282	Homo sapiens	IC50	nM	425.0
	2169594	CHEMBL936668	Inhibition of AKT1	B	Cn1ccc2c(Nc3ccccc3-c3nnc[nH]3)ncnc21		CHEMBL261205	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	2169595	CHEMBL936669	Inhibition of AKT1 in human U87 cells after 2 hrs by ELISA	B	c1ccc2c(c1)N(c1ncnc3[nH]ccc13)CC21CCNCC1		CHEMBL259265	=	IC50	nM	96.0	CHEMBL4282	Homo sapiens	IC50	nM	96.0
	2169596	CHEMBL936669	Inhibition of AKT1 in human U87 cells after 2 hrs by ELISA	B	N#Cc1c[nH]c2ncnc(N3CC4(CCNCC4)c4ccccc43)c12		CHEMBL258837	=	IC50	nM	50.0	CHEMBL4282	Homo sapiens	IC50	nM	50.0
Not Determined	2169597	CHEMBL936669	Inhibition of AKT1 in human U87 cells after 2 hrs by ELISA	B	c1ccc(Cc2c[nH]c3ncnc(N4CC5(CCNCC5)c5ccccc54)c23)cc1		CHEMBL411276		IC50			CHEMBL4282	Homo sapiens	IC50		
	2169598	CHEMBL936669	Inhibition of AKT1 in human U87 cells after 2 hrs by ELISA	B	Cc1c[nH]c2ncnc(N3CC4(CCNCC4)c4ccccc43)c12		CHEMBL259163	=	IC50	nM	122.0	CHEMBL4282	Homo sapiens	IC50	nM	122.0
	2169599	CHEMBL936669	Inhibition of AKT1 in human U87 cells after 2 hrs by ELISA	B	Clc1c[nH]c2ncnc(N3CC4(CCNCC4)c4ccccc43)c12		CHEMBL411515	=	IC50	nM	64.0	CHEMBL4282	Homo sapiens	IC50	nM	64.0
Not Determined	2169600	CHEMBL936669	Inhibition of AKT1 in human U87 cells after 2 hrs by ELISA	B	CS(=O)(=O)N1CCC2(CC1)CN(c1ncnc3[nH]ccc13)c1ccc(F)cc12		CHEMBL410235		IC50			CHEMBL4282	Homo sapiens	IC50		
	2169601	CHEMBL936669	Inhibition of AKT1 in human U87 cells after 2 hrs by ELISA	B	CN1CCC2(CC1)CN(c1ncnc3[nH]ccc13)c1ccccc12		CHEMBL258838	=	IC50	nM	136.0	CHEMBL4282	Homo sapiens	IC50	nM	136.0
	2169602	CHEMBL936669	Inhibition of AKT1 in human U87 cells after 2 hrs by ELISA	B	Fc1ccc2c(c1)C1(CCNCC1)CN2c1ncnc2[nH]ccc12		CHEMBL407718	=	IC50	nM	75.0	CHEMBL4282	Homo sapiens	IC50	nM	75.0
	2169603	CHEMBL936669	Inhibition of AKT1 in human U87 cells after 2 hrs by ELISA	B	Clc1ccc2c(c1)C1(CCNCC1)CN2c1ncnc2[nH]ccc12		CHEMBL449964	=	IC50	nM	51.0	CHEMBL4282	Homo sapiens	IC50	nM	51.0
Not Determined	2169604	CHEMBL936669	Inhibition of AKT1 in human U87 cells after 2 hrs by ELISA	B	CC(=O)N1CCC2(CC1)CN(c1ncnc3[nH]ccc13)c1ccc(F)cc12		CHEMBL411718		IC50			CHEMBL4282	Homo sapiens	IC50		
	2171146	CHEMBL937417	Inhibition of Akt1	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	58.0	CHEMBL4282	Homo sapiens	IC50	nM	58.0
	2171148	CHEMBL937419	Inhibition of Akt1 by cell-based assay	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	200.0	CHEMBL4282	Homo sapiens	IC50	nM	200.0
	2171150	CHEMBL937417	Inhibition of Akt1	B	O=C1N=CC=C2N=C(c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)C(c3ccccc3)=CC12		CHEMBL262341	=	IC50	nM	3.5	CHEMBL4282	Homo sapiens	IC50	nM	3.5
	2171151	CHEMBL937417	Inhibition of Akt1	B	c1ccc(-c2cc3ncccc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL259753	=	IC50	nM	5.6	CHEMBL4282	Homo sapiens	IC50	nM	5.6
	2171152	CHEMBL937417	Inhibition of Akt1	B	c1ccc(-c2cc3cnccc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL259967	=	IC50	nM	7.4	CHEMBL4282	Homo sapiens	IC50	nM	7.4
	2171153	CHEMBL937417	Inhibition of Akt1	B	c1ccc(-c2cc3ccncc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL259968	=	IC50	nM	21.0	CHEMBL4282	Homo sapiens	IC50	nM	21.0
	2171154	CHEMBL937417	Inhibition of Akt1	B	c1ccc(-c2cc3cccnc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL260670	=	IC50	nM	45.0	CHEMBL4282	Homo sapiens	IC50	nM	45.0
	2171155	CHEMBL937417	Inhibition of Akt1	B	c1ccc(-c2cc(C3CCN(Cc4ccc(-c5nc6ncccc6cc5-c5ccccc5)cc4)CC3)n[nH]2)cc1		CHEMBL429703	=	IC50	nM	470.0	CHEMBL4282	Homo sapiens	IC50	nM	470.0
	2171156	CHEMBL937417	Inhibition of Akt1	B	O=c1ccc(-c2cc(C3CCN(Cc4ccc(-c5nc6ncccc6cc5-c5ccccc5)cc4)CC3)n[nH]2)c[nH]1		CHEMBL260184	=	IC50	nM	34.0	CHEMBL4282	Homo sapiens	IC50	nM	34.0
	2171157	CHEMBL937417	Inhibition of Akt1	B	c1ccc(-c2cc3cccnc3nc2-c2ccc(CN3CCC(c4cc(-c5ccccn5)[nH]n4)CC3)cc2)cc1		CHEMBL259982	=	IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	nM	44.0
	2171158	CHEMBL937417	Inhibition of Akt1	B	c1ccc(-c2cc3cccnc3nc2-c2ccc(CN3CCC(c4cc(-c5cccnc5)[nH]n4)CC3)cc2)cc1		CHEMBL407733	=	IC50	nM	250.0	CHEMBL4282	Homo sapiens	IC50	nM	250.0
	2171159	CHEMBL937417	Inhibition of Akt1	B	c1ccc(-c2cc3cccnc3nc2-c2ccc(CN3CCC(c4cc(-c5ccncc5)[nH]n4)CC3)cc2)cc1		CHEMBL261540	=	IC50	nM	120.0	CHEMBL4282	Homo sapiens	IC50	nM	120.0
	2171160	CHEMBL937417	Inhibition of Akt1	B	c1ccc(-c2nc3ccccc3nc2-c2ccc(CN3CCC(c4cc(-c5ccncc5)[nH]n4)CC3)cc2)cc1		CHEMBL261542	=	IC50	nM	75.0	CHEMBL4282	Homo sapiens	IC50	nM	75.0
	2171161	CHEMBL937417	Inhibition of Akt1	B	Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4nc3-c3ccccc3)cc2)CC1		CHEMBL260397	=	IC50	nM	295.0	CHEMBL4282	Homo sapiens	IC50	nM	295.0
	2171162	CHEMBL937417	Inhibition of Akt1	B	CCN(CC)CCNC(=O)c1ccc2nc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc2c1		CHEMBL258696	=	IC50	nM	138.0	CHEMBL4282	Homo sapiens	IC50	nM	138.0
	2171176	CHEMBL937419	Inhibition of Akt1 by cell-based assay	B	O=C1N=CC=C2N=C(c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)C(c3ccccc3)=CC12		CHEMBL262341	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
	2171177	CHEMBL937419	Inhibition of Akt1 by cell-based assay	B	c1ccc(-c2cc3ncccc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL259753	=	IC50	nM	30.0	CHEMBL4282	Homo sapiens	IC50	nM	30.0
	2171178	CHEMBL937419	Inhibition of Akt1 by cell-based assay	B	c1ccc(-c2cc3cnccc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL259967	=	IC50	nM	21.0	CHEMBL4282	Homo sapiens	IC50	nM	21.0
	2171179	CHEMBL937419	Inhibition of Akt1 by cell-based assay	B	c1ccc(-c2cc3ccncc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL259968	=	IC50	nM	31.0	CHEMBL4282	Homo sapiens	IC50	nM	31.0
	2171180	CHEMBL937419	Inhibition of Akt1 by cell-based assay	B	c1ccc(-c2cc3cccnc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL260670	=	IC50	nM	83.0	CHEMBL4282	Homo sapiens	IC50	nM	83.0
Not Determined	2171181	CHEMBL937419	Inhibition of Akt1 by cell-based assay	B	c1ccc(-c2cc(C3CCN(Cc4ccc(-c5nc6ncccc6cc5-c5ccccc5)cc4)CC3)n[nH]2)cc1		CHEMBL429703		IC50			CHEMBL4282	Homo sapiens	IC50		
	2171182	CHEMBL937419	Inhibition of Akt1 by cell-based assay	B	O=c1ccc(-c2cc(C3CCN(Cc4ccc(-c5nc6ncccc6cc5-c5ccccc5)cc4)CC3)n[nH]2)c[nH]1		CHEMBL260184	=	IC50	nM	132.0	CHEMBL4282	Homo sapiens	IC50	nM	132.0
	2171183	CHEMBL937419	Inhibition of Akt1 by cell-based assay	B	c1ccc(-c2cc3cccnc3nc2-c2ccc(CN3CCC(c4cc(-c5ccccn5)[nH]n4)CC3)cc2)cc1		CHEMBL259982	=	IC50	nM	149.0	CHEMBL4282	Homo sapiens	IC50	nM	149.0
Not Determined	2171184	CHEMBL937419	Inhibition of Akt1 by cell-based assay	B	c1ccc(-c2cc3cccnc3nc2-c2ccc(CN3CCC(c4cc(-c5cccnc5)[nH]n4)CC3)cc2)cc1		CHEMBL407733		IC50			CHEMBL4282	Homo sapiens	IC50		
	2171185	CHEMBL937419	Inhibition of Akt1 by cell-based assay	B	c1ccc(-c2cc3cccnc3nc2-c2ccc(CN3CCC(c4cc(-c5ccncc5)[nH]n4)CC3)cc2)cc1		CHEMBL261540	=	IC50	nM	369.0	CHEMBL4282	Homo sapiens	IC50	nM	369.0
	2171186	CHEMBL937419	Inhibition of Akt1 by cell-based assay	B	CCN(CC)CCNC(=O)c1ccc2nc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc2c1		CHEMBL258696	=	IC50	nM	527.0	CHEMBL4282	Homo sapiens	IC50	nM	527.0
	2182406	CHEMBL941305	Inhibition of AKT at 1 uM	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL514554	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2182802	CHEMBL941429	Inhibition of AKT1 at 5 uM	B	O=c1cc(N2CCOCC2)nc2c3ccccc3ccn12		CHEMBL179242	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
Active	2182845	CHEMBL941473	Inhibition of Akt S473D mutant transfected in african green monkey COS7 cells assessed as insulin-induced Ser473 phosphorylation by Western blot	B	O=c1cc(N2CCOCC2)nc2c3ccccc3ccn12		CHEMBL179242		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	2199471	CHEMBL952473	Inhibition of FBS-stimulated increase in Akt phosphorylation in human SW480 cells at 20 uM by immunoblot analysis	B	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21		CHEMBL503		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	2200810	CHEMBL948617	Inhibition of IGF-induced Akt phosphorylation in human MDA-MB-231 cells by Western blot	B	Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1		CHEMBL165		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	2200811	CHEMBL948618	Reversal of induction of Akt inactivation in human MDA-MB-231 cells transfected with constitutively activated Akt mutant	B	Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1		CHEMBL165		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	2200814	CHEMBL948621	Enhancement of Akt inactivation in human MDA-MB-231 cells transfected with dominant negative Akt mutant	B	Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1		CHEMBL165		Activity			CHEMBL4282	Homo sapiens	Activity		
	2239719	CHEMBL996948	Inhibition of PKBalpha at 10 uM	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)ccc2n1CCCc1nnn[nH]1		CHEMBL471329	=	Inhibition	%	31.0	CHEMBL4282	Homo sapiens	INH	%	31.0
	2239747	CHEMBL996948	Inhibition of PKBalpha at 10 uM	B	CS(=O)(=O)NC(=O)CCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL460940	=	Inhibition	%	63.0	CHEMBL4282	Homo sapiens	INH	%	63.0
	2239775	CHEMBL996948	Inhibition of PKBalpha at 10 uM	B	CN(C)CCNC(=O)CCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL462011	=	Inhibition	%	15.0	CHEMBL4282	Homo sapiens	INH	%	15.0
	2239803	CHEMBL996948	Inhibition of PKBalpha at 10 uM	B	CNCCCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL508541	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	2239831	CHEMBL996948	Inhibition of PKBalpha at 10 uM	B	CNCCCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4)cc21)C(=O)NC3=O		CHEMBL455192	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	INH	%	12.0
	2239859	CHEMBL996948	Inhibition of PKBalpha at 10 uM	B	O=C1NC(=O)c2c1c(-c1c(Cl)cccc1Cl)cc1c2c2cc(O)ccc2n1CCCO		CHEMBL471163	=	Inhibition	%	55.0	CHEMBL4282	Homo sapiens	INH	%	55.0
	2239886	CHEMBL996948	Inhibition of PKBalpha at 10 uM	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)ccc2n1CCCO		CHEMBL411662	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	INH	%	12.0
	2239914	CHEMBL996948	Inhibition of PKBalpha at 10 uM	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1[nH]c3ccc(O)cc3c21		CHEMBL379975	=	Inhibition	%	26.0	CHEMBL4282	Homo sapiens	INH	%	26.0
Not Active	2240593	CHEMBL971752	Inhibition of AKT1 at 30 uM	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(C(F)(F)F)cc3)c2)n1		CHEMBL523411		Activity			CHEMBL4282	Homo sapiens	Activity		
	2248183	CHEMBL1012666	Inhibition of AKT1 at 5 uM	B	O=C1NC(=O)/C(=C/c2cccc(C(F)(F)F)c2)S1		CHEMBL183906	=	Inhibition	%	-9.0	CHEMBL4282	Homo sapiens	INH	%	-9.0
	2248213	CHEMBL1012666	Inhibition of AKT1 at 5 uM	B	CCCOc1ccc(/C=C2\SC(=O)NC2=O)cc1		CHEMBL84558	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
	2250929	CHEMBL1022473	Inhibition of AKT1	B	Nc1nccc(-c2cc3c([nH]2)[C@@H](CCF)CNC3=O)n1		CHEMBL524266	>	IC50	nM	4000.0	CHEMBL4282	Homo sapiens	IC50	uM	4.0
	2251054	CHEMBL1011929	Inhibition of AKT1 at 100 nM relative to control	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL525385	=	Inhibition	%	89.0	CHEMBL4282	Homo sapiens	INH	%	89.0
	2282301	CHEMBL957583	Inhibition of AKT at 100 uM	B	COc1ccc2sc(Sc3ncc([N+](=O)[O-])s3)nc2c1		CHEMBL474804	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	2282303	CHEMBL957583	Inhibition of AKT at 100 uM	B	O=[N+]([O-])c1cnc(Sc2nc3ccccc3s2)s1		CHEMBL493539	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
Not Active	2298976	CHEMBL1020730	Inhibition of human PKBalpha at 10 umol/L	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C(=O)N(C)C)cc1)c1ccccc1		CHEMBL525203		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2301931	CHEMBL949868	Inhibition of AKT1 up to 100 uM	B	CN(C)c1ncnc2c1ncn2CC(=O)c1c[nH]c2ccccc12		CHEMBL519977		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	2301955	CHEMBL949868	Inhibition of AKT1 up to 100 uM	B	COc1ncnc2ncn(CC(=O)c3ccccc3)c12		CHEMBL483271		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	2301979	CHEMBL949868	Inhibition of AKT1 up to 100 uM	B	COc1ncnc2c1ncn2CC(=O)c1ccccc1		CHEMBL519976		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	2302003	CHEMBL949868	Inhibition of AKT1 up to 100 uM	B	Nc1ncnc2c1ncn2CC(=O)c1cccnc1		CHEMBL501256		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	2302027	CHEMBL949868	Inhibition of AKT1 up to 100 uM	B	Nc1ncnc2c1ncn2CC(=O)c1ccccn1		CHEMBL504135		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	2302051	CHEMBL949868	Inhibition of AKT1 up to 100 uM	B	Nc1ncnc2ncn(CC(=O)c3ccccc3)c12		CHEMBL485444		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	2302075	CHEMBL949868	Inhibition of AKT1 up to 100 uM	B	Nc1ncnc2c1ncn2CC(=O)c1ccccc1		CHEMBL520515		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	2302099	CHEMBL949868	Inhibition of AKT1 up to 100 uM	B	Nc1ncnc2ncn(CC(=O)c3c[nH]c4ccccc34)c12		CHEMBL485246		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	2302123	CHEMBL949868	Inhibition of AKT1 up to 100 uM	B	Nc1ncnc2c1ncn2CC(=O)c1c[nH]c2ccccc12		CHEMBL521155		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	2302159	CHEMBL950828	Inhibition of PKBalpha S473D mutant at 10 uM	B	Nc1ncnc2ncn(CC(=O)c3c[nH]c4ccccc34)c12		CHEMBL485246		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	2341433	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(N3CCN(C(=O)Cc4c[nH]c5ccccc45)CC3)ncn2)c1		CHEMBL524898	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2341474	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	CN(C)CC(C)(C)CNC(=O)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1		CHEMBL501459	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2341515	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Nc1nc(N2CCOCC2)cc(N2CCC(C(=O)NCCc3ccc(O)cc3)CC2)n1		CHEMBL501728	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	2341556	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	O=C(NCCc1ccc(O)cc1)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1		CHEMBL499617	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2341597	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	O=C(c1nc(SCc2ccc(Cl)cc2)n2ccccc12)N1CCN(c2cc(Nc3cccc(Br)c3)ncn2)CC1		CHEMBL501200	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2341638	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Nc1nc(Nc2ccc3ncsc3c2)cc(N2CCC[C@H]2C(=O)N[C@@H](CO)c2ccccc2)n1		CHEMBL525070	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2341679	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Nc1nc(Nc2ccc3ncsc3c2)cc(N2CCC[C@H]2C(=O)NCCc2cccc(I)c2)n1		CHEMBL501463	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2341720	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	O=C(NC1Cc2ccccc2C1)c1cccc(Nc2ccnc(N3CCN(c4ccccc4)CC3)n2)c1		CHEMBL499624	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	2341761	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCc4ccc(N(C)C)cc4)c3)ncn2)c1		CHEMBL502826	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2341802	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3ccc(CC(=O)Nc4ccc5ncsc5c4)cc3)ncn2)c1		CHEMBL502827	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2341843	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	COc1ccc(NC(=O)Cc2ccc(Nc3cc(N(C)c4cccc(C)c4)ncn3)cc2)cn1		CHEMBL526914	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2341884	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2nccc(Nc3cccc(C(=O)NCc4ccc(N(C)C)cc4)c3)n2)c1		CHEMBL501471	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	2341925	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	O=C(NCc1cccnc1)c1cccc(-c2ccc(Nc3ccc4ncsc4c3)nn2)c1		CHEMBL501182	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	2341966	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N4CCCC5CCCCC54)c3)ncn2)c1		CHEMBL499606	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
	2342007	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	COc1cccc(Nc2cc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)nc(N)n2)c1		CHEMBL499865	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	2342048	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2nccc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)n2)c1		CHEMBL499866	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342089	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	O=C(CN1CCN(c2ncnc3c2CN(Cc2ccccc2)CC3)CC1)Nc1cc(F)ccc1F		CHEMBL520451	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342130	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	O=C(NCc1ccncc1)c1cccc(Nc2cc(Nc3cccc(Br)c3)ncn2)c1		CHEMBL482513	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342171	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2cc(Nc3cccc(C(=O)N(CC(C)O)CC(C)O)c3)ncn2)c1		CHEMBL483318	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	2342221	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCCCn4ccnc4)c3)ncn2)c1		CHEMBL520971	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342259	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N(C)CCc4ccccn4)c3)ncn2)c1		CHEMBL521469	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	2342294	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	CC(=O)N1CCN(C(=O)c2cccc(Nc3cc(N(C)c4cccc(C)c4)ncn3)c2)CC1		CHEMBL521478	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342335	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)NCc4ccncc4)c3)ncn2)c1		CHEMBL483506	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342376	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	CN(CCc1ccccn1)C(=O)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1		CHEMBL483507	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342417	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	COc1cccc(Nc2cc(Nc3cccc(C(=O)NCCCn4ccnc4)c3)nc(N)n2)c1		CHEMBL520980	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	2342458	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	COC[C@@H]1CCCN1C(=O)[C@@H]1CCCN1c1cc(Nc2cccc(OC)c2)nc(N)n1		CHEMBL519962	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342499	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	COc1cccc(Nc2cc(N3CCC[C@H]3C(=O)NCCN3CCCCC3)nc(N)n2)c1		CHEMBL526526	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	2342540	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	O=C(COc1ccccc1)N1CCN(c2nccc(Nc3ccc4ncsc4c3)n2)CC1		CHEMBL482488	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	2342813	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	O=C(NC[C@@H]1CCCO1)c1cccc(Nc2nccc(Nc3ccc4ncsc4c3)n2)c1		CHEMBL500661	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342846	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Clc1ccc2sc(CN3CCN(c4ncnc5c4CN(Cc4ccccc4)CC5)CC3)cc2c1		CHEMBL483710	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	2342848	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	COc1cccc(Nc2cc(N3CCC[C@H]3C(=O)NCCc3ccc(O)cc3)nc(N)n2)c1		CHEMBL483518	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	2342849	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	CN(C)c1ccc(C(=O)N2CCN(c3ncnc4c3CN(Cc3ccccc3)CC4)CC2)c2ccccc12		CHEMBL520331	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	2342867	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(Oc2ccnc(N3CCN(C(=O)c4c(C)noc4C)CC3)n2)c1		CHEMBL482721	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	2342868	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	CN(CCc1ccccn1)C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1		CHEMBL521479	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	2342874	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(CN2CCN(c3cc(N(C)c4cccc(C)c4)ncn3)CC2)c1		CHEMBL446087	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	2342881	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Nc1nc(Nc2ccccc2)cc(N2CCC(C(=O)NCCc3ccccn3)CC2)n1		CHEMBL521002	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342882	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1ccc(CN2CCN(c3nccc(C(C#N)c4ccccn4)n3)CC2)cc1		CHEMBL521145	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342883	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	CN(CCCn1ccnc1)C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1		CHEMBL519658	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342884	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(Nc3cccc(C(=O)N(CC(C)C)CC(C)C)c3)ncn2)c1		CHEMBL484707	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342885	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	O=C(C1CCN(c2nccc(Nc3ccccc3)n2)CC1)N1CC[C@@H](O)C1		CHEMBL484706	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342886	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	CN(C)CC(C)(C)CNC(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1		CHEMBL521000	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342887	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	COC[C@@H]1CCCN1C(=O)[C@@H]1CCCN1c1nccc(Nc2ccccc2)n1		CHEMBL519349	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342888	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	COC[C@@H]1CCCN1C(=O)C1CCCN1c1cc(Nc2cccc(Br)c2)ncn1		CHEMBL484521	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342889	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2ncnc3c2CN(C(=O)c2ccc(N(C)C)c4ccccc24)CC3)c1		CHEMBL484324	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342890	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	O=C(c1nc(SCc2ccc(Cl)cc2)n2ccccc12)N1CCN(c2ncnc3c2CN(Cc2ccccc2)CC3)CC1		CHEMBL446637	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342891	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(Oc2ccnc(N3CCC[C@H]3C(=O)NCCCn3ccnc3)n2)c1		CHEMBL482722	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342892	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	CN(C)CC(C)(C)CNC(=O)C1CCN(c2cc(N3CCOCC3)nc(N)n2)CC1		CHEMBL519311	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342893	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	COC(=O)C(CO)NC(=O)[C@@H]1CCCN1c1nccc(Oc2cccc(C)c2)n1		CHEMBL519310	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342894	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(Oc2ccnc(N3CCC[C@H]3C(=O)NCc3cccnc3)n2)c1		CHEMBL482717	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342895	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Nc1nc(N2CCOCC2)cc(N2CCC(C(=O)NCc3cccs3)CC2)n1		CHEMBL482910	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342896	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cc(C(=O)N2CCN(c3ncnc4c3CN(Cc3ccccc3)CC4)CC2)c(C)n1C		CHEMBL482710	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342897	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(Nc2nccc3c2CN(C(=O)c2cc(C)n(C)c2C)CC3)c1		CHEMBL519146	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342898	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(N(C)c2cc(N3CCN(CC(=O)Nc4nc(-c5ccccc5)cs4)CC3)ncn2)c1		CHEMBL519534	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342899	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Cc1cccc(Oc2ccnc(N3CCN(CC(=O)Nc4cccc5c4CCCC5)CC3)n2)c1		CHEMBL520512	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	2342900	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	COc1ccc(-c2noc(CN3CCN(c4cc(Nc5cccc(O)c5)ncn4)CC3)n2)cc1		CHEMBL483715	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342901	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	CC(=O)CCCCC(=O)N1CCN(c2nccc(Oc3cccc(C)c3)n2)CC1		CHEMBL484713	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2342902	CHEMBL953394	Inhibition of AKT1/PKBalpha at 10 uM by HTRF assay relative to control	B	Nc1nc(Nc2ccc(C(=O)NCCc3ccncc3)cc2)cc(N2CCOCC2)n1		CHEMBL485524	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	2353893	CHEMBL953204	Inhibition of PKBalpha	B	COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1		CHEMBL494979	>	Activity	uM	10.0	CHEMBL4282	Homo sapiens	Activity	uM	10.0
	2356960	CHEMBL958257	Inhibition of PKBalpha at 1 uM relative to control	B	Cc1ccn(-c2cccc(C(F)(F)F)c2)c(=O)c1-c1ccc2nc(N)ncc2c1		CHEMBL504805	>	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	2357005	CHEMBL964659	Inhibition of AKT1 at 1 uM relative to control	B	Cc1ccn(-c2ccc(-c3ncco3)cc2)c(=O)c1-c1ccc2nc(N)ncc2c1		CHEMBL525893	>	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	2360381	CHEMBL980865	Inhibition of Akt Ser 473 phosphorylation in PTEN-null human U87MG cells	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	=	IC50	nM	46.0	CHEMBL4282	Homo sapiens	IC50	uM	0.046
	2360382	CHEMBL980866	Inhibition of Akt Ser 473 phosphorylation in PTEN-null human PC3 cells	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	=	IC50	nM	37.0	CHEMBL4282	Homo sapiens	IC50	uM	0.037
	2360383	CHEMBL980867	Inhibition of Akt Ser 473 phosphorylation in human MDA-MB-361 cells with PIK3CA E545-K mutation	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	=	IC50	nM	28.0	CHEMBL4282	Homo sapiens	IC50	uM	0.028
	2361194	CHEMBL970670	Inhibition of PKBalpha	B	COc1cc2c(Oc3ccc(-c4cnc(Cc5ccccc5)n(C)c4=O)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL505896	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
	2361216	CHEMBL970670	Inhibition of PKBalpha	B	COc1cc2c(Oc3ccc(-c4cnc(Nc5ccc(F)cc5)n(C)c4=O)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL453737	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
	2361239	CHEMBL970670	Inhibition of PKBalpha	B	COc1cc2c(Oc3ccc(-c4cnc(Nc5ccc(F)cc5)n(C)c4=O)nc3)ccnc2cc1OCCCN1CCOCC1		CHEMBL447602	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
	2361597	CHEMBL980899	Inhibition of AKT	B	Cc1cc(C2CCN(CCCF)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12		CHEMBL459729	=	IC50	nM	48390.0	CHEMBL4282	Homo sapiens	IC50	uM	48.39
	2362681	CHEMBL1034885	Inhibition of Akt	B	COc1ccc(-c2cncc(C#N)c2Nc2ccc3[nH]ccc3c2)cc1OC		CHEMBL492251	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	2367150	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2cncc(OC3CCNCC3)c21		CHEMBL493911	=	IC50	nM	79.0	CHEMBL4282	Homo sapiens	IC50	uM	0.079
	2367155	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCCNC[C@H](O)CO)c21		CHEMBL522351	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	uM	0.003
	2367156	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCCNCCc3ccc(OC)cc3)c21		CHEMBL494060	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	uM	0.005
	2367157	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCNC3)c21		CHEMBL521642	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	uM	0.003
	2367158	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	uM	0.002
	2367159	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	uM	0.008
	2367160	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNC3)c21		CHEMBL494088	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	uM	0.008
	2367161	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC[C@@H](N)Cc3ccccc3)c21		CHEMBL523859	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	uM	0.003
	2367162	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCN)c21		CHEMBL453510	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	uM	0.002
	2367163	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	uM	0.01
	2367164	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCCCN)c21		CHEMBL493269	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	uM	0.009
	2367165	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	IC50	nM	794.0	CHEMBL4282	Homo sapiens	IC50	uM	0.794
	2367166	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(C#CCCO)ncc(OCCCN)c21		CHEMBL493875	=	IC50	nM	50.0	CHEMBL4282	Homo sapiens	IC50	uM	0.05
	2367167	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(C#CCO)ncc(OCCCN)c21		CHEMBL523523	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	uM	0.002
	2367168	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCCN)c21		CHEMBL493874	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	uM	0.006
	2367169	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(C#CC3CC3)ncc(OCCCN)c21		CHEMBL494882	=	IC50	nM	79.0	CHEMBL4282	Homo sapiens	IC50	uM	0.079
	2367170	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(-c3cn[nH]c3)ncc(OCCCN)c21		CHEMBL450487	=	IC50	nM	3160.0	CHEMBL4282	Homo sapiens	IC50	uM	3.16
	2367171	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(-c3cc[nH]c3)ncc(OCCCN)c21		CHEMBL523057	=	IC50	nM	32.0	CHEMBL4282	Homo sapiens	IC50	uM	0.032
	2367172	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(-c3ccoc3)ncc(OCCCN)c21		CHEMBL445180	=	IC50	nM	79.0	CHEMBL4282	Homo sapiens	IC50	uM	0.079
	2367173	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(-c3ccc[nH]3)ncc(OCCCN)c21		CHEMBL493251	=	IC50	nM	32.0	CHEMBL4282	Homo sapiens	IC50	uM	0.032
	2367174	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2c(-c3ccccc3)ncc(OCCCN)c21		CHEMBL493250	=	IC50	nM	331.0	CHEMBL4282	Homo sapiens	IC50	uM	0.331
	2367175	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2cncc(CNC3CCNCC3)c21		CHEMBL188434	=	IC50	nM	200.0	CHEMBL4282	Homo sapiens	IC50	uM	0.2
	2367176	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NC3CCNCC3)c21		CHEMBL494662	=	IC50	nM	562.0	CHEMBL4282	Homo sapiens	IC50	uM	0.562
	2367177	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2cncc(OCC3CCNCC3)c21		CHEMBL521823	=	IC50	nM	56.0	CHEMBL4282	Homo sapiens	IC50	uM	0.056
	2367178	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NC3CCCNC3)c21		CHEMBL493067	=	IC50	nM	631.0	CHEMBL4282	Homo sapiens	IC50	uM	0.631
	2367179	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21		CHEMBL493066	=	IC50	nM	501.0	CHEMBL4282	Homo sapiens	IC50	uM	0.501
	2367180	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@@H](N)C3)c21		CHEMBL523695	=	IC50	nM	331.0	CHEMBL4282	Homo sapiens	IC50	uM	0.331
	2367181	CHEMBL1028090	Inhibition of human AKT1	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	IC50	nM	126.0	CHEMBL4282	Homo sapiens	IC50	uM	0.126
	2367232	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(-c3ccccc3)ncc(OCCCN)c21		CHEMBL493250	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
Not Determined	2367251	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064		IC50			CHEMBL4282	Homo sapiens	IC50		
	2367252	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(C#CCCO)ncc(OCCCN)c21		CHEMBL493875	=	IC50	nM	6200.0	CHEMBL4282	Homo sapiens	IC50	uM	6.2
	2367253	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(C#CCO)ncc(OCCCN)c21		CHEMBL523523	=	IC50	nM	1130.0	CHEMBL4282	Homo sapiens	IC50	uM	1.13
	2367254	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCCN)c21		CHEMBL493874	=	IC50	nM	1050.0	CHEMBL4282	Homo sapiens	IC50	uM	1.05
	2367255	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC3CC3)ncc(OCCCN)c21		CHEMBL494882	=	IC50	nM	3900.0	CHEMBL4282	Homo sapiens	IC50	uM	3.9
	2367256	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(-c3cn[nH]c3)ncc(OCCCN)c21		CHEMBL450487	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	2367257	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(-c3cc[nH]c3)ncc(OCCCN)c21		CHEMBL523057	=	IC50	nM	2760.0	CHEMBL4282	Homo sapiens	IC50	uM	2.76
	2367258	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(-c3ccoc3)ncc(OCCCN)c21		CHEMBL445180	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	2367259	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(-c3ccc[nH]3)ncc(OCCCN)c21		CHEMBL493251	=	IC50	nM	3380.0	CHEMBL4282	Homo sapiens	IC50	uM	3.38
	2367278	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCCCN)c21		CHEMBL493269	=	IC50	nM	1510.0	CHEMBL4282	Homo sapiens	IC50	uM	1.51
	2367282	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCCNC[C@H](O)CO)c21		CHEMBL522351	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	2367283	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCCNCCc3ccc(OC)cc3)c21		CHEMBL494060	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	uM	0.14
	2367284	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCNC3)c21		CHEMBL521642	=	IC50	nM	400.0	CHEMBL4282	Homo sapiens	IC50	uM	0.4
	2367285	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	uM	0.14
	2367286	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	IC50	nM	560.0	CHEMBL4282	Homo sapiens	IC50	uM	0.56
	2367287	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNC3)c21		CHEMBL494088	=	IC50	nM	1010.0	CHEMBL4282	Homo sapiens	IC50	uM	1.01
	2367288	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC[C@@H](N)Cc3ccccc3)c21		CHEMBL523859	=	IC50	nM	100.0	CHEMBL4282	Homo sapiens	IC50	uM	0.1
	2367289	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCCN)c21		CHEMBL453510	=	IC50	nM	230.0	CHEMBL4282	Homo sapiens	IC50	uM	0.23
	2367290	CHEMBL1028096	Inhibition of AKT-mediated GSK3-beta phosphorylation in human BT474 cells	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	IC50	nM	2100.0	CHEMBL4282	Homo sapiens	IC50	uM	2.1
	2367357	CHEMBL1028117	Binding affinity to human AKT1	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Ki	nM	1.0	CHEMBL4282	Homo sapiens	Ki	nM	1.0
	2396059	CHEMBL1006298	Inhibition of AKT1 at 1 uM relative to control	B	COc1ccc(/C=N/Nc2[nH]nc(C)c2C(=O)Nc2cccc(NC(C)=O)c2)cc1		CHEMBL515560	=	Inhibition	%	13.0	CHEMBL4282	Homo sapiens	INH	%	13.0
	2401985	CHEMBL1016204	Inhibition of AKT	B	O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccc(-c2ccoc2)c(O)c1		CHEMBL504547	=	IC50	nM	10200.0	CHEMBL4282	Homo sapiens	IC50	uM	10.2
Dose-dependent effect	2407689	CHEMBL961769	Inhibition of AKT phosphorylation in human CL1-0 cells by Western blot	B	COc1ccc2c(CN3CCC(CO)CC3)cc3cc4c(cc3c2c1)OCO4		CHEMBL231594		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	2407692	CHEMBL956738	Inhibition of TNF-alpha-induced AKT activation in human CL1-0 cells by Western blot	B	COc1ccc2c(CN3CCC(CO)CC3)cc3cc4c(cc3c2c1)OCO4		CHEMBL231594		Activity			CHEMBL4282	Homo sapiens	Activity		
	2408688	CHEMBL959242	Inhibition of AKT1	B	NCC(NC(=O)c1ccc(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL471034	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	2408689	CHEMBL959242	Inhibition of AKT1	B	NCC(NC(=O)c1ccc(-c2c[nH]c3ncccc23)s1)c1ccccc1		CHEMBL470192	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
	2408690	CHEMBL959242	Inhibition of AKT1	B	NCC(NC(=O)c1cc(-c2ccnc3[nH]ccc23)cs1)c1ccccc1		CHEMBL512672	=	IC50	nM	40.0	CHEMBL4282	Homo sapiens	IC50	nM	40.0
	2408691	CHEMBL959242	Inhibition of AKT1	B	NCC(NC(=O)c1cc(-c2c[nH]c3ncccc23)cs1)c1ccccc1		CHEMBL512305	=	IC50	nM	25.0	CHEMBL4282	Homo sapiens	IC50	nM	25.0
	2408692	CHEMBL959242	Inhibition of AKT1	B	NCC(NCc1ccc(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL469560	=	IC50	nM	100.0	CHEMBL4282	Homo sapiens	IC50	nM	100.0
	2408693	CHEMBL959242	Inhibition of AKT1	B	NCC(CNc1ccc(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL469561	=	IC50	nM	250.0	CHEMBL4282	Homo sapiens	IC50	nM	250.0
	2408694	CHEMBL959242	Inhibition of AKT1	B	NCC(C(=O)Nc1ccc(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL512480	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	2408695	CHEMBL959242	Inhibition of AKT1	B	NCC(C(=O)Nc1cc(Br)c(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL472291	=	IC50	nM	25.0	CHEMBL4282	Homo sapiens	IC50	nM	25.0
	2408696	CHEMBL959242	Inhibition of AKT1	B	NCC(NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL512135	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
	2408697	CHEMBL959242	Inhibition of AKT1	B	NCC(NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL512135	=	Ki	nM	20.0	CHEMBL4282	Homo sapiens	Ki	nM	20.0
	2408698	CHEMBL959242	Inhibition of AKT1	B	Cc1cc(C(=O)NC(CN)c2ccccc2)sc1-c1ccnc2[nH]ccc12		CHEMBL469781	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
	2408699	CHEMBL959242	Inhibition of AKT1	B	NCC(NC(=O)c1cc(C2CC2)c(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL512858	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	2408700	CHEMBL959242	Inhibition of AKT1	B	NCC(NC(=O)c1cc(-c2ccccc2)c(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL470200	=	IC50	nM	50.0	CHEMBL4282	Homo sapiens	IC50	nM	50.0
	2408701	CHEMBL959242	Inhibition of AKT1	B	NCC(NC(=O)c1cc(-c2cccnc2)c(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL469357	=	IC50	nM	63.0	CHEMBL4282	Homo sapiens	IC50	nM	63.0
	2408702	CHEMBL959242	Inhibition of AKT1	B	NCC(NC(=O)c1cc(-c2cn[nH]c2)c(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL470202	=	IC50	nM	63.0	CHEMBL4282	Homo sapiens	IC50	nM	63.0
	2408703	CHEMBL959242	Inhibition of AKT1	B	NCCNC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL470409	=	IC50	nM	158.0	CHEMBL4282	Homo sapiens	IC50	nM	158.0
	2408704	CHEMBL959242	Inhibition of AKT1	B	NC(CNC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL512148	=	IC50	nM	40.0	CHEMBL4282	Homo sapiens	IC50	nM	40.0
	2408705	CHEMBL959242	Inhibition of AKT1	B	CNCC(NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL470410	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	2408706	CHEMBL959242	Inhibition of AKT1	B	CN(C)CC(NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL470620	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	nM	20.0
	2408707	CHEMBL959242	Inhibition of AKT1	B	NCCC(NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL469802	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
	2408708	CHEMBL959242	Inhibition of AKT1	B	NCCCC(NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL513019	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	nM	20.0
	2408709	CHEMBL959242	Inhibition of AKT1	B	NCC(Cc1ccccc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL469590	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	2408710	CHEMBL959242	Inhibition of AKT1	B	NCC(Cc1ccccc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL469590	=	Ki	nM	0.04	CHEMBL4282	Homo sapiens	Ki	nM	0.04
	2408711	CHEMBL959242	Inhibition of AKT1	B	CNCC(Cc1ccccc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL469591	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	2408712	CHEMBL959242	Inhibition of AKT1	B	CCNCC(Cc1ccccc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL471059	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	2408713	CHEMBL959242	Inhibition of AKT1	B	CC(C)NCC(Cc1ccccc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL470596	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
	2408714	CHEMBL959242	Inhibition of AKT1	B	NC[C@@H](Cc1ccccc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL513728	=	IC50	nM	32.0	CHEMBL4282	Homo sapiens	IC50	nM	32.0
	2408715	CHEMBL959242	Inhibition of AKT1	B	NC[C@H](Cc1ccccc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL470597	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	2408716	CHEMBL959242	Inhibition of AKT1	B	NC[C@H](CC1CCCCC1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL470598	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	2408717	CHEMBL959242	Inhibition of AKT1	B	NC[C@H](Cc1ccncc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL498051	=	Ki	nM	2.0	CHEMBL4282	Homo sapiens	Ki	nM	2.0
	2408718	CHEMBL959242	Inhibition of AKT1	B	COc1ccc(C[C@@H](CN)NC(=O)c2cc(Br)c(-c3ccnc4[nH]ccc34)s2)cc1		CHEMBL524998	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	2408719	CHEMBL959242	Inhibition of AKT1	B	NC[C@H](Cc1ccccc1F)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL498052	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	2408720	CHEMBL959242	Inhibition of AKT1	B	NC[C@H](Cc1cccc(F)c1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL523586	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	2408721	CHEMBL959242	Inhibition of AKT1	B	NC[C@H](Cc1ccc(F)cc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL496690	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	2408722	CHEMBL959242	Inhibition of AKT1	B	NC[C@H](Cc1ccccc1C(F)(F)F)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL520788	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	2408723	CHEMBL959242	Inhibition of AKT1	B	NC[C@H](Cc1cccc(C(F)(F)F)c1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL482536	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	2408724	CHEMBL959242	Inhibition of AKT1	B	NC[C@H](Cc1ccc(C(F)(F)F)cc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL482537	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	2408725	CHEMBL959242	Inhibition of AKT1	B	NC[C@@H](Cc1ccccc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL513728	=	Ki	nM	20.0	CHEMBL4282	Homo sapiens	Ki	nM	20.0
	2408726	CHEMBL959242	Inhibition of AKT1	B	NC[C@H](Cc1ccccc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL470597	=	Ki	nM	0.06	CHEMBL4282	Homo sapiens	Ki	nM	0.06
	2408727	CHEMBL959242	Inhibition of AKT1	B	NC[C@H](CC1CCCCC1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL470598	=	Ki	nM	0.79	CHEMBL4282	Homo sapiens	Ki	nM	0.79
	2408728	CHEMBL959242	Inhibition of AKT1	B	COc1ccc(C[C@@H](CN)NC(=O)c2cc(Br)c(-c3ccnc4[nH]ccc34)s2)cc1		CHEMBL524998	=	Ki	nM	5.0	CHEMBL4282	Homo sapiens	Ki	nM	5.0
	2408729	CHEMBL959242	Inhibition of AKT1	B	NC[C@H](Cc1cccc(F)c1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL523586	=	Ki	nM	0.03	CHEMBL4282	Homo sapiens	Ki	nM	0.03
	2408730	CHEMBL959242	Inhibition of AKT1	B	NC[C@H](Cc1ccc(F)cc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL496690	=	Ki	nM	0.06	CHEMBL4282	Homo sapiens	Ki	nM	0.06
	2408731	CHEMBL959242	Inhibition of AKT1	B	NC[C@H](Cc1ccccc1C(F)(F)F)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL520788	=	Ki	nM	0.05	CHEMBL4282	Homo sapiens	Ki	nM	0.05
	2408732	CHEMBL959242	Inhibition of AKT1	B	NC[C@H](Cc1cccc(C(F)(F)F)c1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL482536	=	Ki	nM	0.1	CHEMBL4282	Homo sapiens	Ki	nM	0.1
	2408733	CHEMBL959242	Inhibition of AKT1	B	NC[C@H](Cc1ccc(C(F)(F)F)cc1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1		CHEMBL482537	=	Ki	nM	2.0	CHEMBL4282	Homo sapiens	Ki	nM	2.0
	2413396	CHEMBL959159	Inhibition of AKT1 at 100 uM	B	O=[N+]([O-])c1ccc(-n2c(O)nnc2Sc2ncc([N+](=O)[O-])s2)cc1		CHEMBL448771	=	Inhibition	%	20.0	CHEMBL4282	Homo sapiens	INH	%	20.0
	2413397	CHEMBL959159	Inhibition of AKT1 at 100 uM	B	Cn1cccc1-c1nnc(Sc2ncc([N+](=O)[O-])s2)n1-c1ccc(Cl)cc1Cl		CHEMBL472074	=	Inhibition	%	14.0	CHEMBL4282	Homo sapiens	INH	%	14.0
	2413398	CHEMBL959159	Inhibition of AKT1 at 100 uM	B	O=[N+]([O-])c1cnc(Sc2nnc(Sc3ncc([N+](=O)[O-])s3)s2)s1		CHEMBL503022	=	Inhibition	%	27.0	CHEMBL4282	Homo sapiens	INH	%	27.0
	2413399	CHEMBL959159	Inhibition of AKT1 at 100 uM	B	Nc1nnc(Sc2ncc([N+](=O)[O-])s2)s1		CHEMBL510038	=	Inhibition	%	11.0	CHEMBL4282	Homo sapiens	INH	%	11.0
	2418053	CHEMBL1018811	Inhibition of AKT1 at 1 uM	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(ccc([C@H]3C[C@@H](N(C)C)[C@H](O)[C@@H](C)O3)c1O)C2=O		CHEMBL2216825	=	Inhibition	%	92.0	CHEMBL4282	Homo sapiens	INH	%	92.0
Not Active	2418055	CHEMBL1018809	Inhibition of AKT at < 10 uM	B	CCOC(=O)C[C@@H]1CC2=C(C(=O)c3ccccc3C2=O)C(C)(C)O1		CHEMBL523332		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2418056	CHEMBL1018809	Inhibition of AKT at < 10 uM	B	CCOC(=O)C[C@@H]1CC2=C(C(=O)c3ccccc3C2=O)[C@H](c2ccc(N)cc2)O1		CHEMBL492510		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2418057	CHEMBL1018809	Inhibition of AKT at < 10 uM	B	CCC[C@@H]1O[C@H](CC(=O)OCC)CC2=C1C(=O)c1ccccc1C2=O		CHEMBL492509		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2418058	CHEMBL1018809	Inhibition of AKT at < 10 uM	B	CCOC(=O)C[C@@H]1CC2=C(C(=O)c3ccccc3C2=O)[C@H](c2cccc(O)c2)O1		CHEMBL492508		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2418059	CHEMBL1018809	Inhibition of AKT at < 10 uM	B	CCOC(=O)C[C@@H]1CC2=C(C(=O)c3ccccc3C2=O)C2(CCCC2)O1		CHEMBL493925		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2418060	CHEMBL1018809	Inhibition of AKT at < 10 uM	B	CCC[C@H]1O[C@H](CC(=O)OCC)CC2=C1C(=O)c1ccccc1C2=O		CHEMBL493114		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2418061	CHEMBL1018809	Inhibition of AKT at < 10 uM	B	CCOC(=O)C[C@@H]1CC2=C(C(=O)c3ccccc3C2=O)[C@@H](C)O1		CHEMBL493113		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2418062	CHEMBL1018809	Inhibition of AKT at < 10 uM	B	CCOC(=O)C[C@@H]1CC2=C(C(=O)c3ccccc3C2=O)[C@@H](c2ccsc2)O1		CHEMBL523174		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2418063	CHEMBL1018809	Inhibition of AKT at < 10 uM	B	CCOC(=O)C[C@@H]1CC2=C(C(=O)c3ccccc3C2=O)[C@@H](c2ccsc2)O1		CHEMBL523174		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2418064	CHEMBL1018809	Inhibition of AKT at < 10 uM	B	CCOC(=O)C[C@@H]1CC2=C(C(=O)c3ccccc3C2=O)[C@H](c2ccc(O)cc2)O1		CHEMBL492496		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2418065	CHEMBL1018809	Inhibition of AKT at < 10 uM	B	CCOC(=O)C[C@@H]1CC2=C(C(=O)c3ccccc3C2=O)[C@@H](COCc2ccccc2)O1		CHEMBL473844		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2418066	CHEMBL1018809	Inhibition of AKT at < 10 uM	B	CCOC(=O)C[C@@H]1CC2=C(C(=O)c3ccccc3C2=O)[C@@H](c2cccs2)O1		CHEMBL473843		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2418067	CHEMBL1018809	Inhibition of AKT at < 10 uM	B	CCOC(=O)C[C@@H]1CC2=C(CO1)C(=O)c1ccccc1C2=O		CHEMBL453668		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2418068	CHEMBL1018808	Inhibition of AKT C296A/C310A mutant up to 40 uM	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(ccc([C@H]3C[C@@H](N(C)C)[C@H](O)[C@@H](C)O3)c1O)C2=O		CHEMBL2216825		Activity			CHEMBL4282	Homo sapiens	Activity		
	2418069	CHEMBL1018807	Inhibition of AKT C296A mutant	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(ccc([C@H]3C[C@@H](N(C)C)[C@H](O)[C@@H](C)O3)c1O)C2=O		CHEMBL2216825	=	IC50	nM	30400.0	CHEMBL4282	Homo sapiens	IC50	uM	30.4
	2418070	CHEMBL1018806	Inhibition of AKT C310A mutant	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(ccc([C@H]3C[C@@H](N(C)C)[C@H](O)[C@@H](C)O3)c1O)C2=O		CHEMBL2216825	=	IC50	nM	38500.0	CHEMBL4282	Homo sapiens	IC50	uM	38.5
	2419112	CHEMBL1018804	Inhibition of AKT	B	CC1(C)O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1ccccc1C2=O		CHEMBL475840	=	IC50	nM	1440.0	CHEMBL4282	Homo sapiens	IC50	uM	1.44
	2419113	CHEMBL1018804	Inhibition of AKT	B	Nc1ccc([C@@H]2O[C@@H]3CC(=O)O[C@@H]3C3=C2C(=O)c2ccccc2C3=O)cc1		CHEMBL514989	=	IC50	nM	850.0	CHEMBL4282	Homo sapiens	IC50	uM	0.85
	2419114	CHEMBL1018804	Inhibition of AKT	B	CCC[C@@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1ccccc1C2=O		CHEMBL525077	=	IC50	nM	383.0	CHEMBL4282	Homo sapiens	IC50	uM	0.383
	2419115	CHEMBL1018804	Inhibition of AKT	B	O=C1C[C@H]2O[C@@H](c3cccc(O)c3)C3=C(C(=O)c4ccccc4C3=O)[C@H]2O1		CHEMBL474000	=	IC50	nM	350.0	CHEMBL4282	Homo sapiens	IC50	uM	0.35
	2419116	CHEMBL1018804	Inhibition of AKT	B	O=C1C[C@H]2OC3(CCCC3)C3=C(C(=O)c4ccccc4C3=O)[C@H]2O1		CHEMBL504537	=	IC50	nM	295.0	CHEMBL4282	Homo sapiens	IC50	uM	0.295
	2419117	CHEMBL1018804	Inhibition of AKT	B	CCC[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1ccccc1C2=O		CHEMBL475826	=	IC50	nM	163.0	CHEMBL4282	Homo sapiens	IC50	uM	0.163
	2419118	CHEMBL1018804	Inhibition of AKT	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1ccccc1C2=O		CHEMBL522996	=	IC50	nM	150.0	CHEMBL4282	Homo sapiens	IC50	uM	0.15
	2419119	CHEMBL1018804	Inhibition of AKT	B	O=C1C[C@H]2O[C@H](c3ccsc3)C3=C(C(=O)c4ccccc4C3=O)[C@H]2O1		CHEMBL521638	=	IC50	nM	122.0	CHEMBL4282	Homo sapiens	IC50	uM	0.122
	2419120	CHEMBL1018804	Inhibition of AKT	B	O=C1C[C@H]2O[C@H](c3ccsc3)C3=C(C(=O)c4ccccc4C3=O)[C@H]2O1		CHEMBL521638	=	IC50	nM	99.0	CHEMBL4282	Homo sapiens	IC50	uM	0.099
	2419121	CHEMBL1018804	Inhibition of AKT	B	O=C1C[C@H]2O[C@@H](c3ccc(O)cc3)C3=C(C(=O)c4ccccc4C3=O)[C@H]2O1		CHEMBL493360	=	IC50	nM	80.0	CHEMBL4282	Homo sapiens	IC50	uM	0.08
	2419122	CHEMBL1018804	Inhibition of AKT	B	O=C1C[C@H]2O[C@H](COCc3ccccc3)C3=C(C(=O)c4ccccc4C3=O)[C@H]2O1		CHEMBL493359	=	IC50	nM	72.0	CHEMBL4282	Homo sapiens	IC50	uM	0.072
	2419123	CHEMBL1018804	Inhibition of AKT	B	O=C1C[C@H]2O[C@H](c3cccs3)C3=C(C(=O)c4ccccc4C3=O)[C@H]2O1		CHEMBL475401	=	IC50	nM	57.0	CHEMBL4282	Homo sapiens	IC50	uM	0.057
	2419124	CHEMBL1018804	Inhibition of AKT	B	O=C1C[C@H]2OCC3=C(C(=O)c4ccccc4C3=O)[C@H]2O1		CHEMBL475400	=	IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	uM	0.044
	2419125	CHEMBL1018804	Inhibition of AKT	B	CCC[C@H]1O[C@H](CC(=O)O)CC2=C1C(=O)c1c(O)cccc1C2=O		CHEMBL444165	=	IC50	nM	424.0	CHEMBL4282	Homo sapiens	IC50	uM	0.424
	2419126	CHEMBL1018804	Inhibition of AKT	B	CCC[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(OC)cccc1C2=O		CHEMBL474391	=	IC50	nM	497.0	CHEMBL4282	Homo sapiens	IC50	uM	0.497
	2419127	CHEMBL1018804	Inhibition of AKT	B	CCC[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(O)cccc1C2=O		CHEMBL474390	=	IC50	nM	198.0	CHEMBL4282	Homo sapiens	IC50	uM	0.198
	2419128	CHEMBL1018804	Inhibition of AKT	B	CC1OC2OC(=O)OC2C2=C1C(=O)c1c(O)cccc1C2=O		CHEMBL1908343	=	IC50	nM	313.0	CHEMBL4282	Homo sapiens	IC50	uM	0.313
	2419129	CHEMBL1018804	Inhibition of AKT	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(ccc([C@H]3C[C@@H](N(C)C)[C@H](O)[C@@H](C)O3)c1O)C2=O		CHEMBL2216825	=	IC50	nM	149.0	CHEMBL4282	Homo sapiens	IC50	uM	0.149
Not Active	2419158	CHEMBL1019647	Inhibition of AKT at > 20 uM	B	CCC[C@H]1O[C@H](CC(=O)O)CC2=C1C(=O)c1c(O)cccc1C2=O		CHEMBL444165		Activity			CHEMBL4282	Homo sapiens	Activity		
	2434917	CHEMBL954509	Inhibition of sulfhydryl-labeled human recombinant Akt1 expressed in baculovirus by affinity capillary electrophoresis assay	B	CC1OC(=O)c2cc(O)c(O)c(O)c21		CHEMBL486813	=	IC50	nM	19700.0	CHEMBL4282	Homo sapiens	IC50	uM	19.7
	2434918	CHEMBL955241	Inhibition of sulfhydryl-labeled human recombinant Akt1 expressed in baculovirus assessed as phosphorylation of recombinant Bad protein by Western blotting	B	CC1OC(=O)c2cc(O)c(O)c(O)c21		CHEMBL486813	=	IC50	nM	30400.0	CHEMBL4282	Homo sapiens	IC50	uM	30.4
	2447591	CHEMBL947431	Inhibition of Akt1	B	O=C1NCCc2nc(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)c(-c3ccccc3)cc21		CHEMBL446134	=	IC50	nM	3.5	CHEMBL4282	Homo sapiens	IC50	nM	3.5
	2447596	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	O=C1NCCc2nc(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)c(-c3ccccc3)cc21		CHEMBL446134	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
	2447597	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	Nc1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6nc(N7CCN(CCO)CC7)ccc6nc5-c5ccccc5)cc4)CC3)[nH]2)cn1		CHEMBL447558	=	IC50	nM	115.0	CHEMBL4282	Homo sapiens	IC50	nM	115.0
	2447598	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	CN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccc(N)nc7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL499961	=	IC50	nM	70.0	CHEMBL4282	Homo sapiens	IC50	nM	70.0
	2447599	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	CN(C)CCN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ncccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL506827	=	IC50	nM	104.0	CHEMBL4282	Homo sapiens	IC50	nM	104.0
	2447600	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	OCCN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ncccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL501612	=	IC50	nM	72.0	CHEMBL4282	Homo sapiens	IC50	nM	72.0
	2447601	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	CN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ncccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL508098	=	IC50	nM	52.0	CHEMBL4282	Homo sapiens	IC50	nM	52.0
	2447602	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	CN(C)CCN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL499554	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
	2447603	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	OCCN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL449989	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
	2447604	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	CN1CCN(c2ccc3nc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL443620	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
	2447605	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7cc[n+]([O-])cc7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL455071	=	IC50	nM	33.0	CHEMBL4282	Homo sapiens	IC50	nM	33.0
	2447606	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	[O-][n+]1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6nc(N7CCN(CCO)CC7)ncc6cc5-c5ccccc5)cc4)CC3)[nH]2)cc1		CHEMBL449200	=	IC50	nM	67.0	CHEMBL4282	Homo sapiens	IC50	nM	67.0
	2447607	CHEMBL947431	Inhibition of Akt1	B	COc1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)[nH]2)cn1		CHEMBL446966	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	2447608	CHEMBL947431	Inhibition of Akt1	B	O=c1[nH]ccc2nc(-c3ccc(CN4CCC(c5nnc(-c6cnccn6)[nH]5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL444136	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	2447609	CHEMBL947431	Inhibition of Akt1	B	Nc1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)[nH]2)cn1		CHEMBL502393	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	2447610	CHEMBL947431	Inhibition of Akt1	B	O=c1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)[nH]2)c[nH]1		CHEMBL488428	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	2447611	CHEMBL947431	Inhibition of Akt1	B	O=c1[nH]ccc2nc(-c3ccc(CN4CCC(c5nnc(-c6ncccn6)[nH]5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL447114	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
	2447612	CHEMBL947431	Inhibition of Akt1	B	CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL443661	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	2447613	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	CN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7cc[n+]([O-])cc7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL507204	=	IC50	nM	88.0	CHEMBL4282	Homo sapiens	IC50	nM	88.0
	2447614	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccc(=O)[nH]c7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL503652	=	IC50	nM	69.0	CHEMBL4282	Homo sapiens	IC50	nM	69.0
	2447615	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	O=c1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6nc(N7CCN(CCO)CC7)ncc6cc5-c5ccccc5)cc4)CC3)[nH]2)c[nH]1		CHEMBL502113	=	IC50	nM	127.0	CHEMBL4282	Homo sapiens	IC50	nM	127.0
	2447616	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	CN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccc(=O)[nH]c7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL450266	=	IC50	nM	71.0	CHEMBL4282	Homo sapiens	IC50	nM	71.0
	2447617	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccc(N)nc7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL503270	=	IC50	nM	37.0	CHEMBL4282	Homo sapiens	IC50	nM	37.0
	2447618	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	Nc1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6nc(N7CCN(CCO)CC7)ncc6cc5-c5ccccc5)cc4)CC3)[nH]2)cn1		CHEMBL503810	=	IC50	nM	38.0	CHEMBL4282	Homo sapiens	IC50	nM	38.0
	2447619	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	CN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccc(N)nc7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL445212	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	nM	20.0
	2447620	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ncccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL505848	=	IC50	nM	35.0	CHEMBL4282	Homo sapiens	IC50	nM	35.0
	2447621	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	OCCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ncccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL455226	=	IC50	nM	37.0	CHEMBL4282	Homo sapiens	IC50	nM	37.0
	2447622	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	CN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ncccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL453288	=	IC50	nM	25.0	CHEMBL4282	Homo sapiens	IC50	nM	25.0
	2447623	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	COc1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)[nH]2)cn1		CHEMBL446966	=	IC50	nM	40.0	CHEMBL4282	Homo sapiens	IC50	nM	40.0
	2447624	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	O=c1[nH]ccc2nc(-c3ccc(CN4CCC(c5nnc(-c6cnccn6)[nH]5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL444136	=	IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	nM	44.0
	2447625	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	Nc1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)[nH]2)cn1		CHEMBL502393	=	IC50	nM	26.0	CHEMBL4282	Homo sapiens	IC50	nM	26.0
	2447626	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	O=c1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)[nH]2)c[nH]1		CHEMBL488428	=	IC50	nM	62.0	CHEMBL4282	Homo sapiens	IC50	nM	62.0
	2447627	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	O=c1[nH]ccc2nc(-c3ccc(CN4CCC(c5nnc(-c6ncccn6)[nH]5)CC4)cc3)c(-c3ccccc3)cc12		CHEMBL447114	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	nM	23.0
	2447628	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL443661	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
	2447629	CHEMBL947433	Inhibition of Akt1 by cellular assay	B	CN1CCN(c2ccc3nc(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)c(-c4ccccc4)nc3n2)CC1		CHEMBL452823	=	IC50	nM	1408.0	CHEMBL4282	Homo sapiens	IC50	nM	1408.0
	2451260	CHEMBL1013131	Inhibition of human PKBalpha at 10 uM	B	CCC(Nc1cc(-c2[nH]c(SC)nc2-c2ccc(F)cc2)ccn1)c1ccccc1		CHEMBL494666	=	Inhibition	%	14.0	CHEMBL4282	Homo sapiens	INH	%	14.0
	2452048	CHEMBL1013131	Inhibition of human PKBalpha at 10 uM	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2452049	CHEMBL1013131	Inhibition of human PKBalpha at 10 uM	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Inhibition	%	39.0	CHEMBL4282	Homo sapiens	INH	%	39.0
	2452050	CHEMBL1013131	Inhibition of human PKBalpha at 10 uM	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Inhibition	%	38.0	CHEMBL4282	Homo sapiens	INH	%	38.0
	2452051	CHEMBL1013131	Inhibition of human PKBalpha at 10 uM	B	COCCn1c(SC)nc(-c2ccc(F)cc2)c1-c1ccnc(NC2CCCCC2)c1		CHEMBL481943	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
	2452052	CHEMBL1013131	Inhibition of human PKBalpha at 10 uM	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NCC3CCCO3)c2)[nH]1		CHEMBL480952	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	INH	%	12.0
	2452053	CHEMBL1013131	Inhibition of human PKBalpha at 10 uM	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)CCCC(C)C)c2)[nH]1		CHEMBL518964	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
	2452054	CHEMBL1013131	Inhibition of human PKBalpha at 10 uM	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NCCc3cccs3)c2)[nH]1		CHEMBL519617	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	2452055	CHEMBL1013131	Inhibition of human PKBalpha at 10 uM	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)CCc3ccccc3)c2)[nH]1		CHEMBL493669	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	2452056	CHEMBL1013131	Inhibition of human PKBalpha at 10 uM	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC3CCc4ccccc43)c2)[nH]1		CHEMBL494871	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	INH	%	12.0
Not Active	2458065	CHEMBL1019232	Inhibition of AKT-mTOR pathway in human U266 cells assessed as p70S6 kinase T389 phosphorylation by Western blot	B	CCOC(=O)c1cn(-c2c(F)c(F)c(C#N)c(F)c2F)c2c(F)c(F)c(F)cc2c1=O		CHEMBL524195		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2458066	CHEMBL1019233	Inhibition of AKT-mTOR pathway in human U266 cells assessed as S6-S240/244 phosphorylation by Western blot	B	CCOC(=O)c1cn(-c2c(F)c(F)c(C#N)c(F)c2F)c2c(F)c(F)c(F)cc2c1=O		CHEMBL524195		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2458094	CHEMBL1019176	Inhibition of AKT-mTOR pathway in human HeLa cells assessed as p70S6 kinase T389 phosphorylation	B	CCOC(=O)c1cn(-c2c(F)c(F)c(C#N)c(F)c2F)c2c(F)c(F)c(F)cc2c1=O		CHEMBL524195		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2458095	CHEMBL1019177	Inhibition of AKT-mTOR pathway in human HeLa cells assessed as S6-S240/244 phosphorylation	B	CCOC(=O)c1cn(-c2c(F)c(F)c(C#N)c(F)c2F)c2c(F)c(F)c(F)cc2c1=O		CHEMBL524195		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2458097	CHEMBL1019179	Inhibition of AKT-mTOR pathway in human DU145 cells assessed as p70S6 kinase T389 phosphorylation	B	CCOC(=O)c1cn(-c2c(F)c(F)c(C#N)c(F)c2F)c2c(F)c(F)c(F)cc2c1=O		CHEMBL524195		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2458098	CHEMBL1020019	Inhibition of AKT-mTOR pathway in human DU145 cells assessed as S6-S240/244 phosphorylation	B	CCOC(=O)c1cn(-c2c(F)c(F)c(C#N)c(F)c2F)c2c(F)c(F)c(F)cc2c1=O		CHEMBL524195		Activity			CHEMBL4282	Homo sapiens	Activity		
	2460251	CHEMBL958718	Inhibition of protein kinase B	B	Cc1n[nH]cc1-c1ccccc1		CHEMBL228114	=	IC50	nM	80000.0	CHEMBL4282	Homo sapiens	IC50	uM	80.0
	2460252	CHEMBL958718	Inhibition of protein kinase B	B	c1ccc(-c2cn[nH]c2)cc1		CHEMBL390066	=	IC50	nM	135000.0	CHEMBL4282	Homo sapiens	IC50	uM	135.0
	2461661	CHEMBL966174	Inhibition of recombinant AKT1	B	Cc1cc(O)cc2oc(=O)c3c(O)cc(O)cc3c12		CHEMBL519982	>	IC50	ug.mL-1	10.0	CHEMBL4282	Homo sapiens	IC50	10'-5g/ml	1.0
	2461686	CHEMBL966174	Inhibition of recombinant AKT1	B	O=C1C[C@H](O)[C@@H]2c3c(ccc(O)c31)-c1ccc(O)c3c1[C@@]2(O)CCC3=O		CHEMBL521470	>	IC50	ug.mL-1	10.0	CHEMBL4282	Homo sapiens	IC50	10'-5g/ml	1.0
	2461687	CHEMBL966174	Inhibition of recombinant AKT1	B	COc1cc(O)c(C(=O)O)c(C2=C(C)C[C@@H](O)C2=O)c1		CHEMBL519395	>	IC50	ug.mL-1	10.0	CHEMBL4282	Homo sapiens	IC50	10'-5g/ml	1.0
	2461688	CHEMBL966174	Inhibition of recombinant AKT1	B	COc1cc(O)c2c(c1)C1(OC2=O)C(C)=CC(=O)C1O		CHEMBL408995	>	IC50	ug.mL-1	10.0	CHEMBL4282	Homo sapiens	IC50	10'-5g/ml	1.0
	2461689	CHEMBL966174	Inhibition of recombinant AKT1	B	COc1cc(O)c2c(c1)-c1cc(O)c(O)cc1COC2=O		CHEMBL507058	>	IC50	ug.mL-1	10.0	CHEMBL4282	Homo sapiens	IC50	10'-5g/ml	1.0
	2461690	CHEMBL966174	Inhibition of recombinant AKT1	B	Cc1cc(O)c(O)cc1-c1cc(O)cc(O)c1C(=O)O		CHEMBL483532	>	IC50	ug.mL-1	10.0	CHEMBL4282	Homo sapiens	IC50	10'-5g/ml	1.0
	2461691	CHEMBL966174	Inhibition of recombinant AKT1	B	COc1cc(O)c(C(=O)O)c(-c2cc(O)c(O)cc2C)c1		CHEMBL483531	>	IC50	ug.mL-1	10.0	CHEMBL4282	Homo sapiens	IC50	10'-5g/ml	1.0
	2461692	CHEMBL966174	Inhibition of recombinant AKT1	B	Cc1cc(O)cc2oc(=O)c3c(O)cc(OS(=O)(=O)O)cc3c12		CHEMBL483525	>	IC50	ug.mL-1	10.0	CHEMBL4282	Homo sapiens	IC50	10'-5g/ml	1.0
	2461768	CHEMBL966174	Inhibition of recombinant AKT1	B	COc1cc(O)c2c(=O)oc3cc(O)cc(C)c3c2c1		CHEMBL483526	=	IC50	ug.mL-1	7.9	CHEMBL4282	Homo sapiens	IC50	10'-6g/ml	7.9
	2461769	CHEMBL966174	Inhibition of recombinant AKT1	B	COc1cc(O)c2c(=O)oc3c(O)c(O)cc(C)c3c2c1		CHEMBL520144	=	IC50	ug.mL-1	5.3	CHEMBL4282	Homo sapiens	IC50	10'-6g/ml	5.3
	2465573	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	CNc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL252857	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	2465575	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	CNc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL252857	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	nM	20.0
	2465577	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	CN1CCN(c2cc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3cn2)CC1		CHEMBL448196	=	IC50	nM	740.0	CHEMBL4282	Homo sapiens	IC50	nM	740.0
	2465578	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	CN1CCN(c2nccc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc23)CC1		CHEMBL443633	=	IC50	nM	720.0	CHEMBL4282	Homo sapiens	IC50	nM	720.0
	2465579	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	CN1CCN(c2nccc3nc(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)c(-c4ccccc4)cc23)CC1		CHEMBL506434	=	IC50	nM	285.0	CHEMBL4282	Homo sapiens	IC50	nM	285.0
	2465580	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	CN1CC(N2CCN(c3ncc4cc(-c5ccccc5)c(-c5ccc(CN6CCC(c7nnc(-c8ccccn8)[nH]7)CC6)cc5)nc4n3)CC2)C1		CHEMBL448991	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
	2465581	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL443661	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	2465582	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	OCCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL453995	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
	2465583	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	c1ccc(-c2cc3cnc(N4CCn5cnnc5C4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1		CHEMBL447044	=	IC50	nM	19.0	CHEMBL4282	Homo sapiens	IC50	nM	19.0
	2465584	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	CN(C)CC(=O)N1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL447168	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	2465585	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	CN(C)C(=O)N1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL447348	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
	2465586	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	CS(=O)(=O)N1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL502426	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
	2465587	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	CC(=O)N1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL453586	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	2465588	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	c1ccc(-c2cc3cnc(-n4ccnc4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1		CHEMBL448926	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	2465589	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	CN(C)C1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL454859	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
	2465590	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	O[C@@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CCN1		CHEMBL499683	=	IC50	nM	25.0	CHEMBL4282	Homo sapiens	IC50	nM	25.0
	2465591	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	CN(C)CCNc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL505758	=	IC50	nM	79.0	CHEMBL4282	Homo sapiens	IC50	nM	79.0
	2465592	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	C[C@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)[C@H](C)CN1		CHEMBL454210	=	IC50	nM	43.0	CHEMBL4282	Homo sapiens	IC50	nM	43.0
	2465593	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	CN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL504251	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
	2465594	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	C[C@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CCN1		CHEMBL508754	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	nM	17.0
	2465595	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	C[C@@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CCN1		CHEMBL503980	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
	2465596	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	C[C@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)C[C@@H](C)N1		CHEMBL450545	=	IC50	nM	45.0	CHEMBL4282	Homo sapiens	IC50	nM	45.0
	2465597	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	O=S1(=O)CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL450772	=	IC50	nM	38.0	CHEMBL4282	Homo sapiens	IC50	nM	38.0
	2465598	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	C[C@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)C[C@@H](C)O1		CHEMBL448826	=	IC50	nM	28.0	CHEMBL4282	Homo sapiens	IC50	nM	28.0
	2465599	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	OC1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL500993	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
	2465600	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	c1ccc(-c2cc3cnc(N4CCOCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1		CHEMBL488654	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	2465601	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	c1ccc(-c2cc3cnc(N4CCCCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1		CHEMBL442718	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
	2465602	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	FC1(F)CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)C1		CHEMBL451961	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	nM	20.0
	2465603	CHEMBL951577	Inhibition of Akt1 phosphorylation by HTRF assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCC(=O)c4ccccc4N)cc3)nc2n1		CHEMBL252456	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
	2465631	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	CN1CCN(c2cc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3cn2)CC1		CHEMBL448196	=	IC50	nM	924.0	CHEMBL4282	Homo sapiens	IC50	nM	924.0
Not Active	2465632	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	CN1CCN(c2nccc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc23)CC1		CHEMBL443633		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2465633	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	CN1CCN(c2nccc3nc(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)c(-c4ccccc4)cc23)CC1		CHEMBL506434		Activity			CHEMBL4282	Homo sapiens	Activity		
	2465634	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	CN1CC(N2CCN(c3ncc4cc(-c5ccccc5)c(-c5ccc(CN6CCC(c7nnc(-c8ccccn8)[nH]7)CC6)cc5)nc4n3)CC2)C1		CHEMBL448991	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	2465635	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	CN(C)CCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL443661	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
	2465636	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	OCCN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL453995	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	nM	17.0
	2465637	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	c1ccc(-c2cc3cnc(N4CCn5cnnc5C4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1		CHEMBL447044	=	IC50	nM	125.0	CHEMBL4282	Homo sapiens	IC50	nM	125.0
	2465638	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	CN(C)CC(=O)N1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL447168	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	2465639	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	CN(C)C(=O)N1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL447348	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
	2465640	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	CS(=O)(=O)N1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL502426	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	nM	20.0
	2465641	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	CC(=O)N1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL453586	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
	2465642	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	c1ccc(-c2cc3cnc(-n4ccnc4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1		CHEMBL448926	=	IC50	nM	35.0	CHEMBL4282	Homo sapiens	IC50	nM	35.0
	2465643	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	CN(C)C1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL454859	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	nM	23.0
	2465644	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	O[C@@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CCN1		CHEMBL499683	=	IC50	nM	61.0	CHEMBL4282	Homo sapiens	IC50	nM	61.0
	2465645	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	CN(C)CCNc1ncc2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)nc2n1		CHEMBL505758	=	IC50	nM	208.0	CHEMBL4282	Homo sapiens	IC50	nM	208.0
	2465646	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	C[C@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)[C@H](C)CN1		CHEMBL454210	=	IC50	nM	194.0	CHEMBL4282	Homo sapiens	IC50	nM	194.0
	2465647	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	CN1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL504251	=	IC50	nM	36.0	CHEMBL4282	Homo sapiens	IC50	nM	36.0
	2465648	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	C[C@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CCN1		CHEMBL508754	=	IC50	nM	75.0	CHEMBL4282	Homo sapiens	IC50	nM	75.0
	2465649	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	C[C@@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CCN1		CHEMBL503980	=	IC50	nM	36.0	CHEMBL4282	Homo sapiens	IC50	nM	36.0
	2465650	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	C[C@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)C[C@@H](C)N1		CHEMBL450545	=	IC50	nM	46.0	CHEMBL4282	Homo sapiens	IC50	nM	46.0
Not Active	2465651	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	O=S1(=O)CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL450772		Activity			CHEMBL4282	Homo sapiens	Activity		
	2465652	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	C[C@H]1CN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)C[C@@H](C)O1		CHEMBL448826	=	IC50	nM	42.0	CHEMBL4282	Homo sapiens	IC50	nM	42.0
	2465653	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	OC1CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)CC1		CHEMBL500993	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	nM	17.0
	2465654	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	c1ccc(-c2cc3cnc(N4CCOCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1		CHEMBL488654	=	IC50	nM	19.0	CHEMBL4282	Homo sapiens	IC50	nM	19.0
	2465655	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	c1ccc(-c2cc3cnc(N4CCCCC4)nc3nc2-c2ccc(CN3CCC(c4nnc(-c5ccccn5)[nH]4)CC3)cc2)cc1		CHEMBL442718	=	IC50	nM	36.0	CHEMBL4282	Homo sapiens	IC50	nM	36.0
	2465656	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	FC1(F)CCN(c2ncc3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6nnc(-c7ccccn7)[nH]6)CC5)cc4)nc3n2)C1		CHEMBL451961	=	IC50	nM	75.0	CHEMBL4282	Homo sapiens	IC50	nM	75.0
	2465657	CHEMBL951579	Inhibition of Akt1 phosphorylation in human by C33a cells by IPKA assay	B	CSc1ncc2cc(-c3ccccc3)c(-c3ccc(CNCCC(=O)c4ccccc4N)cc3)nc2n1		CHEMBL252456	=	IC50	nM	78.0	CHEMBL4282	Homo sapiens	IC50	nM	78.0
	2467260	CHEMBL991663	Inhibition of AKT in presence of 20 uM ATP	B	CCN1CCN(CC/C=C/c2ccc3c(Nc4ccc(Sc5nccn5C)c(Cl)c4)c(C#N)cnc3c2)CC1		CHEMBL489058	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	2469941	CHEMBL1030560	Inhibition of AKT1 after 55 mins	B	O=C(Nc1nc(-c2ccncc2)cs1)C1COc2ccccc2O1		CHEMBL510515	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	2469942	CHEMBL1030560	Inhibition of AKT1 after 55 mins	B	O=C(Nc1ccc(-c2ccncc2)cc1)C1COc2ccccc2O1		CHEMBL485213	=	IC50	nM	6436.0	CHEMBL4282	Homo sapiens	IC50	uM	6.436
	2469943	CHEMBL1030560	Inhibition of AKT1 after 55 mins	B	O=C(Nc1ccc(-c2c[nH]cn2)cc1)C1COc2ccccc2O1		CHEMBL485214	=	IC50	nM	1410.0	CHEMBL4282	Homo sapiens	IC50	uM	1.41
	2469944	CHEMBL1030560	Inhibition of AKT1 after 55 mins	B	COc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL485215	=	IC50	nM	8819.0	CHEMBL4282	Homo sapiens	IC50	uM	8.819
	2469945	CHEMBL1030560	Inhibition of AKT1 after 55 mins	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	=	IC50	nM	7491.0	CHEMBL4282	Homo sapiens	IC50	uM	7.491
	2470103	CHEMBL1032245	Inhibition of AKT1 at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL4282	Homo sapiens	INH	%	10.0
	2476689	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	NC(=O)c1ccc(-c2cc(C(N)=O)c(N)c(-c3ccc(S(N)(=O)=O)cc3)c2)cc1		CHEMBL514582	=	Activity	%	5.6	CHEMBL4282	Homo sapiens	Activity	%	5.6
Not Evaluated	2476892	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	N#Cc1c(NC(=O)c2ccccc2)sc2c1CCCC2		CHEMBL233000		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2478731	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	O=C1Nc2ccccc2/C1=C/c1ccc[nH]1		CHEMBL86755		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2479586	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	N#Cc1ccc(-c2cnc3[nH]cc(NC(=O)c4cccnc4)c3c2)cc1		CHEMBL516312		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2479789	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2480586	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2		CHEMBL514409		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2480788	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878		Activity			CHEMBL4282	Homo sapiens	Activity		
	2486591	CHEMBL994197	Inhibition of Akt1	B	CCn1c2cc(Cl)c(O)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL523823	>	Ki	nM	8210.0	CHEMBL4282	Homo sapiens	Ki	uM	8.21
Active	2488843	CHEMBL1028060	Inhibition of recombinant human FGF2-induced AKT phosphorylation in HUVEC cells by Western blot	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(C(=O)NNc4ccccc4)cc32)c(C)c1CCC(=O)O		CHEMBL480356		Activity			CHEMBL4282	Homo sapiens	Activity		
	2504336	CHEMBL939833	Inhibition of Akt1 by cell based assay	B	Nc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(n6cnc(-c7ccccn7)c6)CC5)cc4)nc3ccn12		CHEMBL508794	=	IC50	nM	18.3	CHEMBL4282	Homo sapiens	IC50	nM	18.3
	2504337	CHEMBL939833	Inhibition of Akt1 by cell based assay	B	OCCNCc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL442919	=	IC50	nM	41.8	CHEMBL4282	Homo sapiens	IC50	nM	41.8
	2504338	CHEMBL939833	Inhibition of Akt1 by cell based assay	B	CN1CCN(Cc2nnc3c4cc(-c5ccccc5)c(-c5ccc(CN6CCC(c7n[nH]c(-c8ccccn8)n7)CC6)cc5)nc4ccn23)CC1		CHEMBL446779	=	IC50	nM	62.5	CHEMBL4282	Homo sapiens	IC50	nM	62.5
	2504339	CHEMBL939833	Inhibition of Akt1 by cell based assay	B	ClCc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL508861	=	IC50	nM	113.5	CHEMBL4282	Homo sapiens	IC50	nM	113.5
	2504340	CHEMBL939833	Inhibition of Akt1 by cell based assay	B	Cc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL445464	=	IC50	nM	24.6	CHEMBL4282	Homo sapiens	IC50	nM	24.6
	2504341	CHEMBL939833	Inhibition of Akt1 by cell based assay	B	c1ccc(-c2cc3c(ccn4cnnc34)nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL447328	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	2504342	CHEMBL939833	Inhibition of Akt1 by cell based assay	B	NC(=O)Nc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL509747	=	IC50	nM	265.5	CHEMBL4282	Homo sapiens	IC50	nM	265.5
	2504343	CHEMBL939833	Inhibition of Akt1 by cell based assay	B	Sc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL502854	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	nM	17.0
	2504344	CHEMBL939833	Inhibition of Akt1 by cell based assay	B	Oc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL506077	=	IC50	nM	27.0	CHEMBL4282	Homo sapiens	IC50	nM	27.0
	2504345	CHEMBL939833	Inhibition of Akt1 by cell based assay	B	Nc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL499555	=	IC50	nM	18.1	CHEMBL4282	Homo sapiens	IC50	nM	18.1
	2504356	CHEMBL939831	Inhibition of human cloned Akt1 expressed in Drosophila S2 cells by HTRF assay	B	Nc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(n6cnc(-c7ccccn7)c6)CC5)cc4)nc3ccn12		CHEMBL508794	=	IC50	nM	3.3	CHEMBL4282	Homo sapiens	IC50	nM	3.3
	2504357	CHEMBL939831	Inhibition of human cloned Akt1 expressed in Drosophila S2 cells by HTRF assay	B	OCCNCc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL442919	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	nM	17.0
	2504358	CHEMBL939831	Inhibition of human cloned Akt1 expressed in Drosophila S2 cells by HTRF assay	B	CN1CCN(Cc2nnc3c4cc(-c5ccccc5)c(-c5ccc(CN6CCC(c7n[nH]c(-c8ccccn8)n7)CC6)cc5)nc4ccn23)CC1		CHEMBL446779	=	IC50	nM	9.9	CHEMBL4282	Homo sapiens	IC50	nM	9.9
	2504359	CHEMBL939831	Inhibition of human cloned Akt1 expressed in Drosophila S2 cells by HTRF assay	B	ClCc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL508861	=	IC50	nM	26.7	CHEMBL4282	Homo sapiens	IC50	nM	26.7
	2504360	CHEMBL939831	Inhibition of human cloned Akt1 expressed in Drosophila S2 cells by HTRF assay	B	Cc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL445464	=	IC50	nM	4.6	CHEMBL4282	Homo sapiens	IC50	nM	4.6
	2504361	CHEMBL939831	Inhibition of human cloned Akt1 expressed in Drosophila S2 cells by HTRF assay	B	c1ccc(-c2cc3c(ccn4cnnc34)nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL447328	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	2504362	CHEMBL939831	Inhibition of human cloned Akt1 expressed in Drosophila S2 cells by HTRF assay	B	NC(=O)Nc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL509747	=	IC50	nM	8.5	CHEMBL4282	Homo sapiens	IC50	nM	8.5
	2504363	CHEMBL939831	Inhibition of human cloned Akt1 expressed in Drosophila S2 cells by HTRF assay	B	Sc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL502854	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
	2504364	CHEMBL939831	Inhibition of human cloned Akt1 expressed in Drosophila S2 cells by HTRF assay	B	Oc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL506077	=	IC50	nM	2.6	CHEMBL4282	Homo sapiens	IC50	nM	2.6
	2504365	CHEMBL939831	Inhibition of human cloned Akt1 expressed in Drosophila S2 cells by HTRF assay	B	Nc1nnc2c3cc(-c4ccccc4)c(-c4ccc(CN5CCC(c6n[nH]c(-c7ccccn7)n6)CC5)cc4)nc3ccn12		CHEMBL499555	=	IC50	nM	2.8	CHEMBL4282	Homo sapiens	IC50	nM	2.8
	2505359	CHEMBL942700	Inhibition of AKT1	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2C1		CHEMBL474425	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	nM	20000.0
	2505363	CHEMBL942700	Inhibition of AKT1	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccc(F)cc2C1		CHEMBL481545	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	nM	20000.0
	2505364	CHEMBL942700	Inhibition of AKT1	B	COc1ccc2c(c1)CC(C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)CO2		CHEMBL482336	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	nM	20000.0
	2506973	CHEMBL942626	Inhibition of PKB alpha at 10 uM	B	COc1cc(O)ccc1-c1ccc2c(-c3nc4c(N5CCN(C)CC5)cccc4[nH]3)n[nH]c2c1		CHEMBL474619	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	2506974	CHEMBL942626	Inhibition of PKB alpha at 10 uM	B	CN1CCN(c2cccc3nc(-c4n[nH]c5cc(-c6ccc(N)cc6)ccc45)[nH]c23)CC1		CHEMBL480391	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	2511563	CHEMBL972522	Inhibition of AKT1	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	uM	0.006
	2511942	CHEMBL969688	Inhibition of human PKBalpha at 1 uM assessed as residual enzyme activity	B	O=C(Nc1ccccc1Cl)c1ccc(Nc2nc(Nc3ccc(O)cc3)ncc2F)cc1		CHEMBL521949	=	Activity	%	96.0	CHEMBL4282	Homo sapiens	Activity	%	96.0
	2512035	CHEMBL970560	Inhibition of PKBalpha at 1 uM	B	CC(=O)N1CCN(C(=O)Cc2ccc(Nc3ncc(F)c(Nc4ccc(C(=O)Nc5ccccc5Cl)cc4)n3)cc2)CC1		CHEMBL508307	=	Inhibition	%	11.0	CHEMBL4282	Homo sapiens	INH	%	11.0
	2527202	CHEMBL984183	Inhibition of PKBalpha/Akt1	B	COc1c(NC(=O)Nc2ccc(-c3ccc(CN4CCOCC4)nc3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O		CHEMBL451523	=	IC50	nM	6400.0	CHEMBL4282	Homo sapiens	IC50	uM	6.4
	2528124	CHEMBL985019	Inhibition of Akt1	B	NCc1ccc(-c2cc3ccncc3cc2OC2CCNCC2)cc1		CHEMBL484967	<	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	pIC50		5.0
	2528125	CHEMBL985019	Inhibition of Akt1	B	c1ccc(-c2cc3ccncc3cc2OC2CCNCC2)cc1		CHEMBL484968	<	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	pIC50		5.0
	2528126	CHEMBL985019	Inhibition of Akt1	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OC2CCNCC2)cc1		CHEMBL519693	=	IC50	nM	5011.87	CHEMBL4282	Homo sapiens	pIC50		5.3
	2562283	CHEMBL984696	Inhibition of human PKBalpha expressed in insect Sf9 cells at 10 uM	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1		CHEMBL477989	=	Inhibition	%	8.0	CHEMBL4282	Homo sapiens	INH	%	8.0
	2562305	CHEMBL984696	Inhibition of human PKBalpha expressed in insect Sf9 cells at 10 uM	B	O/N=C1\CCc2cc(-c3cc(CN4CCOCC4)oc3-c3ccncc3)ccc21		CHEMBL476732	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
Not Active	2564228	CHEMBL989192	Inhibition of AKT	B	CC1(C)CC(=O)c2sc(N3CCOC[C@@H]3Cc3c[nH]c4ccccc34)nc2C1		CHEMBL513924		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	2564229	CHEMBL989192	Inhibition of AKT	B	CC1(C)CNC(=O)c2sc(N3CCOC[C@@H]3Cc3c[nH]c4ccccc34)nc2C1		CHEMBL514869		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2577410	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	NC(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1		CHEMBL511337		Activity			CHEMBL4282	Homo sapiens	Activity		
	2582016	CHEMBL961569	Inhibition of human AKT1	B	N=C(N)SCCCn1c(=O)c2c(c1=O)n1c3ccccc3cc1c1cccc3ccn2c31		CHEMBL489083	=	IC50	nM	9000.0	CHEMBL4282	Homo sapiens	IC50	uM	9.0
Active	2584564	CHEMBL963018	Increase in human Akt phosphorylation expressed in CHO cells	B	CC1(C)CC[C@]2(CCCCC(=O)N[C@@H](Cc3ccccc3)C(=O)O)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](OCc6ccc(C(=O)O)cc6)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1		CHEMBL499413		Activity			CHEMBL4282	Homo sapiens	Activity		
	2584890	CHEMBL956581	Inhibition of PKB	B	O=c1[nH]cnc2[nH]c(-c3ccnc(/C=C/c4ccc(CN5CCOCC5)cc4)c3)cc12		CHEMBL461139	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	2584918	CHEMBL956581	Inhibition of PKB	B	CN(C)CCOc1ccc(/C=C/c2cc(-c3cc4c(=O)[nH]cnc4[nH]3)ccn2)cc1		CHEMBL461140	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	2586392	CHEMBL1009214	Inhibition of Akt1	B	COc1ccc2c(c1)CC(c1nc3c(F)cc(-c4ccnc(N)n4)cc3[nH]1)CO2		CHEMBL452598	=	IC50	nM	5000.0	CHEMBL4282	Homo sapiens	IC50	nM	5000.0
Not Evaluated	2593615	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(C(N)=O)c2)n1		CHEMBL249097		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2593818	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL478649		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2593881	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCNCC1		CHEMBL450519		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2594084	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(C)(C)C)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL515466		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2595027	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	Cc1ccc(NC(=O)c2cccc(N3CCCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL1964275		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2596224	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	CN(C)c1ccc(-c2cc3ncccc3c(NCCCCN)n2)cc1		CHEMBL282342		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2596427	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1		CHEMBL408019		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2597696	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Evaluated	2597899	CHEMBL988961	Binding affinity to human AKT1 at 10 uM relative to control	B	CC(=O)c1c(-c2ccncc2)[nH]c(-c2ccncc2)c1C		CHEMBL526901		Activity			CHEMBL4282	Homo sapiens	Activity		
	2600117	CHEMBL1025728	Inhibition of AKT	B	COc1cc2c(cc1Nc1nc(Nc3cccc4c3C(=O)NC4)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL517163	=	IC50	nM	2.5	CHEMBL4282	Homo sapiens	IC50	nM	2.5
	2609572	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCc2ccccc2)C(C)C)cc1C		CHEMBL505490	=	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	2609573	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCc2ccccc2)C(C)C)cc1-c1ccccc1	Outside typical range	CHEMBL486269	>	IC50	nM	500000.0	CHEMBL4282	Homo sapiens	IC50	uM	500.0
	2609574	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCc2ccccc2)C(C)C)c(-c2ccccc2)c1		CHEMBL449564	=	IC50	nM	16000.0	CHEMBL4282	Homo sapiens	IC50	uM	16.0
	2609575	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	CC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCc2ccccc2)C(C)C)c(-c2cccc3ccccc23)c1		CHEMBL507059	=	IC50	nM	78000.0	CHEMBL4282	Homo sapiens	IC50	uM	78.0
	2609576	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	CC(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCc2ccccc2)C(C)C)cc1-c1ccccc1	Outside typical range	CHEMBL444220	=	IC50	nM	288000.0	CHEMBL4282	Homo sapiens	IC50	uM	288.0
	2609577	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	CC(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)NCc2ccccc2)C(C)C)c(-c2ccccc2)c1	Outside typical range	CHEMBL505303	=	IC50	nM	173000.0	CHEMBL4282	Homo sapiens	IC50	uM	173.0
	2609578	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	N=C(N)NCCNc1ccc(C(=O)Nc2ccc(N(Cc3ccccc3)Cc3ccccc3)cc2)cc1		CHEMBL513216	=	IC50	nM	96000.0	CHEMBL4282	Homo sapiens	IC50	uM	96.0
	2609579	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	N=C(N)NCCNc1ccc(C(=O)Nc2ccc(N(Cc3ccccc3)Cc3ccccc3)cc2)cc1-c1ccccc1		CHEMBL444649	=	IC50	nM	84000.0	CHEMBL4282	Homo sapiens	IC50	uM	84.0
	2609580	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	Cc1ccc(CN(Cc2ccc(C)cc2)c2ccc(NC(=O)c3ccc(NCCNC(=N)N)c(-c4ccccc4)c3)cc2)cc1	Outside typical range	CHEMBL446065	=	IC50	nM	215000.0	CHEMBL4282	Homo sapiens	IC50	uM	215.0
	2609581	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	Cc1cccc(CN(Cc2cccc(C)c2)c2ccc(NC(=O)c3ccc(NCCNC(=N)N)c(-c4ccccc4)c3)cc2)c1	Outside typical range	CHEMBL499846	=	IC50	nM	152000.0	CHEMBL4282	Homo sapiens	IC50	uM	152.0
	2609582	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	N=C(N)NCCNc1ccc(C(=O)Nc2ccc(N(Cc3ccc(-c4ccccc4)cc3)Cc3ccc(-c4ccccc4)cc3)cc2)cc1-c1ccccc1		CHEMBL510540	=	IC50	nM	84000.0	CHEMBL4282	Homo sapiens	IC50	uM	84.0
	2609583	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	N=C(N)NCCNc1ccc(C(=O)Nc2ccc(N(Cc3ccc(F)cc3)Cc3ccc(F)cc3)cc2)cc1-c1ccccc1		CHEMBL448003	=	IC50	nM	55000.0	CHEMBL4282	Homo sapiens	IC50	uM	55.0
	2609584	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	N=C(N)NCCNc1ccc(C(=O)Nc2ccc(N(Cc3cccc4ccccc34)Cc3cccc4ccccc34)cc2)cc1-c1ccccc1		CHEMBL453745	=	IC50	nM	43000.0	CHEMBL4282	Homo sapiens	IC50	uM	43.0
	2609585	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	CC(C)c1ccc(CN(Cc2ccc(C(C)C)cc2)c2ccc(NC(=O)c3ccc(NCCNC(=N)N)c(-c4ccccc4)c3)cc2)cc1		CHEMBL450225	=	IC50	nM	28000.0	CHEMBL4282	Homo sapiens	IC50	uM	28.0
	2609586	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	N=C(N)NCCNc1ccc(C(=O)Nc2ccc(N(Cc3ccc4ccccc4c3)Cc3ccc4ccccc4c3)cc2)cc1-c1ccccc1		CHEMBL446829	=	IC50	nM	23000.0	CHEMBL4282	Homo sapiens	IC50	uM	23.0
	2609587	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	N#Cc1ccc(CN(Cc2ccc(C#N)cc2)c2ccc(NC(=O)c3ccc(NCCNC(=N)N)c(-c4ccccc4)c3)cc2)cc1		CHEMBL449678	=	IC50	nM	19000.0	CHEMBL4282	Homo sapiens	IC50	uM	19.0
	2609588	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	CC(C)c1ccc(CN(Cc2ccc(C(C)C)cc2)c2ccc(NC(=O)c3ccc(NCCNC(=N)N)c(-c4ccc5ccccc5c4)c3)cc2)cc1		CHEMBL447960	=	IC50	nM	38000.0	CHEMBL4282	Homo sapiens	IC50	uM	38.0
	2609589	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	N#Cc1ccc(CN(Cc2ccc(C#N)cc2)c2ccc(NC(=O)c3ccc(NCCNC(=N)N)c(-c4ccc5ccccc5c4)c3)cc2)cc1		CHEMBL509490	=	IC50	nM	17000.0	CHEMBL4282	Homo sapiens	IC50	uM	17.0
	2609590	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	CC(=O)Nc1ccc(-c2cc(C(=O)Nc3ccc(N(Cc4ccccc4)Cc4ccccc4)cc3)ccc2NCCNC(=N)N)cc1	Outside typical range	CHEMBL457630	=	IC50	nM	253000.0	CHEMBL4282	Homo sapiens	IC50	uM	253.0
	2609591	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	COC(=O)c1ccc(-c2cc(C(=O)Nc3ccc(N(Cc4ccccc4)Cc4ccccc4)cc3)ccc2NCCNC(=N)N)cc1	Outside typical range	CHEMBL457309	=	IC50	nM	158000.0	CHEMBL4282	Homo sapiens	IC50	uM	158.0
	2609592	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	N=C(N)NCCNc1ccc(C(=O)Nc2ccc(N(Cc3ccccc3)Cc3ccccc3)cc2)cc1-c1ccc(-c2ccccc2)cc1		CHEMBL469523	=	IC50	nM	83000.0	CHEMBL4282	Homo sapiens	IC50	uM	83.0
	2609593	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	N#Cc1ccc(-c2cc(C(=O)Nc3ccc(N(Cc4ccccc4)Cc4ccccc4)cc3)ccc2NCCNC(=N)N)cc1		CHEMBL451291	=	IC50	nM	78000.0	CHEMBL4282	Homo sapiens	IC50	uM	78.0
	2609594	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	CC(C)c1ccc(-c2cc(C(=O)Nc3ccc(N(Cc4ccccc4)Cc4ccccc4)cc3)ccc2NCCNC(=N)N)cc1		CHEMBL444400	=	IC50	nM	52000.0	CHEMBL4282	Homo sapiens	IC50	uM	52.0
	2609595	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	N=C(N)NCCNc1ccc(C(=O)Nc2ccc(N(Cc3ccccc3)Cc3ccccc3)cc2)cc1-c1ccc2ccccc2c1		CHEMBL444730	=	IC50	nM	44000.0	CHEMBL4282	Homo sapiens	IC50	uM	44.0
	2609596	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	CC(C)c1ccc(CN(Cc2ccc(C(C)C)cc2)c2ccc(NC(=O)c3ccc(NC(=O)CNC(=N)N)c(-c4ccc5ccccc5c4)c3)cc2)cc1		CHEMBL438332	=	IC50	nM	17000.0	CHEMBL4282	Homo sapiens	IC50	uM	17.0
	2609597	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	N#Cc1ccc(CN(Cc2ccc(C#N)cc2)c2ccc(NC(=O)c3ccc(NC(=O)CNC(=N)N)c(-c4ccc5ccccc5c4)c3)cc2)cc1		CHEMBL445038	=	IC50	nM	12000.0	CHEMBL4282	Homo sapiens	IC50	uM	12.0
	2609598	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	N=C(N)NCC(=O)Nc1ccc(-c2cc3cc(N(Cc4ccccc4)Cc4ccccc4)ccc3[nH]2)cc1	Outside typical range	CHEMBL471216	=	IC50	nM	126000.0	CHEMBL4282	Homo sapiens	IC50	uM	126.0
	2609599	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	N#Cc1ccc(CN(Cc2ccc(C#N)cc2)c2ccc3[nH]c(-c4ccc(NC(=O)CNC(=N)N)cc4)cc3c2)cc1		CHEMBL448803	=	IC50	nM	32000.0	CHEMBL4282	Homo sapiens	IC50	uM	32.0
	2609600	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	CC(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)Nc2ccc3c(=O)n(Cc4ccccc4)c(=O)n(Cc4ccccc4)c3c2)cc1	Outside typical range	CHEMBL501390	=	IC50	nM	112000.0	CHEMBL4282	Homo sapiens	IC50	uM	112.0
	2609601	CHEMBL1034080	Inhibition of Akt1 by fluorescence polarization assay	B	CC(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc1ccc(C(=O)Nc2ccc3c(c2)c(=O)n(Cc2ccccc2)c(=O)n3Cc2ccccc2)cc1	Outside typical range	CHEMBL471217	=	IC50	nM	232000.0	CHEMBL4282	Homo sapiens	IC50	uM	232.0
	2613337	CHEMBL1015224	Inhibition of PKBa	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	2619051	CHEMBL1035822	Inhibition of human AKT by IMAP assay	B	C=CCc1c(C)nc2sc3c(N)ncnc3c2c1C		CHEMBL463119	>	Ki	nM	5000.0	CHEMBL4282	Homo sapiens	Ki	nM	5000.0
	2626900	CHEMBL999784	Binding affinity to human AKT1 at 5 uM	B	Cc1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(Nc3ncnc4ccc(N)cc34)cc2)c1		CHEMBL497033	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	2626927	CHEMBL999784	Binding affinity to human AKT1 at 5 uM	B	Cc1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc(Nc3ncnc4ccc(N)cc34)c2)c1		CHEMBL497615	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	2635191	CHEMBL1000630	Inhibition of PKBalpha at 1 uM relative to control	B	CSc1cc(Oc2ccnc3[nH]c(=O)[nH]c23)ccc1NC(=O)Nc1cccc(C(F)(F)F)c1		CHEMBL496009	=	Residual_activity	%	100.0	CHEMBL4282	Homo sapiens	Residual_activity	%	100.0
	2635934	CHEMBL1000630	Inhibition of PKBalpha at 1 uM relative to control	B	O=C(Nc1cc(C(F)(F)F)ccc1F)Nc1ccc(Oc2ccnc3[nH]c(=O)[nH]c23)c2ccccc12		CHEMBL498112	=	Residual_activity	%	100.0	CHEMBL4282	Homo sapiens	Residual_activity	%	100.0
	2636002	CHEMBL1000630	Inhibition of PKBalpha at 1 uM relative to control	B	CC(C)(C)c1cccc(NC(=O)Nc2ccc(Oc3ccnc4[nH]c(=O)[nH]c34)c3ccccc23)c1		CHEMBL496073	=	Residual_activity	%	75.0	CHEMBL4282	Homo sapiens	Residual_activity	%	75.0
	2636768	CHEMBL978881	Inhibition of Akt	B	CN1CCN(CCOc2cccc(-c3cncc(C#N)c3Nc3cccc4[nH]ccc34)c2)CC1		CHEMBL467321	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	2661408	CHEMBL1058614	Inhibition of AKT1	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	2661596	CHEMBL1060460	Inhibition of PKBalpha after 1 hr by mobility shift electrophoresis assay	B	COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1		CHEMBL561708	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
Active	2662179	CHEMBL1062152	Inhibition of Akt phosphorylation in human CL1-0 cells after 48 hrs by Western blot analysis	F	COc1ccc2c(CN3CCC(=O)CC3)cc3cc4c(cc3c2c1)OCO4		CHEMBL550974		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	2662184	CHEMBL1062151	Inhibition of Akt phosphorylation in human A549 cells after 48 hrs by Western blot analysis	F	COc1ccc2c(CN3CCC(=O)CC3)cc3cc4c(cc3c2c1)OCO4		CHEMBL550974		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	2662187	CHEMBL1062151	Inhibition of Akt phosphorylation in human A549 cells after 48 hrs by Western blot analysis	F	COc1ccc2c(CN3CCC(O)CC3)cc3cc4c(cc3c2c1)OCO4		CHEMBL551847		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	2662188	CHEMBL1062152	Inhibition of Akt phosphorylation in human CL1-0 cells after 48 hrs by Western blot analysis	F	COc1ccc2c(CN3CCC(O)CC3)cc3cc4c(cc3c2c1)OCO4		CHEMBL551847		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	2662191	CHEMBL1062151	Inhibition of Akt phosphorylation in human A549 cells after 48 hrs by Western blot analysis	F	COc1ccc2c(CN3CCC[C@H](CO)C3)cc3cc4c(cc3c2c1)OCO4		CHEMBL563209		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	2662192	CHEMBL1062152	Inhibition of Akt phosphorylation in human CL1-0 cells after 48 hrs by Western blot analysis	F	COc1ccc2c(CN3CCC[C@H](CO)C3)cc3cc4c(cc3c2c1)OCO4		CHEMBL563209		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	2662195	CHEMBL1062151	Inhibition of Akt phosphorylation in human A549 cells after 48 hrs by Western blot analysis	F	COc1ccc2c(CN3CCC[C@@H](CO)C3)cc3cc4c(cc3c2c1)OCO4		CHEMBL562107		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	2662196	CHEMBL1062152	Inhibition of Akt phosphorylation in human CL1-0 cells after 48 hrs by Western blot analysis	F	COc1ccc2c(CN3CCC[C@@H](CO)C3)cc3cc4c(cc3c2c1)OCO4		CHEMBL562107		Activity			CHEMBL4282	Homo sapiens	Activity		
	2671907	CHEMBL1026218	Inhibition of recombinant AKT1	B	COc1cc(O)c2c(c1)C(=O)c1cc(C)c(O)cc1C2=O		CHEMBL463054	>	IC50	ug.mL-1	10.0	CHEMBL4282	Homo sapiens	IC50	ug ml-1	10.0
	2671908	CHEMBL1026218	Inhibition of recombinant AKT1	B	COc1cc(O)c2c(c1)C(=O)c1cc(C)c(O)c(O)c1C2=O		CHEMBL556684	>	IC50	ug.mL-1	10.0	CHEMBL4282	Homo sapiens	IC50	ug ml-1	10.0
	2672248	CHEMBL1026218	Inhibition of recombinant AKT1	B	COc1cc(O)c2c(c1)C(=O)C1=C(C2=O)[C@H](O)[C@@H](O)[C@@](C)(O)[C@@H]1O		CHEMBL512054	=	IC50	ug.mL-1	6.7	CHEMBL4282	Homo sapiens	IC50	ug ml-1	6.7
	2672309	CHEMBL1026218	Inhibition of recombinant AKT1	B	COc1cc2c(c(O)c1-c1c(OC)cc(O)c3c1C(=O)C1=C(C3=O)[C@H](O)[C@@H](O)[C@@](C)(O)[C@@H]1O)C(=O)c1cc(O)c(C)cc1C2=O		CHEMBL554993	>	IC50	ug.mL-1	10.0	CHEMBL4282	Homo sapiens	IC50	ug ml-1	10.0
	2676431	CHEMBL1035535	Inhibition of AKT	B	CCOC(=O)c1cnn2c(-c3cccc(NC(=O)c4cccc(C(F)(F)F)c4)c3)ccnc12		CHEMBL565061	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
Active	2682462	CHEMBL1053158	Inhibition of AKT phosphorylation in human MKN45 cells after 1 hr by Western blot analysis	B	O=S(=O)(c1cccc2nonc12)n1ccc2ncc(-c3cnn(C4CCNCC4)c3)cc21		CHEMBL554497		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	2682467	CHEMBL1053161	Inhibition of AKT assessed as residual activity at 20 uM	B	O=S(=O)(c1cccc2nonc12)n1ccc2ncc(-c3cnn(C4CCNCC4)c3)cc21		CHEMBL554497	=	Activity	%	88.0	CHEMBL4282	Homo sapiens	Activity	%	88.0
	2691869	CHEMBL1054693	Inhibition of human PKBalpha assessed as remaining activity at 10 uM	B	Cc1ccccc1-c1c(N)c(C(=O)c2ccc(F)cc2F)cc[n+]1[O-]		CHEMBL551717	=	Activity	%	109.0	CHEMBL4282	Homo sapiens	Activity	%	109.0
	2704618	CHEMBL1054853	Inhibition of AKT1 dPH, S473D mutant at 10 uM by HotSpot assay relative to control	B	Cc1cc(O)cc(-c2nn(CC#N)cc2-c2cc(NC[C@H](C)O)nc(-c3cccnc3)n2)c1		CHEMBL560733	=	Inhibition	%	-2.97	CHEMBL4282	Homo sapiens	INH	%	-2.97
	2705278	CHEMBL1061585	Inhibition of AKT1 by FRET based assay	B	O=C1COc2ccc(-c3cc(-c4ccccc4)cc(-c4ccc5oc(=O)[nH]c5c4)n3)cc2N1		CHEMBL564972	=	IC50	nM	2600.0	CHEMBL4282	Homo sapiens	IC50	uM	2.6
	2705281	CHEMBL1061585	Inhibition of AKT1 by FRET based assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	IC50	nM	1600.0	CHEMBL4282	Homo sapiens	IC50	uM	1.6
	2721689	CHEMBL1054316	Inhibition of PKBalpha at 1 uM	B	C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F		CHEMBL551079	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	2893937	CHEMBL1061913	Percentage PKBalpha activity remaining in the presence of 0.01uM inhibitor	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Activity	%	90.0	CHEMBL4282	Homo sapiens	Activity	%	90.0
Antagonist	2893938	CHEMBL1061913	Percentage PKBalpha activity remaining in the presence of 0.01uM inhibitor	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Activity	%	5.0	CHEMBL4282	Homo sapiens	Activity	%	5.0
	2893939	CHEMBL1061913	Percentage PKBalpha activity remaining in the presence of 0.01uM inhibitor	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	=	Activity	%	79.0	CHEMBL4282	Homo sapiens	Activity	%	79.0
	2893940	CHEMBL1051305	Percentage PKBalpha activity remaining in the presence of 0.1uM inhibitor	B	CC(C)CCN1c2nc(Nc3cc(F)c(O)c(F)c3)ncc2N(C)C(=O)C1C		CHEMBL573107	=	Activity	%	98.0	CHEMBL4282	Homo sapiens	Activity	%	98.0
	2893941	CHEMBL1051305	Percentage PKBalpha activity remaining in the presence of 0.1uM inhibitor	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Activity	%	90.0	CHEMBL4282	Homo sapiens	Activity	%	90.0
Antagonist	2893942	CHEMBL1051305	Percentage PKBalpha activity remaining in the presence of 0.1uM inhibitor	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Activity	%	3.0	CHEMBL4282	Homo sapiens	Activity	%	3.0
	2893943	CHEMBL1051305	Percentage PKBalpha activity remaining in the presence of 0.1uM inhibitor	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Activity	%	95.0	CHEMBL4282	Homo sapiens	Activity	%	95.0
	2893944	CHEMBL1051305	Percentage PKBalpha activity remaining in the presence of 0.1uM inhibitor	B	Cn1cc(C2=C(c3cn(CCCSC(=N)N)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL6291	=	Activity	%	52.0	CHEMBL4282	Homo sapiens	Activity	%	52.0
	2893945	CHEMBL1051305	Percentage PKBalpha activity remaining in the presence of 0.1uM inhibitor	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Activity	%	96.0	CHEMBL4282	Homo sapiens	Activity	%	96.0
	2893946	CHEMBL1051305	Percentage PKBalpha activity remaining in the presence of 0.1uM inhibitor	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	Activity	%	90.0	CHEMBL4282	Homo sapiens	Activity	%	90.0
	2893947	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	=	Activity	%	87.0	CHEMBL4282	Homo sapiens	Activity	%	87.0
	2893948	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	=	Activity	%	94.0	CHEMBL4282	Homo sapiens	Activity	%	94.0
	2893949	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Activity	%	95.0	CHEMBL4282	Homo sapiens	Activity	%	95.0
	2893950	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	CC(C)(C(N)=O)C(=O)NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br		CHEMBL573108	=	Activity	%	57.0	CHEMBL4282	Homo sapiens	Activity	%	57.0
	2893951	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Activity	%	107.0	CHEMBL4282	Homo sapiens	Activity	%	107.0
	2893952	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	=	Activity	%	88.0	CHEMBL4282	Homo sapiens	Activity	%	88.0
	2893953	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Activity	%	95.0	CHEMBL4282	Homo sapiens	Activity	%	95.0
Antagonist	2893954	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Activity	%	32.0	CHEMBL4282	Homo sapiens	Activity	%	32.0
	2893955	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	CC(=O)c1c(O)c(C)c(O)c(Cc2c(O)c3c(c(C(=O)/C=C/c4ccccc4)c2O)OC(C)(C)C=C3)c1O		CHEMBL34241	=	Activity	%	88.0	CHEMBL4282	Homo sapiens	Activity	%	88.0
	2893956	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	C[C@H]1CNCCN1S(=O)(=O)c1cccc2cnccc12		CHEMBL1233654	=	Activity	%	87.0	CHEMBL4282	Homo sapiens	Activity	%	87.0
	2893957	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	O=C1NC(=O)C(c2ccccc2[N+](=O)[O-])=C1Nc1ccc(O)c(Cl)c1		CHEMBL322970	=	Activity	%	92.0	CHEMBL4282	Homo sapiens	Activity	%	92.0
Antagonist	2893958	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	CNCCNS(=O)(=O)c1cccc2cnccc12		CHEMBL148333	=	Activity	%	40.0	CHEMBL4282	Homo sapiens	Activity	%	40.0
Antagonist	2893959	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Activity	%	47.0	CHEMBL4282	Homo sapiens	Activity	%	47.0
	2893960	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Activity	%	73.0	CHEMBL4282	Homo sapiens	Activity	%	73.0
	2893961	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	NC(=O)c1sc(-c2ccsc2)cc1N		CHEMBL193093	=	Activity	%	81.0	CHEMBL4282	Homo sapiens	Activity	%	81.0
	2893962	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21		CHEMBL264406	=	Activity	%	50.0	CHEMBL4282	Homo sapiens	Activity	%	50.0
	2893963	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Activity	%	63.0	CHEMBL4282	Homo sapiens	Activity	%	63.0
Antagonist	2893964	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	Cc1ccc(NC(=O)c2cccc(N(C)C)c2)cc1NC(=O)c1ccc(O)cc1		CHEMBL186526	=	Activity	%	15.0	CHEMBL4282	Homo sapiens	Activity	%	15.0
	2893965	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	=	Activity	%	94.0	CHEMBL4282	Homo sapiens	Activity	%	94.0
	2893966	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H]1OC(C)=O		CHEMBL240954	=	Activity	%	89.0	CHEMBL4282	Homo sapiens	Activity	%	89.0
	2893967	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	O=C(Nc1cc(Cl)cc2c1[nH]c1cnccc12)c1cccnc1		CHEMBL79004	=	Activity	%	90.0	CHEMBL4282	Homo sapiens	Activity	%	90.0
	2893968	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	O=C(NOC[C@@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl.O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL540501	=	Activity	%	92.0	CHEMBL4282	Homo sapiens	Activity	%	92.0
	2893969	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	N#CC(=C(/N)Sc1ccccc1N)/C(C#N)=C(\N)Sc1ccccc1N		CHEMBL34704	=	Activity	%	76.0	CHEMBL4282	Homo sapiens	Activity	%	76.0
	2893970	CHEMBL1061171	Percentage PKBalpha activity remaining in the presence of 10uM inhibitor	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Activity	%	64.0	CHEMBL4282	Homo sapiens	Activity	%	64.0
	2893971	CHEMBL1061914	Percentage PKBalpha activity remaining in the presence of 25uM inhibitor	B	COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1		CHEMBL576349	=	Activity	%	94.0	CHEMBL4282	Homo sapiens	Activity	%	94.0
	2893972	CHEMBL1061914	Percentage PKBalpha activity remaining in the presence of 25uM inhibitor	B	NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12		CHEMBL489157	=	Activity	%	54.0	CHEMBL4282	Homo sapiens	Activity	%	54.0
	2893973	CHEMBL1063726	Percentage PKBalpha activity remaining in the presence of 2uM inhibitor	B	Cn1cc(C2=C(c3ccc(Cl)cc3Cl)C(=O)NC2=O)c2ccccc21		CHEMBL102714	=	Activity	%	88.0	CHEMBL4282	Homo sapiens	Activity	%	88.0
	2893974	CHEMBL1051332	Percentage PKBalpha activity remaining in the presence of 3uM inhibitor	B	Cc1ccc(-c2c(C(=O)CF)n(CCCO)c3ncnc(N)c23)cc1		CHEMBL515414	=	Activity	%	82.0	CHEMBL4282	Homo sapiens	Activity	%	82.0
	2893975	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	Activity	%	90.0	CHEMBL4282	Homo sapiens	Activity	%	90.0
	2893976	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1		CHEMBL412142	=	Activity	%	106.0	CHEMBL4282	Homo sapiens	Activity	%	106.0
	2893977	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Activity	%	75.0	CHEMBL4282	Homo sapiens	Activity	%	75.0
	2893978	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	CC(C)(C(N)=O)C(=O)NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br		CHEMBL573108	=	Activity	%	82.0	CHEMBL4282	Homo sapiens	Activity	%	82.0
	2893979	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Activity	%	103.0	CHEMBL4282	Homo sapiens	Activity	%	103.0
	2893980	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	=	Activity	%	93.0	CHEMBL4282	Homo sapiens	Activity	%	93.0
	2893981	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Activity	%	96.0	CHEMBL4282	Homo sapiens	Activity	%	96.0
	2893982	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Activity	%	89.0	CHEMBL4282	Homo sapiens	Activity	%	89.0
	2893983	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Activity	%	89.0	CHEMBL4282	Homo sapiens	Activity	%	89.0
	2893984	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O		CHEMBL428496	=	Activity	%	97.0	CHEMBL4282	Homo sapiens	Activity	%	97.0
	2893985	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	2893986	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Activity	%	88.0	CHEMBL4282	Homo sapiens	Activity	%	88.0
	2893987	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Activity	%	95.0	CHEMBL4282	Homo sapiens	Activity	%	95.0
	2893988	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	CC(=O)O.O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL265470	=	Activity	%	92.0	CHEMBL4282	Homo sapiens	Activity	%	92.0
	2893989	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Activity	%	97.0	CHEMBL4282	Homo sapiens	Activity	%	97.0
	2893990	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Activity	%	78.0	CHEMBL4282	Homo sapiens	Activity	%	78.0
	2893991	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	COc1ccc2c(c1)[nH]c1c(C)nccc12		CHEMBL269538	=	Activity	%	101.0	CHEMBL4282	Homo sapiens	Activity	%	101.0
	2893992	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	CC1=NCCc2c1[nH]c1cc(O)ccc21		CHEMBL129177	=	Activity	%	89.0	CHEMBL4282	Homo sapiens	Activity	%	89.0
	2893993	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	Cc1nccc2c1[nH]c1ccccc12		CHEMBL12014	=	Activity	%	104.0	CHEMBL4282	Homo sapiens	Activity	%	104.0
	2893994	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	COc1ccc2c3c([nH]c2c1)C(C)=NCC3		CHEMBL340807	=	Activity	%	95.0	CHEMBL4282	Homo sapiens	Activity	%	95.0
	2893995	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	Oc1c(Br)cc(C=C2c3cc(I)ccc3NC2O)cc1Br		CHEMBL1794051	=	Activity	%	90.0	CHEMBL4282	Homo sapiens	Activity	%	90.0
Antagonist	2893996	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	CNCCNS(=O)(=O)c1cccc2cnccc12		CHEMBL148333	=	Activity	%	14.0	CHEMBL4282	Homo sapiens	Activity	%	14.0
	2893997	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	Cc1cncc2cccc(S(=O)(=O)N3CCCNC[C@@H]3C)c12		CHEMBL406821	=	Activity	%	92.0	CHEMBL4282	Homo sapiens	Activity	%	92.0
	2893998	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Activity	%	72.0	CHEMBL4282	Homo sapiens	Activity	%	72.0
	2893999	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21		CHEMBL264406	=	Activity	%	102.0	CHEMBL4282	Homo sapiens	Activity	%	102.0
	2894000	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21		CHEMBL406845	=	Activity	%	98.0	CHEMBL4282	Homo sapiens	Activity	%	98.0
	2894001	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Activity	%	83.0	CHEMBL4282	Homo sapiens	Activity	%	83.0
	2894002	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Activity	%	91.0	CHEMBL4282	Homo sapiens	Activity	%	91.0
	2894003	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Activity	%	95.0	CHEMBL4282	Homo sapiens	Activity	%	95.0
	2894004	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	CCCCCCOC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608532	=	Activity	%	86.0	CHEMBL4282	Homo sapiens	Activity	%	86.0
	2894005	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Activity	%	80.0	CHEMBL4282	Homo sapiens	Activity	%	80.0
	2894006	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Activity	%	84.0	CHEMBL4282	Homo sapiens	Activity	%	84.0
	2894007	CHEMBL1061172	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	B	Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1		CHEMBL306380	=	Activity	%	95.0	CHEMBL4282	Homo sapiens	Activity	%	95.0
	2897177	CHEMBL1061152	Percent residual PKBalpha activity in the presence of 10uM inhibitor	B	O=C(O)Cc1c2ccccc2n2c1[nH]c(=O)c1ccccc12		CHEMBL92361	=	Activity	%	84.0	CHEMBL4282	Homo sapiens	Activity	%	84.0
	2897178	CHEMBL1061152	Percent residual PKBalpha activity in the presence of 10uM inhibitor	B	O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12		CHEMBL28	=	Activity	%	82.0	CHEMBL4282	Homo sapiens	Activity	%	82.0
	2897179	CHEMBL1061152	Percent residual PKBalpha activity in the presence of 10uM inhibitor	B	Cc1cc(O)c2c(c1)C(=O)c1cc(O)cc(O)c1C2=O		CHEMBL289277	=	Activity	%	82.0	CHEMBL4282	Homo sapiens	Activity	%	82.0
	2897677	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897678	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897679	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897680	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897681	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897682	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897683	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897684	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897685	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897686	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897687	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897688	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897689	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897690	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897691	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897692	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897693	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897694	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897695	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897696	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897697	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897698	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897699	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897700	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897701	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897702	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	950.0	CHEMBL4282	Homo sapiens	Kd	nM	950.0
	2897703	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897704	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897705	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897706	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897707	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897708	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897709	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	20.0	CHEMBL4282	Homo sapiens	Kd	nM	20.0
	2897710	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897711	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897712	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897713	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	2897714	CHEMBL1051279	Binding constant for AKT1 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
Antagonist	2902192	CHEMBL1052092	Percentage full-length PKBalpha activity remaining in the presence of 10uM inhibitor	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Activity	%	8.0	CHEMBL4282	Homo sapiens	Activity	%	8.0
Antagonist	2902193	CHEMBL1052093	Percentage full-length PKBalpha activity remaining in the presence of 1uM inhibitor	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Activity	%	22.0	CHEMBL4282	Homo sapiens	Activity	%	22.0
	2915160	CHEMBL1049250	Inhibition of Akt	B	C[C@H](N)COc1cnc(Cl)c(/C=C/c2ccncc2)c1		CHEMBL419932	=	IC50	nM	5290.0	CHEMBL4282	Homo sapiens	IC50	nM	5290.0
	2915161	CHEMBL1049250	Inhibition of Akt	B	NCCOc1cncc(/C=C/c2ccncc2)c1		CHEMBL206382	=	IC50	nM	14710.0	CHEMBL4282	Homo sapiens	IC50	nM	14710.0
	2915162	CHEMBL1049250	Inhibition of Akt	B	CC(C)[C@H](N)COc1cncc(/C=C/c2ccncc2)c1		CHEMBL204059	=	IC50	nM	19320.0	CHEMBL4282	Homo sapiens	IC50	nM	19320.0
	2915163	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1ccccc1		CHEMBL203673	=	IC50	nM	690.0	CHEMBL4282	Homo sapiens	IC50	nM	690.0
	2915164	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)C(c1ccccc1)c1ccccc1		CHEMBL203434	=	IC50	nM	273.0	CHEMBL4282	Homo sapiens	IC50	nM	273.0
	2915165	CHEMBL1049250	Inhibition of Akt	B	N[C@@H](CCc1ccccc1)COc1cncc(/C=C/c2ccncc2)c1		CHEMBL381829	=	IC50	nM	8020.0	CHEMBL4282	Homo sapiens	IC50	nM	8020.0
	2915166	CHEMBL1049250	Inhibition of Akt	B	N[C@@H](COCc1ccccc1)COc1cncc(/C=C/c2ccncc2)c1		CHEMBL206236	=	IC50	nM	4040.0	CHEMBL4282	Homo sapiens	IC50	nM	4040.0
	2915167	CHEMBL1049250	Inhibition of Akt	B	N#Cc1cccc(C[C@H](N)COc2cncc(/C=C/c3ccncc3)c2)c1		CHEMBL205410	=	IC50	nM	320.0	CHEMBL4282	Homo sapiens	IC50	nM	320.0
	2915168	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1cccc2ccccc12		CHEMBL205871	=	IC50	nM	324.0	CHEMBL4282	Homo sapiens	IC50	nM	324.0
	2915169	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL383541	=	IC50	nM	360.0	CHEMBL4282	Homo sapiens	IC50	nM	360.0
	2915170	CHEMBL1049250	Inhibition of Akt	B	Cn1cc(C[C@H](N)COc2cncc(/C=C/c3ccncc3)c2)c2ccccc21		CHEMBL204012	=	IC50	nM	500.0	CHEMBL4282	Homo sapiens	IC50	nM	500.0
	2915171	CHEMBL1049250	Inhibition of Akt	B	C(=C/c1cncc(OCC2CCN2)c1)\c1ccncc1		CHEMBL577186	=	IC50	nM	10870.0	CHEMBL4282	Homo sapiens	IC50	nM	10870.0
	2915172	CHEMBL1049250	Inhibition of Akt	B	Brc1ccc(/C=C/CNCCOc2cncc(/C=C/c3ccncc3)c2)cc1		CHEMBL206328	=	IC50	nM	32250.0	CHEMBL4282	Homo sapiens	IC50	nM	32250.0
	2915173	CHEMBL1049250	Inhibition of Akt	B	CN(C)[C@H](COc1cncc(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL202893	=	IC50	nM	1100.0	CHEMBL4282	Homo sapiens	IC50	nM	1100.0
	2915174	CHEMBL1049250	Inhibition of Akt	B	Cn1cc(C(CN)Oc2cncc(/C=C/c3ccncc3)c2)c2ccccc21		CHEMBL574290	=	IC50	nM	760.0	CHEMBL4282	Homo sapiens	IC50	nM	760.0
	2915175	CHEMBL1049250	Inhibition of Akt	B	COc1cc(/C=C/c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)ccn1		CHEMBL377294	=	IC50	nM	2670.0	CHEMBL4282	Homo sapiens	IC50	nM	2670.0
	2915176	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(/C=C/c2ccnc(Oc3ccccc3)c2)c1)Cc1c[nH]c2ccccc12		CHEMBL378823	=	IC50	nM	6450.0	CHEMBL4282	Homo sapiens	IC50	nM	6450.0
	2915177	CHEMBL1049250	Inhibition of Akt	B	Nc1cc(/C=C/c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)ccn1		CHEMBL381075	=	IC50	nM	121.0	CHEMBL4282	Homo sapiens	IC50	nM	121.0
	2915178	CHEMBL1049250	Inhibition of Akt	B	CNc1cc(/C=C/c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)ccn1		CHEMBL202787	=	IC50	nM	176.0	CHEMBL4282	Homo sapiens	IC50	nM	176.0
	2915179	CHEMBL1049250	Inhibition of Akt	B	CCNc1cc(/C=C/c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)ccn1		CHEMBL382914	=	IC50	nM	163.0	CHEMBL4282	Homo sapiens	IC50	nM	163.0
	2915180	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(/C=C/c2ccnc(NCc3ccccc3)c2)c1)Cc1c[nH]c2ccccc12		CHEMBL381610	=	IC50	nM	147.0	CHEMBL4282	Homo sapiens	IC50	nM	147.0
	2915181	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(/C=C/c2ccnc(-n3ccc4ccccc43)c2)c1)Cc1c[nH]c2ccccc12		CHEMBL206708	=	IC50	nM	3340.0	CHEMBL4282	Homo sapiens	IC50	nM	3340.0
	2915182	CHEMBL1049250	Inhibition of Akt	B	N[C@H](CCc1cnc(Cl)c(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL203329	=	IC50	nM	198.0	CHEMBL4282	Homo sapiens	IC50	nM	198.0
	2915183	CHEMBL1049250	Inhibition of Akt	B	N[C@H](CNc1cnc(Cl)c(/C=C/c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL203384	=	IC50	nM	79.0	CHEMBL4282	Homo sapiens	IC50	nM	79.0
	2915184	CHEMBL1049250	Inhibition of Akt	B	N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(/C=C/c2ccncc2)c1		CHEMBL205415	=	IC50	nM	278.0	CHEMBL4282	Homo sapiens	IC50	nM	278.0
	2915185	CHEMBL1049250	Inhibition of Akt	B	N[C@@H](Cc1ccccc1)C(=O)Nc1cncc(/C=C/c2ccncc2)c1		CHEMBL205514	=	IC50	nM	3200.0	CHEMBL4282	Homo sapiens	IC50	nM	3200.0
	2915186	CHEMBL1049250	Inhibition of Akt	B	N[C@@H](Cc1cccc2ccccc12)C(=O)Nc1cncc(/C=C/c2ccncc2)c1		CHEMBL383527	=	IC50	nM	668.0	CHEMBL4282	Homo sapiens	IC50	nM	668.0
	2915187	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL383264	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	2915188	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cnc(Cl)c(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL378963	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
	2915189	CHEMBL1049250	Inhibition of Akt	B	N#Cc1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2cnccc2c1		CHEMBL379209	=	IC50	nM	4.6	CHEMBL4282	Homo sapiens	IC50	nM	4.6
	2915190	CHEMBL1049250	Inhibition of Akt	B	C=Cc1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2cnccc2c1		CHEMBL209513	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	2915191	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cnc(-c2ccco2)c(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL378843	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
	2915192	CHEMBL1049250	Inhibition of Akt	B	CCc1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2cnccc2c1		CHEMBL572908	=	IC50	nM	0.8	CHEMBL4282	Homo sapiens	IC50	nM	0.8
	2915193	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cc(-c2ccc3cnccc3c2)cnc1Cl)Cc1c[nH]c2ccccc12		CHEMBL210089	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
	2915194	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3cnc(F)cc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL210246	=	IC50	nM	3.5	CHEMBL4282	Homo sapiens	IC50	nM	3.5
	2915195	CHEMBL1049250	Inhibition of Akt	B	C=Cc1cc2cc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)ccc2cn1		CHEMBL377764	=	IC50	nM	22.0	CHEMBL4282	Homo sapiens	IC50	nM	22.0
	2915196	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3cnc(-c4ccccc4)cc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL210544	=	IC50	nM	305.0	CHEMBL4282	Homo sapiens	IC50	nM	305.0
	2915197	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3cnc(-c4ccncc4)cc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL209564	=	IC50	nM	122.0	CHEMBL4282	Homo sapiens	IC50	nM	122.0
	2915198	CHEMBL1049250	Inhibition of Akt	B	Nc1cc2cc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)ccc2cn1		CHEMBL210390	=	IC50	nM	3.4	CHEMBL4282	Homo sapiens	IC50	nM	3.4
	2915199	CHEMBL1049250	Inhibition of Akt	B	Nc1c(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)ccc2cnccc12		CHEMBL380196	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
	2915200	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3ccccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL564795	=	IC50	nM	1117.0	CHEMBL4282	Homo sapiens	IC50	nM	1117.0
	2915201	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3ncccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL573393	=	IC50	nM	312.0	CHEMBL4282	Homo sapiens	IC50	nM	312.0
	2915202	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3nnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL573394	=	IC50	nM	215.0	CHEMBL4282	Homo sapiens	IC50	nM	215.0
	2915203	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3c(O)nccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL207215	=	IC50	nM	1022.0	CHEMBL4282	Homo sapiens	IC50	nM	1022.0
	2915204	CHEMBL1049250	Inhibition of Akt	B	Nc1nccc2cc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)ccc12		CHEMBL208962	=	IC50	nM	188.0	CHEMBL4282	Homo sapiens	IC50	nM	188.0
	2915205	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2cccc3cnccc23)c1)Cc1c[nH]c2ccccc12		CHEMBL581848	=	IC50	nM	331.0	CHEMBL4282	Homo sapiens	IC50	nM	331.0
	2915206	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL208199	=	IC50	nM	245.0	CHEMBL4282	Homo sapiens	IC50	nM	245.0
	2915207	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(C(=O)Nc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL208499	=	IC50	nM	1659.0	CHEMBL4282	Homo sapiens	IC50	nM	1659.0
	2915208	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc(CO)cc2)c1)Cc1c[nH]c2ccccc12		CHEMBL576761	=	IC50	nM	4022.0	CHEMBL4282	Homo sapiens	IC50	nM	4022.0
	2915209	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3[nH]ncc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL374805	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
	2915210	CHEMBL1049250	Inhibition of Akt	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	IC50	nM	0.16	CHEMBL4282	Homo sapiens	IC50	nM	0.16
	2915211	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3[nH]nc(Cl)c3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL226148	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	2915212	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3[nH]nc(C(F)(F)F)c3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL374808	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
	2915213	CHEMBL1049250	Inhibition of Akt	B	CCc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL574087	=	IC50	nM	1.15	CHEMBL4282	Homo sapiens	IC50	nM	1.15
	2915214	CHEMBL1049250	Inhibition of Akt	B	Nc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL577795	=	IC50	nM	2.9	CHEMBL4282	Homo sapiens	IC50	nM	2.9
	2915215	CHEMBL1049250	Inhibition of Akt	B	CN(C)c1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL572905	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
	2915216	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3[nH]nc(-c4ccccc4)c3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL574764	=	IC50	nM	3.9	CHEMBL4282	Homo sapiens	IC50	nM	3.9
	2915217	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3[nH]nc(-c4cccs4)c3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL576733	=	IC50	nM	1.3	CHEMBL4282	Homo sapiens	IC50	nM	1.3
	2915218	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3[nH]nc(C4CC4)c3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL572907	=	IC50	nM	2.6	CHEMBL4282	Homo sapiens	IC50	nM	2.6
	2915219	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3[nH]nc(-c4nccs4)c3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL574995	=	IC50	nM	9.8	CHEMBL4282	Homo sapiens	IC50	nM	9.8
	2915220	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3[nH]nc(-c4ccc[nH]4)c3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL572670	=	IC50	nM	1.2	CHEMBL4282	Homo sapiens	IC50	nM	1.2
	2915221	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3[nH]nc(N4CCOCC4)c3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL578418	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
	2915222	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3[nH]nc(C=O)c3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL574774	=	IC50	nM	1848.0	CHEMBL4282	Homo sapiens	IC50	nM	1848.0
	2915223	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2cc3cn[nH]c3cc2[N+](=O)[O-])c1)Cc1c[nH]c2ccccc12		CHEMBL225788	=	IC50	nM	953.0	CHEMBL4282	Homo sapiens	IC50	nM	953.0
	2915224	CHEMBL1049250	Inhibition of Akt	B	Nc1cc2[nH]ncc2cc1-c1cncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)c1		CHEMBL388729	=	IC50	nM	51.0	CHEMBL4282	Homo sapiens	IC50	nM	51.0
	2915225	CHEMBL1049250	Inhibition of Akt	B	Nc1cc2[nH]nc(Cl)c2cc1-c1cncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)c1		CHEMBL225789	=	IC50	nM	7.1	CHEMBL4282	Homo sapiens	IC50	nM	7.1
	2915226	CHEMBL1049250	Inhibition of Akt	B	Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL376569	=	IC50	nM	0.34	CHEMBL4282	Homo sapiens	IC50	nM	0.34
	2915227	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2cc3c(Cl)n[nH]c3cn2)c1)Cc1ccccc1		CHEMBL226332	=	IC50	nM	59.0	CHEMBL4282	Homo sapiens	IC50	nM	59.0
	2915228	CHEMBL1049250	Inhibition of Akt	B	C=Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL226382	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
	2915229	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2cc3c(-c4ccco4)n[nH]c3cn2)c1)Cc1ccccc1		CHEMBL375485	=	IC50	nM	6.1	CHEMBL4282	Homo sapiens	IC50	nM	6.1
	2915230	CHEMBL1049250	Inhibition of Akt	B	Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL376570	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
	2915231	CHEMBL1049250	Inhibition of Akt	B	Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4cccc(F)c4)c3)cc12		CHEMBL573592	=	IC50	nM	8.4	CHEMBL4282	Homo sapiens	IC50	nM	8.4
	2915232	CHEMBL1049250	Inhibition of Akt	B	Cc1cc(C)c(C[C@H](N)COc2cncc(-c3cc4c(C)n[nH]c4cn3)c2)c(C)c1		CHEMBL572417	=	IC50	nM	39.0	CHEMBL4282	Homo sapiens	IC50	nM	39.0
	2915233	CHEMBL1049250	Inhibition of Akt	B	Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)c3)cc12		CHEMBL572418	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
	2915234	CHEMBL1049250	Inhibition of Akt	B	Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4cccc5c4OC(F)(F)O5)c3)cc12		CHEMBL576135	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
	2915235	CHEMBL1049250	Inhibition of Akt	B	Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4cccc(OCCN5CCOCC5)c4)c3)cc12		CHEMBL575428	=	IC50	nM	751.0	CHEMBL4282	Homo sapiens	IC50	nM	751.0
	2915236	CHEMBL1049250	Inhibition of Akt	B	Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4cccc(OCC5CCNCC5)c4)c3)cc12		CHEMBL576372	=	IC50	nM	6.8	CHEMBL4282	Homo sapiens	IC50	nM	6.8
	2915237	CHEMBL1049250	Inhibition of Akt	B	Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4cccc(OCC5CCCCC5)c4)c3)cc12		CHEMBL574978	=	IC50	nM	1360.0	CHEMBL4282	Homo sapiens	IC50	nM	1360.0
	2915238	CHEMBL1049250	Inhibition of Akt	B	Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4cccc(OCCN)c4)c3)cc12		CHEMBL574979	=	IC50	nM	47.0	CHEMBL4282	Homo sapiens	IC50	nM	47.0
	2915239	CHEMBL1049250	Inhibition of Akt	B	Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4c(F)cccc4F)c3)cc12		CHEMBL573355	=	IC50	nM	65.5	CHEMBL4282	Homo sapiens	IC50	nM	65.5
	2915240	CHEMBL1049250	Inhibition of Akt	B	Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4ccc(F)c(F)c4F)c3)cc12		CHEMBL574986	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
	2915241	CHEMBL1049250	Inhibition of Akt	B	Cc1n[nH]c2cnc(-c3cncc(OC[C@@H](N)Cc4ccc(Br)cc4)c3)cc12		CHEMBL573778	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	2915242	CHEMBL1049250	Inhibition of Akt	B	Cc1ccc(F)cc1C[C@H](N)COc1cncc(-c2cc3c(C)n[nH]c3cn2)c1		CHEMBL573133	=	IC50	nM	3.9	CHEMBL4282	Homo sapiens	IC50	nM	3.9
	2915243	CHEMBL1049250	Inhibition of Akt	B	Cc1cc(C[C@H](N)COc2cncc(-c3cc4c(C)n[nH]c4cn3)c2)ccc1F		CHEMBL573359	=	IC50	nM	2.5	CHEMBL4282	Homo sapiens	IC50	nM	2.5
	2915244	CHEMBL1049250	Inhibition of Akt	B	Cc1cc(F)ccc1C[C@H](N)COc1cncc(-c2cc3c(C)n[nH]c3cn2)c1		CHEMBL575427	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	2915245	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(CCc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL575646	=	IC50	nM	210.0	CHEMBL4282	Homo sapiens	IC50	nM	210.0
	2915246	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(NC(=O)c2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL576565	=	IC50	nM	2020.0	CHEMBL4282	Homo sapiens	IC50	nM	2020.0
	2915247	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(Nc2cccnc2)c1)Cc1c[nH]c2ccccc12		CHEMBL207671	=	IC50	nM	2160.0	CHEMBL4282	Homo sapiens	IC50	nM	2160.0
	2915248	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc(C(=O)O)cc2)c1)Cc1c[nH]c2ccccc12		CHEMBL204892	=	IC50	nM	31280.0	CHEMBL4282	Homo sapiens	IC50	nM	31280.0
	2915249	CHEMBL1049250	Inhibition of Akt	B	NC(=O)Cc1cccc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)c1		CHEMBL206746	=	IC50	nM	1390.0	CHEMBL4282	Homo sapiens	IC50	nM	1390.0
	2915250	CHEMBL1049250	Inhibition of Akt	B	CC(=O)Nc1ccc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc1		CHEMBL381785	=	IC50	nM	227.0	CHEMBL4282	Homo sapiens	IC50	nM	227.0
	2915251	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc(NC(=O)Nc3ccccc3)cn2)c1)Cc1c[nH]c2ccccc12		CHEMBL572859	=	IC50	nM	1120.0	CHEMBL4282	Homo sapiens	IC50	nM	1120.0
	2915252	CHEMBL1049250	Inhibition of Akt	B	Nc1ccc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1cccc(Cl)c1		CHEMBL439340	=	IC50	nM	1450.0	CHEMBL4282	Homo sapiens	IC50	nM	1450.0
	2915253	CHEMBL1049250	Inhibition of Akt	B	NC(=O)c1cccc2c(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cccc12		CHEMBL205781	=	IC50	nM	2170.0	CHEMBL4282	Homo sapiens	IC50	nM	2170.0
	2915254	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2cccc(Nc3ncccn3)c2)c1)Cc1c[nH]c2ccccc12		CHEMBL202972	=	IC50	nM	3670.0	CHEMBL4282	Homo sapiens	IC50	nM	3670.0
	2915255	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(Nc2cccnc2)c1)Cc1ccccc1		CHEMBL382379	=	IC50	nM	6970.0	CHEMBL4282	Homo sapiens	IC50	nM	6970.0
	2915256	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cnc2ccc(-c3ccncc3)cc2c1)Cc1c[nH]c2ccccc12		CHEMBL206819	=	IC50	nM	300.0	CHEMBL4282	Homo sapiens	IC50	nM	300.0
	2915257	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc2nc(-c3ccncc3)ccc12)Cc1c[nH]c2ccccc12		CHEMBL207496	=	IC50	nM	190.0	CHEMBL4282	Homo sapiens	IC50	nM	190.0
	2915258	CHEMBL1049250	Inhibition of Akt	B	N[C@H](CNc1cncc(Oc2cccc3cnccc23)c1)Cc1c[nH]c2ccccc12		CHEMBL206732	=	IC50	nM	210.0	CHEMBL4282	Homo sapiens	IC50	nM	210.0
	2915259	CHEMBL1049250	Inhibition of Akt	B	N[C@H](CNc1cncc(Nc2cccc3cnccc23)c1)Cc1c[nH]c2ccccc12		CHEMBL205994	=	IC50	nM	270.0	CHEMBL4282	Homo sapiens	IC50	nM	270.0
	2915581	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2cc3ccncc3s2)c1)Cc1c[nH]c2ccccc12		CHEMBL516429	=	IC50	nM	179.0	CHEMBL4282	Homo sapiens	IC50	nM	179.0
	2915582	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2cnc3c(c2)CC(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL575385	=	IC50	nM	7.4	CHEMBL4282	Homo sapiens	IC50	nM	7.4
	2915583	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3c(c2)C(=O)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL574268	=	IC50	nM	5.4	CHEMBL4282	Homo sapiens	IC50	nM	5.4
	2915584	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3[nH]c(=O)oc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL575824	=	IC50	nM	4.3	CHEMBL4282	Homo sapiens	IC50	nM	4.3
	2915585	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3[nH]c(=O)sc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL577134	=	IC50	nM	99.0	CHEMBL4282	Homo sapiens	IC50	nM	99.0
	2915586	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3c(c2)CC(=O)N3)c1)Cc1ccccc1		CHEMBL226848	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
	2915587	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3c(c2)C(Cc2ccco2)C(=O)N3)c1)Cc1ccccc1		CHEMBL575811	=	IC50	nM	1.4	CHEMBL4282	Homo sapiens	IC50	nM	1.4
	2915588	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3c(c2)/C(=C/c2ccc[nH]2)C(=O)N3)c1)Cc1ccccc1		CHEMBL388311	=	IC50	nM	0.6	CHEMBL4282	Homo sapiens	IC50	nM	0.6
	2915589	CHEMBL1049250	Inhibition of Akt	B	CC1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL574262	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	2915590	CHEMBL1049250	Inhibition of Akt	B	CCC1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL577375	=	IC50	nM	52.7	CHEMBL4282	Homo sapiens	IC50	nM	52.7
	2915591	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3c(c2)CC(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL579246	=	IC50	nM	3.2	CHEMBL4282	Homo sapiens	IC50	nM	3.2
	2915592	CHEMBL1049250	Inhibition of Akt	B	CC(C)=C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL575384	=	IC50	nM	80.0	CHEMBL4282	Homo sapiens	IC50	nM	80.0
	2915593	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3c(c2)C(F)(F)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL577377	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
	2915594	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3c(c2)C(C2CC2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL574269	=	IC50	nM	3.3	CHEMBL4282	Homo sapiens	IC50	nM	3.3
	2915595	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3c(c2)C(c2ccccc2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL577379	=	IC50	nM	5.9	CHEMBL4282	Homo sapiens	IC50	nM	5.9
	2915596	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3c(c2)C(c2cccnc2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL576386	=	IC50	nM	10.4	CHEMBL4282	Homo sapiens	IC50	nM	10.4
	2915597	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3c(c2)C(c2ccccn2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL573334	=	IC50	nM	10.3	CHEMBL4282	Homo sapiens	IC50	nM	10.3
	2915598	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3c(c2)C(c2ccc[nH]2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL576348	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
	2915599	CHEMBL1049250	Inhibition of Akt	B	Cn1cccc1C1C(=O)Nc2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc21		CHEMBL583705	=	IC50	nM	8.2	CHEMBL4282	Homo sapiens	IC50	nM	8.2
	2915600	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3c(c2)C(c2c[nH]c4ccccc24)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL573096	=	IC50	nM	153.0	CHEMBL4282	Homo sapiens	IC50	nM	153.0
	2915601	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3c(c2)C(c2ncc[nH]2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL579053	=	IC50	nM	7.2	CHEMBL4282	Homo sapiens	IC50	nM	7.2
	2915602	CHEMBL1049250	Inhibition of Akt	B	CCc1c(C)[nH]c(C2C(=O)Nc3ccc(-c4cncc(OC[C@@H](N)Cc5c[nH]c6ccccc56)c4)cc32)c1C		CHEMBL577567	=	IC50	nM	40.3	CHEMBL4282	Homo sapiens	IC50	nM	40.3
	2915603	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3c(c2)C(c2ccco2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL573326	=	IC50	nM	0.17	CHEMBL4282	Homo sapiens	IC50	nM	0.17
	2915604	CHEMBL1049250	Inhibition of Akt	B	N[C@H](COc1cncc(-c2ccc3c(c2)C(c2cccs2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL572884	=	IC50	nM	0.9	CHEMBL4282	Homo sapiens	IC50	nM	0.9
	2915605	CHEMBL1049250	Inhibition of Akt	B	Cc1ccc(C2C(=O)Nc3ccc(-c4cncc(OC[C@@H](N)Cc5c[nH]c6ccccc56)c4)cc32)o1		CHEMBL575631	=	IC50	nM	0.7	CHEMBL4282	Homo sapiens	IC50	nM	0.7
	2915606	CHEMBL1049250	Inhibition of Akt	B	Cc1cc(C2C(=O)Nc3ccc(-c4cncc(OC[C@@H](N)Cc5c[nH]c6ccccc56)c4)cc32)oc1C		CHEMBL577797	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
	2915607	CHEMBL1049250	Inhibition of Akt	B	Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4nc3-c3ccccc3)cc2)CC1		CHEMBL260397	=	IC50	nM	290.0	CHEMBL4282	Homo sapiens	IC50	nM	290.0
	2915608	CHEMBL1049250	Inhibition of Akt	B	O=C(O)c1ccc2nc(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)c(-c3ccccc3)nc2c1		CHEMBL272292	=	IC50	nM	240.0	CHEMBL4282	Homo sapiens	IC50	nM	240.0
	2915609	CHEMBL1049250	Inhibition of Akt	B	O=C(O)c1ccc2nc(-c3ccccc3)c(-c3ccc(CN4CCC(n5c(=O)[nH]c6ccccc65)CC4)cc3)nc2c1		CHEMBL273160	=	IC50	nM	166.0	CHEMBL4282	Homo sapiens	IC50	nM	166.0
	2915610	CHEMBL1049250	Inhibition of Akt	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(-n5cnnn5)cc4nc3-c3ccccc3)cc2)CC1		CHEMBL574476	=	IC50	nM	63.0	CHEMBL4282	Homo sapiens	IC50	nM	63.0
	2915611	CHEMBL1049250	Inhibition of Akt	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc(-n5cnnn5)ccc4nc3-c3ccccc3)cc2)CC1		CHEMBL574289	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	nM	20.0
	2915612	CHEMBL1049250	Inhibition of Akt	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccc(Cn5cnnn5)cc4nc3-c3ccccc3)cc2)CC1		CHEMBL583982	=	IC50	nM	1089.0	CHEMBL4282	Homo sapiens	IC50	nM	1089.0
	2915613	CHEMBL1049250	Inhibition of Akt	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5cn[nH]c5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL180231	=	IC50	nM	85.0	CHEMBL4282	Homo sapiens	IC50	nM	85.0
	2915614	CHEMBL1049250	Inhibition of Akt	B	O=c1cnc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)[nH]1		CHEMBL577792	=	IC50	nM	1500.0	CHEMBL4282	Homo sapiens	IC50	nM	1500.0
	2915615	CHEMBL1049250	Inhibition of Akt	B	Cc1nc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)[nH]c1=O		CHEMBL572629	=	IC50	nM	1003.0	CHEMBL4282	Homo sapiens	IC50	nM	1003.0
	2915616	CHEMBL1049250	Inhibition of Akt	B	CC(C)c1nc(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)[nH]c1=O		CHEMBL575838	=	IC50	nM	21200.0	CHEMBL4282	Homo sapiens	IC50	nM	21200.0
	2915617	CHEMBL1049250	Inhibition of Akt	B	CC(C)(N)c1ccc(-c2nc3ccccc3nc2-c2ccccc2)cc1		CHEMBL362455	=	IC50	nM	3400.0	CHEMBL4282	Homo sapiens	IC50	nM	3400.0
	2915618	CHEMBL1049250	Inhibition of Akt	B	O=c1cnc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)[nH]1		CHEMBL440560	=	IC50	nM	3029.0	CHEMBL4282	Homo sapiens	IC50	nM	3029.0
	2915619	CHEMBL1049250	Inhibition of Akt	B	Cc1nc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)[nH]c1=O		CHEMBL178397	=	IC50	nM	760.0	CHEMBL4282	Homo sapiens	IC50	nM	760.0
	2915620	CHEMBL1049250	Inhibition of Akt	B	O=c1[nH]c(-c2ccccc2)c(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)nc1Cc1ccc(O)cc1		CHEMBL178133	=	IC50	nM	21670.0	CHEMBL4282	Homo sapiens	IC50	nM	21670.0
	2915621	CHEMBL1049250	Inhibition of Akt	B	O=C1C(Nc2ccccc2F)=C(Cl)C(=O)c2[nH]ncc21		CHEMBL220006	=	IC50	nM	15800.0	CHEMBL4282	Homo sapiens	IC50	nM	15800.0
	2915622	CHEMBL1049250	Inhibition of Akt	B	O=C1C(Nc2cccc(F)c2)=C(Cl)C(=O)c2[nH]ncc21		CHEMBL375142	=	IC50	nM	11800.0	CHEMBL4282	Homo sapiens	IC50	nM	11800.0
	2915623	CHEMBL1049250	Inhibition of Akt	B	O=C1C(Nc2cc(F)ccc2F)=C(Cl)C(=O)c2[nH]ncc21		CHEMBL584181	=	IC50	nM	16000.0	CHEMBL4282	Homo sapiens	IC50	nM	16000.0
	2915624	CHEMBL1049250	Inhibition of Akt	B	CCOc1ccc(NC2=C(Cl)C(=O)c3[nH]ncc3C2=O)cc1		CHEMBL375985	=	IC50	nM	4900.0	CHEMBL4282	Homo sapiens	IC50	nM	4900.0
	2915625	CHEMBL1049250	Inhibition of Akt	B	O=C1C(Nc2ccc(C(F)(F)F)cc2)=C(Cl)C(=O)c2[nH]ncc21		CHEMBL222254	=	IC50	nM	12400.0	CHEMBL4282	Homo sapiens	IC50	nM	12400.0
	2915626	CHEMBL1049250	Inhibition of Akt	B	O=C1C(Nc2cccc(Br)c2)=C(Cl)C(=O)c2[nH]ncc21		CHEMBL374701	=	IC50	nM	13900.0	CHEMBL4282	Homo sapiens	IC50	nM	13900.0
	2915627	CHEMBL1049250	Inhibition of Akt	B	O=C1C(Sc2cccc(Cl)c2Cl)=C(Cl)C(=O)c2[nH]ncc21		CHEMBL572400	=	IC50	nM	12300.0	CHEMBL4282	Homo sapiens	IC50	nM	12300.0
	2921444	CHEMBL1057567	Inhibition of AKT1 assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	2924717	CHEMBL1056852	Inhibition of PKBalpha assessed as residual enzyme activity at 10 uM relative to untreated control	B	c1ccc2c(c1)[nH]c1c3cc[nH]c3ccc21		CHEMBL567173	=	Activity	%	110.0	CHEMBL4282	Homo sapiens	Activity	%	110.0
	2924718	CHEMBL1056852	Inhibition of PKBalpha assessed as residual enzyme activity at 10 uM relative to untreated control	B	c1ccc2c(c1)[nH]c1c2ccc2cc[nH]c21		CHEMBL584980	=	Activity	%	120.0	CHEMBL4282	Homo sapiens	Activity	%	120.0
	2924719	CHEMBL1056852	Inhibition of PKBalpha assessed as residual enzyme activity at 10 uM relative to untreated control	B	O=Cc1c[nH]c2ccc3c4ccccc4[nH]c3c12		CHEMBL575754	=	Activity	%	112.0	CHEMBL4282	Homo sapiens	Activity	%	112.0
	2924720	CHEMBL1056852	Inhibition of PKBalpha assessed as residual enzyme activity at 10 uM relative to untreated control	B	O=Cc1c[nH]c2c1ccc1c3ccccc3[nH]c12		CHEMBL583972	=	Activity	%	96.0	CHEMBL4282	Homo sapiens	Activity	%	96.0
	2926200	CHEMBL1049414	Inhibition of PKBalpha assessed as remaining enzyme activity at 3 uM relative to DMSO	B	COc1ccccc1-n1c(-c2ccccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12		CHEMBL574236	=	Activity	%	97.0	CHEMBL4282	Homo sapiens	Activity	%	97.0
	2926294	CHEMBL1057678	Inhibition of PKBalpha assessed as remaining enzyme activity at 1 uM relative to DMSO	B	COc1ccccc1-n1c(-c2cc(O)ccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12		CHEMBL566515	=	Activity	%	98.0	CHEMBL4282	Homo sapiens	Activity	%	98.0
	2938534	CHEMBL1040494	Inhibition of AKT1 at 1 uM	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
Not Active	2938587	CHEMBL1040600	Inhibition of AKT1 at 10 uM	B	O=C1OC(/C=C/c2ccccc2)=N/C1=C\c1cccnc1		CHEMBL565286		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	2943698	CHEMBL1044077	Inhibition of Akt1	B	C=CC(=O)N1CCC[C@H]1C(=O)Nc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OCCOC		CHEMBL571040	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	microM	10.0
	2943710	CHEMBL1044077	Inhibition of Akt1	B	C=CC(=O)N1CCC[C@H]1C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3F)ncnc2cc1OCCOC		CHEMBL569880	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	microM	10.0
	2947564	CHEMBL1047365	Inhibition of PKBalpha at 100 uM	B	COc1cc2nccc(Oc3ccc(NC(=O)N4CCN(c5ccccc5)C4=O)cc3F)c2cc1OC		CHEMBL573761	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	2989963	CHEMBL1039191	Inhibition of PKBalpha at 100 nM by radiometric protein kinase assay	B	CCn1cnc(-c2cc3nccc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccccc6)CC5)cc4F)c3s2)c1		CHEMBL565807	<	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	2992197	CHEMBL1044500	Inhibition of human AKT1 at 20 uM by FRET assay	B	C#Cn1c(C#CCCO)nc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL576620	=	Inhibition	%	29.0	CHEMBL4282	Homo sapiens	INH	%	29.0
	2993556	CHEMBL1040931	Inhibition of human recombinant Akt1	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	2998992	CHEMBL1041964	Inhibition of PKBalpha assessed as residual activity at 10 uM by Cherenkov counting relative to control in presence of 5 uM ATP	B	CC(C)c1onc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL220227	=	Activity	%	94.0	CHEMBL4282	Homo sapiens	Activity	%	94.0
	2999782	CHEMBL1041964	Inhibition of PKBalpha assessed as residual activity at 10 uM by Cherenkov counting relative to control in presence of 5 uM ATP	B	CC(C)c1noc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL375428	=	Activity	%	94.0	CHEMBL4282	Homo sapiens	Activity	%	94.0
	2999859	CHEMBL1048104	Inhibition of PKBalpha assessed as residual activity at 0.1 uM by Cherenkov counting relative to control in presence of 5 uM ATP	B	COc1ccc(/C=C/C(=O)Nc2cc(-c3[nH]c(SC)nc3-c3ccc(F)cc3)ccn2)c(OC)c1		CHEMBL569114	=	Activity	%	105.0	CHEMBL4282	Homo sapiens	Activity	%	105.0
	2999935	CHEMBL1048104	Inhibition of PKBalpha assessed as residual activity at 0.1 uM by Cherenkov counting relative to control in presence of 5 uM ATP	B	COc1ccc(/C=C/C(=O)Nc2cc(-c3[nH]c([S+](C)[O-])nc3-c3ccc(F)cc3)ccn2)c(OC)c1		CHEMBL572006	=	Activity	%	105.0	CHEMBL4282	Homo sapiens	Activity	%	105.0
	3052523	CHEMBL1047774	Residual activity of AKT1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	100.0	CHEMBL4282	Homo sapiens	Residual activity	%	100.0
	3052775	CHEMBL1046508	Residual activity of AKT1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	105.0	CHEMBL4282	Homo sapiens	Residual activity	%	105.0
	3054084	CHEMBL1066602	Residual activity of AKT1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	102.0	CHEMBL4282	Homo sapiens	Residual activity	%	102.0
	3055371	CHEMBL1047774	Residual activity of AKT1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	109.0	CHEMBL4282	Homo sapiens	Residual activity	%	109.0
	3055623	CHEMBL1046508	Residual activity of AKT1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	120.0	CHEMBL4282	Homo sapiens	Residual activity	%	120.0
	3056928	CHEMBL1066602	Residual activity of AKT1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	91.0	CHEMBL4282	Homo sapiens	Residual activity	%	91.0
	3058248	CHEMBL1047774	Residual activity of AKT1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	97.0	CHEMBL4282	Homo sapiens	Residual activity	%	97.0
	3058500	CHEMBL1046508	Residual activity of AKT1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	87.0	CHEMBL4282	Homo sapiens	Residual activity	%	87.0
	3062438	CHEMBL1048631	Binding affinity to human AKT1 at 200 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CSSC[C@@H](C(=O)NCC(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL595545	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	3063573	CHEMBL1045159	Binding affinity to human AKT1 at 500 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(N)=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL595546	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	3063663	CHEMBL1038874	Binding affinity to human AKT1 at 50 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CNC(=O)C[C@@H](C(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL609010	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	3065844	CHEMBL1068650	Inhibition of AKT1 at 10 uM	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Inhibition	%	27.0	CHEMBL4282	Homo sapiens	INH	%	27.0
	3066910	CHEMBL1068650	Inhibition of AKT1 at 10 uM	B	O=C1Nc2ccccc2/C1=C1\C(=O)N(CCCc2ccccc2)c2ccccc21		CHEMBL607196	=	Inhibition	%	14.0	CHEMBL4282	Homo sapiens	INH	%	14.0
	3069161	CHEMBL1068578	Inhibition of pleckstrin homology domain of AKT by surface plasmon resonance spectroscopy	B	O=P(O)(O)OC1[C@H](O)[C@H](P(=O)(O)O)C(OP(=O)(O)O)[C@H](OP(=O)(O)O)[C@H]1O		CHEMBL611046	=	Kd	nM	1500.0	CHEMBL4282	Homo sapiens	Kd	uM	1.5
	3069162	CHEMBL1068578	Inhibition of pleckstrin homology domain of AKT by surface plasmon resonance spectroscopy	B	O=P(O)(O)Oc1ccc(OP(=O)(O)O)c(OP(=O)(O)O)c1OP(=O)(O)O		CHEMBL595349	=	Ki	nM	80.0	CHEMBL4282	Homo sapiens	Ki	uM	0.08
	3069163	CHEMBL1068578	Inhibition of pleckstrin homology domain of AKT by surface plasmon resonance spectroscopy	B	CC1=NN(C(=O)c2ccc(Cl)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL603852	=	Kd	nM	370.0	CHEMBL4282	Homo sapiens	Kd	uM	0.37
	3069164	CHEMBL1068578	Inhibition of pleckstrin homology domain of AKT by surface plasmon resonance spectroscopy	B	CC1=NN(C(=O)c2ccccc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL595581	=	Kd	nM	3660.0	CHEMBL4282	Homo sapiens	Kd	uM	3.66
	3069165	CHEMBL1068578	Inhibition of pleckstrin homology domain of AKT by surface plasmon resonance spectroscopy	B	CC1=NN(C(=O)c2ccc(C(C)(C)C)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL594411	=	Kd	nM	1370.0	CHEMBL4282	Homo sapiens	Kd	uM	1.37
	3069166	CHEMBL1068578	Inhibition of pleckstrin homology domain of AKT by surface plasmon resonance spectroscopy	B	CC1=NN(C(=O)c2ccc(N)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL594412	=	Kd	nM	510.0	CHEMBL4282	Homo sapiens	Kd	uM	0.51
	3069167	CHEMBL1068578	Inhibition of pleckstrin homology domain of AKT by surface plasmon resonance spectroscopy	B	CC1=NN(C(=O)c2ccc(O)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL595347	=	Kd	nM	1350.0	CHEMBL4282	Homo sapiens	Kd	uM	1.35
	3069168	CHEMBL1068578	Inhibition of pleckstrin homology domain of AKT by surface plasmon resonance spectroscopy	B	CC1=NN(C(=O)c2ccc(Cl)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)N(C)c2ncccn2)cc1		CHEMBL592965	=	Kd	nM	1620.0	CHEMBL4282	Homo sapiens	Kd	uM	1.62
	3069169	CHEMBL1068578	Inhibition of pleckstrin homology domain of AKT by surface plasmon resonance spectroscopy	B	Cc1nnc(NS(=O)(=O)c2ccc(NS(=O)(=O)c3ccc4ccccc4c3)cc2)s1		CHEMBL595786	=	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	3069170	CHEMBL1068578	Inhibition of pleckstrin homology domain of AKT by surface plasmon resonance spectroscopy	B	Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL286737	=	Kd	nM	450.0	CHEMBL4282	Homo sapiens	Kd	uM	0.45
Not Active	3069171	CHEMBL1068578	Inhibition of pleckstrin homology domain of AKT by surface plasmon resonance spectroscopy	B	CC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL593946		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Active	3069172	CHEMBL1068578	Inhibition of pleckstrin homology domain of AKT by surface plasmon resonance spectroscopy	B	COCCOCCOCC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL611216		Kd			CHEMBL4282	Homo sapiens	Kd		
	3069173	CHEMBL1068578	Inhibition of pleckstrin homology domain of AKT by surface plasmon resonance spectroscopy	B	CCCCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595582	=	Kd	nM	19600.0	CHEMBL4282	Homo sapiens	Kd	uM	19.6
	3069174	CHEMBL1068578	Inhibition of pleckstrin homology domain of AKT by surface plasmon resonance spectroscopy	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595583	=	Kd	nM	40800.0	CHEMBL4282	Homo sapiens	Kd	uM	40.8
	3069175	CHEMBL1068579	Inhibition of Akt phosphorylation in human BxPC3 cells by Western blotting	B	Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL286737	=	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	3069176	CHEMBL1068579	Inhibition of Akt phosphorylation in human BxPC3 cells by Western blotting	B	CC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL593946	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	3069177	CHEMBL1068579	Inhibition of Akt phosphorylation in human BxPC3 cells by Western blotting	B	COCCOCCOCC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL611216	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	3069178	CHEMBL1068579	Inhibition of Akt phosphorylation in human BxPC3 cells by Western blotting	B	CCCCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595582	=	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	3069179	CHEMBL1068579	Inhibition of Akt phosphorylation in human BxPC3 cells by Western blotting	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595583	=	IC50	nM	6300.0	CHEMBL4282	Homo sapiens	IC50	uM	6.3
	3070283	CHEMBL1074670	Inhibition of Akt phosphorylation in human HT-29 cells after 6 hrs by Western blotting	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595583	=	Inhibition	%	70.0	CHEMBL4282	Homo sapiens	INH	%	70.0
	3070284	CHEMBL1074671	Inhibition of Akt phosphorylation in human HT-29 cells after 12 hrs by Western blotting	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595583	=	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	3072846	CHEMBL1066602	Residual activity of AKT1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	100.0	CHEMBL4282	Homo sapiens	Residual activity	%	100.0
	3075697	CHEMBL1071956	Inhibition of AKT1 in human BT474 cells assessed as phosphorylation of GSK3	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ncccc45)cnc3-c3ccoc3)cc12		CHEMBL594310	=	IC50	nM	930.0	CHEMBL4282	Homo sapiens	IC50	uM	0.93
	3075698	CHEMBL1071956	Inhibition of AKT1 in human BT474 cells assessed as phosphorylation of GSK3	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5c(F)cccc45)cnc3-c3ccoc3)cc12		CHEMBL594309	=	IC50	nM	260.0	CHEMBL4282	Homo sapiens	IC50	uM	0.26
	3075699	CHEMBL1071956	Inhibition of AKT1 in human BT474 cells assessed as phosphorylation of GSK3	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5cc(F)ccc45)cnc3-c3ccoc3)cc12		CHEMBL607374	=	IC50	nM	220.0	CHEMBL4282	Homo sapiens	IC50	uM	0.22
	3075700	CHEMBL1071956	Inhibition of AKT1 in human BT474 cells assessed as phosphorylation of GSK3	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccc(F)cc45)cnc3-c3ccoc3)cc12		CHEMBL605528	=	IC50	nM	360.0	CHEMBL4282	Homo sapiens	IC50	uM	0.36
	3075701	CHEMBL1071956	Inhibition of AKT1 in human BT474 cells assessed as phosphorylation of GSK3	B	Cc1occc1-c1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2[nH]nc(C)c2c1		CHEMBL595939	=	IC50	nM	84.0	CHEMBL4282	Homo sapiens	IC50	uM	0.084
	3075702	CHEMBL1071956	Inhibition of AKT1 in human BT474 cells assessed as phosphorylation of GSK3	B	Cc1[nH]nc2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12		CHEMBL593490	=	IC50	nM	500.0	CHEMBL4282	Homo sapiens	IC50	uM	0.5
	3075719	CHEMBL1071953	Inhibition of truncated AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3cc(F)ccc3O)cc12		CHEMBL594517	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	uM	0.01
	3075720	CHEMBL1071953	Inhibition of truncated AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3ccco3)cc12		CHEMBL595708	=	IC50	nM	790.0	CHEMBL4282	Homo sapiens	IC50	uM	0.79
	3075721	CHEMBL1071953	Inhibition of truncated AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3C#CC(C)(C)O)cc12		CHEMBL594750	=	IC50	nM	10500.0	CHEMBL4282	Homo sapiens	IC50	uM	10.5
	3075722	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5cccnc45)cnc3-c3ccoc3)cc12		CHEMBL605838	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	uM	0.01
	3075723	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccncc45)cnc3-c3ccoc3)cc12		CHEMBL593142	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	uM	0.013
	3075724	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ncccc45)cnc3-c3ccoc3)cc12		CHEMBL594310	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	uM	0.008
	3075725	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5c(F)cccc45)cnc3-c3ccoc3)cc12		CHEMBL594309	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	uM	0.001
	3075726	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5cc(F)ccc45)cnc3-c3ccoc3)cc12		CHEMBL607374	=	IC50	nM	0.8	CHEMBL4282	Homo sapiens	IC50	uM	0.0008
	3075727	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccc(F)cc45)cnc3-c3ccoc3)cc12		CHEMBL605528	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	uM	0.001
	3075728	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1occc1-c1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2[nH]nc(C)c2c1		CHEMBL595939	=	IC50	nM	0.8	CHEMBL4282	Homo sapiens	IC50	uM	0.0008
	3075729	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1[nH]nc2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12		CHEMBL593490	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	uM	0.001
	3075730	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3C#CCCO)cc12		CHEMBL592898	=	IC50	nM	720.0	CHEMBL4282	Homo sapiens	IC50	uM	0.72
	3075731	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3ccc[nH]3)cc12		CHEMBL594749	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	uM	0.015
	3075732	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3ccsc3)cc12		CHEMBL604060	=	IC50	nM	50.0	CHEMBL4282	Homo sapiens	IC50	uM	0.05
	3075733	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3cccs3)cc12		CHEMBL594748	=	IC50	nM	79.0	CHEMBL4282	Homo sapiens	IC50	uM	0.079
	3075734	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3ccoc3)cc12		CHEMBL595709	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	uM	0.01
	3075735	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3cc(Cl)ccc3O)cc12		CHEMBL605733	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	uM	0.003
	3075736	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3cc(F)cc(F)c3O)cc12		CHEMBL596379	=	IC50	nM	63.0	CHEMBL4282	Homo sapiens	IC50	uM	0.063
	3075737	CHEMBL1071952	Inhibition of full length AKT1	B	COc1ccccc1-c1ncc(OC[C@@H](N)Cc2ccccc2)cc1-c1ccc2[nH]nc(C)c2c1		CHEMBL604684	=	IC50	nM	100.0	CHEMBL4282	Homo sapiens	IC50	uM	0.1
	3075738	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3ccc(O)cc3)cc12		CHEMBL595685	=	IC50	nM	500.0	CHEMBL4282	Homo sapiens	IC50	uM	0.5
	3075739	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3cccc(O)c3)cc12		CHEMBL595684	=	IC50	nM	79.0	CHEMBL4282	Homo sapiens	IC50	uM	0.079
	3075740	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3ccccc3O)cc12		CHEMBL595476	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	uM	0.015
	3075741	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4ccccc4)cnc3-c3ccccc3)cc12		CHEMBL605732	=	IC50	nM	50.0	CHEMBL4282	Homo sapiens	IC50	uM	0.05
	3075742	CHEMBL1071952	Inhibition of full length AKT1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	=	IC50	nM	125.0	CHEMBL4282	Homo sapiens	IC50	uM	0.125
	3075743	CHEMBL1071956	Inhibition of AKT1 in human BT474 cells assessed as phosphorylation of GSK3	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccncc45)cnc3-c3ccoc3)cc12		CHEMBL593142	=	IC50	nM	6800.0	CHEMBL4282	Homo sapiens	IC50	uM	6.8
	3075744	CHEMBL1071956	Inhibition of AKT1 in human BT474 cells assessed as phosphorylation of GSK3	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5cccnc45)cnc3-c3ccoc3)cc12		CHEMBL605838	=	IC50	nM	4300.0	CHEMBL4282	Homo sapiens	IC50	uM	4.3
	3076640	CHEMBL1072610	Inhibition of human AKT1	B	Cc1occc1-c1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1		CHEMBL596583	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	uM	0.001
	3076646	CHEMBL1072610	Inhibition of human AKT1	B	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2[nH]nc(C)c2c1		CHEMBL593374	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	uM	0.003
	3076652	CHEMBL1072610	Inhibition of human AKT1	B	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2c1		CHEMBL593375	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	uM	0.001
	3076658	CHEMBL1072610	Inhibition of human AKT1	B	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1		CHEMBL595944	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	uM	0.001
	3076664	CHEMBL1072610	Inhibition of human AKT1	B	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cc2c(C)n[nH]c2cn1		CHEMBL595459	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	uM	0.001
	3076670	CHEMBL1072610	Inhibition of human AKT1	B	Cc1n[nH]c2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c(C#N)nc3-c3ccoc3)nc12		CHEMBL606467	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	uM	0.01
	3076676	CHEMBL1072610	Inhibition of human AKT1	B	Cc1nc(-c2ccoc2)c(-c2cnc3[nH]nc(C)c3n2)cc1OC[C@@H](N)Cc1c[nH]c2ccccc12		CHEMBL594523	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	uM	0.003
	3076682	CHEMBL1072610	Inhibition of human AKT1	B	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2ccccc2)cc1-c1cnc2[nH]nc(C)c2n1		CHEMBL594755	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	uM	0.006
	3076688	CHEMBL1072610	Inhibition of human AKT1	B	CCNc1nc(-c2ccoc2)c(-c2cnc3[nH]nc(C)c3n2)cc1OC[C@@H](N)Cc1ccccc1		CHEMBL593573	=	IC50	nM	500.0	CHEMBL4282	Homo sapiens	IC50	uM	0.5
	3076694	CHEMBL1072610	Inhibition of human AKT1	B	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(Cl)[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1		CHEMBL593813	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	uM	0.001
	3076700	CHEMBL1072610	Inhibition of human AKT1	B	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(C#N)[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1		CHEMBL605410	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	uM	0.001
	3076706	CHEMBL1072610	Inhibition of human AKT1	B	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(C(N)=O)[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1		CHEMBL594072	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	uM	0.001
	3084399	CHEMBL1072678	Inhibition of AKT1	B	NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL590109	=	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	uM	1.0
	3086979	CHEMBL1069941	Inhibition of AKT1	B	Cc1[nH]nc2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12		CHEMBL593490	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	uM	0.001
	3086980	CHEMBL1069941	Inhibition of AKT1	B	Cc1n[nH]c2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12		CHEMBL596072	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	uM	0.001
	3086981	CHEMBL1069941	Inhibition of AKT1	B	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12		CHEMBL596073	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	uM	0.012
	3086982	CHEMBL1069941	Inhibition of AKT1	B	Cc1n[nH]c2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12		CHEMBL596290	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	uM	0.002
	3086983	CHEMBL1069941	Inhibition of AKT1	B	Cc1n[nH]c2cnc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12		CHEMBL603197	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	uM	0.001
	3086984	CHEMBL1069941	Inhibition of AKT1	B	Cc1n[nH]c2cnc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12		CHEMBL594933	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	uM	0.001
	3088558	CHEMBL1049483	Inhibition of PKBalpha	B	CN(C)CCOc1ccc2c(c1)CCn1nc(-c3ccc(Oc4ccccc4)cc3)c(C(N)=O)c1N2		CHEMBL591325	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	3088622	CHEMBL1049496	Inhibition of PKB	B	NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)[nH]c(C(=O)c2c(F)cccc2F)c1N		CHEMBL589630	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	3089518	CHEMBL1067365	Inhibition of PKBalpha	B	Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCC[C@@H](N)C2)ccc2[nH]ccc12		CHEMBL606245	=	IC50	nM	2400.0	CHEMBL4282	Homo sapiens	IC50	nM	2400.0
	3091559	CHEMBL1067153	Inhibition of AKT	B	COc1ccc2nc3[nH]nc(C)c3c(OC)c2c1		CHEMBL603097	=	IC50	nM	11400.0	CHEMBL4282	Homo sapiens	IC50	nM	11400.0
	3094742	CHEMBL1069052	Inhibition of AKT1 at 1 uM by microfluidic substrate phosphorylation assay	B	NC(=O)c1ccc(-c2cc(-c3cccc4c3OCO4)cnc2N)cc1		CHEMBL590335	=	Inhibition	%	-5.0	CHEMBL4282	Homo sapiens	INH	%	-5.0
	3094743	CHEMBL1069052	Inhibition of AKT1 at 1 uM by microfluidic substrate phosphorylation assay	B	NCCNC(=O)c1cc(-c2ccsc2)cnc1N		CHEMBL610226	=	Inhibition	%	-5.0	CHEMBL4282	Homo sapiens	INH	%	-5.0
	3094750	CHEMBL1069052	Inhibition of AKT1 at 1 uM by microfluidic substrate phosphorylation assay	B	NC(=O)c1ccc(-c2cc(-c3scc4c3OCCO4)cnc2N)cc1		CHEMBL602931	=	Inhibition	%	-2.0	CHEMBL4282	Homo sapiens	INH	%	-2.0
	3094787	CHEMBL1069052	Inhibition of AKT1 at 1 uM by microfluidic substrate phosphorylation assay	B	NCCNC(=O)c1cc(-c2scc3c2OCCO3)cnc1N		CHEMBL599171	=	Inhibition	%	8.0	CHEMBL4282	Homo sapiens	INH	%	8.0
	3098438	CHEMBL1067035	Inhibition of human PKBalpha at 0.1 uM	B	COc1ccccc1NC(=O)CC(Nc1ccc(Oc2ccnc3cc(-c4cn(C)cn4)sc23)c(F)c1)C(F)(F)F		CHEMBL591924	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	3099473	CHEMBL1070205	Inhibition of AKT	B	CCCNc1nnc(Sc2ncc([N+](=O)[O-])s2)s1		CHEMBL609039	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	3099474	CHEMBL1070205	Inhibition of AKT	B	COCCNc1nnc(Sc2ncc([N+](=O)[O-])s2)s1		CHEMBL611079	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	3099475	CHEMBL1070205	Inhibition of AKT	B	COc1ccc(CCNc2nnc(Sc3ncc([N+](=O)[O-])s3)s2)cc1OC		CHEMBL599111	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	3099476	CHEMBL1070205	Inhibition of AKT	B	CCC(C)Nc1nnc(Sc2ncc([N+](=O)[O-])s2)s1		CHEMBL599518	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	3104134	CHEMBL1066414	Inhibition of recombinant AKT1 by IMAP assay	B	C[C@@H](Oc1ccc2ncccc2c1)c1c(Cl)ccc(F)c1Cl		CHEMBL600795	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	3104181	CHEMBL1066414	Inhibition of recombinant AKT1 by IMAP assay	B	C[C@@H](Oc1ccc2ncc(C3CC3C(N)=O)cc2c1)c1c(Cl)ccc(F)c1Cl		CHEMBL602472	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	3104230	CHEMBL1066414	Inhibition of recombinant AKT1 by IMAP assay	B	C[C@@H](Oc1ccc2ncc(/C=C/C(N)=O)cc2c1)c1c(Cl)ccc(F)c1Cl		CHEMBL602471	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	3117914	CHEMBL1072190	Inhibition of AKT1	B	CC(=O)N1CCC(Nc2ncc3c(n2)-c2c(c(C(N)=O)nn2C)CC3)CC1		CHEMBL599224	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	3117967	CHEMBL1072190	Inhibition of AKT1	B	Cn1nc(C(N)=O)c2c1-c1nc(NC3CCN(C(=O)c4ccccc4)CC3)ncc1CC2		CHEMBL599428	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	3118020	CHEMBL1072190	Inhibition of AKT1	B	CNC(=O)c1nn(C)c2c1CCc1cnc(NC3CCN(C(=O)C4CCN(S(C)(=O)=O)CC4)CC3)nc1-2		CHEMBL597754	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
Active	3121487	CHEMBL1065077	Inhibition of Akt T308 phosphorylation in human MDA-MB-361 cells xenografted mouse model upto 36 hrs	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3121488	CHEMBL1065078	Inhibition of Akt S473 phosphorylation in human MDA-MB-361 cells xenografted mouse model upto 36 hrs	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445		Activity			CHEMBL4282	Homo sapiens	Activity		
	3124286	CHEMBL1068863	Inhibition of human recombinant AKT1 expressed in Sf21 cells at 10 uM	B	CCc1cccc2c1ccc1c3occ(C)c3c(=O)oc21		CHEMBL215797	=	Inhibition	%	93.0	CHEMBL4282	Homo sapiens	INH	%	93.0
	3127182	CHEMBL1074386	Inhibition of PKB in human PC3M cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(Cc2ccc(Cl)cc2)CCN(c2ccnc3[nH]ccc23)CC1	Outside typical range	CHEMBL596991	=	GI50	nM	0.37	CHEMBL4282	Homo sapiens	GI50	nM	0.37
	3127183	CHEMBL1074388	Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(COCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597793	=	IC50	nM	0.59	CHEMBL4282	Homo sapiens	IC50	nM	0.59
	3127184	CHEMBL1074388	Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL263664	=	IC50	nM	0.66	CHEMBL4282	Homo sapiens	IC50	nM	0.66
	3127185	CHEMBL1074388	Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1	Outside typical range	CHEMBL598194	=	GI50	nM	0.93	CHEMBL4282	Homo sapiens	GI50	nM	0.93
	3127186	CHEMBL1074386	Inhibition of PKB in human PC3M cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(Cc2ccc(Cl)cc2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597414	=	IC50	nM	1.9	CHEMBL4282	Homo sapiens	IC50	nM	1.9
	3127187	CHEMBL1074386	Inhibition of PKB in human PC3M cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598194	=	GI50	nM	2.3	CHEMBL4282	Homo sapiens	GI50	nM	2.3
	3127188	CHEMBL1074388	Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(Cc2ccc(Cl)cc2)CCN(c2ccnc3[nH]ncc23)CC1		CHEMBL598013	=	GI50	nM	2.7	CHEMBL4282	Homo sapiens	GI50	nM	2.7
	3127189	CHEMBL1074388	Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(C(=O)NCc2ccc(Cl)cc2F)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597600	=	GI50	nM	2.8	CHEMBL4282	Homo sapiens	GI50	nM	2.8
	3127190	CHEMBL1074386	Inhibition of PKB in human PC3M cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL263664	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	3127191	CHEMBL1074386	Inhibition of PKB in human PC3M cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(C(=O)NCc2ccc(Cl)cc2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL599849	=	IC50	nM	3.8	CHEMBL4282	Homo sapiens	IC50	nM	3.8
	3127192	CHEMBL1074386	Inhibition of PKB in human PC3M cells assessed as GSK3-beta phosphorylation by ELISA	F	CC(C)(C)c1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1		CHEMBL597211	=	GI50	nM	4.0	CHEMBL4282	Homo sapiens	GI50	nM	4.0
	3127193	CHEMBL1074386	Inhibition of PKB in human PC3M cells assessed as GSK3-beta phosphorylation by ELISA	F	CN(Cc1ccc(Cl)cc1)C(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597803	=	IC50	nM	4.2	CHEMBL4282	Homo sapiens	IC50	nM	4.2
	3127199	CHEMBL1074388	Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA	F	CC(C)(C)c1ccc(CC2(N)CCN(c3ccnc4[nH]ncc34)CC2)cc1		CHEMBL603675	=	IC50	nM	6.5	CHEMBL4282	Homo sapiens	IC50	nM	6.5
	3127200	CHEMBL1074386	Inhibition of PKB in human PC3M cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(Cc2c(Cl)cccc2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597415	=	GI50	nM	6.7	CHEMBL4282	Homo sapiens	GI50	nM	6.7
	3127202	CHEMBL1074388	Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ccnc3[nH]ccc23)CC1		CHEMBL599448	=	IC50	nM	7.2	CHEMBL4282	Homo sapiens	IC50	nM	7.2
	3127204	CHEMBL1074388	Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA	F	CC(C)(C)c1ccc(CC2(N)CCN(c3ncnc4[nH]c(=O)[nH]c34)CC2)cc1		CHEMBL598841	=	GI50	nM	8.8	CHEMBL4282	Homo sapiens	GI50	nM	8.8
	3127221	CHEMBL1074388	Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]c(=O)[nH]c23)CC1		CHEMBL598842	>	IC50	nM	50.0	CHEMBL4282	Homo sapiens	IC50	nM	50.0
Not Determined	3127229	CHEMBL1074386	Inhibition of PKB in human PC3M cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(COCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597793		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	3127230	CHEMBL1074386	Inhibition of PKB in human PC3M cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(C(=O)NCc2ccc(Cl)cc2F)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597600		GI50			CHEMBL4282	Homo sapiens	GI50		
Not Determined	3127231	CHEMBL1074386	Inhibition of PKB in human PC3M cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ccnc3[nH]ccc23)CC1		CHEMBL599448		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	3127232	CHEMBL1074386	Inhibition of PKB in human PC3M cells assessed as GSK3-beta phosphorylation by ELISA	F	CC(C)(C)c1ccc(CC2(N)CCN(c3ncnc4[nH]c(=O)[nH]c34)CC2)cc1		CHEMBL598841		GI50			CHEMBL4282	Homo sapiens	GI50		
Not Determined	3127233	CHEMBL1074386	Inhibition of PKB in human PC3M cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]c(=O)[nH]c23)CC1		CHEMBL598842		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	3127234	CHEMBL1074386	Inhibition of PKB in human PC3M cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(Cc2ccc(Cl)cc2)CCN(c2ccnc3[nH]ncc23)CC1		CHEMBL598013		GI50			CHEMBL4282	Homo sapiens	GI50		
Not Determined	3127235	CHEMBL1074386	Inhibition of PKB in human PC3M cells assessed as GSK3-beta phosphorylation by ELISA	F	CC(C)(C)c1ccc(CC2(N)CCN(c3ccnc4[nH]ncc34)CC2)cc1		CHEMBL603675		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	3127236	CHEMBL1074388	Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA	F	CC(C)(C)c1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1		CHEMBL597211		GI50			CHEMBL4282	Homo sapiens	GI50		
Not Determined	3127237	CHEMBL1074388	Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(Cc2ccc(Cl)cc2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597414		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	3127238	CHEMBL1074388	Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(Cc2c(Cl)cccc2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597415		GI50			CHEMBL4282	Homo sapiens	GI50		
Not Determined	3127239	CHEMBL1074388	Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(C(=O)NCc2ccc(Cl)cc2Cl)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL599849		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	3127240	CHEMBL1074388	Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA	F	CN(Cc1ccc(Cl)cc1)C(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL597803		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	3127241	CHEMBL1074388	Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA	F	NC1(Cc2ccc(Cl)cc2)CCN(c2ccnc3[nH]ccc23)CC1		CHEMBL596991		GI50			CHEMBL4282	Homo sapiens	GI50		
	3127256	CHEMBL1074362	Inhibition of PKB at 1 uM	B	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL263664	>	Inhibition	%	80.0	CHEMBL4282	Homo sapiens	INH	%	80.0
	3128302	CHEMBL1074428	Inhibition of AKT1	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	3128303	CHEMBL1074428	Inhibition of AKT1	B	CC(C)(C)C(=O)N1Cc2c(NC(=O)c3cc(F)cc(F)c3)n[nH]c2C1(C)C		CHEMBL604712	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	3186211	CHEMBL1111477	Inhibition of Akt1	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCNC3)c21		CHEMBL521642	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	3186221	CHEMBL1111477	Inhibition of Akt1	B	c1ccc(-c2cc3c(ccn4cnnc34)nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL447328	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	3186264	CHEMBL1111477	Inhibition of Akt1	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	58.0	CHEMBL4282	Homo sapiens	IC50	nM	58.0
	3186266	CHEMBL1111477	Inhibition of Akt1	B	CCn1c(-c2nonc2N)nc2cncc(OC3CCNCC3)c21		CHEMBL493911	=	IC50	nM	79.0	CHEMBL4282	Homo sapiens	IC50	nM	79.0
	3186277	CHEMBL1111477	Inhibition of Akt1	B	Cn1nnnc1-c1cnc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)c1		CHEMBL182101	=	IC50	nM	273.0	CHEMBL4282	Homo sapiens	IC50	nM	273.0
	3186294	CHEMBL1111477	Inhibition of Akt1	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
	3191044	CHEMBL1101911	Inhibition of AKT1 at 10 uM	B	C[C@H](O)CNc1nccc(-n2ccnc2-c2cccc(NC(=O)c3ccc(Cl)c(C(F)(F)F)c3)c2)n1		CHEMBL1082876	=	Inhibition	%	5.1	CHEMBL4282	Homo sapiens	INH	%	5.1
	3192021	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccccc4)s3)cc12		CHEMBL1087281	=	IC50	nM	76.0	CHEMBL4282	Homo sapiens	IC50	nM	76.0
	3192024	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Cc1n[nH]c2ccc(-c3nnc(NC[C@H](N)Cc4ccccc4)s3)cc12		CHEMBL1088612	>	IC50	nM	2200.0	CHEMBL4282	Homo sapiens	IC50	nM	2200.0
	3192027	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccccc4F)s3)cc12		CHEMBL1088613	=	IC50	nM	198.0	CHEMBL4282	Homo sapiens	IC50	nM	198.0
	3192030	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccccc4Cl)s3)cc12		CHEMBL1080891	=	IC50	nM	47.0	CHEMBL4282	Homo sapiens	IC50	nM	47.0
	3192033	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccccc4C(F)(F)F)s3)cc12		CHEMBL1080892	=	IC50	nM	491.0	CHEMBL4282	Homo sapiens	IC50	nM	491.0
	3192036	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4cccc(F)c4)s3)cc12		CHEMBL1076553	=	IC50	nM	38.0	CHEMBL4282	Homo sapiens	IC50	nM	38.0
	3192039	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4cccc(Cl)c4)s3)cc12		CHEMBL1080893	=	IC50	nM	19.0	CHEMBL4282	Homo sapiens	IC50	nM	19.0
	3192042	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4cccc(C(F)(F)F)c4)s3)cc12		CHEMBL1080561	=	IC50	nM	6.1	CHEMBL4282	Homo sapiens	IC50	nM	6.1
	3193161	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccc(Cl)cc4)s3)cc12		CHEMBL1080740	=	IC50	nM	8.9	CHEMBL4282	Homo sapiens	IC50	nM	8.9
	3193164	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc12		CHEMBL1080911	=	IC50	nM	5.5	CHEMBL4282	Homo sapiens	IC50	nM	5.5
	3193167	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccc(Cl)cc4Cl)s3)cc12		CHEMBL1080912	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
	3193170	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccc(F)c(F)c4)s3)cc12		CHEMBL1080913	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
	3193173	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	CCc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccccc4)s3)cc12		CHEMBL1081426	=	IC50	nM	370.0	CHEMBL4282	Homo sapiens	IC50	nM	370.0
	3193176	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1nnc(-c2ccc3[nH]nc(C4CC4)c3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081437	=	IC50	nM	181.0	CHEMBL4282	Homo sapiens	IC50	nM	181.0
	3193179	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1nnc(-c2ccc3[nH]nc(-c4ccccc4)c3c2)s1)Cc1cccc(C(F)(F)F)c1		CHEMBL1081438	=	IC50	nM	413.0	CHEMBL4282	Homo sapiens	IC50	nM	413.0
	3193182	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1cccc(C(F)(F)F)c1		CHEMBL1076565	=	IC50	nM	25.0	CHEMBL4282	Homo sapiens	IC50	nM	25.0
	3193185	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(F)cc1		CHEMBL1081439	=	IC50	nM	368.0	CHEMBL4282	Homo sapiens	IC50	nM	368.0
	3193188	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(Cl)cc1		CHEMBL1081451	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	nM	24.0
	3193191	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081628	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	3193194	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(Cl)cc1Cl		CHEMBL1076581	=	IC50	nM	40.0	CHEMBL4282	Homo sapiens	IC50	nM	40.0
Dose-dependent effect	3193197	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1nnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1080569		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3193203	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Cc1cc2cc(-c3nnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)ccc2cn1		CHEMBL1081629	=	IC50	nM	280.0	CHEMBL4282	Homo sapiens	IC50	nM	280.0
	3193207	CHEMBL1104223	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc12		CHEMBL1080911	=	IC50	nM	357.0	CHEMBL4282	Homo sapiens	IC50	nM	357.0
	3193208	CHEMBL1104224	Inhibition of human AKT1 in human MDA-MB-468 cells assessed as phosphorylation-mediated nuclear translocation of GFP-tagged FKHRL1 by fluorescence microscopy	B	Cc1n[nH]c2ccc(-c3nnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc12		CHEMBL1080911	=	IC50	nM	333.0	CHEMBL4282	Homo sapiens	IC50	nM	333.0
	3193212	CHEMBL1104223	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081628	=	IC50	nM	444.0	CHEMBL4282	Homo sapiens	IC50	nM	444.0
	3193213	CHEMBL1104224	Inhibition of human AKT1 in human MDA-MB-468 cells assessed as phosphorylation-mediated nuclear translocation of GFP-tagged FKHRL1 by fluorescence microscopy	B	N[C@H](CNc1nnc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081628	=	IC50	nM	154.0	CHEMBL4282	Homo sapiens	IC50	nM	154.0
	3193217	CHEMBL1104223	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1nnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1080569	=	IC50	nM	247.0	CHEMBL4282	Homo sapiens	IC50	nM	247.0
	3193218	CHEMBL1104224	Inhibition of human AKT1 in human MDA-MB-468 cells assessed as phosphorylation-mediated nuclear translocation of GFP-tagged FKHRL1 by fluorescence microscopy	B	N[C@H](CNc1nnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1080569	=	IC50	nM	695.0	CHEMBL4282	Homo sapiens	IC50	nM	695.0
	3193232	CHEMBL1104218	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1nnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1080569	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	3196136	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1nnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1080569	=	IC50	nM	3.2	CHEMBL4282	Homo sapiens	IC50	nM	3.2
	3196139	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1nnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1080569	=	IC50	nM	250.0	CHEMBL4282	Homo sapiens	IC50	uM	0.25
	3196140	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1ncc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081263	=	IC50	nM	4.9	CHEMBL4282	Homo sapiens	IC50	nM	4.9
	3196143	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1ncc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081263	=	IC50	nM	430.0	CHEMBL4282	Homo sapiens	IC50	uM	0.43
	3196144	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1cnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081425	=	IC50	nM	404.0	CHEMBL4282	Homo sapiens	IC50	nM	404.0
Not Determined	3196147	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1cnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081425		IC50			CHEMBL4282	Homo sapiens	IC50		
	3196148	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1cc(-c2ccc3cnccc3c2)no1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081104	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	nM	17.0
Not Determined	3196151	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1cc(-c2ccc3cnccc3c2)no1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081104		IC50			CHEMBL4282	Homo sapiens	IC50		
	3196152	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CCc1cc(-c2ccc3cnccc3c2)no1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081105	=	IC50	nM	40.0	CHEMBL4282	Homo sapiens	IC50	nM	40.0
	3196155	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CCc1cc(-c2ccc3cnccc3c2)no1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081105	=	IC50	nM	3800.0	CHEMBL4282	Homo sapiens	IC50	uM	3.8
	3196156	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CCc1nc(-c2ccc3cnccc3c2)no1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081118	=	IC50	nM	1600.0	CHEMBL4282	Homo sapiens	IC50	nM	1600.0
Not Determined	3196159	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CCc1nc(-c2ccc3cnccc3c2)no1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081118		IC50			CHEMBL4282	Homo sapiens	IC50		
	3196160	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1nnc(-c2ccc3cnccc3c2)o1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081119	=	IC50	nM	85.0	CHEMBL4282	Homo sapiens	IC50	nM	85.0
Not Determined	3196163	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1nnc(-c2ccc3cnccc3c2)o1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081119		IC50			CHEMBL4282	Homo sapiens	IC50		
	3196164	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Nc1cc2cc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)ccc2cn1		CHEMBL1081295	=	IC50	nM	11.6	CHEMBL4282	Homo sapiens	IC50	nM	11.6
	3196167	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	Nc1cc2cc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)ccc2cn1		CHEMBL1081295	=	IC50	nM	890.0	CHEMBL4282	Homo sapiens	IC50	uM	0.89
	3196168	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1ncc(-c2ccc3cncnc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081296	=	IC50	nM	35.0	CHEMBL4282	Homo sapiens	IC50	nM	35.0
	3196171	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1ncc(-c2ccc3cncnc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081296	=	IC50	nM	1300.0	CHEMBL4282	Homo sapiens	IC50	uM	1.3
	3196172	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1ncc(-c2ccc3nnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081974	=	IC50	nM	141.0	CHEMBL4282	Homo sapiens	IC50	nM	141.0
Not Determined	3196175	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1ncc(-c2ccc3nnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081974		IC50			CHEMBL4282	Homo sapiens	IC50		
	3196176	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1ncc(-c2ccc3cn[nH]c3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1079625	=	IC50	nM	613.0	CHEMBL4282	Homo sapiens	IC50	nM	613.0
Not Determined	3196179	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1ncc(-c2ccc3cn[nH]c3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1079625		IC50			CHEMBL4282	Homo sapiens	IC50		
	3196180	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Cn1ncc2ccc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc21		CHEMBL1079626	=	IC50	nM	895.0	CHEMBL4282	Homo sapiens	IC50	nM	895.0
Not Determined	3196183	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	Cn1ncc2ccc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc21		CHEMBL1079626		IC50			CHEMBL4282	Homo sapiens	IC50		
	3196184	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Cn1nc(N)c2ccc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc21		CHEMBL1079627	=	IC50	nM	2406.0	CHEMBL4282	Homo sapiens	IC50	nM	2406.0
Not Determined	3196187	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	Cn1nc(N)c2ccc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc21		CHEMBL1079627		IC50			CHEMBL4282	Homo sapiens	IC50		
	3196188	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Nc1noc2ccc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc12		CHEMBL1081660	=	IC50	nM	453.0	CHEMBL4282	Homo sapiens	IC50	nM	453.0
Not Determined	3196191	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	Nc1noc2ccc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc12		CHEMBL1081660		IC50			CHEMBL4282	Homo sapiens	IC50		
	3196192	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1ncc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081829	=	IC50	nM	8.5	CHEMBL4282	Homo sapiens	IC50	nM	8.5
	3196195	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1ncc(-c2ccc3[nH]ncc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081829	=	IC50	nM	730.0	CHEMBL4282	Homo sapiens	IC50	uM	0.73
	3196196	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1ncc(-c2ccc3nnn(N)c3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081830	=	IC50	nM	77.0	CHEMBL4282	Homo sapiens	IC50	nM	77.0
Not Determined	3196199	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1ncc(-c2ccc3nnn(N)c3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081830		IC50			CHEMBL4282	Homo sapiens	IC50		
	3196200	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1ncc(-c2ccc3c(c2)CC(=O)N3)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081831	=	IC50	nM	18.3	CHEMBL4282	Homo sapiens	IC50	nM	18.3
	3196203	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1ncc(-c2ccc3c(c2)CC(=O)N3)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081831	=	IC50	nM	300.0	CHEMBL4282	Homo sapiens	IC50	uM	0.3
	3196204	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1ncc(-c2ccc3[nH]c(=O)oc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081852	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
	3196207	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1ncc(-c2ccc3[nH]c(=O)oc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081852	=	IC50	nM	500.0	CHEMBL4282	Homo sapiens	IC50	uM	0.5
	3196208	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1ncc(-c2ccc3[nH]c(=O)sc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081853	=	IC50	nM	27.0	CHEMBL4282	Homo sapiens	IC50	nM	27.0
	3196211	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1ncc(-c2ccc3[nH]c(=O)sc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081853	=	IC50	nM	920.0	CHEMBL4282	Homo sapiens	IC50	uM	0.92
	3196212	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	Cn1c(=O)[nH]c2ccc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc21		CHEMBL1082016	=	IC50	nM	15.4	CHEMBL4282	Homo sapiens	IC50	nM	15.4
	3196215	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	Cn1c(=O)[nH]c2ccc(-c3cnc(NC[C@@H](N)Cc4ccc(C(F)(F)F)cc4)s3)cc21		CHEMBL1082016	=	IC50	nM	630.0	CHEMBL4282	Homo sapiens	IC50	uM	0.63
	3196216	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1ncc(-c2ccc3c(c2)CCC(=O)N3)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1082017	=	IC50	nM	3315.0	CHEMBL4282	Homo sapiens	IC50	nM	3315.0
Not Determined	3196219	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1ncc(-c2ccc3c(c2)CCC(=O)N3)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1082017		IC50			CHEMBL4282	Homo sapiens	IC50		
	3196220	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1ncc(-c2ccc3cn[nH]c(=O)c3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1082030	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
Not Determined	3196223	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1ncc(-c2ccc3cn[nH]c(=O)c3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1082030		IC50			CHEMBL4282	Homo sapiens	IC50		
	3196224	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	NC(=O)c1ccc(-c2cnc(NC[C@@H](N)Cc3ccc(C(F)(F)F)cc3)s2)cc1		CHEMBL1081028	>	IC50	nM	3000.0	CHEMBL4282	Homo sapiens	IC50	nM	3000.0
Not Determined	3196227	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	NC(=O)c1ccc(-c2cnc(NC[C@@H](N)Cc3ccc(C(F)(F)F)cc3)s2)cc1		CHEMBL1081028		IC50			CHEMBL4282	Homo sapiens	IC50		
	3196228	CHEMBL1102921	Inhibition of AKT1 after 10 mins by [gamma33]ATP assay	B	N[C@H](CNc1ncc(-c2ccc3c(c2)CNC3=O)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081029	=	IC50	nM	95.0	CHEMBL4282	Homo sapiens	IC50	nM	95.0
	3196231	CHEMBL1102924	Inhibition of human AKT1 in human U87MG cells assessed as PRAS40 phosphorylation after 1 hr by ELISA	B	N[C@H](CNc1ncc(-c2ccc3c(c2)CNC3=O)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1081029	=	IC50	nM	6000.0	CHEMBL4282	Homo sapiens	IC50	uM	6.0
	3199573	CHEMBL1108601	Inhibition of Akt1	B	CC1=C(C#N)c2nc(N)c(C#N)c(C)c2/C1=C/c1ccc(-c2cccc(C(=O)O)c2)o1		CHEMBL193261	=	IC50	nM	60200.0	CHEMBL4282	Homo sapiens	IC50	uM	60.2
	3199574	CHEMBL1108601	Inhibition of Akt1	B	CC1=C(C#N)c2nc(N)c(C#N)c(C)c2/C1=C/c1ccc(-c2ccc(C(=O)O)cc2)o1	Outside typical range	CHEMBL365978	=	IC50	nM	126000.0	CHEMBL4282	Homo sapiens	IC50	uM	126.0
	3210404	CHEMBL1109421	Inhibition of Akt after 1 hr	B	O=C(Nc1cccc(-c2cn3ccnc3c(NCc3ccncc3)n2)c1)Nc1cccc(C(F)(F)F)c1		CHEMBL1081198	=	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	3213870	CHEMBL1111286	Inhibition of AKT1 at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	-1.0	CHEMBL4282	Homo sapiens	INH	%	-1.0
	3219686	CHEMBL1110437	Inhibition of PKBalpha at 100 nM relative to control	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)c1ccc(-c2ccnc(N)n2)s1)C(N)=O		CHEMBL1077375	=	Inhibition	%	97.0	CHEMBL4282	Homo sapiens	INH	%	97.0
	3224749	CHEMBL1102594	Inhibition of AKT1 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	3225002	CHEMBL1102594	Inhibition of AKT1 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	3235772	CHEMBL1113529	Inhibition of PKB by radioactive kinase assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CS)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1090008	=	IC50	nM	400.0	CHEMBL4282	Homo sapiens	IC50	uM	0.4
	3235773	CHEMBL1113529	Inhibition of PKB by radioactive kinase assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089990	=	IC50	nM	840.0	CHEMBL4282	Homo sapiens	IC50	uM	0.84
	3235774	CHEMBL1113529	Inhibition of PKB by radioactive kinase assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089991	=	IC50	nM	1170.0	CHEMBL4282	Homo sapiens	IC50	uM	1.17
	3235775	CHEMBL1113529	Inhibition of PKB by radioactive kinase assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)N(C)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1090001	=	IC50	nM	2030.0	CHEMBL4282	Homo sapiens	IC50	uM	2.03
	3235776	CHEMBL1113529	Inhibition of PKB by radioactive kinase assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1090000	=	IC50	nM	920.0	CHEMBL4282	Homo sapiens	IC50	uM	0.92
	3235777	CHEMBL1113529	Inhibition of PKB by radioactive kinase assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089661	=	IC50	nM	940.0	CHEMBL4282	Homo sapiens	IC50	uM	0.94
	3235778	CHEMBL1113528	Inhibition of PKB at 50 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CS)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1090008	=	Inhibition	%	95.0	CHEMBL4282	Homo sapiens	INH	%	95.0
Not Determined	3235779	CHEMBL1113528	Inhibition of PKB at 50 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089660		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235780	CHEMBL1113528	Inhibition of PKB at 50 uM by radioactive kinase assay relative to control	B	C[C@H](O)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CN)C(=O)N[C@@H](Cc1ccccc1)C(N)=O		CHEMBL1090007		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235781	CHEMBL1113528	Inhibition of PKB at 50 uM by radioactive kinase assay relative to control	B	CC(C)CC[C@H](NC(=O)[C@H](CN)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(C)C)C(=O)O		CHEMBL1090006		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235782	CHEMBL1113528	Inhibition of PKB at 50 uM by radioactive kinase assay relative to control	B	CC(C)CC[C@H](NC(=O)[C@H](CN)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(C)C)C(N)=O		CHEMBL1090005		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3235783	CHEMBL1113528	Inhibition of PKB at 50 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089661	=	Inhibition	%	99.0	CHEMBL4282	Homo sapiens	INH	%	99.0
Not Determined	3235784	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089660		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3235785	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CS)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1090008	=	Inhibition	%	95.0	CHEMBL4282	Homo sapiens	INH	%	95.0
Not Determined	3235786	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	C[C@H](O)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CN)C(=O)N[C@@H](Cc1ccccc1)C(N)=O		CHEMBL1090007		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235787	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CC(C)CC[C@H](NC(=O)[C@H](CN)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(C)C)C(=O)O		CHEMBL1090006		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235788	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CC(C)CC[C@H](NC(=O)[C@H](CN)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(C)C)C(N)=O		CHEMBL1090005		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235789	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O)N(C)C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N		CHEMBL1090004		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235790	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)N(C)C(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O		CHEMBL1090003		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3235791	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)N(C)C(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1090002	=	Inhibition	%	39.0	CHEMBL4282	Homo sapiens	INH	%	39.0
	3235792	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)N(C)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1090001	=	Inhibition	%	77.0	CHEMBL4282	Homo sapiens	INH	%	77.0
	3235793	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1090000	=	Inhibition	%	85.0	CHEMBL4282	Homo sapiens	INH	%	85.0
Not Determined	3235794	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)CN(CCCNC(=N)N)C(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089999		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3235795	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O)N(C)C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N		CHEMBL1090004	=	Inhibition	%	62.0	CHEMBL4282	Homo sapiens	INH	%	62.0
	3235796	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)CNCCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089657	=	Inhibition	%	32.0	CHEMBL4282	Homo sapiens	INH	%	32.0
	3235797	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)N(C)C(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O		CHEMBL1090003	=	Inhibition	%	42.0	CHEMBL4282	Homo sapiens	INH	%	42.0
	3235798	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)N(C)C(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1090002	=	Inhibition	%	92.0	CHEMBL4282	Homo sapiens	INH	%	92.0
	3235799	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)N(C)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1090001	=	Inhibition	%	95.0	CHEMBL4282	Homo sapiens	INH	%	95.0
	3235800	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)CN(CCCNC(=N)N)C(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089999	=	Inhibition	%	30.0	CHEMBL4282	Homo sapiens	INH	%	30.0
	3235801	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1090000	=	Inhibition	%	97.0	CHEMBL4282	Homo sapiens	INH	%	97.0
	3235802	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)CNCCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089657	=	Inhibition	%	95.0	CHEMBL4282	Homo sapiens	INH	%	95.0
	3235803	CHEMBL1113527	Inhibition of PKB at 20 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O		CHEMBL1089998	=	Inhibition	%	48.0	CHEMBL4282	Homo sapiens	INH	%	48.0
	3235804	CHEMBL1113527	Inhibition of PKB at 20 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089997	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	3235805	CHEMBL1113527	Inhibition of PKB at 20 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O		CHEMBL1089996	=	Inhibition	%	46.0	CHEMBL4282	Homo sapiens	INH	%	46.0
	3235806	CHEMBL1113527	Inhibition of PKB at 20 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089995	=	Inhibition	%	85.0	CHEMBL4282	Homo sapiens	INH	%	85.0
	3235807	CHEMBL1113527	Inhibition of PKB at 20 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089994	=	Inhibition	%	92.0	CHEMBL4282	Homo sapiens	INH	%	92.0
	3235808	CHEMBL1113527	Inhibition of PKB at 20 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O		CHEMBL1089993	=	Inhibition	%	69.0	CHEMBL4282	Homo sapiens	INH	%	69.0
	3235809	CHEMBL1113527	Inhibition of PKB at 20 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089992	=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	INH	%	40.0
	3235810	CHEMBL1113527	Inhibition of PKB at 20 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089991	=	Inhibition	%	94.0	CHEMBL4282	Homo sapiens	INH	%	94.0
	3235811	CHEMBL1113527	Inhibition of PKB at 20 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089990	=	Inhibition	%	96.0	CHEMBL4282	Homo sapiens	INH	%	96.0
	3235812	CHEMBL1113527	Inhibition of PKB at 20 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089661	=	Inhibition	%	96.0	CHEMBL4282	Homo sapiens	INH	%	96.0
Not Determined	3235813	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O		CHEMBL1089998		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235814	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089997		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235815	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O		CHEMBL1089996		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3235816	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089995	=	Inhibition	%	61.0	CHEMBL4282	Homo sapiens	INH	%	61.0
	3235817	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089994	=	Inhibition	%	73.0	CHEMBL4282	Homo sapiens	INH	%	73.0
Not Determined	3235818	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O		CHEMBL1089993		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235819	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089992		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3235820	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089991	=	Inhibition	%	83.0	CHEMBL4282	Homo sapiens	INH	%	83.0
	3235821	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089990	=	Inhibition	%	88.0	CHEMBL4282	Homo sapiens	INH	%	88.0
Not Determined	3235822	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N(C)[C@@H](CCC(C)C)C(=O)O		CHEMBL1089989		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235823	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N(C)[C@@H](CCC(C)C)C(N)=O		CHEMBL1089988		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3235824	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N(C)[C@@H](CCC(C)C)C(N)=O		CHEMBL1089659	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
Not Determined	3235825	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N(C)[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O		CHEMBL1089987		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235826	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N(C)[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089675		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235827	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N(C)[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O		CHEMBL1089674		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235828	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N(C)[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089673		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235829	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089656		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3235830	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089672	=	Inhibition	%	13.0	CHEMBL4282	Homo sapiens	INH	%	13.0
Not Determined	3235831	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N(CC(=O)O)CC(C)CC		CHEMBL1089671		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235832	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N(CC(N)=O)CC(C)CC		CHEMBL1089670		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235833	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N(CC(N)=O)CC(C)CC		CHEMBL1089658		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235834	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N(CC(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O)Cc1ccc(O)cc1		CHEMBL1089669		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235835	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N(CC(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O)Cc1ccc(O)cc1		CHEMBL1089668		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3235836	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N(CC(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O)Cc1ccc(O)cc1		CHEMBL1089667	=	Inhibition	%	23.0	CHEMBL4282	Homo sapiens	INH	%	23.0
Not Determined	3235837	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCCN(CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O)C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O		CHEMBL1089666		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Determined	3235838	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCCN(CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O)C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N		CHEMBL1089665		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3235839	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089663	=	Inhibition	%	45.0	CHEMBL4282	Homo sapiens	INH	%	45.0
Not Determined	3235840	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O		CHEMBL1089664		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3235841	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089661	=	Inhibition	%	87.0	CHEMBL4282	Homo sapiens	INH	%	87.0
	3235842	CHEMBL1113526	Inhibition of PKB at 5 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O		CHEMBL1089662	=	Inhibition	%	51.0	CHEMBL4282	Homo sapiens	INH	%	51.0
	3235843	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N(C)[C@@H](CCC(C)C)C(=O)O		CHEMBL1089989	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	3235844	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N(C)[C@@H](CCC(C)C)C(N)=O		CHEMBL1089988	=	Inhibition	%	29.0	CHEMBL4282	Homo sapiens	INH	%	29.0
	3235845	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N(C)[C@@H](CCC(C)C)C(N)=O		CHEMBL1089659	=	Inhibition	%	86.0	CHEMBL4282	Homo sapiens	INH	%	86.0
	3235846	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N(C)[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O		CHEMBL1089987	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	3235847	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N(C)[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089675	=	Inhibition	%	33.0	CHEMBL4282	Homo sapiens	INH	%	33.0
	3235848	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N(C)[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O		CHEMBL1089674	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	3235849	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N(C)[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089673	=	Inhibition	%	75.0	CHEMBL4282	Homo sapiens	INH	%	75.0
	3235850	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089656	=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	INH	%	40.0
	3235851	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089672	=	Inhibition	%	88.0	CHEMBL4282	Homo sapiens	INH	%	88.0
	3235852	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N(CC(=O)O)CC(C)CC		CHEMBL1089671	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	3235853	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N(CC(N)=O)CC(C)CC		CHEMBL1089658	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	3235854	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N(CC(N)=O)CC(C)CC		CHEMBL1089670	=	Inhibition	%	39.0	CHEMBL4282	Homo sapiens	INH	%	39.0
	3235855	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N(CC(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O)Cc1ccc(O)cc1		CHEMBL1089669	=	Inhibition	%	28.0	CHEMBL4282	Homo sapiens	INH	%	28.0
	3235856	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N(CC(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O)Cc1ccc(O)cc1		CHEMBL1089668	=	Inhibition	%	49.0	CHEMBL4282	Homo sapiens	INH	%	49.0
	3235857	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N(CC(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O)Cc1ccc(O)cc1		CHEMBL1089667	=	Inhibition	%	85.0	CHEMBL4282	Homo sapiens	INH	%	85.0
	3235858	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCCN(CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O)C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O		CHEMBL1089666	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	3235859	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCCN(CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O)C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N		CHEMBL1089665	=	Inhibition	%	16.0	CHEMBL4282	Homo sapiens	INH	%	16.0
	3235860	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O		CHEMBL1089664	=	Inhibition	%	66.0	CHEMBL4282	Homo sapiens	INH	%	66.0
	3235861	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089663	=	Inhibition	%	92.0	CHEMBL4282	Homo sapiens	INH	%	92.0
	3235862	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)O		CHEMBL1089662	=	Inhibition	%	95.0	CHEMBL4282	Homo sapiens	INH	%	95.0
	3235863	CHEMBL1113525	Inhibition of PKB at 100 uM by radioactive kinase assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089661	=	Inhibition	%	99.0	CHEMBL4282	Homo sapiens	INH	%	99.0
Active	3242740	CHEMBL1113618	Increase in activated phospho-Akt in human MDA-MB-435 cells at 20 uM after 1 hr by Western blot analysis	B	Nc1nc(N)c2c(n1)[nH]c1cccc(Sc3ccccc3)c12		CHEMBL1093099		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3242751	CHEMBL1113621	Increase in activated phospho-Akt in human MDA-MB-435 cells at 20 uM after 4 hrs by Western blot analysis	B	Nc1nc(N)c2c(n1)[nH]c1cccc(Sc3ccccc3)c12		CHEMBL1093099		Activity			CHEMBL4282	Homo sapiens	Activity		
	3246478	CHEMBL1117089	Inhibition of AKT	B	O=C(Nc1cccc(-c2ncnc3sc(-c4ccncc4)cc23)c1)c1cccc(C(F)(F)F)c1		CHEMBL1090143	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	3260504	CHEMBL1109839	Inhibition of PKBalpha	B	O=C(Nc1cccc(-c2ccnc3cc(-c4ccncc4)nn23)c1)c1cccc(C(F)(F)F)c1		CHEMBL1089082	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	3261356	CHEMBL1105212	Inhibition of PKBalpha at 10 uM assessed as residual activity by [33P]ATP radioactive filter binding assay relative to control	B	CN(C)CCCC(=O)Nc1ccc2nccc(Nc3cccc(Br)c3)c2c1		CHEMBL1089524	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	3261450	CHEMBL1105212	Inhibition of PKBalpha at 10 uM assessed as residual activity by [33P]ATP radioactive filter binding assay relative to control	B	CN(C)CCCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL1088901	=	Activity	%	103.0	CHEMBL4282	Homo sapiens	Activity	%	103.0
	3262023	CHEMBL1114557	Inhibition of AKT1	B	O=C(N[C@H]1CC[C@H](O)CC1)c1ccc2c(c1)Cc1c(-c3ccc(-c4ccc(O)cc4)cc3)n[nH]c1-2		CHEMBL438485	=	IC50	nM	4430.0	CHEMBL4282	Homo sapiens	IC50	uM	4.43
	3262284	CHEMBL1113463	Inhibition of AKT1 at 10 uM	B	O=C1OC(c2ccccc2)=N/C1=C\c1cccnc1		CHEMBL579387	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	INH	%	12.0
	3262285	CHEMBL1113463	Inhibition of AKT1 at 10 uM	B	Cc1cccc(C2=N/C(=C\c3cccnc3)C(=O)O2)c1		CHEMBL1091786	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	3262286	CHEMBL1113463	Inhibition of AKT1 at 10 uM	B	O=C1OC(c2ccc(Cl)cc2)=N/C1=C\c1cccnc1		CHEMBL1091787	=	Inhibition	%	13.0	CHEMBL4282	Homo sapiens	INH	%	13.0
	3262287	CHEMBL1113463	Inhibition of AKT1 at 10 uM	B	O=C1OC(/C=C/c2ccccc2)=N/C1=C\c1cccnc1		CHEMBL565286	=	Inhibition	%	15.0	CHEMBL4282	Homo sapiens	INH	%	15.0
	3262288	CHEMBL1113463	Inhibition of AKT1 at 10 uM	B	O=C1OC(c2ccc(F)c(F)c2)=N/C1=C\c1cccnc1		CHEMBL1091764	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	INH	%	12.0
	3262289	CHEMBL1113463	Inhibition of AKT1 at 10 uM	B	Cc1cc(C2=N/C(=C\c3cccnc3)C(=O)O2)ccc1Br		CHEMBL1091766	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	INH	%	12.0
	3266047	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OCCN)c4)cc3c2cc1OC		CHEMBL1095278	=	IC50	nM	402.0	CHEMBL4282	Homo sapiens	IC50	nM	402.0
	3266048	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OC[C@H](C)N)c4)cc3c2cc1OC		CHEMBL1095279	=	IC50	nM	712.0	CHEMBL4282	Homo sapiens	IC50	nM	712.0
	3266049	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OC[C@@H](C)N)c4)cc3c2cc1OC		CHEMBL1097955	=	IC50	nM	377.0	CHEMBL4282	Homo sapiens	IC50	nM	377.0
	3266050	CHEMBL1103721	Inhibition of AKT	B	CC[C@H](N)COc1cncc(-c2cc3c(cnc4cc(OC)c(OC)cc43)c(N)n2)c1		CHEMBL1097956	=	IC50	nM	422.0	CHEMBL4282	Homo sapiens	IC50	nM	422.0
	3266051	CHEMBL1103721	Inhibition of AKT	B	CC[C@@H](N)COc1cncc(-c2cc3c(cnc4cc(OC)c(OC)cc43)c(N)n2)c1		CHEMBL1094320	=	IC50	nM	318.0	CHEMBL4282	Homo sapiens	IC50	nM	318.0
	3266052	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OC[C@@H](N)CC(C)C)c4)cc3c2cc1OC		CHEMBL1094321	=	IC50	nM	905.0	CHEMBL4282	Homo sapiens	IC50	nM	905.0
	3266053	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OC[C@H](N)CC(C)C)c4)cc3c2cc1OC		CHEMBL1094637	=	IC50	nM	1395.0	CHEMBL4282	Homo sapiens	IC50	nM	1395.0
	3266054	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OC[C@@H](N)Cc5ccccc5)c4)cc3c2cc1OC		CHEMBL1097602	=	IC50	nM	261.0	CHEMBL4282	Homo sapiens	IC50	nM	261.0
	3266055	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OC[C@H](N)Cc5ccccc5)c4)cc3c2cc1OC		CHEMBL1095294	=	IC50	nM	259.0	CHEMBL4282	Homo sapiens	IC50	nM	259.0
	3266056	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OC[C@@H](N)Cc5ccc(F)cc5)c4)cc3c2cc1OC		CHEMBL1095621	=	IC50	nM	183.0	CHEMBL4282	Homo sapiens	IC50	nM	183.0
	3266057	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OC[C@H](N)Cc5ccc(F)cc5)c4)cc3c2cc1OC		CHEMBL1095622	=	IC50	nM	251.0	CHEMBL4282	Homo sapiens	IC50	nM	251.0
	3266058	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OC[C@@H](N)Cc5cccc(C(F)(F)F)c5)c4)cc3c2cc1OC		CHEMBL1098302	=	IC50	nM	209.0	CHEMBL4282	Homo sapiens	IC50	nM	209.0
	3266059	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OC[C@H](N)Cc5cccc(C(F)(F)F)c5)c4)cc3c2cc1OC		CHEMBL1095285	=	IC50	nM	889.0	CHEMBL4282	Homo sapiens	IC50	nM	889.0
	3266060	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OC[C@@H](N)Cc5c[nH]c6ccccc56)c4)cc3c2cc1OC		CHEMBL1095612	=	IC50	nM	302.0	CHEMBL4282	Homo sapiens	IC50	nM	302.0
	3266061	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OC[C@H](N)Cc5c[nH]c6ccccc56)c4)cc3c2cc1OC		CHEMBL1097604	=	IC50	nM	1324.0	CHEMBL4282	Homo sapiens	IC50	nM	1324.0
	3266062	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OC[C@@H](N)Cc5ccccc5Cl)c4)cc3c2cc1OC		CHEMBL1095931	=	IC50	nM	793.0	CHEMBL4282	Homo sapiens	IC50	nM	793.0
	3266063	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OC[C@@H](N)Cc5cccc(Cl)c5)c4)cc3c2cc1OC		CHEMBL1096271	=	IC50	nM	78.0	CHEMBL4282	Homo sapiens	IC50	nM	78.0
	3266064	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OC[C@@H](N)Cc5ccc(Cl)c(Cl)c5)c4)cc3c2cc1OC		CHEMBL1097972	=	IC50	nM	433.0	CHEMBL4282	Homo sapiens	IC50	nM	433.0
	3266065	CHEMBL1103721	Inhibition of AKT	B	COc1cc2ncc3c(N)nc(-c4cncc(OC[C@@H](N)Cc5ccncc5)c4)cc3c2cc1OC		CHEMBL1097973	=	IC50	nM	1750.0	CHEMBL4282	Homo sapiens	IC50	nM	1750.0
	3269014	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@H](CCN)c3ccccc3)cc21		CHEMBL1099298	=	Ki	nM	1.9	CHEMBL4282	Homo sapiens	Ki	nM	1.9
	3269015	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CCN)c3ccccc3)cc21		CHEMBL1099297	=	Ki	nM	0.2	CHEMBL4282	Homo sapiens	Ki	nM	0.2
	3269016	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@H](CN)c3ccccc3)cc21		CHEMBL1099296	=	Ki	nM	3.0	CHEMBL4282	Homo sapiens	Ki	nM	3.0
	3269017	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21		CHEMBL1099276	=	Ki	nM	0.4	CHEMBL4282	Homo sapiens	Ki	nM	0.4
	3269018	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)Cc3ccccc3)cc21		CHEMBL1098938	=	Ki	nM	0.2	CHEMBL4282	Homo sapiens	Ki	nM	0.2
	3269019	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCCN)cc21		CHEMBL1096292	=	Ki	nM	115.0	CHEMBL4282	Homo sapiens	Ki	nM	115.0
	3269020	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCN)cc21		CHEMBL1096291	=	Ki	nM	6.0	CHEMBL4282	Homo sapiens	Ki	nM	6.0
	3269021	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Ki	nM	1.0	CHEMBL4282	Homo sapiens	Ki	nM	1.0
	3269035	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CCCN)cc21		CHEMBL1097974	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	3269036	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CNC)cc21		CHEMBL1098316	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	3269037	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN(C)C)cc21		CHEMBL1099290	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	3269038	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	3269039	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCN)cc21		CHEMBL1096291	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	3269040	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCCN)cc21		CHEMBL1096292	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
	3269041	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCCCN)cc21		CHEMBL1096636	=	IC50	nM	63.0	CHEMBL4282	Homo sapiens	IC50	nM	63.0
	3269042	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21		CHEMBL1098943	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
	3269043	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](C)N)cc21		CHEMBL1098944	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
	3269044	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](C)N)cc21		CHEMBL1099281	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
	3269045	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	3269046	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	3269047	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)Cc3ccccc3)cc21		CHEMBL1098938	=	IC50	nM	0.6	CHEMBL4282	Homo sapiens	IC50	nM	0.6
	3269048	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)Cc3ccccc3)cc21		CHEMBL1098939	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	3269049	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21		CHEMBL1099276	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	3269050	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@H](CN)c3ccccc3)cc21		CHEMBL1099296	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	3269051	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CCN)c3ccccc3)cc21		CHEMBL1099297	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	3269052	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@H](CCN)c3ccccc3)cc21		CHEMBL1099298	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	3269522	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN)cc21		CHEMBL1098241	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	3269523	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	3269524	CHEMBL1109952	Inhibition of AKT	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CCN)cc21		CHEMBL1095624	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
Not Active	3271712	CHEMBL1112896	Inhibition of AKT1	B	COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1		CHEMBL576349		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3271713	CHEMBL1112896	Inhibition of AKT1	B	COc1ccccc1/C=C1/C(=O)Nc2ccccc21		CHEMBL444673		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3271714	CHEMBL1112896	Inhibition of AKT1	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1F		CHEMBL1088391		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3271715	CHEMBL1112896	Inhibition of AKT1	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1[N+](=O)[O-]		CHEMBL1088392		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3271716	CHEMBL1112896	Inhibition of AKT1	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1S(=O)(=O)O		CHEMBL1088529		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3271717	CHEMBL1112896	Inhibition of AKT1	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1ccc2c(c1)OCO2		CHEMBL1086669		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3271718	CHEMBL1112896	Inhibition of AKT1	B	O=C1Nc2ccc(Cl)cc2/C1=C\c1cc(F)cc(F)c1		CHEMBL1086670		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3271719	CHEMBL1112896	Inhibition of AKT1	B	NC(=O)Cc1ccc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL1086795		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3271720	CHEMBL1112896	Inhibition of AKT1	B	COc1ccc(/C=C2/C(=O)Nc3ccc(Cl)cc32)c(OC)c1OC		CHEMBL1086796		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3271721	CHEMBL1112896	Inhibition of AKT1	B	COc1cc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc(OC)c1OC		CHEMBL383871		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3271722	CHEMBL1112896	Inhibition of AKT1	B	COc1cc(OC)c(/C=C2/C(=O)Nc3ccc(Cl)cc32)c(OC)c1		CHEMBL1086939	<	Inhibition	%	20.0	CHEMBL4282	Homo sapiens	INH	%	20.0
Not Active	3271723	CHEMBL1112896	Inhibition of AKT1	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3278001	CHEMBL1117424	Inhibition of AKT	B	COc1cc(Nc2c(C#N)cnc3cc(/C=C/CCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL1088240	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
Active	3291233	CHEMBL1121342	Inhibition of Akt phosphorylation in human OVCAR cells at 1.2 to 5 uM after 16 hrs by Western blot analysis	B	COc1ccc(-c2cc(-c3ccccc3-c3ccccc3)n[nH]2)cc1		CHEMBL1096539		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3291234	CHEMBL1121342	Inhibition of Akt phosphorylation in human OVCAR cells at 1.2 to 5 uM after 16 hrs by Western blot analysis	B	FC(F)(F)c1ccc(-c2cc(-c3ccccc3-c3ccccc3)n[nH]2)cc1		CHEMBL1096824		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3291445	CHEMBL1109159	Inhibition of AKT1 assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
Not Active	3293109	CHEMBL1108232	Inhibition of AKT1 at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)Cc1ccccc1CC2=O		CHEMBL1096459		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3293125	CHEMBL1108232	Inhibition of AKT1 at 10 uM	B	O=C1Cc2ccccc2Cc2cc(Nc3ccc(F)cc3F)ccc21		CHEMBL1096460		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3293141	CHEMBL1108232	Inhibition of AKT1 at 10 uM	B	Nc1cc(F)ccc1Nc1ccc2c(c1)Cc1ccccc1CC2=O		CHEMBL1096466		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3293157	CHEMBL1108232	Inhibition of AKT1 at 10 uM	B	O=C1Cc2ccccc2Cc2cc(Nc3ccccc3)ccc21		CHEMBL1096672		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3293173	CHEMBL1108232	Inhibition of AKT1 at 10 uM	B	Nc1ccc(Nc2ccc3c(c2)Cc2ccccc2CC3=O)cc1		CHEMBL1096769		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3293189	CHEMBL1108232	Inhibition of AKT1 at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)C(=O)Cc1ccccc1C2		CHEMBL1096770		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3293205	CHEMBL1108232	Inhibition of AKT1 at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)Cc1ccccc1C(=O)C2		CHEMBL1096771		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3293221	CHEMBL1108232	Inhibition of AKT1 at 10 uM	B	Nc1cc(F)ccc1Nc1ccc2c(c1)Cc1ccccc1C(=O)C2		CHEMBL1097085		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3293237	CHEMBL1108232	Inhibition of AKT1 at 10 uM	B	O=C1Cc2ccc(Nc3ccccc3)cc2Cc2ccccc21		CHEMBL1097086		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3293253	CHEMBL1108232	Inhibition of AKT1 at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)CC(=O)c1ccccc1C2		CHEMBL1097087		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3293269	CHEMBL1108232	Inhibition of AKT1 at 10 uM	B	Nc1cc(F)ccc1Nc1ccc2c(c1)CC(=O)c1ccccc1C2		CHEMBL1097088		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3293285	CHEMBL1108232	Inhibition of AKT1 at 10 uM	B	O=C1Cc2cc(Nc3ccccc3)ccc2Cc2ccccc21		CHEMBL1096988		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3293301	CHEMBL1108232	Inhibition of AKT1 at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)Oc1ccccc1NC2=O		CHEMBL1098461		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3293317	CHEMBL1108232	Inhibition of AKT1 at 10 uM	B	Nc1cc(F)ccc1Nc1ccc2c(c1)Oc1ccccc1NC2=O		CHEMBL1098462		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3293333	CHEMBL1108232	Inhibition of AKT1 at 10 uM	B	O=C1Cc2ccccc2Cc2cc(-c3ccccc3)ccc21		CHEMBL1096442		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3293349	CHEMBL1108232	Inhibition of AKT1 at 10 uM	B	O=C1Cc2ccccc2Cc2cc(NCc3ccccc3)ccc21		CHEMBL1097171		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3294626	CHEMBL1103938	Inhibition of PKBalpha	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=O)c5cnn(-c6ccccc6)c5C(F)(F)F)cc4F)c3s2)c1		CHEMBL1094718	<	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	INH	%	40.0
	3304858	CHEMBL1119890	Inhibition of AKT	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	>	Ki	nM	10000.0	CHEMBL4282	Homo sapiens	Ki	uM	10.0
	3315905	CHEMBL1120251	Inhibition of PKBalpha	B	CC(C)COC(=O)Nc1ccc(-c2cnc3c(-c4ccc(N5CCN(C)CC5)cc4)cnn3c2N)cc1		CHEMBL1085511	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	3327253	CHEMBL1168271	Inhibition of AKT1 at 10 uM by HotSpot assay	B	CC(=O)Nc1cccc(-c2ccc(-c3ccnc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)cn2)c1.Cl		CHEMBL1164847	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
Not Active	3330452	CHEMBL1167770	Inhibition of histidine-tagged full length AKT1 after 1 hr by IMAP assay	B	CC(C)CN(C)C(=O)c1ccc2cc(-c3cc(Cc4ccccc4)[nH]n3)[nH]c2c1		CHEMBL1164457		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3331822	CHEMBL1168781	Inhibition of AKT1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	3333237	CHEMBL1168781	Inhibition of AKT1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	3334642	CHEMBL1168781	Inhibition of AKT1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	3336062	CHEMBL1168781	Inhibition of AKT1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	3337448	CHEMBL1168781	Inhibition of AKT1 at 1 uM	B	O=C(O)c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1		CHEMBL1163510	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	3337696	CHEMBL1168781	Inhibition of AKT1 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1		CHEMBL1163518	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	3339027	CHEMBL1168781	Inhibition of AKT1 at 1 uM	B	COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1		CHEMBL1163567	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	3339283	CHEMBL1168781	Inhibition of AKT1 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1		CHEMBL1163559	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	3340590	CHEMBL1168781	Inhibition of AKT1 at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	3342006	CHEMBL1168781	Inhibition of AKT1 at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	3354871	CHEMBL1174001	Inhibition of AKT1 at 10 uM by mobility shift assay	B	c1ccc(-c2cnc3cnc(-c4cc[nH]n4)cn23)cc1		CHEMBL1170750	=	Inhibition	%	-4.0	CHEMBL4282	Homo sapiens	INH	%	-4.0
	3354872	CHEMBL1174001	Inhibition of AKT1 at 10 uM by mobility shift assay	B	c1ccc(-c2cnc3cnc(-c4cn[nH]c4)cn23)cc1		CHEMBL1172464	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	3354873	CHEMBL1174001	Inhibition of AKT1 at 10 uM by mobility shift assay	B	c1ccc(-c2cnc3cnc(-c4ccncc4)cn23)cc1	Outside typical range	CHEMBL1170317	=	Inhibition	%	-11.0	CHEMBL4282	Homo sapiens	INH	%	-11.0
	3354874	CHEMBL1174001	Inhibition of AKT1 at 10 uM by mobility shift assay	B	c1n[nH]cc1-c1cnc2ncc(-c3cn[nH]c3)n2c1		CHEMBL1171532	=	Inhibition	%	-6.0	CHEMBL4282	Homo sapiens	INH	%	-6.0
	3354875	CHEMBL1174001	Inhibition of AKT1 at 10 uM by mobility shift assay	B	Cn1cc(-c2cnc3ncc(-c4cn[nH]c4)cn23)cn1		CHEMBL1171533	=	Inhibition	%	-5.0	CHEMBL4282	Homo sapiens	INH	%	-5.0
	3354876	CHEMBL1174001	Inhibition of AKT1 at 10 uM by mobility shift assay	B	c1cc(-c2cnc3ncc(-c4cn[nH]c4)cn23)n[nH]1		CHEMBL1171534	=	Inhibition	%	-6.0	CHEMBL4282	Homo sapiens	INH	%	-6.0
	3354877	CHEMBL1174001	Inhibition of AKT1 at 10 uM by mobility shift assay	B	OCc1cccc(-c2cnc3ncc(-c4cn[nH]c4)cn23)c1		CHEMBL1171699	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	3354878	CHEMBL1174001	Inhibition of AKT1 at 10 uM by mobility shift assay	B	c1ccc2c(-c3cnc4cnc(-c5cn[nH]c5)cn34)c[nH]c2c1		CHEMBL1170126	=	Inhibition	%	11.0	CHEMBL4282	Homo sapiens	INH	%	11.0
	3354879	CHEMBL1174001	Inhibition of AKT1 at 10 uM by mobility shift assay	B	NCc1ccc(-c2cn3c(-c4cn[nH]c4)cnc3cn2)cc1		CHEMBL1170747	=	Inhibition	%	8.0	CHEMBL4282	Homo sapiens	INH	%	8.0
	3354880	CHEMBL1174001	Inhibition of AKT1 at 10 uM by mobility shift assay	B	OCc1cccc(-c2cn3c(-c4cn[nH]c4)cnc3cn2)c1	Outside typical range	CHEMBL1170748	=	Inhibition	%	-14.0	CHEMBL4282	Homo sapiens	INH	%	-14.0
	3354881	CHEMBL1174001	Inhibition of AKT1 at 10 uM by mobility shift assay	B	OCc1ccc(-c2cn3c(-c4cn[nH]c4)cnc3cn2)cc1	Outside typical range	CHEMBL1170749	=	Inhibition	%	-15.0	CHEMBL4282	Homo sapiens	INH	%	-15.0
	3354944	CHEMBL1174001	Inhibition of AKT1 at 10 uM by mobility shift assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Inhibition	%	97.0	CHEMBL4282	Homo sapiens	INH	%	97.0
	3358449	CHEMBL1174063	Inhibition of AKT1 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	81.0	CHEMBL4282	Homo sapiens	INH	%	81.0
	3358891	CHEMBL1174063	Inhibition of AKT1 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	41.0	CHEMBL4282	Homo sapiens	INH	%	41.0
	3368343	CHEMBL1176556	Inhibition of AKT1 at 1 M after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CC[C@@H](N)C3)c12		CHEMBL1173273	=	Inhibition	%	98.0	CHEMBL4282	Homo sapiens	INH	%	98.0
	3368344	CHEMBL1176556	Inhibition of AKT1 at 1 M after 90 mins by IMAP assay	B	N#Cc1c[nH]c2ncnc(N3CC4(CCNCC4)c4ccccc43)c12		CHEMBL258837	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	INH	%	100.0
	3368345	CHEMBL1176555	Inhibition of AKT1-mediated GSK3alpha phosphorylation in human U87 cells after 1 hr by ELISA	B	Cc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(F)cc4F)C3)c12		CHEMBL1170448	=	IC50	nM	310.0	CHEMBL4282	Homo sapiens	IC50	uM	0.31
	3368346	CHEMBL1176555	Inhibition of AKT1-mediated GSK3alpha phosphorylation in human U87 cells after 1 hr by ELISA	B	N[C@]1(CNC(=O)c2ccc(F)cc2F)CCN(c2ncnc3[nH]cc(Cl)c23)C1		CHEMBL1169623	=	IC50	nM	280.0	CHEMBL4282	Homo sapiens	IC50	uM	0.28
	3368347	CHEMBL1176555	Inhibition of AKT1-mediated GSK3alpha phosphorylation in human U87 cells after 1 hr by ELISA	B	N#Cc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(F)cc4F)C3)c12		CHEMBL1170447	=	IC50	nM	1860.0	CHEMBL4282	Homo sapiens	IC50	uM	1.86
	3368348	CHEMBL1176555	Inhibition of AKT1-mediated GSK3alpha phosphorylation in human U87 cells after 1 hr by ELISA	B	CCc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(Cl)cc4)C3)c12		CHEMBL1170446	=	IC50	nM	920.0	CHEMBL4282	Homo sapiens	IC50	uM	0.92
	3368349	CHEMBL1176555	Inhibition of AKT1-mediated GSK3alpha phosphorylation in human U87 cells after 1 hr by ELISA	B	Cc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(Cl)cc4)C3)c12		CHEMBL1170263	=	IC50	nM	1950.0	CHEMBL4282	Homo sapiens	IC50	uM	1.95
	3368350	CHEMBL1176555	Inhibition of AKT1-mediated GSK3alpha phosphorylation in human U87 cells after 1 hr by ELISA	B	N[C@]1(CNC(=O)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]cc(Cl)c23)C1		CHEMBL1170445	=	IC50	nM	350.0	CHEMBL4282	Homo sapiens	IC50	uM	0.35
	3368351	CHEMBL1176555	Inhibition of AKT1-mediated GSK3alpha phosphorylation in human U87 cells after 1 hr by ELISA	B	N#Cc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(Cl)cc4)C3)c12		CHEMBL1170262	=	IC50	nM	6340.0	CHEMBL4282	Homo sapiens	IC50	uM	6.34
	3368352	CHEMBL1176555	Inhibition of AKT1-mediated GSK3alpha phosphorylation in human U87 cells after 1 hr by ELISA	B	CCc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(F)cc4)C3)c12		CHEMBL1170261	=	IC50	nM	650.0	CHEMBL4282	Homo sapiens	IC50	uM	0.65
	3368353	CHEMBL1176555	Inhibition of AKT1-mediated GSK3alpha phosphorylation in human U87 cells after 1 hr by ELISA	B	N[C@]1(CNC(=O)c2ccc(F)cc2)CCN(c2ncnc3[nH]cc(Cl)c23)C1		CHEMBL1169610	=	IC50	nM	360.0	CHEMBL4282	Homo sapiens	IC50	uM	0.36
	3368354	CHEMBL1176555	Inhibition of AKT1-mediated GSK3alpha phosphorylation in human U87 cells after 1 hr by ELISA	B	CCc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(F)cc4F)C3)c12		CHEMBL1171647	=	IC50	nM	310.0	CHEMBL4282	Homo sapiens	IC50	uM	0.31
	3368355	CHEMBL1176555	Inhibition of AKT1-mediated GSK3alpha phosphorylation in human U87 cells after 1 hr by ELISA	B	Cc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(F)cc4)C3)c12		CHEMBL1171994	=	IC50	nM	1460.0	CHEMBL4282	Homo sapiens	IC50	uM	1.46
	3368356	CHEMBL1176555	Inhibition of AKT1-mediated GSK3alpha phosphorylation in human U87 cells after 1 hr by ELISA	B	N#Cc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(F)cc4)C3)c12		CHEMBL1171993	=	IC50	nM	5740.0	CHEMBL4282	Homo sapiens	IC50	uM	5.74
	3368756	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	CCc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(F)cc4F)C3)c12		CHEMBL1171647	=	IC50	nM	0.5	CHEMBL4282	Homo sapiens	IC50	nM	0.5
	3368757	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	N[C@]1(CNC(=O)c2ccc(F)cc2F)CCN(c2ncnc3[nH]cc(Cl)c23)C1		CHEMBL1169623	=	IC50	nM	1.1	CHEMBL4282	Homo sapiens	IC50	nM	1.1
	3368758	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(F)cc4F)C3)c12		CHEMBL1170448	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	3368759	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	N#Cc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(F)cc4F)C3)c12		CHEMBL1170447	=	IC50	nM	7.7	CHEMBL4282	Homo sapiens	IC50	nM	7.7
	3368760	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	CCc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(Cl)cc4)C3)c12		CHEMBL1170446	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
	3368761	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	N[C@]1(CNC(=O)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]cc(Cl)c23)C1		CHEMBL1170445	=	IC50	nM	3.3	CHEMBL4282	Homo sapiens	IC50	nM	3.3
	3368762	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(Cl)cc4)C3)c12		CHEMBL1170263	=	IC50	nM	11.4	CHEMBL4282	Homo sapiens	IC50	nM	11.4
	3368763	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	N#Cc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(Cl)cc4)C3)c12		CHEMBL1170262	=	IC50	nM	17.5	CHEMBL4282	Homo sapiens	IC50	nM	17.5
	3368764	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	CCc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(F)cc4)C3)c12		CHEMBL1170261	=	IC50	nM	1.4	CHEMBL4282	Homo sapiens	IC50	nM	1.4
	3368765	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	N[C@]1(CNC(=O)c2ccc(F)cc2)CCN(c2ncnc3[nH]cc(Cl)c23)C1		CHEMBL1169610	=	IC50	nM	2.6	CHEMBL4282	Homo sapiens	IC50	nM	2.6
	3368766	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(F)cc4)C3)c12		CHEMBL1171994	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	3368767	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	N#Cc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(F)cc4)C3)c12		CHEMBL1171993	=	IC50	nM	7.8	CHEMBL4282	Homo sapiens	IC50	nM	7.8
	3368768	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CCC(N)(CNC(=O)c4ccc(F)cc4)C3)c12		CHEMBL1171673	=	IC50	nM	7.4	CHEMBL4282	Homo sapiens	IC50	nM	7.4
	3368769	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CCC(N)(CNC(=O)c4cccc(F)c4)C3)c12		CHEMBL1171672	=	IC50	nM	38.0	CHEMBL4282	Homo sapiens	IC50	nM	38.0
	3368770	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	CC(=O)NCC1(N)CCN(c2ncnc3[nH]cc(C)c23)C1		CHEMBL1171841	=	IC50	nM	765.0	CHEMBL4282	Homo sapiens	IC50	nM	765.0
	3368771	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CCC(N)(CNC(=O)c4ccccc4)C3)c12		CHEMBL1171842	=	IC50	nM	62.0	CHEMBL4282	Homo sapiens	IC50	nM	62.0
	3368772	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CCC(N)(CNC(=O)c4ccccc4F)C3)c12		CHEMBL1171501	=	IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	nM	44.0
	3368773	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CCC(N)(CNC=O)C3)c12		CHEMBL1173384	=	IC50	nM	160.0	CHEMBL4282	Homo sapiens	IC50	nM	160.0
	3368774	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CCC(N)(CNC=O)C3)c12	Non standard unit for type	CHEMBL1173384	=	IC50		3500.0	CHEMBL4282	Homo sapiens	IC50		3500.0
	3368775	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CCC(N)(CNC=O)C3)c12		CHEMBL1173384	=	IC50	nM	56.0	CHEMBL4282	Homo sapiens	IC50	nM	56.0
	3368776	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CCC(N)(CNC(=O)Cl)C3)c12		CHEMBL1171299	=	IC50	nM	58.0	CHEMBL4282	Homo sapiens	IC50	nM	58.0
	3368777	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CCC(N)(CNC(=O)C(F)(F)F)C3)c12		CHEMBL1171485	=	IC50	nM	61.0	CHEMBL4282	Homo sapiens	IC50	nM	61.0
	3368778	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CCC(N)(CNC(=O)C(C)C)C3)c12		CHEMBL1171839	=	Ratio		50.0	CHEMBL4282	Homo sapiens	Ratio		50.0
	3368779	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CCC(N)(CNC(=O)Oc4ccccc4)C3)c12		CHEMBL1171840	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
	3368780	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CC[C@@H](NCc4ccccc4)C3)c12		CHEMBL1173306	=	IC50	nM	2400.0	CHEMBL4282	Homo sapiens	IC50	uM	2.4
	3368781	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	CCN[C@@H]1CCN(c2ncnc3[nH]cc(C)c23)C1		CHEMBL1173305	=	IC50	nM	1900.0	CHEMBL4282	Homo sapiens	IC50	uM	1.9
	3368782	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CC[C@@H](NC(=O)Nc4ccccc4)C3)c12		CHEMBL1173304	=	IC50	nM	700.0	CHEMBL4282	Homo sapiens	IC50	uM	0.7
	3368783	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CC[C@@H](NS(=O)(=O)c4ccccc4)C3)c12		CHEMBL1173697	=	IC50	nM	600.0	CHEMBL4282	Homo sapiens	IC50	uM	0.6
	3368784	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CC[C@@H](NS(C)(=O)=O)C3)c12		CHEMBL1173696	=	IC50	nM	4000.0	CHEMBL4282	Homo sapiens	IC50	uM	4.0
	3368785	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CC[C@@H](NC(=O)c4ccccc4)C3)c12		CHEMBL1170238	=	IC50	nM	700.0	CHEMBL4282	Homo sapiens	IC50	uM	0.7
	3368786	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	CC(=O)N[C@@H]1CCN(c2ncnc3[nH]cc(C)c23)C1		CHEMBL1173351	=	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	3368787	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Clc1c[nH]c2ncnc(N3CCC4(CCNCC4)C3)c12		CHEMBL1173350	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	3368788	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	NC1CCCN(c2ncnc3[nH]cc(Cl)c23)C1		CHEMBL1173349	=	IC50	nM	200.0	CHEMBL4282	Homo sapiens	IC50	nM	200.0
	3368789	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CC[C@@H](N)C3)c12		CHEMBL1173273	=	IC50	nM	180.0	CHEMBL4282	Homo sapiens	IC50	nM	180.0
	3368790	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	N[C@@H]1CCN(c2ncnc3[nH]cc(Cl)c23)C1		CHEMBL1173272	=	IC50	nM	68.0	CHEMBL4282	Homo sapiens	IC50	nM	68.0
	3368791	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	N#Cc1c[nH]c2ncnc(N3CC4(CCNCC4)c4ccccc43)c12		CHEMBL258837	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	3368792	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	c1ccc(-c2nnc[nH]2)c(Nc2ncnc3[nH]ccc23)c1		CHEMBL261204	=	IC50	nM	288.0	CHEMBL4282	Homo sapiens	IC50	nM	288.0
	3368793	CHEMBL1176552	Inhibition of AKT1 after 90 mins by IMAP assay	B	Cc1c[nH]c2ncnc(N3CC[C@H](N)C3)c12		CHEMBL2021603	=	IC50	nM	240.0	CHEMBL4282	Homo sapiens	IC50	nM	240.0
	3370103	CHEMBL1176706	Inhibition of AKT1 at 10 uM	B	COc1ccc(NC(=O)Nc2ccc3c(c2)NC(=O)/C3=C\c2[nH]cc(C(=O)O)c2C)cc1		CHEMBL1173411	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
Not Active	3376399	CHEMBL1212303	Inhibition of AKT phosphorylation in human U937 cells assessed as p-AKT level by Western blotting	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442		Activity			CHEMBL4282	Homo sapiens	Activity		
	3400034	CHEMBL1217231	Inhibition of human PKBalpha at 10 uM	B	Cc1ccc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL1214141	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
Active	3405301	CHEMBL1218952	Inhibition of AKT phosphorylation in human MCF7 cells assessed as p-AKT level at 5 uM after 20 hrs by Western blotting	B	COc1cc2c(/C=C3/C(=O)Nc4cc(Cl)ccc43)c(Cl)n(C)c2cc1C		CHEMBL1215586		Activity			CHEMBL4282	Homo sapiens	Activity		
	3407680	CHEMBL1219734	Inhibition of AKT1 at 1 uM by radiometric method	B	CCOC(=O)CCc1c(/C=C2\C(=O)Nc3ccc(NS(=O)(=O)c4ccccc4)cc32)[nH]c2c1C(=O)CCC2		CHEMBL1215218	=	Inhibition	%	11.0	CHEMBL4282	Homo sapiens	INH	%	11.0
	3407681	CHEMBL1219734	Inhibition of AKT1 at 1 uM by radiometric method	B	CN(C)CCCc1c(/C=C2\C(=O)Nc3ccc(NS(=O)(=O)c4ccccc4)cc32)[nH]c2c1C(=O)CCC2		CHEMBL1215346	=	Inhibition	%	9.0	CHEMBL4282	Homo sapiens	INH	%	9.0
Dose-dependent effect	3414719	CHEMBL1229006	Inhibition of Akt phosphorylation in human JHU011 cells after 24 hrs by Western blot analysis	B	CC1=C(CO)C(=O)O[C@H]([C@@H](C)[C@H]2CC[C@H]3[C@@H]4C[C@H]5O[C@]56[C@@H](O)C=CC(=O)[C@]6(C)[C@H]4CC[C@@]32C)C1		CHEMBL1221986		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	3414720	CHEMBL1229007	Inhibition of Akt phosphorylation in human UM-SCC2 cells after 24 hrs by Western blot analysis	B	CC1=C(CO)C(=O)O[C@H]([C@@H](C)[C@H]2CC[C@H]3[C@@H]4C[C@H]5O[C@]56[C@@H](O)C=CC(=O)[C@]6(C)[C@H]4CC[C@@]32C)C1		CHEMBL1221986		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	3414721	CHEMBL1229008	Inhibition of Akt phosphorylation in human MDA1986 cells after 24 hrs by Western blot analysis	B	CC1=C(CO)C(=O)O[C@H]([C@@H](C)[C@H]2CC[C@H]3[C@@H]4C[C@H]5O[C@]56[C@@H](O)C=CC(=O)[C@]6(C)[C@H]4CC[C@@]32C)C1		CHEMBL1221986		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	3414722	CHEMBL1229009	Inhibition of Akt phosphorylation in human JMAR cells after 24 hrs by Western blot analysis	B	CC1=C(CO)C(=O)O[C@H]([C@@H](C)[C@H]2CC[C@H]3[C@@H]4C[C@H]5O[C@]56[C@@H](O)C=CC(=O)[C@]6(C)[C@H]4CC[C@@]32C)C1		CHEMBL1221986		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3414723	CHEMBL1229010	Inhibition of Akt in human MDA1986 cells assessed as highest required for enzyme activity after 24 hrs by Western blot analysis	B	CC1=C(CO)C(=O)O[C@H]([C@@H](C)[C@H]2CC[C@H]3[C@@H]4C[C@H]5O[C@]56[C@@H](O)C=CC(=O)[C@]6(C)[C@H]4CC[C@@]32C)C1		CHEMBL1221986	=	Activity	uM	2.5	CHEMBL4282	Homo sapiens	Activity	uM	2.5
Active	3414724	CHEMBL1228513	Inhibition of Akt in human MDA1986 cells assessed as decrease in total protein level at 0.1 to 5 uM after 24 hrs by Western blot analysis	B	CC1=C(CO)C(=O)O[C@H]([C@@H](C)[C@H]2CC[C@H]3[C@@H]4C[C@H]5O[C@]56[C@@H](O)C=CC(=O)[C@]6(C)[C@H]4CC[C@@]32C)C1		CHEMBL1221986		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3414725	CHEMBL1228514	Inhibition of Akt in human JMAR cells assessed as decrease in total protein level at 0.1 to 5 uM after 24 hrs by Western blot analysis	B	CC1=C(CO)C(=O)O[C@H]([C@@H](C)[C@H]2CC[C@H]3[C@@H]4C[C@H]5O[C@]56[C@@H](O)C=CC(=O)[C@]6(C)[C@H]4CC[C@@]32C)C1		CHEMBL1221986		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3414726	CHEMBL1228515	Inhibition of Akt in human UM-SCC2 cells assessed as decrease in total protein level at 0.1 to 5 uM after 24 hrs by Western blot analysis	B	CC1=C(CO)C(=O)O[C@H]([C@@H](C)[C@H]2CC[C@H]3[C@@H]4C[C@H]5O[C@]56[C@@H](O)C=CC(=O)[C@]6(C)[C@H]4CC[C@@]32C)C1		CHEMBL1221986		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3414727	CHEMBL1228516	Inhibition of Akt in human JHU011 cells assessed as decrease in total protein level at 0.1 to 5 uM after 24 hrs by Western blot analysis	B	CC1=C(CO)C(=O)O[C@H]([C@@H](C)[C@H]2CC[C@H]3[C@@H]4C[C@H]5O[C@]56[C@@H](O)C=CC(=O)[C@]6(C)[C@H]4CC[C@@]32C)C1		CHEMBL1221986		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3418843	CHEMBL1226727	Activation of Akt phosphorylation at Thr308 in PDGF-stimulated serum starved human BJ cells at 100 uM treated 2 hrs before PDGF challenge by immunoblotting	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3418844	CHEMBL1226726	Activation of Akt phosphorylation at Thr308 in PDGF-stimulated serum starved human BJ cells at 25 uM treated 2 hrs before PDGF challenge by immunoblotting	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350		Activity			CHEMBL4282	Homo sapiens	Activity		
	3419148	CHEMBL1228778	Inhibition of Akt	B	NC(=O)c1sc2c([N+](=O)[O-])cc(C(F)(F)F)cc2[n+]1[O-]		CHEMBL476124	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	3419165	CHEMBL1228778	Inhibition of Akt	B	NC(=O)c1sc2c([N+](=O)[O-])cc(SC(F)(F)F)cc2[n+]1[O-]		CHEMBL1222044	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	3420226	CHEMBL1226922	Inhibition of AKT1	B	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	3434677	CHEMBL1246546	Inhibition of AKT1 at 5 uM	B	c1cc(-c2cc(C3CCNCC3)n[nH]2)ccn1		CHEMBL1241462	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	3439129	CHEMBL1247975	Inhibition of PKBalpha by HTRF assay	B	CNc1nccc(-c2cccnc2Oc2ccc(NC(=O)c3cccc(C(F)(F)F)c3)cc2C)n1		CHEMBL1242977	>	IC50	nM	8000.0	CHEMBL4282	Homo sapiens	IC50	nM	8000.0
	3439195	CHEMBL1247975	Inhibition of PKBalpha by HTRF assay	B	CNc1nccc(-c2cccnc2Oc2ccc(NC(=O)c3ccccc3Nc3ccccc3)cc2)n1		CHEMBL1243200	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
	3439207	CHEMBL1247975	Inhibition of PKBalpha by HTRF assay	B	CNc1nccc(-c2cccnc2Oc2ccc(Nc3nnc(-c4ccc(F)cc4)c4ccccc34)cc2)n1		CHEMBL1243326	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	nM	25000.0
Active	3439523	CHEMBL1243831	Inhibition of Akt-mediated antiapoptotic activity in human NCI-H526 cells assessed as induction of Akt degradation at 50 uM after 24 hrs by Western blot analysis	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3439524	CHEMBL1243832	Inhibition of Akt-mediated antiapoptotic activity in human NCI-H526 cells assessed as reduction in BAD phosphorylation at 50 uM after 24 hrs by Western blot analysis	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3439525	CHEMBL1243833	Inhibition of Akt-mediated antiapoptotic activity in human NCI-H526 cells assessed as disruption of protein-Apaf-1 complex at 50 uM after 24 hrs by Western blot analysis	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3439526	CHEMBL1243834	Inhibition of Akt-mediated antiapoptotic activity in human SKBR3 cells assessed as induction of cell growth arrest at 50 uM after 24 hrs by propidium iodide staining-based flow cytometry	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3439527	CHEMBL1243835	Inhibition of Akt-mediated antiapoptotic activity in human MCF7 cells assessed as induction of cell growth arrest at 50 uM after 24 hrs by propidium iodide staining-based flow cytometry	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3441528	CHEMBL1244111	Inhibition of VEGF-induced Akt phosphorylation in HUVEC at 100 nM treated 2 hrs before VEGF challenge by Western blotting	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3441529	CHEMBL1244112	Inhibition of bFGF-induced Akt phosphorylation in HUVEC at 100 nM treated 2 hrs before bFGF challenge by Western blotting	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3441532	CHEMBL1244115	Inhibition of VEGF-induced Akt phosphorylation in HUASMC at 100 nM treated 2 hrs before VEGF challenge by Western blotting	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3441533	CHEMBL1244116	Inhibition of bFGF-induced Akt phosphorylation in HUASMC at 100 nM treated 2 hrs before bFGF challenge by Western blotting	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3441607	CHEMBL1244167	Inhibition of CD-28 triggered Akt phosphorylation in human Jurkat JA16 cells assessed as enzyme phosphorylation at Thr308 by immunoblotting analysis relative to control	B	CCCCCCC(=O)CCCCCC/C=C/C[C@@H](O)[C@H](O)[C@@](N)(CO)C(=O)O		CHEMBL55076	=	Inhibition	%	46.1	CHEMBL4282	Homo sapiens	INH	%	46.1
	3441608	CHEMBL1244168	Inhibition of CD-28 triggered Akt phosphorylation in human Jurkat JA16 cells assessed as enzyme phosphorylation at Ser473 by immunoblotting analysis relative to control	B	CCCCCCC(=O)CCCCCC/C=C/C[C@@H](O)[C@H](O)[C@@](N)(CO)C(=O)O		CHEMBL55076	=	Inhibition	%	48.8	CHEMBL4282	Homo sapiens	INH	%	48.8
	3441610	CHEMBL1244168	Inhibition of CD-28 triggered Akt phosphorylation in human Jurkat JA16 cells assessed as enzyme phosphorylation at Ser473 by immunoblotting analysis relative to control	B	C=C(CC[C@]12O[C@H](C(=O)O)[C@@](O)(C(=O)O)[C@](C(=O)O)(O1)[C@H](OC(=O)/C=C/[C@@H](C)C[C@@H](C)CC)[C@H]2O)[C@@H](OC(C)=O)[C@H](C)Cc1ccccc1		CHEMBL280978	=	Inhibition	%	94.6	CHEMBL4282	Homo sapiens	INH	%	94.6
	3441611	CHEMBL1244167	Inhibition of CD-28 triggered Akt phosphorylation in human Jurkat JA16 cells assessed as enzyme phosphorylation at Thr308 by immunoblotting analysis relative to control	B	C=C(CC[C@]12O[C@H](C(=O)O)[C@@](O)(C(=O)O)[C@](C(=O)O)(O1)[C@H](OC(=O)/C=C/[C@@H](C)C[C@@H](C)CC)[C@H]2O)[C@@H](OC(C)=O)[C@H](C)Cc1ccccc1		CHEMBL280978	=	Inhibition	%	105.1	CHEMBL4282	Homo sapiens	INH	%	105.1
Active	3441729	CHEMBL1244184	Inhibition of Akt in human U87 cells at 0.04 to 10 uM by Western blot analysis	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3441732	CHEMBL1244186	Inhibition of Akt in human LN229 cells at 0.04 to 10 uM by Western blot analysis	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3441735	CHEMBL1244184	Inhibition of Akt in human U87 cells at 0.04 to 10 uM by Western blot analysis	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3441738	CHEMBL1244186	Inhibition of Akt in human LN229 cells at 0.04 to 10 uM by Western blot analysis	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3441741	CHEMBL1244184	Inhibition of Akt in human U87 cells at 0.04 to 10 uM by Western blot analysis	B	COc1ccc2c(c1OC)N=C(NC(=O)c1cccnc1)N1CCN=C21		CHEMBL1241857		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3441744	CHEMBL1244186	Inhibition of Akt in human LN229 cells at 0.04 to 10 uM by Western blot analysis	B	COc1ccc2c(c1OC)N=C(NC(=O)c1cccnc1)N1CCN=C21		CHEMBL1241857		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3441747	CHEMBL1244184	Inhibition of Akt in human U87 cells at 0.04 to 10 uM by Western blot analysis	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3441750	CHEMBL1244186	Inhibition of Akt in human LN229 cells at 0.04 to 10 uM by Western blot analysis	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3441789	CHEMBL1243933	Inhibition of VEGF-stimulated Akt activation in HUVEC at 0.04 to 10 uM after 30 mins by Western blot analysis	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3441793	CHEMBL1243933	Inhibition of VEGF-stimulated Akt activation in HUVEC at 0.04 to 10 uM after 30 mins by Western blot analysis	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3443336	CHEMBL1243988	Inhibition of AKT1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21		CHEMBL1241578	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
	3443553	CHEMBL1243988	Inhibition of AKT1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Inhibition	%	9.0	CHEMBL4282	Homo sapiens	INH	%	9.0
	3444708	CHEMBL1243988	Inhibition of AKT1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	3445023	CHEMBL1244719	Binding affinity to AKT1	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	4400.0	CHEMBL4282	Homo sapiens	Kd	nM	4400.0
	3445332	CHEMBL1243988	Inhibition of AKT1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC		CHEMBL1233881	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	3445549	CHEMBL1243988	Inhibition of AKT1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	3445767	CHEMBL1243988	Inhibition of AKT1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL1230790	=	Inhibition	%	13.0	CHEMBL4282	Homo sapiens	INH	%	13.0
	3445957	CHEMBL1243988	Inhibition of AKT1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21		CHEMBL1234815	=	Inhibition	%	10.0	CHEMBL4282	Homo sapiens	INH	%	10.0
	3446536	CHEMBL1249580	Inhibition of human PKBalpha expressed in SF9 cells at 1 uM	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Inhibition	%	77.0	CHEMBL4282	Homo sapiens	INH	%	77.0
	3446565	CHEMBL1249580	Inhibition of human PKBalpha expressed in SF9 cells at 1 uM	B	Cn1cc(C2=C(c3cn(CCCSC(=N)N)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL6291	=	Inhibition	%	73.0	CHEMBL4282	Homo sapiens	INH	%	73.0
	3446589	CHEMBL1249580	Inhibition of human PKBalpha expressed in SF9 cells at 1 uM	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Inhibition	%	91.0	CHEMBL4282	Homo sapiens	INH	%	91.0
	3446614	CHEMBL1249532	Inhibition of human PKBalpha expressed in SF9 cells at 20 uM	B	O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12		CHEMBL50	=	Inhibition	%	99.0	CHEMBL4282	Homo sapiens	INH	%	99.0
	3446641	CHEMBL1249556	Inhibition of human PKBalpha expressed in SF9 cells at 50 uM	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Inhibition	%	60.0	CHEMBL4282	Homo sapiens	INH	%	60.0
	3446669	CHEMBL1249580	Inhibition of human PKBalpha expressed in SF9 cells at 1 uM	B	COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O		CHEMBL428496	=	Inhibition	%	96.0	CHEMBL4282	Homo sapiens	INH	%	96.0
	3446695	CHEMBL1247620	Inhibition of human PKBalpha expressed in SF9 cells at 10 uM	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Inhibition	%	53.0	CHEMBL4282	Homo sapiens	INH	%	53.0
	3446719	CHEMBL1247620	Inhibition of human PKBalpha expressed in SF9 cells at 10 uM	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Inhibition	%	62.0	CHEMBL4282	Homo sapiens	INH	%	62.0
	3446743	CHEMBL1249556	Inhibition of human PKBalpha expressed in SF9 cells at 50 uM	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Inhibition	%	82.0	CHEMBL4282	Homo sapiens	INH	%	82.0
	3446768	CHEMBL1247620	Inhibition of human PKBalpha expressed in SF9 cells at 10 uM	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	=	Inhibition	%	89.0	CHEMBL4282	Homo sapiens	INH	%	89.0
	3446786	CHEMBL1249802	Inhibition of human PKBalpha expressed in SF9 cells	B	N#CC(=C(/N)Sc1ccccc1N)/C(C#N)=C(\N)Sc1ccccc1N		CHEMBL34704	=	IC50	nM	60000.0	CHEMBL4282	Homo sapiens	IC50	uM	60.0
	3446800	CHEMBL1247620	Inhibition of human PKBalpha expressed in SF9 cells at 10 uM	B	N#CC(=C(/N)Sc1ccccc1N)/C(C#N)=C(\N)Sc1ccccc1N		CHEMBL34704	=	Inhibition	%	79.0	CHEMBL4282	Homo sapiens	INH	%	79.0
	3446827	CHEMBL1247620	Inhibition of human PKBalpha expressed in SF9 cells at 10 uM	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Inhibition	%	67.0	CHEMBL4282	Homo sapiens	INH	%	67.0
	3446854	CHEMBL1249532	Inhibition of human PKBalpha expressed in SF9 cells at 20 uM	B	CC(=O)c1c(O)c(C)c(O)c(Cc2c(O)c3c(c(C(=O)/C=C/c4ccccc4)c2O)OC(C)(C)C=C3)c1O		CHEMBL34241	=	Inhibition	%	27.0	CHEMBL4282	Homo sapiens	INH	%	27.0
	3446885	CHEMBL1249532	Inhibition of human PKBalpha expressed in SF9 cells at 20 uM	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Inhibition	%	88.0	CHEMBL4282	Homo sapiens	INH	%	88.0
	3447262	CHEMBL1247620	Inhibition of human PKBalpha expressed in SF9 cells at 10 uM	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Inhibition	%	90.0	CHEMBL4282	Homo sapiens	INH	%	90.0
	3447277	CHEMBL1249802	Inhibition of human PKBalpha expressed in SF9 cells	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	IC50	nM	2600.0	CHEMBL4282	Homo sapiens	IC50	uM	2.6
	3447295	CHEMBL1247620	Inhibition of human PKBalpha expressed in SF9 cells at 10 uM	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Inhibition	%	17.0	CHEMBL4282	Homo sapiens	INH	%	17.0
	3447333	CHEMBL1249580	Inhibition of human PKBalpha expressed in SF9 cells at 1 uM	B	NCCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL270875	=	Inhibition	%	99.0	CHEMBL4282	Homo sapiens	INH	%	99.0
	3447357	CHEMBL1249580	Inhibition of human PKBalpha expressed in SF9 cells at 1 uM	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Inhibition	%	101.0	CHEMBL4282	Homo sapiens	INH	%	101.0
	3447381	CHEMBL1249580	Inhibition of human PKBalpha expressed in SF9 cells at 1 uM	B	CN1C(=O)C(c2c[nH]c3ccccc23)=C(c2c[nH]c3ccccc23)C1=O		CHEMBL291725	=	Inhibition	%	91.0	CHEMBL4282	Homo sapiens	INH	%	91.0
	3447405	CHEMBL1249580	Inhibition of human PKBalpha expressed in SF9 cells at 1 uM	B	Cn1cc(C2=C(c3cn(CCCN)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL269264	=	Inhibition	%	98.0	CHEMBL4282	Homo sapiens	INH	%	98.0
	3447429	CHEMBL1249580	Inhibition of human PKBalpha expressed in SF9 cells at 1 uM	B	Cn1cc(C2=C(c3c4n(c5ccccc35)CCC(CN)C4)C(=O)NC2=O)c2ccccc21		CHEMBL421565	=	Inhibition	%	104.0	CHEMBL4282	Homo sapiens	INH	%	104.0
	3447453	CHEMBL1249580	Inhibition of human PKBalpha expressed in SF9 cells at 1 uM	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Inhibition	%	87.0	CHEMBL4282	Homo sapiens	INH	%	87.0
	3447477	CHEMBL1247620	Inhibition of human PKBalpha expressed in SF9 cells at 10 uM	B	O=C1NCc2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21		CHEMBL16958	=	Inhibition	%	65.0	CHEMBL4282	Homo sapiens	INH	%	65.0
	3447501	CHEMBL1247620	Inhibition of human PKBalpha expressed in SF9 cells at 10 uM	B	CCCCCCOC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608532	=	Inhibition	%	36.0	CHEMBL4282	Homo sapiens	INH	%	36.0
	3447527	CHEMBL1249580	Inhibition of human PKBalpha expressed in SF9 cells at 1 uM	B	CC[C@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@@H]4O		CHEMBL1242366	=	Inhibition	%	31.0	CHEMBL4282	Homo sapiens	INH	%	31.0
	3447689	CHEMBL1250012	Inhibition of Akt1	B	Cc1nc(-c2ccc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2)c(-c2ccccc2)[nH]c1=O		CHEMBL178397	=	Ki	nM	760.0	CHEMBL4282	Homo sapiens	Ki	nM	760.0
	3448039	CHEMBL1249686	Inhibition of human PKBalpha activity at 10 uM by radiometric assay	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	3448115	CHEMBL1249686	Inhibition of human PKBalpha activity at 10 uM by radiometric assay	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Inhibition	%	46.0	CHEMBL4282	Homo sapiens	INH	%	46.0
	3448876	CHEMBL1244719	Binding affinity to AKT1	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	950.0	CHEMBL4282	Homo sapiens	Kd	nM	950.0
	3449555	CHEMBL1244719	Binding affinity to AKT1	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	3449980	CHEMBL1244719	Binding affinity to AKT1	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	3450288	CHEMBL1244719	Binding affinity to AKT1	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	3450909	CHEMBL1244719	Binding affinity to AKT1	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
	3451199	CHEMBL1244719	Binding affinity to AKT1	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	uM	10.0
Active	3460942	CHEMBL1252347	Inhibition of PKB activation in mouse overnight starved NIH3T3 cells assessed as phosphorylated Akt at Ser473 level at 50 ug/ml after 1 hr followed by treated with 1 ug/mL of insulin for 15 mins by Western blotting	B	CCc1ccc(OC(C)=O)c(Cc2cc(CC)ccc2OC(C)=O)c1		CHEMBL1254770		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3460943	CHEMBL1252347	Inhibition of PKB activation in mouse overnight starved NIH3T3 cells assessed as phosphorylated Akt at Ser473 level at 50 ug/ml after 1 hr followed by treated with 1 ug/mL of insulin for 15 mins by Western blotting	B	CC(=O)Oc1ccccc1Cc1cc(CCCl)ccc1OC(C)=O		CHEMBL1254942		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3460944	CHEMBL1252347	Inhibition of PKB activation in mouse overnight starved NIH3T3 cells assessed as phosphorylated Akt at Ser473 level at 50 ug/ml after 1 hr followed by treated with 1 ug/mL of insulin for 15 mins by Western blotting	B	CCc1ccc(Cc2cc(CCCl)ccc2OC(C)=O)c(OC(C)=O)c1		CHEMBL1254860		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3460945	CHEMBL1252347	Inhibition of PKB activation in mouse overnight starved NIH3T3 cells assessed as phosphorylated Akt at Ser473 level at 50 ug/ml after 1 hr followed by treated with 1 ug/mL of insulin for 15 mins by Western blotting	B	CCc1ccc(OC(C)=O)c(Cc2cc(CCCl)ccc2OC(C)=O)c1		CHEMBL1254859		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3460946	CHEMBL1252347	Inhibition of PKB activation in mouse overnight starved NIH3T3 cells assessed as phosphorylated Akt at Ser473 level at 50 ug/ml after 1 hr followed by treated with 1 ug/mL of insulin for 15 mins by Western blotting	B	CC(=O)Oc1ccccc1Cc1ccccc1OC(C)=O		CHEMBL1254943		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3460947	CHEMBL1252347	Inhibition of PKB activation in mouse overnight starved NIH3T3 cells assessed as phosphorylated Akt at Ser473 level at 50 ug/ml after 1 hr followed by treated with 1 ug/mL of insulin for 15 mins by Western blotting	B	CCc1ccc(OC(C)=O)c(Cc2ccccc2OC(C)=O)c1		CHEMBL1254944		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3460948	CHEMBL1252348	Inhibition of PKB/Akt activation in human overnight starved MCF7 cells assessed as phosphorylated Akt at Ser473 level at 50 ug/ml after 1 hr followed by treated with 1 ug/mL of insulin for 15 mins by Western blotting	B	CCc1ccc(OC(C)=O)c(Cc2cc(CCCl)ccc2OC(C)=O)c1		CHEMBL1254859	=	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	3462672	CHEMBL1252170	Inhibition of AKT1	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Ki	nM	0.16	CHEMBL4282	Homo sapiens	Ki	pM	160.0
	3462673	CHEMBL1252171	Inhibition of myristoylated wild type AKT1 expressed in HEK293T cells by in vitro immunoprecipitation kinase assay	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	IC50	nM	2.5	CHEMBL4282	Homo sapiens	IC50	nM	2.5
	3462674	CHEMBL1252171	Inhibition of myristoylated wild type AKT1 expressed in HEK293T cells by in vitro immunoprecipitation kinase assay	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
	3462675	CHEMBL1252171	Inhibition of myristoylated wild type AKT1 expressed in HEK293T cells by in vitro immunoprecipitation kinase assay	B	CC(C)(C)n1nc(Cc2cccc(I)c2)c2c(N)ncnc21		CHEMBL1254115	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
Not Determined	3462676	CHEMBL1252172	Inhibition of myristoylated AKT1 M227G mutant expressed in HEK293T cells by in vitro immunoprecipitation kinase assay	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300		IC50			CHEMBL4282	Homo sapiens	IC50		
	3462677	CHEMBL1252172	Inhibition of myristoylated AKT1 M227G mutant expressed in HEK293T cells by in vitro immunoprecipitation kinase assay	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114	=	IC50	nM	2.8	CHEMBL4282	Homo sapiens	IC50	nM	2.8
	3462678	CHEMBL1252172	Inhibition of myristoylated AKT1 M227G mutant expressed in HEK293T cells by in vitro immunoprecipitation kinase assay	B	CC(C)(C)n1nc(Cc2cccc(I)c2)c2c(N)ncnc21		CHEMBL1254115	=	IC50	nM	28.0	CHEMBL4282	Homo sapiens	IC50	nM	28.0
Active	3462691	CHEMBL1252177	Inhibition of wild type AKT1 expressed in HEK293 cells assessed as reduction of IGF1-induced GSK3-beta Ser9 phosphorylation treated 20 mins before IGF1 stimulation by immunoblotting	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3462692	CHEMBL1252177	Inhibition of wild type AKT1 expressed in HEK293 cells assessed as reduction of IGF1-induced GSK3-beta Ser9 phosphorylation treated 20 mins before IGF1 stimulation by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3462693	CHEMBL1252177	Inhibition of wild type AKT1 expressed in HEK293 cells assessed as reduction of IGF1-induced GSK3-beta Ser9 phosphorylation treated 20 mins before IGF1 stimulation by immunoblotting	B	CC(C)(C)n1nc(Cc2cccc(I)c2)c2c(N)ncnc21		CHEMBL1254115		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3462694	CHEMBL1252178	Induction of AKT1 Thr308 phosphorylation expressed in IGF1-stimulated HEK293 cells treated 20 mins before IGF1 stimulation by immunoblotting	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3462695	CHEMBL1252178	Induction of AKT1 Thr308 phosphorylation expressed in IGF1-stimulated HEK293 cells treated 20 mins before IGF1 stimulation by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3462696	CHEMBL1252178	Induction of AKT1 Thr308 phosphorylation expressed in IGF1-stimulated HEK293 cells treated 20 mins before IGF1 stimulation by immunoblotting	B	CC(C)(C)n1nc(Cc2cccc(I)c2)c2c(N)ncnc21		CHEMBL1254115		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3462697	CHEMBL1252179	Induction of AKT1 Ser473 phosphorylation expressed in IGF1-stimulated HEK293 cells treated 20 mins before IGF1 stimulation by immunoblotting	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3463063	CHEMBL1252179	Induction of AKT1 Ser473 phosphorylation expressed in IGF1-stimulated HEK293 cells treated 20 mins before IGF1 stimulation by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3463064	CHEMBL1252179	Induction of AKT1 Ser473 phosphorylation expressed in IGF1-stimulated HEK293 cells treated 20 mins before IGF1 stimulation by immunoblotting	B	CC(C)(C)n1nc(Cc2cccc(I)c2)c2c(N)ncnc21		CHEMBL1254115		Activity			CHEMBL4282	Homo sapiens	Activity		
Dose-dependent effect	3463065	CHEMBL1252180	Induction of myristoylated AKT1 M227G mutant Thr308 hyperphosphorylation expressed in HEK293T cells after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Dose-dependent effect	3463066	CHEMBL1252180	Induction of myristoylated AKT1 M227G mutant Thr308 hyperphosphorylation expressed in HEK293T cells after 30 mins by immunoblotting	B	CC(C)(C)n1nc(Cc2cccc(I)c2)c2c(N)ncnc21		CHEMBL1254115		Activity			CHEMBL4282	Homo sapiens	Activity		
Dose-dependent effect	3463067	CHEMBL1252181	Induction of myristoylated AKT1 M227G mutant Ser473 hyperphosphorylation expressed in HEK293T cells after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Dose-dependent effect	3463068	CHEMBL1252181	Induction of myristoylated AKT1 M227G mutant Ser473 hyperphosphorylation expressed in HEK293T cells after 30 mins by immunoblotting	B	CC(C)(C)n1nc(Cc2cccc(I)c2)c2c(N)ncnc21		CHEMBL1254115		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463069	CHEMBL1252182	Induction of myristoylated AKT1 M227G mutant Thr308 hyperphosphorylation expressed in HEK293T cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463070	CHEMBL1252183	Induction of myristoylated AKT1 M227G mutant Ser473 hyperphosphorylation expressed in HEK293T cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463075	CHEMBL1252188	Induction of myristoylated AKT1 M227G mutant Thr308 hyperphosphorylation expressed in HEK293T cells at 10 uM after 30 mins by immunoblotting	B	CC(C)(C)n1nc(Cc2cccc(I)c2)c2c(N)ncnc21		CHEMBL1254115		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463076	CHEMBL1252189	Induction of myristoylated AKT1 M227G mutant Ser473 hyperphosphorylation expressed in HEK293T cells at 10 uM after 30 mins by immunoblotting	B	CC(C)(C)n1nc(Cc2cccc(I)c2)c2c(N)ncnc21		CHEMBL1254115		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463081	CHEMBL1252997	Inhibition of myristoylated AKT1 M227G mutant expressed in HEK293T cells assessed as reduction of GSK3-beta Ser9 phosphorylation after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3463082	CHEMBL1252997	Inhibition of myristoylated AKT1 M227G mutant expressed in HEK293T cells assessed as reduction of GSK3-beta Ser9 phosphorylation after 30 mins by immunoblotting	B	CC(C)(C)n1nc(Cc2cccc(I)c2)c2c(N)ncnc21		CHEMBL1254115		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3463083	CHEMBL1252998	Induction of myristoylated AKT1 M227G mutant Thr308 hyperphosphorylation expressed in HEK293T cells at 2.5 uM after 30 mins pretreated with pan-PI3K inhibitor PIK90 for 10 mins before compound addition by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3463084	CHEMBL1252999	Induction of myristoylated AKT1 M227G mutant Ser473 hyperphosphorylation expressed in HEK293T cells at 2.5 uM after 30 mins pretreated with pan-PI3K inhibitor PIK90 for 10 mins before compound addition by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3463089	CHEMBL1253004	Induction of myristoylated AKT1 M227G and R25C mutant Thr308 hyperphosphorylation expressed in HEK293T cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3463090	CHEMBL1253005	Induction of myristoylated AKT1 M227G and R25C mutant Ser473 hyperphosphorylation expressed in HEK293T cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463091	CHEMBL1253006	Induction of membrane localized myristoylated AKT1 M227G mutant Thr308 hyperphosphorylation expressed in HEK293T cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463092	CHEMBL1253007	Induction of membrane localized myristoylated AKT1 M227G mutant Ser473 hyperphosphorylation expressed in HEK293T cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3463093	CHEMBL1253008	Induction of myristoylated AKT1 M227G mutant Thr308 hyperphosphorylation expressed in HEK293T cells at 2.5 uM after 30 mins pretreated with PDK1 inhibitor BX-795 for 10 mins before compound addition by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3463094	CHEMBL1253047	Induction of myristoylated AKT1 M227G mutant Ser473 hyperphosphorylation expressed in HEK293T cells at 2.5 uM after 30 mins pretreated with PDK1 inhibitor BX-795 for 10 mins before compound addition by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463099	CHEMBL1253052	Induction of myristoylated AKT1 M227G mutant Thr308 hyperphosphorylation expressed in HEK293T cells at 2.5 uM after 30 mins pretreated with mTOR kinase inhibitor PP242 for 10 mins before compound addition by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3463102	CHEMBL1253055	Induction of myristoylated AKT1 M227G mutant Ser473 hyperphosphorylation expressed in HEK293T cells at 2.5 uM after 30 mins pretreated with mTOR kinase inhibitor PP242 for 10 mins before compound addition by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463105	CHEMBL1251563	Induction of myristoylated AKT1 M227G Ser473 hyperphosphorylation expressed in HEK293 cells coexpressing flag-tagged wild type AKT1 after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463106	CHEMBL1251564	Induction of myristoylated AKT1 M227G Thr308 hyperphosphorylation expressed in HEK293 cells coexpressing flag-tagged wild type AKT1 after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463107	CHEMBL1253063	Induction of myristoylated AKT1 M227G and kinase dead D292A mutant Thr308 hyperphosphorylation expressed in HEK293T cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463109	CHEMBL1253067	Induction of nonmyristoylated AKT1 M227G and kinase dead D292A mutant Thr308 hyperphosphorylation expressed in HEK293T cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463111	CHEMBL1253065	Induction of myristoylated AKT1 M227G and kinase dead D292A mutant Thr308 hyperphosphorylation expressed in HEK293T cells at 10 uM after 30 mins by immunoblotting	B	CC(C)(C)n1nc(Cc2cccc(I)c2)c2c(N)ncnc21		CHEMBL1254115		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463113	CHEMBL1253069	Induction of nonmyristoylated AKT1 M227G and kinase dead D292A mutant Thr308 hyperphosphorylation expressed in HEK293T cells at 10 uM after 30 mins by immunoblotting	B	CC(C)(C)n1nc(Cc2cccc(I)c2)c2c(N)ncnc21		CHEMBL1254115		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3463115	CHEMBL1251605	Induction of flag-tagged wild type AKT1 Ser473 hyperphosphorylation expressed in HEK293 cells coexpressing myristoylated AKT1 M227G after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3463116	CHEMBL1251606	Induction of flag-tagged wild type AKT1 Thr308 hyperphosphorylation expressed in HEK293 cells coexpressing myristoylated AKT1 M227G after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463117	CHEMBL1251613	Induction of membrane localization of AKT1 in HEK293 cells at 2.5 uM after 15 mins by anti AKt antibody staining based fluorescence microscopy	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463118	CHEMBL1251614	Induction of AKT1 Thr 308 phosphorylation in HEK293 cells at 2.5 uM after 15 mins by immunoblotting	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3463119	CHEMBL1251615	Induction of membrane localization of AKT1 in HEK293 cells at 2.5 uM after 15 mins pretreated with pan-PI3K inhibitor PIK90 10 mins before compound addition by anti AKt antibody staining based fluorescence microscopy	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3463120	CHEMBL1251616	Induction of AKT1 Thr 308 phosphorylation in HEK293 cells at 2.5 uM after 15 mins at 2.5 uM after 15 mins pretreated with pan-PI3K inhibitor PIK90 10 mins before compound addition by immunoblotting	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300		Activity			CHEMBL4282	Homo sapiens	Activity		
	3463121	CHEMBL1251619	Increase in catalytic activity of compound exposed AKT1 M227G mutant expressed in HEK293T cells measured post compound dissociation by in vitro immunoprecipitation kinase assay relative to untreated AKT1 M227G mutant	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114	=	FC		10.0	CHEMBL4282	Homo sapiens	FC		10.0
	3463127	CHEMBL1252170	Inhibition of AKT1	B	COc1ccccc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL1254209	=	IC50	nM	22000.0	CHEMBL4282	Homo sapiens	IC50	nM	22000.0
Active	3463128	CHEMBL1253071	Induction of myristoylated AKT1 M227G and kinase dead D292A mutant Thr308 hyperphosphorylation expressed in MCF7 cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463130	CHEMBL1253073	Induction of myristoylated AKT1 M227G and kinase dead D292A mutant Thr308 hyperphosphorylation expressed in MiaPaCa2 cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463132	CHEMBL1253075	Induction of myristoylated AKT1 M227G and kinase dead D292A mutant Thr308 hyperphosphorylation expressed in PC3 cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463134	CHEMBL1253077	Induction of myristoylated AKT1 M227G Thr308 hyperphosphorylation expressed in MCF7 cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463136	CHEMBL1253079	Induction of myristoylated AKT1 M227G Thr308 hyperphosphorylation expressed in MiaPaCa2 cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463138	CHEMBL1253146	Induction of myristoylated AKT1 M227G Thr308 hyperphosphorylation expressed in PC3 cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463140	CHEMBL1251551	Induction of myristoylated AKT1 M227G and kinase dead D292A mutant Ser473 hyperphosphorylation expressed in MCF7 cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463142	CHEMBL1251553	Induction of myristoylated AKT1 M227G and kinase dead D292A mutant Ser473 hyperphosphorylation expressed in MiaPaCa2 cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463144	CHEMBL1251555	Induction of myristoylated AKT1 M227G and kinase dead D292A mutant Ser473 hyperphosphorylation expressed in PC3 cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463146	CHEMBL1251557	Induction of myristoylated AKT1 M227G Ser473 hyperphosphorylation expressed in MCF7 cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463148	CHEMBL1251559	Induction of myristoylated AKT1 M227G Ser473 hyperphosphorylation expressed in MiaPaCa2 cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463150	CHEMBL1251561	Induction of myristoylated AKT1 M227G Ser473 hyperphosphorylation expressed in PC3 cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463152	CHEMBL1251609	Induction of flag-tagged wild type AKT1 Ser473 hyperphosphorylation expressed in HEK293 cells at 2.5 uM after 30 mins by immunoblotting	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463153	CHEMBL1251610	Induction of flag-tagged wild type AKT1 Thr308 hyperphosphorylation expressed in HEK293 cells at 2.5 uM after 30 mins by immunoblotting	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463154	CHEMBL1251607	Induction of flag tagged AKT1 M227G Ser473 hyperphosphorylation expressed in HEK293 cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463155	CHEMBL1251608	Induction of flag tagged AKT1 M227G Thr308 hyperphosphorylation expressed in HEK293 cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463156	CHEMBL1251611	Induction of mCherry tagged AKT1 M227G Ser473 hyperphosphorylation expressed in HEK293 cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3463157	CHEMBL1251612	Induction of mCherry tagged AKT1 M227G Thr308 hyperphosphorylation expressed in HEK293 cells at 2.5 uM after 30 mins by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3463158	CHEMBL1251617	Induction of AKT1 M227G Ser473 hyperphosphorylation expressed in HEK293 cells at 2.5 uM after 30 mins pretreated with ATP competitive AKT inhibitor Akti-1,2 10 mins before compound addition by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3463159	CHEMBL1251618	Induction of AKT1 M227G Thr308 hyperphosphorylation expressed in HEK293 cells at 2.5 uM after 30 mins pretreated with ATP competitive AKT inhibitor Akti-1,2 10 mins before compound addition by immunoblotting	B	CCCc1cc(-c2cncc(OC[C@@H](N)Cc3c[nH]c4ccccc34)c2)cc2c(C)n[nH]c12		CHEMBL1254114		Activity			CHEMBL4282	Homo sapiens	Activity		
	3463169	CHEMBL1251629	Inhibition of AKT1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	INH	%	100.0
	3463388	CHEMBL1251629	Inhibition of AKT1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	COc1ccccc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL1254209	=	Inhibition	%	16.0	CHEMBL4282	Homo sapiens	INH	%	16.0
	3463932	CHEMBL1251629	Inhibition of AKT1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
Not Active	3468493	CHEMBL1251274	Effect on c-Akt phosphorylation in in human LNCAP cells	B	C[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]1C(=O)N2/C(=N/Cc3ccccc3)[Se]/C(=C/I)C[C@H]12		CHEMBL1254183		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	3468502	CHEMBL1251274	Effect on c-Akt phosphorylation in in human LNCAP cells	B	C[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]1C(=O)N2/C(=N/C3CCCCC3)[Se]/C(=C/I)C[C@H]12		CHEMBL1254268		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3471398	CHEMBL1251512	Activation of AKT	B	CC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1		CHEMBL257158		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3471401	CHEMBL1251512	Activation of AKT	B	CC(=O)N[C@@H]1/C(=N/OC(=O)Nc2ccccc2)CO[C@H](CO)[C@H]1O		CHEMBL1254432		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	3471402	CHEMBL1251512	Activation of AKT	B	CC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)[Se]1		CHEMBL1253585		Activity			CHEMBL4282	Homo sapiens	Activity		
	3502220	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccccc1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258329	=	IC50	nM	884.0	CHEMBL4282	Homo sapiens	IC50	nM	884.0
	3502221	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258330	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	nM	20.0
	3502222	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N#Cc1ccc(C[C@@H](N)C(=O)N2CCN(c3ncnc4ccccc34)CC2)cc1		CHEMBL1258441	=	IC50	nM	284.0	CHEMBL4282	Homo sapiens	IC50	nM	284.0
	3502223	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(F)cc1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258442	=	IC50	nM	118.0	CHEMBL4282	Homo sapiens	IC50	nM	118.0
	3502224	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	COc1ccc(C[C@@H](N)C(=O)N2CCN(c3ncnc4ccccc34)CC2)cc1		CHEMBL1258550	=	IC50	nM	150.0	CHEMBL4282	Homo sapiens	IC50	nM	150.0
	3502225	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	Cc1ccc(C[C@@H](N)C(=O)N2CCN(c3ncnc4ccccc34)CC2)cc1		CHEMBL1258551	=	IC50	nM	74.0	CHEMBL4282	Homo sapiens	IC50	nM	74.0
	3502226	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Br)cc1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258662	=	IC50	nM	30.0	CHEMBL4282	Homo sapiens	IC50	nM	30.0
	3502227	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccccc1Cl)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258663	=	IC50	nM	2346.0	CHEMBL4282	Homo sapiens	IC50	nM	2346.0
	3502228	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1cccc(Cl)c1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258778	=	IC50	nM	595.0	CHEMBL4282	Homo sapiens	IC50	nM	595.0
	3502229	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1Cl)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258779	=	IC50	nM	142.0	CHEMBL4282	Homo sapiens	IC50	nM	142.0
	3502230	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)c(Cl)c1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258898	=	IC50	nM	51.0	CHEMBL4282	Homo sapiens	IC50	nM	51.0
	3502231	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(F)c(F)c1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1258899	=	IC50	nM	81.0	CHEMBL4282	Homo sapiens	IC50	nM	81.0
	3502232	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(C(F)(F)F)cc1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1257163	=	IC50	nM	95.0	CHEMBL4282	Homo sapiens	IC50	nM	95.0
	3502233	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(-c2ccccc2)cc1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1257164	=	IC50	nM	2883.0	CHEMBL4282	Homo sapiens	IC50	nM	2883.0
	3502234	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1cc(F)cc(F)c1)C(=O)N1CCN(c2ncnc3ccccc23)CC1		CHEMBL1257280	=	IC50	nM	690.0	CHEMBL4282	Homo sapiens	IC50	nM	690.0
	3502235	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	COc1cc(C[C@@H](N)C(=O)N2CCN(c3ncnc4ccccc34)CC2)cc(OC)c1		CHEMBL1257281	=	IC50	nM	838.0	CHEMBL4282	Homo sapiens	IC50	nM	838.0
	3502237	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3cc(F)ccc23)CC1		CHEMBL1257401	=	IC50	nM	30.0	CHEMBL4282	Homo sapiens	IC50	nM	30.0
	3502238	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	Cc1cccc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c12		CHEMBL1257510	=	IC50	nM	100.0	CHEMBL4282	Homo sapiens	IC50	nM	100.0
	3502239	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	Cc1ccc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c2c1		CHEMBL1257511	=	IC50	nM	54.0	CHEMBL4282	Homo sapiens	IC50	nM	54.0
	3502240	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3ccc(-c4cn[nH]c4)cc23)CC1		CHEMBL1257628	=	IC50	nM	80.0	CHEMBL4282	Homo sapiens	IC50	nM	80.0
	3502241	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	Nc1ccc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c2c1		CHEMBL1257629	=	IC50	nM	43.0	CHEMBL4282	Homo sapiens	IC50	nM	43.0
	3502242	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	CNc1ccc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c2c1		CHEMBL1257751	=	IC50	nM	98.0	CHEMBL4282	Homo sapiens	IC50	nM	98.0
	3502243	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	CN(C)c1ccc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c2c1		CHEMBL1257752	=	IC50	nM	536.0	CHEMBL4282	Homo sapiens	IC50	nM	536.0
	3502244	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	CC(=O)Nc1ccc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c2c1		CHEMBL1257873	=	IC50	nM	868.0	CHEMBL4282	Homo sapiens	IC50	nM	868.0
	3502245	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	CNS(=O)(=O)c1ccc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c2c1		CHEMBL2021429	=	IC50	nM	174.0	CHEMBL4282	Homo sapiens	IC50	nM	174.0
	3502246	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3ccc(-c4ccccc4)cc23)CC1		CHEMBL1257985	=	IC50	nM	809.0	CHEMBL4282	Homo sapiens	IC50	nM	809.0
	3502247	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	CC(C)(C)c1ccc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c2c1		CHEMBL1257986	=	IC50	nM	1460.0	CHEMBL4282	Homo sapiens	IC50	nM	1460.0
	3502248	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ccnc3ccccc23)CC1		CHEMBL1258101	=	IC50	nM	46.0	CHEMBL4282	Homo sapiens	IC50	nM	46.0
	3502249	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2cnnc3ccccc23)CC1		CHEMBL1258102	=	IC50	nM	21233.0	CHEMBL4282	Homo sapiens	IC50	nM	21233.0
	3502250	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ccnc3ccnn23)CC1		CHEMBL1258215	=	IC50	nM	3321.0	CHEMBL4282	Homo sapiens	IC50	nM	3321.0
	3502251	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3cc[nH]c23)CC1		CHEMBL1258216	=	IC50	nM	114.0	CHEMBL4282	Homo sapiens	IC50	nM	114.0
	3502252	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ccnc3[nH]ccc23)CC1		CHEMBL1258331	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
	3502253	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2cnc3ccccn23)CC1		CHEMBL1258332	=	IC50	nM	8122.0	CHEMBL4282	Homo sapiens	IC50	nM	8122.0
	3502254	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ccncn2)CC1		CHEMBL1258443	=	IC50	nM	22920.0	CHEMBL4282	Homo sapiens	IC50	nM	22920.0
	3502255	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ccnc3cc[nH]c23)CC1		CHEMBL1258444	=	IC50	nM	2048.0	CHEMBL4282	Homo sapiens	IC50	nM	2048.0
	3502256	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL1258552	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	3502257	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL1258553	=	IC50	nM	104.0	CHEMBL4282	Homo sapiens	IC50	nM	104.0
	3502258	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	Cc1c[nH]c2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c12		CHEMBL1258664	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	3502259	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	CCc1c[nH]c2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c12		CHEMBL1258665	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	3502260	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3[nH]cc(C4CC4)c23)CC1		CHEMBL1258780	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	3502261	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3[nH]cc(Cl)c23)CC1		CHEMBL1258781	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	3502262	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	NC[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL1236822	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	3502263	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	Cc1c[nH]c2ncnc(N3CCN(C(=O)[C@H](CN)Cc4ccc(Cl)cc4)CC3)c12		CHEMBL1258900	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	3502264	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	CNC[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL1257165	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
	3502265	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	CN(C)C[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL1257166	=	IC50	nM	88.0	CHEMBL4282	Homo sapiens	IC50	nM	88.0
	3502266	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	Cc1c[nH]c2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(F)cc4)CC3)c12		CHEMBL1257282	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	3502267	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	Cc1c[nH]c2ncnc(N3CCN(C(=O)[C@H](N)C4Cc5ccccc5C4)CC3)c12		CHEMBL1257283	=	IC50	nM	30.0	CHEMBL4282	Homo sapiens	IC50	nM	30.0
	3502268	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	NC[C@@H](C(=O)N1CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL1257402	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	3502269	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	NC[C@@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL1257403	=	IC50	nM	63.0	CHEMBL4282	Homo sapiens	IC50	nM	63.0
	3502270	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	NC[C@@H](C(=O)N1CCN(c2ncnc3[nH]cc(Cl)c23)CC1)c1ccc(Cl)c(Cl)c1		CHEMBL1257512	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	3502271	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	CC(C)c1ccc(C[C@@H](CN)C(=O)N2CCN(c3ncnc4[nH]ccc34)CC2)cc1		CHEMBL1257513	=	IC50	nM	604.0	CHEMBL4282	Homo sapiens	IC50	nM	604.0
	3502601	CHEMBL1259574	Inhibition of AKT1 by IMAP assay	B	Cc1ccc2c(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)ncnc2c1		CHEMBL1255592	=	IC50	nM	3203.0	CHEMBL4282	Homo sapiens	IC50	nM	3203.0
	3504165	CHEMBL1260134	Inhibition of AKT in human BT20 cells assessed as inhibition of S473 phosphorylation	B	Cc1ccc(-c2nc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1258910	=	IC50	nM	5.74	CHEMBL4282	Homo sapiens	IC50	nM	5.74
	3504169	CHEMBL1260134	Inhibition of AKT in human BT20 cells assessed as inhibition of S473 phosphorylation	B	Cc1nc(N)nc2c1nc(-c1cc[nH]n1)c(=O)n2C1CCOCC1		CHEMBL1258911	=	IC50	nM	68.0	CHEMBL4282	Homo sapiens	IC50	nM	68.0
	3504173	CHEMBL1260134	Inhibition of AKT in human BT20 cells assessed as inhibition of S473 phosphorylation	B	COc1ccc(-c2nc3c(C)nc(N)nc3n([C@H]3CC[C@H](O)CC3)c2=O)cn1		CHEMBL1257177	=	IC50	nM	14.3	CHEMBL4282	Homo sapiens	IC50	nM	14.3
	3504176	CHEMBL1260134	Inhibition of AKT in human BT20 cells assessed as inhibition of S473 phosphorylation	B	Cc1ccc(-c2nc3c(C)nc(N)nc3n(C3CCOCC3)c2=O)cn1		CHEMBL1257178	=	IC50	nM	25.0	CHEMBL4282	Homo sapiens	IC50	nM	25.0
	3504180	CHEMBL1260134	Inhibition of AKT in human BT20 cells assessed as inhibition of S473 phosphorylation	B	Cc1ccc(-c2nc3c(C)nc(N)nc3n([C@H]3CC[C@H](O)CC3)c2=O)cn1		CHEMBL1257295	=	IC50	nM	5.7	CHEMBL4282	Homo sapiens	IC50	nM	5.7
	3504206	CHEMBL1260179	Inhibition of AKT1	B	O=C(Nc1n[nH]c2cc(C(=O)N[C@H](CN3CCCC3)c3ccccc3)sc12)c1ccc(N2CCOCC2)cc1		CHEMBL1258913	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	3521251	CHEMBL1272509	Inhibition of AKT1	B	Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc([C@@H](C)N3C[C@H](C)O[C@H](C)C3)ns2)n1		CHEMBL1270399	>	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
Active	3521316	CHEMBL1272556	Inhibition of AKT phosphorylation in human A549 at 5 uM after 24 hrs by Western blot analysis	F	O=C(CCCCC[Se][Se]CCCCCC(=O)Nc1ccccc1)Nc1ccccc1		CHEMBL1086397		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	3521317	CHEMBL1272556	Inhibition of AKT phosphorylation in human A549 at 5 uM after 24 hrs by Western blot analysis	F	N#C[Se]CCCCCC(=O)Nc1ccccc1		CHEMBL1077183		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	3521318	CHEMBL1272556	Inhibition of AKT phosphorylation in human A549 at 5 uM after 24 hrs by Western blot analysis	F	O=C(CCCCCCC(=O)Nc1ccccc1)NO		CHEMBL98		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	3523921	CHEMBL1273652	Inhibition of PKBalpha	B	CC(C)c1n[nH]c(Cl)c1-c1ccnc(Nc2ccc(N3CCC(N(C)C)CC3)cn2)n1		CHEMBL1272116	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	3523922	CHEMBL1273652	Inhibition of PKBalpha	B	CC(C)c1n[nH]c(C(F)(F)F)c1-c1ccnc(Nc2ccc(N3CCC(N(C)C)CC3)cn2)n1		CHEMBL1272171	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	3526998	CHEMBL1275208	Inhibition of AKT1	B	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccccc1		CHEMBL1270230	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
Not Determined	3527787	CHEMBL1274490	Inhibition of AKT1	B	O=S(=O)(Nc1ccnc(NCCc2ccccc2)n1)c1ccc(Cl)cc1		CHEMBL1270522		IC50			CHEMBL4282	Homo sapiens	IC50		
	3527788	CHEMBL1274490	Inhibition of AKT1	B	O=S(=O)(Nc1nc(NCCc2ccccc2)nc2c1CN(Cc1ccccc1)CC2)c1ccc2ccccc2c1		CHEMBL1271447	=	IC50	nM	8500.0	CHEMBL4282	Homo sapiens	IC50	uM	8.5
	3527789	CHEMBL1274490	Inhibition of AKT1	B	Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2c1CN(Cc1ccccc1)CC2		CHEMBL1270331	=	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	3556552	CHEMBL1285568	Inhibition of AKT1 at 1 uM	B	CN1C[C@@H]2C[C@H]1CN2c1cc(F)c(-c2ccnc3c(-c4cccc5[nH]ncc45)c(-c4ccncc4)nn23)c(F)c1		CHEMBL1276179	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	3603099	CHEMBL1291196	Inhibition of AKT1 at 10 uM	B	O=C(Cc1cccc2cnccc12)Nc1scnc1-c1cscn1		CHEMBL1288160	=	Inihibition	%	2.0	CHEMBL4282	Homo sapiens	Inihibition	%	2.0
Not Active	5089459	CHEMBL1633345	Inhibition of AKT1 by biochemical assay	B	C(#Cc1n[nH]c2ncccc12)c1cccnc1		CHEMBL1631903		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5089460	CHEMBL1633345	Inhibition of AKT1 by biochemical assay	B	C(#Cc1n[nH]c2ncccc12)c1ccncc1		CHEMBL1631902		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5089461	CHEMBL1633345	Inhibition of AKT1 by biochemical assay	B	N#Cc1ccc(C#Cc2n[nH]c3ccccc23)cc1		CHEMBL1631901		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5089462	CHEMBL1633345	Inhibition of AKT1 by biochemical assay	B	C(#Cc1n[nH]c2ccccc12)c1ccsc1		CHEMBL1631900		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5089463	CHEMBL1633345	Inhibition of AKT1 by biochemical assay	B	FC(F)(F)c1cc(C#Cc2n[nH]c3ccccc23)cc(C(F)(F)F)c1		CHEMBL1631899		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5089464	CHEMBL1633345	Inhibition of AKT1 by biochemical assay	B	Nc1ccccc1C#Cc1n[nH]c2ccccc12		CHEMBL1631898		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5089465	CHEMBL1633345	Inhibition of AKT1 by biochemical assay	B	C(#CC1CC1)c1n[nH]c2ccccc12		CHEMBL1631897		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5089466	CHEMBL1633345	Inhibition of AKT1 by biochemical assay	B	C(#CC1CCCC1)c1n[nH]c2ccccc12		CHEMBL1631896		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5089467	CHEMBL1633345	Inhibition of AKT1 by biochemical assay	B	Nc1cccc(C#Cc2n[nH]c3ccccc23)c1		CHEMBL1631895		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5089468	CHEMBL1633345	Inhibition of AKT1 by biochemical assay	B	C(#Cc1n[nH]c2ccccc12)c1ccccn1		CHEMBL1631894		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5089469	CHEMBL1633345	Inhibition of AKT1 by biochemical assay	B	CN(C)CC#Cc1n[nH]c2ccccc12		CHEMBL1631893		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5089470	CHEMBL1633345	Inhibition of AKT1 by biochemical assay	B	C(#Cc1n[nH]c2ccccc12)c1ccncc1		CHEMBL1631892		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5089471	CHEMBL1633345	Inhibition of AKT1 by biochemical assay	B	C(#Cc1n[nH]c2ccccc12)c1cccnc1		CHEMBL1631891		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5089472	CHEMBL1633345	Inhibition of AKT1 by biochemical assay	B	Fc1cc(F)cc(C#Cc2n[nH]c3ccccc23)c1		CHEMBL1631890		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5089473	CHEMBL1633345	Inhibition of AKT1 by biochemical assay	B	C(#Cc1n[nH]c2ccccc12)c1ccccc1		CHEMBL1631889		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5089474	CHEMBL1633345	Inhibition of AKT1 by biochemical assay	B	Nc1ccc(C#Cc2n[nH]c3ccccc23)cc1		CHEMBL1631888		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	5116047	CHEMBL1632819	Inhibition of Akt1	B	Cc1c[nH]c2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(F)cc4)CC3)c12		CHEMBL1257282	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	5116048	CHEMBL1632819	Inhibition of Akt1	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3c2CSC3)CC1		CHEMBL1632369	=	IC50	nM	22.0	CHEMBL4282	Homo sapiens	IC50	nM	22.0
	5116049	CHEMBL1632819	Inhibition of Akt1	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3c2CS(=O)(=O)C3)CC1		CHEMBL1632370	=	IC50	nM	52.0	CHEMBL4282	Homo sapiens	IC50	nM	52.0
	5116050	CHEMBL1632819	Inhibition of Akt1	B	CC1SCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c21		CHEMBL1632371	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	5116051	CHEMBL1632819	Inhibition of Akt1	B	CCC1SCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c21		CHEMBL1632372	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
	5116052	CHEMBL1632819	Inhibition of Akt1	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c21		CHEMBL1632373	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	5116053	CHEMBL1632819	Inhibition of Akt1	B	C[C@H]1SCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c21		CHEMBL1632374	=	IC50	nM	260.0	CHEMBL4282	Homo sapiens	IC50	nM	260.0
	5116054	CHEMBL1632819	Inhibition of Akt1	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)c(F)c4)CC3)c21		CHEMBL1632375	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	5116055	CHEMBL1632819	Inhibition of Akt1	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(F)cc4)CC3)c21		CHEMBL1632376	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
	5116056	CHEMBL1632819	Inhibition of Akt1	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(F)c(F)c4)CC3)c21		CHEMBL1632377	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	5116057	CHEMBL1632819	Inhibition of Akt1	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4c[nH]c5ccccc45)CC3)c21		CHEMBL1235979	=	IC50	nM	22.0	CHEMBL4282	Homo sapiens	IC50	nM	22.0
	5116058	CHEMBL1632819	Inhibition of Akt1	B	C[C@@H]1OCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c21		CHEMBL1632378	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
	5116059	CHEMBL1632819	Inhibition of Akt1	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)C(Cc4ccc(Cl)cc4)C4(N)CC4)CC3)c21		CHEMBL1632379	=	IC50	nM	42.0	CHEMBL4282	Homo sapiens	IC50	nM	42.0
	5116060	CHEMBL1632819	Inhibition of Akt1	B	CC(C)NCC(Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3c2[C@H](C)SC3)CC1		CHEMBL1632380	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	5116061	CHEMBL1632819	Inhibition of Akt1	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)C(Cc4ccc(Cl)cc4)CN4CCCC4)CC3)c21		CHEMBL1632381	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	5116062	CHEMBL1632819	Inhibition of Akt1	B	Cc1ccc(CC(CNC(C)C)C(=O)N2CCN(c3ncnc4c3[C@H](C)SC4)CC2)cc1		CHEMBL1632382	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	5116063	CHEMBL1632819	Inhibition of Akt1	B	CC(C)NCC(Cc1ccc(Cl)c(F)c1)C(=O)N1CCN(c2ncnc3c2[C@H](C)SC3)CC1		CHEMBL1632368	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	5116064	CHEMBL1632819	Inhibition of Akt1	B	CC(C)NCC(Cc1ccc(F)c(F)c1)C(=O)N1CCN(c2ncnc3c2[C@H](C)SC3)CC1		CHEMBL1632383	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
	5116065	CHEMBL1632819	Inhibition of Akt1	B	CC(C)NC[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3c2[C@H](C)SC3)CC1		CHEMBL1632384	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	5116066	CHEMBL1632819	Inhibition of Akt1	B	CC(C)NC[C@@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3c2[C@H](C)SC3)CC1		CHEMBL1632385	=	IC50	nM	127.0	CHEMBL4282	Homo sapiens	IC50	nM	127.0
	5116067	CHEMBL1632819	Inhibition of Akt1	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)C(Cc4ccc(Cl)c(F)c4)CC4(N)CC4)CC3)c21		CHEMBL1632386	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	5116068	CHEMBL1632819	Inhibition of Akt1	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)C(Cc4ccc(Cl)cc4)CC(C)(C)N)CC3)c21		CHEMBL1632387	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	5116069	CHEMBL1632819	Inhibition of Akt1	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)C(Cc4ccc(Cl)c(F)c4)CC(C)(C)N)CC3)c21		CHEMBL1632388	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
	5116070	CHEMBL1632819	Inhibition of Akt1	B	Cc1ccc(CC(CNC(C)C)C(=O)N2CCN(c3ncnc4c3[C@H](C)OC4)CC2)cc1		CHEMBL1632389	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
	5116071	CHEMBL1632819	Inhibition of Akt1	B	CC(C)NCC(Cc1ccc(Cl)c(F)c1)C(=O)N1CCN(c2ncnc3c2[C@H](C)OC3)CC1		CHEMBL1632390	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	5116072	CHEMBL1632819	Inhibition of Akt1	B	CC(C)NC[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3c2[C@H](C)OC3)CC1		CHEMBL1632391	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	5116073	CHEMBL1632819	Inhibition of Akt1	B	C[C@@H]1OCc2ncnc(N3CCN(C(=O)C(Cc4ccc(Cl)c(F)c4)CC(C)(C)N)CC3)c21		CHEMBL1632392	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
	5116101	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	Cc1c[nH]c2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(F)cc4)CC3)c12		CHEMBL1257282	=	IC50	nM	160.0	CHEMBL4282	Homo sapiens	IC50	nM	160.0
	5116102	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3c2CSC3)CC1		CHEMBL1632369	=	IC50	nM	3846.0	CHEMBL4282	Homo sapiens	IC50	nM	3846.0
	5116103	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3c2CS(=O)(=O)C3)CC1		CHEMBL1632370	=	IC50	nM	21010.0	CHEMBL4282	Homo sapiens	IC50	nM	21010.0
	5116104	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	CC1SCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c21		CHEMBL1632371	=	IC50	nM	310.0	CHEMBL4282	Homo sapiens	IC50	nM	310.0
	5116105	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	CCC1SCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c21		CHEMBL1632372	=	IC50	nM	1201.0	CHEMBL4282	Homo sapiens	IC50	nM	1201.0
	5116106	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c21		CHEMBL1632373	=	IC50	nM	184.0	CHEMBL4282	Homo sapiens	IC50	nM	184.0
	5116107	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	C[C@H]1SCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c21		CHEMBL1632374	=	IC50	nM	18469.0	CHEMBL4282	Homo sapiens	IC50	nM	18469.0
	5116108	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)c(F)c4)CC3)c21		CHEMBL1632375	=	IC50	nM	176.0	CHEMBL4282	Homo sapiens	IC50	nM	176.0
	5116109	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(F)cc4)CC3)c21		CHEMBL1632376	=	IC50	nM	1592.0	CHEMBL4282	Homo sapiens	IC50	nM	1592.0
	5116110	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(F)c(F)c4)CC3)c21		CHEMBL1632377	=	IC50	nM	602.0	CHEMBL4282	Homo sapiens	IC50	nM	602.0
	5116111	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4c[nH]c5ccccc45)CC3)c21		CHEMBL1235979	=	IC50	nM	3629.0	CHEMBL4282	Homo sapiens	IC50	nM	3629.0
	5116112	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	C[C@@H]1OCc2ncnc(N3CCN(C(=O)[C@H](N)Cc4ccc(Cl)cc4)CC3)c21		CHEMBL1632378	=	IC50	nM	615.0	CHEMBL4282	Homo sapiens	IC50	nM	615.0
	5116113	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)C(Cc4ccc(Cl)cc4)C4(N)CC4)CC3)c21		CHEMBL1632379	=	IC50	nM	2468.0	CHEMBL4282	Homo sapiens	IC50	nM	2468.0
	5116114	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	CC(C)NCC(Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3c2[C@H](C)SC3)CC1		CHEMBL1632380	=	IC50	nM	159.0	CHEMBL4282	Homo sapiens	IC50	nM	159.0
	5116115	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)C(Cc4ccc(Cl)cc4)CN4CCCC4)CC3)c21		CHEMBL1632381	=	IC50	nM	178.0	CHEMBL4282	Homo sapiens	IC50	nM	178.0
	5116116	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	Cc1ccc(CC(CNC(C)C)C(=O)N2CCN(c3ncnc4c3[C@H](C)SC4)CC2)cc1		CHEMBL1632382	=	IC50	nM	216.0	CHEMBL4282	Homo sapiens	IC50	nM	216.0
	5116117	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	CC(C)NCC(Cc1ccc(Cl)c(F)c1)C(=O)N1CCN(c2ncnc3c2[C@H](C)SC3)CC1		CHEMBL1632368	=	IC50	nM	92.0	CHEMBL4282	Homo sapiens	IC50	nM	92.0
	5116118	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	CC(C)NCC(Cc1ccc(F)c(F)c1)C(=O)N1CCN(c2ncnc3c2[C@H](C)SC3)CC1		CHEMBL1632383	=	IC50	nM	759.0	CHEMBL4282	Homo sapiens	IC50	nM	759.0
	5116119	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	CC(C)NC[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3c2[C@H](C)SC3)CC1		CHEMBL1632384	=	IC50	nM	137.0	CHEMBL4282	Homo sapiens	IC50	nM	137.0
Not Determined	5116120	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	CC(C)NC[C@@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3c2[C@H](C)SC3)CC1		CHEMBL1632385		IC50			CHEMBL4282	Homo sapiens	IC50		
	5116121	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)C(Cc4ccc(Cl)c(F)c4)CC4(N)CC4)CC3)c21		CHEMBL1632386	=	IC50	nM	250.0	CHEMBL4282	Homo sapiens	IC50	nM	250.0
	5116122	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)C(Cc4ccc(Cl)cc4)CC(C)(C)N)CC3)c21		CHEMBL1632387	=	IC50	nM	438.0	CHEMBL4282	Homo sapiens	IC50	nM	438.0
	5116123	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	C[C@@H]1SCc2ncnc(N3CCN(C(=O)C(Cc4ccc(Cl)c(F)c4)CC(C)(C)N)CC3)c21		CHEMBL1632388	=	IC50	nM	587.0	CHEMBL4282	Homo sapiens	IC50	nM	587.0
	5116124	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	Cc1ccc(CC(CNC(C)C)C(=O)N2CCN(c3ncnc4c3[C@H](C)OC4)CC2)cc1		CHEMBL1632389	=	IC50	nM	995.0	CHEMBL4282	Homo sapiens	IC50	nM	995.0
	5116125	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	CC(C)NCC(Cc1ccc(Cl)c(F)c1)C(=O)N1CCN(c2ncnc3c2[C@H](C)OC3)CC1		CHEMBL1632390	=	IC50	nM	315.0	CHEMBL4282	Homo sapiens	IC50	nM	315.0
	5116126	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	CC(C)NC[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCN(c2ncnc3c2[C@H](C)OC3)CC1		CHEMBL1632391	=	IC50	nM	125.0	CHEMBL4282	Homo sapiens	IC50	nM	125.0
	5116127	CHEMBL1632821	Inhibition of Akt in human LNCaP cell assessed as inhibition of PRAS40 phosphorylation	B	C[C@@H]1OCc2ncnc(N3CCN(C(=O)C(Cc4ccc(Cl)c(F)c4)CC(C)(C)N)CC3)c21		CHEMBL1632392	=	IC50	nM	592.0	CHEMBL4282	Homo sapiens	IC50	nM	592.0
	5120081	CHEMBL1646685	Inhibition of AKT1 at 10 uM after 60 mins by TR-FRET assay	B	O=c1[nH]nc(-c2ccnc(NC3CCOCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644620	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	5120317	CHEMBL1648674	Inhibition of human PKBalpha at 10 uM after 60 mins by TR-FRET assay	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	99.0	CHEMBL4282	Homo sapiens	INH	%	99.0
	5120857	CHEMBL1646943	Inhibition of AKT1 at 10 uM	B	CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1		CHEMBL1641799	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	5132608	CHEMBL1648757	Inhibition of PKBalpha assessed as residual activity at 10 uM	B	CN(C)C/C=C/C(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1		CHEMBL1641990	=	Activity	%	93.0	CHEMBL4282	Homo sapiens	Activity	%	93.0
	5133751	CHEMBL1648757	Inhibition of PKBalpha assessed as residual activity at 10 uM	B	CN(C)CCCC(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1		CHEMBL1641989	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	5133920	CHEMBL1648757	Inhibition of PKBalpha assessed as residual activity at 10 uM	B	CN1CCN(CCC(=O)Nc2ccc3c(C#N)cnc(Nc4cccc(Br)c4)c3c2)CC1		CHEMBL1641992	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	5139736	CHEMBL1646685	Inhibition of AKT1 at 10 uM after 60 mins by TR-FRET assay	B	O=c1n(Cc2ccccn2)nc(-c2ccnc(NC3CCOCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644615	=	Inhibition	%	-5.0	CHEMBL4282	Homo sapiens	INH	%	-5.0
	5139753	CHEMBL1646685	Inhibition of AKT1 at 10 uM after 60 mins by TR-FRET assay	B	O=c1n(Cc2ccncc2)nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644642	=	Inhibition	%	-2.0	CHEMBL4282	Homo sapiens	INH	%	-2.0
	5139759	CHEMBL1646685	Inhibition of AKT1 at 10 uM after 60 mins by TR-FRET assay	B	O=c1[nH]nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644618	=	Inhibition	%	-1.0	CHEMBL4282	Homo sapiens	INH	%	-1.0
	5139766	CHEMBL1646685	Inhibition of AKT1 at 10 uM after 60 mins by TR-FRET assay	B	O=c1[nH]nc(-c2ccnc(NC3CCCOC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644619	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	5139767	CHEMBL1646685	Inhibition of AKT1 at 10 uM after 60 mins by TR-FRET assay	B	O=c1n(C2CCOCC2)nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644639	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	5140489	CHEMBL1646798	Inhibition of AKT1 at 1 uM	B	CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1		CHEMBL1641799	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	5143836	CHEMBL1656200	Inhibition of AKT1	B	CCN(Cc1cc(Nc2nc(C)cn3c(-c4cn[nH]c4)cnc23)sn1)C(C)(C)CO.Cl		CHEMBL1650533	>	IC50	nM	100.0	CHEMBL4282	Homo sapiens	IC50	nM	100.0
	5143853	CHEMBL1656200	Inhibition of AKT1	B	Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(CN3CCC(F)(F)C3)ns2)n1.Cl		CHEMBL1650545	>	IC50	nM	100.0	CHEMBL4282	Homo sapiens	IC50	nM	100.0
	5143870	CHEMBL1656200	Inhibition of AKT1	B	Cl.[2H]C([2H])(c1cc(Nc2nc(C)cn3c(-c4cn[nH]c4)cnc23)sn1)N1CCC(F)(F)C1		CHEMBL1650551	>	IC50	nM	100.0	CHEMBL4282	Homo sapiens	IC50	nM	100.0
	5190289	CHEMBL1663336	Inhibition of human recombinant AKT at 0.5 uM by radiometric assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	Inhibition	%	90.0	CHEMBL4282	Homo sapiens	INH	%	90.0
	5191353	CHEMBL1663978	Inhibition of PKBalpha at 1 uM	B	COc1cc2nc(-c3cc(F)ccc3O)nc(N[C@@H]3CNC[C@H]3C(C)(C)O)c2cc1OC		CHEMBL1236782	=	Inhibition	%	20.0	CHEMBL4282	Homo sapiens	INH	%	20.0
	5191354	CHEMBL1663978	Inhibition of PKBalpha at 1 uM	B	CC(C)(O)[C@@H]1CNC[C@H]1Nc1nc(-c2cc(-c3cc[nH]n3)ccc2O)nc2ccccc12		CHEMBL1650131	=	Inhibition	%	66.0	CHEMBL4282	Homo sapiens	INH	%	66.0
Not Active	5198861	CHEMBL1670055	Activation of Akt in human MCF7 cells expressing estrogen receptor at 10'-5 M after 4 hrs by Western blotting	F	COc1cc(OC)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(OC)c1		CHEMBL1668823		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	5198862	CHEMBL1670056	Activation of Akt in human MCF7 cells expressing estrogen receptor at 10'-5 M after 9 hrs by Western blotting	F	COc1cc(OC)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(OC)c1		CHEMBL1668823		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	5220299	CHEMBL1681590	Inhibition of AKT at < 10 uM by IMAP assay	B	O=C1NCCCc2c1oc1ccc(O)cc21		CHEMBL1450770		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5220300	CHEMBL1681590	Inhibition of AKT at < 10 uM by IMAP assay	B	O=C1NCCCc2c1[nH]c1ccc(O)cc21		CHEMBL1672570		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5220301	CHEMBL1681590	Inhibition of AKT at < 10 uM by IMAP assay	B	O=C1NCCSc2c1sc1ccc(O)cc21		CHEMBL1672571		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5220302	CHEMBL1681590	Inhibition of AKT at < 10 uM by IMAP assay	B	COc1ccc2sc3c(c2c1)SCCNC3=O		CHEMBL319170		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5220303	CHEMBL1681590	Inhibition of AKT at < 10 uM by IMAP assay	B	[N-]=[N+]=Nc1ccc2sc3c(c2c1)SCCNC3=O		CHEMBL1672572		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5220304	CHEMBL1681590	Inhibition of AKT at < 10 uM by IMAP assay	B	O=C1NCCCSc2c1sc1ccc(O)cc21		CHEMBL1672573		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5220305	CHEMBL1681590	Inhibition of AKT at < 10 uM by IMAP assay	B	COc1ccc2sc3c(c2c1)SCCCNC3=O		CHEMBL1672574		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	5220306	CHEMBL1681590	Inhibition of AKT at < 10 uM by IMAP assay	B	COc1ncc2sc3c(c2n1)SCCNC3=O		CHEMBL1672575		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	5243750	CHEMBL1685854	Inhibition of PKBalpha at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCN(Cc6ccccc6)CC5)cc34)[nH]c2c1		CHEMBL1684543	=	Inhibition	%	96.0	CHEMBL4282	Homo sapiens	INH	%	96.0
	5243858	CHEMBL1686070	Inhibition of PKBalpha at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCN(Cc6ccccc6)CC5)cc34)[nH]c2c1		CHEMBL1684543	=	Inhibition	%	86.0	CHEMBL4282	Homo sapiens	INH	%	86.0
	5243971	CHEMBL1685854	Inhibition of PKBalpha at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCNC5)cc34)[nH]c2c1		CHEMBL1684654	=	Inhibition	%	95.0	CHEMBL4282	Homo sapiens	INH	%	95.0
	5244079	CHEMBL1686070	Inhibition of PKBalpha at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCNC5)cc34)[nH]c2c1		CHEMBL1684654	=	Inhibition	%	69.0	CHEMBL4282	Homo sapiens	INH	%	69.0
	5244952	CHEMBL1685854	Inhibition of PKBalpha at 0.1 uM	B	O=C(Cc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1)c1ccccc1		CHEMBL1684662	=	Inhibition	%	106.0	CHEMBL4282	Homo sapiens	INH	%	106.0
	5245060	CHEMBL1686070	Inhibition of PKBalpha at 1 uM	B	O=C(Cc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1)c1ccccc1		CHEMBL1684662	=	Inhibition	%	95.0	CHEMBL4282	Homo sapiens	INH	%	95.0
	5245211	CHEMBL1685854	Inhibition of PKBalpha at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NS(=O)(=O)c5ncn(C)c5C)cc34)[nH]c2c1		CHEMBL1684525	=	Inhibition	%	115.0	CHEMBL4282	Homo sapiens	INH	%	115.0
	5246041	CHEMBL1686070	Inhibition of PKBalpha at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NS(=O)(=O)c5ncn(C)c5C)cc34)[nH]c2c1		CHEMBL1684525	=	Inhibition	%	111.0	CHEMBL4282	Homo sapiens	INH	%	111.0
	5249419	CHEMBL1686774	Inhibition of AKT1 at 10 uM	B	O=C(Cc1cccc2cnccc12)Nc1scc(Cl)c1-c1ncn[nH]1		CHEMBL1682017	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	5249828	CHEMBL1687323	Inhibition of AKT1 PH S473D mutant at 10 uM	B	COc1ccc(Cn2ncc(NC(=O)c3cc(NC(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)ccc3C)c2N)cc1		CHEMBL1684800	=	Inhibition	%	3.7	CHEMBL4282	Homo sapiens	INH	%	3.7
	5249833	CHEMBL1687351	Inhibition of AKT1 PH S473D mutant	B	COc1ccc(Cn2ncc(NC(=O)c3cc(NC(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)ccc3C)c2N)cc1		CHEMBL1684800	=	IC50	nM	4.72	CHEMBL4282	Homo sapiens	IC50	nM	4.72
	5293786	CHEMBL1696296	Inhibition of AKT1	B	Nc1nccc(-c2ccc3c(N)n[nH]c3c2)n1		CHEMBL1688215	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	5293874	CHEMBL1697109	Inhibition of Akt1 after 60 mins by radiometric assay	B	O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O		CHEMBL1448	=	IC50	nM	59400.0	CHEMBL4282	Homo sapiens	IC50	uM	59.4
Active	5294175	CHEMBL1695408	Inhibition of AKT phosphorylation in human GEO cells	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3F)c3c(N)ncnn32)C1		CHEMBL1667935		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	6159720	CHEMBL1763788	Inhibition of Akt1	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCN(c3ncnc4[nH]cc(C)c34)CC2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1760758	=	IC50	nM	41.0	CHEMBL4282	Homo sapiens	IC50	uM	0.041
	6159721	CHEMBL1763788	Inhibition of Akt1	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCN(c3ncnc4[nH]cc(C)c34)C2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1760759	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	uM	0.002
	6159722	CHEMBL1763788	Inhibition of Akt1	B	CCOCCN(C[C@@H](O)CN1CCC2(CCN(c3ncnc4[nH]nc(C)c34)C2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1760760	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	uM	0.017
	6159723	CHEMBL1763788	Inhibition of Akt1	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCN(c3ncnc4[nH]nc(C)c34)C2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1760761	=	IC50	nM	21.0	CHEMBL4282	Homo sapiens	IC50	uM	0.021
	6159724	CHEMBL1763788	Inhibition of Akt1	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCN(c3ncnc4ccccc34)C2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1760762	=	IC50	nM	38.0	CHEMBL4282	Homo sapiens	IC50	uM	0.038
	6159725	CHEMBL1763788	Inhibition of Akt1	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCN(c3ncncc3C3CC3)C2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1760763	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	uM	0.012
	6159726	CHEMBL1763788	Inhibition of Akt1	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCN(c3ncnc(N)c3C3CC3)C2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1760764	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	uM	0.012
	6159727	CHEMBL1763788	Inhibition of Akt1	B	Cc1cccc(C)c1S(=O)(=O)N1CCC[C@H]1[C@@H](O)CN1CCC[C@@]2(CCN(c3ncnc(N)c3C3CC3)C2)C1		CHEMBL1760765	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	uM	0.009
	6159728	CHEMBL1763788	Inhibition of Akt1	B	Cc1cccc(C)c1S(=O)(=O)N1CCC[C@H]1[C@H](O)CN1CCC[C@@]2(CCN(c3ncnc(N)c3C3CC3)C2)C1		CHEMBL1760766	=	IC50	nM	250.0	CHEMBL4282	Homo sapiens	IC50	uM	0.25
	6159729	CHEMBL1763788	Inhibition of Akt1	B	Cc1cccc(C)c1S(=O)(=O)N1CCC[C@@H]1[C@@H](O)CN1CCC[C@@]2(CCN(c3ncnc(N)c3C3CC3)C2)C1		CHEMBL1760767	=	IC50	nM	19.0	CHEMBL4282	Homo sapiens	IC50	uM	0.019
	6159730	CHEMBL1763788	Inhibition of Akt1	B	Cc1cccc(C)c1S(=O)(=O)NC[C@@H](O)CN1CCC[C@@]2(CCN(c3ncnc(N)c3C3CC3)C2)C1		CHEMBL1760768	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	uM	0.004
	6159731	CHEMBL1763788	Inhibition of Akt1	B	Cc1ccccc1S(=O)(=O)NC[C@@H](O)CN1CCC[C@@]2(CCN(c3ncnc(N)c3C3CC3)C2)C1		CHEMBL1760769	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	uM	0.009
	6159732	CHEMBL1763788	Inhibition of Akt1	B	Nc1ncnc(N2CC[C@@]3(CCCN(C[C@H](O)CNS(=O)(=O)c4ccccc4F)C3)C2)c1C1CC1		CHEMBL1760770	=	IC50	nM	81.0	CHEMBL4282	Homo sapiens	IC50	uM	0.081
	6159733	CHEMBL1763788	Inhibition of Akt1	B	Nc1ncnc(N2CC[C@@]3(CCCN(C[C@H](O)CNS(=O)(=O)c4ccccc4Cl)C3)C2)c1C1CC1		CHEMBL1760771	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	uM	0.009
	6159734	CHEMBL1763788	Inhibition of Akt1	B	Nc1ncnc(N2CC[C@@]3(CCCN(C[C@H](O)CNS(=O)(=O)c4ccccc4Br)C3)C2)c1C1CC1		CHEMBL1760772	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	uM	0.017
	6159735	CHEMBL1763788	Inhibition of Akt1	B	Cc1cc(F)ccc1S(=O)(=O)NC[C@@H](O)CN1CCC[C@@]2(CCN(c3ncnc(N)c3C3CC3)C2)C1		CHEMBL1760773	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	uM	0.008
	6159736	CHEMBL1763788	Inhibition of Akt1	B	Cc1ccc(S(=O)(=O)NC[C@@H](O)CN2CCC[C@@]3(CCN(c4ncnc(N)c4C4CC4)C3)C2)c(C)c1		CHEMBL1760774	=	IC50	nM	160.0	CHEMBL4282	Homo sapiens	IC50	uM	0.16
	6159737	CHEMBL1763788	Inhibition of Akt1	B	Cc1ccncc1S(=O)(=O)NC[C@@H](O)CN1CCC[C@@]2(CCN(c3ncnc(N)c3C3CC3)C2)C1		CHEMBL1760775	=	IC50	nM	1100.0	CHEMBL4282	Homo sapiens	IC50	uM	1.1
	6159738	CHEMBL1763788	Inhibition of Akt1	B	Cc1noc(C)c1S(=O)(=O)NC[C@@H](O)CN1CCC[C@@]2(CCN(c3ncnc(N)c3C3CC3)C2)C1		CHEMBL1760776	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	uM	0.003
	6159777	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCN(c3ncnc4[nH]cc(C)c34)CC2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1760758	=	IC50	nM	1200.0	CHEMBL4282	Homo sapiens	IC50	uM	1.2
	6159778	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCN(c3ncnc4[nH]cc(C)c34)C2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1760759	=	IC50	nM	180.0	CHEMBL4282	Homo sapiens	IC50	uM	0.18
	6159779	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	CCOCCN(C[C@@H](O)CN1CCC2(CCN(c3ncnc4[nH]nc(C)c34)C2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1760760	=	IC50	nM	3100.0	CHEMBL4282	Homo sapiens	IC50	uM	3.1
	6159780	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCN(c3ncnc4[nH]nc(C)c34)C2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1760761	=	IC50	nM	310.0	CHEMBL4282	Homo sapiens	IC50	uM	0.31
	6159781	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCN(c3ncnc4ccccc34)C2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1760762	=	IC50	nM	2400.0	CHEMBL4282	Homo sapiens	IC50	uM	2.4
	6159782	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCN(c3ncncc3C3CC3)C2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1760763	=	IC50	nM	740.0	CHEMBL4282	Homo sapiens	IC50	uM	0.74
	6159783	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCN(c3ncnc(N)c3C3CC3)C2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1760764	=	IC50	nM	470.0	CHEMBL4282	Homo sapiens	IC50	uM	0.47
	6159784	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	Cc1cccc(C)c1S(=O)(=O)N1CCC[C@H]1[C@@H](O)CN1CCC[C@@]2(CCN(c3ncnc(N)c3C3CC3)C2)C1		CHEMBL1760765	=	IC50	nM	690.0	CHEMBL4282	Homo sapiens	IC50	uM	0.69
	6159785	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	Cc1cccc(C)c1S(=O)(=O)N1CCC[C@H]1[C@H](O)CN1CCC[C@@]2(CCN(c3ncnc(N)c3C3CC3)C2)C1		CHEMBL1760766	=	IC50	nM	13000.0	CHEMBL4282	Homo sapiens	IC50	uM	13.0
	6159786	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	Cc1cccc(C)c1S(=O)(=O)N1CCC[C@@H]1[C@@H](O)CN1CCC[C@@]2(CCN(c3ncnc(N)c3C3CC3)C2)C1		CHEMBL1760767	=	IC50	nM	2400.0	CHEMBL4282	Homo sapiens	IC50	uM	2.4
	6159787	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	Cc1cccc(C)c1S(=O)(=O)NC[C@@H](O)CN1CCC[C@@]2(CCN(c3ncnc(N)c3C3CC3)C2)C1		CHEMBL1760768	=	IC50	nM	900.0	CHEMBL4282	Homo sapiens	IC50	uM	0.9
	6159788	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	Cc1ccccc1S(=O)(=O)NC[C@@H](O)CN1CCC[C@@]2(CCN(c3ncnc(N)c3C3CC3)C2)C1		CHEMBL1760769	=	IC50	nM	1200.0	CHEMBL4282	Homo sapiens	IC50	uM	1.2
	6159789	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	Nc1ncnc(N2CC[C@@]3(CCCN(C[C@H](O)CNS(=O)(=O)c4ccccc4F)C3)C2)c1C1CC1		CHEMBL1760770	=	IC50	nM	14000.0	CHEMBL4282	Homo sapiens	IC50	uM	14.0
	6159790	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	Nc1ncnc(N2CC[C@@]3(CCCN(C[C@H](O)CNS(=O)(=O)c4ccccc4Cl)C3)C2)c1C1CC1		CHEMBL1760771	=	IC50	nM	1900.0	CHEMBL4282	Homo sapiens	IC50	uM	1.9
	6159791	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	Nc1ncnc(N2CC[C@@]3(CCCN(C[C@H](O)CNS(=O)(=O)c4ccccc4Br)C3)C2)c1C1CC1		CHEMBL1760772	=	IC50	nM	2000.0	CHEMBL4282	Homo sapiens	IC50	uM	2.0
	6159792	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	Cc1cc(F)ccc1S(=O)(=O)NC[C@@H](O)CN1CCC[C@@]2(CCN(c3ncnc(N)c3C3CC3)C2)C1		CHEMBL1760773	=	IC50	nM	2200.0	CHEMBL4282	Homo sapiens	IC50	uM	2.2
	6159793	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	Cc1ccc(S(=O)(=O)NC[C@@H](O)CN2CCC[C@@]3(CCN(c4ncnc(N)c4C4CC4)C3)C2)c(C)c1		CHEMBL1760774	=	IC50	nM	18000.0	CHEMBL4282	Homo sapiens	IC50	uM	18.0
Not Determined	6159794	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	Cc1ccncc1S(=O)(=O)NC[C@@H](O)CN1CCC[C@@]2(CCN(c3ncnc(N)c3C3CC3)C2)C1		CHEMBL1760775		IC50			CHEMBL4282	Homo sapiens	IC50		
	6159795	CHEMBL1763791	Inhibition of AKT1-mediated PRAS40 phosphorylation in human LNCaP cells	B	Cc1noc(C)c1S(=O)(=O)NC[C@@H](O)CN1CCC[C@@]2(CCN(c3ncnc(N)c3C3CC3)C2)C1		CHEMBL1760776	=	IC50	nM	490.0	CHEMBL4282	Homo sapiens	IC50	uM	0.49
	6161763	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3c(ccc4[nH]ncc34)O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761090	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	uM	0.009
	6161764	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc4c(cc3O2)CNC4=O)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761089	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	uM	0.01
	6161765	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc(C(N)=O)ccc3O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761088	=	IC50	nM	26.0	CHEMBL4282	Homo sapiens	IC50	uM	0.026
	6161767	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc4c(cc3O2)CNC4=O)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761089	=	IC50	nM	35.0	CHEMBL4282	Homo sapiens	IC50	uM	0.035
	6161768	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761085	=	IC50	nM	40.0	CHEMBL4282	Homo sapiens	IC50	uM	0.04
	6161769	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3c(ccc4[nH]ncc34)O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761090	=	IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	uM	0.044
	6161771	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761084	=	IC50	nM	70.0	CHEMBL4282	Homo sapiens	IC50	uM	0.07
	6161772	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc(C#N)ccc3O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761087	=	IC50	nM	170.0	CHEMBL4282	Homo sapiens	IC50	uM	0.17
	6161773	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc(F)ccc3O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761086	=	IC50	nM	180.0	CHEMBL4282	Homo sapiens	IC50	uM	0.18
	6161774	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	Cc1noc(C)c1S(=O)(=O)N(CCOC(C)C)C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1		CHEMBL1761072	=	IC50	nM	300.0	CHEMBL4282	Homo sapiens	IC50	uM	0.3
	6161775	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761083	=	IC50	nM	300.0	CHEMBL4282	Homo sapiens	IC50	uM	0.3
	6161776	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1C		CHEMBL1761082	=	IC50	nM	500.0	CHEMBL4282	Homo sapiens	IC50	uM	0.5
	6161777	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761071	=	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	uM	1.0
	6161778	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1Cl		CHEMBL1761077	=	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	uM	1.0
	6161779	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCCCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761073	=	IC50	nM	1100.0	CHEMBL4282	Homo sapiens	IC50	uM	1.1
	6161780	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1C(F)(F)F		CHEMBL1761081	=	IC50	nM	1300.0	CHEMBL4282	Homo sapiens	IC50	uM	1.3
	6161781	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	COCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761069	=	IC50	nM	2100.0	CHEMBL4282	Homo sapiens	IC50	uM	2.1
	6161782	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc(C(N)=O)ccc3O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761088	=	IC50	nM	2360.0	CHEMBL4282	Homo sapiens	IC50	uM	2.36
	6161783	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc(C#N)ccc3O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761087	=	IC50	nM	2580.0	CHEMBL4282	Homo sapiens	IC50	uM	2.58
	6161784	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761085	=	IC50	nM	2600.0	CHEMBL4282	Homo sapiens	IC50	uM	2.6
	6161786	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	COCCN(CC(O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761067	=	IC50	nM	3400.0	CHEMBL4282	Homo sapiens	IC50	uM	3.4
	6161787	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	Cc1noc(C)c1S(=O)(=O)N(Cc1ccccc1)CC(O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1		CHEMBL1761068	=	IC50	nM	3900.0	CHEMBL4282	Homo sapiens	IC50	uM	3.9
	6161788	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	Cc1noc(C)c1S(=O)(=O)N(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)C1CCCCC1		CHEMBL1761074	=	IC50	nM	4000.0	CHEMBL4282	Homo sapiens	IC50	uM	4.0
	6161789	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc(F)ccc3O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761086	=	IC50	nM	4380.0	CHEMBL4282	Homo sapiens	IC50	uM	4.38
	6161790	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1C#N		CHEMBL1761080	=	IC50	nM	4400.0	CHEMBL4282	Homo sapiens	IC50	uM	4.4
	6161792	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1F		CHEMBL1761079	=	IC50	nM	6200.0	CHEMBL4282	Homo sapiens	IC50	uM	6.2
	6161793	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CCc3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761084	=	IC50	nM	6400.0	CHEMBL4282	Homo sapiens	IC50	uM	6.4
	6161794	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	COCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761069	=	IC50	nM	6500.0	CHEMBL4282	Homo sapiens	IC50	uM	6.5
	6161796	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)cccc1C		CHEMBL1761083	=	IC50	nM	17800.0	CHEMBL4282	Homo sapiens	IC50	uM	17.8
	6161797	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	Cc1noc(C)c1S(=O)(=O)N(CCOC(C)C)C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1		CHEMBL1761072	=	IC50	nM	18600.0	CHEMBL4282	Homo sapiens	IC50	uM	18.6
	6161798	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	COCCN(C[C@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761070	=	IC50	nM	22800.0	CHEMBL4282	Homo sapiens	IC50	uM	22.8
	6161799	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	COCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761069	=	IC50	nM	40000.0	CHEMBL4282	Homo sapiens	IC50	uM	40.0
	6161805	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1cccc(Cl)c1		CHEMBL1761075	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	6161806	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1OC		CHEMBL1761078	>	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	6161807	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	COCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761069	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	6161808	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	COCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761069	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	6161809	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	COCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761069	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	6161810	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	COCCN(C[C@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761070	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	6161811	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761071	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	6161812	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCCCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1c(C)noc1C		CHEMBL1761073	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	6161813	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	Cc1noc(C)c1S(=O)(=O)N(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)C1CCCCC1		CHEMBL1761074	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	6161814	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1cccc(Cl)c1		CHEMBL1761075	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	6161815	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccc(Cl)cc1		CHEMBL1761076	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	6161816	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1Cl		CHEMBL1761077	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	6161817	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1OC		CHEMBL1761078	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	6161818	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1F		CHEMBL1761079	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	6161819	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1C#N		CHEMBL1761080	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	6161820	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1C(F)(F)F		CHEMBL1761081	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	6161821	CHEMBL1764866	Inhibition of AKT1 in human LNCaP cells assessed as PRAS40 phosphorylation at Thr246 after 1.5 hrs	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccccc1C		CHEMBL1761082	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
	6161824	CHEMBL1764865	Inhibition of AKT1 by IMAP assay	B	CCOCCN(C[C@@H](O)CN1CCCC2(CC(=O)c3cc(O)ccc3O2)C1)S(=O)(=O)c1ccc(Cl)cc1		CHEMBL1761076	=	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
	6167000	CHEMBL1768886	Inhibition of AKT1	B	CNc1cncc(-c2c[nH]c(=O)c(NC(=O)c3ccc(N4CCC[C@H]4CN4CCCC4)cc3)c2)n1		CHEMBL1765781	>	Ki	nM	1000.0	CHEMBL4282	Homo sapiens	Ki	uM	1.0
	6169211	CHEMBL1769079	Inhibition of AKT1	B	CNc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2C[C@@H](C(=O)NC3CCCCC3)CC[C@H]2C)n1		CHEMBL1765740	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	6173461	CHEMBL1768215	Inhibition of AKT1 at 25 uM by TR-FRET assay	B	NC(=O)c1ccsc1NC(=O)Cc1csc2ccccc12		CHEMBL1767254	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	6189339	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3ccnc(NCc4ccccc4)n3)cc2s1		CHEMBL1773588	>	IC50	nM	5000.0	CHEMBL4282	Homo sapiens	IC50	nM	5000.0
	6189340	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3ccnc(NC(C)(C)c4ccccc4)n3)cc2s1		CHEMBL1773572	=	IC50	nM	2800.0	CHEMBL4282	Homo sapiens	IC50	nM	2800.0
Not Determined	6189341	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	COc1ccc(C(=O)Nc2nccc(-c3ccc4nc(NC(C)=O)sc4c3)n2)cc1		CHEMBL1773573		IC50			CHEMBL4282	Homo sapiens	IC50		
	6189342	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	COc1ccc(S(=O)(=O)Nc2nccc(-c3ccc4nc(NC(C)=O)sc4c3)n2)cc1		CHEMBL1773574	=	IC50	nM	2500.0	CHEMBL4282	Homo sapiens	IC50	nM	2500.0
	6189343	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	COc1ccc(S(=O)(=O)N(C)c2nccc(-c3ccc4nc(NC(C)=O)sc4c3)n2)cc1		CHEMBL1773575	=	IC50	nM	336.0	CHEMBL4282	Homo sapiens	IC50	nM	336.0
	6189344	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CCN(c1nccc(-c2ccc3nc(NC(C)=O)sc3c2)n1)S(=O)(=O)c1ccc(OC)cc1		CHEMBL1773576	=	IC50	nM	305.0	CHEMBL4282	Homo sapiens	IC50	nM	305.0
	6189345	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3ccnc(NS(=O)(=O)c4ccccc4F)n3)cc2s1		CHEMBL1773577	=	IC50	nM	4010.0	CHEMBL4282	Homo sapiens	IC50	nM	4010.0
	6189346	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3ccnc(N(C)S(=O)(=O)c4ccccc4F)n3)cc2s1		CHEMBL1773578	=	IC50	nM	676.0	CHEMBL4282	Homo sapiens	IC50	nM	676.0
	6189347	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3ccnc(NS(=O)(=O)c4cccc(F)c4)n3)cc2s1		CHEMBL1773579	>	IC50	nM	5000.0	CHEMBL4282	Homo sapiens	IC50	nM	5000.0
	6189348	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3ccnc(NS(=O)(=O)c4ccc(F)cc4)n3)cc2s1		CHEMBL1773580	>	IC50	nM	5000.0	CHEMBL4282	Homo sapiens	IC50	nM	5000.0
	6189349	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3ccnc(NS(=O)(=O)c4ccc(C)cc4)n3)cc2s1		CHEMBL1773581	=	IC50	nM	1260.0	CHEMBL4282	Homo sapiens	IC50	nM	1260.0
	6189350	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3ccnc(N(C)S(=O)(=O)c4ccc(C)cc4)n3)cc2s1		CHEMBL1773582	=	IC50	nM	334.0	CHEMBL4282	Homo sapiens	IC50	nM	334.0
	6189351	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	COc1ccc(S(=O)(=O)Nc2cc(-c3ccc4nc(NC(C)=O)sc4c3)ccn2)cc1		CHEMBL1773558	=	IC50	nM	33.0	CHEMBL4282	Homo sapiens	IC50	nM	33.0
	6189352	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	COc1ccc(S(=O)(=O)Nc2cncc(-c3ccc4nc(NC(C)=O)sc4c3)c2)cc1		CHEMBL1773599	=	IC50	nM	103.0	CHEMBL4282	Homo sapiens	IC50	nM	103.0
	6189353	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	COc1ccc(S(=O)(=O)Nc2cncc(-c3ccc4nc(NC(C)=O)sc4c3)n2)cc1		CHEMBL1773600	=	IC50	nM	739.0	CHEMBL4282	Homo sapiens	IC50	nM	739.0
	6189354	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	COc1ccc(S(=O)(=O)Nc2cccc(-c3ccc4nc(NC(C)=O)sc4c3)c2)cc1		CHEMBL1773601	=	IC50	nM	1160.0	CHEMBL4282	Homo sapiens	IC50	nM	1160.0
	6189368	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	COc1ccc(S(=O)(=O)Nc2cc(-c3ccc4nc(NC(C)=O)sc4c3)cnc2C#N)cc1		CHEMBL1773602	=	IC50	nM	757.0	CHEMBL4282	Homo sapiens	IC50	nM	757.0
	6189369	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	COc1ccc(S(=O)(=O)Nc2cc(-c3ccc4nc(NC(C)=O)sc4c3)cnc2C)cc1		CHEMBL1773603	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
	6189370	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	COc1ccc(S(=O)(=O)Nc2cc(-c3ccc4nc(NC(C)=O)sc4c3)cnc2Cl)cc1		CHEMBL1773604	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	6189400	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccccc4)c3)cc2s1		CHEMBL1773605	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	6189401	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccccc4C(F)(F)F)c3)cc2s1		CHEMBL1773606	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
	6189402	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4cccc(C(F)(F)F)c4)c3)cc2s1		CHEMBL1773728	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
	6189403	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(C(F)(F)F)cc4)c3)cc2s1		CHEMBL1773729	=	IC50	nM	19.0	CHEMBL4282	Homo sapiens	IC50	nM	19.0
	6189404	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccccc4Cl)c3)cc2s1		CHEMBL1773730	=	IC50	nM	4.9	CHEMBL4282	Homo sapiens	IC50	nM	4.9
	6189405	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4cccc(Cl)c4)c3)cc2s1		CHEMBL1773731	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
	6189406	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(Cl)cc4)c3)cc2s1		CHEMBL1773732	=	IC50	nM	8.7	CHEMBL4282	Homo sapiens	IC50	nM	8.7
	6189407	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4cccc(C(C)(C)C)c4)c3)cc2s1		CHEMBL1773733	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
	6189408	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(C(C)(C)C)cc4)c3)cc2s1		CHEMBL1773734	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
	6189409	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccccc4F)c3)cc2s1		CHEMBL1773735	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
	6189410	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4cccc(F)c4)c3)cc2s1		CHEMBL1773736	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
	6189411	CHEMBL1775878	Inhibition of AKT phosphorylation at S473 in human U-87MG cells at 5 mM after 2 hrs	B	CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2s1		CHEMBL1615189	=	IC50	nM	6.3	CHEMBL4282	Homo sapiens	IC50	nM	6.3
Not Active	6192969	CHEMBL1777231	Inhibition of EGF-induced Akt phosphorylation at Ser473 in human MDA-MB-468 cells at 5 uM treated 1.5 hrs before EGF challenge measured after 30 mins by Western blotting	B	C/C(=C\C(=O)N[C@H]1CCc2cccc3c2N(C1=O)[C@H](C(=O)N[C@H](C)CCC(N)=O)C3)c1ccc(C(F)(F)P(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)cc1		CHEMBL1774973		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	6192970	CHEMBL1777231	Inhibition of EGF-induced Akt phosphorylation at Ser473 in human MDA-MB-468 cells at 5 uM treated 1.5 hrs before EGF challenge measured after 30 mins by Western blotting	B	CCCC[C@H](NC(=O)/C=C(\C)c1ccc(C(F)(F)P(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)cc1)C(=O)N1C[C@H]2C[C@H]2[C@H]1C(=O)N[C@@H](CCC(N)=O)C(C)OCc1ccccc1		CHEMBL1774974		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	6192971	CHEMBL1777231	Inhibition of EGF-induced Akt phosphorylation at Ser473 in human MDA-MB-468 cells at 5 uM treated 1.5 hrs before EGF challenge measured after 30 mins by Western blotting	B	CCCC[C@H](NC(=O)/C=C(\C)c1ccc(C(F)(F)P(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)cc1)C(=O)N1C[C@H]2C[C@H]2[C@H]1C(=O)N[C@H](C)CCC(N)=O		CHEMBL1774976		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	6192985	CHEMBL1777236	Inhibition of Akt phosphorylation at Ser473 in human HCC-827 cells at 5 uM after up to 24 hrs by Western blotting	B	C/C(=C\C(=O)N[C@H]1CCc2cccc3c2N(C1=O)[C@H](C(=O)N[C@H](C)CCC(N)=O)C3)c1ccc(C(F)(F)P(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)cc1		CHEMBL1774973		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	6193920	CHEMBL1777657	Inhibition of AKT1 at 10 uM	B	Cc1c(N)ccc2[nH]c(-c3ccc(N)cc3)nc12		CHEMBL529177	=	Inhibition	%	-2.5	CHEMBL4282	Homo sapiens	INH	%	-2.5
	6193931	CHEMBL1777657	Inhibition of AKT1 at 10 uM	B	Oc1ccc(NCn2nnc3ccccc32)cc1		CHEMBL1775067	=	Inhibition	%	8.6	CHEMBL4282	Homo sapiens	INH	%	8.6
	6198101	CHEMBL1776512	Inhibition of AKT1 assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	B	CN1CCN(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3CCO)CC4)c2)CC1		CHEMBL1738758	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	6201879	CHEMBL1781778	Inhibition of AKT1 assessed as FI-H1-peptide phosphorylation by fluorescence polarization assay	B	CC1(C)c2cc(C3CCN(C4COC4)CC3)ccc2C(=O)c2c1[nH]c1cc(C#N)ccc21		CHEMBL1779202	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	6221266	CHEMBL1787828	Inhibition of AKT1 at 10 uM	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
Active	6227085	CHEMBL1787906	Inhibition of serotonin-induced AKT phosphorylation in human PC3 cells at 15 uM after 48 hrs by Western blotting	B	Br.CCCN(CCC)[C@H]1CCc2cccc(O)c2C1		CHEMBL541621		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	6227086	CHEMBL1787907	Inhibition of serotonin-induced AKT phosphorylation in human PC3 cells at 2 uM after 48 hrs by Western blotting	B	CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1		CHEMBL84		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	6230332	CHEMBL1785277	Inhibition of human AKT1	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	6264905	CHEMBL1799788	Inhibition of AKT1 at 1 uM	B	COCCN1CCc2cc(Nc3ncc(Cl)c(N[C@@H]4CCCC[C@H]4NS(C)(=O)=O)n3)c(OC)cc2CC1		CHEMBL1796254	<	Inhibition	%	65.0	CHEMBL4282	Homo sapiens	INH	%	65.0
	6265629	CHEMBL1799788	Inhibition of AKT1 at 1 uM	B	COCCN1CCc2cc(Nc3ncc(Cl)c(N[C@@H]4CCCC[C@H]4N(C)S(C)(=O)=O)n3)c(OC)cc2CC1		CHEMBL1796257	<	Inhibition	%	65.0	CHEMBL4282	Homo sapiens	INH	%	65.0
	6268156	CHEMBL1805343	Inhibition of Akt1	B	CSc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(C)ns2)n1		CHEMBL1270795	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
Not Active	6284090	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800145		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	6284091	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800252		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	6284092	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800254		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	6284093	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800256		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	6284094	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089661	=	Inhibition	%	87.0	CHEMBL4282	Homo sapiens	INH	%	87.0
	6284095	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800146	=	Inhibition	%	85.0	CHEMBL4282	Homo sapiens	INH	%	85.0
	6284096	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCCC[C@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800147	=	Inhibition	%	82.0	CHEMBL4282	Homo sapiens	INH	%	82.0
	6284097	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800148	=	Inhibition	%	80.0	CHEMBL4282	Homo sapiens	INH	%	80.0
	6284098	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800149	=	Inhibition	%	81.0	CHEMBL4282	Homo sapiens	INH	%	81.0
	6284099	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800253	=	Inhibition	%	60.0	CHEMBL4282	Homo sapiens	INH	%	60.0
	6284100	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800255	=	Inhibition	%	74.0	CHEMBL4282	Homo sapiens	INH	%	74.0
	6284101	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800257	=	Inhibition	%	68.0	CHEMBL4282	Homo sapiens	INH	%	68.0
Not Active	6284102	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800258		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	6284103	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CN)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800260	=	Inhibition	%	94.0	CHEMBL4282	Homo sapiens	INH	%	94.0
	6284104	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CN)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800261	=	Inhibition	%	32.0	CHEMBL4282	Homo sapiens	INH	%	32.0
	6284105	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800262	=	Inhibition	%	92.0	CHEMBL4282	Homo sapiens	INH	%	92.0
	6284106	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800263	=	Inhibition	%	27.0	CHEMBL4282	Homo sapiens	INH	%	27.0
	6284107	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCNC(=O)NCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800395	=	Inhibition	%	30.0	CHEMBL4282	Homo sapiens	INH	%	30.0
	6284108	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCNC(=O)NCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800396	=	Inhibition	%	54.0	CHEMBL4282	Homo sapiens	INH	%	54.0
	6284109	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCCNC(=O)NCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800397	=	Inhibition	%	84.0	CHEMBL4282	Homo sapiens	INH	%	84.0
	6284110	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCCCCNC(=O)NCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800398	=	Inhibition	%	68.0	CHEMBL4282	Homo sapiens	INH	%	68.0
	6284111	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCNC(=O)NCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800399	=	Inhibition	%	98.0	CHEMBL4282	Homo sapiens	INH	%	98.0
	6284112	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCNC(=O)NCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800400	=	Inhibition	%	98.0	CHEMBL4282	Homo sapiens	INH	%	98.0
	6284113	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCCNC(=O)NCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800401	=	Inhibition	%	54.0	CHEMBL4282	Homo sapiens	INH	%	54.0
	6284114	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCCCCNC(=O)NCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800402	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	INH	%	100.0
	6284115	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCNC(=O)NCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800403	=	Inhibition	%	98.0	CHEMBL4282	Homo sapiens	INH	%	98.0
	6284116	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCNC(=O)NCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800565	=	Inhibition	%	92.0	CHEMBL4282	Homo sapiens	INH	%	92.0
	6284117	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCCNC(=O)NCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800566	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	INH	%	100.0
	6284118	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCCCCNC(=O)NCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800567	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	INH	%	100.0
	6284119	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCNC(=O)NCCCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800568	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	INH	%	100.0
	6284120	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCNC(=O)NCCCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800569	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	INH	%	100.0
	6284121	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCCNC(=O)NCCCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800570	=	Inhibition	%	94.0	CHEMBL4282	Homo sapiens	INH	%	94.0
	6284122	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCCCCNC(=O)NCCCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800571	=	Inhibition	%	39.0	CHEMBL4282	Homo sapiens	INH	%	39.0
	6284123	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCN)CC(N)=O		CHEMBL1800572	=	Inhibition	%	67.0	CHEMBL4282	Homo sapiens	INH	%	67.0
	6284124	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCN)CC(N)=O		CHEMBL1800695	=	Inhibition	%	63.0	CHEMBL4282	Homo sapiens	INH	%	63.0
	6284125	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNCCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCN)CC(N)=O		CHEMBL1800696	=	Inhibition	%	66.0	CHEMBL4282	Homo sapiens	INH	%	66.0
	6284126	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNCCCCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCN)CC(N)=O		CHEMBL1800697	=	Inhibition	%	64.0	CHEMBL4282	Homo sapiens	INH	%	64.0
	6284127	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(=N)N)NC(=O)CCC(=O)NCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800702	=	Inhibition	%	13.0	CHEMBL4282	Homo sapiens	INH	%	13.0
	6284128	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(=N)N)NC(=O)CCCC(=O)NCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800703	=	Inhibition	%	14.0	CHEMBL4282	Homo sapiens	INH	%	14.0
	6284129	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(=N)N)NC(=O)CCCCC(=O)NCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800704	=	Inhibition	%	18.0	CHEMBL4282	Homo sapiens	INH	%	18.0
	6284130	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(=N)N)NC(=O)CCCCCC(=O)NCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800467	=	Inhibition	%	16.0	CHEMBL4282	Homo sapiens	INH	%	16.0
	6284131	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(=N)N)NC(=O)CCC(=O)NCCCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800468	=	Inhibition	%	25.0	CHEMBL4282	Homo sapiens	INH	%	25.0
	6284132	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(=N)N)NC(=O)CCCC(=O)NCCCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800469	=	Inhibition	%	32.0	CHEMBL4282	Homo sapiens	INH	%	32.0
	6284133	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(=N)N)NC(=O)CCCCC(=O)NCCCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800470	=	Inhibition	%	30.0	CHEMBL4282	Homo sapiens	INH	%	30.0
	6284134	CHEMBL1804367	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 5 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(=N)N)NC(=O)CCCCCC(=O)NCCCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800471	=	Inhibition	%	30.0	CHEMBL4282	Homo sapiens	INH	%	30.0
Not Determined	6284135	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800145		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284136	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCCC[C@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800147		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284137	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800148		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284138	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800149		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284139	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800252		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284140	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800253		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284141	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800254		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284142	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800255		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284143	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800256		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284144	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800257		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284145	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800258		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284146	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CN)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800261		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284147	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800263		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284148	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCN)CC(N)=O		CHEMBL1800264		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284149	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCCCCN)CC(N)=O		CHEMBL1800391		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284150	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCCCCN)CC(N)=O		CHEMBL1800392		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284151	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCCCCN)CC(N)=O		CHEMBL1800393		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284152	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCCCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCCCCN)CC(N)=O		CHEMBL1800394		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284153	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCNC(=O)NCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800395		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284154	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCNC(=O)NCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800396		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284155	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCCNC(=O)NCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800397		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284156	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCCCCNC(=O)NCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800398		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284157	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCCNC(=O)NCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800401		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284158	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCNC(=O)NCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800565		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284159	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCCNC(=O)NCCCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800570		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284160	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCCCCNC(=O)NCCCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800571		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284161	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNCCCCNC(=O)NCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800700		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	6284162	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNCCCCCCNC(=O)NCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800701		IC50			CHEMBL4282	Homo sapiens	IC50		
	6284163	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089661	=	IC50	nM	940.0	CHEMBL4282	Homo sapiens	IC50	uM	0.94
	6284164	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800146	=	IC50	nM	950.0	CHEMBL4282	Homo sapiens	IC50	uM	0.95
	6284165	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CN)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800260	=	IC50	nM	860.0	CHEMBL4282	Homo sapiens	IC50	uM	0.86
	6284166	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1800262	=	IC50	nM	2150.0	CHEMBL4282	Homo sapiens	IC50	uM	2.15
	6284167	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCN)CC(N)=O		CHEMBL1800265	=	IC50	nM	320.0	CHEMBL4282	Homo sapiens	IC50	uM	0.32
	6284168	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCN)CC(N)=O		CHEMBL1800266	=	IC50	nM	220.0	CHEMBL4282	Homo sapiens	IC50	uM	0.22
	6284169	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCCCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCN)CC(N)=O		CHEMBL1800267	=	IC50	nM	320.0	CHEMBL4282	Homo sapiens	IC50	uM	0.32
	6284170	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCN)CC(N)=O		CHEMBL1800259	=	IC50	nM	250.0	CHEMBL4282	Homo sapiens	IC50	uM	0.25
	6284171	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCN)CC(N)=O		CHEMBL1800268	=	IC50	nM	130.0	CHEMBL4282	Homo sapiens	IC50	uM	0.13
	6284172	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCN)CC(N)=O		CHEMBL1800269	=	IC50	nM	150.0	CHEMBL4282	Homo sapiens	IC50	uM	0.15
	6284173	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCCCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCN)CC(N)=O		CHEMBL1800386	=	IC50	nM	110.0	CHEMBL4282	Homo sapiens	IC50	uM	0.11
	6284174	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCCN)CC(N)=O		CHEMBL1800387	=	IC50	nM	176.0	CHEMBL4282	Homo sapiens	IC50	uM	0.176
	6284175	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCCN)CC(N)=O		CHEMBL1800388	=	IC50	nM	128.0	CHEMBL4282	Homo sapiens	IC50	uM	0.128
	6284176	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCCN)CC(N)=O		CHEMBL1800389	=	IC50	nM	130.0	CHEMBL4282	Homo sapiens	IC50	uM	0.13
	6284177	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCCCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCCN)CC(N)=O		CHEMBL1800390	=	IC50	nM	160.0	CHEMBL4282	Homo sapiens	IC50	uM	0.16
	6284178	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCNC(=O)NCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800399	=	IC50	nM	920.0	CHEMBL4282	Homo sapiens	IC50	uM	0.92
	6284179	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCNC(=O)NCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800400	=	IC50	nM	590.0	CHEMBL4282	Homo sapiens	IC50	uM	0.59
	6284180	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCCCCNC(=O)NCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800402	=	IC50	nM	160.0	CHEMBL4282	Homo sapiens	IC50	uM	0.16
	6284181	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCNC(=O)NCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800403	=	IC50	nM	282.0	CHEMBL4282	Homo sapiens	IC50	uM	0.282
	6284182	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCCNC(=O)NCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800566	=	IC50	nM	170.0	CHEMBL4282	Homo sapiens	IC50	uM	0.17
	6284183	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCCCCNC(=O)NCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800567	=	IC50	nM	280.0	CHEMBL4282	Homo sapiens	IC50	uM	0.28
	6284184	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCNC(=O)NCCCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800568	=	IC50	nM	290.0	CHEMBL4282	Homo sapiens	IC50	uM	0.29
	6284185	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(C(=O)[C@@H](N)CCCNC(=N)N)CCCNC(=O)NCCCCCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800569	=	IC50	nM	320.0	CHEMBL4282	Homo sapiens	IC50	uM	0.32
	6284186	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNCCNC(=O)NCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800698	=	IC50	nM	390.0	CHEMBL4282	Homo sapiens	IC50	uM	0.39
	6284187	CHEMBL1804368	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP by cell-free radioactive assay	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNCCCNC(=O)NCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800699	=	IC50	nM	240.0	CHEMBL4282	Homo sapiens	IC50	uM	0.24
	6284188	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCN)CC(N)=O		CHEMBL1800264	=	Inhibition	%	57.0	CHEMBL4282	Homo sapiens	INH	%	57.0
	6284189	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCN)CC(N)=O		CHEMBL1800265	=	Inhibition	%	76.0	CHEMBL4282	Homo sapiens	INH	%	76.0
	6284190	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCN)CC(N)=O		CHEMBL1800266	=	Inhibition	%	84.0	CHEMBL4282	Homo sapiens	INH	%	84.0
	6284191	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCCCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCN)CC(N)=O		CHEMBL1800267	=	Inhibition	%	83.0	CHEMBL4282	Homo sapiens	INH	%	83.0
	6284192	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCN)CC(N)=O		CHEMBL1800259	=	Inhibition	%	76.0	CHEMBL4282	Homo sapiens	INH	%	76.0
	6284193	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCN)CC(N)=O		CHEMBL1800268	=	Inhibition	%	90.0	CHEMBL4282	Homo sapiens	INH	%	90.0
	6284194	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCN)CC(N)=O		CHEMBL1800269	=	Inhibition	%	91.0	CHEMBL4282	Homo sapiens	INH	%	91.0
	6284195	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCCCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCN)CC(N)=O		CHEMBL1800386	=	Inhibition	%	87.0	CHEMBL4282	Homo sapiens	INH	%	87.0
	6284196	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCCN)CC(N)=O		CHEMBL1800387	=	Inhibition	%	84.0	CHEMBL4282	Homo sapiens	INH	%	84.0
	6284197	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCCN)CC(N)=O		CHEMBL1800388	=	Inhibition	%	96.0	CHEMBL4282	Homo sapiens	INH	%	96.0
	6284198	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCCN)CC(N)=O		CHEMBL1800389	=	Inhibition	%	91.0	CHEMBL4282	Homo sapiens	INH	%	91.0
	6284199	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCCCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCCN)CC(N)=O		CHEMBL1800390	=	Inhibition	%	88.0	CHEMBL4282	Homo sapiens	INH	%	88.0
	6284200	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCCCCN)CC(N)=O		CHEMBL1800391	=	Inhibition	%	42.0	CHEMBL4282	Homo sapiens	INH	%	42.0
	6284201	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCCCCN)CC(N)=O		CHEMBL1800392	=	Inhibition	%	51.0	CHEMBL4282	Homo sapiens	INH	%	51.0
	6284202	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCCCCN)CC(N)=O		CHEMBL1800393	=	Inhibition	%	60.0	CHEMBL4282	Homo sapiens	INH	%	60.0
	6284203	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN(CCCCCCN)C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(=O)N(CCCCCCN)CC(N)=O		CHEMBL1800394	=	Inhibition	%	57.0	CHEMBL4282	Homo sapiens	INH	%	57.0
	6284204	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNCCNC(=O)NCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800698	=	Inhibition	%	64.0	CHEMBL4282	Homo sapiens	INH	%	64.0
	6284205	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNCCCNC(=O)NCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800699	=	Inhibition	%	84.0	CHEMBL4282	Homo sapiens	INH	%	84.0
	6284206	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNCCCCNC(=O)NCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800700	=	Inhibition	%	32.0	CHEMBL4282	Homo sapiens	INH	%	32.0
	6284207	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNCCCCCCNC(=O)NCCN(CC(N)=O)C(=O)[C@H](CCC(C)C)NC(=O)[C@H](CN)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O		CHEMBL1800701	=	Inhibition	%	26.0	CHEMBL4282	Homo sapiens	INH	%	26.0
	6284208	CHEMBL1804369	Inhibition of Akt using RPRTSSF peptide and [gamma32]ATP at 0.625 uM by cell-free radioactive assay relative to control	B	CCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CN)C(=O)N[C@@H](CCC(C)C)C(N)=O		CHEMBL1089661	=	Inhibition	%	36.0	CHEMBL4282	Homo sapiens	INH	%	36.0
	6299675	CHEMBL1811572	Inhibition of Akt	B	Cc1ccc(C(=O)NC2CC2)cc1Nc1ncnn2cc(C(=O)c3ccccc3)c(C)c12		CHEMBL1807446	>	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	uM	25.0
Not Active	6307599	CHEMBL1816862	Inhibition of recombinant AKT1 assessed as 33Pi incorporation after 60 mins by scintillation counting	B	C=C[C@]1(C)C=C2[C@@H](O)[C@@H]3OC(=O)[C@@]4(C)CC[C@H]5C[C@]5([C@@H]34)[C@@]2(O)C(=O)C1		CHEMBL1812030		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	6307600	CHEMBL1816862	Inhibition of recombinant AKT1 assessed as 33Pi incorporation after 60 mins by scintillation counting	B	C=C[C@@]1(C)C=C2C(=O)C(O)=C3[C@](C)(C(=O)O)CC[C@@H]4C[C@]34[C@]2(O)C(=O)C1		CHEMBL516554		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	6307601	CHEMBL1816862	Inhibition of recombinant AKT1 assessed as 33Pi incorporation after 60 mins by scintillation counting	B	Cc1cc(O)cc2oc3cc(O)cc(O)c3c(=O)c12		CHEMBL466154	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	6307602	CHEMBL1816862	Inhibition of recombinant AKT1 assessed as 33Pi incorporation after 60 mins by scintillation counting	B	Cc1c(O)c(O)cc2oc3cc(O)cc(O)c3c(=O)c12		CHEMBL454440	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	6317814	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2[nH]nc(N)c2c(=O)[nH]1		CHEMBL1813604	=	Inhibition	%	-3.0	CHEMBL4282	Homo sapiens	INH	%	-3.0
	6317815	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Nc1n[nH]c2cc(-c3cccnc3)[nH]c(=O)c12		CHEMBL1813606	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	6317816	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Nc1n[nH]c2cc(-c3ccccn3)[nH]c(=O)c12		CHEMBL1813607	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	6317817	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Nc1n[nH]c2cc(-c3ccncc3)[nH]c(=O)c12		CHEMBL1813608	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	6317818	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	COc1cccc(-c2cc3[nH]nc(N)c3c(=O)[nH]2)c1		CHEMBL1813609	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	6317819	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	COc1ccc(-c2cc3[nH]nc(N)c3c(=O)[nH]2)cc1		CHEMBL1813610	=	Inhibition	%	21.0	CHEMBL4282	Homo sapiens	INH	%	21.0
	6317820	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	CN1CCN(c2ccc(-c3cc4[nH]nc(N)c4c(=O)[nH]3)cc2)CC1		CHEMBL1813611	=	Inhibition	%	9.0	CHEMBL4282	Homo sapiens	INH	%	9.0
	6317821	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Nc1n[nH]c2cc(-c3cccs3)[nH]c(=O)c12		CHEMBL1813612	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	6317822	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	CC(C)(C)c1cc2[nH]nc(N)c2c(=O)[nH]1		CHEMBL1813613	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	6317823	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Nc1n[nH]c2cc(-c3ccc(N4CCOCC4)cc3)[nH]c(=O)c12		CHEMBL1813614	=	Inhibition	%	-1.0	CHEMBL4282	Homo sapiens	INH	%	-1.0
	6317824	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Nc1n[nH]c2cc(CC3CCNCC3)[nH]c(=O)c12		CHEMBL1813615	=	Inhibition	%	13.0	CHEMBL4282	Homo sapiens	INH	%	13.0
	6317825	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Nc1n[nH]c2c3c([nH]c(=O)c12)CCCC3		CHEMBL1813617	=	Inhibition	%	-3.0	CHEMBL4282	Homo sapiens	INH	%	-3.0
	6317826	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2[nH]nc(N)c2c(N2CCCCC2)n1		CHEMBL1813618	=	Inhibition	%	36.0	CHEMBL4282	Homo sapiens	INH	%	36.0
	6317827	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2[nH]nc(N)c2c(N2CCOCC2)n1		CHEMBL1813619	=	Inhibition	%	17.0	CHEMBL4282	Homo sapiens	INH	%	17.0
	6317828	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2c(c(N)nn2C)c(=O)[nH]1		CHEMBL1813620	=	Inhibition	%	11.0	CHEMBL4282	Homo sapiens	INH	%	11.0
	6317829	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cn1nc(N)c2c(=O)[nH]c(-c3ccccc3)cc21		CHEMBL1813621	=	Inhibition	%	8.0	CHEMBL4282	Homo sapiens	INH	%	8.0
	6317830	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cn1nc(N)c2c(=O)[nH]c(-c3ccccn3)cc21		CHEMBL1813622	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	6317831	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	COc1ccc(-c2cc3c(c(N)nn3C)c(=O)[nH]2)cc1		CHEMBL1813623	=	Inhibition	%	9.0	CHEMBL4282	Homo sapiens	INH	%	9.0
	6317832	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	COc1cccc(-c2cc3c(c(N)nn3C)c(=O)[nH]2)c1		CHEMBL1813624	=	Inhibition	%	-5.0	CHEMBL4282	Homo sapiens	INH	%	-5.0
	6317833	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	CN1CCN(c2ccc(-c3cc4c(c(N)nn4C)c(=O)[nH]3)cc2)CC1		CHEMBL1813625	=	Inhibition	%	8.0	CHEMBL4282	Homo sapiens	INH	%	8.0
	6317834	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	COC(=O)CCc1c(C)[nH]c(=O)c2c(N)nn(C)c12		CHEMBL1813627	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	6317835	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	COc1ccc(-c2c(C)[nH]c(=O)c3c(N)nn(C)c23)cc1		CHEMBL1813628	=	Inhibition	%	13.0	CHEMBL4282	Homo sapiens	INH	%	13.0
	6317836	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2c(c(NC(=O)Nc3ccccc3)nn2C)c(=O)[nH]1		CHEMBL1813630	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	6317837	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	CC(=O)Nc1nn(C)c2cc(-c3ccccc3)[nH]c(=O)c12		CHEMBL1813777	=	Inhibition	%	-9.0	CHEMBL4282	Homo sapiens	INH	%	-9.0
	6317838	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2c(c(NS(C)(=O)=O)nn2C)c(=O)[nH]1		CHEMBL1813778	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	6317839	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	COc1ccc(S(=O)(=O)Nc2nn(C)c3cc(C)[nH]c(=O)c23)c(OC)c1		CHEMBL1813779	=	Inhibition	%	10.0	CHEMBL4282	Homo sapiens	INH	%	10.0
	6317840	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	CC(=O)Nc1nn(C)c2cc(-c3ccc(N4CCN(C)CC4)cc3)[nH]c(=O)c12		CHEMBL1813780	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	6317841	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2c(c(N)nn2C)c(N2CCCCC2)n1		CHEMBL1813781	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
	6317842	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2c(c(N)nn2C)c(N2CCOCC2)n1		CHEMBL1813782	=	Inhibition	%	-8.0	CHEMBL4282	Homo sapiens	INH	%	-8.0
	6317843	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2c(c(N)nn2C)c(N2CC[C@H](O)C2)n1		CHEMBL1813784	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	6317844	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	COCCNc1nc(C)cc2c1c(N)nn2C		CHEMBL1813785	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
	6317845	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	COCCNc1nc(-c2ccccc2)cc2c1c(N)nn2C		CHEMBL1813786	=	Inhibition	%	8.0	CHEMBL4282	Homo sapiens	INH	%	8.0
	6317846	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	COCCNc1nc(C)cc2nn(-c3ccccc3)c(N)c12		CHEMBL1813787	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	6317847	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2nn(-c3ccccc3)c(N)c2c(=O)[nH]1		CHEMBL1813788	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	6317848	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	CC(C)(C)c1cc2nn(-c3ccccc3)c(N)c2c(=O)[nH]1		CHEMBL1813789	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	6317849	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Nc1c2c(=O)[nH]c(-c3ccccc3)cc2nn1-c1ccccc1		CHEMBL1813790	=	Inhibition	%	-2.0	CHEMBL4282	Homo sapiens	INH	%	-2.0
	6317850	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Nc1c2c(=O)[nH]c(-c3ccccn3)cc2nn1-c1ccccc1		CHEMBL1813791	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	6317851	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	COc1ccccc1-c1cc2nn(-c3ccccc3)c(N)c2c(=O)[nH]1		CHEMBL1813792	=	Inhibition	%	15.0	CHEMBL4282	Homo sapiens	INH	%	15.0
	6317852	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	COc1ccc(-c2cc3nn(-c4ccccc4)c(N)c3c(=O)[nH]2)cc1		CHEMBL1813793	=	Inhibition	%	16.0	CHEMBL4282	Homo sapiens	INH	%	16.0
	6317853	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	CN1CCN(c2ccc(-c3cc4nn(-c5ccccc5)c(N)c4c(=O)[nH]3)cc2)CC1		CHEMBL1813795	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	6317854	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Nc1c2c(=O)[nH]c(-c3ccccc3)cc2nn1-c1ccccn1		CHEMBL1813796	=	Inhibition	%	10.0	CHEMBL4282	Homo sapiens	INH	%	10.0
	6317855	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2nn(-c3ccccc3)c(N)c2c(N2CCCCC2)n1		CHEMBL1813797	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	6317856	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1[nH]c(=O)c2c(N)n(-c3ccccc3)nc2c1-c1ccccc1		CHEMBL1813798	=	Inhibition	%	-8.0	CHEMBL4282	Homo sapiens	INH	%	-8.0
	6317857	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cn1nc2c3c(nc(-c4ccccc4)cc31)NCC(=O)N2		CHEMBL1813799	=	Inhibition	%	10.0	CHEMBL4282	Homo sapiens	INH	%	10.0
	6317858	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cn1nc(N)c2cnc(-c3ccccc3)cc21		CHEMBL1813800	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	6317859	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2c(cn1)c(N)nn2C		CHEMBL1813801	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	6317860	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Nc1c2cnc(-c3ccccc3)cc2nn1-c1ccccc1		CHEMBL1813802	=	Inhibition	%	-1.0	CHEMBL4282	Homo sapiens	INH	%	-1.0
	6317861	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2[nH]nc(N)c2cn1		CHEMBL1813803	=	Inhibition	%	-1.0	CHEMBL4282	Homo sapiens	INH	%	-1.0
	6317862	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2[nH]ncc2c(=O)[nH]1		CHEMBL1813804	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	6317863	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2nc(N)nc(N)c2c(=O)[nH]1		CHEMBL1813805	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	6317864	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1cc2nc(-c3ccccc3)nc(N)c2c(=O)[nH]1		CHEMBL1813806	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	6317865	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	Cc1nc(N)c2c(=O)[nH]c(C)cc2n1		CHEMBL1813807	=	Inhibition	%	-2.0	CHEMBL4282	Homo sapiens	INH	%	-2.0
	6317866	CHEMBL1815739	Inhibition of AKT1 at 30 uM by microfluidic mobility shift assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Inhibition	%	96.0	CHEMBL4282	Homo sapiens	INH	%	96.0
	6325302	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	Nc1ncnc2[nH]cnc12		CHEMBL226345	=	Inhibition	%	20.0	CHEMBL4282	Homo sapiens	INH	%	20.0
	6325331	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	c1ccc(Nc2ncccn2)cc1		CHEMBL1650061	=	Inhibition	%	21.0	CHEMBL4282	Homo sapiens	INH	%	21.0
	6325363	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	c1cnc2[nH]ccc2c1		CHEMBL389685	=	Inhibition	%	48.0	CHEMBL4282	Homo sapiens	INH	%	48.0
	6325392	CHEMBL1820096	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells by scintillation proximity assay	B	c1cnc2[nH]ccc2c1		CHEMBL389685	>	IC50	nM	400000.0	CHEMBL4282	Homo sapiens	IC50	uM	400.0
	6325395	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	c1ccc2[nH]ncc2c1		CHEMBL86795	=	Inhibition	%	24.0	CHEMBL4282	Homo sapiens	INH	%	24.0
	6325425	CHEMBL1820096	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells by scintillation proximity assay	B	c1ccc2[nH]ncc2c1		CHEMBL86795	>	IC50	nM	400000.0	CHEMBL4282	Homo sapiens	IC50	uM	400.0
	6325427	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	Nc1ncccc1OCc1ccccc1		CHEMBL194009	=	Inhibition	%	29.0	CHEMBL4282	Homo sapiens	INH	%	29.0
	6325456	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	Nc1[nH]nc2ccccc12		CHEMBL1331627	=	Inhibition	%	19.0	CHEMBL4282	Homo sapiens	INH	%	19.0
	6325486	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	Nc1n[nH]c2ncccc12		CHEMBL1817865	=	Inhibition	%	19.0	CHEMBL4282	Homo sapiens	INH	%	19.0
	6325514	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	c1n[nH]c2c1CCCC2		CHEMBL1817866	=	Inhibition	%	10.0	CHEMBL4282	Homo sapiens	INH	%	10.0
	6325544	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	Nc1ccc2ncc(-c3ccccc3)n2n1		CHEMBL1817867	=	Inhibition	%	67.0	CHEMBL4282	Homo sapiens	INH	%	67.0
	6325887	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	c1ccc(-c2cnc3nccnn23)cc1		CHEMBL1817868	=	Inhibition	%	17.0	CHEMBL4282	Homo sapiens	INH	%	17.0
	6325917	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	Cc1ccc(NC(=O)Nc2cc(C(C)(C)C)nn2-c2ccccc2)cc1		CHEMBL1817869	=	Inhibition	%	9.0	CHEMBL4282	Homo sapiens	INH	%	9.0
	6325946	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccccc2)no1		CHEMBL292785	=	Inhibition	%	19.0	CHEMBL4282	Homo sapiens	INH	%	19.0
	6325975	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	Cc1ccc(NC(=O)Nc2cccc(C(F)(F)F)c2)cc1		CHEMBL1817870	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
	6326004	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	O=C(Nc1ccccc1)Nc1cccc(C(F)(F)F)c1		CHEMBL1605296	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	6326033	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	O=C(Nc1ccccc1)Nc1ccccc1		CHEMBL354676	=	Inhibition	%	11.0	CHEMBL4282	Homo sapiens	INH	%	11.0
	6326063	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	Cc1ccc(C(=O)NC2CC2)cc1F		CHEMBL1817871	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	6326091	CHEMBL1819981	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	B	c1ccc(Nc2ccccc2)cc1		CHEMBL38688	=	Inhibition	%	17.0	CHEMBL4282	Homo sapiens	INH	%	17.0
	6326126	CHEMBL1820096	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells by scintillation proximity assay	B	NCC(NC(=O)c1ccc(-c2ccnc3[nH]ccc23)s1)c1ccccc1		CHEMBL471034	=	IC50	nM	190.0	CHEMBL4282	Homo sapiens	IC50	nM	190.0
	6326132	CHEMBL1820096	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells by scintillation proximity assay	B	c1cnc2[nH]ccc2c1		CHEMBL389685	<	IC50	nM	398107.17	CHEMBL4282	Homo sapiens	pIC50		3.4
	6326135	CHEMBL1820096	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells by scintillation proximity assay	B	c1ccc2[nH]ncc2c1		CHEMBL86795	<	IC50	nM	398107.17	CHEMBL4282	Homo sapiens	pIC50		3.4
	6339239	CHEMBL1828185	Inhibition of AKT1 activity by fluorescence polarization assay	B	CCc1cc2c(cc1N1CCN(C3COC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1823221	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	6339240	CHEMBL1828185	Inhibition of AKT1 activity by fluorescence polarization assay	B	CC1(C)c2cc(C3CCN(C4COC4)CC3)ccc2C(=O)c2c1[nH]c1cc(C#N)ccc21		CHEMBL1779202	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	6339841	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2s1		CHEMBL1615189	=	IC50	nM	6.3	CHEMBL4282	Homo sapiens	IC50	nM	6.3
	6339842	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2s1		CHEMBL1822052	=	IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	nM	44.0
	6339843	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	O=S(=O)(Nc1cc(-c2ccc3ncsc3c2)cnc1Cl)c1ccc(F)cc1		CHEMBL1822053	=	IC50	nM	769.0	CHEMBL4282	Homo sapiens	IC50	nM	769.0
	6339844	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
	6339845	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822055	=	IC50	nM	415.0	CHEMBL4282	Homo sapiens	IC50	nM	415.0
	6339846	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	O=S(=O)(Nc1cc(-c2ccc3nccn3n2)cnc1Cl)c1ccc(F)cc1		CHEMBL1822056	=	IC50	nM	50.0	CHEMBL4282	Homo sapiens	IC50	nM	50.0
	6339847	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	CC(=O)Nc1cn2cc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822057	=	IC50	nM	118.0	CHEMBL4282	Homo sapiens	IC50	nM	118.0
	6339848	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	Nc1cn2cc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822058	>	IC50	nM	12000.0	CHEMBL4282	Homo sapiens	IC50	nM	12000.0
	6339849	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	O=S(=O)(Nc1cc(-c2ccc3nccn3c2)cnc1Cl)c1ccc(F)cc1		CHEMBL1822059	=	IC50	nM	574.0	CHEMBL4282	Homo sapiens	IC50	nM	574.0
	6339850	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2[nH]1		CHEMBL1822060	=	IC50	nM	335.0	CHEMBL4282	Homo sapiens	IC50	nM	335.0
	6339851	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2[nH]1		CHEMBL1822208	>	IC50	nM	12000.0	CHEMBL4282	Homo sapiens	IC50	nM	12000.0
	6339852	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	O=S(=O)(Nc1cc(-c2ccc3nc[nH]c3c2)cnc1Cl)c1ccc(F)cc1		CHEMBL1822209	>	IC50	nM	12000.0	CHEMBL4282	Homo sapiens	IC50	nM	12000.0
	6339853	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2o1		CHEMBL1822210	=	IC50	nM	1100.0	CHEMBL4282	Homo sapiens	IC50	nM	1100.0
	6339854	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2o1		CHEMBL1822211	=	IC50	nM	101.0	CHEMBL4282	Homo sapiens	IC50	nM	101.0
	6339855	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	O=S(=O)(Nc1cc(-c2ccc3ncoc3c2)cnc1Cl)c1ccc(F)cc1		CHEMBL1822212	>	IC50	nM	12000.0	CHEMBL4282	Homo sapiens	IC50	nM	12000.0
	6339856	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	O=S(=O)(Nc1cc(-c2ccc3nncn3c2)cnc1Cl)c1ccc(F)cc1		CHEMBL1822213	>	IC50	nM	12000.0	CHEMBL4282	Homo sapiens	IC50	nM	12000.0
	6339857	CHEMBL1828261	Inhibition of PI3K-mediated Akt phosphorylation at Ser 473 in human U87MG cells after 2 hrs by alphascreen assay	B	O=S(=O)(Nc1cc(-c2ccc3sncc3c2)cnc1Cl)c1ccc(F)cc1		CHEMBL1822214	>	IC50	nM	12000.0	CHEMBL4282	Homo sapiens	IC50	nM	12000.0
	6340469	CHEMBL1825378	Inhibition of AKT1	B	N[C@H](CNc1nnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1080569	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	uM	0.003
	6340470	CHEMBL1825378	Inhibition of AKT1	B	N[C@H](CNc1nnc(-c2ccc3c(c2)CC(=O)N3)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1823630	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	uM	0.02
	6340471	CHEMBL1825378	Inhibition of AKT1	B	N[C@H](CNC(=O)c1ccc2cnccc2c1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1823631	=	IC50	nM	3380.0	CHEMBL4282	Homo sapiens	IC50	uM	3.38
	6340472	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1ccccc1)C1CCNCC1)c1ccc2cnccc2c1		CHEMBL1823632	=	IC50	nM	850.0	CHEMBL4282	Homo sapiens	IC50	uM	0.85
	6340473	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1ccc2ccccc2c1)C1CCNCC1)c1ccc2cnccc2c1		CHEMBL1823633	=	IC50	nM	400.0	CHEMBL4282	Homo sapiens	IC50	uM	0.4
	6340474	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1nccs1)C1CCNCC1)c1ccc2cnccc2c1		CHEMBL1823634	=	IC50	nM	1570.0	CHEMBL4282	Homo sapiens	IC50	uM	1.57
	6340475	CHEMBL1825378	Inhibition of AKT1	B	COc1ccc(C(NC(=O)c2ccc3cnccc3c2)C2CCNCC2)cc1F		CHEMBL1823635	=	IC50	nM	1510.0	CHEMBL4282	Homo sapiens	IC50	uM	1.51
	6340476	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1ccc(F)c(F)c1)C1CCNCC1)c1ccc2cnccc2c1		CHEMBL1823636	=	IC50	nM	2680.0	CHEMBL4282	Homo sapiens	IC50	uM	2.68
	6340477	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1ccc(Cl)c(-c2ccccc2)c1)C1CCNCC1)c1ccc2cnccc2c1		CHEMBL1823637	=	IC50	nM	200.0	CHEMBL4282	Homo sapiens	IC50	uM	0.2
	6340478	CHEMBL1825378	Inhibition of AKT1	B	N#Cc1cc(C(NC(=O)c2ccc3cnccc3c2)C2CCNCC2)ccc1Cl		CHEMBL1823638	=	IC50	nM	80.0	CHEMBL4282	Homo sapiens	IC50	uM	0.08
	6340479	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1cccc(Cl)c1)C1CCNCC1)c1ccc2cnccc2c1		CHEMBL1823639	=	IC50	nM	70.0	CHEMBL4282	Homo sapiens	IC50	uM	0.07
	6340480	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1ccc(Cl)cc1)C1CCNCC1)c1ccc2cnccc2c1		CHEMBL1823640	=	IC50	nM	190.0	CHEMBL4282	Homo sapiens	IC50	uM	0.19
	6340481	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1ccc(Cl)c(F)c1)C1CCNCC1)c1ccc2cnccc2c1		CHEMBL1823641	=	IC50	nM	40.0	CHEMBL4282	Homo sapiens	IC50	uM	0.04
	6340482	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1cccc(Cl)c1Cl)C1CCNCC1)c1ccc2cnccc2c1		CHEMBL1823642	=	IC50	nM	120.0	CHEMBL4282	Homo sapiens	IC50	uM	0.12
	6340483	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCNCC1)c1ccc2cnccc2c1		CHEMBL1823643	=	IC50	nM	40.0	CHEMBL4282	Homo sapiens	IC50	uM	0.04
	6340484	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1cnc(Cl)c(Cl)c1)C1CCNCC1)c1ccc2cnccc2c1		CHEMBL1823644	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	uM	0.14
	6340485	CHEMBL1825378	Inhibition of AKT1	B	O=C1Cc2cc(C(=O)NC(c3ccc(Cl)c(Cl)c3)C3CCNCC3)ccc2N1		CHEMBL1823645	=	IC50	nM	350.0	CHEMBL4282	Homo sapiens	IC50	uM	0.35
	6340486	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCNCC1)c1ccc2[nH]c(=O)oc2c1		CHEMBL1823646	=	IC50	nM	460.0	CHEMBL4282	Homo sapiens	IC50	uM	0.46
	6340487	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCNCC1)c1ccc2[nH]ncc2c1		CHEMBL1823647	=	IC50	nM	250.0	CHEMBL4282	Homo sapiens	IC50	uM	0.25
	6340488	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCNCC1)c1ccc2cnncc2c1		CHEMBL1823648	=	IC50	nM	330.0	CHEMBL4282	Homo sapiens	IC50	uM	0.33
	6340489	CHEMBL1825378	Inhibition of AKT1	B	COc1cc2cnccc2cc1C(=O)NC(c1ccc(Cl)c(Cl)c1)C1CCNCC1		CHEMBL1823649	=	IC50	nM	39.0	CHEMBL4282	Homo sapiens	IC50	uM	0.039
	6340490	CHEMBL1825378	Inhibition of AKT1	B	COc1ccc(-c2cc3cnccc3cc2C(=O)NC(c2ccc(Cl)c(Cl)c2)C2CCNCC2)cc1		CHEMBL1823650	=	IC50	nM	6850.0	CHEMBL4282	Homo sapiens	IC50	uM	6.85
	6340491	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCNCC1)c1ccc2cnc(F)cc2c1		CHEMBL1823651	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	uM	0.02
	6340492	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCNCC1)c1ccc2cnc(Cl)cc2c1		CHEMBL1823652	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	uM	0.14
	6340493	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCCNC1)c1ccc2cnccc2c1		CHEMBL1823653	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	uM	0.02
	6340494	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCNC1)c1ccc2cnccc2c1		CHEMBL1823654	=	IC50	nM	30.0	CHEMBL4282	Homo sapiens	IC50	uM	0.03
	6340495	CHEMBL1825378	Inhibition of AKT1	B	O=C(N[C@@H](c1ccc(Cl)c(Cl)c1)C1CNC1)c1ccc2cnccc2c1		CHEMBL1823655	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	uM	0.007
	6340496	CHEMBL1825378	Inhibition of AKT1	B	O=C(N[C@H](c1ccc(Cl)c(Cl)c1)C1CNC1)c1ccc2cnccc2c1		CHEMBL1823656	=	IC50	nM	110.0	CHEMBL4282	Homo sapiens	IC50	uM	0.11
	6340497	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCCCC1)c1ccc2cnccc2c1		CHEMBL1823657	=	IC50	nM	5800.0	CHEMBL4282	Homo sapiens	IC50	uM	5.8
	6340498	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1cncnc1)c1ccc(Cl)c(Cl)c1)c1ccc2cnccc2c1		CHEMBL1823658	=	IC50	nM	12650.0	CHEMBL4282	Homo sapiens	IC50	uM	12.65
	6340499	CHEMBL1825378	Inhibition of AKT1	B	O=C(NC(c1ccncc1)c1ccc(Cl)c(Cl)c1)c1ccc2cnccc2c1		CHEMBL1823659	=	IC50	nM	20440.0	CHEMBL4282	Homo sapiens	IC50	uM	20.44
	6340500	CHEMBL1825378	Inhibition of AKT1	B	CC(C)CN1CCC([C@@H](NC(=O)c2ccc3cnccc3c2)c2ccc(Cl)c(Cl)c2)CC1		CHEMBL1823660	=	IC50	nM	2140.0	CHEMBL4282	Homo sapiens	IC50	uM	2.14
	6340501	CHEMBL1825378	Inhibition of AKT1	B	O=C(N[C@@H](c1ccc(Cl)c(Cl)c1)C1CCN(Cc2ccccc2)CC1)c1ccc2cnccc2c1		CHEMBL1823661	=	IC50	nM	240.0	CHEMBL4282	Homo sapiens	IC50	uM	0.24
	6340502	CHEMBL1825378	Inhibition of AKT1	B	O=C(N[C@@H](c1ccc(Cl)c(Cl)c1)C1CCN(Cc2ccc(C(F)(F)F)cc2)CC1)c1ccc2cnccc2c1		CHEMBL1823662	=	IC50	nM	2300.0	CHEMBL4282	Homo sapiens	IC50	uM	2.3
	6340503	CHEMBL1825378	Inhibition of AKT1	B	CN1CC([C@@H](NC(=O)c2ccc3cnccc3c2)c2ccc(Cl)c(Cl)c2)C1		CHEMBL1823663	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	uM	0.007
	6340567	CHEMBL1825376	Inhibition of AKT1-mediated PRAS40 phosphorylation in human U87MG cells after 1 hr in presence of 5% FBS by ELISA assay	B	N[C@H](CNc1nnc(-c2ccc3cnccc3c2)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1080569	=	IC50	nM	250.0	CHEMBL4282	Homo sapiens	IC50	uM	0.25
	6340568	CHEMBL1825376	Inhibition of AKT1-mediated PRAS40 phosphorylation in human U87MG cells after 1 hr in presence of 5% FBS by ELISA assay	B	N[C@H](CNc1nnc(-c2ccc3c(c2)CC(=O)N3)s1)Cc1ccc(C(F)(F)F)cc1		CHEMBL1823630	=	IC50	nM	300.0	CHEMBL4282	Homo sapiens	IC50	uM	0.3
	6340569	CHEMBL1825376	Inhibition of AKT1-mediated PRAS40 phosphorylation in human U87MG cells after 1 hr in presence of 5% FBS by ELISA assay	B	O=C(NC(c1ccc(Cl)c(Cl)c1)C1CCNCC1)c1ccc2cnc(F)cc2c1		CHEMBL1823651	=	IC50	nM	390.0	CHEMBL4282	Homo sapiens	IC50	uM	0.39
	6340570	CHEMBL1825376	Inhibition of AKT1-mediated PRAS40 phosphorylation in human U87MG cells after 1 hr in presence of 5% FBS by ELISA assay	B	O=C(N[C@@H](c1ccc(Cl)c(Cl)c1)C1CNC1)c1ccc2cnccc2c1		CHEMBL1823655	=	IC50	nM	240.0	CHEMBL4282	Homo sapiens	IC50	uM	0.24
	6341015	CHEMBL1827640	Activity of AKT1 kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	6343499	CHEMBL1827970	Inhibition of AKT1 at 28 uM by luciferase fragment complementation assay	B	CCOc1ccc(OCC(O)CN(C)Cc2c(C)nn(Cc3ccccc3Cl)c2C)cc1		CHEMBL1223751	>	Inhibition	%	27.0	CHEMBL4282	Homo sapiens	INH	%	27.0
	6343500	CHEMBL1827971	Inhibition of AKT1 at 16 uM by luciferase fragment complementation assay	B	Cc1nn(Cc2ccccc2Cl)c(C)c1CN(C)CC(O)COc1ccc(Cl)cc1		CHEMBL1824695	>	Inhibition	%	27.0	CHEMBL4282	Homo sapiens	INH	%	27.0
	6352264	CHEMBL1825912	Inhibition of PKBalpha assessed as residual activity at 10 uM by radioactivity assay in presence of 5 uM ATP	B	Nc1n[nH]c(N)c1/N=N/c1ccc(O)cc1		CHEMBL215205	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	6353448	CHEMBL1825694	Inhibition of AKT1 at 10 uM	B	O=C(Cn1c(=O)ccc2cc(C(F)(F)F)ccc21)Nc1scc(Br)c1-c1ncn[nH]1		CHEMBL1822146	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
Active	6355779	CHEMBL1832248	Inhibition of PKB-alpha at 50 uM	B	CCCc1ccc(C(CC(=O)O)Cc2nc3cc(I)ccc3[nH]2)cc1		CHEMBL1829842		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	6360094	CHEMBL1832352	Inhibition of Akt at 5 uM assessed as remaining activity	B	CNC(=O)CCc1cc(-c2ccc(-c3ccc(C(F)(F)F)cc3)cc2)n(-c2ccc(N3CCNCC3)cc2)n1		CHEMBL1830587	=	Activity	%	88.0	CHEMBL4282	Homo sapiens	Activity	%	88.0
Not Active	6380292	CHEMBL1837465	Inhibition of AKT phosphorylation in human HT-29 cells assessed as p-AKT level at 1 uM after 24 hrs by Western blotting	B	O=C1C(=O)N(CCCN=C=S)c2c(Br)cc(Br)cc21		CHEMBL1834924		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	6380293	CHEMBL1837465	Inhibition of AKT phosphorylation in human HT-29 cells assessed as p-AKT level at 1 uM after 24 hrs by Western blotting	B	N#CSCc1ccc(CN2C(=O)C(=O)c3cc(Br)cc(Br)c32)cc1		CHEMBL1834929		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	6380294	CHEMBL1837465	Inhibition of AKT phosphorylation in human HT-29 cells assessed as p-AKT level at 1 uM after 24 hrs by Western blotting	B	O=C1C(=O)N(Cc2ccc(CN=C=S)cc2)c2c(Br)cc(Br)cc21		CHEMBL1834931		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	6380295	CHEMBL1837466	Inhibition of AKT phosphorylation in human HT-29 cells assessed as p-AKT level at 2 uM after 24 hrs by Western blotting	B	O=C1C(=O)N(CCCN=C=S)c2c(Br)cc(Br)cc21		CHEMBL1834924		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	6380296	CHEMBL1837466	Inhibition of AKT phosphorylation in human HT-29 cells assessed as p-AKT level at 2 uM after 24 hrs by Western blotting	B	N#CSCc1ccc(CN2C(=O)C(=O)c3cc(Br)cc(Br)c32)cc1		CHEMBL1834929		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	6380297	CHEMBL1837466	Inhibition of AKT phosphorylation in human HT-29 cells assessed as p-AKT level at 2 uM after 24 hrs by Western blotting	B	O=C1C(=O)N(Cc2ccc(CN=C=S)cc2)c2c(Br)cc(Br)cc21		CHEMBL1834931		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	6384579	CHEMBL1837737	Inhibition of human AKT1 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCCc2ccccc2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1		CHEMBL1834114	<	Inhibition	%	35.0	CHEMBL4282	Homo sapiens	INH	%	35.0
	6384580	CHEMBL1837737	Inhibition of human AKT1 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCNc2ccccn2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CCCC1		CHEMBL1834318	<	Inhibition	%	35.0	CHEMBL4282	Homo sapiens	INH	%	35.0
	6384581	CHEMBL1837737	Inhibition of human AKT1 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	C[C@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1834323	<	Inhibition	%	35.0	CHEMBL4282	Homo sapiens	INH	%	35.0
	6384582	CHEMBL1837737	Inhibition of human AKT1 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	CC(C)[C@@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1834324	<	Inhibition	%	35.0	CHEMBL4282	Homo sapiens	INH	%	35.0
	6384583	CHEMBL1837737	Inhibition of human AKT1 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCNc2ccccn2)c2c3c1c(=O)c(C(=O)O)cn3C1(CCCC1)CO2		CHEMBL1834330	<	Inhibition	%	35.0	CHEMBL4282	Homo sapiens	INH	%	35.0
	6386325	CHEMBL1839916	Inhibition of recombinant PKBalpha	B	CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O		CHEMBL1834657	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	7567392	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7567851	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7567880	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7568348	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7568780	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7569365	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7569855	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7570318	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7570745	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7571356	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7571832	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7572295	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7572711	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7572880	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7573337	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7573813	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7574282	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	950.0	CHEMBL4282	Homo sapiens	Kd	nM	950.0
	7574690	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7574858	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7575319	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7575790	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7576255	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7576663	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7576832	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7577291	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7577769	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7578840	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	=	Kd	nM	76.0	CHEMBL4282	Homo sapiens	Kd	nM	76.0
	7579214	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7579664	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7580138	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7580165	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7580568	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7581198	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7581583	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7582028	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7582521	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7582921	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7583544	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7583941	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7584415	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7584877	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7585281	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7585874	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7586286	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7586757	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7587211	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7587812	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7588265	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7588736	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7589187	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7589358	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7589782	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	4400.0	CHEMBL4282	Homo sapiens	Kd	nM	4400.0
	7590249	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7590723	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7591174	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7591331	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7591753	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7592225	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7592698	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7593151	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7593298	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7593733	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7594205	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Kd	nM	2.2	CHEMBL4282	Homo sapiens	Kd	nM	2.2
	7594678	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7595266	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7595710	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7596184	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7596660	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7597238	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7597691	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7598192	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL4282	Homo sapiens	Kd	nM	10000.0
	7598634	CHEMBL1908691	Binding constant for AKT1 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	20.0	CHEMBL4282	Homo sapiens	Kd	nM	20.0
	7922720	CHEMBL1919215	Inhibition of human recombinant AKT1 at 0.5 uM by radiometric filter-binding assay	B	Clc1ccccc1Nc1nc2c(-c3nnc[nH]3)cccc2c2cnccc12		CHEMBL1915438	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	7931066	CHEMBL1919248	Inhibition of AKT1 relative to control	B	Cc1ccccc1Nc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916891	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	7937319	CHEMBL1918853	Inhibition of GST-tagged PKB/Akt1 incubated for 5 mins before eNOS substrate and ATP addition measured after 30 mins by kinase assay	B	CC(C)=CCc1cc(C(=O)/C=C/c2cccc(O)c2)c(O)cc1O		CHEMBL1915456	=	IC50	nM	85900.0	CHEMBL4282	Homo sapiens	IC50	uM	85.9
	7937320	CHEMBL1918853	Inhibition of GST-tagged PKB/Akt1 incubated for 5 mins before eNOS substrate and ATP addition measured after 30 mins by kinase assay	B	CC(C)=CCc1c(O)cc(O)c(C(=O)/C=C/c2ccc(O)cc2)c1O	Outside typical range	CHEMBL466143	=	IC50	nM	143900.0	CHEMBL4282	Homo sapiens	IC50	uM	143.9
Not Active	7937321	CHEMBL1918853	Inhibition of GST-tagged PKB/Akt1 incubated for 5 mins before eNOS substrate and ATP addition measured after 30 mins by kinase assay	B	CC(C)=CCc1cc2c(=O)cc(-c3ccc(O)cc3O)oc2cc1O		CHEMBL1915457		IC50			CHEMBL4282	Homo sapiens	IC50		
	7937322	CHEMBL1918853	Inhibition of GST-tagged PKB/Akt1 incubated for 5 mins before eNOS substrate and ATP addition measured after 30 mins by kinase assay	B	CC(C)=CCc1c(O)cc2oc(-c3ccc(O)cc3O)cc(=O)c2c1O		CHEMBL1915458	=	IC50	nM	54480.0	CHEMBL4282	Homo sapiens	IC50	uM	54.48
	7937323	CHEMBL1918853	Inhibition of GST-tagged PKB/Akt1 incubated for 5 mins before eNOS substrate and ATP addition measured after 30 mins by kinase assay	B	CC(C)=CCc1c(O)cc2oc(-c3ccc(O)c(O)c3)cc(=O)c2c1O		CHEMBL1915459	=	IC50	nM	5400.0	CHEMBL4282	Homo sapiens	IC50	uM	5.4
	7937324	CHEMBL1918853	Inhibition of GST-tagged PKB/Akt1 incubated for 5 mins before eNOS substrate and ATP addition measured after 30 mins by kinase assay	B	CC(C)=CCc1c(O)cc(O)c2c(=O)cc(-c3ccc(O)c(O)c3)oc12		CHEMBL1783943	=	IC50	nM	3900.0	CHEMBL4282	Homo sapiens	IC50	uM	3.9
	7937325	CHEMBL1918853	Inhibition of GST-tagged PKB/Akt1 incubated for 5 mins before eNOS substrate and ATP addition measured after 30 mins by kinase assay	B	CC(=O)Nc1cccc(-n2nnc(SCC(=O)NCc3cccs3)n2)c1		CHEMBL1915460	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
Not Active	7937326	CHEMBL1918853	Inhibition of GST-tagged PKB/Akt1 incubated for 5 mins before eNOS substrate and ATP addition measured after 30 mins by kinase assay	B	Cc1ccc(S(=O)(=O)OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(NC(=O)C(C)C)nc43)C[C@H]2O)cc1		CHEMBL1915461		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Active	7937327	CHEMBL1918853	Inhibition of GST-tagged PKB/Akt1 incubated for 5 mins before eNOS substrate and ATP addition measured after 30 mins by kinase assay	B	O=c1cc(CSc2nnc(O)n2C2Cc3ccccc3C2)c2ccc(O)cc2o1		CHEMBL387393		IC50			CHEMBL4282	Homo sapiens	IC50		
	7937328	CHEMBL1918853	Inhibition of GST-tagged PKB/Akt1 incubated for 5 mins before eNOS substrate and ATP addition measured after 30 mins by kinase assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	IC50	nM	1800.0	CHEMBL4282	Homo sapiens	IC50	uM	1.8
	7937329	CHEMBL1918852	Inhibition of GST-tagged PKB/Akt1 incubated for 5 mins before eNOS substrate and ATP addition at > 50 uM measured after 30 mins by kinase assay	B	CC(=O)Nc1cccc(-n2nnc(SCC(=O)NCc3cccs3)n2)c1		CHEMBL1915460	=	Inhibition	%	19.6	CHEMBL4282	Homo sapiens	INH	%	19.6
	7939951	CHEMBL1919620	Inhibition of human PKBalpha	B	[O-][n+]1ccc2c(-c3ccc(F)cc3Cl)ccnc2c1-c1c(Cl)cccc1Cl		CHEMBL1916359	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	7943721	CHEMBL1921564	Inhibition of AKT1	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	4.95	CHEMBL4282	Homo sapiens	IC50	nM	4.95
	7943761	CHEMBL1921418	Inhibition of AKT1 at 10 uM	B	O=C1CC(c2cccc(NC(=O)c3ccc(Cl)c(C(F)(F)F)c3)c2)=Nc2cnn(Cc3ccccc3)c2N1		CHEMBL1917776	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
Not Active	7950037	CHEMBL1924574	Inhibition of AKT at 5 uM	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2CCN(C)C)c1		CHEMBL1922038		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	7950038	CHEMBL1924574	Inhibition of AKT at 5 uM	B	COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2CCCO)c1		CHEMBL1922039		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	7951318	CHEMBL1926219	Inhibition of recombinant human AKT1 using GSK3 (amino acids 14 to 27) as substrate	B	Cc1ccc(O)cc1CC[C@@H]1[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/CC(C)C		CHEMBL1922224	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	7951319	CHEMBL1926219	Inhibition of recombinant human AKT1 using GSK3 (amino acids 14 to 27) as substrate	B	Cc1ccc(O)cc1CC[C@@H]1C(=O)CC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/CC(C)C		CHEMBL518060	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	7951320	CHEMBL1926219	Inhibition of recombinant human AKT1 using GSK3 (amino acids 14 to 27) as substrate	B	C=C(CC[C@@H](C)[C@H]1CC[C@H]2[C@H](CCc3cc(O)ccc3C)C(=O)CC[C@@]21C)C(C)C		CHEMBL1922225	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	7951321	CHEMBL1926219	Inhibition of recombinant human AKT1 using GSK3 (amino acids 14 to 27) as substrate	B	Cc1ccc(O)cc1CC[C@@H]1C(=O)CC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C		CHEMBL456936	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	7951322	CHEMBL1926219	Inhibition of recombinant human AKT1 using GSK3 (amino acids 14 to 27) as substrate	B	Cc1ccc(O)cc1CC[C@H]1[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC[C@H]1O		CHEMBL517956	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	7951323	CHEMBL1926219	Inhibition of recombinant human AKT1 using GSK3 (amino acids 14 to 27) as substrate	B	Cc1ccc(O)cc1CC[C@@H]1C(=O)CC[C@@]2(C)[C@H]1C[C@H](O)[C@@H]2[C@H](C)CCCC(C)C		CHEMBL456294	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	7951324	CHEMBL1926219	Inhibition of recombinant human AKT1 using GSK3 (amino acids 14 to 27) as substrate	B	C=C(CC[C@@H](C)[C@H]1CC[C@H]2[C@H](CCc3cc(O)ccc3C)[C@H](O)CC[C@@]21C)C(C)C		CHEMBL515982	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	7951325	CHEMBL1926219	Inhibition of recombinant human AKT1 using GSK3 (amino acids 14 to 27) as substrate	B	Cc1ccc(O)cc1CC[C@H]1[C@@H]2C[C@H](O)[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC[C@H]1O		CHEMBL464351	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	7954605	CHEMBL1924334	Inhibition of His-tagged ATP-binding domain of AKT1 assessed as residual activity by measuring GRPRTSSFAEG crosstide phosphorylation at 50 uM using [33P]ATP	B	CC(C)[C@H](NC(=O)[C@@H]1CC[C@H]2[C@H](NC(=O)CNC(=N)N)COC(=O)N12)C(=O)NC(Cc1ccccc1)C(=O)NCc1ccccc1		CHEMBL1922691	=	Activity	%	89.4	CHEMBL4282	Homo sapiens	Activity	%	89.4
	7954606	CHEMBL1924334	Inhibition of His-tagged ATP-binding domain of AKT1 assessed as residual activity by measuring GRPRTSSFAEG crosstide phosphorylation at 50 uM using [33P]ATP	B	CC(C)[C@H](NC(=O)[C@@H]1CC[C@H]2[C@H](NC(=O)CCCCNC(=N)N)COC(=O)N12)C(=O)NC(Cc1ccccc1)C(=O)NCc1ccccc1		CHEMBL1922692	=	Activity	%	21.1	CHEMBL4282	Homo sapiens	Activity	%	21.1
	7954607	CHEMBL1924334	Inhibition of His-tagged ATP-binding domain of AKT1 assessed as residual activity by measuring GRPRTSSFAEG crosstide phosphorylation at 50 uM using [33P]ATP	B	CC(C)[C@H](NC(=O)[C@@H]1CC[C@H]2[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)c3ccccc3)COC(=O)N12)C(=O)NC(Cc1ccccc1)C(=O)NCc1ccccc1		CHEMBL1922693	=	Activity	%	14.6	CHEMBL4282	Homo sapiens	Activity	%	14.6
	7954608	CHEMBL1924334	Inhibition of His-tagged ATP-binding domain of AKT1 assessed as residual activity by measuring GRPRTSSFAEG crosstide phosphorylation at 50 uM using [33P]ATP	B	CC(C)[C@H](NC(=O)[C@@H]1CC[C@H]2[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)Cc3ccccc3)COC(=O)N12)C(=O)NC(Cc1ccccc1)C(=O)NCc1ccccc1		CHEMBL1922694	=	Activity	%	16.8	CHEMBL4282	Homo sapiens	Activity	%	16.8
	7954609	CHEMBL1924334	Inhibition of His-tagged ATP-binding domain of AKT1 assessed as residual activity by measuring GRPRTSSFAEG crosstide phosphorylation at 50 uM using [33P]ATP	B	CC(C)[C@H](NC(=O)[C@@H]1CC[C@H]2[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)OCc3ccccc3)COC(=O)N12)C(=O)NC(Cc1ccccc1)C(=O)NCc1ccccc1		CHEMBL1922695	=	Activity	%	2.2	CHEMBL4282	Homo sapiens	Activity	%	2.2
Dose-dependent effect	7954610	CHEMBL1924333	Inhibition of His-tagged ATP-binding domain of AKT1 assessed as GRPRTSSFAEG crosstide phosphorylation using [33P]ATP	B	CC(C)[C@H](NC(=O)[C@@H]1CC[C@H]2[C@H](NC(=O)CCCCNC(=N)N)COC(=O)N12)C(=O)NC(Cc1ccccc1)C(=O)NCc1ccccc1		CHEMBL1922692		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	7954611	CHEMBL1924333	Inhibition of His-tagged ATP-binding domain of AKT1 assessed as GRPRTSSFAEG crosstide phosphorylation using [33P]ATP	B	CC(C)[C@H](NC(=O)[C@@H]1CC[C@H]2[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)c3ccccc3)COC(=O)N12)C(=O)NC(Cc1ccccc1)C(=O)NCc1ccccc1		CHEMBL1922693		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	7954612	CHEMBL1924333	Inhibition of His-tagged ATP-binding domain of AKT1 assessed as GRPRTSSFAEG crosstide phosphorylation using [33P]ATP	B	CC(C)[C@H](NC(=O)[C@@H]1CC[C@H]2[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)Cc3ccccc3)COC(=O)N12)C(=O)NC(Cc1ccccc1)C(=O)NCc1ccccc1		CHEMBL1922694		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	7954613	CHEMBL1924333	Inhibition of His-tagged ATP-binding domain of AKT1 assessed as GRPRTSSFAEG crosstide phosphorylation using [33P]ATP	B	CC(C)[C@H](NC(=O)[C@@H]1CC[C@H]2[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)OCc3ccccc3)COC(=O)N12)C(=O)NC(Cc1ccccc1)C(=O)NCc1ccccc1		CHEMBL1922695		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	7954614	CHEMBL1924333	Inhibition of His-tagged ATP-binding domain of AKT1 assessed as GRPRTSSFAEG crosstide phosphorylation using [33P]ATP	B	CC(C)[C@H](NC(=O)[C@@H]1CC[C@H]2[C@H](NC(=O)CCCCNC(=N)N)COC(=O)N12)C(=O)NC(Cc1ccccc1)C(=O)NCc1ccccc1		CHEMBL1922692	=	IC50	nM	40200.0	CHEMBL4282	Homo sapiens	IC50	uM	40.2
	7954615	CHEMBL1924333	Inhibition of His-tagged ATP-binding domain of AKT1 assessed as GRPRTSSFAEG crosstide phosphorylation using [33P]ATP	B	CC(C)[C@H](NC(=O)[C@@H]1CC[C@H]2[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)c3ccccc3)COC(=O)N12)C(=O)NC(Cc1ccccc1)C(=O)NCc1ccccc1		CHEMBL1922693	=	IC50	nM	16300.0	CHEMBL4282	Homo sapiens	IC50	uM	16.3
	7954616	CHEMBL1924333	Inhibition of His-tagged ATP-binding domain of AKT1 assessed as GRPRTSSFAEG crosstide phosphorylation using [33P]ATP	B	CC(C)[C@H](NC(=O)[C@@H]1CC[C@H]2[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)Cc3ccccc3)COC(=O)N12)C(=O)NC(Cc1ccccc1)C(=O)NCc1ccccc1		CHEMBL1922694	=	IC50	nM	15000.0	CHEMBL4282	Homo sapiens	IC50	uM	15.0
	7954617	CHEMBL1924333	Inhibition of His-tagged ATP-binding domain of AKT1 assessed as GRPRTSSFAEG crosstide phosphorylation using [33P]ATP	B	CC(C)[C@H](NC(=O)[C@@H]1CC[C@H]2[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)OCc3ccccc3)COC(=O)N12)C(=O)NC(Cc1ccccc1)C(=O)NCc1ccccc1		CHEMBL1922695	=	IC50	nM	3100.0	CHEMBL4282	Homo sapiens	IC50	uM	3.1
	7959663	CHEMBL1932322	Inhibition of AKT1	B	CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O		CHEMBL1929238	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	7959664	CHEMBL1932322	Inhibition of AKT1	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	7969781	CHEMBL1929882	Inhibition of PKBalpha assessed as residual activity at 10 uM using [33P-ATP] by radiometric filter binding assay	B	Cc1ccc(F)cc1-c1nc2[nH]nc(N)c2c2c1CCCC2		CHEMBL1927262	=	Activity	%	79.0	CHEMBL4282	Homo sapiens	Activity	%	79.0
	7970410	CHEMBL1930207	Inhibition of AKT1 at 10 uM	B	NCCN1C(=O)S/C(=C\CCC2CCCCC2)C1=O		CHEMBL1929247	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	7984056	CHEMBL1936504	Inhibition of AKT1	B	CN1CCN(c2ccc(OC(F)(F)F)c(Nc3nccc(-c4cc(C(N)=O)cn4C)n3)c2)CC1		CHEMBL1933576	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	7984057	CHEMBL1936504	Inhibition of AKT1	B	CN1CCN(c2ccc(OC(F)(F)F)c(Nc3nccc(-c4cc5c(n4C)CCNC5=O)n3)c2)CC1		CHEMBL1933582	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	7987180	CHEMBL1935935	Inhibition of AKT1	B	C[C@@H]1CCC(N2CC[C@]3(CN(C(=O)c4cc5ccc(F)cc5[nH]4)c4ccccc43)C2)CN1		CHEMBL1933552	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	7992172	CHEMBL1935984	Inhibition of AKT1 at 1 uM	B	CN(c1ccccc1-c1cc(Cl)c2cnc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)nn12)S(C)(=O)=O		CHEMBL1934353	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
	7997523	CHEMBL1943536	Inhibition of AKT phosphorylation in human SNU449 cells at 25 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(-c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940183	=	Ratio		1.2	CHEMBL4282	Homo sapiens	Ratio		1.2
	7997524	CHEMBL1943536	Inhibition of AKT phosphorylation in human SNU449 cells at 25 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940184	=	Ratio		1.1	CHEMBL4282	Homo sapiens	Ratio		1.1
	7997525	CHEMBL1943537	Inhibition of AKT phosphorylation in human SNU449 cells at 50 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(-c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940183	=	Ratio		0.26	CHEMBL4282	Homo sapiens	Ratio		0.26
	7997526	CHEMBL1943537	Inhibition of AKT phosphorylation in human SNU449 cells at 50 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940184	=	Ratio		0.58	CHEMBL4282	Homo sapiens	Ratio		0.58
	7997527	CHEMBL1943538	Inhibition of AKT phosphorylation in human SNU449 cells at 100 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(-c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940183	=	Ratio		0.07	CHEMBL4282	Homo sapiens	Ratio		0.07
	7997528	CHEMBL1943538	Inhibition of AKT phosphorylation in human SNU449 cells at 100 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940184	=	Ratio		0.39	CHEMBL4282	Homo sapiens	Ratio		0.39
	7997529	CHEMBL1943539	Inhibition of AKT phosphorylation in human SNU449 cells at 25 uM after 72 hrs by Western blotting relative to beta-actin	B	Cc1cccc(-c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940183	=	Ratio		2.2	CHEMBL4282	Homo sapiens	Ratio		2.2
	7997530	CHEMBL1943539	Inhibition of AKT phosphorylation in human SNU449 cells at 25 uM after 72 hrs by Western blotting relative to beta-actin	B	Cc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940184	=	Ratio		1.9	CHEMBL4282	Homo sapiens	Ratio		1.9
	7997531	CHEMBL1943540	Inhibition of AKT phosphorylation in human SNU449 cells at 50 uM after 72 hrs by Western blotting relative to beta-actin	B	Cc1cccc(-c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940183	=	Ratio		0.32	CHEMBL4282	Homo sapiens	Ratio		0.32
	7997532	CHEMBL1943540	Inhibition of AKT phosphorylation in human SNU449 cells at 50 uM after 72 hrs by Western blotting relative to beta-actin	B	Cc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940184	=	Ratio		0.53	CHEMBL4282	Homo sapiens	Ratio		0.53
	7997533	CHEMBL1943541	Inhibition of AKT phosphorylation in human SNU449 cells at 100 uM after 72 hrs by Western blotting relative to beta-actin	B	Cc1cccc(-c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940183	=	Ratio		0.5	CHEMBL4282	Homo sapiens	Ratio		0.5
	7997534	CHEMBL1943541	Inhibition of AKT phosphorylation in human SNU449 cells at 100 uM after 72 hrs by Western blotting relative to beta-actin	B	Cc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940184	=	Ratio		0.64	CHEMBL4282	Homo sapiens	Ratio		0.64
	7997535	CHEMBL1943628	Inhibition of AKT in human SNU449 cells assessed as phosphorylated RpS6 level at 50 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(-c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940183	=	Ratio		0.5	CHEMBL4282	Homo sapiens	Ratio		0.5
	7997536	CHEMBL1943628	Inhibition of AKT in human SNU449 cells assessed as phosphorylated RpS6 level at 50 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940184	=	Ratio		0.64	CHEMBL4282	Homo sapiens	Ratio		0.64
	7997537	CHEMBL1943629	Inhibition of AKT in human SNU449 cells assessed as phosphorylated RpS6 level at 50 uM after 72 hrs by Western blotting relative to beta-actin	B	Cc1cccc(-c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940183	=	Ratio		0.29	CHEMBL4282	Homo sapiens	Ratio		0.29
	7997538	CHEMBL1943629	Inhibition of AKT in human SNU449 cells assessed as phosphorylated RpS6 level at 50 uM after 72 hrs by Western blotting relative to beta-actin	B	Cc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940184	=	Ratio		0.49	CHEMBL4282	Homo sapiens	Ratio		0.49
	7997539	CHEMBL1943630	Inhibition of AKT in human SNU449 cells assessed as phosphorylated GSK3-beta level at 50 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(-c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940183	=	Ratio		0.18	CHEMBL4282	Homo sapiens	Ratio		0.18
	7997540	CHEMBL1943630	Inhibition of AKT in human SNU449 cells assessed as phosphorylated GSK3-beta level at 50 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940184	=	Ratio		0.48	CHEMBL4282	Homo sapiens	Ratio		0.48
	7997541	CHEMBL1943631	Inhibition of AKT in human SNU449 cells assessed as phosphorylated GSK3-beta level at 50 uM after 72 hrs by Western blotting relative to beta-actin	B	Cc1cccc(-c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940183	=	Ratio		0.93	CHEMBL4282	Homo sapiens	Ratio		0.93
	7997542	CHEMBL1943631	Inhibition of AKT in human SNU449 cells assessed as phosphorylated GSK3-beta level at 50 uM after 72 hrs by Western blotting relative to beta-actin	B	Cc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940184	=	Ratio		0.6	CHEMBL4282	Homo sapiens	Ratio		0.6
	7997543	CHEMBL1943632	Inhibition of AKT in human SNU449 cells assessed as phosphorylated beta-casein level at 50 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(-c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940183	=	Ratio		0.57	CHEMBL4282	Homo sapiens	Ratio		0.57
	7997544	CHEMBL1943632	Inhibition of AKT in human SNU449 cells assessed as phosphorylated beta-casein level at 50 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940184	=	Ratio		0.41	CHEMBL4282	Homo sapiens	Ratio		0.41
	7997545	CHEMBL1943633	Inhibition of AKT in human SNU449 cells assessed as phosphorylated beta-casein level at 50 uM after 72 hrs by Western blotting relative to beta-actin	B	Cc1cccc(-c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940183	=	Ratio		0.75	CHEMBL4282	Homo sapiens	Ratio		0.75
	7997546	CHEMBL1943633	Inhibition of AKT in human SNU449 cells assessed as phosphorylated beta-casein level at 50 uM after 72 hrs by Western blotting relative to beta-actin	B	Cc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940184	=	Ratio		0.46	CHEMBL4282	Homo sapiens	Ratio		0.46
	7997547	CHEMBL1943634	Inhibition of AKT in human SNU449 cells assessed as phosphorylated ERK1/2 level at 50 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(-c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940183	=	Ratio		1.5	CHEMBL4282	Homo sapiens	Ratio		1.5
	7997548	CHEMBL1943634	Inhibition of AKT in human SNU449 cells assessed as phosphorylated ERK1/2 level at 50 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940184	=	Ratio		2.0	CHEMBL4282	Homo sapiens	Ratio		2.0
	7997549	CHEMBL1943635	Inhibition of AKT in human SNU449 cells assessed as phosphorylated ERK1/2 level at 50 uM after 72 hrs by Western blotting relative to beta-actin	B	Cc1cccc(-c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940183	=	Ratio		1.1	CHEMBL4282	Homo sapiens	Ratio		1.1
	7997550	CHEMBL1943635	Inhibition of AKT in human SNU449 cells assessed as phosphorylated ERK1/2 level at 50 uM after 72 hrs by Western blotting relative to beta-actin	B	Cc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940184	=	Ratio		0.91	CHEMBL4282	Homo sapiens	Ratio		0.91
	7997565	CHEMBL1942319	Inhibition of AKT in human SNU449 cells assessed as phosphorylated MDM2 level at 50 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(-c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940183	=	Ratio		0.4	CHEMBL4282	Homo sapiens	Ratio		0.4
	7997566	CHEMBL1942319	Inhibition of AKT in human SNU449 cells assessed as phosphorylated MDM2 level at 50 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940184	=	Ratio		0.65	CHEMBL4282	Homo sapiens	Ratio		0.65
	7997567	CHEMBL1942320	Inhibition of AKT in human SNU449 cells assessed as total MDM2 protein level at 50 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(-c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940183	=	Ratio		1.3	CHEMBL4282	Homo sapiens	Ratio		1.3
	7997568	CHEMBL1942320	Inhibition of AKT in human SNU449 cells assessed as total MDM2 protein level at 50 uM after 48 hrs by Western blotting relative to beta-actin	B	Cc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(N)cc3)n(-c3ccc(N)cc3)n2)c1C		CHEMBL1940184	=	Ratio		1.4	CHEMBL4282	Homo sapiens	Ratio		1.4
	8002020	CHEMBL1942065	Inhibition of His-tagged AKT1 using 5FAM-GRPRTSSFAEGCONH2 as substrate by fluorescence based assay	B	CC(C)n1cc(C(=O)c2cncc(N[C@@H]3CCC[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc21		CHEMBL1940246	=	Ki	nM	210.0	CHEMBL4282	Homo sapiens	Ki	nM	210.0
	8002021	CHEMBL1942065	Inhibition of His-tagged AKT1 using 5FAM-GRPRTSSFAEGCONH2 as substrate by fluorescence based assay	B	CC(C)n1cc(C(=O)c2cncc(N[C@@H]3COC[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc21		CHEMBL1938415	=	Ki	nM	260.0	CHEMBL4282	Homo sapiens	Ki	nM	260.0
	8002022	CHEMBL1942065	Inhibition of His-tagged AKT1 using 5FAM-GRPRTSSFAEGCONH2 as substrate by fluorescence based assay	B	CC(C)n1cc(C(=O)c2cncc(N[C@@H]3CCO[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc21		CHEMBL1940248	=	Ki	nM	230.0	CHEMBL4282	Homo sapiens	Ki	nM	230.0
	8002023	CHEMBL1942065	Inhibition of His-tagged AKT1 using 5FAM-GRPRTSSFAEGCONH2 as substrate by fluorescence based assay	B	CC(C)n1cc(C(=O)c2cncc(N[C@@H]3CNC[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc21		CHEMBL1940249	=	Ki	nM	10.0	CHEMBL4282	Homo sapiens	Ki	nM	10.0
	8002024	CHEMBL1942065	Inhibition of His-tagged AKT1 using 5FAM-GRPRTSSFAEGCONH2 as substrate by fluorescence based assay	B	CC(C)n1cc(C(=O)c2cncc(N[C@@H]3CCN[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc21		CHEMBL1940250	=	Ki	nM	100.0	CHEMBL4282	Homo sapiens	Ki	nM	100.0
	8002025	CHEMBL1942065	Inhibition of His-tagged AKT1 using 5FAM-GRPRTSSFAEGCONH2 as substrate by fluorescence based assay	B	CC(C)n1cc(C(=O)c2cncc(N[C@@H]3CCN(C=O)[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc21		CHEMBL1940251	=	Ki	nM	170.0	CHEMBL4282	Homo sapiens	Ki	nM	170.0
	8002026	CHEMBL1942065	Inhibition of His-tagged AKT1 using 5FAM-GRPRTSSFAEGCONH2 as substrate by fluorescence based assay	B	CC(=O)N1CC[C@@H](Nc2cncc(C(=O)c3cn(C(C)C)c4ncnc(N)c34)n2)[C@H]1c1ccc(F)cc1		CHEMBL1940252	=	Ki	nM	360.0	CHEMBL4282	Homo sapiens	Ki	nM	360.0
	8002027	CHEMBL1942065	Inhibition of His-tagged AKT1 using 5FAM-GRPRTSSFAEGCONH2 as substrate by fluorescence based assay	B	CC(=O)N1CC[C@@H](Nc2cncc(C(=O)c3cn(C(C)C)c4ncnc(N)c34)n2)[C@H]1c1ccccc1		CHEMBL1940253	=	Ki	nM	1100.0	CHEMBL4282	Homo sapiens	Ki	nM	1100.0
	8002086	CHEMBL1942178	Inhibition of AKT1 at 1 uM	B	CC(C)n1cc(C(=O)c2cncc(N[C@@H]3CCN(C=O)[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc21		CHEMBL1940251	=	Inhibition	%	62.0	CHEMBL4282	Homo sapiens	INH	%	62.0
	8002087	CHEMBL1942178	Inhibition of AKT1 at 1 uM	B	CC(=O)N1CC[C@@H](Nc2cncc(C(=O)c3cn(C(C)C)c4ncnc(N)c34)n2)[C@H]1c1ccc(F)cc1		CHEMBL1940252	=	Inhibition	%	57.0	CHEMBL4282	Homo sapiens	INH	%	57.0
	8002088	CHEMBL1942178	Inhibition of AKT1 at 1 uM	B	CC(=O)N1CC[C@@H](Nc2cncc(C(=O)c3cn(C(C)C)c4ncnc(N)c34)n2)[C@H]1c1ccccc1		CHEMBL1940253	=	Inhibition	%	15.0	CHEMBL4282	Homo sapiens	INH	%	15.0
	8004482	CHEMBL1943617	Inhibition of AKT-1 at 1 uM	B	O=c1c2ccccc2[se]n1-c1ccccc1		CHEMBL51085	=	Inhibition	%	22.0	CHEMBL4282	Homo sapiens	INH	%	22.0
	8004526	CHEMBL1943617	Inhibition of AKT-1 at 1 uM	B	CC(=O)OC[C@H]1O[C@@H](O[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](n3[se]c4ccccc4c3=O)O[C@@H]2COC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O		CHEMBL1940993	=	Inhibition	%	63.0	CHEMBL4282	Homo sapiens	INH	%	63.0
	8004557	CHEMBL1944084	Inhibition of AKT-1	B	CC(=O)OC[C@H]1O[C@@H](O[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](n3[se]c4ccccc4c3=O)O[C@@H]2COC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O		CHEMBL1940993	=	IC50	nM	830.0	CHEMBL4282	Homo sapiens	IC50	uM	0.83
	8004580	CHEMBL1943617	Inhibition of AKT-1 at 1 uM	B	CC(=O)OC[C@H]1O[C@@H](NC(=O)CCCn2[se]c3ccccc3c2=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O		CHEMBL1940997	=	Inhibition	%	67.0	CHEMBL4282	Homo sapiens	INH	%	67.0
	8005221	CHEMBL1944084	Inhibition of AKT-1	B	CC(=O)OC[C@H]1O[C@@H](NC(=O)CCCn2[se]c3ccccc3c2=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O		CHEMBL1940997	=	IC50	nM	800.0	CHEMBL4282	Homo sapiens	IC50	uM	0.8
	8005233	CHEMBL1943617	Inhibition of AKT-1 at 1 uM	B	O=C(CCCn1[se]c2ccccc2c1=O)N[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL1940999	=	Inhibition	%	60.0	CHEMBL4282	Homo sapiens	INH	%	60.0
	8005264	CHEMBL1944084	Inhibition of AKT-1	B	O=C(CCCn1[se]c2ccccc2c1=O)N[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL1940999	=	IC50	nM	880.0	CHEMBL4282	Homo sapiens	IC50	uM	0.88
Active	8012295	CHEMBL1941711	Inhibition of AKT1 at 10 uM by colorimetric analysis	B	Clc1ccc(-n2cc(-c3ccncc3)nn2)cc1		CHEMBL1938953		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	8012296	CHEMBL1941711	Inhibition of AKT1 at 10 uM by colorimetric analysis	B	Clc1cccc(-n2cc(-c3ccncc3)nn2)c1		CHEMBL1938954		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	8012297	CHEMBL1941711	Inhibition of AKT1 at 10 uM by colorimetric analysis	B	Clc1ccc(-n2nncc2-c2ccncc2)cc1		CHEMBL62965		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	8012298	CHEMBL1941711	Inhibition of AKT1 at 10 uM by colorimetric analysis	B	Clc1cccc(-n2nncc2-c2ccncc2)c1		CHEMBL303351		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	8013071	CHEMBL1947858	Inhibition of PKBalpha using ATP as substrate	B	Cn1c2c(c3ccc(Cl)c(Cl)c31)C(C#N)C1(CCNCC1)NC2=O		CHEMBL1945559	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	8018873	CHEMBL1948963	Inhibition of PKB-alpha assessed as activity remaining at 10 uM	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CC1CCOCC1		CHEMBL1945953	=	Activity	%	97.0	CHEMBL4282	Homo sapiens	Activity	%	97.0
	8018874	CHEMBL1948963	Inhibition of PKB-alpha assessed as activity remaining at 10 uM	B	CC(C)(O)c1ccc(-c2cnc3[nH]c(=O)n(CC4CCCCC4)c3n2)cc1		CHEMBL1945950	=	Activity	%	94.0	CHEMBL4282	Homo sapiens	Activity	%	94.0
	8018875	CHEMBL1948963	Inhibition of PKB-alpha assessed as activity remaining at 10 uM	B	O=c1[nH]c2ncc(-c3ccc4[nH]cnc4c3)nc2n1CC1CCCCC1		CHEMBL1946262	=	Activity	%	92.0	CHEMBL4282	Homo sapiens	Activity	%	92.0
	8046162	CHEMBL1960376	Inhibition of AKT1	B	COc1ccc(-c2ocnc2C(=O)NCc2ccncc2)cc1		CHEMBL1957085	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	8047076	CHEMBL1958811	Inhibition of AKT1 at 1 uM	B	CN1CCN(c2ccc(Nc3nc(N)c(C(=O)c4ccc5c(c4)OCCO5)s3)cc2)CC1		CHEMBL1956070	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	8047307	CHEMBL1960791	Inhibition of AKT1	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21		CHEMBL220241	=	IC50	nM	955.0	CHEMBL4282	Homo sapiens	IC50	nM	955.0
	8047308	CHEMBL1960791	Inhibition of AKT1	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21		CHEMBL1956071	=	IC50	nM	324.0	CHEMBL4282	Homo sapiens	IC50	nM	324.0
	8048829	CHEMBL1959600	Inhibition of AKT1 at 5 to 10 uM	B	CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL1957497	=	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	8048830	CHEMBL1959600	Inhibition of AKT1 at 5 to 10 uM	B	CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cccc5[nH]ncc45)cn3c2Br)CC1		CHEMBL1957498	=	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	8048831	CHEMBL1959600	Inhibition of AKT1 at 5 to 10 uM	B	CS(=O)(=O)N1CCN(Cc2cn3c(C#N)c(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL1957499	=	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	8048832	CHEMBL1959600	Inhibition of AKT1 at 5 to 10 uM	B	CS(=O)(=O)N1CCN(Cc2cn3c(Cl)c(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL1957500	=	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	8048833	CHEMBL1959600	Inhibition of AKT1 at 5 to 10 uM	B	CNC(=O)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1		CHEMBL1957502	=	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	8048834	CHEMBL1959600	Inhibition of AKT1 at 5 to 10 uM	B	O=C(NCCN1CCOCC1)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1		CHEMBL1957504	=	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	8048835	CHEMBL1959600	Inhibition of AKT1 at 5 to 10 uM	B	CN(C)CCCNC(=O)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1		CHEMBL1957505	=	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	8048836	CHEMBL1959600	Inhibition of AKT1 at 5 to 10 uM	B	COCCCNC(=O)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1		CHEMBL1957508	=	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	8060097	CHEMBL1961273	Inhibition of human recombinant AKT1 expressed in Sf9 cells using GSK3(14-27) as substrate after 80 mins by scintillation counting	B	CC(C)n1c2c(c3c1-c1ccccc1C3=O)C(=O)CCC2		CHEMBL1957190	>	IC50	nM	35000.0	CHEMBL4282	Homo sapiens	IC50	uM	35.0
	8060098	CHEMBL1961273	Inhibition of human recombinant AKT1 expressed in Sf9 cells using GSK3(14-27) as substrate after 80 mins by scintillation counting	B	O=c1oc2c(O)c(O)cc3c(=O)oc4c(O)c(O)cc1c4c23		CHEMBL6246	=	IC50	nM	3340.0	CHEMBL4282	Homo sapiens	IC50	uM	3.34
	8061218	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	0.06	CHEMBL4282	Homo sapiens	Inhibition	%	0.06
	8061395	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-2.35	CHEMBL4282	Homo sapiens	Inhibition	%	-2.35
	8061619	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.26	CHEMBL4282	Homo sapiens	Inhibition	%	0.26
	8061726	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	1.05	CHEMBL4282	Homo sapiens	Inhibition	%	1.05
	8062141	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	0.22	CHEMBL4282	Homo sapiens	Inhibition	%	0.22
	8062257	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	0.27	CHEMBL4282	Homo sapiens	Inhibition	%	0.27
	8062643	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	0.19	CHEMBL4282	Homo sapiens	Inhibition	%	0.19
	8062965	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-0.54	CHEMBL4282	Homo sapiens	Inhibition	%	-0.54
	8063097	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	0.47	CHEMBL4282	Homo sapiens	Inhibition	%	0.47
	8063488	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.27	CHEMBL4282	Homo sapiens	Inhibition	%	0.27
	8063596	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	0.43	CHEMBL4282	Homo sapiens	Inhibition	%	0.43
	8063820	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	0.86	CHEMBL4282	Homo sapiens	Inhibition	%	0.86
	8064002	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	0.59	CHEMBL4282	Homo sapiens	Inhibition	%	0.59
	8064117	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	0.36	CHEMBL4282	Homo sapiens	Inhibition	%	0.36
	8064341	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	0.51	CHEMBL4282	Homo sapiens	Inhibition	%	0.51
	8064551	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-0.11	CHEMBL4282	Homo sapiens	Inhibition	%	-0.11
	8064689	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	-0.43	CHEMBL4282	Homo sapiens	Inhibition	%	-0.43
	8064913	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	8065079	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	-0.03	CHEMBL4282	Homo sapiens	Inhibition	%	-0.03
	8065419	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	0.46	CHEMBL4282	Homo sapiens	Inhibition	%	0.46
	8065594	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	1.44	CHEMBL4282	Homo sapiens	Inhibition	%	1.44
	8065933	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	7.63	CHEMBL4282	Homo sapiens	Inhibition	%	7.63
	8066143	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	-0.45	CHEMBL4282	Homo sapiens	Inhibition	%	-0.45
	8066503	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	0.23	CHEMBL4282	Homo sapiens	Inhibition	%	0.23
	8066669	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	0.55	CHEMBL4282	Homo sapiens	Inhibition	%	0.55
	8067017	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	0.17	CHEMBL4282	Homo sapiens	Inhibition	%	0.17
	8067192	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	1.04	CHEMBL4282	Homo sapiens	Inhibition	%	1.04
	8067537	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	0.06	CHEMBL4282	Homo sapiens	Inhibition	%	0.06
	8067747	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	0.43	CHEMBL4282	Homo sapiens	Inhibition	%	0.43
	8068106	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	0.24	CHEMBL4282	Homo sapiens	Inhibition	%	0.24
	8068270	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	Inhibition	%	0.0
	8068494	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	-0.69	CHEMBL4282	Homo sapiens	Inhibition	%	-0.69
	8068619	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	-0.22	CHEMBL4282	Homo sapiens	Inhibition	%	-0.22
	8068793	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	0.21	CHEMBL4282	Homo sapiens	Inhibition	%	0.21
	8069017	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	Inhibition	%	1.0
	8069142	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	1.28	CHEMBL4282	Homo sapiens	Inhibition	%	1.28
	8069437	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	-0.02	CHEMBL4282	Homo sapiens	Inhibition	%	-0.02
	8069822	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	0.38	CHEMBL4282	Homo sapiens	Inhibition	%	0.38
	8069948	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	0.69	CHEMBL4282	Homo sapiens	Inhibition	%	0.69
	8070344	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	0.09	CHEMBL4282	Homo sapiens	Inhibition	%	0.09
	8070469	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	0.13	CHEMBL4282	Homo sapiens	Inhibition	%	0.13
	8070693	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	0.07	CHEMBL4282	Homo sapiens	Inhibition	%	0.07
	8070767	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	0.16	CHEMBL4282	Homo sapiens	Inhibition	%	0.16
	8070991	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	0.52	CHEMBL4282	Homo sapiens	Inhibition	%	0.52
	8071148	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	0.03	CHEMBL4282	Homo sapiens	Inhibition	%	0.03
	8071274	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	-0.73	CHEMBL4282	Homo sapiens	Inhibition	%	-0.73
	8071498	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	0.02	CHEMBL4282	Homo sapiens	Inhibition	%	0.02
	8071671	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	0.59	CHEMBL4282	Homo sapiens	Inhibition	%	0.59
	8072020	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-0.37	CHEMBL4282	Homo sapiens	Inhibition	%	-0.37
	8072101	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	0.76	CHEMBL4282	Homo sapiens	Inhibition	%	0.76
	8072334	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	0.1	CHEMBL4282	Homo sapiens	Inhibition	%	0.1
	8072491	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	0.35	CHEMBL4282	Homo sapiens	Inhibition	%	0.35
	8072840	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	-0.4	CHEMBL4282	Homo sapiens	Inhibition	%	-0.4
	8073007	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	0.53	CHEMBL4282	Homo sapiens	Inhibition	%	0.53
	8073356	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-0.66	CHEMBL4282	Homo sapiens	Inhibition	%	-0.66
	8073699	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	-0.7	CHEMBL4282	Homo sapiens	Inhibition	%	-0.7
	8073932	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	8.37	CHEMBL4282	Homo sapiens	Inhibition	%	8.37
	8074084	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	0.28	CHEMBL4282	Homo sapiens	Inhibition	%	0.28
	8074308	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	0.08	CHEMBL4282	Homo sapiens	Inhibition	%	0.08
	8074438	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	-0.11	CHEMBL4282	Homo sapiens	Inhibition	%	-0.11
	8074595	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	0.16	CHEMBL4282	Homo sapiens	Inhibition	%	0.16
	8074819	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	0.12	CHEMBL4282	Homo sapiens	Inhibition	%	0.12
	8074946	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	-0.64	CHEMBL4282	Homo sapiens	Inhibition	%	-0.64
	8075281	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.28	CHEMBL4282	Homo sapiens	Inhibition	%	0.28
	8075518	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	54.85	CHEMBL4282	Homo sapiens	Inhibition	%	54.85
	8075883	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	1.15	CHEMBL4282	Homo sapiens	Inhibition	%	1.15
	8076025	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-0.49	CHEMBL4282	Homo sapiens	Inhibition	%	-0.49
	8076397	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	0.55	CHEMBL4282	Homo sapiens	Inhibition	%	0.55
	8076531	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	-0.94	CHEMBL4282	Homo sapiens	Inhibition	%	-0.94
	8076857	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	-0.27	CHEMBL4282	Homo sapiens	Inhibition	%	-0.27
	8077104	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	93.67	CHEMBL4282	Homo sapiens	Inhibition	%	93.67
	8077456	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	0.44	CHEMBL4282	Homo sapiens	Inhibition	%	0.44
	8077607	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-0.66	CHEMBL4282	Homo sapiens	Inhibition	%	-0.66
	8077831	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-0.94	CHEMBL4282	Homo sapiens	Inhibition	%	-0.94
	8077974	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	0.01	CHEMBL4282	Homo sapiens	Inhibition	%	0.01
	8078113	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-3.05	CHEMBL4282	Homo sapiens	Inhibition	%	-3.05
	8078337	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-2.1	CHEMBL4282	Homo sapiens	Inhibition	%	-2.1
	8078439	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	0.07	CHEMBL4282	Homo sapiens	Inhibition	%	0.07
	8078689	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	96.39	CHEMBL4282	Homo sapiens	Inhibition	%	96.39
	8078913	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	1.6	CHEMBL4282	Homo sapiens	Inhibition	%	1.6
	8079029	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	0.29	CHEMBL4282	Homo sapiens	Inhibition	%	0.29
	8079411	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-0.9	CHEMBL4282	Homo sapiens	Inhibition	%	-0.9
	8079553	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	0.83	CHEMBL4282	Homo sapiens	Inhibition	%	0.83
	8079916	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	-0.31	CHEMBL4282	Homo sapiens	Inhibition	%	-0.31
	8080021	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	-0.21	CHEMBL4282	Homo sapiens	Inhibition	%	-0.21
	8080245	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	0.39	CHEMBL4282	Homo sapiens	Inhibition	%	0.39
	8080497	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	2.22	CHEMBL4282	Homo sapiens	Inhibition	%	2.22
	8080612	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	0.35	CHEMBL4282	Homo sapiens	Inhibition	%	0.35
	8081000	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-2.52	CHEMBL4282	Homo sapiens	Inhibition	%	-2.52
	8081135	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	-0.19	CHEMBL4282	Homo sapiens	Inhibition	%	-0.19
	8081359	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	0.45	CHEMBL4282	Homo sapiens	Inhibition	%	0.45
	8081503	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	0.33	CHEMBL4282	Homo sapiens	Inhibition	%	0.33
	8081830	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	1.25	CHEMBL4282	Homo sapiens	Inhibition	%	1.25
	8082082	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	3.37	CHEMBL4282	Homo sapiens	Inhibition	%	3.37
	8082195	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	-0.14	CHEMBL4282	Homo sapiens	Inhibition	%	-0.14
	8082419	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	0.24	CHEMBL4282	Homo sapiens	Inhibition	%	0.24
	8082592	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-1.44	CHEMBL4282	Homo sapiens	Inhibition	%	-1.44
	8082939	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	-0.14	CHEMBL4282	Homo sapiens	Inhibition	%	-0.14
	8083095	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	-0.12	CHEMBL4282	Homo sapiens	Inhibition	%	-0.12
	8083418	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	0.47	CHEMBL4282	Homo sapiens	Inhibition	%	0.47
	8083672	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	37.35	CHEMBL4282	Homo sapiens	Inhibition	%	37.35
	8084006	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	0.29	CHEMBL4282	Homo sapiens	Inhibition	%	0.29
	8084191	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	0.85	CHEMBL4282	Homo sapiens	Inhibition	%	0.85
	8084533	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	0.51	CHEMBL4282	Homo sapiens	Inhibition	%	0.51
	8084694	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	0.95	CHEMBL4282	Homo sapiens	Inhibition	%	0.95
	8084918	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	-3.78	CHEMBL4282	Homo sapiens	Inhibition	%	-3.78
	8085016	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	-0.39	CHEMBL4282	Homo sapiens	Inhibition	%	-0.39
	8085272	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-2.34	CHEMBL4282	Homo sapiens	Inhibition	%	-2.34
	8085604	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	0.23	CHEMBL4282	Homo sapiens	Inhibition	%	0.23
	8085793	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	0.69	CHEMBL4282	Homo sapiens	Inhibition	%	0.69
	8086017	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	0.73	CHEMBL4282	Homo sapiens	Inhibition	%	0.73
	8086132	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	0.62	CHEMBL4282	Homo sapiens	Inhibition	%	0.62
	8086518	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	-3.1	CHEMBL4282	Homo sapiens	Inhibition	%	-3.1
	8086617	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	0.31	CHEMBL4282	Homo sapiens	Inhibition	%	0.31
	8086841	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	0.51	CHEMBL4282	Homo sapiens	Inhibition	%	0.51
	8087052	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	-2.11	CHEMBL4282	Homo sapiens	Inhibition	%	-2.11
	8087210	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	0.29	CHEMBL4282	Homo sapiens	Inhibition	%	0.29
	8087548	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	1.37	CHEMBL4282	Homo sapiens	Inhibition	%	1.37
	8087686	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	0.33	CHEMBL4282	Homo sapiens	Inhibition	%	0.33
	8087910	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	-3.52	CHEMBL4282	Homo sapiens	Inhibition	%	-3.52
	8088052	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	2.57	CHEMBL4282	Homo sapiens	Inhibition	%	2.57
	8088424	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	-0.28	CHEMBL4282	Homo sapiens	Inhibition	%	-0.28
	8088552	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	0.32	CHEMBL4282	Homo sapiens	Inhibition	%	0.32
	8088869	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	2.48	CHEMBL4282	Homo sapiens	Inhibition	%	2.48
	8089221	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	1.83	CHEMBL4282	Homo sapiens	Inhibition	%	1.83
	8089369	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	0.31	CHEMBL4282	Homo sapiens	Inhibition	%	0.31
	8089713	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	0.85	CHEMBL4282	Homo sapiens	Inhibition	%	0.85
	8089893	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-0.66	CHEMBL4282	Homo sapiens	Inhibition	%	-0.66
	8090117	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	-0.08	CHEMBL4282	Homo sapiens	Inhibition	%	-0.08
	8090282	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	1.39	CHEMBL4282	Homo sapiens	Inhibition	%	1.39
	8090449	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	0.61	CHEMBL4282	Homo sapiens	Inhibition	%	0.61
	8090673	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	0.11	CHEMBL4282	Homo sapiens	Inhibition	%	0.11
	8090812	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	0.77	CHEMBL4282	Homo sapiens	Inhibition	%	0.77
	8091017	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	0.6	CHEMBL4282	Homo sapiens	Inhibition	%	0.6
	8091378	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	0.97	CHEMBL4282	Homo sapiens	Inhibition	%	0.97
	8091533	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	0.52	CHEMBL4282	Homo sapiens	Inhibition	%	0.52
	8091757	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	-0.49	CHEMBL4282	Homo sapiens	Inhibition	%	-0.49
	8091873	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	1.71	CHEMBL4282	Homo sapiens	Inhibition	%	1.71
	8092234	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	-2.95	CHEMBL4282	Homo sapiens	Inhibition	%	-2.95
	8092385	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	0.79	CHEMBL4282	Homo sapiens	Inhibition	%	0.79
	8092757	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	0.07	CHEMBL4282	Homo sapiens	Inhibition	%	0.07
	8092886	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	1.3	CHEMBL4282	Homo sapiens	Inhibition	%	1.3
	8093110	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	-3.63	CHEMBL4282	Homo sapiens	Inhibition	%	-3.63
	8093198	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	0.44	CHEMBL4282	Homo sapiens	Inhibition	%	0.44
	8093422	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	0.71	CHEMBL4282	Homo sapiens	Inhibition	%	0.71
	8093562	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	38.17	CHEMBL4282	Homo sapiens	Inhibition	%	38.17
	8093701	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	0.65	CHEMBL4282	Homo sapiens	Inhibition	%	0.65
	8093925	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	-2.71	CHEMBL4282	Homo sapiens	Inhibition	%	-2.71
	8094045	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	0.46	CHEMBL4282	Homo sapiens	Inhibition	%	0.46
	8094449	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	-0.39	CHEMBL4282	Homo sapiens	Inhibition	%	-0.39
	8094624	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	0.91	CHEMBL4282	Homo sapiens	Inhibition	%	0.91
	8095004	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	0.45	CHEMBL4282	Homo sapiens	Inhibition	%	0.45
	8095144	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	0.88	CHEMBL4282	Homo sapiens	Inhibition	%	0.88
	8095347	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	0.62	CHEMBL4282	Homo sapiens	Inhibition	%	0.62
	8095571	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	0.77	CHEMBL4282	Homo sapiens	Inhibition	%	0.77
	8095712	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	1.22	CHEMBL4282	Homo sapiens	Inhibition	%	1.22
	8096084	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	0.77	CHEMBL4282	Homo sapiens	Inhibition	%	0.77
	8096201	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	2.32	CHEMBL4282	Homo sapiens	Inhibition	%	2.32
	8096425	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	1.68	CHEMBL4282	Homo sapiens	Inhibition	%	1.68
	8096564	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	0.1	CHEMBL4282	Homo sapiens	Inhibition	%	0.1
	8096720	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	0.35	CHEMBL4282	Homo sapiens	Inhibition	%	0.35
	8096944	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	0.88	CHEMBL4282	Homo sapiens	Inhibition	%	0.88
	8097091	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	-0.67	CHEMBL4282	Homo sapiens	Inhibition	%	-0.67
	8097622	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	1.29	CHEMBL4282	Homo sapiens	Inhibition	%	1.29
	8097772	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	85.25	CHEMBL4282	Homo sapiens	Inhibition	%	85.25
	8098129	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	-3.33	CHEMBL4282	Homo sapiens	Inhibition	%	-3.33
	8098249	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	2.26	CHEMBL4282	Homo sapiens	Inhibition	%	2.26
	8098473	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	0.35	CHEMBL4282	Homo sapiens	Inhibition	%	0.35
	8098653	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	0.02	CHEMBL4282	Homo sapiens	Inhibition	%	0.02
	8098838	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	2.86	CHEMBL4282	Homo sapiens	Inhibition	%	2.86
	8099206	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	0.14	CHEMBL4282	Homo sapiens	Inhibition	%	0.14
	8099348	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	0.53	CHEMBL4282	Homo sapiens	Inhibition	%	0.53
	8099572	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	1.82	CHEMBL4282	Homo sapiens	Inhibition	%	1.82
	8099766	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	-0.12	CHEMBL4282	Homo sapiens	Inhibition	%	-0.12
	8099913	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	1.26	CHEMBL4282	Homo sapiens	Inhibition	%	1.26
	8100137	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	0.76	CHEMBL4282	Homo sapiens	Inhibition	%	0.76
	8100283	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	-3.71	CHEMBL4282	Homo sapiens	Inhibition	%	-3.71
	8100623	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	-0.06	CHEMBL4282	Homo sapiens	Inhibition	%	-0.06
	8100763	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	-0.3	CHEMBL4282	Homo sapiens	Inhibition	%	-0.3
	8101147	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	-0.34	CHEMBL4282	Homo sapiens	Inhibition	%	-0.34
	8101289	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	-1.72	CHEMBL4282	Homo sapiens	Inhibition	%	-1.72
	8101698	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	-2.95	CHEMBL4282	Homo sapiens	Inhibition	%	-2.95
	8101951	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	0.32	CHEMBL4282	Homo sapiens	Inhibition	%	0.32
	8102106	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	-2.33	CHEMBL4282	Homo sapiens	Inhibition	%	-2.33
	8102330	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	1.84	CHEMBL4282	Homo sapiens	Inhibition	%	1.84
	8102461	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	0.87	CHEMBL4282	Homo sapiens	Inhibition	%	0.87
	8102805	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	1.5	CHEMBL4282	Homo sapiens	Inhibition	%	1.5
	8102983	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	0.01	CHEMBL4282	Homo sapiens	Inhibition	%	0.01
	8103179	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	64.25	CHEMBL4282	Homo sapiens	Inhibition	%	64.25
	8103403	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	90.41	CHEMBL4282	Homo sapiens	Inhibition	%	90.41
	8103541	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	0.22	CHEMBL4282	Homo sapiens	Inhibition	%	0.22
	8103915	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	0.98	CHEMBL4282	Homo sapiens	Inhibition	%	0.98
	8104100	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	-0.35	CHEMBL4282	Homo sapiens	Inhibition	%	-0.35
	8104472	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	0.75	CHEMBL4282	Homo sapiens	Inhibition	%	0.75
	8104618	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	-3.3	CHEMBL4282	Homo sapiens	Inhibition	%	-3.3
	8104956	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	0.41	CHEMBL4282	Homo sapiens	Inhibition	%	0.41
	8105096	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	-0.28	CHEMBL4282	Homo sapiens	Inhibition	%	-0.28
	8105320	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	-0.24	CHEMBL4282	Homo sapiens	Inhibition	%	-0.24
	8105486	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	-2.97	CHEMBL4282	Homo sapiens	Inhibition	%	-2.97
	8105624	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	-1.61	CHEMBL4282	Homo sapiens	Inhibition	%	-1.61
	8105848	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	1.36	CHEMBL4282	Homo sapiens	Inhibition	%	1.36
	8105904	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	0.35	CHEMBL4282	Homo sapiens	Inhibition	%	0.35
	8106128	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	2.86	CHEMBL4282	Homo sapiens	Inhibition	%	2.86
	8106293	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	-2.46	CHEMBL4282	Homo sapiens	Inhibition	%	-2.46
	8106673	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	-0.6	CHEMBL4282	Homo sapiens	Inhibition	%	-0.6
	8106802	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	-0.4	CHEMBL4282	Homo sapiens	Inhibition	%	-0.4
	8107147	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	1.68	CHEMBL4282	Homo sapiens	Inhibition	%	1.68
	8107319	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	0.26	CHEMBL4282	Homo sapiens	Inhibition	%	0.26
	8107543	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	0.43	CHEMBL4282	Homo sapiens	Inhibition	%	0.43
	8107744	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	2.47	CHEMBL4282	Homo sapiens	Inhibition	%	2.47
	8107879	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	-0.29	CHEMBL4282	Homo sapiens	Inhibition	%	-0.29
	8108261	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	0.75	CHEMBL4282	Homo sapiens	Inhibition	%	0.75
	8108436	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	-0.4	CHEMBL4282	Homo sapiens	Inhibition	%	-0.4
	8108807	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	0.38	CHEMBL4282	Homo sapiens	Inhibition	%	0.38
	8108949	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	-0.1	CHEMBL4282	Homo sapiens	Inhibition	%	-0.1
	8109173	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	-0.35	CHEMBL4282	Homo sapiens	Inhibition	%	-0.35
	8109287	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	0.36	CHEMBL4282	Homo sapiens	Inhibition	%	0.36
	8109641	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-2.24	CHEMBL4282	Homo sapiens	Inhibition	%	-2.24
	8109812	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	-3.84	CHEMBL4282	Homo sapiens	Inhibition	%	-3.84
	8110168	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	1.33	CHEMBL4282	Homo sapiens	Inhibition	%	1.33
	8110447	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	0.04	CHEMBL4282	Homo sapiens	Inhibition	%	0.04
	8110613	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	-2.95	CHEMBL4282	Homo sapiens	Inhibition	%	-2.95
	8110995	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	10.9	CHEMBL4282	Homo sapiens	Inhibition	%	10.9
	8111118	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	1.36	CHEMBL4282	Homo sapiens	Inhibition	%	1.36
	8111342	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	0.06	CHEMBL4282	Homo sapiens	Inhibition	%	0.06
	8111469	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	68.16	CHEMBL4282	Homo sapiens	Inhibition	%	68.16
	8111859	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	0.16	CHEMBL4282	Homo sapiens	Inhibition	%	0.16
	8112064	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	3.09	CHEMBL4282	Homo sapiens	Inhibition	%	3.09
	8112201	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-0.15	CHEMBL4282	Homo sapiens	Inhibition	%	-0.15
	8112425	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-0.16	CHEMBL4282	Homo sapiens	Inhibition	%	-0.16
	8112593	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	0.6	CHEMBL4282	Homo sapiens	Inhibition	%	0.6
	8112765	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	-0.19	CHEMBL4282	Homo sapiens	Inhibition	%	-0.19
	8112989	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	0.18	CHEMBL4282	Homo sapiens	Inhibition	%	0.18
	8113141	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	20.81	CHEMBL4282	Homo sapiens	Inhibition	%	20.81
	8113501	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	-1.0	CHEMBL4282	Homo sapiens	Inhibition	%	-1.0
	8113625	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	0.41	CHEMBL4282	Homo sapiens	Inhibition	%	0.41
	8113965	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-1.9	CHEMBL4282	Homo sapiens	Inhibition	%	-1.9
	8114141	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	0.68	CHEMBL4282	Homo sapiens	Inhibition	%	0.68
	8114365	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	0.01	CHEMBL4282	Homo sapiens	Inhibition	%	0.01
	8114497	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	0.99	CHEMBL4282	Homo sapiens	Inhibition	%	0.99
	8114773	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	0.76	CHEMBL4282	Homo sapiens	Inhibition	%	0.76
	8114939	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	0.73	CHEMBL4282	Homo sapiens	Inhibition	%	0.73
	8115163	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	0.58	CHEMBL4282	Homo sapiens	Inhibition	%	0.58
	8115328	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	-0.69	CHEMBL4282	Homo sapiens	Inhibition	%	-0.69
	8115672	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	0.62	CHEMBL4282	Homo sapiens	Inhibition	%	0.62
	8115805	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	91.12	CHEMBL4282	Homo sapiens	Inhibition	%	91.12
	8116188	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	-0.56	CHEMBL4282	Homo sapiens	Inhibition	%	-0.56
	8116391	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	70.11	CHEMBL4282	Homo sapiens	Inhibition	%	70.11
	8116749	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-0.05	CHEMBL4282	Homo sapiens	Inhibition	%	-0.05
	8116921	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	1.09	CHEMBL4282	Homo sapiens	Inhibition	%	1.09
	8117316	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	0.52	CHEMBL4282	Homo sapiens	Inhibition	%	0.52
	8117474	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	67.44	CHEMBL4282	Homo sapiens	Inhibition	%	67.44
	8117828	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	-0.87	CHEMBL4282	Homo sapiens	Inhibition	%	-0.87
	8117966	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	-3.0	CHEMBL4282	Homo sapiens	Inhibition	%	-3.0
	8118190	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	-3.59	CHEMBL4282	Homo sapiens	Inhibition	%	-3.59
	8118306	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	1.15	CHEMBL4282	Homo sapiens	Inhibition	%	1.15
	8118702	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	0.89	CHEMBL4282	Homo sapiens	Inhibition	%	0.89
	8118838	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	0.75	CHEMBL4282	Homo sapiens	Inhibition	%	0.75
	8119109	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	1.35	CHEMBL4282	Homo sapiens	Inhibition	%	1.35
	8119492	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	0.7	CHEMBL4282	Homo sapiens	Inhibition	%	0.7
	8119659	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	0.42	CHEMBL4282	Homo sapiens	Inhibition	%	0.42
	8120002	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	-0.01	CHEMBL4282	Homo sapiens	Inhibition	%	-0.01
	8120141	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	1.37	CHEMBL4282	Homo sapiens	Inhibition	%	1.37
	8120365	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	1.23	CHEMBL4282	Homo sapiens	Inhibition	%	1.23
	8120525	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-0.59	CHEMBL4282	Homo sapiens	Inhibition	%	-0.59
	8120726	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	92.77	CHEMBL4282	Homo sapiens	Inhibition	%	92.77
	8121078	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-0.49	CHEMBL4282	Homo sapiens	Inhibition	%	-0.49
	8121250	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	-0.07	CHEMBL4282	Homo sapiens	Inhibition	%	-0.07
	8121474	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	1.54	CHEMBL4282	Homo sapiens	Inhibition	%	1.54
	8121641	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	0.04	CHEMBL4282	Homo sapiens	Inhibition	%	0.04
	8121804	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	1.72	CHEMBL4282	Homo sapiens	Inhibition	%	1.72
	8122028	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	1.07	CHEMBL4282	Homo sapiens	Inhibition	%	1.07
	8122149	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	-2.6	CHEMBL4282	Homo sapiens	Inhibition	%	-2.6
	8122511	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	0.54	CHEMBL4282	Homo sapiens	Inhibition	%	0.54
	8122631	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	2.28	CHEMBL4282	Homo sapiens	Inhibition	%	2.28
	8122855	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	1.23	CHEMBL4282	Homo sapiens	Inhibition	%	1.23
	8123022	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	0.08	CHEMBL4282	Homo sapiens	Inhibition	%	0.08
	8123164	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	-2.43	CHEMBL4282	Homo sapiens	Inhibition	%	-2.43
	8123388	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	-2.44	CHEMBL4282	Homo sapiens	Inhibition	%	-2.44
	8123442	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	0.96	CHEMBL4282	Homo sapiens	Inhibition	%	0.96
	8123666	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	0.97	CHEMBL4282	Homo sapiens	Inhibition	%	0.97
	8123816	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	-1.12	CHEMBL4282	Homo sapiens	Inhibition	%	-1.12
	8123983	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	-4.15	CHEMBL4282	Homo sapiens	Inhibition	%	-4.15
	8124207	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	-3.41	CHEMBL4282	Homo sapiens	Inhibition	%	-3.41
	8124326	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	1.34	CHEMBL4282	Homo sapiens	Inhibition	%	1.34
	8124689	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	0.88	CHEMBL4282	Homo sapiens	Inhibition	%	0.88
	8124854	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-0.52	CHEMBL4282	Homo sapiens	Inhibition	%	-0.52
	8125055	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	2.02	CHEMBL4282	Homo sapiens	Inhibition	%	2.02
	8125279	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	3.72	CHEMBL4282	Homo sapiens	Inhibition	%	3.72
	8125409	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	-0.73	CHEMBL4282	Homo sapiens	Inhibition	%	-0.73
	8125801	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	0.05	CHEMBL4282	Homo sapiens	Inhibition	%	0.05
	8125965	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-0.41	CHEMBL4282	Homo sapiens	Inhibition	%	-0.41
	8126353	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	-2.02	CHEMBL4282	Homo sapiens	Inhibition	%	-2.02
	8126468	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	-1.87	CHEMBL4282	Homo sapiens	Inhibition	%	-1.87
	8126828	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	0.61	CHEMBL4282	Homo sapiens	Inhibition	%	0.61
	8127174	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	1.87	CHEMBL4282	Homo sapiens	Inhibition	%	1.87
	8127341	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	0.91	CHEMBL4282	Homo sapiens	Inhibition	%	0.91
	8127707	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	1.53	CHEMBL4282	Homo sapiens	Inhibition	%	1.53
	8127995	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	1.22	CHEMBL4282	Homo sapiens	Inhibition	%	1.22
	8128147	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	0.52	CHEMBL4282	Homo sapiens	Inhibition	%	0.52
	8128538	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	0.07	CHEMBL4282	Homo sapiens	Inhibition	%	0.07
	8128657	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	0.43	CHEMBL4282	Homo sapiens	Inhibition	%	0.43
	8128881	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.58	CHEMBL4282	Homo sapiens	Inhibition	%	0.58
	8129018	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	0.14	CHEMBL4282	Homo sapiens	Inhibition	%	0.14
	8129189	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-0.58	CHEMBL4282	Homo sapiens	Inhibition	%	-0.58
	8129413	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-0.16	CHEMBL4282	Homo sapiens	Inhibition	%	-0.16
	8129602	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	0.3	CHEMBL4282	Homo sapiens	Inhibition	%	0.3
	8129741	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	-0.67	CHEMBL4282	Homo sapiens	Inhibition	%	-0.67
	8129965	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-0.96	CHEMBL4282	Homo sapiens	Inhibition	%	-0.96
	8130126	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	0.65	CHEMBL4282	Homo sapiens	Inhibition	%	0.65
	8130298	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-1.03	CHEMBL4282	Homo sapiens	Inhibition	%	-1.03
	8130682	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	-1.93	CHEMBL4282	Homo sapiens	Inhibition	%	-1.93
	8130798	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	1.93	CHEMBL4282	Homo sapiens	Inhibition	%	1.93
	8131022	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	1.34	CHEMBL4282	Homo sapiens	Inhibition	%	1.34
	8131161	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	0.38	CHEMBL4282	Homo sapiens	Inhibition	%	0.38
	8131505	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	-2.29	CHEMBL4282	Homo sapiens	Inhibition	%	-2.29
	8131672	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	0.05	CHEMBL4282	Homo sapiens	Inhibition	%	0.05
	8132037	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	0.96	CHEMBL4282	Homo sapiens	Inhibition	%	0.96
	8132323	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-1.91	CHEMBL4282	Homo sapiens	Inhibition	%	-1.91
	8132470	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	0.6	CHEMBL4282	Homo sapiens	Inhibition	%	0.6
	8132694	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	-0.08	CHEMBL4282	Homo sapiens	Inhibition	%	-0.08
	8132862	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	1.96	CHEMBL4282	Homo sapiens	Inhibition	%	1.96
	8133207	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.44	CHEMBL4282	Homo sapiens	Inhibition	%	0.44
	8133345	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	0.38	CHEMBL4282	Homo sapiens	Inhibition	%	0.38
	8133741	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-0.97	CHEMBL4282	Homo sapiens	Inhibition	%	-0.97
	8133921	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	-0.86	CHEMBL4282	Homo sapiens	Inhibition	%	-0.86
	8134293	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-1.46	CHEMBL4282	Homo sapiens	Inhibition	%	-1.46
	8134453	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	0.37	CHEMBL4282	Homo sapiens	Inhibition	%	0.37
	8134637	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-2.28	CHEMBL4282	Homo sapiens	Inhibition	%	-2.28
	8134861	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-2.1	CHEMBL4282	Homo sapiens	Inhibition	%	-2.1
	8135021	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	1.14	CHEMBL4282	Homo sapiens	Inhibition	%	1.14
	8135360	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	1.54	CHEMBL4282	Homo sapiens	Inhibition	%	1.54
	8135501	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	0.36	CHEMBL4282	Homo sapiens	Inhibition	%	0.36
	8135725	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	2.98	CHEMBL4282	Homo sapiens	Inhibition	%	2.98
	8135846	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	-1.29	CHEMBL4282	Homo sapiens	Inhibition	%	-1.29
	8136014	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	1.02	CHEMBL4282	Homo sapiens	Inhibition	%	1.02
	8136238	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	-0.26	CHEMBL4282	Homo sapiens	Inhibition	%	-0.26
	8136382	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	2.04	CHEMBL4282	Homo sapiens	Inhibition	%	2.04
	8136672	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-1.8	CHEMBL4282	Homo sapiens	Inhibition	%	-1.8
	8137031	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	1.46	CHEMBL4282	Homo sapiens	Inhibition	%	1.46
	8137194	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	0.34	CHEMBL4282	Homo sapiens	Inhibition	%	0.34
	8137538	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-2.43	CHEMBL4282	Homo sapiens	Inhibition	%	-2.43
	8137686	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	0.44	CHEMBL4282	Homo sapiens	Inhibition	%	0.44
	8137910	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	-0.35	CHEMBL4282	Homo sapiens	Inhibition	%	-0.35
	8138076	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-1.21	CHEMBL4282	Homo sapiens	Inhibition	%	-1.21
	8138255	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	0.2	CHEMBL4282	Homo sapiens	Inhibition	%	0.2
	8138627	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-2.54	CHEMBL4282	Homo sapiens	Inhibition	%	-2.54
	8138785	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	0.55	CHEMBL4282	Homo sapiens	Inhibition	%	0.55
	8139009	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	0.15	CHEMBL4282	Homo sapiens	Inhibition	%	0.15
	8139194	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	1.14	CHEMBL4282	Homo sapiens	Inhibition	%	1.14
	8139353	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	0.85	CHEMBL4282	Homo sapiens	Inhibition	%	0.85
	8139691	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	1.3	CHEMBL4282	Homo sapiens	Inhibition	%	1.3
	8140056	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	0.19	CHEMBL4282	Homo sapiens	Inhibition	%	0.19
	8140179	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	1.59	CHEMBL4282	Homo sapiens	Inhibition	%	1.59
	8140562	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	0.66	CHEMBL4282	Homo sapiens	Inhibition	%	0.66
	8140705	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	1.04	CHEMBL4282	Homo sapiens	Inhibition	%	1.04
	8140929	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	1.7	CHEMBL4282	Homo sapiens	Inhibition	%	1.7
	8141007	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	1.38	CHEMBL4282	Homo sapiens	Inhibition	%	1.38
	8141361	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	-0.33	CHEMBL4282	Homo sapiens	Inhibition	%	-0.33
	8141521	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	-0.51	CHEMBL4282	Homo sapiens	Inhibition	%	-0.51
	8141745	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	0.48	CHEMBL4282	Homo sapiens	Inhibition	%	0.48
	8141864	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-2.92	CHEMBL4282	Homo sapiens	Inhibition	%	-2.92
	8142249	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	-0.09	CHEMBL4282	Homo sapiens	Inhibition	%	-0.09
	8142417	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	-0.94	CHEMBL4282	Homo sapiens	Inhibition	%	-0.94
	8142593	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	-0.66	CHEMBL4282	Homo sapiens	Inhibition	%	-0.66
	8142817	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	0.82	CHEMBL4282	Homo sapiens	Inhibition	%	0.82
	8142966	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-2.49	CHEMBL4282	Homo sapiens	Inhibition	%	-2.49
	8143345	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	1.42	CHEMBL4282	Homo sapiens	Inhibition	%	1.42
	8143532	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	0.96	CHEMBL4282	Homo sapiens	Inhibition	%	0.96
	8143691	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	0.89	CHEMBL4282	Homo sapiens	Inhibition	%	0.89
	8143915	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	1.19	CHEMBL4282	Homo sapiens	Inhibition	%	1.19
	8144029	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	-2.58	CHEMBL4282	Homo sapiens	Inhibition	%	-2.58
	8144392	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	1.09	CHEMBL4282	Homo sapiens	Inhibition	%	1.09
	8144522	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	2.05	CHEMBL4282	Homo sapiens	Inhibition	%	2.05
	8144746	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	1.54	CHEMBL4282	Homo sapiens	Inhibition	%	1.54
	8144899	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	0.31	CHEMBL4282	Homo sapiens	Inhibition	%	0.31
	8145260	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	1.71	CHEMBL4282	Homo sapiens	Inhibition	%	1.71
	8145349	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	1.39	CHEMBL4282	Homo sapiens	Inhibition	%	1.39
	8145573	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	1.66	CHEMBL4282	Homo sapiens	Inhibition	%	1.66
	8145697	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	0.8	CHEMBL4282	Homo sapiens	Inhibition	%	0.8
	8146082	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	1.09	CHEMBL4282	Homo sapiens	Inhibition	%	1.09
	8146202	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	0.65	CHEMBL4282	Homo sapiens	Inhibition	%	0.65
	8146586	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	-0.27	CHEMBL4282	Homo sapiens	Inhibition	%	-0.27
	8146753	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	-1.34	CHEMBL4282	Homo sapiens	Inhibition	%	-1.34
	8147146	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	-0.05	CHEMBL4282	Homo sapiens	Inhibition	%	-0.05
	8147288	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	0.83	CHEMBL4282	Homo sapiens	Inhibition	%	0.83
	8147665	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	0.68	CHEMBL4282	Homo sapiens	Inhibition	%	0.68
	8147852	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	0.91	CHEMBL4282	Homo sapiens	Inhibition	%	0.91
	8148234	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	1.4	CHEMBL4282	Homo sapiens	Inhibition	%	1.4
	8148348	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	-2.2	CHEMBL4282	Homo sapiens	Inhibition	%	-2.2
	8148572	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	1.44	CHEMBL4282	Homo sapiens	Inhibition	%	1.44
	8148711	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	0.59	CHEMBL4282	Homo sapiens	Inhibition	%	0.59
	8149073	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	3.25	CHEMBL4282	Homo sapiens	Inhibition	%	3.25
	8149232	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	-1.63	CHEMBL4282	Homo sapiens	Inhibition	%	-1.63
	8149590	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	1.98	CHEMBL4282	Homo sapiens	Inhibition	%	1.98
	8149912	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	1.83	CHEMBL4282	Homo sapiens	Inhibition	%	1.83
	8150037	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	-3.62	CHEMBL4282	Homo sapiens	Inhibition	%	-3.62
	8150421	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	0.17	CHEMBL4282	Homo sapiens	Inhibition	%	0.17
	8150541	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	0.76	CHEMBL4282	Homo sapiens	Inhibition	%	0.76
	8150765	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	1.55	CHEMBL4282	Homo sapiens	Inhibition	%	1.55
	8150930	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	-0.06	CHEMBL4282	Homo sapiens	Inhibition	%	-0.06
	8151093	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-2.21	CHEMBL4282	Homo sapiens	Inhibition	%	-2.21
	8151317	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-1.97	CHEMBL4282	Homo sapiens	Inhibition	%	-1.97
	8151494	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	0.3	CHEMBL4282	Homo sapiens	Inhibition	%	0.3
	8151632	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	0.65	CHEMBL4282	Homo sapiens	Inhibition	%	0.65
	8151856	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	0.26	CHEMBL4282	Homo sapiens	Inhibition	%	0.26
	8152010	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	0.72	CHEMBL4282	Homo sapiens	Inhibition	%	0.72
	8152198	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	0.66	CHEMBL4282	Homo sapiens	Inhibition	%	0.66
	8152422	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	-2.98	CHEMBL4282	Homo sapiens	Inhibition	%	-2.98
	8152580	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	0.83	CHEMBL4282	Homo sapiens	Inhibition	%	0.83
	8152918	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	1.19	CHEMBL4282	Homo sapiens	Inhibition	%	1.19
	8153057	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	2.3	CHEMBL4282	Homo sapiens	Inhibition	%	2.3
	8153418	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	0.91	CHEMBL4282	Homo sapiens	Inhibition	%	0.91
	8153575	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	-3.32	CHEMBL4282	Homo sapiens	Inhibition	%	-3.32
	8153799	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	0.58	CHEMBL4282	Homo sapiens	Inhibition	%	0.58
	8153932	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	17.73	CHEMBL4282	Homo sapiens	Inhibition	%	17.73
	8154253	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	1.46	CHEMBL4282	Homo sapiens	Inhibition	%	1.46
	8154379	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	-0.4	CHEMBL4282	Homo sapiens	Inhibition	%	-0.4
	8154603	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	0.07	CHEMBL4282	Homo sapiens	Inhibition	%	0.07
	8154762	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	-0.5	CHEMBL4282	Homo sapiens	Inhibition	%	-0.5
	8155106	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	0.68	CHEMBL4282	Homo sapiens	Inhibition	%	0.68
	8155282	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	0.02	CHEMBL4282	Homo sapiens	Inhibition	%	0.02
	8155667	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	0.64	CHEMBL4282	Homo sapiens	Inhibition	%	0.64
	8155845	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	0.03	CHEMBL4282	Homo sapiens	Inhibition	%	0.03
	8156207	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	0.31	CHEMBL4282	Homo sapiens	Inhibition	%	0.31
	8156419	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	0.96	CHEMBL4282	Homo sapiens	Inhibition	%	0.96
	8156793	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	0.71	CHEMBL4282	Homo sapiens	Inhibition	%	0.71
	8156936	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	0.93	CHEMBL4282	Homo sapiens	Inhibition	%	0.93
	8157280	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	1.18	CHEMBL4282	Homo sapiens	Inhibition	%	1.18
	8157421	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	0.55	CHEMBL4282	Homo sapiens	Inhibition	%	0.55
	8157645	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	0.77	CHEMBL4282	Homo sapiens	Inhibition	%	0.77
	8157775	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	0.17	CHEMBL4282	Homo sapiens	Inhibition	%	0.17
	8158160	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	-3.71	CHEMBL4282	Homo sapiens	Inhibition	%	-3.71
	8158410	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	3.33	CHEMBL4282	Homo sapiens	Inhibition	%	3.33
	8158568	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	-3.57	CHEMBL4282	Homo sapiens	Inhibition	%	-3.57
	8158961	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	0.09	CHEMBL4282	Homo sapiens	Inhibition	%	0.09
	8159096	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	0.61	CHEMBL4282	Homo sapiens	Inhibition	%	0.61
	8159320	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	0.67	CHEMBL4282	Homo sapiens	Inhibition	%	0.67
	8159440	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	-3.71	CHEMBL4282	Homo sapiens	Inhibition	%	-3.71
	8159795	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	0.39	CHEMBL4282	Homo sapiens	Inhibition	%	0.39
	8159936	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	0.19	CHEMBL4282	Homo sapiens	Inhibition	%	0.19
	8160297	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	1.08	CHEMBL4282	Homo sapiens	Inhibition	%	1.08
	8160447	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-1.5	CHEMBL4282	Homo sapiens	Inhibition	%	-1.5
	8160671	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-1.14	CHEMBL4282	Homo sapiens	Inhibition	%	-1.14
	8160741	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	1.39	CHEMBL4282	Homo sapiens	Inhibition	%	1.39
	8161115	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	-0.42	CHEMBL4282	Homo sapiens	Inhibition	%	-0.42
	8161258	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	0.86	CHEMBL4282	Homo sapiens	Inhibition	%	0.86
	8161482	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	0.95	CHEMBL4282	Homo sapiens	Inhibition	%	0.95
	8161607	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	0.96	CHEMBL4282	Homo sapiens	Inhibition	%	0.96
	8161969	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	1.57	CHEMBL4282	Homo sapiens	Inhibition	%	1.57
	8162099	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	1.46	CHEMBL4282	Homo sapiens	Inhibition	%	1.46
	8162323	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	-0.1	CHEMBL4282	Homo sapiens	Inhibition	%	-0.1
	8162483	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	-3.59	CHEMBL4282	Homo sapiens	Inhibition	%	-3.59
	8162736	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	19.5	CHEMBL4282	Homo sapiens	Inhibition	%	19.5
	8162884	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	1.23	CHEMBL4282	Homo sapiens	Inhibition	%	1.23
	8163108	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	-0.15	CHEMBL4282	Homo sapiens	Inhibition	%	-0.15
	8163277	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	0.5	CHEMBL4282	Homo sapiens	Inhibition	%	0.5
	8163635	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	0.42	CHEMBL4282	Homo sapiens	Inhibition	%	0.42
	8163758	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	-2.76	CHEMBL4282	Homo sapiens	Inhibition	%	-2.76
	8164116	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	0.27	CHEMBL4282	Homo sapiens	Inhibition	%	0.27
	8164256	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	-0.24	CHEMBL4282	Homo sapiens	Inhibition	%	-0.24
	8164480	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	0.14	CHEMBL4282	Homo sapiens	Inhibition	%	0.14
	8164635	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	0.4	CHEMBL4282	Homo sapiens	Inhibition	%	0.4
	8165003	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	1.74	CHEMBL4282	Homo sapiens	Inhibition	%	1.74
	8165073	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	1.11	CHEMBL4282	Homo sapiens	Inhibition	%	1.11
	8165297	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	1.38	CHEMBL4282	Homo sapiens	Inhibition	%	1.38
	8165438	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	0.78	CHEMBL4282	Homo sapiens	Inhibition	%	0.78
	8165805	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	-0.23	CHEMBL4282	Homo sapiens	Inhibition	%	-0.23
	8165931	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	1.06	CHEMBL4282	Homo sapiens	Inhibition	%	1.06
	8166293	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	2.41	CHEMBL4282	Homo sapiens	Inhibition	%	2.41
	8166647	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	1.39	CHEMBL4282	Homo sapiens	Inhibition	%	1.39
	8166748	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	1.09	CHEMBL4282	Homo sapiens	Inhibition	%	1.09
	8167060	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	1.6	CHEMBL4282	Homo sapiens	Inhibition	%	1.6
	8167425	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	1.26	CHEMBL4282	Homo sapiens	Inhibition	%	1.26
	8167589	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	0.48	CHEMBL4282	Homo sapiens	Inhibition	%	0.48
	8167946	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	0.42	CHEMBL4282	Homo sapiens	Inhibition	%	0.42
	8168070	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	-0.22	CHEMBL4282	Homo sapiens	Inhibition	%	-0.22
	8168294	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	0.8	CHEMBL4282	Homo sapiens	Inhibition	%	0.8
	8168435	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	0.79	CHEMBL4282	Homo sapiens	Inhibition	%	0.79
	8168795	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-2.14	CHEMBL4282	Homo sapiens	Inhibition	%	-2.14
	8168959	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	1.36	CHEMBL4282	Homo sapiens	Inhibition	%	1.36
	8169325	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	2.3	CHEMBL4282	Homo sapiens	Inhibition	%	2.3
	8169629	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	1.49	CHEMBL4282	Homo sapiens	Inhibition	%	1.49
	8169763	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	0.48	CHEMBL4282	Homo sapiens	Inhibition	%	0.48
	8170132	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	0.58	CHEMBL4282	Homo sapiens	Inhibition	%	0.58
	8170257	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	1.04	CHEMBL4282	Homo sapiens	Inhibition	%	1.04
	8170481	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	1.19	CHEMBL4282	Homo sapiens	Inhibition	%	1.19
	8170621	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	60.67	CHEMBL4282	Homo sapiens	Inhibition	%	60.67
	8170980	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	0.38	CHEMBL4282	Homo sapiens	Inhibition	%	0.38
	8171177	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	0.02	CHEMBL4282	Homo sapiens	Inhibition	%	0.02
	8171394	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	7.87	CHEMBL4282	Homo sapiens	Inhibition	%	7.87
	8171759	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	0.48	CHEMBL4282	Homo sapiens	Inhibition	%	0.48
	8171912	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	-2.98	CHEMBL4282	Homo sapiens	Inhibition	%	-2.98
	8172136	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	-3.97	CHEMBL4282	Homo sapiens	Inhibition	%	-3.97
	8172268	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	0.44	CHEMBL4282	Homo sapiens	Inhibition	%	0.44
	8172620	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	-1.55	CHEMBL4282	Homo sapiens	Inhibition	%	-1.55
	8172762	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	-0.47	CHEMBL4282	Homo sapiens	Inhibition	%	-0.47
	8173122	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-1.44	CHEMBL4282	Homo sapiens	Inhibition	%	-1.44
	8173287	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	0.24	CHEMBL4282	Homo sapiens	Inhibition	%	0.24
	8173511	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	-0.78	CHEMBL4282	Homo sapiens	Inhibition	%	-0.78
	8173652	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	1.65	CHEMBL4282	Homo sapiens	Inhibition	%	1.65
	8173963	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	0.74	CHEMBL4282	Homo sapiens	Inhibition	%	0.74
	8174095	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	1.01	CHEMBL4282	Homo sapiens	Inhibition	%	1.01
	8174319	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	0.52	CHEMBL4282	Homo sapiens	Inhibition	%	0.52
	8174467	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	0.06	CHEMBL4282	Homo sapiens	Inhibition	%	0.06
	8174813	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	1.21	CHEMBL4282	Homo sapiens	Inhibition	%	1.21
	8174956	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	88.21	CHEMBL4282	Homo sapiens	Inhibition	%	88.21
	8175180	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	1.33	CHEMBL4282	Homo sapiens	Inhibition	%	1.33
	8175316	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	0.64	CHEMBL4282	Homo sapiens	Inhibition	%	0.64
	8175572	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	-0.09	CHEMBL4282	Homo sapiens	Inhibition	%	-0.09
	8175735	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	0.47	CHEMBL4282	Homo sapiens	Inhibition	%	0.47
	8175959	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	0.23	CHEMBL4282	Homo sapiens	Inhibition	%	0.23
	8176112	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	3.84	CHEMBL4282	Homo sapiens	Inhibition	%	3.84
	8176485	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	0.14	CHEMBL4282	Homo sapiens	Inhibition	%	0.14
	8176617	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	0.45	CHEMBL4282	Homo sapiens	Inhibition	%	0.45
	8176971	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	0.14	CHEMBL4282	Homo sapiens	Inhibition	%	0.14
	8177113	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	-2.92	CHEMBL4282	Homo sapiens	Inhibition	%	-2.92
	8177337	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	-4.1	CHEMBL4282	Homo sapiens	Inhibition	%	-4.1
	8177475	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	0.56	CHEMBL4282	Homo sapiens	Inhibition	%	0.56
	8177863	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	0.67	CHEMBL4282	Homo sapiens	Inhibition	%	0.67
	8178003	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	2.74	CHEMBL4282	Homo sapiens	Inhibition	%	2.74
	8178315	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	0.44	CHEMBL4282	Homo sapiens	Inhibition	%	0.44
	8178666	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	0.98	CHEMBL4282	Homo sapiens	Inhibition	%	0.98
	8178815	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	0.79	CHEMBL4282	Homo sapiens	Inhibition	%	0.79
	8179162	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	0.9	CHEMBL4282	Homo sapiens	Inhibition	%	0.9
	8179530	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	1.28	CHEMBL4282	Homo sapiens	Inhibition	%	1.28
	8179667	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	0.19	CHEMBL4282	Homo sapiens	Inhibition	%	0.19
	8179924	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	0.8	CHEMBL4282	Homo sapiens	Inhibition	%	0.8
	8180302	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	-3.51	CHEMBL4282	Homo sapiens	Inhibition	%	-3.51
	8180458	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	15.77	CHEMBL4282	Homo sapiens	Inhibition	%	15.77
	8180830	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	-0.46	CHEMBL4282	Homo sapiens	Inhibition	%	-0.46
	8180963	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	0.79	CHEMBL4282	Homo sapiens	Inhibition	%	0.79
	8181187	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	0.22	CHEMBL4282	Homo sapiens	Inhibition	%	0.22
	8181318	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	-0.64	CHEMBL4282	Homo sapiens	Inhibition	%	-0.64
	8181682	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	0.57	CHEMBL4282	Homo sapiens	Inhibition	%	0.57
	8181821	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	4.28	CHEMBL4282	Homo sapiens	Inhibition	%	4.28
	8182045	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	0.52	CHEMBL4282	Homo sapiens	Inhibition	%	0.52
	8182208	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	1.34	CHEMBL4282	Homo sapiens	Inhibition	%	1.34
	8182348	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	1.15	CHEMBL4282	Homo sapiens	Inhibition	%	1.15
	8182572	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	1.34	CHEMBL4282	Homo sapiens	Inhibition	%	1.34
	8182664	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	1.13	CHEMBL4282	Homo sapiens	Inhibition	%	1.13
	8183010	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	0.49	CHEMBL4282	Homo sapiens	Inhibition	%	0.49
	8183159	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	0.36	CHEMBL4282	Homo sapiens	Inhibition	%	0.36
	8183383	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	0.85	CHEMBL4282	Homo sapiens	Inhibition	%	0.85
	8183512	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	0.91	CHEMBL4282	Homo sapiens	Inhibition	%	0.91
	8183878	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	1.17	CHEMBL4282	Homo sapiens	Inhibition	%	1.17
	8184014	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	0.93	CHEMBL4282	Homo sapiens	Inhibition	%	0.93
	8184238	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	-3.17	CHEMBL4282	Homo sapiens	Inhibition	%	-3.17
	8184280	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	0.53	CHEMBL4282	Homo sapiens	Inhibition	%	0.53
	8184504	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	0.84	CHEMBL4282	Homo sapiens	Inhibition	%	0.84
	8184651	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	-3.04	CHEMBL4282	Homo sapiens	Inhibition	%	-3.04
	8184808	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	0.05	CHEMBL4282	Homo sapiens	Inhibition	%	0.05
	8185032	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	0.97	CHEMBL4282	Homo sapiens	Inhibition	%	0.97
	8185181	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	-0.84	CHEMBL4282	Homo sapiens	Inhibition	%	-0.84
	8185536	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	-2.83	CHEMBL4282	Homo sapiens	Inhibition	%	-2.83
	8185667	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	-1.45	CHEMBL4282	Homo sapiens	Inhibition	%	-1.45
	8185891	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	0.67	CHEMBL4282	Homo sapiens	Inhibition	%	0.67
	8186030	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	-0.63	CHEMBL4282	Homo sapiens	Inhibition	%	-0.63
	8186395	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	2.13	CHEMBL4282	Homo sapiens	Inhibition	%	2.13
	8186559	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	0.6	CHEMBL4282	Homo sapiens	Inhibition	%	0.6
	8186922	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	1.23	CHEMBL4282	Homo sapiens	Inhibition	%	1.23
	8187020	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	0.41	CHEMBL4282	Homo sapiens	Inhibition	%	0.41
	8187244	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	1.41	CHEMBL4282	Homo sapiens	Inhibition	%	1.41
	8187368	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	0.95	CHEMBL4282	Homo sapiens	Inhibition	%	0.95
	8187740	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	0.7	CHEMBL4282	Homo sapiens	Inhibition	%	0.7
	8187869	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	0.98	CHEMBL4282	Homo sapiens	Inhibition	%	0.98
	8188093	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	0.11	CHEMBL4282	Homo sapiens	Inhibition	%	0.11
	8188236	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	1.19	CHEMBL4282	Homo sapiens	Inhibition	%	1.19
	8188595	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	-2.91	CHEMBL4282	Homo sapiens	Inhibition	%	-2.91
	8188869	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	0.82	CHEMBL4282	Homo sapiens	Inhibition	%	0.82
	8189017	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	-0.05	CHEMBL4282	Homo sapiens	Inhibition	%	-0.05
	8189397	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	0.57	CHEMBL4282	Homo sapiens	Inhibition	%	0.57
	8189546	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	-1.16	CHEMBL4282	Homo sapiens	Inhibition	%	-1.16
	8189770	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-2.09	CHEMBL4282	Homo sapiens	Inhibition	%	-2.09
	8189902	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	-3.06	CHEMBL4282	Homo sapiens	Inhibition	%	-3.06
	8190258	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	0.15	CHEMBL4282	Homo sapiens	Inhibition	%	0.15
	8190398	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	0.73	CHEMBL4282	Homo sapiens	Inhibition	%	0.73
	8190759	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	0.7	CHEMBL4282	Homo sapiens	Inhibition	%	0.7
	8190923	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	0.96	CHEMBL4282	Homo sapiens	Inhibition	%	0.96
	8191147	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	0.57	CHEMBL4282	Homo sapiens	Inhibition	%	0.57
	8191285	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	0.77	CHEMBL4282	Homo sapiens	Inhibition	%	0.77
	8191605	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	0.83	CHEMBL4282	Homo sapiens	Inhibition	%	0.83
	8191727	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	0.97	CHEMBL4282	Homo sapiens	Inhibition	%	0.97
	8191951	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	0.62	CHEMBL4282	Homo sapiens	Inhibition	%	0.62
	8192100	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	0.8	CHEMBL4282	Homo sapiens	Inhibition	%	0.8
	8192453	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	0.4	CHEMBL4282	Homo sapiens	Inhibition	%	0.4
	8192597	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	0.63	CHEMBL4282	Homo sapiens	Inhibition	%	0.63
	8192957	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	0.02	CHEMBL4282	Homo sapiens	Inhibition	%	0.02
	8193229	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	0.92	CHEMBL4282	Homo sapiens	Inhibition	%	0.92
	8193374	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	-2.56	CHEMBL4282	Homo sapiens	Inhibition	%	-2.56
	8193598	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	-1.2	CHEMBL4282	Homo sapiens	Inhibition	%	-1.2
	8193755	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	0.97	CHEMBL4282	Homo sapiens	Inhibition	%	0.97
	8194128	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-2.19	CHEMBL4282	Homo sapiens	Inhibition	%	-2.19
	8194259	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	0.49	CHEMBL4282	Homo sapiens	Inhibition	%	0.49
	8194614	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	1.09	CHEMBL4282	Homo sapiens	Inhibition	%	1.09
	8194757	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	0.01	CHEMBL4282	Homo sapiens	Inhibition	%	0.01
	8194981	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	1.02	CHEMBL4282	Homo sapiens	Inhibition	%	1.02
	8195114	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	1.07	CHEMBL4282	Homo sapiens	Inhibition	%	1.07
	8195502	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	1.08	CHEMBL4282	Homo sapiens	Inhibition	%	1.08
	8195641	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	1.19	CHEMBL4282	Homo sapiens	Inhibition	%	1.19
	8195963	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	1.06	CHEMBL4282	Homo sapiens	Inhibition	%	1.06
	8196304	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	0.65	CHEMBL4282	Homo sapiens	Inhibition	%	0.65
	8196454	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	0.59	CHEMBL4282	Homo sapiens	Inhibition	%	0.59
	8196806	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	-2.85	CHEMBL4282	Homo sapiens	Inhibition	%	-2.85
	8196947	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	1.08	CHEMBL4282	Homo sapiens	Inhibition	%	1.08
	8197171	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	0.08	CHEMBL4282	Homo sapiens	Inhibition	%	0.08
	8197308	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	0.45	CHEMBL4282	Homo sapiens	Inhibition	%	0.45
	8197583	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	1.2	CHEMBL4282	Homo sapiens	Inhibition	%	1.2
	8197947	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	-0.21	CHEMBL4282	Homo sapiens	Inhibition	%	-0.21
	8198104	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	-2.42	CHEMBL4282	Homo sapiens	Inhibition	%	-2.42
	8198466	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	0.11	CHEMBL4282	Homo sapiens	Inhibition	%	0.11
	8198596	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	0.96	CHEMBL4282	Homo sapiens	Inhibition	%	0.96
	8198820	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	0.9	CHEMBL4282	Homo sapiens	Inhibition	%	0.9
	8198951	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	1.67	CHEMBL4282	Homo sapiens	Inhibition	%	1.67
	8199323	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	0.52	CHEMBL4282	Homo sapiens	Inhibition	%	0.52
	8199457	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	0.45	CHEMBL4282	Homo sapiens	Inhibition	%	0.45
	8199844	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	0.38	CHEMBL4282	Homo sapiens	Inhibition	%	0.38
	8199982	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	1.53	CHEMBL4282	Homo sapiens	Inhibition	%	1.53
	8200206	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	1.31	CHEMBL4282	Homo sapiens	Inhibition	%	1.31
	8200310	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	0.13	CHEMBL4282	Homo sapiens	Inhibition	%	0.13
	8200649	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	0.87	CHEMBL4282	Homo sapiens	Inhibition	%	0.87
	8200799	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	0.99	CHEMBL4282	Homo sapiens	Inhibition	%	0.99
	8201023	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	0.69	CHEMBL4282	Homo sapiens	Inhibition	%	0.69
	8201153	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	-1.83	CHEMBL4282	Homo sapiens	Inhibition	%	-1.83
	8201512	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	0.83	CHEMBL4282	Homo sapiens	Inhibition	%	0.83
	8201645	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-0.62	CHEMBL4282	Homo sapiens	Inhibition	%	-0.62
	8201869	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-0.09	CHEMBL4282	Homo sapiens	Inhibition	%	-0.09
	8201924	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	1.75	CHEMBL4282	Homo sapiens	Inhibition	%	1.75
	8202148	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	0.54	CHEMBL4282	Homo sapiens	Inhibition	%	0.54
	8202288	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-2.07	CHEMBL4282	Homo sapiens	Inhibition	%	-2.07
	8202455	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	-2.29	CHEMBL4282	Homo sapiens	Inhibition	%	-2.29
	8202679	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	0.01	CHEMBL4282	Homo sapiens	Inhibition	%	0.01
	8202804	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	0.95	CHEMBL4282	Homo sapiens	Inhibition	%	0.95
	8203158	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	1.31	CHEMBL4282	Homo sapiens	Inhibition	%	1.31
	8203289	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	-2.15	CHEMBL4282	Homo sapiens	Inhibition	%	-2.15
	8203513	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	-4.81	CHEMBL4282	Homo sapiens	Inhibition	%	-4.81
	8203659	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	0.48	CHEMBL4282	Homo sapiens	Inhibition	%	0.48
	8203793	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	1.07	CHEMBL4282	Homo sapiens	Inhibition	%	1.07
	8204017	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	0.93	CHEMBL4282	Homo sapiens	Inhibition	%	0.93
	8204183	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	0.97	CHEMBL4282	Homo sapiens	Inhibition	%	0.97
	8204544	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	1.02	CHEMBL4282	Homo sapiens	Inhibition	%	1.02
	8204649	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	0.62	CHEMBL4282	Homo sapiens	Inhibition	%	0.62
	8204873	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	-0.24	CHEMBL4282	Homo sapiens	Inhibition	%	-0.24
	8204988	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	0.81	CHEMBL4282	Homo sapiens	Inhibition	%	0.81
	8205361	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	1.04	CHEMBL4282	Homo sapiens	Inhibition	%	1.04
	8205497	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	0.82	CHEMBL4282	Homo sapiens	Inhibition	%	0.82
	8205721	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	1.86	CHEMBL4282	Homo sapiens	Inhibition	%	1.86
	8205860	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	0.17	CHEMBL4282	Homo sapiens	Inhibition	%	0.17
	8206216	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-2.05	CHEMBL4282	Homo sapiens	Inhibition	%	-2.05
	8206492	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	-1.66	CHEMBL4282	Homo sapiens	Inhibition	%	-1.66
	8206635	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-1.22	CHEMBL4282	Homo sapiens	Inhibition	%	-1.22
	8207039	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	1.38	CHEMBL4282	Homo sapiens	Inhibition	%	1.38
	8207165	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	-0.22	CHEMBL4282	Homo sapiens	Inhibition	%	-0.22
	8207519	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	0.84	CHEMBL4282	Homo sapiens	Inhibition	%	0.84
	8207875	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	1.37	CHEMBL4282	Homo sapiens	Inhibition	%	1.37
	8208020	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	0.29	CHEMBL4282	Homo sapiens	Inhibition	%	0.29
	8208376	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	1.5	CHEMBL4282	Homo sapiens	Inhibition	%	1.5
	8208542	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	0.52	CHEMBL4282	Homo sapiens	Inhibition	%	0.52
	8208899	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	1.26	CHEMBL4282	Homo sapiens	Inhibition	%	1.26
	8209228	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	-0.11	CHEMBL4282	Homo sapiens	Inhibition	%	-0.11
	8209344	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	0.97	CHEMBL4282	Homo sapiens	Inhibition	%	0.97
	8209568	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	0.96	CHEMBL4282	Homo sapiens	Inhibition	%	0.96
	8209718	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	0.97	CHEMBL4282	Homo sapiens	Inhibition	%	0.97
	8210078	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	1.41	CHEMBL4282	Homo sapiens	Inhibition	%	1.41
	8210219	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	0.7	CHEMBL4282	Homo sapiens	Inhibition	%	0.7
	8210579	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-0.11	CHEMBL4282	Homo sapiens	Inhibition	%	-0.11
	8210838	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	-2.4	CHEMBL4282	Homo sapiens	Inhibition	%	-2.4
	8210982	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	0.87	CHEMBL4282	Homo sapiens	Inhibition	%	0.87
	8211206	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	0.62	CHEMBL4282	Homo sapiens	Inhibition	%	0.62
	8211376	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	0.34	CHEMBL4282	Homo sapiens	Inhibition	%	0.34
	8211499	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	0.39	CHEMBL4282	Homo sapiens	Inhibition	%	0.39
	8211723	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	-3.58	CHEMBL4282	Homo sapiens	Inhibition	%	-3.58
	8211852	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	2.07	CHEMBL4282	Homo sapiens	Inhibition	%	2.07
	8212208	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	0.84	CHEMBL4282	Homo sapiens	Inhibition	%	0.84
	8212349	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	0.61	CHEMBL4282	Homo sapiens	Inhibition	%	0.61
	8212573	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	1.36	CHEMBL4282	Homo sapiens	Inhibition	%	1.36
	8212706	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	0.55	CHEMBL4282	Homo sapiens	Inhibition	%	0.55
	8212876	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	0.98	CHEMBL4282	Homo sapiens	Inhibition	%	0.98
	8213100	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	0.05	CHEMBL4282	Homo sapiens	Inhibition	%	0.05
	8213229	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	8.06	CHEMBL4282	Homo sapiens	Inhibition	%	8.06
	8213557	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-1.69	CHEMBL4282	Homo sapiens	Inhibition	%	-1.69
	8213894	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	0.74	CHEMBL4282	Homo sapiens	Inhibition	%	0.74
	8214041	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	Inhibition	%	1.0
	8214402	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	2.07	CHEMBL4282	Homo sapiens	Inhibition	%	2.07
	8214536	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	-3.35	CHEMBL4282	Homo sapiens	Inhibition	%	-3.35
	8214760	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	-2.06	CHEMBL4282	Homo sapiens	Inhibition	%	-2.06
	8214912	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-0.28	CHEMBL4282	Homo sapiens	Inhibition	%	-0.28
	8215163	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	1.68	CHEMBL4282	Homo sapiens	Inhibition	%	1.68
	8215540	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	0.76	CHEMBL4282	Homo sapiens	Inhibition	%	0.76
	8215704	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	1.4	CHEMBL4282	Homo sapiens	Inhibition	%	1.4
	8216047	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	-2.63	CHEMBL4282	Homo sapiens	Inhibition	%	-2.63
	8216166	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	0.43	CHEMBL4282	Homo sapiens	Inhibition	%	0.43
	8216390	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	0.68	CHEMBL4282	Homo sapiens	Inhibition	%	0.68
	8216526	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	1.29	CHEMBL4282	Homo sapiens	Inhibition	%	1.29
	8216888	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	-2.25	CHEMBL4282	Homo sapiens	Inhibition	%	-2.25
	8217022	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	1.35	CHEMBL4282	Homo sapiens	Inhibition	%	1.35
	8217420	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	0.39	CHEMBL4282	Homo sapiens	Inhibition	%	0.39
	8217551	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	1.44	CHEMBL4282	Homo sapiens	Inhibition	%	1.44
	8217775	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	1.02	CHEMBL4282	Homo sapiens	Inhibition	%	1.02
	8217876	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-1.52	CHEMBL4282	Homo sapiens	Inhibition	%	-1.52
	8218215	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	0.83	CHEMBL4282	Homo sapiens	Inhibition	%	0.83
	8218342	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	0.53	CHEMBL4282	Homo sapiens	Inhibition	%	0.53
	8218566	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	-4.74	CHEMBL4282	Homo sapiens	Inhibition	%	-4.74
	8218709	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	1.18	CHEMBL4282	Homo sapiens	Inhibition	%	1.18
	8219064	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	-0.2	CHEMBL4282	Homo sapiens	Inhibition	%	-0.2
	8219224	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	0.23	CHEMBL4282	Homo sapiens	Inhibition	%	0.23
	8219474	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	1.55	CHEMBL4282	Homo sapiens	Inhibition	%	1.55
	8219859	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	0.76	CHEMBL4282	Homo sapiens	Inhibition	%	0.76
	8220028	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	0.26	CHEMBL4282	Homo sapiens	Inhibition	%	0.26
	8220381	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	-0.15	CHEMBL4282	Homo sapiens	Inhibition	%	-0.15
	8220719	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	0.52	CHEMBL4282	Homo sapiens	Inhibition	%	0.52
	8220857	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	1.37	CHEMBL4282	Homo sapiens	Inhibition	%	1.37
	8221217	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	5.34	CHEMBL4282	Homo sapiens	Inhibition	%	5.34
	8221350	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	0.12	CHEMBL4282	Homo sapiens	Inhibition	%	0.12
	8221574	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	0.67	CHEMBL4282	Homo sapiens	Inhibition	%	0.67
	8221739	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-0.57	CHEMBL4282	Homo sapiens	Inhibition	%	-0.57
	8222094	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	1.34	CHEMBL4282	Homo sapiens	Inhibition	%	1.34
	8222192	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	0.68	CHEMBL4282	Homo sapiens	Inhibition	%	0.68
	8222416	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	0.26	CHEMBL4282	Homo sapiens	Inhibition	%	0.26
	8222550	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	0.78	CHEMBL4282	Homo sapiens	Inhibition	%	0.78
	8222892	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	1.17	CHEMBL4282	Homo sapiens	Inhibition	%	1.17
	8223036	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	1.66	CHEMBL4282	Homo sapiens	Inhibition	%	1.66
	8223389	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	1.04	CHEMBL4282	Homo sapiens	Inhibition	%	1.04
	8223550	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	0.82	CHEMBL4282	Homo sapiens	Inhibition	%	0.82
	8223774	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	-0.15	CHEMBL4282	Homo sapiens	Inhibition	%	-0.15
	8223800	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	1.8	CHEMBL4282	Homo sapiens	Inhibition	%	1.8
	8224024	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	1.99	CHEMBL4282	Homo sapiens	Inhibition	%	1.99
	8224186	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	-2.27	CHEMBL4282	Homo sapiens	Inhibition	%	-2.27
	8224356	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	0.97	CHEMBL4282	Homo sapiens	Inhibition	%	0.97
	8224580	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	0.77	CHEMBL4282	Homo sapiens	Inhibition	%	0.77
	8224715	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	0.38	CHEMBL4282	Homo sapiens	Inhibition	%	0.38
	8225053	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	5.71	CHEMBL4282	Homo sapiens	Inhibition	%	5.71
	8225187	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	0.91	CHEMBL4282	Homo sapiens	Inhibition	%	0.91
	8225411	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	0.58	CHEMBL4282	Homo sapiens	Inhibition	%	0.58
	8225549	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	0.15	CHEMBL4282	Homo sapiens	Inhibition	%	0.15
	8225908	CHEMBL1961874	GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	1.2	CHEMBL4282	Homo sapiens	Inhibition	%	1.2
	8226066	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-0.36	CHEMBL4282	Homo sapiens	Inhibition	%	-0.36
	8226415	CHEMBL1961875	GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	0.92	CHEMBL4282	Homo sapiens	Inhibition	%	0.92
inactive	9669130	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(-c2[nH]c(-c3ccnc(N)n3)cc2C(N)=O)c1C		CHEMBL1964290	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669131	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)c(OC)c1		CHEMBL2003768	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669132	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncnc2onc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL213505	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669133	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(OC)c(Nc2ccc3nnc(-c4ccccc4)n3n2)c1		CHEMBL1982880	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669134	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669135	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	N#CCOc1ccc(Nc2nc(Nc3cccc(S(N)(=O)=O)c3)ncc2Br)cc1		CHEMBL1987034	=	Ki	nM	316.23	CHEMBL4282	Homo sapiens	pKi		6.5
inactive	9669136	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1993941	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669137	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669138	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1		CHEMBL578061	<	Ki	nM	19952.62	CHEMBL4282	Homo sapiens	pKi		4.7
inactive	9669139	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12		CHEMBL2005886	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669140	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL481491	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669141	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682345	=	Ki	nM	794.33	CHEMBL4282	Homo sapiens	pKi		6.1
inactive	9669142	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(=O)Nc1c(C(N)=O)sc2ccc(Cl)c(Cl)c12		CHEMBL1973142	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669143	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4nc(N)nc(N)c34)cc2)c1		CHEMBL1973145	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669144	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982924	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669145	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCC(=O)Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL2005936	=	Ki	nM	1584.89	CHEMBL4282	Homo sapiens	pKi		5.8
active	9669146	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC1CCC(Nc2nccc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1966628	=	Ki	nM	1258.93	CHEMBL4282	Homo sapiens	pKi		5.9
inactive	9669147	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc(C(N)=O)c3)cc2)c1		CHEMBL1971141	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669148	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC1CCCCC1Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL1995813	=	Ki	nM	630.96	CHEMBL4282	Homo sapiens	pKi		6.2
active	9669149	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1c(C)n(Cc2ccccc2)c2ccc(C(=O)Nc3nc[nH]n3)cc12		CHEMBL1979718	=	Ki	nM	1258.93	CHEMBL4282	Homo sapiens	pKi		5.9
active	9669150	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(COCc1ccccc1)COc1cncc(C=Cc2ccncc2)c1		CHEMBL1993781	=	Ki	nM	1258.93	CHEMBL4282	Homo sapiens	pKi		5.9
inactive	9669151	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1[nH][nH]c2cccc(-c3ccccc3)c12		CHEMBL1989834	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
inactive	9669152	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCn1c2cc(Cl)c(O)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL523823	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669153	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC1(C)CC2=Nc3cc(Cl)ccc3SC2=C(O)C1		CHEMBL1562756	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669154	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3cn[nH]c3c2)n1		CHEMBL244378	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669155	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(OCC(F)(F)F)nccn23)n1		CHEMBL2001957	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669156	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COCCNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1969372	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669157	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncnn2ccc(C(=O)Nc3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1990583	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669158	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	1995.26	CHEMBL4282	Homo sapiens	pKi		5.7
inactive	9669159	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1ccc(Nc2ncnc3ccccc23)cc1		CHEMBL289959	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
active	9669160	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nc2ccc(NS(=O)(=O)c3ccc(N)cc3)cc2nc1C		CHEMBL2006263	=	Ki	nM	1584.89	CHEMBL4282	Homo sapiens	pKi		5.8
active	9669161	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	OC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1993584	=	Ki	nM	2511.89	CHEMBL4282	Homo sapiens	pKi		5.6
inactive	9669162	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCn1c(C)c(-c2ccnc(Nc3cccc(OC)c3)n2)sc1=O		CHEMBL1986263	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669163	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CSc1c[nH]c2ncnc(NCCCO)c12		CHEMBL2000114	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669164	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669165	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cccc12		CHEMBL1975647	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669166	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1968380	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669167	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NCc1ccccc1)Nc1ncc([N+](=O)[O-])s1		CHEMBL1964644	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669168	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NCc1ccc(Cl)c(Cl)c1)Nc1ccc2[nH]ncc2c1		CHEMBL1981782	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9669169	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNC(=O)c1cc2c(-c3ccccc3F)n[nH]c2s1		CHEMBL1977681	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669170	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNC(=O)C(C)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(C)cc5)cc4)csc23)cn1		CHEMBL1970142	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669171	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669172	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	OCCNc1cc2cc(-c3cccnc3)ccc2cn1		CHEMBL1990912	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669173	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669174	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(O)ccc1-n1c2cc(Cl)ccc2c(=O)c2c(N)nc(N)nc21		CHEMBL1995592	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669175	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12		CHEMBL1975128	=	Ki	nM	630.96	CHEMBL4282	Homo sapiens	pKi		6.2
inactive	9669176	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1CCCc2oc3cc(C(F)(F)F)ccc3c(=O)c21		CHEMBL2006493	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669177	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(OC)c(CNC(=O)c2cc(N)c(C#N)c(OC(C)C)n2)c1		CHEMBL1982541	=	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
inactive	9669178	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Clc1cc2nn[nH]c2cc1Cl		CHEMBL1996923	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669179	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1C		CHEMBL1983449	=	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669180	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1[nH]cnc2c1oc1ccc(Cl)cc12		CHEMBL1992323	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669181	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(Cl)nccn23)n1		CHEMBL1969735	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669182	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCc1nc2c(c3cc(OC)c(OC)cc13)C(=O)NC2=O		CHEMBL2003524	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669183	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc2c(c1)C(=Cc1c[nH]cn1)C(=O)N2		CHEMBL2002649	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669184	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1ccc2c(c1)Cc1c[nH]nc1-2		CHEMBL1989423	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
inactive	9669185	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCn1c(C2CCNCC2)nc(-c2ccc(Cl)c(Cl)c2)c1-c1ccnc(NC2CCCCC2)n1		CHEMBL437747	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669186	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Brc1ccc2c(c1)-c1[nH]ncc1C2		CHEMBL1995172	<	Ki	nM	50118.72	CHEMBL4282	Homo sapiens	pKi		4.3
inactive	9669187	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL507936	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669188	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=S(=O)(NCCNCC=Cc1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL1987756	=	Ki	nM	125.89	CHEMBL4282	Homo sapiens	pKi		6.9
inactive	9669189	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCNS(C)(=O)=O)cnc(N)c34)cc2)c1		CHEMBL1994321	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669190	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1NCCc2[nH]c(-c3ccnc(C=Cc4ccccc4)c3)cc21		CHEMBL1997129	=	Ki	nM	1995.26	CHEMBL4282	Homo sapiens	pKi		5.7
inactive	9669191	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cc(Cl)cc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12		CHEMBL1984788	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669192	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	FC(F)(F)c1ccc(-c2nnc3ccc(NC4CC4)nn23)cc1		CHEMBL451964	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669193	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL1964307	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9669194	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Fc1ccc(-c2nc3sccn3c2-c2ccncc2)cc1		CHEMBL2000508	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669195	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCCNc1n[s+]([O-])nc1Nc1ccc(F)cc1		CHEMBL1971694	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669196	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2001547	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669197	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669198	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1F		CHEMBL1994361	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9669199	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(NC(=O)CCNC(=O)Nc2nc(C)c(-c3ccc(-n4cccn4)cc3)s2)no1		CHEMBL1986603	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669200	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669201	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(COc1cncc(-c2cc3cnccc3s2)c1)Cc1c[nH]c2ccccc12		CHEMBL1972840	=	Ki	nM	125.89	CHEMBL4282	Homo sapiens	pKi		6.9
inactive	9669202	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CCO)c5)cnc(N)c34)cc2)cc1		CHEMBL1977148	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669203	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(C=C2SC(=O)NC2=O)ccc1O		CHEMBL2003286	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669204	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccn1		CHEMBL1992306	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669205	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(O)Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL2002165	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669206	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1[nH]cc(I)c2nc(-c3ccccc3)cn12		CHEMBL2001668	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669207	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1n[nH]c2c1C(c1ccccc1I)C(C#N)=C(N)O2		CHEMBL1979318	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669208	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1989518	=	Ki	nM	3981.07	CHEMBL4282	Homo sapiens	pKi		5.4
inactive	9669209	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1998585	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669210	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cn1cncc1C(OCc1c(-c2ccc(OC(F)(F)F)cc2)cc(C#N)c(=O)n1C)c1ccc(C#N)cc1		CHEMBL127898	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669211	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2C		CHEMBL519697	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669212	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(F)c2)c1		CHEMBL2004934	=	Ki	nM	1258.93	CHEMBL4282	Homo sapiens	pKi		5.9
inactive	9669213	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(O)c1cc(-c2cccs2)n2nccc2n1		CHEMBL1977619	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
active	9669214	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12		CHEMBL1975128	=	Ki	nM	630.96	CHEMBL4282	Homo sapiens	pKi		6.2
inactive	9669215	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)C1CCCN(C(=O)c2cc(-c3ccc4[nH]ncc4c3)on2)C1		CHEMBL1970369	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669216	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C(C)C(=O)N(C)C)c5)cnc(N)c34)cc2)cc1		CHEMBL2001485	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669217	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669218	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(C)c2c(n1)sc1c(N)ncnc12		CHEMBL504950	=	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669219	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN(C)CCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1966425	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669220	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)ccc1F		CHEMBL1984363	=	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669221	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNC(=O)COc1ccc(Nc2nc(Nc3ccc(C)c(S(N)(=O)=O)c3)ncc2F)cc1		CHEMBL1978099	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669222	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COC(=O)c1c(-c2ccc(NC(=O)Nc3ccccc3)cc2)c2c(N)ncnn2c1C		CHEMBL1977041	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669223	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cccc2c1Nc1nnc(Cl)cc1C(=O)N2		CHEMBL1968070	=	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
active	9669224	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(=O)Nc1cccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)c1		CHEMBL1988608	=	Ki	nM	1995.26	CHEMBL4282	Homo sapiens	pKi		5.7
inactive	9669225	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)cc1C		CHEMBL184847	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669226	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN(C)c1ccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)cc1		CHEMBL1984367	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669227	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COCC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(C)nccn23)n1		CHEMBL1982563	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9669228	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1CCCN1Cc1ccc2c(c1)[nH]c(=O)c1cccn12		CHEMBL539474	=	Ki	nM	125.89	CHEMBL4282	Homo sapiens	pKi		6.9
active	9669229	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(COc1cncc(-c2ccc3[nH]c(=O)oc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1987679	=	Ki	nM	6.31	CHEMBL4282	Homo sapiens	pKi		8.2
inactive	9669230	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(OC(F)F)cc5)cc4)csc23)cn1		CHEMBL1988387	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669231	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc(NC(=O)c2cnn3c(-c4ccccc4)ccnc23)c1		CHEMBL1997759	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9669232	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673184	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673185	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1[nH]c2cc(Cl)cc(Cl)c2c(-c2cc(Cl)ccc2O)c1O		CHEMBL1974803	=	Ki	nM	3162.28	CHEMBL4282	Homo sapiens	pKi		5.5
inactive	9673186	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL1970074	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673187	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1NCc2c(Br)cccc21		CHEMBL1984500	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
active	9673188	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COCCN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1986970	=	Ki	nM	3162.28	CHEMBL4282	Homo sapiens	pKi		5.5
inactive	9673189	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC1=NN(c2cccc(Br)c2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL2005112	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673190	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1cc(-c2ccncc2)nc(NC2CCCCC2)[nH]1		CHEMBL1958401	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673191	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCN(CC)CCOc1ccc(-c2nc3c(C(N)=O)cccc3[nH]2)cc1		CHEMBL1984044	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673192	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1[nH]c2cc(-c3ccccc3)cnc2[nH]1		CHEMBL2003456	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673193	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)cccc12		CHEMBL1966816	=	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673194	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673195	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL2002992	=	Ki	nM	1258.93	CHEMBL4282	Homo sapiens	pKi		5.9
inactive	9673196	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	N#Cc1cnc(NC(=O)Nc2ccc3cc(C(=O)O)ccc3c2)cn1		CHEMBL560813	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673197	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCOn1c2ccc(Cl)cc2c(=O)c2c(C)nn(C)c21		CHEMBL207253	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673198	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CC(CN2CCCC2)C1		CHEMBL1968791	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673199	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1CC(c2ccc(Cl)cc2Cl)Cc2nc3cc(Cl)ccc3c(O)c21		CHEMBL326282	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673200	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOc1ccccc1C=NNC(=O)c1nnn(-c2nonc2N)c1N1CCCC1		CHEMBL1992732	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673201	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Fc1ccc(-c2nc3occn3c2-c2ccnc(NC3CCNCC3)n2)cc1		CHEMBL1971186	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673202	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Cc1ccc(Cl)cc1)Nc1[nH]nc2c1CCC2		CHEMBL2003482	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673203	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(=O)Nc1cc2ccccn2n1		CHEMBL1976872	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
inactive	9673204	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1nccc2cnc(-c3ccccc3)n12		CHEMBL1969156	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
inactive	9673205	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCCC5)cnc(N)c34)cc2)c1		CHEMBL1973211	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673206	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1984700	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673207	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673208	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CCC(N2CCCC2)CC1		CHEMBL2007151	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673209	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1		CHEMBL1972125	=	Ki	nM	1995.26	CHEMBL4282	Homo sapiens	pKi		5.7
inactive	9673210	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1ccc2[nH]ncc2c1)c1cccc(F)c1		CHEMBL1461728	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673211	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673212	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1cc2cc(-c3ccc4cn[nH]c4c3)cnc2[nH]1		CHEMBL1976134	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673213	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(C(=O)Nc2c(C(N)=O)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL1965131	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673214	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NCCOc1cccc(Nc2ccnc(N)n2)c1		CHEMBL1995448	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673215	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL1972158	=	Ki	nM	1258.93	CHEMBL4282	Homo sapiens	pKi		5.9
inactive	9673216	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL1974457	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673217	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673218	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Oc1ccc(Nc2ncnc3scc(Cl)c23)cc1		CHEMBL2006580	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673219	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1Cl		CHEMBL2006581	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673220	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCCC1		CHEMBL2006481	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673221	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCC#N)c2)n1		CHEMBL1979855	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673222	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1noc2cccc(-c3cccc(O)c3)c12		CHEMBL1970340	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673223	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL2005186	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673224	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCNc1nc2cc(Cl)c(OC)cc2nc1NCC		CHEMBL1995927	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673225	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NCC(O)C(O)Cn1cc(I)c2c(N)ncnc21		CHEMBL1975534	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673226	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1n[nH]c2c1C(c1ccccc1F)C1=C(CC(C)(C)CC1=O)N2		CHEMBL1966703	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673227	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)N(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1969561	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9673228	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN(C)c1cc2sncc2cc1NC(=O)C(=O)O		CHEMBL1997023	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673229	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(C)cc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1964687	<	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9673230	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673231	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cc2c(-c3ccc(Br)c(F)c3F)cncc2s1		CHEMBL1999918	=	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
inactive	9673232	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1974254	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673233	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(C(=O)N2c3ccccc3Sc3c(Cl)cncc32)cc1		CHEMBL1988537	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673234	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(C)c2)c1		CHEMBL1969049	=	Ki	nM	1995.26	CHEMBL4282	Homo sapiens	pKi		5.7
inactive	9673235	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)cc1		CHEMBL2005828	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673236	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccc3ccccc3c2)n1		CHEMBL2002240	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673237	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1		CHEMBL363648	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673238	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(-n2nc(C)c3c(=O)c4cc(Cl)ccc4n(O)c32)cc1		CHEMBL1991143	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673239	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673240	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1sc2c(Br)ccc(Cl)c2c1N		CHEMBL1998611	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673241	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2CCC(N)=O		CHEMBL485556	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673242	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1c(NCc2ccc(Cl)c(Cl)c2)c(Nc2ccncc2)c1=O		CHEMBL1975900	=	Ki	nM	794.33	CHEMBL4282	Homo sapiens	pKi		6.1
active	9673243	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(C=C2SC(=S)NC2=O)ccc1O		CHEMBL1973098	=	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673244	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(=O)CC)c3c2)cc1		CHEMBL1972221	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673245	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNC(=O)C=Cc1cnc(N)c2c(-c3cc(F)c4[nH]c(C)cc4c3)csc12		CHEMBL2006778	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673246	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673247	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1c(F)cccc1F		CHEMBL1996979	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673248	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cccc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12		CHEMBL1997025	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673249	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1968406	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673250	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)csc12		CHEMBL1982476	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673251	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1C(=NNc2cccc3c(=O)[nH][nH]c(=O)c23)C(c2ccccc2)=NN1c1ccccc1		CHEMBL1984274	=	Ki	nM	1584.89	CHEMBL4282	Homo sapiens	pKi		5.8
inactive	9673252	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1998545	<	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
inactive	9673253	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1csc(NC(=O)c2sc3nc(-c4ccncc4)ccc3c2N)n1		CHEMBL1986869	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673254	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(Cl)c(Cl)ccc12		CHEMBL2006010	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673255	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Fc1ccc(-c2ncn(CCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1		CHEMBL1682558	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673256	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O		CHEMBL1990496	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673257	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1n[nH]c2cc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)ccc12		CHEMBL1997623	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673258	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccc(Cl)cc5o4)cc3)c1)CNC2=O		CHEMBL2002479	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9673259	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C		CHEMBL1472492	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673260	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(=NNC(=N)N)c1cc(NC(=O)NCCCN(C)CCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL1993166	=	Ki	nM	398.11	CHEMBL4282	Homo sapiens	pKi		6.4
inactive	9673261	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NCc1ccc(Cl)cc1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL1967094	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673262	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1		CHEMBL1966035	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673263	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NC(CO)c1cc(Cl)cc(Cl)c1)c1ccc(-c2ccncc2)cc1		CHEMBL2003341	=	Ki	nM	3162.28	CHEMBL4282	Homo sapiens	pKi		5.5
active	9673264	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1ccc(-c2n[nH]cc2-c2ccncc2)cc1		CHEMBL1992644	=	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673265	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NS(=O)(=O)c1ccc(NCCSc2ccc(O)cc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)cc1		CHEMBL1992645	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673266	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Oc1cccc(Nc2ncnc3scc(Cl)c23)c1		CHEMBL1982992	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673267	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(-c2ccccc2)n(-c2cc(NN=Cc3ccco3)ncn2)n1		CHEMBL1999590	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673268	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1F		CHEMBL1981079	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673269	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCN(CC)CCCNc1cccc(-c2nc3c(C(N)=O)cccc3[nH]2)n1		CHEMBL1972276	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673270	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1c(NCc2ccc(Cl)cc2)c(Nc2ccncc2)c1=O		CHEMBL1980489	=	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
active	9673271	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCc4cccc(F)c4)cc2NC3=O)ccc1O		CHEMBL2000832	=	Ki	nM	1995.26	CHEMBL4282	Homo sapiens	pKi		5.7
inactive	9673272	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)c1		CHEMBL1967116	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673273	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nn(C)c2c1c(=O)c1cc(Cl)ccc1n2OCC(C)C		CHEMBL1977814	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673274	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nc2ccccn2c1-c1csc(Nc2ccc(O)cc2)n1		CHEMBL513846	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673275	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NCc1ccc(Br)cc1)Nc1ccc2[nH]ncc2c1		CHEMBL1970709	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673276	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	=	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673277	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(-c2cc3nccn3c(Nc3ccccc3C(N)=O)n2)cc1OC		CHEMBL1998112	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673278	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)n1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)cc21		CHEMBL1969126	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673279	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncnc2sc(Br)c(-c3ccc(NC(=O)Cc4cccc(Cl)c4)cc3)c12		CHEMBL1980896	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673280	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(=O)NC1CCN(c2nc3[nH]cc(C(=O)O)c(=O)c3c(C)c2F)C1		CHEMBL1975208	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673281	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673282	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cc2c(Oc3cccc(F)c3)cncc2s1		CHEMBL1964777	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673283	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)C(=O)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1971149	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673284	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc2c(c1)NC(=O)c1ccccc1N2		CHEMBL1999714	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673285	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Cc1ccccc1Cl)Nc1ccc2cn[nH]c2c1		CHEMBL1987533	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673286	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(O)CNc1nccc(-c2c(-c3ccc(F)cc3F)nc3c(CC4CC4)nccn23)n1		CHEMBL1994040	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673287	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL1980995	<	Ki	nM	2.512	CHEMBL4282	Homo sapiens	pKi		8.6
active	9673288	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(COc1cncc(-c2ccc3c(c2)CC(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL1967302	=	Ki	nM	10.0	CHEMBL4282	Homo sapiens	pKi		8.0
inactive	9673289	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)cn1		CHEMBL398951	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673290	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc2cnc3c(c2cc1OC)C(=O)NC3=O		CHEMBL1982506	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673291	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCN(CC)CCNC(=O)C=Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2004716	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673292	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1		CHEMBL1968127	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673293	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(C)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1975233	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673294	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cccc(F)c3F)cc12		CHEMBL1985406	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673295	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cn1nc(C(F)(F)F)c2c(=O)c3cc(Cl)ccc3n(O)c21		CHEMBL207400	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673296	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(O)ccc1-n1cc(C(=O)NN)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL2000894	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673297	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccccc1NC(=O)Nc1ccc2c(c1)CCc1sc3ncnc(N)c3c1-2		CHEMBL1982135	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673298	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncnc2c1sc1ncnc(N)c12		CHEMBL1976090	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673299	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4c(c3)OCO4)csc12		CHEMBL1993243	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673300	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	OCC(CO)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1992922	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673301	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3o2)cc1		CHEMBL2004771	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673302	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CC(CN2CCCC2)C1		CHEMBL1988370	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673303	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1997597	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673304	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	S=c1[nH]nc2c3c4c(sc3n3c(=S)[nH]nc3n12)CCC4		CHEMBL1969537	=	Ki	nM	1995.26	CHEMBL4282	Homo sapiens	pKi		5.7
active	9673305	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Ki	nM	3162.28	CHEMBL4282	Homo sapiens	pKi		5.5
inactive	9673306	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1976093	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673307	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1		CHEMBL210032	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673308	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(COc1cncc(-c2ccc(F)cc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1996543	=	Ki	nM	630.96	CHEMBL4282	Homo sapiens	pKi		6.2
inactive	9673309	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1cccs1		CHEMBL1975256	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673310	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cnc4c(-c5cnn(C)c5)cnn4c3N)cc2)c1		CHEMBL508928	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673311	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc(-c2cc3c(=O)[nH]c4ccccc4n3c2)c1		CHEMBL1991356	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673312	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(C(=O)Nc2nc3ccc(Cl)cc3s2)c(OC)c1		CHEMBL1983309	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673313	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL2004892	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673314	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC1=NN(c2ccccc2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL1999126	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673315	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)Oc1ccc(-c2noc(-c3ccc(NC4CCC(C(=O)O)C4)cc3)n2)cc1Cl		CHEMBL1997503	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673316	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cc2c(Oc3ccc(Br)cc3)cncc2s1		CHEMBL116070	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673317	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(C)c(C)c(OCCCc2c(C(=O)O)[nH]c3c(-c4ccccc4C)cccc23)c1		CHEMBL1990821	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673318	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cc(-c2cccc(N)c2)cc2cccnc12		CHEMBL1970314	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673319	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	OCCCn1cnc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL2004871	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673320	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncn3)cc2)c1		CHEMBL2004872	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673321	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1Nc2ccccc2Nc2ccccc21		CHEMBL1727312	<	Ki	nM	50118.72	CHEMBL4282	Homo sapiens	pKi		4.3
inactive	9673322	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC1CCN(C(=O)CO)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL1969879	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673323	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1cnccn1)Nc1ccnc2ccccc12		CHEMBL1981720	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673324	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(N)COc1cnc(Cl)c(C=Cc2ccncc2)c1		CHEMBL1993548	=	Ki	nM	2511.89	CHEMBL4282	Homo sapiens	pKi		5.6
inactive	9673325	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3nsc4ncnc(N)c34)cc2)c1		CHEMBL262433	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673326	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1		CHEMBL306380	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673327	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nn(C)c2sc(C(N)=O)cc12		CHEMBL1986588	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
active	9673328	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NNC(=S)Nc1ccc(Cl)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1966722	=	Ki	nM	1258.93	CHEMBL4282	Homo sapiens	pKi		5.9
active	9673329	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCNC(C)=O)cc2NC3=O)ccc1O		CHEMBL1975500	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9673330	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4snc(N)c34)cc2)c1		CHEMBL1976328	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673331	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ccnc(N)c34)cc2)c1		CHEMBL394619	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673332	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)cc1OC		CHEMBL1964399	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673333	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(O)c1c2c(nc3ccccc13)C(=C1CCCC1)CC2		CHEMBL1996831	=	Ki	nM	1000.0	CHEMBL4282	Homo sapiens	pKi		6.0
inactive	9673334	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc1)CCN2		CHEMBL411903	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673335	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN)cnc(N)c34)cc2)c1		CHEMBL1965988	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673336	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673337	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL1989646	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673338	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1ccc(Cc2cc(-c3ccc4[nH]ncc4c3)on2)cc1		CHEMBL1682357	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673339	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9673340	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOc1nc(C(=O)NCc2cccnc2)cc(N)c1C#N		CHEMBL209534	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673341	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nccn2c(-c3ccnc(NCCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1978200	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673342	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673343	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN(C)S(=O)(=O)c1ccccc1-c1ccc2c(c1)Nc1ccccc1NC2=O		CHEMBL2006631	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673344	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(C=C2SC(=Nc3ccccc3)NC2=O)ccc1O		CHEMBL1970522	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673345	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673346	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1n[nH]c2nc3ccccc3cc12)c1ccncc1		CHEMBL1990415	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673347	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	C(=Cc1cncc(OC2CCNC2)c1)c1ccncc1		CHEMBL1966087	=	Ki	nM	3162.28	CHEMBL4282	Homo sapiens	pKi		5.5
inactive	9673348	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)cncc21		CHEMBL1964692	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673349	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NC(CO)Cc1ccc(Cl)cc1)c1ccc(-c2ccncc2)cc1		CHEMBL1996931	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673350	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	FC(F)(F)c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C(F)(F)F)c1		CHEMBL1964413	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673351	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL1973483	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673352	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C)c1		CHEMBL1984432	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673353	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL1970735	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673354	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL219722	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673355	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCC(O)C1		CHEMBL1997340	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673356	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOC(=O)C1=C(N)n2c(sc(=Cc3cccs3)c2=O)=C(C(N)=O)C1c1cccs1		CHEMBL2004365	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673357	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc(Nc2ncnc3ccccc23)c1		CHEMBL117697	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673358	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673359	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cn1cc(-c2ccncn2)c(-c2ccc(F)cc2)n1		CHEMBL1989474	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673360	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1nc2ccccc2n1CCCO)c1cccc([N+](=O)[O-])c1		CHEMBL210887	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673361	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673362	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C(F)(F)F)c2)c1		CHEMBL1971021	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673363	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(OC(F)(F)F)c4)c3)cc12		CHEMBL1965836	=	Ki	nM	3.162	CHEMBL4282	Homo sapiens	pKi		8.5
inactive	9673364	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1[nH]cnc2c1sc1c(Cl)ccc(Cl)c12		CHEMBL583144	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673365	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cc2c(-c3ccc(F)cc3)cncc2s1		CHEMBL1974310	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673366	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673367	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncnc2sc3c(c12)-c1ccc(NC(=O)Nc2ccccc2)cc1CC3		CHEMBL1994693	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673368	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cccc(-c2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982957	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673369	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673370	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NNC(=S)Nc1ccc(F)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1975138	=	Ki	nM	501.19	CHEMBL4282	Homo sapiens	pKi		6.3
active	9673371	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1ccc(CNc2cc(-c3c[nH]c4ncccc34)ncn2)cc1		CHEMBL2002346	=	Ki	nM	1000.0	CHEMBL4282	Homo sapiens	pKi		6.0
inactive	9673372	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N		CHEMBL424872	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673373	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC1=NN(c2ccc(C(=O)O)cc2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL2006836	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673374	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#Cc5cccnc5)cnc(N)c34)cc2)c1		CHEMBL1971947	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673375	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1		CHEMBL412142	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673376	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673377	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc2nnc(SCc3cn4ccccc4n3)n2c2ccccc12		CHEMBL1980704	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673378	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1sc2ccc(Cl)c(Cl)c2c1NC(=O)c1ccc(Cl)cc1		CHEMBL2003271	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673379	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1cc2nc(-c3ccccc3)cn2cn1		CHEMBL1972365	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
inactive	9673380	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccncc4)nn12)CCCC3		CHEMBL1966808	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673381	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(C)c1n[nH]c2c1C(c1ccccc1F)C(C#N)=C(N)O2		CHEMBL2004447	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673382	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673383	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	OCCNc1cc2cc(-c3ccsc3)ccc2cn1		CHEMBL1973860	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673384	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NCc1ccc(Cl)cc1)Nc1cccc2[nH]ncc12		CHEMBL1977713	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673385	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1n[nH]c2nnc(-c3ccccc3)c(-c3ccccc3)c12		CHEMBL260135	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673386	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21		CHEMBL220241	=	Ki	nM	501.19	CHEMBL4282	Homo sapiens	pKi		6.3
inactive	9673387	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=S(=O)(O)c1ccc(NCc2ccc3c(c2)OCO3)c2c(O)cccc12		CHEMBL2004544	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673388	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1[nH]cc(I)c2nc(-c3cccc(Cl)c3)cn12		CHEMBL1982610	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673389	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(C2(c3cccc(C)c3)CC2C(=O)Nc2ccncc2)c1		CHEMBL1999496	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673390	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc2c(c1)C(=O)Nc1ccccc1N2		CHEMBL1970873	<	Ki	nM	50118.72	CHEMBL4282	Homo sapiens	pKi		4.3
active	9673391	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CSc1cnc2c(ccc3cnccc32)c1O		CHEMBL2006933	=	Ki	nM	794.33	CHEMBL4282	Homo sapiens	pKi		6.1
inactive	9673392	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ccc(-c2csc3c(C=Cc4nc5ccccc5[nH]4)cnc(N)c23)cc1		CHEMBL1988300	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673393	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC		CHEMBL1991078	=	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
inactive	9673394	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673395	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCCNc1ccc2c3c(cccc13)C(=O)N(CCNCCO)C2=O		CHEMBL1987359	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673396	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(=NNC(=N)N)c1cc(NC(=O)c2cccc(C(=O)Nc3cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c3)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL2000685	=	Ki	nM	158.49	CHEMBL4282	Homo sapiens	pKi		6.8
active	9673397	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	=	Ki	nM	501.19	CHEMBL4282	Homo sapiens	pKi		6.3
active	9673398	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(CO)ccc4F)cc3)c12		CHEMBL1985311	=	Ki	nM	3981.07	CHEMBL4282	Homo sapiens	pKi		5.4
inactive	9673399	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC1CSc2c(C(=O)O)c(=O)c3cc(F)c(N4CCC(N)C4)cc3n21		CHEMBL1989265	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673400	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	=	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673401	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNC1CCN(c2nc3[nH]cc(C(=O)O)c(=O)c3c(C)c2Br)C1		CHEMBL2004647	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673402	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1NN=Cc2c[nH]c3cc(NC(=O)C4CC4c4ccccc4)cc1c23		CHEMBL1969502	=	Ki	nM	158.49	CHEMBL4282	Homo sapiens	pKi		6.8
inactive	9673403	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CCC(N2CCCC2)CC1		CHEMBL1965910	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673404	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)Nc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12		CHEMBL1682553	=	Ki	nM	1258.93	CHEMBL4282	Homo sapiens	pKi		5.9
inactive	9673405	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(-c2c(-c3ccncc3)nc(NCC(N)Cc3ccccc3)n(C)c2=O)c1		CHEMBL1971430	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673406	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)cc1		CHEMBL1997764	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673407	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)c1		CHEMBL1983963	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673408	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1n[nH]c2ccc(-c3cncc(OCC(CN)Cc4ccccc4)c3)cc12		CHEMBL2000271	=	Ki	nM	39.81	CHEMBL4282	Homo sapiens	pKi		7.4
active	9673409	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1[nH]cnc2ccc(Br)cc12		CHEMBL562488	=	Ki	nM	50118.72	CHEMBL4282	Homo sapiens	pKi		4.3
inactive	9673410	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Oc1ccc(-c2n[nH]c(Nc3cccc(Cl)c3)c2-c2ccc(O)cc2)cc1		CHEMBL1985092	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673411	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1ccccc1		CHEMBL2004692	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673412	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL1981410	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673413	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC1(O)CC(c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn23)C1		CHEMBL1996234	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9673414	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(C=C2C(=O)ON=C2c2ccc(Br)cc2)cc1OC		CHEMBL1991434	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673415	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN(C)c1cccc2c(S(=O)(=O)N(CCN)c3cncc(-c4ccc5cnccc5c4)c3)cccc12		CHEMBL1967544	=	Ki	nM	1258.93	CHEMBL4282	Homo sapiens	pKi		5.9
active	9673416	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2		CHEMBL223367	=	Ki	nM	3162.28	CHEMBL4282	Homo sapiens	pKi		5.5
inactive	9673417	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673418	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cn(-c2ccc(O)cc2Cl)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL340384	=	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
inactive	9673419	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1996587	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9673420	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CS(=O)(=O)NCCOc1cncc(-c2ccc3cnccc3c2)c1		CHEMBL1964804	=	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
inactive	9677367	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(-c2cnc3c(Br)cnn3c2)cc1		CHEMBL443962	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677368	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(C=C2SC(=Nc3ccccc3)NC2=O)cc1O		CHEMBL2000354	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677369	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1965507	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677370	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cn1ncc2c1CCCC2=O		CHEMBL1981107	<	Ki	nM	19952.62	CHEMBL4282	Homo sapiens	pKi		4.7
inactive	9677371	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677372	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCC(=O)Nc1n[nH]c2nc3ccccc3cc12		CHEMBL1967564	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677373	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL592030	=	Ki	nM	251.19	CHEMBL4282	Homo sapiens	pKi		6.6
inactive	9677374	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	OCCCNc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL2000071	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677375	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc2c(NC(=O)Nc3cc(C(F)(F)F)ccn3)ccnc2c1		CHEMBL1979176	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677376	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1970317	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677377	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc2c(C)n1		CHEMBL2000408	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677378	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	=	Ki	nM	3981.07	CHEMBL4282	Homo sapiens	pKi		5.4
inactive	9677379	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN1CCC(C(=O)n2nc(N)c3cc(-c4cn(Cc5ccccc5)nn4)ccc32)CC1		CHEMBL1978014	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677380	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1cnccn1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1994538	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677381	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCN(CC)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1		CHEMBL1983195	=	Ki	nM	3162.28	CHEMBL4282	Homo sapiens	pKi		5.5
inactive	9677382	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1975490	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677383	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1964444	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677384	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	OCCNc1cc2cc(-c3ccccc3)ccc2cn1		CHEMBL1989957	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677385	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccsc2)n1		CHEMBL2006567	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677386	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Clc1csc2ncnc(Nc3ccccc3)c12		CHEMBL1986139	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677387	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(Cc1cccc2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1985580	=	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
inactive	9677388	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(Cl)cccc12		CHEMBL1980540	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677389	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN(C)C)cnc(N)c34)cc2)c1		CHEMBL1979883	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677390	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(C)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1984162	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677391	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Fc1cnc(Nc2ccccc2)nc1Nc1ccccc1		CHEMBL491758	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677392	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C(C)(C)C		CHEMBL1986186	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677393	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1cc2[nH]ncc2cc1-c1cc(CN2CCCCC2)no1		CHEMBL1682360	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677394	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1n[nH]c2c1C(c1ccccc1Cl)C(C#N)=C(N)O2		CHEMBL1970189	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677395	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncnc2c1c(I)nn2C1CCC(O)CC1		CHEMBL1996791	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677396	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3c(C)sc4ncnc(N)c34)cc2)c1		CHEMBL371206	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677397	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(C=NNc2ncnc3c2[nH]c2ccccc23)cc1OC		CHEMBL1974664	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677398	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677399	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NC(CO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1974288	=	Ki	nM	1995.26	CHEMBL4282	Homo sapiens	pKi		5.7
inactive	9677400	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)c1		CHEMBL196363	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677401	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nn(C)c2sc(C(N)=O)c(N)c12		CHEMBL1996837	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
inactive	9677402	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(-c2cc3nccn3c(Nc3ncccc3C(N)=O)n2)cc1OC		CHEMBL1190711	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677403	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1n[nH]c2cccc(-c3ccc(Br)cc3)c12		CHEMBL1990346	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
active	9677404	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1		CHEMBL1968705	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9677405	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL404367	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677406	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)Cc1cc(-c2ccc3[nH]nc(N)c3c2)on1		CHEMBL1966343	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677407	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1n[nH]c2ccc(-c3cncc(OCCN)c3)cc12		CHEMBL1967887	=	Ki	nM	1995.26	CHEMBL4282	Homo sapiens	pKi		5.7
inactive	9677408	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(=O)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL2000568	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677409	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)cc1C		CHEMBL2000335	=	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
inactive	9677410	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC1CSc2c(C(=O)O)c(=O)c3cc(F)c(N4CCC(N)C4)c(F)c3n21		CHEMBL1977604	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677411	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1n[nH]c2c(Cl)cccc12		CHEMBL1980161	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
inactive	9677412	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677413	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cn1cc(-c2cnn3c(N)c(-c4ccc(NC(=O)Nc5cccc(C(F)(F)F)c5)cc4)cnc23)cn1		CHEMBL1988717	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677414	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1		CHEMBL1974328	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677415	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677416	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677417	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1ccccc1)Nc1ccccn1		CHEMBL143703	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
inactive	9677418	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1ccc2[nH]ncc2c1)c1ccc(Cl)cc1		CHEMBL1973808	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677419	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2000429	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677420	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)cc1		CHEMBL1972576	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677421	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NN=Cc1ccc(Sc2nc3ccccc3[nH]2)o1)c1cccc([N+](=O)[O-])c1		CHEMBL1992555	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677422	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	=	Ki	nM	79.43	CHEMBL4282	Homo sapiens	pKi		7.1
active	9677423	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1992342	=	Ki	nM	3162.28	CHEMBL4282	Homo sapiens	pKi		5.5
active	9677424	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(Cl)ccc1NC(=S)NNC(=O)C(O)(c1ccccc1)c1ccccc1		CHEMBL1988173	=	Ki	nM	158.49	CHEMBL4282	Homo sapiens	pKi		6.8
inactive	9677425	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	C(=NNc1nc2ccccc2[nH]1)c1c[nH]c2ccccc12		CHEMBL535331	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677426	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	N#CC1=C(N)n2c(sc(=Cc3ccco3)c2=O)=C(C(N)=O)C1c1ccco1		CHEMBL1989805	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677427	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Ki	nM	3162.28	CHEMBL4282	Homo sapiens	pKi		5.5
inactive	9677428	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)Cn1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL1965423	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677429	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCC(N)(C#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12)CC		CHEMBL1983025	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677430	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1983945	=	Ki	nM	100.0	CHEMBL4282	Homo sapiens	pKi		7.0
active	9677431	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1977135	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9677432	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1NC(=S)SC1=C1C(=O)Nc2ccc(Br)cc21		CHEMBL2001920	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677433	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cc2c(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cncc2s1		CHEMBL2002322	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677434	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(F)c(-c2ccc3nnc(N)n3c2)c1		CHEMBL2002323	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677435	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(N)=O)n2)cc(OC)c1OC		CHEMBL1241473	=	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
active	9677436	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CS(=O)(=O)N(Cc1ccc2[nH]c(=O)c3cccn3c2c1)C1CC1		CHEMBL1978448	=	Ki	nM	31.62	CHEMBL4282	Homo sapiens	pKi		7.5
inactive	9677437	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COC(=O)c1ccccc1-c1ccc2c(c1)Nc1ccccc1NC2=O		CHEMBL2004513	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677438	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NCCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1972258	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677439	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCN(CC)CC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2001257	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677440	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(Cl)cc4Cl)c(=O)c3=O)ccc21		CHEMBL2005548	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677441	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)cc1		CHEMBL1992536	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677442	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccccc1-c1c(C(=O)O)n(CCCOc2cccc3ccccc23)c2ccccc12		CHEMBL1987793	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677443	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCN1CCN(CCCC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1		CHEMBL1992740	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677444	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	OCCCn1cnc(-c2ccccc2)c1-c1ccncc1		CHEMBL2002373	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677445	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1cccc(Cl)c1		CHEMBL1973348	<	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
active	9677446	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2NCCCN)c1		CHEMBL2006188	=	Ki	nM	1584.89	CHEMBL4282	Homo sapiens	pKi		5.8
inactive	9677447	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1967531	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677448	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCC(=O)Nc1nn(C(=O)CC)c2nc3ccccc3cc12		CHEMBL1970913	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677449	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(C)=O)c3c2)cc1		CHEMBL1973893	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677450	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOC(=O)c1cccc2[nH]c(-c3ccc(N4CCC(N)C4)cc3)nc12		CHEMBL1995736	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677451	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677452	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc(C(C)NC(=O)c2cc(C)c(-c3ccc4[nH]nc(C)c4c3)s2)c1		CHEMBL1997534	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677453	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1996500	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677454	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)Cn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL1985095	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677455	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(O)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1998551	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677456	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1977374	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677457	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COCc1nnn(-c2nonc2N)c1C(=O)NN=C(C)c1ccc(O)cc1O		CHEMBL1991180	=	Ki	nM	158.49	CHEMBL4282	Homo sapiens	pKi		6.8
inactive	9677458	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677459	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)cn2c1		CHEMBL1682540	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677460	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1c(O)cccc1NC(=O)c1cnn2c(-c3ccccc3)ccnc12		CHEMBL1978656	=	Ki	nM	3162.28	CHEMBL4282	Homo sapiens	pKi		5.5
active	9677461	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12		CHEMBL1976420	=	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677462	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1		CHEMBL1994864	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677463	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCCO)c(Cl)cc1NC(=O)N2		CHEMBL413779	=	Ki	nM	630.96	CHEMBL4282	Homo sapiens	pKi		6.2
inactive	9677464	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOCC5CC5)c4)n[nH]c2-3)CC1		CHEMBL2002446	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677465	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1nc(-c2cc3c(Oc4ccc(I)cc4)cncc3s2)[nH]o1		CHEMBL497151	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677466	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1		CHEMBL246970	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677467	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(O)ccc1-n1cc(C(N)=O)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL340921	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677468	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCCCO)c(Cl)cc1NC(=O)N2		CHEMBL373598	=	Ki	nM	1000.0	CHEMBL4282	Homo sapiens	pKi		6.0
inactive	9677469	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	N#Cc1ccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)nc1		CHEMBL1999718	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677470	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1Nc2ccc3ncsc3c2C1=CNc1ccc(S(=O)(=O)Nc2ccccn2)cc1		CHEMBL1973540	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677471	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1Nc2ccccc2Nc2nnc(I)cc21		CHEMBL1977346	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677472	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL1971649	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677473	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2003657	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677474	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677475	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	OCCNc1cc2cc(-c3ccncc3)ccc2cn1		CHEMBL1998435	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677476	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCCCC2)n1		CHEMBL2006439	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677477	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)N(C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1)C(C)C		CHEMBL2006156	=	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
inactive	9677478	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(-c2ccc(NC(=O)Nc3cc(F)cc(F)c3)cc2)c2c(N)noc12		CHEMBL1969190	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677479	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)n[nH]c12		CHEMBL1973937	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677480	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677481	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1991674	<	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
active	9677482	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1		CHEMBL1982711	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9677483	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	FC(F)(F)Oc1ccc(-c2ccc3[nH]cc(C4=CCNCC4)c3c2)cc1		CHEMBL1987982	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677484	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1984842	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677485	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1		CHEMBL1969102	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677486	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1682346	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
active	9677487	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCN(CC)CC#Cc1ccc2c(c1)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL2007044	=	Ki	nM	3981.07	CHEMBL4282	Homo sapiens	pKi		5.4
inactive	9677488	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNC(=O)N1CCN(CCCOc2ccc3c(c2)-c2[nH]nc(-c4ccc(C#N)nc4)c2C3)CC1		CHEMBL2001998	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677489	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(C=C(C#N)c2nc3ccccc3[nH]2)c(Br)cc1O		CHEMBL1994241	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677490	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2		CHEMBL223460	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677491	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1ccc(Cl)cc1		CHEMBL1998829	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677492	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677493	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc(OCC(N)=O)cc1		CHEMBL1988838	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677494	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCN1CCN(c2ccc(Nc3nccc(-c4c(-c5cccc(C(=O)Nc6ccccc6F)c5)nc5ccccn45)n3)cc2)CC1		CHEMBL1981725	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677495	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]ncc34)cc2)c1		CHEMBL375284	=	Ki	nM	3162.28	CHEMBL4282	Homo sapiens	pKi		5.5
inactive	9677496	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COCCn1cc(-c2ccncn2)c(-c2ccc(Cl)cc2)n1		CHEMBL1982866	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677497	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2005792	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677498	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1ccc(CSc2nc(-c3ccncc3)n[nH]2)cc1		CHEMBL1968926	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677499	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOc1nc(C(=O)NCc2ccncc2)cc(N)c1C#N		CHEMBL1984206	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9677500	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1c(-c2ccccc2)c2cc(Cl)ccc2[nH]c1=O		CHEMBL462120	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677501	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C1CCCCC1		CHEMBL1991577	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677502	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1n[nH]c2nc(Cl)sc12		CHEMBL1991867	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
inactive	9677503	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4ccccc4F)cc3)c12		CHEMBL1965570	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677504	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccccc4)nn12)CCCC3		CHEMBL2007592	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677505	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677506	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cncc2cccc(S(=O)(=O)N3CCCNCC3C)c12		CHEMBL1082440	=	Ki	nM	3981.07	CHEMBL4282	Homo sapiens	pKi		5.4
inactive	9677507	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(CO)N1CCC(c2[nH]nc(-c3ccc(Cl)cc3F)c2-c2ccncn2)CC1		CHEMBL1614705	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677508	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CS(=O)(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1		CHEMBL1972362	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677509	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)s2)c1		CHEMBL1984633	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677510	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677511	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2007372	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677512	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc(C(C)NC(=O)N2CC=C(c3c[nH]c4ncccc34)CC2)c1		CHEMBL1965845	=	Ki	nM	1995.26	CHEMBL4282	Homo sapiens	pKi		5.7
active	9677513	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(OC)c(NC(=O)c2cnn3c(-c4ccccc4)ccnc23)c1		CHEMBL1982167	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9677514	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cccc2[nH]c(-c3ccc(NC(=O)c4cccc(S(=O)(=O)N5CCOCC5)c4)cc3)nc12		CHEMBL1986597	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677515	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL1971017	=	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
inactive	9677516	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cccc2[nH]c(-c3ccncc3)nc12		CHEMBL1990482	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677517	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Fc1ccc(-c2nc3cnccn3c2-c2ccnc(NCC3CC3)n2)cc1		CHEMBL1990904	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677518	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NCC1CCCCC1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL2005475	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677519	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCS(=O)(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1		CHEMBL2000104	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677520	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677521	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC1=NN(c2ccc(Cl)c(Cl)c2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL1997349	=	Ki	nM	3981.07	CHEMBL4282	Homo sapiens	pKi		5.4
inactive	9677522	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2C)c1		CHEMBL183844	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677523	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL220057	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677524	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1ccc(Nc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682545	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677525	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1974935	=	Ki	nM	19.95	CHEMBL4282	Homo sapiens	pKi		7.7
inactive	9677526	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(OC2CCCC2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL2001224	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677527	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677528	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(O)Cc1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1976732	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677529	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(S(N)(=O)=O)cc4)c(=O)c3=O)ccc21		CHEMBL1969506	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677530	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NC(CO)c1ccccc1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1964937	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677531	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1		CHEMBL1980163	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677532	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL590109	=	Ki	nM	794.33	CHEMBL4282	Homo sapiens	pKi		6.1
inactive	9677533	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(-c2nn(C3CCC(N4CCN(C(C)=O)CC4)CC3)c3ncnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C		CHEMBL1970879	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677534	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1c(C=O)c(O)n2c(nc3ccccc32)c1C#N		CHEMBL1989856	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677535	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(=O)N(c1ccncc1)c1c(NC(C)C(C)(C)C)c(=O)c1=O		CHEMBL2005899	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677536	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)c(NC3CCCCC3)n2c1		CHEMBL1682552	=	Ki	nM	1258.93	CHEMBL4282	Homo sapiens	pKi		5.9
inactive	9677537	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677538	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cncc(C=Cc2ccncc2)c1		CHEMBL1972568	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677539	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN1CCC1COc1cncc(CCc2ccncc2)c1		CHEMBL1996155	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9677540	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCc1cc(-c2ccc3[nH]ncc3c2)on1		CHEMBL1682359	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677541	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(C)c(C=C2C(=O)Nc3ccccc32)[nH]1		CHEMBL2002702	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677542	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1ccccc1		CHEMBL1991846	=	Ki	nM	1000.0	CHEMBL4282	Homo sapiens	pKi		6.0
inactive	9677543	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)c1		CHEMBL1969523	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677544	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1ccccc1)Nc1ccccc1		CHEMBL354676	<	Ki	nM	50118.72	CHEMBL4282	Homo sapiens	pKi		4.3
inactive	9677545	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(C=O)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL207995	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677546	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1988995	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677547	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1Nc2cc(CCOc3ccc(N4CCOCC4)cc3)ccc2Nc2cc(-c3cn(Cc4cc(F)c(F)c(F)c4)c4cnccc34)ccc21		CHEMBL2001923	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677548	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(=O)N1CCC(Nc2nccc(-c3c(-c4ccc(F)cc4)nc4occn34)n2)CC1		CHEMBL1986781	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677549	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1nc(-c2ccc3[nH]ncc3c2)cc(-c2ccccc2)[nH]1		CHEMBL526133	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677550	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21		CHEMBL1230122	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677551	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nn(C)c2sc3c(=O)[nH]cnc3c12		CHEMBL1967538	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
inactive	9677552	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3[nH]2)cc1		CHEMBL1979057	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677553	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(CCOc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1OCC(O)CO		CHEMBL1981045	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677554	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COCCOCC#Cc1cc(-c2n[nH]c3c2C(=O)c2cc(CN4CCN(C)CC4)ccc2-3)cs1		CHEMBL387971	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677555	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1ccc(Cn2nnc(-c3ccc4[nH]ncc4c3)c2C2CC2)cc1		CHEMBL1975418	=	Ki	nM	1584.89	CHEMBL4282	Homo sapiens	pKi		5.8
inactive	9677556	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1[nH]c2ccc(Cl)cc2c(-c2ccccc2)c1C1=NNC(c2ccccc2)C1		CHEMBL1992796	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677557	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1999428	=	Ki	nM	3162.28	CHEMBL4282	Homo sapiens	pKi		5.5
inactive	9677558	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCC(O)CO)c(Cl)cc1NC(=O)N2		CHEMBL223257	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677559	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCN1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1967560	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677560	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3noc4ncnc(N)c34)cc2)c1		CHEMBL211378	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677561	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1982465	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677562	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NCCCCCCNC(=O)NCc1cccnc1)NCc1cccnc1		CHEMBL2003420	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677563	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccccc1NC(=O)Nc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL1984586	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677564	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1c(Cl)c(N2CCC(CN)C2)nc2[nH]cc(C(=O)O)c(=O)c12		CHEMBL1999774	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677565	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1c(O)ccc2c1CCCC2=NNC(=O)Cc1cccc2ccccc12		CHEMBL1972659	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677566	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	OC1CCN(c2ncnc3[nH]cc(-c4ccccc4)c23)CC1		CHEMBL1973395	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677567	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(NC(=O)Nc2ccc(-c3cccc4onc(N)c34)cc2)cc1Cl		CHEMBL272453	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677568	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1nnc2ccc(-c3ccccc3)cn12		CHEMBL1987143	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
active	9677569	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3C)cc2)c1		CHEMBL1970217	=	Ki	nM	630.96	CHEMBL4282	Homo sapiens	pKi		6.2
inactive	9677570	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1Nc2ccccc2Nc2nnccc21		CHEMBL1971801	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677571	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1Nc2ccccc2Nc2nnc(Cl)cc21		CHEMBL1968850	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677572	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOC(=O)c1ccc2[nH]c3c(c2c1)CCNC3=O		CHEMBL2005528	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677573	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)c1		CHEMBL185569	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677574	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1cc2[nH]ncc2cc1-c1cn(CC2CCOCC2)nn1		CHEMBL1969843	=	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677575	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(-c2ccc3[nH]nc(C(=O)Nc4ccccc4)c3c2)ccc1O		CHEMBL2007002	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677576	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677577	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN1CCC(NC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)CC1		CHEMBL1987007	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677578	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Clc1cc(-c2c[nH]c3ncccc23)cc(NCc2ccccc2)n1		CHEMBL1969588	=	Ki	nM	3981.07	CHEMBL4282	Homo sapiens	pKi		5.4
inactive	9677579	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(Nc2nccc(Nc3cc(C4CCCCC4)no3)n2)cc(OC)c1OC		CHEMBL1984711	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677580	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1		CHEMBL1967878	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677581	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(OC)c(Nc2ccc3nnc(-c4ccccc4)n3n2)cc1Cl		CHEMBL1990212	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677582	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	=	Ki	nM	100.0	CHEMBL4282	Homo sapiens	pKi		7.0
inactive	9677583	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL484390	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677584	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1c(NCc2cccc(C(F)(F)F)c2)c(Nc2ccncc2)c1=O		CHEMBL1979252	=	Ki	nM	1995.26	CHEMBL4282	Homo sapiens	pKi		5.7
inactive	9677585	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1ccc(Cc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682341	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677586	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		CHEMBL2004290	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677587	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccc(F)cc3)cc12		CHEMBL1986499	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9677588	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc(C=C2SC(=Nc3ccccc3)NC2=O)c1		CHEMBL1972937	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677589	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	C#Cc1cc2c(cc1OC)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL1972250	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677590	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1C1CCOc2c(F)cccc21		CHEMBL2000393	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677591	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COC(=O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL2004072	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677592	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C)c2)c1		CHEMBL2004311	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677593	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Brc1cnc2[nH]cc(-c3ccccc3)c2c1		CHEMBL1992634	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677594	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1242373	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677595	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCNNc1cc(C)c(C#N)c2nc3ccccc3n12		CHEMBL2000433	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677596	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	N#CC(=Cc1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL1974157	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677597	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Fc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL316264	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677598	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1988075	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677599	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1991678	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9677600	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncnc(Nc2cc(CNC(=O)C(F)(F)F)c(O)c(-c3ccc(Cl)cc3)c2)n1		CHEMBL2001239	=	Ki	nM	3981.07	CHEMBL4282	Homo sapiens	pKi		5.4
inactive	9677601	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncnc2scc(C(=O)Nc3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1988594	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677602	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncnc2c1c(I)nn2C1OC(CO)C(O)C1O		CHEMBL2001288	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9677603	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL260092	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681562	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681563	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NN=Cc1ccc(O)cc1O)Nc1cccc2nsnc12		CHEMBL1999811	=	Ki	nM	3162.28	CHEMBL4282	Homo sapiens	pKi		5.5
inactive	9681564	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1n[nH]c2ncc(C#N)c(-c3ccccc3)c12		CHEMBL1965495	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681565	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CSc1ccc2nc3c(c(Cl)c2c1)CCNC3=O		CHEMBL1985074	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681566	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc2n1CC1CC1		CHEMBL1982874	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681567	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL2000481	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681568	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1		CHEMBL1173055	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681569	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN(C)CC(=O)NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1991725	=	Ki	nM	158.49	CHEMBL4282	Homo sapiens	pKi		6.8
inactive	9681570	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4sncc34)cc2)c1		CHEMBL1992242	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681571	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2007296	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681572	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL208637	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681573	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ncc3c2)n1		CHEMBL396523	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681574	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1NC(=O)C(Nc2ccccc2)=C1Cl		CHEMBL2007138	<	Ki	nM	19952.62	CHEMBL4282	Homo sapiens	pKi		4.7
inactive	9681575	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1970203	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681576	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(c1cc(Cc2n[nH]c(=O)c3c2CCCC3)ccc1F)N1CCN(c2ncccn2)CC1		CHEMBL1986530	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681577	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1c(NCCc2ccc(Oc3ccccc3)cc2)c(Nc2ccncc2)c1=O		CHEMBL1999321	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681578	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1cnc2[nH]cc(-c3ccnc(NC4CCCCC4)n3)c2c1		CHEMBL385478	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681579	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4sc(C)nc4c3)csc12		CHEMBL1968590	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681580	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(Nc2ncnc3ccc(-c4ccc(CN5CC6C(CO)C6C5)cc4)cc23)ccc1Oc1ccccc1		CHEMBL1999749	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681581	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCCCC4)cc3OC)nc2N1C1CCCC1		CHEMBL2005375	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681582	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Clc1ccc(-c2n[nH]cc2-c2ccncn2)cc1Cl		CHEMBL1984191	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681583	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(C(=O)O)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1983006	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681584	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN1CCCC1COc1cncc(CCc2ccccc2)c1		CHEMBL1972183	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681585	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Br		CHEMBL1971029	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681586	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)Nc1n[nH]c2ccc(N)cc12		CHEMBL1995391	<	Ki	nM	19952.62	CHEMBL4282	Homo sapiens	pKi		4.7
inactive	9681587	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL394790	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681588	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1NCCc2[nH]c(-c3ccnc(-c4ccccc4F)c3)cc21		CHEMBL226471	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681589	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nc2c(sc3c(Br)ccc(Cl)c32)c(=O)o1		CHEMBL1974702	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681590	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1996111	=	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681591	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nccn2c(-c3ccnc(NCC4(O)CC4)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1965589	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681592	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NCCCCCCNC(=O)Nc1cccnc1)Nc1cccnc1		CHEMBL1998193	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681593	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)O)s3)c2cc1OC		CHEMBL474432	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681594	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1cc2c(s1)CCc1cn[nH]c1-2		CHEMBL2001539	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
inactive	9681595	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nnc(-c2cc3c(Oc4ccc(C(F)(F)F)cc4)cncc3s2)o1		CHEMBL1988153	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681596	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681597	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1		CHEMBL1969664	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681598	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cc2c(-c3ccccc3)cncc2s1		CHEMBL1999556	=	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
inactive	9681599	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1		CHEMBL1988437	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681600	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(COc1cc(C=Cc2ccncc2)cnc1Cl)Cc1c[nH]c2ccccc12		CHEMBL1968245	=	Ki	nM	63.1	CHEMBL4282	Homo sapiens	pKi		7.2
active	9681601	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NCCC(C(=O)Nc1ccc2[nH]ncc2c1)c1ccc(Cl)c(Cl)c1		CHEMBL1998121	=	Ki	nM	10.0	CHEMBL4282	Homo sapiens	pKi		8.0
inactive	9681602	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CC(C)(C)N)cnc(N)c34)cc2)c1		CHEMBL1979577	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681603	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CC4CC4)nccn23)n1		CHEMBL1991800	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681604	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(CCOc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1CC#N		CHEMBL1985566	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681605	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCC(CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL52387	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681606	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nn(-c2ccccc2)c2c1c(=O)c1cc(Cl)ccc1n2O		CHEMBL379835	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681607	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cn1cc(C(CN)c2cncc(C=Cc3ccncc3)c2)c2ccccc21		CHEMBL1979357	=	Ki	nM	630.96	CHEMBL4282	Homo sapiens	pKi		6.2
inactive	9681608	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	N#Cc1ncc2nc1OCC(O)C(O)COc1ccc(Cl)cc1NC(=O)N2		CHEMBL1980802	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681609	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1c(NCc2ccc(Cl)cc2Cl)c(Nc2ccc3[nH]ncc3c2)c1=O		CHEMBL1979554	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681610	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCCOc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1996817	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681611	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2ccncc2)c1-c1ccccc1		CHEMBL1419458	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681612	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOc1nc(C(=O)NCc2ccc(S(N)(=O)=O)cc2)cc(N)c1C#N		CHEMBL2004355	=	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
inactive	9681613	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681614	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCn1c2cc(Cl)c(F)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL468280	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681615	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(C)c2oc(Nc3ccc(-c4cccc(C(N)=O)c4N)cc3F)nc2c1		CHEMBL1990884	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681616	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C		CHEMBL1990885	<	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9681617	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL256835	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681618	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1980142	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681619	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL41783	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681620	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccc2nccnc12		CHEMBL2004438	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681621	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc2c1Nc1cc(Nc3ccncc3)ccc1C(=O)N2		CHEMBL2006276	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681622	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)noc12		CHEMBL271381	<	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
inactive	9681623	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(C(=O)Nc2c(C#N)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL2006785	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681624	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1982466	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681625	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(-c2ccc3c(c2)Nc2ccc([N+](=O)[O-])cc2NC3=O)ccc1O		CHEMBL1995740	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681626	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(O)c1cc2c(-c3ccccc3)cncc2s1		CHEMBL1996390	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681627	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	1995.26	CHEMBL4282	Homo sapiens	pKi		5.7
inactive	9681628	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL234085	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681629	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1995832	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681630	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1n[nH]c2sc(C(=O)NCCc3ccc(Cl)cc3)cc12		CHEMBL1998414	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681631	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Oc1ccc(Nc2[nH]nc(-c3ccc(O)cc3)c2-c2ccc(O)cc2)cc1		CHEMBL1969042	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681632	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccccc1		CHEMBL1999931	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
active	9681633	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1[nH]sc2c1c(=O)c1cc(F)c(NCc3ccccc3)c(F)c1n2C1CC1		CHEMBL1991640	=	Ki	nM	1995.26	CHEMBL4282	Homo sapiens	pKi		5.7
inactive	9681634	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(CNc2ccc3nnc(-c4ccccc4)n3n2)cc1		CHEMBL1375418	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681635	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681636	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1[nH]c(C=C2C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL2007064	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681637	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COC(C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL1981047	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681638	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc(C(CN)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1976240	=	Ki	nM	199.53	CHEMBL4282	Homo sapiens	pKi		6.7
inactive	9681639	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc(-c2ccc(NC(=O)Nc3ccc(F)c(C)c3)cc2)c2c(N)noc12		CHEMBL1979093	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681640	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1[nH]c2sccc2c2nc(-c3ccncc3)nn12		CHEMBL1968151	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681641	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Clc1ccc(CNc2ccc3nnc(-c4ccccc4)n3n2)cc1		CHEMBL1381197	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681642	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)c1		CHEMBL1987009	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681643	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccccc4)c3)cc12		CHEMBL2002726	=	Ki	nM	39.81	CHEMBL4282	Homo sapiens	pKi		7.4
inactive	9681644	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1cnccn1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL2003817	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681645	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ncccc2N1		CHEMBL336961	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681646	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1nnc(-c2cc3c(Oc4ccc(Cl)cc4)cncc3s2)o1		CHEMBL1994830	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681647	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(Cl)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1987054	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681648	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncc(-c2ccncc2)c2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1970083	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681649	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1NCCc2[nH]c(-c3ccnc(-c4cnc5ccccc5c4)c3)cc21		CHEMBL226403	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681650	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cc(C)ccc4F)cc3)csc12		CHEMBL2005631	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681651	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncc(C=CC(=O)NCCCn2ccnc2)c2scc(-c3ccc(Br)cc3)c12		CHEMBL1994938	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681652	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681653	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1977223	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681654	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(C)C(=O)Oc1ccc2c(c1)nc(NC(=O)c1cccc([N+](=O)[O-])c1)n2CCCO		CHEMBL1236126	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681655	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NCCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL1966279	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681656	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Clc1cc(NC2CCCCC2)nc(-c2c[nH]c3ncccc23)n1		CHEMBL1997846	=	Ki	nM	1995.26	CHEMBL4282	Homo sapiens	pKi		5.7
inactive	9681657	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)Cn1c(N)nc2c(F)cc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2004419	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681658	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(=NNC(=N)N)c1cc(NC(=O)NCCCCCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL1991728	=	Ki	nM	398.11	CHEMBL4282	Homo sapiens	pKi		6.4
inactive	9681659	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cc2c(-c3ccc(F)cc3F)cncc2s1		CHEMBL1975787	<	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
inactive	9681660	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(C=C(C#N)c2n[nH]c(N)c2C#N)ccc1O		CHEMBL2002407	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681661	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1ccc2cn[nH]c2c1)c1ccc(Cl)cc1		CHEMBL1972489	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681662	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Brc1ccc2[nH]nc(-c3ccccc3)c2c1		CHEMBL1994074	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681663	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1		CHEMBL1992937	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681664	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1cccc2cn[nH]c12		CHEMBL451401	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
active	9681665	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN(C)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1		CHEMBL1986328	=	Ki	nM	3981.07	CHEMBL4282	Homo sapiens	pKi		5.4
inactive	9681666	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL95692	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681667	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1		CHEMBL1090356	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681668	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(C(F)(F)F)cc12		CHEMBL1976455	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681669	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1		CHEMBL1983923	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681670	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681671	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1ccc(CNc2nc3ccc(-c4ccncc4)cc3s2)cc1		CHEMBL1983534	=	Ki	nM	3162.28	CHEMBL4282	Homo sapiens	pKi		5.5
active	9681672	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1c(NCc2ccccc2F)c(Nc2ccncc2)c1=O		CHEMBL1982361	=	Ki	nM	3981.07	CHEMBL4282	Homo sapiens	pKi		5.4
inactive	9681673	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOC(=O)C1=c2sc(=Cc3ccco3)c(=O)n2C(N)=C(C#N)C1c1ccco1		CHEMBL1999112	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681674	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	OCCC(Nc1nc2ccc(-c3ccncc3)cc2s1)c1ccccc1		CHEMBL1982122	=	Ki	nM	398.11	CHEMBL4282	Homo sapiens	pKi		6.4
inactive	9681675	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1ccc(-c2cccc3sncc23)cc1)Nc1ccc(F)c(C(F)(F)F)c1		CHEMBL2000801	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681676	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682546	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681677	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1991395	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681678	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN1CCN(c2cccc(Nc3nccc(-c4c(C(N)=O)nc5ccccn45)n3)c2)CC1		CHEMBL1971245	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681679	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1987648	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681680	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOC(=O)c1cn(-c2ccc(O)cc2C)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL1996780	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681681	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NCc1ccccc1)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL1972142	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681682	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCCCCCCCCCCOc1ccc(NC(=N)N)cc1NC(=N)N		CHEMBL1980715	=	Ki	nM	3981.07	CHEMBL4282	Homo sapiens	pKi		5.4
active	9681683	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(F)c1		CHEMBL2003638	=	Ki	nM	1584.89	CHEMBL4282	Homo sapiens	pKi		5.8
inactive	9681684	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681685	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	N#Cc1ccc2nc(N)n(-c3nc(-c4ccccc4)cs3)c2c1		CHEMBL1996066	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681686	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(COc1cncc(-c2cc3ccncc3s2)c1)Cc1c[nH]c2ccccc12		CHEMBL1966524	=	Ki	nM	12.59	CHEMBL4282	Homo sapiens	pKi		7.9
inactive	9681687	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1c2c([nH]c3cc(-c4ccco4)nn13)CSC2		CHEMBL1972152	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681688	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(C(=O)O)ccc4F)cc3)c12		CHEMBL1993722	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681689	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=c1[nH]c2sc3c(c2c2nc(-c4cccnc4)nn12)CCCC3		CHEMBL1970806	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681690	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nc(COc2ccccc2Cl)sc1-c1ccnc(N)n1		CHEMBL1375640	=	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681691	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL1979970	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681692	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCN4CCOCC4)cc2-3)cn1		CHEMBL249282	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681693	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(C)NC(=O)c1ccc2nc3[nH]c4ccccc4c3nc2c1		CHEMBL1969264	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681694	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	N#Cc1c(O)[nH]c(=O)c2c(=N)oc3ccc(Cl)cc3c12		CHEMBL1973711	=	Ki	nM	3981.07	CHEMBL4282	Homo sapiens	pKi		5.4
inactive	9681695	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN1CCN(CCCNc2cccc(-c3nc4c(C(N)=O)cccc4[nH]3)n2)CC1		CHEMBL2006237	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681696	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(C(N)=O)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1967720	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681697	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC1C2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)CC12		CHEMBL1624529	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681698	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1nccn2c(C3CC(CN4CCCC4)C3)nc(-c3cccc(OCc4ccccc4)c3)c12		CHEMBL1991138	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681699	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1F		CHEMBL1969755	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681700	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1979516	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681701	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681702	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(O)c1ccc(N2C(=O)c3ccccc3C2=O)cc1O		CHEMBL1972820	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681703	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NNc1cc(N2CCOCC2)nc(OCCc2ccccn2)n1		CHEMBL1996208	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681704	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)OC1=NNC(=O)C1=Cc1c[nH]c2ccccc12		CHEMBL1989029	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681705	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681706	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN(C)CC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1965631	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681707	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccccc1NC(=O)Nc1ccc(NC(=O)c2csc3ncnc(N)c23)cc1		CHEMBL1980144	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681708	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2OC)c1		CHEMBL1991188	=	Ki	nM	5011.87	CHEMBL4282	Homo sapiens	pKi		5.3
inactive	9681709	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1972849	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681710	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N		CHEMBL377408	=	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681711	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681712	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL231209	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681713	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(C)OC(=O)n1cc(-c2cncn2C2CCCCC2)c2ccccc21		CHEMBL1975357	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681714	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Br)c4)cc3)c12		CHEMBL1976220	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681715	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL259922	<	Ki	nM	6309.57	CHEMBL4282	Homo sapiens	pKi		5.2
inactive	9681716	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CN1CCN(C2CCC(n3cc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1997617	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681717	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CCN)nccn23)n1		CHEMBL1982383	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681718	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CCCCn1c(NC(=O)c2cccc(C#N)c2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL1969301	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681719	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CSc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17370	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681720	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4ccccc4C(F)(F)F)cc3)c12		CHEMBL1987910	=	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681721	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1ccc2c(NC(=O)Nc3cccc(Br)n3)ccnc2c1		CHEMBL1983932	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681722	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681723	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	NC(=O)c1csc2c1NCCC2=O		CHEMBL1973399	<	Ki	nM	79432.82	CHEMBL4282	Homo sapiens	pKi		4.1
inactive	9681724	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	c1ccc2c(c1)nnn2Cc1cn(-c2ccc3[nH]ncc3c2)nn1		CHEMBL1966069	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681725	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681726	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc2cc(-c3csc4c(-c5cccc(S(C)(=O)=O)c5)cnc(N)c34)ccc2[nH]1		CHEMBL1997822	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681727	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1cc(OCC2CCC(C(=O)O)C2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL1991285	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681728	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1		CHEMBL243088	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681729	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc(-c2ccc3c(c2)NC(=O)c2ccc(-c4ccccc4NS(C)(=O)=O)cc2N3)cc(OC)c1OC		CHEMBL1984038	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681730	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl		CHEMBL1993661	=	Ki	nM	3981.07	CHEMBL4282	Homo sapiens	pKi		5.4
inactive	9681731	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1cccc(F)c1F		CHEMBL1974416	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
active	9681732	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	CSc1nn(-c2ccccn2)c(N)c1C(N)=O		CHEMBL2004615	=	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681733	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	Cc1nn(C)c(C)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(=O)O)[nH]c12		CHEMBL1984039	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681734	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2		CHEMBL1980391	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
inactive	9681735	CHEMBL1963809	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: AKT1	F	O=C(c1cccc(-c2cnc3[nH]ccc3c2)c1)N1CCOCC1		CHEMBL1997872	<	Ki	nM	7943.28	CHEMBL4282	Homo sapiens	pKi		5.1
	10838643	CHEMBL2014521	Inhibition of AKT1 at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	23.0	CHEMBL4282	Homo sapiens	INH	%	23.0
	10839581	CHEMBL2015712	Inhibition of PKBalpha assessed as residual activity at 10 uM relative to control	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Activity	%	109.0	CHEMBL4282	Homo sapiens	Activity	%	109.0
	10839677	CHEMBL2016319	Inhibition of PKBalpha assessed as residual activity at 1 uM relative to control	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Activity	%	102.0	CHEMBL4282	Homo sapiens	Activity	%	102.0
	10840582	CHEMBL2014740	Inhibition of Akt1	B	CCc1n[nH]c2ncnc(N3CCN(c4cc(Cl)cc(NCCN(C)C)c4C)CC3)c12		CHEMBL2012701	=	IC50	nM	371.0	CHEMBL4282	Homo sapiens	IC50	nM	371.0
	10840583	CHEMBL2014740	Inhibition of Akt1	B	Cc1c(NCCN(C)C)cc(Cl)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL2012702	=	IC50	nM	53.0	CHEMBL4282	Homo sapiens	IC50	nM	53.0
	10840584	CHEMBL2014740	Inhibition of Akt1	B	Cc1c(NCCN(C)C)cc(Cl)cc1N1CCN(c2ncnc3[nH]nc(C(F)(F)F)c23)CC1		CHEMBL2012703	=	IC50	nM	74.0	CHEMBL4282	Homo sapiens	IC50	nM	74.0
Active	10843835	CHEMBL2016133	Inhibition of PKB at 1 uM	B	CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3		CHEMBL2010872		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	10849699	CHEMBL2019658	Inhibition of AKT1	B	CSc1ccccc1Nc1nc(N2CCNCC2)nc2c(NCC3CC3)ncnc12		CHEMBL2017214	>	IC50	nM	40000.0	CHEMBL4282	Homo sapiens	IC50	uM	40.0
	10850637	CHEMBL2019915	Inhibition of human AKT1	B	O=C(Nc1ccc(N2CCNCC2)cc1)c1ccc(-c2ccc(Cl)cc2)o1		CHEMBL1938680	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	nM	30000.0
	10858119	CHEMBL2020583	Inhibition of AKT1 after 3 hrs by luciferase based chemiluminescence assay	B	CCc1n[nH]c2ncnc(N3CCN(c4cc(Cl)cc(NCCN(C)C)c4C)CC3)c12		CHEMBL2012701	=	IC50	nM	371.0	CHEMBL4282	Homo sapiens	IC50	nM	371.0
	10858120	CHEMBL2020583	Inhibition of AKT1 after 3 hrs by luciferase based chemiluminescence assay	B	CCc1n[nH]c2ncnc(N3CCN(c4cc(Cl)cc(NCCN5CCCC5)c4C)CC3)c12		CHEMBL2012699	=	IC50	nM	434.0	CHEMBL4282	Homo sapiens	IC50	nM	434.0
	10858121	CHEMBL2020583	Inhibition of AKT1 after 3 hrs by luciferase based chemiluminescence assay	B	Cc1c(NCCN(C)C)cc(Cl)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL2012702	=	IC50	nM	53.0	CHEMBL4282	Homo sapiens	IC50	nM	53.0
	10858122	CHEMBL2020583	Inhibition of AKT1 after 3 hrs by luciferase based chemiluminescence assay	B	Cc1c(NCCN2CCCC2)cc(Cl)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL2016771	=	IC50	nM	42.0	CHEMBL4282	Homo sapiens	IC50	nM	42.0
	10858135	CHEMBL2020675	Inhibition of AKT1-mediated GSK3beta phosphorylation in human PC3 cells after 3 hrs by chemiluminescence assay	B	CCc1n[nH]c2ncnc(N3CCN(c4cc(Cl)cc(NCCN(C)C)c4C)CC3)c12		CHEMBL2012701	=	IC50	nM	9026.0	CHEMBL4282	Homo sapiens	IC50	nM	9026.0
	10858136	CHEMBL2020675	Inhibition of AKT1-mediated GSK3beta phosphorylation in human PC3 cells after 3 hrs by chemiluminescence assay	B	CCc1n[nH]c2ncnc(N3CCN(c4cc(Cl)cc(NCCN5CCCC5)c4C)CC3)c12		CHEMBL2012699	=	IC50	nM	3589.0	CHEMBL4282	Homo sapiens	IC50	nM	3589.0
	10858137	CHEMBL2020675	Inhibition of AKT1-mediated GSK3beta phosphorylation in human PC3 cells after 3 hrs by chemiluminescence assay	B	Cc1c(NCCN(C)C)cc(Cl)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL2012702	=	IC50	nM	4285.0	CHEMBL4282	Homo sapiens	IC50	nM	4285.0
	10858138	CHEMBL2020675	Inhibition of AKT1-mediated GSK3beta phosphorylation in human PC3 cells after 3 hrs by chemiluminescence assay	B	Cc1c(NCCN2CCCC2)cc(Cl)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL2016771	=	IC50	nM	1271.0	CHEMBL4282	Homo sapiens	IC50	nM	1271.0
	10858148	CHEMBL2020583	Inhibition of AKT1 after 3 hrs by luciferase based chemiluminescence assay	B	CCOc1cc(NCCN2CCCC2)c(C)c(N2CCN(c3ncnc4[nH]nc(Br)c34)CC2)c1		CHEMBL2016885	=	IC50	nM	56.0	CHEMBL4282	Homo sapiens	IC50	nM	56.0
	10858149	CHEMBL2020583	Inhibition of AKT1 after 3 hrs by luciferase based chemiluminescence assay	B	Cc1c(NCCN2CCCC2)cc(OCC(C)C)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL2016886	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
	10858150	CHEMBL2020583	Inhibition of AKT1 after 3 hrs by luciferase based chemiluminescence assay	B	Cc1c(NCCN2CCCC2)cc(C(=O)Nc2ccccc2)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL2016887	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
	10858151	CHEMBL2020583	Inhibition of AKT1 after 3 hrs by luciferase based chemiluminescence assay	B	Cc1c(NCCN2CCCC2)cc(COCC(F)(F)F)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL2016888	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
	10858152	CHEMBL2020583	Inhibition of AKT1 after 3 hrs by luciferase based chemiluminescence assay	B	Cc1c(NCCN2CCCC2)cc(CCC(C)(C)C)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL2016889	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
	10858153	CHEMBL2020583	Inhibition of AKT1 after 3 hrs by luciferase based chemiluminescence assay	B	Cc1noc(-c2cc(NCCN3CCCC3)c(C)c(N3CCN(c4ncnc5[nH]nc(Br)c45)CC3)c2)n1		CHEMBL2016890	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	10858154	CHEMBL2020583	Inhibition of AKT1 after 3 hrs by luciferase based chemiluminescence assay	B	COC(=O)c1cc(NCCN2CCCC2)c(C)c(N2CCN(c3ncnc4[nH]nc(Br)c34)CC2)c1		CHEMBL2016891	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	10858155	CHEMBL2020583	Inhibition of AKT1 after 3 hrs by luciferase based chemiluminescence assay	B	CCC(=O)c1cc(NCCN2CCCC2)c(C)c(N2CCN(c3ncnc4[nH]nc(Br)c34)CC2)c1		CHEMBL2016892	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	10858156	CHEMBL2020583	Inhibition of AKT1 after 3 hrs by luciferase based chemiluminescence assay	B	Cc1c(NCCN2CCCC2)cc(C(=O)CCC(F)(F)F)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL2016893	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	10858782	CHEMBL2020675	Inhibition of AKT1-mediated GSK3beta phosphorylation in human PC3 cells after 3 hrs by chemiluminescence assay	B	CCOc1cc(NCCN2CCCC2)c(C)c(N2CCN(c3ncnc4[nH]nc(Br)c34)CC2)c1		CHEMBL2016885	=	IC50	nM	9067.0	CHEMBL4282	Homo sapiens	IC50	nM	9067.0
	10858783	CHEMBL2020675	Inhibition of AKT1-mediated GSK3beta phosphorylation in human PC3 cells after 3 hrs by chemiluminescence assay	B	Cc1c(NCCN2CCCC2)cc(OCC(C)C)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL2016886	=	IC50	nM	700.0	CHEMBL4282	Homo sapiens	IC50	nM	700.0
	10858784	CHEMBL2020675	Inhibition of AKT1-mediated GSK3beta phosphorylation in human PC3 cells after 3 hrs by chemiluminescence assay	B	Cc1c(NCCN2CCCC2)cc(C(=O)Nc2ccccc2)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL2016887	=	IC50	nM	7811.0	CHEMBL4282	Homo sapiens	IC50	nM	7811.0
	10858785	CHEMBL2020675	Inhibition of AKT1-mediated GSK3beta phosphorylation in human PC3 cells after 3 hrs by chemiluminescence assay	B	Cc1c(NCCN2CCCC2)cc(COCC(F)(F)F)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL2016888	=	IC50	nM	730.0	CHEMBL4282	Homo sapiens	IC50	nM	730.0
	10858786	CHEMBL2020675	Inhibition of AKT1-mediated GSK3beta phosphorylation in human PC3 cells after 3 hrs by chemiluminescence assay	B	Cc1c(NCCN2CCCC2)cc(CCC(C)(C)C)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL2016889	=	IC50	nM	1982.0	CHEMBL4282	Homo sapiens	IC50	nM	1982.0
	10858787	CHEMBL2020675	Inhibition of AKT1-mediated GSK3beta phosphorylation in human PC3 cells after 3 hrs by chemiluminescence assay	B	Cc1noc(-c2cc(NCCN3CCCC3)c(C)c(N3CCN(c4ncnc5[nH]nc(Br)c45)CC3)c2)n1		CHEMBL2016890	=	IC50	nM	665.0	CHEMBL4282	Homo sapiens	IC50	nM	665.0
	10858788	CHEMBL2020675	Inhibition of AKT1-mediated GSK3beta phosphorylation in human PC3 cells after 3 hrs by chemiluminescence assay	B	COC(=O)c1cc(NCCN2CCCC2)c(C)c(N2CCN(c3ncnc4[nH]nc(Br)c34)CC2)c1		CHEMBL2016891	=	IC50	nM	1843.0	CHEMBL4282	Homo sapiens	IC50	nM	1843.0
	10858789	CHEMBL2020675	Inhibition of AKT1-mediated GSK3beta phosphorylation in human PC3 cells after 3 hrs by chemiluminescence assay	B	CCC(=O)c1cc(NCCN2CCCC2)c(C)c(N2CCN(c3ncnc4[nH]nc(Br)c34)CC2)c1		CHEMBL2016892	=	IC50	nM	976.0	CHEMBL4282	Homo sapiens	IC50	nM	976.0
	10858790	CHEMBL2020675	Inhibition of AKT1-mediated GSK3beta phosphorylation in human PC3 cells after 3 hrs by chemiluminescence assay	B	Cc1c(NCCN2CCCC2)cc(C(=O)CCC(F)(F)F)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL2016893	=	IC50	nM	194.0	CHEMBL4282	Homo sapiens	IC50	nM	194.0
	10889045	CHEMBL2032470	Inhibition of PKBalpha	B	COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1		CHEMBL460472	=	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	10889072	CHEMBL2032470	Inhibition of PKBalpha	B	COc1cc2nccc(Oc3ccc(NC(=O)c4c(C)n(C)n(-c5ccccc5)c4=O)cc3F)c2cc1OC		CHEMBL2031893	=	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	10909517	CHEMBL2039955	Inhibition of AKT1	B	NC(=O)c1cnc(-c2ccc(C3(N)CCC3)cc2)c(-c2ccccc2)c1		CHEMBL2035040	=	IC50	nM	1042.0	CHEMBL4282	Homo sapiens	IC50	uM	1.042
	10909518	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-n3c(-c4ccccc4)nc4ccccc4c3=O)cc2)CCC1		CHEMBL2035039	=	IC50	nM	41722.0	CHEMBL4282	Homo sapiens	IC50	uM	41.722
	10909519	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3nc4ccccc4c(=O)n3-c3ccccc3)cc2)CCC1		CHEMBL2035038	=	IC50	nM	7024.0	CHEMBL4282	Homo sapiens	IC50	uM	7.024
	10909520	CHEMBL2039955	Inhibition of AKT1	B	Cn1cnc2c(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)ccc21		CHEMBL2035037	=	IC50	nM	2799.0	CHEMBL4282	Homo sapiens	IC50	uM	2.799
	10909521	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3c(-c4ccccc4)ccc4ncnn34)cc2)CCC1		CHEMBL2035036	=	IC50	nM	2135.0	CHEMBL4282	Homo sapiens	IC50	uM	2.135
	10909522	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3c(-c4ccccc4)ccn4ncnc34)cc2)CCC1		CHEMBL2035035	=	IC50	nM	2668.0	CHEMBL4282	Homo sapiens	IC50	uM	2.668
	10909523	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3c(-c4ccccc4)ncc4nccn34)cc2)CCC1		CHEMBL2035034	=	IC50	nM	5404.0	CHEMBL4282	Homo sapiens	IC50	uM	5.404
	10909524	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3c(-c4ccccc4)ccn4ccnc34)cc2)CCC1		CHEMBL2035033	=	IC50	nM	1807.0	CHEMBL4282	Homo sapiens	IC50	uM	1.807
	10909525	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3c(-c4ccccc4)ccc4ccnn34)cc2)CCC1		CHEMBL2035032	=	IC50	nM	2716.0	CHEMBL4282	Homo sapiens	IC50	uM	2.716
	10909526	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3ncc4cccnc4c3-c3ccccc3)cc2)CCC1		CHEMBL2035031	=	IC50	nM	465.0	CHEMBL4282	Homo sapiens	IC50	uM	0.465
	10909527	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3ncc4ccncc4c3-c3ccccc3)cc2)CCC1		CHEMBL2035030	=	IC50	nM	193.0	CHEMBL4282	Homo sapiens	IC50	uM	0.193
	10909528	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3ncc4cnccc4c3-c3ccccc3)cc2)CCC1		CHEMBL2035029	=	IC50	nM	117.0	CHEMBL4282	Homo sapiens	IC50	uM	0.117
	10909529	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3ncc4ncccc4c3-c3ccccc3)cc2)CCC1		CHEMBL2035028	=	IC50	nM	188.0	CHEMBL4282	Homo sapiens	IC50	uM	0.188
	10909530	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3ncc4ccccc4c3-c3ccccc3)cc2)CCC1		CHEMBL2035027	=	IC50	nM	301.0	CHEMBL4282	Homo sapiens	IC50	uM	0.301
	10909531	CHEMBL2039955	Inhibition of AKT1	B	CCn1cnc2cnc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)c21		CHEMBL2035026	=	IC50	nM	8976.0	CHEMBL4282	Homo sapiens	IC50	uM	8.976
	10909532	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3ncc4nccn4c3-c3ccccc3)cc2)CCC1		CHEMBL2035025	=	IC50	nM	1262.0	CHEMBL4282	Homo sapiens	IC50	uM	1.262
	10909533	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3ncc4cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL2035024	=	IC50	nM	787.0	CHEMBL4282	Homo sapiens	IC50	uM	0.787
	10909534	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3nn4ccc(=O)nc4cc3-c3ccccc3)cc2)CCC1		CHEMBL2035023	=	IC50	nM	8665.0	CHEMBL4282	Homo sapiens	IC50	uM	8.665
	10909535	CHEMBL2039955	Inhibition of AKT1	B	NC(=O)c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL2035022	=	IC50	nM	348.0	CHEMBL4282	Homo sapiens	IC50	uM	0.348
	10909536	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3nc4ccccn4c3-c3ccccc3)cc2)CCC1		CHEMBL2035021	=	IC50	nM	387.0	CHEMBL4282	Homo sapiens	IC50	uM	0.387
	10909537	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3nn4ccccc4c3-c3ccccc3)cc2)CCC1		CHEMBL2035020	=	IC50	nM	199.0	CHEMBL4282	Homo sapiens	IC50	uM	0.199
	10909538	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3nn4ccnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL2035019	=	IC50	nM	528.0	CHEMBL4282	Homo sapiens	IC50	uM	0.528
	10909539	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3nn4cccc4cc3-c3ccccc3)cc2)CCC1		CHEMBL2035018	=	IC50	nM	926.0	CHEMBL4282	Homo sapiens	IC50	uM	0.926
	10909540	CHEMBL2039955	Inhibition of AKT1	B	NC1(c2ccc(-c3nc4ccccc4cc3-c3ccccc3)cc2)CCC1		CHEMBL2035017	=	IC50	nM	243.0	CHEMBL4282	Homo sapiens	IC50	uM	0.243
	10912549	CHEMBL2038022	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	Cn1c(=O)c2ccc(-c3nc4ccccc4n3C)nc2n(C)c1=O		CHEMBL2036871	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
Not Active	10912554	CHEMBL2038037	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate at <10 uM after 80 mins by scintillation counting	B	Cn1c(=O)c2ccc(-c3nc4ccccc4n3C)nc2n(C)c1=O		CHEMBL2036871		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	10912565	CHEMBL2038022	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	COc1ccc(Nc2ncc3c(n2)-c2ccccc2NC(=O)C3)cc1O		CHEMBL603463	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	10913459	CHEMBL2038022	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3ccccc3)n2)nc2ccccc21		CHEMBL2036725	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
Not Active	10913464	CHEMBL2038037	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate at <10 uM after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3ccccc3)n2)nc2ccccc21		CHEMBL2036725		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	10913475	CHEMBL2038022	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	Cc1ccc(Nc2nccc(-c3nc4ccccc4n3C)n2)cc1		CHEMBL2036726	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
Not Active	10913480	CHEMBL2038037	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate at <10 uM after 80 mins by scintillation counting	B	Cc1ccc(Nc2nccc(-c3nc4ccccc4n3C)n2)cc1		CHEMBL2036726		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	10913491	CHEMBL2038022	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3ccc(Cl)cc3)n2)nc2ccccc21		CHEMBL2036727	=	IC50	nM	41000.0	CHEMBL4282	Homo sapiens	IC50	uM	41.0
Not Active	10913496	CHEMBL2038037	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate at <10 uM after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3ccc(Cl)cc3)n2)nc2ccccc21		CHEMBL2036727		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	10913507	CHEMBL2038022	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)nc2ccccc21		CHEMBL2036728	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
Not Active	10913512	CHEMBL2038037	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate at <10 uM after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)nc2ccccc21		CHEMBL2036728		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	10913523	CHEMBL2038022	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	CCOc1ccc(Nc2nccc(-c3nc4ccccc4n3C)n2)cc1		CHEMBL2036867	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
Not Active	10913528	CHEMBL2038037	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate at <10 uM after 80 mins by scintillation counting	B	CCOc1ccc(Nc2nccc(-c3nc4ccccc4n3C)n2)cc1		CHEMBL2036867		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	10913539	CHEMBL2038022	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	COc1ccc(Nc2nccc(-c3nc4ccccc4n3C)n2)cc1		CHEMBL2036868	=	IC50	nM	75000.0	CHEMBL4282	Homo sapiens	IC50	uM	75.0
Not Active	10913544	CHEMBL2038037	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate at <10 uM after 80 mins by scintillation counting	B	COc1ccc(Nc2nccc(-c3nc4ccccc4n3C)n2)cc1		CHEMBL2036868		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	10913555	CHEMBL2038022	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3ccc(O)cc3)n2)nc2ccccc21		CHEMBL2036869	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	10913560	CHEMBL2038022	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3cccc(O)c3)n2)nc2ccccc21		CHEMBL2036870	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	10913565	CHEMBL2038022	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	Cn1c(-c2ccnc(Nc3ccc(O)c(Cl)c3)n2)nc2ccccc21		CHEMBL2036865	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	10913570	CHEMBL2038022	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	COc1ccc(Nc2nccc(-c3nc4ccccc4n3C)n2)cc1O		CHEMBL2036866	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	10913585	CHEMBL2038022	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1		CHEMBL1200485	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	10913600	CHEMBL2038022	Inhibition of recombinant AKT1 using GSK3 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	10923983	CHEMBL2044306	Inhibition of AKT1 at 1 uM incubated for 30 mins prior to substrate addition study done at apparent ATP Km for enzyme	B	C[C@H](/C=C\C(F)(F)F)Oc1cc(-c2cc(-c3cc(CN(C)C)cs3)cnc2N)ccc1C(N)=O		CHEMBL2042135	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	10926130	CHEMBL2046214	Inhibition of human PKBalpha assessed as remaining activity at 0.8 uM after 40 mins by scintillation counting	B	CC(C)Nc1cc(-c2oc3ccccc3c(=O)c2-c2ccc(F)cc2)ccn1		CHEMBL2041958	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	10926131	CHEMBL2046214	Inhibition of human PKBalpha assessed as remaining activity at 0.8 uM after 40 mins by scintillation counting	B	O=c1c(-c2ccc(F)cc2)c(-c2ccnc(NC3CCCCC3)c2)oc2ccccc12		CHEMBL2041962	=	Activity	%	107.0	CHEMBL4282	Homo sapiens	Activity	%	107.0
	10934974	CHEMBL2051510	Inhibition of AKT1 at 10 uM	B	O=C(Nc1ccc(Oc2ccnc(-c3ncc(C(F)(F)F)[nH]3)c2)cc1)Nc1ccc(Cl)c(C(F)(F)F)c1		CHEMBL2047981	=	Inhibition	%	11.7	CHEMBL4282	Homo sapiens	INH	%	11.7
	10974725	CHEMBL2067501	Inhibition of AKT1 by AKT1/PKBalpha KinEASE FP fluorescein green assay	B	COc1cc(C=C(C(=O)/C=C/c2cccc(OC)c2OC)C(=O)/C=C/c2cccc(OC)c2OC)ccc1O		CHEMBL2063990	=	IC50	nM	810.0	CHEMBL4282	Homo sapiens	IC50	uM	0.81
	10974726	CHEMBL2067501	Inhibition of AKT1 by AKT1/PKBalpha KinEASE FP fluorescein green assay	B	COc1ccc(OC)c(/C=C/C(=O)C(=Cc2cc(Br)c(O)c(OC)c2)C(=O)/C=C/c2cc(OC)ccc2OC)c1		CHEMBL2064002	=	IC50	nM	5020.0	CHEMBL4282	Homo sapiens	IC50	uM	5.02
	10974727	CHEMBL2067501	Inhibition of AKT1 by AKT1/PKBalpha KinEASE FP fluorescein green assay	B	COc1ccc(/C=C/C(=O)C(=Cc2ccc(OC)c(O)c2)C(=O)/C=C/c2ccc(OC)cc2OC)c(OC)c1		CHEMBL2064009	=	IC50	nM	1660.0	CHEMBL4282	Homo sapiens	IC50	uM	1.66
Dose-dependent effect	10974728	CHEMBL2067502	Inhibition of AKT1-mediated GSK3beta phosphorylation in human A549 cells incubated for 12 hrs by Western blot	B	COc1cc(C=C(C(=O)/C=C/c2cccc(OC)c2OC)C(=O)/C=C/c2cccc(OC)c2OC)ccc1O		CHEMBL2063990		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	10978486	CHEMBL2066179	Inhibition of human recombinant Akt1/PKBalpha expressed in insect cells using CREBtide as substrate assessed as residual activity at 1 uM after 60 mins by Cerep assay	B	N#Cc1ccc(-c2ccc(CSc3nnc(-c4ccc5c(c4)OCO5)o3)cc2)cc1		CHEMBL2064515	>	Activity	%	80.0	CHEMBL4282	Homo sapiens	Activity	%	80.0
	10980233	CHEMBL2065105	Inhibition of AKT1 at 10 uM by FRET assay	B	CSc1ccccc1Nc1nc(N2CC3(CNC3)C2)nc2c(NCC3CC3)ncnc12		CHEMBL2017253	=	Inhibition	%	25.0	CHEMBL4282	Homo sapiens	INH	%	25.0
	10980234	CHEMBL2065105	Inhibition of AKT1 at 10 uM by FRET assay	B	CSc1ccccc1Nc1nc(N2CCN(C3CCNCC3)CC2)nc2c(NCC3CC3)ncnc12		CHEMBL2063926	<	Inhibition	%	15.0	CHEMBL4282	Homo sapiens	INH	%	15.0
	10980292	CHEMBL2065136	Inhibition of AKT1 by FRET assay	B	CSc1ccccc1Nc1nc(N2CCN(C3CCNCC3)CC2)nc2c(NCC3CC3)ncnc12		CHEMBL2063926	<	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
Not Active	10986935	CHEMBL2072239	Inhibition of PKBalpha at 10 uM	B	NS(=O)(=O)c1cc(-c2nc3ccccc3s2)cs1		CHEMBL2069711		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	11011590	CHEMBL2091231	Inhibition of AKT1 at 10 uM by luciferase assay	B	O=C1NC(=O)c2c1c(-c1ccccc1)cc1[nH]c3ccc(O)cc3c21		CHEMBL214253		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	11011614	CHEMBL2091231	Inhibition of AKT1 at 10 uM by luciferase assay	B	Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1		CHEMBL238125	>	Inhibition	%	25.0	CHEMBL4282	Homo sapiens	INH	%	25.0
Not Active	11011656	CHEMBL2091231	Inhibition of AKT1 at 10 uM by luciferase assay	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21		CHEMBL268368		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	11013457	CHEMBL2092260	Inhibition of AKT1 at 3 uM	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3)s2)cc1		CHEMBL2087023	=	Inhibition	%	0.8	CHEMBL4282	Homo sapiens	INH	%	0.8
	11016399	CHEMBL2092097	Inhibition of AKT1 at 1 uM	B	CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1		CHEMBL2087474	<	Inhibition	%	30.0	CHEMBL4282	Homo sapiens	INH	%	30.0
	11016400	CHEMBL2092097	Inhibition of AKT1 at 1 uM	B	Cc1nc(N)ncc1-c1cn2cc(CN3CCN(S(C)(=O)=O)CC3)nc2c(N2CCOCC2)n1		CHEMBL2087480	<	Inhibition	%	30.0	CHEMBL4282	Homo sapiens	INH	%	30.0
	11016401	CHEMBL2092097	Inhibition of AKT1 at 1 uM	B	CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3c2Br)CC1		CHEMBL2087491	<	Inhibition	%	30.0	CHEMBL4282	Homo sapiens	INH	%	30.0
	11016402	CHEMBL2092097	Inhibition of AKT1 at 1 uM	B	Cc1c(CN2CCN(S(C)(=O)=O)CC2)nc2c(N3CCOCC3)nc(-c3cnc(N)nc3)cn12		CHEMBL2087492	<	Inhibition	%	30.0	CHEMBL4282	Homo sapiens	INH	%	30.0
	11016403	CHEMBL2092097	Inhibition of AKT1 at 1 uM	B	CS(=O)(=O)N1CCN(Cc2cn3c(Cl)c(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1		CHEMBL2087493	<	Inhibition	%	30.0	CHEMBL4282	Homo sapiens	INH	%	30.0
	11016519	CHEMBL2092414	Inhibition of AKT1 at 5 uM	B	CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1		CHEMBL2087474	<	Inhibition	%	30.0	CHEMBL4282	Homo sapiens	INH	%	30.0
	11016520	CHEMBL2092414	Inhibition of AKT1 at 5 uM	B	Cc1nc(N)ncc1-c1cn2cc(CN3CCN(S(C)(=O)=O)CC3)nc2c(N2CCOCC2)n1		CHEMBL2087480	<	Inhibition	%	30.0	CHEMBL4282	Homo sapiens	INH	%	30.0
	11016521	CHEMBL2092414	Inhibition of AKT1 at 5 uM	B	CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3c2Br)CC1		CHEMBL2087491	<	Inhibition	%	30.0	CHEMBL4282	Homo sapiens	INH	%	30.0
	11016522	CHEMBL2092414	Inhibition of AKT1 at 5 uM	B	Cc1c(CN2CCN(S(C)(=O)=O)CC2)nc2c(N3CCOCC3)nc(-c3cnc(N)nc3)cn12		CHEMBL2087492	<	Inhibition	%	30.0	CHEMBL4282	Homo sapiens	INH	%	30.0
	11016523	CHEMBL2092414	Inhibition of AKT1 at 5 uM	B	CS(=O)(=O)N1CCN(Cc2cn3c(Cl)c(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1		CHEMBL2087493	<	Inhibition	%	30.0	CHEMBL4282	Homo sapiens	INH	%	30.0
	12046236	CHEMBL2157256	Inhibition of AKT1 at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
Not Active	12047412	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2c(O)cccc21		CHEMBL2152966		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047413	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2c1cccc2C1CCOCC1		CHEMBL2152967		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047414	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	CC1(C)OC[C@H](COc2cccc3c2CCc2cc(Nc4ccc(F)cc4F)ccc2C3=O)O1		CHEMBL2152968		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047415	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2c(OC[C@H](O)CO)cccc21		CHEMBL2152969		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047416	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2c(OCCN3CCOCC3)cccc21		CHEMBL2152970		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047417	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	COc1cccc2c1CCc1cc(Nc3ccccc3N)ccc1C2=O		CHEMBL2152971		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047418	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	CC1(C)OC[C@H](COc2cccc3c2CCc2cc(Nc4ccccc4N)ccc2C3=O)O1		CHEMBL2152972		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047419	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)CCc1c(OC[C@H](O)CO)cccc1C2=O		CHEMBL2152973		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047541	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccccc3Cl)cc1CC2		CHEMBL2152781		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047557	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	COc1cccc2c1CCc1cc(Nc3ccc(F)cc3F)ccc1C2=O		CHEMBL2152965		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047558	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2cc(OC[C@@H](O)CO)ccc21		CHEMBL2152960		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047559	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	CC1(C)OC[C@@H](COc2ccc3c(c2)CCc2cc(Nc4ccc(F)cc4F)ccc2C3=O)O1		CHEMBL2152959		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047560	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2cc(OC[C@H](O)CO)ccc21		CHEMBL2152958		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047561	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	CC1(C)OC[C@H](COc2ccc3c(c2)CCc2cc(Nc4ccc(F)cc4F)ccc2C3=O)O1		CHEMBL2152957		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047562	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OCCCN3CCOCC3)cc21		CHEMBL2152950		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047563	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	CC1(C)OC[C@@H](CCOc2ccc3c(c2)C(=O)c2ccc(Nc4ccc(F)cc4F)cc2CC3)O1		CHEMBL2152947		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047564	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@@H](O)CO)cc21		CHEMBL2152946		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047565	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	CC1(C)OC[C@H](COc2ccc3c(c2)C(=O)c2ccc(Nc4ccc(F)cc4F)cc2CC3)O1		CHEMBL2152943		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047566	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC3CCOCC3)cc21		CHEMBL2152942		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047567	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OCCCO)cc21		CHEMBL2152941		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047568	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OCCO)cc21		CHEMBL2152940		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047569	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	Nc1ccccc1Nc1ccc2c(=O)c3cc(OCCN4CCOCC4)ccc3ccc2c1		CHEMBL2152939		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047570	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)CCc1ccc(OC[C@H](O)CO)cc1C2=O		CHEMBL2152936		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047571	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	CC1(C)OC[C@H](COc2ccc3c(c2)C(=O)c2ccc(Nc4ccccc4N)cc2CC3)O1		CHEMBL2152798		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047572	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	COc1ccc2ccc3cc(Nc4ccc(F)cc4F)ccc3c(=O)c2c1		CHEMBL2152792		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047573	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(-c3ccccc3)cc1CC2		CHEMBL2152791		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047574	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3cc(F)cc(F)c3F)cc1CC2		CHEMBL2152789		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12047575	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccc(F)c(C)c3)cc1CC2		CHEMBL2152788		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12048329	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccc(C(F)(F)F)cc3N)cc1CC2		CHEMBL2152787		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12048330	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccc(F)cc3C)cc1CC2		CHEMBL2152786		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12048331	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccc(F)cc3Cl)cc1CC2		CHEMBL2152785		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12048332	CHEMBL2155535	Inhibition of AKT1 at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccccc3C(F)(F)F)cc1CC2		CHEMBL2152782		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	12060756	CHEMBL2156891	Inhibition of AKT1	B	CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N		CHEMBL2152252	>	IC50	nM	3600.0	CHEMBL4282	Homo sapiens	IC50	nM	3600.0
	12060757	CHEMBL2156891	Inhibition of AKT1	B	CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3C)c2)cnc1N		CHEMBL2152253	>	IC50	nM	3600.0	CHEMBL4282	Homo sapiens	IC50	nM	3600.0
	12060916	CHEMBL2157051	Binding affinity to AKT1 at 1 uM by high throughput binding assay relative to control	B	Nc1cc(NS(=O)(=O)c2cccc(C(F)(F)F)c2)cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)c1		CHEMBL2152288	=	Activity	%	94.0	CHEMBL4282	Homo sapiens	Activity	%	94.0
	12074615	CHEMBL2161012	Inhibition of Akt1 at 1 uM	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL1908842	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	12074694	CHEMBL2161415	Inhibition of PKBalpha at 1 uM	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL1908842	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	12079794	CHEMBL2167411	Inhibition of TNFalpha-stimulated ICAM-1 expression in HUVEC transfected with activated AKT1 assessed as ICAM1 level at 10 uM incubated for 16 hrs by Western blot (Rvb = 249%)	B	C=C1CC[C@H]2[C@@](C)(CC[C@@H](O)[C@@]2(C)CO)[C@@H]1C/C=C1/C(=O)OC[C@H]1O		CHEMBL186141	=	Activity	%	177.0	CHEMBL4282	Homo sapiens	Activity	%	177.0
	12079795	CHEMBL2167410	Inhibition of TNFalpha-stimulated AKT1-mediated ICAM-1 expression in HUVEC assessed as ICAM1 level at 10 uM pretreated for 16 hrs before TNFalpha challenge measured after 6 hrs by Western blot analysis (Rvb = 345%)	B	C=C1CC[C@H]2[C@@](C)(CC[C@@H](O)[C@@]2(C)CO)[C@@H]1C/C=C1/C(=O)OC[C@H]1O		CHEMBL186141	=	Activity	%	36.0	CHEMBL4282	Homo sapiens	Activity	%	36.0
	12079796	CHEMBL2167409	Inhibition of TNFalpha-stimulated Akt1 phosphorylation at Ser473 assessed as pAKT level in HUVEC at 10 uM pretreated for 16 hrs before TNFalpha challenge measured after 6 hrs by Western blot analysis (Rvb = 249%)	B	C=C1CC[C@H]2[C@@](C)(CC[C@@H](O)[C@@]2(C)CO)[C@@H]1C/C=C1/C(=O)OC[C@H]1O		CHEMBL186141	=	Activity	%	127.0	CHEMBL4282	Homo sapiens	Activity	%	127.0
	12079797	CHEMBL2167408	Inhibition of activated Akt1 phosphorylation at Ser473 expressed in HUVEC transfected with activated AKT1 assessed as pAKT level at 10 uM after 16 hrs by Western blot analysis (Rvb = 272%)	B	C=C1CC[C@H]2[C@@](C)(CC[C@@H](O)[C@@]2(C)CO)[C@@H]1C/C=C1/C(=O)OC[C@H]1O		CHEMBL186141	=	Activity	%	111.0	CHEMBL4282	Homo sapiens	Activity	%	111.0
Not Active	12079798	CHEMBL2167424	Induction of Akt1 phosphorylation at Ser473 expressed in HUVEC by Western blot analysis	B	C=C1CC[C@H]2[C@@](C)(CC[C@@H](O)[C@@]2(C)CO)[C@@H]1C/C=C1/C(=O)OC[C@H]1O		CHEMBL186141		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	12079799	CHEMBL2167425	Inhibition of TNFalpha-stimulated Akt1 phosphorylation at Ser473 in HUVEC at 10 uM pretreated for 16 hrs before TNFalpha challenge measured after 15 mins by Western blot analysis	B	C=C1CC[C@H]2[C@@](C)(CC[C@@H](O)[C@@]2(C)CO)[C@@H]1C/C=C1/C(=O)OC[C@H]1O		CHEMBL186141		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	12094388	CHEMBL2166167	Inhibition of human PKBalpha at 10 uM	B	CCOc1ccc(Nc2c(C)c(N[C@H]3CCCNC3)nc3ccnn23)cc1		CHEMBL1235213	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
Not Active	12104057	CHEMBL2176490	Binding affinity to AKT1 at 1 uM by radioligand displacement assay	B	CNc1nn2cc3c(nc2c1S(=O)(=O)c1ccccc1)CCN(C)C3		CHEMBL2172192		Activity			CHEMBL4282	Homo sapiens	Activity		
	12112604	CHEMBL2174423	Inhibition of AKT1 at 1 uM by 33P kinase hotspot assay	B	NC(=O)c1ccc(Nc2ncc(F)c(Nc3ccccc3Cl)n2)cc1		CHEMBL2170414	=	Inhibition	%	8.0	CHEMBL4282	Homo sapiens	INH	%	8.0
	12112605	CHEMBL2174423	Inhibition of AKT1 at 1 uM by 33P kinase hotspot assay	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
Active	12143248	CHEMBL2187087	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells by SPR analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177836		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	12143249	CHEMBL2186658	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells in presence of A674563	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177836		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	12143250	CHEMBL2183045	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218		deltaTm			CHEMBL4282	Homo sapiens	deltaTm		
Not Active	12143251	CHEMBL2183042	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as fluorescence quenching by Trp fluorescence assay	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218		deltaTm			CHEMBL4282	Homo sapiens	deltaTm		
Not Active	12143252	CHEMBL2183042	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as fluorescence quenching by Trp fluorescence assay	B	N=P([O-])(OP(=O)([O-])[O-])OP(=O)([O-])OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O.[Li+].[Li+].[Li+].[Li+]		CHEMBL2177838		deltaTm			CHEMBL4282	Homo sapiens	deltaTm		
Not Active	12143253	CHEMBL2183044	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 1.2 mM	B	N=P([O-])(OP(=O)([O-])[O-])OP(=O)([O-])OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O.[Li+].[Li+].[Li+].[Li+]		CHEMBL2177838		deltaTm			CHEMBL4282	Homo sapiens	deltaTm		
Not Active	12143258	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ncccc1-c1nc2cccnc2n1-c1cccc(CNC(=O)c2ccccc2)c1		CHEMBL2177823		deltaTm			CHEMBL4282	Homo sapiens	deltaTm		
Not Active	12143259	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	NCc1ccc(-n2c(-c3cccnc3)nc3cccnc32)cc1		CHEMBL2177848		deltaTm			CHEMBL4282	Homo sapiens	deltaTm		
Not Active	12143260	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	CC(C)(C)c1cccc(-n2c(-c3cccnc3N)nc3cccnc32)c1		CHEMBL2177846		deltaTm			CHEMBL4282	Homo sapiens	deltaTm		
Not Active	12143261	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	CC(C)(C)c1ccc(-n2c(-c3cccnc3)nc3cccnc32)cc1		CHEMBL2177844		deltaTm			CHEMBL4282	Homo sapiens	deltaTm		
Not Active	12143262	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	COc1ccccc1Cn1c(-c2ccncc2)nc2cc(Br)cnc21		CHEMBL2177843		deltaTm			CHEMBL4282	Homo sapiens	deltaTm		
Not Active	12143263	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	COc1ccccc1Cn1c(-c2cccnc2N)nc2cc(Br)cnc21		CHEMBL2177842		deltaTm			CHEMBL4282	Homo sapiens	deltaTm		
Not Active	12143264	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	COc1ccccc1Cn1c(-c2cccnc2N)nc2cccnc21		CHEMBL2177841		deltaTm			CHEMBL4282	Homo sapiens	deltaTm		
Not Active	12143265	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	CC(C)(C)c1ccc(-n2c(-c3ccncc3)nc3cccnc32)cc1		CHEMBL2177839		deltaTm			CHEMBL4282	Homo sapiens	deltaTm		
	12143266	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	CC(C)(C)c1ccc(-n2c(-c3cccnc3)nc3cccnc32)cc1	Outside typical range	CHEMBL2177844	=	IC50	nM	185000.0	CHEMBL4282	Homo sapiens	IC50	uM	185.0
	12143276	CHEMBL2183039	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells by indirect affinity mass spectrometry assay	B	COc1ccccc1Cn1c(-c2ccncc2)nc2cc(Br)cnc21		CHEMBL2177843	=	IC50	nM	5900.0	CHEMBL4282	Homo sapiens	IC50	uM	5.9
	12143279	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	COc1ccccc1Cn1c(-c2cccnc2N)nc2cccnc21		CHEMBL2177841	=	IC50	nM	58000.0	CHEMBL4282	Homo sapiens	IC50	uM	58.0
	12143293	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cccnc2n1-c1cccc(CNC(=O)c2ccccc2)c1		CHEMBL2177823	=	IC50	nM	13000.0	CHEMBL4282	Homo sapiens	IC50	uM	13.0
	12143296	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177836	=	Delta Tm	degrees C	13.0	CHEMBL4282	Homo sapiens	deltaTm	degrees C	13.0
	12143297	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5ccccc5)cc4)c3n2)c1		CHEMBL2177834	=	Delta Tm	degrees C	12.8	CHEMBL4282	Homo sapiens	deltaTm	degrees C	12.8
	12143298	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5ccccc5)cc4)c3n2)c1		CHEMBL2177827	=	Delta Tm	degrees C	11.4	CHEMBL4282	Homo sapiens	deltaTm	degrees C	11.4
	12143299	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177837	=	Delta Tm	degrees C	11.1	CHEMBL4282	Homo sapiens	deltaTm	degrees C	11.1
	12143300	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177828	=	Delta Tm	degrees C	11.1	CHEMBL4282	Homo sapiens	deltaTm	degrees C	11.1
	12143301	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177835	=	Delta Tm	degrees C	11.0	CHEMBL4282	Homo sapiens	deltaTm	degrees C	11.0
	12143302	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177829	=	Delta Tm	degrees C	10.8	CHEMBL4282	Homo sapiens	deltaTm	degrees C	10.8
	12143305	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177832	=	Delta Tm	degrees C	9.7	CHEMBL4282	Homo sapiens	deltaTm	degrees C	9.7
	12143308	CHEMBL2186216	Inhibition of Akt 1 in human AN3CA cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(C3CCCC3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177826	=	IC50	nM	9400.0	CHEMBL4282	Homo sapiens	IC50	uM	9.4
	12143309	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177833	=	Delta Tm	degrees C	9.4	CHEMBL4282	Homo sapiens	deltaTm	degrees C	9.4
	12143310	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177831	=	Delta Tm	degrees C	9.2	CHEMBL4282	Homo sapiens	deltaTm	degrees C	9.2
	12143311	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	NCc1ccc(-n2c(-c3cccnc3)nc3cccnc32)cc1		CHEMBL2177848	=	IC50	nM	8800.0	CHEMBL4282	Homo sapiens	IC50	uM	8.8
	12143314	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ncccc1-c1nc2cc(Br)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177825	=	Delta Tm	degrees C	8.1	CHEMBL4282	Homo sapiens	deltaTm	degrees C	8.1
	12143315	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177818	=	Delta Tm	degrees C	6.7	CHEMBL4282	Homo sapiens	deltaTm	degrees C	6.7
	12143316	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177819	=	Delta Tm	degrees C	6.4	CHEMBL4282	Homo sapiens	deltaTm	degrees C	6.4
	12143317	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(NC(=O)c2ccccc2)cc1		CHEMBL2177817	=	Delta Tm	degrees C	7.3	CHEMBL4282	Homo sapiens	deltaTm	degrees C	7.3
	12143318	CHEMBL2183040	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells at 30 uM by indirect affinity mass spectrometry assay	B	CC(C)(C)c1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL2177840	=	Inhibition	%	6.3	CHEMBL4282	Homo sapiens	INH	%	6.3
	12143320	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ncccc1-c1nc2cc(C3CCCC3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177826	=	Delta Tm	degrees C	6.0	CHEMBL4282	Homo sapiens	deltaTm	degrees C	6.0
	12143321	CHEMBL2183039	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells by indirect affinity mass spectrometry assay	B	N=P([O-])(OP(=O)([O-])[O-])OP(=O)([O-])OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O.[Li+].[Li+].[Li+].[Li+]		CHEMBL2177838	=	IC50	nM	5900.0	CHEMBL4282	Homo sapiens	IC50	uM	5.9
	12143322	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)C2CCCCC2)cc1		CHEMBL2177820	=	Delta Tm	degrees C	5.7	CHEMBL4282	Homo sapiens	deltaTm	degrees C	5.7
	12143323	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ncccc1-c1nc2cc(-c3ccccc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177830	=	Delta Tm	degrees C	5.61	CHEMBL4282	Homo sapiens	deltaTm	degrees C	5.61
	12143324	CHEMBL2186214	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177819	=	IC50	nM	5600.0	CHEMBL4282	Homo sapiens	IC50	uM	5.6
	12143327	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNCc2ccccc2)cc1		CHEMBL2177824	=	Delta Tm	degrees C	4.9	CHEMBL4282	Homo sapiens	deltaTm	degrees C	4.9
	12143329	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)Cc2ccccc2)cc1		CHEMBL2177821	=	Delta Tm	degrees C	4.7	CHEMBL4282	Homo sapiens	deltaTm	degrees C	4.7
	12143330	CHEMBL2186216	Inhibition of Akt 1 in human AN3CA cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177832	=	IC50	nM	4200.0	CHEMBL4282	Homo sapiens	IC50	uM	4.2
	12143331	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	Nc1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL2177816	=	Delta Tm	degrees C	4.1	CHEMBL4282	Homo sapiens	deltaTm	degrees C	4.1
	12143332	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	CC(C)(C)c1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL2177840	=	IC50	nM	3900.0	CHEMBL4282	Homo sapiens	IC50	uM	3.9
	12143333	CHEMBL2186214	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(C3CCCC3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177826	=	IC50	nM	3700.0	CHEMBL4282	Homo sapiens	IC50	uM	3.7
	12143334	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	CC(=O)Nc1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL2177815	=	Delta Tm	degrees C	3.7	CHEMBL4282	Homo sapiens	deltaTm	degrees C	3.7
	12143337	CHEMBL2183041	Binding affinity to Akt1 (144 to 480) expressed in Sf9 cells assessed as fluorescence quenching by Trp fluorescence assay	B	N=P([O-])(OP(=O)([O-])[O-])OP(=O)([O-])OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O.[Li+].[Li+].[Li+].[Li+]		CHEMBL2177838	=	Delta Tm	degrees C	3.3	CHEMBL4282	Homo sapiens	deltaTm	degrees C	3.3
	12143338	CHEMBL2186218	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177832	=	IC50	nM	3200.0	CHEMBL4282	Homo sapiens	IC50	uM	3.2
	12143339	CHEMBL2186217	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(Br)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177825	=	IC50	nM	3100.0	CHEMBL4282	Homo sapiens	IC50	uM	3.1
	12143341	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	NCc1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL2177847	=	Delta Tm	degrees C	2.6	CHEMBL4282	Homo sapiens	deltaTm	degrees C	2.6
	12143342	CHEMBL2186218	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177829	=	IC50	nM	2500.0	CHEMBL4282	Homo sapiens	IC50	uM	2.5
	12143343	CHEMBL2186214	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(Br)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177825	=	IC50	nM	2500.0	CHEMBL4282	Homo sapiens	IC50	uM	2.5
	12143344	CHEMBL2186214	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177818	=	IC50	nM	2500.0	CHEMBL4282	Homo sapiens	IC50	uM	2.5
	12143345	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	CC(=O)NCc1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL2177822	=	Delta Tm	degrees C	2.3	CHEMBL4282	Homo sapiens	deltaTm	degrees C	2.3
	12143348	CHEMBL2186218	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177837	=	IC50	nM	2100.0	CHEMBL4282	Homo sapiens	IC50	uM	2.1
	12143349	CHEMBL2186217	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(C3CCCC3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177826	=	IC50	nM	2100.0	CHEMBL4282	Homo sapiens	IC50	uM	2.1
	12143352	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	CC(C)(C)c1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL2177840	=	Delta Tm	degrees C	1.9	CHEMBL4282	Homo sapiens	deltaTm	degrees C	1.9
	12143353	CHEMBL2183043	Binding affinity to Akt1 (144 to 480) expressed in Sf9 cells assessed as change in melting temperature at 1.2 mM	B	N=P([O-])(OP(=O)([O-])[O-])OP(=O)([O-])OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O.[Li+].[Li+].[Li+].[Li+]		CHEMBL2177838	=	Delta Tm	degrees C	1.9	CHEMBL4282	Homo sapiens	deltaTm	degrees C	1.9
	12143354	CHEMBL2186217	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3ccccc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177830	=	IC50	nM	1800.0	CHEMBL4282	Homo sapiens	IC50	uM	1.8
	12143360	CHEMBL2186218	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177831	=	IC50	nM	1500.0	CHEMBL4282	Homo sapiens	IC50	uM	1.5
	12143361	CHEMBL2186218	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177828	=	IC50	nM	1500.0	CHEMBL4282	Homo sapiens	IC50	uM	1.5
	12143362	CHEMBL2186214	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177832	=	IC50	nM	1400.0	CHEMBL4282	Homo sapiens	IC50	uM	1.4
	12143363	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	CC(=O)Nc1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL2177815	=	IC50	nM	1300.0	CHEMBL4282	Homo sapiens	IC50	uM	1.3
	12143365	CHEMBL2186217	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177837	=	IC50	nM	1300.0	CHEMBL4282	Homo sapiens	IC50	uM	1.3
	12143366	CHEMBL2186215	Inhibition of Akt 1 in human A2780 cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177818	=	IC50	nM	1300.0	CHEMBL4282	Homo sapiens	IC50	uM	1.3
	12143367	CHEMBL2183046	Binding affinity to Akt1 (144 to 480) expressed in Sf9 cells assessed as change in melting temperature at 15 uM	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	=	Delta Tm	degrees C	1.3	CHEMBL4282	Homo sapiens	deltaTm	degrees C	1.3
	12143372	CHEMBL2186216	Inhibition of Akt 1 in human AN3CA cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3ccccc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177830	=	IC50	nM	1100.0	CHEMBL4282	Homo sapiens	IC50	uM	1.1
	12143374	CHEMBL2186218	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3ccccc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177830	=	IC50	nM	980.0	CHEMBL4282	Homo sapiens	IC50	uM	0.98
	12143375	CHEMBL2186217	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177831	=	IC50	nM	950.0	CHEMBL4282	Homo sapiens	IC50	uM	0.95
	12143376	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	NCc1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL2177847	=	IC50	nM	930.0	CHEMBL4282	Homo sapiens	IC50	uM	0.93
	12143377	CHEMBL2186217	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5ccccc5)cc4)c3n2)c1		CHEMBL2177834	=	IC50	nM	910.0	CHEMBL4282	Homo sapiens	IC50	uM	0.91
	12143378	CHEMBL2183047	Binding affinity to Akt1 (1 to 480) expressed in Sf9 cells assessed as change in melting temperature at 30 uM	B	CC(C)(C)c1ccc(-n2c(-c3cccnc3N)nc3cc(Br)cnc32)cc1		CHEMBL2177845	=	Delta Tm	degrees C	0.9	CHEMBL4282	Homo sapiens	deltaTm	degrees C	0.9
	12143379	CHEMBL2186218	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5ccccc5)cc4)c3n2)c1		CHEMBL2177834	=	IC50	nM	840.0	CHEMBL4282	Homo sapiens	IC50	uM	0.84
	12143380	CHEMBL2186218	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177833	=	IC50	nM	820.0	CHEMBL4282	Homo sapiens	IC50	uM	0.82
	12143381	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	CC(=O)NCc1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL2177822	=	IC50	nM	810.0	CHEMBL4282	Homo sapiens	IC50	uM	0.81
	12143383	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL2177816	=	IC50	nM	740.0	CHEMBL4282	Homo sapiens	IC50	uM	0.74
	12143384	CHEMBL2186217	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177832	=	IC50	nM	740.0	CHEMBL4282	Homo sapiens	IC50	uM	0.74
	12143386	CHEMBL2186215	Inhibition of Akt 1 in human A2780 cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177837	=	IC50	nM	690.0	CHEMBL4282	Homo sapiens	IC50	uM	0.69
	12143387	CHEMBL2186215	Inhibition of Akt 1 in human A2780 cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3ccccc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177830	=	IC50	nM	680.0	CHEMBL4282	Homo sapiens	IC50	uM	0.68
	12143390	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)Cc2ccccc2)cc1		CHEMBL2177821	=	IC50	nM	660.0	CHEMBL4282	Homo sapiens	IC50	uM	0.66
	12143392	CHEMBL2186217	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177833	=	IC50	nM	580.0	CHEMBL4282	Homo sapiens	IC50	uM	0.58
	12143393	CHEMBL2186217	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177829	=	IC50	nM	480.0	CHEMBL4282	Homo sapiens	IC50	uM	0.48
	12143394	CHEMBL2186217	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177835	=	IC50	nM	410.0	CHEMBL4282	Homo sapiens	IC50	uM	0.41
	12143395	CHEMBL2186213	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177819	=	IC50	nM	410.0	CHEMBL4282	Homo sapiens	IC50	uM	0.41
	12143397	CHEMBL2186215	Inhibition of Akt 1 in human A2780 cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177819	=	IC50	nM	370.0	CHEMBL4282	Homo sapiens	IC50	uM	0.37
	12143398	CHEMBL2186216	Inhibition of Akt 1 in human AN3CA cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177837	=	IC50	nM	340.0	CHEMBL4282	Homo sapiens	IC50	uM	0.34
	12143399	CHEMBL2186213	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3ccccc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177830	=	IC50	nM	330.0	CHEMBL4282	Homo sapiens	IC50	uM	0.33
	12143400	CHEMBL2186217	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5ccccc5)cc4)c3n2)c1		CHEMBL2177827	=	IC50	nM	310.0	CHEMBL4282	Homo sapiens	IC50	uM	0.31
	12143401	CHEMBL2186213	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(C3CCCC3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177826	=	IC50	nM	270.0	CHEMBL4282	Homo sapiens	IC50	uM	0.27
	12143402	CHEMBL2183039	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells by indirect affinity mass spectrometry assay	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	12143403	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNCc2ccccc2)cc1		CHEMBL2177824	=	IC50	nM	260.0	CHEMBL4282	Homo sapiens	IC50	uM	0.26
	12143404	CHEMBL2186216	Inhibition of Akt 1 in human AN3CA cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177828	=	IC50	nM	260.0	CHEMBL4282	Homo sapiens	IC50	uM	0.26
	12143405	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)C2CCCCC2)cc1		CHEMBL2177820	=	IC50	nM	250.0	CHEMBL4282	Homo sapiens	IC50	uM	0.25
	12143406	CHEMBL2186217	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177836	=	IC50	nM	250.0	CHEMBL4282	Homo sapiens	IC50	uM	0.25
	12143407	CHEMBL2186218	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177836	=	IC50	nM	220.0	CHEMBL4282	Homo sapiens	IC50	uM	0.22
	12143408	CHEMBL2186215	Inhibition of Akt 1 in human A2780 cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(C3CCCC3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177826	=	IC50	nM	210.0	CHEMBL4282	Homo sapiens	IC50	uM	0.21
	12143409	CHEMBL2186213	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177818	=	IC50	nM	210.0	CHEMBL4282	Homo sapiens	IC50	uM	0.21
	12143410	CHEMBL2186215	Inhibition of Akt 1 in human A2780 cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177833	=	IC50	nM	200.0	CHEMBL4282	Homo sapiens	IC50	uM	0.2
	12143411	CHEMBL2186213	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177837	=	IC50	nM	190.0	CHEMBL4282	Homo sapiens	IC50	uM	0.19
	12143412	CHEMBL2186215	Inhibition of Akt 1 in human A2780 cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177835	=	IC50	nM	180.0	CHEMBL4282	Homo sapiens	IC50	uM	0.18
	12143413	CHEMBL2186216	Inhibition of Akt 1 in human AN3CA cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5ccccc5)cc4)c3n2)c1		CHEMBL2177834	=	IC50	nM	170.0	CHEMBL4282	Homo sapiens	IC50	uM	0.17
	12143414	CHEMBL2186215	Inhibition of Akt 1 in human A2780 cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(Br)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177825	=	IC50	nM	170.0	CHEMBL4282	Homo sapiens	IC50	uM	0.17
	12143415	CHEMBL2186214	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3ccccc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177830	=	IC50	nM	160.0	CHEMBL4282	Homo sapiens	IC50	uM	0.16
	12143416	CHEMBL2186217	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177828	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	uM	0.14
	12143417	CHEMBL2186215	Inhibition of Akt 1 in human A2780 cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5ccccc5)cc4)c3n2)c1		CHEMBL2177834	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	uM	0.14
	12143419	CHEMBL2186213	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5ccccc5)cc4)c3n2)c1		CHEMBL2177834	=	IC50	nM	130.0	CHEMBL4282	Homo sapiens	IC50	uM	0.13
	12143420	CHEMBL2186213	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177828	=	IC50	nM	120.0	CHEMBL4282	Homo sapiens	IC50	uM	0.12
	12143421	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cc(C3CCCC3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177826	=	IC50	nM	110.0	CHEMBL4282	Homo sapiens	IC50	uM	0.11
	12143422	CHEMBL2186214	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5ccccc5)cc4)c3n2)c1		CHEMBL2177834	=	IC50	nM	110.0	CHEMBL4282	Homo sapiens	IC50	uM	0.11
	12143423	CHEMBL2186213	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177831	=	IC50	nM	100.0	CHEMBL4282	Homo sapiens	IC50	uM	0.1
	12143424	CHEMBL2186214	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177837	=	IC50	nM	95.0	CHEMBL4282	Homo sapiens	IC50	uM	0.095
	12143425	CHEMBL2186216	Inhibition of Akt 1 in human AN3CA cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177831	=	IC50	nM	91.0	CHEMBL4282	Homo sapiens	IC50	uM	0.091
	12143426	CHEMBL2186214	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177828	=	IC50	nM	90.0	CHEMBL4282	Homo sapiens	IC50	uM	0.09
	12143427	CHEMBL2186214	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177831	=	IC50	nM	80.0	CHEMBL4282	Homo sapiens	IC50	uM	0.08
	12143428	CHEMBL2186214	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177829	=	IC50	nM	69.0	CHEMBL4282	Homo sapiens	IC50	uM	0.069
	12143429	CHEMBL2186213	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177835	=	IC50	nM	68.0	CHEMBL4282	Homo sapiens	IC50	uM	0.068
	12143430	CHEMBL2186215	Inhibition of Akt 1 in human A2780 cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177832	=	IC50	nM	67.0	CHEMBL4282	Homo sapiens	IC50	uM	0.067
	12143431	CHEMBL2186213	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177829	=	IC50	nM	65.0	CHEMBL4282	Homo sapiens	IC50	uM	0.065
	12143432	CHEMBL2186215	Inhibition of Akt 1 in human A2780 cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177831	=	IC50	nM	62.0	CHEMBL4282	Homo sapiens	IC50	uM	0.062
	12143433	CHEMBL2186215	Inhibition of Akt 1 in human A2780 cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177829	=	IC50	nM	55.0	CHEMBL4282	Homo sapiens	IC50	uM	0.055
	12143434	CHEMBL2186215	Inhibition of Akt 1 in human A2780 cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5ccccc5)cc4)c3n2)c1		CHEMBL2177827	=	IC50	nM	54.0	CHEMBL4282	Homo sapiens	IC50	uM	0.054
	12143435	CHEMBL2186213	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177833	=	IC50	nM	54.0	CHEMBL4282	Homo sapiens	IC50	uM	0.054
	12143436	CHEMBL2186216	Inhibition of Akt 1 in human AN3CA cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177829	=	IC50	nM	51.0	CHEMBL4282	Homo sapiens	IC50	uM	0.051
	12143437	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177829	=	IC50	nM	50.0	CHEMBL4282	Homo sapiens	IC50	uM	0.05
	12143438	CHEMBL2186216	Inhibition of Akt 1 in human AN3CA cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177833	=	IC50	nM	49.0	CHEMBL4282	Homo sapiens	IC50	uM	0.049
	12143439	CHEMBL2186216	Inhibition of Akt 1 in human AN3CA cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5ccccc5)cc4)c3n2)c1		CHEMBL2177827	=	IC50	nM	49.0	CHEMBL4282	Homo sapiens	IC50	uM	0.049
	12143440	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177837	=	IC50	nM	47.0	CHEMBL4282	Homo sapiens	IC50	uM	0.047
	12143441	CHEMBL2186214	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5ccccc5)cc4)c3n2)c1		CHEMBL2177827	=	IC50	nM	47.0	CHEMBL4282	Homo sapiens	IC50	uM	0.047
	12143442	CHEMBL2186214	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177833	=	IC50	nM	46.0	CHEMBL4282	Homo sapiens	IC50	uM	0.046
	12143443	CHEMBL2186213	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5ccccc5)cc4)c3n2)c1		CHEMBL2177827	=	IC50	nM	46.0	CHEMBL4282	Homo sapiens	IC50	uM	0.046
	12143444	CHEMBL2186216	Inhibition of Akt 1 in human AN3CA cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177836	=	IC50	nM	45.0	CHEMBL4282	Homo sapiens	IC50	uM	0.045
	12143445	CHEMBL2186214	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177836	=	IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	uM	0.044
	12143446	CHEMBL2186213	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177832	=	IC50	nM	34.0	CHEMBL4282	Homo sapiens	IC50	uM	0.034
	12143447	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cc(-c3ccccc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177830	=	IC50	nM	33.0	CHEMBL4282	Homo sapiens	IC50	uM	0.033
	12143448	CHEMBL2186215	Inhibition of Akt 1 in human A2780 cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177836	=	IC50	nM	32.0	CHEMBL4282	Homo sapiens	IC50	uM	0.032
	12143450	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177832	=	IC50	nM	28.0	CHEMBL4282	Homo sapiens	IC50	uM	0.028
	12143451	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177818	=	IC50	nM	28.0	CHEMBL4282	Homo sapiens	IC50	uM	0.028
	12143453	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cc(Br)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177825	=	IC50	nM	27.0	CHEMBL4282	Homo sapiens	IC50	uM	0.027
	12143454	CHEMBL2186213	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177836	=	IC50	nM	27.0	CHEMBL4282	Homo sapiens	IC50	uM	0.027
	12143455	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177835	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	uM	0.024
	12143456	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177819	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	uM	0.023
	12145185	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177828	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	uM	0.017
	12145186	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5ccccc5)cc4)c3n2)c1		CHEMBL2177827	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	uM	0.016
	12145187	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5ccccc5)cc4)c3n2)c1		CHEMBL2177834	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	uM	0.015
	12145188	CHEMBL2186215	Inhibition of Akt 1 in human A2780 cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177828	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	uM	0.015
	12145189	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(NC(=O)c2ccccc2)cc1		CHEMBL2177817	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	uM	0.014
	12145190	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177831	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	uM	0.008
	12145191	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2cccc(F)c2)cc1		CHEMBL2177833	=	IC50	nM	5.2	CHEMBL4282	Homo sapiens	IC50	uM	0.0052
	12145192	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1		CHEMBL2177836	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	uM	0.005
	12145230	CHEMBL2186218	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177835	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12145231	CHEMBL2186218	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CC(=O)Nc5ccccc5)cc4)c3n2)c1		CHEMBL2177827	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12145232	CHEMBL2186218	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(C3CCCC3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177826	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12145233	CHEMBL2186218	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(Br)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177825	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12145234	CHEMBL2186218	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177819	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12145235	CHEMBL2186218	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177818	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12145236	CHEMBL2186217	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177819	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12145237	CHEMBL2186217	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation PRAS40 at T246 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177818	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12145238	CHEMBL2186216	Inhibition of Akt 1 in human AN3CA cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177835	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12145239	CHEMBL2186216	Inhibition of Akt 1 in human AN3CA cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(Br)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177825	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12145240	CHEMBL2186216	Inhibition of Akt 1 in human AN3CA cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177819	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12145241	CHEMBL2186216	Inhibition of Akt 1 in human AN3CA cells assessed as phosphorylation of Akt at T308 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177818	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12145242	CHEMBL2186214	Inhibition of Akt1 in human AN3CA cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177835	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12145243	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	CC(C)(C)c1cccc(-n2c(-c3cccnc3N)nc3cccnc32)c1	Outside typical range	CHEMBL2177846	>	IC50	nM	300000.0	CHEMBL4282	Homo sapiens	IC50	uM	300.0
	12145244	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	CC(C)(C)c1ccc(-n2c(-c3cccnc3N)nc3cc(Br)cnc32)cc1	Outside typical range	CHEMBL2177845	>	IC50	nM	300000.0	CHEMBL4282	Homo sapiens	IC50	uM	300.0
	12145245	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	COc1ccccc1Cn1c(-c2ccncc2)nc2cc(Br)cnc21	Outside typical range	CHEMBL2177843	>	IC50	nM	300000.0	CHEMBL4282	Homo sapiens	IC50	uM	300.0
	12145246	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	COc1ccccc1Cn1c(-c2cccnc2N)nc2cc(Br)cnc21	Outside typical range	CHEMBL2177842	>	IC50	nM	300000.0	CHEMBL4282	Homo sapiens	IC50	uM	300.0
	12145247	CHEMBL2186223	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells using biotin-GRPRTSSFAEG as substrate after 20 mins by Alpha-screen assay	B	CC(C)(C)c1ccc(-n2c(-c3ccncc3)nc3cccnc32)cc1	Outside typical range	CHEMBL2177839	>	IC50	nM	300000.0	CHEMBL4282	Homo sapiens	IC50	uM	300.0
	12145250	CHEMBL2183041	Binding affinity to Akt1 (144 to 480) expressed in Sf9 cells assessed as fluorescence quenching by Trp fluorescence assay	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	=	Delta Tm	degrees C	2.12	CHEMBL4282	Homo sapiens	deltaTm	degrees C	2.12
	12145318	CHEMBL2183039	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells by indirect affinity mass spectrometry assay	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177818	=	IC50	nM	14000.0	CHEMBL4282	Homo sapiens	IC50	uM	14.0
	12145319	CHEMBL2183039	Inhibition of Akt1 (1 to 480) expressed in Sf9 cells by indirect affinity mass spectrometry assay	B	Nc1ncccc1-c1nc2cc(C3CCCC3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177826	=	IC50	nM	12000.0	CHEMBL4282	Homo sapiens	IC50	uM	12.0
	12145323	CHEMBL2186213	Inhibition of Akt1 in human A2780 cells assessed as phosphorylation of Akt at S473 after 2 hrs by Western Blot analysis	B	Nc1ncccc1-c1nc2cc(Br)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177825	<	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	uM	0.012
Not Active	12146590	CHEMBL2182487	Activation of PKBalpha at 50 uM relative to control	B	O=C(O)/C=C(/CCc1ccc(Cl)cc1)c1ccccc1		CHEMBL539134		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	12146591	CHEMBL2182487	Activation of PKBalpha at 50 uM relative to control	B	O=C(CC(c1ccccc1)C(C(=O)O)C(=O)O)c1ccc(C(F)(F)F)cc1		CHEMBL2177668		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	12146592	CHEMBL2182487	Activation of PKBalpha at 50 uM relative to control	B	O=C(CC(c1ccccc1)C(C(=O)O)C(=O)O)c1ccc(Cl)cc1		CHEMBL2177675		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	12146593	CHEMBL2182488	Activation of PKBalpha at 2 uM relative to control	B	O=C(O)/C=C(/CCc1ccc(Cl)cc1)c1ccccc1		CHEMBL539134		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	12146594	CHEMBL2182488	Activation of PKBalpha at 2 uM relative to control	B	O=C(CC(c1ccccc1)C(C(=O)O)C(=O)O)c1ccc(C(F)(F)F)cc1		CHEMBL2177668		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	12146595	CHEMBL2182488	Activation of PKBalpha at 2 uM relative to control	B	O=C(CC(c1ccccc1)C(C(=O)O)C(=O)O)c1ccc(Cl)cc1		CHEMBL2177675		Activity			CHEMBL4282	Homo sapiens	Activity		
	12149897	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC4CCOCC4)c4ccc(Cl)c(F)c4)CC3)c21		CHEMBL2177362	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
	12149898	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNCC4CC4)c4ccc(C(F)(F)F)c(F)c4)CC3)c21		CHEMBL2177361	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	12149899	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC(C)(C)CO)c4ccc(C(F)(F)F)c(F)c4)CC3)c21		CHEMBL2178598	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	12149900	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC(C)(C)C)c4ccc(C(F)(F)F)c(F)c4)CC3)c21		CHEMBL2178597	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	12149901	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)c(F)c1		CHEMBL2177372	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	12149902	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CN)c4ccc(C(F)(F)F)cc4)CC3)c21		CHEMBL2177371	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
	12149903	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@@H](c4ccc(Cl)cc4)[C@@H]4COCCN4)CC3)c21		CHEMBL2177370	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
	12149904	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@@H](c4ccc(Cl)cc4)[C@@H]4CCCCN4)CC3)c21		CHEMBL2177369	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
	12149905	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNCC4CCOCC4)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177368	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	12149906	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CO[C@H]1CC[C@H](NC[C@@H](C(=O)N2CCN(c3ncnc4c3[C@H](C)C[C@H]4O)CC2)c2ccc(Cl)cc2)CC1		CHEMBL2177367	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	12149907	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC4CCOCC4)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177366	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	12149908	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@@H](c4ccc(Cl)cc4)[C@@H]4CCCN4)CC3)c21		CHEMBL2177379	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	12149909	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)N(C)C[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177365	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
	12149910	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC4CCCCC4)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177364	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
	12149911	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CN4CCC(F)CC4)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177363	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	12149912	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC(C)(C)CO)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177378	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	12149913	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	COCCNC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177377	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
	12149914	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNCC(F)(F)F)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177376	=	IC50	nM	902.0	CHEMBL4282	Homo sapiens	IC50	nM	902.0
	12150579	CHEMBL2188514	Inhibition of human recombinant PKBalpha by radiometric kinase assay	B	CN1CCN(c2ccc(Nc3ncc4nc(Nc5ccccc5)n(C5CCCC5)c4n3)cc2)CC1		CHEMBL2178352	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12151660	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNCCF)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177375	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
	12151661	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNCC4CC4)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177374	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	12151662	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CN)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177373	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	nM	24.0
	12151663	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC4CCOCC4)c4ccc(Cl)c(F)c4)CC3)c21		CHEMBL2177362	=	IC50	nM	139.0	CHEMBL4282	Homo sapiens	IC50	nM	139.0
	12151664	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNCC4CC4)c4ccc(C(F)(F)F)c(F)c4)CC3)c21		CHEMBL2177361	=	IC50	nM	65.0	CHEMBL4282	Homo sapiens	IC50	nM	65.0
	12151665	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC(C)(C)CO)c4ccc(C(F)(F)F)c(F)c4)CC3)c21		CHEMBL2178598	=	IC50	nM	47.0	CHEMBL4282	Homo sapiens	IC50	nM	47.0
	12151666	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC(C)(C)C)c4ccc(C(F)(F)F)c(F)c4)CC3)c21		CHEMBL2178597	=	IC50	nM	92.0	CHEMBL4282	Homo sapiens	IC50	nM	92.0
	12151667	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)c(F)c1		CHEMBL2177372	=	IC50	nM	234.0	CHEMBL4282	Homo sapiens	IC50	nM	234.0
	12151668	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CN)c4ccc(C(F)(F)F)cc4)CC3)c21		CHEMBL2177371	=	IC50	nM	603.0	CHEMBL4282	Homo sapiens	IC50	nM	603.0
	12151669	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@@H](c4ccc(Cl)cc4)[C@@H]4COCCN4)CC3)c21		CHEMBL2177370	=	IC50	nM	855.0	CHEMBL4282	Homo sapiens	IC50	nM	855.0
	12151670	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@@H](c4ccc(Cl)cc4)[C@@H]4CCCCN4)CC3)c21		CHEMBL2177369	=	IC50	nM	530.0	CHEMBL4282	Homo sapiens	IC50	nM	530.0
	12151671	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNCC4CCOCC4)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177368	=	IC50	nM	102.0	CHEMBL4282	Homo sapiens	IC50	nM	102.0
	12151672	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	CO[C@H]1CC[C@H](NC[C@@H](C(=O)N2CCN(c3ncnc4c3[C@H](C)C[C@H]4O)CC2)c2ccc(Cl)cc2)CC1		CHEMBL2177367	=	IC50	nM	132.0	CHEMBL4282	Homo sapiens	IC50	nM	132.0
	12151673	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC4CCOCC4)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177366	=	IC50	nM	184.0	CHEMBL4282	Homo sapiens	IC50	nM	184.0
	12151674	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@@H](c4ccc(Cl)cc4)[C@@H]4CCCN4)CC3)c21		CHEMBL2177379	=	IC50	nM	241.0	CHEMBL4282	Homo sapiens	IC50	nM	241.0
	12151675	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	CC(C)N(C)C[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177365	=	IC50	nM	139.0	CHEMBL4282	Homo sapiens	IC50	nM	139.0
	12151676	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC4CCCCC4)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177364	=	IC50	nM	367.0	CHEMBL4282	Homo sapiens	IC50	nM	367.0
	12151677	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CN4CCC(F)CC4)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177363	=	IC50	nM	196.0	CHEMBL4282	Homo sapiens	IC50	nM	196.0
	12151678	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNC(C)(C)CO)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177378	=	IC50	nM	75.0	CHEMBL4282	Homo sapiens	IC50	nM	75.0
	12151679	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	COCCNC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177377	=	IC50	nM	384.0	CHEMBL4282	Homo sapiens	IC50	nM	384.0
Not Determined	12151680	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNCC(F)(F)F)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177376		IC50			CHEMBL4282	Homo sapiens	IC50		
	12151681	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNCCF)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177375	=	IC50	nM	1296.0	CHEMBL4282	Homo sapiens	IC50	nM	1296.0
	12151682	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CNCC4CC4)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177374	=	IC50	nM	179.0	CHEMBL4282	Homo sapiens	IC50	nM	179.0
	12151683	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C[C@@H]1C[C@@H](O)c2ncnc(N3CCN(C(=O)[C@H](CN)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177373	=	IC50	nM	1454.0	CHEMBL4282	Homo sapiens	IC50	nM	1454.0
	12151736	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)CC3(F)F)CC1)c1ccc(Cl)cc1		CHEMBL2177383	=	IC50	nM	1169.0	CHEMBL4282	Homo sapiens	IC50	nM	1169.0
	12151737	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@@H]3F)CC1)c1ccc(Cl)cc1		CHEMBL2177382	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
	12151738	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3F)CC1)c1ccc(Cl)cc1		CHEMBL2177381	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	12151739	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177380	=	IC50	nM	68.0	CHEMBL4282	Homo sapiens	IC50	nM	68.0
	12151740	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177390	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	12151741	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](CO)CC3)CC1)c1ccc(Cl)cc1		CHEMBL2177389	=	IC50	nM	81.0	CHEMBL4282	Homo sapiens	IC50	nM	81.0
	12151742	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](CF)CC3)CC1)c1ccc(Cl)cc1		CHEMBL2177388	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	12151743	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	C=C[C@@H]1CCc2ncnc(N3CCN(C(=O)[C@H](CNC(C)C)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177387	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	12151744	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2C(C)(C)CC3)CC1)c1ccc(Cl)cc1		CHEMBL2177386	>	IC50	nM	2000.0	CHEMBL4282	Homo sapiens	IC50	nM	2000.0
	12151745	CHEMBL2187635	Competitive inhibition of wild-type full-length amino-terminal polyhistidine-tagged human Akt1 expressed in recombinant baculovirus system using fluorescence labeled substrate after 60 mins by fluorescence polarization assay in presence of ATP	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)CC3)CC1)c1ccc(Cl)cc1		CHEMBL2177385	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
Active	12151759	CHEMBL2187628	Inhibition of Akt1-mediated PRAS40 phosphorylation in human BT474M1 cells	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177390		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	12151760	CHEMBL2187629	Inhibition of Akt1-mediated PRAS40 phosphorylation in human MCF7 cells overexpressing Her2	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177390		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	12151761	CHEMBL2187630	Inhibition of Akt1-mediated PRAS40 phosphorylation in human PC3 cells	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177390		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	12151762	CHEMBL2187631	Inhibition of Akt1-mediated PRAS40 phosphorylation in human LNCAP cells	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177390		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	12151785	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)CC3(F)F)CC1)c1ccc(Cl)cc1		CHEMBL2177383	=	IC50	nM	8548.0	CHEMBL4282	Homo sapiens	IC50	nM	8548.0
	12151786	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@@H]3F)CC1)c1ccc(Cl)cc1		CHEMBL2177382	=	IC50	nM	901.0	CHEMBL4282	Homo sapiens	IC50	nM	901.0
	12151787	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3F)CC1)c1ccc(Cl)cc1		CHEMBL2177381	=	IC50	nM	152.0	CHEMBL4282	Homo sapiens	IC50	nM	152.0
	12151788	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177380	=	IC50	nM	740.0	CHEMBL4282	Homo sapiens	IC50	nM	740.0
	12151789	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177390	=	IC50	nM	157.0	CHEMBL4282	Homo sapiens	IC50	nM	157.0
	12151790	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](CO)CC3)CC1)c1ccc(Cl)cc1		CHEMBL2177389	=	IC50	nM	846.0	CHEMBL4282	Homo sapiens	IC50	nM	846.0
	12151791	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](CF)CC3)CC1)c1ccc(Cl)cc1		CHEMBL2177388	=	IC50	nM	123.0	CHEMBL4282	Homo sapiens	IC50	nM	123.0
	12151792	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	C=C[C@@H]1CCc2ncnc(N3CCN(C(=O)[C@H](CNC(C)C)c4ccc(Cl)cc4)CC3)c21		CHEMBL2177387	=	IC50	nM	176.0	CHEMBL4282	Homo sapiens	IC50	nM	176.0
Not Determined	12151793	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2C(C)(C)CC3)CC1)c1ccc(Cl)cc1		CHEMBL2177386		IC50			CHEMBL4282	Homo sapiens	IC50		
	12151794	CHEMBL2188026	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)CC3)CC1)c1ccc(Cl)cc1		CHEMBL2177385	=	IC50	nM	287.0	CHEMBL4282	Homo sapiens	IC50	nM	287.0
	12166142	CHEMBL2211615	Binding affinity to AKT1 at 1 uM	B	Cc1nc(N)nc(-c2cc(Cl)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1		CHEMBL2206921	<	Activity	%	50.0	CHEMBL4282	Homo sapiens	Activity	%	50.0
	12170750	CHEMBL2209471	Inhibition of PKBa assessed as residual activity at 1 uM	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	94.0	CHEMBL4282	Homo sapiens	Activity	%	94.0
	12170881	CHEMBL2213200	Inhibition of PKBa assessed as residual activity at 10 uM	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	96.0	CHEMBL4282	Homo sapiens	Activity	%	96.0
	12173743	CHEMBL2212081	Inhibition of AKT1 assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	12195477	CHEMBL2210945	Inhibition of recombinant AKT1 after 1 hr by scintillation counter analysis in presence of gamma-[33P]ATP	B	CC(C)(C)Nc1c(Nc2ccnc(Nc3ccc(-c4ccncc4)cc3)n2)c(=O)c1=O		CHEMBL2205426	>	Ki	nM	8000.0	CHEMBL4282	Homo sapiens	Ki	nM	8000.0
	12195629	CHEMBL2212878	Inhibition of human recombinant AKT1 expressed in insect cells using CKRREILSRRPSYRK as substrate assessed as residual activity at 1 uM after 60 mins relative to staurosporine	B	CCN(CC)CCOc1ccc(/C=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL2206008	=	Activity	%	101.1	CHEMBL4282	Homo sapiens	Activity	%	101.1
	12205213	CHEMBL2217254	Inhibition of human AKT1 using biotinylated GSKalpha peptide (SGRARTSSFA) as a substrate after 1 hr	B	CCC[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(O)cccc1C2=O		CHEMBL474390	=	IC50	nM	313.0	CHEMBL4282	Homo sapiens	IC50	nM	313.0
	12205214	CHEMBL2217254	Inhibition of human AKT1 using biotinylated GSKalpha peptide (SGRARTSSFA) as a substrate after 1 hr	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(ccc([C@H]3C[C@@H](N(C)C)[C@H](O)[C@@H](C)O3)c1O)C2=O		CHEMBL2216825	=	IC50	nM	149.0	CHEMBL4282	Homo sapiens	IC50	nM	149.0
	12253900	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	98.0	CHEMBL4282	Homo sapiens	Residual Activity	%	98.0
	12253901	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	99.0	CHEMBL4282	Homo sapiens	Residual Activity	%	99.0
	12253902	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	96.0	CHEMBL4282	Homo sapiens	Residual Activity	%	96.0
	12253903	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	95.0	CHEMBL4282	Homo sapiens	Residual Activity	%	95.0
	12253904	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	98.0	CHEMBL4282	Homo sapiens	Residual Activity	%	98.0
	12253905	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	96.0	CHEMBL4282	Homo sapiens	Residual Activity	%	96.0
	12253906	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	96.0	CHEMBL4282	Homo sapiens	Residual Activity	%	96.0
	12253907	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	86.0	CHEMBL4282	Homo sapiens	Residual Activity	%	86.0
	12253908	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	100.0	CHEMBL4282	Homo sapiens	Residual Activity	%	100.0
	12253909	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	95.0	CHEMBL4282	Homo sapiens	Residual Activity	%	95.0
	12253910	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	101.0	CHEMBL4282	Homo sapiens	Residual Activity	%	101.0
	12253911	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	95.0	CHEMBL4282	Homo sapiens	Residual Activity	%	95.0
	12253912	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	99.0	CHEMBL4282	Homo sapiens	Residual Activity	%	99.0
	12253913	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	96.0	CHEMBL4282	Homo sapiens	Residual Activity	%	96.0
	12253914	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	95.0	CHEMBL4282	Homo sapiens	Residual Activity	%	95.0
	12253915	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	87.0	CHEMBL4282	Homo sapiens	Residual Activity	%	87.0
	12253916	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	99.0	CHEMBL4282	Homo sapiens	Residual Activity	%	99.0
	12253917	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	98.0	CHEMBL4282	Homo sapiens	Residual Activity	%	98.0
	12253918	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12253919	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	98.0	CHEMBL4282	Homo sapiens	Residual Activity	%	98.0
	12253920	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	97.0	CHEMBL4282	Homo sapiens	Residual Activity	%	97.0
	12253921	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	101.0	CHEMBL4282	Homo sapiens	Residual Activity	%	101.0
	12253922	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	100.0	CHEMBL4282	Homo sapiens	Residual Activity	%	100.0
	12253923	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	93.0	CHEMBL4282	Homo sapiens	Residual Activity	%	93.0
	12253924	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	99.0	CHEMBL4282	Homo sapiens	Residual Activity	%	99.0
	12253925	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	101.0	CHEMBL4282	Homo sapiens	Residual Activity	%	101.0
	12253926	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	102.0	CHEMBL4282	Homo sapiens	Residual Activity	%	102.0
	12253927	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12253928	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12253929	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12253930	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	96.0	CHEMBL4282	Homo sapiens	Residual Activity	%	96.0
	12253931	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	97.0	CHEMBL4282	Homo sapiens	Residual Activity	%	97.0
	12253932	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	98.0	CHEMBL4282	Homo sapiens	Residual Activity	%	98.0
	12253933	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12253934	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12253935	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12253936	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12253937	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	105.0	CHEMBL4282	Homo sapiens	Residual Activity	%	105.0
	12253938	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	100.0	CHEMBL4282	Homo sapiens	Residual Activity	%	100.0
	12253939	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	95.0	CHEMBL4282	Homo sapiens	Residual Activity	%	95.0
	12253940	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12253941	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	101.0	CHEMBL4282	Homo sapiens	Residual Activity	%	101.0
	12253942	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12253943	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	96.0	CHEMBL4282	Homo sapiens	Residual Activity	%	96.0
	12253944	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	101.0	CHEMBL4282	Homo sapiens	Residual Activity	%	101.0
	12253945	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12253946	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	101.0	CHEMBL4282	Homo sapiens	Residual Activity	%	101.0
	12253947	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	89.0	CHEMBL4282	Homo sapiens	Residual Activity	%	89.0
	12253948	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12253949	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12253950	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	110.0	CHEMBL4282	Homo sapiens	Residual Activity	%	110.0
	12253951	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	105.0	CHEMBL4282	Homo sapiens	Residual Activity	%	105.0
	12253952	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	99.0	CHEMBL4282	Homo sapiens	Residual Activity	%	99.0
	12253953	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	102.0	CHEMBL4282	Homo sapiens	Residual Activity	%	102.0
	12253954	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12253955	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	97.0	CHEMBL4282	Homo sapiens	Residual Activity	%	97.0
	12253956	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	105.0	CHEMBL4282	Homo sapiens	Residual Activity	%	105.0
	12253957	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12253958	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12253959	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12253960	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	101.0	CHEMBL4282	Homo sapiens	Residual Activity	%	101.0
	12253961	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	97.0	CHEMBL4282	Homo sapiens	Residual Activity	%	97.0
	12253962	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12253963	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	96.0	CHEMBL4282	Homo sapiens	Residual Activity	%	96.0
	12253964	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12253965	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12253966	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12253967	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12253968	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12253969	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12253970	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12253971	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12253972	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12253973	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12253974	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	102.0	CHEMBL4282	Homo sapiens	Residual Activity	%	102.0
	12255383	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12255384	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	102.0	CHEMBL4282	Homo sapiens	Residual Activity	%	102.0
	12255385	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	99.0	CHEMBL4282	Homo sapiens	Residual Activity	%	99.0
	12255386	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12255387	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	13.0	CHEMBL4282	Homo sapiens	Residual Activity	%	13.0
	12255388	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	100.0	CHEMBL4282	Homo sapiens	Residual Activity	%	100.0
	12255389	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12255390	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12255391	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	88.0	CHEMBL4282	Homo sapiens	Residual Activity	%	88.0
	12255392	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	101.0	CHEMBL4282	Homo sapiens	Residual Activity	%	101.0
	12255393	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12255394	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12255395	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	102.0	CHEMBL4282	Homo sapiens	Residual Activity	%	102.0
	12255396	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	99.0	CHEMBL4282	Homo sapiens	Residual Activity	%	99.0
	12255397	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255398	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12255399	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255400	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	113.0	CHEMBL4282	Homo sapiens	Residual Activity	%	113.0
	12255401	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	113.0	CHEMBL4282	Homo sapiens	Residual Activity	%	113.0
	12255402	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12255403	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255404	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12255405	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255406	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255407	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	105.0	CHEMBL4282	Homo sapiens	Residual Activity	%	105.0
	12255408	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	110.0	CHEMBL4282	Homo sapiens	Residual Activity	%	110.0
	12255409	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	101.0	CHEMBL4282	Homo sapiens	Residual Activity	%	101.0
	12255410	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12255411	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255412	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12255413	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255414	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255415	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12255416	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255417	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255418	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255419	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	110.0	CHEMBL4282	Homo sapiens	Residual Activity	%	110.0
	12255420	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12255421	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	113.0	CHEMBL4282	Homo sapiens	Residual Activity	%	113.0
	12255422	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12255423	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	114.0	CHEMBL4282	Homo sapiens	Residual Activity	%	114.0
	12255424	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	114.0	CHEMBL4282	Homo sapiens	Residual Activity	%	114.0
	12255425	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	116.0	CHEMBL4282	Homo sapiens	Residual Activity	%	116.0
	12255426	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	105.0	CHEMBL4282	Homo sapiens	Residual Activity	%	105.0
	12255427	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255428	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	110.0	CHEMBL4282	Homo sapiens	Residual Activity	%	110.0
	12255429	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	113.0	CHEMBL4282	Homo sapiens	Residual Activity	%	113.0
	12255430	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255431	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	116.0	CHEMBL4282	Homo sapiens	Residual Activity	%	116.0
	12255432	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	113.0	CHEMBL4282	Homo sapiens	Residual Activity	%	113.0
	12255433	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12255434	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	113.0	CHEMBL4282	Homo sapiens	Residual Activity	%	113.0
	12255435	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	124.0	CHEMBL4282	Homo sapiens	Residual Activity	%	124.0
	12255436	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	118.0	CHEMBL4282	Homo sapiens	Residual Activity	%	118.0
	12255437	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	122.0	CHEMBL4282	Homo sapiens	Residual Activity	%	122.0
	12255438	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	118.0	CHEMBL4282	Homo sapiens	Residual Activity	%	118.0
	12255439	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	116.0	CHEMBL4282	Homo sapiens	Residual Activity	%	116.0
	12255440	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	113.0	CHEMBL4282	Homo sapiens	Residual Activity	%	113.0
	12255441	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255442	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255443	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255444	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	120.0	CHEMBL4282	Homo sapiens	Residual Activity	%	120.0
	12255445	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	115.0	CHEMBL4282	Homo sapiens	Residual Activity	%	115.0
	12255446	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	114.0	CHEMBL4282	Homo sapiens	Residual Activity	%	114.0
	12255447	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255448	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255449	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	95.0	CHEMBL4282	Homo sapiens	Residual Activity	%	95.0
	12255450	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255451	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	114.0	CHEMBL4282	Homo sapiens	Residual Activity	%	114.0
	12255452	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	119.0	CHEMBL4282	Homo sapiens	Residual Activity	%	119.0
	12255453	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255454	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	115.0	CHEMBL4282	Homo sapiens	Residual Activity	%	115.0
	12255455	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	105.0	CHEMBL4282	Homo sapiens	Residual Activity	%	105.0
	12255456	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255457	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	113.0	CHEMBL4282	Homo sapiens	Residual Activity	%	113.0
	12255458	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12255459	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	116.0	CHEMBL4282	Homo sapiens	Residual Activity	%	116.0
	12255460	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255461	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12255462	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255463	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	110.0	CHEMBL4282	Homo sapiens	Residual Activity	%	110.0
	12255464	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	113.0	CHEMBL4282	Homo sapiens	Residual Activity	%	113.0
	12255465	CHEMBL2219392	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	113.0	CHEMBL4282	Homo sapiens	Residual Activity	%	113.0
	12255466	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	102.0	CHEMBL4282	Homo sapiens	Residual Activity	%	102.0
	12255467	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12255468	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	99.0	CHEMBL4282	Homo sapiens	Residual Activity	%	99.0
	12255469	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	94.0	CHEMBL4282	Homo sapiens	Residual Activity	%	94.0
	12255470	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	98.0	CHEMBL4282	Homo sapiens	Residual Activity	%	98.0
	12255471	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	96.0	CHEMBL4282	Homo sapiens	Residual Activity	%	96.0
	12255472	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	101.0	CHEMBL4282	Homo sapiens	Residual Activity	%	101.0
	12255473	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	98.0	CHEMBL4282	Homo sapiens	Residual Activity	%	98.0
	12255474	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	105.0	CHEMBL4282	Homo sapiens	Residual Activity	%	105.0
	12255475	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12255476	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255477	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12255478	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12255479	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255480	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255481	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12255482	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255483	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	110.0	CHEMBL4282	Homo sapiens	Residual Activity	%	110.0
	12255484	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12255485	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12255486	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255487	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255488	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	110.0	CHEMBL4282	Homo sapiens	Residual Activity	%	110.0
	12255489	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12255490	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12255491	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12255492	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12255493	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	105.0	CHEMBL4282	Homo sapiens	Residual Activity	%	105.0
	12255494	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255495	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	102.0	CHEMBL4282	Homo sapiens	Residual Activity	%	102.0
	12255496	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255497	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	101.0	CHEMBL4282	Homo sapiens	Residual Activity	%	101.0
	12255498	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	90.0	CHEMBL4282	Homo sapiens	Residual Activity	%	90.0
	12255499	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12255500	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12255501	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	105.0	CHEMBL4282	Homo sapiens	Residual Activity	%	105.0
	12255502	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255503	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	98.0	CHEMBL4282	Homo sapiens	Residual Activity	%	98.0
	12255504	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255505	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	101.0	CHEMBL4282	Homo sapiens	Residual Activity	%	101.0
	12255506	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12255507	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255508	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	105.0	CHEMBL4282	Homo sapiens	Residual Activity	%	105.0
	12255509	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12255510	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12255511	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12255512	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	114.0	CHEMBL4282	Homo sapiens	Residual Activity	%	114.0
	12255513	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	105.0	CHEMBL4282	Homo sapiens	Residual Activity	%	105.0
	12255514	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255515	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	117.0	CHEMBL4282	Homo sapiens	Residual Activity	%	117.0
	12255516	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	120.0	CHEMBL4282	Homo sapiens	Residual Activity	%	120.0
	12255517	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255518	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12255519	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255520	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	120.0	CHEMBL4282	Homo sapiens	Residual Activity	%	120.0
	12255521	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12255522	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	110.0	CHEMBL4282	Homo sapiens	Residual Activity	%	110.0
	12255523	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255524	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	119.0	CHEMBL4282	Homo sapiens	Residual Activity	%	119.0
	12255525	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	110.0	CHEMBL4282	Homo sapiens	Residual Activity	%	110.0
	12255526	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	114.0	CHEMBL4282	Homo sapiens	Residual Activity	%	114.0
	12255527	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	99.0	CHEMBL4282	Homo sapiens	Residual Activity	%	99.0
	12255528	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	114.0	CHEMBL4282	Homo sapiens	Residual Activity	%	114.0
	12255529	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	98.0	CHEMBL4282	Homo sapiens	Residual Activity	%	98.0
	12255530	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12255531	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	121.0	CHEMBL4282	Homo sapiens	Residual Activity	%	121.0
	12255532	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	114.0	CHEMBL4282	Homo sapiens	Residual Activity	%	114.0
	12255533	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12255534	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12255535	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255536	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255537	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12255538	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12255539	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	122.0	CHEMBL4282	Homo sapiens	Residual Activity	%	122.0
	12255540	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	115.0	CHEMBL4282	Homo sapiens	Residual Activity	%	115.0
	12255541	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	113.0	CHEMBL4282	Homo sapiens	Residual Activity	%	113.0
	12255542	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255543	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12255544	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12255545	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	1.0	CHEMBL4282	Homo sapiens	Residual Activity	%	1.0
	12255546	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	101.0	CHEMBL4282	Homo sapiens	Residual Activity	%	101.0
	12255547	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12255548	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12255549	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	76.0	CHEMBL4282	Homo sapiens	Residual Activity	%	76.0
	12255550	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	105.0	CHEMBL4282	Homo sapiens	Residual Activity	%	105.0
	12255551	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	105.0	CHEMBL4282	Homo sapiens	Residual Activity	%	105.0
	12255552	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12255553	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	105.0	CHEMBL4282	Homo sapiens	Residual Activity	%	105.0
	12255554	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12255555	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	98.0	CHEMBL4282	Homo sapiens	Residual Activity	%	98.0
	12255556	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12255557	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	99.0	CHEMBL4282	Homo sapiens	Residual Activity	%	99.0
	12255558	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	101.0	CHEMBL4282	Homo sapiens	Residual Activity	%	101.0
	12255559	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	95.0	CHEMBL4282	Homo sapiens	Residual Activity	%	95.0
	12255560	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12255561	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	98.0	CHEMBL4282	Homo sapiens	Residual Activity	%	98.0
	12255562	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12255563	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255564	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255565	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255566	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12255567	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	37.0	CHEMBL4282	Homo sapiens	Residual Activity	%	37.0
	12255568	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12255569	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	95.0	CHEMBL4282	Homo sapiens	Residual Activity	%	95.0
	12255570	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	104.0	CHEMBL4282	Homo sapiens	Residual Activity	%	104.0
	12255571	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	110.0	CHEMBL4282	Homo sapiens	Residual Activity	%	110.0
	12255572	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12255573	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255574	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	110.0	CHEMBL4282	Homo sapiens	Residual Activity	%	110.0
	12255575	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	110.0	CHEMBL4282	Homo sapiens	Residual Activity	%	110.0
	12255576	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12255577	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	102.0	CHEMBL4282	Homo sapiens	Residual Activity	%	102.0
	12255578	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255579	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12255580	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255581	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255582	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12255583	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255584	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	115.0	CHEMBL4282	Homo sapiens	Residual Activity	%	115.0
	12255585	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12255586	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12255587	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255588	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12255589	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255590	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	101.0	CHEMBL4282	Homo sapiens	Residual Activity	%	101.0
	12255591	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255592	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	114.0	CHEMBL4282	Homo sapiens	Residual Activity	%	114.0
	12255593	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	94.0	CHEMBL4282	Homo sapiens	Residual Activity	%	94.0
	12255594	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12255595	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12255596	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255597	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	106.0	CHEMBL4282	Homo sapiens	Residual Activity	%	106.0
	12255598	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	110.0	CHEMBL4282	Homo sapiens	Residual Activity	%	110.0
	12255599	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	113.0	CHEMBL4282	Homo sapiens	Residual Activity	%	113.0
	12255600	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12255601	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12255602	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255603	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	114.0	CHEMBL4282	Homo sapiens	Residual Activity	%	114.0
	12255604	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255605	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12255606	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12255607	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	22.0	CHEMBL4282	Homo sapiens	Residual Activity	%	22.0
	12255608	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	100.0	CHEMBL4282	Homo sapiens	Residual Activity	%	100.0
	12255609	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255610	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12255611	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12255612	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12255613	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12255614	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12255615	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12255616	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12257026	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12257027	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	109.0	CHEMBL4282	Homo sapiens	Residual Activity	%	109.0
	12257028	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	111.0	CHEMBL4282	Homo sapiens	Residual Activity	%	111.0
	12257029	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	107.0	CHEMBL4282	Homo sapiens	Residual Activity	%	107.0
	12257030	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	108.0	CHEMBL4282	Homo sapiens	Residual Activity	%	108.0
	12257031	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	112.0	CHEMBL4282	Homo sapiens	Residual Activity	%	112.0
	12257032	CHEMBL2219393	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	103.0	CHEMBL4282	Homo sapiens	Residual Activity	%	103.0
	12628450	CHEMBL2321173	Inhibition of PKB alpha (unknown origin) at 10 uM	B	N#Cc1c(N)nc2sc(C(=O)c3cccc(Cl)c3)c(N)c2c1-c1ccccc1Cl		CHEMBL2313853	>	Inhibition	%	80.0	CHEMBL4282	Homo sapiens	INH	%	80.0
	12629565	CHEMBL2319139	Inhibition of AKT1 (unknown origin)	B	O=C(NCCCN1CCOC1=O)c1cnc(NCc2cc(Cl)ccc2Cl)nc1NC1CCCC1		CHEMBL2312304	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	12629566	CHEMBL2319139	Inhibition of AKT1 (unknown origin)	B	O=C(NCCCN1CCCC1=O)c1cnc(NCc2cc(Cl)ccc2Cl)nc1NC1CCCC1		CHEMBL2312303	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	12629567	CHEMBL2319139	Inhibition of AKT1 (unknown origin)	B	COc1ccccc1CNc1ncc(C(=O)NCCCN2CCCC2=O)c(NC2CCCC2)n1		CHEMBL2312301	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	12629568	CHEMBL2319139	Inhibition of AKT1 (unknown origin)	B	COc1ccc(CCNc2ncc(C(=O)NCCCN3CCCC3=O)c(NC3CCCC3)n2)cc1OC		CHEMBL2312290	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	12631757	CHEMBL2317787	Inhibition of AKT1 (unknown origin) in presence of ATP	B	Cc1cc(-c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2NC2CCC(N(C)C)CC2)on1		CHEMBL2312654	=	IC50	nM	3100.0	CHEMBL4282	Homo sapiens	IC50	uM	3.1
	12631758	CHEMBL2317787	Inhibition of AKT1 (unknown origin) in presence of ATP	B	CN1CCC(NC(=O)c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2N[C@@H]2COC[C@H]2O)CC1		CHEMBL2312652	=	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	12631759	CHEMBL2317787	Inhibition of AKT1 (unknown origin) in presence of ATP	B	CN1CCC(NC(=O)c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2NC2CCC(N(C)C)CC2)CC1		CHEMBL2312649	=	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	12631760	CHEMBL2317787	Inhibition of AKT1 (unknown origin) in presence of ATP	B	CN1CCC(NC(=O)c2cnc(NCc3cc(Cl)ccc3Cl)nc2NC2CCCC2)CC1		CHEMBL2312646	=	IC50	nM	18580.0	CHEMBL4282	Homo sapiens	IC50	uM	18.58
	12631761	CHEMBL2317787	Inhibition of AKT1 (unknown origin) in presence of ATP	B	COc1ccccc1CNc1ncc(C(=O)NC2CCN(C)CC2)c(NC2CCCC2)n1		CHEMBL2312645	=	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	12649538	CHEMBL2329514	Inhibition of AKT1 (unknown origin) at 1 uM	B	CC(C)(C)[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1		CHEMBL2325895	=	Inhibition	%	-1.0	CHEMBL4282	Homo sapiens	INH	%	-1.0
	12649539	CHEMBL2329514	Inhibition of AKT1 (unknown origin) at 1 uM	B	C[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1		CHEMBL2325894	=	Inhibition	%	-9.0	CHEMBL4282	Homo sapiens	INH	%	-9.0
	12649540	CHEMBL2329514	Inhibition of AKT1 (unknown origin) at 1 uM	B	C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)C#N		CHEMBL2325906	=	Inhibition	%	-2.0	CHEMBL4282	Homo sapiens	INH	%	-2.0
	12649541	CHEMBL2329514	Inhibition of AKT1 (unknown origin) at 1 uM	B	C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)C		CHEMBL2325903	=	Inhibition	%	-10.0	CHEMBL4282	Homo sapiens	INH	%	-10.0
	12649684	CHEMBL2329567	Inhibition of AKT1 (unknown origin) at 10 uM	B	C[C@@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(=O)N1CC(C#N)C1		CHEMBL2325894	=	Inhibition	%	-9.0	CHEMBL4282	Homo sapiens	INH	%	-9.0
	12649685	CHEMBL2329567	Inhibition of AKT1 (unknown origin) at 10 uM	B	C[C@H](NC(=O)c1c[nH]c2ncc(C3CC3)nc12)C(C)(C)O		CHEMBL2325904	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	12649686	CHEMBL2329567	Inhibition of AKT1 (unknown origin) at 10 uM	B	CC(C)NC(=O)c1c[nH]c2ncc(C3CC3)nc12		CHEMBL2325901	=	Inhibition	%	16.0	CHEMBL4282	Homo sapiens	INH	%	16.0
	12656675	CHEMBL2328964	Inhibition of IGF-1 induced Akt phosphorylation in PTEN-deficient human MDA-MB-468 cells pretreated for 2 hrs before IGF1 induction measured after 15 mins by Western blot analysis	B	N[C@@H](Cc1ccccc1)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1		CHEMBL2322664	<	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
Dose-dependent effect	12656676	CHEMBL2328964	Inhibition of IGF-1 induced Akt phosphorylation in PTEN-deficient human MDA-MB-468 cells pretreated for 2 hrs before IGF1 induction measured after 15 mins by Western blot analysis	B	N[C@@H](Cc1ccccc1)C(=O)N1CCN(c2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1		CHEMBL2322664		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	12657929	CHEMBL2330108	Inhibition of AKT1 (unknown origin) using [gamma33P]ATP assessed as residual activity at 1 uM after 120 mins by radiometric assay	B	O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21		CHEMBL58	=	Activity	%	108.7	CHEMBL4282	Homo sapiens	Activity	%	108.7
	12660680	CHEMBL2330802	Inhibition of Akt1 (unknown origin) at 1 uM	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	>	Inhibition	%	75.0	CHEMBL4282	Homo sapiens	INH	%	75.0
	12662154	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	12662155	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	COCCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325740	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
	12662156	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325739	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	12662157	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325738	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	12662158	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325737	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
	12662159	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CS(=O)(=O)NCCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325736	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
	12662160	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CS(=O)(=O)NCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325735	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
	12662161	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCS(N)(=O)=O)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325734	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	12662162	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CS(N)(=O)=O)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325733	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
	12662163	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(=O)NCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325732	=	IC50	nM	31.0	CHEMBL4282	Homo sapiens	IC50	nM	31.0
	12662164	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CN(C)C(=O)CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325731	=	IC50	nM	42.0	CHEMBL4282	Homo sapiens	IC50	nM	42.0
	12662165	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC(=O)C(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325730	=	IC50	nM	30.0	CHEMBL4282	Homo sapiens	IC50	nM	30.0
	12662166	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)N[C@@H](CCN2CCCCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325729	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	12662167	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)N[C@@H](CCN2CCCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325728	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	12662168	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CN(C)CC[C@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325727	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	12662169	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCCN2CCCCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325996	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	12662170	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCCN2CCOCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325995	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	12662171	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(CCCN2CCCC2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325994	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	12662172	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CN(C)CCCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325993	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	12662173	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CN(C)CCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325992	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
	12662174	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	COc1ccc(C(C)NC(=O)C2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1OC		CHEMBL2325991	=	IC50	nM	1192.0	CHEMBL4282	Homo sapiens	IC50	nM	1192.0
	12662175	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(S(C)(=O)=O)cc1		CHEMBL2325990	=	IC50	nM	183.0	CHEMBL4282	Homo sapiens	IC50	nM	183.0
	12662176	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccccn1		CHEMBL2325989	=	IC50	nM	2753.0	CHEMBL4282	Homo sapiens	IC50	nM	2753.0
	12662177	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1cccnc1		CHEMBL2325988	=	IC50	nM	1313.0	CHEMBL4282	Homo sapiens	IC50	nM	1313.0
	12662178	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(F)cc1		CHEMBL2325987	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
	12662179	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccccc1		CHEMBL2325986	=	IC50	nM	149.0	CHEMBL4282	Homo sapiens	IC50	nM	149.0
	12662180	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(Cc2ccccc2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325985	=	IC50	nM	31.0	CHEMBL4282	Homo sapiens	IC50	nM	31.0
	12662181	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(c2ccccc2)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325984	=	IC50	nM	41.0	CHEMBL4282	Homo sapiens	IC50	nM	41.0
	12662182	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NC(c2ccc(Cl)cc2)C2CC2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325983	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
	12662183	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CCC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325982	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
	12662184	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	CC(NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325997	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
	12662185	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	C[C@@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325742	=	IC50	nM	276.0	CHEMBL4282	Homo sapiens	IC50	nM	276.0
	12662186	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598194	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
	12662187	CHEMBL2330886	Inhibition of recombinant Akt1 (unknown origin) using 5-FAM-labeled peptide as substrate after 1 hr by caliper off-chip incubation mobility shift assay	B	C[C@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)c1ccc(Cl)cc1		CHEMBL2325743	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	12671119	CHEMBL2345518	Inhibition of AKT1 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2cc(N3CCOCC3)ccc12		CHEMBL2333120	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	12671120	CHEMBL2345518	Inhibition of AKT1 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333115	=	Inhibition	%	32.0	CHEMBL4282	Homo sapiens	INH	%	32.0
	12671121	CHEMBL2345518	Inhibition of AKT1 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2ccc(-c3ccncc3)cc12		CHEMBL2333114	=	Inhibition	%	25.0	CHEMBL4282	Homo sapiens	INH	%	25.0
	12671122	CHEMBL2345518	Inhibition of AKT1 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2cc(-c3ccncc3)ccc12		CHEMBL2333112	=	Inhibition	%	13.0	CHEMBL4282	Homo sapiens	INH	%	13.0
	12671123	CHEMBL2345518	Inhibition of AKT1 (unknown origin) at 10 uM relative to control	B	CS(=O)(=O)c1ccc(-c2ccc3c(NC4CCC4)c(C(N)=O)nnc3c2)cc1		CHEMBL2333129	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	12671124	CHEMBL2345518	Inhibition of AKT1 (unknown origin) at 10 uM relative to control	B	C[C@@H](Nc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12)C1CC1		CHEMBL2333128	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	12671125	CHEMBL2345518	Inhibition of AKT1 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12		CHEMBL2333125	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	12671317	CHEMBL2344170	Inhibition of AKT1 (unknown origin)	B	O=C(NCCc1ccc(O)c(Br)c1)/C(Cc1cc(Br)c(O)c(-c2cc(C/C(=N/O)C(=O)NCCc3ccc(O)c(Br)c3)cc(Br)c2O)c1)=N\O		CHEMBL505637	=	IC50	nM	1900.0	CHEMBL4282	Homo sapiens	IC50	uM	1.9
	12672925	CHEMBL2341631	Inhibition of recombinant PKB alpha (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336379	=	Activity	%	107.0	CHEMBL4282	Homo sapiens	Activity	%	107.0
	12672926	CHEMBL2341631	Inhibition of recombinant PKB alpha (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336377	=	Activity	%	99.0	CHEMBL4282	Homo sapiens	Activity	%	99.0
	12679731	CHEMBL2345841	Inhibition of AKT1 (unknown origin) at 1 uM	B	Cc1ccc(-c2ccc3ncc4c(c3n2)n(C2CCN(C(=O)[C@H](C)O)CC2)c(=O)n4C)cn1		CHEMBL2331664	=	Inhibition	%	-3.0	CHEMBL4282	Homo sapiens	INH	%	-3.0
	12693298	CHEMBL2341972	Inhibition of AKT1 (unknown origin)	B	Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F		CHEMBL2333365	>	IC50	nM	3500.0	CHEMBL4282	Homo sapiens	IC50	nM	3500.0
	12700061	CHEMBL2344124	Inhibition of recombinant AKT1 (unknown origin) by FRET-based Z'-LYTE assay	B	CN1C/C(=C\c2ccccn2)C(=O)[C@@H](Cc2ccccn2)C1		CHEMBL2338335	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	12700073	CHEMBL2344124	Inhibition of recombinant AKT1 (unknown origin) by FRET-based Z'-LYTE assay	B	CN1C/C(=C\c2ccccn2)C(=O)[C@H](Cc2ccccn2)C1		CHEMBL2338334	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	12700085	CHEMBL2344124	Inhibition of recombinant AKT1 (unknown origin) by FRET-based Z'-LYTE assay	B	O=C1/C(=C/c2ccccn2)CSC/C1=C\c1ccccn1		CHEMBL2036343	=	IC50	nM	3600.0	CHEMBL4282	Homo sapiens	IC50	uM	3.6
	12700097	CHEMBL2344124	Inhibition of recombinant AKT1 (unknown origin) by FRET-based Z'-LYTE assay	B	CN1C/C(=C\c2ccccn2)C(=O)/C(=C/c2ccccn2)C1		CHEMBL2338333	=	IC50	nM	2600.0	CHEMBL4282	Homo sapiens	IC50	uM	2.6
	12700110	CHEMBL2344124	Inhibition of recombinant AKT1 (unknown origin) by FRET-based Z'-LYTE assay	B	O=C1/C(=C/c2ccccn2)CNC/C1=C\c1ccccn1		CHEMBL574646	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	uM	0.02
	12700160	CHEMBL2342698	Inhibition of recombinant AKT1 (unknown origin) at 5 uM by FRET-based Z'-LYTE assay	B	O=C1/C(=C/c2ccccn2)CNC/C1=C\c1ccccn1		CHEMBL574646	=	Inhibition	%	107.0	CHEMBL4282	Homo sapiens	INH	%	107.0
	12700172	CHEMBL2344124	Inhibition of recombinant AKT1 (unknown origin) by FRET-based Z'-LYTE assay	B	O=C1/C(=C/c2ccccc2F)CNC/C1=C\c1ccccc1F		CHEMBL379849	=	IC50	nM	780.0	CHEMBL4282	Homo sapiens	IC50	uM	0.78
	12705261	CHEMBL2345797	Inhibition of Akt1 (unknown origin)	B	CN1c2ccc(NCc3ccc(C(C)(C)C)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333444	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12705262	CHEMBL2345797	Inhibition of Akt1 (unknown origin)	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2C)S(=O)(=O)N3C)cc1		CHEMBL2333435	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12705263	CHEMBL2345797	Inhibition of Akt1 (unknown origin)	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	12713906	CHEMBL2349705	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA	B	CCCCCCCCCCCCCCCCCCOCC(COP(=O)([O-])OCC[N+](C)(C)C)OC		CHEMBL28509	=	IC50	nM	3500.0	CHEMBL4282	Homo sapiens	IC50	uM	3.5
	12713907	CHEMBL2349705	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	=	IC50	nM	5300.0	CHEMBL4282	Homo sapiens	IC50	uM	5.3
	12713908	CHEMBL2349705	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA	B	CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C		CHEMBL125	=	IC50	nM	9600.0	CHEMBL4282	Homo sapiens	IC50	uM	9.6
	12713909	CHEMBL2349705	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA	B	CCCCCCCCCCCCCCCCCCCCCC[C@@]1(C(=O)OCC)CCC[C@@H]1OP(=O)([O-])OCC[N+](C)(C)C		CHEMBL2349083	=	IC50	nM	19100.0	CHEMBL4282	Homo sapiens	IC50	uM	19.1
	12713910	CHEMBL2349705	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA	B	CCCCCCCCCCCCCCCCCCCC[C@@]1(C(=O)OCC)CCC[C@@H]1OP(=O)([O-])OCC[N+](C)(C)C		CHEMBL2349082	=	IC50	nM	6900.0	CHEMBL4282	Homo sapiens	IC50	uM	6.9
	12713911	CHEMBL2349705	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA	B	CCCCCCCCCCCCCCCCCC[C@@]1(C(=O)OCC)CCC[C@@H]1OP(=O)([O-])OCC[N+](C)(C)C		CHEMBL2349081	=	IC50	nM	3000.0	CHEMBL4282	Homo sapiens	IC50	uM	3.0
	12713912	CHEMBL2349705	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA	B	CCCCCCCCCCCCCCCC[C@@]1(C(=O)OCC)CCC[C@@H]1OP(=O)([O-])OCC[N+](C)(C)C		CHEMBL2349080	=	IC50	nM	5000.0	CHEMBL4282	Homo sapiens	IC50	uM	5.0
	12713913	CHEMBL2349705	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA	B	CCCCCCCCCCCCC[C@@]1(C(=O)OCC)CCC[C@@H]1OP(=O)([O-])OCC[N+](C)(C)C		CHEMBL2349079	=	IC50	nM	6200.0	CHEMBL4282	Homo sapiens	IC50	uM	6.2
	12713914	CHEMBL2349705	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA	B	CCCCCCCCCCCCCCCCCCCCCC[C@@]1(C(=O)OCC)CCC[C@H]1OP(=O)([O-])OCC[N+](C)(C)C		CHEMBL2349078	=	IC50	nM	5500.0	CHEMBL4282	Homo sapiens	IC50	uM	5.5
	12713915	CHEMBL2349705	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA	B	CCCCCCCCCCCCCCCCCCCC[C@@]1(C(=O)OCC)CCC[C@H]1OP(=O)([O-])OCC[N+](C)(C)C		CHEMBL2349077	=	IC50	nM	7000.0	CHEMBL4282	Homo sapiens	IC50	uM	7.0
	12713916	CHEMBL2349705	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA	B	CCCCCCCCCCCCCCCCCC[C@@]1(C(=O)OCC)CCC[C@H]1OP(=O)([O-])OCC[N+](C)(C)C		CHEMBL2349076	=	IC50	nM	10900.0	CHEMBL4282	Homo sapiens	IC50	uM	10.9
	12713917	CHEMBL2349705	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA	B	CCCCCCCCCCCCCCCC[C@@]1(C(=O)OCC)CCC[C@H]1OP(=O)([O-])OCC[N+](C)(C)C		CHEMBL2349075	=	IC50	nM	2000.0	CHEMBL4282	Homo sapiens	IC50	uM	2.0
	12713918	CHEMBL2349705	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA	B	CCCCCCCCCCCCC[C@@]1(C(=O)OCC)CCC[C@H]1OP(=O)([O-])OCC[N+](C)(C)C		CHEMBL2349074	=	IC50	nM	3100.0	CHEMBL4282	Homo sapiens	IC50	uM	3.1
	12716044	CHEMBL2350816	Inhibition of PKBalpha (unknown origin)	B	CNc1nc(C)c(-c2nc(Nc3cccc(N4CCCNCC4)c3)ncc2C#N)s1		CHEMBL2312185	>	IC50	nM	5000.0	CHEMBL4282	Homo sapiens	IC50	nM	5000.0
	12718779	CHEMBL2353277	Inhibition of AKT1 (unknown origin) after 10 mins by mobility shift assay	B	O=C1Nc2ccccc2/C1=C/c1c[nH]nc1-c1ccccc1[N+](=O)[O-]		CHEMBL2347053	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
	12718803	CHEMBL2350687	Inhibition of AKT1 (unknown origin) at 3 uM after 10 mins by mobility shift assay relative to control	B	O=C1Nc2ccccc2/C1=C/c1c[nH]nc1-c1ccccc1[N+](=O)[O-]		CHEMBL2347053	=	Inhibition	%	7.8	CHEMBL4282	Homo sapiens	INH	%	7.8
	12718826	CHEMBL2350710	Inhibition of AKT1 (unknown origin) at 10 uM after 10 mins by mobility shift assay relative to control	B	O=C1Nc2ccccc2/C1=C/c1c[nH]nc1-c1ccccc1[N+](=O)[O-]		CHEMBL2347053	=	Inhibition	%	8.3	CHEMBL4282	Homo sapiens	INH	%	8.3
	12721827	CHEMBL2353811	Inhibition of AKT1 (unknown origin) at 1 uM relative to control	B	CCNC(=O)Nc1nc2ccc(-c3ccccc3OC)cc2s1		CHEMBL2347710	=	Inhibition	%	67.0	CHEMBL4282	Homo sapiens	INH	%	67.0
	12723674	CHEMBL2350772	Inhibition of AKT1 (unknown origin) at 10 uM by single point assay	B	C[C@@H](Nc1c(C#N)cnc2cc(-c3ccc(-n4ccoc4=O)cc3)ccc12)C1CC1		CHEMBL2347818	=	Inhibition	%	-2.0	CHEMBL4282	Homo sapiens	INH	%	-2.0
	12724790	CHEMBL2352291	Inhibition of AKT1 (unknown origin) at 1 uM by single point assay	B	CC(C)Nc1c(C#N)cnc2cc(-c3cnn(C)c3)ccc12		CHEMBL2347824	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	12724791	CHEMBL2352291	Inhibition of AKT1 (unknown origin) at 1 uM by single point assay	B	CC(C)Nc1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12		CHEMBL2347823	=	Inhibition	%	10.0	CHEMBL4282	Homo sapiens	INH	%	10.0
	12727694	CHEMBL2350870	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	95.0	CHEMBL4282	Homo sapiens	Activity	%	95.0
	12728980	CHEMBL2350157	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	96.0	CHEMBL4282	Homo sapiens	Activity	%	96.0
	12729359	CHEMBL2351457	Inhibition of Akt1 (unknown origin) at 1 uM	B	FC(F)(F)c1cccc(Sc2ccc3nnc(-c4ccccc4)n3n2)c1		CHEMBL2348936	>	Inhibition	%	18.0	CHEMBL4282	Homo sapiens	INH	%	18.0
	12730123	CHEMBL2350870	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	104.0	CHEMBL4282	Homo sapiens	Activity	%	104.0
	12730941	CHEMBL2350115	Inhibition of AKT1 (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	97.0	CHEMBL4282	Homo sapiens	Activity	%	97.0
	13282450	CHEMBL2378504	Inhibition of AKT1 (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3ncn4cc(F)cc(F)c34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376158	=	Inhibition	%	9.0	CHEMBL4282	Homo sapiens	INH	%	9.0
	13282451	CHEMBL2378504	Inhibition of AKT1 (unknown origin) at 10 uM relative to control	B	Cn1nc(-c2cnc3[nH]cc(C(=O)N[C@@H](C(=O)N4CC(C#N)C4)C4CC4)c3n2)c2ccc(Cl)cc21		CHEMBL2376154	=	Inhibition	%	74.0	CHEMBL4282	Homo sapiens	INH	%	74.0
	13282452	CHEMBL2378504	Inhibition of AKT1 (unknown origin) at 10 uM relative to control	B	CC[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376153	=	Inhibition	%	23.0	CHEMBL4282	Homo sapiens	INH	%	23.0
	13282453	CHEMBL2378504	Inhibition of AKT1 (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)cc(F)c34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376152	=	Inhibition	%	-6.0	CHEMBL4282	Homo sapiens	INH	%	-6.0
	13282454	CHEMBL2378504	Inhibition of AKT1 (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3nn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1	Outside typical range	CHEMBL2376144	=	Inhibition	%	-11.0	CHEMBL4282	Homo sapiens	INH	%	-11.0
	13282455	CHEMBL2378504	Inhibition of AKT1 (unknown origin) at 10 uM relative to control	B	C[C@@H](NC(=O)c1c[nH]c2ncc(-c3cn(C)c4cc(Cl)ccc34)nc12)C(=O)N1CC(C#N)C1		CHEMBL2376143	=	Inhibition	%	-5.0	CHEMBL4282	Homo sapiens	INH	%	-5.0
	13295617	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
	13295618	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	Cc1nc(N)nc2c1cc(-c1cnc3ccccc3c1)c(=O)n2[C@H]1CC[C@H](OCC(N)=O)CC1		CHEMBL2375953	=	IC50	nM	56.8	CHEMBL4282	Homo sapiens	IC50	nM	56.8
	13295619	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	Cc1nc(N)nc2c1cc(-c1cnn(C)c1)c(=O)n2[C@H]1CC[C@H](OCC(N)=O)CC1		CHEMBL2375954	=	IC50	nM	376.0	CHEMBL4282	Homo sapiens	IC50	nM	376.0
	13295620	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	Cc1nc(N)nc2c1cc(-c1cn[nH]c1)c(=O)n2[C@H]1CC[C@H](OCC(N)=O)CC1		CHEMBL2375955	=	IC50	nM	256.0	CHEMBL4282	Homo sapiens	IC50	nM	256.0
	13295621	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	COc1ncc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCC(N)=O)CC3)c2=O)cn1		CHEMBL2375956	=	IC50	nM	51.9	CHEMBL4282	Homo sapiens	IC50	nM	51.9
	13295622	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	COc1ncc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCC(N)=O)CC3)c2=O)cc1F		CHEMBL2375957	=	IC50	nM	5.82	CHEMBL4282	Homo sapiens	IC50	nM	5.82
	13295623	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCC(N)=O)CC3)c2=O)cn1		CHEMBL2375958	=	IC50	nM	19.3	CHEMBL4282	Homo sapiens	IC50	nM	19.3
	13295624	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	Cc1nc(N)nc2c1cc(-c1cnc3ccccc3c1)c(=O)n2[C@H]1CC[C@@H](OCC(N)=O)CC1		CHEMBL2375959	=	IC50	nM	116.0	CHEMBL4282	Homo sapiens	IC50	nM	116.0
	13295625	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	Cc1nc(N)nc2c1cc(-c1cnn(C)c1)c(=O)n2[C@H]1CC[C@@H](OCC(N)=O)CC1		CHEMBL2375960	=	IC50	nM	988.0	CHEMBL4282	Homo sapiens	IC50	nM	988.0
	13295626	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	Cc1nc(N)nc2c1cc(-c1cn[nH]c1)c(=O)n2[C@H]1CC[C@@H](OCC(N)=O)CC1		CHEMBL2375962	=	IC50	nM	148.0	CHEMBL4282	Homo sapiens	IC50	nM	148.0
	13295627	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	COc1ncc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@@H](OCC(N)=O)CC3)c2=O)cn1		CHEMBL2375961	=	IC50	nM	82.9	CHEMBL4282	Homo sapiens	IC50	nM	82.9
	13295628	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	COc1ncc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@@H](OCC(N)=O)CC3)c2=O)cc1F		CHEMBL2375963	=	IC50	nM	8.22	CHEMBL4282	Homo sapiens	IC50	nM	8.22
	13295629	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@@H](OCC(N)=O)CC3)c2=O)cn1		CHEMBL2375964	=	IC50	nM	23.3	CHEMBL4282	Homo sapiens	IC50	nM	23.3
	13295630	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	Cc1nc(N)nc2c1cc(-c1cnc3ccccc3c1)c(=O)n2[C@H]1CC[C@H](OCO)CC1		CHEMBL2375965	=	IC50	nM	23.8	CHEMBL4282	Homo sapiens	IC50	nM	23.8
	13295631	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	Cc1nc(N)nc2c1cc(-c1cnn(C)c1)c(=O)n2[C@H]1CC[C@H](OCO)CC1		CHEMBL2375966	=	IC50	nM	288.0	CHEMBL4282	Homo sapiens	IC50	nM	288.0
	13295632	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	Cc1nc(N)nc2c1cc(-c1cn[nH]c1)c(=O)n2[C@H]1CC[C@H](OCO)CC1		CHEMBL2375967	=	IC50	nM	25.9	CHEMBL4282	Homo sapiens	IC50	nM	25.9
	13295633	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	COc1ncc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCO)CC3)c2=O)cn1		CHEMBL2375365	=	IC50	nM	22.0	CHEMBL4282	Homo sapiens	IC50	nM	22.0
	13295634	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	COc1ncc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCO)CC3)c2=O)cc1F		CHEMBL2375968	=	IC50	nM	5.24	CHEMBL4282	Homo sapiens	IC50	nM	5.24
	13295635	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	Cc1nc(N)nc2c1cc(-c1cnc3ccccc3c1)c(=O)n2[C@H]1CC[C@@H](OCO)CC1		CHEMBL2375969	=	IC50	nM	104.0	CHEMBL4282	Homo sapiens	IC50	nM	104.0
	13295636	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	Cc1nc(N)nc2c1cc(-c1cnn(C)c1)c(=O)n2[C@H]1CC[C@@H](OCO)CC1		CHEMBL2375970	=	IC50	nM	310.0	CHEMBL4282	Homo sapiens	IC50	nM	310.0
	13295637	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	Cc1nc(N)nc2c1cc(-c1cn[nH]c1)c(=O)n2[C@H]1CC[C@@H](OCO)CC1		CHEMBL2376092	=	IC50	nM	11.2	CHEMBL4282	Homo sapiens	IC50	nM	11.2
	13295638	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	COc1ncc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@@H](OCO)CC3)c2=O)cn1		CHEMBL2376093	=	IC50	nM	29.4	CHEMBL4282	Homo sapiens	IC50	nM	29.4
Not Determined	13295639	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	COc1ncc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@@H](OCO)CC3)c2=O)cc1F		CHEMBL2376094		IC50			CHEMBL4282	Homo sapiens	IC50		
	13295640	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@@H](OCO)CC3)c2=O)cn1		CHEMBL2376095	=	IC50	nM	21.6	CHEMBL4282	Homo sapiens	IC50	nM	21.6
	13295641	CHEMBL2379605	Inhibition of AKT phosphorylation at Ser 473 in human BT20 cells	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCC(=O)O)CC3)c2=O)cn1		CHEMBL2376096	=	IC50	nM	2070.0	CHEMBL4282	Homo sapiens	IC50	nM	2070.0
	13296927	CHEMBL2383903	Inhibition of human AKT1	B	NC(=O)c1cnc(N[C@H]2CC[C@H](N)CC2)c2nc(-c3ccc(Cl)cc3)cn12		CHEMBL2381601	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	13311870	CHEMBL2382842	Inhibition of human AKT1	B	COc1ccc2c(c1)C(=O)N(c1nc(C(=O)Nc3cnccc3N3CCNCC3)cs1)C2		CHEMBL2381116	=	IC50	nM	4800.0	CHEMBL4282	Homo sapiens	IC50	nM	4800.0
	13321299	CHEMBL2388368	Inhibition of AKT1 (unknown origin)	B	O=C1c2oc(-c3ccc(Cl)cc3)cc2Cc2cc(N3CCNCC3)ccc2N1Cc1ccccc1-c1cccnc1		CHEMBL2385543	=	IC50	nM	16000.0	CHEMBL4282	Homo sapiens	IC50	uM	16.0
	13327709	CHEMBL2390012	Inhibition of AKT1 (unknown origin) at 1 uM	B	CC(C)(C)c1cc(NC(=O)NCc2ccc(-c3cc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)[nH]n3)cc2)no1	Outside typical range	CHEMBL2386802	=	Inhibition	%	-17.0	CHEMBL4282	Homo sapiens	INH	%	-17.0
	13327710	CHEMBL2390012	Inhibition of AKT1 (unknown origin) at 1 uM	B	Cc1cc(-c2cc(NC(=O)c3ccc(CN4CCN(C)CC4)cc3)[nH]n2)ccc1NC(=O)Nc1cc(C(C)(C)C)on1	Outside typical range	CHEMBL2386796	=	Inhibition	%	-20.0	CHEMBL4282	Homo sapiens	INH	%	-20.0
Not Active	13328783	CHEMBL2388651	Inhibition of AKT1 (unknown origin)	B	Cc1cccc2nc(Cn3cnc4ccccc43)cc(=O)n12		CHEMBL2386917		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	13330243	CHEMBL2390249	Inhibition of AKT phosphorylation in human A375 cells at 50 uM after 24 hrs by Western blotting analysis	B	CCCOc1c2cc(CCCn3cc(CCO[C@H]4O[C@H](CO)[C@H](O)C5=C4SC[C@]4(C[C@@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O4)O5)nn3)cc1Cc1cc(CCCn3cc(CCO[C@H]4O[C@H](CO)[C@H](O)C5=C4SC[C@]4(C[C@@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O4)O5)nn3)cc(c1OCCC)Cc1cc(CCCn3cc(CCO[C@H]4O[C@H](CO)[C@H](O)C5=C4SC[C@]4(C[C@@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O4)O5)nn3)cc(c1OCCC)Cc1cc(CCCn3cc(CCO[C@H]4O[C@H](CO)[C@H](O)C5=C4SC[C@]4(C[C@@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O4)O5)nn3)cc(c1OCCC)C2		CHEMBL2387151		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	13340101	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Inhibition	%	96.52	CHEMBL4282	Homo sapiens	INH	%	96.52
	13340105	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	O=C(Nc1cc(Sc2ncn[nH]2)c(O)c2ccccc12)c1ccccc1[N+](=O)[O-]		CHEMBL2391406	=	Inhibition	%	85.77	CHEMBL4282	Homo sapiens	INH	%	85.77
	13340119	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	O=C(Nc1cc(Sc2ncnc3nc[nH]c23)c(O)c2ccccc12)c1ccccc1[N+](=O)[O-]		CHEMBL2391420	=	Inhibition	%	50.73	CHEMBL4282	Homo sapiens	INH	%	50.73
	13340120	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	O=C(Nc1cc(Sc2ncn[nH]2)c(O)c2ccccc12)c1ccc(Cl)cc1		CHEMBL2391405	=	Inhibition	%	50.13	CHEMBL4282	Homo sapiens	INH	%	50.13
	13340727	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	O=C(Nc1cc(Sc2ncn[nH]2)c(O)c2ccccc12)c1cccc(Cl)c1		CHEMBL2391413	=	Inhibition	%	45.96	CHEMBL4282	Homo sapiens	INH	%	45.96
	13340733	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	O=C(Nc1cc(Sc2ncn[nH]2)c(O)c2ccccc12)c1ccc2ccccc2c1		CHEMBL2391403	=	Inhibition	%	41.64	CHEMBL4282	Homo sapiens	INH	%	41.64
	13340735	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	O=C(/C=C/c1ccc([N+](=O)[O-])cc1)Nc1cc(Sc2ncn[nH]2)c(O)c2ccccc12		CHEMBL2391412	=	Inhibition	%	40.59	CHEMBL4282	Homo sapiens	INH	%	40.59
	13340740	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	O=C(Nc1cc(Sc2ncn[nH]2)c(O)c2ccccc12)c1ccc([N+](=O)[O-])cc1		CHEMBL2391414	=	Inhibition	%	37.34	CHEMBL4282	Homo sapiens	INH	%	37.34
	13340745	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	O=C(/C=C/c1ccc(Cl)cc1)Nc1cc(Sc2ncn[nH]2)c(O)c2ccccc12		CHEMBL2391415	=	Inhibition	%	31.84	CHEMBL4282	Homo sapiens	INH	%	31.84
	13340747	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	COc1ccc(/C=C/C(=O)Nc2cc(Sc3ncn[nH]3)c(O)c3ccccc23)cc1OC		CHEMBL2391408	=	Inhibition	%	31.65	CHEMBL4282	Homo sapiens	INH	%	31.65
	13340750	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	COc1ccc(C(=O)Nc2cc(Sc3ncn[nH]3)c(O)c3ccccc23)cc1		CHEMBL2391407	=	Inhibition	%	30.84	CHEMBL4282	Homo sapiens	INH	%	30.84
	13340752	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	O=C(Nc1cc(Sc2ncn[nH]2)c(O)c2ccccc12)c1cccc([N+](=O)[O-])c1		CHEMBL2391409	=	Inhibition	%	29.26	CHEMBL4282	Homo sapiens	INH	%	29.26
	13340757	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	O=C(/C=C/c1ccccc1)Nc1cc(Sc2ncn[nH]2)c(O)c2ccccc12		CHEMBL2391404	=	Inhibition	%	26.15	CHEMBL4282	Homo sapiens	INH	%	26.15
	13340765	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	O=C(Nc1cc(Sc2ncnc3nc[nH]c23)c(O)c2ccccc12)c1ccc(Cl)cc1		CHEMBL2391419	=	Inhibition	%	21.72	CHEMBL4282	Homo sapiens	INH	%	21.72
	13340770	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	Cc1cccc(C(=O)Nc2cc(Sc3ncn[nH]3)c(O)c3ccccc23)c1		CHEMBL2391411	=	Inhibition	%	20.2	CHEMBL4282	Homo sapiens	INH	%	20.2
	13340771	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	COc1cccc(C(=O)Nc2cc(Sc3ncn[nH]3)c(O)c3ccccc23)c1		CHEMBL2391410	=	Inhibition	%	19.38	CHEMBL4282	Homo sapiens	INH	%	19.38
	13340786	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	Cn1nnnc1Sc1cc(NC(=O)c2ccc(Cl)cc2)c2ccccc2c1O		CHEMBL2391418	=	Inhibition	%	13.1	CHEMBL4282	Homo sapiens	INH	%	13.1
	13340795	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	Cc1nnc(Sc2cc(NC(=O)c3ccc(Cl)cc3)c3ccccc3c2O)s1		CHEMBL2391416	=	Inhibition	%	8.48	CHEMBL4282	Homo sapiens	INH	%	8.48
	13340800	CHEMBL2394294	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins by fluorescence assay	B	O=C(Nc1cc(Sc2nncs2)c(O)c2ccccc12)c1ccc(Cl)cc1		CHEMBL2391417	=	Inhibition	%	7.5	CHEMBL4282	Homo sapiens	INH	%	7.5
	13351572	CHEMBL2399776	Inhibition of human PKBalpha at 10 uM relative to control	B	Cl.O=c1[nH]nc2c(NCCCc3ccncc3)cc(Cl)cn12		CHEMBL2397859	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	INH	%	12.0
	13371358	CHEMBL2404111	Inhibition of AKT1 (unknown origin) at 10 uM by Z'-LYTE kinase assay	B	c1ccc(-c2csc3ncnc(N4CCc5ccccc5C4)c23)cc1		CHEMBL1483261	=	Inhibition	%	5.32	CHEMBL4282	Homo sapiens	INH	%	5.32
	13375949	CHEMBL2406111	Inhibition of AKT1 (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	13416907	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Inhibition	%	97.0	CHEMBL4282	Homo sapiens	INH	%	97.0
	13416908	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=C(C1CCC2(CCN(c3ncnc4[nH]cnc34)CC2)NC1)N1CCOCC1		CHEMBL2420907	=	Inhibition	%	66.0	CHEMBL4282	Homo sapiens	INH	%	66.0
	13416909	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	CN(C)C(=O)C1CCC2(CCN(c3ncnc4[nH]cnc34)CC2)NC1		CHEMBL2420906	=	Inhibition	%	69.0	CHEMBL4282	Homo sapiens	INH	%	69.0
	13416910	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	CNC(=O)C1CCC2(CCN(c3ncnc4[nH]cnc34)CC2)NC1		CHEMBL2420905	=	Inhibition	%	83.0	CHEMBL4282	Homo sapiens	INH	%	83.0
	13416911	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	OCC1CCC2(CCN(c3ncnc4[nH]cnc34)CC2)NC1		CHEMBL2417586	=	Inhibition	%	80.0	CHEMBL4282	Homo sapiens	INH	%	80.0
	13416912	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=C(O)C1CCC2(CCN(c3ncnc4[nH]cnc34)CC2)NC1		CHEMBL2420904	=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	INH	%	40.0
	13416913	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	COC(=O)C1CCC2(CCN(c3ncnc4[nH]cnc34)CC2)NC1		CHEMBL2420903	=	Inhibition	%	61.0	CHEMBL4282	Homo sapiens	INH	%	61.0
	13416914	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(C2CCC3(CCN(c4ncnc5[nH]cnc45)CC3)NC2)cc1		CHEMBL2420902	=	Inhibition	%	85.0	CHEMBL4282	Homo sapiens	INH	%	85.0
	13416915	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(CC2CCC3(CCN(c4ncnc5[nH]cnc45)CC3)NC2)cc1		CHEMBL2420901	=	Inhibition	%	78.0	CHEMBL4282	Homo sapiens	INH	%	78.0
	13416916	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(CC2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1		CHEMBL2420900	=	Inhibition	%	101.0	CHEMBL4282	Homo sapiens	INH	%	101.0
	13416917	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(C2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1		CHEMBL2420899	=	Inhibition	%	99.0	CHEMBL4282	Homo sapiens	INH	%	99.0
	13416918	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCC2(CC1)CC(O)CCN2		CHEMBL2420898	=	Inhibition	%	36.0	CHEMBL4282	Homo sapiens	INH	%	36.0
	13416919	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	OC1CCNC2(CCN(c3ncnc4[nH]cnc34)CC2)C1		CHEMBL2420897	=	Inhibition	%	94.0	CHEMBL4282	Homo sapiens	INH	%	94.0
	13416920	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCC2(CCC(O)CN2)CC1		CHEMBL2420928	=	Inhibition	%	21.0	CHEMBL4282	Homo sapiens	INH	%	21.0
	13416921	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	OC1CCC2(CCN(c3ncnc4[nH]cnc34)CC2)NC1		CHEMBL2420927	=	Inhibition	%	93.0	CHEMBL4282	Homo sapiens	INH	%	93.0
	13416922	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCC3(CCCOC3)CC2)c2nc[nH]c2n1		CHEMBL2420926	=	Inhibition	%	25.0	CHEMBL4282	Homo sapiens	INH	%	25.0
	13416923	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCC3(CCCCO3)CC2)c2nc[nH]c2n1		CHEMBL2420925	=	Inhibition	%	26.0	CHEMBL4282	Homo sapiens	INH	%	26.0
	13416924	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCC3(CCCCC3)CC2)c2nc[nH]c2n1		CHEMBL2420924	=	Inhibition	%	16.0	CHEMBL4282	Homo sapiens	INH	%	16.0
	13416925	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCCC12CCNCC2		CHEMBL2420923	=	Inhibition	%	27.0	CHEMBL4282	Homo sapiens	INH	%	27.0
	13416926	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCCC2(CCCNC2)C1		CHEMBL2420922	=	Inhibition	%	30.0	CHEMBL4282	Homo sapiens	INH	%	30.0
	13416927	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCCC2(CCNCC2)C1		CHEMBL2420921	=	Inhibition	%	24.0	CHEMBL4282	Homo sapiens	INH	%	24.0
	13416928	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCC2(CCNC2)CC1		CHEMBL2420920	=	Inhibition	%	18.0	CHEMBL4282	Homo sapiens	INH	%	18.0
	13416929	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCC2(CCCNC2)CC1		CHEMBL2420919	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	13416930	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCC2(CCCN2)CC1		CHEMBL2420918	=	Inhibition	%	28.0	CHEMBL4282	Homo sapiens	INH	%	28.0
	13416931	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	O=S(=O)(c1cccc2cnccc12)N1CCC2(CCCCN2)CC1		CHEMBL2420917	=	Inhibition	%	27.0	CHEMBL4282	Homo sapiens	INH	%	27.0
	13416932	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	NC1(Cc2ccccc2)CCN(S(=O)(=O)c2cccc3cnccc23)CC1		CHEMBL2420916	=	Inhibition	%	15.0	CHEMBL4282	Homo sapiens	INH	%	15.0
	13416933	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCCC23CCNCC3)c2nc[nH]c2n1		CHEMBL2420915	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	INH	%	12.0
	13416934	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCCC3(CCCNC3)C2)c2nc[nH]c2n1		CHEMBL2420914	=	Inhibition	%	77.0	CHEMBL4282	Homo sapiens	INH	%	77.0
	13416935	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCCC3(CCNCC3)C2)c2nc[nH]c2n1		CHEMBL2420913	=	Inhibition	%	85.0	CHEMBL4282	Homo sapiens	INH	%	85.0
	13416936	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCC3(CCNC3)CC2)c2nc[nH]c2n1		CHEMBL2420912	=	Inhibition	%	94.0	CHEMBL4282	Homo sapiens	INH	%	94.0
	13416937	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCC3(CCCNC3)CC2)c2nc[nH]c2n1		CHEMBL2420911	=	Inhibition	%	98.0	CHEMBL4282	Homo sapiens	INH	%	98.0
	13416938	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCC3(CCCN3)CC2)c2nc[nH]c2n1		CHEMBL2420910	=	Inhibition	%	91.0	CHEMBL4282	Homo sapiens	INH	%	91.0
	13416939	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1nc(N2CCC3(CCCCN3)CC2)c2nc[nH]c2n1		CHEMBL2420909	=	Inhibition	%	87.0	CHEMBL4282	Homo sapiens	INH	%	87.0
	13416940	CHEMBL2424338	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	NC1(Cc2ccccc2)CCN(c2ncnc3[nH]cnc23)CC1		CHEMBL2420908	=	Inhibition	%	93.0	CHEMBL4282	Homo sapiens	INH	%	93.0
	13421003	CHEMBL2424130	Inhibition of AKT1 (unknown origin) by microfluidic mobility shift assay	B	c1nc(N2CCC3(CCCNC3)CC2)c2nc[nH]c2n1		CHEMBL2420911	=	IC50	nM	1600.0	CHEMBL4282	Homo sapiens	IC50	uM	1.6
	13421004	CHEMBL2424130	Inhibition of AKT1 (unknown origin) by microfluidic mobility shift assay	B	c1nc(N2CCC3(CCCCN3)CC2)c2nc[nH]c2n1		CHEMBL2420909	=	IC50	nM	14000.0	CHEMBL4282	Homo sapiens	IC50	uM	14.0
Active	13435522	CHEMBL2423508	Inhibition of AKT phosphorylation at Ser473 in human DU145 cells at 0.1 uM after 72 hrs by Western blotting analysis relative to control	B	COc1ccc(/C(=C\c2cn(C(C)=O)c3ccc(OCc4ccccc4)cc23)C(=O)O)cc1		CHEMBL2417658		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	13437177	CHEMBL2423516	Inhibition of AKT phosphorylation at Ser473 in human DU145 cells at 1 uM after 72 hrs by Western blotting analysis relative to control	B	COc1ccc(/C(=C\c2cn(C(C)=O)c3ccc(OCc4ccccc4)cc23)C(=O)O)cc1		CHEMBL2417658	=	Inhibition	%	20.0	CHEMBL4282	Homo sapiens	INH	%	20.0
	13440839	CHEMBL2429582	Inhibition of PKB-a (unknown origin) at 1 uM by [33P]-ATP filter-binding assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc4c(N)ncnc43)cc2)cc1	Outside typical range	CHEMBL2425144	=	Inhibition	%	-20.0	CHEMBL4282	Homo sapiens	INH	%	-20.0
	13442406	CHEMBL2428028	Competitive binding affinity to AKT1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	13445541	CHEMBL2428028	Competitive binding affinity to AKT1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-c3n[nH]c4ccccc34)n2)CC1		CHEMBL2425644	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
Active	13447337	CHEMBL2428554	Inhibition of AKT phosphorylation at Ser473 in human G361 cells at 0.22 to 6 uM after 24 hrs by immunoblotting analysis	B	O=C(N[C@H](Cc1ccccc1)C(=O)Nc1ccc(Cl)cc1)c1cc(Cl)ccc1O		CHEMBL2425584		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	13448596	CHEMBL2428028	Competitive binding affinity to AKT1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	13448732	CHEMBL2428028	Competitive binding affinity to AKT1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O=C([C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1)N1CCOCC1		CHEMBL2425649	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	13451527	CHEMBL2428028	Competitive binding affinity to AKT1 (unknown origin) at 10 uM in presence of ATP relative to control	B	N[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425652	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	13453017	CHEMBL2429582	Inhibition of PKB-a (unknown origin) at 1 uM by [33P]-ATP filter-binding assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cccnc3)cc2)cc1		CHEMBL2425156	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	13453065	CHEMBL2429582	Inhibition of PKB-a (unknown origin) at 1 uM by [33P]-ATP filter-binding assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(C)c3)cc2)cc1		CHEMBL2425145	=	Inhibition	%	28.0	CHEMBL4282	Homo sapiens	INH	%	28.0
	13454712	CHEMBL2428028	Competitive binding affinity to AKT1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	13464326	CHEMBL2433457	Inhibition of human PKBalpha assessed as residual activity at 1 uM relative to control	B	CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12		CHEMBL407002	=	Activity	%	94.0	CHEMBL4282	Homo sapiens	Activity	%	94.0
	13465271	CHEMBL2433647	Inhibition of human PKBalpha assessed as residual activity at 10 uM relative to control	B	CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12		CHEMBL407002	=	Activity	%	91.0	CHEMBL4282	Homo sapiens	Activity	%	91.0
	13465298	CHEMBL2433269	Inhibition of human PKBalpha assessed as residual activity at 25 uM relative to control	B	COc1cc(OC)c(C=C2C(=O)Nc3ccccc32)c(OC)c1		CHEMBL576349	=	Activity	%	94.0	CHEMBL4282	Homo sapiens	Activity	%	94.0
	13465321	CHEMBL2433647	Inhibition of human PKBalpha assessed as residual activity at 10 uM relative to control	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Activity	%	107.0	CHEMBL4282	Homo sapiens	Activity	%	107.0
	13465347	CHEMBL2433457	Inhibition of human PKBalpha assessed as residual activity at 1 uM relative to control	B	CC(=O)Nc1nccc(-c2c(-c3ccccc3)noc2C)n1		CHEMBL2430324	=	Activity	%	112.27	CHEMBL4282	Homo sapiens	Activity	%	112.27
	13465378	CHEMBL2433647	Inhibition of human PKBalpha assessed as residual activity at 10 uM relative to control	B	CC(=O)Nc1nccc(-c2c(-c3ccccc3)noc2C)n1		CHEMBL2430324	=	Activity	%	115.2	CHEMBL4282	Homo sapiens	Activity	%	115.2
	13465409	CHEMBL2433457	Inhibition of human PKBalpha assessed as residual activity at 1 uM relative to control	B	CC(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1		CHEMBL2430323	=	Activity	%	89.52	CHEMBL4282	Homo sapiens	Activity	%	89.52
	13465440	CHEMBL2433647	Inhibition of human PKBalpha assessed as residual activity at 10 uM relative to control	B	CC(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1		CHEMBL2430323	=	Activity	%	51.15	CHEMBL4282	Homo sapiens	Activity	%	51.15
	13472920	CHEMBL2438112	Inhibition of AKT (unknown origin) after 30 mins by fluorescence assay	B	O=[N+]([O-])c1ccc(S(=O)(=O)Nc2ccc(O)c(Sc3ncn[nH]3)c2)cc1		CHEMBL2436727	=	IC50	nM	1260.0	CHEMBL4282	Homo sapiens	IC50	uM	1.26
	13472981	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Inhibition	%	96.52	CHEMBL4282	Homo sapiens	INH	%	96.52
	13472982	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	O=C(Nc1ccc(O)c(Sc2ncnc3nc[nH]c23)c1)c1ccc([N+](=O)[O-])cc1		CHEMBL2436643	=	Inhibition	%	64.63	CHEMBL4282	Homo sapiens	INH	%	64.63
	13472983	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	Cn1nnnc1Sc1cc(NC(=O)c2ccc([N+](=O)[O-])cc2)ccc1O		CHEMBL2436642	=	Inhibition	%	10.05	CHEMBL4282	Homo sapiens	INH	%	10.05
Not Active	13472984	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	O=C(Nc1ccc(O)c(Sc2nncs2)c1)c1ccc([N+](=O)[O-])cc1		CHEMBL2436641		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	13472985	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	Cc1nnc(Sc2cc(NC(=O)c3ccc([N+](=O)[O-])cc3)ccc2O)s1		CHEMBL2436640	=	Inhibition	%	12.35	CHEMBL4282	Homo sapiens	INH	%	12.35
	13472986	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	O=C(Nc1ccc(O)c(Sc2ncn[nH]2)c1)c1ccc([N+](=O)[O-])cc1		CHEMBL2436639	=	Inhibition	%	50.67	CHEMBL4282	Homo sapiens	INH	%	50.67
	13472987	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	CC(C)c1cc(C(C)C)c(S(=O)(=O)Nc2ccc(O)c(Sc3ncn[nH]3)c2)c(C(C)C)c1		CHEMBL2436638	=	Inhibition	%	14.51	CHEMBL4282	Homo sapiens	INH	%	14.51
	13472988	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	O=[N+]([O-])c1ccc(S(=O)(=O)Nc2ccc(O)c(Sc3ncnc4nc[nH]c34)c2)cc1		CHEMBL2436637	=	Inhibition	%	37.45	CHEMBL4282	Homo sapiens	INH	%	37.45
	13472989	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	Cn1nnnc1Sc1cc(NS(=O)(=O)c2ccc([N+](=O)[O-])cc2)ccc1O		CHEMBL2436636	=	Inhibition	%	11.48	CHEMBL4282	Homo sapiens	INH	%	11.48
	13472990	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	O=[N+]([O-])c1ccc(S(=O)(=O)Nc2ccc(O)c(Sc3nncs3)c2)cc1		CHEMBL2436635	=	Inhibition	%	14.87	CHEMBL4282	Homo sapiens	INH	%	14.87
	13472991	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	Cc1nnc(Sc2cc(NS(=O)(=O)c3ccc([N+](=O)[O-])cc3)ccc2O)s1		CHEMBL2436634	=	Inhibition	%	14.25	CHEMBL4282	Homo sapiens	INH	%	14.25
	13472992	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	O=[N+]([O-])c1ccc(S(=O)(=O)Nc2ccc(O)c(Sc3ncn[nH]3)c2)cc1		CHEMBL2436727	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	INH	%	100.0
	13472993	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	CS(=O)(=O)Nc1ccc(O)c(Sc2ncn[nH]2)c1		CHEMBL2436726	=	Inhibition	%	14.3	CHEMBL4282	Homo sapiens	INH	%	14.3
	13472994	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	Cc1cc(C)c(S(=O)(=O)Nc2ccc(O)c(Sc3nc[nH]n3)c2)c(C)c1		CHEMBL1510393	=	Inhibition	%	19.66	CHEMBL4282	Homo sapiens	INH	%	19.66
Not Active	13472995	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	O=S(=O)(Nc1ccc(O)c(Sc2ncn[nH]2)c1)c1ccc2ccccc2c1		CHEMBL2436644		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	13472996	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	COc1ccc(S(=O)(=O)Nc2ccc(O)c(Sc3nc[nH]n3)c2)cc1		CHEMBL1491588	=	Inhibition	%	12.1	CHEMBL4282	Homo sapiens	INH	%	12.1
	13472997	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	Cc1ccc(S(=O)(=O)Nc2ccc(O)c(Sc3nc[nH]n3)c2)cc1		CHEMBL1497487	=	Inhibition	%	29.79	CHEMBL4282	Homo sapiens	INH	%	29.79
	13472998	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	O=S(=O)(Nc1ccc(O)c(Sc2ncn[nH]2)c1)c1cccc2ccccc12		CHEMBL2436723	=	Inhibition	%	20.37	CHEMBL4282	Homo sapiens	INH	%	20.37
	13472999	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	O=S(=O)(Nc1ccc(O)c(Sc2ncn[nH]2)c1)c1ccc(Cl)cc1		CHEMBL2436724	=	Inhibition	%	56.39	CHEMBL4282	Homo sapiens	INH	%	56.39
	13473000	CHEMBL2438113	Inhibition of AKT (unknown origin) at 10 uM after 30 mins by fluorescence assay relative to control	B	O=S(=O)(Nc1ccc(O)c(Sc2ncn[nH]2)c1)c1c(Cl)cccc1Cl		CHEMBL2436725	=	Inhibition	%	48.38	CHEMBL4282	Homo sapiens	INH	%	48.38
Not Active	13475279	CHEMBL2439000	Inhibition of human wild type AKT1 at 1 uM by qPCR analysis	B	CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1		CHEMBL2436978		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	13507659	CHEMBL2444020	Inhibition of AKT1 (unknown origin)	B	CN(C)c1ccc(Oc2cc(O)cc(O)c2-c2cc(C(=O)NC3CCN(C4CCC5(CC4)OCCO5)CC3)no2)cc1		CHEMBL2443026	>	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
	13507660	CHEMBL2444020	Inhibition of AKT1 (unknown origin)	B	CC(C)Nc1ccc(Oc2cc(O)cc(O)c2-c2cc(C(=O)NC3CCN(C)CC3)no2)cc1		CHEMBL2443139	>	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
	13507661	CHEMBL2444020	Inhibition of AKT1 (unknown origin)	B	CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc(N(C)C)cc3)on2)CC1		CHEMBL2443138	>	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
	13507662	CHEMBL2444020	Inhibition of AKT1 (unknown origin)	B	CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc([N+](=O)[O-])cc3)on2)CC1		CHEMBL2443044	>	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
Not Active	13508492	CHEMBL2447367	Inhibition of AKT1 (unknown origin) at 30 uM	B	O=C(Nc1ccc2c(c1)B(O)OC2)c1c(C(F)(F)F)ccc(Cl)c1F		CHEMBL2441375		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	13865493	CHEMBL3101072	Inhibition of AKT1 in human PC3 cells assessed as inhibition of GSK3beta phosphorylation after 4 hrs by Western blotting analysis	B	COc1ccc(OC[C@H](N)Cc2ccccc2)c2cc(-c3nc(C)no3)n(C)c12		CHEMBL3099289		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	13865494	CHEMBL3101072	Inhibition of AKT1 in human PC3 cells assessed as inhibition of GSK3beta phosphorylation after 4 hrs by Western blotting analysis	B	COC(=O)c1cc2c(OC[C@@H](N)Cc3ccccc3)ccc(OC)c2n1C		CHEMBL3099295		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	13865516	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Inhibition	%	58.3	CHEMBL4282	Homo sapiens	INH	%	58.3
	13865517	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COC(=O)c1cc2c(OCCN)cccc2[nH]1		CHEMBL3099294	=	Inhibition	%	48.6	CHEMBL4282	Homo sapiens	INH	%	48.6
	13865518	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COc1ccc(OC[C@@H](N)CC(C)C)c2cc(-c3nc(C)no3)n(C)c12		CHEMBL3099293	=	Inhibition	%	42.0	CHEMBL4282	Homo sapiens	INH	%	42.0
	13865519	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COc1ccc(OC[C@@H](N)CCSC)c2cc(-c3nc(C)no3)n(C)c12		CHEMBL3099292	=	Inhibition	%	55.5	CHEMBL4282	Homo sapiens	INH	%	55.5
	13865520	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COc1ccc(OC[C@H](N)Cc2c[nH]c3ccccc23)c2cc(-c3ncno3)n(C)c12		CHEMBL3099291	=	Inhibition	%	56.7	CHEMBL4282	Homo sapiens	INH	%	56.7
	13865521	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COc1ccc(OC[C@@H](N)Cc2c[nH]c3ccccc23)c2cc(-c3ncno3)n(C)c12		CHEMBL3099290	=	Inhibition	%	43.3	CHEMBL4282	Homo sapiens	INH	%	43.3
	13865522	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COc1ccc(OC[C@H](N)Cc2ccccc2)c2cc(-c3nc(C)no3)n(C)c12		CHEMBL3099289	=	Inhibition	%	78.6	CHEMBL4282	Homo sapiens	INH	%	78.6
	13865523	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COc1ccc(OC[C@@H](N)Cc2ccccc2)c2cc(-c3nc(C)no3)n(C)c12		CHEMBL3099288	=	Inhibition	%	55.7	CHEMBL4282	Homo sapiens	INH	%	55.7
	13865524	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COC(=O)c1cc2c(OC[C@H](N)Cc3c[nH]c4ccccc34)ccc(Cl)c2n1C		CHEMBL3099287	=	Inhibition	%	58.4	CHEMBL4282	Homo sapiens	INH	%	58.4
	13865525	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COC(=O)c1cc2c(OC[C@@H](N)Cc3c[nH]c4ccccc34)ccc(Cl)c2n1C		CHEMBL3099286	=	Inhibition	%	73.5	CHEMBL4282	Homo sapiens	INH	%	73.5
	13865526	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COC(=O)c1cc2c(OC[C@H](N)Cc3ccccc3)ccc(Cl)c2n1C		CHEMBL3099285	=	Inhibition	%	60.3	CHEMBL4282	Homo sapiens	INH	%	60.3
	13865527	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COC(=O)c1cc2c(OC[C@@H](N)Cc3ccccc3)ccc(Cl)c2n1C		CHEMBL3099284	=	Inhibition	%	34.2	CHEMBL4282	Homo sapiens	INH	%	34.2
	13865528	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COC(=O)c1cc2c(OC[C@H](N)Cc3c[nH]c4ccccc34)ccc(Br)c2n1C		CHEMBL3099283	=	Inhibition	%	36.0	CHEMBL4282	Homo sapiens	INH	%	36.0
	13865529	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COC(=O)c1cc2c(OC[C@@H](N)Cc3c[nH]c4ccccc34)ccc(Br)c2n1C		CHEMBL3099302	=	Inhibition	%	73.0	CHEMBL4282	Homo sapiens	INH	%	73.0
	13865530	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COC(=O)c1cc2c(OC[C@H](N)Cc3ccccc3)ccc(Br)c2n1C		CHEMBL3099301	=	Inhibition	%	55.4	CHEMBL4282	Homo sapiens	INH	%	55.4
	13865531	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COC(=O)c1cc2c(OC[C@@H](N)Cc3ccccc3)ccc(Br)c2n1C		CHEMBL3099300	=	Inhibition	%	56.1	CHEMBL4282	Homo sapiens	INH	%	56.1
	13865532	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	CC[C@H](C)[C@H](N)COc1ccc(OC)c2c1cc(C(=O)OC)n2C		CHEMBL3099299	=	Inhibition	%	48.7	CHEMBL4282	Homo sapiens	INH	%	48.7
	13865533	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COC(=O)c1cc2c(OC[C@@H](N)CCSC)ccc(OC)c2n1C		CHEMBL3099298	=	Inhibition	%	7.7	CHEMBL4282	Homo sapiens	INH	%	7.7
	13865534	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COC(=O)c1cc2c(OC[C@@H](N)CC(C)C)ccc(OC)c2n1C		CHEMBL3099297	=	Inhibition	%	27.8	CHEMBL4282	Homo sapiens	INH	%	27.8
	13865535	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COC(=O)c1cc2c(OC[C@H](N)Cc3ccccc3)ccc(OC)c2n1C		CHEMBL3099296	=	Inhibition	%	38.9	CHEMBL4282	Homo sapiens	INH	%	38.9
	13865536	CHEMBL3101074	Inhibition of AKT1 in human PC3 cells using GSK-3beta fusion protein as substrate at 10 nM after 1 hr by Western blotting analysis relative to control	B	COC(=O)c1cc2c(OC[C@@H](N)Cc3ccccc3)ccc(OC)c2n1C		CHEMBL3099295	=	Inhibition	%	72.5	CHEMBL4282	Homo sapiens	INH	%	72.5
	13870250	CHEMBL3100278	Inhibition of AKT1 (unknown origin) by high-throughput screen assay	B	CCC[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(O)cccc1C2=O		CHEMBL474390	=	IC50	nM	198.0	CHEMBL4282	Homo sapiens	IC50	nM	198.0
	13870251	CHEMBL3100278	Inhibition of AKT1 (unknown origin) by high-throughput screen assay	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(ccc([C@H]3C[C@@H](N(C)C)[C@H](O)[C@@H](C)O3)c1O)C2=O		CHEMBL2216825	=	IC50	nM	149.0	CHEMBL4282	Homo sapiens	IC50	nM	149.0
	13870252	CHEMBL3100278	Inhibition of AKT1 (unknown origin) by high-throughput screen assay	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1ccccc1C2=O		CHEMBL522996	=	IC50	nM	150.0	CHEMBL4282	Homo sapiens	IC50	nM	150.0
	13870260	CHEMBL3100280	Inhibition of recombinant AKT1 (unknown origin) using serine/threonine 06 peptide as substrate after 1 hr by FRET based Z'-LYTE assay	B	O=C1C[C@H]2OCC3=C(C(=O)c4ccccc4C3=O)[C@H]2O1		CHEMBL475400	=	IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	uM	0.044
	13870261	CHEMBL3100280	Inhibition of recombinant AKT1 (unknown origin) using serine/threonine 06 peptide as substrate after 1 hr by FRET based Z'-LYTE assay	B	O=C1C=CC(=O)c2ccccc21		CHEMBL55934	=	IC50	nM	10980.0	CHEMBL4282	Homo sapiens	IC50	uM	10.98
	13870262	CHEMBL3100280	Inhibition of recombinant AKT1 (unknown origin) using serine/threonine 06 peptide as substrate after 1 hr by FRET based Z'-LYTE assay	B	C=CC(=O)c1ccccc1		CHEMBL3099615	=	IC50	nM	12270.0	CHEMBL4282	Homo sapiens	IC50	uM	12.27
	13870263	CHEMBL3100280	Inhibition of recombinant AKT1 (unknown origin) using serine/threonine 06 peptide as substrate after 1 hr by FRET based Z'-LYTE assay	B	COC(=O)CC/C=C/C(=O)c1ccccc1		CHEMBL3099614	=	IC50	nM	13670.0	CHEMBL4282	Homo sapiens	IC50	uM	13.67
	13870264	CHEMBL3100280	Inhibition of recombinant AKT1 (unknown origin) using serine/threonine 06 peptide as substrate after 1 hr by FRET based Z'-LYTE assay	B	COC/C=C/C(=O)c1ccccc1		CHEMBL3099613	=	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	13870265	CHEMBL3100280	Inhibition of recombinant AKT1 (unknown origin) using serine/threonine 06 peptide as substrate after 1 hr by FRET based Z'-LYTE assay	B	O=C1C[C@@H](O)[C@@H](C2=CC(=O)c3ccccc3C2=O)O1		CHEMBL3099612	=	IC50	nM	2940.0	CHEMBL4282	Homo sapiens	IC50	uM	2.94
	13870266	CHEMBL3100280	Inhibition of recombinant AKT1 (unknown origin) using serine/threonine 06 peptide as substrate after 1 hr by FRET based Z'-LYTE assay	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1ccccc1C2=O		CHEMBL522996	=	IC50	nM	280.0	CHEMBL4282	Homo sapiens	IC50	uM	0.28
	13870267	CHEMBL3100280	Inhibition of recombinant AKT1 (unknown origin) using serine/threonine 06 peptide as substrate after 1 hr by FRET based Z'-LYTE assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	uM	0.011
	13871783	CHEMBL3101244	Inhibition of human PKBalpha assessed as residual activity at 1 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	94.0	CHEMBL4282	Homo sapiens	Activity	%	94.0
	13878449	CHEMBL3108329	Inhibition of AKT1 (unknown origin)	B	O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12		CHEMBL50	=	IC50	nM	5390.0	CHEMBL4282	Homo sapiens	IC50	uM	5.39
	13878450	CHEMBL3108329	Inhibition of AKT1 (unknown origin)	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	30.0	CHEMBL4282	Homo sapiens	IC50	uM	0.03
	13878451	CHEMBL3108329	Inhibition of AKT1 (unknown origin)	B	Cc1c(O)c(O)c(O)c(C=O)c1-c1cc2c(C=O)c(C)c(O)c(O)c2o1		CHEMBL3104855	=	IC50	nM	4070.0	CHEMBL4282	Homo sapiens	IC50	uM	4.07
	13878452	CHEMBL3108329	Inhibition of AKT1 (unknown origin)	B	Cc1c(O)c(O)c(O)c2c1COC2=O		CHEMBL3104854	=	IC50	nM	23200.0	CHEMBL4282	Homo sapiens	IC50	uM	23.2
	13878453	CHEMBL3108329	Inhibition of AKT1 (unknown origin)	B	COCc1c(C)c(O)c(O)c(O)c1C=O		CHEMBL3104853	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	13878454	CHEMBL3108329	Inhibition of AKT1 (unknown origin)	B	COC1OC(=O)c2c(O)c(O)c(O)c(C)c21		CHEMBL3104852	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	13878455	CHEMBL3108329	Inhibition of AKT1 (unknown origin)	B	Cc1c(O)c(O)c2c(c1C=O)[C@@H]1O[C@H](O2)c2c(C)c(O)c(O)c(O)c2C1=O		CHEMBL3104851	=	IC50	nM	2150.0	CHEMBL4282	Homo sapiens	IC50	uM	2.15
Active	13881576	CHEMBL3108553	Inhibition of human AKT1 at 5 x 10'-8 M	B	Oc1ccc(-c2cnc3[nH]cc(-c4ccc(O)c(O)c4)c3c2)cc1O		CHEMBL3102955		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	13897478	CHEMBL3111649	Inhibition of recombinant AKT1 (unknown origin) using GSK3 (14 to 27) as substrate assessed as incorporation of [gamma-33P]-ATP into substrate by radiometric assay	B	COC(=O)c1cc(O)c(O)c(C[C@]2(C)[C@@H](C)CC[C@@]3(C)C(C)=CCC[C@H]32)c1		CHEMBL3109404	=	IC50	nM	48400.0	CHEMBL4282	Homo sapiens	IC50	uM	48.4
	13897479	CHEMBL3111649	Inhibition of recombinant AKT1 (unknown origin) using GSK3 (14 to 27) as substrate assessed as incorporation of [gamma-33P]-ATP into substrate by radiometric assay	B	COc1cc2nc(C)oc2c(C[C@]2(C)[C@@H](C)CC[C@@]3(C)C(C)=CCC[C@H]32)c1O		CHEMBL3109402	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	13897480	CHEMBL3111649	Inhibition of recombinant AKT1 (unknown origin) using GSK3 (14 to 27) as substrate assessed as incorporation of [gamma-33P]-ATP into substrate by radiometric assay	B	CC1=CCC[C@@H]2[C@@]1(C)CC[C@H](C)[C@@]2(C)CC1=C(O)C(=O)C=C(NCCC(C)C)C1=O		CHEMBL3109401	=	IC50	nM	73200.0	CHEMBL4282	Homo sapiens	IC50	uM	73.2
Not Active	13898482	CHEMBL3110519	Inhibition of AKT1 (unknown origin) at 5 uM after 120 mins	B	CN(CC(=O)N(Cc1ccc(C2CCCCC2)cc1)c1ccc(C(=O)NO)cc1)S(=O)(=O)c1c(F)c(F)c(F)c(F)c1F		CHEMBL3108910		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	13898483	CHEMBL3110519	Inhibition of AKT1 (unknown origin) at 5 uM after 120 mins	B	CN(CC(=O)N(Cc1ccc(C2CCCCC2)cc1)c1ccc(C(=O)O)cc1)S(=O)(=O)c1c(F)c(F)c(F)c(F)c1F		CHEMBL3108909		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	13898484	CHEMBL3110519	Inhibition of AKT1 (unknown origin) at 5 uM after 120 mins	B	CC(=O)Oc1cc(N(Cc2ccc(C3CCCCC3)cc2)C(=O)CN(C)S(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)ccc1C(=O)O		CHEMBL3108782		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	13906444	CHEMBL3117479	Inhibition of AKT1 (unknown origin) after 30 mins	B	COc1ccc(S(=O)(=O)Nc2cc(Sc3ncnc4nc[nH]c34)c(O)c3ccccc23)cc1OC		CHEMBL3113284		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	13906453	CHEMBL3117486	Inhibition of AKT1 (unknown origin) at 10 uM after 30 mins relative to control	B	COc1ccc(S(=O)(=O)Nc2cc(Sc3ncnc4nc[nH]c34)c(O)c3ccccc23)cc1OC		CHEMBL3113284	=	Inhibition	%	92.1	CHEMBL4282	Homo sapiens	INH	%	92.1
	13906549	CHEMBL3117479	Inhibition of AKT1 (unknown origin) after 30 mins	B	COc1ccc(S(=O)(=O)Nc2cc(Sc3ncnc4nc[nH]c34)c(O)c3ccccc23)cc1OC		CHEMBL3113284	=	IC50	nM	1730.0	CHEMBL4282	Homo sapiens	IC50	uM	1.73
	13906552	CHEMBL3117479	Inhibition of AKT1 (unknown origin) after 30 mins	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	130.0	CHEMBL4282	Homo sapiens	IC50	uM	0.13
Not Active	13919561	CHEMBL3118634	Inhibition of Akt1 in human OVCAR8 cells assessed as effect on total GSK3beta level at 1 uM by Western blotting analysis	B	CC(C)(C)NC(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3112595		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	13919580	CHEMBL3118842	Inhibition of Akt1 in human OVCAR8 cells assessed as GSK3beta phosphorylation at 1 uM by Western blotting analysis	B	CC(C)(C)NC(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3112595		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	13919581	CHEMBL3118843	Inhibition of Akt1-mediated phosphorylation at Ser473 in human OVCAR8 cells at 1 uM by Western blotting analysis	B	CC(C)(C)NC(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3112595		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	13919655	CHEMBL3118848	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate at 10 uM preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	Clc1ccc(C(Nc2ccccc2)c2ccc(-c3cn[nH]c3)cc2)cc1		CHEMBL3113147	=	Inhibition	%	29.0	CHEMBL4282	Homo sapiens	INH	%	29.0
	13919656	CHEMBL3118848	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate at 10 uM preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	Clc1ccc(C(Nc2ccccc2)c2ccc(-c3ccncc3)cc2)cc1		CHEMBL3113138	=	Inhibition	%	26.0	CHEMBL4282	Homo sapiens	INH	%	26.0
	13919657	CHEMBL3118848	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate at 10 uM preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	Clc1ccc(C(NC2CCCCC2)c2ccc(-c3cccnc3)cc2)cc1		CHEMBL3113133	=	Inhibition	%	20.0	CHEMBL4282	Homo sapiens	INH	%	20.0
	13919658	CHEMBL3118848	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate at 10 uM preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	CC(C)(C)NC(c1ccc(Cl)cc1)c1ccc(-c2cccnc2)cc1		CHEMBL3113132	=	Inhibition	%	19.0	CHEMBL4282	Homo sapiens	INH	%	19.0
	13919659	CHEMBL3118848	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate at 10 uM preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	CC(C)CNC(c1ccc(Cl)cc1)c1ccc(-c2cccnc2)cc1		CHEMBL3113131	=	Inhibition	%	10.0	CHEMBL4282	Homo sapiens	INH	%	10.0
	13919660	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	NCCNC(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3113150	=	IC50	nM	820.0	CHEMBL4282	Homo sapiens	IC50	uM	0.82
	13919661	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	OCCNC(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3113149	=	IC50	nM	650.0	CHEMBL4282	Homo sapiens	IC50	uM	0.65
	13919662	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	Clc1ccc(C(NCc2ccccc2)c2ccc(-c3cn[nH]c3)cc2)cc1		CHEMBL3113148	=	IC50	nM	1320.0	CHEMBL4282	Homo sapiens	IC50	uM	1.32
	13919663	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	Clc1ccc(C(NC2CCCCC2)c2ccc(-c3cn[nH]c3)cc2)cc1		CHEMBL3113146	=	IC50	nM	1100.0	CHEMBL4282	Homo sapiens	IC50	uM	1.1
	13919664	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	Clc1ccc(C(NC2CC2)c2ccc(-c3cn[nH]c3)cc2)cc1		CHEMBL3113145	=	IC50	nM	480.0	CHEMBL4282	Homo sapiens	IC50	uM	0.48
	13919665	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	CC(C)(C)NC(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3112595	=	IC50	nM	38.0	CHEMBL4282	Homo sapiens	IC50	uM	0.038
	13919666	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	CC(C)CNC(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3113144	=	IC50	nM	900.0	CHEMBL4282	Homo sapiens	IC50	uM	0.9
	13919667	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	CC(C)NC(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3113143	=	IC50	nM	370.0	CHEMBL4282	Homo sapiens	IC50	uM	0.37
	13919668	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	Clc1ccc(C(NCc2ccccc2)c2ccc(-c3ncnc4[nH]cnc34)cc2)cc1		CHEMBL3113142	=	IC50	nM	740.0	CHEMBL4282	Homo sapiens	IC50	uM	0.74
	13919669	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	Clc1ccc(C(NC2CCCCC2)c2ccc(-c3ncnc4[nH]cnc34)cc2)cc1		CHEMBL3113141	=	IC50	nM	640.0	CHEMBL4282	Homo sapiens	IC50	uM	0.64
	13919670	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	CC(C)CNC(c1ccc(Cl)cc1)c1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL3113140	=	IC50	nM	740.0	CHEMBL4282	Homo sapiens	IC50	uM	0.74
	13919671	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	Clc1ccc(C(NCc2ccccc2)c2ccc(-c3ccncc3)cc2)cc1		CHEMBL3113139	=	IC50	nM	1250.0	CHEMBL4282	Homo sapiens	IC50	uM	1.25
	13919672	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	Clc1ccc(C(NC2CCCCC2)c2ccc(-c3ccncc3)cc2)cc1		CHEMBL3113137	=	IC50	nM	1260.0	CHEMBL4282	Homo sapiens	IC50	uM	1.26
	13919673	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	CC(C)(C)NC(c1ccc(Cl)cc1)c1ccc(-c2ccncc2)cc1		CHEMBL3113136	=	IC50	nM	170.0	CHEMBL4282	Homo sapiens	IC50	uM	0.17
	13919674	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	CC(C)CNC(c1ccc(Cl)cc1)c1ccc(-c2ccncc2)cc1		CHEMBL3113135	=	IC50	nM	1430.0	CHEMBL4282	Homo sapiens	IC50	uM	1.43
	13919675	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	CC(C)NC(c1ccc(Cl)cc1)c1ccc(-c2ccncc2)cc1		CHEMBL3113134	=	IC50	nM	220.0	CHEMBL4282	Homo sapiens	IC50	uM	0.22
	13919676	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	Clc1ccc(C(NC2CC2)c2ccc(-c3ncnc4[nH]cnc34)cc2)cc1		CHEMBL3113130	=	IC50	nM	470.0	CHEMBL4282	Homo sapiens	IC50	uM	0.47
	13919677	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	CC(C)NC(c1ccc(Cl)cc1)c1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL3113129	=	IC50	nM	160.0	CHEMBL4282	Homo sapiens	IC50	uM	0.16
	13919678	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	IC50	nM	1720.0	CHEMBL4282	Homo sapiens	IC50	uM	1.72
	13919679	CHEMBL3118849	Inhibition of Akt1 (unknown origin) using ATP/eNOS as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence polarization assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	40.0	CHEMBL4282	Homo sapiens	IC50	uM	0.04
Not Active	13932960	CHEMBL3124155	Binding affinity to Akt in human SQ20B cells after 10 to 12 hrs by pull down assay	B	O=C(CCC(=O)ON1C(=O)CCC1=O)NCCNC(=O)COC(=O)NCCOCCOCCOCCOCCOCCOCCNC(=O)C1CCN(C2CCN(Cc3c(O)ccc4oc(-c5ccccc5)cc34)CC2)CC1		CHEMBL3120211		Activity			CHEMBL4282	Homo sapiens	Activity		
	13933027	CHEMBL3124141	Inhibition of Akt/mTOR in human 786-O cells assessed as inhibition of nuclear export of transcription factor FOXO1a	B	CN(C)Cc1c(O)ccc2oc(Cc3ccccc3)cc12		CHEMBL526034	=	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	uM	20.0
Not Active	13939906	CHEMBL3129424	Inhibition of AKT phosphorylation in human PANC1 cells at 1 to 20 uM by Western blotting analysis	B	CN(C)CCCN1C(=O)c2ccc3c4ccc5c6c(ccc(c7ccc(c2c37)C1=O)c64)C(=O)N(CCCN(C)C)C5=O		CHEMBL3126485		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	13950553	CHEMBL3131349	Inhibition of AKT1 (unknown origin) using ATP/eNOS as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence polarization assay	B	Nc1ncnc(N2CCN(C(=O)C(N)Cc3ccccc3)CC2)c1Br		CHEMBL3127380	=	IC50	nM	436.52	CHEMBL4282	Homo sapiens	pIC50		6.36
	13950554	CHEMBL3131349	Inhibition of AKT1 (unknown origin) using ATP/eNOS as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence polarization assay	B	Nc1ncnc(N2CCN(C(=O)C(N)Cc3ccc(Cl)cc3)CC2)c1Br		CHEMBL3127379	=	IC50	nM	7.762	CHEMBL4282	Homo sapiens	pIC50		8.11
	13950555	CHEMBL3131349	Inhibition of AKT1 (unknown origin) using ATP/eNOS as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence polarization assay	B	Nc1ncnc(N2CCN(C(=O)C(N)Cc3ccc(Cl)cc3)CC2)c1Cl		CHEMBL3127378	=	IC50	nM	16.98	CHEMBL4282	Homo sapiens	pIC50		7.77
	13950556	CHEMBL3131349	Inhibition of AKT1 (unknown origin) using ATP/eNOS as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence polarization assay	B	Nc1ncnc(N2CCN(C(=O)[C@@H](N)Cc3ccccc3)CC2)c1Cl		CHEMBL3127377	=	IC50	nM	1819.7	CHEMBL4282	Homo sapiens	pIC50		5.74
	13950557	CHEMBL3131349	Inhibition of AKT1 (unknown origin) using ATP/eNOS as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence polarization assay	B	NCC1(c2ccc(Cl)c(Cl)c2)CCN(c2cc(N)ncn2)CC1		CHEMBL3127376	=	IC50	nM	4365.16	CHEMBL4282	Homo sapiens	pIC50		5.36
	13950558	CHEMBL3131349	Inhibition of AKT1 (unknown origin) using ATP/eNOS as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence polarization assay	B	CNc1cc(N2CCC(CN)(c3ccc(Cl)c(Cl)c3)CC2)ncn1		CHEMBL3124965	=	IC50	nM	1995.26	CHEMBL4282	Homo sapiens	pIC50		5.7
	13950573	CHEMBL3131349	Inhibition of AKT1 (unknown origin) using ATP/eNOS as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence polarization assay	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	IC50	nM	2200.0	CHEMBL4282	Homo sapiens	IC50	uM	2.2
	13950574	CHEMBL3131349	Inhibition of AKT1 (unknown origin) using ATP/eNOS as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence polarization assay	B	Nc1ncnc(N2CCN(C(=O)C(N)Cc3ccccc3)CC2)c1Br		CHEMBL3127380	=	IC50	nM	432.0	CHEMBL4282	Homo sapiens	IC50	uM	0.432
	13950575	CHEMBL3131349	Inhibition of AKT1 (unknown origin) using ATP/eNOS as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence polarization assay	B	Nc1ncnc(N2CCN(C(=O)C(N)Cc3ccc(Cl)cc3)CC2)c1Br		CHEMBL3127379	=	IC50	nM	7.7	CHEMBL4282	Homo sapiens	IC50	uM	0.0077
	13950576	CHEMBL3131349	Inhibition of AKT1 (unknown origin) using ATP/eNOS as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence polarization assay	B	Nc1ncnc(N2CCN(C(=O)C(N)Cc3ccc(Cl)cc3)CC2)c1Cl		CHEMBL3127378	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	uM	0.017
	13950577	CHEMBL3131349	Inhibition of AKT1 (unknown origin) using ATP/eNOS as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence polarization assay	B	Nc1ncnc(N2CCN(C(=O)[C@@H](N)Cc3ccccc3)CC2)c1Cl		CHEMBL3127377	=	IC50	nM	1830.0	CHEMBL4282	Homo sapiens	IC50	uM	1.83
	13950578	CHEMBL3131349	Inhibition of AKT1 (unknown origin) using ATP/eNOS as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence polarization assay	B	NCC1(c2ccc(Cl)c(Cl)c2)CCN(c2cc(N)ncn2)CC1		CHEMBL3127376	=	IC50	nM	4320.0	CHEMBL4282	Homo sapiens	IC50	uM	4.32
	13950579	CHEMBL3131349	Inhibition of AKT1 (unknown origin) using ATP/eNOS as substrate incubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence polarization assay	B	CNc1cc(N2CCC(CN)(c3ccc(Cl)c(Cl)c3)CC2)ncn1		CHEMBL3124965	=	IC50	nM	1830.0	CHEMBL4282	Homo sapiens	IC50	uM	1.83
	13953209	CHEMBL3132641	Inhibition of human PKBalpha assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125727	=	Activity	%	119.0	CHEMBL4282	Homo sapiens	Activity	%	119.0
	13953239	CHEMBL3132641	Inhibition of human PKBalpha assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125726	=	Activity	%	107.0	CHEMBL4282	Homo sapiens	Activity	%	107.0
	13954594	CHEMBL3132641	Inhibition of human PKBalpha assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125728	=	Activity	%	111.0	CHEMBL4282	Homo sapiens	Activity	%	111.0
	13965690	CHEMBL3135240	Inhibition of human AKT1 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 70 uM after 90 mins by microfluidic peptide phosphorylation assay	B	CNCc1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL376388	=	Inhibition	%	64.5	CHEMBL4282	Homo sapiens	INH	%	64.5
	13966068	CHEMBL3136905	Inhibition of human AKT1 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 1000 uM after 90 mins by microfluidic peptide phosphorylation assay	B	c1cnc2[nH]ccc2c1		CHEMBL389685	=	Inhibition	%	65.5	CHEMBL4282	Homo sapiens	INH	%	65.5
	13973343	CHEMBL3135743	Inhibition of human AKT1 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.1 uM after 90 mins by microfluidic peptide phosphorylation assay	B	C[C@H](CN(C)C)Oc1nc(Nc2cc3cccc(Cl)c3cn2)cnc1C#N		CHEMBL1928705	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
Not Active	13973390	CHEMBL3134656	Inhibition of AKT1 (unknown origin) using GSK3 (14 to 27) as substrate after 60 mins by scintillation counting	B	Oc1cccc(Nc2ccnc3[nH]c4ccccc4c23)c1		CHEMBL3133821		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	13974061	CHEMBL3134721	Inhibition of human AKT1 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.35 uM after 90 mins by microfluidic peptide phosphorylation assay	B	COC(=O)c1cnc(Nc2cnc(C#N)cn2)cc1NCC1CCNCC1		CHEMBL1928692	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	13974152	CHEMBL3136366	Inhibition of human AKT1 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 9 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CN(c2ncnc3[nH]c4cnccc4c23)CCO1		CHEMBL1928677	=	Inhibition	%	52.0	CHEMBL4282	Homo sapiens	INH	%	52.0
	13974243	CHEMBL3135624	Inhibition of human AKT1 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 90 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CN(c2ncnc3[nH]cnc23)CCO1		CHEMBL560373	=	Inhibition	%	91.5	CHEMBL4282	Homo sapiens	INH	%	91.5
	13974981	CHEMBL3135147	Inhibition of human AKT1 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 420 uM after 90 mins by microfluidic peptide phosphorylation assay	B	c1nc(N2CCOCC2)c2nc[nH]c2n1		CHEMBL271138	=	Inhibition	%	61.5	CHEMBL4282	Homo sapiens	INH	%	61.5
	13975072	CHEMBL3136717	Inhibition of human AKT1 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.02 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598194	=	Inhibition	%	44.5	CHEMBL4282	Homo sapiens	INH	%	44.5
	13975163	CHEMBL3134946	Inhibition of human AKT1 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.06 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL263664	=	Inhibition	%	34.0	CHEMBL4282	Homo sapiens	INH	%	34.0
	13975254	CHEMBL3136535	Inhibition of human AKT1 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 2 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL259141	=	Inhibition	%	83.0	CHEMBL4282	Homo sapiens	INH	%	83.0
	13975897	CHEMBL3136264	Inhibition of human AKT1 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 8 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL261249	=	Inhibition	%	96.0	CHEMBL4282	Homo sapiens	INH	%	96.0
	13975990	CHEMBL3136299	Inhibition of human AKT1 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.2 uM after 90 mins by microfluidic peptide phosphorylation assay	B	Clc1ccc(C2(c3ccc(-c4ncnc5[nH]cnc45)cc3)CCNCC2)cc1		CHEMBL228133	=	Inhibition	%	94.0	CHEMBL4282	Homo sapiens	INH	%	94.0
	13976081	CHEMBL3136181	Inhibition of human AKT1 catalytic domain expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 95 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCCc1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL227727	=	Inhibition	%	81.0	CHEMBL4282	Homo sapiens	INH	%	81.0
Active	14526545	CHEMBL3223926	Inhibition of AKT phosphorylation in human TG10 cells at 300 uM after 30 mins by Western blot analysis	B	O=c1ccc2nccc3c4ccccc4n1c23		CHEMBL156897		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	14526546	CHEMBL3223926	Inhibition of AKT phosphorylation in human TG10 cells at 300 uM after 30 mins by Western blot analysis	B	COc1cc2nccc3c4ccccc4n(c1=O)c23		CHEMBL508649		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	14526547	CHEMBL3223926	Inhibition of AKT phosphorylation in human TG10 cells at 300 uM after 30 mins by Western blot analysis	B	O=c1ccc2nccc3c4cc(OCc5ccccc5)ccc4n1c23		CHEMBL3218583		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	14526548	CHEMBL3223927	Inhibition of AKT phosphorylation in human TG1 cells at 300 uM after 30 mins by Western blot analysis	B	O=c1ccc2nccc3c4ccccc4n1c23		CHEMBL156897		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	14526549	CHEMBL3223927	Inhibition of AKT phosphorylation in human TG1 cells at 300 uM after 30 mins by Western blot analysis	B	COc1cc2nccc3c4ccccc4n(c1=O)c23		CHEMBL508649		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	14526550	CHEMBL3223927	Inhibition of AKT phosphorylation in human TG1 cells at 300 uM after 30 mins by Western blot analysis	B	O=c1ccc2nccc3c4cc(OCc5ccccc5)ccc4n1c23		CHEMBL3218583		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	14526551	CHEMBL3223928	Inhibition of AKT phosphorylation in human NSC-24 cells at 300 uM after 30 mins by Western blot analysis	B	COc1cc2nccc3c4ccccc4n(c1=O)c23		CHEMBL508649		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	14526552	CHEMBL3223928	Inhibition of AKT phosphorylation in human NSC-24 cells at 300 uM after 30 mins by Western blot analysis	B	O=c1ccc2nccc3c4cc(OCc5ccccc5)ccc4n1c23		CHEMBL3218583		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	14544042	CHEMBL3224099	Inhibition of AKT1 (unknown origin) at 10 uM	B	CC1(C)C(=O)Nc2cc3nccc(Oc4ccc(NC(=O)Nc5ccc(F)c(C(F)(F)F)c5)cc4Cl)c3cc21		CHEMBL3218350	=	Inhibition	%	16.5	CHEMBL4282	Homo sapiens	INH	%	16.5
	14545789	CHEMBL3224459	Inhibition of AKT1 (unknown origin) assessed as residual activity at 1 uM	B	CS(=O)(=O)O.O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218297	=	Activity	%	44.0	CHEMBL4282	Homo sapiens	Activity	%	44.0
	14545812	CHEMBL3224479	Inhibition of AKT1 (unknown origin)	B	CS(=O)(=O)O.O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218297	=	IC50	nM	2.16	CHEMBL4282	Homo sapiens	IC50	nM	2.16
	14553660	CHEMBL3223951	Inhibition of AKT1 (unknown origin) at 10 uM assessed as residual enzyme activity	B	COc1ccc(-c2n[nH]c3ncc(-c4ccc(Cl)cc4N)cc23)cc1		CHEMBL3220823	=	Activity	%	93.6	CHEMBL4282	Homo sapiens	Activity	%	93.6
Not Active	14574923	CHEMBL3241780	Inhibition of Akt phosphorylation in human H1975 cells harboring EGFR L858R/T790M mutant at 1 uM by Western blotting analysis	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	14574924	CHEMBL3241780	Inhibition of Akt phosphorylation in human H1975 cells harboring EGFR L858R/T790M mutant at 1 uM by Western blotting analysis	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)CCN3CCN(CCOc4no[n+]([O-])c4S(=O)(=O)c4ccccc4)CC3)c2)n1		CHEMBL3237937		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	14582430	CHEMBL3240213	Inhibition of human AKT1 assessed as enzyme activity at 1 uM relative to control	B	CCCS(=O)(=O)Nc1cccc(Nc2ccc3ncn(C)c(=O)c3c2)c1C#N		CHEMBL3236464	=	Activity	%	108.5	CHEMBL4282	Homo sapiens	Activity	%	108.5
	14593771	CHEMBL3241187	Inhibition of human AKT1	B	Oc1cccc(Nc2ccnc3[nH]c4ccccc4c23)c1		CHEMBL3133821	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	14648060	CHEMBL3265840	Inhibition of human PKB-alpha at 1 uM relative to control	B	CC(C)CCNc1ccc(-c2cnc3ccc(NC4CCN(C)CC4)nn23)cn1		CHEMBL2380687	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	14648061	CHEMBL3265840	Inhibition of human PKB-alpha at 1 uM relative to control	B	N[C@H]1CC[C@H](Nc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)CC1		CHEMBL3264059	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	14659337	CHEMBL3267557	Inhibition of AKT1 (unknown origin) at 1 uM	B	CCOP(=O)(CC)Cc1cccc(Nc2cc(-c3ccccc3OC)ncn2)c1		CHEMBL3264107	=	Inhibition	%	11.0	CHEMBL4282	Homo sapiens	INH	%	11.0
	14659338	CHEMBL3267557	Inhibition of AKT1 (unknown origin) at 1 uM	B	CCCP(=O)(Cc1cccc(Nc2cc(-c3ccccc3OC)ncn2)c1)OCC		CHEMBL3264108	=	Inhibition	%	-1.0	CHEMBL4282	Homo sapiens	INH	%	-1.0
	14663196	CHEMBL3268841	Inhibition of AKT1 (unknown origin) at 1 uM relative to control	B	CCOC(=O)c1sc(-c2ccncc2)nc1O		CHEMBL3261228	=	Inhibition	%	75.0	CHEMBL4282	Homo sapiens	INH	%	75.0
	14663197	CHEMBL3268841	Inhibition of AKT1 (unknown origin) at 1 uM relative to control	B	NC(=O)c1sc(-c2ccnc(N)n2)nc1-c1ccc(Cl)cc1Cl		CHEMBL3261514	=	Inhibition	%	80.0	CHEMBL4282	Homo sapiens	INH	%	80.0
	14663198	CHEMBL3268841	Inhibition of AKT1 (unknown origin) at 1 uM relative to control	B	COc1ccc(-c2nc(-c3ccnc(N)n3)sc2C(N)=O)c(Cl)c1		CHEMBL3261517	=	Inhibition	%	66.0	CHEMBL4282	Homo sapiens	INH	%	66.0
	14672862	CHEMBL3266374	Inhibition of AKT1 (unknown origin) at 1 uM by Z'-LYTE assay relative to control	B	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccc2ccccc2n1		CHEMBL3265344	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	14751163	CHEMBL3301291	Inhibition of AKT1 (unknown origin)	B	CC(C)(C)CNC(=O)CC1CNC(=O)c2cc(-c3ccsc3)cn21		CHEMBL3298400	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	14751164	CHEMBL3301291	Inhibition of AKT1 (unknown origin)	B	CN1CCN(C[C@@H](NC(=O)C[C@H]2CNC(=O)c3cc(-c4cccc(Cl)c4)cn32)C2CCCCC2)CC1		CHEMBL3297762	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	14984400	CHEMBL3384391	Inhibition of AKT1 (unknown origin) at 1 uM	B	CN1CCN(c2ccc(-c3cnc4[nH]c5cnc(C#N)cc5c4c3)cc2)CC1		CHEMBL3359895	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	14984466	CHEMBL3381881	Inhibition of AKT1 (unknown origin) at 0.1 uM	B	CN1CCN(c2ccc(-c3cnc4[nH]c5cnc(C#N)cc5c4c3)cc2)CC1		CHEMBL3359895	=	Inhibition	%	-5.0	CHEMBL4282	Homo sapiens	INH	%	-5.0
	14992854	CHEMBL3372235	Inhibition of recombinant AKT1 (unknown origin) after 60 mins by z'-lyte kinase assay	B	O=C1/C(=C\c2ccc(O)c(O)c2)Oc2ccccc21		CHEMBL3361128	=	IC50	nM	38600.0	CHEMBL4282	Homo sapiens	IC50	uM	38.6
Active	15002872	CHEMBL3362002	Inhibition of AKT1 phosphorylation in human U373 cells at 10 uM after 24 hrs by Western blot analysis	B	CC1(C)CC(NC(=O)[C@H](Cc2ccc(OCc3c(Cl)cccc3Cl)cc2)NC(=O)/C=C/c2c(F)c(F)c(F)c(F)c2F)CC(C)(C)N1		CHEMBL3314186		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	15002873	CHEMBL3362001	Inhibition of AKT1 phosphorylation in human HEK293 cells overexpressing CHI3L1 gene at 10 uM after 24 hrs by Western blot analysis	B	CC1(C)CC(NC(=O)[C@H](Cc2ccc(OCc3c(Cl)cccc3Cl)cc2)NC(=O)/C=C/c2c(F)c(F)c(F)c(F)c2F)CC(C)(C)N1		CHEMBL3314186		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	15002875	CHEMBL3361999	Inhibition of AKT1 phosphorylation in human HEK293 cells overexpressing CHI3L1 gene at 50 uM after 24 hrs by Western blot analysis	B	CC1(C)CC(NC(=O)[C@H](Cc2ccc(OCc3c(Cl)cccc3Cl)cc2)NC(=O)/C=C/c2c(F)c(F)c(F)c(F)c2F)CC(C)(C)N1		CHEMBL3314186		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	15002878	CHEMBL3361996	Inhibition of AKT1 phosphorylation in human U373 cells overexpressing CHI3L1 gene after 24 hrs by Western blot analysis	B	N=C(N)NCCC[C@H](NC(=O)C1CC2CCCCC2N1C(=O)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)/C=C/c1c(F)c(F)c(F)c(F)c1F)C1Cc2ccccc2C1)C1Cc2ccccc2C1)C(=O)O		CHEMBL3314188		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	15002879	CHEMBL3361996	Inhibition of AKT1 phosphorylation in human U373 cells overexpressing CHI3L1 gene after 24 hrs by Western blot analysis	B	CC1(C)CC(NC(=O)[C@H](Cc2ccc(OCc3c(Cl)cccc3Cl)cc2)NC(=O)/C=C/c2c(F)c(F)c(F)c(F)c2F)CC(C)(C)N1		CHEMBL3314186		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	15002882	CHEMBL3361994	Inhibition of AKT1 phosphorylation in human HEK293 cells overexpressing CHI3L1 gene after 24 hrs by Western blot analysis	B	N=C(N)NCCC[C@H](NC(=O)C1CC2CCCCC2N1C(=O)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)/C=C/c1c(F)c(F)c(F)c(F)c1F)C1Cc2ccccc2C1)C1Cc2ccccc2C1)C(=O)O		CHEMBL3314188		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	15002883	CHEMBL3361994	Inhibition of AKT1 phosphorylation in human HEK293 cells overexpressing CHI3L1 gene after 24 hrs by Western blot analysis	B	CC1(C)CC(NC(=O)[C@H](Cc2ccc(OCc3c(Cl)cccc3Cl)cc2)NC(=O)/C=C/c2c(F)c(F)c(F)c(F)c2F)CC(C)(C)N1		CHEMBL3314186		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	15008087	CHEMBL3369106	Inhibition of human PKBalpha at 1 uM by radiometric Assay	B	NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)Cc4ccccc4)cc23)c1	Outside typical range	CHEMBL3330255	=	Inhibition	%	-18.0	CHEMBL4282	Homo sapiens	INH	%	-18.0
	15008088	CHEMBL3369106	Inhibition of human PKBalpha at 1 uM by radiometric Assay	B	COC(C(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1)c1ccccc1		CHEMBL3330401	=	Inhibition	%	-8.0	CHEMBL4282	Homo sapiens	INH	%	-8.0
	15008089	CHEMBL3369106	Inhibition of human PKBalpha at 1 uM by radiometric Assay	B	NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)C(c4ccsc4)N4CCCC4)cc23)c1		CHEMBL3330410	=	Inhibition	%	8.0	CHEMBL4282	Homo sapiens	INH	%	8.0
	15009815	CHEMBL3363738	Inhibition of AKT1 (unknown origin) at 10 uM	B	C[C@H](O)CNc1nccc(-n2ccnc2Cc2cccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c2)n1		CHEMBL3309549	=	Inhibition	%	12.9	CHEMBL4282	Homo sapiens	INH	%	12.9
	15013909	CHEMBL3364170	Inhibition of Akt1 (unknown origin)	B	CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)C(CCCCCCCCn1cc(CCCC(=O)NC(CCCCCCCCn2cc(C[C@H](NC(C)=O)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(N)=O)nn2)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)NCCNC(=O)CCCC[C@H]2SC[C@H]3NC(=O)N[C@H]32)C(C)C)nn1)NC(C)=O)C(N)=O		CHEMBL3314097	=	Kd	nM	200.0	CHEMBL4282	Homo sapiens	Kd	nM	200.0
	15014099	CHEMBL3361854	Inhibition of AKT1 (unknown origin) at 100 nM	B	O=C(N[C@H](CO)c1ccc(Cl)c(F)c1)N1CCc2cnc(NC3CCOCC3)nc2C1		CHEMBL3298678	=	Inhibition	%	-0.1	CHEMBL4282	Homo sapiens	INH	%	-0.1
	15019134	CHEMBL3364070	Inhibition of AKT1 (unknown origin) after 1 hr by Z'-LYTE kinase assay in presence of 75 uM ATP	B	C=CC(=O)[C@H](Cc1ccccc1)NC(=O)OC(C)(C)C		CHEMBL3298512	=	IC50	nM	580.0	CHEMBL4282	Homo sapiens	IC50	uM	0.58
	15019135	CHEMBL3364070	Inhibition of AKT1 (unknown origin) after 1 hr by Z'-LYTE kinase assay in presence of 75 uM ATP	B	CC(C)(C)OC(=O)N[C@@H](Cc1ccccc1)C(=O)NCCI		CHEMBL3298513	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	15019136	CHEMBL3364070	Inhibition of AKT1 (unknown origin) after 1 hr by Z'-LYTE kinase assay in presence of 75 uM ATP	B	CC(C)(C)OC(=O)N[C@@H](Cc1ccccc1)C(=O)NCCBr		CHEMBL3298514	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	15019137	CHEMBL3364070	Inhibition of AKT1 (unknown origin) after 1 hr by Z'-LYTE kinase assay in presence of 75 uM ATP	B	CC(C)(C)OC(=O)N[C@@H](Cc1ccccc1)C(=O)NCCCl		CHEMBL3298515	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	15019138	CHEMBL3364070	Inhibition of AKT1 (unknown origin) after 1 hr by Z'-LYTE kinase assay in presence of 75 uM ATP	B	CC(C)(C)OC(=O)N[C@@H](Cc1ccccc1)C(=O)NCCN1C(=O)C=CC1=O		CHEMBL3298516	=	IC50	nM	4480.0	CHEMBL4282	Homo sapiens	IC50	uM	4.48
	15019139	CHEMBL3364070	Inhibition of AKT1 (unknown origin) after 1 hr by Z'-LYTE kinase assay in presence of 75 uM ATP	B	CC(C)(C)OC(=O)NN(Cc1ccccc1)C(=O)CCl		CHEMBL3298610	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	15019140	CHEMBL3364070	Inhibition of AKT1 (unknown origin) after 1 hr by Z'-LYTE kinase assay in presence of 75 uM ATP	B	CC(C)(C)OC(=O)NN(Cc1ccccc1)C(=O)CBr		CHEMBL3298611	=	IC50	nM	24660.0	CHEMBL4282	Homo sapiens	IC50	uM	24.66
	15019141	CHEMBL3364070	Inhibition of AKT1 (unknown origin) after 1 hr by Z'-LYTE kinase assay in presence of 75 uM ATP	B	CC(C)(C)OC(=O)NN(Cc1ccccc1)C(=O)CI		CHEMBL3298792	=	IC50	nM	16130.0	CHEMBL4282	Homo sapiens	IC50	uM	16.13
	15019142	CHEMBL3364070	Inhibition of AKT1 (unknown origin) after 1 hr by Z'-LYTE kinase assay in presence of 75 uM ATP	B	C=CC(=O)N(Cc1ccccc1)NC(=O)OC(C)(C)C		CHEMBL3298928	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	15019143	CHEMBL3364070	Inhibition of AKT1 (unknown origin) after 1 hr by Z'-LYTE kinase assay in presence of 75 uM ATP	B	CC(C)(C)OC(=O)NN(Cc1ccccc1)C(=O)CN1C(=O)C=CC1=O		CHEMBL3298929	=	IC50	nM	4680.0	CHEMBL4282	Homo sapiens	IC50	uM	4.68
	15019144	CHEMBL3364070	Inhibition of AKT1 (unknown origin) after 1 hr by Z'-LYTE kinase assay in presence of 75 uM ATP	B	CCC(=O)[C@H](Cc1ccccc1)NC(=O)OC(C)(C)C		CHEMBL3358446	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	15019145	CHEMBL3364070	Inhibition of AKT1 (unknown origin) after 1 hr by Z'-LYTE kinase assay in presence of 75 uM ATP	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	IC50	nM	0.6	CHEMBL4282	Homo sapiens	IC50	uM	0.0006
	15019146	CHEMBL3364070	Inhibition of AKT1 (unknown origin) after 1 hr by Z'-LYTE kinase assay in presence of 75 uM ATP	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	uM	0.01
tde	15019147	CHEMBL3364071	Irreversible inhibition of AKT1 (unknown origin) Z'-LYTE kinase assay in presence of ATP	B	C=CC(=O)[C@H](Cc1ccccc1)NC(=O)OC(C)(C)C		CHEMBL3298512		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	15019149	CHEMBL3364073	Inhibition of AKT1 (unknown origin) at 1 uM in presence of 100 uM ATP	B	C=CC(=O)[C@H](Cc1ccccc1)NC(=O)OC(C)(C)C		CHEMBL3298512	=	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
Active	15019211	CHEMBL3364729	Binding affinity to AKT1 (unknown origin) assessed as covalent modification at Cys199 residue by mass spectrometry	B	C=CC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1cn(CCCCCCNC(=S)Nc2ccc(-c3c4ccc(=O)cc-4oc4cc(O)ccc34)c(C(=O)O)c2)nn1		CHEMBL3298931		Activity			CHEMBL4282	Homo sapiens	Activity		
	15019212	CHEMBL3364360	Inhibition of AKT1 (unknown origin) after 30 mins by scintillation counting analysis in presence of 100 uM ATP	B	COC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(=N)N)C(=O)NCCCC(=O)O		CHEMBL3299032	=	IC50	nM	200.0	CHEMBL4282	Homo sapiens	IC50	uM	0.2
	15022480	CHEMBL3380431	Inhibition of AKT1 (unknown origin) at 1 uM	B	COc1ccc(C(=O)NC(=O)Nc2ccc3c(c2)NC(=O)/C3=C\c2[nH]c(C)c(C(=O)NCCN3CCCC3)c2C)c(F)c1		CHEMBL3329684	=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	INH	%	40.0
	15025401	CHEMBL3362509	Inhibition of Akt (unknown origin) at 1 uM by radioisotope-based P81 filter-binding assay	B	O=C1Nc2cc(NC(=O)c3c[nH]cc(-c4ccccc4F)c3=O)ccc2/C1=C/c1ccc[nH]1		CHEMBL3322590	=	Inhibition	%	2.8	CHEMBL4282	Homo sapiens	INH	%	2.8
Active	15035145	CHEMBL3370966	Inhibition of Akt phosphorylation at Ser473 in human NCI-H460 cells at 0 to 20 uM for 24 hrs by Western blot analysis	B	COc1cc(O)cc(CCc2ccc(O)c(OC)c2)c1		CHEMBL219553		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	15036713	CHEMBL3381058	Inhibition of AKT1 (unknown origin)	B	Nc1nc2c3c(F)cccc3nc(Cc3ccc4c(c3)OCO4)n2n1		CHEMBL3309990	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	15036714	CHEMBL3381058	Inhibition of AKT1 (unknown origin)	B	Nc1ccc2c(c1)nc(Cc1ccc3c(c1)OCO3)n1nc(N)nc21		CHEMBL3309995	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	15036715	CHEMBL3381058	Inhibition of AKT1 (unknown origin)	B	OCCCNc1ccc2c(c1)nc(-c1ccc3c(c1)OCO3)n1ncnc21		CHEMBL3309997	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	15036716	CHEMBL3381058	Inhibition of AKT1 (unknown origin)	B	Nc1nc2c3ccc(NCCO)cc3nc(Cc3ccc4c(c3)OCO4)n2n1		CHEMBL3309998	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	15036717	CHEMBL3381058	Inhibition of AKT1 (unknown origin)	B	CN1CCN(c2cc(F)c3c(c2)nc(Cc2ccc4c(c2)OCO4)n2nc(N)nc32)CC1		CHEMBL3310151	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	15037091	CHEMBL3368321	Inhibition of AKT1 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2cnc3[nH]cc(-c4ccc(OC)c(OC)c4)c3c2)cc1OC		CHEMBL3102948	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	INH	%	100.0
	15037092	CHEMBL3368321	Inhibition of AKT1 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1cc(-c2c[nH]c3ncc(-c4cccc(N)c4)cc23)cc(OC)c1OC		CHEMBL3319457	=	Inhibition	%	87.0	CHEMBL4282	Homo sapiens	INH	%	87.0
	15037093	CHEMBL3368321	Inhibition of AKT1 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2c[nH]c3ncc(-c4ccc(C(=O)N5CCOCC5)c(N)c4)cc23)cc1OC		CHEMBL3319467	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	INH	%	100.0
	15037094	CHEMBL3368321	Inhibition of AKT1 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2c[nH]c3ncc(-c4cc(OC)c(OC)c(OC)c4)cc23)cc1OC		CHEMBL3319468	=	Inhibition	%	98.0	CHEMBL4282	Homo sapiens	INH	%	98.0
	15037095	CHEMBL3368321	Inhibition of AKT1 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2cnc3[nH]cc(-c4ccc(OC)c(OC)c4)c3c2)cc1N		CHEMBL3319470	=	Inhibition	%	92.0	CHEMBL4282	Homo sapiens	INH	%	92.0
	15053965	CHEMBL3369600	Inhibition of AKT1 (unknown origin)	B	Clc1ccc(-c2ccc(-c3nccn3-c3ccc(N4CCNCC4)cc3)o2)cc1		CHEMBL3314140	>	IC50	nM	15000.0	CHEMBL4282	Homo sapiens	IC50	uM	15.0
	15055294	CHEMBL3380460	Inhibition of human recombinant AKT1 using GSK3/14-27 substrate	B	COc1cc(-c2nc(-c3c[nH]c4ccccc34)c[nH]c2=O)cc(OC)c1OC		CHEMBL3358966	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
Active	15071549	CHEMBL3390047	Inhibition of EGF-induced AKT phosphorylation in human MCF7 cells at 1 uM by ELISA	B	CCN(CC)CCO/N=C(\c1ccc(SC)cc1)c1cccc2ccccc12.O=C(O)C(=O)O		CHEMBL3356484		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	15071550	CHEMBL3390048	Inhibition of EGF-induced AKT phosphorylation in human MDA-MB-231 cells at 1 uM by ELISA	B	CCN(CC)CCO/N=C(\c1ccc(SC)cc1)c1cccc2ccccc12.O=C(O)C(=O)O		CHEMBL3356484		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	15071557	CHEMBL3390055	Inhibition of basal level AKT phosphorylation in human MCF7 cells at 1 uM by ELISA	B	CCN(CC)CCO/N=C(\c1ccc(SC)cc1)c1cccc2ccccc12.O=C(O)C(=O)O		CHEMBL3356484		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	15071558	CHEMBL3390056	Inhibition of basal level AKT phosphorylation in human MDA-MB-231 cells at 1 uM by ELISA	B	CCN(CC)CCO/N=C(\c1ccc(SC)cc1)c1cccc2ccccc12.O=C(O)C(=O)O		CHEMBL3356484		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	15072480	CHEMBL3379515	Inhibition of PKBalpha (unknown origin) assessed as remaining enzyme activity at 10 uM by radioactive [33P]-ATP filter binding assay	B	Cc1ccc(-c2cc(C(=O)Nc3ccnc(Cl)c3)nn2-c2ccc3ccccc3n2)cc1		CHEMBL3338802	=	Activity	%	90.0	CHEMBL4282	Homo sapiens	Activity	%	90.0
	15080990	CHEMBL3384751	Inhibition of Akt1 PH domain (unknown origin)	B	CC(C)(N)c1ccc(-c2nc3ccccc3nc2-c2ccccc2)cc1	Outside typical range	CHEMBL362455	>	IC50	nM	250000.0	CHEMBL4282	Homo sapiens	IC50	uM	250.0
	15080991	CHEMBL3384750	Inhibition of Akt1 (unknown origin)	B	CC(C)(N)c1ccc(-c2nc3ccccc3nc2-c2ccccc2)cc1		CHEMBL362455	=	IC50	nM	3400.0	CHEMBL4282	Homo sapiens	IC50	uM	3.4
	15091122	CHEMBL3390657	Inhibition of human recombinant Akt1/PKBalpha expressed insect cells using CKRREILSRRPSYRK substrate assessed as remaining enzyme activity at 1 uM after 60 mins relative to control	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Br)c(O)c(Br)c1		CHEMBL2206014	=	Activity	%	87.0	CHEMBL4282	Homo sapiens	Activity	%	87.0
	15107867	CHEMBL3385203	Inhibition of wild type AKT1 (unknown origin) incubated for 5 mins by HTRF assay	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN(C)C		CHEMBL3357634	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	15116483	CHEMBL3376471	Inhibition of AKT1 (unknown origin)	B	CC(=O)c1ccc(N2CCN(C(=O)CN3CC[C@@H](C(=O)Nc4ccc(O)c(Cl)c4)C3)CC2)cc1		CHEMBL3356117	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	uM	30.0
	15122493	CHEMBL3367699	Inhibition of human PKBalpha assessed as residual activity at 10 uM by KinaseProfiler assay	B	CCOC(=O)C1=C(C)N=c2s/c(=C\c3ccc(O)c(O)c3)c(=O)n2C1c1ccc(Cl)cc1		CHEMBL3331445	=	Activity	%	90.0	CHEMBL4282	Homo sapiens	Activity	%	90.0
	15126970	CHEMBL3367699	Inhibition of human PKBalpha assessed as residual activity at 10 uM by KinaseProfiler assay	B	CCOC(=O)C1=C(C)N=c2s/c(=C\c3cc(O)c(O)c(O)c3)c(=O)n2C1c1ccc(Cl)cc1		CHEMBL3331446	=	Activity	%	50.0	CHEMBL4282	Homo sapiens	Activity	%	50.0
	15127002	CHEMBL3367699	Inhibition of human PKBalpha assessed as residual activity at 10 uM by KinaseProfiler assay	B	Brc1c(Br)c(Br)c2[nH]nnc2c1Br		CHEMBL177820	=	Activity	%	61.0	CHEMBL4282	Homo sapiens	Activity	%	61.0
	15149185	CHEMBL3395787	Inhibition of AKT1 (PKBa) (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay	B	CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(Sc3cccc(I)n3)n2C2CCCCC2)ccn1		CHEMBL3394118	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	15149186	CHEMBL3395787	Inhibition of AKT1 (PKBa) (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay	B	COC(Cn1c(SC2CCC(C(=O)O)CC2O)nc(-c2ccc(F)cc2)c1-c1ccnc(NC(C)=O)c1)OC		CHEMBL3394112	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	15149187	CHEMBL3395787	Inhibition of AKT1 (PKBa) (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay	B	CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(S/C=C\C(=O)O)n2CC2CCCO2)ccn1		CHEMBL3394108	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	15149188	CHEMBL3395787	Inhibition of AKT1 (PKBa) (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay	B	CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(S/C=C\C(=O)O)n2C2CCCCC2)ccn1		CHEMBL3394105	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	15149189	CHEMBL3395787	Inhibition of AKT1 (PKBa) (unknown origin) at 5.5 uM by Caliper Mobility Shift Assay	B	CC(=O)Nc1cc(-c2c(-c3ccc(F)cc3)nc(S/C=C\C(=O)O)n2C2CC2)ccn1		CHEMBL3394102	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	15160284	CHEMBL3398960	Inhibition of recombinant N-terminal His-tagged AKT1 (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) using Ser/Thr 6 peptide substrate by Z'-LYTE kinase assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	17.6	CHEMBL4282	Homo sapiens	IC50	nM	17.6
	15160321	CHEMBL3399037	Inhibition of recombinant N-terminal His-tagged AKT1 (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) at 2 uM using Ser/Thr 6 peptide substrate by Z'-LYTE kinase assay	B	Cc1cccc2c(C3=C(c4nnc5ccccn45)C(=O)NC3=O)cn(C)c12		CHEMBL3398192	=	Inhibition	%	13.2	CHEMBL4282	Homo sapiens	INH	%	13.2
	15160322	CHEMBL3399037	Inhibition of recombinant N-terminal His-tagged AKT1 (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) at 2 uM using Ser/Thr 6 peptide substrate by Z'-LYTE kinase assay	B	Cn1cc(C2=C(c3nnc4ccccn34)C(=O)NC2=O)c2cc(Cl)ccc21		CHEMBL3398195	=	Inhibition	%	24.0	CHEMBL4282	Homo sapiens	INH	%	24.0
	15160323	CHEMBL3399037	Inhibition of recombinant N-terminal His-tagged AKT1 (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) at 2 uM using Ser/Thr 6 peptide substrate by Z'-LYTE kinase assay	B	Cn1cc(C2=C(c3nnc4ccccn34)C(=O)NC2=O)c2cc(Br)ccc21		CHEMBL3398197	=	Inhibition	%	6.1	CHEMBL4282	Homo sapiens	INH	%	6.1
	15160324	CHEMBL3399037	Inhibition of recombinant N-terminal His-tagged AKT1 (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) at 2 uM using Ser/Thr 6 peptide substrate by Z'-LYTE kinase assay	B	CCCCn1cc(C2=C(c3nnc4ccccn34)C(=O)NC2=O)c2ccccc21		CHEMBL3398201	=	Inhibition	%	4.2	CHEMBL4282	Homo sapiens	INH	%	4.2
	15160325	CHEMBL3399037	Inhibition of recombinant N-terminal His-tagged AKT1 (unknown origin) expressed in Escherichia coli strain BL21-Codon Plus (DE3) at 2 uM using Ser/Thr 6 peptide substrate by Z'-LYTE kinase assay	B	CC(C)n1cc(C2=C(c3nnc4ccccn34)C(=O)NC2=O)c2ccccc21		CHEMBL3398202	=	Inhibition	%	12.5	CHEMBL4282	Homo sapiens	INH	%	12.5
	15190931	CHEMBL3412788	Inhibition of AKT1 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1NC(=S)Nc1ccccc1		CHEMBL3408381	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	15190932	CHEMBL3412788	Inhibition of AKT1 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=c1\sc(-c2ccccc2)nn1-c1ccccc1		CHEMBL3408382	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	15190933	CHEMBL3412788	Inhibition of AKT1 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	CC(=O)c1nn(-c2ccccc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1		CHEMBL3408383	=	Inhibition	%	23.0	CHEMBL4282	Homo sapiens	INH	%	23.0
	15190934	CHEMBL3412788	Inhibition of AKT1 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	CC(=O)c1nn(-c2ccc(C)cc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1		CHEMBL3408384	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	INH	%	12.0
	15190935	CHEMBL3412788	Inhibition of AKT1 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	COc1ccc(-n2nc(C(C)=O)s/c2=N\c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)cc1		CHEMBL3408385	=	Inhibition	%	14.0	CHEMBL4282	Homo sapiens	INH	%	14.0
	15190936	CHEMBL3412788	Inhibition of AKT1 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	CC(=O)c1nn(-c2ccc(Cl)cc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1		CHEMBL3408386	=	Inhibition	%	24.0	CHEMBL4282	Homo sapiens	INH	%	24.0
	15190937	CHEMBL3412788	Inhibition of AKT1 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	CCOC(=O)c1nn(-c2ccccc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1		CHEMBL3408387	=	Inhibition	%	23.0	CHEMBL4282	Homo sapiens	INH	%	23.0
	15190938	CHEMBL3412788	Inhibition of AKT1 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	CCOC(=O)c1nn(-c2ccc(C)cc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1		CHEMBL3408388	=	Inhibition	%	21.0	CHEMBL4282	Homo sapiens	INH	%	21.0
	15190939	CHEMBL3412788	Inhibition of AKT1 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	CCOC(=O)c1nn(-c2ccc(Cl)cc2)/c(=N/c2nc(-c3ccccc3)cc(-c3ccccc3)c2C#N)s1		CHEMBL3408389	=	Inhibition	%	31.0	CHEMBL4282	Homo sapiens	INH	%	31.0
	15190940	CHEMBL3412788	Inhibition of AKT1 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=c1\sc(C(=O)Nc2ccccc2)nn1-c1ccccc1		CHEMBL3408390	=	Inhibition	%	34.0	CHEMBL4282	Homo sapiens	INH	%	34.0
	15190941	CHEMBL3412788	Inhibition of AKT1 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=C1\SCC(=O)N1c1ccccc1		CHEMBL3408391	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	15190942	CHEMBL3412788	Inhibition of AKT1 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=c1\scc(-c2ccccc2)n1-c1ccccc1		CHEMBL3408392	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	15190943	CHEMBL3412788	Inhibition of AKT1 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=C1\S/C(=C2\SC(c3ccccc3)=NN2c2ccccc2)C(=O)N1c1ccccc1		CHEMBL3408393	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	INH	%	12.0
	15190944	CHEMBL3412788	Inhibition of AKT1 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	CC(=O)C1=NN(c2ccccc2)/C(=C2/S/C(=N\c3nc(-c4ccccc4)cc(-c4ccccc4)c3C#N)N(c3ccccc3)C2=O)S1		CHEMBL3408394	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	15190945	CHEMBL3412788	Inhibition of AKT1 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	CCOC(=O)C1=NN(c2ccccc2)/C(=C2/S/C(=N\c3nc(-c4ccccc4)cc(-c4ccccc4)c3C#N)N(c3ccccc3)C2=O)S1		CHEMBL3408395	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	15190946	CHEMBL3412788	Inhibition of AKT1 (unknown origin) assessed as inhibition of peptide phosphorylation at 30 uM by based microfluidic mobility shift assay	B	N#Cc1c(-c2ccccc2)cc(-c2ccccc2)nc1/N=C1\S/C(=C2\SC(C(=O)Nc3ccccc3)=NN2c2ccccc2)C(=O)N1c1ccccc1		CHEMBL3408396	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
Not Active	15217642	CHEMBL3419836	Inhibition of PKBalpha (unknown origin) assessed as reduction in kinase activity at 10 uM using ATP	B	COCCCNC(=O)c1sc2ncnc(Nc3cc(C)cn(C)c3=O)c2c1C		CHEMBL3417204		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	15217643	CHEMBL3419836	Inhibition of PKBalpha (unknown origin) assessed as reduction in kinase activity at 10 uM using ATP	B	COCCn1cc(C)cc(Nc2ncnc3sc(C(=O)O)c(C)c23)c1=O		CHEMBL3417199		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	15217644	CHEMBL3419836	Inhibition of PKBalpha (unknown origin) assessed as reduction in kinase activity at 10 uM using ATP	B	Cc1cc(Nc2ncnc3sc(C(=O)O)c(C)c23)c(=O)n(C)c1		CHEMBL3417198		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	15224295	CHEMBL3420129	Inhibition of AKT protein phosphorylation in FU-resistant human HCT8 cells at 1 uM incubated for 24 hrs by Western blotting method	B	COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@](C)(CC[C@H]4C(C)(C)C(=O)C(C#N)=C[C@]34C)[C@]1(C)CC2		CHEMBL1762621		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	15224296	CHEMBL3420128	Inhibition of AKT protein phosphorylation in human HCT8 cells at 1 uM incubated for 24 hrs by Western blotting method	B	COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@](C)(CC[C@H]4C(C)(C)C(=O)C(C#N)=C[C@]34C)[C@]1(C)CC2		CHEMBL1762621		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	15224303	CHEMBL3420121	Inhibition of AKT protein phosphorylation in FU-resistant human HCT8 cells at 0.25 to 1 uM incubated for 24 hrs by Western blotting method	B	CC1(C)CC[C@]2(C(=O)NCC(=O)OCC#CCOc3no[n+]([O-])c3S(=O)(=O)c3ccccc3)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]3(C)CC[C@H]3C(C)(C)C(=O)C(C#N)=C[C@]43C)[C@@H]2C1		CHEMBL3417569		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	15224304	CHEMBL3420120	Inhibition of AKT protein phosphorylation in human HCT8 cells at 0.25 to 1 uM incubated for 24 hrs by Western blotting method	B	CC1(C)CC[C@]2(C(=O)NCC(=O)OCC#CCOc3no[n+]([O-])c3S(=O)(=O)c3ccccc3)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]3(C)CC[C@H]3C(C)(C)C(=O)C(C#N)=C[C@]43C)[C@@H]2C1		CHEMBL3417569		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	15228357	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	CC(C)CCCC1(C)CCc2cc(S(N)(=O)=O)cc(Br)c2O1		CHEMBL3414688	=	Kd	nM	220.0	CHEMBL4282	Homo sapiens	Kd	uM	0.22
	15228358	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	CC(C)CCCC1(C)CCc2cc(S(N)(=O)=O)cc(F)c2O1		CHEMBL3414687	=	Kd	nM	350.0	CHEMBL4282	Homo sapiens	Kd	uM	0.35
	15228359	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	Cc1c(S(N)(=O)=O)cc2c(c1C)OC(C)(CCCC(C)C)CC2		CHEMBL3414686	=	Kd	nM	200.0	CHEMBL4282	Homo sapiens	Kd	uM	0.2
	15228360	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	CC(C)CCCC1(C)CCc2cc(N)ccc2O1		CHEMBL3414685	=	Kd	nM	210.0	CHEMBL4282	Homo sapiens	Kd	uM	0.21
	15228361	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	Cc1cc(O)cc2c1NC(C)(CCCC(C)C)CC2		CHEMBL3414684	=	Kd	nM	30.0	CHEMBL4282	Homo sapiens	Kd	uM	0.03
	15228362	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	CC(C)CCCC1(C)CCc2ccc(O)c(O)c2O1		CHEMBL3414683	=	Kd	nM	980.0	CHEMBL4282	Homo sapiens	Kd	uM	0.98
	15228363	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	CC(C)CCCC1(C)CCc2c(O)cccc2O1		CHEMBL3414682	=	Kd	nM	340.0	CHEMBL4282	Homo sapiens	Kd	uM	0.34
	15228364	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	CC(C)CCCC1(C)CCc2cc(O)cc(Br)c2O1		CHEMBL3414681	=	Kd	nM	390.0	CHEMBL4282	Homo sapiens	Kd	uM	0.39
	15228365	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	CC(C)CCCC1(C)CCc2cc(O)cc(F)c2O1		CHEMBL3414680	=	Kd	nM	340.0	CHEMBL4282	Homo sapiens	Kd	uM	0.34
	15228366	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	COc1cc(O)cc2c1OC(C)(CCCC(C)C)CC2		CHEMBL3414679	=	Kd	nM	1880.0	CHEMBL4282	Homo sapiens	Kd	uM	1.88
	15228367	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	CC(C)CCCC1(C)CCc2cc(O)cc(O)c2O1		CHEMBL3414678	=	Kd	nM	1180.0	CHEMBL4282	Homo sapiens	Kd	uM	1.18
	15228368	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	CC(C)CCCC1(C)CCc2cc(O)cc(C(F)(F)F)c2O1		CHEMBL3414677	=	Kd	nM	450.0	CHEMBL4282	Homo sapiens	Kd	uM	0.45
	15228369	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	CC(C)CCCC1(C)CC(=O)c2cc(O)ccc2O1		CHEMBL3414676	=	Kd	nM	280.0	CHEMBL4282	Homo sapiens	Kd	uM	0.28
	15228370	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	Cc1cc(O)cc2c1OC(C)(CCCC(C)C)CC2=O		CHEMBL3414675	=	Kd	nM	320.0	CHEMBL4282	Homo sapiens	Kd	uM	0.32
	15228371	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	Cc1c(O)cc2c(c1C)OC(C)(CCCC(C)C)CC2=O		CHEMBL3414674	=	Kd	nM	410.0	CHEMBL4282	Homo sapiens	Kd	uM	0.41
	15228372	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	CC(C)CCCC1(C)CCc2cc(O)ccc2O1		CHEMBL3414673	=	Kd	nM	350.0	CHEMBL4282	Homo sapiens	Kd	uM	0.35
	15228373	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	Cc1cc(O)cc2c1OC(C)(CCCC(C)C)CC2		CHEMBL3414672	=	Kd	nM	410.0	CHEMBL4282	Homo sapiens	Kd	uM	0.41
	15228374	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	COc1cc2c(c(C)c1C)OC(C)(CCCC(C)C)CC2		CHEMBL3414671	=	Kd	nM	8500.0	CHEMBL4282	Homo sapiens	Kd	uM	8.5
	15228375	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	Cc1c(O)cc2c(c1C)OC(C)(CCCC(C)C)CC2		CHEMBL3414670	=	Kd	nM	520.0	CHEMBL4282	Homo sapiens	Kd	uM	0.52
	15228376	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	Cc1c(O)cc2c(c1C)O[C@](C)(CCCC(C)C)CC2		CHEMBL3414669	=	Kd	nM	540.0	CHEMBL4282	Homo sapiens	Kd	uM	0.54
Not Determined	15228377	CHEMBL3419779	Binding affinity to GST-tagged PH domain of AKT (unknown origin) by surface Plasmon resonance spectroscopy	B	Cc1c(O)cc2c(c1C)O[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC2		CHEMBL2151591		Kd			CHEMBL4282	Homo sapiens	Kd		
	15249269	CHEMBL3428299	Inhibition of human AKT1 using KGSGSGRPRTSSFAEG peptide substrate at 1 uM by 33P Hotspot assay	B	CN1CCN(c2ccc(Nc3ncc(Cl)c(NC[C@H]4CCCO4)n3)cc2)CC1		CHEMBL3426891	=	Inhibition	%	4.7	CHEMBL4282	Homo sapiens	INH	%	4.7
	15251837	CHEMBL3428244	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL443738	=	Activity	%	82.0	CHEMBL4282	Homo sapiens	Activity	%	82.0
	15251960	CHEMBL3428244	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427170	=	Activity	%	28.0	CHEMBL4282	Homo sapiens	Activity	%	28.0
	15252062	CHEMBL3428244	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427171	=	Activity	%	84.0	CHEMBL4282	Homo sapiens	Activity	%	84.0
	15252707	CHEMBL3428244	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427172	=	Activity	%	80.0	CHEMBL4282	Homo sapiens	Activity	%	80.0
	15252809	CHEMBL3428244	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@@H](C(=O)O)CS3)sc2c1		CHEMBL3427173	=	Activity	%	68.0	CHEMBL4282	Homo sapiens	Activity	%	68.0
	15252911	CHEMBL3428244	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@H](C(=O)O)CS3)sc2c1		CHEMBL3427174	=	Activity	%	78.0	CHEMBL4282	Homo sapiens	Activity	%	78.0
	15253201	CHEMBL3430009	Inhibition of human PKBalpha	B	CCn1nc(C#Cc2cc(C(=O)Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)ccc2C)c2c(N)ncnc21		CHEMBL3426225	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	15253585	CHEMBL3428244	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@H]1CSC(c2nc3ccc(OC)cc3s2)=N1		CHEMBL3427175	=	Activity	%	79.0	CHEMBL4282	Homo sapiens	Activity	%	79.0
	15253687	CHEMBL3428244	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@@H]1CSC(c2nc3ccc(OC)cc3s2)=N1		CHEMBL3427176	=	Activity	%	90.0	CHEMBL4282	Homo sapiens	Activity	%	90.0
	15253789	CHEMBL3428244	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@@H](C(=O)O)C(C)(C)S3)sc2c1		CHEMBL3427177	=	Activity	%	78.0	CHEMBL4282	Homo sapiens	Activity	%	78.0
	15254455	CHEMBL3428244	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@H](C(=O)O)C(C)(C)S3)sc2c1		CHEMBL3427178	=	Activity	%	48.0	CHEMBL4282	Homo sapiens	Activity	%	48.0
	15254557	CHEMBL3428244	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	CC1(C)SC(c2nc3ccc(O)cc3s2)=N[C@H]1C(=O)O		CHEMBL3427179	=	Activity	%	94.0	CHEMBL4282	Homo sapiens	Activity	%	94.0
	15255247	CHEMBL3428244	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	CC1(C)SC(c2nc3ccc(O)cc3s2)=N[C@@H]1C(=O)O		CHEMBL3427180	=	Activity	%	88.0	CHEMBL4282	Homo sapiens	Activity	%	88.0
	15255350	CHEMBL3428244	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2ccc3cc(O)ccc3n2)=N1		CHEMBL3427181	=	Activity	%	94.0	CHEMBL4282	Homo sapiens	Activity	%	94.0
	15255452	CHEMBL3428244	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2ccc3cc(O)ccc3n2)=N1		CHEMBL3427182	=	Activity	%	93.0	CHEMBL4282	Homo sapiens	Activity	%	93.0
	15256184	CHEMBL3428244	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2ccc3cccc(O)c3n2)=N1		CHEMBL3427183	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	15256286	CHEMBL3428244	Inhibition of PKBalpha (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2ccc3cccc(O)c3n2)=N1		CHEMBL3427184	=	Activity	%	84.0	CHEMBL4282	Homo sapiens	Activity	%	84.0
tde	15468171	CHEMBL3540286	Induction of AKT phosphorylation at Ser473 in neonatal HDF at 10 uM by Western blot analysis	B	CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@]12C		CHEMBL398412		Activity			CHEMBL4282	Homo sapiens	Activity		
	15649112	CHEMBL3595097	Inhibition of AKT1 (unknown origin)	B	N#Cc1ccc(N2CC[C@@H](Nc3c(C(N)=O)cnc4[nH]ccc34)[C@@H](F)C2)nc1		CHEMBL3593777	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
	15650175	CHEMBL3595495	Inhibition of human AKT1 at 0.1 uM relative to control	B	CCc1cc(NC(=O)Nc2ccc(-c3cnc(Nc4cc(N5CCN(CC)CC5)nc(C)n4)s3)cc2)no1		CHEMBL3593290	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	15654937	CHEMBL3599519	Inhibition of PKBalpha (unknown origin) at 0.5 uM relative to control	B	Nc1nccc(-c2c[nH]c3ccccc23)n1		CHEMBL48082	=	Inhibition	%	22.3	CHEMBL4282	Homo sapiens	INH	%	22.3
	15654938	CHEMBL3599519	Inhibition of PKBalpha (unknown origin) at 0.5 uM relative to control	B	Nc1nccc(-c2cn(C(=O)N3CCOCC3)c3ccc(Br)cc23)n1		CHEMBL3133762	=	Inhibition	%	16.4	CHEMBL4282	Homo sapiens	INH	%	16.4
	15654939	CHEMBL3599519	Inhibition of PKBalpha (unknown origin) at 0.5 uM relative to control	B	Cc1noc(C)c1Cn1cc(-c2ccnc(N)n2)c2ccccc21		CHEMBL3133770	=	Inhibition	%	10.9	CHEMBL4282	Homo sapiens	INH	%	10.9
Active	15664486	CHEMBL3599554	Inhibition of Akt PH domain (unknown origin) binding to PI(3,4)P2 at 100 uM by lipid overlay assay	B	O=C(NC(=S)Nc1cc([N+](=O)[O-])cc(Cl)c1O)c1ccccc1		CHEMBL3596523		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	15664525	CHEMBL3599554	Inhibition of Akt PH domain (unknown origin) binding to PI(3,4)P2 at 100 uM by lipid overlay assay	B	O=C(c1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cn(-c2cc(Cl)ccc2O)nn1		CHEMBL3596540		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	15665854	CHEMBL3602850	Inhibition of recombinant AKT1 (unknown origin) at 1 uM after 3 hrs	B	CS(=O)(=O)NCc1ccc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nn12		CHEMBL3601472	=	Inhibition	%	-1.0	CHEMBL4282	Homo sapiens	INH	%	-1.0
	15685870	CHEMBL3607946	Inhibition of human AKT1	B	NC(=O)c1cc(F)cc2c1C(=O)N(C1CCN(C3CCC(F)(F)CC3)CC1)C2		CHEMBL3606021	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
Active	15701744	CHEMBL3615410	Inhibition of AKT phosphorylation in human NCI-H1650 cells at 20 to 40 uM after 12 hrs by Western blot analysis	B	O=S(=O)(NCCN1c2ccccc2Sc2ccc(Cl)cc21)c1ccc(Cl)cc1		CHEMBL3612697		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	15702390	CHEMBL3615410	Inhibition of AKT phosphorylation in human NCI-H1650 cells at 20 to 40 uM after 12 hrs by Western blot analysis	B	O=S(=O)(NCCCN1c2ccccc2CCc2ccc(Cl)cc21)c1ccc(OC(F)(F)F)cc1		CHEMBL3612693		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	15702485	CHEMBL3615410	Inhibition of AKT phosphorylation in human NCI-H1650 cells at 20 to 40 uM after 12 hrs by Western blot analysis	B	CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1		CHEMBL422		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	15710558	CHEMBL3615480	Inhibition of AKT1 (unknown origin) by radiometric assay	B	Cc1c[nH]c2ncnc(N3CCC(CN)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c12		CHEMBL3356433	<	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	15710559	CHEMBL3615480	Inhibition of AKT1 (unknown origin) by radiometric assay	B	COC(=O)c1cccc(NC(=O)C2(CN(C)C)CCN(c3ncnc4[nH]c(C)c(C)c34)CC2)c1		CHEMBL3613623	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
	15710560	CHEMBL3615480	Inhibition of AKT1 (unknown origin) by radiometric assay	B	Cc1[nH]c2ncnc(N3CCC(CN(C)C)(C(=O)Nc4cccc(OC(=O)N(C)C)c4)CC3)c2c1C		CHEMBL3613624	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
	15723361	CHEMBL3619880	Inhibition of AKT1 (unknown origin) at 10 uM after 40 mins by scintillation counting analysis	B	Cc1ccc(NC(=O)c2cc(N3CCN(C)CC3)cc(C(F)(F)F)c2)cc1NC(=O)c1cnoc1C		CHEMBL3616960	=	Inhibition	%	5.73	CHEMBL4282	Homo sapiens	INH	%	5.73
Not Active	15723362	CHEMBL3619880	Inhibition of AKT1 (unknown origin) at 10 uM after 40 mins by scintillation counting analysis	B	Cc1ccccc1C(=O)Nc1cnoc1C		CHEMBL3616990		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	15723421	CHEMBL3620015	Inhibition of AKT1 (unknown origin) after 40 mins by scintillation counting analysis	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	4.62	CHEMBL4282	Homo sapiens	IC50	nM	4.62
Active	15742887	CHEMBL3626274	Inhibition of AKT phosphorylation at Ser473, Thr308 in human Jurkat cells at 0.1 to 1 uM after 24 hrs by Western blot analysis	B	O=C(C1CC1)n1ccc2c3c(=O)cc(-c4ccccc4)[nH]c3ccc21		CHEMBL3623601		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	15753781	CHEMBL3630456	Inhibition of human Akt1 at 10 uM by kinase inhibition assay	B	Clc1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2SC3)cc1		CHEMBL3628818	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	15753864	CHEMBL3630456	Inhibition of human Akt1 at 10 uM by kinase inhibition assay	B	COc1ccc(Nc2ncc3c(n2)-c2ccccc2SC3)cc1		CHEMBL3628537	=	Inhibition	%	1.4	CHEMBL4282	Homo sapiens	INH	%	1.4
	15753940	CHEMBL3630456	Inhibition of human Akt1 at 10 uM by kinase inhibition assay	B	COc1ccc2c(c1)SCc1cnc(-c3ccccc3)nc1-2		CHEMBL481789	=	Inhibition	%	-4.0	CHEMBL4282	Homo sapiens	INH	%	-4.0
	15753959	CHEMBL3630466	Inhibition of human Akt1 by kinase inhibition assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	10'-8M	1.2
	15754277	CHEMBL3631703	Inhibition of AKT1 (unknown origin) at 1 uM by FRET method	B	N#Cc1ccnc(Nc2cc(C3CCN(C4COC4)CC3)n(C3CCCC3)n2)c1		CHEMBL3629013	=	Inhibition	%	-3.6	CHEMBL4282	Homo sapiens	INH	%	-3.6
	15756119	CHEMBL3631609	Inhibition of AKT1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	3.36	CHEMBL4282	Homo sapiens	INH	%	3.36
Not Active	15756575	CHEMBL3632145	Modulation of Akt phosphorylation in human U251MG cells at 5 uM after 0.5 to 24 hrs by immunoblot analysis	B	C/C=C(\C)C(=O)O[C@H]1C[C@@H](C)[C@]2(O)CC[C@](C)(/C=C3/OC(=O)C(COC(C)=O)=C31)O2		CHEMBL2062865		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	15756576	CHEMBL3632145	Modulation of Akt phosphorylation in human U251MG cells at 5 uM after 0.5 to 24 hrs by immunoblot analysis	B	C/C=C(\C)C(=O)O[C@H]1C[C@@H](C)[C@]2(OC)CC[C@](C)(/C=C3/OC(=O)C(COC(C)=O)=C31)O2		CHEMBL2062868		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	15756577	CHEMBL3632145	Modulation of Akt phosphorylation in human U251MG cells at 5 uM after 0.5 to 24 hrs by immunoblot analysis	B	C/C=C(/C)C(=O)O[C@H]1C[C@@H](C)[C@]2(O)CC[C@](C)(/C=C3/OC(=O)C(COC(C)=O)=C31)O2		CHEMBL3628030		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	15756578	CHEMBL3632145	Modulation of Akt phosphorylation in human U251MG cells at 5 uM after 0.5 to 24 hrs by immunoblot analysis	B	C/C=C(\C)C(=O)OCC1=C2/C(=C\[C@@]3(C)CC[C@](O)(O3)[C@H](C)C[C@@H]2O)OC1=O		CHEMBL3628032		Activity			CHEMBL4282	Homo sapiens	Activity		
	15757714	CHEMBL3631609	Inhibition of AKT1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	4.64	CHEMBL4282	Homo sapiens	INH	%	4.64
	15757980	CHEMBL3631609	Inhibition of AKT1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	4.96	CHEMBL4282	Homo sapiens	INH	%	4.96
234067	16258426	CHEMBL3706030	Fluorescence Polarization Assay: In order to identify compounds that disrupt the interaction between PIP3 and PH domains, a high-throughput fluorescence polarization (FP)-binding assay was developed using recombinant 1-123 amino acid N-terminal fragment of human Akt1 (also referred to herein simply as Akt), encompassing the PH domain (PH123 protein), and fluorescent NBD-labeled PIP3 molecule. The amino acid sequence of human Akt1 is publicly available as, for example, GenBank Accession No. NP001014432.1 (SEQ ID NO:1), and the corresponding DNA sequence is publicly available as, for example, GenBank Accession No. NM001014432. Briefly, 5 μM recombinant GST fusion proteins containing 1-123 a.a. N-terminal fragment of human Akt1 (PH 123) or 100 nM 441-551 a.a. region of human PDK1 were incubated with 15 nM TMR-labeled PIP3, PIP2, or PIP5 in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 5 mM b-ME for 15 min at room temperature in the dark.	B	Cc1cc(C)cc(C(=O)NC(=S)Nc2c(O)cc(C(F)(F)F)cc2C(F)(F)F)c1		CHEMBL3693947	=	IC50	nM	20800.0	CHEMBL4282	Homo sapiens	IC50	nM	20800.0
256507	16259826	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccc(-c5ccn[nH]5)cc3-4)cc2)C1		CHEMBL3701762	=	IC50	nM	0.8	CHEMBL4282	Homo sapiens	IC50	nM	0.8
256519	16260143	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccc(C(=O)NCCO)cc3-4)cc2)C1		CHEMBL3701774	=	IC50	nM	2.4	CHEMBL4282	Homo sapiens	IC50	nM	2.4
256461	16262098	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cccc(F)c3-4)cc2)C1		CHEMBL3701718	=	IC50	nM	4.6	CHEMBL4282	Homo sapiens	IC50	nM	4.6
256512	16262803	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccc(C(N)=O)cc3-4)cc2)C1		CHEMBL3701767	=	IC50	nM	1.6	CHEMBL4282	Homo sapiens	IC50	nM	1.6
256497	16265639	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ncccc3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701752	=	IC50	nM	1.4	CHEMBL4282	Homo sapiens	IC50	nM	1.4
256522	16266041	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(O)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccc(C(=O)O)cc3-4)cc2)C1		CHEMBL3701777	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
256460	16267045	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cccc(F)c3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701717	=	IC50	nM	3.7	CHEMBL4282	Homo sapiens	IC50	nM	3.7
256516	16267522	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CN(C)C(=O)c1ccc2c(c1)OCn1c-2nc(-c2ccc(C3(N)CC(C)(O)C3)cc2)c1-c1ccccc1		CHEMBL3701771	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
234064	16268415	CHEMBL3706030	Fluorescence Polarization Assay: In order to identify compounds that disrupt the interaction between PIP3 and PH domains, a high-throughput fluorescence polarization (FP)-binding assay was developed using recombinant 1-123 amino acid N-terminal fragment of human Akt1 (also referred to herein simply as Akt), encompassing the PH domain (PH123 protein), and fluorescent NBD-labeled PIP3 molecule. The amino acid sequence of human Akt1 is publicly available as, for example, GenBank Accession No. NP001014432.1 (SEQ ID NO:1), and the corresponding DNA sequence is publicly available as, for example, GenBank Accession No. NM001014432. Briefly, 5 μM recombinant GST fusion proteins containing 1-123 a.a. N-terminal fragment of human Akt1 (PH 123) or 100 nM 441-551 a.a. region of human PDK1 were incubated with 15 nM TMR-labeled PIP3, PIP2, or PIP5 in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 5 mM b-ME for 15 min at room temperature in the dark.	B	Cc1cc(C)cc(C(=O)NC(=S)Nc2cc([N+](=O)[O-])ccc2O)c1		CHEMBL3596524	=	IC50	nM	27100.0	CHEMBL4282	Homo sapiens	IC50	nM	27100.0
219800	16268760	CHEMBL3705350	Kinase Assay: Activated Akt isoforms and pleckstrin homology domain deletion constructs were assayed utilizing a GSK-derived biotinylated peptide substrate. The extend of peptide was determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide.	B	N=C(c1ccccc1)n1c(=N)ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)cc21		CHEMBL3679633	=	IC50	nM	2.3	CHEMBL4282	Homo sapiens	IC50	nM	2.3
256467	16268844	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccc(F)cc3-4)cc2)C1		CHEMBL3701724	=	IC50	nM	6.4	CHEMBL4282	Homo sapiens	IC50	nM	6.4
219802	16269298	CHEMBL3705350	Kinase Assay: Activated Akt isoforms and pleckstrin homology domain deletion constructs were assayed utilizing a GSK-derived biotinylated peptide substrate. The extend of peptide was determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide.	B	CC(=N)n1c(=N)ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)cc21		CHEMBL3679630	=	IC50	nM	8.2	CHEMBL4282	Homo sapiens	IC50	nM	8.2
256514	16270429	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCNC(=O)c1ccc2c(c1)-c1nc(-c3ccc(C4(N)CC(C)(O)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701769	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
256482	16270536	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCOc1cccc2c1-c1nc(-c3ccc(C4(N)CC(O)(C5CC5)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701738	=	IC50	nM	28.0	CHEMBL4282	Homo sapiens	IC50	nM	28.0
256481	16273574	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cccc(Cl)c3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701737	=	IC50	nM	8.2	CHEMBL4282	Homo sapiens	IC50	nM	8.2
256501	16275675	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3nccnc3-4)cc2)C1		CHEMBL3701756	=	IC50	nM	6.4	CHEMBL4282	Homo sapiens	IC50	nM	6.4
256523	16275757	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(O)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cc(C(=O)O)ccc3-4)cc2)C1		CHEMBL3701778	=	IC50	nM	3.1	CHEMBL4282	Homo sapiens	IC50	nM	3.1
256477	16277635	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	COc1ccc2c(c1)OCn1c-2nc(-c2ccc(C3(N)CC(O)(C4CC4)C3)cc2)c1-c1ccccc1		CHEMBL3701734	=	IC50	nM	3.7	CHEMBL4282	Homo sapiens	IC50	nM	3.7
256480	16278551	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	COc1ccc2c(c1)OCn1c-2nc(-c2ccc(C3(N)CC(C)(O)C3)cc2)c1-c1ccccc1		CHEMBL3701736	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
256471	16279397	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccccc3-4)cc2)C1		CHEMBL3701728	=	IC50	nM	5.3	CHEMBL4282	Homo sapiens	IC50	nM	5.3
256478	16279485	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	COc1cccc2c1-c1nc(-c3ccc(C4(N)CC(O)(C5CC5)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701732	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
256508	16280013	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccc(-c5cn[nH]c5)cc3-4)cc2)C1		CHEMBL3701763	=	IC50	nM	1.3	CHEMBL4282	Homo sapiens	IC50	nM	1.3
256520	16280218	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCONC(=O)c1ccc2c(c1)-c1nc(-c3ccc(C4(N)CC(C)(O)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701775	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
256511	16281589	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CNC(=O)c1ccc2c(c1)-c1nc(-c3ccc(C4(N)CC(C)(O)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701766	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
256492	16283497	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccncc3-4)cc2)CCC1		CHEMBL3701748	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
256509	16285541	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	Cc1cnc2c(c1)OCn1c-2nc(-c2ccc(C3(N)CC(C)(O)C3)cc2)c1-c1ccccc1		CHEMBL3701764	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
256506	16287453	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccc(C#N)cc3-4)cc2)C1		CHEMBL3701761	=	IC50	nM	4.4	CHEMBL4282	Homo sapiens	IC50	nM	4.4
256486	16288423	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cccnc3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701742	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
256515	16288912	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CNC(=O)c1ccc2c(c1)OCn1c-2nc(-c2ccc(C3(N)CC(C)(O)C3)cc2)c1-c1ccccc1		CHEMBL3701770	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
256505	16294889	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cc(C#N)ccc3-4)cc2)C1		CHEMBL3701760	=	IC50	nM	6.2	CHEMBL4282	Homo sapiens	IC50	nM	6.2
234066	16294896	CHEMBL3706030	Fluorescence Polarization Assay: In order to identify compounds that disrupt the interaction between PIP3 and PH domains, a high-throughput fluorescence polarization (FP)-binding assay was developed using recombinant 1-123 amino acid N-terminal fragment of human Akt1 (also referred to herein simply as Akt), encompassing the PH domain (PH123 protein), and fluorescent NBD-labeled PIP3 molecule. The amino acid sequence of human Akt1 is publicly available as, for example, GenBank Accession No. NP001014432.1 (SEQ ID NO:1), and the corresponding DNA sequence is publicly available as, for example, GenBank Accession No. NM001014432. Briefly, 5 μM recombinant GST fusion proteins containing 1-123 a.a. N-terminal fragment of human Akt1 (PH 123) or 100 nM 441-551 a.a. region of human PDK1 were incubated with 15 nM TMR-labeled PIP3, PIP2, or PIP5 in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 5 mM b-ME for 15 min at room temperature in the dark.	B	Cc1cc(C)cc(C(=O)NC(=S)Nc2cc(C(F)(F)F)ccc2O)c1		CHEMBL3693946	=	IC50	nM	22600.0	CHEMBL4282	Homo sapiens	IC50	nM	22600.0
256521	16297843	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cc(C(N)=O)ccc3-4)cc2)C1		CHEMBL3701776	=	IC50	nM	1.3	CHEMBL4282	Homo sapiens	IC50	nM	1.3
256463	16300558	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccsc3)COc3cccc(F)c3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701720	=	IC50	nM	7.1	CHEMBL4282	Homo sapiens	IC50	nM	7.1
256490	16301470	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccncc3-4)cc2)C1		CHEMBL3701746	=	IC50	nM	4.2	CHEMBL4282	Homo sapiens	IC50	nM	4.2
256464	16301914	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccncc3)COc3cccc(F)c3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701721	=	IC50	nM	22.0	CHEMBL4282	Homo sapiens	IC50	nM	22.0
256462	16303293	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cccc(F)c3-4)cc2)CCC1		CHEMBL3701719	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
256465	16303795	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccsc3)COc3cccc(F)c3-4)cc2)C1		CHEMBL3701722	=	IC50	nM	9.8	CHEMBL4282	Homo sapiens	IC50	nM	9.8
234065	16306425	CHEMBL3706030	Fluorescence Polarization Assay: In order to identify compounds that disrupt the interaction between PIP3 and PH domains, a high-throughput fluorescence polarization (FP)-binding assay was developed using recombinant 1-123 amino acid N-terminal fragment of human Akt1 (also referred to herein simply as Akt), encompassing the PH domain (PH123 protein), and fluorescent NBD-labeled PIP3 molecule. The amino acid sequence of human Akt1 is publicly available as, for example, GenBank Accession No. NP001014432.1 (SEQ ID NO:1), and the corresponding DNA sequence is publicly available as, for example, GenBank Accession No. NM001014432. Briefly, 5 μM recombinant GST fusion proteins containing 1-123 a.a. N-terminal fragment of human Akt1 (PH 123) or 100 nM 441-551 a.a. region of human PDK1 were incubated with 15 nM TMR-labeled PIP3, PIP2, or PIP5 in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 5 mM b-ME for 15 min at room temperature in the dark.	B	Cc1cc(C)cc(C(=O)NC(=S)Nc2c(O)cc(C)c(Cl)c2C)c1		CHEMBL3693945	=	IC50	nM	17500.0	CHEMBL4282	Homo sapiens	IC50	nM	17500.0
17442	16307705	CHEMBL3705350	Kinase Assay: Activated Akt isoforms and pleckstrin homology domain deletion constructs were assayed utilizing a GSK-derived biotinylated peptide substrate. The extend of peptide was determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide.	B	N[C@]1(c2ccc(-c3nc4ccc5nnc(C(F)F)n5c4cc3-c3ccccc3)cc2)C[C@](O)(C2CC2)C1		CHEMBL3679636	=	IC50	nM	0.34	CHEMBL4282	Homo sapiens	IC50	nM	0.34
256518	16308026	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCONC(=O)c1ccc2c(c1)OCn1c-2nc(-c2ccc(C3(N)CC(C)(O)C3)cc2)c1-c1ccccc1		CHEMBL3701773	=	IC50	nM	2.1	CHEMBL4282	Homo sapiens	IC50	nM	2.1
256472	16308087	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccccc3-4)cc2)CCC1		CHEMBL3701729	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
256468	16308698	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cc(F)ccc3-4)cc2)C1		CHEMBL3701725	=	IC50	nM	8.5	CHEMBL4282	Homo sapiens	IC50	nM	8.5
256502	16309362	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3nccnc3-4)cc2)C1		CHEMBL3701757	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
256487	16311206	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cccnc3-4)cc2)C1		CHEMBL3701743	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
256504	16313022	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cc(CO)ccc3-4)cc2)C1		CHEMBL3701759	=	IC50	nM	8.6	CHEMBL4282	Homo sapiens	IC50	nM	8.6
256499	16313609	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ncccc3-4)cc2)CCC1		CHEMBL3701754	=	IC50	nM	3.9	CHEMBL4282	Homo sapiens	IC50	nM	3.9
17441	16313735	CHEMBL3705350	Kinase Assay: Activated Akt isoforms and pleckstrin homology domain deletion constructs were assayed utilizing a GSK-derived biotinylated peptide substrate. The extend of peptide was determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide.	B	N[C@]1(c2ccc(-c3nc4ccc5nnc(C6NCNN6)n5c4cc3-c3ccccc3)cc2)C[C@](O)(C2CC2)C1		CHEMBL3679635	=	IC50	nM	0.7	CHEMBL4282	Homo sapiens	IC50	nM	0.7
256517	16316246	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cc(C(=O)NCCO)ccc3-4)cc2)C1		CHEMBL3701772	=	IC50	nM	3.1	CHEMBL4282	Homo sapiens	IC50	nM	3.1
234069	16316648	CHEMBL3706030	Fluorescence Polarization Assay: In order to identify compounds that disrupt the interaction between PIP3 and PH domains, a high-throughput fluorescence polarization (FP)-binding assay was developed using recombinant 1-123 amino acid N-terminal fragment of human Akt1 (also referred to herein simply as Akt), encompassing the PH domain (PH123 protein), and fluorescent NBD-labeled PIP3 molecule. The amino acid sequence of human Akt1 is publicly available as, for example, GenBank Accession No. NP001014432.1 (SEQ ID NO:1), and the corresponding DNA sequence is publicly available as, for example, GenBank Accession No. NM001014432. Briefly, 5 μM recombinant GST fusion proteins containing 1-123 a.a. N-terminal fragment of human Akt1 (PH 123) or 100 nM 441-551 a.a. region of human PDK1 were incubated with 15 nM TMR-labeled PIP3, PIP2, or PIP5 in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 5 mM b-ME for 15 min at room temperature in the dark.	B	Cc1cc(C)cc(C(=O)NC(=S)Nc2cc(-c3ccccc3)ccc2O)c1		CHEMBL3693949	=	IC50	nM	13400.0	CHEMBL4282	Homo sapiens	IC50	nM	13400.0
256491	16317082	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccncc3-4)cc2)C1		CHEMBL3701747	=	IC50	nM	6.6	CHEMBL4282	Homo sapiens	IC50	nM	6.6
256483	16318121	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCOc1cccc2c1-c1nc(-c3ccc(C4(N)CC(C)(O)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701739	=	IC50	nM	30.0	CHEMBL4282	Homo sapiens	IC50	nM	30.0
256475	16320160	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	COc1cccc2c1-c1nc(-c3ccc(C4(N)CC(O)(C5CC5)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701732	=	IC50	nM	4.8	CHEMBL4282	Homo sapiens	IC50	nM	4.8
256484	16324058	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	COc1cc(OC)c2c(c1)OCn1c-2nc(-c2ccc(C3(N)CC(O)(C4CC4)C3)cc2)c1-c1ccccc1		CHEMBL3701740	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
256473	16324115	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccsc3)COc3ccccc3-4)cc2)CCC1		CHEMBL3701730	=	IC50	nM	27.0	CHEMBL4282	Homo sapiens	IC50	nM	27.0
256470	16325514	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccccc3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701727	=	IC50	nM	3.9	CHEMBL4282	Homo sapiens	IC50	nM	3.9
256513	16325900	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CN(C)C(=O)c1ccc2c(c1)-c1nc(-c3ccc(C4(N)CC(C)(O)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701768	=	IC50	nM	4.4	CHEMBL4282	Homo sapiens	IC50	nM	4.4
256476	16327742	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	COc1ccc2c(c1)-c1nc(-c3ccc(C4(N)CC(O)(C5CC5)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701733	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
256503	16333209	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccc(CO)cc3-4)cc2)C1		CHEMBL3701758	=	IC50	nM	2.2	CHEMBL4282	Homo sapiens	IC50	nM	2.2
256495	16335421	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cnccc3-4)cc2)C1		CHEMBL3701750	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
256510	16338302	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	COc1ccc2c(n1)-c1nc(-c3ccc(C4(N)CC(C)(O)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701765	=	IC50	nM	5.5	CHEMBL4282	Homo sapiens	IC50	nM	5.5
256494	16338450	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cnccc3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701749	=	IC50	nM	1.6	CHEMBL4282	Homo sapiens	IC50	nM	1.6
256488	16338934	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cccnc3-4)cc2)CCC1		CHEMBL3701744	=	IC50	nM	35.0	CHEMBL4282	Homo sapiens	IC50	nM	35.0
256466	16339646	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccncc3)COc3cccc(F)c3-4)cc2)C1		CHEMBL3701723	=	IC50	nM	25.0	CHEMBL4282	Homo sapiens	IC50	nM	25.0
256489	16340981	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cccnc3-4)cc2)C1		CHEMBL3701745	=	IC50	nM	33.0	CHEMBL4282	Homo sapiens	IC50	nM	33.0
256479	16342057	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	COc1ccc2c(c1)-c1nc(-c3ccc(C4(N)CC(C)(O)C4)cc3)c(-c3ccccc3)n1CO2		CHEMBL3701735	=	IC50	nM	2.9	CHEMBL4282	Homo sapiens	IC50	nM	2.9
256485	16343794	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	Cc1ccc2c(c1)OCn1c-2nc(-c2ccc(C3(N)CC(O)(C4CC4)C3)cc2)c1-c1ccccc1		CHEMBL3701741	=	IC50	nM	26.0	CHEMBL4282	Homo sapiens	IC50	nM	26.0
219801	16344251	CHEMBL3705350	Kinase Assay: Activated Akt isoforms and pleckstrin homology domain deletion constructs were assayed utilizing a GSK-derived biotinylated peptide substrate. The extend of peptide was determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide.	B	N=C(N)n1c(=N)ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)cc21		CHEMBL3679629	=	IC50	nM	6.1	CHEMBL4282	Homo sapiens	IC50	nM	6.1
219799	16344381	CHEMBL3705350	Kinase Assay: Activated Akt isoforms and pleckstrin homology domain deletion constructs were assayed utilizing a GSK-derived biotinylated peptide substrate. The extend of peptide was determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide.	B	N=c1ccc2nc(-c3ccc(C4(NC(=O)Cc5cccnc5)CCC4)cc3)c(-c3ccccc3)cc2n1C(N)=O		CHEMBL3679634	=	IC50	nM	39.0	CHEMBL4282	Homo sapiens	IC50	nM	39.0
256469	16345644	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3c(F)cccc3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701726	=	IC50	nM	2.3	CHEMBL4282	Homo sapiens	IC50	nM	2.3
234068	16345716	CHEMBL3706030	Fluorescence Polarization Assay: In order to identify compounds that disrupt the interaction between PIP3 and PH domains, a high-throughput fluorescence polarization (FP)-binding assay was developed using recombinant 1-123 amino acid N-terminal fragment of human Akt1 (also referred to herein simply as Akt), encompassing the PH domain (PH123 protein), and fluorescent NBD-labeled PIP3 molecule. The amino acid sequence of human Akt1 is publicly available as, for example, GenBank Accession No. NP001014432.1 (SEQ ID NO:1), and the corresponding DNA sequence is publicly available as, for example, GenBank Accession No. NM001014432. Briefly, 5 μM recombinant GST fusion proteins containing 1-123 a.a. N-terminal fragment of human Akt1 (PH 123) or 100 nM 441-551 a.a. region of human PDK1 were incubated with 15 nM TMR-labeled PIP3, PIP2, or PIP5 in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 5 mM b-ME for 15 min at room temperature in the dark.	B	Cc1cc(C)cc(C(=O)NC(=S)Nc2c(O)cc(C)c(Br)c2C)c1		CHEMBL3693948	=	IC50	nM	18100.0	CHEMBL4282	Homo sapiens	IC50	nM	18100.0
256500	16347838	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3nccnc3-4)cc2)CC(O)(C2CC2)C1		CHEMBL3701755	=	IC50	nM	5.4	CHEMBL4282	Homo sapiens	IC50	nM	5.4
256493	16349150	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CCC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccncc3-4)cc2)C1		CHEMBL3701746	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
256474	16349244	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccncc3)COc3ccccc3-4)cc2)CCC1		CHEMBL3701731	=	IC50	nM	51.0	CHEMBL4282	Homo sapiens	IC50	nM	51.0
256496	16349596	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	NC1(c2ccc(-c3nc4n(c3-c3ccccc3)COc3cnccc3-4)cc2)CCC1		CHEMBL3701751	=	IC50	nM	5.5	CHEMBL4282	Homo sapiens	IC50	nM	5.5
234063	16352115	CHEMBL3706030	Fluorescence Polarization Assay: In order to identify compounds that disrupt the interaction between PIP3 and PH domains, a high-throughput fluorescence polarization (FP)-binding assay was developed using recombinant 1-123 amino acid N-terminal fragment of human Akt1 (also referred to herein simply as Akt), encompassing the PH domain (PH123 protein), and fluorescent NBD-labeled PIP3 molecule. The amino acid sequence of human Akt1 is publicly available as, for example, GenBank Accession No. NP001014432.1 (SEQ ID NO:1), and the corresponding DNA sequence is publicly available as, for example, GenBank Accession No. NM001014432. Briefly, 5 μM recombinant GST fusion proteins containing 1-123 a.a. N-terminal fragment of human Akt1 (PH 123) or 100 nM 441-551 a.a. region of human PDK1 were incubated with 15 nM TMR-labeled PIP3, PIP2, or PIP5 in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 5 mM b-ME for 15 min at room temperature in the dark.	B	O=C(NC(=S)Nc1cc([N+](=O)[O-])cc(Cl)c1O)c1ccccc1		CHEMBL3596523	=	IC50	nM	31000.0	CHEMBL4282	Homo sapiens	IC50	nM	31000.0
219804	16353205	CHEMBL3705350	Kinase Assay: Activated Akt isoforms and pleckstrin homology domain deletion constructs were assayed utilizing a GSK-derived biotinylated peptide substrate. The extend of peptide was determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide.	B	C[C@]1(O)C[C@@](N)(c2ccc(-c3nc4ccc5nnc(C(F)F)n5c4cc3-c3ccccc3)cc2)C1		CHEMBL3679632	=	IC50	nM	0.38	CHEMBL4282	Homo sapiens	IC50	nM	0.38
219803	16353825	CHEMBL3705350	Kinase Assay: Activated Akt isoforms and pleckstrin homology domain deletion constructs were assayed utilizing a GSK-derived biotinylated peptide substrate. The extend of peptide was determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide.	B	N=C(c1ccccc1)n1c(=N)ccc2nc(-c3ccc(C4(N)CC(F)(F)C4)cc3)c(-c3ccccc3)cc21		CHEMBL3679631	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
256498	16355204	CHEMBL3705737	Kinase Inhibition Assay: Preparation of AKT1 and AKT2 and measurement of in vitro inhibitory activity of the above-mentioned compounds against AKT1 and AKT2 kinase activity were carried out with reference to the method disclosed in Biochem. J. Vol. 385, pp 399-408 (2005). In the preparation of AKT1 and AKT2, human AKT1 and AKT2 to which a middle T antigen tag was added were expressed in Sf 9 insect cells, and then AKT1 and AKT2 were prepared following affinity purification and activation by PDK1. The prepared AKT1 and AKT2 were stored at Ã¢ 80C. until the time of measurement of inhibitory activity of the compounds. In the measurement of inhibitory activity of the compounds, AKT1 or AKT2 and each compound of the present invention were preincubated at 25C. for 120 minutes in a buffer solution for reaction (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT). As a substrate, biotinylated Crosstide (bioton-KGSGSGRPRTSSFAEG), MgCl2, and ATP were added to final concentrations.	B	CC1(O)CC(N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ncccc3-4)cc2)C1		CHEMBL3701753	=	IC50	nM	1.4	CHEMBL4282	Homo sapiens	IC50	nM	1.4
	16376433	CHEMBL3734457	Inhibition of recombinant human AKT1 using fluorescein-labeled peptide as substrate by fluorescence-electrophoretic mobility shift assay	B	Cl.NCCN1C(=O)S/C(=C\CCC2CCCCC2)C1=O		CHEMBL3732044	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	16379639	CHEMBL3738548	Inhibition of AKT1 (unknown origin) at 200 nM by electrophoretic mobility shift assay	B	COc1ccc2c(c1CN1CCNCC1)O/C(=C\c1n[nH]c3ncccc13)C2=O		CHEMBL3735816	=	Inhibition	%	-0.2	CHEMBL4282	Homo sapiens	INH	%	-0.2
	16379640	CHEMBL3738548	Inhibition of AKT1 (unknown origin) at 200 nM by electrophoretic mobility shift assay	B	COc1ccc2c(c1C(C)N1CCNCC1)O/C(=C\c1n[nH]c3ncccc13)C2=O		CHEMBL3735890	=	Inhibition	%	1.7	CHEMBL4282	Homo sapiens	INH	%	1.7
Not Active	16388223	CHEMBL3738881	Inhibition of recombinant Akt1 (unknown origin) incubated for 1 hr by Z'Lyte assay	B	COc1cc2c(cc1OC)CN(CC(=O)Nc1ccc3c(c1)/C(=C/c1cnc[nH]1)C(=O)N3)CC2		CHEMBL3091673		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	16388224	CHEMBL3738881	Inhibition of recombinant Akt1 (unknown origin) incubated for 1 hr by Z'Lyte assay	B	CS(=O)(=O)Nc1ccc2c(c1)/C(=C/c1cccs1)C(=O)N2		CHEMBL3735078		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	16388225	CHEMBL3738881	Inhibition of recombinant Akt1 (unknown origin) incubated for 1 hr by Z'Lyte assay	B	CS(=O)(=O)Nc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL3736436		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	16397321	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1c(C(=O)c2coc3c2cc(O)c2ccccc23)[nH]c(-c2ccccc2)c1-c1ccccc1		CHEMBL3740492	=	Inhibition	%	13.0	CHEMBL4282	Homo sapiens	INH	%	13.0
	16397322	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1c(C(=O)c2coc3ccc(O)cc23)[nH]c(-c2ccccc2)c1-c1ccccc1		CHEMBL3741960	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	INH	%	12.0
	16397323	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1-c1ccc(NC(=O)c2ccccc2)c(=O)o1		CHEMBL3740003	=	Inhibition	%	32.0	CHEMBL4282	Homo sapiens	INH	%	32.0
	16397324	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Oc1nnc(-c2c[nH]c(-c3ccccc3)c2-c2ccccc2)c2cn(-c3ccc(Cl)cc3)nc12		CHEMBL3742200	=	Inhibition	%	65.0	CHEMBL4282	Homo sapiens	INH	%	65.0
	16397325	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1ccc(-n2cc3c(-c4c[nH]c(-c5ccccc5)c4-c4ccccc4)nnc(O)c3n2)cc1		CHEMBL3739586	=	Inhibition	%	78.0	CHEMBL4282	Homo sapiens	INH	%	78.0
	16397326	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Oc1nnc(-c2c[nH]c(-c3ccccc3)c2-c2ccccc2)c2cn(-c3ccccc3)nc12		CHEMBL3740923	=	Inhibition	%	90.0	CHEMBL4282	Homo sapiens	INH	%	90.0
	16397327	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1-c1nnc(C)c2nn(-c3ccc(Cl)cc3)cc12		CHEMBL3741655	=	Inhibition	%	42.0	CHEMBL4282	Homo sapiens	INH	%	42.0
	16397328	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1ccc(-n2cc3c(-c4c(C)[nH]c(-c5ccccc5)c4-c4ccccc4)nnc(C)c3n2)cc1		CHEMBL3742060	=	Inhibition	%	56.0	CHEMBL4282	Homo sapiens	INH	%	56.0
	16397329	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1-c1nnc(C)c2nn(-c3ccccc3)cc12		CHEMBL3740582	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	INH	%	12.0
	16397330	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1C(=O)c1cn(-c2ccccc2)nc1-c1ccccc1		CHEMBL3741069	=	Inhibition	%	24.0	CHEMBL4282	Homo sapiens	INH	%	24.0
	16397331	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1C(=O)c1cn(-c2ccc(Cl)cc2)nc1C(=O)Nc1ccccc1		CHEMBL3740385	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	16397332	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1ccc(-n2cc(C(=O)c3c(C)[nH]c(-c4ccccc4)c3-c3ccccc3)c(C(=O)Nc3ccccc3)n2)cc1		CHEMBL3740713	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	INH	%	12.0
	16397333	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1C(=O)c1cn(-c2ccccc2)nc1C(=O)Nc1ccccc1		CHEMBL3740930	=	Inhibition	%	45.0	CHEMBL4282	Homo sapiens	INH	%	45.0
	16397334	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	CCOC(=O)c1nn(-c2ccc(Cl)cc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1		CHEMBL3741526	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	16397335	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	CCOC(=O)c1nn(-c2ccc(C)cc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1		CHEMBL3742349	=	Inhibition	%	46.0	CHEMBL4282	Homo sapiens	INH	%	46.0
	16397336	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	CCOC(=O)c1nn(-c2ccccc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1		CHEMBL3740131	=	Inhibition	%	35.0	CHEMBL4282	Homo sapiens	INH	%	35.0
	16397337	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	CC(=O)c1nn(-c2ccc(Cl)cc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1		CHEMBL3739587	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
	16397338	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	CC(=O)c1nn(-c2ccc(C)cc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1		CHEMBL3740247	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	16397339	CHEMBL3743110	Inhibition of AKT1 (unknown origin) at 30 uM by microfluidic assay relative to control	B	CC(=O)c1nn(-c2ccccc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1		CHEMBL3739750	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
Active	16411813	CHEMBL3743444	Inhibition of EGF-induced AKT phosphorylation at S473 in human MDA-MB-468 cells at 5 uM incubated for 2 hrs followed by stimulation with EGF for 1 hr by Western blot assay	B	CN(C(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)/C=C/c1ccc(C(F)(F)P(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)cc1)C(C)(C)C)c1ccccc1		CHEMBL3741039		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	16411814	CHEMBL3743444	Inhibition of EGF-induced AKT phosphorylation at S473 in human MDA-MB-468 cells at 5 uM incubated for 2 hrs followed by stimulation with EGF for 1 hr by Western blot assay	B	C/C(=C\C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N(C)c1ccccc1)C(C)(C)C)c1ccc(C(F)(F)P(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)cc1		CHEMBL3740136		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	16411815	CHEMBL3743445	Inhibition of EGF-induced AKT phosphorylation at S473 in human MDA-MB-468 cells at 100 nM incubated for 2 hrs followed by stimulation with EGF for 1 hr by Western blot assay	B	CC(C)(C)C(=O)OCOP(=O)(OCOC(=O)C(C)(C)C)C(F)(F)c1ccc(/C=C/C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)Nc2ccccc2)C(C)(C)C)cc1		CHEMBL3741165		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	16413402	CHEMBL3743742	Inhibition of AKT1 (unknown origin)	B	O=C(O)C1CN(Cc2ccc(OCc3ccc(Cl)c(Cl)c3)cc2)C1		CHEMBL3741589	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	16417052	CHEMBL3751441	Inhibition of AKT1 (unknown origin) at 10 uM	B	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCN(S(C)(=O)=O)CC3)nc21		CHEMBL3747699	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	16417053	CHEMBL3751441	Inhibition of AKT1 (unknown origin) at 10 uM	B	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(Nc3ccc(N4CCC(O)CC4)cc3)nc21		CHEMBL3746959	=	Inhibition	%	11.0	CHEMBL4282	Homo sapiens	INH	%	11.0
	16417054	CHEMBL3751441	Inhibition of AKT1 (unknown origin) at 10 uM	B	CN1CCN(CCCNc2ncc3cc(Oc4ccc(F)cc4F)c(=O)n(C)c3n2)CC1		CHEMBL3746022	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	16417055	CHEMBL3751441	Inhibition of AKT1 (unknown origin) at 10 uM	B	CN1CCN(c2ccc(Nc3ncc4cc(Oc5ccc(F)cc5F)c(=O)n(C)c4n3)cc2)CC1		CHEMBL3745734	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	16417056	CHEMBL3751441	Inhibition of AKT1 (unknown origin) at 10 uM	B	Cn1c(=O)c(Oc2c(Cl)cccc2Cl)cc2cnc(NC3CCOCC3)nc21		CHEMBL3747351	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	16417057	CHEMBL3751441	Inhibition of AKT1 (unknown origin) at 10 uM	B	CN1CCN(c2ccc(Nc3ncc4cc(Oc5c(Cl)cccc5Cl)c(=O)n(C)c4n3)cc2)CC1		CHEMBL3747023	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	16417058	CHEMBL3751441	Inhibition of AKT1 (unknown origin) at 10 uM	B	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NCCc3ccccn3)nc21		CHEMBL3746951	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
	16417059	CHEMBL3751441	Inhibition of AKT1 (unknown origin) at 10 uM	B	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(Nc3ccc(N4CCCCC4)cc3)nc21		CHEMBL3746973	=	Inhibition	%	9.0	CHEMBL4282	Homo sapiens	INH	%	9.0
	16417060	CHEMBL3751441	Inhibition of AKT1 (unknown origin) at 10 uM	B	CN(C)CCNc1ncc2cc(Oc3ccc(F)cc3F)c(=O)n(C)c2n1		CHEMBL3745857	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	16421938	CHEMBL3750421	Inhibition of PKBalpha (unknown origin)	B	C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1		CHEMBL3651966	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	16425308	CHEMBL3751076	Inhibition of AKT1 (unknown origin) at 1 uM	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	=	Inhibition	%	2.5	CHEMBL4282	Homo sapiens	INH	%	2.5
	16429043	CHEMBL3750781	Inhibition of AKT1 (unknown origin) at 1 uM	B	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCN(S(N)(=O)=O)CC3)nc21		CHEMBL3747489	=	Inhibition	%	8.0	CHEMBL4282	Homo sapiens	INH	%	8.0
	16431723	CHEMBL3749731	Inhibition of human AKT1 using [KGSGSGRPRTSSFAEG] as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
Active	16436842	CHEMBL3757492	Inhibition of Akt phosphorylation in human HuH7 cells after 24 to 48 hrs by Western blot analysis	B	Cc1ccc(C2=Nn3c(nnc3C(C)c3ccc(CC(C)C)cc3)SC2)cc1		CHEMBL3754438		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	16436843	CHEMBL3757492	Inhibition of Akt phosphorylation in human HuH7 cells after 24 to 48 hrs by Western blot analysis	B	COc1ccc(C2=Nn3c(nnc3C(C)c3ccc(CC(C)C)cc3)SC2)cc1		CHEMBL3754804		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	16436844	CHEMBL3757491	Inhibition of Akt phosphorylation in human Mahlavu cells after 24 to 48 hrs by Western blot analysis	B	Cc1ccc(C2=Nn3c(nnc3C(C)c3ccc(CC(C)C)cc3)SC2)cc1		CHEMBL3754438		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	16436845	CHEMBL3757491	Inhibition of Akt phosphorylation in human Mahlavu cells after 24 to 48 hrs by Western blot analysis	B	COc1ccc(C2=Nn3c(nnc3C(C)c3ccc(CC(C)C)cc3)SC2)cc1		CHEMBL3754804		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	16450756	CHEMBL3762142	Inhibition of AKT1 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	3.5	CHEMBL4282	Homo sapiens	INH	%	3.5
	16451697	CHEMBL3762142	Inhibition of AKT1 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4c(Cl)cccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758602	=	Inhibition	%	11.1	CHEMBL4282	Homo sapiens	INH	%	11.1
Active	16456727	CHEMBL3761124	Inhibition of PMACI-induced phosphorylation of Akt at Ser273 in HMC1 cells at 12.5 to 50 uM pretreated for 30 mins followed by addition of PMACI incubated for 5 mins by Western blot analysis	B	O=C(/C=C/c1ccc(O)c(O)c1)O[C@@H](C(=O)O)[C@@H](OC(=O)/C=C/c1ccc(O)c(O)c1)C(=O)O		CHEMBL282731		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	16456950	CHEMBL3760810	Inhibition of recombinant human AKT for 60 mins by ELISA	B	Cc1ccc(-c2ncc(OCC3CCNCC3)cc2-c2ccc(C#N)cc2)cc1		CHEMBL3759201	=	IC50	nM	87600.0	CHEMBL4282	Homo sapiens	IC50	uM	87.6
Active	16460527	CHEMBL3760244	Inhibition of AKT1 phosphorylation in human HuH7 cells at 1 to 10 uM after 24 hrs by immunoblot analysis	B	CN(C)CCCNC(=O)c1cccc2nc3c(nc12)-c1ccccc1/C3=N\OCCCN(C)C.Cl		CHEMBL3759822		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	16465845	CHEMBL3768034	Inhibition of human AKT1 at 10 uM	B	Cc1cncn1-c1cc(C(=O)Nc2cccc(CNc3ccc4c(C(=O)N[C@@H](C)C(N)=O)[nH]nc4c3)c2)cc(C(F)(F)F)c1		CHEMBL3764798	=	Inhibition	%	7.08	CHEMBL4282	Homo sapiens	INH	%	7.08
	16467131	CHEMBL3767267	Antagonist activity at human AKT1-PH domain (1 to 121 residues) assessed as reduction of AKT1-PH interaction with PC/PE/PS/PI(3,4,5)P3 after 30 mins by competitive SPR analysis	B	N=C(N/C(=N/O)c1nonc1N)c1ccccc1Br		CHEMBL3764688	=	IC50	nM	16350.0	CHEMBL4282	Homo sapiens	IC50	uM	16.35
	16467132	CHEMBL3767267	Antagonist activity at human AKT1-PH domain (1 to 121 residues) assessed as reduction of AKT1-PH interaction with PC/PE/PS/PI(3,4,5)P3 after 30 mins by competitive SPR analysis	B	N=C(N/C(=N/O)c1nonc1N)N1CCCN=C1N		CHEMBL3764684	=	IC50	nM	3230.0	CHEMBL4282	Homo sapiens	IC50	uM	3.23
	16467133	CHEMBL3767267	Antagonist activity at human AKT1-PH domain (1 to 121 residues) assessed as reduction of AKT1-PH interaction with PC/PE/PS/PI(3,4,5)P3 after 30 mins by competitive SPR analysis	B	N=C(N/C(=N/O)c1nonc1N)c1ccccc1N		CHEMBL3763907	=	IC50	nM	8610.0	CHEMBL4282	Homo sapiens	IC50	uM	8.61
	16467134	CHEMBL3767267	Antagonist activity at human AKT1-PH domain (1 to 121 residues) assessed as reduction of AKT1-PH interaction with PC/PE/PS/PI(3,4,5)P3 after 30 mins by competitive SPR analysis	B	N=C(N/C(=N/O)c1nonc1N)c1ccccc1		CHEMBL3764457	=	IC50	nM	7190.0	CHEMBL4282	Homo sapiens	IC50	uM	7.19
	16467135	CHEMBL3767267	Antagonist activity at human AKT1-PH domain (1 to 121 residues) assessed as reduction of AKT1-PH interaction with PC/PE/PS/PI(3,4,5)P3 after 30 mins by competitive SPR analysis	B	N=C(N)NC(=N)N/C(=N/O)c1nonc1N		CHEMBL3764886	=	IC50	nM	1850.0	CHEMBL4282	Homo sapiens	IC50	uM	1.85
	16467143	CHEMBL3767264	Antagonist activity at human AKT1-PH domain (1 to 121 residues) assessed as reduction of AKT1-PH interaction with PC/PE/PS/PI(3,4,5)P3 at 50 uM after 30 mins by competitive SPR analysis relative to control	B	N=C(N/C(=N/O)c1nonc1N)c1ccccc1Br		CHEMBL3764688	=	Inhibition	%	80.0	CHEMBL4282	Homo sapiens	INH	%	80.0
	16467144	CHEMBL3767264	Antagonist activity at human AKT1-PH domain (1 to 121 residues) assessed as reduction of AKT1-PH interaction with PC/PE/PS/PI(3,4,5)P3 at 50 uM after 30 mins by competitive SPR analysis relative to control	B	N=C(N/C(=N/O)c1nonc1N)N1CCCN=C1N		CHEMBL3764684	=	Inhibition	%	92.0	CHEMBL4282	Homo sapiens	INH	%	92.0
	16467145	CHEMBL3767264	Antagonist activity at human AKT1-PH domain (1 to 121 residues) assessed as reduction of AKT1-PH interaction with PC/PE/PS/PI(3,4,5)P3 at 50 uM after 30 mins by competitive SPR analysis relative to control	B	N=C(N/C(=N/O)c1nonc1N)c1ccccc1N		CHEMBL3763907	=	Inhibition	%	74.0	CHEMBL4282	Homo sapiens	INH	%	74.0
	16467146	CHEMBL3767264	Antagonist activity at human AKT1-PH domain (1 to 121 residues) assessed as reduction of AKT1-PH interaction with PC/PE/PS/PI(3,4,5)P3 at 50 uM after 30 mins by competitive SPR analysis relative to control	B	N=C(N/C(=N/O)c1nonc1N)c1ccccc1		CHEMBL3764457	=	Inhibition	%	54.0	CHEMBL4282	Homo sapiens	INH	%	54.0
	16467147	CHEMBL3767264	Antagonist activity at human AKT1-PH domain (1 to 121 residues) assessed as reduction of AKT1-PH interaction with PC/PE/PS/PI(3,4,5)P3 at 50 uM after 30 mins by competitive SPR analysis relative to control	B	N=C(N)NC(=N)N/C(=N/O)c1nonc1N		CHEMBL3764886	=	Inhibition	%	95.0	CHEMBL4282	Homo sapiens	INH	%	95.0
Dose-dependent effect	16467152	CHEMBL3767423	Antagonist activity at human AKT1-PH domain (1 to 121 residues) assessed as reduction in PI(3,4,5)P3/AKT1-PH interaction by FRET analysis	B	N=C(N)NC(=N)N/C(=N/O)c1nonc1N		CHEMBL3764886		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	16467153	CHEMBL3767423	Antagonist activity at human AKT1-PH domain (1 to 121 residues) assessed as reduction in PI(3,4,5)P3/AKT1-PH interaction by FRET analysis	B	N=C(N/C(=N/O)c1nonc1N)N1CCCN=C1N		CHEMBL3764684		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	16467154	CHEMBL3767424	Antagonist activity at GST-tagged human AKT1-PH domain (1 to 121 residues) assessed as reduction in PC/PE/PS/PI(3,4,5)P3/AKT1-PH interaction at 50 uM by liposome pull-down assay	B	N=C(N)NC(=N)N/C(=N/O)c1nonc1N		CHEMBL3764886		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	16467155	CHEMBL3767424	Antagonist activity at GST-tagged human AKT1-PH domain (1 to 121 residues) assessed as reduction in PC/PE/PS/PI(3,4,5)P3/AKT1-PH interaction at 50 uM by liposome pull-down assay	B	N=C(N/C(=N/O)c1nonc1N)N1CCCN=C1N		CHEMBL3764684		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	16467161	CHEMBL3767427	Inhibition of AKT1 phosphorylation at Thr-308 in human MDA-MB-231 cells at 25 uM after 48 hrs by immunoblot analysis	B	N=C(N/C(=N/O)c1nonc1N)N1CCCN=C1N		CHEMBL3764684		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	16467174	CHEMBL3767431	Induction of human AKT1-PH aggregration assessed as mean hydrodynamic diameter after 10 mins dynamic light scattering assay	B	N=C(N)NC(=N)N/C(=N/O)c1nonc1N		CHEMBL3764886	=	Activity	nm	190.0	CHEMBL4282	Homo sapiens	Activity	nm	190.0
	16467175	CHEMBL3767431	Induction of human AKT1-PH aggregration assessed as mean hydrodynamic diameter after 10 mins dynamic light scattering assay	B	N=C(N/C(=N/O)c1nonc1N)N1CCCN=C1N		CHEMBL3764684	=	Activity	nm	190.0	CHEMBL4282	Homo sapiens	Activity	nm	190.0
Active	16467176	CHEMBL3767432	Binding affinity to human AKT1-PH domain assessed as change in beta-sheet content at 1:3 molar ratio of protein to compound by CD spectra analysis	B	N=C(N)NC(=N)N/C(=N/O)c1nonc1N		CHEMBL3764886		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	16467177	CHEMBL3767432	Binding affinity to human AKT1-PH domain assessed as change in beta-sheet content at 1:3 molar ratio of protein to compound by CD spectra analysis	B	N=C(N/C(=N/O)c1nonc1N)N1CCCN=C1N		CHEMBL3764684		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	16467178	CHEMBL3767433	Binding affinity to human AKT1-PH domain assessed as enthalpy change by isothermal titration calorimetric analysis	B	N=C(N)NC(=N)N/C(=N/O)c1nonc1N		CHEMBL3764886		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	16467179	CHEMBL3767433	Binding affinity to human AKT1-PH domain assessed as enthalpy change by isothermal titration calorimetric analysis	B	N=C(N/C(=N/O)c1nonc1N)N1CCCN=C1N		CHEMBL3764684		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	16467180	CHEMBL3767434	Binding affinity to human AKT1-PH domain assessed as entropy change by isothermal titration calorimetric analysis	B	N=C(N)NC(=N)N/C(=N/O)c1nonc1N		CHEMBL3764886		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	16467181	CHEMBL3767434	Binding affinity to human AKT1-PH domain assessed as entropy change by isothermal titration calorimetric analysis	B	N=C(N/C(=N/O)c1nonc1N)N1CCCN=C1N		CHEMBL3764684		Activity			CHEMBL4282	Homo sapiens	Activity		
Dose-dependent effect	16467182	CHEMBL3767267	Antagonist activity at human AKT1-PH domain (1 to 121 residues) assessed as reduction of AKT1-PH interaction with PC/PE/PS/PI(3,4,5)P3 after 30 mins by competitive SPR analysis	B	N=C(N)NC(=N)N/C(=N/O)c1nonc1N		CHEMBL3764886		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	16467183	CHEMBL3767267	Antagonist activity at human AKT1-PH domain (1 to 121 residues) assessed as reduction of AKT1-PH interaction with PC/PE/PS/PI(3,4,5)P3 after 30 mins by competitive SPR analysis	B	N=C(N/C(=N/O)c1nonc1N)N1CCCN=C1N		CHEMBL3764684		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	16485697	CHEMBL3773978	Inhibition of human recombinant AKT1 assessed as residual activity at 10 uM after 1 hr by qPCR analysis relative to control	B	Cc1c(Cl)cccc1NC(=O)c1sc2nc3c(cc2c1N)C(=O)CC3		CHEMBL3771285	=	Activity	%	90.0	CHEMBL4282	Homo sapiens	Activity	%	90.0
	16495180	CHEMBL3777508	Inhibition of N-terminal His6-tagged recombinant human PKBalpha expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	10.0	CHEMBL4282	Homo sapiens	Activity	%	10.0
	16496099	CHEMBL3777508	Inhibition of N-terminal His6-tagged recombinant human PKBalpha expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	4.0	CHEMBL4282	Homo sapiens	Activity	%	4.0
Not Active	16496869	CHEMBL3776417	Inhibition of human PKBalpha (118 to 480 residues) at 1 uM by radioactive [33P]-ATP filter binding assay	B	O=c1[nH]cnc2c(-n3cc(CCN4CCC(c5cccc(Cl)c5)CC4)cn3)nccc12		CHEMBL3774537		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	16507162	CHEMBL3779014	Inhibition of recombinant PKBalpha (unknown origin) assessed as residual activity at 1 uM relative to control	B	CC(O)CNc1nc(NCc2ccc(-c3ccccn3)cc2)c2[nH]nc(C(C)C)c2n1		CHEMBL3774632	>=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	16508286	CHEMBL3777508	Inhibition of N-terminal His6-tagged recombinant human PKBalpha expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	9.0	CHEMBL4282	Homo sapiens	Activity	%	9.0
Not Active	16514096	CHEMBL3782144	Inhibition of partial length human AKT1 expressed in bacterial system at 1 uM	B	Cc1cnc(N)nc1OCC(C)(C)CO		CHEMBL3780032		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	16518661	CHEMBL3782579	Inhibition of Akt1 (unknown origin)	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	IC50	nM	58.0	CHEMBL4282	Homo sapiens	IC50	nM	58.0
	16540736	CHEMBL3789974	Inhibition of AKT1 (unknown origin) in presence of [gamma33P]ATP	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1		CHEMBL1614712	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	16540737	CHEMBL3789974	Inhibition of AKT1 (unknown origin) in presence of [gamma33P]ATP	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1		CHEMBL3787112	=	IC50	nM	7000.0	CHEMBL4282	Homo sapiens	IC50	uM	7.0
	16540738	CHEMBL3789974	Inhibition of AKT1 (unknown origin) in presence of [gamma33P]ATP	B	CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4cc(OC[C@@H]5CCCO5)ccc4F)c4c(N)ncnc43)C2)CC1		CHEMBL3785951	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	16559676	CHEMBL3794898	Inhibition of human N-terminal GST-tagged AKT1 catalytic domain (104 to 480 residues) expressed in baculovirus expression system using fluorescence labelled crosstide as substrate at 50 times IC50 by electrophoretic mobility shift assay relative to control	B	O=C(Nc1ccccc1)c1n[nH]c2ccccc12		CHEMBL508964	=	Inhibition	%	-2.4	CHEMBL4282	Homo sapiens	INH	%	-2.4
	16559677	CHEMBL3794898	Inhibition of human N-terminal GST-tagged AKT1 catalytic domain (104 to 480 residues) expressed in baculovirus expression system using fluorescence labelled crosstide as substrate at 50 times IC50 by electrophoretic mobility shift assay relative to control	B	O=C(Nc1ccc(C(=O)N2CCN(c3ccccc3)CC2)cc1)c1n[nH]c2ccccc12		CHEMBL3793843	=	Inhibition	%	-1.1	CHEMBL4282	Homo sapiens	INH	%	-1.1
	16559678	CHEMBL3794898	Inhibition of human N-terminal GST-tagged AKT1 catalytic domain (104 to 480 residues) expressed in baculovirus expression system using fluorescence labelled crosstide as substrate at 50 times IC50 by electrophoretic mobility shift assay relative to control	B	O=C(Nc1ccc(CN2CCN(c3ccccc3)CC2)cc1)c1n[nH]c2ccccc12		CHEMBL3792850	=	Inhibition	%	-3.3	CHEMBL4282	Homo sapiens	INH	%	-3.3
	16578351	CHEMBL3804405	Inhibition of partial length wild type human AKT1 expressed in bacterial system assessed as enzyme activity at 1 uM relative to control	B	CN(C)S(=O)(=O)Nc1ccc(F)c(Nc2ncccc2-c2ncnc3[nH]cnc23)c1F		CHEMBL3798256	=	Activity	%	87.0	CHEMBL4282	Homo sapiens	Activity	%	87.0
	16587020	CHEMBL3807432	Inhibition of AKT1 (unknown origin) in presence of gamma33-ATP	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	16589627	CHEMBL3807483	Inhibition of Akt1 (unknown origin) at 1 ug/ml after 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)NC2(c3ccc(Cl)c(Cl)c3)CCNCC2)oc1Cl		CHEMBL3805228	=	Inhibition	%	98.2	CHEMBL4282	Homo sapiens	INH	%	98.2
	16589674	CHEMBL3807472	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli at 1 ug/ml using peptide substrate after 1 hr by HTRF assay	B	Cn1ncc(Br)c1-c1oc(C(=O)NC2(c3ccc(Cl)c(Cl)c3)CCNCC2)cc1Br		CHEMBL3805273	=	Inhibition	%	43.5	CHEMBL4282	Homo sapiens	INH	%	43.5
	16589675	CHEMBL3807472	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli at 1 ug/ml using peptide substrate after 1 hr by HTRF assay	B	Cn1ncc(Br)c1-c1cc(C(=O)NC2(c3ccc(Cl)c(Cl)c3)CCNCC2)n(C)c1Br		CHEMBL3805877	=	Inhibition	%	30.3	CHEMBL4282	Homo sapiens	INH	%	30.3
	16589676	CHEMBL3807472	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli at 1 ug/ml using peptide substrate after 1 hr by HTRF assay	B	Cn1nccc1-c1oc(C(=O)NC2(c3ccc(Cl)c(Cl)c3)CCNCC2)cc1Br		CHEMBL3806085	=	Inhibition	%	49.4	CHEMBL4282	Homo sapiens	INH	%	49.4
	16589677	CHEMBL3807471	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide substrate after 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	uM	0.018
	16589678	CHEMBL3807471	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide substrate after 1 hr by HTRF assay	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	=	IC50	nM	34.0	CHEMBL4282	Homo sapiens	IC50	uM	0.034
	16589679	CHEMBL3807471	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide substrate after 1 hr by HTRF assay	B	Cn1ncc(Br)c1-c1ccc(C(=O)NC2(c3ccc(Cl)c(Cl)c3)CCNCC2)cc1		CHEMBL3805037	=	IC50	nM	1400.0	CHEMBL4282	Homo sapiens	IC50	uM	1.4
	16589680	CHEMBL3807471	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide substrate after 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1ccc(C(=O)NC2(c3ccc(Cl)c(Cl)c3)CCNCC2)cc1		CHEMBL3805006	=	IC50	nM	1910.0	CHEMBL4282	Homo sapiens	IC50	uM	1.91
	16589681	CHEMBL3807471	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide substrate after 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1c(Cl)c(C(=O)NC2(c3ccc(Cl)c(Cl)c3)CCNCC2)n(C)c1Cl		CHEMBL3805319	=	IC50	nM	850.0	CHEMBL4282	Homo sapiens	IC50	uM	0.85
	16589682	CHEMBL3807471	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide substrate after 1 hr by HTRF assay	B	Cn1cc(-c2c(Br)cnn2C)cc1C(=O)NC1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL3805443	=	IC50	nM	1260.0	CHEMBL4282	Homo sapiens	IC50	uM	1.26
	16589683	CHEMBL3807471	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide substrate after 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1oc(C(=O)NC2(c3ccc(Cl)c(Cl)c3)CCNCC2)cc1Br		CHEMBL3805457	=	IC50	nM	1480.0	CHEMBL4282	Homo sapiens	IC50	uM	1.48
	16589684	CHEMBL3807471	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide substrate after 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)NC2(c3ccc(Cl)c(Cl)c3)CCNCC2)oc1Cl		CHEMBL3805228	=	IC50	nM	61.0	CHEMBL4282	Homo sapiens	IC50	uM	0.061
	16589685	CHEMBL3807471	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide substrate after 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)NC2(c3ccc(F)cc3)CCNCC2)oc1Cl		CHEMBL3805691	=	IC50	nM	390.0	CHEMBL4282	Homo sapiens	IC50	uM	0.39
	16589686	CHEMBL3807471	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide substrate after 1 hr by HTRF assay	B	Cn1ncc(Br)c1-c1coc(C(=O)NC2(c3ccc(Cl)c(Cl)c3)CCNCC2)c1		CHEMBL3805855	=	IC50	nM	440.0	CHEMBL4282	Homo sapiens	IC50	uM	0.44
	16589687	CHEMBL3807471	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide substrate after 1 hr by HTRF assay	B	Cn1ncc(Br)c1-c1coc(C(=O)NC2(c3ccc(F)cc3)CCNCC2)c1		CHEMBL3805617	=	IC50	nM	2020.0	CHEMBL4282	Homo sapiens	IC50	uM	2.02
	16589688	CHEMBL3807471	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide substrate after 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1coc(C(=O)NC2(c3ccc(F)cc3)CCNCC2)c1		CHEMBL3806229	=	IC50	nM	920.0	CHEMBL4282	Homo sapiens	IC50	uM	0.92
	16589689	CHEMBL3807471	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide substrate after 1 hr by HTRF assay	B	Cn1nccc1-c1csc(C(=O)NC2(c3ccc(Cl)c(Cl)c3)CCNCC2)c1		CHEMBL3805163	=	IC50	nM	71.0	CHEMBL4282	Homo sapiens	IC50	uM	0.071
	16589690	CHEMBL3807471	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide substrate after 1 hr by HTRF assay	B	Cn1ncc(Br)c1-c1csc(C(=O)NC2(c3ccc(F)cc3)CCNCC2)c1		CHEMBL3805232	=	IC50	nM	360.0	CHEMBL4282	Homo sapiens	IC50	uM	0.36
	16589691	CHEMBL3807471	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide substrate after 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1csc(C(=O)NC2(c3ccc(F)cc3)CCNCC2)c1		CHEMBL3806131	=	IC50	nM	320.0	CHEMBL4282	Homo sapiens	IC50	uM	0.32
	16589692	CHEMBL3807471	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide substrate after 1 hr by HTRF assay	B	Cn1nccc1-c1csc(C(=O)NC2(c3ccc(F)cc3)CCNCC2)c1		CHEMBL3805292	=	IC50	nM	920.0	CHEMBL4282	Homo sapiens	IC50	uM	0.92
	16589701	CHEMBL3807613	Inhibition of Akt1 (unknown origin) after 1 hr by HTRF assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	17.6	CHEMBL4282	Homo sapiens	IC50	nM	17.6
	16597032	CHEMBL3812222	Inhibition of human Akt1 expressed in bacterial system assessed as enzyme activity at 10 uM by KINOMEScan assay	B	O=C1C2=C(C(=O)c3c(O)ccc(O)c31)[C@@H](O)[C@@H](O)[C@@H](O)C2		CHEMBL1987813	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	16612662	CHEMBL3815505	Inhibition of human PKBalpha (118 to 480 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL405665	=	Activity	%	-23.0	CHEMBL4282	Homo sapiens	Activity	%	-23.0
	16612663	CHEMBL3815505	Inhibition of human PKBalpha (118 to 480 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCCCc1cc(-c2c[nH]c3ncccc23)nc(N)n1		CHEMBL3814340	=	Activity	%	-23.0	CHEMBL4282	Homo sapiens	Activity	%	-23.0
	16612664	CHEMBL3815505	Inhibition of human PKBalpha (118 to 480 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1		CHEMBL3814140	=	Activity	%	-10.0	CHEMBL4282	Homo sapiens	Activity	%	-10.0
	16612665	CHEMBL3815505	Inhibition of human PKBalpha (118 to 480 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCCCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1		CHEMBL3815046	=	Activity	%	-9.0	CHEMBL4282	Homo sapiens	Activity	%	-9.0
Active	16613655	CHEMBL3816455	Decrease in phosphorylated Akt level in human MDA-MB-231 cells after 24 hrs by western blotting method	B	O=C(O[C@@H]1O[C@@H]2COC(=O)c3cc(O)c(O)c(O)c3-c3c(cc(O)c(O)c3O)C(=O)O[C@H]2[C@@H]2OC(=O)c3cc(O)c(O)c(O)c3-c3c(cc(O)c(O)c3O)C(=O)O[C@@H]12)c1cc(O)c(O)c(Oc2c(O)c(O)c(O)c3c2C(=O)O[C@H]2[C@@H]4OC(=O)c5cc(O)c(O)c(O)c5-c5c(cc(O)c(O)c5O)C(=O)O[C@H]4[C@@H](OC(=O)c4cc(O)c(O)c(O)c4)O[C@@H]2COC(=O)c2cc(O)c(O)c(O)c2-3)c1		CHEMBL508647		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	16613761	CHEMBL3816554	Inhibition of human AKT1 at 1 uM using [KGSGSGRPRTSSFAEG] as substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	-8.0	CHEMBL4282	Homo sapiens	INH	%	-8.0
	16618284	CHEMBL3817001	Inhibition of full length recombinant human His-tagged AKT1 expressed in baculovirus expression system at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	16621475	CHEMBL3820468	Inhibition of AKT1 (unknown origin) incubated for 1 hr by spectrophotometric analysis	B	CN1C(=O)COc2c1cnc1ccc(Sc3nnc4c(F)cc(-c5cnn(C)c5)cn34)cc21		CHEMBL3818247	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	nM	30000.0
Not Active	16621545	CHEMBL3820683	Inhibition of AKT phosphorylation in human HuH7 cells at 100 to 1000 nM after 6 to 24 hrs by Western blot analysis	B	CN1C(=O)COc2c1cnc1ccc(Sc3nnc4c(F)cc(-c5cnn(C)c5)cn34)cc21.CS(=O)(=O)O		CHEMBL3818440		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	16622190	CHEMBL3820468	Inhibition of AKT1 (unknown origin) incubated for 1 hr by spectrophotometric analysis	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
	16625051	CHEMBL3821460	Inhibition of human Akt1 PH domain using AKTide-2T as substrate at 100 uM by ELISA	B	O.O=C(O)C(F)(F)F.O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5nc[nH]c5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL3819449	=	Inhibition	%	89.0	CHEMBL4282	Homo sapiens	INH	%	89.0
	16625052	CHEMBL3821460	Inhibition of human Akt1 PH domain using AKTide-2T as substrate at 100 uM by ELISA	B	CCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@H](CS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL1615675	=	Inhibition	%	77.0	CHEMBL4282	Homo sapiens	INH	%	77.0
	16625053	CHEMBL3821460	Inhibition of human Akt1 PH domain using AKTide-2T as substrate at 100 uM by ELISA	B	CCCCCC(=O)OCC(COC(=O)CCCCC)O[C@@H]1O[C@H](CS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL1615685	=	Inhibition	%	13.0	CHEMBL4282	Homo sapiens	INH	%	13.0
	16625054	CHEMBL3821460	Inhibition of human Akt1 PH domain using AKTide-2T as substrate at 100 uM by ELISA	B	CCCCCCCCCCCCCCCCCC(=O)OCC(CO)O[C@@H]1O[C@H](CS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL3818018	=	Inhibition	%	86.0	CHEMBL4282	Homo sapiens	INH	%	86.0
	16625055	CHEMBL3821460	Inhibition of human Akt1 PH domain using AKTide-2T as substrate at 100 uM by ELISA	B	CCCCCCCCCCCC(=O)OCC(CO)O[C@@H]1O[C@H](CS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL3819373	=	Inhibition	%	31.0	CHEMBL4282	Homo sapiens	INH	%	31.0
	16625056	CHEMBL3821460	Inhibition of human Akt1 PH domain using AKTide-2T as substrate at 100 uM by ELISA	B	CCCCCC(=O)OCC(CO)O[C@@H]1O[C@H](CS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL3819007	=	Inhibition	%	18.0	CHEMBL4282	Homo sapiens	INH	%	18.0
	16625057	CHEMBL3821460	Inhibition of human Akt1 PH domain using AKTide-2T as substrate at 100 uM by ELISA	B	O=S(=O)([O-])C[C@H]1O[C@@H](OC(CO)CO)[C@H](O)[C@@H](O)[C@@H]1O.[K+]		CHEMBL3818140	=	Inhibition	%	13.0	CHEMBL4282	Homo sapiens	INH	%	13.0
	16625058	CHEMBL3821460	Inhibition of human Akt1 PH domain using AKTide-2T as substrate at 100 uM by ELISA	B	CCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL539202	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	16625059	CHEMBL3821460	Inhibition of human Akt1 PH domain using AKTide-2T as substrate at 100 uM by ELISA	B	CO[C@@H]1O[C@H](CS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]1O.[K+]		CHEMBL3819268	=	Inhibition	%	28.0	CHEMBL4282	Homo sapiens	INH	%	28.0
	16625060	CHEMBL3821460	Inhibition of human Akt1 PH domain using AKTide-2T as substrate at 100 uM by ELISA	B	CCCCCCCCO[C@@H]1O[C@H](CS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]1O.[K+]		CHEMBL3819502	=	Inhibition	%	14.0	CHEMBL4282	Homo sapiens	INH	%	14.0
	16625061	CHEMBL3821460	Inhibition of human Akt1 PH domain using AKTide-2T as substrate at 100 uM by ELISA	B	CCCCCCCCO[C@@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL3818066	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
Not Active	16625062	CHEMBL3821460	Inhibition of human Akt1 PH domain using AKTide-2T as substrate at 100 uM by ELISA	B	CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]		CHEMBL23393		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	16625063	CHEMBL3821461	Inhibition of human Akt1 PH domain using AKTide-2T as substrate by ELISA	B	CCCCCCCCCCCCCCCCCC(=O)OCC(CO)O[C@@H]1O[C@H](CS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL3818018	=	IC50	nM	31330.0	CHEMBL4282	Homo sapiens	IC50	uM	31.33
	16625064	CHEMBL3821461	Inhibition of human Akt1 PH domain using AKTide-2T as substrate by ELISA	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	=	IC50	nM	43350.0	CHEMBL4282	Homo sapiens	IC50	uM	43.35
Active	16625093	CHEMBL3821472	Inhibition of Akt in human IGROV1 cells assessed as reduction in GSK3alpha phosphorylation at Ser21 at 3 uM after 24 hrs by Western blot analysis	B	CCCCCCCCCCCCCCCCCC(=O)OCC(CO)O[C@@H]1O[C@H](CS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL3818018		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	16625094	CHEMBL3821473	Inhibition of Akt in human IGROV1 cells assessed as reduction in GSK3beta phosphorylation at Ser9 at 3 uM after 24 hrs by Western blot analysis	B	CCCCCCCCCCCCCCCCCC(=O)OCC(CO)O[C@@H]1O[C@H](CS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL3818018		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	16625095	CHEMBL3821474	Inhibition of Akt in human IGROV1 cells assessed as reduction in BAD phosphorylation at Ser136 at 3 uM after 24 hrs by Western blot analysis	B	CCCCCCCCCCCCCCCCCC(=O)OCC(CO)O[C@@H]1O[C@H](CS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL3818018		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	16625096	CHEMBL3821625	Inhibition of human Akt1 PH domain using AKTide-2T as substrate at 1 uM by ELISA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	16625097	CHEMBL3821626	Inhibition of Akt in human IGROV1 cells assessed as reduction in GSK3alpha phosphorylation at Ser21 at 3 to 10 uM after 24 hrs by Western blot analysis	B	O.O=C(O)C(F)(F)F.O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5nc[nH]c5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL3819449		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	16625098	CHEMBL3821627	Inhibition of Akt in human IGROV1 cells assessed as reduction in GSK3beta phosphorylation at Ser9 at 3 to 10 uM after 24 hrs by Western blot analysis	B	O.O=C(O)C(F)(F)F.O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5nc[nH]c5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL3819449		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	16625099	CHEMBL3821628	Inhibition of Akt in human IGROV1 cells assessed as reduction in BAD phosphorylation at Ser136 at 3 to 10 uM after 24 hrs by Western blot analysis	B	O.O=C(O)C(F)(F)F.O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5nc[nH]c5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL3819449		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	16625100	CHEMBL3821461	Inhibition of human Akt1 PH domain using AKTide-2T as substrate by ELISA	B	CCCCCCCCCCCCCCCCCC(=O)OCC(CO)O[C@@H]1O[C@H](CS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]1O		CHEMBL3818018		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	16627560	CHEMBL3820356	Inhibition of full length recombinant human N-terminal His6-tagged PKB-alpha expressed in baculovirus infected Sf21 cells at 1 uM by radiometric assay relative to control	B	Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(Oc4ccccc4)nc23)ccc1C(=O)NC1CC1		CHEMBL3819210	=	Inhibition	%	-1.0	CHEMBL4282	Homo sapiens	INH	%	-1.0
	16627561	CHEMBL3820356	Inhibition of full length recombinant human N-terminal His6-tagged PKB-alpha expressed in baculovirus infected Sf21 cells at 1 uM by radiometric assay relative to control	B	O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4CC(O)C5)cc3)c2c1		CHEMBL3818239	=	Inhibition	%	-4.0	CHEMBL4282	Homo sapiens	INH	%	-4.0
	16641966	CHEMBL3826117	Inhibition of His-tagged full-length human AKT1 expressed in baculovirus system at 100 nM by Z-lyte assay	B	O=C(CNC(=O)c1cccn(Cc2ccc(F)c(F)c2)c1=O)Nc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL3824119	=	Inhibition	%	-8.0	CHEMBL4282	Homo sapiens	INH	%	-8.0
	16654173	CHEMBL3830962	Inhibition of human PKBalpha assessed as remaining enzyme activity at 50 uM after 30 mins by 33P-ATP filter-binding assay	B	Cc1cc(=O)c2c(O)cc(O)c([C@H]3CCN(C)C[C@H]3O)c2o1		CHEMBL1077604	=	Activity	%	76.0	CHEMBL4282	Homo sapiens	Activity	%	76.0
	16837422	CHEMBL3876093	Inhibition of human recombinant full length His-tagged AKT1alpha expressed in baculovirus expression system	B	CC1(C)C(=O)N([C@H]2CCc3c(O)cccc32)c2nc(Nc3ccccc3)ncc21		CHEMBL3884319	=	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
Active	16862201	CHEMBL3880120	Induction of anti-CD3-stimulated Akt phosphorylation in human PBMC preincubated for 15 mins followed by anti-CD3 stimulation measured after 5 to 15 mins by phosflow method	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413		Activity			CHEMBL4282	Homo sapiens	Activity		
	16881148	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccccc2C(F)(F)F)sc1Cl		CHEMBL3892820	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881149	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Br)c1-c1cc(C(=O)N[C@H](CN)Cc2ccccc2C(F)(F)F)sc1Cl		CHEMBL3890070	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881150	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cc1cnn(C)c1-c1cc(C(=O)N[C@H](CN)Cc2ccccc2C(F)(F)F)sc1Cl		CHEMBL3952025	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881151	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1nccc1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL3942525	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881152	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	CCc1sc(C(=O)N[C@H](CN)Cc2cccc(F)c2)cc1-c1c(Cl)cnn1C		CHEMBL3907254	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881153	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccccc2C(F)(F)F)oc1Cl		CHEMBL3904492	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881154	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cc1cnn(C)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)oc1Cl		CHEMBL3968297	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881155	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cc1sc(C(=O)N[C@H](CN)Cc2cccc(F)c2)cc1-c1c(Cl)cnn1C		CHEMBL3965875	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881156	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Br)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL3926382	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881157	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Br)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(C(F)(F)F)c2)sc1Cl		CHEMBL3923631	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881158	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Br)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)cc2)sc1Cl		CHEMBL3905729	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881159	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	COc1sc(C(=O)N[C@H](CN)Cc2cccc(F)c2)cc1-c1c(Cl)cnn1C		CHEMBL3963487	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881160	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)sc1Cl		CHEMBL3953883	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881161	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1nccc1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3929383	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881162	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	CCn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)cc2)sc1Cl		CHEMBL3932335	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881163	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cc1cnn(C)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL3935057	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881164	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	CCn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)sc1Cl		CHEMBL3971992	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881165	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	CCn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3903718	>=	IC50	nM	2.512	CHEMBL4282	Homo sapiens	pIC50		8.6
	16881166	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	pIC50		9.0
	16881167	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)oc1Cl		CHEMBL3953878	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	pIC50		9.0
	16881168	CHEMBL3880964	Inhibition of full length human AKT1 expressed in Sf9 cells assessed as reduction in substrate phosphorylation using biotin-ahx-ARKRERAYSFGHHA-amide substrate and [gamma-33P]ATP incubated for 40 mins by top count microplate scintillation counting method	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	=	IC50	nM	1.995	CHEMBL4282	Homo sapiens	pIC50		8.7
220746	17609745	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3679710	=	IC50	nM	2800.0	CHEMBL4282	Homo sapiens	IC50	nM	2800.0
220747	17609746	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1coc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)c1		CHEMBL3679711	=	IC50	nM	6300.0	CHEMBL4282	Homo sapiens	IC50	nM	6300.0
220748	17609747	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Nc1cc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)ccn1		CHEMBL3679712	=	IC50	nM	13000.0	CHEMBL4282	Homo sapiens	IC50	nM	13000.0
220749	17609748	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1c[nH]c(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)c1		CHEMBL3679713	=	IC50	nM	7900.0	CHEMBL4282	Homo sapiens	IC50	nM	7900.0
220750	17609749	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cn1		CHEMBL3679714	=	IC50	nM	2100.0	CHEMBL4282	Homo sapiens	IC50	nM	2100.0
220751	17609750	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3679715	=	IC50	nM	13000.0	CHEMBL4282	Homo sapiens	IC50	nM	13000.0
220752	17609751	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(C)(C)c1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3679716	=	IC50	nM	4700.0	CHEMBL4282	Homo sapiens	IC50	nM	4700.0
220753	17609752	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	FC(F)(F)c1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3679717	=	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	nM	30000.0
220754	17609753	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Clc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3679718	=	IC50	nM	5100.0	CHEMBL4282	Homo sapiens	IC50	nM	5100.0
220755	17609754	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc2c(c1)Nc1ncccc1-n1c(-c3ccc4ccccc4c3)nnc1-2		CHEMBL3679719	=	IC50	nM	29000.0	CHEMBL4282	Homo sapiens	IC50	nM	29000.0
220756	17609755	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3679720	=	IC50	nM	730.0	CHEMBL4282	Homo sapiens	IC50	nM	730.0
220757	17609756	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CN(C)c1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3679721	=	IC50	nM	1600.0	CHEMBL4282	Homo sapiens	IC50	nM	1600.0
220758	17609757	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Clc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1Cl		CHEMBL3679722	=	IC50	nM	5100.0	CHEMBL4282	Homo sapiens	IC50	nM	5100.0
220759	17609758	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CN1c2ccccc2-c2nnc(-c3ccc4ccccc4c3)n2-c2ccccc21		CHEMBL3679723	=	IC50	nM	67000.0	CHEMBL4282	Homo sapiens	IC50	nM	67000.0
220760	17609759	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Fc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3679724	=	IC50	nM	23000.0	CHEMBL4282	Homo sapiens	IC50	nM	23000.0
220761	17609760	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Fc1cccc(F)c1-c1nnc2n1-c1cccnc1Nc1ccccc1-2		CHEMBL3679725	=	IC50	nM	28000.0	CHEMBL4282	Homo sapiens	IC50	nM	28000.0
220762	17609761	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Fc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)c(F)c1		CHEMBL3679726	=	IC50	nM	7200.0	CHEMBL4282	Homo sapiens	IC50	nM	7200.0
220763	17609762	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Nc1cccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)c1		CHEMBL3679727	=	IC50	nM	8100.0	CHEMBL4282	Homo sapiens	IC50	nM	8100.0
220764	17609763	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Oc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3679728	=	IC50	nM	2200.0	CHEMBL4282	Homo sapiens	IC50	nM	2200.0
220765	17609764	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc(-c2nnc3n2-c2ccccc2Nc2ccccc2-3)cc1		CHEMBL3679729	=	IC50	nM	1900.0	CHEMBL4282	Homo sapiens	IC50	nM	1900.0
220766	17609765	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CN(C)c1ccc(-c2nnc3n2-c2ccccc2Nc2ccccc2-3)cc1		CHEMBL3679730	=	IC50	nM	3500.0	CHEMBL4282	Homo sapiens	IC50	nM	3500.0
220767	17609766	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Nc1ccc(-c2nnc3n2-c2ccccc2Nc2ccccc2-3)cc1		CHEMBL3679731	=	IC50	nM	1800.0	CHEMBL4282	Homo sapiens	IC50	nM	1800.0
220768	17609767	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	OCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684334	=	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
220769	17609768	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684335	=	IC50	nM	83.0	CHEMBL4282	Homo sapiens	IC50	nM	83.0
220770	17609769	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COC(=O)c1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684336	=	IC50	nM	2600.0	CHEMBL4282	Homo sapiens	IC50	nM	2600.0
220771	17609770	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(c1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1		CHEMBL3684337	=	IC50	nM	800.0	CHEMBL4282	Homo sapiens	IC50	nM	800.0
220772	17609771	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1cccc(C(=O)Nc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)c1		CHEMBL3684338	=	IC50	nM	160.0	CHEMBL4282	Homo sapiens	IC50	nM	160.0
220773	17609772	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccc2ccccc2c1		CHEMBL3684339	=	IC50	nM	680.0	CHEMBL4282	Homo sapiens	IC50	nM	680.0
220774	17609773	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1		CHEMBL3684340	=	IC50	nM	2500.0	CHEMBL4282	Homo sapiens	IC50	nM	2500.0
220775	17609774	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1ccc(C(=O)Nc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)cc1		CHEMBL3684341	=	IC50	nM	100.0	CHEMBL4282	Homo sapiens	IC50	nM	100.0
220776	17609775	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1ccc(C(=O)Nc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)cc1		CHEMBL3684342	=	IC50	nM	160.0	CHEMBL4282	Homo sapiens	IC50	nM	160.0
220777	17609776	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CCCC(=O)Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684343	=	IC50	nM	730.0	CHEMBL4282	Homo sapiens	IC50	nM	730.0
220778	17609777	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(C)CC(=O)Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684344	=	IC50	nM	700.0	CHEMBL4282	Homo sapiens	IC50	nM	700.0
220779	17609778	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1cccc2ccccc12		CHEMBL3684345	=	IC50	nM	640.0	CHEMBL4282	Homo sapiens	IC50	nM	640.0
220780	17609779	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Cc1cccc2ccccc12)Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684346	=	IC50	nM	950.0	CHEMBL4282	Homo sapiens	IC50	nM	950.0
220781	17609780	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(C)(C)CC(=O)Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684347	=	IC50	nM	340.0	CHEMBL4282	Homo sapiens	IC50	nM	340.0
220782	17609781	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccc(F)c(F)c1		CHEMBL3684348	=	IC50	nM	150.0	CHEMBL4282	Homo sapiens	IC50	nM	150.0
220783	17609782	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	[C-]#[N+]c1ccc(C(=O)Nc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)cc1		CHEMBL3684349	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	nM	140.0
220784	17609783	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CCC(=O)Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684350	=	IC50	nM	1800.0	CHEMBL4282	Homo sapiens	IC50	nM	1800.0
220785	17609784	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1cccnc1		CHEMBL3684351	=	IC50	nM	260.0	CHEMBL4282	Homo sapiens	IC50	nM	260.0
220786	17609785	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1ccccc1C(=O)Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684352	=	IC50	nM	520.0	CHEMBL4282	Homo sapiens	IC50	nM	520.0
220787	17609786	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1cc2ccccc2s1		CHEMBL3684353	=	IC50	nM	360.0	CHEMBL4282	Homo sapiens	IC50	nM	360.0
220788	17609787	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(C)(C)C(=O)Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684354	=	IC50	nM	420.0	CHEMBL4282	Homo sapiens	IC50	nM	420.0
220789	17609788	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(C)(C)c1ccc(C(=O)Nc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)cc1		CHEMBL3684355	=	IC50	nM	230.0	CHEMBL4282	Homo sapiens	IC50	nM	230.0
220790	17609789	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CN(C)c1ccc(C(=O)Nc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)cc1		CHEMBL3684356	=	IC50	nM	1900.0	CHEMBL4282	Homo sapiens	IC50	nM	1900.0
220791	17609790	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccc(F)c(C(F)(F)F)c1		CHEMBL3684357	=	IC50	nM	5300.0	CHEMBL4282	Homo sapiens	IC50	nM	5300.0
220792	17609791	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccc2c(c1)OCO2		CHEMBL3684358	=	IC50	nM	53.0	CHEMBL4282	Homo sapiens	IC50	nM	53.0
220793	17609792	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1cc(C(=O)Nc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)no1		CHEMBL3639832	=	IC50	nM	120.0	CHEMBL4282	Homo sapiens	IC50	nM	120.0
220794	17609793	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Cc1ccccc1)Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684359	=	IC50	nM	240.0	CHEMBL4282	Homo sapiens	IC50	nM	240.0
220795	17609794	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccco1		CHEMBL3684360	=	IC50	nM	130.0	CHEMBL4282	Homo sapiens	IC50	nM	130.0
220796	17609795	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccccc1F		CHEMBL3684361	=	IC50	nM	110.0	CHEMBL4282	Homo sapiens	IC50	nM	110.0
220797	17609796	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccc(C(F)(F)F)cc1		CHEMBL3684362	=	IC50	nM	650.0	CHEMBL4282	Homo sapiens	IC50	nM	650.0
220798	17609797	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COCC(=O)Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684363	=	IC50	nM	1500.0	CHEMBL4282	Homo sapiens	IC50	nM	1500.0
220799	17609798	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(CCc1ccccc1)Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684364	=	IC50	nM	1800.0	CHEMBL4282	Homo sapiens	IC50	nM	1800.0
220800	17609799	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1cnc2ccccc2n1		CHEMBL3684365	=	IC50	nM	160.0	CHEMBL4282	Homo sapiens	IC50	nM	160.0
220801	17609800	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccc(F)cc1		CHEMBL3684366	=	IC50	nM	110.0	CHEMBL4282	Homo sapiens	IC50	nM	110.0
220802	17609801	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)C1CCC1		CHEMBL3684367	=	IC50	nM	700.0	CHEMBL4282	Homo sapiens	IC50	nM	700.0
220803	17609802	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccncc1		CHEMBL3684368	=	IC50	nM	350.0	CHEMBL4282	Homo sapiens	IC50	nM	350.0
220804	17609803	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccccc1		CHEMBL3684369	=	IC50	nM	70.0	CHEMBL4282	Homo sapiens	IC50	nM	70.0
220805	17609804	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	[C-]#[N+]c1cccc(C(=O)Nc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)c1		CHEMBL3684370	=	IC50	nM	76.0	CHEMBL4282	Homo sapiens	IC50	nM	76.0
220806	17609805	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccc(-c2ccccc2)cc1		CHEMBL3684371	=	IC50	nM	780.0	CHEMBL4282	Homo sapiens	IC50	nM	780.0
220807	17609806	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684372	=	IC50	nM	690.0	CHEMBL4282	Homo sapiens	IC50	nM	690.0
220808	17609807	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nnc6n5-c5cccnc5Nc5ccccc5-6)cc4)CC3)[nH]2)nc1		CHEMBL3684373	=	IC50	nM	84.0	CHEMBL4282	Homo sapiens	IC50	nM	84.0
220809	17609808	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CS(=O)(=O)OCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684374	=	IC50	nM	490.0	CHEMBL4282	Homo sapiens	IC50	nM	490.0
220810	17609809	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc2c(c1)Nc1ncccc1-n1c(-c3ccc(CN4CCCC4)cc3)nnc1-2		CHEMBL3684375	=	IC50	nM	4300.0	CHEMBL4282	Homo sapiens	IC50	nM	4300.0
220811	17609810	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc(CNCc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)cc1		CHEMBL3684376	=	IC50	nM	1900.0	CHEMBL4282	Homo sapiens	IC50	nM	1900.0
220812	17609811	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Fc1ccccc1N1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684377	=	IC50	nM	2800.0	CHEMBL4282	Homo sapiens	IC50	nM	2800.0
220813	17609812	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(C)CCNCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684378	=	IC50	nM	4400.0	CHEMBL4282	Homo sapiens	IC50	nM	4400.0
220814	17609813	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc2c(c1)Nc1ncccc1-n1c(-c3ccc(CNC4CCC4)cc3)nnc1-2		CHEMBL3684379	=	IC50	nM	4500.0	CHEMBL4282	Homo sapiens	IC50	nM	4500.0
220815	17609814	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CCN(Cc1ccncc1)Cc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684380	=	IC50	nM	2100.0	CHEMBL4282	Homo sapiens	IC50	nM	2100.0
220816	17609815	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(C)CNCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684381	=	IC50	nM	6400.0	CHEMBL4282	Homo sapiens	IC50	nM	6400.0
220817	17609816	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CN(C)C(=O)CN1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684382	=	IC50	nM	8000.0	CHEMBL4282	Homo sapiens	IC50	nM	8000.0
220818	17609817	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COCCNCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684383	=	IC50	nM	4600.0	CHEMBL4282	Homo sapiens	IC50	nM	4600.0
220819	17609818	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc2c(c1)Nc1ncccc1-n1c(-c3ccc(CN4CCN(Cc5ccncc5)CC4)cc3)nnc1-2		CHEMBL3684384	=	IC50	nM	5200.0	CHEMBL4282	Homo sapiens	IC50	nM	5200.0
220820	17609819	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CN(CCc1ccccn1)Cc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684385	=	IC50	nM	1100.0	CHEMBL4282	Homo sapiens	IC50	nM	1100.0
220821	17609820	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	OCC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684386	=	IC50	nM	8300.0	CHEMBL4282	Homo sapiens	IC50	nM	8300.0
220822	17609821	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COCCN(C)Cc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684387	=	IC50	nM	4700.0	CHEMBL4282	Homo sapiens	IC50	nM	4700.0
220823	17609822	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C1CCCN1CCCNCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684388	=	IC50	nM	4400.0	CHEMBL4282	Homo sapiens	IC50	nM	4400.0
220824	17609823	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CN(CCc1ccccc1)Cc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684389	=	IC50	nM	780.0	CHEMBL4282	Homo sapiens	IC50	nM	780.0
220825	17609824	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	OC1(c2ccccc2)CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684390	=	IC50	nM	1900.0	CHEMBL4282	Homo sapiens	IC50	nM	1900.0
220826	17609825	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CCN(CC)C(=O)C1CCCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)C1		CHEMBL3684391	=	IC50	nM	4800.0	CHEMBL4282	Homo sapiens	IC50	nM	4800.0
220827	17609826	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc(CN2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)cc1		CHEMBL3684392	=	IC50	nM	5300.0	CHEMBL4282	Homo sapiens	IC50	nM	5300.0
220828	17609827	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	OC1CCCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)C1		CHEMBL3684393	=	IC50	nM	5700.0	CHEMBL4282	Homo sapiens	IC50	nM	5700.0
220829	17609828	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc2c(c1)Nc1ncccc1-n1c(-c3ccc(CN4CCOCC4)cc3)nnc1-2		CHEMBL3684394	=	IC50	nM	1600.0	CHEMBL4282	Homo sapiens	IC50	nM	1600.0
220830	17609829	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(C)CN(C)Cc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684395	=	IC50	nM	7100.0	CHEMBL4282	Homo sapiens	IC50	nM	7100.0
220831	17609830	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(=O)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)C1		CHEMBL3684396	=	IC50	nM	3400.0	CHEMBL4282	Homo sapiens	IC50	nM	3400.0
220832	17609831	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CCCNCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684397	=	IC50	nM	5800.0	CHEMBL4282	Homo sapiens	IC50	nM	5800.0
220833	17609832	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CN1CCC(N(C)Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684398	=	IC50	nM	5500.0	CHEMBL4282	Homo sapiens	IC50	nM	5500.0
220834	17609833	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CCOC(=O)N1CCC(NCc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684399	=	IC50	nM	2300.0	CHEMBL4282	Homo sapiens	IC50	nM	2300.0
220835	17609834	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CCCN(C)Cc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684400	=	IC50	nM	2500.0	CHEMBL4282	Homo sapiens	IC50	nM	2500.0
220836	17609835	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1ccc(CN2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)cc1		CHEMBL3684401	=	IC50	nM	2800.0	CHEMBL4282	Homo sapiens	IC50	nM	2800.0
220837	17609836	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(c1ccco1)N1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684402	=	IC50	nM	1400.0	CHEMBL4282	Homo sapiens	IC50	nM	1400.0
220838	17609837	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc2c(c1)Nc1ncccc1-n1c(-c3ccc(CNCC4CC4)cc3)nnc1-2		CHEMBL3684403	=	IC50	nM	6700.0	CHEMBL4282	Homo sapiens	IC50	nM	6700.0
220839	17609838	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc(CCN2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)cc1		CHEMBL3684404	=	IC50	nM	5800.0	CHEMBL4282	Homo sapiens	IC50	nM	5800.0
220840	17609839	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccc(F)cc1		CHEMBL3684405	=	IC50	nM	300.0	CHEMBL4282	Homo sapiens	IC50	nM	300.0
220841	17609840	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1cccnc1		CHEMBL3684406	=	IC50	nM	200.0	CHEMBL4282	Homo sapiens	IC50	nM	200.0
220842	17609841	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccco1		CHEMBL3684407	=	IC50	nM	1100.0	CHEMBL4282	Homo sapiens	IC50	nM	1100.0
220843	17609842	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CN(C)c1ccc(C(=O)NCc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)cc1		CHEMBL3684408	=	IC50	nM	110.0	CHEMBL4282	Homo sapiens	IC50	nM	110.0
220844	17609843	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccccc1		CHEMBL3684409	=	IC50	nM	200.0	CHEMBL4282	Homo sapiens	IC50	nM	200.0
220845	17609844	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)C1CCC1		CHEMBL3684410	=	IC50	nM	1800.0	CHEMBL4282	Homo sapiens	IC50	nM	1800.0
220846	17609845	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccccc1		CHEMBL3684411	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	nM	140.0
220847	17609846	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1ccc(S(=O)(=O)NCc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)cc1		CHEMBL3684412	=	IC50	nM	800.0	CHEMBL4282	Homo sapiens	IC50	nM	800.0
220848	17609847	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cn1cnc(S(=O)(=O)NCc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)c1		CHEMBL3684413	=	IC50	nM	240.0	CHEMBL4282	Homo sapiens	IC50	nM	240.0
220849	17609848	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cn1ccc(S(=O)(=O)NCc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)n1		CHEMBL3684414	=	IC50	nM	120.0	CHEMBL4282	Homo sapiens	IC50	nM	120.0
220850	17609849	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1cccnc1		CHEMBL3684415	=	IC50	nM	220.0	CHEMBL4282	Homo sapiens	IC50	nM	220.0
220851	17609850	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(Nc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccccc1		CHEMBL3684416	=	IC50	nM	6600.0	CHEMBL4282	Homo sapiens	IC50	nM	6600.0
220852	17609851	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)Nc1ccccc1		CHEMBL3684417	=	IC50	nM	2900.0	CHEMBL4282	Homo sapiens	IC50	nM	2900.0
220853	17609852	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(NCCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccccc1		CHEMBL3684418	=	IC50	nM	5800.0	CHEMBL4282	Homo sapiens	IC50	nM	5800.0
220854	17609853	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1ccc(S(=O)(=O)NCCc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)cc1		CHEMBL3684419	=	IC50	nM	9100.0	CHEMBL4282	Homo sapiens	IC50	nM	9100.0
220855	17609854	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NCCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)Nc1ccccc1		CHEMBL3684420	=	IC50	nM	120.0	CHEMBL4282	Homo sapiens	IC50	nM	120.0
220856	17609855	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NCCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccccc1		CHEMBL3684421	=	IC50	nM	630.0	CHEMBL4282	Homo sapiens	IC50	nM	630.0
220857	17609856	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccccc1F		CHEMBL3684422	=	IC50	nM	170.0	CHEMBL4282	Homo sapiens	IC50	nM	170.0
220858	17609857	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1cccc(F)c1		CHEMBL3684423	=	IC50	nM	400.0	CHEMBL4282	Homo sapiens	IC50	nM	400.0
220859	17609858	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1cccc(S(=O)(=O)NCc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)c1		CHEMBL3684424	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	nM	140.0
220860	17609859	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1cccc(S(=O)(=O)NCc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)c1		CHEMBL3684425	=	IC50	nM	110.0	CHEMBL4282	Homo sapiens	IC50	nM	110.0
220861	17609860	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1cccc(Cl)c1		CHEMBL3684426	=	IC50	nM	150.0	CHEMBL4282	Homo sapiens	IC50	nM	150.0
220862	17609861	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccc(F)cc1		CHEMBL3684427	=	IC50	nM	120.0	CHEMBL4282	Homo sapiens	IC50	nM	120.0
220863	17609862	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1ccc(S(=O)(=O)NCc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)cc1		CHEMBL3684428	=	IC50	nM	110.0	CHEMBL4282	Homo sapiens	IC50	nM	110.0
220864	17609863	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)c1ccc(Cl)cc1		CHEMBL3684429	=	IC50	nM	220.0	CHEMBL4282	Homo sapiens	IC50	nM	220.0
220865	17609864	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(=O)Nc1ccc(S(=O)(=O)NCc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)cc1		CHEMBL3684430	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	nM	140.0
220866	17609865	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)Nc1ccccc1F		CHEMBL3684431	=	IC50	nM	310.0	CHEMBL4282	Homo sapiens	IC50	nM	310.0
220867	17609866	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)Nc1cccc(F)c1		CHEMBL3684432	=	IC50	nM	1100.0	CHEMBL4282	Homo sapiens	IC50	nM	1100.0
220868	17609867	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1cccc(NC(=O)NCc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)c1		CHEMBL3684433	=	IC50	nM	130.0	CHEMBL4282	Homo sapiens	IC50	nM	130.0
220869	17609868	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)Nc1ccc(F)cc1		CHEMBL3684434	=	IC50	nM	1200.0	CHEMBL4282	Homo sapiens	IC50	nM	1200.0
220870	17609869	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1cccc(NC(=O)NCc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)c1		CHEMBL3684435	=	IC50	nM	480.0	CHEMBL4282	Homo sapiens	IC50	nM	480.0
220871	17609870	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	NC1(c2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CCC1		CHEMBL3684436	=	IC50	nM	99.0	CHEMBL4282	Homo sapiens	IC50	nM	99.0
220872	17609871	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	ClCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684437	=	IC50	nM	1900.0	CHEMBL4282	Homo sapiens	IC50	nM	1900.0
220873	17609872	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nnc4n3-c3ccccc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684438	=	IC50	nM	940.0	CHEMBL4282	Homo sapiens	IC50	nM	940.0
220874	17609873	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nnc6n5-c5ccccc5Nc5ccccc5-6)cc4)CC3)[nH]2)nc1		CHEMBL3684439	=	IC50	nM	250.0	CHEMBL4282	Homo sapiens	IC50	nM	250.0
220875	17609874	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	[C-]#[N+]c1ccc(C(=O)NC2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)cc1		CHEMBL3684440	=	IC50	nM	1700.0	CHEMBL4282	Homo sapiens	IC50	nM	1700.0
220876	17609875	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc2c(c1)Nc1ncccc1-n1c(-c3ccc(CN4CCC(c5nnc(-c6ccncc6)[nH]5)CC4)cc3)nnc1-2		CHEMBL3684441	=	IC50	nM	170.0	CHEMBL4282	Homo sapiens	IC50	nM	170.0
220877	17609876	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(c1ccc(F)cc1)N1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684442	=	IC50	nM	3200.0	CHEMBL4282	Homo sapiens	IC50	nM	3200.0
220878	17609877	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(C1CCCC1)N1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684443	=	IC50	nM	3400.0	CHEMBL4282	Homo sapiens	IC50	nM	3400.0
220879	17609878	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1ccccc1C(=O)N1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684444	=	IC50	nM	430.0	CHEMBL4282	Homo sapiens	IC50	nM	430.0
220880	17609879	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(CCc1ccccc1)N1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684445	=	IC50	nM	3400.0	CHEMBL4282	Homo sapiens	IC50	nM	3400.0
220881	17609880	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1cccc(C(=O)N2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)c1		CHEMBL3684446	=	IC50	nM	1300.0	CHEMBL4282	Homo sapiens	IC50	nM	1300.0
220882	17609881	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1ccc(C(=O)N2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)cc1		CHEMBL3684447	=	IC50	nM	1400.0	CHEMBL4282	Homo sapiens	IC50	nM	1400.0
220883	17609882	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1cccc(C(=O)N2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)c1		CHEMBL3684448	=	IC50	nM	2200.0	CHEMBL4282	Homo sapiens	IC50	nM	2200.0
220884	17609883	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	[C-]#[N+]c1ccc(C(=O)N2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)cc1		CHEMBL3684449	=	IC50	nM	990.0	CHEMBL4282	Homo sapiens	IC50	nM	990.0
220885	17609884	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Cc1ccccc1)N1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684450	=	IC50	nM	6000.0	CHEMBL4282	Homo sapiens	IC50	nM	6000.0
220886	17609885	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(c1ccccc1F)N1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684451	=	IC50	nM	450.0	CHEMBL4282	Homo sapiens	IC50	nM	450.0
220887	17609886	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1cc(C(=O)N2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)no1		CHEMBL3684452	=	IC50	nM	2900.0	CHEMBL4282	Homo sapiens	IC50	nM	2900.0
220888	17609887	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(c1ccc(F)c(F)c1)N1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684453	=	IC50	nM	4900.0	CHEMBL4282	Homo sapiens	IC50	nM	4900.0
220889	17609888	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(c1ccccc1)N1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684454	=	IC50	nM	1900.0	CHEMBL4282	Homo sapiens	IC50	nM	1900.0
220890	17609889	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COC(=O)c1sccc1S(=O)(=O)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684455	=	IC50	nM	790.0	CHEMBL4282	Homo sapiens	IC50	nM	790.0
220891	17609890	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1noc(C)c1S(=O)(=O)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684456	=	IC50	nM	6800.0	CHEMBL4282	Homo sapiens	IC50	nM	6800.0
220892	17609891	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1)c1ccccc1F		CHEMBL3684457	=	IC50	nM	2300.0	CHEMBL4282	Homo sapiens	IC50	nM	2300.0
220893	17609892	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(CC1CCCCC1)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3639833	=	IC50	nM	3400.0	CHEMBL4282	Homo sapiens	IC50	nM	3400.0
220894	17609893	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1)C1CC1		CHEMBL3684458	=	IC50	nM	5300.0	CHEMBL4282	Homo sapiens	IC50	nM	5300.0
220895	17609894	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1cccc(S(=O)(=O)NC2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)c1		CHEMBL3684459	=	IC50	nM	3000.0	CHEMBL4282	Homo sapiens	IC50	nM	3000.0
220896	17609895	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(=O)Nc1ccc(S(=O)(=O)NC2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)cc1		CHEMBL3684460	=	IC50	nM	5000.0	CHEMBL4282	Homo sapiens	IC50	nM	5000.0
220897	17609896	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(Cc1ccccc1)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684461	=	IC50	nM	1800.0	CHEMBL4282	Homo sapiens	IC50	nM	1800.0
220898	17609897	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1nc(C)c(S(=O)(=O)NC2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)s1		CHEMBL3684462	=	IC50	nM	5300.0	CHEMBL4282	Homo sapiens	IC50	nM	5300.0
220899	17609898	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(C)CS(=O)(=O)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684463	=	IC50	nM	6400.0	CHEMBL4282	Homo sapiens	IC50	nM	6400.0
220900	17609899	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(=O)c1ccc(S(=O)(=O)NC2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)cc1		CHEMBL3684464	=	IC50	nM	3400.0	CHEMBL4282	Homo sapiens	IC50	nM	3400.0
220901	17609900	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1)c1ccc2c(c1)OCCO2		CHEMBL3684465	=	IC50	nM	2000.0	CHEMBL4282	Homo sapiens	IC50	nM	2000.0
220902	17609901	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1)c1cccc(F)c1		CHEMBL3684466	=	IC50	nM	2700.0	CHEMBL4282	Homo sapiens	IC50	nM	2700.0
220903	17609902	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(c1ccc2c(c1)OCO2)N1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684467	=	IC50	nM	6900.0	CHEMBL4282	Homo sapiens	IC50	nM	6900.0
220904	17609903	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	[C-]#[N+]c1cccc(C(=O)N2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)c1		CHEMBL3684468	=	IC50	nM	2000.0	CHEMBL4282	Homo sapiens	IC50	nM	2000.0
220905	17609904	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1ccc(C(=O)N2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)cc1		CHEMBL3684469	=	IC50	nM	3000.0	CHEMBL4282	Homo sapiens	IC50	nM	3000.0
220906	17609905	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(c1ccccn1)N1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684470	=	IC50	nM	4200.0	CHEMBL4282	Homo sapiens	IC50	nM	4200.0
220907	17609906	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C1NCN(c2ccccc2)C12CCN(Cc1ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc1)CC2		CHEMBL3684471	=	IC50	nM	950.0	CHEMBL4282	Homo sapiens	IC50	nM	950.0
220908	17609907	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	[C-]#[N+]C1(c2ccccc2)CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684472	=	IC50	nM	7300.0	CHEMBL4282	Homo sapiens	IC50	nM	7300.0
220909	17609908	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(c1ccc(F)cc1)C1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684473	=	IC50	nM	1800.0	CHEMBL4282	Homo sapiens	IC50	nM	1800.0
220910	17609909	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc(F)cc1)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684474	=	IC50	nM	330.0	CHEMBL4282	Homo sapiens	IC50	nM	330.0
220911	17609910	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1ccc(C)cc1NC(=O)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684475	=	IC50	nM	720.0	CHEMBL4282	Homo sapiens	IC50	nM	720.0
220912	17609911	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccccc1F)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684476	=	IC50	nM	440.0	CHEMBL4282	Homo sapiens	IC50	nM	440.0
220913	17609912	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1ccc(NC(=O)NC2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)cc1		CHEMBL3684477	=	IC50	nM	440.0	CHEMBL4282	Homo sapiens	IC50	nM	440.0
220914	17609913	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1ccc(CCNC(=O)NC2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)cc1OC		CHEMBL3684478	=	IC50	nM	6000.0	CHEMBL4282	Homo sapiens	IC50	nM	6000.0
220915	17609914	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1cccc(NC(=O)NC2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)c1		CHEMBL3684479	=	IC50	nM	660.0	CHEMBL4282	Homo sapiens	IC50	nM	660.0
220916	17609915	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1cccc(CNC(=O)NC2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)c1		CHEMBL3684480	=	IC50	nM	780.0	CHEMBL4282	Homo sapiens	IC50	nM	780.0
220917	17609916	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1ccc(NC(=O)NC2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)cc1Cl		CHEMBL3684481	=	IC50	nM	1200.0	CHEMBL4282	Homo sapiens	IC50	nM	1200.0
220918	17609917	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NCc1ccccc1Cl)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684482	=	IC50	nM	910.0	CHEMBL4282	Homo sapiens	IC50	nM	910.0
220919	17609918	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1cccc(C(F)(F)F)c1)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684483	=	IC50	nM	630.0	CHEMBL4282	Homo sapiens	IC50	nM	630.0
220920	17609919	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccc2c(c1)CCO2)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684484	=	IC50	nM	530.0	CHEMBL4282	Homo sapiens	IC50	nM	530.0
220921	17609920	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1cccc(Cl)c1)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684485	=	IC50	nM	1200.0	CHEMBL4282	Homo sapiens	IC50	nM	1200.0
220922	17609921	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CCCc1ccccc1NC(=O)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684486	=	IC50	nM	770.0	CHEMBL4282	Homo sapiens	IC50	nM	770.0
220923	17609922	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1cccc(F)c1)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684487	=	IC50	nM	790.0	CHEMBL4282	Homo sapiens	IC50	nM	790.0
220924	17609923	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1ccccc1NC(=O)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684488	=	IC50	nM	700.0	CHEMBL4282	Homo sapiens	IC50	nM	700.0
220925	17609924	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NCCc1ccc(Cl)cc1)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684489	=	IC50	nM	940.0	CHEMBL4282	Homo sapiens	IC50	nM	940.0
220926	17609925	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1ccccc1CNC(=O)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684490	=	IC50	nM	1200.0	CHEMBL4282	Homo sapiens	IC50	nM	1200.0
220927	17609926	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NCCc1cccs1)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684491	=	IC50	nM	750.0	CHEMBL4282	Homo sapiens	IC50	nM	750.0
220928	17609927	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1ccccc1NC(=O)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684492	=	IC50	nM	700.0	CHEMBL4282	Homo sapiens	IC50	nM	700.0
220929	17609928	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	COc1ccc(NC(=O)NC2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)c(C)c1		CHEMBL3684493	=	IC50	nM	840.0	CHEMBL4282	Homo sapiens	IC50	nM	840.0
220930	17609929	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1cc(COCc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)no1		CHEMBL3684494	=	IC50	nM	2100.0	CHEMBL4282	Homo sapiens	IC50	nM	2100.0
220931	17609930	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc(-n2cc(COCc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)nn2)cc1		CHEMBL3684495	=	IC50	nM	490.0	CHEMBL4282	Homo sapiens	IC50	nM	490.0
220932	17609931	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc2c(c1)Nc1ncccc1-n1c(-c3ccc(CN4CCC(c5c[nH]c6ccccc56)CC4)cc3)nnc1-2		CHEMBL3684496	=	IC50	nM	500.0	CHEMBL4282	Homo sapiens	IC50	nM	500.0
220933	17609932	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc(OC2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)cc1		CHEMBL3684497	=	IC50	nM	830.0	CHEMBL4282	Homo sapiens	IC50	nM	830.0
220934	17609933	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc(OC2CCCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)C2)cc1		CHEMBL3684498	=	IC50	nM	920.0	CHEMBL4282	Homo sapiens	IC50	nM	920.0
220935	17609934	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1noc(C2CCCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)C2)n1		CHEMBL3684499	=	IC50	nM	410.0	CHEMBL4282	Homo sapiens	IC50	nM	410.0
220936	17609935	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=c1[nH]c(-c2ccccc2)cn1C1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684500	=	IC50	nM	48.0	CHEMBL4282	Homo sapiens	IC50	nM	48.0
220937	17609936	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(C)(N)c1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684501	=	IC50	nM	340.0	CHEMBL4282	Homo sapiens	IC50	nM	340.0
220938	17609937	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NC1(c2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CCC1)c1ccccc1		CHEMBL3684502	=	IC50	nM	73.0	CHEMBL4282	Homo sapiens	IC50	nM	73.0
220939	17609938	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(Nc1ccccc1)NC1(c2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CCC1		CHEMBL3684503	=	IC50	nM	1200.0	CHEMBL4282	Homo sapiens	IC50	nM	1200.0
220940	17609939	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(NC1(c2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CCC1)c1ccccc1		CHEMBL3684504	=	IC50	nM	280.0	CHEMBL4282	Homo sapiens	IC50	nM	280.0
220941	17609940	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc2c(c1)Nc1ncccc1-n1c(-c3ccc(C4CCCN4)cc3)nnc1-2		CHEMBL3684505	=	IC50	nM	1100.0	CHEMBL4282	Homo sapiens	IC50	nM	1100.0
220942	17609941	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(NC1(c2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CCC1)c1ccc(F)cc1		CHEMBL3684506	=	IC50	nM	580.0	CHEMBL4282	Homo sapiens	IC50	nM	580.0
220943	17609942	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1ccc(S(=O)(=O)NC2(c3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CCC2)cc1		CHEMBL3684507	=	IC50	nM	340.0	CHEMBL4282	Homo sapiens	IC50	nM	340.0
220944	17609943	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1cccc(S(=O)(=O)NC2(c3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CCC2)c1		CHEMBL3684508	=	IC50	nM	460.0	CHEMBL4282	Homo sapiens	IC50	nM	460.0
220945	17609944	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NC1(c2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CCC1)c1ccc(F)cc1		CHEMBL3684509	=	IC50	nM	610.0	CHEMBL4282	Homo sapiens	IC50	nM	610.0
220946	17609945	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(C)(C)OC(=O)NC1CCN(Cc2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684510	=	IC50	nM	1900.0	CHEMBL4282	Homo sapiens	IC50	nM	1900.0
220947	17609946	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Fc1ccc2c(CCNCc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)c[nH]c2c1		CHEMBL3684511	=	IC50	nM	210.0	CHEMBL4282	Homo sapiens	IC50	nM	210.0
220948	17609947	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Clc1ccc2nc(CCNCc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)[nH]c2c1		CHEMBL3684512	=	IC50	nM	150.0	CHEMBL4282	Homo sapiens	IC50	nM	150.0
220949	17609948	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=S(=O)(NC1(c2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CCC1)c1cccc(F)c1		CHEMBL3684513	=	IC50	nM	760.0	CHEMBL4282	Homo sapiens	IC50	nM	760.0
220950	17609949	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cn1ccc(S(=O)(=O)NC2(c3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CCC2)n1		CHEMBL3684514	=	IC50	nM	640.0	CHEMBL4282	Homo sapiens	IC50	nM	640.0
220951	17609950	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1cc(C(=O)NC2(c3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CCC2)no1		CHEMBL3684515	=	IC50	nM	240.0	CHEMBL4282	Homo sapiens	IC50	nM	240.0
220952	17609951	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc(-c2nnc(C3CCN(Cc4ccc(-c5nnc6n5-c5cccnc5Nc5ccccc5-6)cc4)CC3)o2)cc1		CHEMBL3684516	=	IC50	nM	660.0	CHEMBL4282	Homo sapiens	IC50	nM	660.0
220953	17609952	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1ccc2c(c1)-c1nnc(-c3ccc(C4(N)CCC4)cc3)n1-c1cccnc1N2		CHEMBL3684525	=	IC50	nM	960.0	CHEMBL4282	Homo sapiens	IC50	nM	960.0
220954	17609953	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	NC1(c2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CCCCC1		CHEMBL3684526	=	IC50	nM	500.0	CHEMBL4282	Homo sapiens	IC50	nM	500.0
220955	17609954	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1cccc2c1Nc1ncccc1-n1c(-c3ccc(C4(N)CCC4)cc3)nnc1-2		CHEMBL3684527	=	IC50	nM	1400.0	CHEMBL4282	Homo sapiens	IC50	nM	1400.0
220956	17609955	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	NC1(c2ccc(-c3nnc4n3-c3cccnc3Nc3ccc(Br)cc3-4)cc2)CCC1		CHEMBL3684528	=	IC50	nM	130.0	CHEMBL4282	Homo sapiens	IC50	nM	130.0
220957	17609956	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	NC1(c2ccc(-c3nnc4n3-c3cnccc3Nc3ccccc3-4)cc2)CCC1		CHEMBL3684529	=	IC50	nM	5000.0	CHEMBL4282	Homo sapiens	IC50	nM	5000.0
220958	17609957	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(C)(C)OC(=O)NC1(c2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684530	=	IC50	nM	1400.0	CHEMBL4282	Homo sapiens	IC50	nM	1400.0
220959	17609958	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	NC1(c2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684531	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	nM	140.0
220960	17609959	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Cc1ccc2c(c1)Nc1ncccc1-n1c(-c3ccc(C4(N)CCC4)cc3)nnc1-2		CHEMBL3684532	=	IC50	nM	490.0	CHEMBL4282	Homo sapiens	IC50	nM	490.0
220961	17609960	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	NC1(c2ccc(-c3nnc4n3-c3cccnc3Nc3ccc(-c5ccccc5)cc3-4)cc2)CCC1		CHEMBL3684533	=	IC50	nM	1200.0	CHEMBL4282	Homo sapiens	IC50	nM	1200.0
220962	17609961	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	OCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccc(Br)cc2-3)cc1		CHEMBL3684534	=	IC50	nM	5200.0	CHEMBL4282	Homo sapiens	IC50	nM	5200.0
220963	17609962	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	O=C(NC1(c2ccc(-c3nnc4n3-c3ccc(Cl)nc3Nc3ccccc3-4)cc2)CCC1)C(F)(F)F		CHEMBL3684535	=	IC50	nM	9300.0	CHEMBL4282	Homo sapiens	IC50	nM	9300.0
220964	17609963	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccc(Br)cc2-3)cc1		CHEMBL3684536	=	IC50	nM	6100.0	CHEMBL4282	Homo sapiens	IC50	nM	6100.0
220965	17609964	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Brc1ccc2c(c1)-c1nnc(-c3ccc(CN4CCC(c5nnc(-c6ccccn6)[nH]5)CC4)cc3)n1-c1cccnc1N2		CHEMBL3684537	=	IC50	nM	96.0	CHEMBL4282	Homo sapiens	IC50	nM	96.0
220966	17609965	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	c1ccc(CCNC2(c3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CCC2)cc1		CHEMBL3684538	=	IC50	nM	3800.0	CHEMBL4282	Homo sapiens	IC50	nM	3800.0
220967	17609966	CHEMBL3705356	Biochemical Assay: Biochemical assay using Akt AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	NC1(c2ccc(-c3nnc4n3-c3cc(-c5ccccc5)cnc3Nc3ccccc3-4)cc2)CCC1		CHEMBL3684539	=	IC50	nM	2600.0	CHEMBL4282	Homo sapiens	IC50	nM	2600.0
220968	17609967	CHEMBL3705043	Biochemical Assay: Biochemical assay using CisBio KinEASE HTRF Assay technology.	B	CC(C)(C)OC(=O)N1CCN(C(=O)c2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684517	=	IC50	nM	41000.0	CHEMBL4282	Homo sapiens	IC50	nM	41000.0
220969	17609968	CHEMBL3705043	Biochemical Assay: Biochemical assay using CisBio KinEASE HTRF Assay technology.	B	O=C(c1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1)N1CCNCC1		CHEMBL3684518	=	IC50	nM	17000.0	CHEMBL4282	Homo sapiens	IC50	nM	17000.0
220970	17609969	CHEMBL3705043	Biochemical Assay: Biochemical assay using CisBio KinEASE HTRF Assay technology.	B	CC(C)(C)OC(=O)NC1CCN(C(=O)c2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684519	=	IC50	nM	56000.0	CHEMBL4282	Homo sapiens	IC50	nM	56000.0
220971	17609970	CHEMBL3705043	Biochemical Assay: Biochemical assay using CisBio KinEASE HTRF Assay technology.	B	NC1CCN(C(=O)c2ccc(-c3nnc4n3-c3cccnc3Nc3ccccc3-4)cc2)CC1		CHEMBL3684520	=	IC50	nM	70000.0	CHEMBL4282	Homo sapiens	IC50	nM	70000.0
220972	17609971	CHEMBL3705043	Biochemical Assay: Biochemical assay using CisBio KinEASE HTRF Assay technology.	B	CC(C)(C)OC(=O)NCCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684521	=	IC50	nM	4300.0	CHEMBL4282	Homo sapiens	IC50	nM	4300.0
220973	17609972	CHEMBL3705043	Biochemical Assay: Biochemical assay using CisBio KinEASE HTRF Assay technology.	B	CC(C)(C)OC(=O)NCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684522	=	IC50	nM	14000.0	CHEMBL4282	Homo sapiens	IC50	nM	14000.0
220974	17609973	CHEMBL3705043	Biochemical Assay: Biochemical assay using CisBio KinEASE HTRF Assay technology.	B	NCCc1ccc(-c2nnc3n2-c2cccnc2Nc2ccccc2-3)cc1		CHEMBL3684523	=	IC50	nM	14000.0	CHEMBL4282	Homo sapiens	IC50	nM	14000.0
220975	17609974	CHEMBL3705043	Biochemical Assay: Biochemical assay using CisBio KinEASE HTRF Assay technology.	B	COc1cccc(C(=O)NC2CCN(Cc3ccc(-c4nnc5n4-c4cccnc4Nc4ccccc4-5)cc3)CC2)c1		CHEMBL3684524	=	IC50	nM	7600.0	CHEMBL4282	Homo sapiens	IC50	nM	7600.0
228740	17616944	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	CC(C)(C)C(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640733	=	Kd	nM	0.4	CHEMBL4282	Homo sapiens	Kd	nM	0.4
228741	17616945	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	CC(=O)OC(C)(C)C(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640734	=	Kd	nM	0.7	CHEMBL4282	Homo sapiens	Kd	nM	0.7
228742	17616946	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	CC(C)(O)C(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640735	=	Kd	nM	1.4	CHEMBL4282	Homo sapiens	Kd	nM	1.4
228743	17616947	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	C[C@H](O)CNC(=O)c1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640736	=	Kd	nM	7.1	CHEMBL4282	Homo sapiens	Kd	nM	7.1
228744	17616948	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	C[C@@H](O)CNC(=O)c1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640737	=	Kd	nM	1.2	CHEMBL4282	Homo sapiens	Kd	nM	1.2
228745	17616949	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	CN(C)C(=O)C1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640738	=	Kd	nM	0.2	CHEMBL4282	Homo sapiens	Kd	nM	0.2
228746	17616950	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	CCN(CC)C(=O)C1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640739	=	Kd	nM	0.2	CHEMBL4282	Homo sapiens	Kd	nM	0.2
228747	17616951	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	Nc1ncccc1-c1nc2ccc(-c3cccc(N4CCC(C(=O)N5CCOCC5)CC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640740	=	Kd	nM	0.2	CHEMBL4282	Homo sapiens	Kd	nM	0.2
228748	17616952	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	CC(=O)NC1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640741	=	Kd	nM	0.2	CHEMBL4282	Homo sapiens	Kd	nM	0.2
228749	17616953	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	CCC(=O)N1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640742	=	Kd	nM	1.4	CHEMBL4282	Homo sapiens	Kd	nM	1.4
228750	17616954	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	Nc1ncccc1-c1nc2ccc(-c3cccc(N4CCN(C(=O)C5CC5)CC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640743	=	Kd	nM	1.1	CHEMBL4282	Homo sapiens	Kd	nM	1.1
228751	17616955	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	CC(C)C(=O)N1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640744	=	Kd	nM	1.1	CHEMBL4282	Homo sapiens	Kd	nM	1.1
228752	17616956	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	CC(C)(C)C(=O)N1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640745	=	Kd	nM	1.7	CHEMBL4282	Homo sapiens	Kd	nM	1.7
228753	17616957	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	C[C@H]1CN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)C[C@@H](C)O1		CHEMBL3640746	=	Kd	nM	3.1	CHEMBL4282	Homo sapiens	Kd	nM	3.1
228754	17616958	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	Nc1ncccc1-c1nc2ccc(-c3cccc(N4CCS(=O)(=O)CC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640747	=	Kd	nM	0.8	CHEMBL4282	Homo sapiens	Kd	nM	0.8
228755	17616959	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Nc1ncccc1-c1nc2ccc(Nc3ccc(N4CCOCC4)cc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640749	=	Kd	nM	57.3	CHEMBL4282	Homo sapiens	Kd	nM	57.3
228756	17616960	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	Nc1ncccc1-c1nc2ccc(Sc3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640750	=	Kd	nM	109.5	CHEMBL4282	Homo sapiens	Kd	nM	109.5
228757	17616961	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	Nc1ncccc1-c1nc2ccc(Oc3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640751	=	Kd	nM	83.1	CHEMBL4282	Homo sapiens	Kd	nM	83.1
228758	17616962	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Nc1ncccc1-c1nc2ccc(-c3cccc(NC(=O)C4CC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640732	=	IC50	nM	3.09	CHEMBL4282	Homo sapiens	IC50	nM	3.09
228759	17616963	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(C)(C)C(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640733	=	IC50	nM	1.7	CHEMBL4282	Homo sapiens	IC50	nM	1.7
228760	17616964	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(=O)OC(C)(C)C(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640734	=	IC50	nM	4.46	CHEMBL4282	Homo sapiens	IC50	nM	4.46
228761	17616965	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(C)(O)C(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640735	=	IC50	nM	1.63	CHEMBL4282	Homo sapiens	IC50	nM	1.63
228762	17616966	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	C[C@H](O)CNC(=O)c1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640736	=	IC50	nM	2.45	CHEMBL4282	Homo sapiens	IC50	nM	2.45
228763	17616967	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	C[C@@H](O)CNC(=O)c1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640737	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
228764	17616968	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CN(C)C(=O)C1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640738	=	IC50	nM	2.51	CHEMBL4282	Homo sapiens	IC50	nM	2.51
228765	17616969	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CCN(CC)C(=O)C1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640739	=	IC50	nM	4.15	CHEMBL4282	Homo sapiens	IC50	nM	4.15
228766	17616970	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Nc1ncccc1-c1nc2ccc(-c3cccc(N4CCC(C(=O)N5CCOCC5)CC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640740	=	IC50	nM	3.36	CHEMBL4282	Homo sapiens	IC50	nM	3.36
228767	17616971	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(=O)NC1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640741	=	IC50	nM	1.44	CHEMBL4282	Homo sapiens	IC50	nM	1.44
228768	17616972	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CCC(=O)N1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640742	=	IC50	nM	2.15	CHEMBL4282	Homo sapiens	IC50	nM	2.15
228769	17616973	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Nc1ncccc1-c1nc2ccc(-c3cccc(N4CCN(C(=O)C5CC5)CC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640743	=	IC50	nM	1.84	CHEMBL4282	Homo sapiens	IC50	nM	1.84
228770	17616974	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	CC(C)(C)C(=O)N1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640745	=	IC50	nM	3.42	CHEMBL4282	Homo sapiens	IC50	nM	3.42
228771	17616975	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	C[C@H]1CN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)C[C@@H](C)O1		CHEMBL3640746	=	IC50	nM	4.36	CHEMBL4282	Homo sapiens	IC50	nM	4.36
228772	17616976	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Nc1ncccc1-c1nc2ccc(-c3cccc(N4CCS(=O)(=O)CC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640747	=	IC50	nM	1.79	CHEMBL4282	Homo sapiens	IC50	nM	1.79
228773	17616977	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Nc1ncccc1-c1nc2ccc(Nc3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640748	=	IC50	nM	3.77	CHEMBL4282	Homo sapiens	IC50	nM	3.77
228774	17616978	CHEMBL3705709	Alpha Screen Assay : AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen™ (Amplified Luminescent Proximity Homogeneous Assay) technology.	B	Nc1ncccc1-c1nc2ccc(Nc3ccc(N4CCOCC4)cc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640749	=	IC50	nM	8.72	CHEMBL4282	Homo sapiens	IC50	nM	8.72
228775	17616979	CHEMBL3705710	Thermal Shift Assay : Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone.	B	Nc1ncccc1-c1nc2ccc(-c3cccc(NC(=O)C4CC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640732	=	Kd	nM	7.0	CHEMBL4282	Homo sapiens	Kd	nM	7.0
261990	17644518	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	COC(=O)c1ccccc1-c1nc2ccc(-c3cccc(N4CCOCC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3649665	=	IC50	nM	12.6	CHEMBL4282	Homo sapiens	IC50	nM	12.6
261991	17644519	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	Cc1ccccc1-c1nc2ccc(-c3cccc(N4CCOCC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3649666	=	IC50	nM	11.5	CHEMBL4282	Homo sapiens	IC50	nM	11.5
261992	17644520	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	NC1(c2ccc(-n3c(C4CCCCC4)nc4ccc(-c5cccc(N6CCOCC6)c5)nc43)cc2)CCC1		CHEMBL3649667	=	IC50	nM	3.47	CHEMBL4282	Homo sapiens	IC50	nM	3.47
261993	17644521	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	NC1(c2ccc(-n3c(C4CC4)nc4ccc(-c5cccc(N6CCOCC6)c5)nc43)cc2)CCC1		CHEMBL3649668	=	IC50	nM	1.99	CHEMBL4282	Homo sapiens	IC50	nM	1.99
261994	17644522	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	Nc1ncnc(Cl)c1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3649669	=	IC50	nM	7.17	CHEMBL4282	Homo sapiens	IC50	nM	7.17
261995	17644523	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	Cn1cc(-c2nc3ccc(-c4ccccc4)nc3n2-c2ccc(C3(N)CCC3)cc2)c(N)n1		CHEMBL3649670	=	IC50	nM	5.78	CHEMBL4282	Homo sapiens	IC50	nM	5.78
261996	17644524	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	Nc1nccnc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3649671	=	IC50	nM	1.69	CHEMBL4282	Homo sapiens	IC50	nM	1.69
261997	17644525	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	NC1(c2ccc(-n3c(-c4cccnc4)nc4ccc(-c5ccccc5)nc43)cc2)CCC1		CHEMBL3649672	=	IC50	nM	4.3	CHEMBL4282	Homo sapiens	IC50	nM	4.3
261998	17644526	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	NC1(c2ccc(-n3c(-c4ccccc4)nc4ccc(-c5ccccc5)nc43)cc2)CCC1		CHEMBL3649673	=	IC50	nM	7.75	CHEMBL4282	Homo sapiens	IC50	nM	7.75
261999	17644527	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	NC1(c2ccc(-n3c(-c4ccccc4O)nc4ccc(-c5ccccc5)nc43)cc2)CCC1		CHEMBL3649674	=	IC50	nM	4.74	CHEMBL4282	Homo sapiens	IC50	nM	4.74
262000	17644528	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	NC1(c2ccc(-n3c(-c4cccnc4F)nc4ccc(-c5ccccc5)nc43)cc2)CCC1		CHEMBL3649675	=	IC50	nM	7.27	CHEMBL4282	Homo sapiens	IC50	nM	7.27
262001	17644529	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	Nc1ccccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3649676	=	IC50	nM	5.67	CHEMBL4282	Homo sapiens	IC50	nM	5.67
262002	17644530	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	NC1(c2ccc(-n3c(-c4ccccn4)nc4ccc(-c5cccc(N6CCOCC6)c5)nc43)cc2)CCC1		CHEMBL3649677	=	IC50	nM	5260.0	CHEMBL4282	Homo sapiens	IC50	nM	5260.0
262003	17644531	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	NC1(c2ccc(-n3c(-c4cc[nH]n4)nc4ccc(-c5cccc(N6CCOCC6)c5)nc43)cc2)CCC1		CHEMBL3649678	=	IC50	nM	1160.0	CHEMBL4282	Homo sapiens	IC50	nM	1160.0
262004	17644532	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	NC1(c2ccc(-n3c(-c4cccc(O)c4)nc4ccc(-c5cccc(N6CCOCC6)c5)nc43)cc2)CCC1		CHEMBL3649679	=	IC50	nM	4.42	CHEMBL4282	Homo sapiens	IC50	nM	4.42
262005	17644533	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	COc1ccc(-c2nc3ccc(-c4cccc(N5CCOCC5)c4)nc3n2-c2ccc(C3(N)CCC3)cc2)cc1		CHEMBL3649680	=	IC50	nM	4.78	CHEMBL4282	Homo sapiens	IC50	nM	4.78
262006	17644534	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	NC1(c2ccc(-n3c(-c4cccc(F)c4)nc4ccc(-c5cccc(N6CCOCC6)c5)nc43)cc2)CCC1		CHEMBL3649681	=	IC50	nM	35.5	CHEMBL4282	Homo sapiens	IC50	nM	35.5
262007	17644535	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	NC1(c2ccc(-n3c(-c4cccc(Cl)c4)nc4ccc(-c5cccc(N6CCOCC6)c5)nc43)cc2)CCC1		CHEMBL3649682	=	IC50	nM	5.9	CHEMBL4282	Homo sapiens	IC50	nM	5.9
262008	17644536	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	NC1(c2ccc(-n3c(-c4ccc(Cl)cc4)nc4ccc(-c5cccc(N6CCOCC6)c5)nc43)cc2)CCC1		CHEMBL3649683	=	IC50	nM	6.27	CHEMBL4282	Homo sapiens	IC50	nM	6.27
262009	17644537	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	NC1(c2ccc(-n3c(-c4ncccn4)nc4ccc(-c5cccc(N6CCOCC6)c5)nc43)cc2)CCC1		CHEMBL3649684	=	IC50	nM	5.71	CHEMBL4282	Homo sapiens	IC50	nM	5.71
262010	17644538	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	NC1(c2ccc(-n3c(-c4ccnnc4)nc4ccc(-c5cccc(N6CCOCC6)c5)nc43)cc2)CCC1		CHEMBL3649685	=	IC50	nM	4.96	CHEMBL4282	Homo sapiens	IC50	nM	4.96
262011	17644539	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	CN(C)C(=O)c1cccc(-c2ccc3nc(-c4ccccc4)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3649686	=	IC50	nM	4.27	CHEMBL4282	Homo sapiens	IC50	nM	4.27
262012	17644540	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	NC1(c2ccc(-n3c(-c4ccccc4)nc4ccc(NCc5ccccc5)nc43)cc2)CCC1		CHEMBL3649687	=	IC50	nM	871.0	CHEMBL4282	Homo sapiens	IC50	nM	871.0
262013	17644541	CHEMBL3706066	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	NC1(c2ccc(-n3c(-c4ccccc4)nc4ccc(Nc5ccccc5)nc43)cc2)CCC1		CHEMBL3649688	=	IC50	nM	4.13	CHEMBL4282	Homo sapiens	IC50	nM	4.13
273513	17655835	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(F)cccc21		CHEMBL3112848	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
273514	17655836	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(F)cccc21		CHEMBL3112848	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
273515	17655837	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1(C)CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21		CHEMBL3112865	=	IC50	nM	21.0	CHEMBL4282	Homo sapiens	IC50	nM	21.0
273516	17655838	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3112866	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
273517	17655839	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3112866	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
273518	17655840	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3112866	=	IC50	nM	27.0	CHEMBL4282	Homo sapiens	IC50	nM	27.0
273519	17655841	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3112866	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
273529	17655851	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N2CCN(c3cccc(C(F)(F)F)c3)CC2)c2cncnc12		CHEMBL3939475	=	IC50	nM	23000.0	CHEMBL4282	Homo sapiens	IC50	nM	23000.0
282721	17665066	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	c1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CC(c4nnc(-c5ccccn5)[nH]4)C3)cc2)cc1		CHEMBL3667041	<	IC50	nM	50.0	CHEMBL4282	Homo sapiens	IC50	nM	50.0
282722	17665067	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CC(c5nnc(-c6ccccn6)[nH]5)C4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3667042	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	nM	23.0
282723	17665068	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1cnc2nc(-c3ccc(CN4CC(c5nnc(-c6ccccn6)[nH]5)C4)cc3)c(-c3ccccc3)cn12		CHEMBL3667043	<	IC50	nM	50.0	CHEMBL4282	Homo sapiens	IC50	nM	50.0
282724	17665069	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Clc1cnc2nc(-c3ccc(CN4CC(c5nnc(-c6ccccn6)[nH]5)C4)cc3)c(-c3ccccc3)cn12		CHEMBL3667044	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
282725	17665070	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	c1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CCC(c4nc5ccncc5[nH]4)CC3)cc2)cc1		CHEMBL3667045	=	IC50	nM	157.0	CHEMBL4282	Homo sapiens	IC50	nM	157.0
282726	17665071	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	c1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CCC(c4nc5cccnc5[nH]4)CC3)cc2)cc1		CHEMBL3672010	=	IC50	nM	56.0	CHEMBL4282	Homo sapiens	IC50	nM	56.0
282727	17665072	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	N#Cc1ccc2nc(C3CCN(Cc4ccc(-c5nc6nccn6cc5-c5ccccc5)cc4)CC3)[nH]c2c1		CHEMBL3672011	=	IC50	nM	83.0	CHEMBL4282	Homo sapiens	IC50	nM	83.0
282728	17665073	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	c1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CCC(c4cnc5ccccc5n4)CC3)cc2)cc1		CHEMBL3672012	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
282729	17665074	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	N#Cc1ccc2nc(C3CCN(Cc4ccc(-c5nc6ccnn6cc5-c5ccccc5)cc4)CC3)[nH]c2c1		CHEMBL3672013	=	IC50	nM	39.0	CHEMBL4282	Homo sapiens	IC50	nM	39.0
282730	17665075	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5nc6ccc(F)cc6[nH]5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672014	=	IC50	nM	112.0	CHEMBL4282	Homo sapiens	IC50	nM	112.0
282731	17665076	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5nc6ccncc6[nH]5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672015	=	IC50	nM	3000.0	CHEMBL4282	Homo sapiens	IC50	nM	3000.0
282732	17665077	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	c1ccc(-c2cn3nccc3nc2-c2ccc(CN3CCC(c4nc5cccnc5[nH]4)CC3)cc2)cc1		CHEMBL3672016	=	IC50	nM	42.0	CHEMBL4282	Homo sapiens	IC50	nM	42.0
282733	17665078	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	FC(F)(F)c1ccc2nc(C3CCN(Cc4ccc(-c5nc6ccnn6cc5-c5ccccc5)cc4)CC3)[nH]c2c1		CHEMBL3672017	=	IC50	nM	338.0	CHEMBL4282	Homo sapiens	IC50	nM	338.0
282734	17665079	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1ccc2nc(C3CCN(Cc4ccc(-c5nc6ccnn6cc5-c5ccccc5)cc4)CC3)[nH]c2c1		CHEMBL3672018	=	IC50	nM	42.0	CHEMBL4282	Homo sapiens	IC50	nM	42.0
282735	17665080	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Nc1ncnc2c1cnn2C1CCN(Cc2ccc(-c3nc4ccnn4cc3-c3ccccc3)cc2)CC1		CHEMBL3672019	=	IC50	nM	25.0	CHEMBL4282	Homo sapiens	IC50	nM	25.0
282736	17665081	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5nc6ccc(C#N)cc6[nH]5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672020	=	IC50	nM	525.0	CHEMBL4282	Homo sapiens	IC50	nM	525.0
282737	17665082	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5nc6ccc(C(F)(F)F)cc6[nH]5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672021	=	IC50	nM	1450.0	CHEMBL4282	Homo sapiens	IC50	nM	1450.0
282738	17665083	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(n5ncc6c(N)ncnc65)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672022	=	IC50	nM	288.0	CHEMBL4282	Homo sapiens	IC50	nM	288.0
282739	17665084	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5nc6cccnc6[nH]5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672023	=	IC50	nM	315.0	CHEMBL4282	Homo sapiens	IC50	nM	315.0
282740	17665085	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672024	=	IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	nM	44.0
282741	17665086	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5cnc6ccccc6n5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672025	=	IC50	nM	4370.0	CHEMBL4282	Homo sapiens	IC50	nM	4370.0
282742	17665087	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6ncc(C)n6cc5-c5ccccc5)cc4)C3)n[nH]2)n1		CHEMBL3672026	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
282743	17665088	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)cn2c1Br		CHEMBL3672027	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
282744	17665089	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1cnn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CC(c5n[nH]c(-c6cccc(C)n6)n5)C4)cc3)nc12		CHEMBL3672028	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
282745	17665090	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1cnn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)nc12		CHEMBL3672029	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
282746	17665091	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CC(C)c1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672030	=	IC50	nM	84.0	CHEMBL4282	Homo sapiens	IC50	nM	84.0
282747	17665092	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CC(C)c1nc2nc(-c3ccc(CN4CCC(c5cnc6ccccc6n5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672031	=	IC50	nM	6700.0	CHEMBL4282	Homo sapiens	IC50	nM	6700.0
282748	17665093	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(C(C)C)nn6cc5-c5ccccc5)cc4)C3)n[nH]2)n1		CHEMBL3672032	=	IC50	nM	70.0	CHEMBL4282	Homo sapiens	IC50	nM	70.0
282749	17665094	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1cnn2cc(-c3ccc(F)cc3F)c(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)nc12		CHEMBL3672033	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
282750	17665095	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CC(c4n[nH]c(-c5ccccn5)n4)C3)cc2)cc1		CHEMBL3672034	=	IC50	nM	26.0	CHEMBL4282	Homo sapiens	IC50	nM	26.0
282751	17665096	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CCC(c4cnc5ccccc5n4)CC3)cc2)cc1		CHEMBL3672035	=	IC50	nM	365.0	CHEMBL4282	Homo sapiens	IC50	nM	365.0
282752	17665097	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(C)nn6cc5-c5ccc(F)cc5F)cc4)C3)n[nH]2)n1		CHEMBL3672036	=	IC50	nM	29.0	CHEMBL4282	Homo sapiens	IC50	nM	29.0
282753	17665098	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	c1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CCC(c4cnc5ccccc5n4)CC3)cc2)cc1		CHEMBL3672012	=	IC50	nM	70.0	CHEMBL4282	Homo sapiens	IC50	nM	70.0
282754	17665099	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cn2cc(-c3ccccc3)c(-c3ccc(CN4CCC(c5cnc6ccccc6n5)CC4)cc3)nc2n1		CHEMBL3672037	=	IC50	nM	77.0	CHEMBL4282	Homo sapiens	IC50	nM	77.0
282755	17665100	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(C)cn6cc5-c5ccccc5)cc4)C3)n[nH]2)n1		CHEMBL3672038	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
282756	17665101	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(C7CC7)nn6cc5-c5ccc(F)cc5)cc4)C3)n[nH]2)n1		CHEMBL3672039	=	IC50	nM	29.0	CHEMBL4282	Homo sapiens	IC50	nM	29.0
282757	17665102	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	c1ccc(-c2cn3nc(C4CC4)nc3nc2-c2ccc(CN3CCC(c4cnc5ccccc5n4)CC3)cc2)cc1		CHEMBL3672040	=	IC50	nM	247.0	CHEMBL4282	Homo sapiens	IC50	nM	247.0
282758	17665103	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(C7CC7)nn6cc5-c5ccccc5)cc4)C3)n[nH]2)n1		CHEMBL3672041	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
282759	17665104	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCc1cnn2cc(-c3ccccc3)c(-c3ccc(CN4CC(c5n[nH]c(-c6cccc(C)n6)n5)C4)cc3)nc12		CHEMBL3672042	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
282760	17665105	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CNc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672043	=	IC50	nM	63.0	CHEMBL4282	Homo sapiens	IC50	nM	63.0
282761	17665106	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CC(C)Nc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672044	=	IC50	nM	22.0	CHEMBL4282	Homo sapiens	IC50	nM	22.0
282762	17665107	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)c(C)n2n1		CHEMBL3672045	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
282763	17665108	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(C)nn6c(C)c5-c5ccccc5)cc4)C3)n[nH]2)n1		CHEMBL3672046	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
282764	17665109	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)c(NC3CCC3)n2n1		CHEMBL3672047	=	IC50	nM	32.0	CHEMBL4282	Homo sapiens	IC50	nM	32.0
282765	17665110	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CNc1c(-c2ccccc2)c(-c2ccc(CN3CC(c4n[nH]c(-c5cccc(C)n5)n4)C3)cc2)nc2nc(C)nn12		CHEMBL3672048	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
282766	17665111	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)c(NC(C)C)n2n1		CHEMBL3672049	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
282767	17665112	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)c(NC(C)C)n2n1		CHEMBL3672049	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
282768	17665113	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1cnn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CCC(c5n[nH]c(-c6cccc(C)n6)n5)CC4)cc3)nc12		CHEMBL3672050	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
282769	17665114	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1cnn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)nc12		CHEMBL3672051	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
282770	17665115	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CCN(Cc4ccc(-c5nc6nc(C)nn6cc5-c5cccc(F)c5)cc4)CC3)n[nH]2)n1		CHEMBL3672052	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
282771	17665116	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)c(-c3cccc(F)c3)cn2n1		CHEMBL3672053	=	IC50	nM	28.0	CHEMBL4282	Homo sapiens	IC50	nM	28.0
282772	17665117	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6cc(Cl)ccn6)n5)CC4)cc3)c(-c3ccc(F)cc3F)cn2n1		CHEMBL3672054	=	IC50	nM	22.0	CHEMBL4282	Homo sapiens	IC50	nM	22.0
282773	17665118	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CCN(Cc4ccc(-c5nc6nc(C)nn6cc5-c5ccc(F)cc5F)cc4)CC3)n[nH]2)n1		CHEMBL3672055	=	IC50	nM	62.0	CHEMBL4282	Homo sapiens	IC50	nM	62.0
282774	17665119	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6cnccn6)n5)CC4)cc3)c(-c3ccc(F)cc3F)cn2n1		CHEMBL3672056	=	IC50	nM	355.0	CHEMBL4282	Homo sapiens	IC50	nM	355.0
282775	17665120	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CCN(Cc4ccc(-c5nc6nc(C7CC7)nn6cc5-c5ccc(F)cc5)cc4)CC3)n[nH]2)n1		CHEMBL3672057	=	IC50	nM	41.0	CHEMBL4282	Homo sapiens	IC50	nM	41.0
282776	17665121	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1ccc(-c2cn3nc(C4CC4)nc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL3672058	=	IC50	nM	32.0	CHEMBL4282	Homo sapiens	IC50	nM	32.0
282777	17665122	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1ccc(-c2cn3nc(C4CC4)nc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5cc(Cl)ccn5)n4)CC3)cc2)cc1		CHEMBL3672059	=	IC50	nM	56.0	CHEMBL4282	Homo sapiens	IC50	nM	56.0
282778	17665123	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CCN(Cc4ccc(-c5nc6nccn6cc5-c5ccc(F)cc5)cc4)CC3)n[nH]2)n1		CHEMBL3672060	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
282779	17665124	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL3672061	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
282780	17665125	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1ccc(-c2cn3ccnc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5cnccn5)n4)CC3)cc2)cc1		CHEMBL3672062	=	IC50	nM	186.0	CHEMBL4282	Homo sapiens	IC50	nM	186.0
282781	17665126	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CCN(Cc4ccc(-c5nc6ncc(Br)n6cc5-c5ccc(F)cc5)cc4)CC3)n[nH]2)n1		CHEMBL3672063	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
282782	17665127	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Fc1ccc(-c2cn3c(Cl)cnc3nc2-c2ccc(CN3CCC(c4n[nH]c(-c5ccccn5)n4)CC3)cc2)cc1		CHEMBL3672064	=	IC50	nM	25.0	CHEMBL4282	Homo sapiens	IC50	nM	25.0
282783	17665128	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CCN(Cc4ccc(-c5nc6nccn6cc5-c5ccccc5F)cc4)CC3)n[nH]2)n1		CHEMBL3672065	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
282784	17665129	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Brc1cnc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)cn12		CHEMBL3672066	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
282785	17665130	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cn2cc(-c3ccccc3)c(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)nc2n1		CHEMBL3672067	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
282786	17665131	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(C)c(Br)n6cc5-c5ccccc5)cc4)C3)n[nH]2)n1		CHEMBL3672068	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
282787	17665132	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CNc1c(-c2ccccc2)c(-c2ccc(CN3CC(c4n[nH]c(-c5ccccn5)n4)C3)cc2)nc2nccn12		CHEMBL3672069	=	IC50	nM	30.0	CHEMBL4282	Homo sapiens	IC50	nM	30.0
282788	17665133	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CNc1c(-c2ccccc2)c(-c2ccc(CN3CC(c4n[nH]c(-c5ccccn5)n4)C3)cc2)nc2ncc(Br)n12		CHEMBL3672070	=	IC50	nM	42.0	CHEMBL4282	Homo sapiens	IC50	nM	42.0
282789	17665134	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CNc1c(-c2ccccc2)c(-c2ccc(CN3CC(c4n[nH]c(-c5ccccn5)n4)C3)cc2)nc2nc(C)cn12		CHEMBL3672071	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
282790	17665135	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CNc1c(-c2ccccc2)c(-c2ccc(CN3CC(c4n[nH]c(-c5cccc(C)n5)n4)C3)cc2)nc2nc(C)cn12		CHEMBL3672072	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
282791	17665136	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	OCc1cnn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)nc12		CHEMBL3672094	=	IC50	nM	55.0	CHEMBL4282	Homo sapiens	IC50	nM	55.0
282792	17665137	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1nn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)nc2c1CO		CHEMBL3672073	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
282793	17665138	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1nn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CC(c5n[nH]c(-c6cccc(C)n6)n5)C4)cc3)nc2c1CO		CHEMBL3672074	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
282794	17665139	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1nn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CCC(c5n[nH]c(-c6cccc(C)n6)n5)CC4)cc3)nc2c1CO		CHEMBL3672075	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
282795	17665140	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1nn2cc(-c3c(F)cccc3F)c(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)nc2c1CO		CHEMBL3672076	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
282796	17665141	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cn2c(NC(C)C)c(-c3ccccc3)c(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)nc2n1		CHEMBL3672077	=	IC50	nM	30.0	CHEMBL4282	Homo sapiens	IC50	nM	30.0
282797	17665142	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(C)cn6c(NC(C)C)c5-c5ccccc5)cc4)C3)n[nH]2)n1		CHEMBL3672078	=	IC50	nM	33.0	CHEMBL4282	Homo sapiens	IC50	nM	33.0
282798	17665143	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CC(C)Nc1c(-c2ccccc2)c(-c2ccc(CN3CC(c4n[nH]c(-c5ccccn5)n4)C3)cc2)nc2nccn12		CHEMBL3672079	=	IC50	nM	25.0	CHEMBL4282	Homo sapiens	IC50	nM	25.0
282799	17665144	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CNc1c(-c2ccccc2)c(-c2ccc(CN3CC(c4n[nH]c(-c5ccccn5)n4)C3)cc2)nc2nc(-c3ccccn3)nn12		CHEMBL3672080	=	IC50	nM	29.0	CHEMBL4282	Homo sapiens	IC50	nM	29.0
282800	17665145	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CC(C)Nc1c(-c2ccccc2)c(-c2ccc(CN3CC(c4n[nH]c(-c5ccccn5)n4)C3)cc2)nc2nc(-c3ccccn3)nn12		CHEMBL3672081	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	nM	24.0
282801	17665146	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cccc(-c2nc(C3CN(Cc4ccc(-c5nc6nc(-c7ccccn7)nn6c(NC(C)C)c5-c5ccccc5)cc4)C3)n[nH]2)n1		CHEMBL3672082	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
282802	17665147	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	c1ccc(-c2cn3nc(C4CC4)nc3nc2-c2ccc(CN3CC(c4n[nH]c(-c5ccccn5)n4)C3)cc2)cc1		CHEMBL3639709	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
282803	17665148	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CSc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6cccc(C)n6)n5)C4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672083	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
282804	17665149	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CSc1nc2nc(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672084	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
282805	17665150	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CSc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672085	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
282806	17665151	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CSc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6ncccn6)n5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672086	=	IC50	nM	77.0	CHEMBL4282	Homo sapiens	IC50	nM	77.0
282807	17665152	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CSc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6cnccn6)n5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672087	=	IC50	nM	26.0	CHEMBL4282	Homo sapiens	IC50	nM	26.0
282808	17665153	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CSc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6cccc(C)n6)n5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672088	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
282809	17665154	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CS(=O)(=O)c1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)c(-c3ccccc3)cn2n1		CHEMBL3672089	=	IC50	nM	54.0	CHEMBL4282	Homo sapiens	IC50	nM	54.0
282810	17665155	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1cn2cc(-c3ccccc3)c(-c3ccc(CN4CC(c5n[nH]c(-c6cccc(C)n6)n5)C4)cc3)nc2n1		CHEMBL3672090	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
282811	17665156	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1cn2cc(-c3ccccc3)c(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)nc2n1		CHEMBL3672091	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
282812	17665157	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	OCc1cn2cc(-c3ccccc3)c(-c3ccc(CN4CC(c5n[nH]c(-c6ccccn6)n5)C4)cc3)nc2n1		CHEMBL3672092	=	IC50	nM	72.0	CHEMBL4282	Homo sapiens	IC50	nM	72.0
282813	17665158	CHEMBL3705788	TR-FRET Assay: Akt1 inhibitory activity of compounds of the present invention may be quantified0 employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in am- ide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a IOOfold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2nc(-c3ccc(CN4CCC(c5n[nH]c(-c6ccccn6)n5)CC4)cc3)c(-c3cc(F)ccc3F)cn2n1		CHEMBL3672093	=	IC50	nM	60.0	CHEMBL4282	Homo sapiens	IC50	nM	60.0
286538	17668883	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	Nc1ncccc1-c1nc2ccc(-c3cccc(NC(=O)C4CC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640732	=	Kd	nM	7.0	CHEMBL4282	Homo sapiens	Kd	nM	7.0
286539	17668884	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	CC(C)(C)C(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640733	=	Kd	nM	0.4	CHEMBL4282	Homo sapiens	Kd	nM	0.4
286540	17668885	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	CC(=O)OC(C)(C)C(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640734	=	Kd	nM	0.7	CHEMBL4282	Homo sapiens	Kd	nM	0.7
286541	17668886	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	CC(C)(O)C(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640735	=	Kd	nM	1.4	CHEMBL4282	Homo sapiens	Kd	nM	1.4
286542	17668887	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	C[C@H](O)CNC(=O)c1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640736	=	Kd	nM	7.1	CHEMBL4282	Homo sapiens	Kd	nM	7.1
286543	17668888	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	C[C@@H](O)CNC(=O)c1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640737	=	Kd	nM	1.2	CHEMBL4282	Homo sapiens	Kd	nM	1.2
286544	17668889	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	CN(C)C(=O)C1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640738	=	Kd	nM	0.2	CHEMBL4282	Homo sapiens	Kd	nM	0.2
286545	17668890	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	CCN(CC)C(=O)C1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640739	=	Kd	nM	0.2	CHEMBL4282	Homo sapiens	Kd	nM	0.2
286546	17668891	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	Nc1ncccc1-c1nc2ccc(-c3cccc(N4CCC(C(=O)N5CCOCC5)CC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640740	=	Kd	nM	0.2	CHEMBL4282	Homo sapiens	Kd	nM	0.2
286547	17668892	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	CC(=O)NC1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640741	=	Kd	nM	0.2	CHEMBL4282	Homo sapiens	Kd	nM	0.2
286548	17668893	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	CCC(=O)N1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640742	=	Kd	nM	1.4	CHEMBL4282	Homo sapiens	Kd	nM	1.4
286549	17668894	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	Nc1ncccc1-c1nc2ccc(-c3cccc(N4CCN(C(=O)C5CC5)CC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640743	=	Kd	nM	1.1	CHEMBL4282	Homo sapiens	Kd	nM	1.1
286550	17668895	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	CC(C)C(=O)N1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640744	=	Kd	nM	1.1	CHEMBL4282	Homo sapiens	Kd	nM	1.1
286551	17668896	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	CC(C)(C)C(=O)N1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640745	=	Kd	nM	1.7	CHEMBL4282	Homo sapiens	Kd	nM	1.7
286552	17668897	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	C[C@H]1CN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)C[C@@H](C)O1		CHEMBL3640746	=	Kd	nM	3.1	CHEMBL4282	Homo sapiens	Kd	nM	3.1
286553	17668898	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	Nc1ncccc1-c1nc2ccc(-c3cccc(N4CCS(=O)(=O)CC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640747	=	Kd	nM	0.8	CHEMBL4282	Homo sapiens	Kd	nM	0.8
286554	17668899	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	Nc1ncccc1-c1nc2ccc(Nc3ccc(N4CCOCC4)cc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640749	=	Kd	nM	57.3	CHEMBL4282	Homo sapiens	Kd	nM	57.3
286555	17668900	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	Nc1ncccc1-c1nc2ccc(Sc3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640750	=	Kd	nM	109.5	CHEMBL4282	Homo sapiens	Kd	nM	109.5
286556	17668901	CHEMBL3705365	Thermal Shift Assay: Binding analysis. Protein-ligand binding was identified with the thermal shift assay which is based on the ligand-induced stabilization of the protein tertiary structure. The thermal stability of the ligand-Akt1 complex was assessed by subjecting the complex to a set temperature gradient and by comparison of the meltion temperature of the Akt1-ligand complex with the melting temperature of the protein alone. Protein unfolding was monitored by the fluorescence readout of an environmentally sensitive fluorescent dye, 1-anilinonaphthalene-8-sulfonic acid (ANS). Protein-ligand mixture containing 15 uM compound, 200 ng/mL full length inactive Akt1, 200 uM ANS in the binding buffer (25 mM Tris-HCl (pH. 7.5), 100 mM NaCl, 10% Glycerol, and 5 mM DTT) was prepared in a PCR plate. The PCR plate was placed into a RT-PCR instrument and a temperature gradient was performed, increasing from 27 to 80 C., at 1 C./30 sec heat rate with a dwell time of 20 sec.	B	Nc1ncccc1-c1nc2ccc(Oc3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640751	=	Kd	nM	83.1	CHEMBL4282	Homo sapiens	Kd	nM	83.1
286557	17668902	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	Nc1ncccc1-c1nc2ccc(-c3cccc(NC(=O)C4CC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640732	=	IC50	nM	3.09	CHEMBL4282	Homo sapiens	IC50	nM	3.09
286558	17668903	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	CC(C)(C)C(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640733	=	IC50	nM	1.7	CHEMBL4282	Homo sapiens	IC50	nM	1.7
286559	17668904	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	CC(=O)OC(C)(C)C(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640734	=	IC50	nM	4.46	CHEMBL4282	Homo sapiens	IC50	nM	4.46
286560	17668905	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	CC(C)(O)C(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640735	=	IC50	nM	1.63	CHEMBL4282	Homo sapiens	IC50	nM	1.63
286561	17668906	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	C[C@H](O)CNC(=O)c1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640736	=	IC50	nM	2.45	CHEMBL4282	Homo sapiens	IC50	nM	2.45
286562	17668907	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	C[C@@H](O)CNC(=O)c1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL3640737	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
286563	17668908	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	CN(C)C(=O)C1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640738	=	IC50	nM	2.51	CHEMBL4282	Homo sapiens	IC50	nM	2.51
286564	17668909	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	CCN(CC)C(=O)C1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640739	=	IC50	nM	4.15	CHEMBL4282	Homo sapiens	IC50	nM	4.15
286565	17668910	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	Nc1ncccc1-c1nc2ccc(-c3cccc(N4CCC(C(=O)N5CCOCC5)CC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640740	=	IC50	nM	3.36	CHEMBL4282	Homo sapiens	IC50	nM	3.36
286566	17668911	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	CC(=O)NC1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640741	=	IC50	nM	1.44	CHEMBL4282	Homo sapiens	IC50	nM	1.44
286567	17668912	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	CCC(=O)N1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640742	=	IC50	nM	2.15	CHEMBL4282	Homo sapiens	IC50	nM	2.15
286568	17668913	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	Nc1ncccc1-c1nc2ccc(-c3cccc(N4CCN(C(=O)C5CC5)CC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640743	=	IC50	nM	1.84	CHEMBL4282	Homo sapiens	IC50	nM	1.84
286569	17668914	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	CC(C)(C)C(=O)N1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1		CHEMBL3640745	=	IC50	nM	3.42	CHEMBL4282	Homo sapiens	IC50	nM	3.42
286570	17668915	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	C[C@H]1CN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)C[C@@H](C)O1		CHEMBL3640746	=	IC50	nM	4.36	CHEMBL4282	Homo sapiens	IC50	nM	4.36
286571	17668916	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	Nc1ncccc1-c1nc2ccc(-c3cccc(N4CCS(=O)(=O)CC4)c3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640747	=	IC50	nM	1.79	CHEMBL4282	Homo sapiens	IC50	nM	1.79
286572	17668917	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	Nc1ncccc1-c1nc2ccc(Nc3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640748	=	IC50	nM	3.77	CHEMBL4282	Homo sapiens	IC50	nM	3.77
286573	17668918	CHEMBL3705364	Alpha Screen Assay: AKT1 activity was assayed using the GSK3-derived biotinylated peptide substrate, crosstide (biotin-GRPRTSSFAEG), and AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology. AKT1 activation was achieved by the addition of the activating kinases PDK1 and MAPKAPK2, lipid vesicles, and ATP. The extent of peptide phosphorylation was determined using a phospho-AKT substrate antibody and acceptor beads conjugated to Protein A and donor beads conjugated to streptavidin that bind to the biotin on the peptide. Excitation of the donor beads converted ambient oxygen to excited singlet oxygen which, when in close proximity to acceptor beads, reacted with acceptor beads resulting in signal amplification.	B	Nc1ncccc1-c1nc2ccc(Nc3ccc(N4CCOCC4)cc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL3640749	=	IC50	nM	8.72	CHEMBL4282	Homo sapiens	IC50	nM	8.72
287935	17670299	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ncccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699664	=	IC50	nM	348.0	CHEMBL4282	Homo sapiens	IC50	nM	348.0
287936	17670300	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2n1		CHEMBL3699665	=	IC50	nM	1157.0	CHEMBL4282	Homo sapiens	IC50	nM	1157.0
287937	17670301	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4nc(C5CC5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699666	=	IC50	nM	1009.0	CHEMBL4282	Homo sapiens	IC50	nM	1009.0
287938	17670302	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4nc(-c5ccccc5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699667	=	IC50	nM	176.0	CHEMBL4282	Homo sapiens	IC50	nM	176.0
287939	17670303	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1ccccc1-c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2n1		CHEMBL3699668	=	IC50	nM	4695.0	CHEMBL4282	Homo sapiens	IC50	nM	4695.0
287940	17670304	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cnc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699669	=	IC50	nM	388.0	CHEMBL4282	Homo sapiens	IC50	nM	388.0
287941	17670305	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cnc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699670	=	IC50	nM	109.0	CHEMBL4282	Homo sapiens	IC50	nM	109.0
287942	17670306	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCOc1cnc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699671	=	IC50	nM	233.0	CHEMBL4282	Homo sapiens	IC50	nM	233.0
287943	17670307	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ncc(-c5ccccc5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699672	=	IC50	nM	685.0	CHEMBL4282	Homo sapiens	IC50	nM	685.0
287944	17670308	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	N#Cc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699673	=	IC50	nM	287.0	CHEMBL4282	Homo sapiens	IC50	nM	287.0
287945	17670309	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-n5cccn5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699674	=	IC50	nM	102.0	CHEMBL4282	Homo sapiens	IC50	nM	102.0
287946	17670310	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)c1cc(OC)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699675	=	IC50	nM	53.0	CHEMBL4282	Homo sapiens	IC50	nM	53.0
287947	17670311	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(C(N)=O)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699676	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	nM	24.0
287948	17670312	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CNC(=O)Nc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3699677	=	IC50	nM	588.0	CHEMBL4282	Homo sapiens	IC50	nM	588.0
287949	17670313	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4nc(-n5ccccc5=O)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699678	=	IC50	nM	2268.0	CHEMBL4282	Homo sapiens	IC50	nM	2268.0
287950	17670314	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-n5cccn5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699679	=	IC50	nM	228.0	CHEMBL4282	Homo sapiens	IC50	nM	228.0
287951	17670315	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2n1		CHEMBL3699680	=	IC50	nM	142.0	CHEMBL4282	Homo sapiens	IC50	nM	142.0
287952	17670316	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4nc(O)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699681	=	IC50	nM	544.0	CHEMBL4282	Homo sapiens	IC50	nM	544.0
287953	17670317	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCCOc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2n1		CHEMBL3699682	=	IC50	nM	230.0	CHEMBL4282	Homo sapiens	IC50	nM	230.0
287954	17670318	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	N#Cc1cccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699683	=	IC50	nM	64.0	CHEMBL4282	Homo sapiens	IC50	nM	64.0
287955	17670319	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3699684	=	IC50	nM	829.0	CHEMBL4282	Homo sapiens	IC50	nM	829.0
287956	17670320	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699685	=	IC50	nM	100.0	CHEMBL4282	Homo sapiens	IC50	nM	100.0
287957	17670321	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	N#Cc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3699686	=	IC50	nM	145.0	CHEMBL4282	Homo sapiens	IC50	nM	145.0
287958	17670322	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699687	=	IC50	nM	203.0	CHEMBL4282	Homo sapiens	IC50	nM	203.0
287959	17670323	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3699688	=	IC50	nM	96.0	CHEMBL4282	Homo sapiens	IC50	nM	96.0
287960	17670324	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CNC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699689	=	IC50	nM	144.0	CHEMBL4282	Homo sapiens	IC50	nM	144.0
287961	17670325	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COCc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699690	=	IC50	nM	723.0	CHEMBL4282	Homo sapiens	IC50	nM	723.0
287962	17670326	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699691	=	IC50	nM	173.0	CHEMBL4282	Homo sapiens	IC50	nM	173.0
287963	17670327	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CC(O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699692	=	IC50	nM	171.0	CHEMBL4282	Homo sapiens	IC50	nM	171.0
287964	17670328	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(CO)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699693	=	IC50	nM	1771.0	CHEMBL4282	Homo sapiens	IC50	nM	1771.0
287965	17670329	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(CO)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699694	=	IC50	nM	168.0	CHEMBL4282	Homo sapiens	IC50	nM	168.0
287966	17670330	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699696	=	IC50	nM	36.0	CHEMBL4282	Homo sapiens	IC50	nM	36.0
287967	17670331	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699697	=	IC50	nM	67.0	CHEMBL4282	Homo sapiens	IC50	nM	67.0
287968	17670332	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCOc1cccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699698	=	IC50	nM	130.0	CHEMBL4282	Homo sapiens	IC50	nM	130.0
287969	17670333	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3699699	=	IC50	nM	1657.0	CHEMBL4282	Homo sapiens	IC50	nM	1657.0
287970	17670334	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5cn[nH]c5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699700	=	IC50	nM	188.0	CHEMBL4282	Homo sapiens	IC50	nM	188.0
287971	17670335	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)c1cccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699701	=	IC50	nM	47.0	CHEMBL4282	Homo sapiens	IC50	nM	47.0
287972	17670336	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COCCNCc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699702	=	IC50	nM	5643.0	CHEMBL4282	Homo sapiens	IC50	nM	5643.0
287973	17670337	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(CO)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699703	=	IC50	nM	504.0	CHEMBL4282	Homo sapiens	IC50	nM	504.0
287974	17670338	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1ccc(COc2ccn3c(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc3n2)cn1		CHEMBL3639985	=	IC50	nM	221.0	CHEMBL4282	Homo sapiens	IC50	nM	221.0
287975	17670339	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COCCOc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2n1		CHEMBL3699704	=	IC50	nM	1186.0	CHEMBL4282	Homo sapiens	IC50	nM	1186.0
287976	17670340	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(COc2ccn3c(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc3n2)ccn1		CHEMBL3699705	=	IC50	nM	179.0	CHEMBL4282	Homo sapiens	IC50	nM	179.0
287977	17670341	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCOc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2n1		CHEMBL3699706	=	IC50	nM	190.0	CHEMBL4282	Homo sapiens	IC50	nM	190.0
287978	17670342	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CC(C)Oc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2n1		CHEMBL3699707	=	IC50	nM	1225.0	CHEMBL4282	Homo sapiens	IC50	nM	1225.0
287979	17670343	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4nc(OC5CCCCC5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699708	=	IC50	nM	1315.0	CHEMBL4282	Homo sapiens	IC50	nM	1315.0
287980	17670344	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4nc(Oc5ccccc5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699709	=	IC50	nM	1385.0	CHEMBL4282	Homo sapiens	IC50	nM	1385.0
287981	17670345	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCc1cnc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699710	=	IC50	nM	379.0	CHEMBL4282	Homo sapiens	IC50	nM	379.0
287982	17670346	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5ccc(F)cc5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699711	=	IC50	nM	989.0	CHEMBL4282	Homo sapiens	IC50	nM	989.0
287983	17670347	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3699712	=	IC50	nM	226.0	CHEMBL4282	Homo sapiens	IC50	nM	226.0
287984	17670348	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699713	=	IC50	nM	61.0	CHEMBL4282	Homo sapiens	IC50	nM	61.0
287985	17670349	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(C5CC5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699714	=	IC50	nM	1636.0	CHEMBL4282	Homo sapiens	IC50	nM	1636.0
287986	17670350	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699715	=	IC50	nM	260.0	CHEMBL4282	Homo sapiens	IC50	nM	260.0
287987	17670351	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(Br)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699716	=	IC50	nM	33.0	CHEMBL4282	Homo sapiens	IC50	nM	33.0
287988	17670352	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL2035022	=	IC50	nM	204.0	CHEMBL4282	Homo sapiens	IC50	nM	204.0
287989	17670353	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(C(=O)N5CCCC5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699718	=	IC50	nM	19417.0	CHEMBL4282	Homo sapiens	IC50	nM	19417.0
287990	17670354	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCOC(=O)c1cccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699719	=	IC50	nM	62.0	CHEMBL4282	Homo sapiens	IC50	nM	62.0
287991	17670355	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(F)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699720	=	IC50	nM	142.0	CHEMBL4282	Homo sapiens	IC50	nM	142.0
287992	17670356	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(Cl)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699721	=	IC50	nM	43.0	CHEMBL4282	Homo sapiens	IC50	nM	43.0
287993	17670357	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(F)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699722	=	IC50	nM	101.0	CHEMBL4282	Homo sapiens	IC50	nM	101.0
287994	17670358	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(C5CC5)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699723	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	nM	140.0
287995	17670359	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	C=Cc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699724	=	IC50	nM	300.0	CHEMBL4282	Homo sapiens	IC50	nM	300.0
287996	17670360	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	C=Cc1cccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699725	=	IC50	nM	180.0	CHEMBL4282	Homo sapiens	IC50	nM	180.0
287997	17670361	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(-c5cn[nH]c5)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699726	=	IC50	nM	99.0	CHEMBL4282	Homo sapiens	IC50	nM	99.0
287998	17670362	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(C(=O)O)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699727	=	IC50	nM	91.0	CHEMBL4282	Homo sapiens	IC50	nM	91.0
287999	17670363	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(Br)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699728	=	IC50	nM	19.0	CHEMBL4282	Homo sapiens	IC50	nM	19.0
288000	17670364	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CC(C)NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699729	=	IC50	nM	1708.0	CHEMBL4282	Homo sapiens	IC50	nM	1708.0
288001	17670365	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(C(=O)NCCF)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699730	=	IC50	nM	423.0	CHEMBL4282	Homo sapiens	IC50	nM	423.0
288002	17670366	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(C(=O)NCCO)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699731	=	IC50	nM	1136.0	CHEMBL4282	Homo sapiens	IC50	nM	1136.0
288003	17670367	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COCCNC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699732	=	IC50	nM	452.0	CHEMBL4282	Homo sapiens	IC50	nM	452.0
288004	17670368	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(C(=O)NC5CC5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699733	=	IC50	nM	493.0	CHEMBL4282	Homo sapiens	IC50	nM	493.0
288005	17670369	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(C(=O)NCC5CC5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699734	=	IC50	nM	342.0	CHEMBL4282	Homo sapiens	IC50	nM	342.0
288006	17670370	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(C(=O)NO)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699735	=	IC50	nM	257.0	CHEMBL4282	Homo sapiens	IC50	nM	257.0
288007	17670371	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)c1cc(Cl)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699736	=	IC50	nM	31.0	CHEMBL4282	Homo sapiens	IC50	nM	31.0
288008	17670372	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CN(C)C(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699737	=	IC50	nM	1904.0	CHEMBL4282	Homo sapiens	IC50	nM	1904.0
288009	17670373	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCNC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699738	=	IC50	nM	376.0	CHEMBL4282	Homo sapiens	IC50	nM	376.0
288010	17670374	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(C5CC5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699739	=	IC50	nM	734.0	CHEMBL4282	Homo sapiens	IC50	nM	734.0
288011	17670375	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4nc(OCCN5CCCC5=O)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699740	=	IC50	nM	1659.0	CHEMBL4282	Homo sapiens	IC50	nM	1659.0
288012	17670376	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)C1(COc2ccn3c(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc3n2)CC1		CHEMBL3699741	=	IC50	nM	1066.0	CHEMBL4282	Homo sapiens	IC50	nM	1066.0
288013	17670377	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(Cl)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699742	=	IC50	nM	113.0	CHEMBL4282	Homo sapiens	IC50	nM	113.0
288014	17670378	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(F)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699743	=	IC50	nM	64.0	CHEMBL4282	Homo sapiens	IC50	nM	64.0
288015	17670379	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(-c5ccc(F)cc5)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699744	=	IC50	nM	308.0	CHEMBL4282	Homo sapiens	IC50	nM	308.0
288016	17670380	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(-c5cccc(F)c5)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699745	=	IC50	nM	208.0	CHEMBL4282	Homo sapiens	IC50	nM	208.0
288017	17670381	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cncc(-c2cccn3c(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc23)c1		CHEMBL3699746	=	IC50	nM	106.0	CHEMBL4282	Homo sapiens	IC50	nM	106.0
288018	17670382	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(-c5ccn[nH]5)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699747	=	IC50	nM	64.0	CHEMBL4282	Homo sapiens	IC50	nM	64.0
288019	17670383	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(-c5ccc6cn[nH]c6c5)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699748	=	IC50	nM	390.0	CHEMBL4282	Homo sapiens	IC50	nM	390.0
288020	17670384	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(C)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699749	=	IC50	nM	58.0	CHEMBL4282	Homo sapiens	IC50	nM	58.0
288021	17670385	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1Cl		CHEMBL3699750	=	IC50	nM	170.0	CHEMBL4282	Homo sapiens	IC50	nM	170.0
288022	17670386	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(F)cc(F)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699751	=	IC50	nM	52.0	CHEMBL4282	Homo sapiens	IC50	nM	52.0
288023	17670387	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(Cl)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699752	=	IC50	nM	25.0	CHEMBL4282	Homo sapiens	IC50	nM	25.0
288024	17670388	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCOC(=O)c1cc(Br)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699753	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	nM	17.0
288025	17670389	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(Cl)cc(Cl)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699754	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
288026	17670390	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1C#N		CHEMBL3699755	=	IC50	nM	247.0	CHEMBL4282	Homo sapiens	IC50	nM	247.0
288027	17670391	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(Cl)c(Cl)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699756	=	IC50	nM	150.0	CHEMBL4282	Homo sapiens	IC50	nM	150.0
288028	17670392	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1c(Cl)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1Br		CHEMBL3699757	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
288029	17670393	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(Br)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699758	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	nM	17.0
288030	17670394	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(Br)cc(Cl)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699759	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
288031	17670395	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1c(Cl)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1-c1ccc(F)cc1		CHEMBL3699760	=	IC50	nM	1368.0	CHEMBL4282	Homo sapiens	IC50	nM	1368.0
288032	17670396	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1c(Cl)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1-c1ccn[nH]1		CHEMBL3699761	=	IC50	nM	187.0	CHEMBL4282	Homo sapiens	IC50	nM	187.0
288033	17670397	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1c(-c2ccn[nH]2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1C		CHEMBL3699762	=	IC50	nM	330.0	CHEMBL4282	Homo sapiens	IC50	nM	330.0
288034	17670398	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2cccnc2)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699763	=	IC50	nM	150.0	CHEMBL4282	Homo sapiens	IC50	nM	150.0
288035	17670399	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cncc(-c2cc(C)cn3c(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc23)c1		CHEMBL3699764	=	IC50	nM	371.0	CHEMBL4282	Homo sapiens	IC50	nM	371.0
288036	17670400	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2ccn[nH]2)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699765	=	IC50	nM	229.0	CHEMBL4282	Homo sapiens	IC50	nM	229.0
288037	17670401	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2cn[nH]c2)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699766	=	IC50	nM	81.0	CHEMBL4282	Homo sapiens	IC50	nM	81.0
288038	17670402	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1cc(Br)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699768	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
288039	17670403	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(C(N)=O)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3699769	=	IC50	nM	893.0	CHEMBL4282	Homo sapiens	IC50	nM	893.0
288040	17670404	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1cc(-c2cn[nH]c2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699770	=	IC50	nM	67.0	CHEMBL4282	Homo sapiens	IC50	nM	67.0
288041	17670405	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1cc(-c2ccn[nH]2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699771	=	IC50	nM	69.0	CHEMBL4282	Homo sapiens	IC50	nM	69.0
288042	17670406	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1cc(-c2cccnc2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699772	=	IC50	nM	177.0	CHEMBL4282	Homo sapiens	IC50	nM	177.0
288043	17670407	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1c(C(N)=O)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1C		CHEMBL3699773	=	IC50	nM	201.0	CHEMBL4282	Homo sapiens	IC50	nM	201.0
288044	17670408	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(C(N)=O)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699774	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
288045	17670409	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2cn[nH]c2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699775	=	IC50	nM	106.0	CHEMBL4282	Homo sapiens	IC50	nM	106.0
288046	17670410	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2ccn[nH]2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699776	=	IC50	nM	99.0	CHEMBL4282	Homo sapiens	IC50	nM	99.0
288047	17670411	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2cccnc2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3699777	=	IC50	nM	175.0	CHEMBL4282	Homo sapiens	IC50	nM	175.0
288048	17670412	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2cc(C)c3nc(-c4ccc(C5(N)CCC5)cc4)c(-c4ccccc4)n3c2)[nH]n1		CHEMBL3699778	=	IC50	nM	217.0	CHEMBL4282	Homo sapiens	IC50	nM	217.0
288049	17670413	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccccn4c3-c3ccccc3)cc2)CCC1		CHEMBL2035021	=	IC50	nM	151.0	CHEMBL4282	Homo sapiens	IC50	nM	151.0
288050	17670414	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCOc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703102	=	IC50	nM	204.0	CHEMBL4282	Homo sapiens	IC50	nM	204.0
288051	17670415	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	C=Cc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703103	=	IC50	nM	1951.0	CHEMBL4282	Homo sapiens	IC50	nM	1951.0
288052	17670416	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5ccncc5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703104	=	IC50	nM	181.0	CHEMBL4282	Homo sapiens	IC50	nM	181.0
288053	17670417	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5cccnc5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703105	=	IC50	nM	129.0	CHEMBL4282	Homo sapiens	IC50	nM	129.0
288054	17670418	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5ccccn5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703106	=	IC50	nM	204.0	CHEMBL4282	Homo sapiens	IC50	nM	204.0
288055	17670419	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5cc[nH]n5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703107	=	IC50	nM	153.0	CHEMBL4282	Homo sapiens	IC50	nM	153.0
288056	17670420	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5ncc[nH]5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703108	=	IC50	nM	71.0	CHEMBL4282	Homo sapiens	IC50	nM	71.0
288057	17670421	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5cnc[nH]5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703109	=	IC50	nM	212.0	CHEMBL4282	Homo sapiens	IC50	nM	212.0
288058	17670422	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cn1cncc1-c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703110	=	IC50	nM	236.0	CHEMBL4282	Homo sapiens	IC50	nM	236.0
288059	17670423	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(-c5nn[nH]n5)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703111	=	IC50	nM	26.0	CHEMBL4282	Homo sapiens	IC50	nM	26.0
288060	17670424	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCOC(=O)c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703112	=	IC50	nM	86.0	CHEMBL4282	Homo sapiens	IC50	nM	86.0
288061	17670425	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(C(=O)O)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703113	=	IC50	nM	550.0	CHEMBL4282	Homo sapiens	IC50	nM	550.0
288062	17670426	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CNC(=O)c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703114	=	IC50	nM	409.0	CHEMBL4282	Homo sapiens	IC50	nM	409.0
288063	17670427	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)/C=C/c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703115	=	IC50	nM	345.0	CHEMBL4282	Homo sapiens	IC50	nM	345.0
288064	17670428	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)/C=C/c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703116	=	IC50	nM	174.0	CHEMBL4282	Homo sapiens	IC50	nM	174.0
288065	17670429	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)CCc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703117	=	IC50	nM	3436.0	CHEMBL4282	Homo sapiens	IC50	nM	3436.0
288066	17670430	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCNC(=O)c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703118	=	IC50	nM	601.0	CHEMBL4282	Homo sapiens	IC50	nM	601.0
288067	17670431	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(C(=O)NO)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703119	=	IC50	nM	132.0	CHEMBL4282	Homo sapiens	IC50	nM	132.0
288068	17670432	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CC(=O)c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703120	=	IC50	nM	175.0	CHEMBL4282	Homo sapiens	IC50	nM	175.0
288069	17670433	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5cnc[nH]5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703121	=	IC50	nM	195.0	CHEMBL4282	Homo sapiens	IC50	nM	195.0
288070	17670434	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5ncc[nH]5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703122	=	IC50	nM	321.0	CHEMBL4282	Homo sapiens	IC50	nM	321.0
288071	17670435	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5cc[nH]n5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703123	=	IC50	nM	171.0	CHEMBL4282	Homo sapiens	IC50	nM	171.0
288072	17670436	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5cn[nH]c5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703124	=	IC50	nM	219.0	CHEMBL4282	Homo sapiens	IC50	nM	219.0
288073	17670437	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cn1cncc1-c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703125	=	IC50	nM	2320.0	CHEMBL4282	Homo sapiens	IC50	nM	2320.0
288074	17670438	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cn1cc(-c2ccc3nc(-c4ccc(C5(N)CCC5)cc4)c(-c4ccccc4)n3c2)cn1		CHEMBL3703126	=	IC50	nM	691.0	CHEMBL4282	Homo sapiens	IC50	nM	691.0
288075	17670439	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5nn[nH]n5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703127	=	IC50	nM	74.0	CHEMBL4282	Homo sapiens	IC50	nM	74.0
288076	17670440	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5ccncc5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703128	=	IC50	nM	533.0	CHEMBL4282	Homo sapiens	IC50	nM	533.0
288077	17670441	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5cccnc5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703129	=	IC50	nM	541.0	CHEMBL4282	Homo sapiens	IC50	nM	541.0
288078	17670442	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5ccccn5)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703130	=	IC50	nM	530.0	CHEMBL4282	Homo sapiens	IC50	nM	530.0
288079	17670443	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(Br)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3699695	=	IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	nM	44.0
288080	17670444	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(Cl)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703131	=	IC50	nM	36.0	CHEMBL4282	Homo sapiens	IC50	nM	36.0
288081	17670445	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)/C=C/c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703132	=	IC50	nM	196.0	CHEMBL4282	Homo sapiens	IC50	nM	196.0
288082	17670446	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)/C=C/c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703133	=	IC50	nM	347.0	CHEMBL4282	Homo sapiens	IC50	nM	347.0
288083	17670447	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCOC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703134	=	IC50	nM	93.0	CHEMBL4282	Homo sapiens	IC50	nM	93.0
288084	17670448	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703135	=	IC50	nM	55.0	CHEMBL4282	Homo sapiens	IC50	nM	55.0
288085	17670449	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(Cl)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3703136	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	nM	24.0
288086	17670450	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(OC)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703137	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	nM	23.0
288087	17670451	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CCc1cc(OC)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703138	=	IC50	nM	148.0	CHEMBL4282	Homo sapiens	IC50	nM	148.0
288088	17670452	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(-c2cnc[nH]2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3703139	=	IC50	nM	139.0	CHEMBL4282	Homo sapiens	IC50	nM	139.0
288089	17670453	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(-c2ncc[nH]2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3703140	=	IC50	nM	198.0	CHEMBL4282	Homo sapiens	IC50	nM	198.0
288090	17670454	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cn1cc(-c2ccn3c(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc3c2)cn1		CHEMBL3703141	=	IC50	nM	558.0	CHEMBL4282	Homo sapiens	IC50	nM	558.0
288091	17670455	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Nc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703142	=	IC50	nM	514.0	CHEMBL4282	Homo sapiens	IC50	nM	514.0
288092	17670456	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CC(=O)Nc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703143	=	IC50	nM	554.0	CHEMBL4282	Homo sapiens	IC50	nM	554.0
288093	17670457	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)Nc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703144	=	IC50	nM	457.0	CHEMBL4282	Homo sapiens	IC50	nM	457.0
288094	17670458	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CON(C)C(=O)c1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703145	=	IC50	nM	2145.0	CHEMBL4282	Homo sapiens	IC50	nM	2145.0
288095	17670459	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Nc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703146	=	IC50	nM	854.0	CHEMBL4282	Homo sapiens	IC50	nM	854.0
288096	17670460	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CC(=O)Nc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703147	=	IC50	nM	62.0	CHEMBL4282	Homo sapiens	IC50	nM	62.0
288097	17670461	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)Nc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703148	=	IC50	nM	256.0	CHEMBL4282	Homo sapiens	IC50	nM	256.0
288098	17670462	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CNC(=O)Nc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703149	=	IC50	nM	327.0	CHEMBL4282	Homo sapiens	IC50	nM	327.0
288099	17670463	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CS(=O)(=O)Nc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703150	=	IC50	nM	2988.0	CHEMBL4282	Homo sapiens	IC50	nM	2988.0
288100	17670464	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	C=Cc1cc(OC)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703151	=	IC50	nM	191.0	CHEMBL4282	Homo sapiens	IC50	nM	191.0
288101	17670465	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	N[C@]1(c2ccc(-c3nc4nc(O)ccn4c3-c3ccccc3)cc2)C[C@H](O)C1		CHEMBL3703152	=	IC50	nM	384.0	CHEMBL4282	Homo sapiens	IC50	nM	384.0
288102	17670466	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4nc(OCCN5C(=O)c6ccccc6C5=O)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703153	=	IC50	nM	548.0	CHEMBL4282	Homo sapiens	IC50	nM	548.0
288103	17670467	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(O)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703154	=	IC50	nM	303.0	CHEMBL4282	Homo sapiens	IC50	nM	303.0
288104	17670468	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c(O)cccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703155	=	IC50	nM	590.0	CHEMBL4282	Homo sapiens	IC50	nM	590.0
288105	17670469	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1cccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3703156	=	IC50	nM	58.0	CHEMBL4282	Homo sapiens	IC50	nM	58.0
288106	17670470	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1cc(Cl)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703157	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
288107	17670471	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	C#Cc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703158	=	IC50	nM	1658.0	CHEMBL4282	Homo sapiens	IC50	nM	1658.0
288108	17670472	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)CCc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703159	=	IC50	nM	12688.0	CHEMBL4282	Homo sapiens	IC50	nM	12688.0
288109	17670473	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)COc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703161	=	IC50	nM	158.0	CHEMBL4282	Homo sapiens	IC50	nM	158.0
288110	17670474	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)COc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703162	=	IC50	nM	397.0	CHEMBL4282	Homo sapiens	IC50	nM	397.0
288111	17670475	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CN(C)C(=O)COc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703163	=	IC50	nM	258.0	CHEMBL4282	Homo sapiens	IC50	nM	258.0
288112	17670476	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	[C-]#[N+]COc1ccn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c1		CHEMBL3703164	=	IC50	nM	655.0	CHEMBL4282	Homo sapiens	IC50	nM	655.0
288113	17670477	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)COc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703165	=	IC50	nM	179.0	CHEMBL4282	Homo sapiens	IC50	nM	179.0
288114	17670478	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	[C-]#[N+]COc1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703166	=	IC50	nM	96.0	CHEMBL4282	Homo sapiens	IC50	nM	96.0
288115	17670479	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4cc(O)ccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703167	=	IC50	nM	1273.0	CHEMBL4282	Homo sapiens	IC50	nM	1273.0
288116	17670480	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4ccc(-c5cccnc5O)cn4c3-c3ccccc3)cc2)CCC1		CHEMBL3703168	=	IC50	nM	1510.0	CHEMBL4282	Homo sapiens	IC50	nM	1510.0
288117	17670481	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2ccc3nc(-c4ccc(C5(N)CCC5)cc4)c(-c4ccccc4)n3c2)[nH]n1		CHEMBL3640020	=	IC50	nM	688.0	CHEMBL4282	Homo sapiens	IC50	nM	688.0
288118	17670482	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(-c2cn[nH]c2)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3703169	=	IC50	nM	81.0	CHEMBL4282	Homo sapiens	IC50	nM	81.0
288119	17670483	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n12		CHEMBL3703170	=	IC50	nM	1505.0	CHEMBL4282	Homo sapiens	IC50	nM	1505.0
288120	17670484	CHEMBL3705510	TR-FRET Assay: For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 uM=>final conc. in the 5 ul assay volume is 10 uM) and substrate (1.67 uM=>final conc. in the 5 ul assay volume is 1 uM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	N#Cc1cc(Cl)c2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2c1		CHEMBL3703171	=	IC50	nM	141.0	CHEMBL4282	Homo sapiens	IC50	nM	141.0
290690	17672927	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4ccnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL2035019	=	IC50	nM	246.0	CHEMBL4282	Homo sapiens	IC50	nM	246.0
290691	17672928	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cn2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)cc2n1		CHEMBL3639713	=	IC50	nM	17257.0	CHEMBL4282	Homo sapiens	IC50	nM	17257.0
290692	17672929	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cnc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn12		CHEMBL3672479	=	IC50	nM	441.0	CHEMBL4282	Homo sapiens	IC50	nM	441.0
290693	17672930	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	N#Cc1cccc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)c1		CHEMBL3672480	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
290694	17672931	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CS(=O)(=O)c1ccc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)cc1		CHEMBL3672481	=	IC50	nM	110.0	CHEMBL4282	Homo sapiens	IC50	nM	110.0
290695	17672932	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	N#Cc1ccc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)cc1		CHEMBL3672482	=	IC50	nM	129.0	CHEMBL4282	Homo sapiens	IC50	nM	129.0
290696	17672933	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1cccc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)c1		CHEMBL3672483	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
290697	17672934	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccc(F)cc5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672484	=	IC50	nM	36.0	CHEMBL4282	Homo sapiens	IC50	nM	36.0
290698	17672935	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1ccc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)cc1		CHEMBL3672485	=	IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	nM	44.0
290699	17672936	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5cccc(CO)c5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672486	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
290700	17672937	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccc(CO)cc5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672487	=	IC50	nM	19.0	CHEMBL4282	Homo sapiens	IC50	nM	19.0
290701	17672938	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccc(S(N)(=O)=O)cc5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672488	=	IC50	nM	47.0	CHEMBL4282	Homo sapiens	IC50	nM	47.0
290702	17672939	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(Br)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672489	=	IC50	nM	74.0	CHEMBL4282	Homo sapiens	IC50	nM	74.0
290703	17672940	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccc(F)c(CO)c5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672490	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
290704	17672941	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC(=O)c1ccc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)cc1		CHEMBL3672491	=	IC50	nM	27.0	CHEMBL4282	Homo sapiens	IC50	nM	27.0
290705	17672942	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC(=O)c1cccc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)c1		CHEMBL3672492	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
290706	17672943	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5cn[nH]c5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672493	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
290707	17672944	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccc(O)nc5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672494	=	IC50	nM	146.0	CHEMBL4282	Homo sapiens	IC50	nM	146.0
290708	17672945	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)c1ccc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)cn1		CHEMBL3672495	=	IC50	nM	19.0	CHEMBL4282	Homo sapiens	IC50	nM	19.0
290709	17672946	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccn[nH]5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672496	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
290710	17672947	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccc6cn[nH]c6c5)cnc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672497	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
290711	17672948	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCOC(=O)c1cncc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)c1		CHEMBL3672498	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
290712	17672949	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COc1cncc(-c2cnc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)c1		CHEMBL3672499	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
290713	17672950	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn2c1-c1cccc(C(N)=O)c1		CHEMBL3672500	=	IC50	nM	15038.0	CHEMBL4282	Homo sapiens	IC50	nM	15038.0
290714	17672951	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn2c1-c1ccc(F)c(CO)c1		CHEMBL3672501	=	IC50	nM	10115.0	CHEMBL4282	Homo sapiens	IC50	nM	10115.0
290715	17672952	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn2c1-c1cn[nH]c1		CHEMBL3672502	=	IC50	nM	4780.0	CHEMBL4282	Homo sapiens	IC50	nM	4780.0
290716	17672953	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn2c1-c1ccc(F)cc1		CHEMBL3672503	=	IC50	nM	4428.0	CHEMBL4282	Homo sapiens	IC50	nM	4428.0
290717	17672954	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn2c1-c1ccc(C(N)=O)cc1		CHEMBL3672504	=	IC50	nM	12083.0	CHEMBL4282	Homo sapiens	IC50	nM	12083.0
290718	17672955	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn2c1-c1ccn[nH]1		CHEMBL3672505	=	IC50	nM	2732.0	CHEMBL4282	Homo sapiens	IC50	nM	2732.0
290719	17672956	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1cc(-c2c(C)nc3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nn23)[nH]n1		CHEMBL3672506	=	IC50	nM	14853.0	CHEMBL4282	Homo sapiens	IC50	nM	14853.0
290720	17672957	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccc(F)cc5)c(Br)nc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672507	=	IC50	nM	68.0	CHEMBL4282	Homo sapiens	IC50	nM	68.0
290721	17672958	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC1(c2ccc(-c3nn4c(-c5ccc(F)cc5)c(Cl)nc4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672508	=	IC50	nM	99.0	CHEMBL4282	Homo sapiens	IC50	nM	99.0
290722	17672959	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	NC(=O)/C=C/c1cnc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn12		CHEMBL3672509	=	IC50	nM	38.0	CHEMBL4282	Homo sapiens	IC50	nM	38.0
290723	17672960	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	C=Cc1cnc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn12		CHEMBL3672510	=	IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	nM	44.0
290724	17672961	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	Cc1nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn2c1/C=C/C(N)=O		CHEMBL3672511	=	IC50	nM	18031.0	CHEMBL4282	Homo sapiens	IC50	nM	18031.0
290725	17672962	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	COC(=O)/C=C/c1c(C)nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn12		CHEMBL3672512	=	IC50	nM	5966.0	CHEMBL4282	Homo sapiens	IC50	nM	5966.0
290726	17672963	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	C=Cc1c(C)nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn12		CHEMBL3672513	=	IC50	nM	8937.0	CHEMBL4282	Homo sapiens	IC50	nM	8937.0
290727	17672964	CHEMBL3706239	TR-FRET assay: Akt1 inhibitory activity of compounds of the present invention was quantified employing the Akt1 TR-FRET assay as described in the following paragraphs. His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction.	B	CCc1c(C)nc2cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nn12		CHEMBL3672514	=	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	nM	20000.0
290765	17673002	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5cc(F)ccc5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672515	=	IC50	nM	93.0	CHEMBL4282	Homo sapiens	IC50	nM	93.0
290766	17673003	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5cc(F)ccc5nn4c(NC4CC4)c3-c3ccccc3)cc2)CCC1		CHEMBL3672516	=	IC50	nM	528.0	CHEMBL4282	Homo sapiens	IC50	nM	528.0
290767	17673004	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CNc1c(-c2ccccc2)c(-c2ccc(C3(N)CCC3)cc2)nc2c3cc(F)ccc3nn12		CHEMBL3672517	=	IC50	nM	2630.0	CHEMBL4282	Homo sapiens	IC50	nM	2630.0
290768	17673005	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	N#Cc1cccc(-c2ccc3c(c2)nn2cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc32)c1		CHEMBL3672518	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	nM	140.0
290769	17673006	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CS(=O)(=O)c1ccc(-c2ccc3c(c2)nn2cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc32)cc1		CHEMBL3672519	=	IC50	nM	59.0	CHEMBL4282	Homo sapiens	IC50	nM	59.0
290770	17673007	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5ccc(-c6ccc(F)cc6)cc5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672520	=	IC50	nM	229.0	CHEMBL4282	Homo sapiens	IC50	nM	229.0
290771	17673008	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5ccc(Br)cc5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672521	=	IC50	nM	87.0	CHEMBL4282	Homo sapiens	IC50	nM	87.0
290772	17673009	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5ccc(-c6ccc(F)c(CO)c6)cc5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672522	=	IC50	nM	43.0	CHEMBL4282	Homo sapiens	IC50	nM	43.0
290773	17673010	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5ccc(-c6ccc(F)c(O)c6)cc5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672523	=	IC50	nM	35.0	CHEMBL4282	Homo sapiens	IC50	nM	35.0
290774	17673011	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COc1cc(-c2ccc3c(c2)nn2cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc32)ccc1F		CHEMBL3672524	=	IC50	nM	458.0	CHEMBL4282	Homo sapiens	IC50	nM	458.0
290775	17673012	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CS(=O)(=O)c1cccc(-c2ccc3c(c2)nn2cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc32)c1		CHEMBL3672525	=	IC50	nM	25.0	CHEMBL4282	Homo sapiens	IC50	nM	25.0
290776	17673013	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)c1ccc2c(c1)nn1cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc21		CHEMBL3672526	=	IC50	nM	111.0	CHEMBL4282	Homo sapiens	IC50	nM	111.0
290777	17673014	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1cccc(-c2ccc3c(c2)nn2cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc32)c1		CHEMBL3672527	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
290778	17673015	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)c1ccc(-c2ccc3c(c2)nn2cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc32)cc1		CHEMBL3672528	=	IC50	nM	21.0	CHEMBL4282	Homo sapiens	IC50	nM	21.0
290779	17673016	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5ccc(-c6cn[nH]c6)cc5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672529	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	nM	17.0
290780	17673017	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5ccc(-c6ccc(O)nc6)cc5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672530	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
290781	17673018	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)c1ccc(-c2ccc3c(c2)nn2cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc32)cn1		CHEMBL3672531	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	nM	23.0
290782	17673019	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5cc(-c6ccc(F)cc6)ccc5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672532	=	IC50	nM	110.0	CHEMBL4282	Homo sapiens	IC50	nM	110.0
290783	17673020	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1ccc(-c2ccc3nn4cc(-c5ccccc5)c(-c5ccc(C6(N)CCC6)cc5)nc4c3c2)cc1		CHEMBL3672533	=	IC50	nM	120.0	CHEMBL4282	Homo sapiens	IC50	nM	120.0
290784	17673021	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)c1cccc(-c2ccc3nn4cc(-c5ccccc5)c(-c5ccc(C6(N)CCC6)cc5)nc4c3c2)c1		CHEMBL3672534	=	IC50	nM	130.0	CHEMBL4282	Homo sapiens	IC50	nM	130.0
290785	17673022	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	N#Cc1cccc(-c2ccc3nn4cc(-c5ccccc5)c(-c5ccc(C6(N)CCC6)cc5)nc4c3c2)c1		CHEMBL3672535	=	IC50	nM	67.0	CHEMBL4282	Homo sapiens	IC50	nM	67.0
290786	17673023	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5cc(Br)ccc5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672536	=	IC50	nM	41.0	CHEMBL4282	Homo sapiens	IC50	nM	41.0
290787	17673024	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	N#Cc1ccc(-c2ccc3nn4cc(-c5ccccc5)c(-c5ccc(C6(N)CCC6)cc5)nc4c3c2)cc1		CHEMBL3672537	=	IC50	nM	97.0	CHEMBL4282	Homo sapiens	IC50	nM	97.0
290788	17673025	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5cc(-c6cccc(CO)c6)ccc5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672538	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
290789	17673026	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5cc(-c6ccc(CO)cc6)ccc5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672539	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
290790	17673027	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5cc(-c6ccc(S(N)(=O)=O)cc6)ccc5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672540	=	IC50	nM	31.0	CHEMBL4282	Homo sapiens	IC50	nM	31.0
290791	17673028	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5cc(-c6ccc(F)c(CO)c6)ccc5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672541	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
290792	17673029	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5cc(-c6cn[nH]c6)ccc5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672542	=	IC50	nM	19.0	CHEMBL4282	Homo sapiens	IC50	nM	19.0
290793	17673030	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	N#Cc1ccc(-c2cccc3nn4cc(-c5ccccc5)c(-c5ccc(C6(N)CCC6)cc5)nc4c23)cc1		CHEMBL3672543	=	IC50	nM	320.0	CHEMBL4282	Homo sapiens	IC50	nM	320.0
290794	17673031	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	N#Cc1cccc(-c2cccc3c2nn2cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc32)c1		CHEMBL3672544	=	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
290795	17673032	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5cccc(Br)c5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672545	=	IC50	nM	170.0	CHEMBL4282	Homo sapiens	IC50	nM	170.0
290796	17673033	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5cccc(-c6ccc(F)cc6)c5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672546	=	IC50	nM	5600.0	CHEMBL4282	Homo sapiens	IC50	nM	5600.0
290797	17673034	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5cccc(-c6ccc(CO)cc6)c5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672547	=	IC50	nM	720.0	CHEMBL4282	Homo sapiens	IC50	nM	720.0
290798	17673035	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	CS(=O)(=O)c1cccc(-c2cccc3c2nn2cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc32)c1		CHEMBL3672548	=	IC50	nM	17000.0	CHEMBL4282	Homo sapiens	IC50	nM	17000.0
290799	17673036	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5cccc(-c6cn[nH]c6)c5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672549	=	IC50	nM	160.0	CHEMBL4282	Homo sapiens	IC50	nM	160.0
290800	17673037	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	N#Cc1cccc2c1nn1cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc21		CHEMBL3672550	=	IC50	nM	49.0	CHEMBL4282	Homo sapiens	IC50	nM	49.0
290801	17673038	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)c1cccc2c1nn1cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc21		CHEMBL3672551	=	IC50	nM	740.0	CHEMBL4282	Homo sapiens	IC50	nM	740.0
290802	17673039	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5cccc(O)c5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672552	=	IC50	nM	100.0	CHEMBL4282	Homo sapiens	IC50	nM	100.0
290803	17673040	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)/C=C/c1cccc2c1nn1cc(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc21		CHEMBL3672553	=	IC50	nM	580.0	CHEMBL4282	Homo sapiens	IC50	nM	580.0
290804	17673041	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5ccc(-c6ccn[nH]6)cc5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672554	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
290805	17673042	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2ccc3c(c2)nn2cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc32)[nH]n1		CHEMBL3672555	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
290806	17673043	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC1(c2ccc(-c3nc4c5cc(-c6ccn[nH]6)ccc5nn4cc3-c3ccccc3)cc2)CCC1		CHEMBL3672556	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
290807	17673044	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	Cc1cc(-c2ccc3nn4cc(-c5ccccc5)c(-c5ccc(C6(N)CCC6)cc5)nc4c3c2)[nH]n1		CHEMBL3672557	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
290808	17673045	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	COC(=O)/C=C/c1ccc2nn3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc3c2c1		CHEMBL3672558	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
290809	17673046	CHEMBL3706240	TR-FRET assay: For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio- One, Frickenhausen, Germany), 2 ul of a solution of Akt1 in assay buffer [50 mM TRIS/HCI pH 7.5, 5 mM MgCI2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 ul of a solution of adenosine-tri-phosphate (ATP, 16.7 ul => final cone, in the 5 ul assay volume is 10 ul) and substrate (1 .67 ul => final cone, in the 5 ul assay volume is 1 ul) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot.	B	NC(=O)/C=C/c1ccc2nn3cc(-c4ccccc4)c(-c4ccc(C5(N)CCC5)cc4)nc3c2c1		CHEMBL3672559	=	IC50	nM	30.0	CHEMBL4282	Homo sapiens	IC50	nM	30.0
292767	17675004	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	CCOC(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3696234	=	IC50	nM	102.0	CHEMBL4282	Homo sapiens	IC50	nM	102.0
292768	17675005	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)cc1		CHEMBL2151821	=	IC50	nM	321.0	CHEMBL4282	Homo sapiens	IC50	nM	321.0
292769	17675006	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(Cl)c1		CHEMBL2151921	=	IC50	nM	100.0	CHEMBL4282	Homo sapiens	IC50	nM	100.0
292770	17675007	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(F)c1		CHEMBL2151924	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	nM	23.0
292771	17675008	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	COc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F		CHEMBL2151927	=	IC50	nM	318.0	CHEMBL4282	Homo sapiens	IC50	nM	318.0
292772	17675009	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1F		CHEMBL2151819	=	IC50	nM	727.0	CHEMBL4282	Homo sapiens	IC50	nM	727.0
292773	17675010	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	Cc1ccccc1NC(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL2151822	=	IC50	nM	3498.0	CHEMBL4282	Homo sapiens	IC50	nM	3498.0
292774	17675011	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	COc1ccccc1NC(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3696238	=	IC50	nM	632.0	CHEMBL4282	Homo sapiens	IC50	nM	632.0
292775	17675012	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(F)c1F		CHEMBL3639951	=	IC50	nM	737.0	CHEMBL4282	Homo sapiens	IC50	nM	737.0
292776	17675013	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(F)c1		CHEMBL2151820	=	IC50	nM	570.0	CHEMBL4282	Homo sapiens	IC50	nM	570.0
292777	17675014	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(Cl)cc1		CHEMBL2151920	=	IC50	nM	1420.0	CHEMBL4282	Homo sapiens	IC50	nM	1420.0
292778	17675015	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	COc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1		CHEMBL2151922	=	IC50	nM	850.0	CHEMBL4282	Homo sapiens	IC50	nM	850.0
292779	17675016	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(C(F)(F)F)c1		CHEMBL3696240	=	IC50	nM	1481.0	CHEMBL4282	Homo sapiens	IC50	nM	1481.0
292780	17675017	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(Br)c1		CHEMBL2151923	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	nM	23.0
292781	17675018	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	COC(=O)c1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1		CHEMBL3696242	=	IC50	nM	1314.0	CHEMBL4282	Homo sapiens	IC50	nM	1314.0
292782	17675019	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(C(=O)O)c1		CHEMBL3696243	=	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
292783	17675020	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	CC(C)c1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1		CHEMBL3696244	=	IC50	nM	350.0	CHEMBL4282	Homo sapiens	IC50	nM	350.0
292784	17675021	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	Cc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1		CHEMBL2151919	=	IC50	nM	39.0	CHEMBL4282	Homo sapiens	IC50	nM	39.0
292785	17675022	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	N#Cc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1		CHEMBL3696246	=	IC50	nM	2287.0	CHEMBL4282	Homo sapiens	IC50	nM	2287.0
292786	17675023	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	Cc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F		CHEMBL2151925	=	IC50	nM	171.0	CHEMBL4282	Homo sapiens	IC50	nM	171.0
292787	17675024	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(Cl)c1		CHEMBL2151926	=	IC50	nM	116.0	CHEMBL4282	Homo sapiens	IC50	nM	116.0
292788	17675025	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(O)c1		CHEMBL3696250	=	IC50	nM	3635.0	CHEMBL4282	Homo sapiens	IC50	nM	3635.0
292789	17675026	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(Br)c1		CHEMBL2151048	=	IC50	nM	93.0	CHEMBL4282	Homo sapiens	IC50	nM	93.0
292790	17675027	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cc(F)c(F)c(F)c1		CHEMBL3696251	=	IC50	nM	609.0	CHEMBL4282	Homo sapiens	IC50	nM	609.0
292791	17675028	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(CO)c1		CHEMBL3696252	=	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
292792	17675029	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(C2CC2)c1		CHEMBL3696253	=	IC50	nM	200.0	CHEMBL4282	Homo sapiens	IC50	nM	200.0
292793	17675030	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1O		CHEMBL3696254	=	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
292794	17675031	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(OC(F)F)c1		CHEMBL3696255	=	IC50	nM	480.0	CHEMBL4282	Homo sapiens	IC50	nM	480.0
292795	17675032	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	COc1cc(NC(=O)C(C)c2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F		CHEMBL3696256	=	IC50	nM	1763.0	CHEMBL4282	Homo sapiens	IC50	nM	1763.0
292796	17675033	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	Cc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1C		CHEMBL3696257	=	IC50	nM	1494.0	CHEMBL4282	Homo sapiens	IC50	nM	1494.0
292797	17675034	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	Cc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1F		CHEMBL3696258	=	IC50	nM	290.0	CHEMBL4282	Homo sapiens	IC50	nM	290.0
292798	17675035	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc2ocnc12		CHEMBL3696259	=	IC50	nM	400.0	CHEMBL4282	Homo sapiens	IC50	nM	400.0
292799	17675036	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(OC(F)(F)F)c1		CHEMBL3696260	=	IC50	nM	549.0	CHEMBL4282	Homo sapiens	IC50	nM	549.0
292800	17675037	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	CC(C)Oc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1		CHEMBL3696261	=	IC50	nM	308.0	CHEMBL4282	Homo sapiens	IC50	nM	308.0
292801	17675038	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	COc1cc(F)ccc1NC(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3696262	=	IC50	nM	261.0	CHEMBL4282	Homo sapiens	IC50	nM	261.0
292802	17675039	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	CC(C)(C)OC(=O)NCCc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1		CHEMBL3696263	=	IC50	nM	2498.0	CHEMBL4282	Homo sapiens	IC50	nM	2498.0
292803	17675040	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(C(F)(F)F)c1		CHEMBL3696264	=	IC50	nM	346.0	CHEMBL4282	Homo sapiens	IC50	nM	346.0
292804	17675041	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	C#Cc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1		CHEMBL3696265	=	IC50	nM	184.0	CHEMBL4282	Homo sapiens	IC50	nM	184.0
292805	17675042	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)cc1O		CHEMBL3696267	=	IC50	nM	6721.0	CHEMBL4282	Homo sapiens	IC50	nM	6721.0
292806	17675043	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21		CHEMBL3112690	=	IC50	nM	133.0	CHEMBL4282	Homo sapiens	IC50	nM	133.0
292807	17675044	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(C2CC2)c1		CHEMBL3696268	=	IC50	nM	227.0	CHEMBL4282	Homo sapiens	IC50	nM	227.0
292808	17675045	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(OC(F)(F)F)c1		CHEMBL3696270	=	IC50	nM	807.0	CHEMBL4282	Homo sapiens	IC50	nM	807.0
292809	17675046	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(OCCO)c1		CHEMBL3696271	=	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
292810	17675047	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(I)c1		CHEMBL3696272	=	IC50	nM	137.0	CHEMBL4282	Homo sapiens	IC50	nM	137.0
292811	17675048	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	COC(=O)c1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F		CHEMBL2151928	=	IC50	nM	5865.0	CHEMBL4282	Homo sapiens	IC50	nM	5865.0
292812	17675049	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	CCOc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1		CHEMBL3696273	=	IC50	nM	760.0	CHEMBL4282	Homo sapiens	IC50	nM	760.0
292813	17675050	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	COc1c(F)ccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1F		CHEMBL3696274	=	IC50	nM	417.0	CHEMBL4282	Homo sapiens	IC50	nM	417.0
292814	17675051	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCOc2ccccc21		CHEMBL3696277	=	IC50	nM	530.0	CHEMBL4282	Homo sapiens	IC50	nM	530.0
292815	17675052	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c([N+](=O)[O-])c1		CHEMBL2151929	=	IC50	nM	6155.0	CHEMBL4282	Homo sapiens	IC50	nM	6155.0
292816	17675053	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cc(F)ccc1O		CHEMBL3696279	=	IC50	nM	6460.0	CHEMBL4282	Homo sapiens	IC50	nM	6460.0
292817	17675054	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	CCOC(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3696281	=	IC50	nM	2207.0	CHEMBL4282	Homo sapiens	IC50	nM	2207.0
292818	17675055	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	Cn1c(CC(=O)Nc2ccc(F)c(Cl)c2)nc(N2CCOCC2)cc1=O		CHEMBL2151935	=	IC50	nM	202.0	CHEMBL4282	Homo sapiens	IC50	nM	202.0
292819	17675056	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	Cn1c(CC(=O)Nc2cccc(Br)c2)nc(N2CCOCC2)cc1=O		CHEMBL3696282	=	IC50	nM	250.0	CHEMBL4282	Homo sapiens	IC50	nM	250.0
292820	17675057	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	CC(C)(C)OC(=O)n1ccc2c(NC(=O)Cc3nc(N4CCOCC4)cc(=O)[nH]3)cccc21		CHEMBL3696284	=	IC50	nM	5375.0	CHEMBL4282	Homo sapiens	IC50	nM	5375.0
292821	17675058	CHEMBL3706188	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody that specifically recognises pAKT-S473.On day 1, the PC3 cells are seeded into 6-well plates (TPP, #92006) at the concentration of 0.8x106 cells/well in 1800 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (SVF Gibco, #10500-056) and 1% glutamine (L-Glu Gibco #25030-024), and incubated at 37 C., 5% CO2, overnight.On day 2, the cells are incubated in the presence or absence of the test products for 1 to 2 hours at 37 C. in the presence of 5% CO2. The molecules, diluted in dimethyl sulphoxide (DMSO Sigma #D2650), are added from a 10-times concentrated stock solution, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 uM, or ....	B	COCc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F		CHEMBL3696286	=	IC50	nM	650.0	CHEMBL4282	Homo sapiens	IC50	nM	650.0
292822	17675059	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	CN(C)c1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1		CHEMBL3696235	=	IC50	nM	145.0	CHEMBL4282	Homo sapiens	IC50	nM	145.0
292823	17675060	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)cc1F		CHEMBL3696236	=	IC50	nM	51.0	CHEMBL4282	Homo sapiens	IC50	nM	51.0
292824	17675061	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccsc1		CHEMBL3696237	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	nM	23.0
292825	17675062	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cc(F)cc(F)c1		CHEMBL3696239	=	IC50	nM	71.0	CHEMBL4282	Homo sapiens	IC50	nM	71.0
292826	17675063	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(F)c1		CHEMBL2151820	=	IC50	nM	74.0	CHEMBL4282	Homo sapiens	IC50	nM	74.0
292827	17675064	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	CC(C)(C)c1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1		CHEMBL3696241	=	IC50	nM	42.0	CHEMBL4282	Homo sapiens	IC50	nM	42.0
292828	17675065	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	N#Cc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F		CHEMBL3696245	=	IC50	nM	247.0	CHEMBL4282	Homo sapiens	IC50	nM	247.0
292829	17675066	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)cn1		CHEMBL3696247	=	IC50	nM	71.0	CHEMBL4282	Homo sapiens	IC50	nM	71.0
292830	17675067	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccnc1		CHEMBL3696248	=	IC50	nM	1030.0	CHEMBL4282	Homo sapiens	IC50	nM	1030.0
292831	17675068	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cc1cc(F)ccc1NC(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3696249	=	IC50	nM	58.0	CHEMBL4282	Homo sapiens	IC50	nM	58.0
292832	17675069	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1F		CHEMBL3696258	=	IC50	nM	60.0	CHEMBL4282	Homo sapiens	IC50	nM	60.0
292833	17675070	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc2ocnc12		CHEMBL3696259	=	IC50	nM	148.0	CHEMBL4282	Homo sapiens	IC50	nM	148.0
292834	17675071	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(OC2CCCC2)c1		CHEMBL3696266	=	IC50	nM	146.0	CHEMBL4282	Homo sapiens	IC50	nM	146.0
292835	17675072	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(F)c1F		CHEMBL3696269	=	IC50	nM	66.0	CHEMBL4282	Homo sapiens	IC50	nM	66.0
292836	17675073	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(OC(F)(F)F)c1		CHEMBL3696270	=	IC50	nM	67.0	CHEMBL4282	Homo sapiens	IC50	nM	67.0
292837	17675074	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	CCOc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1		CHEMBL3696273	=	IC50	nM	71.0	CHEMBL4282	Homo sapiens	IC50	nM	71.0
292838	17675075	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	COc1c(F)ccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1F		CHEMBL3696274	=	IC50	nM	50.0	CHEMBL4282	Homo sapiens	IC50	nM	50.0
292839	17675076	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cc(F)c(F)cc1F		CHEMBL3696275	=	IC50	nM	290.0	CHEMBL4282	Homo sapiens	IC50	nM	290.0
292840	17675077	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cc(Cl)c(F)c(Cl)c1		CHEMBL3696276	=	IC50	nM	77.0	CHEMBL4282	Homo sapiens	IC50	nM	77.0
292841	17675078	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(C(=O)O)c1		CHEMBL3696278	=	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
292842	17675079	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)cc1Br		CHEMBL3696280	=	IC50	nM	131.0	CHEMBL4282	Homo sapiens	IC50	nM	131.0
292843	17675080	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)Nc2ccc(F)c(Cl)c2)nc(N2CCOCC2)cc1=O		CHEMBL2151935	=	IC50	nM	79.0	CHEMBL4282	Homo sapiens	IC50	nM	79.0
292844	17675081	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	CCn1c(CC(=O)Nc2ccc(F)cc2)nc(N2CCOCC2)cc1=O		CHEMBL3696283	=	IC50	nM	195.0	CHEMBL4282	Homo sapiens	IC50	nM	195.0
292845	17675082	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	CC(C)(C)OC(=O)n1ccc2c(NC(=O)Cc3nc(N4CCOCC4)cc(=O)[nH]3)cccc21		CHEMBL3696284	=	IC50	nM	120.0	CHEMBL4282	Homo sapiens	IC50	nM	120.0
292846	17675083	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	CC(C)C(C(=O)Nc1ccc(F)cc1)c1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3696285	=	IC50	nM	89.0	CHEMBL4282	Homo sapiens	IC50	nM	89.0
292847	17675084	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(I)c1		CHEMBL3696287	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
292848	17675085	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(OC(F)(F)C(F)F)c1		CHEMBL3696288	=	IC50	nM	69.0	CHEMBL4282	Homo sapiens	IC50	nM	69.0
292849	17675086	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(C(F)F)c1		CHEMBL3696289	=	IC50	nM	77.0	CHEMBL4282	Homo sapiens	IC50	nM	77.0
292850	17675087	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Nc1ccc(F)cc1)C(F)(F)c1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3696290	=	IC50	nM	698.0	CHEMBL4282	Homo sapiens	IC50	nM	698.0
292851	17675088	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)Nc2ccc(F)c(F)c2)nc(N2CCOCC2)cc1=O		CHEMBL2151932	=	IC50	nM	129.0	CHEMBL4282	Homo sapiens	IC50	nM	129.0
292852	17675089	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)N2CCc3ccccc32)nc(N2CCOCC2)cc1=O		CHEMBL3112861	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	nM	20.0
292853	17675090	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)Nc2ccc(F)c(Br)c2)nc(N2CCOCC2)cc1=O		CHEMBL2151933	=	IC50	nM	94.0	CHEMBL4282	Homo sapiens	IC50	nM	94.0
292854	17675091	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)Nc2ccc(F)c(CO)c2)nc(N2CCOCC2)cc1=O		CHEMBL3696291	=	IC50	nM	1940.0	CHEMBL4282	Homo sapiens	IC50	nM	1940.0
292855	17675092	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)Nc2cccc(C3CC3)c2)nc(N2CCOCC2)cc1=O		CHEMBL3696292	=	IC50	nM	133.0	CHEMBL4282	Homo sapiens	IC50	nM	133.0
292856	17675093	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	COc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)n2C)ccc1F		CHEMBL2151934	=	IC50	nM	115.0	CHEMBL4282	Homo sapiens	IC50	nM	115.0
292857	17675094	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc2occc12		CHEMBL3696293	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	nM	17.0
292858	17675095	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)Nc2ccccc2)nc(N2CCOCC2)cc1=O		CHEMBL2151930	=	IC50	nM	340.0	CHEMBL4282	Homo sapiens	IC50	nM	340.0
292859	17675096	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)Nc2ccc(F)c(C3CC3)c2)nc(N2CCOCC2)cc1=O		CHEMBL3696294	=	IC50	nM	26.0	CHEMBL4282	Homo sapiens	IC50	nM	26.0
292860	17675097	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(F)c1O		CHEMBL3696295	=	IC50	nM	75.0	CHEMBL4282	Homo sapiens	IC50	nM	75.0
292861	17675098	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(F)cccc21		CHEMBL3112848	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
292862	17675099	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(Cl)cccc21		CHEMBL3112849	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
292863	17675100	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	C#Cc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F		CHEMBL3696296	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
292864	17675101	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(O)cccc21		CHEMBL3696297	=	IC50	nM	71.0	CHEMBL4282	Homo sapiens	IC50	nM	71.0
292865	17675102	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(F)cc(F)cc21		CHEMBL3696298	=	IC50	nM	57.0	CHEMBL4282	Homo sapiens	IC50	nM	57.0
292866	17675103	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)Nc2ccc(F)c(I)c2)nc(N2CCOCC2)cc1=O		CHEMBL3696299	=	IC50	nM	63.0	CHEMBL4282	Homo sapiens	IC50	nM	63.0
292867	17675104	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c1ccc(F)c2F		CHEMBL3696300	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
292868	17675105	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccc(F)cc21		CHEMBL3696301	=	IC50	nM	35.0	CHEMBL4282	Homo sapiens	IC50	nM	35.0
292869	17675106	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	CC1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3112862	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
292870	17675107	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)Nc2ccc(F)c(C(F)F)c2)nc(N2CCOCC2)cc1=O		CHEMBL3696302	=	IC50	nM	260.0	CHEMBL4282	Homo sapiens	IC50	nM	260.0
292871	17675108	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)Nc2cc(F)c(F)c(F)c2)nc(N2CCOCC2)cc1=O		CHEMBL3696303	=	IC50	nM	219.0	CHEMBL4282	Homo sapiens	IC50	nM	219.0
292872	17675109	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1ccc2c(NC(=O)Cc3nc(N4CCOCC4)cc(=O)[nH]3)cccc21		CHEMBL3696304	=	IC50	nM	666.0	CHEMBL4282	Homo sapiens	IC50	nM	666.0
292873	17675110	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cc1cccc2c1CCN2C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3112851	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
292874	17675111	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	CC1CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21		CHEMBL3112864	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
292875	17675112	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)N2CCc3c(F)cccc32)nc(N2CCOCC2)cc1=O		CHEMBL3696305	=	IC50	nM	43.0	CHEMBL4282	Homo sapiens	IC50	nM	43.0
292876	17675113	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2cc(F)ccc21		CHEMBL3112847	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
292877	17675114	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)N2CCc3c(Cl)cccc32)nc(N2CCOCC2)cc1=O		CHEMBL3696306	=	IC50	nM	42.0	CHEMBL4282	Homo sapiens	IC50	nM	42.0
292878	17675115	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc2sccc12		CHEMBL3696307	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
292879	17675116	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1c2ccccc2CC1CO		CHEMBL3696308	=	IC50	nM	27.0	CHEMBL4282	Homo sapiens	IC50	nM	27.0
292880	17675117	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1OCCN1CCCCC1		CHEMBL3696309	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	nM	24.0
292881	17675118	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	COCCOc1ccccc1NC(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3696310	=	IC50	nM	56.0	CHEMBL4282	Homo sapiens	IC50	nM	56.0
292882	17675119	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)N2CCc3c(O)cccc32)nc(N2CCOCC2)cc1=O		CHEMBL3696311	=	IC50	nM	43.0	CHEMBL4282	Homo sapiens	IC50	nM	43.0
292883	17675120	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	COc1cccc2c1CCN2C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3696312	=	IC50	nM	278.0	CHEMBL4282	Homo sapiens	IC50	nM	278.0
292884	17675121	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc2C1		CHEMBL3696313	=	IC50	nM	301.0	CHEMBL4282	Homo sapiens	IC50	nM	301.0
292885	17675122	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1OCCN1CCCC1		CHEMBL3696314	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	nM	23.0
292886	17675123	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1OCc1cccnc1		CHEMBL3696315	=	IC50	nM	664.0	CHEMBL4282	Homo sapiens	IC50	nM	664.0
292887	17675124	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cc1cccc2c1CCN2C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3699779	=	IC50	nM	26.0	CHEMBL4282	Homo sapiens	IC50	nM	26.0
292888	17675125	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	CN(C)CC1CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21		CHEMBL3699780	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
292889	17675126	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)N2CCc3c(Br)cccc32)nc(N2CCOCC2)cc1=O		CHEMBL3699781	=	IC50	nM	51.0	CHEMBL4282	Homo sapiens	IC50	nM	51.0
292890	17675127	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3112866	=	IC50	nM	19.0	CHEMBL4282	Homo sapiens	IC50	nM	19.0
292891	17675128	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	C[C@@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3112867	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
292892	17675129	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	CC1CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)n2C)c2ccccc21		CHEMBL3699782	=	IC50	nM	194.0	CHEMBL4282	Homo sapiens	IC50	nM	194.0
292893	17675130	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	COCC1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3699783	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
292894	17675131	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	CCOc1cccc2c1CCN2C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3699784	=	IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	nM	44.0
292895	17675132	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	NC(=O)C1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3699785	=	IC50	nM	503.0	CHEMBL4282	Homo sapiens	IC50	nM	503.0
292896	17675133	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	CC1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3699786	=	IC50	nM	77.0	CHEMBL4282	Homo sapiens	IC50	nM	77.0
292897	17675134	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)N2CCc3ccc(F)cc32)nc(N2CCOCC2)cc1=O		CHEMBL3699787	=	IC50	nM	124.0	CHEMBL4282	Homo sapiens	IC50	nM	124.0
292898	17675135	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	C[C@@H]1CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21		CHEMBL3699788	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
292899	17675136	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	C[C@H]1CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21		CHEMBL3699811	=	IC50	nM	57.0	CHEMBL4282	Homo sapiens	IC50	nM	57.0
292900	17675137	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)N2CCc3cc(F)c(F)cc32)nc(N2CCOCC2)cc1=O		CHEMBL3699789	=	IC50	nM	61.0	CHEMBL4282	Homo sapiens	IC50	nM	61.0
292901	17675138	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)N2CCc3c2ccc(F)c3F)nc(N2CCOCC2)cc1=O		CHEMBL3699790	=	IC50	nM	69.0	CHEMBL4282	Homo sapiens	IC50	nM	69.0
292902	17675139	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1Cc2ccccc2C1		CHEMBL3699791	=	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
292903	17675140	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cn1c(CC(=O)Nc2cccc3sccc23)nc(N2CCOCC2)cc1=O		CHEMBL3699792	=	IC50	nM	70.0	CHEMBL4282	Homo sapiens	IC50	nM	70.0
292904	17675141	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCCc2c(Cl)cccc21		CHEMBL3699793	=	IC50	nM	41.0	CHEMBL4282	Homo sapiens	IC50	nM	41.0
292905	17675142	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(CO)cccc21		CHEMBL3699794	=	IC50	nM	533.0	CHEMBL4282	Homo sapiens	IC50	nM	533.0
292906	17675143	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)cc1OCC1CCNCC1		CHEMBL3699795	=	IC50	nM	174.0	CHEMBL4282	Homo sapiens	IC50	nM	174.0
292907	17675144	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2cc(Cl)ccc21		CHEMBL3112592	=	IC50	nM	124.0	CHEMBL4282	Homo sapiens	IC50	nM	124.0
292908	17675145	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(Br)cccc21		CHEMBL3112850	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
292909	17675146	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	CN(C)C[C@H]1CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21		CHEMBL3699796	=	IC50	nM	26.0	CHEMBL4282	Homo sapiens	IC50	nM	26.0
292910	17675147	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	CN(C)C[C@@H]1CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21		CHEMBL3699812	=	IC50	nM	68.0	CHEMBL4282	Homo sapiens	IC50	nM	68.0
292911	17675148	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	COCCOc1cc(F)ccc1NC(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3699797	=	IC50	nM	35.0	CHEMBL4282	Homo sapiens	IC50	nM	35.0
292912	17675149	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc2[nH]cnc12		CHEMBL3699798	=	IC50	nM	3000.0	CHEMBL4282	Homo sapiens	IC50	nM	3000.0
292913	17675150	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	COC(=O)c1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1O		CHEMBL3699799	=	IC50	nM	302.0	CHEMBL4282	Homo sapiens	IC50	nM	302.0
292914	17675151	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	COc1cccc2c1CCN2C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3112852	=	IC50	nM	60.0	CHEMBL4282	Homo sapiens	IC50	nM	60.0
292915	17675152	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(Br)c1O		CHEMBL3699800	=	IC50	nM	22.0	CHEMBL4282	Homo sapiens	IC50	nM	22.0
292916	17675153	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc2c1OCCN2		CHEMBL3699801	=	IC50	nM	473.0	CHEMBL4282	Homo sapiens	IC50	nM	473.0
292917	17675154	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	COC(=O)c1cc(F)ccc1NC(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3699802	=	IC50	nM	432.0	CHEMBL4282	Homo sapiens	IC50	nM	432.0
292918	17675155	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	CCN(CC)CC1CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21		CHEMBL3639986	=	IC50	nM	38.0	CHEMBL4282	Homo sapiens	IC50	nM	38.0
292919	17675156	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ncccc21		CHEMBL3699803	=	IC50	nM	180.0	CHEMBL4282	Homo sapiens	IC50	nM	180.0
292920	17675157	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2cc(F)c(F)cc21		CHEMBL3699804	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
292921	17675158	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc2c1NCCC2		CHEMBL3699805	=	IC50	nM	234.0	CHEMBL4282	Homo sapiens	IC50	nM	234.0
292922	17675159	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCOc2c(Cl)cccc21		CHEMBL3699806	=	IC50	nM	43.0	CHEMBL4282	Homo sapiens	IC50	nM	43.0
292923	17675160	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	Cc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1O		CHEMBL3699807	=	IC50	nM	189.0	CHEMBL4282	Homo sapiens	IC50	nM	189.0
292924	17675161	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc([N+](=O)[O-])c1O		CHEMBL3699808	=	IC50	nM	29.0	CHEMBL4282	Homo sapiens	IC50	nM	29.0
292925	17675162	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	N#Cc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1O		CHEMBL3699809	=	IC50	nM	938.0	CHEMBL4282	Homo sapiens	IC50	nM	938.0
292926	17675163	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(C(F)(F)F)c1O		CHEMBL3699810	=	IC50	nM	49.0	CHEMBL4282	Homo sapiens	IC50	nM	49.0
292927	17675164	CHEMBL3706189	Inhibitory Assay: This test is based on measuring the expression of the AKT protein phosphorylated on serine 473 (P-AKT-S473), in the PC3 human prostate carcinoma line, by means of the technique based on a sandwich immunoassay using the MSD Multi-spot Biomarker Detection kit from Meso Scale Discovery: phospho-Akt (Ser473) whole cell lysate kit (#K151CAD) or phospho-Akt (Ser473)/Total Akt whole cell lysate kit (#K15100D). The primary antibody specific for P-AKT-S473 (Kit #K151CAD) is coated on to an electrode in each well of the 96-well plates of the MSD, kit: after the addition of a protein lysate to each well, the signal is visualised by adding a secondary detection antibody labelled with an electrochemoluminescent compound. The procedure followed is that described in the kit.On day 1, the PC3 cells are seeded into 96-well plates (TPP, #92096) at the concentration of 35 000 cells/well in 200 ul of DMEM medium (DMEM Gibco #11960-044) containing 10% of foetal calf serum (FCS Gibco, #10500-056).	B	CC1(C)CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21		CHEMBL3112865	=	IC50	nM	28.0	CHEMBL4282	Homo sapiens	IC50	nM	28.0
320038	17699959	CHEMBL3705654	In Vitro Assay: This assay determines the ability of test compounds to inhibit phosphorylation of Serine 473 in Akt as assessed using Acumen Explorer technology (Acumen Bioscience Limited), a plate reader that can be used to rapidly quantitate features of images generated by laser-scanning.	B	C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc4c(c3)C(=O)NCCN4)nc2n1		CHEMBL3693591	=	IC50	nM	381.3	CHEMBL4282	Homo sapiens	IC50	nM	381.3
320039	17699960	CHEMBL3705654	In Vitro Assay: This assay determines the ability of test compounds to inhibit phosphorylation of Serine 473 in Akt as assessed using Acumen Explorer technology (Acumen Bioscience Limited), a plate reader that can be used to rapidly quantitate features of images generated by laser-scanning.	B	C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(N)c3)nc2n1		CHEMBL3688934	=	IC50	nM	14.15	CHEMBL4282	Homo sapiens	IC50	nM	14.15
320040	17699961	CHEMBL3705654	In Vitro Assay: This assay determines the ability of test compounds to inhibit phosphorylation of Serine 473 in Akt as assessed using Acumen Explorer technology (Acumen Bioscience Limited), a plate reader that can be used to rapidly quantitate features of images generated by laser-scanning.	B	C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc4[nH]nc(N)c4c3)nc2n1		CHEMBL3688935	=	IC50	nM	60.66	CHEMBL4282	Homo sapiens	IC50	nM	60.66
320041	17699962	CHEMBL3705654	In Vitro Assay: This assay determines the ability of test compounds to inhibit phosphorylation of Serine 473 in Akt as assessed using Acumen Explorer technology (Acumen Bioscience Limited), a plate reader that can be used to rapidly quantitate features of images generated by laser-scanning.	B	CC(C)S(=O)(=O)Nc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL3693446	=	IC50	nM	505.1	CHEMBL4282	Homo sapiens	IC50	nM	505.1
320042	17699963	CHEMBL3705654	In Vitro Assay: This assay determines the ability of test compounds to inhibit phosphorylation of Serine 473 in Akt as assessed using Acumen Explorer technology (Acumen Bioscience Limited), a plate reader that can be used to rapidly quantitate features of images generated by laser-scanning.	B	CNC(=O)C1CCN(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccc(N)nc4)nc3n2)CC1		CHEMBL3693558	=	IC50	nM	682.1	CHEMBL4282	Homo sapiens	IC50	nM	682.1
320043	17699964	CHEMBL3705654	In Vitro Assay: This assay determines the ability of test compounds to inhibit phosphorylation of Serine 473 in Akt as assessed using Acumen Explorer technology (Acumen Bioscience Limited), a plate reader that can be used to rapidly quantitate features of images generated by laser-scanning.	B	C[C@H]1COCCN1c1nc(N2CCOCC2)nc2nc(-c3ccc(N)nc3)ccc12		CHEMBL3693559	=	IC50	nM	295.1	CHEMBL4282	Homo sapiens	IC50	nM	295.1
326863	17705590	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1)N1CCc2c(F)cccc21		CHEMBL3961677	=	IC50	nM	22.0	CHEMBL4282	Homo sapiens	IC50	nM	22.0
326864	17705591	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC(C(=O)N1CCc2c(F)cccc21)c1nc(N2CCOCC2)c(F)c(=O)n1C		CHEMBL3896167	=	IC50	nM	938.0	CHEMBL4282	Homo sapiens	IC50	nM	938.0
326865	17705592	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	Cn1c(CC(=O)N2CCc3c(F)cccc32)nc(N2CCOCC2)c(F)c1=O		CHEMBL3956312	=	IC50	nM	158.0	CHEMBL4282	Homo sapiens	IC50	nM	158.0
326866	17705593	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3974788	=	IC50	nM	503.0	CHEMBL4282	Homo sapiens	IC50	nM	503.0
326867	17705594	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3893935	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
326868	17705595	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3918391	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
326869	17705596	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3918391	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
326870	17705597	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)n1C		CHEMBL3905243	=	IC50	nM	107.0	CHEMBL4282	Homo sapiens	IC50	nM	107.0
326871	17705598	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)n1C		CHEMBL3942235	=	IC50	nM	120.0	CHEMBL4282	Homo sapiens	IC50	nM	120.0
326872	17705599	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(F)cccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3917798	=	IC50	nM	116.0	CHEMBL4282	Homo sapiens	IC50	nM	116.0
326873	17705600	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(F)cccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3917798	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	nM	24.0
326874	17705601	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2cc(F)c(F)cc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3890826	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
326875	17705602	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2cc(F)c(F)cc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3890826	=	IC50	nM	162.0	CHEMBL4282	Homo sapiens	IC50	nM	162.0
326876	17705603	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)n1C		CHEMBL3896311	=	IC50	nM	55.0	CHEMBL4282	Homo sapiens	IC50	nM	55.0
326877	17705604	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)n1C		CHEMBL3896311	=	IC50	nM	65.0	CHEMBL4282	Homo sapiens	IC50	nM	65.0
326878	17705605	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3913066	=	IC50	nM	483.0	CHEMBL4282	Homo sapiens	IC50	nM	483.0
326879	17705606	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3913066	=	IC50	nM	45.0	CHEMBL4282	Homo sapiens	IC50	nM	45.0
326880	17705607	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3916280	=	IC50	nM	38.0	CHEMBL4282	Homo sapiens	IC50	nM	38.0
326881	17705608	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3916280	=	IC50	nM	19.0	CHEMBL4282	Homo sapiens	IC50	nM	19.0
326882	17705609	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(ccc(F)c2F)N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3931890	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
326883	17705610	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(ccc(F)c2F)N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3931890	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
326884	17705611	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(F)cccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)n1C		CHEMBL3922944	=	IC50	nM	98.0	CHEMBL4282	Homo sapiens	IC50	nM	98.0
326885	17705612	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(F)cccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)n1C		CHEMBL3922944	=	IC50	nM	203.0	CHEMBL4282	Homo sapiens	IC50	nM	203.0
326886	17705613	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(ccc(F)c2F)N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)n1C		CHEMBL3917496	=	IC50	nM	310.0	CHEMBL4282	Homo sapiens	IC50	nM	310.0
326887	17705614	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(ccc(F)c2F)N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)n1C		CHEMBL3917496	=	IC50	nM	98.0	CHEMBL4282	Homo sapiens	IC50	nM	98.0
326888	17705615	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2cc(F)c(F)cc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)n1C		CHEMBL3951881	=	IC50	nM	211.0	CHEMBL4282	Homo sapiens	IC50	nM	211.0
326889	17705616	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2cc(F)c(F)cc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)n1C		CHEMBL3951881	=	IC50	nM	270.0	CHEMBL4282	Homo sapiens	IC50	nM	270.0
326890	17705617	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)n1C		CHEMBL3974610	=	IC50	nM	476.0	CHEMBL4282	Homo sapiens	IC50	nM	476.0
326891	17705618	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)n1C		CHEMBL3974610	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	nM	20.0
326892	17705619	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)n1C		CHEMBL3982597	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
326893	17705620	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)n1C		CHEMBL3982597	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
326894	17705621	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2ccc(F)cc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3890103	=	IC50	nM	40.0	CHEMBL4282	Homo sapiens	IC50	nM	40.0
326895	17705622	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2ccc(F)cc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3890103	=	IC50	nM	77.0	CHEMBL4282	Homo sapiens	IC50	nM	77.0
326896	17705623	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(ccc(F)c2Cl)N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1		CHEMBL3970127	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
326897	17705624	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)c(Cl)c(=O)[nH]1		CHEMBL3952768	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	nM	140.0
326898	17705625	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)c(Cl)c(=O)[nH]1		CHEMBL3981502	=	IC50	nM	55.0	CHEMBL4282	Homo sapiens	IC50	nM	55.0
326899	17705626	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)c(Br)c(=O)[nH]1		CHEMBL3950856	=	IC50	nM	56.0	CHEMBL4282	Homo sapiens	IC50	nM	56.0
326900	17705627	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1)N1c2ccccc2CC1CO		CHEMBL3923121	=	IC50	nM	1138.0	CHEMBL4282	Homo sapiens	IC50	nM	1138.0
326901	17705628	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)c(F)c(=O)[nH]1)N1c2ccccc2CC1CO		CHEMBL3923121	=	IC50	nM	568.0	CHEMBL4282	Homo sapiens	IC50	nM	568.0
326902	17705629	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1CN(c2cc(=O)[nH]c(CC(=O)Nc3ccc(F)cc3)n2)CCO1		CHEMBL3935564	=	IC50	nM	26.0	CHEMBL4282	Homo sapiens	IC50	nM	26.0
326903	17705630	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1CN(c2cc(=O)[nH]c(CC(=O)Nc3ccc(F)cc3)n2)CCO1		CHEMBL3935564	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
326904	17705631	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOC(CF)C2)cc(=O)[nH]1)Nc1ccc(F)cc1		CHEMBL3978959	=	IC50	nM	271.0	CHEMBL4282	Homo sapiens	IC50	nM	271.0
326905	17705632	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOC(CF)C2)cc(=O)[nH]1)Nc1ccc(F)cc1		CHEMBL3978959	=	IC50	nM	118.0	CHEMBL4282	Homo sapiens	IC50	nM	118.0
326906	17705633	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	Cn1c(CC(=O)Nc2ccc(F)c(Cl)c2)nc(N2CCOC(CF)C2)cc1=O		CHEMBL3983824	=	IC50	nM	127.0	CHEMBL4282	Homo sapiens	IC50	nM	127.0
326907	17705634	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOC(CF)C2)cc(=O)[nH]1)N1CCc2c(F)cccc21		CHEMBL3984868	=	IC50	nM	58.0	CHEMBL4282	Homo sapiens	IC50	nM	58.0
326908	17705635	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOC(CF)C2)cc(=O)[nH]1)N1CCc2c(F)cccc21		CHEMBL3984868	=	IC50	nM	21.0	CHEMBL4282	Homo sapiens	IC50	nM	21.0
326909	17705636	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1CN(c2cc(=O)[nH]c(CC(=O)N3CCc4c(F)cccc43)n2)CCO1		CHEMBL3928308	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
326910	17705637	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1CN(c2cc(=O)[nH]c(CC(=O)N3CCc4c(F)cccc43)n2)CCO1		CHEMBL3928308	=	IC50	nM	156.0	CHEMBL4282	Homo sapiens	IC50	nM	156.0
326911	17705638	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1CN(c2cc(=O)[nH]c(CC(=O)N3CCc4c(F)cccc43)n2)CCO1		CHEMBL3928308	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
326912	17705639	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOC3CCCC32)cc(=O)[nH]1)N1CCc2c(F)cccc21		CHEMBL3943810	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
326913	17705640	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(-c2ccncc2)cc(=O)[nH]1)N1CCc2c(F)cccc21		CHEMBL3977387	=	IC50	nM	370.0	CHEMBL4282	Homo sapiens	IC50	nM	370.0
326914	17705641	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	COc1cc(-c2cc(=O)[nH]c(CC(=O)N3CCc4c(F)cccc43)n2)ccn1		CHEMBL3938410	=	IC50	nM	3000.0	CHEMBL4282	Homo sapiens	IC50	nM	3000.0
326915	17705642	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CCC1CN(c2cc(=O)[nH]c(CC(=O)Nc3ccc(F)cc3)n2)CCO1		CHEMBL3972428	=	IC50	nM	280.0	CHEMBL4282	Homo sapiens	IC50	nM	280.0
326916	17705643	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CCC1CN(c2cc(=O)[nH]c(CC(=O)Nc3ccc(F)cc3)n2)CCO1		CHEMBL3972428	=	IC50	nM	105.0	CHEMBL4282	Homo sapiens	IC50	nM	105.0
326917	17705644	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	Cc1cc(-c2cc(=O)[nH]c(CC(=O)N3CCc4c(F)cccc43)n2)ccn1		CHEMBL3961321	=	IC50	nM	244.0	CHEMBL4282	Homo sapiens	IC50	nM	244.0
326918	17705645	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(-c2ccnc(F)c2)cc(=O)[nH]1)N1CCc2c(F)cccc21		CHEMBL3986565	=	IC50	nM	2855.0	CHEMBL4282	Homo sapiens	IC50	nM	2855.0
326919	17705646	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOC(CO)C2)cc(=O)[nH]1)N1CCc2c(Cl)cccc21		CHEMBL3893924	=	IC50	nM	27.0	CHEMBL4282	Homo sapiens	IC50	nM	27.0
326920	17705647	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOC(CO)C2)cc(=O)[nH]1)N1CCc2c(Cl)cccc21		CHEMBL3893924	=	IC50	nM	240.0	CHEMBL4282	Homo sapiens	IC50	nM	240.0
326921	17705648	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOC(CO)C2)cc(=O)[nH]1)N1CCc2c(F)cccc21		CHEMBL3954012	=	IC50	nM	1332.0	CHEMBL4282	Homo sapiens	IC50	nM	1332.0
326922	17705649	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1CN(c2cc(=O)[nH]c(CC(=O)N3CCc4c(Cl)cccc43)n2)CCO1		CHEMBL3926375	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
326923	17705650	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1CN(c2cc(=O)[nH]c(CC(=O)N3c4ccccc4C[C@@H]3C)n2)CCO1		CHEMBL3908338	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	nM	24.0
326924	17705651	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOC(CF)C2)cc(=O)[nH]1		CHEMBL3981833	=	IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	nM	44.0
326925	17705652	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOC(CO)C2)cc(=O)[nH]1		CHEMBL3899292	=	IC50	nM	156.0	CHEMBL4282	Homo sapiens	IC50	nM	156.0
326926	17705653	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3970476	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
326927	17705654	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3970476	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
326928	17705655	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3970476	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
326929	17705656	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	Cn1c(CC(=O)N2CC(C)(C)c3c(Cl)cccc32)nc(N2CCOCC2)cc1=O		CHEMBL3897578	=	IC50	nM	35.0	CHEMBL4282	Homo sapiens	IC50	nM	35.0
326930	17705657	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1(C)CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2cccc(Cl)c21		CHEMBL3911266	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
326931	17705658	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(O)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3910203	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	nM	24.0
326932	17705659	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	Cn1c(CC(=O)N2CC(C)(C)c3c(F)cccc32)nc(N2CCOCC2)cc1=O		CHEMBL3934544	=	IC50	nM	45.0	CHEMBL4282	Homo sapiens	IC50	nM	45.0
326933	17705660	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1(C)CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2cccc(F)c21		CHEMBL3981254	=	IC50	nM	52.0	CHEMBL4282	Homo sapiens	IC50	nM	52.0
326934	17705661	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(O)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3910203	=	IC50	nM	115.0	CHEMBL4282	Homo sapiens	IC50	nM	115.0
326935	17705662	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(O)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3910203	=	IC50	nM	22.0	CHEMBL4282	Homo sapiens	IC50	nM	22.0
326936	17705663	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2cccc(O)c21		CHEMBL3970508	=	IC50	nM	57.0	CHEMBL4282	Homo sapiens	IC50	nM	57.0
326937	17705664	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3932198	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
326938	17705665	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3932198	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
326939	17705666	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3901730	=	IC50	nM	28.0	CHEMBL4282	Homo sapiens	IC50	nM	28.0
326940	17705667	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3901730	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
326941	17705668	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(ccc(F)c2F)N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3910755	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
326942	17705669	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(ccc(F)c2F)N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3910755	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
326943	17705670	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(ccc(F)c2F)N1C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3916147	=	IC50	nM	19.0	CHEMBL4282	Homo sapiens	IC50	nM	19.0
326944	17705671	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(ccc(F)c2F)N1C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3916147	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
326945	17705672	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2cc(F)c(F)cc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3925163	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	nM	17.0
326946	17705673	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2cc(F)c(F)cc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3925163	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
326947	17705674	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2cc(F)c(F)cc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3937641	=	IC50	nM	32.0	CHEMBL4282	Homo sapiens	IC50	nM	32.0
326948	17705675	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2cc(F)c(F)cc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3937641	=	IC50	nM	114.0	CHEMBL4282	Homo sapiens	IC50	nM	114.0
326949	17705676	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3971065	=	IC50	nM	39.0	CHEMBL4282	Homo sapiens	IC50	nM	39.0
326950	17705677	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3971065	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
326951	17705678	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(F)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3965878	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
326952	17705679	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(F)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3965878	=	IC50	nM	98.0	CHEMBL4282	Homo sapiens	IC50	nM	98.0
326953	17705680	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(F)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3893392	=	IC50	nM	53.0	CHEMBL4282	Homo sapiens	IC50	nM	53.0
326954	17705681	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(F)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3893392	=	IC50	nM	73.0	CHEMBL4282	Homo sapiens	IC50	nM	73.0
326955	17705682	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3917877	=	IC50	nM	36.0	CHEMBL4282	Homo sapiens	IC50	nM	36.0
326956	17705683	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3917877	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
326957	17705684	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3908482	=	IC50	nM	55.0	CHEMBL4282	Homo sapiens	IC50	nM	55.0
326958	17705685	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3908482	=	IC50	nM	242.0	CHEMBL4282	Homo sapiens	IC50	nM	242.0
326959	17705686	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2ccc(F)cc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3896158	=	IC50	nM	27.0	CHEMBL4282	Homo sapiens	IC50	nM	27.0
326960	17705687	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2ccc(F)cc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3896158	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
326961	17705688	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(ccc(F)c2Cl)N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3930708	=	IC50	nM	7.0	CHEMBL4282	Homo sapiens	IC50	nM	7.0
326962	17705689	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(ccc(F)c2Cl)N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3930708	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
326963	17705690	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC(C)C1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3918242	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
326964	17705691	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC(C)C1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3918242	=	IC50	nM	243.0	CHEMBL4282	Homo sapiens	IC50	nM	243.0
326965	17705692	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC(C(=O)N1CCc2c(F)cccc21)c1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3937375	=	IC50	nM	29.0	CHEMBL4282	Homo sapiens	IC50	nM	29.0
326966	17705693	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CCC1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3959404	=	IC50	nM	380.0	CHEMBL4282	Homo sapiens	IC50	nM	380.0
326967	17705694	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CCC1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3959404	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
326968	17705695	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC(F)(C(=O)N1CCc2c(F)cccc21)c1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3947247	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	nM	140.0
326969	17705696	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC(F)(C(=O)N1CCc2c(F)cccc21)c1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3947247	=	IC50	nM	260.0	CHEMBL4282	Homo sapiens	IC50	nM	260.0
326970	17705697	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	N#Cc1cccc2c1CCN2C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3922497	=	IC50	nM	101.0	CHEMBL4282	Homo sapiens	IC50	nM	101.0
326971	17705698	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CC2(CC2)c2ccccc21		CHEMBL3950222	=	IC50	nM	26.0	CHEMBL4282	Homo sapiens	IC50	nM	26.0
326972	17705699	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccc3)cccc21		CHEMBL3112855	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	nM	24.0
326973	17705700	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(OC(F)(F)F)cccc21		CHEMBL3112854	=	IC50	nM	54.0	CHEMBL4282	Homo sapiens	IC50	nM	54.0
326974	17705701	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	Cn1c(CC(=O)N2CCc3c2cccc3C(F)(F)F)nc(N2CCOCC2)cc1=O		CHEMBL3927896	=	IC50	nM	63.0	CHEMBL4282	Homo sapiens	IC50	nM	63.0
326975	17705702	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c1cccc2C(F)(F)F		CHEMBL3112853	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
326976	17705703	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	COc1ccccc1-c1cccc2c1CCN2C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3931282	=	IC50	nM	32.0	CHEMBL4282	Homo sapiens	IC50	nM	32.0
326977	17705704	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CCCN1CCCCC1c1cccc2c1CCN2C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3908806	=	IC50	nM	102.0	CHEMBL4282	Homo sapiens	IC50	nM	102.0
326978	17705705	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	Cn1c(CC(=O)N2CCc3c(OC(F)F)cccc32)nc(N2CCOCC2)cc1=O		CHEMBL3936766	=	IC50	nM	60.0	CHEMBL4282	Homo sapiens	IC50	nM	60.0
326979	17705706	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(OC(F)F)cccc21		CHEMBL3921269	=	IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	nM	44.0
326980	17705707	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccncc3)cccc21		CHEMBL3112858	=	IC50	nM	94.0	CHEMBL4282	Homo sapiens	IC50	nM	94.0
326981	17705708	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CN1CCC2(CC1)CN(C(=O)Cc1nc(N3CCOCC3)cc(=O)[nH]1)c1ccccc12		CHEMBL3945651	=	IC50	nM	26.0	CHEMBL4282	Homo sapiens	IC50	nM	26.0
326982	17705709	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccn3)cccc21		CHEMBL3112856	=	IC50	nM	66.0	CHEMBL4282	Homo sapiens	IC50	nM	66.0
326983	17705710	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3cccnc3)cccc21		CHEMBL3112857	=	IC50	nM	53.0	CHEMBL4282	Homo sapiens	IC50	nM	53.0
326984	17705711	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccc3Cl)cccc21		CHEMBL3971261	=	IC50	nM	42.0	CHEMBL4282	Homo sapiens	IC50	nM	42.0
326985	17705712	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)n1C1CC1)N1CCc2c(Cl)cccc21		CHEMBL3914529	=	IC50	nM	37.0	CHEMBL4282	Homo sapiens	IC50	nM	37.0
326986	17705713	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1c2ccccc2C2CCCC21		CHEMBL3893813	=	IC50	nM	30.0	CHEMBL4282	Homo sapiens	IC50	nM	30.0
326987	17705714	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CS(=O)(=O)N1CCN(Cc2cccc3c2CCN3C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)CC1		CHEMBL3985936	=	IC50	nM	259.0	CHEMBL4282	Homo sapiens	IC50	nM	259.0
326988	17705715	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CN1CCN(Cc2cccc3c2CCN3C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)CC1		CHEMBL3112860	=	IC50	nM	272.0	CHEMBL4282	Homo sapiens	IC50	nM	272.0
326989	17705716	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccc3F)cccc21		CHEMBL3953697	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	nM	23.0
326990	17705717	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CN1CCN(Cc2cccc3c2CCN3C(=O)Cc2nc(N3CCOCC3)cc(=O)n2C)CC1		CHEMBL3930747	=	IC50	nM	520.0	CHEMBL4282	Homo sapiens	IC50	nM	520.0
326991	17705718	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CC2(CCOCC2)c2ccccc21		CHEMBL3904288	=	IC50	nM	155.0	CHEMBL4282	Homo sapiens	IC50	nM	155.0
326992	17705719	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	Cn1c(CC(=O)N2CC3(CCOCC3)c3ccccc32)nc(N2CCOCC2)cc1=O		CHEMBL3936162	=	IC50	nM	106.0	CHEMBL4282	Homo sapiens	IC50	nM	106.0
326993	17705720	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	Cn1c(CC(=O)N2CC3(CCNCC3)c3ccccc32)nc(N2CCOCC2)cc1=O		CHEMBL3893381	=	IC50	nM	196.0	CHEMBL4282	Homo sapiens	IC50	nM	196.0
326994	17705721	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1c2ccccc2CC1c1ccccc1		CHEMBL3945090	=	IC50	nM	205.0	CHEMBL4282	Homo sapiens	IC50	nM	205.0
326995	17705722	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1c2ccccc2CC1c1ccccc1		CHEMBL3945090	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
326996	17705723	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CN1CCN(c2cccc3c2CCN3C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)CC1		CHEMBL3112859	=	IC50	nM	167.0	CHEMBL4282	Homo sapiens	IC50	nM	167.0
326997	17705724	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1c2ccccc2CC1c1ccc(F)cc1		CHEMBL3914007	=	IC50	nM	435.0	CHEMBL4282	Homo sapiens	IC50	nM	435.0
326998	17705725	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1c2ccccc2CC1c1ccc(F)cc1		CHEMBL3914007	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
326999	17705726	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(OC(F)F)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3964324	=	IC50	nM	33.0	CHEMBL4282	Homo sapiens	IC50	nM	33.0
327000	17705727	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(OC(F)F)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3964324	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
327001	17705728	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(OC(F)F)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3939903	=	IC50	nM	167.0	CHEMBL4282	Homo sapiens	IC50	nM	167.0
327002	17705729	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(OC(F)F)cccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)n1C		CHEMBL3939903	=	IC50	nM	60.0	CHEMBL4282	Homo sapiens	IC50	nM	60.0
327003	17705730	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(N3CCOCC3)cccc21		CHEMBL3930892	=	IC50	nM	111.0	CHEMBL4282	Homo sapiens	IC50	nM	111.0
327004	17705731	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1c2ccccc2CC1C1CC1		CHEMBL3964685	=	IC50	nM	48.0	CHEMBL4282	Homo sapiens	IC50	nM	48.0
327005	17705732	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1c2ccccc2CC1C1CC1		CHEMBL3964685	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
327006	17705733	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(cccc2C(F)(F)F)N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3940961	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
327007	17705734	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(cccc2C(F)(F)F)N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1		CHEMBL3940961	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
327008	17705735	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1c2ccccc2CC1CF		CHEMBL3968336	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
327009	17705736	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)n1-c1ccccc1)N1CCc2ccccc21		CHEMBL3943531	=	IC50	nM	51.0	CHEMBL4282	Homo sapiens	IC50	nM	51.0
327010	17705737	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1c2ccccc2CC1CF		CHEMBL3968336	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
327011	17705738	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	Nn1c(CC(=O)N2CCc3ccccc32)nc(N2CCOCC2)cc1=O		CHEMBL3932244	=	IC50	nM	131.0	CHEMBL4282	Homo sapiens	IC50	nM	131.0
327012	17705739	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	N#Cn1c(CC(=O)N2CCc3ccccc32)nc(N2CCOCC2)cc1=O		CHEMBL3974771	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	nM	24.0
327013	17705740	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=S)[nH]1		CHEMBL3907424	=	IC50	nM	22.0	CHEMBL4282	Homo sapiens	IC50	nM	22.0
327014	17705741	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@H]1Cc2ccccc2N1C(=S)Cc1nc(N2CCOCC2)cc(=S)[nH]1		CHEMBL3971967	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
327015	17705742	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=S)[nH]1		CHEMBL3898401	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
327016	17705743	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=S)n1C		CHEMBL3964814	=	IC50	nM	41.0	CHEMBL4282	Homo sapiens	IC50	nM	41.0
327017	17705744	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=S)n1C		CHEMBL3929547	=	IC50	nM	71.0	CHEMBL4282	Homo sapiens	IC50	nM	71.0
327018	17705745	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	Cn1c(CC(=O)N2CCc3c(F)cccc32)nc(N2CCOCC2)cc1=S		CHEMBL3944470	=	IC50	nM	31.0	CHEMBL4282	Homo sapiens	IC50	nM	31.0
327019	17705746	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	Cn1c(CC(=O)N2CCc3c(Cl)cccc32)nc(N2CCOCC2)cc1=S		CHEMBL3916531	=	IC50	nM	33.0	CHEMBL4282	Homo sapiens	IC50	nM	33.0
327020	17705747	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(ccc(F)c2F)N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=S)[nH]1		CHEMBL3925391	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
327021	17705748	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	CC1Cc2c(ccc(F)c2F)N1C(=S)Cc1nc(N2CCOCC2)c(F)c(=S)[nH]1		CHEMBL3900870	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
327022	17705749	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=S)[nH]1		CHEMBL3930072	=	IC50	nM	221.0	CHEMBL4282	Homo sapiens	IC50	nM	221.0
327023	17705750	CHEMBL3887079	Sandwich Immunoassay: This test is based on measurement of the expression of AKT protein phosphorylated on serine 473 (P-AKT-S473) in the PC3 human prostate carcinoma line, by the technique based on a sandwich immunoassay using the Kit MSD Multi-spot Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Akt whole cell lysate Total (# K15100D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated onto an electrode in each well of 96-well plates of the MSD kit: after adding a protein lysate in each well, the revelation of the signal done by the addition of a secondary antibody labeled with an electrochemiluminescent detection compound. The procedure is described in the kit.On day 1, the PC3 cells are inoculated in 96-well plates (TPP # 92096) at a concentration of 35000 cells / well in 200 uL DMEM medium (DMEM Gibco # 1 1960-044) containing 10% fetal calf serum (FBS Gibco, # 10500-056) and 1% glutamine.	B	C[C@@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)c(F)c(=S)[nH]1		CHEMBL3902097	=	IC50	nM	61.0	CHEMBL4282	Homo sapiens	IC50	nM	61.0
328326	17706916	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NCC1CCCN(c2ccc(C(N)=O)c3ncncc23)C1		CHEMBL3947957	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328327	17706917	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cccc(N2CCC(Nc3ccc(C(N)=O)c4ncncc34)CC2)c1		CHEMBL3921030	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328328	17706918	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN1CCC(Nc2ccc(C(N)=O)c3ncncc23)C1		CHEMBL3948835	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328329	17706919	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CNCC1CCCN(c2ccc(C(N)=O)c3ncncc23)C1		CHEMBL3933454	=	IC50	nM	18000.0	CHEMBL4282	Homo sapiens	IC50	nM	18000.0
328330	17706920	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NC[C@@H]2CCNC2)c2cncnc12		CHEMBL4110740	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328331	17706921	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NC[C@H]2CCNC2)c2cncnc12		CHEMBL3942427	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328332	17706922	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NCc2cccnc2)c2cncnc12		CHEMBL3972029	=	IC50	nM	70000.0	CHEMBL4282	Homo sapiens	IC50	nM	70000.0
328333	17706923	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NCc2cccc(Cl)c2)c2cncnc12		CHEMBL3954224	=	IC50	nM	12000.0	CHEMBL4282	Homo sapiens	IC50	nM	12000.0
328334	17706924	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N2CCC(CCc3ccccc3)C2)c2cncnc12		CHEMBL3930070	=	IC50	nM	3100.0	CHEMBL4282	Homo sapiens	IC50	nM	3100.0
328335	17706925	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N2CCC(OCc3ccccc3)C2)c2cncnc12		CHEMBL3945508	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328336	17706926	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N2CCC(O)(c3ccccc3)C2)c2cncnc12		CHEMBL3890779	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328337	17706927	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cccc([C@@H]2CN(c3ccc(C(N)=O)c4ncncc34)C[C@H]2CO)c1		CHEMBL3940185	=	IC50	nM	8200.0	CHEMBL4282	Homo sapiens	IC50	nM	8200.0
328338	17706928	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(C)C(CNc1ccc(C(N)=O)c2ncncc12)c1cccc(Cl)c1		CHEMBL3908671	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328339	17706929	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NCC(c2ccccc2)N2CCNCC2)c2cncnc12		CHEMBL3931144	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328340	17706930	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NC2CCNCC2c2ccc(F)cc2)c2cncnc12		CHEMBL3903158	=	IC50	nM	2500.0	CHEMBL4282	Homo sapiens	IC50	nM	2500.0
328341	17706931	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NC2CNCC2c2cccc(C(F)(F)F)c2)c2cncnc12		CHEMBL3921054	=	IC50	nM	4500.0	CHEMBL4282	Homo sapiens	IC50	nM	4500.0
328342	17706932	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NC2CNCC2c2cccc(OC(F)(F)F)c2)c2cncnc12		CHEMBL3896544	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328343	17706933	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cccc(C2CCNCC2Nc2ccc(C(N)=O)c3ncncc23)c1		CHEMBL3909073	=	IC50	nM	9000.0	CHEMBL4282	Homo sapiens	IC50	nM	9000.0
328344	17706934	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NC2CNCCC2c2cccc(C(F)(F)F)c2)c2cncnc12		CHEMBL3933453	=	IC50	nM	2100.0	CHEMBL4282	Homo sapiens	IC50	nM	2100.0
328345	17706935	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NC2CNCCC2c2ccc(Cl)c(F)c2)c2cncnc12		CHEMBL3896518	=	IC50	nM	130.0	CHEMBL4282	Homo sapiens	IC50	nM	130.0
328346	17706936	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NC2CNCCC2c2ccc(F)c(Cl)c2)c2cncnc12		CHEMBL3924538	=	IC50	nM	570.0	CHEMBL4282	Homo sapiens	IC50	nM	570.0
328347	17706937	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N[C@H]2CNCC[C@@H]2c2ccc(F)c(Cl)c2)c2cncnc12		CHEMBL4109551	=	IC50	nM	850.0	CHEMBL4282	Homo sapiens	IC50	nM	850.0
328348	17706938	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N[C@@H]2CNCC[C@H]2c2ccc(F)c(Cl)c2)c2cncnc12		CHEMBL3919102	=	IC50	nM	5700.0	CHEMBL4282	Homo sapiens	IC50	nM	5700.0
328349	17706939	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NC2CNCCC2c2ccc(F)cc2)c2cncnc12		CHEMBL3980317	=	IC50	nM	2000.0	CHEMBL4282	Homo sapiens	IC50	nM	2000.0
328350	17706940	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N[C@H]2CNCC[C@@H]2c2ccc(F)cc2)c2cncnc12		CHEMBL4106661	=	IC50	nM	2200.0	CHEMBL4282	Homo sapiens	IC50	nM	2200.0
328351	17706941	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N[C@@H]2CNCC[C@H]2c2ccc(F)cc2)c2cncnc12		CHEMBL3910187	=	IC50	nM	900.0	CHEMBL4282	Homo sapiens	IC50	nM	900.0
328352	17706942	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N2CCN(c3ccc(C(F)(F)F)cc3)CC2)c2cncnc12		CHEMBL3919249	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328353	17706943	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N2CCN(c3ccccc3)CC2)c2cncnc12		CHEMBL3905526	=	IC50	nM	15000.0	CHEMBL4282	Homo sapiens	IC50	nM	15000.0
328354	17706944	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N2CCN(c3ccc(F)c(F)c3)CC2)c2cncnc12		CHEMBL3932697	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328355	17706945	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N2CCN(c3ccc(F)c(Cl)c3)CC2)c2cncnc12		CHEMBL3906249	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328356	17706946	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N2CCN(c3cccc(F)c3)CC2)c2cncnc12		CHEMBL3918934	=	IC50	nM	6400.0	CHEMBL4282	Homo sapiens	IC50	nM	6400.0
328357	17706947	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N2CCN(c3cccc(Cl)c3)CC2)c2cncnc12		CHEMBL3943330	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328358	17706948	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NCc2ccccc2)c2cncnc12		CHEMBL3960835	=	IC50	nM	57000.0	CHEMBL4282	Homo sapiens	IC50	nM	57000.0
328359	17706949	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NCCc2ccccc2)c2cncnc12		CHEMBL3891824	=	IC50	nM	5600.0	CHEMBL4282	Homo sapiens	IC50	nM	5600.0
328360	17706950	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NCCc2cccc(F)c2)c2cncnc12		CHEMBL3968412	=	IC50	nM	2400.0	CHEMBL4282	Homo sapiens	IC50	nM	2400.0
328361	17706951	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NCCc2ccc(F)cc2)c2cncnc12		CHEMBL3949722	=	IC50	nM	4800.0	CHEMBL4282	Homo sapiens	IC50	nM	4800.0
328362	17706952	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NCCc2ccc(F)c(F)c2)c2cncnc12		CHEMBL3942274	=	IC50	nM	41000.0	CHEMBL4282	Homo sapiens	IC50	nM	41000.0
328363	17706953	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NCCCCc2ccccc2)c2cncnc12		CHEMBL3932743	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328364	17706954	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(CCc1ccccc1)c1ccc(C(N)=O)c2ncncc12		CHEMBL3933947	=	IC50	nM	14000.0	CHEMBL4282	Homo sapiens	IC50	nM	14000.0
328365	17706955	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(NCCc2ccc(Cl)c(Cl)c2)c2cncnc12		CHEMBL3902499	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328366	17706956	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N(CCc2ccccc2)[C@@H]2CCCNC2)c2cncnc12		CHEMBL4108594	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328367	17706957	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N2CCC(c3cccc(C(F)(F)F)c3)C(N)C2)c2cncnc12		CHEMBL3948252	=	IC50	nM	8100.0	CHEMBL4282	Homo sapiens	IC50	nM	8100.0
328368	17706958	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N2CCN(c3ccc(F)cc3)CC2)c2cncnc12		CHEMBL3923951	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328369	17706959	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1ccc(N2CCN(c3ccc(Cl)c(Cl)c3)CC2)c2cncnc12		CHEMBL3911505	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
328370	17706960	CHEMBL3887082	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 ul of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.50 0.1 ng/uL His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 uM substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338) 0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25° C, and then stopped by the addition of 70 ul of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1ccc(Cl)cc1N1CCN(c2ccc(C(N)=O)c3ncncc23)CC1		CHEMBL3969122	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
329769	17708359	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2Br)CC1		CHEMBL3917944	=	IC50	nM	66.0	CHEMBL4282	Homo sapiens	IC50	nM	66.0
329770	17708360	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4cccc(C(F)(F)F)c4)c[nH]3)CC2)c1Br		CHEMBL3926903	=	IC50	nM	1700.0	CHEMBL4282	Homo sapiens	IC50	nM	1700.0
329771	17708361	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	FC(F)(F)c1cccc(-c2c[nH]c(C3CCN(c4ncncc4Br)CC3)n2)c1		CHEMBL3895400	=	IC50	nM	6100.0	CHEMBL4282	Homo sapiens	IC50	nM	6100.0
329772	17708362	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C=O)CC1		CHEMBL3904322	=	IC50	nM	160.0	CHEMBL4282	Homo sapiens	IC50	nM	160.0
329773	17708363	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1		CHEMBL3941307	=	IC50	nM	110.0	CHEMBL4282	Homo sapiens	IC50	nM	110.0
329774	17708364	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1		CHEMBL3916864	=	IC50	nM	9.1	CHEMBL4282	Homo sapiens	IC50	nM	9.1
329775	17708365	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2C)CC1		CHEMBL3964789	=	IC50	nM	440.0	CHEMBL4282	Homo sapiens	IC50	nM	440.0
329776	17708366	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2ccc(F)cc2)CC1		CHEMBL3925871	=	IC50	nM	2200.0	CHEMBL4282	Homo sapiens	IC50	nM	2200.0
329777	17708367	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COc1ccc(-c2c(N)ncnc2N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3C)CC2)cc1		CHEMBL3985874	=	IC50	nM	520.0	CHEMBL4282	Homo sapiens	IC50	nM	520.0
329778	17708368	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1ccc(-c2c(N)ncnc2N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3C)CC2)cc1		CHEMBL3980785	=	IC50	nM	8300.0	CHEMBL4282	Homo sapiens	IC50	nM	8300.0
329779	17708369	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2ccc(CO)cc2)CC1		CHEMBL3910716	=	IC50	nM	250.0	CHEMBL4282	Homo sapiens	IC50	nM	250.0
329780	17708370	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2cccc(C#N)c2)CC1		CHEMBL3909655	=	IC50	nM	150.0	CHEMBL4282	Homo sapiens	IC50	nM	150.0
329781	17708371	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2ccc(C#N)cc2)CC1		CHEMBL3897066	=	IC50	nM	2.7	CHEMBL4282	Homo sapiens	IC50	nM	2.7
329782	17708372	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1ccc(-c2c(N)ncnc2N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3C)CC2)cn1		CHEMBL3901580	=	IC50	nM	1700.0	CHEMBL4282	Homo sapiens	IC50	nM	1700.0
329783	17708373	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1ccc(-c2c(N)ncnc2N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3C)CC2)s1		CHEMBL3940535	=	IC50	nM	2700.0	CHEMBL4282	Homo sapiens	IC50	nM	2700.0
329784	17708374	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2CO)CC1		CHEMBL3927385	=	IC50	nM	1100.0	CHEMBL4282	Homo sapiens	IC50	nM	1100.0
329785	17708375	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1		CHEMBL3964726	=	IC50	nM	1600.0	CHEMBL4282	Homo sapiens	IC50	nM	1600.0
329786	17708376	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1		CHEMBL3936329	=	IC50	nM	84.0	CHEMBL4282	Homo sapiens	IC50	nM	84.0
329787	17708377	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2ccncc2)CC1		CHEMBL3978717	=	IC50	nM	860.0	CHEMBL4282	Homo sapiens	IC50	nM	860.0
329788	17708378	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2ccc(N)nc2)CC1		CHEMBL3904694	=	IC50	nM	2700.0	CHEMBL4282	Homo sapiens	IC50	nM	2700.0
329789	17708379	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncncc2Br)CC1		CHEMBL3892829	=	IC50	nM	1400.0	CHEMBL4282	Homo sapiens	IC50	nM	1400.0
329790	17708380	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)c[nH]3)CC2)c1Br		CHEMBL3906130	=	IC50	nM	600.0	CHEMBL4282	Homo sapiens	IC50	nM	600.0
329791	17708381	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)c[nH]3)CC2)c1-c1ccc(F)cc1		CHEMBL3979925	=	IC50	nM	9500.0	CHEMBL4282	Homo sapiens	IC50	nM	9500.0
329792	17708382	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2cncnc2)CC1		CHEMBL3929608	=	IC50	nM	440.0	CHEMBL4282	Homo sapiens	IC50	nM	440.0
329793	17708383	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2cccnc2)CC1		CHEMBL3958964	=	IC50	nM	880.0	CHEMBL4282	Homo sapiens	IC50	nM	880.0
329794	17708384	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COC/C=C/c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2C)CC1		CHEMBL3889930	=	IC50	nM	740.0	CHEMBL4282	Homo sapiens	IC50	nM	740.0
329795	17708385	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1ncc(-c2c(N)ncnc2N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3C)CC2)s1		CHEMBL3922417	=	IC50	nM	850.0	CHEMBL4282	Homo sapiens	IC50	nM	850.0
329796	17708386	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCC3)CC2)c1Br		CHEMBL3982415	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
329797	17708387	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCC3)CC2)c1-c1ccc(F)cc1		CHEMBL3916957	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	nM	140.0
329798	17708388	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCC3)CC2)c1-c1ccccc1F		CHEMBL3944868	=	IC50	nM	75.0	CHEMBL4282	Homo sapiens	IC50	nM	75.0
329799	17708389	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCC3)CC2)c1-c1ccc(F)c(F)c1		CHEMBL3907965	=	IC50	nM	110.0	CHEMBL4282	Homo sapiens	IC50	nM	110.0
329800	17708390	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	C=Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCCC2)CC1		CHEMBL3932421	=	IC50	nM	6.8	CHEMBL4282	Homo sapiens	IC50	nM	6.8
329801	17708391	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCCC3)CC2)c1Br		CHEMBL3956468	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
329802	17708392	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCCC3)CC2)c1-c1ccc(F)cc1		CHEMBL3932445	=	IC50	nM	350.0	CHEMBL4282	Homo sapiens	IC50	nM	350.0
329803	17708393	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCCC3)CC2)c1-c1ccccc1F		CHEMBL3977191	=	IC50	nM	130.0	CHEMBL4282	Homo sapiens	IC50	nM	130.0
329804	17708394	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCCC3)CC2)c1-c1cccc(F)c1		CHEMBL3947929	=	IC50	nM	85.0	CHEMBL4282	Homo sapiens	IC50	nM	85.0
329805	17708395	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	C=Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCCCC2)CC1		CHEMBL3972216	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
329806	17708396	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1cc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCCC3)CC2)ncn1		CHEMBL3939144	=	IC50	nM	410.0	CHEMBL4282	Homo sapiens	IC50	nM	410.0
329807	17708397	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2Br)CC1		CHEMBL3961106	=	IC50	nM	9.3	CHEMBL4282	Homo sapiens	IC50	nM	9.3
329808	17708398	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2ccc(F)cc2)CC1		CHEMBL3933645	=	IC50	nM	230.0	CHEMBL4282	Homo sapiens	IC50	nM	230.0
329809	17708399	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2ccncc2)CC1		CHEMBL3895298	=	IC50	nM	43.0	CHEMBL4282	Homo sapiens	IC50	nM	43.0
329810	17708400	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2ccc(N)nc2)CC1		CHEMBL3973946	=	IC50	nM	180.0	CHEMBL4282	Homo sapiens	IC50	nM	180.0
329811	17708401	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2cnc(N)nc2)CC1		CHEMBL3922652	=	IC50	nM	450.0	CHEMBL4282	Homo sapiens	IC50	nM	450.0
329812	17708402	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	C=C(C)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN(C)C)CC1		CHEMBL3954073	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
329813	17708403	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	C=Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN(C)C)CC1		CHEMBL3931848	=	IC50	nM	7.9	CHEMBL4282	Homo sapiens	IC50	nM	7.9
329814	17708404	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3962807	=	IC50	nM	2.6	CHEMBL4282	Homo sapiens	IC50	nM	2.6
329815	17708405	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(Cl)c3)cn2CCN2CCC2)CC1		CHEMBL3940867	=	IC50	nM	1.9	CHEMBL4282	Homo sapiens	IC50	nM	1.9
329816	17708406	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(OC(F)F)cc3)cn2CCN2CCC2)CC1		CHEMBL3970397	=	IC50	nM	479.0	CHEMBL4282	Homo sapiens	IC50	nM	479.0
329817	17708407	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(C3CCCCC3)cn2CCN2CCC2)CC1		CHEMBL3925234	=	IC50	nM	76.0	CHEMBL4282	Homo sapiens	IC50	nM	76.0
329818	17708408	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3949501	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
329819	17708409	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(Cl)c3)cn2CCN2CCC2)CC1		CHEMBL3962020	=	IC50	nM	7.5	CHEMBL4282	Homo sapiens	IC50	nM	7.5
329820	17708410	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(C3CCCCC3)cn2CCN2CCC2)CC1		CHEMBL3961623	=	IC50	nM	1400.0	CHEMBL4282	Homo sapiens	IC50	nM	1400.0
329821	17708411	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(OC(F)F)cc3)cn2CCN2CCC2)CC1		CHEMBL3972226	=	IC50	nM	15000.0	CHEMBL4282	Homo sapiens	IC50	nM	15000.0
329822	17708412	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN(C)C)CC1		CHEMBL3911401	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
329823	17708413	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2CCC2CC2)CC1		CHEMBL3897534	=	IC50	nM	190.0	CHEMBL4282	Homo sapiens	IC50	nM	190.0
329824	17708414	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCOCCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN(C)C)CC1		CHEMBL3901997	=	IC50	nM	340.0	CHEMBL4282	Homo sapiens	IC50	nM	340.0
329825	17708415	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2/C=C/C2CC2)CC1		CHEMBL3903026	=	IC50	nM	43.0	CHEMBL4282	Homo sapiens	IC50	nM	43.0
329826	17708416	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCO/C=C/c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN(C)C)CC1		CHEMBL3973987	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
329827	17708417	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2ccc(C(C)(C)O)cc2)CC1		CHEMBL3904383	=	IC50	nM	190.0	CHEMBL4282	Homo sapiens	IC50	nM	190.0
329828	17708418	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COC(=O)c1ccc(-c2c(N)ncnc2N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN(C)C)CC2)cc1		CHEMBL3937511	=	IC50	nM	95.0	CHEMBL4282	Homo sapiens	IC50	nM	95.0
329829	17708419	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2ccc(C(=O)O)cc2)CC1		CHEMBL3979190	=	IC50	nM	33.0	CHEMBL4282	Homo sapiens	IC50	nM	33.0
329830	17708420	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C2=CCCC2)CC1		CHEMBL3950150	=	IC50	nM	31.0	CHEMBL4282	Homo sapiens	IC50	nM	31.0
329831	17708421	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C2CC2)CC1		CHEMBL3900512	=	IC50	nM	4.8	CHEMBL4282	Homo sapiens	IC50	nM	4.8
329832	17708422	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CC(F)C2)CC1		CHEMBL3890270	=	IC50	nM	71.0	CHEMBL4282	Homo sapiens	IC50	nM	71.0
329833	17708423	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CC(C)C2)CC1		CHEMBL3963881	=	IC50	nM	7.7	CHEMBL4282	Homo sapiens	IC50	nM	7.7
329834	17708424	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CC(F)(F)C2)CC1		CHEMBL3934633	=	IC50	nM	1600.0	CHEMBL4282	Homo sapiens	IC50	nM	1600.0
329835	17708425	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCN(C)Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN(C)C)CC1		CHEMBL3931709	=	IC50	nM	520.0	CHEMBL4282	Homo sapiens	IC50	nM	520.0
329836	17708426	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)Oc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3904712	=	IC50	nM	7.9	CHEMBL4282	Homo sapiens	IC50	nM	7.9
329837	17708427	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3954017	=	IC50	nM	6.1	CHEMBL4282	Homo sapiens	IC50	nM	6.1
329838	17708428	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1-c1cn[nH]c1		CHEMBL3927188	=	IC50	nM	6.9	CHEMBL4282	Homo sapiens	IC50	nM	6.9
329839	17708429	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3cncc(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3951221	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
329840	17708430	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3cccc(OC(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3980688	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
329841	17708431	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3cncc(Cl)c3)cn2CCN2CCC2)CC1		CHEMBL3907940	=	IC50	nM	31.0	CHEMBL4282	Homo sapiens	IC50	nM	31.0
329842	17708432	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCOc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3932390	=	IC50	nM	4.1	CHEMBL4282	Homo sapiens	IC50	nM	4.1
329843	17708433	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1OCC(F)(F)F		CHEMBL3895450	=	IC50	nM	6.6	CHEMBL4282	Homo sapiens	IC50	nM	6.6
329844	17708434	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccnc(Cl)c3)cn2CCN2CCC2)CC1		CHEMBL3923440	=	IC50	nM	16.5	CHEMBL4282	Homo sapiens	IC50	nM	16.5
329845	17708435	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccnc(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3920419	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
329846	17708436	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(N)=O)c3)cn2CCN2CCC2)CC1		CHEMBL3962465	=	IC50	nM	49.0	CHEMBL4282	Homo sapiens	IC50	nM	49.0
329847	17708437	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(OC)c(C(N)=O)c3)cn2CCN2CCC2)CC1		CHEMBL3950201	=	IC50	nM	160.0	CHEMBL4282	Homo sapiens	IC50	nM	160.0
329848	17708438	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(OC)c3)cn2CCN2CCC2)CC1		CHEMBL3935483	=	IC50	nM	4.8	CHEMBL4282	Homo sapiens	IC50	nM	4.8
329849	17708439	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1-c1cnoc1		CHEMBL3941451	=	IC50	nM	1.6	CHEMBL4282	Homo sapiens	IC50	nM	1.6
329850	17708440	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1-c1cc[nH]c1		CHEMBL3965271	=	IC50	nM	1.9	CHEMBL4282	Homo sapiens	IC50	nM	1.9
329851	17708441	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccnc(C)c3)cn2CCN2CCC2)CC1		CHEMBL3965063	=	IC50	nM	106.0	CHEMBL4282	Homo sapiens	IC50	nM	106.0
329852	17708442	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccnc(OC)c3)cn2CCN2CCC2)CC1		CHEMBL3904876	=	IC50	nM	940.0	CHEMBL4282	Homo sapiens	IC50	nM	940.0
329853	17708443	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3cncc(C)c3)cn2CCN2CCC2)CC1		CHEMBL3941855	=	IC50	nM	465.0	CHEMBL4282	Homo sapiens	IC50	nM	465.0
329854	17708444	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3917410	=	IC50	nM	6.6	CHEMBL4282	Homo sapiens	IC50	nM	6.6
329855	17708445	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COc1c(N)ncnc1N1CCC(c2nc(-c3ccnc(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3890310	=	IC50	nM	21.0	CHEMBL4282	Homo sapiens	IC50	nM	21.0
329856	17708446	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCOc1c(N)ncnc1N1CCC(c2nc(-c3ccnc(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3959379	=	IC50	nM	8.2	CHEMBL4282	Homo sapiens	IC50	nM	8.2
329857	17708447	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)Oc1c(N)ncnc1N1CCC(c2nc(-c3ccnc(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3927446	=	IC50	nM	9.1	CHEMBL4282	Homo sapiens	IC50	nM	9.1
329858	17708448	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccnc(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1OCC(F)(F)F		CHEMBL3965033	=	IC50	nM	21.0	CHEMBL4282	Homo sapiens	IC50	nM	21.0
329859	17708449	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3cccc(C(F)(F)F)n3)cn2CCN2CCC2)CC1		CHEMBL3968002	=	IC50	nM	420.0	CHEMBL4282	Homo sapiens	IC50	nM	420.0
329860	17708450	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COc1cc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)ccc1F		CHEMBL3938454	=	IC50	nM	2.4	CHEMBL4282	Homo sapiens	IC50	nM	2.4
329861	17708451	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COc1cc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)ccc1F		CHEMBL3933597	=	IC50	nM	2.4	CHEMBL4282	Homo sapiens	IC50	nM	2.4
329862	17708452	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)ccc1F		CHEMBL3961056	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
329863	17708453	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3cccc(Cl)n3)cn2CCN2CCC2)CC1		CHEMBL3905865	=	IC50	nM	780.0	CHEMBL4282	Homo sapiens	IC50	nM	780.0
329864	17708454	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)ccc1F		CHEMBL3972162	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
329865	17708455	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccnc(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3947888	=	IC50	nM	9.7	CHEMBL4282	Homo sapiens	IC50	nM	9.7
329866	17708456	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccnc(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1Br		CHEMBL3977147	=	IC50	nM	2.2	CHEMBL4282	Homo sapiens	IC50	nM	2.2
329867	17708457	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccnc(C(F)(F)F)c4)cn3CCNCCCCl)CC2)c1Br		CHEMBL3951747	=	IC50	nM	2.8	CHEMBL4282	Homo sapiens	IC50	nM	2.8
329868	17708458	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccnc(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3956421	=	IC50	nM	90.0	CHEMBL4282	Homo sapiens	IC50	nM	90.0
329869	17708459	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccoc3)cn2CCN2CCC2)CC1		CHEMBL3908333	=	IC50	nM	250.0	CHEMBL4282	Homo sapiens	IC50	nM	250.0
329870	17708460	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccsc3)cn2CCN2CCC2)CC1		CHEMBL3970947	=	IC50	nM	91.0	CHEMBL4282	Homo sapiens	IC50	nM	91.0
329871	17708461	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccccc3)cn2CCN2CCC2)CC1		CHEMBL3931262	=	IC50	nM	165.0	CHEMBL4282	Homo sapiens	IC50	nM	165.0
329872	17708462	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3cnoc3)cn2CCN2CCC2)CC1		CHEMBL3906804	=	IC50	nM	220.0	CHEMBL4282	Homo sapiens	IC50	nM	220.0
329873	17708463	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccoc3)cn2CCN2CCC2)CC1		CHEMBL3962137	=	IC50	nM	3600.0	CHEMBL4282	Homo sapiens	IC50	nM	3600.0
329874	17708464	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccsc3)cn2CCN2CCC2)CC1		CHEMBL3922482	=	IC50	nM	1900.0	CHEMBL4282	Homo sapiens	IC50	nM	1900.0
329875	17708465	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3cnoc3)cn2CCN2CCC2)CC1		CHEMBL3929885	=	IC50	nM	760.0	CHEMBL4282	Homo sapiens	IC50	nM	760.0
329876	17708466	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccccc3)cn2CCN2CCC2)CC1		CHEMBL3913487	=	IC50	nM	1900.0	CHEMBL4282	Homo sapiens	IC50	nM	1900.0
329877	17708467	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2C2CCNC2)CC1		CHEMBL3935986	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
329878	17708468	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2C2CCNC2)CC1		CHEMBL3908032	=	IC50	nM	100.0	CHEMBL4282	Homo sapiens	IC50	nM	100.0
329879	17708469	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN)CC1		CHEMBL3968744	=	IC50	nM	6.6	CHEMBL4282	Homo sapiens	IC50	nM	6.6
329880	17708470	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CC2CNC2)CC1		CHEMBL3942663	=	IC50	nM	27.0	CHEMBL4282	Homo sapiens	IC50	nM	27.0
329881	17708471	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CC2CNC2)CC1		CHEMBL3957354	=	IC50	nM	64.5	CHEMBL4282	Homo sapiens	IC50	nM	64.5
329882	17708472	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2C2CNC2)CC1		CHEMBL3891763	=	IC50	nM	240.0	CHEMBL4282	Homo sapiens	IC50	nM	240.0
329883	17708473	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2C2CNC2)CC1		CHEMBL3952076	=	IC50	nM	670.0	CHEMBL4282	Homo sapiens	IC50	nM	670.0
329884	17708474	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccnc(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1Cl		CHEMBL3980922	=	IC50	nM	2.5	CHEMBL4282	Homo sapiens	IC50	nM	2.5
329885	17708475	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3cn[nH]c3)cn2CCN2CCC2)CC1		CHEMBL3963232	=	IC50	nM	2200.0	CHEMBL4282	Homo sapiens	IC50	nM	2200.0
329886	17708476	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CC2CCN2)CC1		CHEMBL3906193	=	IC50	nM	31.0	CHEMBL4282	Homo sapiens	IC50	nM	31.0
329887	17708477	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CC2CCCN2)CC1		CHEMBL3968352	=	IC50	nM	2.9	CHEMBL4282	Homo sapiens	IC50	nM	2.9
329888	17708478	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CC3CNC3)CC2)c1Cl		CHEMBL3897233	=	IC50	nM	16.5	CHEMBL4282	Homo sapiens	IC50	nM	16.5
329889	17708479	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CC3CCN3)CC2)c1Cl		CHEMBL3896152	=	IC50	nM	38.0	CHEMBL4282	Homo sapiens	IC50	nM	38.0
329890	17708480	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CC2CCN2)CC1		CHEMBL3955405	=	IC50	nM	220.0	CHEMBL4282	Homo sapiens	IC50	nM	220.0
329891	17708481	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CC2CNC2)CC1		CHEMBL3892286	=	IC50	nM	19.0	CHEMBL4282	Homo sapiens	IC50	nM	19.0
329892	17708482	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CC2CCN2)CC1		CHEMBL3961268	=	IC50	nM	280.0	CHEMBL4282	Homo sapiens	IC50	nM	280.0
329893	17708483	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CC2CCCN2)CC1		CHEMBL3901251	=	IC50	nM	220.0	CHEMBL4282	Homo sapiens	IC50	nM	220.0
329894	17708484	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2C2CCNCC2)CC1		CHEMBL3968856	=	IC50	nM	480.0	CHEMBL4282	Homo sapiens	IC50	nM	480.0
329895	17708485	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2C2CCNCC2)CC1		CHEMBL3906695	=	IC50	nM	160.0	CHEMBL4282	Homo sapiens	IC50	nM	160.0
329896	17708486	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN1CC(Cn2cc(-c3ccc(F)c(C(F)(F)F)c3)nc2C2CCN(c3ncnc(N)c3C(N)=O)CC2)C1		CHEMBL3977344	=	IC50	nM	81.0	CHEMBL4282	Homo sapiens	IC50	nM	81.0
329897	17708487	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2C2CCNCC2)CC1		CHEMBL3915684	=	IC50	nM	190.0	CHEMBL4282	Homo sapiens	IC50	nM	190.0
329898	17708488	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN)CC1		CHEMBL3899777	=	IC50	nM	3.6	CHEMBL4282	Homo sapiens	IC50	nM	3.6
329899	17708489	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NCCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1		CHEMBL3926535	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
329900	17708490	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCO)c(C3CCN(c4ncnc(N)c4-c4cn[nH]c4)CC3)n2)ccc1F		CHEMBL3900157	=	IC50	nM	670.0	CHEMBL4282	Homo sapiens	IC50	nM	670.0
329901	17708491	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCNC3CC3)c(C3CCN(c4ncnc(N)c4-c4cn[nH]c4)CC3)n2)ccc1F		CHEMBL3983786	=	IC50	nM	150.0	CHEMBL4282	Homo sapiens	IC50	nM	150.0
329902	17708492	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CNCCn1cc(-c2ccc(F)c(C)c2)nc1C1CCN(c2ncnc(N)c2-c2cn[nH]c2)CC1		CHEMBL3913969	=	IC50	nM	21.0	CHEMBL4282	Homo sapiens	IC50	nM	21.0
329903	17708493	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCN(C)C)c(C3CCN(c4ncnc(N)c4-c4cn[nH]c4)CC3)n2)ccc1F		CHEMBL3957657	=	IC50	nM	4.8	CHEMBL4282	Homo sapiens	IC50	nM	4.8
329904	17708494	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4-c4cn[nH]c4)CC3)n2)ccc1F		CHEMBL3922949	=	IC50	nM	5.5	CHEMBL4282	Homo sapiens	IC50	nM	5.5
329905	17708495	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCNC(C)(C)C)c(C3CCN(c4ncnc(N)c4-c4cn[nH]c4)CC3)n2)ccc1F		CHEMBL3970663	=	IC50	nM	5.5	CHEMBL4282	Homo sapiens	IC50	nM	5.5
329906	17708496	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CNCCn1cc(-c2ccnc(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2Br)CC1		CHEMBL3899490	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
329907	17708497	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CNCCn1cc(-c2ccnc(C(F)(F)F)c2)nc1C1CCN(c2cc(N)ncn2)CC1		CHEMBL3912226	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
329908	17708498	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccnc(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1-c1cnoc1		CHEMBL3908552	=	IC50	nM	2.7	CHEMBL4282	Homo sapiens	IC50	nM	2.7
329909	17708499	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CNCCn1cc(-c2ccnc(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1		CHEMBL3949795	=	IC50	nM	1.7	CHEMBL4282	Homo sapiens	IC50	nM	1.7
329910	17708500	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CNCCn1cc(-c2ccnc(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C2C=NOC2)CC1		CHEMBL3978853	=	IC50	nM	120.0	CHEMBL4282	Homo sapiens	IC50	nM	120.0
329911	17708501	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccnc(C(F)(F)F)c3)cn2CCNC)CC1		CHEMBL3910789	=	IC50	nM	2.1	CHEMBL4282	Homo sapiens	IC50	nM	2.1
329912	17708502	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CNCCn1cc(-c2ccnc(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2Cl)CC1		CHEMBL3948454	=	IC50	nM	1.4	CHEMBL4282	Homo sapiens	IC50	nM	1.4
329913	17708503	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccnc(C(F)(F)F)c4)cn3CCNC3CC3)CC2)c1Cl		CHEMBL3931731	=	IC50	nM	3.6	CHEMBL4282	Homo sapiens	IC50	nM	3.6
329914	17708504	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCNCCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2OC(C)C)CC1		CHEMBL3943127	=	IC50	nM	0.52	CHEMBL4282	Homo sapiens	IC50	nM	0.52
329915	17708505	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)Oc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CC2CNC2)CC1		CHEMBL3925183	=	IC50	nM	4.5	CHEMBL4282	Homo sapiens	IC50	nM	4.5
329916	17708506	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCOc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CC2CNC2)CC1		CHEMBL3900660	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	nM	5.0
329917	17708507	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCOc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C)c3)cn2CCN2CCC2)CC1		CHEMBL3916178	=	IC50	nM	2.1	CHEMBL4282	Homo sapiens	IC50	nM	2.1
329918	17708508	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4OC(C)C)CC3)n2)ccc1F		CHEMBL3985943	=	IC50	nM	2.7	CHEMBL4282	Homo sapiens	IC50	nM	2.7
329919	17708509	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccnc(C(C)C)c3)cn2CCN2CCC2)CC1		CHEMBL3944209	=	IC50	nM	4.2	CHEMBL4282	Homo sapiens	IC50	nM	4.2
329920	17708510	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)c1cc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4Cl)CC3)n2)ccn1		CHEMBL3912769	=	IC50	nM	2.4	CHEMBL4282	Homo sapiens	IC50	nM	2.4
329921	17708511	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)c1cc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4Br)CC3)n2)ccn1		CHEMBL3966806	=	IC50	nM	0.15	CHEMBL4282	Homo sapiens	IC50	nM	0.15
329922	17708512	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	C=Cc1c(N)ncnc1N1CCC(c2nc(-c3ccnc(C(C)C)c3)cn2CCN2CCC2)CC1		CHEMBL3891980	=	IC50	nM	2.2	CHEMBL4282	Homo sapiens	IC50	nM	2.2
329923	17708513	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	C=Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CC2CNC2)CC1		CHEMBL3952282	=	IC50	nM	74.0	CHEMBL4282	Homo sapiens	IC50	nM	74.0
329924	17708514	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C)c3)cn2CC2CNC2)CC1		CHEMBL3981085	=	IC50	nM	2.3	CHEMBL4282	Homo sapiens	IC50	nM	2.3
329925	17708515	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCOc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C)c3)cn2CC2CNC2)CC1		CHEMBL3943569	=	IC50	nM	6.6	CHEMBL4282	Homo sapiens	IC50	nM	6.6
329926	17708516	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CC3CNC3)c(C3CCN(c4ncnc(N)c4OCC(F)(F)F)CC3)n2)ccc1F		CHEMBL3976254	=	IC50	nM	7.1	CHEMBL4282	Homo sapiens	IC50	nM	7.1
329927	17708517	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CC3CNC3)c(C3CCN(c4ncnc(N)c4OC(C)C)CC3)n2)ccc1F		CHEMBL3987123	=	IC50	nM	6.4	CHEMBL4282	Homo sapiens	IC50	nM	6.4
329928	17708518	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C)c3)cn2CC2CNC2)CC1		CHEMBL3967750	=	IC50	nM	2.3	CHEMBL4282	Homo sapiens	IC50	nM	2.3
329929	17708519	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CC3CNC3)c(C3CCN(c4ncnc(N)c4C(C)C)CC3)n2)ccc1F		CHEMBL3974201	=	IC50	nM	4.5	CHEMBL4282	Homo sapiens	IC50	nM	4.5
329930	17708520	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4Br)CC3)n2)ccc1F		CHEMBL3899716	=	IC50	nM	0.1	CHEMBL4282	Homo sapiens	IC50	nM	0.1
329931	17708521	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CC3CNC3)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)ccc1F		CHEMBL3943038	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
329932	17708522	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CNc1ncnc(N2CCC(c3nc(-c4ccnc(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1Cl		CHEMBL3984446	=	IC50	nM	7200.0	CHEMBL4282	Homo sapiens	IC50	nM	7200.0
329933	17708523	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CNc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C)c4)cn3CC3CNC3)CC2)c1Cl		CHEMBL3923651	=	IC50	nM	5700.0	CHEMBL4282	Homo sapiens	IC50	nM	5700.0
329934	17708524	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CC3CNC3)c(C3CCC(c4ncnc(N)c4C(C)C)CC3)n2)ccc1F		CHEMBL3899097	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
329935	17708525	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)cc3)cn2CCN2CCOCC2)CC1		CHEMBL3953761	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
329936	17708526	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(F)c3)cn2CCN2CCOCC2)CC1		CHEMBL3971381	=	IC50	nM	370.0	CHEMBL4282	Homo sapiens	IC50	nM	370.0
329937	17708527	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)cc3)cn2CCN2CC3(COC3)C2)CC1		CHEMBL3909262	=	IC50	nM	130.0	CHEMBL4282	Homo sapiens	IC50	nM	130.0
329938	17708528	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(F)c3)cn2CCN2CC3(COC3)C2)CC1		CHEMBL3976391	=	IC50	nM	255.0	CHEMBL4282	Homo sapiens	IC50	nM	255.0
329939	17708529	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(F)c3)cn2CCN2CC(F)C2)CC1		CHEMBL3922457	=	IC50	nM	385.0	CHEMBL4282	Homo sapiens	IC50	nM	385.0
329940	17708530	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)cc3)cn2CCN2CC(F)C2)CC1		CHEMBL3894443	=	IC50	nM	640.0	CHEMBL4282	Homo sapiens	IC50	nM	640.0
329941	17708531	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)cc3)cn2CCN2CCC3(COC3)C2)CC1		CHEMBL3943713	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
329942	17708532	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(F)c3)cn2CCN2CCC3(COC3)C2)CC1		CHEMBL3926249	=	IC50	nM	89.0	CHEMBL4282	Homo sapiens	IC50	nM	89.0
329943	17708533	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(F)c3)cn2CCN2CCC23COC3)CC1		CHEMBL3971435	=	IC50	nM	2500.0	CHEMBL4282	Homo sapiens	IC50	nM	2500.0
329944	17708534	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)cc3)cn2CCN2CCC23COC3)CC1		CHEMBL3941846	=	IC50	nM	3600.0	CHEMBL4282	Homo sapiens	IC50	nM	3600.0
329945	17708535	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3cnc(F)c(Cl)c3)cn2CCN2CCC2)CC1		CHEMBL3966203	=	IC50	nM	1.3	CHEMBL4282	Homo sapiens	IC50	nM	1.3
329946	17708536	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccnc(F)c3)cn2CCN2CCC2)CC1		CHEMBL3932866	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
329947	17708537	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc4[nH]ncc4c3)cn2CCN2CCC2)CC1		CHEMBL3955055	=	IC50	nM	105.0	CHEMBL4282	Homo sapiens	IC50	nM	105.0
329948	17708538	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCCC2)CC1		CHEMBL3927440	=	IC50	nM	7.6	CHEMBL4282	Homo sapiens	IC50	nM	7.6
329949	17708539	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCC3)CC2)c1Cl		CHEMBL3986793	=	IC50	nM	2.2	CHEMBL4282	Homo sapiens	IC50	nM	2.2
329950	17708540	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(O)c(C(F)(F)F)c4)cn3CCN3CCCC3)CC2)c1Cl		CHEMBL3961556	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
329951	17708541	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCC3)CC2)c1F		CHEMBL3895789	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	nM	23.0
329952	17708542	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	C=C(C)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCCCC2)CC1		CHEMBL3923786	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
329953	17708543	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	C=C(C)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCCC2)CC1		CHEMBL3901242	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	nM	20.0
329954	17708544	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1cc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCC3)CC2)ncn1		CHEMBL3932730	=	IC50	nM	180.0	CHEMBL4282	Homo sapiens	IC50	nM	180.0
329955	17708545	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCCC2)CC1		CHEMBL3910308	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
329956	17708546	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCCC3)CC2)c1Cl		CHEMBL3938237	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
329957	17708547	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1Br		CHEMBL3894578	=	IC50	nM	2.3	CHEMBL4282	Homo sapiens	IC50	nM	2.3
329958	17708548	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1Cl		CHEMBL3919089	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
329959	17708549	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1-c1ccc(F)cc1		CHEMBL3903522	=	IC50	nM	2.3	CHEMBL4282	Homo sapiens	IC50	nM	2.3
329960	17708550	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	C=Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3931504	=	IC50	nM	4.2	CHEMBL4282	Homo sapiens	IC50	nM	4.2
329961	17708551	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1cc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCC3)CC2)ncn1		CHEMBL3917257	=	IC50	nM	71.0	CHEMBL4282	Homo sapiens	IC50	nM	71.0
329962	17708552	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COC(=O)c1ccc(-c2c(N)ncnc2N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCC3)CC2)cc1		CHEMBL3987000	=	IC50	nM	43.0	CHEMBL4282	Homo sapiens	IC50	nM	43.0
329963	17708553	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COC(=O)c1ccc(-c2c(N)ncnc2N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCC3)CC2)cc1		CHEMBL3926246	=	IC50	nM	78.0	CHEMBL4282	Homo sapiens	IC50	nM	78.0
329964	17708554	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1-c1ccc(C(=O)O)cc1		CHEMBL3901741	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
329965	17708555	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCC3)CC2)c1-c1ccc(C(=O)O)cc1		CHEMBL3960331	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
329966	17708556	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(F)c4)cn3CCN3CCCC3)CC2)c1Br		CHEMBL3944201	=	IC50	nM	1.7	CHEMBL4282	Homo sapiens	IC50	nM	1.7
329967	17708557	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)cc4)cn3CCN3CCCC3)CC2)c1Br		CHEMBL3911853	=	IC50	nM	2.9	CHEMBL4282	Homo sapiens	IC50	nM	2.9
329968	17708558	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4cccc(F)c4)cn3CCN3CCCC3)CC2)c1Br		CHEMBL3949523	=	IC50	nM	5.9	CHEMBL4282	Homo sapiens	IC50	nM	5.9
329969	17708559	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(C(F)(F)F)c(F)c4)cn3CCN3CCCC3)CC2)c1Br		CHEMBL3950518	=	IC50	nM	71.0	CHEMBL4282	Homo sapiens	IC50	nM	71.0
329970	17708560	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3922798	=	IC50	nM	4.1	CHEMBL4282	Homo sapiens	IC50	nM	4.1
329971	17708561	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3cccc(F)c3)cn2CCN2CCCC2)CC1		CHEMBL3969229	=	IC50	nM	46.0	CHEMBL4282	Homo sapiens	IC50	nM	46.0
329972	17708562	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)cc3)cn2CCN2CCCC2)CC1		CHEMBL3894577	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	nM	20.0
329973	17708563	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(F)c3)cn2CCN2CCCC2)CC1		CHEMBL3954781	=	IC50	nM	8.2	CHEMBL4282	Homo sapiens	IC50	nM	8.2
329974	17708564	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(C(F)(F)F)c(F)c3)cn2CCN2CCCC2)CC1		CHEMBL3983416	=	IC50	nM	470.0	CHEMBL4282	Homo sapiens	IC50	nM	470.0
329975	17708565	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(C(F)(F)F)c(F)c4)cn3CCN3CCCC3)CC2)c1Cl		CHEMBL3929830	=	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
329976	17708566	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4cccc(F)c4)cn3CCN3CCCC3)CC2)c1Cl		CHEMBL3978595	=	IC50	nM	8.1	CHEMBL4282	Homo sapiens	IC50	nM	8.1
329977	17708567	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)cc4)cn3CCN3CCCC3)CC2)c1Cl		CHEMBL3912632	=	IC50	nM	3.3	CHEMBL4282	Homo sapiens	IC50	nM	3.3
329978	17708568	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(F)c4)cn3CCN3CCCC3)CC2)c1Cl		CHEMBL3940627	=	IC50	nM	3.2	CHEMBL4282	Homo sapiens	IC50	nM	3.2
329979	17708569	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	C=Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(C(F)(F)F)c(F)c3)cn2CCN2CCCC2)CC1		CHEMBL3964344	=	IC50	nM	210.0	CHEMBL4282	Homo sapiens	IC50	nM	210.0
329980	17708570	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	C=Cc1c(N)ncnc1N1CCC(c2nc(-c3cccc(F)c3)cn2CCN2CCCC2)CC1		CHEMBL3928074	=	IC50	nM	21.0	CHEMBL4282	Homo sapiens	IC50	nM	21.0
329981	17708571	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	C=Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)cc3)cn2CCN2CCCC2)CC1		CHEMBL3974191	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
329982	17708572	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	C=Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(F)c3)cn2CCN2CCCC2)CC1		CHEMBL3913177	=	IC50	nM	9.7	CHEMBL4282	Homo sapiens	IC50	nM	9.7
329983	17708573	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1cc(N2CCC(c3nc(-c4ccc(F)c(F)c4)cn3CCN3CCCC3)CC2)ncn1		CHEMBL3973291	=	IC50	nM	63.0	CHEMBL4282	Homo sapiens	IC50	nM	63.0
329984	17708574	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1cc(N2CCC(c3nc(-c4cccc(F)c4)cn3CCN3CCCC3)CC2)ncn1		CHEMBL3907714	=	IC50	nM	210.0	CHEMBL4282	Homo sapiens	IC50	nM	210.0
329985	17708575	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(C(F)(F)F)c(F)c3)cn2CCN2CC[C@H](F)C2)CC1		CHEMBL3889695	=	IC50	nM	64.0	CHEMBL4282	Homo sapiens	IC50	nM	64.0
329986	17708576	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(C(F)(F)F)c(F)c3)cn2CCN2CC[C@@H](F)C2)CC1		CHEMBL4108380	=	IC50	nM	25.0	CHEMBL4282	Homo sapiens	IC50	nM	25.0
329987	17708577	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(C(F)(F)F)c(F)c3)cn2CCN2CCC(F)(F)CC2)CC1		CHEMBL3913067	=	IC50	nM	520.0	CHEMBL4282	Homo sapiens	IC50	nM	520.0
329988	17708578	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(C(F)(F)F)c(F)c3)cn2CCN2CCCC(F)(F)C2)CC1		CHEMBL3950042	=	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
329989	17708579	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(C(F)(F)F)c(F)c3)cn2CCN2CCC(F)CC2)CC1		CHEMBL3908831	=	IC50	nM	86.0	CHEMBL4282	Homo sapiens	IC50	nM	86.0
329990	17708580	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(C(F)(F)F)c(F)c3)cn2CCN2CCCC(F)C2)CC1		CHEMBL3976022	=	IC50	nM	210.0	CHEMBL4282	Homo sapiens	IC50	nM	210.0
329991	17708581	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(Cl)c(F)c3)cn2CCN2CCCC2)CC1		CHEMBL3977596	=	IC50	nM	76.0	CHEMBL4282	Homo sapiens	IC50	nM	76.0
329992	17708582	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(Cl)c3)cn2CCN2CCCC2)CC1		CHEMBL3906990	=	IC50	nM	0.4	CHEMBL4282	Homo sapiens	IC50	nM	0.4
329993	17708583	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(C(F)(F)F)c(F)c4)cn3CCN3CCCCC3)CC2)c1C1CCC1		CHEMBL3891427	=	IC50	nM	28.0	CHEMBL4282	Homo sapiens	IC50	nM	28.0
329994	17708584	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(C(F)(F)F)c(F)c4)cn3CCN3CCCC3)CC2)c1C1CCC1		CHEMBL3915954	=	IC50	nM	9.1	CHEMBL4282	Homo sapiens	IC50	nM	9.1
329995	17708585	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(F)c4)cn3CCN3CCCC3)CC2)c1C1CCC1		CHEMBL3961562	=	IC50	nM	9.4	CHEMBL4282	Homo sapiens	IC50	nM	9.4
329996	17708586	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)cc4)cn3CCN3CCCC3)CC2)c1C1CCC1		CHEMBL3892575	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
329997	17708587	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4cccc(F)c4)cn3CCN3CCCC3)CC2)c1C1CCC1		CHEMBL3969159	=	IC50	nM	20.0	CHEMBL4282	Homo sapiens	IC50	nM	20.0
329998	17708588	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(C(F)(F)F)c(F)c4)cn3CCN3CCCC3)CC2)c1C1CCC1		CHEMBL3915954	=	IC50	nM	380.0	CHEMBL4282	Homo sapiens	IC50	nM	380.0
329999	17708589	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(C(F)(F)F)cc4)cn3CCN3CCCC3)CC2)c1C1CCC1		CHEMBL3942949	=	IC50	nM	430.0	CHEMBL4282	Homo sapiens	IC50	nM	430.0
330000	17708590	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(Cl)c(F)c4)cn3CCN3CCCC3)CC2)c1C1CCC1		CHEMBL3972543	=	IC50	nM	67.0	CHEMBL4282	Homo sapiens	IC50	nM	67.0
330001	17708591	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4cccc(C(F)(F)F)c4)cn3CCN3CCCC3)CC2)c1C1CCC1		CHEMBL3981168	=	IC50	nM	8.1	CHEMBL4282	Homo sapiens	IC50	nM	8.1
330002	17708592	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(Cl)c4)cn3CCN3CCCC3)CC2)c1C1CCC1		CHEMBL3952378	=	IC50	nM	4.9	CHEMBL4282	Homo sapiens	IC50	nM	4.9
330003	17708593	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(Cl)cc4)cn3CCN3CCCC3)CC2)c1C1CCC1		CHEMBL3892087	=	IC50	nM	79.0	CHEMBL4282	Homo sapiens	IC50	nM	79.0
330004	17708594	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4cccc(Cl)c4)cn3CCN3CCCC3)CC2)c1C1CCC1		CHEMBL3957616	=	IC50	nM	6.2	CHEMBL4282	Homo sapiens	IC50	nM	6.2
330005	17708595	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(C(F)(F)F)cc4)cn3CCN3CCCC3)CC2)c1Br		CHEMBL3897494	=	IC50	nM	110.0	CHEMBL4282	Homo sapiens	IC50	nM	110.0
330006	17708596	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(Cl)c(F)c4)cn3CCN3CCCC3)CC2)c1Br		CHEMBL3968655	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
330007	17708597	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4cccc(C(F)(F)F)c4)cn3CCN3CCCC3)CC2)c1Br		CHEMBL3906488	=	IC50	nM	4.2	CHEMBL4282	Homo sapiens	IC50	nM	4.2
330008	17708598	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(Cl)c4)cn3CCN3CCCC3)CC2)c1Br		CHEMBL3980219	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
330009	17708599	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	C=Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(C(F)(F)F)cc3)cn2CCN2CCCC2)CC1		CHEMBL3919026	=	IC50	nM	190.0	CHEMBL4282	Homo sapiens	IC50	nM	190.0
330010	17708600	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1cc(N2CCC(c3nc(-c4ccc(C(F)(F)F)cc4)cn3CCN3CCCC3)CC2)ncn1		CHEMBL3890965	=	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
330011	17708601	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(C(F)(F)F)cc3)cn2CCN2CCCC2)CC1		CHEMBL3950595	=	IC50	nM	180.0	CHEMBL4282	Homo sapiens	IC50	nM	180.0
330012	17708602	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3cccc(C(F)(F)F)c3)cn2CCN2CCCC2)CC1		CHEMBL3982706	=	IC50	nM	9.6	CHEMBL4282	Homo sapiens	IC50	nM	9.6
330013	17708603	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(Cl)cc3)cn2CCN2CCCC2)CC1		CHEMBL3945304	=	IC50	nM	190.0	CHEMBL4282	Homo sapiens	IC50	nM	190.0
330014	17708604	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3cccc(Cl)c3)cn2CCN2CCCC2)CC1		CHEMBL3905187	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
330015	17708605	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC(F)(F)C2)CC1		CHEMBL3973744	=	IC50	nM	430.0	CHEMBL4282	Homo sapiens	IC50	nM	430.0
330016	17708606	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCCCC2)CC1		CHEMBL3899177	=	IC50	nM	9.3	CHEMBL4282	Homo sapiens	IC50	nM	9.3
330017	17708607	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3cccc(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3921412	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
330018	17708608	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3cccc(F)c3)cn2CCN2CCC2)CC1		CHEMBL3894252	=	IC50	nM	79.5	CHEMBL4282	Homo sapiens	IC50	nM	79.5
330019	17708609	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3cccc(Cl)c3)cn2CCN2CCC2)CC1		CHEMBL3939097	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
330020	17708610	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(C(F)(F)F)c(F)c4)cn3CCN3CCC3)CC2)c1C1CCC1		CHEMBL3948660	=	IC50	nM	7.3	CHEMBL4282	Homo sapiens	IC50	nM	7.3
330021	17708611	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(Cl)c3)cn2CCN2CCC2)CC1		CHEMBL3985540	=	IC50	nM	9.2	CHEMBL4282	Homo sapiens	IC50	nM	9.2
330022	17708612	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(F)c3)cn2CCN2CCC2)CC1		CHEMBL3912123	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	nM	24.0
330023	17708613	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1[N+](=O)[O-]		CHEMBL3927590	=	IC50	nM	2.7	CHEMBL4282	Homo sapiens	IC50	nM	2.7
330024	17708614	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1N		CHEMBL3899565	=	IC50	nM	51.5	CHEMBL4282	Homo sapiens	IC50	nM	51.5
330025	17708615	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCC3)CC2)c1C=O		CHEMBL3890352	=	IC50	nM	1.4	CHEMBL4282	Homo sapiens	IC50	nM	1.4
330026	17708616	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCC3)CC2)c1C(=O)O		CHEMBL3918796	=	IC50	nM	730.0	CHEMBL4282	Homo sapiens	IC50	nM	730.0
330027	17708617	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Nc1ncnc(N2CCC(c3nc(-c4ccc(F)c(C(F)(F)F)c4)cn3CCN3CCCC3)CC2)c1C=O		CHEMBL3941283	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
330028	17708618	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(=O)Nc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3913301	=	IC50	nM	190.0	CHEMBL4282	Homo sapiens	IC50	nM	190.0
330029	17708619	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCOc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(Cl)c3)cn2CCN2CCCC2)CC1		CHEMBL3928772	=	IC50	nM	2.1	CHEMBL4282	Homo sapiens	IC50	nM	2.1
330030	17708620	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)Oc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(Cl)c3)cn2CCN2CCCC2)CC1		CHEMBL3904291	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
330031	17708621	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCOc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN(C)C)CC1		CHEMBL3976247	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
330032	17708622	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)Oc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN(C)C)CC1		CHEMBL3905494	=	IC50	nM	7.6	CHEMBL4282	Homo sapiens	IC50	nM	7.6
330033	17708623	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCOc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C)c3)cn2CCN(C)C)CC1		CHEMBL3948085	=	IC50	nM	1.7	CHEMBL4282	Homo sapiens	IC50	nM	1.7
330034	17708624	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCN(C)C)c(C3CCN(c4ncnc(N)c4OC(C)C)CC3)n2)ccc1F		CHEMBL3984164	=	IC50	nM	1.9	CHEMBL4282	Homo sapiens	IC50	nM	1.9
330035	17708625	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C)c3)cn2CCN(C)C)CC1		CHEMBL3960833	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	nM	23.0
330036	17708626	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C)c3)cn2CCN(CC)CC)CC1		CHEMBL3891820	=	IC50	nM	2.6	CHEMBL4282	Homo sapiens	IC50	nM	2.6
330037	17708627	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C)c3)cn2CCN2CCCC2)CC1		CHEMBL3975180	=	IC50	nM	6.6	CHEMBL4282	Homo sapiens	IC50	nM	6.6
330038	17708628	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCOc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C)c3)cn2CCN2CCCC2)CC1		CHEMBL3900809	=	IC50	nM	6.6	CHEMBL4282	Homo sapiens	IC50	nM	6.6
330039	17708629	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCN3CCCC3)c(C3CCN(c4ncnc(N)c4OC(C)C)CC3)n2)ccc1F		CHEMBL3939239	=	IC50	nM	8.9	CHEMBL4282	Homo sapiens	IC50	nM	8.9
330040	17708630	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C)c3)cn2CCN(CC)C(C)C)CC1		CHEMBL3968774	=	IC50	nM	8.9	CHEMBL4282	Homo sapiens	IC50	nM	8.9
330041	17708631	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCOC1CN(c2cc(N)ncn2)CCC1c1nc(-c2ccc(F)c(C)c2)cn1CCN(CC)C(C)C		CHEMBL3975500	=	IC50	nM	7.3	CHEMBL4282	Homo sapiens	IC50	nM	7.3
330042	17708632	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCN(CCn1cc(-c2ccc(F)c(C)c2)nc1C1CCN(c2ncnc(N)c2OC(C)C)CC1)C(C)C		CHEMBL3904672	=	IC50	nM	6.3	CHEMBL4282	Homo sapiens	IC50	nM	6.3
330043	17708633	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCOc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C)c3)cn2CCN(CC)CC)CC1		CHEMBL3986943	=	IC50	nM	0.8	CHEMBL4282	Homo sapiens	IC50	nM	0.8
330044	17708634	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCN(CC)CCn1cc(-c2ccc(F)c(C)c2)nc1C1CCN(c2ncnc(N)c2OC(C)C)CC1		CHEMBL3913659	=	IC50	nM	2.6	CHEMBL4282	Homo sapiens	IC50	nM	2.6
330045	17708635	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCCC2)CC1		CHEMBL3959291	=	IC50	nM	3.2	CHEMBL4282	Homo sapiens	IC50	nM	3.2
330046	17708636	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(F)c3)cn2CCN2CCCC2)CC1		CHEMBL3890225	=	IC50	nM	7.6	CHEMBL4282	Homo sapiens	IC50	nM	7.6
330047	17708637	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(Cl)c3)cn2CCN2CCCC2)CC1		CHEMBL3967010	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
330048	17708638	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)cc3)cn2CCN2CCCC2)CC1		CHEMBL3899172	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
330049	17708639	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3cccc(F)c3)cn2CCN2CCCC2)CC1		CHEMBL3968052	=	IC50	nM	21.0	CHEMBL4282	Homo sapiens	IC50	nM	21.0
330050	17708640	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3cccc(C(F)(F)F)c3)cn2CCN2CCCC2)CC1		CHEMBL3896892	=	IC50	nM	7.6	CHEMBL4282	Homo sapiens	IC50	nM	7.6
330051	17708641	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3cccc(Cl)c3)cn2CCN2CCCC2)CC1		CHEMBL3918965	=	IC50	nM	8.4	CHEMBL4282	Homo sapiens	IC50	nM	8.4
330052	17708642	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCCCC2)CC1		CHEMBL3927877	=	IC50	nM	2.3	CHEMBL4282	Homo sapiens	IC50	nM	2.3
330053	17708643	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(F)c3)cn2CCN2CCC2)CC1		CHEMBL3950203	=	IC50	nM	9.3	CHEMBL4282	Homo sapiens	IC50	nM	9.3
330054	17708644	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(OC(F)F)c(F)c3)cn2CCN2CCC2)CC1		CHEMBL3972741	=	IC50	nM	4.1	CHEMBL4282	Homo sapiens	IC50	nM	4.1
330055	17708645	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3cc[nH]c(=O)c3)cn2CCN2CCC2)CC1		CHEMBL3975126	=	IC50	nM	500.0	CHEMBL4282	Homo sapiens	IC50	nM	500.0
330056	17708646	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)cc1C(F)(F)F		CHEMBL3949201	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	nM	24.0
330057	17708647	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)c1cc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)ccn1		CHEMBL3966620	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
330058	17708648	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1cc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)ccn1		CHEMBL3936879	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
330059	17708649	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccnc(C4CC4)c3)cn2CCN2CCC2)CC1		CHEMBL3968742	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	nM	23.0
330060	17708650	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)cc1F		CHEMBL3965676	=	IC50	nM	48.0	CHEMBL4282	Homo sapiens	IC50	nM	48.0
330061	17708651	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COc1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)cc1F		CHEMBL3948379	=	IC50	nM	59.0	CHEMBL4282	Homo sapiens	IC50	nM	59.0
330062	17708652	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)cc1Cl		CHEMBL3980667	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
330063	17708653	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COc1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)cc1Cl		CHEMBL3943041	=	IC50	nM	31.0	CHEMBL4282	Homo sapiens	IC50	nM	31.0
330064	17708654	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCN3CCCC3)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)ccc1F		CHEMBL3972635	=	IC50	nM	3.5	CHEMBL4282	Homo sapiens	IC50	nM	3.5
330065	17708655	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCN(C)C)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)ccc1F		CHEMBL3971598	=	IC50	nM	0.9	CHEMBL4282	Homo sapiens	IC50	nM	0.9
330066	17708656	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCN(CC)CCn1cc(-c2ccc(F)c(C)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1		CHEMBL3896910	=	IC50	nM	2.5	CHEMBL4282	Homo sapiens	IC50	nM	2.5
330067	17708657	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCN(CCn1cc(-c2ccc(F)c(C)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1)C(C)C		CHEMBL3957053	=	IC50	nM	2.8	CHEMBL4282	Homo sapiens	IC50	nM	2.8
330068	17708658	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(F)c3)cn2CCN2CCC2)CC1		CHEMBL3985709	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	nM	140.0
330069	17708659	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(F)c3)cn2CCN2CCCC2)CC1		CHEMBL3940823	=	IC50	nM	120.0	CHEMBL4282	Homo sapiens	IC50	nM	120.0
330070	17708660	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(Cl)c3)cn2CCN2CCCC2)CC1		CHEMBL3973734	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
330071	17708661	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCCC2)CC1		CHEMBL3955767	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
330072	17708662	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)c1cc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)ccn1		CHEMBL3928144	=	IC50	nM	37.0	CHEMBL4282	Homo sapiens	IC50	nM	37.0
330073	17708663	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)cc3)cn2CCN2CCCC2)CC1		CHEMBL3966878	=	IC50	nM	380.0	CHEMBL4282	Homo sapiens	IC50	nM	380.0
330074	17708664	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3cccc(F)c3)cn2CCN2CCCC2)CC1		CHEMBL3933596	=	IC50	nM	620.0	CHEMBL4282	Homo sapiens	IC50	nM	620.0
330075	17708665	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3cccc(C(F)(F)F)c3)cn2CCN2CCCC2)CC1		CHEMBL3972161	=	IC50	nM	92.0	CHEMBL4282	Homo sapiens	IC50	nM	92.0
330076	17708666	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3cccc(Cl)c3)cn2CCN2CCCC2)CC1		CHEMBL3942559	=	IC50	nM	76.0	CHEMBL4282	Homo sapiens	IC50	nM	76.0
330077	17708667	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCCCC2)CC1		CHEMBL3980207	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
330078	17708668	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(OC(F)F)c3)cn2CCN2CCC2)CC1		CHEMBL3954717	=	IC50	nM	29.0	CHEMBL4282	Homo sapiens	IC50	nM	29.0
330079	17708669	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3cc[nH]c(=O)c3)cn2CCN2CCC2)CC1		CHEMBL3948232	=	IC50	nM	5800.0	CHEMBL4282	Homo sapiens	IC50	nM	5800.0
330080	17708670	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)cc1C(F)(F)F		CHEMBL3920410	=	IC50	nM	420.0	CHEMBL4282	Homo sapiens	IC50	nM	420.0
330081	17708671	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1cc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)ccn1		CHEMBL3913252	=	IC50	nM	450.0	CHEMBL4282	Homo sapiens	IC50	nM	450.0
330082	17708672	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccnc(C4CC4)c3)cn2CCN2CCC2)CC1		CHEMBL3941240	=	IC50	nM	61.0	CHEMBL4282	Homo sapiens	IC50	nM	61.0
330083	17708673	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)(C)c1cc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)ccn1		CHEMBL3918747	=	IC50	nM	170.0	CHEMBL4282	Homo sapiens	IC50	nM	170.0
330084	17708674	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)cc1F		CHEMBL3922125	=	IC50	nM	2400.0	CHEMBL4282	Homo sapiens	IC50	nM	2400.0
330085	17708675	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COc1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)cc1F		CHEMBL3899515	=	IC50	nM	13000.0	CHEMBL4282	Homo sapiens	IC50	nM	13000.0
330086	17708676	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)cc1Cl		CHEMBL3927542	=	IC50	nM	220.0	CHEMBL4282	Homo sapiens	IC50	nM	220.0
330087	17708677	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COc1ccc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)cc1Cl		CHEMBL3912088	=	IC50	nM	990.0	CHEMBL4282	Homo sapiens	IC50	nM	990.0
330088	17708678	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCN(C)C)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)ccc1F		CHEMBL3977710	=	IC50	nM	32.0	CHEMBL4282	Homo sapiens	IC50	nM	32.0
330089	17708679	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCN(CC)CCn1cc(-c2ccc(F)c(C)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1		CHEMBL3976090	=	IC50	nM	55.0	CHEMBL4282	Homo sapiens	IC50	nM	55.0
330090	17708680	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCN3CCCC3)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)ccc1F		CHEMBL3905309	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
330091	17708681	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCN(CCn1cc(-c2ccc(F)c(C)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1)C(C)C		CHEMBL3908761	=	IC50	nM	48.0	CHEMBL4282	Homo sapiens	IC50	nM	48.0
330092	17708682	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3cnc(N(C)C)nc3)cn2CCN2CCC2)CC1		CHEMBL3982217	=	IC50	nM	5700.0	CHEMBL4282	Homo sapiens	IC50	nM	5700.0
330093	17708683	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccccc3F)cn2CCN2CCC2)CC1		CHEMBL3905622	=	IC50	nM	140.0	CHEMBL4282	Homo sapiens	IC50	nM	140.0
330094	17708684	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3cccc(S(N)(=O)=O)c3)cn2CCN2CCC2)CC1		CHEMBL3979122	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
330095	17708685	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CS(=O)(=O)c1cccc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)c1		CHEMBL3894291	=	IC50	nM	80.0	CHEMBL4282	Homo sapiens	IC50	nM	80.0
330096	17708686	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CS(=O)(=O)c1cccc(-c2cn(CCN3CCC3)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)c1		CHEMBL3890873	=	IC50	nM	560.0	CHEMBL4282	Homo sapiens	IC50	nM	560.0
330097	17708687	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCO)CC1		CHEMBL3913464	=	IC50	nM	130.0	CHEMBL4282	Homo sapiens	IC50	nM	130.0
330098	17708688	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCNCC2CC2)CC1		CHEMBL3983282	=	IC50	nM	1.6	CHEMBL4282	Homo sapiens	IC50	nM	1.6
330099	17708689	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCNCC2CC2)CC1		CHEMBL3900963	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
330100	17708690	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)N(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1		CHEMBL3909180	=	IC50	nM	2.7	CHEMBL4282	Homo sapiens	IC50	nM	2.7
330101	17708691	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)N(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1		CHEMBL3976678	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	nM	11.0
330102	17708692	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(C)CCN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1		CHEMBL3912087	=	IC50	nM	76.0	CHEMBL4282	Homo sapiens	IC50	nM	76.0
330103	17708693	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COCCN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1		CHEMBL3974022	=	IC50	nM	26.0	CHEMBL4282	Homo sapiens	IC50	nM	26.0
330104	17708694	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COCCNCCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1		CHEMBL3903066	=	IC50	nM	2.5	CHEMBL4282	Homo sapiens	IC50	nM	2.5
330105	17708695	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(C)CCN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1		CHEMBL3963052	=	IC50	nM	730.0	CHEMBL4282	Homo sapiens	IC50	nM	730.0
330106	17708696	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COCCN(C)CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1		CHEMBL3897576	=	IC50	nM	440.0	CHEMBL4282	Homo sapiens	IC50	nM	440.0
330107	17708697	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COCCNCCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1		CHEMBL3957688	=	IC50	nM	67.0	CHEMBL4282	Homo sapiens	IC50	nM	67.0
330108	17708698	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CN(CCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1)Cc1ccccc1		CHEMBL3986416	=	IC50	nM	760.0	CHEMBL4282	Homo sapiens	IC50	nM	760.0
330109	17708699	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)NCCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1		CHEMBL3924599	=	IC50	nM	5.4	CHEMBL4282	Homo sapiens	IC50	nM	5.4
330110	17708700	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)NCCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1		CHEMBL3919834	=	IC50	nM	2.5	CHEMBL4282	Homo sapiens	IC50	nM	2.5
330111	17708701	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	COCC(C)NCCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1		CHEMBL3917106	=	IC50	nM	85.0	CHEMBL4282	Homo sapiens	IC50	nM	85.0
330112	17708702	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)CNCCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1		CHEMBL3980521	=	IC50	nM	0.7	CHEMBL4282	Homo sapiens	IC50	nM	0.7
330113	17708703	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)CNCCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1		CHEMBL3919344	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
330114	17708704	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CNCCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1		CHEMBL3894849	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
330115	17708705	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)(C)NCCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1		CHEMBL3895898	=	IC50	nM	1.9	CHEMBL4282	Homo sapiens	IC50	nM	1.9
330116	17708706	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CNCCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1		CHEMBL3967166	=	IC50	nM	33.0	CHEMBL4282	Homo sapiens	IC50	nM	33.0
330117	17708707	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CC(C)(C)NCCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1		CHEMBL3904852	=	IC50	nM	9.7	CHEMBL4282	Homo sapiens	IC50	nM	9.7
330118	17708708	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCNCC3CC3)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)ccc1F		CHEMBL3972479	=	IC50	nM	2.3	CHEMBL4282	Homo sapiens	IC50	nM	2.3
330119	17708709	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCN(C)C(C)C)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)ccc1F		CHEMBL3963056	=	IC50	nM	2.7	CHEMBL4282	Homo sapiens	IC50	nM	2.7
330120	17708710	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCNC(C)C)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)ccc1F		CHEMBL3890076	=	IC50	nM	2.9	CHEMBL4282	Homo sapiens	IC50	nM	2.9
330121	17708711	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	N#Cc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCNC2CCCC2)CC1		CHEMBL3960355	=	IC50	nM	0.8	CHEMBL4282	Homo sapiens	IC50	nM	0.8
330122	17708712	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCC(C)(C)NCCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1		CHEMBL3891300	=	IC50	nM	4.3	CHEMBL4282	Homo sapiens	IC50	nM	4.3
330123	17708713	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCNCC3CC3)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)ccc1F		CHEMBL3974713	=	IC50	nM	8.4	CHEMBL4282	Homo sapiens	IC50	nM	8.4
330124	17708714	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCO)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)ccc1F		CHEMBL3900331	=	IC50	nM	440.0	CHEMBL4282	Homo sapiens	IC50	nM	440.0
330125	17708715	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCN(C)C(C)C)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)ccc1F		CHEMBL3946371	=	IC50	nM	42.0	CHEMBL4282	Homo sapiens	IC50	nM	42.0
330126	17708716	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCNC(C)C)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)ccc1F		CHEMBL3975681	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
330127	17708717	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCNC2CCCC2)CC1		CHEMBL3951639	=	IC50	nM	8.4	CHEMBL4282	Homo sapiens	IC50	nM	8.4
330128	17708718	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCC(C)(C)NCCn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1		CHEMBL3983708	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
330129	17708719	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCNC3CCCC3)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)ccc1F		CHEMBL3927358	=	IC50	nM	0.7	CHEMBL4282	Homo sapiens	IC50	nM	0.7
330130	17708720	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCNCC(C)C)c(C3CCN(c4ncnc(N)c4C#N)CC3)n2)ccc1F		CHEMBL3954981	=	IC50	nM	1.4	CHEMBL4282	Homo sapiens	IC50	nM	1.4
330131	17708721	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCNC3CCCC3)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)ccc1F		CHEMBL3934916	=	IC50	nM	5.6	CHEMBL4282	Homo sapiens	IC50	nM	5.6
330132	17708722	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCNCC(C)C)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)ccc1F		CHEMBL3974261	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	nM	13.0
330133	17708723	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CCO)c(C3CCN(c4ncnc(N)c4C(N)=O)CC3)n2)ccc1F		CHEMBL3897830	=	IC50	nM	47.0	CHEMBL4282	Homo sapiens	IC50	nM	47.0
330134	17708724	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CNCCn1cc(-c2ccc(F)c(C)c2)nc1C1CCN(c2ncnc(N)c2C#N)CC1		CHEMBL3969016	=	IC50	nM	1.7	CHEMBL4282	Homo sapiens	IC50	nM	1.7
330135	17708725	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCO)CC1		CHEMBL3949232	=	IC50	nM	180.0	CHEMBL4282	Homo sapiens	IC50	nM	180.0
330136	17708726	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCOc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C)c3)cn2CCO)CC1		CHEMBL3924930	=	IC50	nM	340.0	CHEMBL4282	Homo sapiens	IC50	nM	340.0
330137	17708727	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CNCCn1cc(-c2ccc(F)c(C)c2)nc1C1CCN(c2ncnc(N)c2C(N)=O)CC1		CHEMBL3940462	=	IC50	nM	16.0	CHEMBL4282	Homo sapiens	IC50	nM	16.0
330138	17708728	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCOc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCNC(C)C)CC1		CHEMBL3912471	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
330139	17708729	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	Cc1cc(-c2cn(CC3CN(CO)C3)c(C3CCN(c4ncnc(N)c4C(C)C)CC3)n2)ccc1F		CHEMBL3974777	=	IC50	nM	56.0	CHEMBL4282	Homo sapiens	IC50	nM	56.0
330140	17708730	CHEMBL3887297	AKT Enzyme Assay: A TTP Mosquito liquid handling instrument is used to place 125 nl of the appropriate concentration of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate. To this reaction components are added to a final volume of 12.5 .mu.l: 0.1 ng/.mu.l His-AKT (Full Length), (Invitrogen, Part # P2999, Lot #641228C). 160 uM ATP (Fluka, 02055) 1 mM DTT (Sigma, D0632) 1 mM MgCl2 (Sigma, M1028) 1 .mu.M substrate peptide (sequence FITC-AHA-GRPRTSSFAEG-NH2), synthesized by Tufts Peptide Synthesis service. 100 mM HEPES pH 7.5 (Calbiochem, 391338)0.015% Brij-35 (Sigma, B4184)The reaction is incubated for 90 min at 25 C, and then stopped by the addition of 70 .mu.l of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 10 mM EDTA (Sigma, E7889)).The plate is read on a Caliper LC 3000 in an Off-Chip mobility shift assay format, using the following parameters for a 12-sipper chip: screening pressure -2.3 psi, upstream voltage -500, and downstream voltage -3000.	B	CCc1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C)c3)cn2CC2CN(C)C2)CC1		CHEMBL3936990	=	IC50	nM	0.3	CHEMBL4282	Homo sapiens	IC50	nM	0.3
337091	17714921	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	O=C(Nc1csc(-c2nncn2C2CC2)n1)c1cc(-n2cnc(C3CC3)c2)c(N2CC(C(F)F)C2)cn1		CHEMBL3908126	=	IC50	nM	2.2	CHEMBL4282	Homo sapiens	IC50	nM	2.2
337092	17714922	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	N#CC1CN(c2cnc(C(=O)Nc3csc(-c4nncn4C4CC4)n3)cc2-n2cnc(C3CC3)c2)C1		CHEMBL3975211	=	IC50	nM	0.9	CHEMBL4282	Homo sapiens	IC50	nM	0.9
337093	17714923	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	CC1(C#N)CN(c2cnc(C(=O)Nc3csc(-c4nncn4C4CC4)n3)cc2-n2cnc(C3CC3)c2)C1		CHEMBL3935565	=	IC50	nM	1.9	CHEMBL4282	Homo sapiens	IC50	nM	1.9
337094	17714924	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	COC1(C)CN(c2cnc(C(=O)Nc3csc(-c4nncn4C4CC4)n3)cc2-n2cnc(C3CC3)c2)C1		CHEMBL3905950	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
337095	17714925	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	O=C(Nc1csc(-c2nncn2C2CC2)n1)c1cc(-n2cnc(C3CC3)c2)c(N2CC(F)(F)C2)cn1		CHEMBL3957940	=	IC50	nM	2.8	CHEMBL4282	Homo sapiens	IC50	nM	2.8
337096	17714926	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	COC1CCN(c2cnc(C(=O)Nc3csc(-c4nncn4C4CC4)n3)cc2-n2cnc(C3CC3)c2)C1		CHEMBL3895494	=	IC50	nM	2.8	CHEMBL4282	Homo sapiens	IC50	nM	2.8
337097	17714927	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	O=C(Nc1csc(-c2nncn2C2CC2)n1)c1cc(-n2cnc(C3CC3)c2)c(N2CCC(C(F)(F)F)CC2)cn1		CHEMBL3924518	=	IC50	nM	3.2	CHEMBL4282	Homo sapiens	IC50	nM	3.2
337098	17714928	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	O=C(Nc1csc(-c2nncn2C2CC2)n1)c1cc(-n2cnc(C3CC3)c2)c(N2CCC(F)CC2)cn1		CHEMBL3920406	=	IC50	nM	2.5	CHEMBL4282	Homo sapiens	IC50	nM	2.5
337099	17714929	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	N#CC1CCN(c2cnc(C(=O)Nc3csc(-c4nncn4C4CC4)n3)cc2-n2cnc(C3CC3)c2)CC1		CHEMBL3898363	=	IC50	nM	2.2	CHEMBL4282	Homo sapiens	IC50	nM	2.2
337100	17714930	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	COC1CCN(c2cnc(C(=O)Nc3csc(-c4nncn4C4CC4)n3)cc2-n2cnc(C3CC3)c2)CC1		CHEMBL3943452	=	IC50	nM	3.2	CHEMBL4282	Homo sapiens	IC50	nM	3.2
337101	17714931	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	CNC(=O)C1CCN(c2cnc(C(=O)Nc3csc(-c4nncn4C4CC4)n3)cc2-n2cnc(C3CC3)c2)CC1		CHEMBL3969572	=	IC50	nM	0.4	CHEMBL4282	Homo sapiens	IC50	nM	0.4
337102	17714932	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	COC1(C)CCN(c2cnc(C(=O)Nc3csc(-c4nncn4C4CC4)n3)cc2-n2cnc(C3CC3)c2)CC1		CHEMBL3981380	=	IC50	nM	14.2	CHEMBL4282	Homo sapiens	IC50	nM	14.2
337103	17714933	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	O=C(Nc1csc(-c2nncn2C2CC2)n1)c1cc(-n2cnc(C3CC3)c2)c(N2CCN(CC(F)(F)F)CC2)cn1		CHEMBL3953443	=	IC50	nM	2.9	CHEMBL4282	Homo sapiens	IC50	nM	2.9
337104	17714934	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	O=C(Nc1csc(-c2nncn2C2CC2)n1)c1cc(-n2cnc(C3CC3)c2)c(N2CCCOCC2)cn1		CHEMBL3893943	=	IC50	nM	3.8	CHEMBL4282	Homo sapiens	IC50	nM	3.8
337105	17714935	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	O=C(Nc1csc(-c2nncn2C2CC2)n1)c1cc(-n2cnc(C3CC3)c2)c(N2CCN3CCCC3C2)cn1		CHEMBL3964706	=	IC50	nM	2.7	CHEMBL4282	Homo sapiens	IC50	nM	2.7
337106	17714936	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	O=C(Nc1csc(-c2nncn2C2CC2)n1)c1cc(-n2cnc(C3CC3)c2)c(N2CCN3C(=O)OCC3C2)cn1		CHEMBL3963748	=	IC50	nM	2.7	CHEMBL4282	Homo sapiens	IC50	nM	2.7
337107	17714937	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	O=C(Nc1csc(-c2nncn2C2CC2)n1)c1cc(-n2cnc(C3CC3)c2)c(N2CC3CC3C2)cn1		CHEMBL3922577	=	IC50	nM	1.1	CHEMBL4282	Homo sapiens	IC50	nM	1.1
337108	17714938	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	O=C(Nc1csc(-c2nncn2C2CC2)n1)c1cc(-n2cnc(C3CC3)c2)c(N2CC(N3CCOCC3)C2)cn1		CHEMBL3986247	=	IC50	nM	2.3	CHEMBL4282	Homo sapiens	IC50	nM	2.3
337109	17714939	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	O=C(Nc1csc(-c2nncn2C2CC2)n1)c1cc(-n2cnc(C3CC3)c2)c(N2CCN(C3CC3)CC2)cn1		CHEMBL3954180	=	IC50	nM	2.8	CHEMBL4282	Homo sapiens	IC50	nM	2.8
337110	17714940	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	O=C(Nc1csc(-c2nncn2C2CC2)n1)c1cc(-n2cnc(C3CC3)c2)c(N2CCN(CC3CC3)CC2)cn1		CHEMBL3978053	=	IC50	nM	2.5	CHEMBL4282	Homo sapiens	IC50	nM	2.5
337111	17714941	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	O=C(Nc1csc(-c2nncn2C2CC2)n1)c1cc(-n2cnc(C3CC3)c2)c(N2CCC3(CC2)COC3)cn1		CHEMBL3948895	=	IC50	nM	1.9	CHEMBL4282	Homo sapiens	IC50	nM	1.9
337112	17714942	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	O=C(Nc1csc(-c2nncn2C2CC2)n1)c1cc(-n2cnc(C3CC3)c2)c(N2CC3(CCOCC3)C2)cn1		CHEMBL3973753	=	IC50	nM	4.5	CHEMBL4282	Homo sapiens	IC50	nM	4.5
337113	17714943	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	COCC1CN(c2cnc(C(=O)Nc3csc(-c4nncn4[C@@H](C)C(F)(F)F)n3)cc2-n2cnc(C3CC3)c2)C1		CHEMBL3946920	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
337114	17714944	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CC(C)(C#N)C3)cn2)cs1)C(F)(F)F		CHEMBL3893968	=	IC50	nM	1.4	CHEMBL4282	Homo sapiens	IC50	nM	1.4
337115	17714945	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	COC1(C)CN(c2cnc(C(=O)Nc3csc(-c4nncn4[C@@H](C)C(F)(F)F)n3)cc2-n2cnc(C3CC3)c2)C1		CHEMBL3953748	=	IC50	nM	2.0	CHEMBL4282	Homo sapiens	IC50	nM	2.0
337116	17714946	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CC(C(F)F)C3)cn2)cs1)C(F)(F)F		CHEMBL3930015	=	IC50	nM	1.7	CHEMBL4282	Homo sapiens	IC50	nM	1.7
337117	17714947	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CCC(F)(F)C3)cn2)cs1)C(F)(F)F		CHEMBL3961734	=	IC50	nM	2.1	CHEMBL4282	Homo sapiens	IC50	nM	2.1
337118	17714948	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	COC1CCN(c2cnc(C(=O)Nc3csc(-c4nncn4[C@@H](C)C(F)(F)F)n3)cc2-n2cnc(C3CC3)c2)C1		CHEMBL3909615	=	IC50	nM	1.9	CHEMBL4282	Homo sapiens	IC50	nM	1.9
337119	17714949	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CCC(C#N)CC3)cn2)cs1)C(F)(F)F		CHEMBL3917308	=	IC50	nM	1.7	CHEMBL4282	Homo sapiens	IC50	nM	1.7
337120	17714950	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	COC1CCN(c2cnc(C(=O)Nc3csc(-c4nncn4[C@@H](C)C(F)(F)F)n3)cc2-n2cnc(C3CC3)c2)CC1		CHEMBL3904498	=	IC50	nM	2.3	CHEMBL4282	Homo sapiens	IC50	nM	2.3
337121	17714951	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	CNC(=O)C1CCN(c2cnc(C(=O)Nc3csc(-c4nncn4[C@@H](C)C(F)(F)F)n3)cc2-n2cnc(C3CC3)c2)CC1		CHEMBL3908356	=	IC50	nM	2.3	CHEMBL4282	Homo sapiens	IC50	nM	2.3
337122	17714952	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CCC(C(F)(F)F)CC3)cn2)cs1)C(F)(F)F		CHEMBL3976987	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
337123	17714953	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CCN(CC(F)(F)F)CC3)cn2)cs1)C(F)(F)F		CHEMBL3902880	=	IC50	nM	1.2	CHEMBL4282	Homo sapiens	IC50	nM	1.2
337124	17714954	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CCC(F)CC3)cn2)cs1)C(F)(F)F		CHEMBL3962884	=	IC50	nM	1.7	CHEMBL4282	Homo sapiens	IC50	nM	1.7
337125	17714955	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	COC1(C)CCN(c2cnc(C(=O)Nc3csc(-c4nncn4[C@@H](C)C(F)(F)F)n3)cc2-n2cnc(C3CC3)c2)CC1		CHEMBL3893936	=	IC50	nM	2.2	CHEMBL4282	Homo sapiens	IC50	nM	2.2
337126	17714956	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CCCOCC3)cn2)cs1)C(F)(F)F		CHEMBL3954144	=	IC50	nM	1.9	CHEMBL4282	Homo sapiens	IC50	nM	1.9
337127	17714957	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CCN4CCCC4C3)cn2)cs1)C(F)(F)F		CHEMBL3979677	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
337128	17714958	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CC4CN(C)CC4C3)cn2)cs1)C(F)(F)F		CHEMBL3899813	=	IC50	nM	2.4	CHEMBL4282	Homo sapiens	IC50	nM	2.4
337129	17714959	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CCN4C(=O)OCC4C3)cn2)cs1)C(F)(F)F		CHEMBL3926976	=	IC50	nM	2.3	CHEMBL4282	Homo sapiens	IC50	nM	2.3
337130	17714960	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CC4CC4C3)cn2)cs1)C(F)(F)F		CHEMBL3953359	=	IC50	nM	2.2	CHEMBL4282	Homo sapiens	IC50	nM	2.2
337131	17714961	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CC(N4CCOCC4)C3)cn2)cs1)C(F)(F)F		CHEMBL3924482	=	IC50	nM	1.9	CHEMBL4282	Homo sapiens	IC50	nM	1.9
337132	17714962	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CCN(C4CC4)CC3)cn2)cs1)C(F)(F)F		CHEMBL3925596	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
337133	17714963	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CCN(CC4CC4)CC3)cn2)cs1)C(F)(F)F		CHEMBL3897512	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
337134	17714964	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CCC4(CC3)COC4)cn2)cs1)C(F)(F)F		CHEMBL3961404	=	IC50	nM	2.1	CHEMBL4282	Homo sapiens	IC50	nM	2.1
337135	17714965	CHEMBL3887422	Time-Resolved Fluorescence Resonance energy transfer (TR-FRET) Immunoassay: The assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection. This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF KinEASE-STK manual from Cisbio. Test compound, 1 uM STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mM Mg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30 minutes then 100 uM ATP was added to start the kinase reaction and incubated for 3 hr. Peptide antibody labeled with 1xEu3+ Cryptate buffer containing 10 mM EDTA and 125 nM Streptavidin XL665 were added to stop the reaction and phosphorylated peptide substrate was detected using Envision 2103 Multilabeled reader from PerkinElmer. The fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.	B	C[C@H](n1cnnc1-c1nc(NC(=O)c2cc(-n3cnc(C4CC4)c3)c(N3CC4(CCOCC4)C3)cn2)cs1)C(F)(F)F		CHEMBL3903012	=	IC50	nM	2.6	CHEMBL4282	Homo sapiens	IC50	nM	2.6
381886	17755432	CHEMBL3888207	Akt1 TR-FRET assay: His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany). For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 °C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 °C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.05 ng/μl (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. #35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5). The resulting mixture was incubated 1 h at 22 °C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a HTRF reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.	B	NC1(c2ccc(-c3nc4c(O)nccn4c3-c3ccccc3)cc2)CCC1		CHEMBL3982161	=	IC50	nM	1600.0	CHEMBL4282	Homo sapiens	IC50	nM	1600.0
381887	17755433	CHEMBL3888207	Akt1 TR-FRET assay: His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany). For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 °C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 °C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.05 ng/μl (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. #35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5). The resulting mixture was incubated 1 h at 22 °C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a HTRF reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.	B	Cc1cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c(C)n1		CHEMBL3944710	=	IC50	nM	61.0	CHEMBL4282	Homo sapiens	IC50	nM	61.0
381888	17755434	CHEMBL3888207	Akt1 TR-FRET assay: His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany). For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 °C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 °C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.05 ng/μl (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. #35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5). The resulting mixture was incubated 1 h at 22 °C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a HTRF reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.	B	COc1nc(Br)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3977365	=	IC50	nM	22.0	CHEMBL4282	Homo sapiens	IC50	nM	22.0
381889	17755435	CHEMBL3888207	Akt1 TR-FRET assay: His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany). For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 °C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 °C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.05 ng/μl (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. #35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5). The resulting mixture was incubated 1 h at 22 °C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a HTRF reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.	B	CCc1cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c(OC)n1		CHEMBL3895917	=	IC50	nM	110.0	CHEMBL4282	Homo sapiens	IC50	nM	110.0
381890	17755436	CHEMBL3888207	Akt1 TR-FRET assay: His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany). For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 °C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 °C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.05 ng/μl (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. #35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5). The resulting mixture was incubated 1 h at 22 °C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a HTRF reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.	B	CCOC(=O)c1cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2cn1		CHEMBL3968885	=	IC50	nM	100.0	CHEMBL4282	Homo sapiens	IC50	nM	100.0
381891	17755437	CHEMBL3888207	Akt1 TR-FRET assay: His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany). For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 °C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 °C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.05 ng/μl (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. #35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5). The resulting mixture was incubated 1 h at 22 °C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a HTRF reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.	B	NC(=O)c1cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2cn1		CHEMBL3932688	=	IC50	nM	110.0	CHEMBL4282	Homo sapiens	IC50	nM	110.0
381892	17755438	CHEMBL3888207	Akt1 TR-FRET assay: His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany). For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 °C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 °C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.05 ng/μl (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. #35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5). The resulting mixture was incubated 1 h at 22 °C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a HTRF reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.	B	COC(=O)c1cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc2c(OC)n1		CHEMBL3956697	=	IC50	nM	64.0	CHEMBL4282	Homo sapiens	IC50	nM	64.0
381893	17755439	CHEMBL3888207	Akt1 TR-FRET assay: His-tagged human recombinant kinase full-length Akt1 expressed in insect cells was purchased form Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany). For the assay 50 nl of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Akt1 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22 °C. to allow prebinding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22 °C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.05 ng/μl (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. #35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1% (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5). The resulting mixture was incubated 1 h at 22 °C. to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a HTRF reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold conc. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.	B	COc1nc(C(N)=O)cn2c(-c3ccccc3)c(-c3ccc(C4(N)CCC4)cc3)nc12		CHEMBL3931748	=	IC50	nM	29.0	CHEMBL4282	Homo sapiens	IC50	nM	29.0
390587	17762697	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CC1=NN(C(=O)c2ccc(Cl)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL603852	=	Kd	nM	390.0	CHEMBL4282	Homo sapiens	Kd	nM	390.0
390588	17762698	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	NS(=O)(=O)c1nnc(NS(=O)(=O)c2cccc3cccnc23)s1		CHEMBL1994702	=	Kd	nM	1790.0	CHEMBL4282	Homo sapiens	Kd	nM	1790.0
390589	17762699	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CC1=NN(C(=O)c2ccc(Cl)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2nnc(C)s2)cc1		CHEMBL3931875	=	Kd	nM	4580.0	CHEMBL4282	Homo sapiens	Kd	nM	4580.0
390590	17762700	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	COc1cc(NS(=O)(=O)c2ccc(NS(=O)(=O)c3c(C)noc3C)cc2)nc(OC)n1		CHEMBL3912759	=	Kd	nM	6270.0	CHEMBL4282	Homo sapiens	Kd	nM	6270.0
390591	17762701	CHEMBL3888334	Cellular Assay: Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	CC1=NN(C(=O)c2ccc(Cl)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL603852	=	IC50	nM	24000.0	CHEMBL4282	Homo sapiens	IC50	nM	24000.0
390592	17762702	CHEMBL3888334	Cellular Assay: Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	NS(=O)(=O)c1nnc(NS(=O)(=O)c2cccc3cccnc23)s1		CHEMBL1994702	=	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	nM	50000.0
390593	17762703	CHEMBL3888334	Cellular Assay: Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	CC1=NN(C(=O)c2ccc(Cl)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2nnc(C)s2)cc1		CHEMBL3931875	=	IC50	nM	5000.0	CHEMBL4282	Homo sapiens	IC50	nM	5000.0
390594	17762704	CHEMBL3888334	Cellular Assay: Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	COc1cc(NS(=O)(=O)c2ccc(NS(=O)(=O)c3c(C)noc3C)cc2)nc(OC)n1		CHEMBL3912759	=	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
390595	17762705	CHEMBL3888335	Cellular Assay: Inhibition of AKT was measured by Western blotting using specific antibodies against phospho-Ser473-AKT in MiaPaCa-2 cells.Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL286737	=	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	nM	20000.0
390596	17762706	CHEMBL3888335	Cellular Assay: Inhibition of AKT was measured by Western blotting using specific antibodies against phospho-Ser473-AKT in MiaPaCa-2 cells.Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	O=C(Nc1ccccc1)c1ccccc1NC(=O)c1ccccc1C(=O)O		CHEMBL1733315	=	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	nM	50000.0
390597	17762707	CHEMBL3888335	Cellular Assay: Inhibition of AKT was measured by Western blotting using specific antibodies against phospho-Ser473-AKT in MiaPaCa-2 cells.Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	CCOc1ccccc1C(=O)Nc1ccccc1C(=O)O		CHEMBL3985551	=	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	nM	25000.0
390598	17762708	CHEMBL3888335	Cellular Assay: Inhibition of AKT was measured by Western blotting using specific antibodies against phospho-Ser473-AKT in MiaPaCa-2 cells.Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	COc1cc(NS(=O)(=O)c2ccc(Nc3ccco3)cc2)nc(OC)n1		CHEMBL3987198	=	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	nM	50000.0
390599	17762709	CHEMBL3888335	Cellular Assay: Inhibition of AKT was measured by Western blotting using specific antibodies against phospho-Ser473-AKT in MiaPaCa-2 cells.Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	COc1cc(NS(=O)(=O)c2ccc(NC(=O)c3ccco3)cc2)nc(OC)n1		CHEMBL1533790	=	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	nM	50000.0
390600	17762710	CHEMBL3888335	Cellular Assay: Inhibition of AKT was measured by Western blotting using specific antibodies against phospho-Ser473-AKT in MiaPaCa-2 cells.Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	COc1cc(NS(=O)(=O)c2ccc(NC(C)=O)cc2)nc(OC)n1		CHEMBL1349361	=	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	nM	50000.0
390601	17762711	CHEMBL3888335	Cellular Assay: Inhibition of AKT was measured by Western blotting using specific antibodies against phospho-Ser473-AKT in MiaPaCa-2 cells.Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	Cc1nnc(NS(=O)(=O)c2ccc(NS(=O)(=O)c3ccc4ccccc4c3)cc2)s1		CHEMBL595786	=	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	nM	25000.0
390602	17762712	CHEMBL3888335	Cellular Assay: Inhibition of AKT was measured by Western blotting using specific antibodies against phospho-Ser473-AKT in MiaPaCa-2 cells.Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	Nc1ccc(S(=O)(=O)Nc2ccc(S(=O)(=O)Nc3nnc(S(N)(=O)=O)s3)cc2)cc1		CHEMBL3910424	=	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	nM	50000.0
390603	17762713	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL286737	=	Kd	nM	15130.0	CHEMBL4282	Homo sapiens	Kd	nM	15130.0
390604	17762714	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595582	=	Kd	nM	10230.0	CHEMBL4282	Homo sapiens	Kd	nM	10230.0
390605	17762715	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL593946	=	Kd	nM	10230.0	CHEMBL4282	Homo sapiens	Kd	nM	10230.0
390606	17762716	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	COCCOCCOCC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL611216	=	Kd	nM	20410.0	CHEMBL4282	Homo sapiens	Kd	nM	20410.0
390607	17762717	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595583	=	Kd	nM	13490.0	CHEMBL4282	Homo sapiens	Kd	nM	13490.0
390608	17762718	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL286737	=	Kd	nM	450.0	CHEMBL4282	Homo sapiens	Kd	nM	450.0
390609	17762719	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595582	=	Kd	nM	19600.0	CHEMBL4282	Homo sapiens	Kd	nM	19600.0
390610	17762720	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595583	=	Kd	nM	40800.0	CHEMBL4282	Homo sapiens	Kd	nM	40800.0
390611	17762721	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL286737	>	Ki	nM	50000.0	CHEMBL4282	Homo sapiens	Ki	nM	50000.0
390612	17762722	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595582	=	Ki	nM	21800.0	CHEMBL4282	Homo sapiens	Ki	nM	21800.0
390613	17762723	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL593946	>	Ki	nM	50000.0	CHEMBL4282	Homo sapiens	Ki	nM	50000.0
390614	17762724	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	COCCOCCOCC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL611216	>	Ki	nM	50000.0	CHEMBL4282	Homo sapiens	Ki	nM	50000.0
390615	17762725	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595583	=	Ki	nM	2400.0	CHEMBL4282	Homo sapiens	Ki	nM	2400.0
390616	17762726	CHEMBL3888334	Cellular Assay: Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL286737	=	IC50	nM	20000.0	CHEMBL4282	Homo sapiens	IC50	nM	20000.0
390617	17762727	CHEMBL3888334	Cellular Assay: Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL286737	=	IC50	nM	25000.0	CHEMBL4282	Homo sapiens	IC50	nM	25000.0
390618	17762728	CHEMBL3888334	Cellular Assay: Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	CCCCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595582	=	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
390619	17762729	CHEMBL3888334	Cellular Assay: Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	CCCCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595582	=	IC50	nM	15000.0	CHEMBL4282	Homo sapiens	IC50	nM	15000.0
390620	17762730	CHEMBL3888334	Cellular Assay: Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	CC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL593946	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	nM	50000.0
390621	17762731	CHEMBL3888334	Cellular Assay: Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	COCCOCCOCC(=O)Nc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL611216	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	nM	50000.0
390622	17762732	CHEMBL3888334	Cellular Assay: Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595583	=	IC50	nM	6300.0	CHEMBL4282	Homo sapiens	IC50	nM	6300.0
390623	17762733	CHEMBL3888334	Cellular Assay: Inhibition of AKT was measured by Western blots using specific antibodies against phospho-Ser473-AKT in HT-29 lung cancer cells. Inhibition of the phosphorylation of AKT and its downstream targets was measured by Western blotting using rabbit polyclonal antibodies to phospho-Ser473-AKT, phospho-Thr308-AKT, total-AKT, phospho-Ser9-GSK3β, phospho-Ser21-GSK3β, phospho-Ser241-PDK1 and phospho-Thr389p70S6-kinase (New England Biolabs/Cell Signaling Technology Inc.) using β-Actin as a loading control as described in Mol Cancer Ther 7:2621 (2008). Bands corresponding to phospho-Ser473-AKT and total AKT were quantified using Eagle Eye software (BioRad) and Kodak X-Omat™ Blue XB (NEN™, Life Science Products). Cell growth inhibition was determined using a microcytotoxicity assay and apoptosis was measured as described in Mol Cancer Ther 7:2621 (2008).	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595583	=	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
390624	17762734	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595583	=	Kd	nM	13490.0	CHEMBL4282	Homo sapiens	Kd	nM	13490.0
390625	17762735	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(C)s2)cc1		CHEMBL1685052	=	Kd	nM	8320.0	CHEMBL4282	Homo sapiens	Kd	nM	8320.0
390626	17762736	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(CC)s2)cc1		CHEMBL1685053	=	Kd	nM	7590.0	CHEMBL4282	Homo sapiens	Kd	nM	7590.0
390627	17762737	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(C(C)(C)C)s2)cc1		CHEMBL1685054	=	Kd	nM	4070.0	CHEMBL4282	Homo sapiens	Kd	nM	4070.0
390628	17762738	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCc1nnc(NS(=O)(=O)c2ccc(NC(C)=O)cc2)s1		CHEMBL1685033	=	Kd	nM	6030.0	CHEMBL4282	Homo sapiens	Kd	nM	6030.0
390629	17762739	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1		CHEMBL1355299	=	Kd	nM	7760.0	CHEMBL4282	Homo sapiens	Kd	nM	7760.0
390630	17762740	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2nnc(CC)s2)cc1		CHEMBL1685039	=	Kd	nM	5250.0	CHEMBL4282	Homo sapiens	Kd	nM	5250.0
390631	17762741	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595583	=	Kd	nM	40800.0	CHEMBL4282	Homo sapiens	Kd	nM	40800.0
390632	17762742	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(C)s2)cc1		CHEMBL1685052	=	Kd	nM	48700.0	CHEMBL4282	Homo sapiens	Kd	nM	48700.0
390633	17762743	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(C)s2)cc1		CHEMBL1685052	=	Kd	nM	36300.0	CHEMBL4282	Homo sapiens	Kd	nM	36300.0
390634	17762744	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(CC)s2)cc1		CHEMBL1685053	=	Kd	nM	73000.0	CHEMBL4282	Homo sapiens	Kd	nM	73000.0
390635	17762745	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(CC)s2)cc1		CHEMBL1685053	=	Kd	nM	7900.0	CHEMBL4282	Homo sapiens	Kd	nM	7900.0
390636	17762746	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(C(C)(C)C)s2)cc1	Outside typical range	CHEMBL1685054	=	Kd	nM	587000.0	CHEMBL4282	Homo sapiens	Kd	nM	587000.0
390637	17762747	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(CC(=O)O)s2)cc1	Outside typical range	CHEMBL1681823	=	Kd	nM	110000.0	CHEMBL4282	Homo sapiens	Kd	nM	110000.0
390638	17762748	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(CC(=O)O)s2)cc1	Outside typical range	CHEMBL1681823	=	Kd	nM	114000.0	CHEMBL4282	Homo sapiens	Kd	nM	114000.0
390639	17762749	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(CC(=O)OCC)s2)cc1		CHEMBL1685055	=	Kd	nM	20700.0	CHEMBL4282	Homo sapiens	Kd	nM	20700.0
390640	17762750	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(C(=O)OCC)s2)cc1	Outside typical range	CHEMBL1685056	=	Kd	nM	736000.0	CHEMBL4282	Homo sapiens	Kd	nM	736000.0
390641	17762751	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(C(=O)OCC)s2)cc1	Outside typical range	CHEMBL1685056	=	Kd	nM	616000.0	CHEMBL4282	Homo sapiens	Kd	nM	616000.0
390642	17762752	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(CO)s2)cc1	Outside typical range	CHEMBL1685057	=	Kd	nM	429000.0	CHEMBL4282	Homo sapiens	Kd	nM	429000.0
390643	17762753	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(S(N)(=O)=O)s2)cc1		CHEMBL1685058	=	Kd	nM	4600.0	CHEMBL4282	Homo sapiens	Kd	nM	4600.0
390644	17762754	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2nnc(C)s2)cc1		CHEMBL1685038	=	Kd	nM	46700.0	CHEMBL4282	Homo sapiens	Kd	nM	46700.0
390645	17762755	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2nnc(CC)s2)cc1	Outside typical range	CHEMBL1685039	=	Kd	nM	178000.0	CHEMBL4282	Homo sapiens	Kd	nM	178000.0
390646	17762756	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2nnc(C(C)(C)C)s2)cc1	Outside typical range	CHEMBL1685040	=	Kd	nM	284000.0	CHEMBL4282	Homo sapiens	Kd	nM	284000.0
390647	17762757	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2nnc(C(C)(C)C)s2)cc1	Outside typical range	CHEMBL1685040	=	Kd	nM	281000.0	CHEMBL4282	Homo sapiens	Kd	nM	281000.0
390648	17762758	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2nnc(CC(=O)OCC)s2)cc1	Outside typical range	CHEMBL1685042	=	Kd	nM	105000.0	CHEMBL4282	Homo sapiens	Kd	nM	105000.0
390649	17762759	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2nnc(C(=O)OCC)s2)cc1	Outside typical range	CHEMBL1685043	=	Kd	nM	109000.0	CHEMBL4282	Homo sapiens	Kd	nM	109000.0
390650	17762760	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2nnc(CO)s2)cc1		CHEMBL1685044	=	Kd	nM	24500.0	CHEMBL4282	Homo sapiens	Kd	nM	24500.0
390651	17762761	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL1685046	=	Kd	nM	23700.0	CHEMBL4282	Homo sapiens	Kd	nM	23700.0
390652	17762762	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL1685047	=	Kd	nM	19100.0	CHEMBL4282	Homo sapiens	Kd	nM	19100.0
390653	17762763	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL1685048	=	Kd	nM	25800.0	CHEMBL4282	Homo sapiens	Kd	nM	25800.0
390654	17762764	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL1685049	=	Kd	nM	58900.0	CHEMBL4282	Homo sapiens	Kd	nM	58900.0
390655	17762765	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1	Outside typical range	CHEMBL1685050	=	Kd	nM	987000.0	CHEMBL4282	Homo sapiens	Kd	nM	987000.0
390656	17762766	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595583	=	Ki	nM	2400.0	CHEMBL4282	Homo sapiens	Ki	nM	2400.0
390657	17762767	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL1685046	>	Ki	nM	50000.0	CHEMBL4282	Homo sapiens	Ki	nM	50000.0
390658	17762768	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL1685047	>	Ki	nM	50000.0	CHEMBL4282	Homo sapiens	Ki	nM	50000.0
390659	17762769	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL1685048	=	Ki	nM	8400.0	CHEMBL4282	Homo sapiens	Ki	nM	8400.0
390660	17762770	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL1685049	=	Ki	nM	6700.0	CHEMBL4282	Homo sapiens	Ki	nM	6700.0
390661	17762771	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL1685050	=	Ki	nM	6900.0	CHEMBL4282	Homo sapiens	Ki	nM	6900.0
390662	17762772	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL1685051	=	Ki	nM	11400.0	CHEMBL4282	Homo sapiens	Ki	nM	11400.0
390663	17762773	CHEMBL3888333	SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.	B	CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OC1[C@H](O)[C@H](OP(=O)(O)O)C(OP(=O)(O)O)[C@H](OP(=O)(O)O)[C@H]1O)OC(=O)CCCCCCCCCCCCCCC		CHEMBL3900299	=	Ki	nM	260.0	CHEMBL4282	Homo sapiens	Ki	nM	260.0
390664	17762774	CHEMBL3888336	Silico Screening Assay: KT1 PH domain small molecule inhibitors were identified using the crystal structure of the AKT1 PH domain bound by PtdIns(1,3,4,5)P4 as descried in Thomas C C, Deak M, Alessi D R, van Aalten D M, High-resolution structure of the pleckstrin homology domain of protein kinase b/AKT bound to phosphatidylinositol (3,4,5)-trisphosphate, Curr Biol 12:1256 (2002), which is hereby incorporated by reference in its entirety, using a pharmacophore query search of the National Cancer Institute database. The high-resolution crystal structure of the isolated PH domain of human AKT1 in complex Ins(1,3,4,5)P4 was utilized to define a pharmacophore pocket for screening using Unity in Sybyl (version 7.2; Tripos Inc., St Louis, Mo.). The pharmacophore pocket included all the residues of the AKT1 crystal structure within 5 Å of the Ins(1,3,4,5)P4 binding site, i.e., Lys14, Arg15, Gly16, Gtu17, Tyr18, Ile19, Lys20, Thr21, Arg23, Pro24, Arg25, Lys39, Pro51, Leu52, Asn53, Asn54, Phe55, Gln79, ile84, Glu85, Arg86 and Phe88, and attributes to various atoms on the ligand and/or protein binding site were assigned. The defined pharmacophore pocket was then used to search virtual chemical databases and candidate compounds were identified. Various docking orientations were analyzed on the basis of FlexX scores, G-score, and X-score.	B	CC1=NN(C(=O)c2ccc(Cl)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL603852	=	Kd	nM	1200.0	CHEMBL4282	Homo sapiens	Kd	nM	1200.0
390665	17762775	CHEMBL3888336	Silico Screening Assay: KT1 PH domain small molecule inhibitors were identified using the crystal structure of the AKT1 PH domain bound by PtdIns(1,3,4,5)P4 as descried in Thomas C C, Deak M, Alessi D R, van Aalten D M, High-resolution structure of the pleckstrin homology domain of protein kinase b/AKT bound to phosphatidylinositol (3,4,5)-trisphosphate, Curr Biol 12:1256 (2002), which is hereby incorporated by reference in its entirety, using a pharmacophore query search of the National Cancer Institute database. The high-resolution crystal structure of the isolated PH domain of human AKT1 in complex Ins(1,3,4,5)P4 was utilized to define a pharmacophore pocket for screening using Unity in Sybyl (version 7.2; Tripos Inc., St Louis, Mo.). The pharmacophore pocket included all the residues of the AKT1 crystal structure within 5 Å of the Ins(1,3,4,5)P4 binding site, i.e., Lys14, Arg15, Gly16, Gtu17, Tyr18, Ile19, Lys20, Thr21, Arg23, Pro24, Arg25, Lys39, Pro51, Leu52, Asn53, Asn54, Phe55, Gln79, ile84, Glu85, Arg86 and Phe88, and attributes to various atoms on the ligand and/or protein binding site were assigned. The defined pharmacophore pocket was then used to search virtual chemical databases and candidate compounds were identified. Various docking orientations were analyzed on the basis of FlexX scores, G-score, and X-score.	B	CC1=NN(C(=O)c2ccccc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL595581	=	Kd	nM	2400.0	CHEMBL4282	Homo sapiens	Kd	nM	2400.0
390666	17762776	CHEMBL3888336	Silico Screening Assay: KT1 PH domain small molecule inhibitors were identified using the crystal structure of the AKT1 PH domain bound by PtdIns(1,3,4,5)P4 as descried in Thomas C C, Deak M, Alessi D R, van Aalten D M, High-resolution structure of the pleckstrin homology domain of protein kinase b/AKT bound to phosphatidylinositol (3,4,5)-trisphosphate, Curr Biol 12:1256 (2002), which is hereby incorporated by reference in its entirety, using a pharmacophore query search of the National Cancer Institute database. The high-resolution crystal structure of the isolated PH domain of human AKT1 in complex Ins(1,3,4,5)P4 was utilized to define a pharmacophore pocket for screening using Unity in Sybyl (version 7.2; Tripos Inc., St Louis, Mo.). The pharmacophore pocket included all the residues of the AKT1 crystal structure within 5 Å of the Ins(1,3,4,5)P4 binding site, i.e., Lys14, Arg15, Gly16, Gtu17, Tyr18, Ile19, Lys20, Thr21, Arg23, Pro24, Arg25, Lys39, Pro51, Leu52, Asn53, Asn54, Phe55, Gln79, ile84, Glu85, Arg86 and Phe88, and attributes to various atoms on the ligand and/or protein binding site were assigned. The defined pharmacophore pocket was then used to search virtual chemical databases and candidate compounds were identified. Various docking orientations were analyzed on the basis of FlexX scores, G-score, and X-score.	B	CC1=NN(C(=O)c2ccc(C(C)(C)C)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL594411	=	Kd	nM	1200.0	CHEMBL4282	Homo sapiens	Kd	nM	1200.0
390667	17762777	CHEMBL3888336	Silico Screening Assay: KT1 PH domain small molecule inhibitors were identified using the crystal structure of the AKT1 PH domain bound by PtdIns(1,3,4,5)P4 as descried in Thomas C C, Deak M, Alessi D R, van Aalten D M, High-resolution structure of the pleckstrin homology domain of protein kinase b/AKT bound to phosphatidylinositol (3,4,5)-trisphosphate, Curr Biol 12:1256 (2002), which is hereby incorporated by reference in its entirety, using a pharmacophore query search of the National Cancer Institute database. The high-resolution crystal structure of the isolated PH domain of human AKT1 in complex Ins(1,3,4,5)P4 was utilized to define a pharmacophore pocket for screening using Unity in Sybyl (version 7.2; Tripos Inc., St Louis, Mo.). The pharmacophore pocket included all the residues of the AKT1 crystal structure within 5 Å of the Ins(1,3,4,5)P4 binding site, i.e., Lys14, Arg15, Gly16, Gtu17, Tyr18, Ile19, Lys20, Thr21, Arg23, Pro24, Arg25, Lys39, Pro51, Leu52, Asn53, Asn54, Phe55, Gln79, ile84, Glu85, Arg86 and Phe88, and attributes to various atoms on the ligand and/or protein binding site were assigned. The defined pharmacophore pocket was then used to search virtual chemical databases and candidate compounds were identified. Various docking orientations were analyzed on the basis of FlexX scores, G-score, and X-score.	B	CC1=NN(C(=O)c2ccc(N)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL594412	=	Kd	nM	3000.0	CHEMBL4282	Homo sapiens	Kd	nM	3000.0
390668	17762778	CHEMBL3888336	Silico Screening Assay: KT1 PH domain small molecule inhibitors were identified using the crystal structure of the AKT1 PH domain bound by PtdIns(1,3,4,5)P4 as descried in Thomas C C, Deak M, Alessi D R, van Aalten D M, High-resolution structure of the pleckstrin homology domain of protein kinase b/AKT bound to phosphatidylinositol (3,4,5)-trisphosphate, Curr Biol 12:1256 (2002), which is hereby incorporated by reference in its entirety, using a pharmacophore query search of the National Cancer Institute database. The high-resolution crystal structure of the isolated PH domain of human AKT1 in complex Ins(1,3,4,5)P4 was utilized to define a pharmacophore pocket for screening using Unity in Sybyl (version 7.2; Tripos Inc., St Louis, Mo.). The pharmacophore pocket included all the residues of the AKT1 crystal structure within 5 Å of the Ins(1,3,4,5)P4 binding site, i.e., Lys14, Arg15, Gly16, Gtu17, Tyr18, Ile19, Lys20, Thr21, Arg23, Pro24, Arg25, Lys39, Pro51, Leu52, Asn53, Asn54, Phe55, Gln79, ile84, Glu85, Arg86 and Phe88, and attributes to various atoms on the ligand and/or protein binding site were assigned. The defined pharmacophore pocket was then used to search virtual chemical databases and candidate compounds were identified. Various docking orientations were analyzed on the basis of FlexX scores, G-score, and X-score.	B	CC1=NN(C(=O)c2ccc(O)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL595347	=	Kd	nM	1300.0	CHEMBL4282	Homo sapiens	Kd	nM	1300.0
390669	17762779	CHEMBL3888336	Silico Screening Assay: KT1 PH domain small molecule inhibitors were identified using the crystal structure of the AKT1 PH domain bound by PtdIns(1,3,4,5)P4 as descried in Thomas C C, Deak M, Alessi D R, van Aalten D M, High-resolution structure of the pleckstrin homology domain of protein kinase b/AKT bound to phosphatidylinositol (3,4,5)-trisphosphate, Curr Biol 12:1256 (2002), which is hereby incorporated by reference in its entirety, using a pharmacophore query search of the National Cancer Institute database. The high-resolution crystal structure of the isolated PH domain of human AKT1 in complex Ins(1,3,4,5)P4 was utilized to define a pharmacophore pocket for screening using Unity in Sybyl (version 7.2; Tripos Inc., St Louis, Mo.). The pharmacophore pocket included all the residues of the AKT1 crystal structure within 5 Å of the Ins(1,3,4,5)P4 binding site, i.e., Lys14, Arg15, Gly16, Gtu17, Tyr18, Ile19, Lys20, Thr21, Arg23, Pro24, Arg25, Lys39, Pro51, Leu52, Asn53, Asn54, Phe55, Gln79, ile84, Glu85, Arg86 and Phe88, and attributes to various atoms on the ligand and/or protein binding site were assigned. The defined pharmacophore pocket was then used to search virtual chemical databases and candidate compounds were identified. Various docking orientations were analyzed on the basis of FlexX scores, G-score, and X-score.	B	CC1=NN(C(=O)c2ccc(Cl)cc2)C(O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL3923074	=	Kd	nM	850.0	CHEMBL4282	Homo sapiens	Kd	nM	850.0
390682	17762792	CHEMBL3888336	Silico Screening Assay: KT1 PH domain small molecule inhibitors were identified using the crystal structure of the AKT1 PH domain bound by PtdIns(1,3,4,5)P4 as descried in Thomas C C, Deak M, Alessi D R, van Aalten D M, High-resolution structure of the pleckstrin homology domain of protein kinase b/AKT bound to phosphatidylinositol (3,4,5)-trisphosphate, Curr Biol 12:1256 (2002), which is hereby incorporated by reference in its entirety, using a pharmacophore query search of the National Cancer Institute database. The high-resolution crystal structure of the isolated PH domain of human AKT1 in complex Ins(1,3,4,5)P4 was utilized to define a pharmacophore pocket for screening using Unity in Sybyl (version 7.2; Tripos Inc., St Louis, Mo.). The pharmacophore pocket included all the residues of the AKT1 crystal structure within 5 Å of the Ins(1,3,4,5)P4 binding site, i.e., Lys14, Arg15, Gly16, Gtu17, Tyr18, Ile19, Lys20, Thr21, Arg23, Pro24, Arg25, Lys39, Pro51, Leu52, Asn53, Asn54, Phe55, Gln79, ile84, Glu85, Arg86 and Phe88, and attributes to various atoms on the ligand and/or protein binding site were assigned. The defined pharmacophore pocket was then used to search virtual chemical databases and candidate compounds were identified. Various docking orientations were analyzed on the basis of FlexX scores, G-score, and X-score.	B	CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OC1[C@H](O)[C@H](OP(=O)(O)O)C(OP(=O)(O)O)[C@H](OP(=O)(O)O)[C@H]1O)OC(=O)CCCCCCCCCCCCCCC		CHEMBL3900299	=	Kd	nM	3080.0	CHEMBL4282	Homo sapiens	Kd	nM	3080.0
390683	17762793	CHEMBL3888336	Silico Screening Assay: KT1 PH domain small molecule inhibitors were identified using the crystal structure of the AKT1 PH domain bound by PtdIns(1,3,4,5)P4 as descried in Thomas C C, Deak M, Alessi D R, van Aalten D M, High-resolution structure of the pleckstrin homology domain of protein kinase b/AKT bound to phosphatidylinositol (3,4,5)-trisphosphate, Curr Biol 12:1256 (2002), which is hereby incorporated by reference in its entirety, using a pharmacophore query search of the National Cancer Institute database. The high-resolution crystal structure of the isolated PH domain of human AKT1 in complex Ins(1,3,4,5)P4 was utilized to define a pharmacophore pocket for screening using Unity in Sybyl (version 7.2; Tripos Inc., St Louis, Mo.). The pharmacophore pocket included all the residues of the AKT1 crystal structure within 5 Å of the Ins(1,3,4,5)P4 binding site, i.e., Lys14, Arg15, Gly16, Gtu17, Tyr18, Ile19, Lys20, Thr21, Arg23, Pro24, Arg25, Lys39, Pro51, Leu52, Asn53, Asn54, Phe55, Gln79, ile84, Glu85, Arg86 and Phe88, and attributes to various atoms on the ligand and/or protein binding site were assigned. The defined pharmacophore pocket was then used to search virtual chemical databases and candidate compounds were identified. Various docking orientations were analyzed on the basis of FlexX scores, G-score, and X-score.	B	CC1=NN(C(=O)c2ccc(Cl)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL603852	=	Kd	nM	370.0	CHEMBL4282	Homo sapiens	Kd	nM	370.0
390684	17762794	CHEMBL3888336	Silico Screening Assay: KT1 PH domain small molecule inhibitors were identified using the crystal structure of the AKT1 PH domain bound by PtdIns(1,3,4,5)P4 as descried in Thomas C C, Deak M, Alessi D R, van Aalten D M, High-resolution structure of the pleckstrin homology domain of protein kinase b/AKT bound to phosphatidylinositol (3,4,5)-trisphosphate, Curr Biol 12:1256 (2002), which is hereby incorporated by reference in its entirety, using a pharmacophore query search of the National Cancer Institute database. The high-resolution crystal structure of the isolated PH domain of human AKT1 in complex Ins(1,3,4,5)P4 was utilized to define a pharmacophore pocket for screening using Unity in Sybyl (version 7.2; Tripos Inc., St Louis, Mo.). The pharmacophore pocket included all the residues of the AKT1 crystal structure within 5 Å of the Ins(1,3,4,5)P4 binding site, i.e., Lys14, Arg15, Gly16, Gtu17, Tyr18, Ile19, Lys20, Thr21, Arg23, Pro24, Arg25, Lys39, Pro51, Leu52, Asn53, Asn54, Phe55, Gln79, ile84, Glu85, Arg86 and Phe88, and attributes to various atoms on the ligand and/or protein binding site were assigned. The defined pharmacophore pocket was then used to search virtual chemical databases and candidate compounds were identified. Various docking orientations were analyzed on the basis of FlexX scores, G-score, and X-score.	B	CC1=NN(C(=O)c2ccccc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL595581	=	Kd	nM	3660.0	CHEMBL4282	Homo sapiens	Kd	nM	3660.0
390685	17762795	CHEMBL3888336	Silico Screening Assay: KT1 PH domain small molecule inhibitors were identified using the crystal structure of the AKT1 PH domain bound by PtdIns(1,3,4,5)P4 as descried in Thomas C C, Deak M, Alessi D R, van Aalten D M, High-resolution structure of the pleckstrin homology domain of protein kinase b/AKT bound to phosphatidylinositol (3,4,5)-trisphosphate, Curr Biol 12:1256 (2002), which is hereby incorporated by reference in its entirety, using a pharmacophore query search of the National Cancer Institute database. The high-resolution crystal structure of the isolated PH domain of human AKT1 in complex Ins(1,3,4,5)P4 was utilized to define a pharmacophore pocket for screening using Unity in Sybyl (version 7.2; Tripos Inc., St Louis, Mo.). The pharmacophore pocket included all the residues of the AKT1 crystal structure within 5 Å of the Ins(1,3,4,5)P4 binding site, i.e., Lys14, Arg15, Gly16, Gtu17, Tyr18, Ile19, Lys20, Thr21, Arg23, Pro24, Arg25, Lys39, Pro51, Leu52, Asn53, Asn54, Phe55, Gln79, ile84, Glu85, Arg86 and Phe88, and attributes to various atoms on the ligand and/or protein binding site were assigned. The defined pharmacophore pocket was then used to search virtual chemical databases and candidate compounds were identified. Various docking orientations were analyzed on the basis of FlexX scores, G-score, and X-score.	B	CC1=NN(C(=O)c2ccc(C(C)(C)C)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL594411	=	Kd	nM	1370.0	CHEMBL4282	Homo sapiens	Kd	nM	1370.0
390686	17762796	CHEMBL3888336	Silico Screening Assay: KT1 PH domain small molecule inhibitors were identified using the crystal structure of the AKT1 PH domain bound by PtdIns(1,3,4,5)P4 as descried in Thomas C C, Deak M, Alessi D R, van Aalten D M, High-resolution structure of the pleckstrin homology domain of protein kinase b/AKT bound to phosphatidylinositol (3,4,5)-trisphosphate, Curr Biol 12:1256 (2002), which is hereby incorporated by reference in its entirety, using a pharmacophore query search of the National Cancer Institute database. The high-resolution crystal structure of the isolated PH domain of human AKT1 in complex Ins(1,3,4,5)P4 was utilized to define a pharmacophore pocket for screening using Unity in Sybyl (version 7.2; Tripos Inc., St Louis, Mo.). The pharmacophore pocket included all the residues of the AKT1 crystal structure within 5 Å of the Ins(1,3,4,5)P4 binding site, i.e., Lys14, Arg15, Gly16, Gtu17, Tyr18, Ile19, Lys20, Thr21, Arg23, Pro24, Arg25, Lys39, Pro51, Leu52, Asn53, Asn54, Phe55, Gln79, ile84, Glu85, Arg86 and Phe88, and attributes to various atoms on the ligand and/or protein binding site were assigned. The defined pharmacophore pocket was then used to search virtual chemical databases and candidate compounds were identified. Various docking orientations were analyzed on the basis of FlexX scores, G-score, and X-score.	B	CC1=NN(C(=O)c2ccc(N)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL594412	=	Kd	nM	510.0	CHEMBL4282	Homo sapiens	Kd	nM	510.0
390687	17762797	CHEMBL3888336	Silico Screening Assay: KT1 PH domain small molecule inhibitors were identified using the crystal structure of the AKT1 PH domain bound by PtdIns(1,3,4,5)P4 as descried in Thomas C C, Deak M, Alessi D R, van Aalten D M, High-resolution structure of the pleckstrin homology domain of protein kinase b/AKT bound to phosphatidylinositol (3,4,5)-trisphosphate, Curr Biol 12:1256 (2002), which is hereby incorporated by reference in its entirety, using a pharmacophore query search of the National Cancer Institute database. The high-resolution crystal structure of the isolated PH domain of human AKT1 in complex Ins(1,3,4,5)P4 was utilized to define a pharmacophore pocket for screening using Unity in Sybyl (version 7.2; Tripos Inc., St Louis, Mo.). The pharmacophore pocket included all the residues of the AKT1 crystal structure within 5 Å of the Ins(1,3,4,5)P4 binding site, i.e., Lys14, Arg15, Gly16, Gtu17, Tyr18, Ile19, Lys20, Thr21, Arg23, Pro24, Arg25, Lys39, Pro51, Leu52, Asn53, Asn54, Phe55, Gln79, ile84, Glu85, Arg86 and Phe88, and attributes to various atoms on the ligand and/or protein binding site were assigned. The defined pharmacophore pocket was then used to search virtual chemical databases and candidate compounds were identified. Various docking orientations were analyzed on the basis of FlexX scores, G-score, and X-score.	B	CC1=NN(C(=O)c2ccc(O)cc2)C(=O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL595347	=	Kd	nM	1350.0	CHEMBL4282	Homo sapiens	Kd	nM	1350.0
390688	17762798	CHEMBL3888336	Silico Screening Assay: KT1 PH domain small molecule inhibitors were identified using the crystal structure of the AKT1 PH domain bound by PtdIns(1,3,4,5)P4 as descried in Thomas C C, Deak M, Alessi D R, van Aalten D M, High-resolution structure of the pleckstrin homology domain of protein kinase b/AKT bound to phosphatidylinositol (3,4,5)-trisphosphate, Curr Biol 12:1256 (2002), which is hereby incorporated by reference in its entirety, using a pharmacophore query search of the National Cancer Institute database. The high-resolution crystal structure of the isolated PH domain of human AKT1 in complex Ins(1,3,4,5)P4 was utilized to define a pharmacophore pocket for screening using Unity in Sybyl (version 7.2; Tripos Inc., St Louis, Mo.). The pharmacophore pocket included all the residues of the AKT1 crystal structure within 5 Å of the Ins(1,3,4,5)P4 binding site, i.e., Lys14, Arg15, Gly16, Gtu17, Tyr18, Ile19, Lys20, Thr21, Arg23, Pro24, Arg25, Lys39, Pro51, Leu52, Asn53, Asn54, Phe55, Gln79, ile84, Glu85, Arg86 and Phe88, and attributes to various atoms on the ligand and/or protein binding site were assigned. The defined pharmacophore pocket was then used to search virtual chemical databases and candidate compounds were identified. Various docking orientations were analyzed on the basis of FlexX scores, G-score, and X-score.	B	CC1=NN(C(=O)c2ccc(Cl)cc2)C(O)C1/N=N/c1ccc(S(=O)(=O)Nc2ncccn2)cc1		CHEMBL3923074	=	Kd	nM	1620.0	CHEMBL4282	Homo sapiens	Kd	nM	1620.0
412002	17776717	CHEMBL3888646	Mobility Shift Assay: Agents: 1-fold kinase buffer without MnCl2: 50 mM HEPES, pH 7.5, 0.0015% Brij-35, 10 mM MgCl2, 2 mM DTT. 1-fold kinase buffer with MnCl2: 50 mM HEPES, pH 7.5, 0.0015% Brij-35, 10 mM MgCl2, 10 mM MnCl2, 2 mM DTT. Termination solution: 100 mM HEPES, pH 7.5, 0.0015% Brij-35, 0.2% Coating Reagent#3, 50 mM EDTA. 2.5-fold kinase solution: The kinase was added to the 1-fold kinase buffer to form a 2.5-fold kinase solution. 2.5-fold substrate solution: FAM fluorescence-labelled polypeptide and ATP were added to the 1-fold kinase buffer to form a 2.5-fold substrate solution. Compounds: The final test concentration of the compound was 10 μM at maximum. Firstly, a 50-fold concentration (i.e. 500 μM) was prepared with 100% DMSO. The compound was diluted with 100% DMSO by 5 folds at 5 concentrations (successively 500 μM, 100 μM, 20 μM, 4 μM, and 0.8 μM). After diluting with 1-fold kinase buffer by 10 folds, 5 μl of the samples were transferred to a 384-well reaction plate. Two negative control wells and two positive control wells were set at each line respectively. Replication was made in a 96-well plate in five concentrations of 5-fold compound. 10% DMSO was added to the positive control well, and 5 μl of EDTA (250 mM) was added to the negative control well. Procedure: To the 384-well reaction plate was added 5-fold compound dissolved in 10% DMSO at 5 μl/well. To the 384-well reaction plate was added 2.5-fold kinase solution at 10 Î¼l/well. The plate was incubated at room temperature for 10 mins. To the 384-well reaction plate was added 2.5-fold substrate solution at 10 μl/well. The plate was incubated at 28° C. for a certain period. 25 μl termination solution was added to terminate the reaction.	B	Nc1ccc(-c2ccc3ncc4c(=O)[nH]c(=O)n(-c5cccc(C(F)(F)F)c5)c4c3n2)cn1		CHEMBL3903725	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
Inactive	17882717	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882718	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882719	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882720	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882721	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882722	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882723	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882724	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882725	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Active	17882726	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	=	Kd	nM	3883.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	3883.0
Inactive	17882727	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882728	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882729	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Active	17882730	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Kd	nM	554.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	554.0
Inactive	17882731	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882732	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882733	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882734	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882735	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882736	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882737	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882738	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882739	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882740	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882741	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882742	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882743	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882744	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882745	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882746	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882747	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882748	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1		CHEMBL2048872	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882749	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882750	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882751	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882752	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882753	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882754	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882755	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882756	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1		CHEMBL2364611	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882757	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882758	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882759	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL3545154	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882760	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882761	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Active	17882762	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	=	Kd	nM	11.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	11.0
Inactive	17882763	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882764	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882765	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882766	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882767	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL1078178	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882768	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882769	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882770	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882771	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882772	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882773	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882774	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882775	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882776	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882777	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Active	17882778	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	=	Kd	nM	440.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	440.0
Inactive	17882779	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882780	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882781	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882782	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882783	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882784	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882785	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882786	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17882787	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	=	Kd	nM	63.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	63.0
Inactive	17882788	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882789	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882790	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882791	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882792	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882793	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882794	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882795	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21		CHEMBL3334567	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882796	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC		CHEMBL405130	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882797	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882798	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882799	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882800	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882801	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882802	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882803	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882804	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882805	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882806	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882807	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882808	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882809	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882810	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882811	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882812	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882813	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882814	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882815	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882816	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882817	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882818	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882819	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882820	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882821	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882822	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882823	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882824	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882825	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882826	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882827	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882828	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882829	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882830	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882831	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882832	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882833	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882834	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882835	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882836	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882837	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C		CHEMBL411907	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882838	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882839	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882840	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F		CHEMBL3039513	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882841	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882842	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882843	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882844	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882845	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882846	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882847	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882848	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882849	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC		CHEMBL283120	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882850	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882851	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882852	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882853	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882854	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882855	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882856	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882857	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882858	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882859	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL2376648	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882860	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882861	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882862	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882863	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882864	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882865	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882866	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882867	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882868	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882869	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882870	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882871	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882872	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882873	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882874	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882875	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882876	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882877	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882878	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882879	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882880	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3545308	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882881	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882882	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882883	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882884	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882885	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882886	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882887	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882888	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882889	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882890	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882891	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882892	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882893	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1		CHEMBL3590106	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882894	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882895	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882896	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882897	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882898	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882899	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882900	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882901	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882902	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882903	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882904	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882905	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882906	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882907	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882908	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882909	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882910	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882911	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882912	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882913	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882914	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882915	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882916	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882917	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882918	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882919	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882920	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882921	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882922	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882923	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882924	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882925	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882926	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882927	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882928	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1		CHEMBL3544964	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882929	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882930	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882931	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882932	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882933	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882934	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882935	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882936	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882937	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882938	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882939	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882940	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1		CHEMBL2396661	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882941	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882942	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882943	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882944	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21		CHEMBL3545366	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882945	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882946	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882947	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1		CHEMBL1822792	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882948	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882949	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882950	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882951	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882952	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882953	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882954	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882955	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882956	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882957	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882958	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17882959	CHEMBL3991623	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	>	Kd	nM	30000.0	CHEMBL4282	Homo sapiens	Kd apparent	nM	30000.0
Active	17955620	CHEMBL3993527	Inhibition of AKT phosphorylation in P-gp overexpressing/drug resistant human K562/A02 cells at 8 uM after 24 hrs by Western blot analysis	B	COC(=O)c1cc(OC)c2c(c1-c1c(C(=O)OC3CCN(CC(=O)OCCCCOc4no[n+]([O-])c4S(=O)(=O)c4ccccc4)CC3)cc(OC)c3c1OCO3)OCO2		CHEMBL4067307		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	17955624	CHEMBL3993531	Inhibition of AKT phosphorylation in human K562/A02 cells at 1 uM measured after 48 hrs by Western blot analysis	B	COC(=O)c1cc(OC)c2c(c1-c1c(C(=O)OC3CCN(CC(=O)OCCCCOc4no[n+]([O-])c4S(=O)(=O)c4ccccc4)CC3)cc(OC)c3c1OCO3)OCO2		CHEMBL4067307		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	17955628	CHEMBL3993534	Inhibition of AKT phosphorylation in human K562/A02 cells at 2 uM in presence of hemoglobin measured after 24 hrs by Western blot analysis	B	COC(=O)c1cc(OC)c2c(c1-c1c(C(=O)OC3CCN(CC(=O)OCCCCOc4no[n+]([O-])c4S(=O)(=O)c4ccccc4)CC3)cc(OC)c3c1OCO3)OCO2		CHEMBL4067307		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	17964871	CHEMBL3994980	Inhibition of human AKT1 expressed in bacterial expression system assessed as residual activity at 1 uM by KINOMEscan assay relative to control	B	CNc1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)on3)c(C)c2)ncn1		CHEMBL4060295	=	Activity	%	89.0	CHEMBL4282	Homo sapiens	Activity	%	89.0
	17971051	CHEMBL3995854	Inhibition of human AKT1 at 10 uM using KGSGSGRPRTSSFAEG as substrate in presence of [33P]ATP by Hotspot assay relative to control	B	COc1cc2cc(Oc3ccc(NC(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)cc3)c(C)nc2cc1OC		CHEMBL4100501	=	Inhibition	%	0.06	CHEMBL4282	Homo sapiens	INH	%	0.06
	17979238	CHEMBL3998043	Inhibition of full length recombinant human His-tagged PKBalpha expressed in baculovirus expression system at 10 uM by Z'-LYTE assay relative to control	B	CC1=Nc2c(Sc3ccccc3)ncnc2Sc2ccccc21		CHEMBL4061152	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	17996247	CHEMBL4001397	Inhibition of human wild type partial length AKT1 expressed in bacterial expression system at 10 uM by KinomeScan method relative to control	B	Cc1nc2nc(Sc3ccccc3)cnc2cc1NC(=O)Nc1ccccc1		CHEMBL4083528	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	18008347	CHEMBL4003700	Inhibition of AKT1 (unknown origin)	B	CN(C)CCn1cc(-c2ccn3c(-c4ccc(C(N)=O)c(OCc5cccc(F)c5)c4)cnc3c2)cn1		CHEMBL4062453	=	IC50	nM	608.0	CHEMBL4282	Homo sapiens	IC50	nM	608.0
	18012407	CHEMBL4004227	Inhibition of recombinant human N-terminal GST-tagged AKT1 catalytic domain (104 to 480 residues) expressed in baculovirus expression system	B	COc1cc2ncccc2cc1NC(=O)c1csc2cncnc12		CHEMBL3822972	>	IC50	nM	50000.0	CHEMBL4282	Homo sapiens	IC50	uM	50.0
	18031599	CHEMBL4007682	Inhibition of AKT (unknown origin) after 60 mins by TR-FRET assay	B	CC1(C)OCC(=O)Nc2cc(Nc3nc(NCC(F)(F)F)c4occc4n3)ccc21		CHEMBL4069365	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	18053055	CHEMBL4011902	Inhibition of AKT1 (unknown origin) at 0.1 uM pretreated for 30 mins followed by substrate addition measured after 5 hrs in presence of 1 mM ATP relative to control	B	COC(=O)C1=C(Nc2ccccc2Cl)O/C(=C\c2c[nH]c3ncccc23)C1=O		CHEMBL4089159	=	Inhibition	%	14.0	CHEMBL4282	Homo sapiens	INH	%	14.0
Active	18057101	CHEMBL4012476	Inhibition of osteopontin-induced AKT phosphorylation in human A549 cells at 1 to 2 uM after 15 mins by Western blot method	B	CC1=CC(=O)c2c(O)cccc2C1=O		CHEMBL295316		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18063007	CHEMBL4013696	Inhibition of Akt phosphorylation at T308 residue in human KU812 cells at 10 uM after 24 hrs by Western blot method	B	CC1(C)CCN(CCOc2ccc3c(ccn3-c3cccnc3)c2)c2ccccc21		CHEMBL4064177		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18063053	CHEMBL4013689	Inhibition of Akt phosphorylation at T308 residue in human MV4-11 cells at 10 uM after 24 hrs by Western blot method	B	CC1(C)CCN(CCOc2ccc3c(ccn3-c3cccnc3)c2)c2ccccc21		CHEMBL4064177		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18063058	CHEMBL4013678	Inhibition of Akt phosphorylation at T308 residue in human KG1a cells at 10 uM after 24 hrs by Western blot method	B	CC1(C)CCN(CCOc2ccc3c(ccn3-c3cccnc3)c2)c2ccccc21		CHEMBL4064177		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18066696	CHEMBL4014524	Inhibition of human AKT1 at 10 uM relative to control	B	CCOc1cc(/C=C2\Oc3ccc(OC)cc3C2=O)ccc1O		CHEMBL4105195	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	18066697	CHEMBL4014524	Inhibition of human AKT1 at 10 uM relative to control	B	COc1ccc2c(c1)C(=O)/C(=C/c1ccc(O)c(O)c1)O2		CHEMBL4087337	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	18066698	CHEMBL4014524	Inhibition of human AKT1 at 10 uM relative to control	B	O=C1/C(=C/c2ccc(O)c(O)c2)Oc2cc(O)ccc21		CHEMBL490355	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
Not Determined	18066753	CHEMBL4014550	Inhibition of human AKT1	B	COc1ccc(-c2cnc3scc(NC(=O)C4CCCCC4)c3c2)cc1OC		CHEMBL3334979		IC50			CHEMBL4282	Homo sapiens	IC50		
	18083099	CHEMBL4018014	Inhibition of human AKT1 at 1 uM relative to control	B	CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1		CHEMBL2087474	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
Not Active	18083100	CHEMBL4018014	Inhibition of human AKT1 at 1 uM relative to control	B	Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CCN(S(=O)(=O)C2CC2)C4)cn1		CHEMBL4098032		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	18083101	CHEMBL4018014	Inhibition of human AKT1 at 1 uM relative to control	B	CS(=O)(=O)N1CCc2c(nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn23)C1		CHEMBL4068727		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18083102	CHEMBL4018014	Inhibition of human AKT1 at 1 uM relative to control	B	Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CN(c2ccc(F)cc2)CC4)cn1		CHEMBL4088855	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
Tde	18095474	CHEMBL4021056	Induction of Akt phosphorylation in human HepG2 cells at 5 uM by Western blot analysis	B	CC(C)(C(=O)/C=C/c1ccc(O)c(O)c1)C(=O)/C=C/c1ccc(O)c(O)c1		CHEMBL4069935		Activity			CHEMBL4282	Homo sapiens	Activity		
	18102177	CHEMBL4022195	Inhibition of recombinant full length human His-tagged AKT1 expressed in baculovirus expression system using ser/thr 6 as substrate after 1 hr by FRET-based Z'-Lyte assay	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	=	IC50	nM	38.0	CHEMBL4282	Homo sapiens	IC50	nM	38.0
	18105907	CHEMBL4022690	Inhibition of human AKT1/PKB using phospho-AKT peptide substrate after 1 hr by scintillation counting method	B	Nc1nc(NCCNc2ncc(-n3ccnc3)c(-c3ccc(Cl)cc3Cl)n2)ccc1[N+](=O)[O-]		CHEMBL3185148	>	IC50	nM	5000.0	CHEMBL4282	Homo sapiens	IC50	uM	5.0
	18105908	CHEMBL4022690	Inhibition of human AKT1/PKB using phospho-AKT peptide substrate after 1 hr by scintillation counting method	B	Nc1nc(NCCNc2ncc(-c3ncc[nH]3)c(-c3ccc(Cl)cc3Cl)n2)ccc1[N+](=O)[O-]		CHEMBL1080901	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	18105909	CHEMBL4022690	Inhibition of human AKT1/PKB using phospho-AKT peptide substrate after 1 hr by scintillation counting method	B	Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1		CHEMBL412142	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	18114488	CHEMBL4025006	Inhibition of wild-type human partial length AKT1 expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	18119324	CHEMBL4026195	Inhibition of Akt phosphorylation in human PC3 cells at 2 nM after 24 hrs by Western blot method relative to control	B	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C		CHEMBL92	=	FC		1.01	CHEMBL4282	Homo sapiens	FC		1.01
	18119325	CHEMBL4026172	Inhibition of Akt phosphorylation in human PC3 cells at 50 nM after 24 hrs by Western blot method relative to control	B	C[C@H]1CCC/C=C/[C@@H]2C[C@H](O)C[C@H]2[C@H](O)/C=C/C(=O)O1		CHEMBL19980	=	FC		0.99	CHEMBL4282	Homo sapiens	FC		0.99
	18119359	CHEMBL4026205	Potentiation of 2 nM docetaxel-induced inhibition of Akt phosphorylation in human PC3 cells at 50 nM after 24 hrs by Western blot method relative to control	B	C[C@H]1CCC/C=C/[C@@H]2C[C@H](O)C[C@H]2[C@H](O)/C=C/C(=O)O1		CHEMBL19980	=	FC		0.97	CHEMBL4282	Homo sapiens	FC		0.97
	18121802	CHEMBL4026909	Binding affinity to AKT1 (unknown origin)	B	NC(=O)[C@H](CCCCNC(=S)Nc1ccc(-c2c3ccc(=O)cc-3oc3cc(O)ccc23)c(C(=O)O)c1)NC(=O)CN1C[C@H](Cc2ccccc2)NC(=O)CN(C(=O)CCC(=O)O)C[C@H](CCC(=O)O)NC(=O)CN(C(=O)Cc2ccc3c(c2)OCO3)C[C@H](CCC(=O)O)NC(=O)CN(C(=O)CCC2CCCCC2)C[C@H](Cc2ccccc2)NC(=O)c2ccc(cc2)CSCCC1=O		CHEMBL4071045	=	Kd	nM	3620.0	CHEMBL4282	Homo sapiens	Kd	uM	3.62
Not Active	18134448	CHEMBL4029528	Inhibition of Akt1 (unknown origin) at <1 uM using AKT1 substrate pretreated for 5 mins followed by substrate addition after 20 mins in presence of [gamma33P]ATP by scintillation counter method	B	COCCNC(=O)c1ccc(Oc2sc(C(N)=O)c3c2-c2sncc2CC3)cn1		CHEMBL4066819		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	18134479	CHEMBL4029528	Inhibition of Akt1 (unknown origin) at <1 uM using AKT1 substrate pretreated for 5 mins followed by substrate addition after 20 mins in presence of [gamma33P]ATP by scintillation counter method	B	CSc1sc(C(N)=O)c2c1-c1sncc1CC2		CHEMBL4082469		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18135444	CHEMBL4029696	Inhibition of partial length wild type human PKBalpha expressed in bacterial expression system assessed as residual activity at 10 uM by KINOMEscan assay relative to control	B	O=C1NC(=S)S/C1=C\c1cscn1		CHEMBL4061891	=	Activity	%	106.0	CHEMBL4282	Homo sapiens	Activity	%	106.0
	18135461	CHEMBL4029696	Inhibition of partial length wild type human PKBalpha expressed in bacterial expression system assessed as residual activity at 10 uM by KINOMEscan assay relative to control	B	O=C1NC(=S)S/C1=C\c1csc(-c2ccc(C(F)(F)F)cc2)n1		CHEMBL4075290	=	Activity	%	63.0	CHEMBL4282	Homo sapiens	Activity	%	63.0
	18135478	CHEMBL4029696	Inhibition of partial length wild type human PKBalpha expressed in bacterial expression system assessed as residual activity at 10 uM by KINOMEscan assay relative to control	B	O=C1NC(=S)N2C(=O)C3Nc4cc(Cl)cc(Cl)c4C3C=C12		CHEMBL4096175	=	Activity	%	76.0	CHEMBL4282	Homo sapiens	Activity	%	76.0
	18135495	CHEMBL4029696	Inhibition of partial length wild type human PKBalpha expressed in bacterial expression system assessed as residual activity at 10 uM by KINOMEscan assay relative to control	B	N=C1NC(=O)/C(=C/c2csc(-c3ccc(C(F)(F)F)cc3)n2)S1		CHEMBL4064860	=	Activity	%	101.0	CHEMBL4282	Homo sapiens	Activity	%	101.0
Active	18140565	CHEMBL4031119	Induction of EGF-induced AKT phosphorylation at Ser473 in human Capan1 cells at 25 uM after 1 hr by Western blot method	B	Cc1ccc(-n2nc3c(=O)n(CCCC(=O)NCC(C)c4ccccc4)nc(C)c3c2C)cc1		CHEMBL1387422		Activity			CHEMBL4282	Homo sapiens	Activity		
	18153139	CHEMBL4034250	Inhibition of AKT1 (unknown origin) labeling at ATP binding loop at 10 uM relative to control	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	7.5	CHEMBL4282	Homo sapiens	INH	%	7.5
Not Active	18156568	CHEMBL4035112	Inhibition of Akt phosphorylation in human MDA-MB-468 cells by Western blot method	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2ccccc2)nc2cc(Cl)ccc12		CHEMBL4094697		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	18156569	CHEMBL4035112	Inhibition of Akt phosphorylation in human MDA-MB-468 cells by Western blot method	B	CCN(CC)CCCC(C)Nc1nc(/C=C/c2c(Cl)cc(Cl)cc2Cl)nc2ccc(N)cc12		CHEMBL4090364		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	18157503	CHEMBL4035295	Inhibition of Akt-phosphorylation in human UACC-903 cells after 24 hrs by Western blot analysis	B	O=C1c2cccc3cccc(c23)C(=O)N1CCCCCCN=C=[Se]		CHEMBL4084498		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	18171182	CHEMBL4037719	Inhibition of TGF-beta1-induced AKT phosphorylation in human HCT116 cells after 48 hrs by Western blot analysis	B	Cc1nc(C)c(/C=C/C(=O)N2CCC=C(Cl)C2=O)nc1C		CHEMBL4062698		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18171184	CHEMBL4037721	Inhibition of TGF-beta1-induced AKT phosphorylation in human HCT116 cells at 50 nM after 48 hrs by Western blot analysis	B	COc1cc(/C=C/C(=O)N2CCC=CC2=O)cc(OC)c1OC		CHEMBL465843		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18174260	CHEMBL4038658	Effect on AKT phosphorylation in human Bel7402/5-FU cells assessed as ratio of phosphorylated AKT to beta-actin level at 0.1 uM after 48 hrs by Western blot analysis (Rvb = 0.39 No_unit)	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](OC(=O)c3ccccc3OC(C)=O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC		CHEMBL4095266	=	Ratio		0.29	CHEMBL4282	Homo sapiens	Ratio		0.29
	18174263	CHEMBL4038661	Effect on AKT phosphorylation in human Bel7402/5-FU cells assessed as ratio of phosphorylated AKT to beta-actin level at 2 uM after 48 hrs by Western blot analysis (Rvb = 0.39 No_unit)	B	COc1ccc2c(c1)c(CC(=O)O[C@H]1c3cc4c(cc3[C@@H](c3cc(OC)c(OC)c(OC)c3)[C@H]3C(=O)OC[C@H]13)OCO4)c(C)n2C(=O)c1ccc(Cl)cc1		CHEMBL4105437	=	Ratio		0.4	CHEMBL4282	Homo sapiens	Ratio		0.4
	18174266	CHEMBL4038664	Effect on AKT phosphorylation in human Bel7402/5-FU cells assessed as ratio of phosphorylated AKT to beta-actin level at 10 uM after 48 hrs by Western blot analysis (Rvb = 0.39 No_unit)	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](OC(=O)C(C)c3ccc(CC(C)C)cc3)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC		CHEMBL4087564	=	Ratio		0.42	CHEMBL4282	Homo sapiens	Ratio		0.42
	18174269	CHEMBL4038667	Effect on AKT phosphorylation in human Bel7402/5-FU cells assessed as ratio of phosphorylated AKT to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.39 No_unit)	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC		CHEMBL61	=	Ratio		0.35	CHEMBL4282	Homo sapiens	Ratio		0.35
Not Active	18178718	CHEMBL4039109	Induction of Akt phosphorylation in human Huh7 cells up to 50 uM measured after 2 hrs by Western blot method	B	C/C(=C\Cn1c[n+](C)c2ncnc(N)c21)CC[C@]1(C)[C@@H](C)CC[C@@]2(C)C(COC(=O)c3cc(Br)c[nH]3)=CCC[C@H]21		CHEMBL3586411		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	18178719	CHEMBL4039109	Induction of Akt phosphorylation in human Huh7 cells up to 50 uM measured after 2 hrs by Western blot method	B	C/C(=C\Cn1c[n+](C)c2ncnc(N)c21)CC[C@]1(C)[C@@H](C)CC[C@@]2(C)C(COC(=O)c3ccc[nH]3)=CCC[C@H]21		CHEMBL1186032		Activity			CHEMBL4282	Homo sapiens	Activity		
Dose-dependent effect	18178721	CHEMBL4039111	Induction of Akt phosphorylation in human Huh7 cells measured after 2 hrs by Western blot method	B	C/C(=C\Cn1c[n+](C)c2ncnc(N)c21)CC[C@]1(C)[C@@H](C)CC[C@@]2(C)C(COC(=O)c3cc(Br)c[nH]3)=CCC[C@H]21		CHEMBL3586411		Activity			CHEMBL4282	Homo sapiens	Activity		
Dose-dependent effect	18178722	CHEMBL4039111	Induction of Akt phosphorylation in human Huh7 cells measured after 2 hrs by Western blot method	B	C/C(=C\Cn1c[n+](C)c2ncnc(N)c21)CC[C@]1(C)[C@@H](C)CC[C@@]2(C)C(COC(=O)c3ccc[nH]3)=CCC[C@H]21		CHEMBL1186032		Activity			CHEMBL4282	Homo sapiens	Activity		
Dose-dependent effect	18178725	CHEMBL4039113	Activation of AKT in human Huh7 cells assessed as increase in insulin-stimulated Akt phosphorylation preincubated for 1 to 2 hrs followed by insulin addition measured after 5 mins by Western blot method	B	C/C(=C\Cn1c[n+](C)c2ncnc(N)c21)CC[C@]1(C)[C@@H](C)CC[C@@]2(C)C(COC(=O)c3ccc[nH]3)=CCC[C@H]21		CHEMBL1186032		Activity			CHEMBL4282	Homo sapiens	Activity		
	18203396	CHEMBL4043817	Inhibition of wild-type human partial length AKT1 expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	88.0	CHEMBL4282	Homo sapiens	Activity	%	88.0
	18209597	CHEMBL4045455	Inhibition of Akt phosphorylation in human MDA-MB-231 cells at 3.125 uM after 24 hrs by Western blot analysis relative to control	B	COc1cc2oc(-c3ccc(O)cc3)cc(=O)c2c(O)c1OC		CHEMBL348436	=	FC		0.68	CHEMBL4282	Homo sapiens	FC		0.68
	18209598	CHEMBL4045456	Inhibition of Akt phosphorylation in human MDA-MB-231 cells at 6.25 uM after 24 hrs by Western blot analysis relative to control	B	COc1cc2oc(-c3ccc(O)cc3)cc(=O)c2c(O)c1OC		CHEMBL348436	=	FC		0.66	CHEMBL4282	Homo sapiens	FC		0.66
	18211661	CHEMBL4045631	Inhibition of AKT1 labeling at ATP binding site (GTFGKVILVK) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	27.4	CHEMBL4282	Homo sapiens	INH	%	27.4
	18211778	CHEMBL4045874	Inhibition of AKT1 labeling at ATP binding site (GTFGKVILVK) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	21.0	CHEMBL4282	Homo sapiens	INH	%	21.0
	18212127	CHEMBL4046145	Inhibition of AKT1 (unknown origin) at 1 uM relative to control	B	Cc1c(-c2ccncc2)c[nH]c1C(N)=O		CHEMBL4100387	<	Inhibition	%	20.0	CHEMBL4282	Homo sapiens	INH	%	20.0
Active	18220994	CHEMBL4047658	Inhibition of AKT phosphorylation at Ser473 residues in human PANC1 cells at 50 uM measured within 3 hrs under nutrient deprived condition by Western blot analysis	B	CC1=C[C@H]2[C@H](C(C)C)CC[C@](C)(O)[C@@H]2CC1		CHEMBL2228955		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	18220995	CHEMBL4047659	Inhibition of AKT in human PANC1 cells assessed as reduction in mTOR phosphorylation at Ser2448 residue measured after 3 hrs under nutrient deprived condition by Western blot analysis	B	CC1=C[C@H]2[C@H](C(C)C)CC[C@](C)(O)[C@@H]2CC1		CHEMBL2228955		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18220996	CHEMBL4047660	Inhibition of AKT in human PANC1 cells assessed as reduction in mTOR phosphorylation at Ser2448 residue at 50 uM measured after 3 hrs under nutrient deprived condition by Western blot analysis	B	CC1=C[C@H]2[C@H](C(C)C)CC[C@](C)(O)[C@@H]2CC1		CHEMBL2228955	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	INH	%	100.0
	18231693	CHEMBL4050183	Inhibition of human AKT1 using KGSGSGRPRTSSFAEG as substrate in presence of [gamma-32P]ATP	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	5.94	CHEMBL4282	Homo sapiens	IC50	10'-9M	5.94
Not Determined	18231723	CHEMBL4050183	Inhibition of human AKT1 using KGSGSGRPRTSSFAEG as substrate in presence of [gamma-32P]ATP	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339		IC50			CHEMBL4282	Homo sapiens	IC50		
	18232141	CHEMBL4050284	Inhibition of human PKBa assessed as residual activity at 1 uM in presence of [33P]ATP by filter binding assay relative to control	B	NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4077554	=	Activity	%	89.0	CHEMBL4282	Homo sapiens	Activity	%	89.0
	18250435	CHEMBL4054252	Inhibition of recombinant human PKBalpha using CREBtide (CKRREILSRRPSYRK) as substrate at 100 uM after 60 mins in presence of ATP relative to control	B	CCCCCCCCCCCCCCC(=O)NC1CCN(C(=O)C2Sc3ccccc3N(CC)C2=O)CC1		CHEMBL4081419	=	Inhibition	%	52.0	CHEMBL4282	Homo sapiens	INH	%	52.0
Dose-dependent effect	18250718	CHEMBL4054392	Inhibition of Akt phosphorylation in human U87 cells after 72 hrs by Western blot method	B	C=C[C@]1(C)CC[C@@H](C(=C)COC(=O)CCC(=O)OCCOc2no[n+]([O-])c2S(=O)(=O)c2ccccc2)C[C@H]1C(=C)C		CHEMBL4070551		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18253449	CHEMBL4055008	Inhibition of wild-type human partial length AKT1 expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	79.0	CHEMBL4282	Homo sapiens	Activity	%	79.0
	18253450	CHEMBL4055008	Inhibition of wild-type human partial length AKT1 expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	95.0	CHEMBL4282	Homo sapiens	Activity	%	95.0
	18265737	CHEMBL4057172	Inhibition of AKT1 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	-1.7	CHEMBL4282	Homo sapiens	INH	%	-1.7
	18265953	CHEMBL4057403	Inhibition of AKT1 (unknown origin) at 0.49 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(NC(=O)C3CC3)noc2c1		CHEMBL4088455	=	Inhibition	%	2.3	CHEMBL4282	Homo sapiens	INH	%	2.3
	18266169	CHEMBL4057619	Inhibition of AKT1 (unknown origin) at 0.078 uM relative to control	B	COC(=O)Nc1noc2cc(-c3c(-c4ccccn4)n[nH]c3C)ccc12		CHEMBL4066592	=	Inhibition	%	-1.0	CHEMBL4282	Homo sapiens	INH	%	-1.0
	18282053	CHEMBL4120008	Inhibition of recombinant full length His-tagged human AKT1 expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@@H]1[C@H]2CN(C3COC3)C[C@H]21		CHEMBL3719135	=	Inhibition	%	1.7	CHEMBL4282	Homo sapiens	INH	%	1.7
	18282372	CHEMBL4120008	Inhibition of recombinant full length His-tagged human AKT1 expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	Nc1ncc(-c2cc([C@@H]3[C@H]4CN(C5COC5)C[C@H]43)n(CC3CC3)n2)cc1C(F)(F)F		CHEMBL3715238	=	Inhibition	%	-0.4	CHEMBL4282	Homo sapiens	INH	%	-0.4
	18282715	CHEMBL4120300	Inhibition of AKT1 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	-1.7	CHEMBL4282	Homo sapiens	INH	%	-1.7
	18282942	CHEMBL4120527	Inhibition of AKT1 (unknown origin) at 0.19 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2c1		CHEMBL4125807	=	Inhibition	%	1.7	CHEMBL4282	Homo sapiens	INH	%	1.7
	18283115	CHEMBL4120700	Inhibition of AKT1 (unknown origin) at 0.164 uM relative to control	B	COC(=O)Nc1cc(-c2c(C3CC3)n[nH]c2C)cc2[nH]ncc12		CHEMBL4129737	=	Inhibition	%	9.3	CHEMBL4282	Homo sapiens	INH	%	9.3
	18286283	CHEMBL4121518	Inhibition of recombinant full length His-tagged human AKT1 expressed in baculovirus expression system at 10 uM in presence of ATP relative to control	B	CC(C)(C)NS(=O)(=O)c1ccc(-c2sc(C(=O)N[C@H]3C[C@H](C(=O)O)C3)nc2CC2CCCCC2)c2ccccc12		CHEMBL4128926	=	Inhibition	%	-5.0	CHEMBL4282	Homo sapiens	INH	%	-5.0
	18288050	CHEMBL4121773	Inhibition of human recombinant AKT1 expressed in insect cells incubated for 60 mins measured at apparent ATP Km level by kinase ADP-FP assay	B	C[C@@H]1CC(=O)Nc2ncnc(N3CCC(c4nc(-c5ccc(F)c(C(F)(F)F)c5)cn4CCN4CCCC4)CC3)c21		CHEMBL4128457	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	uM	0.003
	18288051	CHEMBL4121773	Inhibition of human recombinant AKT1 expressed in insect cells incubated for 60 mins measured at apparent ATP Km level by kinase ADP-FP assay	B	C[C@@H]1CC(=O)Nc2ncnc(N3CCC(c4nc(C(F)(F)F)cn4CCN4CCCC4)CC3)c21		CHEMBL4129817	=	IC50	nM	11.0	CHEMBL4282	Homo sapiens	IC50	uM	0.011
	18288052	CHEMBL4121773	Inhibition of human recombinant AKT1 expressed in insect cells incubated for 60 mins measured at apparent ATP Km level by kinase ADP-FP assay	B	C[C@@H]1CC(=O)Nc2ncnc(N3CCC(c4nc(C5CCOCC5)cn4CCN4CCCC4)CC3)c21		CHEMBL4126067	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	uM	0.004
	18288053	CHEMBL4121773	Inhibition of human recombinant AKT1 expressed in insect cells incubated for 60 mins measured at apparent ATP Km level by kinase ADP-FP assay	B	C[C@@H]1CC(=O)Nc2ncnc(N3CCC(c4nc(CCC(F)(F)F)cn4CCN4CCCC4)CC3)c21		CHEMBL4129379	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	uM	0.005
	18288075	CHEMBL4121779	Inhibition of AKT1 in human U87MG cells assessed as reduction in GSK3beta Ser9 phosphorylation incubated for 1 hr by alpha screen Surefire assay	B	C[C@@H]1CC(=O)Nc2ncnc(N3CCC(c4nc(-c5ccc(F)c(C(F)(F)F)c5)cn4CCN4CCCC4)CC3)c21		CHEMBL4128457	=	IC50	nM	39.0	CHEMBL4282	Homo sapiens	IC50	uM	0.039
	18288076	CHEMBL4121779	Inhibition of AKT1 in human U87MG cells assessed as reduction in GSK3beta Ser9 phosphorylation incubated for 1 hr by alpha screen Surefire assay	B	C[C@@H]1CC(=O)Nc2ncnc(N3CCC(c4nc(C(F)(F)F)cn4CCN4CCCC4)CC3)c21		CHEMBL4129817	=	IC50	nM	2460.0	CHEMBL4282	Homo sapiens	IC50	uM	2.46
	18288077	CHEMBL4121779	Inhibition of AKT1 in human U87MG cells assessed as reduction in GSK3beta Ser9 phosphorylation incubated for 1 hr by alpha screen Surefire assay	B	C[C@@H]1CC(=O)Nc2ncnc(N3CCC(c4nc(C5CCOCC5)cn4CCN4CCCC4)CC3)c21		CHEMBL4126067	=	IC50	nM	230.0	CHEMBL4282	Homo sapiens	IC50	uM	0.23
	18288078	CHEMBL4121779	Inhibition of AKT1 in human U87MG cells assessed as reduction in GSK3beta Ser9 phosphorylation incubated for 1 hr by alpha screen Surefire assay	B	C[C@@H]1CC(=O)Nc2ncnc(N3CCC(c4nc(CCC(F)(F)F)cn4CCN4CCCC4)CC3)c21		CHEMBL4129379	=	IC50	nM	92.0	CHEMBL4282	Homo sapiens	IC50	uM	0.092
	18288964	CHEMBL4122040	Inhibition of AKT phosphorylation in human K562/VCR cells at 0.1 uM after 48 hrs by Western blot method relative to beta-actin	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](OC(=O)CN3C(=O)/C(=C5\Nc6ccccc6C5=O)c5ccccc53)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC		CHEMBL4125872	=	FC		0.43	CHEMBL4282	Homo sapiens	FC		0.43
	18288965	CHEMBL4122039	Inhibition of AKT phosphorylation in human K562/VCR cells at 0.05 uM after 48 hrs by Western blot method relative to beta-actin	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC		CHEMBL61	=	FC		0.33	CHEMBL4282	Homo sapiens	FC		0.33
	18288966	CHEMBL4122039	Inhibition of AKT phosphorylation in human K562/VCR cells at 0.05 uM after 48 hrs by Western blot method relative to beta-actin	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](OC(=O)CN3C(=O)/C(=C5\Nc6ccccc6C5=O)c5ccccc53)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC		CHEMBL4125872	=	FC		0.6	CHEMBL4282	Homo sapiens	FC		0.6
	18316975	CHEMBL4133296	Inhibition of AKT (unknown origin) assessed as residual activity at 10 uM relative to control	B	COc1ccc(Nc2nccc(-c3sc(SCCN4CCOCC4)nc3C)n2)c(OC)c1		CHEMBL4174540	>	Activity	%	40.0	CHEMBL4282	Homo sapiens	Activity	%	40.0
	18316976	CHEMBL4133296	Inhibition of AKT (unknown origin) assessed as residual activity at 10 uM relative to control	B	COc1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)c(OC)c1		CHEMBL4173067	>	Activity	%	40.0	CHEMBL4282	Homo sapiens	Activity	%	40.0
Active	18317434	CHEMBL4133399	Inhibition of Akt Ser473 phosphorylation in human HepG2 cells at 10 uM after 48 hrs by Western blot analysis	B	CCCCCCC#Cc1ccc(CO[C@H]2CN[C@H](C(=O)NCc3cc4ccccc4[nH]3)C2)cc1		CHEMBL4159290		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18317435	CHEMBL4133399	Inhibition of Akt Ser473 phosphorylation in human HepG2 cells at 10 uM after 48 hrs by Western blot analysis	B	CCC[C@@](N)(CO)CCc1ccc(OCCCCCC(C)C)cc1		CHEMBL4171193		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18317440	CHEMBL4133402	Inhibition of Akt Ser473 phosphorylation in human Hep3B cells at 10 uM after 48 hrs by Western blot analysis	B	CCCCCCC#Cc1ccc(CO[C@H]2CN[C@H](C(=O)NCc3cc4ccccc4[nH]3)C2)cc1		CHEMBL4159290		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18317441	CHEMBL4133402	Inhibition of Akt Ser473 phosphorylation in human Hep3B cells at 10 uM after 48 hrs by Western blot analysis	B	CCC[C@@](N)(CO)CCc1ccc(OCCCCCC(C)C)cc1		CHEMBL4171193		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18317516	CHEMBL4133414	Inhibition of Akt Thr408 phosphorylation in human HepG2 cells at 10 uM after 48 hrs by Western blot analysis	B	CCCCCCC#Cc1ccc(CO[C@H]2CN[C@H](C(=O)NCc3cc4ccccc4[nH]3)C2)cc1		CHEMBL4159290		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18317517	CHEMBL4133414	Inhibition of Akt Thr408 phosphorylation in human HepG2 cells at 10 uM after 48 hrs by Western blot analysis	B	CCC[C@@](N)(CO)CCc1ccc(OCCCCCC(C)C)cc1		CHEMBL4171193		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18317518	CHEMBL4133415	Inhibition of Akt Thr408 phosphorylation in human Hep3B cells at 10 uM after 48 hrs by Western blot analysis	B	CCCCCCC#Cc1ccc(CO[C@H]2CN[C@H](C(=O)NCc3cc4ccccc4[nH]3)C2)cc1		CHEMBL4159290		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18317519	CHEMBL4133415	Inhibition of Akt Thr408 phosphorylation in human Hep3B cells at 10 uM after 48 hrs by Western blot analysis	B	CCC[C@@](N)(CO)CCc1ccc(OCCCCCC(C)C)cc1		CHEMBL4171193		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18318395	CHEMBL4133622	Inhibition of AKT phosphorylation in human MDA-MB-231 cells at antiproliferative IC50 after 48 hrs by Western blot method	B	CCOC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1ccccc1		CHEMBL4163627		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18318396	CHEMBL4133622	Inhibition of AKT phosphorylation in human MDA-MB-231 cells at antiproliferative IC50 after 48 hrs by Western blot method	B	CCOC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1ccccc1F		CHEMBL4160193		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18318397	CHEMBL4133622	Inhibition of AKT phosphorylation in human MDA-MB-231 cells at antiproliferative IC50 after 48 hrs by Western blot method	B	CCOC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1ccc(OC)cc1		CHEMBL4169791		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18318398	CHEMBL4133622	Inhibition of AKT phosphorylation in human MDA-MB-231 cells at antiproliferative IC50 after 48 hrs by Western blot method	B	CCOC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1CC(C)C		CHEMBL4173126		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18318408	CHEMBL4133625	Inhibition of PH domain lacking AKT1 (unknown origin) using Tamara-labeled GRPRTSSFAEG peptide as substrate after 90 mins by fluorescence polarization IMAP assay	B	CCOC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1ccccc1		CHEMBL4163627	=	IC50	nM	4.7	CHEMBL4282	Homo sapiens	IC50	nM	4.7
	18318409	CHEMBL4133625	Inhibition of PH domain lacking AKT1 (unknown origin) using Tamara-labeled GRPRTSSFAEG peptide as substrate after 90 mins by fluorescence polarization IMAP assay	B	CCOC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1ccccc1F		CHEMBL4160193	=	IC50	nM	8.2	CHEMBL4282	Homo sapiens	IC50	nM	8.2
	18318410	CHEMBL4133625	Inhibition of PH domain lacking AKT1 (unknown origin) using Tamara-labeled GRPRTSSFAEG peptide as substrate after 90 mins by fluorescence polarization IMAP assay	B	CCOC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1ccc(F)cc1		CHEMBL4159491	=	IC50	nM	176.0	CHEMBL4282	Homo sapiens	IC50	nM	176.0
	18318411	CHEMBL4133625	Inhibition of PH domain lacking AKT1 (unknown origin) using Tamara-labeled GRPRTSSFAEG peptide as substrate after 90 mins by fluorescence polarization IMAP assay	B	CCOC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1ccc(OC)cc1		CHEMBL4169791	=	IC50	nM	1.72	CHEMBL4282	Homo sapiens	IC50	nM	1.72
	18318412	CHEMBL4133625	Inhibition of PH domain lacking AKT1 (unknown origin) using Tamara-labeled GRPRTSSFAEG peptide as substrate after 90 mins by fluorescence polarization IMAP assay	B	CCOC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1cccc(OC)c1		CHEMBL4163164	=	IC50	nM	251.0	CHEMBL4282	Homo sapiens	IC50	nM	251.0
	18318413	CHEMBL4133625	Inhibition of PH domain lacking AKT1 (unknown origin) using Tamara-labeled GRPRTSSFAEG peptide as substrate after 90 mins by fluorescence polarization IMAP assay	B	CCOC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1ccc(OC)c(OC)c1		CHEMBL4171390	=	IC50	nM	115.0	CHEMBL4282	Homo sapiens	IC50	nM	115.0
	18318414	CHEMBL4133625	Inhibition of PH domain lacking AKT1 (unknown origin) using Tamara-labeled GRPRTSSFAEG peptide as substrate after 90 mins by fluorescence polarization IMAP assay	B	CCOC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1ccc(C)cc1		CHEMBL4161273	=	IC50	nM	980.0	CHEMBL4282	Homo sapiens	IC50	nM	980.0
	18318415	CHEMBL4133625	Inhibition of PH domain lacking AKT1 (unknown origin) using Tamara-labeled GRPRTSSFAEG peptide as substrate after 90 mins by fluorescence polarization IMAP assay	B	CCOC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1CC(C)C		CHEMBL4173126	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
	18318416	CHEMBL4133625	Inhibition of PH domain lacking AKT1 (unknown origin) using Tamara-labeled GRPRTSSFAEG peptide as substrate after 90 mins by fluorescence polarization IMAP assay	B	COC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1ccccc1		CHEMBL4172716	=	IC50	nM	56.0	CHEMBL4282	Homo sapiens	IC50	nM	56.0
	18318417	CHEMBL4133625	Inhibition of PH domain lacking AKT1 (unknown origin) using Tamara-labeled GRPRTSSFAEG peptide as substrate after 90 mins by fluorescence polarization IMAP assay	B	COC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1ccccc1F		CHEMBL4164809	=	IC50	nM	432.0	CHEMBL4282	Homo sapiens	IC50	nM	432.0
	18318418	CHEMBL4133625	Inhibition of PH domain lacking AKT1 (unknown origin) using Tamara-labeled GRPRTSSFAEG peptide as substrate after 90 mins by fluorescence polarization IMAP assay	B	COC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1ccc(F)cc1		CHEMBL4169321	=	IC50	nM	313.0	CHEMBL4282	Homo sapiens	IC50	nM	313.0
	18318419	CHEMBL4133625	Inhibition of PH domain lacking AKT1 (unknown origin) using Tamara-labeled GRPRTSSFAEG peptide as substrate after 90 mins by fluorescence polarization IMAP assay	B	COC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1ccc(OC)cc1		CHEMBL4161394	=	IC50	nM	640.0	CHEMBL4282	Homo sapiens	IC50	nM	640.0
	18318420	CHEMBL4133625	Inhibition of PH domain lacking AKT1 (unknown origin) using Tamara-labeled GRPRTSSFAEG peptide as substrate after 90 mins by fluorescence polarization IMAP assay	B	COC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1cccc(OC)c1		CHEMBL4170874	=	IC50	nM	482.0	CHEMBL4282	Homo sapiens	IC50	nM	482.0
	18318421	CHEMBL4133625	Inhibition of PH domain lacking AKT1 (unknown origin) using Tamara-labeled GRPRTSSFAEG peptide as substrate after 90 mins by fluorescence polarization IMAP assay	B	COC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1ccc(OC)c(OC)c1		CHEMBL4160580	=	IC50	nM	311.0	CHEMBL4282	Homo sapiens	IC50	nM	311.0
	18318422	CHEMBL4133625	Inhibition of PH domain lacking AKT1 (unknown origin) using Tamara-labeled GRPRTSSFAEG peptide as substrate after 90 mins by fluorescence polarization IMAP assay	B	COC(=O)c1c(C)nc(NNC(=O)c2cccc3c(=O)c4ccccc4[nH]c23)nc1-c1ccc(C)cc1		CHEMBL4176130	=	IC50	nM	738.0	CHEMBL4282	Homo sapiens	IC50	nM	738.0
Active	18324959	CHEMBL4135147	Activation of AKT in palmitate-induced insulin-resistant human HepG2 cells assessed as increase in AKT phosphorylation at 12.5 uM incubated for 24 hrs by Western blot method	B	O=C(O)[C@H]1O[C@@H](Oc2cc3oc(-c4ccccc4)cc(=O)c3c(O)c2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O		CHEMBL4172944		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18324960	CHEMBL4135147	Activation of AKT in palmitate-induced insulin-resistant human HepG2 cells assessed as increase in AKT phosphorylation at 12.5 uM incubated for 24 hrs by Western blot method	B	O=c1cc(-c2ccccc2)oc2cc(O)c(O)c(O)c12		CHEMBL8260		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18324961	CHEMBL4135147	Activation of AKT in palmitate-induced insulin-resistant human HepG2 cells assessed as increase in AKT phosphorylation at 12.5 uM incubated for 24 hrs by Western blot method	B	O=C(O)[C@H]1O[C@@H](Oc2cc3oc(-c4ccccc4)cc(=O)c3c(O)c2O)[C@H](O)[C@@H](O)[C@@H]1O		CHEMBL485818		Activity			CHEMBL4282	Homo sapiens	Activity		
Tde	18324962	CHEMBL4135146	Activation of AKT in palmitate-induced insulin-resistant human HepG2 cells assessed as increase in AKT phosphorylation by Western blot method	B	O=C(O)[C@H]1O[C@@H](Oc2cc3oc(-c4ccccc4)cc(=O)c3c(O)c2O)[C@H](O)[C@@H](O)[C@@H]1O		CHEMBL485818		Activity			CHEMBL4282	Homo sapiens	Activity		
Dose-dependent effect	18324963	CHEMBL4135146	Activation of AKT in palmitate-induced insulin-resistant human HepG2 cells assessed as increase in AKT phosphorylation by Western blot method	B	O=C(O)[C@H]1O[C@@H](Oc2cc3oc(-c4ccccc4)cc(=O)c3c(O)c2O)[C@H](O)[C@@H](O)[C@@H]1O		CHEMBL485818		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18324992	CHEMBL4135154	Activation of AKT in palmitate-induced insulin-resistant human HepG2 cells assessed as reduction in PEPCK mRNA expression at 12.5 uM incubated for 24 hrs after 1 hr pre-incubation of cells with 10 uM AMPK inhibitor compound C by real-time PCR method	B	O=C(O)[C@H]1O[C@@H](Oc2cc3oc(-c4ccccc4)cc(=O)c3c(O)c2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O		CHEMBL4172944		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18324993	CHEMBL4135155	Activation of AKT in palmitate-induced insulin-resistant human HepG2 cells assessed as reduction in G6Pase mRNA expression at 12.5 uM incubated for 24 hrs after 1 hr pre-incubation of cells with 10 uM AMPK inhibitor compound C by real-time PCR method	B	O=C(O)[C@H]1O[C@@H](Oc2cc3oc(-c4ccccc4)cc(=O)c3c(O)c2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O		CHEMBL4172944		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18324994	CHEMBL4135156	Activation of AKT in palmitate-induced insulin-resistant human HepG2 cells assessed as reduction in GLUT2 mRNA expression at 12.5 uM incubated for 24 hrs after 1 hr pre-incubation of cells with 10 uM AMPK inhibitor compound C by real-time PCR method	B	O=C(O)[C@H]1O[C@@H](Oc2cc3oc(-c4ccccc4)cc(=O)c3c(O)c2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O		CHEMBL4172944		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	18324995	CHEMBL4135157	Activation of AKT in palmitate-induced insulin-resistant human HepG2 cells assessed as reduction in PEPCK mRNA expression at 12.5 uM incubated for 24 hrs after 1 hr pre-incubation of cells with 0.5 uM AKT inhibitor MK2202 by real-time PCR method	B	O=C(O)[C@H]1O[C@@H](Oc2cc3oc(-c4ccccc4)cc(=O)c3c(O)c2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O		CHEMBL4172944		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	18324996	CHEMBL4135158	Activation of AKT in palmitate-induced insulin-resistant human HepG2 cells assessed as reduction in G6Pase mRNA expression at 12.5 uM incubated for 24 hrs after 1 hr pre-incubation of cells with 0.5 uM AKT inhibitor MK2202 by real-time PCR method	B	O=C(O)[C@H]1O[C@@H](Oc2cc3oc(-c4ccccc4)cc(=O)c3c(O)c2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O		CHEMBL4172944		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18324997	CHEMBL4135159	Activation of AKT in palmitate-induced insulin-resistant human HepG2 cells assessed as reduction in GLUT2 mRNA expression at 12.5 uM incubated for 24 hrs after 1 hr pre-incubation of cells with 0.5 uM AKT inhibitor MK2202 by real-time PCR method	B	O=C(O)[C@H]1O[C@@H](Oc2cc3oc(-c4ccccc4)cc(=O)c3c(O)c2O)[C@H](O)[C@@H](O)[C@@H]1O		CHEMBL485818		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18324998	CHEMBL4135159	Activation of AKT in palmitate-induced insulin-resistant human HepG2 cells assessed as reduction in GLUT2 mRNA expression at 12.5 uM incubated for 24 hrs after 1 hr pre-incubation of cells with 0.5 uM AKT inhibitor MK2202 by real-time PCR method	B	O=c1cc(-c2ccccc2)oc2cc(O)c(O)c(O)c12		CHEMBL8260		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18324999	CHEMBL4135159	Activation of AKT in palmitate-induced insulin-resistant human HepG2 cells assessed as reduction in GLUT2 mRNA expression at 12.5 uM incubated for 24 hrs after 1 hr pre-incubation of cells with 0.5 uM AKT inhibitor MK2202 by real-time PCR method	B	O=C(O)[C@H]1O[C@@H](Oc2cc3oc(-c4ccccc4)cc(=O)c3c(O)c2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O		CHEMBL4172944		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18325000	CHEMBL4135159	Activation of AKT in palmitate-induced insulin-resistant human HepG2 cells assessed as reduction in GLUT2 mRNA expression at 12.5 uM incubated for 24 hrs after 1 hr pre-incubation of cells with 0.5 uM AKT inhibitor MK2202 by real-time PCR method	B	COc1c(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)cc2oc(-c3ccccc3)cc(=O)c2c1O		CHEMBL4171934		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18356335	CHEMBL4140709	Induction of Akt phosphorylation at Ser473 residues in H2O2 treated human TIG3 cells at 0.3 uM pretreated with H2O2 for 2 hrs followed by compound addition by immunoblot analysis	B	CC1=C(CO)C(=O)O[C@@H]([C@@H](C)[C@H]2CC[C@H]3[C@@H]4C[C@H]5O[C@]56[C@@H](O)C=CC(=O)[C@]6(C)[C@H]4CC[C@@]32C)C1		CHEMBL517080		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18356336	CHEMBL4140710	Induction of Akt phosphorylation at Ser473 residues in H2O2 treated human TIG3 cells at 0.6 uM pretreated with H2O2 for 2 hrs followed by compound addition by immunoblot analysis	B	CO[C@H]1CC(=O)[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@H]4[C@H](C)[C@H]4CC(C)=C(CO)C(=O)O4)[C@@H]3C[C@H]3O[C@]32[C@H]1O		CHEMBL1934583		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18356343	CHEMBL4140718	Induction of AKT-mediated beta-catenin expression level in H2O2 treated human TIG3 cells at 0.3 uM pretreated with H2O2 for 2 hrs followed by compound addition by immunoblot analysis	B	CC1=C(CO)C(=O)O[C@@H]([C@@H](C)[C@H]2CC[C@H]3[C@@H]4C[C@H]5O[C@]56[C@@H](O)C=CC(=O)[C@]6(C)[C@H]4CC[C@@]32C)C1		CHEMBL517080		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18356344	CHEMBL4140719	Induction of AKT-mediated beta-catenin expression level in H2O2 treated human TIG3 cells at 0.6 uM pretreated with H2O2 for 2 hrs followed by compound addition by immunoblot analysis	B	CO[C@H]1CC(=O)[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@H]4[C@H](C)[C@H]4CC(C)=C(CO)C(=O)O4)[C@@H]3C[C@H]3O[C@]32[C@H]1O		CHEMBL1934583		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18372775	CHEMBL4143800	Upregulation of AKT phosphorylation at Thr308 residue in human MCF7 cells at 2 uM after 24 to 48 hrs by Western blot method	B	COc1ccc2nc3cc(Cl)ccc3c(NCCCN3C(=O)CCSC3c3cccs3)c2c1		CHEMBL4166078		Activity			CHEMBL4282	Homo sapiens	Activity		
	18379897	CHEMBL4145799	Inhibition of AKT1 (unknown origin) at 10 uM relative to control	B	COc1cc(NC(=O)Nc2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(C)cc2OC)cc(OC)c1		CHEMBL4159506	=	Inhibition	%	6.13	CHEMBL4282	Homo sapiens	INH	%	6.13
	18379950	CHEMBL4145851	Inhibition of AKT1 (unknown origin)	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	3.8	CHEMBL4282	Homo sapiens	IC50	nM	3.8
Active	18384813	CHEMBL4146664	Induction of Akt phosphorylation in H2O2-treated human SH-SY5Y cells at 0.1 uM by ELISA	B	COc1ccccc1-c1cn2ccnnc2n1		CHEMBL4166461		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18384814	CHEMBL4146664	Induction of Akt phosphorylation in H2O2-treated human SH-SY5Y cells at 0.1 uM by ELISA	B	c1ccc(-c2cn3ccnnc3n2)cc1		CHEMBL4159983		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	18384815	CHEMBL4146664	Induction of Akt phosphorylation in H2O2-treated human SH-SY5Y cells at 0.1 uM by ELISA	B	COc1ccc(-c2nc3nnccn3c2-c2ccc([N+](=O)[O-])cc2)cc1		CHEMBL4164716		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18384816	CHEMBL4146664	Induction of Akt phosphorylation in H2O2-treated human SH-SY5Y cells at 0.1 uM by ELISA	B	COc1ccc(-c2nc3nnccn3c2-c2ccc(OC(F)(F)F)cc2)cc1		CHEMBL4171898		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18384817	CHEMBL4146664	Induction of Akt phosphorylation in H2O2-treated human SH-SY5Y cells at 0.1 uM by ELISA	B	COc1ccc(-c2nc3nnccn3c2-c2ccccc2)cc1		CHEMBL4161301		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18384818	CHEMBL4146664	Induction of Akt phosphorylation in H2O2-treated human SH-SY5Y cells at 0.1 uM by ELISA	B	COc1ccc(-c2nc3nnccn3c2-c2ccc(C)c([N+](=O)[O-])c2)cc1		CHEMBL4176408		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18384819	CHEMBL4146664	Induction of Akt phosphorylation in H2O2-treated human SH-SY5Y cells at 0.1 uM by ELISA	B	COc1ccc(-c2nc3nnccn3c2-c2cccs2)cc1		CHEMBL4163128		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18384820	CHEMBL4146665	Induction of Akt phosphorylation in H2O2-treated human SH-SY5Y cells assessed as increase in pBad levels at 0.1 uM by ELISA	B	COc1ccccc1-c1cn2ccnnc2n1		CHEMBL4166461		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18384821	CHEMBL4146665	Induction of Akt phosphorylation in H2O2-treated human SH-SY5Y cells assessed as increase in pBad levels at 0.1 uM by ELISA	B	c1ccc(-c2cn3ccnnc3n2)cc1		CHEMBL4159983		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	18384822	CHEMBL4146665	Induction of Akt phosphorylation in H2O2-treated human SH-SY5Y cells assessed as increase in pBad levels at 0.1 uM by ELISA	B	COc1ccc(-c2nc3nnccn3c2-c2ccc([N+](=O)[O-])cc2)cc1		CHEMBL4164716		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18384823	CHEMBL4146665	Induction of Akt phosphorylation in H2O2-treated human SH-SY5Y cells assessed as increase in pBad levels at 0.1 uM by ELISA	B	COc1ccc(-c2nc3nnccn3c2-c2ccc(OC(F)(F)F)cc2)cc1		CHEMBL4171898		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18384824	CHEMBL4146665	Induction of Akt phosphorylation in H2O2-treated human SH-SY5Y cells assessed as increase in pBad levels at 0.1 uM by ELISA	B	COc1ccc(-c2nc3nnccn3c2-c2ccccc2)cc1		CHEMBL4161301		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18384825	CHEMBL4146665	Induction of Akt phosphorylation in H2O2-treated human SH-SY5Y cells assessed as increase in pBad levels at 0.1 uM by ELISA	B	COc1ccc(-c2nc3nnccn3c2-c2ccc(C)c([N+](=O)[O-])c2)cc1		CHEMBL4176408		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	18384826	CHEMBL4146665	Induction of Akt phosphorylation in H2O2-treated human SH-SY5Y cells assessed as increase in pBad levels at 0.1 uM by ELISA	B	COc1ccc(-c2nc3nnccn3c2-c2cccs2)cc1		CHEMBL4163128		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18384827	CHEMBL4146666	Induction of Akt phosphorylation in H2O2-treated human SH-SY5Y cells at 1 uM by ELISA	B	COc1ccc(-c2nc3nnccn3c2-c2ccc(C)cc2)cc1		CHEMBL4168157		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18384828	CHEMBL4146667	Induction of Akt phosphorylation in H2O2-treated human SH-SY5Y cells assessed as increase in pBad levels at 1 uM by ELISA	B	COc1ccc(-c2nc3nnccn3c2-c2ccc(C)cc2)cc1		CHEMBL4168157		Activity			CHEMBL4282	Homo sapiens	Activity		
	18402519	CHEMBL4150391	Inhibition of AKT1 (unknown origin) using FAM-labeled peptide as substrate by mobility shift assay	B	COc1ncc(-c2cc(OC3CCOCC3)c3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL4166144	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	18402608	CHEMBL4150391	Inhibition of AKT1 (unknown origin) using FAM-labeled peptide as substrate by mobility shift assay	B	COc1ncc(-c2cc(O[C@@H]3CCOC3)c3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL4176771	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	18402701	CHEMBL4150391	Inhibition of AKT1 (unknown origin) using FAM-labeled peptide as substrate by mobility shift assay	B	CNc1nc(C)c2cc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cc(OC3CCOCC3)c2n1		CHEMBL4166594	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	18402782	CHEMBL4150391	Inhibition of AKT1 (unknown origin) using FAM-labeled peptide as substrate by mobility shift assay	B	CNc1nc(C)c2cc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cc(O[C@@H]3CCOC3)c2n1		CHEMBL4174909	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	18420975	CHEMBL4153930	Inhibition of DNA-tagged AKT1 (unknown origin) expressed in HEK293 cells at 10 uM after 1 hr by real-time fluorescent quantitative PCR analysis	B	Fc1ccc(Nc2nc(N3CCOCC3)c3nc[nH]c3n2)cc1		CHEMBL4175978	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	18431045	CHEMBL4155726	Inhibition of recombinant full length His-tagged human AKT1 expressed in baculovirus expression system at 1 uM by Z'-Lyte assay relative to control	B	O=C1Nc2ccc(C(=O)N[C@H](CO)c3ccccc3)cc2/C1=C(\c1ccccc1)c1ncc[nH]1		CHEMBL4160587	=	Inhibition	%	16.0	CHEMBL4282	Homo sapiens	INH	%	16.0
	18434104	CHEMBL4156087	Inhibition of recombinant human full length His-tagged AKT1 expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	OC[C@@H](Nc1ncnc2sc(-c3ccc(O)cc3)cc12)c1ccccc1		CHEMBL4177361	=	Inhibition	%	-1.0	CHEMBL4282	Homo sapiens	INH	%	-1.0
	18434240	CHEMBL4156087	Inhibition of recombinant human full length His-tagged AKT1 expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	CCC(=O)Nc1ccc(-c2c[nH]c3ncnc(N[C@H](C)c4ccccc4)c23)cc1		CHEMBL4167749	=	Inhibition	%	-4.0	CHEMBL4282	Homo sapiens	INH	%	-4.0
	18434300	CHEMBL4156087	Inhibition of recombinant human full length His-tagged AKT1 expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	CN(C)CCn1cc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL4159505	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	18434372	CHEMBL4156087	Inhibition of recombinant human full length His-tagged AKT1 expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	OCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1		CHEMBL4175024	=	Inhibition	%	-4.0	CHEMBL4282	Homo sapiens	INH	%	-4.0
	18436521	CHEMBL4156333	Inhibition of Akt in human A549 cells after 24 hrs by ELISA	B	O=C(CSc1nnc(COc2ccc3c(c2)CCCC3)o1)Nc1nc2ccc(F)cc2s1		CHEMBL4170467	=	IC50	nM	98330.0	CHEMBL4282	Homo sapiens	IC50	uM	98.33
	18436522	CHEMBL4156333	Inhibition of Akt in human A549 cells after 24 hrs by ELISA	B	COc1ccc2nc(NC(=O)CSc3nnc(COc4ccc5c(c4)CCCC5)o3)sc2c1		CHEMBL4163608	=	IC50	nM	27500.0	CHEMBL4282	Homo sapiens	IC50	uM	27.5
	18436523	CHEMBL4156333	Inhibition of Akt in human A549 cells after 24 hrs by ELISA	B	O=C(CSc1nnc(COc2ccc3c(c2)CCCC3)o1)Nc1ncc([N+](=O)[O-])s1	Outside typical range	CHEMBL4168160	=	IC50	nM	138330.0	CHEMBL4282	Homo sapiens	IC50	uM	138.33
	18436524	CHEMBL4156333	Inhibition of Akt in human A549 cells after 24 hrs by ELISA	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	IC50	nM	17330.0	CHEMBL4282	Homo sapiens	IC50	uM	17.33
	18440072	CHEMBL4156896	Binding affinity to wild-type human partial length AKT1 expressed in bacterial expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	77.0	CHEMBL4282	Homo sapiens	Activity	%	77.0
	18443320	CHEMBL4157941	Inhibition of human PKBa assessed as enzyme residual activity at 100 nM by radiometric filter binding assay relative to control	B	NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc1ncc(-c2ccc(C(=O)O)cc2)s1)C(=O)O		CHEMBL4177303	=	Activity	%	105.0	CHEMBL4282	Homo sapiens	Activity	%	105.0
	18449496	CHEMBL4177939	Inhibition of AKT1 (unknown origin) at 1 uM	B	CCOC(=O)C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccc(F)cc1Br		CHEMBL3742114	=	Inhibition	%	-3.0	CHEMBL4282	Homo sapiens	INH	%	-3.0
	18449840	CHEMBL4178079	Inhibition of human PKBalpha S473D mutant (118 to 480 residues) assessed as residual activity at 500 nM in presence of 33P-ATP by filter binding assay relative to control	B	Cc1cccc(-c2nc(N)sc2-c2ccc3ncccc3n2)c1		CHEMBL4209540	=	Activity	%	115.0	CHEMBL4282	Homo sapiens	Activity	%	115.0
	18450279	CHEMBL4178299	Inhibition of recombinant human full length N-terminal GST-tagged AKT1 expressed in baculovirus infected Sf9 cells assessed as change in enzyme activity at 1 uM in presence of 2 uM ATP relative to control	B	CCN1CCN(Cc2ccc(-c3cc4c(-c5cccc(N6CCOc7cc(C8CC8)cc(F)c7C6=O)c5CO)ccnc4[nH]3)nc2)CC1		CHEMBL3967108	=	Activity	%	-15.0	CHEMBL4282	Homo sapiens	Activity	%	-15.0
	18450329	CHEMBL4178299	Inhibition of recombinant human full length N-terminal GST-tagged AKT1 expressed in baculovirus infected Sf9 cells assessed as change in enzyme activity at 1 uM in presence of 2 uM ATP relative to control	B	O=C1c2c(F)cc(C3CC3)cc2OCCN1c1cccc(-c2ccnc3[nH]c(C4=CCN(C5COC5)CC4)cc23)c1CO		CHEMBL3966346	=	Activity	%	-3.0	CHEMBL4282	Homo sapiens	Activity	%	-3.0
Active	18461754	CHEMBL4180748	Inhibition of 6-OHDA induced AKT phosphorylation in human SH-SY5Y cells at 2.5 to 10 uM pretreated for 1 hr followed by 6-OHDA addition after 1 hr by Western blot analysis	B	COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1		CHEMBL243664		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18462189	CHEMBL4180876	Inhibition of recombinant human full length His6-tagged PKBa (118 to 480 residues) S473D mutant expressed in Sf21 insect cells assessed as residual activity at 1 uM after 30 mins in presence of [gamma-33P]ATP relative to control	B	CC(C)=CCC/C(C)=C/Cn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@H]3CC[C@H](N)CC3)nc21		CHEMBL4203120	=	Activity	%	83.0	CHEMBL4282	Homo sapiens	Activity	%	83.0
	18463782	CHEMBL4181198	Inhibition of recombinant human N-terminal His6-tagged PKBalpha (118 to end residue) S473D mutant expressed in baculovirus Sf21 insect cells at 10 uM by filter binding radioactive ATP transferase assay relative to control	B	C=C(C)n1c(=O)n(C(C)=O)c2cc(Br)cnc21		CHEMBL4212680	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	18470571	CHEMBL4182565	Inhibition of human AKT1 at 10 uM by ADP-Glo kinase assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Inhibition	%	61.0	CHEMBL4282	Homo sapiens	INH	%	61.0
	18470733	CHEMBL4182565	Inhibition of human AKT1 at 10 uM by ADP-Glo kinase assay	B	Cc1nc(N)c2ccn(C3CCN(C(=O)c4ccc(S(=O)(=O)F)cc4)CC3)c2n1		CHEMBL4206295	=	Inhibition	%	24.0	CHEMBL4282	Homo sapiens	INH	%	24.0
	18470734	CHEMBL4182565	Inhibition of human AKT1 at 10 uM by ADP-Glo kinase assay	B	Nc1ncnc2c1ccn2C1CCN(C(=O)c2ccc(S(=O)(=O)F)cc2)CC1		CHEMBL4218073	=	Inhibition	%	20.0	CHEMBL4282	Homo sapiens	INH	%	20.0
	18484512	CHEMBL4185675	Binding affinity to wild-type human partial length AKT1 expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	99.0	CHEMBL4282	Homo sapiens	Activity	%	99.0
	18485109	CHEMBL4185675	Binding affinity to wild-type human partial length AKT1 expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
Dose-dependent effect	18485972	CHEMBL4186273	Inhibition of BDNF-induced AKT phosphorylation in human SKOV3 cells after 24 hrs by Western blot analysis	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	18485973	CHEMBL4186273	Inhibition of BDNF-induced AKT phosphorylation in human SKOV3 cells after 24 hrs by Western blot analysis	B	Oc1cc(O)c2cc(O)c(-c3cc(O)c(O)c(O)c3)[o+]c2c1.[Cl-]		CHEMBL590878		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18486016	CHEMBL4186288	Inhibition of p110alpha[E545K]-IRS1 interaction-initiated Akt phosphorylation at Ser473 residue in DLD1 human colon cancer cells at 50 uM by Western blot analysis	B	CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(C)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@]1(C)CCCCCCC=CCCC[C@@](C)(C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC1=O)[C@@H](C)O		CHEMBL4208853		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18486017	CHEMBL4186288	Inhibition of p110alpha[E545K]-IRS1 interaction-initiated Akt phosphorylation at Ser473 residue in DLD1 human colon cancer cells at 50 uM by Western blot analysis	B	CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(C)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@]1(C)CCCCCCC=CCCC[C@@](C)(C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC1=O)[C@@H](C)O		CHEMBL4208853		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18486018	CHEMBL4186288	Inhibition of p110alpha[E545K]-IRS1 interaction-initiated Akt phosphorylation at Ser473 residue in DLD1 human colon cancer cells at 50 uM by Western blot analysis	B	CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CS)C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccccc2)NC1=O)[C@@H](C)O		CHEMBL4211732		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18489486	CHEMBL4187227	Inhibition of wild-type human partial length AKT1 expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	Fc1cc(F)cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)c1		CHEMBL4207079	=	Activity	%	92.0	CHEMBL4282	Homo sapiens	Activity	%	92.0
	18499142	CHEMBL4188932	Inhibition of AKT phosphorylation in HUVEC at 3.125 uM after 24 hrs by Western blot analysis relative to control	B	CC(C)(O)c1ccc2c(c1)[C@H](O)C[C@@H]1[C@]2(C)CCC[C@@]1(C)C(=O)O		CHEMBL452778	=	FC		1.1	CHEMBL4282	Homo sapiens	FC		1.1
	18499143	CHEMBL4188933	Inhibition of AKT phosphorylation in HUVEC at 6.25 uM after 24 hrs by Western blot analysis relative to control	B	CC(C)(O)c1ccc2c(c1)[C@H](O)C[C@@H]1[C@]2(C)CCC[C@@]1(C)C(=O)O		CHEMBL452778	=	FC		0.68	CHEMBL4282	Homo sapiens	FC		0.68
	18499534	CHEMBL4188970	Inhibition of AKT (unknown origin) using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP	B	CNc1ncc2c(-c3ccc(N4CCN(C(=O)C(C)(C)C)CC4)nc3)nn(CC3CCCC3)c2n1		CHEMBL4204515	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	18499535	CHEMBL4188970	Inhibition of AKT (unknown origin) using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP	B	CCN1CCN(c2ccc(-c3nn(CC4CCCC4)c4nc(NC)ncc34)cn2)CC1		CHEMBL4213775	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	18499536	CHEMBL4188970	Inhibition of AKT (unknown origin) using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP	B	CNc1ncc2c(-c3ccc(N4CCN(C)CC4)nc3)nn(CC3CCCC3)c2n1		CHEMBL4208852	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	18499537	CHEMBL4188970	Inhibition of AKT (unknown origin) using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP	B	CNc1ncc2c(-c3ccc(N4CCN(C)CC4)cc3)nn(CC3CCCC3)c2n1		CHEMBL4218175	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	18499538	CHEMBL4188970	Inhibition of AKT (unknown origin) using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP	B	Nc1nc(Nc2ccc3c(c2)CC[C@@H](N2CCCC2)CC3)nn1-c1cc2c(nn1)-c1ccccc1CCC2		CHEMBL3809489	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	18499539	CHEMBL4188970	Inhibition of AKT (unknown origin) using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP	B	CNc1ncc2c(-c3ccc(N4CCN(C(=O)C(C)(C)C)CC4)nc3)nn(Cc3cn(Cc4ccccc4)nn3)c2n1		CHEMBL4207004	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	18499540	CHEMBL4188970	Inhibition of AKT (unknown origin) using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP	B	CCN1CCN(c2ccc(-c3nn(Cc4cn(Cc5ccccc5)nn4)c4nc(NC)ncc34)cn2)CC1		CHEMBL4217649	=	IC50	nM	1900.0	CHEMBL4282	Homo sapiens	IC50	uM	1.9
	18499541	CHEMBL4188970	Inhibition of AKT (unknown origin) using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP	B	CNc1ncc2c(-c3ccc(N4CCN(C)CC4)nc3)nn(Cc3cn(Cc4ccccc4)nn3)c2n1		CHEMBL4218369	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	18499542	CHEMBL4188970	Inhibition of AKT (unknown origin) using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP	B	CNc1ncc2c(-c3ccc(N4CCNCC4)cc3)nn(Cc3cn(Cc4ccccc4)nn3)c2n1		CHEMBL4211308	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	18499543	CHEMBL4188970	Inhibition of AKT (unknown origin) using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP	B	CNc1ncc2c(-c3ccc(N4CCNCC4)nc3)nn(Cc3cn(-c4ccsc4C(=O)OC)nn3)c2n1		CHEMBL4205191	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	18499544	CHEMBL4188970	Inhibition of AKT (unknown origin) using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP	B	CNc1ncc2c(-c3ccc(N4CCNCC4)nc3)nn(Cc3cn(Cc4ccccc4)nn3)c2n1		CHEMBL4210084	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	18499545	CHEMBL4188970	Inhibition of AKT (unknown origin) using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP	B	CNc1ncc2c(-c3ccc(OC)cc3)nn(CC3OCCO3)c2n1		CHEMBL4209569	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	18499546	CHEMBL4188970	Inhibition of AKT (unknown origin) using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP	B	CNc1ncc2c(-c3ccc(N4CCNCC4)nc3)nn(CC3OCCO3)c2n1		CHEMBL4214476	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	18499547	CHEMBL4188970	Inhibition of AKT (unknown origin) using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP	B	CNc1ncc2c(-c3ccc(N4CCNCC4)nc3)nn(CC3CCCC3)c2n1		CHEMBL4213003	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	18507657	CHEMBL4191134	Inhibition of recombinant full-length human PKBalpha at 1 uM using GRPRTSSFAEGKK as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	-1.0	CHEMBL4282	Homo sapiens	INH	%	-1.0
	18514149	CHEMBL4192490	Inhibition of AKT1 (unknown origin) using biotinylated-STK as substrate after 45 mins by HTRF assay	B	O=C(Cc1ccc(Cl)cc1)N1CCN(c2ncnc3[nH]cc(Br)c23)CC1		CHEMBL4214539	=	IC50	nM	18.0	CHEMBL4282	Homo sapiens	IC50	nM	18.0
	18514150	CHEMBL4192490	Inhibition of AKT1 (unknown origin) using biotinylated-STK as substrate after 45 mins by HTRF assay	B	CC(C)(C)c1ccc(C2(C(=O)N3CCN(c4ncnc5[nH]ccc45)CC3)CCNCC2)cc1		CHEMBL4208194	>	IC50	nM	40.0	CHEMBL4282	Homo sapiens	IC50	nM	40.0
	18514151	CHEMBL4192490	Inhibition of AKT1 (unknown origin) using biotinylated-STK as substrate after 45 mins by HTRF assay	B	COc1ccc(C2(C(=O)N3CCN(c4ncnc5[nH]ccc45)CC3)CCNCC2)cc1		CHEMBL4217489	=	IC50	nM	35.6	CHEMBL4282	Homo sapiens	IC50	nM	35.6
	18514152	CHEMBL4192490	Inhibition of AKT1 (unknown origin) using biotinylated-STK as substrate after 45 mins by HTRF assay	B	O=C(N1CCN(c2ncnc3[nH]ccc23)CC1)C1(c2ccc(Cl)cc2)CCNCC1		CHEMBL4212569	=	IC50	nM	26.5	CHEMBL4282	Homo sapiens	IC50	nM	26.5
	18514153	CHEMBL4192490	Inhibition of AKT1 (unknown origin) using biotinylated-STK as substrate after 45 mins by HTRF assay	B	O=C(N1CCN(c2ncnc3[nH]ccc23)CC1)C1(c2ccc(Br)cc2)CCNCC1		CHEMBL4211584	=	IC50	nM	27.1	CHEMBL4282	Homo sapiens	IC50	nM	27.1
	18514154	CHEMBL4192490	Inhibition of AKT1 (unknown origin) using biotinylated-STK as substrate after 45 mins by HTRF assay	B	O=C(N1CCN(c2ncnc3[nH]ccc23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4206698	>	IC50	nM	40.0	CHEMBL4282	Homo sapiens	IC50	nM	40.0
	18514155	CHEMBL4192490	Inhibition of AKT1 (unknown origin) using biotinylated-STK as substrate after 45 mins by HTRF assay	B	O=C(N1CCN(c2ncnc3[nH]cc(Cl)c23)CC1)C1(c2cccc(Br)c2)CCNCC1		CHEMBL4217723	=	IC50	nM	5.6	CHEMBL4282	Homo sapiens	IC50	nM	5.6
	18514156	CHEMBL4192490	Inhibition of AKT1 (unknown origin) using biotinylated-STK as substrate after 45 mins by HTRF assay	B	O=C(N1CCN(c2ncnc3[nH]cc(Cl)c23)CC1)C1(c2ccc(Cl)cc2)CCNCC1		CHEMBL4204854	=	IC50	nM	1.9	CHEMBL4282	Homo sapiens	IC50	nM	1.9
	18514157	CHEMBL4192490	Inhibition of AKT1 (unknown origin) using biotinylated-STK as substrate after 45 mins by HTRF assay	B	O=C(N1CCN(c2ncnc3[nH]cc(Cl)c23)CC1)C1(c2ccc(Br)cc2)CCNCC1		CHEMBL4202879	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
	18514158	CHEMBL4192490	Inhibition of AKT1 (unknown origin) using biotinylated-STK as substrate after 45 mins by HTRF assay	B	O=C(N1CCN(c2ncnc3[nH]cc(Cl)c23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4213657	=	IC50	nM	2.9	CHEMBL4282	Homo sapiens	IC50	nM	2.9
	18514159	CHEMBL4192490	Inhibition of AKT1 (unknown origin) using biotinylated-STK as substrate after 45 mins by HTRF assay	B	O=C(N1CCN(c2ncnc3[nH]cc(Br)c23)CC1)C1(c2ccccc2)CCNCC1		CHEMBL4217841	=	IC50	nM	20.3	CHEMBL4282	Homo sapiens	IC50	nM	20.3
	18514160	CHEMBL4192490	Inhibition of AKT1 (unknown origin) using biotinylated-STK as substrate after 45 mins by HTRF assay	B	O=C(N1CCN(c2ncnc3[nH]cc(Br)c23)CC1)C1(c2cccc(Br)c2)CCNCC1		CHEMBL4212000	=	IC50	nM	7.6	CHEMBL4282	Homo sapiens	IC50	nM	7.6
	18514161	CHEMBL4192490	Inhibition of AKT1 (unknown origin) using biotinylated-STK as substrate after 45 mins by HTRF assay	B	COc1ccc(C2(C(=O)N3CCN(c4ncnc5[nH]cc(Br)c45)CC3)CCNCC2)cc1		CHEMBL4216977	=	IC50	nM	14.1	CHEMBL4282	Homo sapiens	IC50	nM	14.1
	18514162	CHEMBL4192490	Inhibition of AKT1 (unknown origin) using biotinylated-STK as substrate after 45 mins by HTRF assay	B	O=C(N1CCN(c2ncnc3[nH]cc(Br)c23)CC1)C1(c2ccc(Cl)cc2)CCNCC1		CHEMBL4207231	=	IC50	nM	1.5	CHEMBL4282	Homo sapiens	IC50	nM	1.5
	18514163	CHEMBL4192490	Inhibition of AKT1 (unknown origin) using biotinylated-STK as substrate after 45 mins by HTRF assay	B	O=C(N1CCN(c2ncnc3[nH]cc(Br)c23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4207643	=	IC50	nM	4.3	CHEMBL4282	Homo sapiens	IC50	nM	4.3
	18514164	CHEMBL4192490	Inhibition of AKT1 (unknown origin) using biotinylated-STK as substrate after 45 mins by HTRF assay	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	IC50	nM	1.7	CHEMBL4282	Homo sapiens	IC50	nM	1.7
Active	18514216	CHEMBL4192523	Inhibition of AKT in human JeKo1 cells assessed as induction of AKT phosphorylation at Ser473 up to 5 uM after 24 hrs by Western blot analysis	B	O=C(N1CCN(c2ncnc3[nH]cc(Cl)c23)CC1)C1(c2ccc(Br)cc2)CCNCC1		CHEMBL4202879		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18514217	CHEMBL4192524	Inhibition of AKT in human JeKo1 cells assessed as induction of AKT phosphorylation at Thr308 up to 5 uM after 24 hrs by Western blot analysis	B	O=C(N1CCN(c2ncnc3[nH]cc(Cl)c23)CC1)C1(c2ccc(Br)cc2)CCNCC1		CHEMBL4202879		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	18514218	CHEMBL4192525	Inhibition of AKT in human JeKo1 cells assessed as down-regulation of GSK3beta phosphorylation at Ser9 after 24 hrs by Western blot analysis	B	O=C(N1CCN(c2ncnc3[nH]cc(Cl)c23)CC1)C1(c2ccc(Br)cc2)CCNCC1		CHEMBL4202879		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18514219	CHEMBL4192526	Inhibition of AKT in human JeKo1 cells assessed as down-regulation of S6 phosphorylation after 24 hrs by Western blot analysis	B	O=C(N1CCN(c2ncnc3[nH]cc(Cl)c23)CC1)C1(c2ccc(Br)cc2)CCNCC1		CHEMBL4202879		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	18554881	CHEMBL4200172	Inhibition of AKT phosphorylation at Ser473 in human PANC1 cells in nutrient deprived medium by Western blot analysis	B	CC(C)=CCC/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12		CHEMBL1078442		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Tde	18554882	CHEMBL4200172	Inhibition of AKT phosphorylation at Ser473 in human PANC1 cells in nutrient deprived medium by Western blot analysis	B	CC(C)=CCC/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12		CHEMBL1078442		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18577637	CHEMBL4222222	Inhibition of recombinant human full length His-tagged AKT1 expressed in baculovirus expression system at 1 uM using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay relative to control	B	C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cc3OC)n2)c1		CHEMBL4225781	=	Inhibition	%	0.2	CHEMBL4282	Homo sapiens	INH	%	0.2
	18577661	CHEMBL4222222	Inhibition of recombinant human full length His-tagged AKT1 expressed in baculovirus expression system at 1 uM using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay relative to control	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	=	Inhibition	%	1.9	CHEMBL4282	Homo sapiens	INH	%	1.9
	18577685	CHEMBL4222222	Inhibition of recombinant human full length His-tagged AKT1 expressed in baculovirus expression system at 1 uM using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay relative to control	B	C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3699588	=	Inhibition	%	5.3	CHEMBL4282	Homo sapiens	INH	%	5.3
	18578782	CHEMBL4222453	Inhibition of AKT1 (unknown origin)	B	CCN(CCO)Cc1cc(Nc2nc(C)cn3c(-c4cn[nH]c4)cnc23)sn1		CHEMBL4228240	>	IC50	nM	500.0	CHEMBL4282	Homo sapiens	IC50	nM	500.0
	18578783	CHEMBL4222453	Inhibition of AKT1 (unknown origin)	B	Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(Cc3ccccn3)ns2)n1		CHEMBL4227082	>	IC50	nM	500.0	CHEMBL4282	Homo sapiens	IC50	nM	500.0
	18578784	CHEMBL4222453	Inhibition of AKT1 (unknown origin)	B	Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(C(NC(C)(C)C)c3ccccn3)ns2)n1		CHEMBL4225923	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	uM	1.0
Active	18584152	CHEMBL4223162	Inhibition of AKT1 phosphorylation in human PC3 cells at 14 uM after 12 to 24 hrs by Western blot analysis	B	CSc1c(C(=O)c2ccc(Br)cc2)c(N)c2ccccc2c1C#N		CHEMBL4225101		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18653779	CHEMBL4230014	Inhibition of AKT1 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	-1.0	CHEMBL4282	Homo sapiens	INH	%	-1.0
	18653780	CHEMBL4230014	Inhibition of AKT1 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	18655645	CHEMBL4230575	Binding affinity to wild-type human partial length AKT1 expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	95.0	CHEMBL4282	Homo sapiens	Activity	%	95.0
	18656498	CHEMBL4231206	Inhibition of recombinant human AKT1 expressed in insect cells using CREBtide as substrate after 60 mins by LANCE method	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	56.0	CHEMBL4282	Homo sapiens	IC50	10'-8M	5.6
	18663903	CHEMBL4232865	Inhibition of human AKT1 expressed in bacterial expression system assessed as residual activity at 5 uM by KINOMEscan assay relative to control	B	CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12		CHEMBL4247704	=	Activity	%	98.0	CHEMBL4282	Homo sapiens	Activity	%	98.0
	18663978	CHEMBL4232962	Binding affinity to human AKT1 expressed in bacterial expression system by KINOMEscan assay	B	CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12		CHEMBL4247704	>=	Kd	nM	5000.0	CHEMBL4282	Homo sapiens	Kd	uM	5.0
	18665496	CHEMBL4233284	Inhibition of AKT1 (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4251324	>	IC50	nM	5000.0	CHEMBL4282	Homo sapiens	IC50	nM	5000.0
	18665568	CHEMBL4233284	Inhibition of AKT1 (unknown origin)	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	18674526	CHEMBL4235309	Inhibition of Akt1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4249925	>	Ki	nM	10000.0	CHEMBL4282	Homo sapiens	Ki	nM	10000.0
	18674527	CHEMBL4235309	Inhibition of Akt1 (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4245242	>	Ki	nM	10000.0	CHEMBL4282	Homo sapiens	Ki	nM	10000.0
	18674528	CHEMBL4235309	Inhibition of Akt1 (unknown origin)	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1		CHEMBL4248525	>	Ki	nM	10000.0	CHEMBL4282	Homo sapiens	Ki	nM	10000.0
Active	18697174	CHEMBL4254186	Inhibition of Akt phosphorylation in human HepG2 cells at 0.5 to 2 uM after 48 hrs by Western blot analysis	B	Cc1ccc(-c2nc(NCc3ccc(C(=O)NO)cc3)cc3c2[nH]c2ccccc23)cc1		CHEMBL4288953		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18697176	CHEMBL4254188	Inhibition of Akt phosphorylation in human HepG2 cells at 2 uM after 48 hrs by Western blot analysis	B	O=C(CCCCCCC(=O)Nc1ccccc1)NO		CHEMBL98		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18697607	CHEMBL4254280	Inhibition of wild-type human partial length AKT1 expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCNc1cc(-c2ccc(NC(=O)Nc3cccc(Cl)c3)cc2C(F)(F)F)ccn1		CHEMBL4281348	=	Activity	%	90.0	CHEMBL4282	Homo sapiens	Activity	%	90.0
	18702507	CHEMBL4255100	Inhibition of recombinant full length human His-tagged AKT1 expressed in baculovirus expression system at 1 uM relative to control	B	COc1ccc(S(N)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4278211	=	Inhibition	%	8.0	CHEMBL4282	Homo sapiens	INH	%	8.0
	18702532	CHEMBL4255100	Inhibition of recombinant full length human His-tagged AKT1 expressed in baculovirus expression system at 1 uM relative to control	B	COc1ccc(C(N)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4282644	=	Inhibition	%	-10.0	CHEMBL4282	Homo sapiens	INH	%	-10.0
	18702576	CHEMBL4255100	Inhibition of recombinant full length human His-tagged AKT1 expressed in baculovirus expression system at 1 uM relative to control	B	COc1ccc(S(C)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4287097	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	18702628	CHEMBL4255100	Inhibition of recombinant full length human His-tagged AKT1 expressed in baculovirus expression system at 1 uM relative to control	B	COc1cc(C)c(S(N)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4283739	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
	18702672	CHEMBL4255100	Inhibition of recombinant full length human His-tagged AKT1 expressed in baculovirus expression system at 1 uM relative to control	B	COc1cc(C)c(C(N)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4294318	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	18702715	CHEMBL4255100	Inhibition of recombinant full length human His-tagged AKT1 expressed in baculovirus expression system at 1 uM relative to control	B	COc1cc(C)c(S(C)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4289040	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	18706763	CHEMBL4256123	Inhibition of AKT1 (unknown origin) at 50 ug/ml by mobility shift assay relative to control	B	CC(C)c1ccc2c(c1)CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(=O)O		CHEMBL12850	=	Inhibition	%	53.6	CHEMBL4282	Homo sapiens	INH	%	53.6
	18706779	CHEMBL4256136	Inhibition of AKT1 (unknown origin) by mobility shift assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	12.0	CHEMBL4282	Homo sapiens	IC50	nM	12.0
	18708949	CHEMBL4256669	Inhibition of AKT1 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	Nc1ccc[nH]c1=O		CHEMBL4286709	=	Inhibition	%	42.0	CHEMBL4282	Homo sapiens	INH	%	42.0
	18708993	CHEMBL4256669	Inhibition of AKT1 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	Cn1cc(-c2c[nH]c(=O)c(N)c2)cn1		CHEMBL4288628	=	Inhibition	%	97.0	CHEMBL4282	Homo sapiens	INH	%	97.0
	18709007	CHEMBL4256669	Inhibition of AKT1 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	Nc1cc(-c2ccncc2)c[nH]c1=O		CHEMBL12856	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	INH	%	12.0
	18709039	CHEMBL4256669	Inhibition of AKT1 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	COc1ncc(-c2ccncc2)cc1N		CHEMBL4291350	=	Inhibition	%	22.0	CHEMBL4282	Homo sapiens	INH	%	22.0
	18709068	CHEMBL4256669	Inhibition of AKT1 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	Nc1cc(-c2ccnc3ccccc23)c[nH]c1=O		CHEMBL4280308	=	Inhibition	%	15.0	CHEMBL4282	Homo sapiens	INH	%	15.0
	18709097	CHEMBL4256669	Inhibition of AKT1 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	CNc1nccc(-c2c[nH]c(=O)c(N)c2)n1		CHEMBL4292538	=	Inhibition	%	89.0	CHEMBL4282	Homo sapiens	INH	%	89.0
	18709126	CHEMBL4256669	Inhibition of AKT1 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	Nc1cc(-c2ccnc(NC3CC3)n2)c[nH]c1=O		CHEMBL4282263	=	Inhibition	%	18.0	CHEMBL4282	Homo sapiens	INH	%	18.0
	18709173	CHEMBL4256669	Inhibition of AKT1 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	Cc1nc(O)c(N)cc1-c1ccncc1		CHEMBL302219	=	Inhibition	%	10.0	CHEMBL4282	Homo sapiens	INH	%	10.0
	18709203	CHEMBL4256695	Inhibition of AKT1 (unknown origin) at 30 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	O=C(Nc1cc(-c2ccncc2)c[nH]c1=O)c1ccccc1		CHEMBL1738828	=	Inhibition	%	12.0	CHEMBL4282	Homo sapiens	INH	%	12.0
	18709232	CHEMBL4256669	Inhibition of AKT1 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	COc1cccc(C(=O)Nc2cc(-c3ccncc3)c[nH]c2=O)c1		CHEMBL4285109	=	Inhibition	%	24.0	CHEMBL4282	Homo sapiens	INH	%	24.0
	18709274	CHEMBL4256695	Inhibition of AKT1 (unknown origin) at 30 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	CN1CCN(c2ccc(C(=O)Nc3cc(-c4ccncc4)c[nH]c3=O)cc2)CC1		CHEMBL4286130	=	Inhibition	%	13.0	CHEMBL4282	Homo sapiens	INH	%	13.0
	18709307	CHEMBL4256695	Inhibition of AKT1 (unknown origin) at 30 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control	B	O=C(Nc1cc(-c2ccnc(NC3CC3)n2)c[nH]c1=O)c1ccccc1		CHEMBL4291472	=	Inhibition	%	73.0	CHEMBL4282	Homo sapiens	INH	%	73.0
Not Active	18713237	CHEMBL4257021	Binding affinity to His-tagged AKT1 PH domain (unknown origin) by SPR spectroscopy	B	COc1c(/C=C/C(=O)O)cc(NS(=O)(=O)c2cccs2)c2c1OCO2		CHEMBL4280751		Kd			CHEMBL4282	Homo sapiens	Kd		
	18713238	CHEMBL4257021	Binding affinity to His-tagged AKT1 PH domain (unknown origin) by SPR spectroscopy	B	CCOC(=O)CCc1cc(NS(=O)(=O)c2cccs2)c2c(c1OC)OCO2	Outside typical range	CHEMBL4280394	>	Kd	nM	500000.0	CHEMBL4282	Homo sapiens	Kd	uM	500.0
	18713239	CHEMBL4257021	Binding affinity to His-tagged AKT1 PH domain (unknown origin) by SPR spectroscopy	B	CCOC(=O)/C=C/c1cc(NS(=O)(=O)c2cccs2)c2c(c1OC)OCO2	Outside typical range	CHEMBL4279325	>	Kd	nM	500000.0	CHEMBL4282	Homo sapiens	Kd	uM	500.0
	18713240	CHEMBL4257021	Binding affinity to His-tagged AKT1 PH domain (unknown origin) by SPR spectroscopy	B	CCOC(=O)/C=C/c1cc(NS(=O)(=O)c2cccs2)c2c(c1O)OCO2		CHEMBL4293794	=	Kd	nM	75200.0	CHEMBL4282	Homo sapiens	Kd	uM	75.2
Not Determined	18713241	CHEMBL4257021	Binding affinity to His-tagged AKT1 PH domain (unknown origin) by SPR spectroscopy	B	O=C(O)/C=C/c1cc(NS(=O)(=O)c2cccs2)c2c(c1O)OCO2		CHEMBL4283567		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	18713242	CHEMBL4257021	Binding affinity to His-tagged AKT1 PH domain (unknown origin) by SPR spectroscopy	B	O=C(O)CCc1cc(NS(=O)(=O)c2cccs2)c2c(c1O)OCO2		CHEMBL4287230		Kd			CHEMBL4282	Homo sapiens	Kd		
	18728807	CHEMBL4259693	Inhibition of AKT1 (unknown origin) using biotin-labelled STK as substrate measured after 45 mins by HTRF method	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(Cl)cc2)CCNCC1		CHEMBL4284420	=	IC50	nM	66.6	CHEMBL4282	Homo sapiens	IC50	nM	66.6
	18728808	CHEMBL4259693	Inhibition of AKT1 (unknown origin) using biotin-labelled STK as substrate measured after 45 mins by HTRF method	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(Br)cc2)CCNCC1		CHEMBL4282775	=	IC50	nM	32.9	CHEMBL4282	Homo sapiens	IC50	nM	32.9
	18728809	CHEMBL4259693	Inhibition of AKT1 (unknown origin) using biotin-labelled STK as substrate measured after 45 mins by HTRF method	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4285143	=	IC50	nM	24.3	CHEMBL4282	Homo sapiens	IC50	nM	24.3
	18728810	CHEMBL4259693	Inhibition of AKT1 (unknown origin) using biotin-labelled STK as substrate measured after 45 mins by HTRF method	B	O=C(N1CCN(c2ncnc3[nH]nc(Br)c23)CC1)C1(c2ccc(Cl)cc2)CCNCC1		CHEMBL4281435	=	IC50	nM	26.9	CHEMBL4282	Homo sapiens	IC50	nM	26.9
	18728811	CHEMBL4259693	Inhibition of AKT1 (unknown origin) using biotin-labelled STK as substrate measured after 45 mins by HTRF method	B	O=C(N1CCN(c2ncnc3[nH]nc(Br)c23)CC1)C1(c2ccc(Br)cc2)CCNCC1		CHEMBL4292059	=	IC50	nM	51.9	CHEMBL4282	Homo sapiens	IC50	nM	51.9
	18728812	CHEMBL4259693	Inhibition of AKT1 (unknown origin) using biotin-labelled STK as substrate measured after 45 mins by HTRF method	B	O=C(N1CCN(c2ncnc3[nH]nc(Br)c23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4284849	=	IC50	nM	30.5	CHEMBL4282	Homo sapiens	IC50	nM	30.5
	18728813	CHEMBL4259693	Inhibition of AKT1 (unknown origin) using biotin-labelled STK as substrate measured after 45 mins by HTRF method	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	IC50	nM	21.3	CHEMBL4282	Homo sapiens	IC50	nM	21.3
	18728814	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]ncc23)CC1)C1(c2ccc(F)cc2)CCNCC1		CHEMBL4279320	=	Inhibition	%	7.4	CHEMBL4282	Homo sapiens	INH	%	7.4
	18728815	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]ncc23)CC1)C1(c2ccc(Cl)cc2)CCNCC1		CHEMBL4286037	=	Inhibition	%	38.7	CHEMBL4282	Homo sapiens	INH	%	38.7
	18728816	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]ncc23)CC1)C1(c2ccc(Br)cc2)CCNCC1		CHEMBL4290887	=	Inhibition	%	11.6	CHEMBL4282	Homo sapiens	INH	%	11.6
	18728817	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]ncc23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4278247	=	Inhibition	%	52.1	CHEMBL4282	Homo sapiens	INH	%	52.1
	18728818	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(F)cc2)CCNCC1		CHEMBL4278081	=	Inhibition	%	86.7	CHEMBL4282	Homo sapiens	INH	%	86.7
	18728819	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(Cl)cc2)CCNCC1		CHEMBL4284420	=	Inhibition	%	91.9	CHEMBL4282	Homo sapiens	INH	%	91.9
	18728820	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(Br)cc2)CCNCC1		CHEMBL4282775	=	Inhibition	%	95.4	CHEMBL4282	Homo sapiens	INH	%	95.4
	18728821	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4285143	=	Inhibition	%	94.3	CHEMBL4282	Homo sapiens	INH	%	94.3
	18728822	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Br)c23)CC1)C1(c2ccc(F)cc2)CCNCC1		CHEMBL4292972	=	Inhibition	%	93.2	CHEMBL4282	Homo sapiens	INH	%	93.2
	18728823	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Br)c23)CC1)C1(c2ccc(Cl)cc2)CCNCC1		CHEMBL4281435	=	Inhibition	%	96.7	CHEMBL4282	Homo sapiens	INH	%	96.7
	18728824	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Br)c23)CC1)C1(c2ccc(Br)cc2)CCNCC1		CHEMBL4292059	=	Inhibition	%	96.5	CHEMBL4282	Homo sapiens	INH	%	96.5
	18728825	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Br)c23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4284849	=	Inhibition	%	93.8	CHEMBL4282	Homo sapiens	INH	%	93.8
	18728826	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]cnc23)CC1)C1(c2ccc(F)cc2)CCNCC1		CHEMBL4276919	=	Inhibition	%	94.2	CHEMBL4282	Homo sapiens	INH	%	94.2
	18728827	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]cnc23)CC1)C1(c2ccc(Cl)cc2)CCNCC1		CHEMBL4288244	=	Inhibition	%	45.6	CHEMBL4282	Homo sapiens	INH	%	45.6
	18728828	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]cnc23)CC1)C1(c2ccc(Br)cc2)CCNCC1		CHEMBL4280343	=	Inhibition	%	68.0	CHEMBL4282	Homo sapiens	INH	%	68.0
	18728829	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]cnc23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4291663	=	Inhibition	%	51.4	CHEMBL4282	Homo sapiens	INH	%	51.4
	18728830	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3ccccc23)CC1)C1(c2ccc(F)cc2)CCNCC1		CHEMBL4283804	=	Inhibition	%	23.0	CHEMBL4282	Homo sapiens	INH	%	23.0
	18728831	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3ccccc23)CC1)C1(c2ccc(Cl)cc2)CCNCC1		CHEMBL4295080	=	Inhibition	%	34.2	CHEMBL4282	Homo sapiens	INH	%	34.2
	18728832	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3ccccc23)CC1)C1(c2ccc(Br)cc2)CCNCC1		CHEMBL4287157	=	Inhibition	%	6.1	CHEMBL4282	Homo sapiens	INH	%	6.1
	18728833	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3ccccc23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4277316	=	Inhibition	%	21.9	CHEMBL4282	Homo sapiens	INH	%	21.9
	18728834	CHEMBL4259695	Inhibition of AKT1 (unknown origin) at 1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Inhibition	%	99.5	CHEMBL4282	Homo sapiens	INH	%	99.5
	18728835	CHEMBL4259694	Inhibition of AKT1 (unknown origin) at 0.1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(F)cc2)CCNCC1		CHEMBL4278081	=	Inhibition	%	60.9	CHEMBL4282	Homo sapiens	INH	%	60.9
	18728836	CHEMBL4259694	Inhibition of AKT1 (unknown origin) at 0.1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(Cl)cc2)CCNCC1		CHEMBL4284420	=	Inhibition	%	83.4	CHEMBL4282	Homo sapiens	INH	%	83.4
	18728837	CHEMBL4259694	Inhibition of AKT1 (unknown origin) at 0.1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(Br)cc2)CCNCC1		CHEMBL4282775	=	Inhibition	%	84.5	CHEMBL4282	Homo sapiens	INH	%	84.5
	18728838	CHEMBL4259694	Inhibition of AKT1 (unknown origin) at 0.1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4285143	=	Inhibition	%	83.7	CHEMBL4282	Homo sapiens	INH	%	83.7
	18728839	CHEMBL4259694	Inhibition of AKT1 (unknown origin) at 0.1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Br)c23)CC1)C1(c2ccc(F)cc2)CCNCC1		CHEMBL4292972	=	Inhibition	%	53.3	CHEMBL4282	Homo sapiens	INH	%	53.3
	18728840	CHEMBL4259694	Inhibition of AKT1 (unknown origin) at 0.1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Br)c23)CC1)C1(c2ccc(Cl)cc2)CCNCC1		CHEMBL4281435	=	Inhibition	%	86.7	CHEMBL4282	Homo sapiens	INH	%	86.7
	18728841	CHEMBL4259694	Inhibition of AKT1 (unknown origin) at 0.1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Br)c23)CC1)C1(c2ccc(Br)cc2)CCNCC1		CHEMBL4292059	=	Inhibition	%	90.6	CHEMBL4282	Homo sapiens	INH	%	90.6
	18728842	CHEMBL4259694	Inhibition of AKT1 (unknown origin) at 0.1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Br)c23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4284849	=	Inhibition	%	90.9	CHEMBL4282	Homo sapiens	INH	%	90.9
	18728843	CHEMBL4259694	Inhibition of AKT1 (unknown origin) at 0.1 uM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	=	Inhibition	%	98.5	CHEMBL4282	Homo sapiens	INH	%	98.5
	18728882	CHEMBL4259712	Inhibition of AKT1 (unknown origin) at 10 nM after 40 mins by scintillation counting method relative to control	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4285143	=	Inhibition	%	82.0	CHEMBL4282	Homo sapiens	INH	%	82.0
Active	18728887	CHEMBL4259717	Inhibition of AKT phosphorylation in human PC3 cells at 1 to 10 uM after 4 hrs by Western blot analysis	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4285143		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18728888	CHEMBL4259718	Activation of AKT phosphorylation in human PC3 cells at 1 to 10 uM after 4 hrs by Western blot analysis	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	18728889	CHEMBL4259719	Inhibition of AKT in human PC3 cells assessed as reduction in GSK3beta phosphorylation at 1 to 10 uM after 4 hrs by Western blot analysis	B	O=C(N1CCN(c2ncnc3[nH]nc(Cl)c23)CC1)C1(c2ccc(Cl)c(Cl)c2)CCNCC1		CHEMBL4285143		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18728890	CHEMBL4259719	Inhibition of AKT in human PC3 cells assessed as reduction in GSK3beta phosphorylation at 1 to 10 uM after 4 hrs by Western blot analysis	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18728919	CHEMBL4259735	Inhibition of AKT1 (unknown origin) at 50 nM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(Cc1ccc(Cl)cc1)N1CCN(c2ncnc3[nH]cc(Br)c23)CC1		CHEMBL4214539	=	Inhibition	%	69.7	CHEMBL4282	Homo sapiens	INH	%	69.7
	18728920	CHEMBL4259735	Inhibition of AKT1 (unknown origin) at 50 nM using biotin-labelled STK as substrate measured after 45 mins by HTRF method relative to control	B	O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(c2ncnc3[nH]cc(Br)c23)CC1		CHEMBL4280704	=	Inhibition	%	65.5	CHEMBL4282	Homo sapiens	INH	%	65.5
Not Active	18746191	CHEMBL4262988	Inhibition of AKT phosphorylation in human PC3 cells at 2.5 to 3.5 uM after 24 hrs by Western blot method	B	COc1cc(/C=C/C(C)=O)ccc1O		CHEMBL106509		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18746193	CHEMBL4262986	Inhibition of AKT phosphorylation in human PC3 cells at 2.5 to 4.5 uM after 24 hrs by Western blot method	B	COc1cc(/C=C/C(C)=O)ccc1OCc1cn(-c2c(Cl)cccc2Cl)nn1		CHEMBL4281462		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18751079	CHEMBL4263726	Inhibition of AKT1 (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	18752050	CHEMBL4264164	Binding affinity to wild-type human partial length AKT1 expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	92.0	CHEMBL4282	Homo sapiens	Activity	%	92.0
	18761564	CHEMBL4266615	Inhibition of recombinant human N-terminal His6-tagged full length PKBalpha expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CN(C)[C@H]1CC[C@H](Nc2ncnc3[nH]cc([C@H]4CC[C@H](C(N)=O)CC4)c23)CC1		CHEMBL4279192	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	18761835	CHEMBL4266615	Inhibition of recombinant human N-terminal His6-tagged full length PKBalpha expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C(C)C)c34)CC2)CC1		CHEMBL4278882	=	Inhibition	%	-3.0	CHEMBL4282	Homo sapiens	INH	%	-3.0
	18761998	CHEMBL4266615	Inhibition of recombinant human N-terminal His6-tagged full length PKBalpha expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C5CCOCC5)c34)CC2)CC1		CHEMBL4290222	=	Inhibition	%	-4.0	CHEMBL4282	Homo sapiens	INH	%	-4.0
Active	18762680	CHEMBL4266783	Inhibition of AKT phosphorylation at Ser473 in human WBras1 cells at 1.25 uM after 24 hrs by Western blot analysis	B	CCCCCCCCCCCCSC1=NCCCN1		CHEMBL4282288		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18762681	CHEMBL4266784	Inhibition of AKT phosphorylation at Ser473 in human WBras1 cells at 2.5 uM after 24 hrs by Western blot analysis	B	CCCCCCCCCCCCSC(=NC)NC		CHEMBL4284829		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18762682	CHEMBL4266785	Inhibition of AKT phosphorylation at Ser473 in human WBras1 cells at 25 uM after 24 hrs by Western blot analysis	B	C=CCCCCCCCCC1OCCN1CC		CHEMBL4276900		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18762683	CHEMBL4266786	Inhibition of AKT phosphorylation at Ser473 in human WBras1 cells at 1.25 uM after 4 hrs by Western blot analysis	B	CCCCCCCCCCCCSC1=NCCCN1		CHEMBL4282288		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18762684	CHEMBL4266787	Inhibition of AKT phosphorylation at Ser473 in human WBras1 cells at 2.5 uM after 4 hrs by Western blot analysis	B	CCCCCCCCCCCCSC(=NC)NC		CHEMBL4284829		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18762685	CHEMBL4266788	Inhibition of AKT phosphorylation at Ser473 in human WBras1 cells at 25 uM after 4 hrs by Western blot analysis	B	C=CCCCCCCCCC1OCCN1CC		CHEMBL4276900		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18762686	CHEMBL4266789	Inhibition of AKT phosphorylation at Ser473 in human NCI-H2009 cells at 1.25 uM after 24 to 48 hrs by Western blot analysis	B	CCCCCCCCCCCCSC1=NCCCN1		CHEMBL4282288		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	18762687	CHEMBL4266790	Inhibition of AKT phosphorylation at Ser473 in human NCI-H2009 cells at 2.5 uM after 24 to 48 hrs by Western blot analysis	B	CCCCCCCCCCCCSC(=NC)NC		CHEMBL4284829		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	18762688	CHEMBL4266791	Inhibition of AKT phosphorylation at Ser473 in human NCI-H2009 cells at 25 uM after 24 hrs by Western blot analysis	B	C=CCCCCCCCCC1OCCN1CC		CHEMBL4276900		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18762689	CHEMBL4266792	Inhibition of AKT phosphorylation at Ser473 in human NCI-H2009 cells at 2.5 uM after 1 to 4 hrs by Western blot analysis	B	CCCCCCCCCCCCSC1=NCCCN1		CHEMBL4282288		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	18762690	CHEMBL4266793	Inhibition of AKT phosphorylation at Ser473 in human NCI-H2009 cells up to 10 uM after 4 hrs by Western blot analysis	B	CCCCCCCCCCCCSC(=NC)NC		CHEMBL4284829		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18763119	CHEMBL4266916	Inhibition of AKT1 (unknown origin) at 10 uM	B	CNC(=O)Nc1sc2c(C(C)C)cc(NS(=O)(=O)c3cccs3)cc2c1C(N)=O		CHEMBL4288081	=	Inhibition	%	13.63	CHEMBL4282	Homo sapiens	INH	%	13.63
	18764409	CHEMBL4267055	Inhibition of human PKBalpha at 100 nM	B	CN1CCC(c2nc(-c3ccc(F)cc3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1		CHEMBL4288103	<	Inhibition	%	70.0	CHEMBL4282	Homo sapiens	INH	%	70.0
	18764410	CHEMBL4267055	Inhibition of human PKBalpha at 100 nM	B	CN1CCC(c2nc(-c3cccc(S(C)(=O)=O)c3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1		CHEMBL4286880	<	Inhibition	%	70.0	CHEMBL4282	Homo sapiens	INH	%	70.0
	18764411	CHEMBL4267055	Inhibition of human PKBalpha at 100 nM	B	CN1CCC(c2nc(-c3ccc(F)c(NS(C)(=O)=O)c3)c(-c3ccnc(NCC4CC4)n3)s2)CC1		CHEMBL4286841	<	Inhibition	%	70.0	CHEMBL4282	Homo sapiens	INH	%	70.0
	18764769	CHEMBL4267180	Inhibition of Akt phosphorylation in HUVEC at 3.125 uM after 24 hrs by Western blot analysis relative to control	B	COc1ccc(-c2cc(=O)c3c(O)c(OC)c(O)cc3o2)cc1OC		CHEMBL312750	=	FC		0.82	CHEMBL4282	Homo sapiens	FC		0.82
	18764770	CHEMBL4267181	Inhibition of Akt phosphorylation in HUVEC at 6.25 uM after 24 hrs by Western blot analysis relative to control	B	COc1ccc(-c2cc(=O)c3c(O)c(OC)c(O)cc3o2)cc1OC		CHEMBL312750	=	FC		0.8	CHEMBL4282	Homo sapiens	FC		0.8
	18765573	CHEMBL4267274	Inhibition of recombinant human N-terminal His-tagged full length human AKT1 (1 to 480 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using FAM-labeled peptide as substrate after 10 mins by mobility shift assay relative to control	B	COc1cccc(Nc2cc(Nc3cc(OC)ccc3OC)ncn2)c1		CHEMBL4288300	=	Inhibition	%	-2.1	CHEMBL4282	Homo sapiens	INH	%	-2.1
	18765574	CHEMBL4267274	Inhibition of recombinant human N-terminal His-tagged full length human AKT1 (1 to 480 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using FAM-labeled peptide as substrate after 10 mins by mobility shift assay relative to control	B	COc1ccc(Nc2cc(NC(=O)c3ccccc3)ncn2)cc1		CHEMBL4283823	=	Inhibition	%	-3.4	CHEMBL4282	Homo sapiens	INH	%	-3.4
	18765575	CHEMBL4267274	Inhibition of recombinant human N-terminal His-tagged full length human AKT1 (1 to 480 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using FAM-labeled peptide as substrate after 10 mins by mobility shift assay relative to control	B	O=C(O)CCCC(=O)Nc1cc(Nc2cccc(Cl)c2)ncn1		CHEMBL4282460	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	18765576	CHEMBL4267274	Inhibition of recombinant human N-terminal His-tagged full length human AKT1 (1 to 480 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using FAM-labeled peptide as substrate after 10 mins by mobility shift assay relative to control	B	CCOC(=O)c1ccc(Nc2cc(NC(=O)CCCC(=O)O)ncn2)cc1		CHEMBL4290750	=	Inhibition	%	4.7	CHEMBL4282	Homo sapiens	INH	%	4.7
	18765577	CHEMBL4267274	Inhibition of recombinant human N-terminal His-tagged full length human AKT1 (1 to 480 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using FAM-labeled peptide as substrate after 10 mins by mobility shift assay relative to control	B	COc1cccc(Nc2cc(NC(=O)CCCC(=O)O)ncn2)c1		CHEMBL4294156	=	Inhibition	%	6.8	CHEMBL4282	Homo sapiens	INH	%	6.8
	18765578	CHEMBL4267274	Inhibition of recombinant human N-terminal His-tagged full length human AKT1 (1 to 480 residues) expressed in baculovirus infected Sf9 insect cells at 1 uM using FAM-labeled peptide as substrate after 10 mins by mobility shift assay relative to control	B	O=C(O)CCCC(=O)Nc1cc(N2CCOCC2)ncn1		CHEMBL4283970	=	Inhibition	%	-3.0	CHEMBL4282	Homo sapiens	INH	%	-3.0
Dose-dependent effect	18771350	CHEMBL4268453	Inhibition of AKT phosphorylation in human HeLa cells after 24 hrs by Western blot analysis	B	C[C@]12CC[C@H](O[C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](c3ccc(=O)oc3)[C@@H](O)C[C@]12O		CHEMBL4287932		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	18774498	CHEMBL4268857	Inhibition of AKT phosphorylation in human NCI-H1975 cells at 10 uM after 24 hrs by Western blot analysis	A	CCc1ccc(C(=O)C(Cl)Cl)cc1[N+](=O)[O-]		CHEMBL4288385		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	18774499	CHEMBL4268857	Inhibition of AKT phosphorylation in human NCI-H1975 cells at 10 uM after 24 hrs by Western blot analysis	A	CC(C)c1ccc(C(=O)C(Cl)Cl)cc1[N+](=O)[O-]		CHEMBL4282023		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	18774500	CHEMBL4268857	Inhibition of AKT phosphorylation in human NCI-H1975 cells at 10 uM after 24 hrs by Western blot analysis	A	CC(C)Oc1ccc(C(=O)C(Cl)Cl)cc1[N+](=O)[O-]		CHEMBL4278654		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18774501	CHEMBL4268857	Inhibition of AKT phosphorylation in human NCI-H1975 cells at 10 uM after 24 hrs by Western blot analysis	A	O=C(c1ccccc1)C(Cl)Cl		CHEMBL3560171		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18782855	CHEMBL4270721	Inhibition of PKBalpha (unknown origin) assessed as residual enzyme activity at 1 uM relative to untreated control	B	Cc1cccc(-c2nn3c(c2-c2ccc(O)cc2)C(C)C(C)(C)C3)n1		CHEMBL4277021	>	Activity	%	80.0	CHEMBL4282	Homo sapiens	Activity	%	80.0
	18786944	CHEMBL4271859	Inhibition of AKT (unknown origin) at 30 uM relative to control	B	O=c1cc(-c2ccc(-c3ccccc3)cc2)c2ccc(N3CCC(NCCc4ccccc4)CC3)cc2o1		CHEMBL4276817	=	Inhibition	%	9.87	CHEMBL4282	Homo sapiens	INH	%	9.87
Active	18787177	CHEMBL4271949	Inhibition of AKT signaling pathway (unknown origin)	A	O=C(c1ccc(-c2ccc(O)cc2)cc1)C(Cl)Cl		CHEMBL4291759		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18787184	CHEMBL4271956	Inhibition of AKT phosphorylation in human NCI-H1650 cells at 2 uM after 12 hrs by Western blot analysis	A	O=C(c1ccc(-c2ccc(O)cc2)cc1)C(Cl)Cl		CHEMBL4291759		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18787195	CHEMBL4271956	Inhibition of AKT phosphorylation in human NCI-H1650 cells at 2 uM after 12 hrs by Western blot analysis	A	O=C(c1ccc(-c2ccc(O)c([N+](=O)[O-])c2)cc1)C(Cl)Cl		CHEMBL4289177		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18787315	CHEMBL4271956	Inhibition of AKT phosphorylation in human NCI-H1650 cells at 2 uM after 12 hrs by Western blot analysis	A	O=C(c1ccccc1)C(Cl)Cl		CHEMBL3560171		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	18788873	CHEMBL4272373	Inhibition of Akt phosphorylation in human HL60 cells after 24 to 48 hrs by Western blot analysis	B	Fc1cccc(CNc2nc(Oc3c(F)c(F)c(F)c(F)c3F)nc(N3CCC(N4CCCCC4)CC3)n2)c1		CHEMBL4289020		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18788912	CHEMBL4272345	Inhibition of Akt phosphorylation in human MM162 cells at 0.1 to 10 uM after 24 hrs by Western blot analysis	B	Fc1cccc(CNc2nc(Oc3c(F)c(F)c(F)c(F)c3F)nc(N3CCC(N4CCCCC4)CC3)n2)c1		CHEMBL4289020		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18788919	CHEMBL4272338	Inhibition of Akt phosphorylation in human MM043 cells at 0.1 to 10 uM after 24 hrs by Western blot analysis	B	Fc1cccc(CNc2nc(Oc3c(F)c(F)c(F)c(F)c3F)nc(N3CCC(N4CCCCC4)CC3)n2)c1		CHEMBL4289020		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18788922	CHEMBL4272335	Inhibition of Akt phosphorylation in human HBL cells at 0.1 to 10 uM after 24 to 48 hrs by Western blot analysis	B	CN(C)CCNc1nc(Oc2c(F)c(F)c(F)c(F)c2F)nc(N2CCCc3ccccc3C2)n1		CHEMBL4290771		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18788923	CHEMBL4272335	Inhibition of Akt phosphorylation in human HBL cells at 0.1 to 10 uM after 24 to 48 hrs by Western blot analysis	B	Fc1cccc(CNc2nc(Oc3c(F)c(F)c(F)c(F)c3F)nc(N3CCC(N4CCCCC4)CC3)n2)c1		CHEMBL4289020		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	18789022	CHEMBL4272373	Inhibition of Akt phosphorylation in human HL60 cells after 24 to 48 hrs by Western blot analysis	B	CN(C)CCNc1nc(Oc2c(F)c(F)c(F)c(F)c2F)nc(N2CCCc3ccccc3C2)n1		CHEMBL4290771		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18789024	CHEMBL4272375	Inhibition of Akt phosphorylation in human HBL cells at 1 to 10 uM after 24 hrs by Western blot analysis	B	NCCOCCOCCNc1nc(NCc2cccc(F)c2)nc(Oc2c(F)c(F)c(F)c(F)c2F)n1		CHEMBL4293894		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	18847346	CHEMBL4304874	Inhibition of wild-type human partial length AKT1 expressed in bacterial expression system at 1 uM by Kinomescan method	B	O=C(Nc1ccc2[nH]nc(-c3ccc4[nH]ccc4c3)c2c1)c1c(Cl)cccc1Cl		CHEMBL4517719		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18851342	CHEMBL4305834	Inhibition of AKT1 (unknown origin)	B	Cc1nc2c(F)cc(-c3nc(Nc4ccc5c(n4)CCN(CCN(C)C)C5)ncc3F)cc2n1C(C)C		CHEMBL4448494	>	IC50	nM	30000.0	CHEMBL4282	Homo sapiens	IC50	nM	30000.0
	18854034	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	Cl.Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)s1		CHEMBL4438248	=	IC50	nM	10.2	CHEMBL4282	Homo sapiens	IC50	nM	10.2
	18854035	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	Cl.Cn1ncc(Cl)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)s1		CHEMBL4454791	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
	18854036	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	Cl.Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)s1		CHEMBL4445702	=	IC50	nM	10.6	CHEMBL4282	Homo sapiens	IC50	nM	10.6
	18854037	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	Cl.Cn1ncc(Cl)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)s1		CHEMBL4435124	=	IC50	nM	1.0	CHEMBL4282	Homo sapiens	IC50	nM	1.0
	18854038	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	Cl.Cn1ncc(Br)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)s1		CHEMBL4444441	=	IC50	nM	5.46	CHEMBL4282	Homo sapiens	IC50	nM	5.46
	18854039	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	Cl.Cn1ncc(Cl)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)c(C(F)(F)F)c2)s1		CHEMBL4460688	=	IC50	nM	65.2	CHEMBL4282	Homo sapiens	IC50	nM	65.2
	18854040	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	Cc1cnn(C)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)s1.Cl		CHEMBL4579551	=	IC50	nM	9.0	CHEMBL4282	Homo sapiens	IC50	nM	9.0
	18854041	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	C=Cc1cnn(C)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)s1.Cl		CHEMBL4467970	=	IC50	nM	46.9	CHEMBL4282	Homo sapiens	IC50	nM	46.9
	18854042	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	CCc1cnn(C)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)s1.Cl		CHEMBL4554198	=	IC50	nM	48.9	CHEMBL4282	Homo sapiens	IC50	nM	48.9
	18854043	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	Cl.Cn1ncc(C(=O)O)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)s1		CHEMBL4461200	=	IC50	nM	101.0	CHEMBL4282	Homo sapiens	IC50	nM	101.0
	18854044	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	Cl.Cn1ncc(CO)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)s1		CHEMBL4455194	=	IC50	nM	62.2	CHEMBL4282	Homo sapiens	IC50	nM	62.2
	18854045	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	Cl.Cn1ncc(-c2ccccc2)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)s1		CHEMBL4526242	=	IC50	nM	70.4	CHEMBL4282	Homo sapiens	IC50	nM	70.4
	18854046	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	Cl.Cn1ncc(-c2ccncc2)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)s1		CHEMBL4577134	=	IC50	nM	99.9	CHEMBL4282	Homo sapiens	IC50	nM	99.9
	18854047	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	=	IC50	nM	9.6	CHEMBL4282	Homo sapiens	IC50	nM	9.6
	18854048	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	=	IC50	nM	16.9	CHEMBL4282	Homo sapiens	IC50	nM	16.9
	18854049	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1csc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)c1		CHEMBL4442226	=	IC50	nM	13.7	CHEMBL4282	Homo sapiens	IC50	nM	13.7
	18854050	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	Cl.Cn1ncc(Cl)c1-c1csc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)c1		CHEMBL4451854	=	IC50	nM	1.26	CHEMBL4282	Homo sapiens	IC50	nM	1.26
	18854051	CHEMBL4307005	Inhibition of Akt1 (unknown origin) expressed in Escherichia coli using peptide as substrate incubated for 1 hr by HTRF assay	B	Cl.Cn1ncc(Cl)c1-c1csc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)c(C(F)(F)F)c2)c1		CHEMBL4545734	=	IC50	nM	35.3	CHEMBL4282	Homo sapiens	IC50	nM	35.3
	18854052	CHEMBL4307006	Inhibition of Akt1 (unknown origin)	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	=	Ki	nM	0.08	CHEMBL4282	Homo sapiens	Ki	nM	0.08
	18854053	CHEMBL4307006	Inhibition of Akt1 (unknown origin)	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)sc1Cl		CHEMBL4515689	=	IC50	nM	102.0	CHEMBL4282	Homo sapiens	IC50	nM	102.0
Dose-dependent effect	18854118	CHEMBL4307023	Inhibition of Akt in human HCT116 cells assessed as reduction in GSK3beta phosphorylation after 72 hrs by Western blot analysis	B	Cl.Cn1ncc(Cl)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)s1		CHEMBL4435124		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	18854119	CHEMBL4307023	Inhibition of Akt in human HCT116 cells assessed as reduction in GSK3beta phosphorylation after 72 hrs by Western blot analysis	B	Cl.Cn1ncc(Cl)c1-c1csc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)c1		CHEMBL4451854		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	18854120	CHEMBL4307024	Inhibition of Akt in human HCT116 cells assessed as reduction in PRAS40 phosphorylation after 72 hrs by Western blot analysis	B	Cl.Cn1ncc(Cl)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)s1		CHEMBL4435124		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	18854121	CHEMBL4307024	Inhibition of Akt in human HCT116 cells assessed as reduction in PRAS40 phosphorylation after 72 hrs by Western blot analysis	B	Cl.Cn1ncc(Cl)c1-c1csc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)c1		CHEMBL4451854		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	18854122	CHEMBL4307025	Inhibition of Akt phosphorylation at Ser-473 and thr-308 in human HCT116 cells after 72 hrs by Western blot analysis	B	Cl.Cn1ncc(Cl)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)s1		CHEMBL4435124		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	18854123	CHEMBL4307025	Inhibition of Akt phosphorylation at Ser-473 and thr-308 in human HCT116 cells after 72 hrs by Western blot analysis	B	Cl.Cn1ncc(Cl)c1-c1csc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)c1		CHEMBL4451854		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18857697	CHEMBL4307639	Inhibition of full length His-tagged recombinant human AKT1 expressed in Baculovirus expression system at 0.1 uM using Fluorescein-Crosstide as substrate incubated for 1 hr by TR-FRET assay relative to control	B	Cc1cc([C@@](C)(O)C#Cc2ccc3c(c2)-c2nc(C(N)=O)c(C4CC4)n2CCO3)no1		CHEMBL3941082	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	18857785	CHEMBL4307681	Binding affinity to wild-type human partial length AKT1 expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	95.0	CHEMBL4282	Homo sapiens	Activity	%	95.0
	18864252	CHEMBL4309575	Inhibition of human AKT1 at 10 uM using KGSGSGRPRTSSFAEG as substrate after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	COc1cc(Cl)cc(-c2nn(-c3cccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)c3)cc2-c2ccncc2)c1		CHEMBL4436746	=	Inhibition	%	-5.92	CHEMBL4282	Homo sapiens	INH	%	-5.92
	18886113	CHEMBL4313439	Inhibition of human AKT1 at 10 uM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	B	COc1ccc(-c2nn(-c3cccc(NC(=O)c4cccc(C(F)(F)F)c4)c3)cc2-c2ccncc2)cc1Cl		CHEMBL4553144	=	Inhibition	%	7.06	CHEMBL4282	Homo sapiens	INH	%	7.06
	18886198	CHEMBL4313439	Inhibition of human AKT1 at 10 uM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	B	COc1ccc(-c2nn(-c3cccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)c3)cc2-c2ccncc2)cc1Cl		CHEMBL4559825	=	Inhibition	%	4.08	CHEMBL4282	Homo sapiens	INH	%	4.08
	18890187	CHEMBL4314038	Inhibition of recombinant full-legth His-tagged human AKT1 expressed in baculovirus expression system at 0.5 uM using Ser/Thr 06 as substrate in presence of ATP at Km concentration after 1 hr by Z'-LYTE assay relative to control	B	COc1cc(C(=O)NC2CCNCC2)ccc1Nc1nc(Nc2ccccc2P(C)(C)=O)c2cc[nH]c2n1		CHEMBL4448754	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
Active	18904532	CHEMBL4317159	Inhibition of Akt phosphorylation in human Mahlavu cells at 1 uM after 72 hrs by Western blot analysis	B	COc1ccc2c3c(c4cc(OC)c(OC)cc4c2c1)CN1CCCCC1C3O		CHEMBL4446479		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18904533	CHEMBL4317160	Inhibition of Akt phosphorylation in human HuH7 cells at 1 uM after 72 hrs by Western blot analysis	B	COc1ccc2c3c(c4cc(OC)c(OC)cc4c2c1)CN1CCCCC1C3O		CHEMBL4446479		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	18904542	CHEMBL4317165	Inhibition of AKT phosphorylation in human Mahlavu cells at 1 uM after 24 to 72 hrs by Western blot analysis	B	COc1ccc2c3c(c4cc(OC)c(OC)cc4c2c1)CN1CCCCC1C3O		CHEMBL4446479		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18934067	CHEMBL4326599	Inhibition of human AKT1 at 10 uM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	B	CC(=O)N1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(N4Cc5cccc(N(C)S(C)(=O)=O)c5C4)n3)cc2)CC1		CHEMBL4476226	=	Inhibition	%	-3.6	CHEMBL4282	Homo sapiens	INH	%	-3.6
	18937691	CHEMBL4327575	Inhibition of human AKT1 assessed as residual activity at 1 uM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	100.2	CHEMBL4282	Homo sapiens	Activity	%	100.2
	18937692	CHEMBL4327575	Inhibition of human AKT1 assessed as residual activity at 1 uM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	99.84	CHEMBL4282	Homo sapiens	Activity	%	99.84
	18938416	CHEMBL4327936	Inhibition of human AKT1 assessed as residual activity at 100 uM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL4282	Homo sapiens	Activity	%	65.0
	18938781	CHEMBL4328300	Inhibition of human AKT1 using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	7.04	CHEMBL4282	Homo sapiens	IC50	10'-9M	7.04
	18950207	CHEMBL4331059	Inhibition of human AKT1 assessed as residual activity at 10 uM using KGSGSGRPRTSSFAEG as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by Hotspot assay relative to control	B	CN1CCC(Nc2ccc(C(=O)Nc3cc(-c4cc(C#N)cs4)n[nH]3)cc2)CC1		CHEMBL4473820	=	Activity	%	90.71	CHEMBL4282	Homo sapiens	Activity	%	90.71
	18953671	CHEMBL4331946	Inhibition of PKBa (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(NC3CCCCC3)c12		CHEMBL4440433	=	Inhibition	%	29.0	CHEMBL4282	Homo sapiens	INH	%	29.0
	18953737	CHEMBL4331946	Inhibition of PKBa (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(Nc3ccccc3F)c12		CHEMBL4449552	=	Inhibition	%	34.0	CHEMBL4282	Homo sapiens	INH	%	34.0
	18953860	CHEMBL4331946	Inhibition of PKBa (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(OC3CCCCC3)c12		CHEMBL4524629	=	Inhibition	%	55.0	CHEMBL4282	Homo sapiens	INH	%	55.0
	18953952	CHEMBL4332005	Inhibition of PKBa (unknown origin) at 1 uM relative to control	B	CC(C)n1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cn1		CHEMBL4589022	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	18954016	CHEMBL4332005	Inhibition of PKBa (unknown origin) at 1 uM relative to control	B	c1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cc(N2CCOCC2)n1		CHEMBL4460272	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	18954083	CHEMBL4331946	Inhibition of PKBa (unknown origin) at 10 uM relative to control	B	Cc1n[nH]c2ccnc(Nc3ccc4ncsc4c3)c12		CHEMBL4588446	=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	INH	%	40.0
	18958688	CHEMBL4333275	Binding affinity to wild-type human partial length AKT1 expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	84.0	CHEMBL4282	Homo sapiens	Activity	%	84.0
Dose-dependent effect	18961716	CHEMBL4334349	Inhibition of AKT phosphorylation in human PC3 cells after 24 hrs by Western blot analysis	B	Cc1ccccc1CN1C(=O)C2=C(CCN(Cc3ccccc3)C2)N2CCN=C12		CHEMBL4297310		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	18961717	CHEMBL4334349	Inhibition of AKT phosphorylation in human PC3 cells after 24 hrs by Western blot analysis	B	CCn1c2c(c(=O)n(Cc3ccccc3)c1=O)CN(Cc1ccccc1)CC2		CHEMBL4580598		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Dose-dependent effect	18961718	CHEMBL4334349	Inhibition of AKT phosphorylation in human PC3 cells after 24 hrs by Western blot analysis	B	CC(C)n1c2c(c(=O)n(Cc3ccccc3)c1=O)CN(Cc1ccccc1)CC2		CHEMBL4456677		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	18972854	CHEMBL4337353	Inhibition of full-length N-terminal GST-tagged human AKT1 catalytic domain (104 to 408 residues) expressed in baculovirus expression system at 10 uM using propeptide-6 as substrate after 30 mins by electrophoretic mobility shift assay relative to control	B	Cc1ccc(C(=O)NC2CC2)cc1NC(=O)c1ccc2c(c1)OCCO2		CHEMBL4580637	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
	19021448	CHEMBL4347668	Inhibition of recombinant human AKT1 at 20 nM using CREBtide as substrate measured after 60 mins by LANCE assay relative to control	B	O=C(CCCCCn1cc(Nc2ncc(Cl)c(Nc3ccc(Cl)cc3)n2)cn1)NO		CHEMBL4526274	=	Inhibition	%	38.0	CHEMBL4282	Homo sapiens	INH	%	38.0
	19021449	CHEMBL4347669	Inhibition of recombinant human AKT1 at 200 nM using CREBtide as substrate measured after 60 mins by LANCE assay relative to control	B	O=C(CCCCCn1cc(Nc2ncc(Cl)c(Nc3ccc(Cl)cc3)n2)cn1)NO		CHEMBL4526274	=	Inhibition	%	40.0	CHEMBL4282	Homo sapiens	INH	%	40.0
	19030018	CHEMBL4349157	Inhibition of recombinant full length human His-tagged AKT1 expressed in baculovirus expression system assessed as enzyme residual activity at 0.4 uM using fluorophore-labeled serine/threonine-06 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)CC1		CHEMBL4443805	=	Activity	%	96.0	CHEMBL4282	Homo sapiens	Activity	%	96.0
	19032175	CHEMBL4349768	Inhibition of recombinant human N-terminal GST/His6-tagged and C-terminal His6-tagged AKT1(V106 to A480) expressed in Sf9 insect cells at 20 nM using phosphatidylserine as substrate incubated for 60 mins in presence of [33P]-ATP by scintillation counting method	B	Cn1cc(-c2n[nH]c3ccc(NCc4cc(F)ccc4S(C)(=O)=O)cc23)cn1		CHEMBL4555442	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
	19035284	CHEMBL4350380	Inhibition of human AKT1 assessed as residual activity at 10 uM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	B	O=C1NC2(CCCCC2)n2c1c(Cl)cc(Nc1ccncn1)c2=O		CHEMBL4439094	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
Active	19041001	CHEMBL4352262	Inhibition of human AKT1 at 10 uM using KGSGSGRPRTSSFAEG as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	19043735	CHEMBL4353204	Inhibition of human AKT1 using KGSGSGRPRTSSFAEG as substrate at 0.1 uM in presence of 33P-gamma ATP by hotspot kinase assay relative to control	B	CN1CCC(Nc2ccc(C(=O)Nc3cc(-c4ccc5c(c4)OCO5)n[nH]3)cc2)CC1		CHEMBL4456471	=	Inhibition	%	90.76	CHEMBL4282	Homo sapiens	INH	%	90.76
Not Active	19049225	CHEMBL4354371	Effect on ATK phosphorylation in BDNF-induced human SH-SY5Y cells up to 2 uM preincubated for 6 hrs followed by BDNF addition and measured after 30 mins by Western blot analysis	A	Cc1c(C#Cc2cnc3cnc(-c4ccc(N)cc4)cn23)cccc1C(=O)Nc1cc(CN2CCN(C)CC2)cc(C(C)C)c1		CHEMBL4447582		Activity			CHEMBL4282	Homo sapiens	Activity		
	19059452	CHEMBL4357753	Binding affinity to wild-type human partial length AKT1 expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	89.0	CHEMBL4282	Homo sapiens	Activity	%	89.0
	19067254	CHEMBL4360635	Inhibition of AKT (unknown origin)	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	=	IC50	nM	180.0	CHEMBL4282	Homo sapiens	IC50	nmol/L	180.0
Active	19069532	CHEMBL4361231	Inhibition of AKT autophosphorylation at T308 residue in human GISTT1 cells harboring c-KIT 560 to 578 deletion mutant up to 0.3 uM measured after 2 hrs by Western blot analysis	B	COc1cc2nccc(Oc3ccc(NC(=O)Cc4ccc(Cl)c(C(F)(F)F)c4)cc3)c2cc1OC		CHEMBL4577779		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	19069533	CHEMBL4361232	Inhibition of AKT autophosphorylation at T308 residue in human GIST5R cells harboring c-KIT 560 to 578 deletion/T670I mutant up to 0.3 uM measured after 2 hrs by Western blot analysis	B	COc1cc2nccc(Oc3ccc(NC(=O)Cc4ccc(Cl)c(C(F)(F)F)c4)cc3)c2cc1OC		CHEMBL4577779		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	19069534	CHEMBL4361233	Inhibition of AKT autophosphorylation at T308 residue in human GISTT1 cells harboring c-KIT 560 to 578 deletion/T670I mutant up to 0.3 uM measured after 2 hrs by Western blot analysis	B	COc1cc2nccc(Oc3ccc(NC(=O)Cc4ccc(Cl)c(C(F)(F)F)c4)cc3)c2cc1OC		CHEMBL4577779		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	19069535	CHEMBL4361234	Inhibition of AKT autophosphorylation at T308 residue in human GISTT1 cells harboring c-KIT 560 to 578 deletion mutant at 0.1 uM measured after 2 hrs by Western blot analysis	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	19069536	CHEMBL4361235	Inhibition of AKT autophosphorylation at T308 residue in human GIST5R cells harboring c-KIT 560 to 578 deletion/T670I mutant at 0.1 uM measured after 2 hrs by Western blot analysis	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	19069537	CHEMBL4361236	Inhibition of AKT autophosphorylation at T308 residue in human GISTT1 cells harboring c-KIT 560 to 578 deletion/T670I mutant at 0.1 uM measured after 2 hrs by Western blot analysis	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	19090025	CHEMBL4365599	Inhibition of wild-type human partial length AKT1 expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	19091804	CHEMBL4366278	Inhibition of human AKT1 at 100 nM using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1		CHEMBL4528675	=	Inhibition	%	18.2	CHEMBL4282	Homo sapiens	INH	%	18.2
Not Active	19109035	CHEMBL4370065	Effect on AKT activity in human HCT116 cells assessed as AKT phosphorylation at T308 residues at 2.5 uM after 3 hrs by Western blot analysis	B	O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12		CHEMBL50		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	19109036	CHEMBL4370065	Effect on AKT activity in human HCT116 cells assessed as AKT phosphorylation at T308 residues at 2.5 uM after 3 hrs by Western blot analysis	B	O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12		CHEMBL151		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	19109037	CHEMBL4370065	Effect on AKT activity in human HCT116 cells assessed as AKT phosphorylation at T308 residues at 2.5 uM after 3 hrs by Western blot analysis	B	COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1O		CHEMBL90568		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	19109071	CHEMBL4370074	Effect on AKT activity in human HCT116 cells assessed as AKT phosphorylation at T308 residues at 10 uM after 3 hrs by Western blot analysis	B	O=[N+]([O-])c1ccc(CNc2nc(NCc3cccc(C(F)(F)F)c3)nc3[nH]cnc23)cc1		CHEMBL467591		Activity			CHEMBL4282	Homo sapiens	Activity		
	19111746	CHEMBL4370591	Inhibition of AKT (unknown origin) using Kemptide as substrate at 1 uM after 60 mins by ADP-Glo luminescence assay relative to control	B	Cc1cc(Nc2nc(Nc3ccc(C(=O)NC4CC(C)(C)N([O])C(C)(C)C4)cc3)ncc2F)no1		CHEMBL4522901	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	19111747	CHEMBL4370591	Inhibition of AKT (unknown origin) using Kemptide as substrate at 1 uM after 60 mins by ADP-Glo luminescence assay relative to control	B	CCCCOC(=O)Cc1cc(Nc2nc(Nc3ccc(C(=O)NC4CC(C)(C)N([O])C(C)(C)C4)cc3)ncc2F)n[nH]1		CHEMBL4443086	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	19137939	CHEMBL4375942	Inhibition of AKT phosphorylation in human K562 cells	B	Cc1c(Cc2ccc(NC(=O)Nc3ccc(Br)cc3)nc2)c(=O)oc2cc(O)c(C(C)(C)C)cc12		CHEMBL4464965	<	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	19137944	CHEMBL4375942	Inhibition of AKT phosphorylation in human K562 cells	B	Cc1c(Cc2ccc(NC(=O)Nc3ccccc3Cl)nc2)c(=O)oc2cc(O)c(C(C)(C)C)cc12		CHEMBL4516895	<	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	19137949	CHEMBL4375942	Inhibition of AKT phosphorylation in human K562 cells	B	COc1ccc(NC(=O)Nc2ccc(Cc3c(C)c4cc(C(C)(C)C)c(O)cc4oc3=O)cn2)cc1		CHEMBL4551568	<	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	19137954	CHEMBL4375942	Inhibition of AKT phosphorylation in human K562 cells	B	Cc1ccc(NC(=O)Nc2ccc(Cc3c(C)c4cc(C(C)(C)C)c(O)cc4oc3=O)cn2)cc1		CHEMBL4463428	<	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	19137959	CHEMBL4375942	Inhibition of AKT phosphorylation in human K562 cells	B	Cc1c(Cc2ccc(NC(=O)Nc3cccc(Cl)c3)nc2)c(=O)oc2cc(O)c(C(C)(C)C)cc12		CHEMBL4551206	<	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	19137964	CHEMBL4375942	Inhibition of AKT phosphorylation in human K562 cells	B	Cc1c(Cc2ccc(NC(=O)Nc3ccc(F)cc3)nc2)c(=O)oc2cc(O)c(C(C)(C)C)cc12		CHEMBL4570215	<	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	19137969	CHEMBL4375942	Inhibition of AKT phosphorylation in human K562 cells	B	Cc1c(Cc2ccc(NC(=O)Nc3ccc(F)c(F)c3)nc2)c(=O)oc2cc(O)c(C(C)(C)C)cc12		CHEMBL4439821	<	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	19159280	CHEMBL4382384	Binding affinity to wild-type human partial length AKT1 expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	98.0	CHEMBL4282	Homo sapiens	Activity	%	98.0
	19167540	CHEMBL4384269	Inhibition of PKBalpha (unknown origin) expressed in Sf9 insect cells using Biotin-SGRARTSSFAEPG as substrate after 30 mins by ELISA	B	COc1ccc(O)c(C(=O)c2ccc(C(=O)N[C@@H]3CCCNC[C@H]3NC(=O)c3ccncc3)cc2)c1F.Cl.Cl		CHEMBL4468352	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	19180956	CHEMBL4387166	Inhibition of recombinant full length human His-tagged AKT1 expressed in baculovirus expression system at 0.1 uM using serine/threonine-06 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Inhibition	%	6.5	CHEMBL4282	Homo sapiens	INH	%	6.5
	19181182	CHEMBL4387166	Inhibition of recombinant full length human His-tagged AKT1 expressed in baculovirus expression system at 0.1 uM using serine/threonine-06 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2		CHEMBL4545456	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	19191245	CHEMBL4389580	Inhibition of wild-type human partial length AKT1 expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	INH	%	100.0
	19191727	CHEMBL4389103	Inhibition of wild-type human partial length AKT1 expressed in bacterial expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	INH	%	100.0
	19200016	CHEMBL4391206	Binding affinity to wild-type human partial length AKT1 expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
Dose-dependent effect	19221911	CHEMBL4395309	Inhibition of Akt phosphorylation in human A549 cells incubated for 8 hrs by Western blot analysis	B	COC(=O)/C=C\c1ccc(OC)c(OCCOC(=O)[C@]2(C)CC[C@]3(C)CC[C@]4(C)C5=CC=C6C(=CC(=O)C(O)=C6C)[C@]5(C)CC[C@@]4(C)[C@@H]3C2)c1		CHEMBL4587085		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	19224212	CHEMBL4395636	Activation of AKT in human MCF7 cells assessed as increase in AKT phosphorylation at ser473 residue at 80 uM incubated for 48 hrs by Western blot analysis	B	O=C1c2ccccc2C(=O)N1c1ccc([Se][Se]c2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1		CHEMBL4465463		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	19224213	CHEMBL4395636	Activation of AKT in human MCF7 cells assessed as increase in AKT phosphorylation at ser473 residue at 80 uM incubated for 48 hrs by Western blot analysis	B	N#C[Se]c1ccc(NC(=O)C2C3C=CC(O3)C2C(=O)O)cc1		CHEMBL4534145		Activity			CHEMBL4282	Homo sapiens	Activity		
	19225450	CHEMBL4395870	Inhibition of recombinant human AKT1 at 1 uM using CREBtide as substrate measured after 60 mins in presence of ATP by LANCE assay relative to control	B	CCc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1		CHEMBL4536012	=	Inhibition	%	2.06	CHEMBL4282	Homo sapiens	INH	%	2.06
Not Active	19227875	CHEMBL4396549	Effect on AKT phosphorylation at S473 in heterozygous PTEN-positive human DU145 cells as reduction in AKT phosphorylation at S473 residue at 48 hr IC50 incubated for 48 hrs by Western immunoblot assay	B	COc1ccc(CNCCCN2C(=O)c3ccc4c5c(ccc(c35)C2=O)C(=O)N(CCCNCc2ccc(OC)c(OC)c2OC)C4=O)c(OC)c1OC		CHEMBL4444654		Activity			CHEMBL4282	Homo sapiens	Activity		
Not Active	19227876	CHEMBL4396549	Effect on AKT phosphorylation at S473 in heterozygous PTEN-positive human DU145 cells as reduction in AKT phosphorylation at S473 residue at 48 hr IC50 incubated for 48 hrs by Western immunoblot assay	B	COc1ccccc1CNCCCN1C(=O)c2ccc3c4c(ccc(c24)C1=O)C(=O)N(CCCNCCCCN)C3=O		CHEMBL4092588		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	19227877	CHEMBL4396550	Effect on AKT phosphorylation at S473 homozygous PTEN-deficient human PC3 cells as reduction in AKT phosphorylation at S473 residue at 48 hr IC50 incubated for 48 to 96 hrs by Western immunoblot assay	B	COc1ccc(CNCCCN2C(=O)c3ccc4c5c(ccc(c35)C2=O)C(=O)N(CCCNCc2ccc(OC)c(OC)c2OC)C4=O)c(OC)c1OC		CHEMBL4444654		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	19227878	CHEMBL4396550	Effect on AKT phosphorylation at S473 homozygous PTEN-deficient human PC3 cells as reduction in AKT phosphorylation at S473 residue at 48 hr IC50 incubated for 48 to 96 hrs by Western immunoblot assay	B	COc1ccccc1CNCCCN1C(=O)c2ccc3c4c(ccc(c24)C1=O)C(=O)N(CCCNCCCCN)C3=O		CHEMBL4092588		Activity			CHEMBL4282	Homo sapiens	Activity		
	19230931	CHEMBL4397177	Inhibition of AKT (unknown origin) at 100 nM by [gamma-33P]ATP-based radiometric or Alphascreen assay relative to control	B	Cc1cc(-n2cc(C(=O)N3CCO[C@@H](C)C3)c3ccc(O[C@@H](C)c4ccc(F)cn4)nc32)n[nH]1	Outside typical range	CHEMBL4440381	=	Inhibition	%	-11.0	CHEMBL4282	Homo sapiens	INH	%	-11.0
	19237273	CHEMBL4398963	Inhibition of AKT1 (unknown origin) at 10 uM using peptide as substrate incubated for 10 mins by caliper assay relative to control	B	O=C(Nc1nc(NCc2ccc(Cl)cc2)c2nc[nH]c2n1)c1ccccc1		CHEMBL4474543	=	Inhibition	%	16.4	CHEMBL4282	Homo sapiens	INH	%	16.4
	19239565	CHEMBL4399357	Inhibition of AKT1 (unknown origin) at 10 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by scintillation counting analysis relative to control	B	COc1ccc(NC(=O)c2cccc(/C=C3\CC(=O)N(c4ccc(C)cc4)C3=O)c2)cc1		CHEMBL4439227	=	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
Not Active	19253737	CHEMBL4402227	Inhibition of AKT phosphorylation in human A549 cells at 3 uM measured after 24 hrs in presence of NAC by Western blot analysis	B	CCCCCCCCCS(=O)(=O)C12OC1C(=O)c1c(OC)ccc(OC)c1C2=O		CHEMBL4435598		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	19253768	CHEMBL4402227	Inhibition of AKT phosphorylation in human A549 cells at 3 uM measured after 24 hrs in presence of NAC by Western blot analysis	B	CCCS(=O)(=O)C12OC1C(=O)c1c(OC)ccc(OC)c1C2=O		CHEMBL4578595		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	19253777	CHEMBL4402218	Modulation of AKT in human A549 cells assessed as increase in p27 levels measured after 24 hrs in presence of Akt inhibitor-LY10249 by Western blot analysis	B	CCCS(=O)(=O)C12OC1C(=O)c1c(OC)ccc(OC)c1C2=O		CHEMBL4578595		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	19253778	CHEMBL4402217	Modulation of AKT in human A549 cells assessed as decrease in cyclinD1 levels measured after 24 hrs in presence of Akt inhibitor-LY10249 by Western blot analysis	B	CCCS(=O)(=O)C12OC1C(=O)c1c(OC)ccc(OC)c1C2=O		CHEMBL4578595		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	19253779	CHEMBL4402216	Modulation of AKT in human A549 cells assessed as decrease in CDK6 levels measured after 24 hrs in presence of Akt inhibitor-LY10249 by Western blot analysis	B	CCCS(=O)(=O)C12OC1C(=O)c1c(OC)ccc(OC)c1C2=O		CHEMBL4578595		Activity			CHEMBL4282	Homo sapiens	Activity		
Tde	19253792	CHEMBL4402203	Inhibition of AKT phosphorylation in human A549 cells at 3 uM by Western blot analysis	B	CCCS(=O)(=O)C12OC1C(=O)c1c(OC)ccc(OC)c1C2=O		CHEMBL4578595		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	19253813	CHEMBL4402218	Modulation of AKT in human A549 cells assessed as increase in p27 levels measured after 24 hrs in presence of Akt inhibitor-LY10249 by Western blot analysis	B	CCCCCCCCCS(=O)(=O)C12OC1C(=O)c1c(OC)ccc(OC)c1C2=O		CHEMBL4435598		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	19253814	CHEMBL4402217	Modulation of AKT in human A549 cells assessed as decrease in cyclinD1 levels measured after 24 hrs in presence of Akt inhibitor-LY10249 by Western blot analysis	B	CCCCCCCCCS(=O)(=O)C12OC1C(=O)c1c(OC)ccc(OC)c1C2=O		CHEMBL4435598		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	19253815	CHEMBL4402216	Modulation of AKT in human A549 cells assessed as decrease in CDK6 levels measured after 24 hrs in presence of Akt inhibitor-LY10249 by Western blot analysis	B	CCCCCCCCCS(=O)(=O)C12OC1C(=O)c1c(OC)ccc(OC)c1C2=O		CHEMBL4435598		Activity			CHEMBL4282	Homo sapiens	Activity		
Tde	19253828	CHEMBL4402203	Inhibition of AKT phosphorylation in human A549 cells at 3 uM by Western blot analysis	B	CCCCCCCCCS(=O)(=O)C12OC1C(=O)c1c(OC)ccc(OC)c1C2=O		CHEMBL4435598		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	19266301	CHEMBL4405251	Inhibition of wild-type human partial length AKT1 expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL4282	Homo sapiens	INH	%	50.0
	19273724	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)NC2(c3ccc(Cl)c(Cl)c3)CCNCC2)oc1Cl		CHEMBL3805228	=	IC50	nM	61.0	CHEMBL4282	Homo sapiens	IC50	nM	61.0
	19273725	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CNCC[C@@H]2c2ccc(F)c(F)c2)oc1Cl		CHEMBL4552655	=	IC50	nM	2.5	CHEMBL4282	Homo sapiens	IC50	nM	2.5
	19274123	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	=	IC50	nM	25.43	CHEMBL4282	Homo sapiens	IC50	nM	25.43
	19274124	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	CC(=O)OCC[C@@H]1C[C@@H](c2ccc(F)c(F)c2)[C@H](NC(=O)c2cc(-c3c(Cl)cnn3C)c(Cl)o2)CN1		CHEMBL4531735	=	IC50	nM	3.4	CHEMBL4282	Homo sapiens	IC50	nM	3.4
	19274125	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	CC(=O)NCC[C@@H]1C[C@@H](c2ccc(F)c(F)c2)[C@H](NC(=O)c2cc(-c3c(Cl)cnn3C)c(Cl)o2)CN1		CHEMBL4460525	=	IC50	nM	2.49	CHEMBL4282	Homo sapiens	IC50	nM	2.49
	19274126	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CCNS(C)(=O)=O)C[C@H]2c2ccc(F)c(F)c2)oc1Cl		CHEMBL4441416	=	IC50	nM	3.29	CHEMBL4282	Homo sapiens	IC50	nM	3.29
	19274127	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	CNC(=O)C[C@@H]1C[C@@H](c2ccc(F)c(F)c2)[C@H](NC(=O)c2cc(-c3c(Cl)cnn3C)c(Cl)o2)CN1		CHEMBL4440965	=	IC50	nM	1.37	CHEMBL4282	Homo sapiens	IC50	nM	1.37
	19274128	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CC(O)CO)C[C@H]2c2ccc(F)c(F)c2)oc1Cl		CHEMBL4567295	=	IC50	nM	3.31	CHEMBL4282	Homo sapiens	IC50	nM	3.31
	19274129	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CCO)C[C@H]2c2ccc(F)c(F)c2)oc1Cl		CHEMBL4441825	=	IC50	nM	0.98	CHEMBL4282	Homo sapiens	IC50	nM	0.98
	19274130	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CC(=O)NCC(O)CO)C[C@H]2c2ccc(Cl)c(Cl)c2)oc1Cl		CHEMBL4593086	=	IC50	nM	3.13	CHEMBL4282	Homo sapiens	IC50	nM	3.13
	19274131	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CC(=O)NCCO)C[C@H]2c2ccc(Cl)c(Cl)c2)oc1Cl		CHEMBL4554668	=	IC50	nM	1.41	CHEMBL4282	Homo sapiens	IC50	nM	1.41
	19274132	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CC(=O)NC3CCC3)C[C@H]2c2ccc(Cl)c(Cl)c2)oc1Cl		CHEMBL4447158	=	IC50	nM	7.98	CHEMBL4282	Homo sapiens	IC50	nM	7.98
	19274133	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CC(=O)NC3CC3)C[C@H]2c2ccc(Cl)c(Cl)c2)oc1Cl		CHEMBL4589576	=	IC50	nM	3.95	CHEMBL4282	Homo sapiens	IC50	nM	3.95
	19274134	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	CNC(=O)C[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)[C@H](NC(=O)c2cc(-c3c(Cl)cnn3C)c(Cl)o2)CN1		CHEMBL4475923	=	IC50	nM	2.64	CHEMBL4282	Homo sapiens	IC50	nM	2.64
	19274135	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CC(N)=O)C[C@H]2c2ccc(Cl)c(Cl)c2)oc1Cl		CHEMBL4438877	=	IC50	nM	3.24	CHEMBL4282	Homo sapiens	IC50	nM	3.24
	19274136	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CC(=O)O)C[C@H]2c2ccc(Cl)c(Cl)c2)oc1Cl		CHEMBL4447967	=	IC50	nM	1.94	CHEMBL4282	Homo sapiens	IC50	nM	1.94
	19274137	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CCn3cncn3)C[C@H]2c2ccc(Cl)c(Cl)c2)oc1Cl		CHEMBL4519793	=	IC50	nM	4.47	CHEMBL4282	Homo sapiens	IC50	nM	4.47
	19274138	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CCN3CCC(O)CC3)C[C@H]2c2ccc(Cl)c(Cl)c2)oc1Cl		CHEMBL4518523	=	IC50	nM	5.99	CHEMBL4282	Homo sapiens	IC50	nM	5.99
	19274139	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CCN3CCOCC3)C[C@H]2c2ccc(Cl)c(Cl)c2)oc1Cl		CHEMBL4450403	=	IC50	nM	8.78	CHEMBL4282	Homo sapiens	IC50	nM	8.78
	19274140	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CCN3CCCCC3)C[C@H]2c2ccc(Cl)c(Cl)c2)oc1Cl		CHEMBL4524940	=	IC50	nM	5.65	CHEMBL4282	Homo sapiens	IC50	nM	5.65
	19274141	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CCN3CCCC3)C[C@H]2c2ccc(Cl)c(Cl)c2)oc1Cl		CHEMBL4546392	=	IC50	nM	6.41	CHEMBL4282	Homo sapiens	IC50	nM	6.41
	19274142	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	CN(C)CC[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)[C@H](NC(=O)c2cc(-c3c(Cl)cnn3C)c(Cl)o2)CN1		CHEMBL4590906	=	IC50	nM	3.4	CHEMBL4282	Homo sapiens	IC50	nM	3.4
	19274143	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	COCC[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)[C@H](NC(=O)c2cc(-c3c(Cl)cnn3C)c(Cl)o2)CN1		CHEMBL4568343	=	IC50	nM	7.01	CHEMBL4282	Homo sapiens	IC50	nM	7.01
	19274144	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CC(O)CO)C[C@H]2c2ccc(Cl)c(Cl)c2)oc1Cl		CHEMBL4470606	=	IC50	nM	3.79	CHEMBL4282	Homo sapiens	IC50	nM	3.79
	19274145	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CCO)C[C@H]2c2ccc(Cl)c(Cl)c2)oc1Cl		CHEMBL4517950	=	IC50	nM	2.74	CHEMBL4282	Homo sapiens	IC50	nM	2.74
	19274146	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CN[C@H](CCCO)C[C@H]2c2ccc(Cl)c(Cl)c2)oc1Cl		CHEMBL4451765	=	IC50	nM	2.56	CHEMBL4282	Homo sapiens	IC50	nM	2.56
	19274147	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	C=CC[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)[C@H](NC(=O)c2cc(-c3c(Cl)cnn3C)c(Cl)o2)CN1		CHEMBL4449509	=	IC50	nM	12.41	CHEMBL4282	Homo sapiens	IC50	nM	12.41
	19274148	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	CCC[C@@H]1C[C@@H](c2ccc(Cl)c(Cl)c2)[C@H](NC(=O)c2cc(-c3c(Cl)cnn3C)c(Cl)o2)CN1		CHEMBL4467439	=	IC50	nM	10.44	CHEMBL4282	Homo sapiens	IC50	nM	10.44
	19274149	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Br)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)nc1		CHEMBL4544069	=	IC50	nM	181.8	CHEMBL4282	Homo sapiens	IC50	nM	181.8
	19274150	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)nc1		CHEMBL4470602	=	IC50	nM	104.1	CHEMBL4282	Homo sapiens	IC50	nM	104.1
	19274151	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)nc1		CHEMBL4522719	=	IC50	nM	76.6	CHEMBL4282	Homo sapiens	IC50	nM	76.6
	19274152	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Br)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)cn1		CHEMBL4587088	=	IC50	nM	269.8	CHEMBL4282	Homo sapiens	IC50	nM	269.8
	19274153	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)cn1		CHEMBL4451405	=	IC50	nM	215.0	CHEMBL4282	Homo sapiens	IC50	nM	215.0
	19274154	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)cn1		CHEMBL4528834	=	IC50	nM	57.7	CHEMBL4282	Homo sapiens	IC50	nM	57.7
	19274155	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)cc1		CHEMBL4593509	=	IC50	nM	72.3	CHEMBL4282	Homo sapiens	IC50	nM	72.3
	19274156	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Br)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)cc1		CHEMBL4445690	=	IC50	nM	73.5	CHEMBL4282	Homo sapiens	IC50	nM	73.5
	19274157	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)cc1		CHEMBL4574492	=	IC50	nM	27.3	CHEMBL4282	Homo sapiens	IC50	nM	27.3
	19274158	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)cc1		CHEMBL4460756	=	IC50	nM	21.6	CHEMBL4282	Homo sapiens	IC50	nM	21.6
	19274159	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Br)c1-c1cc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)n(C)c1Br		CHEMBL4560290	=	IC50	nM	199.1	CHEMBL4282	Homo sapiens	IC50	nM	199.1
	19274160	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)n(C)c1Cl		CHEMBL4446884	=	IC50	nM	149.3	CHEMBL4282	Homo sapiens	IC50	nM	149.3
	19274161	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1cc(-c2c(Br)cnn2C)cc1C(=O)N[C@@H]1CNCC[C@H]1c1ccc(Cl)cc1		CHEMBL4588742	=	IC50	nM	255.3	CHEMBL4282	Homo sapiens	IC50	nM	255.3
	19274162	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1cc(-c2c(Cl)cnn2C)cc1C(=O)N[C@@H]1CNCC[C@H]1c1ccc(Cl)cc1		CHEMBL4457188	=	IC50	nM	211.9	CHEMBL4282	Homo sapiens	IC50	nM	211.9
	19274163	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)c(C(F)(F)F)c2)sc1Cl		CHEMBL4453662	=	IC50	nM	321.6	CHEMBL4282	Homo sapiens	IC50	nM	321.6
	19274164	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)sc1Cl		CHEMBL4582476	=	IC50	nM	222.2	CHEMBL4282	Homo sapiens	IC50	nM	222.2
	19274165	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(F)c2)sc1Cl		CHEMBL4515689	=	IC50	nM	101.6	CHEMBL4282	Homo sapiens	IC50	nM	101.6
	19274166	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)sc1Cl		CHEMBL4543839	=	IC50	nM	448.9	CHEMBL4282	Homo sapiens	IC50	nM	448.9
	19274167	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1nccc1-c1csc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)c1		CHEMBL4530506	=	IC50	nM	187.9	CHEMBL4282	Homo sapiens	IC50	nM	187.9
	19274168	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Br)c1-c1oc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)cc1Br		CHEMBL4439720	=	IC50	nM	29.8	CHEMBL4282	Homo sapiens	IC50	nM	29.8
	19274169	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1oc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)cc1Br		CHEMBL4583911	=	IC50	nM	40.0	CHEMBL4282	Homo sapiens	IC50	nM	40.0
	19274170	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1nccc1-c1oc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)cc1Br		CHEMBL4544411	=	IC50	nM	162.5	CHEMBL4282	Homo sapiens	IC50	nM	162.5
	19274171	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Br)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)o1		CHEMBL4578995	=	IC50	nM	31.2	CHEMBL4282	Homo sapiens	IC50	nM	31.2
	19274172	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)o1		CHEMBL4450141	=	IC50	nM	13.7	CHEMBL4282	Homo sapiens	IC50	nM	13.7
	19274173	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)o1		CHEMBL4522820	=	IC50	nM	230.2	CHEMBL4282	Homo sapiens	IC50	nM	230.2
	19274174	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Br)c1-c1coc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)c1		CHEMBL4465905	=	IC50	nM	35.6	CHEMBL4282	Homo sapiens	IC50	nM	35.6
	19274175	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1coc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)c1		CHEMBL4529738	=	IC50	nM	5.1	CHEMBL4282	Homo sapiens	IC50	nM	5.1
	19274176	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1nccc1-c1coc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)c1		CHEMBL4518386	=	IC50	nM	29.4	CHEMBL4282	Homo sapiens	IC50	nM	29.4
	19274177	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	O=C(N[C@@H]1CNCC[C@H]1c1ccc(Cl)cc1)c1ccc(-c2ncnc3c2CCC3O)s1		CHEMBL4454985	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
	19274178	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	CNc1cc(-c2ccc(C(=O)N[C@@H]3CNCC[C@H]3c3ccc(Cl)cc3)o2)ncn1		CHEMBL4435265	=	IC50	nM	529.5	CHEMBL4282	Homo sapiens	IC50	nM	529.5
	19274179	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1cc(-c2coc(C(=O)N[C@@H]3CNCC[C@H]3c3ccc(Cl)cc3)c2)cn1		CHEMBL4585334	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
	19274180	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	O=C(N[C@@H]1CNCC[C@H]1c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)o1		CHEMBL4540052	=	IC50	nM	50.3	CHEMBL4282	Homo sapiens	IC50	nM	50.3
	19274181	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1cc(-c2ccc(C(=O)N[C@@H]3CNCC[C@H]3c3ccc(Cl)cc3)o2)cn1		CHEMBL4531682	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
	19274182	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)oc1Cl		CHEMBL4554683	=	IC50	nM	17.3	CHEMBL4282	Homo sapiens	IC50	nM	17.3
	19274183	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CNCC[C@H]2c2cccc(C(F)(F)F)c2)oc1Cl		CHEMBL4585120	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
	19274184	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(Cl)c(Cl)c2)oc1Cl		CHEMBL4445510	=	IC50	nM	2.9	CHEMBL4282	Homo sapiens	IC50	nM	2.9
	19274185	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H]2CNCC[C@@H]2c2ccc(F)c(F)c2)oc1Cl.O=C(O)[C@H](O)[C@@H](O)C(=O)O		CHEMBL4533641	=	IC50	nM	51.2	CHEMBL4282	Homo sapiens	IC50	nM	51.2
	19274186	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)oc1Cl.O=C(O)[C@H](O)[C@@H](O)C(=O)O		CHEMBL4457064	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	19274187	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H]2CNCC[C@@H]2c2ccc(C(F)(F)F)cc2)oc1Cl.O=C(O)[C@H](O)[C@@H](O)C(=O)O		CHEMBL4435138	=	IC50	nM	127.4	CHEMBL4282	Homo sapiens	IC50	nM	127.4
	19274188	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(C(F)(F)F)cc2)oc1Cl.O=C(O)[C@H](O)[C@@H](O)C(=O)O		CHEMBL4591854	=	IC50	nM	9.3	CHEMBL4282	Homo sapiens	IC50	nM	9.3
	19274189	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	=	IC50	nM	4.7	CHEMBL4282	Homo sapiens	IC50	nM	4.7
	19274190	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)NC2CNCC2c2ccc(C(F)(F)F)cc2)oc1Cl		CHEMBL4461188	=	IC50	nM	538.0	CHEMBL4282	Homo sapiens	IC50	nM	538.0
	19274191	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Br)c1-c1coc(C(=O)NC2CNCC2c2ccc(F)c(F)c2)c1		CHEMBL4449288	=	IC50	nM	3646.0	CHEMBL4282	Homo sapiens	IC50	nM	3646.0
	19274192	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1coc(C(=O)NC2CNCC2c2ccc(F)c(F)c2)c1		CHEMBL4473634	=	IC50	nM	1566.0	CHEMBL4282	Homo sapiens	IC50	nM	1566.0
	19274193	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)NC2CNCCC2c2ccc(F)c(F)c2)oc1Cl.O=C(O)[C@H](O)[C@@H](O)C(=O)O		CHEMBL4465572	=	IC50	nM	6.4	CHEMBL4282	Homo sapiens	IC50	nM	6.4
	19274194	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)NC2CNCCC2c2ccc(C(F)(F)F)cc2)oc1Cl.O=C(O)[C@H](O)[C@@H](O)C(=O)O		CHEMBL4536780	=	IC50	nM	7.2	CHEMBL4282	Homo sapiens	IC50	nM	7.2
	19274195	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)NC2CNCCC2c2ccc(Cl)cc2)oc1Cl.O=C(O)[C@H](O)[C@@H](O)C(=O)O		CHEMBL4443488	=	IC50	nM	17.3	CHEMBL4282	Homo sapiens	IC50	nM	17.3
	19274196	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1ncc(Cl)c1-c1cc(C(=O)NC2CNCCC2c2ccccc2)oc1Cl.O=C(O)[C@H](O)[C@@H](O)C(=O)O		CHEMBL4471578	=	IC50	nM	17.6	CHEMBL4282	Homo sapiens	IC50	nM	17.6
	19274197	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1nccc1-c1coc(C(=O)NC2CNCCC2c2ccc(F)c(F)c2)c1.O=C(O)[C@H](O)[C@@H](O)C(=O)O		CHEMBL4570911	=	IC50	nM	191.0	CHEMBL4282	Homo sapiens	IC50	nM	191.0
	19274198	CHEMBL4407340	Inhibition of human Akt1 expressed in Escherichia coli using STK Substrate 2-biotin as substrate incubated for 1 hr by HTRF assay	B	Cn1nccc1-c1coc(C(=O)NC2CNCCC2c2ccccc2)c1.O=C(O)[C@H](O)[C@@H](O)C(=O)O		CHEMBL4446375	=	IC50	nM	709.6	CHEMBL4282	Homo sapiens	IC50	nM	709.6
	19274922	CHEMBL4407589	Inhibition of recombinant human full-length His-tagged AKT1 expressed in baculovirus expression system at 25 uM using FRET-labeled Ser/Thr 05 peptide as substrate measured after 1 hr by Z'-lyte assay relative to control	A	Nc1ncc2cc(-c3c(Br)cccc3Br)c(N)nc2n1		CHEMBL57531	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	19274923	CHEMBL4407589	Inhibition of recombinant human full-length His-tagged AKT1 expressed in baculovirus expression system at 25 uM using FRET-labeled Ser/Thr 05 peptide as substrate measured after 1 hr by Z'-lyte assay relative to control	A	Nc1ncc2cc(-c3c(Cl)cccc3-c3cccnc3)c(N3C[C@H]4[C@H](N)[C@H]4C3)nc2n1		CHEMBL4453148	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
	19274924	CHEMBL4407589	Inhibition of recombinant human full-length His-tagged AKT1 expressed in baculovirus expression system at 25 uM using FRET-labeled Ser/Thr 05 peptide as substrate measured after 1 hr by Z'-lyte assay relative to control	A	CC(C)COc1cccc(Cl)c1-c1cc2cnc(N)nc2nc1N1C[C@H]2[C@H](N)[C@H]2C1		CHEMBL4546703	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	19276094	CHEMBL4408097	Inhibition of recombinant human PKBalpha at 1 uM using as CKRREILSRRPSYRK substrate incubated for 60 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	36.0	CHEMBL4282	Homo sapiens	INH	%	36.0
	19303771	CHEMBL4414223	Inhibition of PKBalpha (unknown origin) assessed as residual activity at 50 uM relative to control	B	O=C(O)c1ccc(Nc2nc(-c3cccc([N+](=O)[O-])c3)cs2)cc1		CHEMBL4462082	=	Activity	%	85.0	CHEMBL4282	Homo sapiens	Activity	%	85.0
	19319992	CHEMBL4417586	Inhibition of N-terminal GST tagged human AKT1 catalytic domain (104 to 480 AA) expressed in baculovirus at 10 uM using FAM-labelled peptide as substrate pre-incubated for 10 mins followed by substrate addition by mobility shift assay relative to control	B	COc1ccc(OC)c(Nc2cc(NC(=O)Nc3c(Cl)cccc3Cl)ncn2)c1		CHEMBL4548481	=	Inhibition	%	19.41	CHEMBL4282	Homo sapiens	INH	%	19.41
Not Active	19334826	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	CC(=O)Nc1cccc(-n2nnc(SCC(=O)c3cc(-c4ccccc4)no3)n2)c1		CHEMBL4588492		Activity			CHEMBL4282	Homo sapiens	Activity		
	19334827	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	CCOC(=O)Cc1nn(Cc2nc(-c3ccc(C)cc3)cs2)c(=O)c2ccccc12		CHEMBL1422005	=	Kd	nM	17300.0	CHEMBL4282	Homo sapiens	Kd	uM	17.3
	19334828	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	Cc1ccc(-c2csc(Cn3nc(CC(=O)O)c4ccccc4c3=O)n2)cc1		CHEMBL4446354	=	Kd	nM	51600.0	CHEMBL4282	Homo sapiens	Kd	uM	51.6
	19334829	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	Cc1ccc(-c2csc(Cn3nc(CC4OCCCO4)c4ccccc4c3=O)n2)cc1		CHEMBL4528582	=	Kd	nM	66300.0	CHEMBL4282	Homo sapiens	Kd	uM	66.3
Not Determined	19334830	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	Cc1ccc(-c2csc(Cn3nc(Cc4nccs4)c4ccccc4c3=O)n2)cc1		CHEMBL4542845		Kd			CHEMBL4282	Homo sapiens	Kd		
	19334831	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	Cc1ccc(-c2csc(Cn3nc(CC4OCC(=O)O4)c4ccccc4c3=O)n2)cc1		CHEMBL4576938	=	Kd	nM	2530.0	CHEMBL4282	Homo sapiens	Kd	uM	2.53
	19334832	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	CCNC(=O)Cc1nn(Cc2nc(-c3ccc(C)cc3)cs2)c(=O)c2ccccc12		CHEMBL4464276	=	Kd	nM	2530.0	CHEMBL4282	Homo sapiens	Kd	uM	2.53
	19334833	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	Cc1ccc(-c2csc(Cn3nc(NS(=O)(=O)c4cccs4)c4ccccc4c3=O)n2)cc1		CHEMBL4542842	=	Kd	nM	34200.0	CHEMBL4282	Homo sapiens	Kd	uM	34.2
Not Determined	19334834	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	Cc1ccc(-c2csc(Cn3nc(CC=O)c4ccccc4c3=O)n2)cc1		CHEMBL4533907		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19334835	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	Cc1ccc(-c2csc(Cn3nc(CC4CN=CCO4)c4ccccc4c3=O)n2)cc1		CHEMBL4465082		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19334836	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	Cc1ccc(-c2csc(Cn3nc(CC(=O)NCCC(N)=O)c4ccccc4c3=O)n2)cc1		CHEMBL4435105		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19334837	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	Cc1ccc(-c2csc(Cn3nc(CC(=O)NCC(N)=O)c4ccccc4c3=O)n2)cc1		CHEMBL4519349		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19334838	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	Cc1ccc(-c2csc(Cn3nc(CC(=O)N4CCN(C)CC4)c4ccccc4c3=O)n2)cc1		CHEMBL4482955		Kd			CHEMBL4282	Homo sapiens	Kd		
	19334839	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	Cc1ccc(-c2nc(SCC(=O)O)c3c(=O)n(C)c(=O)n(C)c3n2)cc1	Outside typical range	CHEMBL4579008	=	Kd	nM	0.00128	CHEMBL4282	Homo sapiens	Kd	10'-6 uM	1.28
Active	19334840	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	COc1ccc(OC)c(-c2cc(C(=O)O)c3nc(C)[nH]c3n2)c1		CHEMBL4441334		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	19334841	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	O=C(O)CCc1ccc(-c2ccc(Br)cc2)n1CCC(=O)O		CHEMBL4540854		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	19334842	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	Cc1c(Cl)ccc2c(C(=O)O)cc(-c3cccnc3)nc12		CHEMBL4557494		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	19334843	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	Nc1cccc(-c2cc(C(=O)O)c3cc(Cl)ccc3n2)c1		CHEMBL4526378		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	19334844	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	O=C(O)COc1cc(OCC(=O)O)c2c3c(c(=O)oc2c1)CCCC3		CHEMBL4527518		Activity			CHEMBL4282	Homo sapiens	Activity		
Active	19334845	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	O=C(O)CSc1cc(NS(=O)(=O)c2cccs2)c2ccccc2c1O		CHEMBL2030270		Activity			CHEMBL4282	Homo sapiens	Activity		
	19334846	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	O=C(O)c1ccc2c(c1)C1C=CCC1C(C(=O)O)N2		CHEMBL244695	=	Kd	nM	0.474	CHEMBL4282	Homo sapiens	Kd	10'-4microM	4.74
Not Determined	19334847	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	COc1c(CCC(=O)O)cc(NS(=O)(=O)c2cccs2)c2c1OCO2		CHEMBL4472901		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Active	19334848	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	COc1c(/C=C/C(=O)O)cc(NS(=O)(=O)c2cccs2)c2c1OCO2		CHEMBL4280751		Kd			CHEMBL4282	Homo sapiens	Kd		
	19334849	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	CCOC(=O)CCc1cc(NS(=O)(=O)c2cccs2)c2c(c1OC)OCO2	Outside typical range	CHEMBL4280394	>	Kd	nM	500000.0	CHEMBL4282	Homo sapiens	Kd	uM	500.0
	19334850	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	CCOC(=O)/C=C/c1cc(NS(=O)(=O)c2cccs2)c2c(c1OC)OCO2	Outside typical range	CHEMBL4279325	>	Kd	nM	500000.0	CHEMBL4282	Homo sapiens	Kd	uM	500.0
Not Determined	19334851	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	CCOC(=O)CCc1cc(NS(=O)(=O)c2cccs2)c2c(c1O)OCO2		CHEMBL4442523		Kd			CHEMBL4282	Homo sapiens	Kd		
	19334852	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	CCOC(=O)/C=C/c1cc(NS(=O)(=O)c2cccs2)c2c(c1O)OCO2		CHEMBL4293794	=	Kd	nM	75200.0	CHEMBL4282	Homo sapiens	Kd	uM	75.2
Not Determined	19334853	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	O=C(O)/C=C/c1cc(NS(=O)(=O)c2cccs2)c2c(c1O)OCO2		CHEMBL4283567		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19334854	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	O=C(O)CCc1cc(NS(=O)(=O)c2cccs2)c2c(c1O)OCO2		CHEMBL4287230		Kd			CHEMBL4282	Homo sapiens	Kd		
	19334855	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	CCOC(=O)/C=C/c1c(O)c(OC)cc(NS(=O)(=O)c2cccs2)c1SC	Outside typical range	CHEMBL4451466	=	Kd	nM	330000.0	CHEMBL4282	Homo sapiens	Kd	uM	330.0
	19334856	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	COc1cc(NS(=O)(=O)c2cccs2)c(SC)c(/C=C/C(=O)O)c1O		CHEMBL4439996	=	Kd	nM	4800.0	CHEMBL4282	Homo sapiens	Kd	uM	4.8
	19334857	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	CCOC(=O)/C=C/c1c(O)c(O)cc(NS(=O)(=O)c2cccs2)c1SC		CHEMBL4437164	=	Kd	nM	6220.0	CHEMBL4282	Homo sapiens	Kd	uM	6.22
	19334858	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	CSc1c(NS(=O)(=O)c2cccs2)cc(O)c(O)c1/C=C/C(=O)O		CHEMBL4451129	=	Kd	nM	13500.0	CHEMBL4282	Homo sapiens	Kd	uM	13.5
	19334859	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	CCOC(=O)/C=C/c1c(O)c(OC)cc(N)c1SC	Outside typical range	CHEMBL4529653	=	Kd	nM	286000.0	CHEMBL4282	Homo sapiens	Kd	uM	286.0
	19334860	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	COc1cc(N)c(SC)c(/C=C/C(=O)O)c1O	Outside typical range	CHEMBL4515226	=	Kd	nM	133000.0	CHEMBL4282	Homo sapiens	Kd	uM	133.0
	19334861	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	CCOC(=O)/C=C/c1c(O)c(O)cc(N)c1SC	Outside typical range	CHEMBL4473695	=	Kd	nM	140000.0	CHEMBL4282	Homo sapiens	Kd	uM	140.0
	19334862	CHEMBL4419259	Binding affinity to AKT PH-domain (unknown origin) at 0.01 to 50 uM by SPR spectroscopy	B	CSc1c(N)cc(O)c(O)c1/C=C/C(=O)O	Outside typical range	CHEMBL4552253	=	Kd	nM	178000.0	CHEMBL4282	Homo sapiens	Kd	uM	178.0
Not Determined	19349053	CHEMBL4420445	Binding affinity to His-tagged AKT1 PHD (unknown origin) by SPR assay	B	O=C(O)CCc1cc(NS(=O)(=O)c2cccs2)c2c(c1O)OCO2		CHEMBL4287230		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19349054	CHEMBL4420445	Binding affinity to His-tagged AKT1 PHD (unknown origin) by SPR assay	B	O=C(O)/C=C/c1cc(NS(=O)(=O)c2cccs2)c2c(c1O)OCO2		CHEMBL4283567		Kd			CHEMBL4282	Homo sapiens	Kd		
	19349055	CHEMBL4420445	Binding affinity to His-tagged AKT1 PHD (unknown origin) by SPR assay	B	CCOC(=O)/C=C/c1cc(NS(=O)(=O)c2cccs2)c2c(c1O)OCO2		CHEMBL4293794	=	Kd	nM	75200.0	CHEMBL4282	Homo sapiens	Kd	uM	75.2
Not Determined	19349056	CHEMBL4420445	Binding affinity to His-tagged AKT1 PHD (unknown origin) by SPR assay	B	CCOC(=O)CCc1cc(NS(=O)(=O)c2cccs2)c2c(c1O)OCO2		CHEMBL4442523		Kd			CHEMBL4282	Homo sapiens	Kd		
	19349057	CHEMBL4420445	Binding affinity to His-tagged AKT1 PHD (unknown origin) by SPR assay	B	CCOC(=O)/C=C/c1cc(NS(=O)(=O)c2cccs2)c2c(c1OC)OCO2	Outside typical range	CHEMBL4279325	>	Kd	nM	500000.0	CHEMBL4282	Homo sapiens	Kd	uM	500.0
	19349058	CHEMBL4420445	Binding affinity to His-tagged AKT1 PHD (unknown origin) by SPR assay	B	CCOC(=O)CCc1cc(NS(=O)(=O)c2cccs2)c2c(c1OC)OCO2	Outside typical range	CHEMBL4280394	>	Kd	nM	500000.0	CHEMBL4282	Homo sapiens	Kd	uM	500.0
Not Active	19349059	CHEMBL4420445	Binding affinity to His-tagged AKT1 PHD (unknown origin) by SPR assay	B	COc1c(/C=C/C(=O)O)cc(NS(=O)(=O)c2cccs2)c2c1OCO2		CHEMBL4280751		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19349060	CHEMBL4420445	Binding affinity to His-tagged AKT1 PHD (unknown origin) by SPR assay	B	COc1c(CCC(=O)O)cc(NS(=O)(=O)c2cccs2)c2c1OCO2		CHEMBL4472901		Kd			CHEMBL4282	Homo sapiens	Kd		
	19367168	CHEMBL4424038	Inhibition of EGF-stimulated Akt phosphorylation in human MDA-MB-468-Luc cells at 10'-5 M pre-incubated for 1 hr before EGF stimulation for 15 mins by Western blot analysis relative to control	B	CCN(CC)c1ccc(-c2ccc(C(=O)OC)cc2)nn1		CHEMBL4455065	>	Inhibition	%	70.0	CHEMBL4282	Homo sapiens	INH	%	70.0
Active	19367169	CHEMBL4424038	Inhibition of EGF-stimulated Akt phosphorylation in human MDA-MB-468-Luc cells at 10'-5 M pre-incubated for 1 hr before EGF stimulation for 15 mins by Western blot analysis relative to control	B	CCOC(=O)c1ccc(-c2ccc(N(CC)CC)nn2)cc1		CHEMBL4567455		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	19367170	CHEMBL4424038	Inhibition of EGF-stimulated Akt phosphorylation in human MDA-MB-468-Luc cells at 10'-5 M pre-incubated for 1 hr before EGF stimulation for 15 mins by Western blot analysis relative to control	B	CCOC(=O)c1ccc(-c2ccc(N(C)C)nn2)cc1		CHEMBL4439712		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	19367171	CHEMBL4424038	Inhibition of EGF-stimulated Akt phosphorylation in human MDA-MB-468-Luc cells at 10'-5 M pre-incubated for 1 hr before EGF stimulation for 15 mins by Western blot analysis relative to control	B	COC(=O)c1ccc(-c2ccc(N(C)C)nn2)cc1		CHEMBL4442270		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	19371150	CHEMBL4424902	Inhibition of human full-length N-terminal His6-tagged PKBalpha expressed in baculovirus infected Sf21 insect cells using Crosstide as substrate	A	COc1cc(C2CN(C(=O)c3cc(COC[C@@H](O)CO)ccn3)C2)ccc1OCc1ccc(C2CC2)cc1		CHEMBL4474690	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	nM	1000.0
	19411486	CHEMBL4427679	Inhibition of AKT1 (unknown origin)	B	Cc1cnc(-c2cc(Cl)ccc2F)cc1-n1c(=O)n(CC(N)=O)c2cnccc21		CHEMBL4564126	>=	IC50	nM	5000.0	CHEMBL4282	Homo sapiens	IC50	uM	5.0
	19411542	CHEMBL4427623	Inhibition of AKT1 (unknown origin) at 1 uM relative to control	B	Cc1cnc(-c2cc(Cl)ccc2F)cc1-n1c(=O)n(CC(N)=O)c2cnccc21		CHEMBL4564126	<=	Inhibition	%	16.0	CHEMBL4282	Homo sapiens	INH	%	16.0
Active	19426928	CHEMBL4428253	Inhibition of Akt phosphorylation in human A549/CDDP cells at 0.6 to 1.2 uM after 24 hrs by Western blot method	B	COc1cc(/C=C/C(=O)/C=C/c2nc(C)c(C)nc2C)ccc1O		CHEMBL4451948		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	19426929	CHEMBL4428252	Inhibition of Akt phosphorylation in human A549 cells at 2.1 to 4.2 uM after 24 hrs by Western blot method	B	COc1cc(/C=C/C(=O)/C=C/c2nc(C)c(C)nc2C)ccc1O		CHEMBL4451948		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	19432877	CHEMBL4429545	Inhibition of AKT1 (unknown origin) at 1 uM	B	Cc1nccc(Nc2cc(NC3CCN(c4ccc(C#N)cc4)CC3)c(C(N)=O)cn2)n1		CHEMBL4463436	=	Inhibition	%	10.0	CHEMBL4282	Homo sapiens	INH	%	10.0
	19440240	CHEMBL4431276	Inhibition of AKT1 (unknown origin) at 20 nM relative to control	B	c1ccc(Nc2nc(Nc3cn[nH]c3)nc3[nH]ccc23)cc1		CHEMBL4448847	=	Inhibition	%	-3.0	CHEMBL4282	Homo sapiens	INH	%	-3.0
	19440241	CHEMBL4431276	Inhibition of AKT1 (unknown origin) at 20 nM relative to control	B	Clc1cccc(Nc2nc(Nc3cn[nH]c3)ncc2Cl)c1		CHEMBL4453646	=	Inhibition	%	7.5	CHEMBL4282	Homo sapiens	INH	%	7.5
	19471305	CHEMBL4478653	Inhibition of full length active AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate/PDK1/MAPKAPK2/DOPS/DOPC/PtdIns(3,4,5)P3 addition measured after 30 mins by Alphascreen assay	B	Cl.Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL4523032	=	IC50	nM	5.0	CHEMBL4282	Homo sapiens	IC50	uM	0.005
	19471306	CHEMBL4478653	Inhibition of full length active AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate/PDK1/MAPKAPK2/DOPS/DOPC/PtdIns(3,4,5)P3 addition measured after 30 mins by Alphascreen assay	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1.Cl		CHEMBL4519558	=	IC50	nM	2.3	CHEMBL4282	Homo sapiens	IC50	uM	0.0023
	19471307	CHEMBL4478653	Inhibition of full length active AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate/PDK1/MAPKAPK2/DOPS/DOPC/PtdIns(3,4,5)P3 addition measured after 30 mins by Alphascreen assay	B	Cl.Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL4574111	=	IC50	nM	2.6	CHEMBL4282	Homo sapiens	IC50	uM	0.0026
	19471308	CHEMBL4478653	Inhibition of full length active AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate/PDK1/MAPKAPK2/DOPS/DOPC/PtdIns(3,4,5)P3 addition measured after 30 mins by Alphascreen assay	B	Cl.Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL4544109	=	IC50	nM	34.0	CHEMBL4282	Homo sapiens	IC50	uM	0.034
	19471317	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cc1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL4535365	=	IC50	nM	720.0	CHEMBL4282	Homo sapiens	IC50	uM	0.72
	19471318	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	CC(C)(C)c1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL2177840	=	IC50	nM	5900.0	CHEMBL4282	Homo sapiens	IC50	uM	5.9
	19471319	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.NCc1ccc(-n2c(-c3cccnc3N)nc3cccnc32)cc1		CHEMBL4517839	=	IC50	nM	1700.0	CHEMBL4282	Homo sapiens	IC50	uM	1.7
	19471320	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cc1ccnc2c1nc(-c1cccnc1N)n2-c1ccc(CN)cc1.Cl		CHEMBL4568743	=	IC50	nM	500.0	CHEMBL4282	Homo sapiens	IC50	uM	0.5
	19471321	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cc1cnc2c(c1)nc(-c1cccnc1N)n2-c1ccc(CN)cc1.Cl		CHEMBL4565210	=	IC50	nM	270.0	CHEMBL4282	Homo sapiens	IC50	uM	0.27
	19471322	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cc1cc2nc(-c3cccnc3N)n(-c3ccc(CN)cc3)c2nc1C.Cl		CHEMBL4543768	>	IC50	nM	1000.0	CHEMBL4282	Homo sapiens	IC50	uM	1.0
	19471323	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.NCc1ccc(-n2c(-c3cccnc3N)nc3ccc(Cl)nc32)cc1		CHEMBL4545250	=	IC50	nM	270.0	CHEMBL4282	Homo sapiens	IC50	uM	0.27
	19471324	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.NCc1ccc(-n2c(-c3cccnc3N)nc3cc(Br)cnc32)cc1		CHEMBL4558319	=	IC50	nM	320.0	CHEMBL4282	Homo sapiens	IC50	uM	0.32
	19471325	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.NCc1ccc(-n2c(-c3cccnc3N)nc3ccc(-c4ccccc4)nc32)cc1		CHEMBL4513257	=	IC50	nM	3.7	CHEMBL4282	Homo sapiens	IC50	uM	0.0037
	19471326	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CN)cc4)c3n2)c1.Cl		CHEMBL4546484	=	IC50	nM	13.0	CHEMBL4282	Homo sapiens	IC50	uM	0.013
	19471327	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	CC(=O)Nc1ccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CN)cc4)c3n2)cc1.Cl		CHEMBL4586184	=	IC50	nM	72.0	CHEMBL4282	Homo sapiens	IC50	uM	0.072
	19471328	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.NCc1ccc(-n2c(-c3cccnc3N)nc3ccc(-c4cn[nH]c4)nc32)cc1		CHEMBL4576518	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	uM	0.017
	19471329	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.NCc1ccc(-n2c(-c3cccnc3N)nc3cc(-c4cccnc4)cnc32)cc1		CHEMBL4550916	=	IC50	nM	36.0	CHEMBL4282	Homo sapiens	IC50	uM	0.036
	19471330	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	CC(C)(N)c1ccc(-n2c(-c3cccnc3N)nc3ccc(-c4ccccc4)nc32)cc1		CHEMBL4528363	=	IC50	nM	5.4	CHEMBL4282	Homo sapiens	IC50	uM	0.0054
	19471331	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL4523032	=	IC50	nM	2.7	CHEMBL4282	Homo sapiens	IC50	uM	0.0027
	19471332	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	CC(=O)NC1(c2ccc(-n3c(-c4cccnc4N)nc4ccc(-c5ccccc5)nc43)cc2)CCC1		CHEMBL4553900	=	IC50	nM	35.0	CHEMBL4282	Homo sapiens	IC50	uM	0.035
	19471333	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	COC(=O)C1(c2ccc(-n3c(-c4cccnc4N)nc4ccc(-c5ccccc5)nc43)cc2)CCC1		CHEMBL4526693	=	IC50	nM	540.0	CHEMBL4282	Homo sapiens	IC50	uM	0.54
	19471334	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	NC(=O)C1(c2ccc(-n3c(-c4cccnc4N)nc4ccc(-c5ccccc5)nc43)cc2)CCC1		CHEMBL4517319	=	IC50	nM	35.0	CHEMBL4282	Homo sapiens	IC50	uM	0.035
	19471335	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1.Cl		CHEMBL4519558	=	IC50	nM	2.8	CHEMBL4282	Homo sapiens	IC50	uM	0.0028
	19471336	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1		CHEMBL4574111	=	IC50	nM	1.9	CHEMBL4282	Homo sapiens	IC50	uM	0.0019
	19471337	CHEMBL4478656	Inhibition of full length unphosphorylated AKT1 (1 to 480 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-GRPRTSSFAEG as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins by Alphascreen assay	B	Cl.Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL4544109	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	uM	0.006
	19471400	CHEMBL4478663	Inhibition of AKT1 phosphorylation at Ser473 in EGF/insulin-stimulated human AN3CA cells incubated for 1 hr followed by stimulation for 15 mins by Western blot analysis	B	Cl.Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL4523032	=	IC50	nM	40.0	CHEMBL4282	Homo sapiens	IC50	uM	0.04
	19471401	CHEMBL4478663	Inhibition of AKT1 phosphorylation at Ser473 in EGF/insulin-stimulated human AN3CA cells incubated for 1 hr followed by stimulation for 15 mins by Western blot analysis	B	Cl.Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL4544109	=	IC50	nM	56.0	CHEMBL4282	Homo sapiens	IC50	uM	0.056
	19471402	CHEMBL4478664	Inhibition of AKT1 phosphorylation at Ser473 in EGF/insulin-stimulated human A2780 cells incubated for 1 hr followed by stimulation for 15 mins by Western blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1.Cl		CHEMBL4519558	=	IC50	nM	41.0	CHEMBL4282	Homo sapiens	IC50	uM	0.041
	19471403	CHEMBL4478665	Inhibition of AKT1 phosphorylation at Thr308 in EGF/insulin-stimulated human AN3CA cells incubated for 1 hr followed by stimulation for 15 mins by Western blot analysis	B	Cl.Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL4523032	=	IC50	nM	61.0	CHEMBL4282	Homo sapiens	IC50	uM	0.061
	19471404	CHEMBL4478665	Inhibition of AKT1 phosphorylation at Thr308 in EGF/insulin-stimulated human AN3CA cells incubated for 1 hr followed by stimulation for 15 mins by Western blot analysis	B	Cl.Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL4544109	=	IC50	nM	63.0	CHEMBL4282	Homo sapiens	IC50	uM	0.063
	19471405	CHEMBL4478666	Inhibition of AKT1 phosphorylation at Thr308 in EGF/insulin-stimulated human A2780 cells incubated for 1 hr followed by stimulation for 15 mins by Western blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1.Cl		CHEMBL4519558	=	IC50	nM	37.0	CHEMBL4282	Homo sapiens	IC50	uM	0.037
	19471406	CHEMBL4478667	Inhibition of AKT1 in EGF/insulin-stimulated human AN3CA cells assessed as reduction in phosphorylation at Thr246 incubated for 1 hr followed by stimulation for 15 mins by Western blot analysis	B	Cl.Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL4523032	=	IC50	nM	310.0	CHEMBL4282	Homo sapiens	IC50	uM	0.31
	19471407	CHEMBL4478667	Inhibition of AKT1 in EGF/insulin-stimulated human AN3CA cells assessed as reduction in phosphorylation at Thr246 incubated for 1 hr followed by stimulation for 15 mins by Western blot analysis	B	Cl.Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(C2(N)CCC2)cc1		CHEMBL4544109	=	IC50	nM	640.0	CHEMBL4282	Homo sapiens	IC50	uM	0.64
	19471408	CHEMBL4478668	Inhibition of AKT1 in EGF/insulin-stimulated human A2780 cells assessed as reduction in phosphorylation at Thr246 incubated for 1 hr followed by stimulation for 15 mins by Western blot analysis	B	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1.Cl		CHEMBL4519558	>	IC50	nM	3000.0	CHEMBL4282	Homo sapiens	IC50	uM	3.0
	19476543	CHEMBL4479691	Inhibition of full-length recombinant human His-tagged AKT1-alpha expressed in baculovirus expression system by Z'-LYTE assay	B	O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1		CHEMBL4569508	=	IC50	nM	24000.0	CHEMBL4282	Homo sapiens	IC50	nM	24000.0
	19476643	CHEMBL4479691	Inhibition of full-length recombinant human His-tagged AKT1-alpha expressed in baculovirus expression system by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)NCC(F)(F)F)c4)cnn3c2)cn1		CHEMBL4550702	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
	19476743	CHEMBL4479691	Inhibition of full-length recombinant human His-tagged AKT1-alpha expressed in baculovirus expression system by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)N[C@@H]5CCCC[C@@H]5N)c4)cnn3c2)cn1		CHEMBL4568087	=	IC50	nM	80.0	CHEMBL4282	Homo sapiens	IC50	nM	80.0
	19476843	CHEMBL4479691	Inhibition of full-length recombinant human His-tagged AKT1-alpha expressed in baculovirus expression system by Z'-LYTE assay	B	Cc1sc(C(=O)N[C@@H]2[C@H](N)CCCC2(F)F)cc1-c1cnn2cc(Cl)cnc12		CHEMBL4552628	=	IC50	nM	870.0	CHEMBL4282	Homo sapiens	IC50	nM	870.0
	19491205	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	O=P(O)(O)O[C@H]1[C@@H](O)[C@@H](OP(=O)(O)O)[C@H](O)[C@@H](OP(=O)(O)O)[C@@H]1OP(=O)(O)O		CHEMBL23552	=	Kd	nM	3080.0	CHEMBL4282	Homo sapiens	Kd	uM	3.08
	19491206	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)C[C@@H](O)[C@H](O)[C@H]1O)OC		CHEMBL1685066	=	Kd	nM	5040.0	CHEMBL4282	Homo sapiens	Kd	uM	5.04
	19491207	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1		CHEMBL595583	=	Ki	nM	2400.0	CHEMBL4282	Homo sapiens	Ki	uM	2.4
Not Determined	19491208	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	CCc1ccc(C(=O)OC)cc1CSc1nnc(-c2ccc(C(F)(F)F)cc2)n1Cc1ccoc1		CHEMBL4564787		Kd			CHEMBL4282	Homo sapiens	Kd		
	19491209	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(S(N)(=O)=O)s2)cc1		CHEMBL1685058	=	Ki	nM	6000.0	CHEMBL4282	Homo sapiens	Ki	uM	6.0
	19491210	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(C(=O)OCC)s2)cc1		CHEMBL1685056	=	Ki	nM	18900.0	CHEMBL4282	Homo sapiens	Ki	uM	18.9
	19491211	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(CC(=O)OCC)s2)cc1		CHEMBL1685055	=	Ki	nM	4300.0	CHEMBL4282	Homo sapiens	Ki	uM	4.3
	19491212	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nnc(CC(=O)O)s2)cc1		CHEMBL1681823	=	Ki	nM	5000.0	CHEMBL4282	Homo sapiens	Ki	uM	5.0
Not Active	19491213	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	Cc1nnc(NS(=O)(=O)c2ccc(NS(=O)(=O)c3ccc4ccccc4c3)cc2)s1		CHEMBL595786		Kd			CHEMBL4282	Homo sapiens	Kd		
	19491214	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	COc1cc(NS(=O)(=O)c2ccc(NS(=O)(=O)c3c(C)noc3C)cc2)nc(OC)n1		CHEMBL3912759	=	Kd	nM	6270.0	CHEMBL4282	Homo sapiens	Kd	uM	6.27
	19491215	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	O=C(O)c1ccccc1C(=O)Nc1ccccc1SCCS(=O)(=O)c1ccc(Cl)cc1		CHEMBL4577370	=	Kd	nM	4580.0	CHEMBL4282	Homo sapiens	Kd	uM	4.58
Not Determined	19491216	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	Cn1c(Cc2ccsc2)nnc1SCC(=O)Nc1cc(Cl)cc(Cl)c1		CHEMBL4539727		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19491217	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	Cc1onc(-c2ccccc2)c1-c1nc(CSc2nc3ccccc3[nH]2)no1		CHEMBL4536878		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19491218	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	Cc1noc(C)c1NC(=O)NCc1csc(-c2cccs2)n1		CHEMBL4557539		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19491219	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	O=S(=O)(NCc1csc(-c2cccs2)n1)c1ccc(N2CCOCC2)nc1		CHEMBL4591779		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19491220	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	CS(=O)(=O)CCSc1ncccc1C(=O)Sc1ccc(Cl)cc1Cl		CHEMBL4530453		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19491221	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	Cc1cc2ncc(-c3cnc(SCCS(=O)(=O)c4ccc(Cl)cc4)nc3)c(C)n2n1		CHEMBL4538899		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19491222	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	CS(=O)(=NS(=O)(=O)c1ccc(-c2ccccn2)s1)c1ccc(Cl)cc1		CHEMBL4563636		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19491223	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	O=c1[nH]nc(SCc2csc(-c3ccccc3)n2)n1Cc1ccco1		CHEMBL4590344		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19491224	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	Cc1nc(-c2ccc(S(=O)(=O)N3CCN(C4c5ccccc5-c5ccccc54)CC3)s2)cs1		CHEMBL1572640		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19491225	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	Cn1cnc(S(=O)(=O)Nc2ccccc2SCCS(=O)(=O)c2ccc(Cl)cc2)c1		CHEMBL4576057		Kd			CHEMBL4282	Homo sapiens	Kd		
Not Determined	19491226	CHEMBL4482513	Binding affinity to AKT1 (unknown origin) by surface plasmon resonance assay	B	O=S(=O)(NCc1csc2ccc(Cl)cc12)c1cc(S(=O)(=O)c2ccccc2)cs1		CHEMBL4533777		Kd			CHEMBL4282	Homo sapiens	Kd		
	20600459	CHEMBL4603290	Inhibition of recombinant full length human His-tagged AKT1 expressed in baculovirus expression system using serine/threonine-06 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	uM	100.0
	20601674	CHEMBL4603806	Inhibition of recombinant human His-tagged full length AKT1 expressed in baculovirus expression system using Ser/Thr06 peptide as substrate at 0.6 uM incubated for 1 hr by Z'lyte assay relative to control	B	C=CC(=O)NCCOc1cc(Cc2ccccc2)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12		CHEMBL4646281	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	20642203	CHEMBL4613505	Inhibition of PKBalpha (unknown origin)	B	O=C(/C=C/c1nc2ccccc2[nH]1)c1c(O)nc2ccc(Cl)cc2c1-c1ccccc1		CHEMBL190313	=	IC50	nM	1640.0	CHEMBL4282	Homo sapiens	IC50	uM	1.64
	20642208	CHEMBL4613505	Inhibition of PKBalpha (unknown origin)	B	Cc1ccc2[nH]c(/C=C/C(=O)c3c(-c4ccccc4)c4cc(Cl)ccc4[nH]c3=O)nc2c1		CHEMBL4637800	=	IC50	nM	1640.0	CHEMBL4282	Homo sapiens	IC50	uM	1.64
	20642213	CHEMBL4613505	Inhibition of PKBalpha (unknown origin)	B	O=C(/C=C/c1nc2cc(Br)ccc2[nH]1)c1c(-c2ccccc2)c2cc(Cl)ccc2[nH]c1=O		CHEMBL4648204	=	IC50	nM	1640.0	CHEMBL4282	Homo sapiens	IC50	uM	1.64
	20642218	CHEMBL4613505	Inhibition of PKBalpha (unknown origin)	B	O=C(/C=C/c1nc2cc(F)ccc2[nH]1)c1c(-c2ccccc2)c2cc(Cl)ccc2[nH]c1=O		CHEMBL4644882	=	IC50	nM	1640.0	CHEMBL4282	Homo sapiens	IC50	uM	1.64
	20642223	CHEMBL4613505	Inhibition of PKBalpha (unknown origin)	B	O=C(/C=C/c1nc2ccccc2[nH]1)c1c(-c2ccccc2)c2ccccc2[nH]c1=O		CHEMBL4646965	=	IC50	nM	1640.0	CHEMBL4282	Homo sapiens	IC50	uM	1.64
	20642228	CHEMBL4613505	Inhibition of PKBalpha (unknown origin)	B	O=C(/C=C/c1nc2ccccc2[nH]1)c1c(-c2ccccc2)c2cc(Br)ccc2[nH]c1=O		CHEMBL4636228	=	IC50	nM	1640.0	CHEMBL4282	Homo sapiens	IC50	uM	1.64
	20642233	CHEMBL4613505	Inhibition of PKBalpha (unknown origin)	B	Cc1ccc2[nH]c(=O)c(C(=O)/C=C/c3nc4ccccc4[nH]3)c(-c3ccccc3)c2c1		CHEMBL4643610	=	IC50	nM	1640.0	CHEMBL4282	Homo sapiens	IC50	uM	1.64
	20642238	CHEMBL4613505	Inhibition of PKBalpha (unknown origin)	B	Cn1c(=O)c(C(=O)/C=C/c2nc3cc(F)ccc3[nH]2)c(-c2ccccc2)c2cc(Cl)ccc21		CHEMBL4646743	=	IC50	nM	1640.0	CHEMBL4282	Homo sapiens	IC50	uM	1.64
	20642243	CHEMBL4613505	Inhibition of PKBalpha (unknown origin)	B	O=C(/C=C/c1nc2cc(F)ccc2[nH]1)c1c(-c2ccc(F)cc2)c2cc(F)ccc2[nH]c1=O		CHEMBL4638124	=	IC50	nM	1640.0	CHEMBL4282	Homo sapiens	IC50	uM	1.64
	20642248	CHEMBL4613505	Inhibition of PKBalpha (unknown origin)	B	O=C(/C=C/c1nc2cc(F)c(F)cc2[nH]1)c1c(-c2ccc(F)cc2)c2cc(F)ccc2[nH]c1=O		CHEMBL4645387	=	IC50	nM	1640.0	CHEMBL4282	Homo sapiens	IC50	uM	1.64
	20642253	CHEMBL4613505	Inhibition of PKBalpha (unknown origin)	B	O=C(/C=C/c1nc2cc(F)c(F)cc2[nH]1)c1c(-c2ccc(F)cc2)c2cc(Cl)ccc2[nH]c1=O		CHEMBL4633766	=	IC50	nM	1640.0	CHEMBL4282	Homo sapiens	IC50	uM	1.64
	20642258	CHEMBL4613505	Inhibition of PKBalpha (unknown origin)	B	O=C(/C=C/c1nc2cc(F)c(F)cc2[nH]1)c1c(-c2ccc(F)c(F)c2)c2cc(F)ccc2[nH]c1=O		CHEMBL4649562	=	IC50	nM	1640.0	CHEMBL4282	Homo sapiens	IC50	uM	1.64
	20646941	CHEMBL4614476	Inhibition of AKT phosphorylation at S473 residue in human HepG2 cells assessed as ratio of phosphorylated Akt to total Akt level at 0.5 uM after 4 hrs by Western blot analysis (Rvb = 1 No_unit)	B	CC[C@@]12SS[C@]3(C(=O)N1C)[C@@H](O)C1(C45c6ccccc6N[C@@H]4N4C(=O)[C@]6([C@@H](C)O)SS[C@]4(C(=O)N6C)[C@H]5O)c4ccccc4N[C@@H]1N3C2=O		CHEMBL4645085	=	Ratio		1.4	CHEMBL4282	Homo sapiens	Ratio		1.4
	20646942	CHEMBL4614476	Inhibition of AKT phosphorylation at S473 residue in human HepG2 cells assessed as ratio of phosphorylated Akt to total Akt level at 0.5 uM after 4 hrs by Western blot analysis (Rvb = 1 No_unit)	B	CCC1(SC)C(=O)N2[C@H]3N(C)c4ccccc4C3(C34c5ccccc5N(C)[C@@H]3N3C(=O)C(SC)([C@@H](C)O)N(C)C(=O)C3(SC)[C@H]4O)[C@H](O)C2(SC)C(=O)N1C		CHEMBL4632683	=	Ratio		1.4	CHEMBL4282	Homo sapiens	Ratio		1.4
	20646943	CHEMBL4614477	Inhibition of AKT phosphorylation at S473 residue in human HepG2 cells assessed as ratio of phosphorylated Akt to total ERK level at 0.5 uM after 4 hrs by Western blot analysis (Rvb = 1 No_unit)	B	CC[C@@]12SS[C@]3(C(=O)N1C)[C@@H](O)C1(C45c6ccccc6N[C@@H]4N4C(=O)[C@]6([C@@H](C)O)SS[C@]4(C(=O)N6C)[C@H]5O)c4ccccc4N[C@@H]1N3C2=O		CHEMBL4645085	=	Ratio		1.2	CHEMBL4282	Homo sapiens	Ratio		1.2
	20646944	CHEMBL4614477	Inhibition of AKT phosphorylation at S473 residue in human HepG2 cells assessed as ratio of phosphorylated Akt to total ERK level at 0.5 uM after 4 hrs by Western blot analysis (Rvb = 1 No_unit)	B	CCC1(SC)C(=O)N2[C@H]3N(C)c4ccccc4C3(C34c5ccccc5N(C)[C@@H]3N3C(=O)C(SC)([C@@H](C)O)N(C)C(=O)C3(SC)[C@H]4O)[C@H](O)C2(SC)C(=O)N1C		CHEMBL4632683	=	Ratio		1.1	CHEMBL4282	Homo sapiens	Ratio		1.1
Active	20687283	CHEMBL4624559	Inhibition of AKT phosphorylation at ser 473 residue in human Ishikawa cells at 20 uM after 48 hrs by Western blot analysis	B	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1		CHEMBL567		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	20687284	CHEMBL4624560	Inhibition of AKT phosphorylation at ser 473 residue in human KLE cells at 20 uM after 48 hrs by Western blot analysis	B	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1		CHEMBL567		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	20702792	CHEMBL4627701	Inhibition of AKT (unknown origin) assessed as reduction in PI3K phosphorylation at 10 ug/ml by cell based assay relative to control	B	COCC(=O)CCC(=O)Nc1ccccc1C(=O)OC		CHEMBL4646108	=	Inhibition	%	70.0	CHEMBL4282	Homo sapiens	INH	%	70.0
	22391758	CHEMBL4666992	Inhibition of recombinant human His-tagged full length AKT1 expressed in baculovirus expression system using Ser/Thr 06 as substrate at 0.1 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	O=C(Nc1c[nH]nc1-c1cc(Cl)ccc1OC(F)F)c1cnn2cccnc12		CHEMBL4744172	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	22391759	CHEMBL4666992	Inhibition of recombinant human His-tagged full length AKT1 expressed in baculovirus expression system using Ser/Thr 06 as substrate at 0.1 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	Cn1cc(NC(=O)c2cnn3cccnc23)c(-c2cc(Cl)ccc2OC(F)F)n1		CHEMBL4777342	=	Inhibition	%	-6.0	CHEMBL4282	Homo sapiens	INH	%	-6.0
	22391760	CHEMBL4666992	Inhibition of recombinant human His-tagged full length AKT1 expressed in baculovirus expression system using Ser/Thr 06 as substrate at 0.1 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	O=C(Nc1c[nH]nc1-c1cc2ccccc2cc1OC(F)F)c1cnn2cccnc12		CHEMBL4745474	=	Inhibition	%	-5.0	CHEMBL4282	Homo sapiens	INH	%	-5.0
	22392009	CHEMBL4667104	Inhibition of recombinant human His-tagged full length AKT1 expressed in baculovirus expression system using Ser/Thr 06 as substrate at 10 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	CN1C(=O)[C@@H](NC(=O)c2n[nH]c3ncc(C(F)(F)C(F)(F)F)cc23)COc2ccccc21		CHEMBL4785812	=	Inhibition	%	-0.5	CHEMBL4282	Homo sapiens	INH	%	-0.5
	22423849	CHEMBL4674500	Inhibition of human AKT1 using KGSGSGRPRTSSFAEG as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	101.68	CHEMBL4282	Homo sapiens	Activity	%	101.68
	22423850	CHEMBL4674500	Inhibition of human AKT1 using KGSGSGRPRTSSFAEG as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	91.82	CHEMBL4282	Homo sapiens	Activity	%	91.82
	22482660	CHEMBL4687866	Inhibition of human PKBalpha assessed as residual activity at 10 uM relative to control	A	CN1CCC(CNC2=NC(=O)/C(=C/c3csc(-c4ccc(OC(F)(F)F)cc4)n3)S2)CC1		CHEMBL4757567	=	Activity	%	111.0	CHEMBL4282	Homo sapiens	Activity	%	111.0
	22752743	CHEMBL4700194	Inhibition of human AKT1 at 1 uM by kinase-profiling analysis	B	C#Cc1nc(Nc2ccccc2)nc2[nH]cnc12		CHEMBL4094562	=	Inhibition	%	33.0	CHEMBL4282	Homo sapiens	INH	%	33.0
Not Determined	22752744	CHEMBL4700194	Inhibition of human AKT1 at 1 uM by kinase-profiling analysis	B	C#Cc1nc(Nc2ccc(S(N)(=O)=O)cc2)nc2[nH]cnc12		CHEMBL4074015		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	22759634	CHEMBL4701762	Inhibition of human AKT1 at 1 uM using fluorescently labeled peptide substrate measured after 3 hrs by microfluidic mobility shift assay relative to control	B	CN(C)C(=O)c1ccc(Oc2nc(-c3cnc(N)s3)nc(N3CCOCC3)n2)cc1		CHEMBL4782133	=	Inhibition	%	-1.0	CHEMBL4282	Homo sapiens	INH	%	-1.0
	22768198	CHEMBL4703611	Inhibition of human PKBalpha	B	COc1cccc(Cn2cnc3ccc(-c4cn[nH]c4)cc3c2=O)c1		CHEMBL4742990	=	IC50	nM	1449.0	CHEMBL4282	Homo sapiens	IC50	nM	1449.0
	22768199	CHEMBL4703611	Inhibition of human PKBalpha	B	COc1cccc(Cn2ncc3ccc(-c4cn[nH]c4)cc3c2=O)c1		CHEMBL4744858	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	nM	10000.0
	22784726	CHEMBL4708150	Inhibition of Akt-1 (unknown origin)	B	COc1cc2cc(COCc3c(-c4ccc(F)cc4)nc(N(C)S(C)(=O)=O)nc3C(C)C)oc(=O)c2cc1OC		CHEMBL4759850	=	IC50	nM	4300.0	CHEMBL4282	Homo sapiens	IC50	uM	4.3
	22784727	CHEMBL4708150	Inhibition of Akt-1 (unknown origin)	B	COc1cc2c(cc1OC)/C(=C/COCc1c(-c3ccc(F)cc3)nc(N(C)S(C)(=O)=O)nc1C(C)C)OC2=O		CHEMBL4756388	=	IC50	nM	3700.0	CHEMBL4282	Homo sapiens	IC50	uM	3.7
	22784728	CHEMBL4708150	Inhibition of Akt-1 (unknown origin)	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	=	IC50	nM	3.0	CHEMBL4282	Homo sapiens	IC50	nM	3.0
	22784746	CHEMBL4708162	Binding affinity to Akt1 (unknown origin)	B	COc1cc2cc(COCc3c(-c4ccc(F)cc4)nc(N(C)S(C)(=O)=O)nc3C(C)C)oc(=O)c2cc1OC		CHEMBL4759850	=	Activity	kcal/mol	-11.3	CHEMBL4282	Homo sapiens	Activity	kcal/mol	-11.3
	22784747	CHEMBL4708162	Binding affinity to Akt1 (unknown origin)	B	COc1cc2c(cc1OC)/C(=C/COCc1c(-c3ccc(F)cc3)nc(N(C)S(C)(=O)=O)nc1C(C)C)OC2=O		CHEMBL4756388	=	Activity	kcal/mol	-10.9	CHEMBL4282	Homo sapiens	Activity	kcal/mol	-10.9
	22784748	CHEMBL4708162	Binding affinity to Akt1 (unknown origin)	B	COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1		CHEMBL53463	=	Activity	kcal/mol	-8.8	CHEMBL4282	Homo sapiens	Activity	kcal/mol	-8.8
	22790968	CHEMBL4709473	Inhibition of AKT1 (unknown origin) assessed as residual activity at 0.1 uM preincubated for 20 min followed by [gamma33P]ATP addition and measured after 120 mins by Hotspot assay relative to control	B	Cc1cccn(-c2ccc(-c3ccc4c(C(=O)NCc5ccncc5)n[nH]c4c3)c(Cl)c2)c1=O		CHEMBL4758500	=	Activity	%	98.85	CHEMBL4282	Homo sapiens	Activity	%	98.85
	22804191	CHEMBL4712060	Inhibition of AKT1 (unknown origin) at 100 uM pre-incubated for 20 mins followed by 33P-gamma-ATP addition and measured after 120 mins by filter-binding method relative to control	B	COc1ccc(-n2cc(-c3ccc4nonc4c3)c3cc(-c4ccc(C(=O)O)cc4)cnc32)cc1		CHEMBL4747136	=	Inhibition	%	35.0	CHEMBL4282	Homo sapiens	INH	%	35.0
	22804192	CHEMBL4712060	Inhibition of AKT1 (unknown origin) at 100 uM pre-incubated for 20 mins followed by 33P-gamma-ATP addition and measured after 120 mins by filter-binding method relative to control	B	O=C(O)c1ccc(-c2cnc3[nH]cc(-c4ccc5nonc5c4)c3c2)cc1		CHEMBL4752578	=	Inhibition	%	89.0	CHEMBL4282	Homo sapiens	INH	%	89.0
	22809793	CHEMBL4713328	Inhibition of recombinant full length human PKBalpha assessed as residual activity at 1 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins in presence of Km ATP by radiometric scintillation counting analysis relative to control	B	CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2ccc(Cl)cc2)[C@H](C)C1		CHEMBL4761365	=	Activity	%	89.0	CHEMBL4282	Homo sapiens	Activity	%	89.0
	22820550	CHEMBL4716277	Inhibition of recombinant full length N-terminal His6-tagged human PKBalpha expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	=	Activity	%	-3.0	CHEMBL4282	Homo sapiens	Activity	%	-3.0
	22820551	CHEMBL4716277	Inhibition of recombinant full length N-terminal His6-tagged human PKBalpha expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control	B	COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCNC2		CHEMBL4782674	=	Activity	%	102.0	CHEMBL4282	Homo sapiens	Activity	%	102.0
	22822928	CHEMBL4716837	Inhibition of AKT (unknown origin)	B	Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3c(C)[nH]nc3n2)c(OC(C)C)cc1C1CCN(C)CC1		CHEMBL3651854	=	IC50	nM	7600.0	CHEMBL4282	Homo sapiens	IC50	uM	7.6
	22843851	CHEMBL4720837	Inhibition of human AKT1 using KGSGSGRPRTSSFAEG as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	4.57	CHEMBL4282	Homo sapiens	IC50	10^-9M	4.57
	22844327	CHEMBL4721190	Inhibition of human AKT1 assessed as residual activity using KGSGSGRPRTSSFAEG as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	96.53	CHEMBL4282	Homo sapiens	Activity	%	96.53
	22844611	CHEMBL4721286	Inhibition of wild-type human partial length AKT1 expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	103.85	CHEMBL4282	Homo sapiens	Activity	%	103.85
Not Active	22889482	CHEMBL4729001	Inhibition of wild-type human partial length AKT1 expressed in bacterial expression system at 1 uM by Kinomescan method	B	COc1cc(OCc2ccnc(Nc3cnn(C)c3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4748740		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	22909853	CHEMBL4734045	Inhibition of recombinant full length human His-tagged AKT1 using serine/threonine-06 peptide as substrate at 10 uM incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	c1ccc(CSc2ncnc3[nH]cnc23)cc1		CHEMBL397434		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	22909854	CHEMBL4734045	Inhibition of recombinant full length human His-tagged AKT1 using serine/threonine-06 peptide as substrate at 10 uM incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	Clc1cccc(CSc2ncnc3[nH]cnc23)c1		CHEMBL4754930		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	22909855	CHEMBL4734045	Inhibition of recombinant full length human His-tagged AKT1 using serine/threonine-06 peptide as substrate at 10 uM incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	Brc1ccccc1CSc1ncnc2[nH]cnc12		CHEMBL4776788		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	22922118	CHEMBL4736849	Inhibition of PKBalpha (unknown origin) assessed as enzyme remaining activity at 5 uM relative to control	B	COc1ccc(-c2ccnc(N[C@H]3CO[C@@H]4[C@@H](NC(=O)Nc5ccc(C(C)=O)cc5)CO[C@H]34)n2)cc1		CHEMBL4758751	>	Activity	%	50.0	CHEMBL4282	Homo sapiens	Activity	%	50.0
Not Active	22936024	CHEMBL4739721	Inhibition of human AKT1 at 1 uM using substrate peptide by off-chip mobility shift assay	B	CC(=O)c1ccc(C(N)=O)cc1Oc1ccc(OCCOC2CCOCC2)cc1		CHEMBL4749965		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	22948988	CHEMBL4765725	Inhibition of human AKT1 (104 to 408 residues) assessed as residual activity at 0.1 uM relative to control	B	CNS(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(OC)cc13)C(=O)N2		CHEMBL104519	=	Activity	%	93.0	CHEMBL4282	Homo sapiens	Activity	%	93.0
	22948989	CHEMBL4765725	Inhibition of human AKT1 (104 to 408 residues) assessed as residual activity at 0.1 uM relative to control	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(O)cc13)C(=O)N2		CHEMBL4798255	=	Activity	%	105.0	CHEMBL4282	Homo sapiens	Activity	%	105.0
	22948990	CHEMBL4765725	Inhibition of human AKT1 (104 to 408 residues) assessed as residual activity at 0.1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(=O)(=O)N(C)C)cc31)cn2C		CHEMBL322153	=	Activity	%	101.0	CHEMBL4282	Homo sapiens	Activity	%	101.0
	22948991	CHEMBL4765725	Inhibition of human AKT1 (104 to 408 residues) assessed as residual activity at 0.1 uM relative to control	B	COc1ccc2[nH]cc(/C=C3\C(=O)Nc4ccc(S(N)(=O)=O)cc43)c2c1		CHEMBL106226	=	Activity	%	115.0	CHEMBL4282	Homo sapiens	Activity	%	115.0
	22948992	CHEMBL4765725	Inhibition of human AKT1 (104 to 408 residues) assessed as residual activity at 0.1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(N)(=O)=O)cc31)cn2C		CHEMBL104333	=	Activity	%	92.0	CHEMBL4282	Homo sapiens	Activity	%	92.0
	22948993	CHEMBL4765725	Inhibition of human AKT1 (104 to 408 residues) assessed as residual activity at 0.1 uM relative to control	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Activity	%	92.0	CHEMBL4282	Homo sapiens	Activity	%	92.0
	22948994	CHEMBL4765726	Inhibition of human AKT1 (104 to 408 residues) assessed as residual activity at 1 uM relative to control	B	CNS(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(OC)cc13)C(=O)N2		CHEMBL104519	=	Activity	%	98.0	CHEMBL4282	Homo sapiens	Activity	%	98.0
	22948995	CHEMBL4765726	Inhibition of human AKT1 (104 to 408 residues) assessed as residual activity at 1 uM relative to control	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(O)cc13)C(=O)N2		CHEMBL4798255	=	Activity	%	105.0	CHEMBL4282	Homo sapiens	Activity	%	105.0
	22948996	CHEMBL4765726	Inhibition of human AKT1 (104 to 408 residues) assessed as residual activity at 1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(=O)(=O)N(C)C)cc31)cn2C		CHEMBL322153	=	Activity	%	93.0	CHEMBL4282	Homo sapiens	Activity	%	93.0
	22948997	CHEMBL4765726	Inhibition of human AKT1 (104 to 408 residues) assessed as residual activity at 1 uM relative to control	B	COc1ccc2[nH]cc(/C=C3\C(=O)Nc4ccc(S(N)(=O)=O)cc43)c2c1		CHEMBL106226	=	Activity	%	101.0	CHEMBL4282	Homo sapiens	Activity	%	101.0
	22948998	CHEMBL4765726	Inhibition of human AKT1 (104 to 408 residues) assessed as residual activity at 1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(N)(=O)=O)cc31)cn2C		CHEMBL104333	=	Activity	%	96.0	CHEMBL4282	Homo sapiens	Activity	%	96.0
	22948999	CHEMBL4765726	Inhibition of human AKT1 (104 to 408 residues) assessed as residual activity at 1 uM relative to control	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Activity	%	97.0	CHEMBL4282	Homo sapiens	Activity	%	97.0
	22952954	CHEMBL4766891	Inhibition of recombinant full length human PKBalpha assessed as residual activity at 10 uM using GRPRTSSFAEGKK as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	101.0	CHEMBL4282	Homo sapiens	Activity	%	101.0
	22955538	CHEMBL4767595	Inhibition of His-tagged human full length AKT1 expressed in baculovirus expression system at 1 uM by Selectscreen kinase assay	B	COc1ccccc1-c1csc2cnc(Nc3ccc(C(=O)NC4CCNCC4)c(F)c3)nc12		CHEMBL4785582	=	Inhibition	%	15.0	CHEMBL4282	Homo sapiens	INH	%	15.0
Dose-dependent effect	22965746	CHEMBL4769496	Inhibition of Akt phosphorylation in human HepG2 cells by Western blot analysis	B	C/C=C(/C)C(=O)OC[C@@]1(O)C(=O)C[C@H]2CC3=C[C@H](C/C(C)=C/[C@@H](O)[C@@H]21)OC3=O		CHEMBL4782179		Activity			CHEMBL4282	Homo sapiens	Activity		
	23120154	CHEMBL4804338	Inhibition of AKT1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	IC50	nM	26400.0	CHEMBL4282	Homo sapiens	IC50	uM	26.4
	23120155	CHEMBL4804338	Inhibition of AKT1 in human NCI-H929 cells by mass spectroscopic analysis	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	IC50	nM	11100.0	CHEMBL4282	Homo sapiens	IC50	uM	11.1
	23120156	CHEMBL4804338	Inhibition of AKT1 in human NCI-H929 cells by mass spectroscopic analysis	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	IC50	nM	2100.0	CHEMBL4282	Homo sapiens	IC50	uM	2.1
	23120157	CHEMBL4804338	Inhibition of AKT1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O	Outside typical range	CHEMBL4855730	=	IC50	nM	-15200.0	CHEMBL4282	Homo sapiens	IC50	uM	-15.2
	23120158	CHEMBL4804338	Inhibition of AKT1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	IC50	nM	1600.0	CHEMBL4282	Homo sapiens	IC50	uM	1.6
	23120159	CHEMBL4804338	Inhibition of AKT1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	IC50	nM	32800.0	CHEMBL4282	Homo sapiens	IC50	uM	32.8
	23121199	CHEMBL4804520	Inhibition of AKT1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	23121200	CHEMBL4804520	Inhibition of AKT1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	23121201	CHEMBL4804520	Inhibition of AKT1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	23121202	CHEMBL4804520	Inhibition of AKT1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	23121203	CHEMBL4804520	Inhibition of AKT1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	23121204	CHEMBL4804520	Inhibition of AKT1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	Inhibition	%	0.0	CHEMBL4282	Homo sapiens	INH	%	0.0
	23122438	CHEMBL4804789	Inhibition of human AKT1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	89.0	CHEMBL4282	Homo sapiens	Activity	%	89.0
	23123133	CHEMBL4805377	Inhibition of human AKT1 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	95.0	CHEMBL4282	Homo sapiens	Activity	%	95.0
	23123752	CHEMBL4805996	Inhibition of DNA-tagged human AKT1 assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	23124248	CHEMBL4806321	Inhibition of AKT1 (unknown origin) at 10 uM relative to control	B	Cn1cc(-n2cnc3c(NCc4nc5cc(Cl)c(Cl)cc5[nH]4)nc(N4CCOCC4)nc32)cn1		CHEMBL4877117	=	Inhibition	%	1.0	CHEMBL4282	Homo sapiens	INH	%	1.0
	23124356	CHEMBL4806394	Inhibition of human AKT1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	23124357	CHEMBL4806394	Inhibition of human AKT1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	100.0	CHEMBL4282	Homo sapiens	Activity	%	100.0
	23127801	CHEMBL4807742	Inhibition of AKT1 (106 to 480) (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	>	Activity	%	75.0	CHEMBL4282	Homo sapiens	Activity	%	75.0
	23127802	CHEMBL4807742	Inhibition of AKT1 (106 to 480) (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	>	Activity	%	75.0	CHEMBL4282	Homo sapiens	Activity	%	75.0
	23127803	CHEMBL4807742	Inhibition of AKT1 (106 to 480) (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Activity	%	75.0	CHEMBL4282	Homo sapiens	Activity	%	75.0
	23158840	CHEMBL4812092	Inhibition of human N-terminal His-tagged full length AKT1 (1 to 480 residues) expressed in Sf9 cells at 10 uM preincubated for 10 mins followed by peptide substrate addition relative to control	B	CC(C)(C)OC(=O)c1ccc(NC(=O)c2ccc(Cl)c(S(N)(=O)=O)c2)cc1		CHEMBL4860361	=	Inhibition	%	3.48	CHEMBL4282	Homo sapiens	INH	%	3.48
Active	23166840	CHEMBL4813377	Inhibition of Akt in human PC-3M cells assessed as reduction of phosphorylated PI3K expression at 1 to 10 nM measured by western blot assay	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](OC(=O)CNC(=O)OC(C)(C)C)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC		CHEMBL4174065		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	23183478	CHEMBL4817109	Inhibition of AKT (unknown origin)	B	Cc1c(CN2CCN(C(=O)c3cc4cccc(C(N)=O)c4o3)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL4865059	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
Not Determined	23183479	CHEMBL4817109	Inhibition of AKT (unknown origin)	B	NC(=O)c1cccc2cc(C(=O)N3CCN(Cc4cc5nc(-c6cnc(N)nc6)nc(N6CCOCC6)c5s4)CC3)oc12		CHEMBL4871210		IC50			CHEMBL4282	Homo sapiens	IC50		
Not Determined	23183480	CHEMBL4817109	Inhibition of AKT (unknown origin)	B	NC(=O)c1cccc2cc(C(=O)N3CCN(Cc4cc5nc(-c6cnc(N)nc6)nc(N6CCOCC6)c5o4)CC3)oc12		CHEMBL4868231		IC50			CHEMBL4282	Homo sapiens	IC50		
	23183481	CHEMBL4817109	Inhibition of AKT (unknown origin)	B	Cc1c(CN2CCN(C(=O)c3cc(Cc4n[nH]c(=O)c5ccccc45)ccc3F)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL4858564	>	IC50	nM	100000.0	CHEMBL4282	Homo sapiens	IC50	nM	100000.0
Dose-Dependent Effect	23185202	CHEMBL4817465	Inhibition of Akt in human PANC-1 cells assessed as reduction in phosphorylation at Ser473 incubated for 6 hrs by Western blot analysis	B	COc1c(O)cc(-c2coc3c(CC=C(C)C)c(O)cc(O)c3c2=O)cc1CC=C(C)C		CHEMBL4849030		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	23203339	CHEMBL4821216	Inhibition of Akt in human HepG2 cells assessed as reduction in Akt phosphorylation by Westernblot analysis	B	C=CCn1c(SCC(=O)Nc2ccc(C(=O)O)cc2)nnc1-c1ccncc1		CHEMBL4846060		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Active	23203340	CHEMBL4821216	Inhibition of Akt in human HepG2 cells assessed as reduction in Akt phosphorylation by Westernblot analysis	B	O=C(CSc1nnc(-c2ccncc2)n1-c1ccccc1)Nc1ccc(C(=O)O)cc1		CHEMBL1722006		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	23203655	CHEMBL4821260	Inhibition of AKT phosphorylation at Ser473 residue in human HT-1080 cells at 2 uM after 24 hrs by Western blotting analysis	B	COc1ccc(Cn2nc(-c3ccccc3)c3cc(C(=N)Nc4ccc(N5CCN(C)CC5)cc4)ncc32)cc1		CHEMBL4875721	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	INH	%	100.0
Active	23203656	CHEMBL4821260	Inhibition of AKT phosphorylation at Ser473 residue in human HT-1080 cells at 2 uM after 24 hrs by Western blotting analysis	B	COc1ccc(Cn2nc(-c3ccccc3)c3cc(C(=N)Nc4ccc(N5CCN(C)CC5)cc4)nc(Nc4cc(OC)c(OC)c(OC)c4)c32)cc1		CHEMBL4853942		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
Not Active	23203657	CHEMBL4821260	Inhibition of AKT phosphorylation at Ser473 residue in human HT-1080 cells at 2 uM after 24 hrs by Western blotting analysis	B	COc1ccc(Cn2nc(-c3ccccc3)c3cc(C(=N)Nc4ccccc4)nc(NC4CCCCC4)c32)cc1		CHEMBL4861636		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	23203658	CHEMBL4821260	Inhibition of AKT phosphorylation at Ser473 residue in human HT-1080 cells at 2 uM after 24 hrs by Western blotting analysis	B	COc1ccc(Cn2nc(-c3ccccc3)c3cc(C(=N)Nc4ccc(N5CCN(C)CC5)cc4)nc(N4CCOCC4)c32)cc1		CHEMBL4872148	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	INH	%	100.0
	23203659	CHEMBL4821260	Inhibition of AKT phosphorylation at Ser473 residue in human HT-1080 cells at 2 uM after 24 hrs by Western blotting analysis	B	CN1CCN(c2ccc(NC(=N)c3cc4c(-c5ccccc5)n[nH]c4c(NC4CCCCC4)n3)cc2)CC1		CHEMBL4868398	=	Inhibition	%	100.0	CHEMBL4282	Homo sapiens	INH	%	100.0
	23246238	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)cc1		CHEMBL4460756	=	IC50	nM	21.6	CHEMBL4282	Homo sapiens	IC50	nM	21.6
	23246239	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)cc1F		CHEMBL4867422	=	IC50	nM	2.7	CHEMBL4282	Homo sapiens	IC50	nM	2.7
	23246240	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1nccc1-c1cc(F)c(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)cc1F		CHEMBL4855363	=	IC50	nM	9.2	CHEMBL4282	Homo sapiens	IC50	nM	9.2
	23246241	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1nccc1-c1cc(F)c(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)c(Cl)c1		CHEMBL4868266	=	IC50	nM	47.0	CHEMBL4282	Homo sapiens	IC50	nM	47.0
	23246242	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1nccc1-c1cc(F)c(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)c(F)c1		CHEMBL4868168	=	IC50	nM	26.3	CHEMBL4282	Homo sapiens	IC50	nM	26.3
	23246243	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1ncc(Cl)c1-c1cc(F)c(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)c(F)c1		CHEMBL4873154	=	IC50	nM	97.1	CHEMBL4282	Homo sapiens	IC50	nM	97.1
	23246244	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1ncc(Br)c1-c1cc(F)c(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)c(F)c1		CHEMBL4859898	=	IC50	nM	95.7	CHEMBL4282	Homo sapiens	IC50	nM	95.7
	23246245	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1ncc(Cl)c1-c1cc(F)c(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)cc1F		CHEMBL4869482	=	IC50	nM	48.9	CHEMBL4282	Homo sapiens	IC50	nM	48.9
	23246246	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1ncc(Br)c1-c1cc(F)c(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)cc1F		CHEMBL4873815	=	IC50	nM	66.2	CHEMBL4282	Homo sapiens	IC50	nM	66.2
	23246247	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1ncc(Cl)c1-c1cc(F)c(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)c(Cl)c1		CHEMBL4877032	=	IC50	nM	142.5	CHEMBL4282	Homo sapiens	IC50	nM	142.5
	23246248	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1ncc(Br)c1-c1cc(F)c(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)c(Cl)c1		CHEMBL4878473	=	IC50	nM	136.8	CHEMBL4282	Homo sapiens	IC50	nM	136.8
	23246249	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1nccc1-c1cc(F)c(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)cc2)c(F)c1		CHEMBL4852887	=	IC50	nM	107.2	CHEMBL4282	Homo sapiens	IC50	nM	107.2
	23246250	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1nccc1-c1cc(F)c(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)cc2)cc1F		CHEMBL4877044	=	IC50	nM	35.3	CHEMBL4282	Homo sapiens	IC50	nM	35.3
	23246251	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1		CHEMBL2177390	=	IC50	nM	1.3	CHEMBL4282	Homo sapiens	IC50	nM	1.3
	23246252	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cc(F)cc(F)c2)c(Cl)c1		CHEMBL4875495	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
	23246253	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cc(F)cc(F)c2)c(F)c1		CHEMBL4866810	=	IC50	nM	4.6	CHEMBL4282	Homo sapiens	IC50	nM	4.6
	23246254	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2cc(F)cc(F)c2)cc1F		CHEMBL4874391	=	IC50	nM	1.8	CHEMBL4282	Homo sapiens	IC50	nM	1.8
	23246255	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)c(Cl)c1		CHEMBL4858782	=	IC50	nM	24.0	CHEMBL4282	Homo sapiens	IC50	nM	24.0
	23246256	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)c(F)c1		CHEMBL4556790	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	23246257	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	Cl.O=C(N[C@@H]1CNCC[C@H]1c1ccc(F)c(F)c1)c1ccc(-c2ccn[nH]2)cc1F		CHEMBL4854839	=	IC50	nM	83.0	CHEMBL4282	Homo sapiens	IC50	nM	83.0
	23246258	CHEMBL4830024	Inhibition of N-terminal GST-tagged human AKT1 (104 to 408 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by mobility shift assay	B	CCn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)c(F)c1.Cl		CHEMBL4847466	=	IC50	nM	176.0	CHEMBL4282	Homo sapiens	IC50	nM	176.0
	23251862	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	NC(=O)c1cccc2c(NCc3ccc4c(c3)OCO4)ncnc12		CHEMBL3675353	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	23251863	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	NC(=O)c1cccc2c(NCc3ccc4c(c3)OCO4)ccnc12		CHEMBL3675367	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	23251864	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	NC(=O)c1cccc2c(NCc3ccc4c(c3)OCO4)nccc12		CHEMBL4853114	>	IC50	nM	10000.0	CHEMBL4282	Homo sapiens	IC50	uM	10.0
	23251865	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	CNCC(Nc1ncnc2c(C(N)=O)cccc12)c1cccc(F)c1		CHEMBL3675415	=	IC50	nM	15.0	CHEMBL4282	Homo sapiens	IC50	nM	15.0
	23251866	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	CNC[C@@H](Nc1ncnc2c(C(N)=O)cccc12)c1cccc(F)c1		CHEMBL3685329	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	23251867	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	NC(=O)c1cccc2c(N[C@H](CN3CCC3)c3cccc(F)c3)ncnc12		CHEMBL4851020	=	IC50	nM	22.0	CHEMBL4282	Homo sapiens	IC50	nM	22.0
	23251868	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	NC(=O)c1cccc2c(N[C@H](CN3CCCC3)c3cccc(F)c3)ncnc12		CHEMBL4857965	=	IC50	nM	563.0	CHEMBL4282	Homo sapiens	IC50	nM	563.0
	23251869	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	NC(=O)c1cccc2c(N[C@H](CN3CCC3)c3cccc(Cl)c3)ncnc12		CHEMBL4855657	=	IC50	nM	14.0	CHEMBL4282	Homo sapiens	IC50	nM	14.0
	23251870	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	NC(=O)c1cccc2c(N[C@H](CN3CCC3)c3cccc(C(F)(F)F)c3)ncnc12		CHEMBL4876446	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	23251871	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	NC(=O)c1cccc2c(N[C@H](CN3CCC3)c3ccc(F)cc3)ncnc12		CHEMBL4875416	=	IC50	nM	23.0	CHEMBL4282	Homo sapiens	IC50	nM	23.0
	23251872	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	NC(=O)c1cccc2c(N[C@H](CN3CCC3)c3ccc(C(F)(F)F)cc3)ncnc12		CHEMBL4871853	=	IC50	nM	17.0	CHEMBL4282	Homo sapiens	IC50	nM	17.0
	23251873	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	NC(=O)c1cccc2c(N[C@H](CN3CCC3)c3ccc(F)c(F)c3)ncnc12		CHEMBL4860970	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	23251874	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	NC(=O)c1cccc2c(N[C@H](CN3CCC3)c3ccc(Cl)c(F)c3)ncnc12		CHEMBL4856439	=	IC50	nM	10.0	CHEMBL4282	Homo sapiens	IC50	nM	10.0
	23251875	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	NC(=O)c1cccc2c(N[C@H](CN3CCC3)c3ccc(F)c(C(F)(F)F)c3)ncnc12		CHEMBL4846712	=	IC50	nM	6.0	CHEMBL4282	Homo sapiens	IC50	nM	6.0
	23251876	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	NC(=O)c1cccc2c(N[C@H](CN3CCC3)c3ccc(Cl)c(C(F)(F)F)c3)ncnc12		CHEMBL4871106	=	IC50	nM	4.0	CHEMBL4282	Homo sapiens	IC50	nM	4.0
	23251877	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	CNC[C@@H](Nc1nc(C)nc2c(C(N)=O)cccc12)c1cccc(F)c1		CHEMBL4854144	=	IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	nM	44.0
	23251878	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	CCc1nc(N[C@H](CNC)c2cccc(F)c2)c2cccc(C(N)=O)c2n1		CHEMBL4869229	=	IC50	nM	212.0	CHEMBL4282	Homo sapiens	IC50	nM	212.0
	23251879	CHEMBL4831258	Inhibition of His-tagged human AKT1 expressed in baculovirus expression system using TC-AHA-GRPRTSSFAEG-NH2 as substrate incubated for 90 mins by mobility shift assay	B	CNC[C@@H](Nc1nc(C(F)(F)F)nc2c(C(N)=O)cccc12)c1cccc(F)c1		CHEMBL4853030	=	IC50	nM	400.0	CHEMBL4282	Homo sapiens	IC50	nM	400.0
	23265827	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	=	Inhibition	%	99.0	CHEMBL4282	Homo sapiens	INH	%	99.0
	23265828	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	Cl.NC1(C(=O)N[C@H](C(=O)NO)c2ccccc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4875183	=	Inhibition	%	63.0	CHEMBL4282	Homo sapiens	INH	%	63.0
	23265829	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	Cl.NC1(C(=O)N[C@@H](Cc2ccccc2)C(=O)NO)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4875638	=	Inhibition	%	10.0	CHEMBL4282	Homo sapiens	INH	%	10.0
	23265830	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	CC(C)C[C@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)C(=O)NO.Cl		CHEMBL4878231	=	Inhibition	%	28.0	CHEMBL4282	Homo sapiens	INH	%	28.0
	23265831	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	Cl.NC1(C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)NO)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4873890	=	Inhibition	%	28.0	CHEMBL4282	Homo sapiens	INH	%	28.0
	23265832	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	CC(C)[C@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)C(=O)NO.Cl		CHEMBL4879254	=	Inhibition	%	17.0	CHEMBL4282	Homo sapiens	INH	%	17.0
	23265833	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	Cl.NC1(C(=O)N[C@@H](C(=O)NO)c2ccccc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4867186	=	Inhibition	%	81.0	CHEMBL4282	Homo sapiens	INH	%	81.0
	23265834	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	Cl.NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NO)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4855668	=	Inhibition	%	37.0	CHEMBL4282	Homo sapiens	INH	%	37.0
	23265835	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	CC(C)C[C@@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)C(=O)NO.Cl		CHEMBL4860306	=	Inhibition	%	70.0	CHEMBL4282	Homo sapiens	INH	%	70.0
	23265836	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	Cl.NC1(C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)NO)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4858787	=	Inhibition	%	21.0	CHEMBL4282	Homo sapiens	INH	%	21.0
	23265837	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	CC(C)[C@@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)C(=O)NO.Cl		CHEMBL4866789	=	Inhibition	%	31.0	CHEMBL4282	Homo sapiens	INH	%	31.0
	23265838	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	O=C(N[C@H](Cc1ccccc1)C(=O)NO)C1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4849351	=	Inhibition	%	22.0	CHEMBL4282	Homo sapiens	INH	%	22.0
	23265839	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	CC(C)C[C@@H](NC(=O)C1CCN(c2ncnc3[nH]ccc23)CC1)C(=O)NO		CHEMBL4851365	=	Inhibition	%	24.0	CHEMBL4282	Homo sapiens	INH	%	24.0
	23265840	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	O=C(NO)[C@@H](Cc1ccccc1)NC(=O)N1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4872931	=	Inhibition	%	37.0	CHEMBL4282	Homo sapiens	INH	%	37.0
	23265841	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	CC(C)C[C@@H](NC(=O)N1CCN(c2ncnc3[nH]ccc23)CC1)C(=O)NO		CHEMBL4857333	=	Inhibition	%	49.0	CHEMBL4282	Homo sapiens	INH	%	49.0
	23265842	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	O=C(NC1CCN(c2ncnc3[nH]ccc23)CC1)N[C@H](Cc1ccccc1)C(=O)NO		CHEMBL4870948	=	Inhibition	%	8.0	CHEMBL4282	Homo sapiens	INH	%	8.0
	23265843	CHEMBL4834346	Inhibition of AKT1 (unknown origin) at 1 uM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis relative to control	B	CC(C)C[C@@H](NC(=O)NC1CCN(c2ncnc3[nH]ccc23)CC1)C(=O)NO		CHEMBL4854059	=	Inhibition	%	8.0	CHEMBL4282	Homo sapiens	INH	%	8.0
	23265844	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	=	Inhibition	%	85.0	CHEMBL4282	Homo sapiens	INH	%	85.0
	23265845	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	Cl.NC1(C(=O)N[C@H](C(=O)NO)c2ccccc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4875183	=	Inhibition	%	35.0	CHEMBL4282	Homo sapiens	INH	%	35.0
	23265846	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	Cl.NC1(C(=O)N[C@@H](Cc2ccccc2)C(=O)NO)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4875638	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	23265847	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	CC(C)C[C@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)C(=O)NO.Cl		CHEMBL4878231	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	23265848	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	Cl.NC1(C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)NO)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4873890	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	23265849	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	CC(C)[C@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)C(=O)NO.Cl		CHEMBL4879254	=	Inhibition	%	5.0	CHEMBL4282	Homo sapiens	INH	%	5.0
	23265850	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	Cl.NC1(C(=O)N[C@@H](C(=O)NO)c2ccccc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4867186	=	Inhibition	%	60.0	CHEMBL4282	Homo sapiens	INH	%	60.0
	23265851	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	Cl.NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NO)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4855668	=	Inhibition	%	21.0	CHEMBL4282	Homo sapiens	INH	%	21.0
	23265852	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	CC(C)C[C@@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)C(=O)NO.Cl		CHEMBL4860306	=	Inhibition	%	43.0	CHEMBL4282	Homo sapiens	INH	%	43.0
	23265853	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	Cl.NC1(C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)NO)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4858787	=	Inhibition	%	3.0	CHEMBL4282	Homo sapiens	INH	%	3.0
	23265854	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	CC(C)[C@@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)C(=O)NO.Cl		CHEMBL4866789	=	Inhibition	%	6.0	CHEMBL4282	Homo sapiens	INH	%	6.0
	23265855	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	O=C(N[C@H](Cc1ccccc1)C(=O)NO)C1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4849351	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	23265856	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	CC(C)C[C@@H](NC(=O)C1CCN(c2ncnc3[nH]ccc23)CC1)C(=O)NO		CHEMBL4851365	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	23265857	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	O=C(NO)[C@@H](Cc1ccccc1)NC(=O)N1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4872931	=	Inhibition	%	11.0	CHEMBL4282	Homo sapiens	INH	%	11.0
	23265858	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	CC(C)C[C@@H](NC(=O)N1CCN(c2ncnc3[nH]ccc23)CC1)C(=O)NO		CHEMBL4857333	=	Inhibition	%	29.0	CHEMBL4282	Homo sapiens	INH	%	29.0
	23265859	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	O=C(NC1CCN(c2ncnc3[nH]ccc23)CC1)N[C@H](Cc1ccccc1)C(=O)NO		CHEMBL4870948	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	23265860	CHEMBL4834347	Inhibition of AKT1 (unknown origin) at 200 nM incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	CC(C)C[C@@H](NC(=O)NC1CCN(c2ncnc3[nH]ccc23)CC1)C(=O)NO		CHEMBL4854059	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	23265861	CHEMBL4834348	Inhibition of AKT1 (unknown origin) incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	CC(C)C[C@@H](NC(=O)C1(N)CCN(c2ncnc3[nH]ccc23)CC1)C(=O)NO.Cl		CHEMBL4860306	=	IC50	nM	270.0	CHEMBL4282	Homo sapiens	IC50	nM	270.0
	23265862	CHEMBL4834348	Inhibition of AKT1 (unknown origin) incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	=	IC50	nM	8.0	CHEMBL4282	Homo sapiens	IC50	nM	8.0
	23265863	CHEMBL4834348	Inhibition of AKT1 (unknown origin) incubated for 40 mins in presence of ATP by Kinase-Glo reagent based luminescence analysis	B	Cl.NC1(C(=O)N[C@@H](C(=O)NO)c2ccccc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL4867186	=	IC50	nM	121.0	CHEMBL4282	Homo sapiens	IC50	nM	121.0
Not Active	23270420	CHEMBL4835214	Inhibition of Akt1/PKBalpha (unknown origin) at 10 uM	B	C[C@H]1CN(C(=O)CC[C@@]2(C3CC3)NC(=O)NC2=O)CCN1c1cc(F)cc(F)c1		CHEMBL4650334		Inhibition	%		CHEMBL4282	Homo sapiens	INH		
	23291475	CHEMBL4839611	Inhibition of human recombinant PKBalpha at 5 nM radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2Cl)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4467948	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
	23291476	CHEMBL4839611	Inhibition of human recombinant PKBalpha at 5 nM radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2ccc(OC(F)(F)F)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N	Outside typical range	CHEMBL4850154	=	Inhibition	%	-19.0	CHEMBL4282	Homo sapiens	INH	%	-19.0
	23291477	CHEMBL4839611	Inhibition of human recombinant PKBalpha at 5 nM radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4862806	=	Inhibition	%	-5.0	CHEMBL4282	Homo sapiens	INH	%	-5.0
	23291478	CHEMBL4839612	Inhibition of human recombinant PKBalpha at 50 nM radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2Cl)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4467948	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	23291479	CHEMBL4839612	Inhibition of human recombinant PKBalpha at 50 nM radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2ccc(OC(F)(F)F)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4850154	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	23291480	CHEMBL4839612	Inhibition of human recombinant PKBalpha at 50 nM radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4862806	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	23291481	CHEMBL4839613	Inhibition of human recombinant PKBalpha at 500 nM radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2Cl)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4467948	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	23291482	CHEMBL4839613	Inhibition of human recombinant PKBalpha at 500 nM radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2ccc(OC(F)(F)F)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4850154	=	Inhibition	%	-5.0	CHEMBL4282	Homo sapiens	INH	%	-5.0
	23291483	CHEMBL4839613	Inhibition of human recombinant PKBalpha at 500 nM radiometric scintillation counting analysis relative to control	B	Cc1ccc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N	Outside typical range	CHEMBL4862806	=	Inhibition	%	-15.0	CHEMBL4282	Homo sapiens	INH	%	-15.0
	23295523	CHEMBL4840535	Inhibition of recombinant His-tagged human full length AKT1 expressed in baculovirus expression system at 1 uM measured by select screen assay relative to control	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4c3CN(Cc3cc(F)cc(F)c3)C4(C)C)cc2)CC1		CHEMBL4849505	=	Inhibition	%	2.0	CHEMBL4282	Homo sapiens	INH	%	2.0
	23299306	CHEMBL4841753	Inhibition of AKT1 (unknown origin) at 1000 nM relative to control	B	Nc1c(-c2nc3cc(N4CCN(C(=O)CCCCCNc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)ccc3[nH]2)c(=O)[nH]c2cccc(F)c12		CHEMBL4860038	=	Inhibition	%	7.0	CHEMBL4282	Homo sapiens	INH	%	7.0
	23299307	CHEMBL4841753	Inhibition of AKT1 (unknown origin) at 1000 nM relative to control	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Inhibition	%	4.0	CHEMBL4282	Homo sapiens	INH	%	4.0
Not Active	23317273	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	82.0	CHEMBL4282	Homo sapiens	% Control	%	82.0
Not Active	23317741	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	98.0	CHEMBL4282	Homo sapiens	% Control	%	98.0
Not Active	23318415	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	84.0	CHEMBL4282	Homo sapiens	% Control	%	84.0
Not Active	23318891	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23319531	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23320003	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	85.7	CHEMBL4282	Homo sapiens	% Control	%	85.7
Not Active	23320681	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	90.0	CHEMBL4282	Homo sapiens	% Control	%	90.0
Not Active	23321149	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23321779	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	97.0	CHEMBL4282	Homo sapiens	% Control	%	97.0
Not Active	23322247	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23322936	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23323404	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	63.0	CHEMBL4282	Homo sapiens	% Control	%	63.0
Not Active	23324096	CHEMBL4880715	PKBalpha (h) Millipore kinase activity assay	B	CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1	Outside typical range	CHEMBL4593677		Inhibition	%	-13.0	CHEMBL4282	Homo sapiens	% inhibition	%	-13.0
Not Active	23324258	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23324893	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	83.0	CHEMBL4282	Homo sapiens	% Control	%	83.0
Not Active	23325361	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	75.0	CHEMBL4282	Homo sapiens	% Control	%	75.0
Not Active	23326008	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23326476	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	78.0	CHEMBL4282	Homo sapiens	% Control	%	78.0
Not Active	23327176	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	96.0	CHEMBL4282	Homo sapiens	% Control	%	96.0
Not Active	23327644	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	94.0	CHEMBL4282	Homo sapiens	% Control	%	94.0
Not Active	23328231	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	91.0	CHEMBL4282	Homo sapiens	% Control	%	91.0
Not Active	23328699	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	93.0	CHEMBL4282	Homo sapiens	% Control	%	93.0
Not Active	23329477	CHEMBL4881184	PKBalpha (h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	113.0	CHEMBL4282	Homo sapiens	% residual kinase activity	%	113.0
Not Active	23329645	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23330113	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23330869	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	96.0	CHEMBL4282	Homo sapiens	% Control	%	96.0
Not Active	23331337	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	90.0	CHEMBL4282	Homo sapiens	% Control	%	90.0
Not Active	23331924	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	90.9	CHEMBL4282	Homo sapiens	% Control	%	90.9
Not Active	23332392	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23333108	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	90.4	CHEMBL4282	Homo sapiens	% Control	%	90.4
Not Active	23333747	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23334215	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23334933	CHEMBL4881555	PKBalpha (h) Upstate kinase activity assay	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		Inhibition	%	84.0	CHEMBL4282	Homo sapiens	% inhibition	%	84.0
Not Active	23335194	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23335662	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	75.0	CHEMBL4282	Homo sapiens	% Control	%	75.0
Not Active	23336289	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23336757	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23337511	CHEMBL4881882	AKT1 Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	99.0	CHEMBL4282	Homo sapiens	% Ctrl	%	99.0
Not Active	23337838	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	94.0	CHEMBL4282	Homo sapiens	% Control	%	94.0
Not Active	23338306	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	97.0	CHEMBL4282	Homo sapiens	% Control	%	97.0
Not Active	23338918	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23339386	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	86.0	CHEMBL4282	Homo sapiens	% Control	%	86.0
Not Active	23340023	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23340491	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23341148	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23341616	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23342232	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	97.0	CHEMBL4282	Homo sapiens	% Control	%	97.0
Not Active	23342700	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Slightly Active	23343240	CHEMBL4882425	AKT1 Invitrogen selectivity data (BI)	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Ctrl	%	24.0	CHEMBL4282	Homo sapiens	% Ctrl	%	24.0
Not Active	23343330	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23343798	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23344436	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	95.0	CHEMBL4282	Homo sapiens	% Control	%	95.0
Not Active	23345009	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23345477	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23346054	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23346523	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	92.3	CHEMBL4282	Homo sapiens	% Control	%	92.3
Not Active	23347133	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23347614	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	90.0	CHEMBL4282	Homo sapiens	% Control	%	90.0
Not Active	23348193	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23348661	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	89.0	CHEMBL4282	Homo sapiens	% Control	%	89.0
Active	23349248	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	5.0	CHEMBL4282	Homo sapiens	% Control	%	5.0
Not Active	23349866	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	96.0	CHEMBL4282	Homo sapiens	% Control	%	96.0
Not Active	23350334	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	97.0	CHEMBL4282	Homo sapiens	% Control	%	97.0
Not Active	23350939	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23351407	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23351960	CHEMBL4882653	AKT1 (PKB alpha) Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	6.75	CHEMBL4282	Homo sapiens	% Inhibition	%	6.7502
Not Active	23352431	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	87.0	CHEMBL4282	Homo sapiens	% Control	%	87.0
Not Active	23352899	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23353781	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	99.0	CHEMBL4282	Homo sapiens	% Control	%	99.0
Not Active	23354249	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23354981	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	82.0	CHEMBL4282	Homo sapiens	% Control	%	82.0
Not Active	23355449	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	92.0	CHEMBL4282	Homo sapiens	% Control	%	92.0
Not Active	23356085	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23356553	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23357162	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23357809	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	93.0	CHEMBL4282	Homo sapiens	% Control	%	93.0
Not Active	23358277	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23358863	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	99.9	CHEMBL4282	Homo sapiens	% Control	%	99.9
Not Active	23359461	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23359929	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23360514	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23360982	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23361555	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23362091	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	94.0	CHEMBL4282	Homo sapiens	% Control	%	94.0
Not Active	23362559	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	82.0	CHEMBL4282	Homo sapiens	% Control	%	82.0
Not Active	23363208	CHEMBL4883220	AKT1 (PKB alpha) Kinase activity screen	B	CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5ccncc5)ccc4n3)cc2)CC1	Outside typical range	CHEMBL4531334		Inhibition	%	-11.85	CHEMBL4282	Homo sapiens	% inhibition	%	-11.8458
Not Active	23363209	CHEMBL4883220	AKT1 (PKB alpha) Kinase activity screen	B	CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5ccncc5)ccc4n3)cc2)CC1		CHEMBL4531334		Inhibition	%	-8.238	CHEMBL4282	Homo sapiens	% inhibition	%	-8.2383
Not Active	23364201	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	72.0	CHEMBL4282	Homo sapiens	% Control	%	72.0
Not Active	23364669	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	74.0	CHEMBL4282	Homo sapiens	% Control	%	74.0
Not Active	23365408	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23365951	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23366541	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23367009	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23367467	CHEMBL4883820	AKT1 ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	102.0	CHEMBL4282	Homo sapiens	% Residual activity with Skepinone-L	%	102.0
Not Active	23367887	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23368355	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	95.0	CHEMBL4282	Homo sapiens	% Control	%	95.0
Not Active	23368954	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23369422	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23370193	CHEMBL4884435	PKBalpha (h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	91.0	CHEMBL4282	Homo sapiens	% residual kinase activity	%	91.0
Not Active	23370390	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	75.0	CHEMBL4282	Homo sapiens	% Control	%	75.0
Not Active	23370858	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	94.0	CHEMBL4282	Homo sapiens	% Control	%	94.0
Not Active	23371667	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23372135	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
	23373706	CHEMBL4885483	Akt1 [PKBalpha(AKT1PHFB)] Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL4282	Homo sapiens	pIC50		6.0
Active	23374886	CHEMBL4885855	TR-FRET (AKT1, 10 uM ATP)	B	NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1		CHEMBL4751394		IC50	nM	5.2	CHEMBL4282	Homo sapiens	IC50	nM	5.2
Active	23374887	CHEMBL4885856	TR-FRET (AKT1, 2 mM ATP)	B	NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1		CHEMBL4751394		IC50	nM	44.0	CHEMBL4282	Homo sapiens	IC50	nM	44.0
Active	23374890	CHEMBL4885859	SPR (active AKT1)	B	NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1		CHEMBL4751394		Kd	nM	2.7	CHEMBL4282	Homo sapiens	Kd	nM	2.7
Active	23374891	CHEMBL4885860	SPR (inactive AKT1)	B	NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1		CHEMBL4751394		Kd	nM	1.3	CHEMBL4282	Homo sapiens	Kd	nM	1.3
Not Active	23374892	CHEMBL4885861	TR-FRET (delta PH domain AKT1)	B	NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1	Non standard unit for type	CHEMBL4751394	>	IC50	µM	20.0	CHEMBL4282	Homo sapiens	IC50	µM	20.0
Active	23374904	CHEMBL4885873	NanoBRET (AKT1)	B	NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1		CHEMBL4751394		IC50	nM	2.84	CHEMBL4282	Homo sapiens	IC50	nM	2.84
Not Active	23374906	CHEMBL4885873	NanoBRET (AKT1)	B	NC1(c2ccc(-c3nc4c(O)ccnn4c3-c3ccccc3)cc2)CCC1	Non standard unit for type	CHEMBL5016886		IC50	µM	6.0	CHEMBL4282	Homo sapiens	IC50	µM	6.0
Not Active	23374908	CHEMBL4885875	Biochemical assay (AKT1)	B	NC1(c2ccc(-c3nc4c(O)ccnn4c3-c3ccccc3)cc2)CCC1	Non standard unit for type	CHEMBL5016886		IC50	µM	3.74	CHEMBL4282	Homo sapiens	IC50	µM	3.74
Not Active	23374912	CHEMBL4885906	AKT1 Kinase panel	B	CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O		CHEMBL4475494		Inhibition	%	0.5	CHEMBL4282	Homo sapiens	% Inhibition	%	0.5
Not Active	23375405	CHEMBL4886387	v-akt murine thymoma viral oncogene homolog 1 Millipore kinase panel	B	COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1		CHEMBL2180408		Inhibition	%	35.0	CHEMBL4282	Homo sapiens	% inhibition	%	35.0
Not Active	23375562	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	98.0	CHEMBL4282	Homo sapiens	% Control	%	98.0
Not Active	23376030	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	67.0	CHEMBL4282	Homo sapiens	% Control	%	67.0
Not Active	23376608	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23377077	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	89.0	CHEMBL4282	Homo sapiens	% Control	%	89.0
Not Active	23377935	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	91.0	CHEMBL4282	Homo sapiens	% Control	%	91.0
Not Active	23378403	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	77.0	CHEMBL4282	Homo sapiens	% Control	%	77.0
Not Active	23379570	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23380038	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	91.0	CHEMBL4282	Homo sapiens	% Control	%	91.0
Not Active	23380732	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23381380	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23381848	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23382386	CHEMBL4887108	AKT1 Invitrogen kinase activity assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		Inhibition	%	4.0	CHEMBL4282	Homo sapiens	% inhibition	%	4.0
Not Active	23382472	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23382940	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23383694	CHEMBL4887348	AKT1 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	99.0	CHEMBL4282	Homo sapiens	% Ctrl	%	99.0
Not Active	23383695	CHEMBL4887348	AKT1 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	96.0	CHEMBL4282	Homo sapiens	% Ctrl	%	96.0
Not Active	23384414	CHEMBL4888009	PKBalpha(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	-1.04	CHEMBL4282	Homo sapiens	% inhibition	%	-1.04
Not Active	23384627	CHEMBL4888153	AKT1 (PKB alpha) SelectScreen Kinase panel (LifeTechnologies)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1		CHEMBL4795065		Inhibition	%	98.0	CHEMBL4282	Homo sapiens	% Inhibition	%	98.0
Active	23384725	CHEMBL4888140	Homogeneous Time Resolved Fluorescence (HTRF) assay (AKT1)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1		CHEMBL4795065		IC50	nM	0.8	CHEMBL4282	Homo sapiens	IC50	nM	0.8
Active	23384728	CHEMBL4888143	NanoBRET assay (AKT1)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1		CHEMBL4795065		IC50	nM	21.0	CHEMBL4282	Homo sapiens	IC50	nM	21.0
Not Active	23384736	CHEMBL4888140	Homogeneous Time Resolved Fluorescence (HTRF) assay (AKT1)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5ccc6c(c5)NC(=O)CO6)cc4)CC3)c2c1	Non standard unit for type	CHEMBL4802051		IC50	µM	9.2	CHEMBL4282	Homo sapiens	IC50	µM	9.2
Not Active	23384739	CHEMBL4888143	NanoBRET assay (AKT1)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5ccc6c(c5)NC(=O)CO6)cc4)CC3)c2c1	Non standard unit for type	CHEMBL4802051		IC50	µM	1.9	CHEMBL4282	Homo sapiens	IC50	µM	1.9
Not Active	23384855	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	100.0	CHEMBL4282	Homo sapiens	% Control	%	100.0
Not Active	23385322	CHEMBL4879579	KinomeScan assay: inhibition of AKT1	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	89.0	CHEMBL4282	Homo sapiens	% Control	%	89.0
Not Active	23385861	CHEMBL4888334	PKBalpha Invitrogen kinase panel	B	COc1nc2ccc([C@@](O)(c3ccccc3)C3CCN(C(C)=O)CC3)cc2c(Cl)c1Cc1ccc(-n2cccn2)cc1		CHEMBL4802042		Inhibition	%	-5.0	CHEMBL4282	Homo sapiens	% inhibition	%	-5.0
